uric acid has been researched along with Hyperuricemia in 3041 studies
Uric Acid: An oxidation product, via XANTHINE OXIDASE, of oxypurines such as XANTHINE and HYPOXANTHINE. It is the final oxidation product of purine catabolism in humans and primates, whereas in most other mammals URATE OXIDASE further oxidizes it to ALLANTOIN.
uric acid : An oxopurine that is the final oxidation product of purine metabolism.
6-hydroxy-1H-purine-2,8(7H,9H)-dione : A tautomer of uric acid having oxo groups at C-2 and C-8 and a hydroxy group at C-6.
7,9-dihydro-1H-purine-2,6,8(3H)-trione : An oxopurine in which the purine ring is substituted by oxo groups at positions 2, 6, and 8.
Hyperuricemia: Excessive URIC ACID or urate in blood as defined by its solubility in plasma at 37 degrees C; greater than 0.42mmol per liter (7.0mg/dL) in men or 0.36mmol per liter (6.0mg/dL) in women. This condition is caused by overproduction of uric acid or impaired renal clearance. Hyperuricemia can be acquired, drug-induced or genetically determined (LESCH-NYHAN SYNDROME). It is associated with HYPERTENSION and GOUT.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Gender-based evidence on the association between serum uric acid (SUA) and left ventricular hypertrophy (LVH), as assessed by echocardiography, is still based on single studies." | 9.94 | Uric acid and left ventricular hypertrophy: a gender-based meta-analysis of echocardiographic studies. ( Carugo, S; Cuspidi, C; Faggiano, A; Gherbesi, E; Grassi, G; Sala, C; Tadic, M, 2024) |
| " Obesity, lipids, glucose tolerance and insulin resistance are risk factors for numerous cardiovascular diseases and are often accompanied by a considerable increase in serum uric acid (SUA) concentrations." | 9.94 | Insights into the relationship between serum uric acid and pulmonary hypertension (Review). ( Chen, M; He, Y; Lei, W; Luo, H; Shui, X; Zheng, J; Zhou, Y, 2024) |
| "Our study demonstrated the efficiency of benzbromarone in hypertensive patients with concomitant asymptomatic hyperuricemia, including the benefits on ameliorating LV diastolic dysfunction as well as improving composite endpoints." | 9.69 | Uric acid-lowering therapy with benzbromarone in hypertension with asymptomatic hyperuricemia: a randomized study focusing left ventricular diastolic function. ( Gu, J; Han, Z; Ke, J; Lin, H; Pan, J, 2023) |
| "To assess the efficacy of febuxostat combined with hydration on contrast-induced nephropathy (CIN) in coronary heart disease patients with hyperuricemia undergoing percutaneous coronary intervention (PCI)." | 9.51 | Febuxostat combined with hydration for the prevention of contrast-induced nephropathy in hyperuricemia patients undergoing percutaneous coronary intervention: A CONSORT-compliant randomized controlled trial. ( He, Z; Li, M; Ma, G; Teng, W; Xia, Z; Zhai, X, 2022) |
| "To investigate whether serum urate levels, number of gout flares, and tophi burden are related to death from cardiovascular (CV) causes after treatment with febuxostat or allopurinol in patients with gout from the Cardiovascular Safety of Febuxostat or Allopurinol in Patients With Gout and Cardiovascular Comorbidities (CARES) trial." | 9.51 | Evaluation of the Relationship Between Serum Urate Levels, Clinical Manifestations of Gout, and Death From Cardiovascular Causes in Patients Receiving Febuxostat or Allopurinol in an Outcomes Trial. ( Becker, MA; Borer, JS; Castillo, M; Gorelick, PB; Gunawardhana, L; Hunt, B; Saag, KG; Whelton, A; White, WB, 2022) |
| "The sodium-glucose cotransporter-2 inhibitor empagliflozin decreases the risk of cardiovascular death or hospitalization for heart failure (HF) in patients with HF with reduced ejection fraction." | 9.51 | Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial. ( Anker, SD; Brueckmann, M; Butler, J; Doehner, W; Ferreira, JP; Filippatos, G; Januzzi, JL; Kaempfer, C; Packer, M; Pocock, SJ; Salsali, A; Zannad, F, 2022) |
| "The predominant mechanism driving hyperuricemia in gout is renal uric acid underexcretion; however, the standard urate-lowering therapy (ULT) recommendation is first-line xanthine oxidase inhibitor (XOI), irrespective of the cause of hyperuricemia." | 9.51 | Superiority of Low-Dose Benzbromarone to Low-Dose Febuxostat in a Prospective, Randomized Comparative Effectiveness Trial in Gout Patients With Renal Uric Acid Underexcretion. ( Chen, Y; Cheng, X; Cui, L; Dalbeth, N; He, Y; Hu, S; Ji, A; Li, C; Li, H; Liu, Z; Lu, J; Ma, L; Qi, H; Ran, Z; Sun, M; Terkeltaub, R; Wang, C; Xue, X; Yan, F; Yu, Q; Yuan, X, 2022) |
| "We aimed to assess the differences in the gut microbiome among participants with different uric acid levels (hyperuricemia [HUA] patients, low serum uric acid [LSU] patients, and controls with normal levels) and to develop a model to predict HUA based on microbial biomarkers." | 9.51 | Diagnostic model for predicting hyperuricemia based on alterations of the gut microbiome in individuals with different serum uric acid levels. ( Bai, B; Chen, W; Cui, Y; He, Y; Kahaer, M; Li, R; Liang, M; Liu, J; Liu, Y; Ma, Y; Sun, Y; Tian, T; Xiong, W; Yang, S; Zhang, B, 2022) |
| "The present study compared the efficacy and safety of low-dose febuxostat versus allopurinol in chronic kidney disease (CKD) patients complicated with hyperuricemia (HUA)." | 9.51 | Low-dose febuxostat exhibits a superior renal-protective effect and non-inferior safety profile compared to allopurinol in chronic kidney disease patients complicated with hyperuricemia: A double-centre, randomized, controlled study. ( Cao, B; Yang, N, 2022) |
| "Febuxostat is potentially more effective than allopurinol for treating patients with chronic HF and hyperuricemia." | 9.41 | Comparison between febuxostat and allopurinol uric acid-lowering therapy in patients with chronic heart failure and hyperuricemia: a multicenter randomized controlled trial. ( Ishibashi, T; Kobayashi, A; Konno, I; Kunii, H; Machii, H; Miyamoto, T; Nakazato, K; Niizeki, T; Nozaki, N; Suzuki, S; Takeishi, Y; Tsuda, A; Tsuda, T; Yamaguchi, O; Yamaki, T; Yokokawa, T; Yoshihisa, A, 2021) |
| "Relevant clinical studies up to January 28, 2023 were identified and retrieved from electronic databases including PubMed, Scopus, EMBASE and Web of Science, with periodontitis, uric acid, hyperuricemia and gout as the keywords." | 9.41 | Association between periodontitis and uric acid levels in blood and oral fluids: a systematic review and meta-analysis. ( Mei, ZS; Ye, LW; Yu, T; Zhao, L; Zhou, YH, 2023) |
| "A direct relationship between serum uric acid levels and hypertension, cardiovascular, renal and metabolic diseases has been reported in many basic and epidemiological studies." | 9.41 | Update in uric acid, hypertension, and cardiovascular diseases. ( Ae, R; Andres-Hernando, A; Borghi, C; Hisatome, I; Kanbay, M; Kodama, T; Kuwabara, M; Lanaspa, MA, 2023) |
| "The relationship between Serum Uric Acid (UA) and Cardiovascular (CV) diseases has already been extensively evaluated, and it was found to be an independent predictor of all-cause and cardiovascular mortality but also acute coronary syndrome, stroke and heart failure." | 9.41 | The Results of the URRAH (Uric Acid Right for Heart Health) Project: A Focus on Hyperuricemia in Relation to Cardiovascular and Kidney Disease and its Role in Metabolic Dysregulation. ( Agabiti Rosei, E; Angeli, F; Barbagallo, CM; Bernardino, B; Bombelli, M; Borghi, C; Cappelli, F; Casiglia, E; Cianci, R; Ciccarelli, M; Cicero, AFG; Cirillo, M; Cirillo, P; D'Elia, L; Dell'Oro, R; Desideri, G; Facchetti, R; Ferri, C; Galletti, F; Gesualdo, L; Giannattasio, C; Grassi, G; Iaccarino, G; Lippa, L; Mallamaci, F; Maloberti, A; Masi, S; Masulli, M; Mazza, A; Mengozzi, A; Muiesan, ML; Nazzaro, P; Palatini, P; Parati, G; Pauletto, P; Pontremoli, R; Pugliese, NR; Quarti-Trevano, F; Rattazzi, M; Reboldi, G; Rivasi, G; Russo, E; Salvetti, M; Tikhonoff, V; Tocci, G; Ungar, A; Verdecchia, P; Viazzi, F; Virdis, A; Volpe, M, 2023) |
| "Thirty-nine subjects with persistent hyperuricemia were randomized to receive curcumin (500-mg capsules twice daily, 20 subjects) or placebo (19 subjects)." | 9.41 | Effect of Curcumin on Serum Urate in Asymptomatic Hyperuricemia: A Randomized Placebo-Controlled Trial. ( Asavatanabodee, P; Bupparenoo, P; Chaiamnuay, S; Narongroeknawin, P; Pakchotanon, R, 2021) |
| "Elevated serum uric acid is a cardiovascular risk factor in patients with hypertension, even when blood pressure (BP) is well controlled." | 9.41 | Comparative effects of topiroxostat and febuxostat on arterial properties in hypertensive patients with hyperuricemia. ( Abe, Y; Fukumoto, Y; Hisatome, I; Hongou, M; Hoshide, S; Kario, K; Kasai, T; Kiuchi, M; Kiyosue, A; Kuga, H; Kuramochi, J; Miyazaki, S; Nishizawa, M; Ohtani, H; Tomita, F; Yasu, T, 2021) |
| "Febuxostat had stronger renoprotective and antioxidant effects than topiroxostat in patients with hyperuricemia and CKD." | 9.34 | Changeover Trial of Febuxostat and Topiroxostat for Hyperuricemia with Cardiovascular Disease: Sub-Analysis for Chronic Kidney Disease (TROFEO CKD Trial). ( Osaka, S; Sekino, H; Sezai, A; Tanaka, M; Taoka, M; Unosawa, S, 2020) |
| " We evaluated the efficacy and safety of dotinurad versus febuxostat, a widely used drug in Japan, in hyperuricemic Japanese patients with or without gout." | 9.34 | A non-inferiority study of the novel selective urate reabsorption inhibitor dotinurad versus febuxostat in hyperuricemic patients with or without gout. ( Furuno, K; Hosoya, T; Kanda, S, 2020) |
| "Dotinurad 2 mg was verified to have a non-inferior serum uric acid lowering effect compared with benzbromarone 50 mg, in Japanese hyperuricemic patients with or without gout." | 9.34 | Dotinurad versus benzbromarone in Japanese hyperuricemic patient with or without gout: a randomized, double-blind, parallel-group, phase 3 study. ( Fushimi, M; Hosoya, T; Ohashi, T; Sano, T; Sasaki, T, 2020) |
| "In Japanese patients with asymptomatic hyperuricemia, 24 months of febuxostat treatment did not delay carotid atherosclerosis progression, compared with non-pharmacological care." | 9.34 | Febuxostat does not delay progression of carotid atherosclerosis in patients with asymptomatic hyperuricemia: A randomized, controlled trial. ( Eguchi, K; Higashi, Y; Ishibashi, R; Ishizaka, N; Ishizu, T; Kanzaki, Y; Kario, K; Kato, T; Maemura, K; Murohara, T; Node, K; Ohishi, M; Oyama, JI; Sata, M; Sezai, A; Taguchi, I; Tanaka, A; Teragawa, H; Tomiyama, H; Toyoda, S; Ueda, S; Yamada, H; Yokote, K, 2020) |
| "Uric acid is generated with reactive oxygen species via xanthine oxidase (XO), and hyperuricemia, which is identified as the excess of uric acid in the blood, has been associated with vascular endothelial dysfunction." | 9.34 | Randomized, Open-Label, Cross-Over Comparison of the Effects of Benzbromarone and Febuxostat on Endothelial Function in Patients with Hyperuricemia. ( Doi, Y; Fukae, S; Ikeda, S; Kawano, H; Koga, S; Maemura, K; Minami, T; Nakata, T; Tsuneto, A; Yonekura, T, 2020) |
| " A total of 65 patients with hyperuricemia and diabetic nephropathy with microalbuminuria were enrolled and assigned to either the topiroxostat group or the placebo group." | 9.27 | Uric acid-lowering and renoprotective effects of topiroxostat, a selective xanthine oxidoreductase inhibitor, in patients with diabetic nephropathy and hyperuricemia: a randomized, double-blind, placebo-controlled, parallel-group study (UPWARD study). ( Honda, D; Hosoya, T; Kimura, K; Narita, K; Okui, D; Sakamoto, R; Sasaki, T; Wada, T, 2018) |
| " In the benzbromarone group, kidney stones in one case increased in quantity." | 9.27 | Safety and Efficacy of Benzbromarone and Febuxostat in Hyperuricemia Patients with Chronic Kidney Disease: A Prospective Pilot Study. ( Bao, H; Cheng, J; Liu, X; Peng, A; Qin, L; Song, Y; Wang, L; Yu, H; Zhou, X, 2018) |
| "Japanese male subjects aged 21-65 years with gout (n = 37) or asymptomatic hyperuricaemia (n = 35) and serum urate (sUA) ⩾8 mg/dl were randomized to febuxostat (10, 20, 40 mg) in combination with verinurad (2." | 9.27 | Verinurad combined with febuxostat in Japanese adults with gout or asymptomatic hyperuricaemia: a phase 2a, open-label study. ( Gillen, M; Hall, J; Ito, Y; Liu, S; Shen, Z; Shiramoto, M; Yamamoto, A; Yan, X, 2018) |
| "The aim of this research work was to observe and analyze the efficacy of febuxostat and allopurinol in the treatment of gout with hyperuricemia." | 9.27 | The efficacy of febuxostat and allopurinol in the treatment of gout with hyperuricemia. ( Wang, S, 2018) |
| "This multicenter, open-label study evaluated the efficacy and safety of long-term twice-daily oral topiroxostat administration in patients with or without gout." | 9.27 | Multicenter, Open-Label Study of Long-Term Topiroxostat (FYX-051) Administration in Japanese Hyperuricemic Patients with or Without Gout. ( Hosoya, T; Ishikawa, T; Ogawa, Y; Ohashi, T; Sakamoto, R, 2018) |
| "We previously reported that febuxostat was more effective for hyperuricemia than allopurinol." | 9.24 | Cross-Over Trial of Febuxostat and Topiroxostat for Hyperuricemia With Cardiovascular Disease (TROFEO Trial). ( Abe, K; Kanno, S; Obata, K; Sekino, H; Sezai, A, 2017) |
| "Previous studies have discussed the relationship between simple renal cysts (SRC) and serum uric acid level in healthy individuals." | 9.24 | Hyperuricemia and overexcretion of uric acid increase the risk of simple renal cysts in type 2 diabetes. ( Bao, Y; Chen, H; Han, J; Han, Y; Jia, W; Lu, J; Zhang, L; Zhang, M; Zhao, F, 2017) |
| "There is little evidence guiding selection of nondiuretic, antihypertensive agents with a goal of lowering uric acid (SUA) and minimizing gout risk." | 9.24 | Metoprolol Increases Uric Acid and Risk of Gout in African Americans With Chronic Kidney Disease Attributed to Hypertension. ( Appel, LJ; Juraschek, SP; Miller, ER, 2017) |
| "In this double-blind, placebo-controlled study, 314 subjects with hyperuricemia (serum uric acid [UA] level of ≥7." | 9.24 | Effects of Febuxostat in Early Gout: A Randomized, Double-Blind, Placebo-Controlled Study. ( Choi, HK; Dalbeth, N; Gunawardhana, L; Hunt, B; MacDonald, PA; Palmer, WE; Saag, KG; Thienel, U, 2017) |
| "Hyperuricemia is associated with hypertension, with elevated serum uric acid levels postulated to have a causal role in the development of hypertension." | 9.24 | Effect of Febuxostat on Ambulatory Blood Pressure in Subjects With Hyperuricemia and Hypertension: A Phase 2 Randomized Placebo-Controlled Study. ( Feig, DI; Gunawardhana, L; Hunt, B; McLean, L; Palmer, RN; Punzi, HA; Whelton, A, 2017) |
| "Since uric acid is associated with cardiovascular and renal disease, a treatment to maintain blood uric acid level may be required in patients with hyperuricemia." | 9.24 | Rationale, design, and baseline characteristics of a study to evaluate the effect of febuxostat in preventing cerebral, cardiovascular, and renal events in patients with hyperuricemia. ( Hayashi, T; Hiramitsu, S; Hisatome, I; Jinnouchi, H; Kakuda, H; Kawai, N; Kimura, K; Kojima, S; Matsui, K; Mori, H; Ogawa, H; Ohya, Y; Saito, Y; Sugawara, M; Tokutake, E; Uchiyama, K; Wakasa, Y; Waki, M; Yokota, N, 2017) |
| "Our objectives were to determine whether a change in serum uric acid (sUA) resulted in a corresponding change in the fractional excretion of uric acid (FEUA) and whether the renal response was different in patients with gout versus healthy subjects." | 9.24 | Patients with gout differ from healthy subjects in renal response to changes in serum uric acid. ( Liu, S; Miner, JN; Perez-Ruiz, F, 2017) |
| "Uric acid (UA) has been associated with hypertension, renal disease and cardiovascular disease." | 9.24 | Effective uric acid-lowering treatment for hypertensive patients with hyperuricemia. ( Arima, H; Hayashi, S; Ishizuka, A; Iwashima, Y; Kawano, Y; Kishida, M; Nakamura, S; Ohta, Y; Yoshihara, F, 2017) |
| "Topiroxostat, a selective xanthine oxidoreductase inhibitor, is used in Japan for the treatment of hyperuricemic patients with or without gout." | 9.24 | Clinical efficacy and safety of topiroxostat in Japanese hyperuricemic patients with or without gout: a randomized, double-blinded, controlled phase 2b study. ( Hosoya, T; Ohashi, T; Sasaki, T, 2017) |
| "Increased serum uric acid (SUA) levels are commonly seen in patients with metabolic syndrome and are widely accepted as risk factors for hypertension, gout, non-alcoholic fatty liver disease, chronic kidney disease (CKD), and cardiovascular diseases." | 9.22 | Uric acid in metabolic syndrome: Does uric acid have a definitive role? ( Copur, S; Demiray, A; Kanbay, M, 2022) |
| "Uric acid is the final product of purine metabolism, and its increased serum levels have been directly involved in the pathogenesis and natural history of hypertension." | 9.22 | Uric Acid and Hypertension: a Review of Evidence and Future Perspectives for the Management of Cardiovascular Risk. ( Agnoletti, D; Borghi, C; Cicero, AFG; Lurbe, E; Virdis, A, 2022) |
| "Uric acid (UA) is the final product of purine metabolism in the human body, and impaired purine metabolism can increase the uric acid in serum, finally resulting in hyperuricemia (HUA)." | 9.22 | Excess Uric Acid Induces Gouty Nephropathy Through Crystal Formation: A Review of Recent Insights. ( Dong, B; Geng, Z; Mei, Y; Xu, L, 2022) |
| "This phase IIIB study compared the efficacy and safety of febuxostat and allopurinol in gout patients with or without tophi who were HLA-B*5801 negative." | 9.22 | Safety and efficacy of oral febuxostat for treatment of HLA-B*5801-negative gout: a randomized, open-label, multicentre, allopurinol-controlled study. ( Chen, CJ; Chen, DY; Hsu, PN; Lai, JH; Lin, HY; Yu, KH, 2016) |
| "The aim of this study was to compare the effect of high fruit and soybean products diet and standard diet interventions on serum uric acid (SUA) in asymptomatic hyperuricemia adults." | 9.22 | Comparison of the effect of high fruit and soybean products diet and standard diet interventions on serum uric acid in asymptomatic hyperuricemia adults: an open randomized controlled trial. ( Gao, Y; Huang, G; Liu, W; Wang, X; Zhang, M; Zhang, Y, 2016) |
| "Control of serum uric acid (sUA) levels is very important during chemotherapy in patients with malignant tumors, as the risks of tumor lysis syndrome (TLS) and renal events are increased with increasing levels of sUA." | 9.22 | Efficacy and safety of febuxostat for prevention of tumor lysis syndrome in patients with malignant tumors receiving chemotherapy: a phase III, randomized, multi-center trial comparing febuxostat and allopurinol. ( Fujimaki, K; Fujisaki, T; Gemba, K; Goto, T; Kaneko, M; Kawai, Y; Kiguchi, T; Kirito, K; Maemondo, M; Nakajima, A; Okamoto, M; Takeda, K; Tamura, K; Ueda, T, 2016) |
| "In Japan, although topiroxostat, a selective xanthine oxidoreductase inhibitor, has been used for the treatment of patients with hyperuricemia including gout, no published randomized controlled studies evaluating the dose-dependent relationship with respect to the serum urate-lowering efficacy have been reported." | 9.22 | Clinical efficacy and safety of topiroxostat in Japanese male hyperuricemic patients with or without gout: an exploratory, phase 2a, multicentre, randomized, double-blind, placebo-controlled study. ( Hashimoto, H; Hosoya, T; Ohashi, T; Sakamoto, R; Sasaki, T, 2016) |
| " Patients who had inadequate serum urate levels (a gout patient: serum urate level ≥416·4 μmol/L; an asymptomatic hyperuricemic patient with specific complications (urinary lithiasis, hypertension, hyperlipidemia and/or diabetes): serum urate level ≥475·8 μmol/L; and an asymptomatic hyperuricemic patient with no specific complications: serum urate level ≥535·3 μmol/L) were randomized to topiroxostat 120 mg/day or allopurinol 200 mg/day, with an equal allocation ratio, for 16 weeks." | 9.22 | Comparison of topiroxostat and allopurinol in Japanese hyperuricemic patients with or without gout: a phase 3, multicentre, randomized, double-blind, double-dummy, active-controlled, parallel-group study. ( Hashimoto, H; Hosoya, T; Ogawa, Y; Ohashi, T; Sakamoto, R, 2016) |
| "Elevated serum uric acid (UA), a biomarker of renal insufficiency, is also an independent prognostic marker for morbidity in coronary artery disease (CAD) and poses serious health risks." | 9.22 | Almond supplementation reduces serum uric acid in coronary artery disease patients: a randomized controlled trial. ( Amin, F; Arslan, J; Ghani, S; Gilani, AU; Jamshed, H; Masroor, M; Sultan, FA, 2016) |
| "The association between serum uric acid (UA) levels and atrial fibrillation (AF) in the general population in Japan is not well known." | 9.22 | Uric Acid Level and Prevalence of Atrial Fibrillation in a Japanese General Population of 285,882. ( Kawasoe, S; Kubozono, T; Maenohara, S; Miyahara, H; Miyata, M; Ohishi, M; Ojima, S; Oketani, N; Yoshifuku, S, 2016) |
| "We assume that decreasing uric acid levels with allopurinol treatment seems to be helpful in restoring endothelial functions, preventing metabolic acidosis and slowing down the progression of CKD." | 9.20 | The effects of allopurinol on metabolic acidosis and endothelial functions in chronic kidney disease patients. ( Altuntaş, A; Bayram, D; İnal, S; Kıdır, V; Orhan, H; Tuğrul Sezer, M, 2015) |
| "The NU-FLASH trial demonstrated that febuxostat was more effective for hyperuricemia than allopurinol." | 9.20 | Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery patients with chronic kidney disease (NU-FLASH trial for CKD). ( Hata, H; Ishii, Y; Nakata, K; Osaka, S; Sezai, A; Shiono, M; Soma, M; Yaoita, H, 2015) |
| "We assessed the efficacy and adverse effects of febuxostat in male hyperuricemia patients." | 9.20 | Effects of febuxostat on serum urate level in Japanese hyperuricemia patients. ( Fujimori, S; Hidaka, Y; Higami, K; Hosoya, T; Inaba, M; Ishimura, E; Kakuda, H; Mineo, I; Moriwaki, Y; Nishikawa, H; Ohtawara, A; Ooyama, H; Taniguchi, A; Ueda, T; Yamamoto, T; Yamanaka, H; Yamauchi, T, 2015) |
| "To compare the efficiency and safety of febuxostat with those of allopurinol in Chinese patients with gout and hyperuricemia." | 9.20 | A phase 3, multicenter, randomized, allopurinol-controlled study assessing the safety and efficacy of oral febuxostat in Chinese gout patients with hyperuricemia. ( Chen, S; Ji, H; Ji, Q; Lin, J; Liu, B; Liu, H; Liu, P; Liu, X; Lu, Y; Ming, J; Peng, Y; Wang, J; Wang, Y; Xu, S; Zhang, Y, 2015) |
| "The aim of this study was to investigate the long-term effective control of serum uric acid by allopurinol on the carotid intima-media thickness (IMT) in patients with type 2 diabetes (T2DM) and asymptomatic hyperuricemia (HUA)." | 9.20 | The Effects of Allopurinol on the Carotid Intima-media Thickness in Patients with Type 2 Diabetes and Asymptomatic Hyperuricemia: A Three-year Randomized Parallel-controlled Study. ( Chen, Y; Liu, P; Wang, D; Wang, H; Wang, Y; Zhang, F, 2015) |
| "Allopurinol lowers uric acid and improves insulin resistance and systemic inflammation in asymptomatic hyperuricemia." | 9.20 | Lowering Uric Acid With Allopurinol Improves Insulin Resistance and Systemic Inflammation in Asymptomatic Hyperuricemia. ( Afsar, B; ALanaspa, M; Bakan, A; Elcioglu, OC; Erek, A; Johnson, RJ; Kanbay, M; Kostek, O; Mutlu, HH; Odabas, AR; Ozkok, A; Semerci, A; Sharma, S; Smits, G; Takir, M; Telci, O, 2015) |
| "The FEATHER (FEbuxostat versus placebo rAndomized controlled Trial regarding reduced renal function in patients with Hyperuricemia complicated by chRonic kidney disease stage 3) study is a prospective, multicenter, double-blind, randomized, placebo-controlled trial of febuxostat-a novel, nonpurine, selective, xanthine oxidase inhibitor." | 9.19 | The effect of febuxostat to prevent a further reduction in renal function of patients with hyperuricemia who have never had gout and are complicated by chronic kidney disease stage 3: study protocol for a multicenter randomized controlled study. ( Hayakawa, H; Hosoya, T; Iimuro, S; Imai, N; Inaba, M; Itoh, S; Kimura, K; Kuwabara, M; Makino, H; Matsuo, S; Ohno, I; Shibagaki, Y; Tomino, Y; Uchida, S; Yamamoto, T, 2014) |
| "Topiroxostat, a selective xanthine oxidase inhibitor, shows effective reduction in the serum urate level in hyperuricemic patients with or without gout." | 9.19 | Effects of topiroxostat on the serum urate levels and urinary albumin excretion in hyperuricemic stage 3 chronic kidney disease patients with or without gout. ( Fujimori, S; Hara, S; Hisatome, I; Hosoya, T; Nomura, S; Ohno, I; Uchida, S; Yamamoto, T, 2014) |
| "Gout patients (n = 512) with serum uric acid (sUA) concentrations of at least 8." | 9.19 | An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia. ( Bao, C; Du, H; Gu, J; Huang, A; Huang, X; Jiang, L; Li, J; Li, X; Li, Z; Liu, Y; Zhang, Y; Zhang, Z; Zhao, D; Zhu, P; Zuo, X, 2014) |
| "We evaluated the association between baseline uric acid and the primary composite outcome of doubling of interstitium or ESRD from interstitial fibrosis and tubular atrophy (IF/TA) in the Angiotensin II Blockade for Chronic Allograft Nephropathy (ABCAN) Trial participants." | 9.19 | Uric acid and allograft loss from interstitial fibrosis/tubular atrophy: post hoc analysis from the angiotensin II blockade in chronic allograft nephropathy trial. ( Hart, A; Ibrahim, HN; Jackson, S; Kasiske, BL; Matas, AJ; Mauer, MS; Najafian, B; Spong, R, 2014) |
| "The aim of this study was to evaluate the pharmacodynamics (PDs), pharmacokinetics (PKs) and safety of lesinurad (selective uric acid reabsorption inhibitor) in combination with febuxostat (xanthine oxidase inhibitor) in patients with gout." | 9.19 | Pharmacodynamic, pharmacokinetic and tolerability evaluation of concomitant administration of lesinurad and febuxostat in gout patients with hyperuricaemia. ( Baumgartner, S; Fleischmann, R; Hingorani, V; Kerr, B; Manhard, K; Miner, JN; Polvent, E; Quart, B; Shen, Z; Suster, M; Yeh, LT, 2014) |
| "The aims of this study were to establish whether, in patients with gout, MPO is released from neutrophils and urate is oxidized to allantoin and if these effects are attenuated by allopurinol." | 9.19 | Myeloperoxidase and oxidation of uric acid in gout: implications for the clinical consequences of hyperuricaemia. ( Drake, J; Forbes, LV; Kettle, AJ; Khalilova, IS; Stamp, LK; Turner, R; Zhang, M, 2014) |
| "To evaluate the efficacy and safety of IL-1 inhibitor rilonacept (IL-1 Trap) for gout flare (GF) prevention during initiation of uric acid-lowering therapy (ULT) with allopurinol in a multiregional phase 3 clinical trial." | 9.17 | Rilonacept for gout flare prevention during initiation of uric acid-lowering therapy: results from the PRESURGE-2 international, phase 3, randomized, placebo-controlled trial. ( Evans, RR; Fouche, L; King-Davis, S; Luo, SF; Mitha, E; Schumacher, HR; Wang, J; Weinstein, SP; Yancopoulos, GD, 2013) |
| "Febuxostat has been reported to have a stronger effect on hyperuricemia than allopurinol." | 9.17 | Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery patients (NU-FLASH Trial). ( Hata, H; Hata, M; Nakata, K; Sezai, A; Shiono, M; Soma, M; Wakui, S; Yoshitake, I, 2013) |
| "Assess the impact of urate-lowering therapy on renal function in subjects with gout who were treated with febuxostat for ≤ 48 months." | 9.17 | Preservation of renal function during gout treatment with febuxostat: a quantitative study. ( Chefo, S; Gunawardhana, L; MacDonald, PA; Whelton, A, 2013) |
| "Thirty-four symptomatic CHF participants with hyperuricemia (≥ 565 μmol/L) were randomized to receive prednisone (1 mg/kg/d, orally) or allopurinol (100 mg, thrice daily, orally) for 4 weeks." | 9.17 | Prednisone in Uric Acid lowering in Symptomatic Heart Failure Patients With Hyperuricemia (PUSH-PATH) study. ( Gao, Y; Ji, L; Ji, Z; Liu, C; Liu, G; Liu, K; Tian, L; Wang, L; Zhao, Q; Zhen, Y, 2013) |
| "To compare the characteristics of female versus male gout patients and assess urate-lowering efficacy and safety of febuxostat or allopurinol treatment in women with gout." | 9.16 | Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol. ( Becker, MA; Chefo, S; Chohan, S; Jackson, RL; MacDonald, PA, 2012) |
| "0 mg/dL) gout subjects were enrolled in the 6-month, double-blind, randomized, comparative CONFIRMS trial and randomized, 1:1:1, to receive febuxostat, 40 mg or 80 mg, or allopurinol (200 mg or 300 mg based on renal function) once daily." | 9.16 | The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age. ( Hunt, B; Jackson, RL; MacDonald, PA, 2012) |
| "Epidemiological, experimental and clinical studies support a role for uric acid in acute kidney injury (AKI)." | 9.16 | Lowering serum uric acid to prevent acute kidney injury. ( Arif, AA; Dass, B; Dhatt, GS; Ejaz, AA; Ejaz, NI; Faldu, C; Johnson, RJ; Kambhampati, G; Lanaspa, MA; Maroz, N; Shah, G, 2012) |
| "To determine the efficacy and safety of increasing the allopurinol dose above the proposed creatinine clearance-based dose in patients with gout." | 9.15 | Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment. ( Barclay, ML; Chapman, PT; Frampton, C; James, J; O'Donnell, JL; Stamp, LK; Zhang, M, 2011) |
| "To evaluate the independent impact of congestive heart failure (CHF) status (compensation or decompensation) on serum uric acid levels among men with high cardiovascular risk profile." | 9.15 | The independent impact of congestive heart failure status and diuretic use on serum uric acid among men with a high cardiovascular risk profile: a prospective longitudinal study. ( Choi, HK; Misra, D; Zhang, Y; Zhu, Y, 2011) |
| "Febuxostat or allopurinol was administered to patients with hyperuricemia including gout for 8 weeks to compare the efficacy and safety of these drugs." | 9.15 | An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: p ( Fujimori, S; Hada, T; Hosoya, T; Kamatani, N; Kohri, K; Matsuzawa, Y; Nakamura, T; Ueda, T; Yamamoto, T; Yamanaka, H, 2011) |
| "A multicenter study with randomized, placebo-controlled, double-blind, parallel, intergroup comparison was carried out to evaluate the dose-response relationship, efficacy, and safety of febuxostat in 202 patients with hyperuricemia (including patients with gout) in Japan." | 9.15 | Placebo-controlled double-blind dose-response study of the non-purine-selective xanthine oxidase inhibitor febuxostat (TMX-67) in patients with hyperuricemia (including gout patients) in japan: late phase 2 clinical study. ( Fujimori, S; Hada, T; Hisashi, Y; Hosoya, T; Kamatani, N; Kenjiro, K; Kohri, K; Matsuzawa, Y; Nakamura, T; Naoyuki, K; Shin, F; Takanori, U; Tatsuo, H; Tetsuya, Y; Toshikazu, H; Toshitaka, N; Ueda, T; Yamamoto, T; Yamanaka, H; Yuji, M, 2011) |
| "Febuxostat was administered to patients with hyperuricemia including gout in Japan to compare its efficacy and safety with those of allopurinol." | 9.15 | An allopurinol-controlled, multicenter, randomized, open-label, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phas ( Fujimori, S; Hada, T; Hisashi, Y; Hosoya, T; Kamatani, N; Kenjiro, K; Kohri, K; Matsuzawa, Y; Nakamura, T; Naoyuki, K; Shin, F; Takanori, U; Tatsuo, H; Tetsuya, Y; Toshikazu, H; Toshitaka, N; Ueda, T; Yamamoto, T; Yamanaka, H; Yuji, M, 2011) |
| "In previous clinical studies of hyperuricemia including gout, although serum uric acid (sUA) levels reduced to 6." | 9.15 | Multicenter, open-label study of long-term administration of febuxostat (TMX-67) in Japanese patients with hyperuricemia including gout. ( Fujimori, S; Hada, T; Hosoya, T; Kamatani, N; Kohri, K; Matsuzawa, Y; Nakamura, T; Ueda, T; Yamamoto, T; Yamanaka, H, 2011) |
| "Losartan may be an effective agent for treatment of hyperuricemia and PTE in Han Chinese patients after kidney transplantation." | 9.14 | Efficacy and safety of losartan in treatment of hyperuricemia and posttransplantation erythrocytosis: results of a prospective, open, randomized, case-control study. ( Chen, J; Cheng, M; Ding, X; Han, F; Le, Y; Xu, L; Zhang, L; Zhu, X, 2009) |
| " The treatment effect of the uricosuric agent benzbromarone was tested in 14 patients with CHF with hyperuricemia in a double-blind, placebo-controlled, randomized crossover study design." | 9.14 | Uric acid-lowering treatment with benzbromarone in patients with heart failure: a double-blind placebo-controlled crossover preliminary study. ( Anker, SD; Doehner, W; Furuse, Y; Hisatome, I; Igawa, O; Ishida, K; Kato, M; Kinugasa, Y; Kinugawa, T; Ogino, K; Osaki, S; Shigemasa, C, 2010) |
| "The purpose of this study was to compare urate-lowering (UL) efficacy and safety of daily febuxostat and allopurinol in subjects with gout and serum urate (sUA) > or = 8." | 9.14 | The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. ( Becker, MA; Espinoza, LR; Lademacher, C; Lloyd, E; MacDonald, P; Schumacher, HR; Wells, AF, 2010) |
| "Rasburicase is effective in controlling plasma uric acid in pediatric patients with hematologic malignancies." | 9.14 | Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone--results of a multicenter phase III study. ( Abboud, CN; Brown, A; Cortes, J; Craig, M; Dey, BR; Krishnamurthy, M; Laadem, A; Luger, S; Matous, J; Maziarz, RT; Moore, JO; Pham, D; Schiller, GJ; Seiter, K; Wetzler, M, 2010) |
| " Of 2,963 patients with coronary artery disease enrolled in the Bezafibrate Infarction Prevention study, 1,410 had MS, as established by the presence of ≥3 of the following 5 criteria: serum fasting glucose >110 mg/dl, triglycerides >150 mg/dl, high-density lipoprotein cholesterol <40 mg/dl in men and <50 mg/dl in women, systolic and diastolic blood pressures >130 and 80 mm Hg, respectively, and body mass index >28 kg/m²." | 9.14 | Effect of the metabolic syndrome and hyperuricemia on outcome in patients with coronary artery disease (from the Bezafibrate Infarction Prevention Study). ( Behar, S; Boyko, V; Brodov, Y; Chouraqui, P, 2010) |
| "To determine whether lowering uric acid lowers blood pressure (BP) in hyperuricemic adolescents with newly diagnosed hypertension." | 9.13 | Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. ( Feig, DI; Johnson, RJ; Soletsky, B, 2008) |
| "To compare the urate-lowering efficacy and safety of febuxostat, allopurinol, and placebo in a large group of subjects with hyperuricemia and gout, including persons with impaired renal function." | 9.13 | Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. ( Becker, MA; Hunt, B; Joseph-Ridge, N; Lademacher, C; Macdonald, PA; Schumacher, HR; Streit, J; Wortmann, RL, 2008) |
| "To survey the prevalence of hyperuricacidemia and serum uric acid (SUA) changes and electrolyte changes after 6 weeks antihypertensive treatment with thiazide diuretics, losartan or losartan+hydrochlorothiazide (Hyzaar) in patients with essential hypertension (EH)." | 9.13 | [Serum uric acid prevalence and changes post various antihypertensive agents in patients with essential hypertension]. ( Chen, H; Gui, W; Lu, LH; Wu, XY; Yang, LQ; Yu, L, 2008) |
| "To evaluate the major cardiovascular (CV) events of febuxostat compared to allopurinol for the treatment of gout or asymptomatic hyperuricemia." | 9.12 | The major cardiovascular events of febuxostat versus allopurinol in treating gout or asymptomatic hyperuricemia: a systematic review and meta-analysis. ( Li, H; Sun, J; Wang, M; Wen, C; Xie, Z; Zhang, M; Zhang, Y; Zhao, T, 2021) |
| " Elevated uric acid levels are risk factors for gout, hypertension, and chronic kidney diseases." | 9.12 | Uric Acid in Inflammation and the Pathogenesis of Atherosclerosis. ( Kimura, Y; Kono, H; Tsukui, D, 2021) |
| "This network meta-analysis aimed to assess the current efficacy of decreasing the uric acid (UA) level with drugs to reduce mortality in patients with heart failure (HF)." | 9.12 | Network Meta-Analysis of Drug Therapies for Lowering Uric Acid and Mortality Risk in Patients with Heart Failure. ( Fujihara, K; Horikawa, C; Kitazawa, M; Kodama, S; Matsubayashi, Y; Sato, T; Sone, H; Watanabe, K; Yaguchi, Y; Yamada, M; Yamada, T; Yamamoto, M, 2021) |
| "The description of gout dates back almost 5000 years, and scientific interest in uric acid increased when it was found to be involved in the pathogenesis of gout." | 9.12 | The Impact of Uric Acid and Hyperuricemia on Cardiovascular and Renal Systems. ( Agnoletti, D; Borghi, C; Cicero, AFG, 2021) |
| "Increasing evidence supports the hypothesis that high serum uric acid (SUA) levels are related to atrial fibrillation (AF)." | 9.12 | Relationship between serum uric acid levels and different types of atrial fibrillation: An updated meta-analysis. ( Hou, Y; Li, H; Li, Z; Ren, M; Shang, L; Wang, X; Zhang, Y; Zhou, J, 2021) |
| "This meta-analysis aimed to investigate whether uric acid lowering treatment can improve β-cell function and insulin sensitivity." | 9.12 | Uric acid lowering improves insulin sensitivity and lowers blood pressure: a meta-analysis of randomized parallel-controlled clinical trials. ( Ma, G; Wang, T; Zong, Q, 2021) |
| "It is still undefined whether serum uric acid (SUA) is an independent risk factor for target organ damage (TOD) and cardiovascular events in human hypertension." | 9.12 | Lack of association between serum uric acid and organ damage in a never-treated essential hypertensive population at low prevalence of hyperuricemia. ( Cuspidi, C; Esposito, A; Mancia, G; Meani, S; Sala, C; Valerio, C; Zanchetti, A, 2007) |
| "To observe the clinical effect of Rebixiao granule (RBXG) in treating repeatedly attacking acute gouty arthritis and through experimental study on blood uric acid to explore RBXG's therapeutic mechanism." | 9.11 | Effects of Rebixiao granules on blood uric acid in patients with repeatedly attacking acute gouty arthritis. ( Ji, W; Lu, Y; Tan, WF; Zhu, XX, 2005) |
| "Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase, is a potential alternative to allopurinol for patients with hyperuricemia and gout." | 9.11 | Febuxostat compared with allopurinol in patients with hyperuricemia and gout. ( Becker, MA; Eustace, D; Joseph-Ridge, N; MacDonald, PA; Palo, WA; Schumacher, HR; Streit, J; Wortmann, RL, 2005) |
| "To assess the short-term urate-lowering effect of fenofibrate in men on long-term allopurinol therapy for hyperuricaemia and gout." | 9.10 | Fenofibrate enhances urate reduction in men treated with allopurinol for hyperuricaemia and gout. ( Ball, SG; Feher, MD; Hepburn, AL; Hogarth, MB; Kaye, SA, 2003) |
| " The pooled analysis found that patients with primary hyperparathyroidism had a significantly higher level of serum uric acid than individuals without hyperparathyroidism with the pooled MD of 65." | 9.05 | Primary hyperparathyroidism is associated with a higher level of serum uric acid: A systematic review and meta-analysis. ( Charoenngam, N; Ponvilawan, B; Ungprasert, P, 2020) |
| " The Mesh Terms considered were: uric acid, antioxidant, oxidant, metabolic syndrome, diabetes, cerebrovascular diseases, stroke, haemorrhagic stroke, neurocognitive disorders, and their combinations." | 9.05 | Uric Acid in Metabolic and Cerebrovascular Disorders: A Review. ( Andriani, A; Calculli, G; Ciccone, MM; Cortese, AM; Cortese, F; Giordano, P; Meliota, G; Scicchitano, P; Truncellito, L, 2020) |
| "Among kidney transplant patients, treating hyperuricemia with febuxostat showed a higher odds of reaching the target of serum uric acid < 6 mg/dL compared with allopurinol without causing significant side effects including change in tacrolimus level, liver function, decline in renal graft function, and bone marrow function." | 9.05 | Efficacy and safety of febuxostat for treatment of asymptomatic hyperuricemia among kidney transplant patients: A meta-analysis of observational studies. ( Bathini, T; Chang, YT; Cheungpasitporn, W; Chewcharat, A; Crisafio, A; Mao, MA; Thongprayoon, C, 2020) |
| "This study aimed to investigate the association of serum uric acid (SUA) levels with dyslipidemia and its components and to further explore the age- and gender-specific association of SUA levels with dyslipidemia in Chinese adults." | 9.05 | Association between serum uric acid levels and dyslipidemia in Chinese adults: A cross-sectional study and further meta-analysis. ( Chen, S; Chen, Y; Miao, M; Wang, J; Xu, C; Xu, L; Yang, H, 2020) |
| "Current research has proved that psoriasis is associated with serum uric acid (SUAC) levels." | 9.01 | The association of serum uric acid levels in psoriasis patients: A systematic review and network meta-analysis. ( Du, H; Liu, M; Liu, W; Yuan, Y, 2019) |
| "Conflicting results have been reported on the prognostic significance of serum uric acid (SUA) in patients with acute heart failure (AHF)." | 9.01 | Prognostic value of serum uric acid in patients with acute heart failure: A meta-analysis. ( Deng, X; Huang, G; Luo, G; Qin, J; Wang, L; Yu, D; Zhang, M; Zhou, S, 2019) |
| "Studies have demonstrated the presence of a strong association between serum uric acid (SUA) and acute kidney injury (AKI) consistently across several disease models." | 9.01 | The Role of Uric Acid in Acute Kidney Injury. ( Alquadan, KF; Beaver, TM; Dass, B; Ejaz, AA; Johnson, RJ; Lapsia, V; Mohandas, R; Shimada, M, 2019) |
| "This study aimed to examine whether the uric acid level or gout is causally associated with bone mineral density (BMD)." | 9.01 | Uric acid level, gout and bone mineral density: A Mendelian randomization study. ( Lee, YH; Song, GG, 2019) |
| " allopurinol was associated with the improved safety outcome and have comparable mortality and net clinical outcome in patients with hyperuricemia." | 9.01 | The net clinical benefits of febuxostat versus allopurinol in patients with gout or asymptomatic hyperuricemia - A systematic review and meta-analysis. ( Chang, WC; Chen, TC; Hsu, FS; Hwang, JJ; Lee, CC; Liu, CW; Lo, C; Shau, WY; Wang, ML, 2019) |
| " For many years, hyperuricemia was attributed to the effects of insulin resistance to reduce urinary excretion of uric acid, and it was believed that uric acid may not have any causal role in the metabolic syndrome." | 8.98 | Uric Acid as a Cause of the Metabolic Syndrome. ( Jensen, T; Johnson, RJ; King, C; Lanaspa, MA; Sánchez-Lozada, LG; Tolan, DR, 2018) |
| "Xanthine oxidoreductase (XOR) could contribute to the pathogenesis of metabolic syndrome through the oxidative stress and the inflammatory response induced by XOR-derived reactive oxygen species and uric acid." | 8.98 | The role of xanthine oxidoreductase and uric acid in metabolic syndrome. ( Battelli, MG; Bolognesi, A; Bortolotti, M; Polito, L, 2018) |
| "The relationship between serum uric acid (UA) and the risk of intracerebral hemorrhage (ICH) remains controversial." | 8.98 | Serum uric acid concentrations and risk of intracerebral hemorrhage: A systematic review and meta-analysis. ( Liang, Y; Lin, J; Qu, H; Xu, J; Zhang, X; Zhao, C; Zhao, M; Zhou, Z, 2018) |
| "Gout develops in four stages beginning with an asymptomatic increase in blood levels of uric acid." | 8.98 | Crystal arthritides - gout and calcium pyrophosphate arthritis : Part 2: clinical features, diagnosis and differential diagnostics. ( Bertsch, T; Bollheimer, LC; Härle, P; Schlee, S; Sieber, CC, 2018) |
| "Conflicting findings of the association between serum uric acid (UA) and stroke have been reported in both men and women, and it is unclear whether this association was different between men and women." | 8.95 | Sex-Specific Relationship Between Serum Uric Acid and Risk of Stroke: A Dose-Response Meta-Analysis of Prospective Studies. ( Xu, T; Zhang, Y; Zhong, C; Zhong, X, 2017) |
| "The mechanisms of hyperhomocysteinemia (HHcy) and hyperuricemia (HUA) that promote atherosclerosis were seldom explored and always indefinite." | 8.95 | Role of Hyperhomocysteinemia and Hyperuricemia in Pathogenesis of Atherosclerosis. ( Chen, H; Chen, J; Gu, Y; Liu, N; Yang, K; Zhao, J, 2017) |
| "This was a pooled analysis of phase III trials on allopurinol and febuxostat, including 4101 patients with gout and hyperuricemia." | 8.95 | Potency on lowering serum uric acid in gout patients: a pooled analysis of registrative studies comparing febuxostat vs. allopurinol. ( Cimmino, MA; Cutolo, M; Perez-Ruiz, F, 2017) |
| "The aim of this study was to examine the associations of tea consumption with the serum uric acid (SUA) level, hyperuricemia (HU) and the risk of gout." | 8.95 | Is tea consumption associated with the serum uric acid level, hyperuricemia or the risk of gout? A systematic review and meta-analysis. ( Cui, Y; Deng, YH; Huang, YZ; Lei, GH; Li, LJ; Li, XA; Xie, X; Zeng, C; Zhang, Y, 2017) |
| "Recent evidence would indicate that high serum uric acid (SUA) levels can be a significant and independent risk factor for hypertension and cardiovascular diseases, such as ischemic heart disease and heart failure." | 8.93 | Uric acid lowering therapy in cardiovascular diseases. ( Iellamo, F; Romeo, F; Sposato, B; Volterrani, M, 2016) |
| "Uric acid, once viewed as an inert metabolic end-product of purine metabolism, has been recently incriminated in a number of chronic disease states, including hypertension, metabolic syndrome, diabetes, non-alcoholic fatty liver disease, and chronic kidney disease." | 8.93 | Uric acid in metabolic syndrome: From an innocent bystander to a central player. ( Jensen, T; Johnson, RJ; Kanbay, M; Lanaspa, MA; Le, M; Nakagawa, T; Rivard, C; Roncal-Jimenez, C; Solak, Y, 2016) |
| "Several studies were published to assess the association between serum uric acid levels and atrial fibrillation risk, but no consistent results were reported." | 8.93 | Association Between Serum Uric Acid Levels and Atrial Fibrillation Risk. ( Huang, DS; Ma, YJ; Shen, D; Sun, HY; Wang, YM; Zhang, CH; Zhang, LW, 2016) |
| "High levels of serum uric acid (SUAC) are frequently detected in patients with psoriasis." | 8.93 | Association of Serum Uric Acid Levels in Psoriasis: A Systematic Review and Meta-Analysis. ( Cui, R; Li, B; Li, F; Li, X; Miao, X; Wang, H; Wang, Y; Yang, Q, 2016) |
| " It is caused by factors that elevate the concentration of serum uric acid (sUA), leading to hyperuricemia (sUA >6." | 8.93 | Overview of Serum Uric Acid Treatment Targets in Gout: Why Less Than 6 mg/dL? ( Edwards, NL; Ruoff, G, 2016) |
| " Hyperuricemia is a key biochemical feature in preeclampsia with elevated levels of uric acid being diagnosed as early as the 10(th) week of gestation." | 8.91 | The involvement of uric acid in the pathogenesis of preeclampsia. ( Athanasiadis, A; Kourtis, A; Makedou, K; Masoura, S; Theodoridis, T; Zepiridis, L, 2015) |
| "Emerging evidence has shown that serum uric acid (SUA) elevation might cause metabolic derangements, including metabolic syndrome (MetS) and non-alcoholic fatty liver disease (NAFLD); however, magnitude of the risk has not been quantified." | 8.91 | Dose-response Relationship of Serum Uric Acid with Metabolic Syndrome and Non-alcoholic Fatty Liver Disease Incidence: A Meta-analysis of Prospective Studies. ( Liu, Z; Que, S; Zheng, S; Zhou, L, 2015) |
| "We aimed to perform a systematic review and meta-analysis to assess the association between serum uric acid and incident heart failure (HF)/prognosis of HF patients." | 8.90 | Uric acid and risk of heart failure: a systematic review and meta-analysis. ( Chen, J; Huang, B; Huang, H; Huang, Y; Jing, X; Li, J; Li, Y; Wang, J; Yao, H, 2014) |
| "To discuss the evolving data regarding uric acid as a potential cause of hypertension and progressive renal dysfunction and its clinical and research implications." | 8.90 | Serum uric acid and the risk of hypertension and chronic kidney disease. ( Feig, DI, 2014) |
| "The relationship between elevated serum uric acid level and metabolic syndrome (MS) has been debated." | 8.90 | Association of serum uric acid and metabolic syndrome in type 2 diabetes. ( Bonakdaran, S; Kharaqani, B, 2014) |
| "Over the last decade, the biologic interference of uric acid with the cardiovascular (CV) system and the kidney has been intensively investigated, and several experimental studies in animal models and in vitro documented that hyperuricemia may trigger hypertension and incite endothelial dysfunction, vascular damage and renal disease." | 8.89 | Uric acid, hypertension, and cardiovascular and renal complications. ( Mallamaci, F; Zoccali, C, 2013) |
| "To evaluate the safety and efficacy of febuxostat compared to allopurinol for the treatment of chronic gout." | 8.89 | A systematic review and meta-analysis on the safety and efficacy of febuxostat versus allopurinol in chronic gout. ( Ehteshami-Afshar, A; Faruque, LI; Homik, J; Tjosvold, L; Tonelli, M; Wiebe, N, 2013) |
| " Concordantly, recent studies have revived the controversy over the role of circulating uric acid, hyperuricemia, and gout as an independent prognostic factor for cardiovascular morbidity and mortality." | 8.89 | Chronic hyperuricemia, uric acid deposit and cardiovascular risk. ( Cheli, P; Del Pinto, R; Desideri, G; Di Giosia, P; Ferri, C; Ferri, L; Grassi, D; Properzi, G, 2013) |
| "Febuxostat has been approved for the treatment of hyperuricemia in patients with/without gout." | 8.89 | Efficacy and tolerability of febuxostat in hyperuricemic patients with or without gout: a systematic review and meta-analysis. ( Chen, S; Cheng, Q; Li, Q; Liu, L; Luo, T; Lv, Q; Mei, M; Yang, S; Ye, P; Zhang, W, 2013) |
| "Elevated uric acid levels are a common finding in patients with metabolic syndrome and in those with cardiovascular and renal disease, but the meaning of this elevation is still unclear." | 8.88 | Uric acid: a starring role in the intricate scenario of metabolic syndrome with cardio-renal damage? ( Di Giorgio, C; Gesualdo, L; Morrone, LF; Stellato, D, 2012) |
| "Uric acid has been suspected to be a risk factor for hypertension since the 1870s." | 8.88 | The role of uric acid in the pathogenesis of hypertension in the young. ( Feig, DI, 2012) |
| "Uric acid (UA) increase is considered an important risk factor for the development of cardiovascular disease (CVD) favoring oxidative stress and endothelial dysfunction and is also involved in metabolic syndrome (MS) pathophysiology." | 8.88 | The uric acid metabolism pathway as a therapeutic target in hyperuricemia related to metabolic syndrome. ( Dichi, I; Lozovoy, MA; Simão, AN, 2012) |
| "Uric acid is a terminal metabolite of the degradation of nucleotides, which increases their blood levels in patients with preeclampsia-eclampsia, increasing its synthesis by damage and death of trophoblastic cells in proliferation and decreased urinary excretion due a lower glomerular filtration rate and increased absorption in the proximal tubule." | 8.87 | [Role of uric acid in preeclampsia-eclampsia]. ( Rico-Trejo, EI; Vázquez-Rodríguez, JG, 2011) |
| "Many patients with acute gout (11%-49%) have normal serum uric acid (SUA) levels." | 8.87 | Clinical inquiry. Are serum uric acid levels always elevated in acute gout? ( Fletcher, A; Leiszler, M; Poddar, S, 2011) |
| "A link between serum uric acid and the development of hypertension was first hypothesized in the 1870s." | 8.87 | Uric acid and hypertension. ( Feig, DI, 2011) |
| "Uric acid was first associated with primary hypertension in 1874, yet its role in this condition remains unclear." | 8.86 | Uric acid and hypertension: cause or effect? ( Feig, DI; Jalal, D; Johnson, RJ; Kanbay, M; Mazzali, M; Segal, MS; Shafiu, M, 2010) |
| "Interest has been renewed over the role of uric acid in the pathogenesis of hypertension, endothelial dysfunction and renal dysfunction, which are all features of pre-eclampsia." | 8.86 | Could uric acid have a pathogenic role in pre-eclampsia? ( Brown, MA; Martin, AC, 2010) |
| "After uric acid was recognized as the causative factor in gout, increased prevalence of renal disease and hypertension in this patient population caught the attention of the medical community." | 8.86 | Uric acid in hypertension and renal disease: the chicken or the egg? ( Covic, A; Dogan, E; Kanbay, M; Lanaspa, MA; Solak, Y, 2010) |
| "Febuxostat, a nonpurine selective inhibitor of both the oxidized and reduced forms of xanthine oxidase, was approved in February 2009 by the US Food and Drug Administration for the management of hyperuricemia in adults with gout." | 8.85 | Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout. ( Ernst, ME; Fravel, MA, 2009) |
| "Although in the past decade a large number of studies have been performed to identify the relationship between uric acid and stroke, the issue remains unresolved and it is not clear whether the correlation between uric acid and stroke is circumstantial or causal." | 8.84 | The role of uric acid in stroke: the issue remains unresolved. ( Dimitroula, HV; Hatzitolios, AI; Karvounis, HI, 2008) |
| "Impaired renal uric acid excretion is the major mechanism of hyperuricemia in patients with primary gout." | 8.84 | Control of renal uric acid excretion and gout. ( Kamatani, N; Taniguchi, A, 2008) |
| " Recently it has been identified that hypertension are frequently associated with myogenic hyperuricemia converted from overproduced hypoxanthine in the skeletal muscles." | 8.84 | [Idiopathic hyperuricemia with overproduction of uric acid]. ( Hisatome, I; Igawa, O; Mizuta, E, 2008) |
| "Hyperuricemia reflects extracellular fluid supersaturation for uric acid." | 8.84 | [Primary hyperuricemia due to decreased renal uric acid excretion]. ( Ueda, T; Yamauchi, T, 2008) |
| "Epidemiologic studies published during the past 3 years support the possible role of uric acid in the onset of essential hypertension." | 8.83 | Uric acid and hypertension. ( Feig, DI; Johnson, RJ; Kang, DH; Mazzali, M; Nakagawa, T, 2006) |
| "Elevated serum uric acid (SUA) levels are commonly seen in patients with the metabolic syndrome (MetS)." | 8.83 | Elevated serum uric acid levels in metabolic syndrome: an active component or an innocent bystander? ( Athyros, VG; Elisaf, MS; Liberopoulos, EN; Mikhailidis, DP; Tsouli, SG, 2006) |
| "Pre-eclampsia is strongly associated with hyperuricemia, and in some studies the increase in serum uric acid has been found to correlate with both maternal and fetal morbidity." | 8.82 | Uric acid, endothelial dysfunction and pre-eclampsia: searching for a pathogenetic link. ( Finch, J; Granger, J; Johnson, RJ; Kanellis, J; Kang, DH; Karumanchi, SA; Nakagawa, T, 2004) |
| "Although allopurinol has been available for approximately 50 years, hyperuricemia and its sequelae are not only prevalent, but the incidence and costs associated with this disorder continue to increase." | 8.82 | Serum uric acid-lowering therapies: where are we heading in management of hyperuricemia and the potential role of uricase. ( Bomalaski, JS; Clark, MA, 2004) |
| "Although hyperuricemia has long been associated with renal disease, uric acid has not been considered as a true mediator of progression of renal disease." | 8.82 | Uric acid and chronic renal disease: possible implication of hyperuricemia on progression of renal disease. ( Kang, DH; Nakagawa, T, 2005) |
| "Cellular cytoplasmic xanthine oxidase (XO)-mediated uric acid synthesis and extracellular excess uric acid exposure are both causes of cardiomyocytic injury under the condition of hyperuricemia (HUA)." | 8.31 | Assessment of the influence on left ventricle by potassium oxonate and hypoxanthine-induced chronic hyperuricemia. ( Huang, Q; Jiang, Y; Li, Y; Liao, H; Lin, C; Luo, J; Pang, J; Wu, T; Yan, C; Yang, Y; Zhang, L; Zhang, W; Zheng, Q, 2023) |
| "The study objective was to verify the uric acid-lowering effects and the regulation of the gut-kidney axis mediated by sulforaphane and identify host-microbial co-metabolites in hyperuricemia." | 8.31 | Sulforaphane-driven reprogramming of gut microbiome and metabolome ameliorates the progression of hyperuricemia. ( Halimulati, M; Huang, X; Li, L; Ma, Y; Wang, R; Zhang, Z, 2023) |
| "Food intake influences uric acid (UA) levels and hyperuricemia (HU), but evidence on the role of ultra-processed foods (UPFs) are scarce." | 8.31 | Ultra-processed foods: Cross-sectional and longitudinal association with uric acid and hyperuricemia in ELSA-Brasil. ( Barreto, SM; Bisi Molina, MDC; Coelho, CG; Fajardo, VC; Haueisen Sander Diniz, MF; Pinho Ribeiro, AL; Telles, RW, 2023) |
| " This study aimed to investigate the effects of berberine on uric acid (UA) metabolism and gut microbiota in a hyperuricemia rat model established using potassium oxonate." | 8.31 | Berberine Regulates the Metabolism of Uric Acid and Modulates Intestinal Flora in Hyperuricemia Rats Model. ( Chen, Q; He, X; Li, D; Liu, Y; Sun, C; Wang, H; Wu, F; Zhou, Y, 2023) |
| " The results showed that MFPP could effectively reduce the serum uric acid (SUA) levels compared with the model group rats; kidney histopathology and the levels of inflammatory factors (TNF-α, IL-6, and IL-10) indicated that MFPP attenuated HUA-induced kidney inflammation." | 8.31 | Marine Fish Protein Peptide Regulating Potassium Oxonate-Induced Intestinal Dysfunction in Hyperuricemia Rats Helps Alleviate Kidney Inflammation. ( Hu, Q; Luo, J; Peng, X; Wu, C; Zhang, G, 2023) |
| " Patients (N = 133) with chronic heart failure and comorbid hyperuricemia who enrolled in the Excited-UA study were divided into three tertiles based on their serum uric acid level 24 weeks after initiating xanthine oxidase inhibitor treatment with topiroxostat or allopurinol (i." | 8.31 | Optimal uric acid reduction to improve vascular endothelial function in patients with chronic heart failure complicated by hyperuricemia. ( Abe, S; Iida, K; Inoue, K; Inoue, R; Inoue, T; Kato, T; Kitahara, K; Kohno, Y; Koshiji, N; Naganuma, J; Sakuma, M; Toyoda, S; Yamauchi, F; Yokomachi, J, 2023) |
| "Previous studies have found a relationship between hypertension or cardiovascular disease and simple renal cysts (SRCs) in health check-up population, but SRCs incidence is still controversially associated with serum uric acid (SUA) concentration in the nondiabetic participants." | 8.31 | Association between serum uric acid levels and simple renal cyst risk in a nondiabetic population: A nested case-control study. ( Chen, M; Wang, S; Xie, J; Yang, X; Zhao, D, 2023) |
| "Correlation influence factor analysis of gout patients' serum uric acid (SUA) levels, their examination fees, and various complications were explored." | 8.31 | Association between serum uric acid levels of patients with gout and their complications and examination fees: A cross-sectional analysis. ( Dang, W; Liu, J; Wang, J; Xu, D; You, L; Zhao, L, 2023) |
| "Objective To investigate the level of serum uric acid in patients with diabetes insipidus (DI),summarize the clinical characteristics of central diabetes insipidus (CDI) patients with hyperuricemia (HUA),and analyze the factors affecting the level of serum uric acid in the patients with CDI." | 8.31 | [Serum Uric Acid Level and Its Influencing Factors in Patients with Diabetes Insipidus]. ( Chi, Y; Duan, L; Ping, F; Wang, SH; Wang, X; Yuan, T; Zhu, HJ, 2023) |
| "To explore pro-inflammatory cytokines status in the tear fluid of patients with hyperuricemia and gout and its association with uric acid level." | 8.31 | Uric acid is independently associated with interleukin-1β levels in tear fluid of hyperuricemia and gout patients. ( Hu, X; Liu, C; Lu, H; Lu, T; Wu, M, 2023) |
| "Spontaneous serum uric acid (SUA) decrease has been found in many patients during acute gout attacks, but its mechanism remains unclear." | 8.31 | Intestinal uric acid excretion contributes to serum uric acid decrease during acute gout attack. ( Cao, L; Du, X; Lin, C; Wan, W; Xu, R; Yang, X; Zhao, T; Zhou, M; Zhu, X; Zou, H, 2023) |
| "The objective of the study was to compare the relative effects of benzbromarone and allopurinol on the risk of developing chronic kidney disease in persons with asymptomatic hyperuricemia." | 8.31 | Comparison of benzbromarone and allopurinol on the risk of chronic kidney disease in people with asymptomatic hyperuricemia. ( Hwang, BF; Kuo, YH; Lai, SW; Liao, KF; Liu, CS, 2023) |
| "Serum uric acid (UA) level is associated with the high cumulative incidence or prevalence of coronary artery disease (CAD), and hyperuricemia is considered as an independent risk marker for CAD." | 8.31 | Overnight changes in uric acid, xanthine oxidoreductase and oxidative stress levels and their relationships with sleep-disordered breathing in patients with coronary artery disease. ( Daida, H; Hiki, M; Ishiwata, S; Kasai, T; Kato, T; Kuwabara, M; Matsumoto, H; Murase, T; Murata, A; Naito, R; Nakamura, T; Sato, A; Shimizu, M; Shitara, J; Suda, S; Yatsu, S, 2023) |
| "To research the uric acid (UA)-lowering activity and mechanism of AR and the representative compounds through the constructed hyperuricemia mouse and cellular models." | 8.31 | The antihyperuricemia activity of Astragali Radix through regulating the expression of uric acid transporters via PI3K/Akt signalling pathway. ( Barreira, JCM; Chen, JS; Chen, YY; Feng, CY; Guo, X; Li, NY; Liu, C; Prieto, MA; Sun, JY; Sun, KX; Zhang, JD; Zhang, MQ, 2023) |
| " It suppressed liver xanthine oxidase activity to decrease uric acid synthesis and modulated renal urate transporters to stimulate uric acid excretion, alleviating kidney damage caused by hyperuricemia." | 8.31 | Paeonia × suffruticosa Andrews leaf extract and its main component apigenin 7-O-glucoside ameliorate hyperuricemia by inhibiting xanthine oxidase activity and regulating renal urate transporters. ( An, J; Li, C; Li, Y; Lin, F; Ma, S; Wang, S; Xie, Y; Xu, L; Zhang, Y; Zhao, Y, 2023) |
| "37 g/kg/d) on potassium oxonate (750 mg/kg/d)-induced hyperuricemia in rats were evaluated by serum uric acid (UA), creatinine (CRE), blood urea nitrogen (BUN), and renal pathological changes." | 8.31 | Dispelling Dampness, Relieving Turbidity and Dredging Collaterals Decoction, Attenuates Potassium Oxonate-Induced Hyperuricemia in Rat Models. ( Huang, XY; Li, W; Liu, HB; Liu, T; Luo, T; Luo, Y; Wu, Y; Yang, M; Zhang, YL, 2023) |
| "The upper limits of normal serum uric acid (SUA) or the lower limits of hyperuricemia were frequently set at 420 or 360 μmol/L (7." | 8.31 | High-normal serum uric acid predicts macrovascular events in patients with type 2 diabetes mellitus without hyperuricemia based on a 10-year cohort. ( Chen, Y; Fu, H; Li, Y; Lv, Y; Ma, C; Wan, G; Xie, R; Yang, G; Yu, H; Yuan, M; Yuan, S; Zhang, J; Zhang, W; Zhang, X; Zhu, L, 2023) |
| "This study was to observe the effect of Sodium TanshinoneⅡA Sulfonate (ST-ⅡAS) on blood uric acid (UA), human Soluble Intercellular Adhesion Molecule-1 (sICAM-1), Endothelin-1 (ET-1) and percentage of brachial artery Flow-Mediated Dilatation (FMD) in individuals with Hyperuricemia Complicated Coronary Heart Disease (HC-CHD)." | 8.31 | Effect of Sodium TanshinoneⅡA Sulfonate on Uric Acid, Sicam-1, ET-1 and FMD in Patients with Coronary Heart Disease Complicated with Hyperuricemia. ( Liu, X; Sun, L; Wang, Y; Zhang, J; Zhou, W, 2023) |
| "Diabetes and other metabolic diseases have been linked to the development of periodontitis, but little research has been done to determine whether serum uric acid (SUA) levels and hyperuricemia play a role." | 8.31 | Association between serum uric acid, hyperuricemia and periodontitis: a cross-sectional study using NHANES data. ( Hu, M; Jia, Y; Mao, Z; Qiu, T; Wei, X; Xu, J, 2023) |
| "Higher serum uric acid (SUA) can cause gout, which is principally characterized by arthritis due to monosodium urate crystal deposition in the lower extremities." | 8.31 | Association between serum uric acid levels and peripheral artery disease in Chinese adults with hypertension. ( Bao, H; Cheng, X; Han, F; Hu, F; Huang, X; Wang, T; Yu, C; Zhou, W; Zhu, L, 2023) |
| "This cohort study intended to elucidate the association between serum uric acid (SUA) levels and cardiovascular disease events in Japanese patients with obesity." | 8.31 | Novel pathological implications of serum uric acid with cardiovascular disease risk in obesity. ( Kasahara, M; Kasama, S; Kato, H; Kato, S; Kusakabe, T; Ozu, N; Satoh-Asahara, N; Tanaka, M; Wakabayashi, D; Yamakage, H, 2023) |
| "Previous evidence suggests that higher blood uric acid (UA) levels are associated with adverse cardiovascular outcomes during pregnancy and subsequent birth outcomes." | 8.31 | Associations of early pregnancy serum uric acid levels with risk of gestational diabetes and birth outcomes: a retrospective cohort study. ( Chen, GD; Guo, XL; Li, PS; Liu, ZP; Ma, HT; Pang, TT; Shen, XY; Wan, YC; Zhou, ZX, 2023) |
| "It is not clear whether serum uric acid (SUA) levels and their changes over time are associated with the risk of stroke." | 8.12 | Serum Uric Acid Levels and Their Changes and Risk of Stroke: A 7-Year Prospective Cohort Study in Northwest China. ( Bai, Y; Cheng, Z; Liu, Y; Luo, Y; Lv, K; Miao, Q; Wang, M; Yin, C; Zhang, D; Zheng, S, 2022) |
| "The role of serum uric acid (SUA) in stroke remains controversial and analyses of changes in SUA and stroke are limited." | 8.12 | Effect of changes in serum uric acid on the risk of stroke and its subtypes. ( Chen, S; Luo, Y; Mo, D; Tian, X; Wang, A; Wang, Y; Wu, S; Zhang, L; Zuo, Y, 2022) |
| "Patients with high baseline serum uric acid levels or who achieved high steady-state serum favipiravir concentrations during therapy were susceptible to hyperuricemia." | 8.12 | Baseline uric acid levels and steady-state favipiravir concentrations are associated with occurrence of hyperuricemia among COVID-19 patients. ( Doi, Y; Iwasaki, H; Koseki, T; Mizuno, T; Nakajima, K; Takahashi, K; Yamada, S, 2022) |
| " Pregnant women were divided into hyperuricemia-HU (uric acid ≥ 6 mg/dL) or normouricemia (uric acid, 2." | 8.12 | Serum uric acid levels associated with biochemical parameters linked to preeclampsia severity and to adverse perinatal outcomes. ( da Silva, JVF; de Mendonça, ELSS; de Oliveira, ACM; Mello, CS, 2022) |
| "Asymptomatic hyperuricemia (AHU) is elevated serum uric acid (UA) without symptoms." | 8.12 | Effects of uric acid-lowering therapy in patients with essential arterial hypertension. ( Bijak, M; Bilo, G; Drożdż, D; Drożdż, T; Gruszka, K; Hering, D; Jankowski, P; Rajzer, M; Terlecki, M; Wojciechowska, W, 2022) |
| "Our study supports a potential detrimental role of low levels of plasma uric acid on cognitive function among Chinese adults without hyperuricemia." | 8.12 | Association of plasma uric acid levels with cognitive function among non-hyperuricemia adults: A prospective study. ( Chen, X; Huang, Y; Li, W; Li, X; Liu, Z; Ma, Y; Shen, J; Wang, J; Xu, X; Yang, J; Yuan, C; Zhang, S, 2022) |
| " We herein report a Fabry disease patient with enzyme replacement therapy (ERT)-resistant proteinuria who showed improvement in the estimated glomerular filtration rate (eGFR) decline rate after uric acid (UA)-lowering therapy." | 8.12 | Improvement in Decline Rate of Estimated Glomerular Filtration Rate after Febuxostat Treatment in a Fabry Disease Patient with Enzyme Replacement Therapy-resistant Proteinuria. ( Chin-Kanasaki, M; Imamura-Uehara, Y; Kato, K; Kume, S; Kuwagata, S; Maegawa, H; Nakagawa, Y; Ohno, S; Takeda, N; Yamahara, K; Yasuda-Yamahara, M, 2022) |
| ": The aim of this study is to assess the relationship between serum uric acid concentration and lipid profile parameters and to estimate the prevalence of hyperuricemia in the city of Jeddah." | 8.12 | Prevalence of hyperuricemia and the relationship between serum uric acid concentrations and lipid parameters among King Abdulaziz University Hospital patients. ( Aljahdali, MA; Aljuhani, JM; Alotaibi, DS; Galai, TA; Ghamri, RA; Ismail, RA, 2022) |
| "The above study shows that serum uric acid levels are significantly elevated in patients with metabolic syndrome." | 8.12 | Study of Serum Uric Acid Levels in Patients of Metabolic Syndrome in a Tertiary Care Centre in South India. ( Kulkarni, A; N, R; Subhash, N; T, AK, 2022) |
| "Uric acid (UA) and high-density lipoprotein cholesterol (HDL-C) are positively and negatively associated with atherosclerosis, respectively." | 8.12 | Elevated serum uric acid was associated with pre-inflammatory state and impacted the role of HDL-C on carotid atherosclerosis. ( Dong, H; Hu, X; Li, G; Li, W; Liu, J; Wang, C; Zhou, Y, 2022) |
| "Characterized by an excessively increased uric acid (UA) level in serum, hyperuricemia induces gout and also poses a great threat to renal and cardiovascular systems." | 8.12 | Noninvasive and Individual-Centered Monitoring of Uric Acid for Precaution of Hyperuricemia via Optical Supramolecular Sensing. ( Chai, S; Chai, X; Geng, WC; Guo, DS; Li, JJ; Wang, L; Wang, Y; Yu, H; Yue, YX; Zhang, Y, 2022) |
| "Gouty arthritis is generally induced by the accumulation of monosodium urate (MSU) crystals in the joints due to elevated serum uric acid levels, potentially leading to serious pathological disorders such as nephrolithiasis, renal failure, and acute gouty arthritis." | 8.12 | Carvacrol Alleviates Hyperuricemia-Induced Oxidative Stress and Inflammation by Modulating the NLRP3/NF-κB Pathwayt. ( Al Kury, LT; Alattar, A; Alshaman, R; Atzaz, N; Li, S; Riaz, M; Shah, FA, 2022) |
| "Adipose tissue plays a crucial role in serum uric acid (UA) metabolism, but the relative contribution of adipose tissue insulin resistance (IR) to serum UA levels and hyperuricemia have not explicitly been illustrated." | 8.12 | Adipose Tissue Insulin Resistance Is Positively Associated With Serum Uric Acid Levels and Hyperuricemia in Northern Chinese Adults. ( An, Y; Bian, N; Chang, X; Leng, S; Liu, J; Sun, H; Wang, G, 2022) |
| "The role of uric acid as a risk factor for cerebrovascular disease, particularly acute ischemic stroke, is controversial and there is little information about this in our setting." | 8.12 | Relationship of Serum Uric Acid Level with Acute Ischemic Stroke: A Single-Center, Hospital-Based Study from Bangladesh. ( Hossain, MS; Jasmine, T; Kamrul-Hasan, AB; Rahman, MM; Saha, PK; Sarker, MA, 2022) |
| " In this study, the xanthine oxidase (XO) inhibition and uric acid-lowering effect of corni fructus extract (CFE) were evaluated in mice with potassium oxonate-induced hyperuricemia." | 8.12 | Protective effects of corni fructus extract in mice with potassium oxonate-induced hyperuricemia. ( Chen, C; Chen, FA; Chen, HC; Chiu, PY; Li, YL; Wang, CC, 2022) |
| "Patients with psoriasis had higher serum uric acid levels than healthy controls (6." | 8.12 | Effects of secukinumab and adalimumab on serum uric acid level in patients with plaque psoriasis. ( Cai, L; Li, C; Liu, X; Zhang, H; Zhang, J; Zhang, S; Zhao, Y; Zhao, Z, 2022) |
| " Ongoing research is examining the association of obesity, dietary patterns, and blood pressure (BP) with serum uric acid (sUA)." | 8.12 | Correlation of obesity, dietary patterns, and blood pressure with uric acid: data from the NHANES 2017-2018. ( Fan, GJ; Lin, YP; Lu, QY; Yao, J; Zhang, Y; Zhao, J, 2022) |
| "To investigate whether serum uric acid (SUA) levels and hyperuricemia can be predictive biomarkers of incident metabolic syndrome(MS) among different body mass index(BMI) categories, and to investigate SUA cutoffs that best discriminate individuals with incident MS." | 8.12 | Serum uric acid is a predictive biomarker of incident metabolic syndrome at the Brazilian longitudinal study of adult Health (ELSA - Brasil). ( B Duncan, B; Haueisen Sander Diniz, MF; Inês Schmidt, M; Isabel Rodrigues Galvão, A; Luiz P Ribeiro, A; M Benseñor, I; M R Beleigoli, A; Maria Barreto, S; Vidigal, PG; Weiss Telles, R, 2022) |
| "Undoubtedly, the relationship between serum uric acid (SUA) and obesity is less data for Chinese patients with obesity." | 8.12 | Prevalence of hyperuricemia in patients with severe obesity and the relationship between serum uric acid and severe obesity: A decade retrospective cross-section study in Chinese adults. ( Chan, W; Cheang, C; Dong, Z; Law, S; Ren, J; Wang, C, 2022) |
| "Little research has been conducted into the effects of the combined manifestation of hyperuricemia and hyperhomocysteinemia on cardiometabolic risk factors and markers in young subjects." | 8.12 | The Presence of Hyperhomocysteinemia Does Not Aggravate the Cardiometabolic Risk Imposed by Hyperuricemia in Young Individuals: A Retrospective Analysis of a Cross-Sectional Study. ( Gurecká, R; Koborová, I; Podracká, Ľ; Repiská, G; Šebeková, K, 2022) |
| "The purpose of this study was to determine the serum uric acid levels and the prevalence of hyperuricemia among Chinese adults in 2015 and compare the differences between urban and rural areas, as well as the differences between eastern, central, and western regions." | 8.12 | Status of Serum Uric Acid and Hyperuricemia among Adults in China: China Nutrition and Health Surveillance (2015). ( Bo, YC; Piao, W; Yu, DM; Zhao, LY, 2022) |
| " However, a better understanding of the relationship among uric acid (UA) values, glomerular filtration rate (GFR) and albuminuria may shed light on the mechanisms underlying the excess of cardiovascular mortality associated with both chronic kidney disease and hyperuricemia and lead to better risk stratification." | 8.12 | Association of uric acid with kidney function and albuminuria: the Uric Acid Right for heArt Health (URRAH) Project. ( Barbagallo, CM; Bombelli, M; Borghi, C; Casiglia, E; Cicero, AFG; Cirillo, M; Cirillo, P; D'Elia, L; Desideri, G; Ferri, C; Galletti, F; Gesualdo, L; Giannattasio, C; Grassi, G; Iaccarino, G; Leoncini, G; Mallamaci, F; Maloberti, A; Masi, S; Mazza, A; Mengozzi, A; Muiesan, ML; Nazzaro, P; Palatini, P; Parati, G; Pontremoli, R; Rattazzi, M; Rivasi, G; Russo, E; Salvetti, M; Tikhonoff, V; Tocci, G; Ungar, A; Verdecchia, P; Viazzi, F; Virdis, A; Volpe, M, 2022) |
| "Heavy metals, including cadmium, are suspected to increase serum uric acid levels and hyperuricemia in both gender, but the evidences about this are inconclusive." | 8.12 | Association Between Low-Level Blood Cadmium Exposure and Hyperuricemia in the American General Population: a Cross-sectional Study. ( Li, S; Sun, D; Zeng, A; Zhou, Y, 2022) |
| "Rats with hyperuricemia induced by fructose and potassium oxonate were administered with DoMRE and vehicle control, respectively, to compare the effects of the drugs." | 8.12 | Effects of Macroporous Resin Extract of Dendrobium officinale Leaves in Rats with Hyperuricemia Induced by Fructose and Potassium Oxonate. ( Chen, SH; Dong, YJ; He, XL; Li, B; Li, LZ; Lv, GY; Wang, YZ; Xu, WF; Yu, QX; Zheng, X; Zhou, C; Zhu, LJ, 2022) |
| "In the context of an aging population, this study aims to evaluate serum uric acid levels and arterial hypertension prevalence and control in a subgroup of Romanian adults (>65 years), concerning the influence of age on these parameters." | 8.02 | Arterial Hypertension and Serum Uric Acid in Elderly- SEPHAR III Study. ( Albulescu, N; Ardelean, M; Buzas, R; Dorobantu, M; Gheorghe-Fronea, OF; Ivan, VS; Lighezan, DF; Morgovan, AF, 2021) |
| "Elevated serum uric acid (SUA) levels, body shape index (BSI) and body roundness index (BRI) were associated with incident metabolic syndrome (MetS)." | 8.02 | Serum uric acid is associated with incident metabolic syndrome independent of body shape index and body roundness index in healthy individuals. ( Chen, CC; Liu, CW; Tseng, GS; Tu, CM; Wei, TE, 2021) |
| "Serum uric acid (SUA) has been found correlated with an increased risk of hypertension, but evidence is sparse regarding the association in Gansu Province, especially in Yugur people." | 8.02 | Association between Serum Uric Acid and Hypertension in Han and Yugur of Gansu Province: The China National Health Survey. ( Chang, L; He, H; Pan, L; Ren, X; Shan, G; Wang, Y; Xi, J; Yu, C; Zhao, H, 2021) |
| "Previous studies reported that the level of serum uric acid (SUA) was an important risk factor for acute cerebral infarction (ACI)." | 8.02 | The Prognostic Value of Serum Uric Acid in Hospitalized Patients with Acute Cerebral Infarction. ( Cao, L; Liu, B; Pan, Y; Yang, J, 2021) |
| "Asymptomatic hyperuricemia patients exposed to a higher level of uric acid (>=428 mmol/L) could significantly increase the incidence risk of CHD and stroke, with or without hyperuricemia-related comorbidities." | 8.02 | High-level uric acid in asymptomatic hyperuricemia could be an isolated risk factor of cardio-cerebrovascular diseases: A prospective cohort study. ( Bai, Y; Cheng, Z; Hu, X; Li, J; Li, N; Ren, X; Shi, D; Wang, M; Yang, J; Yin, C; Zhang, D; Zheng, S; Zheng, T, 2021) |
| " Nevertheless, the association between uric acid levels and the development of albuminuria has been under-investigated in patients with type 2 diabetes mellitus." | 8.02 | Association between uric acid level and incidence of albuminuria in patients with type 2 diabetes mellitus: A 4.5-year cohort study. ( Chen, LJ; Chen, YY; Ku, PW; Lai, YJ; Yen, YF, 2021) |
| "Data on the relationship of baseline serum uric acid (SUA) with development of low-density lipoprotein cholesterol (LDL-C) level in patients with first acute myocardial infarction (AMI) are limited." | 8.02 | Association between baseline serum uric acid and development of LDL-C level in patients with first acute myocardial infarction. ( Chen, Y; Dai, C; Ding, C; Hu, L; Liao, H; Liao, Y; Ruan, Y; Xia, Y; Yang, R; Zhao, Y; Zou, K, 2021) |
| "To evaluate the efficacy of serum uric acid on inpatient morbidity and mortality among acute coronary syndrome patients." | 8.02 | The effect of serum uric acid in hospitalised patients with acute coronary syndrome in Al-Yarmouk Teaching Hospital. ( Abdul Khaliq, SM; Al-Sharifi, AN, 2021) |
| "This study aims to investigate the correlation between serum uric acid levels and body fat distribution in patients with polycystic ovary syndrome (PCOS)." | 8.02 | Correlation Between Serum Uric Acid and Body Fat Distribution in Patients With Polycystic Ovary Syndrome. ( Cai, M; Cui, R; Dilimulati, D; Fei, H; Gao, X; Lin, Z; Qu, S; Shao, X; Sun, H; Zeng, Q; Zhang, M; Zhang, Y, 2021) |
| "To evaluate the prognostic impact of serum uric acid (SUA) on clinical outcomes in patients with acute decompensated heart failure, as well as identify the correlation between hyperuricemia and renal function and diuretic resistance in these patients." | 8.02 | [Prognostic impact of uric acid in patients with acute decompensated heart failure]. ( Lapteva, AE; Mindzaev, DR; Nasonova, SN; Tereshchenko, SN; Zhirov, IV, 2021) |
| "To investigate the efficacy and tolerability of febuxostat in gout patients on dialysis." | 8.02 | Efficacy and tolerability of febuxostat in gout patients on dialysis. ( Choi, SW; Choi, SY; Lee, S; Lim, DH; Oh, JS; So, MW, 2021) |
| "The objectives of our study were to compare the efficacy of febuxostat with allopurinol in Thai subjects with gout, as well as to determine the predictive factors of responsiveness to urate-lowering agents and to evaluate the safety of febuxostat in a real-world setting." | 8.02 | Efficacy of febuxostat versus allopurinol and the predictors of achieving target serum urate in a cohort of Thai people with gout. ( Jatuworapruk, K; Lertnawapan, R, 2021) |
| "This cross-sectional study investigates the association between insulin resistance (IR) and serum uric acid (sUA) and relative fat (RFM) and lean mass (RLM) profiles in children with chronic kidney disease (CKD)." | 8.02 | Association between relative fat mass, uric acid, and insulin resistance in children with chronic kidney disease. ( Christoforidis, A; Dotis, J; Karava, V; Kollios, K; Kondou, A; Liakopoulos, V; Papachristou, F; Printza, N; Tsioni, K, 2021) |
| "This study assessed factors associated with achieving target serum uric acid (sUA) level and occurrence of gouty arthritis in Japanese clinical practice." | 8.02 | Factors associated with achieving target serum uric acid level and occurrence of gouty arthritis: A retrospective observational study of Japanese health insurance claims data. ( Horiuchi, H; Koto, R; Nakajima, A; Yamanaka, H, 2021) |
| "Insufficient renal urate excretion and/or overproduction of uric acid (UA) are the dominant causes of hyperuricemia." | 8.02 | Baicalein alleviates hyperuricemia by promoting uric acid excretion and inhibiting xanthine oxidase. ( Cao, Y; Chen, Y; Jiang, Y; Li, L; Li, Y; Lin, C; Pang, J; Tian, Y; Wu, T; Yang, Y; Zhao, Z; Zhou, P, 2021) |
| "The URic acid Right for heArt Health (URRAH) study is a nationwide, multicentre, observational cohort study involving data on individuals recruited from all the Italy territory under the patronage of the Italian Society of Hypertension with an average follow-up period of 122." | 8.02 | Relationships between diuretic-related hyperuricemia and cardiovascular events: data from the URic acid Right for heArt Health study. ( Barbagallo, CM; Bernardino, B; Bombelli, M; Borghi, C; Casiglia, E; Cicero, AFG; Cirillo, M; Cirillo, P; D'elia, L; Dell'Oro, R; Desideri, G; Facchetti, R; Ferri, C; Galletti, F; Giannattasio, C; Grassi, G; Iaccarino, G; Lippa, L; Loreto, G; Mallamaci, F; Maloberti, A; Masi, S; Mazza, A; Muiesan, ML; Nazzaro, P; Palatini, P; Parati, G; Pauletto, P; Pontremoli, R; Quarti-Trevano, F; Rattazzi, M; Rivasi, G; Rosei, EA; Salvetti, M; Tikhonoff, V; Tocci, G; Ungar, A; Verdecchia, P; Viazzi, F; Virdis, A; Volpe, M, 2021) |
| "Our study analyzes the frequency and risk factors of hyperuricemia and the use of allopurinol in a representative cohort of the older Polish adult population." | 8.02 | Prevalence of Hyperuricemia and the Use of Allopurinol in Older Poles-Results from a Population-Based PolSenior Study. ( Broczek, K; Chudek, J; Grodzicki, T; Mossakowska, M; Owczarek, AJ; Wierucki, Ł; Winder, M, 2021) |
| "Concentration of uric acid (UA) in serum is one of the markers used to diagnose gout and hyperuricemia." | 8.02 | A convenient sampling and noninvasive dried spot method of uric acid in human saliva: Comparison of serum uric acid value and salivary uric acid in healthy volunteers and hyperuricemia patients. ( Di, L; Han, Y; Jin, W; Min, JZ; Shi, Q; Xu, CY; Zhao, LL, 2021) |
| "In this nonrandomized, open-label, single-arm trial, we administered topiroxostat 40-160 mg/day to HFpEF patients with hyperuricemia or gout to achieve a target uric acid level of 6." | 8.02 | Effect of Topiroxostat on Brain Natriuretic Peptide Level in Patients with Heart Failure with Preserved Ejection Fraction: A Pilot Study. ( Asai, K; Koen, M; Kubota, Y; Shimizu, W; Wakita, M, 2021) |
| "Although high serum uric acid (SUA) at baseline has been linked to increased risk for metabolic syndrome (MetS), the association of longitudinal SUA changes with MetS risk is unclear." | 8.02 | Dose-response relationship between distinct serum uric acid trajectories and metabolic syndrome risk: A 5-year prospective cohort study. ( Guo, X; Han, Y; Li, Q; Liu, J; Ma, Z; Tao, L; Yang, X; Zhang, J; Zhang, S, 2021) |
| "To report a case of ribavirin-associated severe hyperuricemia in an immunocompromised patient treated for respiratory syncytial virus (RSV) infection." | 8.02 | Acute and severe ribavirin-associated hyperuricemia and acute kidney injury: An underrecognized adverse effect. ( Ammuri, H; Elias, A; Frisch, A; Kurnik, D; Sakran, R; Sliman, H, 2021) |
| "Elevated serum uric acid (SUA) is associated with hypertension according to its traditional definition." | 8.02 | Elevated serum uric acid is associated with incident hypertension in the health according to various contemporary blood pressure guidelines. ( Hwang, JJ; Ke, SR; Liu, CW; Tseng, GS; Wu, YW, 2021) |
| "The relationship between uric acid and incident hypertension tended to be dependent on age and sex." | 8.02 | Age and sex dependent association of uric acid and incident hypertension. ( Choi, CU; Choi, JY; Go, TH; Kang, DO; Kang, DR; Kim, EJ; Kim, JY; Kim, W; Lee, J; Na, JO; Park, CG; Rha, SW; Roh, SY; Seo, HS, 2021) |
| "The present study evaluated the association of electronic cigarette (EC) exposure with serum uric acid (UA) level and hyperuricemia (HUA) using a nationally representative sample of South Korea." | 8.02 | Association of electronic cigarette exposure with serum uric acid level and hyperuricemia: 2016-2017 Korea National Health and Nutritional Examination Survey. ( Kang, J; Kim, T; Kim, Y, 2021) |
| "Patients with primary hypertension and without any uric acid (UA)-lowering treatment were enrolled." | 8.02 | Association of hyperuricemia and hypertension phenotypes in hypertensive patients without uric acid lowering treatment. ( Hou, J; Liao, H; Lin, J; Liu, C; Qiu, D; Zhang, M, 2021) |
| "To investigate the association between serum uric acid (SUA) levels and vision-threatening diabetic retinopathy (VTDR) in patients with type 2 diabetes." | 8.02 | Higher Serum Uric Acid Levels Are Associated With an Increased Risk of Vision-Threatening Diabetic Retinopathy in Type 2 Diabetes Patients. ( Chan, Z; Chen, H; Gu, C; Hu, Y; Li, C; She, X; Shi, Y; Wang, Y; Zhao, S; Zheng, Z; Zhou, C, 2021) |
| "Increased concentration of uric acid may play a role in the pathogenesis of primary hypertension (PH)." | 8.02 | [Uric acid in children and adolescents with primary hypertension]. ( Pańczyk-Tomaszewska, M; Skrzypczyk, P; Szyszka, M, 2021) |
| "Serum uric acid (SUA) levels have been reported to be associated with an increased risk of coronary artery disease (CAD) among patients with diabetes in observational study." | 8.02 | Genetically predicted serum uric acid levels and the risk of coronary artery disease in patients with diabetes: A Mendelian randomization study. ( Chen, S; Fu, G; Wang, Y; Xu, T; Yang, F; Zhang, K; Zhang, W, 2021) |
| "Hyperuricemia (HUA) is induced by abnormal purine metabolism and elevated serum uric acid (UA) concentrations, and it is often accompanied by inflammatory responses and intestinal disorders." | 8.02 | Chlorogenic acid supplementation ameliorates hyperuricemia, relieves renal inflammation, and modulates intestinal homeostasis. ( Hu, N; Lin, Y; Wang, J; Wang, S; Wang, X; Zhang, B; Zhao, X; Zhou, X, 2021) |
| "The purpose of this study was to investigate the application value of serum 25(OH)D3, uric acid, triglyceride (TG), and homeostasis model assessment of insulin resistance (HOMA-IR) in male patients with hyperuricemia combined with hypogonadism." | 8.02 | The application value of serum 25(OH)D3, uric acid, triglyceride, and homeostasis model assessment of insulin resistance in male patients with hyperuricemia combined with hypogonadism. ( Chen, W; Wang, J; Yun, C; Zhang, Q, 2021) |
| "Recently, studies have shown a positive association between serum uric acid (UA) and metabolic syndrome (MS)." | 8.02 | Uric acid: A new marker for metabolic syndrome? Results of a population-based study with adults. ( da Silva, DCG; de Magalhães, ELG; Ferreira, FG; Hinnig, PF; Juvanhol, LL; Longo, GZ; Roberto, DMT, 2021) |
| " The effects of API on renal function, inflammation, fibrosis, and uric acid (UA) metabolism in mice with HN were evaluated." | 8.02 | Apigenin ameliorates hyperuricemic nephropathy by inhibiting URAT1 and GLUT9 and relieving renal fibrosis via the Wnt/β-catenin pathway. ( Cao, Y; Chen, Y; Huang, Q; Jiang, Y; Li, L; Li, Y; Luo, J; Pang, J; Wu, T; Zhang, L; Zhao, Z; Zhou, P, 2021) |
| "High uric acid (HUA) is associated with insulin resistance (IR) in cardiomyocytes." | 8.02 | Metformin protects against insulin resistance induced by high uric acid in cardiomyocytes via AMPK signalling pathways in vitro and in vivo. ( Chen, Y; Jiao, Z; Li, Y; Li, Z; Xie, Y, 2021) |
| "Background Serum uric acid (SUA) has been demonstrated as a risk factor for myocardial infarction (MI) and all-cause mortality; however, the impact of cumulative SUA (cumSUA) remains unclear." | 8.02 | Cumulative Serum Uric Acid and Its Time Course Are Associated With Risk of Myocardial Infarction and All-Cause Mortality. ( Chen, S; Luo, Y; Mo, D; Tian, X; Wang, A; Wu, S; Zhang, L; Zuo, Y, 2021) |
| "We investigated serum uric acid changes and incident hyperuricemia in relation to the achieved blood pressure (BP) after 12 weeks of antihypertensive therapy with the irbesartan/hydrochlorothiazide combination." | 8.02 | Incident hyperuricemia in relation to antihypertensive therapy with the irbesartan/hydrochlorothiazide combination. ( Huang, QF; Li, Y; Wang, JG; Zhang, D, 2021) |
| "In patients with gout, treating to target serum uric acid levels (sUA) of ≤6." | 8.02 | Serum uric acid control for prevention of gout flare in patients with asymptomatic hyperuricaemia: a retrospective cohort study of health insurance claims and medical check-up data in Japan. ( Horiuchi, H; Koto, R; Nakajima, A; Yamanaka, H, 2021) |
| "Berberine (BBR) is an active component of Phellodendri Cortex (PC), which is a traditional Chinese medicine that has been prescribed clinically for hyperuricemia (HUA) for hundreds of years." | 8.02 | Effect of Berberine on Hyperuricemia and Kidney Injury: A Network Pharmacology Analysis and Experimental Validation in a Mouse Model. ( Chen, J; Huang, Z; Li, Q; Li, Y; Liu, D; Su, Z; Xie, J; Zeng, H; Zheng, J, 2021) |
| "The prognostic value of serum uric acid (SUA) for incident acute coronary syndrome (ACS) in hypertensive subjects is uncertain." | 7.96 | J-shaped association between serum uric acid and acute coronary syndrome in patients with essential hypertension. ( Chen, CL; Feng, YQ; Huang, JY; Huang, YQ; Liu, L; Shen, G; Yu, YL; Zhang, B, 2020) |
| "The results showed that, in patients with CKD and hyperuricemia, febuxostat can be used to reduce the serum uric acid level." | 7.96 | Comparison of long-term efficacy and renal safety of febuxostat and allopurinol in patients with chronic kidney diseases . ( Yang, AY, 2020) |
| " The effects of phloretin on renal function, fibrosis, oxidative stress, inflammation, and UA metabolism in HUA mice were evaluated." | 7.96 | Phloretin ameliorates hyperuricemia-induced chronic renal dysfunction through inhibiting NLRP3 inflammasome and uric acid reabsorption. ( Chen, Y; Cheng, J; Cui, D; Li, L; Liu, J; Liu, S; Lu, Y; Mao, R; Tang, M; Wang, C; Yuan, Y; Zhao, M, 2020) |
| "Leveraging a longitudinal cohort including 1981 Chinese adults who had blood pressures, urinary albumin to creatinine ratio (UACR), and uric acid measured twice 4 years apart, we examined the temporal relationships among hyperuricemia, microalbuminuria, and hypertension by cross-lagged panel analysis followed by a causal mediation analysis to confirm the temporal consequence." | 7.96 | Microalbuminuria mediates the association between serum uric acid and elevation of blood pressure: a longitudinal analysis in the Gusu cohort. ( He, Y; Jiang, Y; Li, J; Ma, S; Peng, H; Ren, L; Yu, J; Zhang, M; Zhang, Q, 2020) |
| "While rasburicase has shown efficacy to rapidly correct hyperuricemia compared with allopurinol, its overall impact in improving clinically significant outcomes, such as acute kidney injury (AKI), in tumor lysis syndrome (TLS) is unknown." | 7.96 | Comparative effectiveness of rasburicase versus allopurinol for cancer patients with renal dysfunction and hyperuricemia. ( Estey, E; Frieze, D; Garcia, DA; Hingorani, S; Khalighi, PR; Li, A; Li, S; Martens, KL; Silgard, E; White, AA, 2020) |
| " Male SD rats were assigned to control group or oxonic acid-induced hyperuricemia (HUA) group." | 7.96 | ABCG2 expression and uric acid metabolism of the intestine in hyperuricemia model rat. ( Asakawa, S; Hosoyamada, M; Kuribayashi-Okuma, E; Li, J; Morimoto, C; Murase, T; Nakamura, T; Nemoto, Y; Shibata, S; Tamura, Y; Uchida, S, 2020) |
| "Hyperuricemia is an abnormal increase in uric acid levels in the blood." | 7.96 | Impact of Lesinurad and allopurinol on experimental Hyperuricemia in mice: biochemical, molecular and Immunohistochemical study. ( Alghamdi, YS; Nassan, MA; Soliman, MM, 2020) |
| "Despite the growing pieces of evidence linking hyperuricemia with metabolic syndrome and cardiovascular disease, the relationship between dyslipidemia and serum uric acid has not yet been established." | 7.96 | Association between dyslipidemia and serum uric acid levels in Korean adults: Korea National Health and Nutrition Examination Survey 2016-2017. ( Seo, J; Son, M; Yang, S, 2020) |
| " Our study was to discover different lipid levels of gout and asymptomatic hyperuricemia and the predictors of sUA (serum uric acid) levels." | 7.96 | The comparison of dyslipidemia and serum uric acid in patients with gout and asymptomatic hyperuricemia: a cross-sectional study. ( Gu, J; Huang, Y; Jiang, Y; Li, X; Liang, J; Ou, J; Song, W; Wei, Q, 2020) |
| "The role of serum uric acid (SUA) in development of myocardial infarction (MI) is controversial." | 7.96 | Associations between changes in serum uric acid and the risk of myocardial infarction. ( An, J; Chen, S; He, Y; Li, H; Luo, Y; Tian, X; Wang, A; Wu, S; Zhang, L; Zuo, Y, 2020) |
| " This study was designed to evaluate the influences of long-term xanthine oxidase inhibitor (febuxostat) prescription on left ventricular hypertrophy (LVH), left ventricular (LV) diastolic function, and new-onset heart failure with preserved ejection fraction (HFpEF) in these patients." | 7.96 | Association between long-term prescription of febuxostat and the progression of heart failure with preserved ejection fraction in patients with hypertension and asymptomatic hyperuricemia. ( Gu, J; Lin, H; Pan, JA; Wang, CQ; Zhang, JF, 2020) |
| "To assess the serum iron and ferritin levels in relation to the prevalence of hyperuricemia (HU) and the serum uric acid (SUA) level." | 7.96 | Associations of serum iron and ferritin with hyperuricemia and serum uric acid. ( Li, H; Wang, Y; Wu, J; Xie, D; Xiong, Y; Yang, T; Yang, Z, 2020) |
| "Observational studies have shown that high levels of serum uric acid (UA) were associated with atrial fibrillation (AF)." | 7.96 | A mendelian randomization analysis: The causal association between serum uric acid and atrial fibrillation. ( Hong, M; Hwang, I; Jee, SH; Joung, B; Kim, TH; Lee, MH; Pak, HN; Park, JW; Uhm, JS; Yang, PS; Yu, HT, 2020) |
| "This is a retrospective analysis of 100 CKD patients treated with febuxostat for asymptomatic hyperuricemia in two private Lebanese clinics." | 7.96 | A formula predicting the effective dose of febuxostat in chronic kidney disease patients with asymptomatic hyperuricemia based on a retrospective study and a validation cohort . ( Aoun, M; Chelala, D; Dfouni, A; Salloum, R; Sleilaty, G, 2020) |
| "Topiroxostat, a selective xanthine oxidoreductase inhibitor, is used for the management of hyperuricemic patients with or without gout in Japan." | 7.96 | Long-Term Safety and Effectiveness of the Xanthine Oxidoreductase Inhibitor, Topiroxostat in Japanese Hyperuricemic Patients with or Without Gout: A 54-week Open-label, Multicenter, Post-marketing Observational Study. ( Hashimoto, T; Ichikawa, K; Ishikawa, T; Kanno, Y; Maeda, T; Nakagawa, T; Sato, Y, 2020) |
| "To investigate the effects of serum uric acid (SUA) level and its fluctuation on renal dysfunction in gout patients." | 7.96 | Uric acid fluctuation had no effect on renal function among gout patients. ( Fu, Y; Mo, M; Shao, B; Shen, J; Shen, Y; Si, S; Wang, S; Wu, H; Xin, X; Yu, Y; Zhu, J, 2020) |
| " The present study was undertaken to evaluate the therapeutic effects and the underlying mechanisms of polydatin on potassium oxonate-induced hyperuricemia in rats through metabonomic technology from a holistic view." | 7.96 | NMR-Based Metabonomic Study Reveals Intervention Effects of Polydatin on Potassium Oxonate-Induced Hyperuricemia in Rats. ( Gong, M; Han, B; Li, Z; Qiu, Y; Zou, Z, 2020) |
| " Subsequently, he showed increased uric acid levels and developed acute gouty arthritis." | 7.96 | Acute Gouty Arthritis During Favipiravir Treatment for Coronavirus Disease 2019. ( Hase, R; Ishida, K; Kurata, R; Kurita, T; Mito, H; Muranaka, E, 2020) |
| "Conflicting findings have been reported regarding the sex-specific association between serum uric acid (SUA) level and type 2 diabetes mellitus (T2DM) risk, and no study has explored the association between the change in hyperuricemia status and T2DM risk." | 7.96 | Sex-Specific Association of Serum Uric Acid Level and Change in Hyperuricemia Status with Risk of Type 2 Diabetes Mellitus: A Large Cohort Study in China. ( Chen, H; Han, D; Hu, D; Hu, F; Li, Y; Liu, D; Lou, Y; Ma, J; Peng, X; Qin, P; Wang, C; Wang, L; Xu, S; Zhao, D; Zhao, P, 2020) |
| "Lesch-Nyhan syndrome (LNS) is an X-linked recessive disorder presenting with uric acid overproduction, neurocognitive disability, and behavioral disturbances." | 7.96 | Delayed emergence from propofol anesthesia in a patient with Lesch-Nyhan syndrome: A case report. ( Jeon, S; Jung, SM; Lee, J, 2020) |
| "results indicate serum uric acid is positively correlated with hypertension and a reliable indicator of LVH in study population." | 7.96 | Serum uric acid and left ventricular hypertrophy in hypertensive patients in Ado-Ekiti. ( Adebayo, RA; Adewuya, OA; Ajayi, EA; Ojo, OE; Olaoye, OB, 2020) |
| "The electrolytic drinking water intake is benefit for the excretion of uric acid of hyperuricemia rat." | 7.96 | [Electrolytic drinking water improves the metabolism of uric acid in the SD rats with hyperuricemia]. ( Huang, L; Liang, X; Luo, Z; Shi, H; Tan, L, 2020) |
| "12 a week-long combined therapy of the allopurinol-reducing drug with the anti-inflammatory dose movalis prevents the exacerbation of the articular syndrome and improves the quality of life of patients with gout." | 7.96 | [Evaluation of a 12-week allopurinol-lowering therapy in combination with the non-steroidal anti-inflammatory drug meloxicam in patients with gout]. ( Gromova, MA; Kislyak, OA; Malysheva, NV; Tsurko, VV, 2020) |
| " Serum uric acid levels and estimated glomerular filtration rate (eGFR) of patients with gouty arthritis were collected at baseline and 1 year after febuxostat administration." | 7.96 | Renal safety and urate-lowering efficacy of febuxostat in gout patients with stage 4-5 chronic kidney disease not yet on dialysis. ( Kim, JM; Kim, SH; Lee, SY; Son, CN, 2020) |
| "Plasma cysteine, glutamine, phenylalanine, threonine, and long-chain acylcarnitines are positively associated with incident hyperuricemia." | 7.96 | Associations of Amino Acid and Acylcarnitine Profiles With Incident Hyperuricemia in Middle-Aged and Older Chinese Individuals. ( Gao, X; Huo, S; Lin, X; Niu, Z; Sun, L; Sun, Q; Wang, F; Xiong, Q; Zeng, R; Zhang, H; Zong, G, 2020) |
| "To assess the association between the consumption of non-soy legumes and different subtypes of non-soy legumes and serum uric acid (SUA) or hyperuricemia in elderly individuals with overweight or obesity and metabolic syndrome." | 7.96 | Cross-sectional association between non-soy legume consumption, serum uric acid and hyperuricemia: the PREDIMED-Plus study. ( Abellán Cano, I; Alonso-Gómez, ÁM; Babio, N; Becerra-Tomás, N; Bernal-Lopez, MR; Bueno-Cavanillas, A; Casas, R; Cenoz, JC; Corbella, E; Corella, D; Crespo-Oliva, E; Daimiel, L; Del Mar Bibiloni, M; Díaz-López, A; Estruch, R; Fernandez-Brufal, N; Fernández-Carrión, R; Fernández-García, JC; Freixer, G; Gaforio, JJ; Lapetra, J; Llimona, R; López-Miranda, J; Martín-Sánchez, V; Martínez, JA; Martínez-González, MÁ; Matía-Martín, P; Mena-Sánchez, G; Morey, M; Navarrete-Muñoz, EM; Pintó, X; Prieto, RM; Quifer, M; Razquin, C; Romaguera, D; Ros, E; Ruiz-Canela, M; Salas-Salvadó, J; Salaverria Lete, I; Sanchez-Villegas, A; Santos-Lozano, JM; Serra-Majem, L; Sorli, JV; Tojal Sierra, L; Torres, L; Tur, JA; Vázquez, C; Vidal, J; Vioque, J; Wärnberg, J; Zulet, MÁ, 2020) |
| "There is limited evidence examining the relationship between elevated serum uric acid (sUA) concentration and heart failure (HF) in United States (US) adults." | 7.91 | Elevated Serum Uric Acid and Self-Reported Heart Failure in US Adults: 2007-2016 National Health and Nutrition Examination Survey. ( Churilla, JR; Guevara, L; Rand, BG; Richardson, MR; Stone, ML, 2019) |
| "To analyze the efficacy and safety of benzbromarone in elderly hypertensive patients with hyperuricemia." | 7.91 | Clinical efficacy and safety of benzbromarone in elderly hypertensive patients with hyperuricemia. ( Gao, H, 2019) |
| "This study aims to evaluate whether serum Bisphenol A (BPA) is a risk factor for hyperuricemia." | 7.91 | Serum Bisphenol A is an independent risk factor of hyperuricemia: A 6-year prospective study. ( Cheng, Q; Gao, R; Hu, J; Li, J; Li, Q; Luo, T; Ma, L; Peng, C; Qing, H; Wang, Y; Wang, Z; Yang, S; Yang, Y; Zhang, A; Zhang, L, 2019) |
| "The role of serum uric acid in ischemic stroke is controversial." | 7.91 | Association between serum uric acid and carotid disease in patients with atherosclerotic acute ischemic stroke. ( Arévalo-Lorido, JC; Carretero-Gómez, J; Robles Pérez-Monteoliva, NR, 2019) |
| "Uric acid to lymphocyte ratio, combining the effect of uric acid and lymphocyte count, produced more prognostic value in elderly patients with rheumatic heart disease undergoing valve replacement surgery, which could be considered as a preoperative risk-stratified method." | 7.91 | Joint effects of uric acid and lymphocyte count on adverse outcomes in elderly patients with rheumatic heart disease undergoing valve replacement surgery. ( Chen, WJ; Duan, CY; Geng, QS; Jiang, L; Qin, TH; Wei, XB; Yu, Y, 2019) |
| " However, the dose-response effects of serum uric acid (SUA) on the prevalence of MetS and electrocardiographic left ventricular hypertrophy (LVH) are unclear." | 7.91 | The dose-response effects of uric acid on the prevalence of metabolic syndrome and electrocardiographic left ventricular hypertrophy in healthy individuals. ( Chang, WC; Chen, KH; Hwang, JJ; Liu, CW; Tseng, CK; Wu, YW, 2019) |
| "A retrospective cohort study was performed in early post-renal transplant recipients with new onset of hyperuricemia receiving febuxostat or allopurinol therapy." | 7.91 | Comparison of efficacy and safety between febuxostat and allopurinol in early post-renal transplant recipients with new onset of hyperuricemia. ( Chen, P; Chen, X; Fu, Q; Gao, X; Li, J; Liu, L; Shen, X; Wang, C, 2019) |
| "The association between uric acid (UA) and coronary artery disease (CAD) was controversial." | 7.91 | Association between serum uric acid levels and coronary artery disease in different age and gender: a cross-sectional study. ( Chen, L; Li, J; Qi, G; Shi, L; Sun, Y; Tian, W; Zhang, H; Zhao, S, 2019) |
| "The aim of this study was to assess the association between serum uric acid concentration (SUAC) and the parameters of the metabolic syndrome (MetS) and insulin resistance (IR)." | 7.91 | Associations Between Serum Uric Acid Concentrations and Cardiometabolic Risk and Renal Injury in Obese and Overweight Children ( Ersoy, B; Özalp Kızılay, D; Şen, S, 2019) |
| "To further explore the possibility of xanthine and hypoxanthine to be gout biomarkers as substitutes for uric acid." | 7.91 | Study on the diagnosis of gout with xanthine and hypoxanthine. ( Deng, B; Deng, M; Fei, X; Huang, Z; Wang, Y; Ye, L, 2019) |
| "Potassium oxonate (PO) was used to establish a mouse model of hyperuricemia." | 7.91 | Modified Chuanhu anti-gout mixture, a traditional Chinese medicine, protects against potassium oxonate-induced hyperuricemia and renal dysfunction in mice. ( Che, K; Fei, H; Hou, X; Wang, J; Wang, Y; You, W; Zou, Y, 2019) |
| "It has not been determined whether changes in serum uric acid (SUA) level are associated with incident metabolic syndrome (MetS)." | 7.91 | The Protective Effects of Increasing Serum Uric Acid Level on Development of Metabolic Syndrome. ( Bae, JC; Jee, JH; Jin, SM; Kim, JH; Lee, MK; Yu, TY, 2019) |
| " Total 220 antenatal women ≥34 weeks of gestation with 110 cases having hypertensive disorder of pregnancy and 110 controls with normal blood pressure were compared for maternal uric acid and calcium levels and maternal, perinatal outcomes." | 7.91 | Maternal serum uric acid and calcium as predictors of hypertensive disorder of pregnancy: A case control study. ( Kumar, N; Singh, AK, 2019) |
| " The RSGE treatment dose-dependently reduced PO- and MSU-induced paw edema, serum TNF-α, IL-1β, IL-6, IL-12, uric acid, and BUN, while significantly elevated serum IL-10, urinary uric acid and creatinine levels as compared with the respective values in the hyperuricemic and gouty mice group (vehicle group)." | 7.91 | Protective effects of Rhizoma smilacis glabrae extracts on potassium oxonate- and monosodium urate-induced hyperuricemia and gout in mice. ( Chang, Y; Liang, C; Liang, G; Nie, Y; Xiao, D; Zeng, S; Zhan, S; Zheng, Q; Zheng, X, 2019) |
| "This study investigated the association between serum uric acid (sUA) and stroke risk in men with hypertriglyceridemia." | 7.91 | Is serum uric acid a predictive factor for stroke in men with hypertriglyceridemia? ( Hsu, CY; Lai, YJ, 2019) |
| "Allopurinol is the first-line medication for hyperuricemia treatment." | 7.91 | Highly Acylated Anthocyanins from Purple Sweet Potato ( Ipomoea batatas L.) Alleviate Hyperuricemia and Kidney Inflammation in Hyperuricemic Mice: Possible Attenuation Effects on Allopurinol. ( Wang, Y; Yang, Y; Zhang, JL; Zhang, ZC; Zhou, Q, 2019) |
| "Few studies have investigated the sex-related associations between serum uric acid and depression." | 7.91 | Associations between serum uric acid and depression among middle-aged and elderly participants in China. ( Ding, G; Li, Y; Yu, D; Zhao, L, 2019) |
| "Although mizoribine (MZR) is used as an immunosuppressant after renal transplantation, the occurrence of hyperuricemia has been reported." | 7.91 | Hyperuricemia in Living Donor Kidney Transplantation Patients During Mizoribine Administration Caused Mainly by Changes in Kidney Function. ( Chen, XG; Liu, H; Shen, ZY; Shi, Y, 2019) |
| "To observe the effect of acupuncture at "Shenshu"(BL23)-"Taixi"(KI3)on the levels of serum uric acid (SUA) and expression of renal urate-anion transporter 1 (URAT1) and organic anion transporter 1 (OAT1) proteins in hyperuricemia (HUA) rats, so as to explore its underlying mechanisms in improving HUA." | 7.91 | [Effect of acupuncture stimulation of "Shenshu"(BL23)-"Taixi"(KI3)on levels of serum uric acid and renal URAT1 and OAT1 protein expression in hyperuricemia rats]. ( Chen, HY; He, XQ; Liu, XF; Sui, MH; Tang, XQ; Wang, J; Yun, S, 2019) |
| " Therefore, this study aimed to evaluate the association between lead, cadmium and mercury exposure and hyperuricemia in the Korean general population." | 7.91 | Associations between blood lead, cadmium, and mercury levels with hyperuricemia in the Korean general population: A retrospective analysis of population-based nationally representative data. ( Jung, W; Kang, J; Kim, Y; Lihm, H, 2019) |
| " The objective is to determine whether therapy with TNF inhibitors (TNFis) affects SUA levels in patients with systemic autoimmune rheumatic diseases (SARDs) and whether SUA changes correlate with pro-inflammatory cytokines or with the oxidative stress marker allantoin." | 7.91 | Serum uric acid increases in patients with systemic autoimmune rheumatic diseases after 3 months of treatment with TNF inhibitors. ( Hasikova, L; Herrmann, M; Hulejova, H; Kalikova, K; Kozlik, P; Mahajan, A; Pavlikova, M; Stiburkova, B; Zavada, J, 2019) |
| "This was a hospital-based prospective cohort study that included patients with ischemic stroke with baseline uric acid levels and 3-month post-stroke follow-up data." | 7.88 | The Prognostic Value of Serum Uric Acid in the Acute Phase of Ischemic Stroke in Black Africans. ( Ayeah, CM; Ba, H; Hentchoya, R; Luma, HN; Mapoure, YN, 2018) |
| "Heterogeneous results have been obtained in the relationship between serum uric acid (SUA) and target organ damage (TOD) in patients with hypertension." | 7.88 | Sex-related relationships between uric acid and target organ damage in hypertension. ( Casati, M; Falbo, R; Giannattasio, C; Grassi, G; Maggioni, S; Maloberti, A; Nava, S; Occhi, L; Panzeri, F; Signorini, S; Triglione, N, 2018) |
| "The role of serum uric acid (SUA) as a prognostic marker for incident heart failure (HF) in hypertensive subjects is uncertain." | 7.88 | Serum uric acid as a potential marker for heart failure risk in men on antihypertensive treatment: The British Regional Heart Study. ( Lennon, L; Papacosta, O; Wannamethee, SG; Whincup, PH, 2018) |
| "After oral administration of Dioscin in potassium oxonate (PO) induced hyperuricemia rats and adenine-PO induced hyperuricemia mice models, serum uric acid and creatinine levels, clearance of uric acid and creatinine, fractional excretion of uric acid, and renal pathological lesions were determined were used to evaluate the antihyperuricemic effects." | 7.88 | Effect and mechanism of dioscin from Dioscorea spongiosa on uric acid excretion in animal model of hyperuricemia. ( Chen, Q; Jin, L; Li, J; Liu, J; Wang, T; Wang, W; Yu, H; Zhang, Y, 2018) |
| "Insulin and uric acid were shown affect the prevalence of Metabolic Syndrome (MetS), but no studies examine their interaction." | 7.88 | Low serum uric acid concentration augments insulin effects on the prevalence of metabolic syndrome. ( Gonzalez-Mejia, ME; Pérez-Fuentes, R; Porchia, LM; Ruiz-Vivanco, G; Torres-Rasgado, E, 2018) |
| "Uric acid is best known for its role in gout-the most prevalent inflammatory arthritis in humans-that is also described as an unusual complication of anorexia nervosa (AN)." | 7.88 | Anorexia nervosa and uric acid beyond gout: An idea worth researching. ( Maas, J; Simeunovic Ostojic, M, 2018) |
| "This narrative review aims to highlight recent findings on the relation between uric acid level and cognitive decline or dementia." | 7.88 | Uric acid and cognitive decline: a double-edge sword? ( Bardin, T; Latourte, A; Richette, P, 2018) |
| "The relationship between hyperuricemia and hypertensive disorders is well established; however, until today, the role of uric acid in the clinical course of severe preeclampsia has not been elucidated." | 7.88 | Uric Acid in Pregnancy: New Concepts. ( Briones Garduño, JC; Diaz de Leon Ponce, MA; Moreno Santillan, AA, 2018) |
| "The purpose of this study was to examine the association between serum uric acid (sUA) and the incidence of hypertension in nonmetabolic syndrome (non-MetS) subjects." | 7.88 | Assessment of the association between serum uric acid levels and the incidence of hypertension in nonmetabolic syndrome subjects: A prospective observational study. ( Chen, Q; Chen, WY; Huang, X; Wu, JN; Yin, YJ, 2018) |
| "The relationship between serum uric acid (SUA) levels and stroke is controversial." | 7.88 | Serum uric acid levels and outcome during admission in acute ischaemic stroke, depending on renal function. ( Arévalo-Lorido, JC; Carretero-Gómez, J; Robles, NR, 2018) |
| "The objective of the present study was to evaluate clinical implications of serum uric acid (UA) on the progression of heart failure with preserved ejection fraction (HFpEF) in hypertensive patients." | 7.88 | Serum uric acid is associated with incidence of heart failure with preserved ejection fraction and cardiovascular events in patients with arterial hypertension. ( Fan, YQ; Gu, J; Wang, CQ; Zhang, HL; Zhang, JF, 2018) |
| "Conflicting results suggest a link between serum uric acid (SUA), inflammation and glucose/insulin homeostasis; however, the role of adiposity in this relationship is not clear." | 7.88 | The link between insulin resistance parameters and serum uric acid is mediated by adiposity. ( Banach, M; Katsiki, N; Mazidi, M; Mikhailidis, DP, 2018) |
| "To provide insight into pharmacological treatment of hyperuricemia we developed a semi-mechanistic, dynamical model of uric acid (UA) disposition in human." | 7.88 | Individualized treatment strategies for hyperuricemia informed by a semi-mechanistic exposure-response model of uric acid dynamics. ( Aksenov, S; Eriksson, UG; Peck, CC; Stanski, DR, 2018) |
| "Hyperuricemia was induced by potassium oxonate in male rats." | 7.88 | Hypouricemic and Nephroprotective Effects of an Active Fraction from Polyrhachis Vicina Roger On Potassium Oxonate-Induced Hyperuricemia in Rats. ( Chen, N; Chu, S; He, F; Li, D; Liao, L; Lu, W; Nong, Z; Su, H; Su, Q; Wang, L; Wei, B; Wei, G; Ya, Q; Zeng, X; Zhao, J, 2018) |
| "Elevated serum uric acid (sUA) concentrations have been associated with worse prognosis in heart failure (HF) but little is known about elderly patients." | 7.88 | Elevated serum uric acid concentration at discharge confers additive prognostic value in elderly patients with acute heart failure. ( Alunni, G; Ambrosio, G; Biagioli, P; Borghi, C; Carluccio, E; Coiro, S; D'Antonio, A; Girerd, N; Mengoni, A; Murrone, A; Zuchi, C, 2018) |
| "The present study suggests that luteolin and luteolin-4'-O-glucoside could be developed as therapeutics for treating hyperuricemia and gouty arthritis." | 7.88 | Luteolin-4'-O-glucoside and its aglycone, two major flavones of Gnaphalium affine D. Don, resist hyperuricemia and acute gouty arthritis activity in animal models. ( Hu, YJ; Liang, WQ; Lin, Y; Liu, PG; Pu, JB; Xu, P; Zhang, HJ; Zhou, J, 2018) |
| "Uric acid (UA), an antioxidant with neuroprotective effects, favorably affects stroke outcome." | 7.88 | Associations between Uric Acid Level and 3-Month Functional Outcome in Acute Ischemic Stroke Patients Treated with/without Edaravone. ( Ando, Y; Inatomi, Y; Naganuma, M; Nakajima, M; Yonehara, T, 2018) |
| " In a rat hyperuricemic model, treatment with Morin/HES-DOCA-NPs demonstrated superior therapeutic efficacy over Morin in decreasing serum uric acid level, increasing the uricosuric action, as well as attenuating hyperuricemia-associated inflammation in kidney of rats." | 7.88 | Preparation, characterization and systemic application of self-assembled hydroxyethyl starch nanoparticles-loaded flavonoid Morin for hyperuricemia therapy. ( Li, J; Lu, L; Ma, Q; Yang, Y; Zhang, J, 2018) |
| "Febuxostat is tolerable in chronic kidney disease (CKD) patients with hyperuricemia." | 7.88 | The impact of serum uric acid reduction on renal function and blood pressure in chronic kidney disease patients with hyperuricemia. ( Fujigaki, Y; Goto, D; Kato, A; Ohashi, N; Ohishi, K; Sato, T; Takeda, A; Tsuji, T; Yasuda, H, 2018) |
| "Fraxini Cortex (also known as Qinpi, QP) has been used for the treatment of hyperuricemia with a significant difference on efficacy of QP from different regions." | 7.88 | Research on the pharmacodynamics and mechanism of Fraxini Cortex on hyperuricemia based on the regulation of URAT1 and GLUT9. ( Feng, L; Han, L; Jia, X; Li, C; Li, Z; Liu, J; Qiao, X; Song, J; Tan, X; Wang, G; Yuan, X; Zhang, X; Zhou, Y, 2018) |
| "Uric acid is a molecule that is known to act as a natural antioxidant in acute oxidative stress conditions such as acute ischemic stroke (AIS)." | 7.88 | Can high uric acid levels be an independent risk factor for acute ischemic stroke due to large-artery atherosclerosis? ( Acar, AB; Acar, T; Gül, SS; Güzey Aras, Y, 2018) |
| "There is an ongoing debate regarding the relationship between uric acid and osteoarthritis (OA)." | 7.88 | Serum uric acid level is not associated with osteoarthritis in Korean population: data from the Seventh Korea National Health and Nutrition Examination Survey 2016. ( Choe, JY; Kim, SK; Kwak, SG, 2018) |
| " SUA was downregulated during acute gouty arthritis, which might be associated with increased urinary excretion of uric acid." | 7.88 | Renal excretion is a cause of decreased serum uric acid during acute gout. ( Cao, L; Guo, M; Lv, X; Wan, W; Xue, Y; Zhao, T; Zheng, S; Zhu, X; Zou, H, 2018) |
| " Elevated serum uric acid has been demonstrated to be associated with obesity in the adult population in many countries; however, there is still a lack of evidence for the Bangladeshi population." | 7.88 | Prevalence of hyperuricemia and the relationship between serum uric acid and obesity: A study on Bangladeshi adults. ( Ahmed, S; Ali, N; Haque, T; Islam, F; Islam, S; Kathak, RR; Mahmood, S; Mohanto, NC; Molla, NH; Nurunnabi, SM; Perveen, R; Rahman, M; Rahman, S; Sumon, AH, 2018) |
| "We indicated that uric acid, AIP, and proteinuria are closely related." | 7.88 | Relationship Between Uric Acid, Proteinuria, and Atherogenic Index of Plasma in Renal Transplant Patients. ( Biyik, Z; Guney, I, 2018) |
| " We injected uric acid intraperitoneally, 125mg/kg/day for 7 days (UA7) and 14 days (UA14), to induce hyperuricemia and then gave allopurinol 50mg/kg/day for 7 days to lower serum uric acid levels (UA7AL7 and UA14AL7)." | 7.88 | Reduction of Serum Uric Acid Associated with Attenuation of Renal Injury, Inflammation and Macrophages M1/M2 Ratio in Hyperuricemic Mice Model. ( Arfian, N; Haryono, A; Nugrahaningsih, DAA; Romi, MM; Sari, DCR, 2018) |
| "Metabolic Syndrome (Mets) and increased serum uric acid (SUA), are well known renal risk predictors and often coexist in patients with type 2 diabetes (T2D)." | 7.85 | Metabolic syndrome, serum uric acid and renal risk in patients with T2D. ( Ceriello, A; De Cosmo, S; Fioretto, P; Genovese, S; Giorda, C; Guida, P; Piscitelli, P; Pontremoli, R; Russo, G; Viazzi, F, 2017) |
| "Little is known about the relationship serum uric acid (SUA) and hypertension in Chinese population." | 7.85 | An observational study on the relationship between serum uric acid and hypertension in a Northern Chinese population aged 45 to 59 years. ( Cheng, HY; Huang, XL; Liu, SS; Shi, YX; Yu, FN, 2017) |
| "Hyperuricemia is a clinical condition characterized by an elevated level of serum uric acid and is a key risk factor for the development of gout and metabolic disorders." | 7.85 | Salvia plebeia Extract Inhibits Xanthine Oxidase Activity In Vitro and Reduces Serum Uric Acid in an Animal Model of Hyperuricemia. ( Choi, CW; Choi, Y; Hong, SS; Hyun, JM; Kim, JK; Kim, P; Kim, WJ; Kwon, JG; Lee, JK; Lee, JS; Park, K; Seo, C; Song, MJ; Sung, H, 2017) |
| "To investigate the effects of intragastric administration of Clostridium butyricum in regulating serum uric acid, lipopolysaccharides (LPS), interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) in rats with hyperuricemia rats." | 7.85 | [Effects of Clostridium butyricum on serum uric acid and inflammatory mediators in rats with hyperuricemia]. ( Fang, ZR; Liu, LL; Liu, YB; Shen, YT; Wang, L, 2017) |
| " pensylvanicum extract showed activity in reducing serum uric acid (Sur) through effect renal glucose transporter 9 (GLUT9), organic anion transporter 1 (OAT1) and urate transporter 1 (URAT1) mainly and inhibited XO activity in vivo of mice with PO induced hyperuricemia." | 7.85 | Caffeoylquinic acid derivatives rich extract from Gnaphalium pensylvanicum willd. Ameliorates hyperuricemia and acute gouty arthritis in animal model. ( Hu, YJ; Jiang, Y; Lin, Y; Pan, HH; Song, XJ; Zhang, HJ, 2017) |
| "Previous studies have examined the association between elevated serum uric acid (SUA) level and hypertension; however, the association in the Chinese elderly is still uncertain." | 7.85 | Association between serum uric acid level and hypertension in a Chinese elderly rural population. ( He, Y; Jiang, B; Liu, M; Wang, J; Wang, Y; Wu, L; Zeng, J; Zhang, D, 2017) |
| "The present study aimed to identify a potential association between serum UA and cardiac troponin I (cTnI) levels and to find out whether uric acid could differentiate patients presenting with the acute myocardial infarction (AMI) and unstable angina pectoris (UAP) in hyperuricemic and normouricemic acute coronary syndrome (ACS) patients." | 7.85 | Serum Uric Acid Could Differentiate Acute Myocardial Infarction and Unstable Angina Pectoris in Hyperuricemic Acute Coronary Syndrome Patients. ( Hasic, S; Jadric, R; Kadic, D; Kiseljakovic, E; Spahic, E, 2017) |
| " Patients in the 3rd serum uric acid tertile had a higher prevalence of any cardiac conduction defects than those belonging to 2nd or 1st tertile, respectively (35." | 7.85 | Relation of elevated serum uric acid levels to first-degree heart block and other cardiac conduction defects in hospitalized patients with type 2 diabetes. ( Bonapace, S; Bonora, E; Dugo, C; Mantovani, A; Morani, G; Pichiri, I; Rigolon, R; Targher, G; Zoppini, G, 2017) |
| "Previous studies found elevated serum uric acid (SUA) was associated with the development or progression of non-alcoholic fatty liver disease (NAFLD) in general population; in this study we aim to investigate the association of SUA and the severity of NAFLD based on grade of fatty liver on ultrasonography in non-obese subjects." | 7.85 | Serum uric acid and non-alcoholic fatty liver disease in non-obesity Chinese adults. ( Chen, H; Gong, L; Luo, R; Peng, B; Ren, W; Wang, Y; Zheng, X, 2017) |
| "Uric acid (UA) plays important roles in inducing renal inflammation, intra-renal vasoconstriction and renal damage." | 7.85 | Uric acid causes kidney injury through inducing fibroblast expansion, Endothelin-1 expression, and inflammation. ( Arfian, N; Romi, MM; Sari, DCR; Setyaningsih, WAW; Tranggono, U, 2017) |
| "To investigate the effects of gender on the association of serum uric acid (SUA) levels and atrial fibrillation (AF) prevalence in a community-based Chinese population." | 7.85 | Association between serum uric acid and atrial fibrillation: a cross-sectional community-based study in China. ( Chen, Y; Han, X; Liu, H; Liu, Y; Qiu, J; Xia, Y; Yang, Y; Yin, X; Zhou, Y, 2017) |
| "Hyperuricemia leads to insulin resistance, whereas insulin resistance decreases renal excretion of uric acid, both mechanisms link elevated serum uric acid with metabolic syndrome." | 7.85 | Circulating Levels of Uric Acid and Risk for Metabolic Syndrome. ( Durán-Salgado, MB; Garro-Almendaro, AK; Huerta-Ramírez, S; Lozano-Nuevo, JJ; Morales-López, H; Rubio-Guerra, AF; Vargas-Ayala, G, 2017) |
| " This study investigated the association between serum uric acid and the incidence of nonfatal stroke in a Japanese community-based population." | 7.85 | Associations between serum uric acid levels and the incidence of nonfatal stroke: a nationwide community-based cohort study. ( Asahi, K; Fujimoto, S; Hirayama, A; Ichikawa, K; Iseki, K; Kamei, K; Kasahara, M; Kondo, M; Konta, T; Kubota, I; Moriyama, T; Narita, I; Shibagaki, Y; Tsuruya, K; Watanabe, T; Yamagata, K, 2017) |
| "Objective To explore the possible correlation between uric acid levels and leukoaraiosis (LA)." | 7.85 | The association of uric acid with leukoaraiosis. ( Cai, RW; Chen, YF; Huang, YH; Li, JJ; Li, MM; Lin, YY, 2017) |
| "The aim of the study was to compare reductions in uric acid (UA), length of stay (LOS), and hospitalization costs in patients with tumor lysis syndrome (TLS) treated with rasburicase or allopurinol." | 7.85 | A Clinical and Economic Comparison of Rasburicase and Allopurinol in the Treatment of Patients With Clinical or Laboratory Tumor Lysis Syndrome. ( Cairo, MS; Eaddy, MT; Tangirala, K; Thompson, S, 2017) |
| "To explore the effects of Rhizoma Polygoni Cuspidati and Ramulus Cinnamomi compatibility (PR) on uric acid metabolism and the expression of urinary neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury molecule-1 (KIM-1) in rats with hyperuricemia." | 7.85 | Effect of Rhizoma Polygoni Cuspidati and Ramulus Cinnamomi compatibility on uric acid metabolism and urinary neutrophil gelatinase-associated lipocalin and kidney injury molecule-1 in rats with hyperuricemia. ( Han, B; Hu, XG; Huang, HZ; Lei, M; Li, Z; Shi, W; Zhou, XM; Zhu, CX, 2017) |
| "The objective was to determine whether serum uric acid concentrations were associated with metabolic syndrome in a population from Wuhan." | 7.85 | Positive association between metabolic syndrome and serum uric acid in Wuhan. ( Chen, M; Fan, ZF; Fu, YQ; Li, D; Wang, L; Yang, H; Zeng, W; Zeng, XY; Zheng, JS, 2017) |
| "Potassium oxonate, a selectively competitive uricase inhibitor, produced hyperuricemia (HUA) in rodents in a previous study." | 7.85 | Potassium oxonate induces acute hyperuricemia in the tree shrew (tupaia belangeri chinensis). ( Li, ZL; Ma, KL; Tang, DH; Wang, CY; Ye, YS; Zheng, H, 2017) |
| "Associations between high serum uric acid (SUA) levels and high blood pressure (BP), as well as between SUA levels and metabolic syndrome (MetS) have already been reported." | 7.83 | Uric acid blood levels and relationship with the components of metabolic syndrome in hypertensive patients. ( Kalogeropoulos, P; Karamanou, AG; Moustakas, G; Papavasileiou, MV; Patsianis, S; Pittaras, A, 2016) |
| "This cross-sectional study from January 2012 to December 2012 aimed to examine the sex-specific association between serum uric acid (SUA) levels/hyperuricemia and hypertension among Japanese patients." | 7.83 | Association Between Serum Uric Acid Levels/Hyperuricemia and Hypertension Among 85,286 Japanese Workers. ( Fujibayashi, K; Fukuda, H; Hisaoka, T; Isonuma, H; Jose, PA; Matsuo, H; Miwa, Y; Naito, T; Nakayama, A; Sanada, H; Suzuki, A; Uehara, Y; Yokokawa, H, 2016) |
| "The objective of this paper is to assess whether pulmonary hypertension (PH) may be detected at one point in time or longitudinally predicted by serum uric acid (sUA) levels in systemic lupus erythematosus (SLE)." | 7.83 | Levels of uric acid may predict the future development of pulmonary hypertension in systemic lupus erythematosus: a seven-year follow-up study. ( Amezcua-Guerra, LM; Castillo-Martínez, D; Juárez, M; Lozada-Navarro, AC; Marroquín-Fabián, E; Mora-Ramírez, M; Sánchez-Muñoz, F; Sandoval, J; Vargas-Barrón, J, 2016) |
| "Serum uric acid (SUA) is the end-product of purine metabolism in humans, and its levels often increase in subjects with metabolic syndrome (MetS)." | 7.83 | High serum uric acid levels increase the risk of metabolic syndrome in elderly women: The PRO.V.A study. ( Crepaldi, G; Giantin, V; Maggi, S; Manzato, E; Maselli, M; Musacchio, E; Perissinotto, E; Sartori, L; Sergi, G; Toffanello, ED; Veronese, N; Zambon, S; Zurlo, A, 2016) |
| "Psoriasis has been reported to be associated with raised serum uric acid levels and gout, and uric acid has been demonstrated to mediate inflammatory pathways via secretion of pro-inflammatory chemokines." | 7.83 | Psoriasis and uric acid: a population-based cross-sectional study. ( Lai, YC; Yew, YW, 2016) |
| "To examine the cross-sectional associations of the serum uric acid level and hyperuricemia (HU) with the radiographic features of osteoarthritis (OA), including osteophytes (OST) and joint space narrowing (JSN), a total of 4685 subjects were included in this study." | 7.83 | The associations of serum uric acid level and hyperuricemia with knee osteoarthritis. ( Ding, X; Gao, SG; Lei, GH; Li, H; Li, YS; Wei, J; Xiong, YL; Yang, T; Zeng, C; Zhang, Y, 2016) |
| "Longitudinal changes in uric acid levels were independently associated with the renal function decline in elderly patients with hypertension." | 7.83 | Influence of changes in serum uric acid levels on renal function in elderly patients with hypertension: a retrospective cohort study with 3.5-year follow-up. ( Chen, H; Huang, F; Lin, C; Lin, F; Zhang, H; Zhu, P, 2016) |
| "This study sought to observe the effects of allopurinol on the cardiac function of non-hyperuricaemic patients with chronic heart failure and determine the safety of allopurinol for clinical applications." | 7.83 | Allopurinol ameliorates cardiac function in non-hyperuricaemic patients with chronic heart failure. ( Deng, SB; Kao, GY; Li, J; Ma, Y; She, Q; Wang, JS; Xiao, J, 2016) |
| "Elevated uric acid (UA) is associated with the presence of the metabolic syndrome (MetS)." | 7.83 | Overweight modifies the longitudinal association between uric acid and some components of the metabolic syndrome: The Tromsø Study. ( Eriksen, BO; Jenssen, TG; Norvik, JV; Solbu, MD; Storhaug, HM; Ytrehus, K; Zykova, SN, 2016) |
| "The serum level of uric acid (UA) is a well-known prognostic factor for heart failure (HF) patients." | 7.83 | The prognostic impact of uric acid in patients with severely decompensated acute heart failure. ( Asai, K; Hata, N; Kobayashi, N; Matsushita, M; Nishigoori, S; Okazaki, H; Shibuya, J; Shimizu, W; Shinada, T; Shiomura, R; Shirakabe, A; Yamamoto, Y, 2016) |
| " The effects and possible molecular mechanisms of astilbin on potassium oxonate-induced hyperuricemia mice were investigated in this study." | 7.83 | Astilbin improves potassium oxonate-induced hyperuricemia and kidney injury through regulating oxidative stress and inflammation response in mice. ( Chen, J; Wang, M; Zhang, N; Zhao, J, 2016) |
| " We evaluated the association between serum uric acid and uACR in persons with 0, and 1-2 metabolic syndrome (MetS) components and determined the modification effects of visceral adiposity index (VAI), mean arterial pressure (MAP), and fasting glucose on this association." | 7.83 | The Impact of Blood Pressure and Visceral Adiposity on the Association of Serum Uric Acid With Albuminuria in Adults Without Full Metabolic Syndrome. ( Bruthans, J; Cifkova, R; Hamet, P; Krajcoviechova, A; Tahir, MR; Tremblay, J; Wohlfahrt, P, 2016) |
| " Therefore, the aim of this study was to determine whether coffee, tea, and caffeine intake influences serum uric acid and the risk of hyperuricemia in the Korean Multi-Rural Communities Cohort." | 7.81 | The effect of coffee, tea, and caffeine consumption on serum uric acid and the risk of hyperuricemia in Korean Multi-Rural Communities Cohort. ( Bae, J; Choi, BY; Chun, BY; Kim, MK; Kim, SK; Lee, YH; Park, PS; Shin, DH; Shin, MH, 2015) |
| "A larger LAAPD and an elevated serum uric acid level were found to be independent predictors of LA thrombosis in patients with MS in SR." | 7.81 | Usefulness of the uric acid and CHA₂DS₂-VASc score in prediction of left atrial thrombosis in patients with mitral stenosis and sinus rhythm. ( Akın, F; Akturk, F; Aslan, S; Bırand, A; Celık, O; Ozturk, D; Ozyılmaz, SO; Yıldırım, A, 2015) |
| "There is very limited information on the association between arsenic and serum uric acid levels or gout." | 7.81 | Arsenic exposure, hyperuricemia, and gout in US adults. ( Fadrowski, JJ; Guallar, E; Kuo, CC; Lin, YS; Navas-Acien, A; Weaver, V, 2015) |
| "Several studies have demonstrated a relationship between increased serum uric acid (SUA) concentrations and the prevalence of metabolic syndrome (MetS) in the oriental population." | 7.81 | Associations between serum uric acid concentrations and metabolic syndrome and its components in the PREDIMED study. ( Babio, N; Basora, J; Becerra-Tomás, N; Corella, D; Estruch, R; Fitó, M; Martínez-González, MA; Ortega-Calvo, M; Recondo, J; Ros, E; Salas-Salvadó, J; Serra-Majem, L; Wärnberg, J, 2015) |
| "To quantify the risk of non-fatal acute myocardial infarction (AMI) among users of allopurinol." | 7.81 | Allopurinol use and risk of non-fatal acute myocardial infarction. ( Álvarez, A; Bryant, V; de Abajo, FJ; García-Poza, P; García-Rodríguez, LA; Gil, MJ; Rodríguez, A, 2015) |
| " Allopurinol is a commonly used medication to treat hyperuricemia and its complications." | 7.81 | Anti-hyperuricemia effects of allopurinol are improved by Smilax riparia, a traditional Chinese herbal medicine. ( Anderson, S; He, Y; Mi, C; Wang, CZ; Wang, SQ; Wu, XH; Yuan, CS; Zhang, J; Zhang, YW, 2015) |
| "Hyperhomocysteinemia and hyperuricemia are both considered risk factors for coronary artery disease." | 7.81 | Assessment of a possible link between hyperhomocysteinemia and hyperuricemia. ( Cohen, E; Garty, M; Goldberg, E; Krause, I; Levi, A; Vecht-Lifshitz, SE, 2015) |
| "We asked, is uric acid as effective as proteinuria at identifying perinatal risk in high-risk women with gestational hypertension? Uric acid was measured in samples obtained ≈4." | 7.81 | Uric Acid Determination in Gestational Hypertension: Is it as Effective a Delineator of Risk as Proteinuria in High-Risk Women? ( Althouse, AD; Clifton, RG; Roberts, JM; Schmella, MJ, 2015) |
| "Inefficient renal excretion of uric acid is the main pathophysiological mechanism for hyperuricemia in gout patients." | 7.81 | Renal clearance of uric acid is linked to insulin resistance and lower excretion of sodium in gout patients. ( Aniel-Quiroga, MA; Chinchilla, SP; Erauskin, GG; Herrero-Beites, AM; Merriman, T; Perez-Ruiz, F, 2015) |
| "Prednisone therapy was administered for a short time to 191 symptomatic HF patients with hyperuricemia (serum uric acid > 7 mg/dl)." | 7.81 | Prednisone in Uric Acid Lowering in Symptomatic Heart Failure Patients with Hyperuricemia -- The PUSH-PATH3 Study. ( Duan, L; Ji, L; Li, L; Liu, C; Liu, G; Liu, K; Ma, G; Meng, H; Tian, L; Wang, L; Zhai, J; Zhao, Q; Zhen, Y; Zheng, M, 2015) |
| "To explore the effect of Compound Tufuling Granules ([characters: see text], CTG) on regulating glucose transporter 9 (GLUT9) expression in the kidney to influence the uric acid excretion by the kidney and serum uric acid (SUA) level in hyperuricemia mice." | 7.81 | Compound Tufuling Granules ([characters: see text]) regulate glucose transporter 9 expression in kidney to influence serum uric acid level in hyperuricemia mice. ( Li, J; Liu, YW; Sun, WF; Zhang, HH; Zhang, XX, 2015) |
| "It is controversial whether serum uric acid (SUA) is a risk factor for the prevalence of metabolic syndrome (MetS)." | 7.81 | Cross-sectional and longitudinal associations between serum uric acid and metabolic syndrome: Results from Fangchenggang Area Male Health and Examination Survey in China. ( Chen, D; Gao, Y; Jiang, Y; Lin, X; Lu, Z; Mo, Z; Tan, A; Wu, C; Yang, X; Yao, Z; Zhang, H, 2015) |
| "Recent studies have demonstrated an association between serum uric acid (SUA) levels and metabolic syndrome (MetS)." | 7.81 | Prospective study of serum uric acid levels and incident metabolic syndrome in a Korean rural cohort. ( Ahn, SV; Choi, E; Chung, CH; Kim, HM; Koh, SB; Lee, ES; Lee, EY; Lim, JS; Yadav, D, 2015) |
| " Linear regression was used to evaluate associations between uric acid and clinical and laboratory findings associated with metabolic syndrome." | 7.81 | [Metabolic complications of obesity during adolescence, particularly regarding elevated uric acid levels]. ( Almási, A; Barkai, L; Fehér, V; Kiss-Tóth, E; Ságodi, L, 2015) |
| " Allopurinol is a commonly used medication to treat hyperuricemia and its complications." | 7.81 | Pallidifloside D from Smilax riparia enhanced allopurinol effects in hyperuricemia mice. ( Anderson, S; He, Y; Hou, PY; Mi, C; Wang, SQ; Wu, XH; Yu, F; Zhang, J; Zhang, YW, 2015) |
| "There are data describing that cardiovascular risks related to serum uric acid (SUA) levels may begin below the current diagnostic level for hyperuricemia." | 7.81 | Uric acid levels within the normal range predict increased risk of hypertension: a cohort study. ( Dinour, D; Holtzman, EJ; Leiba, A; Shani, M; Vinker, S, 2015) |
| "Uric acid (UA) is associated with high blood pressure in adolescents and with left ventricular hypertrophy (LVH) and cardiovascular disease (CVD) in adults." | 7.81 | Elevated uric acid and obesity-related cardiovascular disease risk factors among hypertensive youth. ( Appel, LJ; Brady, TM; Fadrowski, JJ; Holmes, KW; Loeffler, LF; Miller, ER; Reschke, LD, 2015) |
| "To explore the association between serum uric acid (SUA) levels, metabolic syndrome (MetS) and cardiovascular disease (CVD) in patients treated with lipid-lowering agents from multiple centers in China." | 7.81 | The association between serum uric acid levels, metabolic syndrome and cardiovascular disease in middle aged and elderly Chinese: results from the DYSlipidemia International Study. ( Chen, K; Fang, Y; Hu, D; Mu, Y; Nie, Y; Tian, Y; Wang, H; Xie, Z, 2015) |
| "The aim of this study was to assess the correlation between blood lead levels and both serum uric acid and hyperuricemia in adult residents living within an area of China with lead pollution." | 7.81 | The Effects of Lead Exposure on Serum Uric Acid and Hyperuricemia in Chinese Adults: A Cross-Sectional Study. ( Dai, H; Deng, Q; Huang, Z; Li, Y; Lu, Y; Ning, X; Xiao, T; Yuan, H, 2015) |
| "An elevated serum concentration of uric acid may be associated with an increased risk of acute kidney injury (AKI)." | 7.81 | Relationship between Serum Uric Acid Concentration and Acute Kidney Injury after Coronary Artery Bypass Surgery. ( Baek, SH; Chin, JH; Choi, IC; Choi, JH; Ji, SM; Joung, KW; Kim, JY; Lee, EH, 2015) |
| "To investigate the mechanisms underlying the therapeutic effects of losartan on hyperuricemia-induced aortic atherosclerosis, in an experimental rabbit model." | 7.81 | Losartan alleviates hyperuricemia-induced atherosclerosis in a rabbit model. ( Ding, Y; Li, N; Miao, P; Zheng, H, 2015) |
| "Our objective was to evaluate data on the cost-effectiveness of febuxostat compared with standard clinical practice with allopurinol in patients with gout that was presented to the Scottish Medicines Consortium (SMC) in 2010." | 7.80 | Cost-effectiveness of febuxostat in chronic gout. ( Beard, SM; Nuki, G; Pearson, IV; von Scheele, BG, 2014) |
| "Serum levels of uric acid (UA) are associated with metabolic syndrome (MetS)." | 7.80 | Serum uric acid is an independent predictor of metabolic syndrome in a Japanese health screening population. ( Oda, E, 2014) |
| "Between 2009 and 2012, we conducted a study among 406 consecutive first-ever ischemic stroke patients to assess the relationship between uric acid and carotid artery." | 7.80 | Association of uric acid and carotid artery disease in patients with ischemic stroke. ( Kabaroglu, C; Karaman, B; Kumral, E; Orman, M, 2014) |
| "We assessed the effect of increased serum uric acid (SUA) concentration and hyperuricemia on subclinical organ damage." | 7.80 | Serum uric acid concentration and asymptomatic hyperuricemia with subclinical organ damage in general population. ( Li, Y; Lu, J; Wu, X; Yang, C, 2014) |
| "We tested the hypothesis that uric acid levels predict new-onset hypertension in the Japanese general population." | 7.80 | Uric acid levels predict future blood pressure and new onset hypertension in the general Japanese population. ( Dohi, Y; Kimura, G; Takase, H, 2014) |
| "To investigate the effect of total saponin of dioscorea (TSD) on uric acid excretion indicators in chronic hyperuricemia rats, and to study the correlation between blood levels of uric acid (SUA) and uric acid excretion indicators." | 7.80 | [Effect of total saponin of dioscorea on uric acid excretion indicators in chronic hyperuricemia rats]. ( Chen, GL; Li, L; Na, S; Wu, S, 2014) |
| "Post-transplant hyperuricemia (PTHU), defined as serum uric acid concentration ≥7." | 7.80 | Efficacy and safety of febuxostat in the treatment of hyperuricemia in stable kidney transplant recipients. ( Hara, T; Hayashida, Y; Inui, M; Kakehi, Y; Kohno, M; Moriwaki, K; Nishijima, Y; Nishiyama, A; Sofue, T; Ueda, N, 2014) |
| "Serum uric acid (UA) is now beginning to be considered a risk predictor for cardiovascular diseases." | 7.80 | Serum uric acid as a risk predictor for erectile dysfunction. ( Heydari, R; Mehrsai, A; Pourmand, G; Salem, S, 2014) |
| " Despite evidence of uric acid-induced endothelial dysfunction, a relationship with insulin resistance has not been clearly established." | 7.80 | Uric acid induces endothelial dysfunction by vascular insulin resistance associated with the impairment of nitric oxide synthesis. ( Choi, YJ; Hien, TT; Kang, DH; Kang, KW; Kim, KC; Lee, BH; Lee, J; Lee, KY; Lee, MY; Lee, SM; Yoon, Y, 2014) |
| "The cause and effect relationship between serum uric acid levels and hypertension can be difficult to evaluate because antihypertensive drugs sometimes affect uric acid levels." | 7.80 | Relationship between serum uric acid levels and hypertension among Japanese individuals not treated for hyperuricemia and hypertension. ( Asano, T; Hisatome, I; Komatsu, I; Kuwabara, M; Masuda, K; Mizuno, A; Nishi, Y; Niwa, K; Takahashi, O; Yamazoe, M, 2014) |
| "Elevated albuminuria as well as an increased serum uric acid concentration is associated with poor cardiovascular outcome." | 7.80 | The association of albuminuria with tubular reabsorption of uric acid: results from a general population cohort. ( Bakker, SJ; de Jong, PE; Gansevoort, RT; Joosten, MM; Scheven, L, 2014) |
| "This is the first large study showing that serum uric acid is not associated with an increase in the risk of periprocedural myocardial infarction in patients undergoing percutaneous coronary revascularization." | 7.80 | Uric acid and risk of periprocedural myocardial infarction in patients undergoing percutaneous coronary intervention. ( Barbieri, L; De Luca, G; Di Giovine, G; Marino, P; Schaffer, A; Verdoia, M, 2014) |
| "To assess the relationship between serum uric acid and target organ damage (left ventricular hypertrophy and microalbuminuria) in untreated patients with essential hypertension." | 7.80 | Serum uric acid and target organ damage in essential hypertension. ( Odia, OJ; Ofori, SN, 2014) |
| "The aim of this study was to determine the association between vitamin C intake and risk of hyperuricemia or serum uric acid levels in male and female subjects in the Korean Multi-Rural Communities Prospective Cohort." | 7.80 | The effect of vitamin C intake on the risk of hyperuricemia and serum uric acid level in Korean Multi-Rural Communities Cohort. ( Bae, J; Choi, BY; Chun, BY; Kim, MK; Kim, SK; Lee, YH; Park, PS; Shin, DH; Shin, MH, 2014) |
| "To identify the risk factors of kidney injuries in hypertensive patients with uric acid (UA) metabolic disorders in order to choose the optimal management tactics, by analyzing the changes in markers for endothelial dysfunction (endothelin-1 (ET-1), microalbuminuria (MAU), intima-media thickness (IMT)) and tubulointerstitial tissue lesion (beta2-microglobulin (beta2-MG, monocyte chemotactic protein-1 (MCP-1))." | 7.80 | [Clinical value of the determination of markers for endothelial dysfunction (endothelin-1, microalbuminuria) and tubulointerstitial tissue lesion (β2-microglobulin, monocyte chemotactic protein-1) in hypertensive patients with uric acid metabolic disorder ( Balkarov, IM; Kozlovskaia, LV; Shcherbak, AV; Stakhova, TIu; Taranova, MV, 2014) |
| "Excess circulating uric acid, a product of hepatic glycolysis and purine metabolism, often accompanies metabolic syndrome." | 7.80 | Early-onset metabolic syndrome in mice lacking the intestinal uric acid transporter SLC2A9. ( DeBosch, BJ; Fujiwara, H; Kluth, O; Moley, K; Schürmann, A, 2014) |
| "Gout with uric acid underexcretion is associated with transporter gene SNP related mainly to tubular reabsorption, whereas uric acid normoexcretion is associated only with tubular secretion SNP." | 7.80 | Tubular urate transporter gene polymorphisms differentiate patients with gout who have normal and decreased urinary uric acid excretion. ( Bailén, R; Banegas, JR; de Miguel, E; Puig, JG; Torres, RJ, 2014) |
| "To date, no study in the published literature has investigated the role of various serum uric acid (SUA) concentrations in the development of angiographically-proven coronary artery disease (CAD) in premenopausal women." | 7.80 | Association of serum uric acid and coronary artery disease in premenopausal women. ( Cao, SJ; He, LJ; Yang, Q; Yang, SW; Zhang, JW; Zhou, YJ, 2014) |
| "The association between serum uric acid (SUA) levels and metabolic syndrome (MetS) has recently been reported in several cross-sectional and longitudinal studies." | 7.80 | A possible role of serum uric acid as a marker of metabolic syndrome. ( Cho, S; Kim, SR; Lee, YJ, 2014) |
| " Of note, diabetic subjects with glycosuria, who represented 24% of the diabetic participants, had a null prevalence of hyperuricemia, and statistically higher values for fractional excretion of uric acid, Na excretion index, and prevalence of microalbuminuria than those without glycosuria." | 7.80 | Serum uric acid and disorders of glucose metabolism: the role of glycosuria. ( Andrade, JA; Garcia Rosa, ML; Greffin, S; Kang, HC; Lugon, JR, 2014) |
| "While the prevalence of gout was calculated by counting patients with this diagnosis hyperuricemia was inferred in patients taking allopurinol at hospital admission or discharge, on the assumption that this drug was only prescribed owing to the finding of high serum levels of uric acid." | 7.80 | Gout, allopurinol intake and clinical outcomes in the hospitalized multimorbid elderly. ( Conca, A; Corrao, S; Djade, CD; Franchi, C; Mannucci, PM; Marcucci, M; Marengoni, A; Nobili, A; Pasina, L; Salerno, F; Tettamanti, M, 2014) |
| "Current evidence shows that uric acid is a potent antioxidant whose serum concentration increases rapidly after acute ischemic stroke (AIS)." | 7.79 | Serum uric acid and outcome after acute ischemic stroke: PREMIER study. ( Arauz, A; Barinagarrementeria, F; Cantú-Brito, C; Chiquete, E; León-Jiménez, C; Murillo-Bonilla, LM; Ochoa-Guzmán, A; Orozco-Valera, DR; Ramos-Moreno, A; Ruiz-Sandoval, JL; Villarreal-Careaga, J, 2013) |
| "Experimental and epidemiological studies have demonstrated that urinary angiotensinogen (AGT) is a novel biomarker for the intrarenal activity of the renin-angiotensin system in hypertension (HT)." | 7.79 | Urinary angiotensinogen as a marker of intrarenal angiotensin II activity in adolescents with primary hypertension. ( Kuroczycka-Saniutycz, E; Milewski, R; Sulik, A; Wasilewska, A, 2013) |
| "The purpose of this work was to investigate if in adolescents with hyperuricemia serum levels of asymmetric and symmetric dimethylarginine (ADMA, SDMA) are increased and if their levels correlate with serum uric acid (UA)." | 7.79 | Asymmetric and symmetric dimethylarginine in adolescents with hyperuricemia. ( Korzeniecka-Kozerska, A; Taranta-Janusz, K; Tenderenda-Banasiuk, E; Wasilewska, A, 2013) |
| "The aim of this study was to compare serum uric acid values in two ethnically distinct Chinese populations: Uyghur, with a high prevalence of nonalcoholic fatty liver disease, and Han, with a lower prevalence." | 7.79 | Serum uric acid levels and non-alcoholic fatty liver disease in Uyghur and Han ethnic groups in northwestern China. ( Cai, W; Miao, L; Sun, YP; Wu, X; Yao, H; Zhang, B; Zou, Y, 2013) |
| "Our study showed that uric acid is not associated with platelet aggregation, the extent of coronary artery disease and IMT." | 7.78 | Uric acid does not affect the prevalence and extent of coronary artery disease. Results from a prospective study. ( Bellomo, G; Cassetti, E; Coppo, L; De Luca, G; Di Mario, C; Iorio, S; Marino, P; Santagostino, M; Secco, GG; Venegoni, L; Verdoia, M, 2012) |
| "We evaluated the association of serum uric acid (SUA) level and development of coronary collateral vessels (CCVs) in patients with acute coronary syndrome (ACS)." | 7.78 | High levels of serum uric acid impair development of coronary collaterals in patients with acute coronary syndrome. ( Demircelik, MB; Doger, C; Duran, M; Murat, SN; Ocak, A; Ornek, E; Turfan, M; Vatankulu, MA; Yalcin, AA, 2012) |
| ", isotretinoin used for severe acne) and high doses of preformed vitamin A have been implicated in the pathogenesis of hyperuricemia and gout, whereas a trial reported that β-carotene may lower serum uric acid (UA) levels." | 7.78 | Independent association of serum retinol and β-carotene levels with hyperuricemia: A national population study. ( Choi, HK; Choi, WJ; Curhan, G; Ford, ES; Rankin, JI, 2012) |
| "We aimed to elucidate the relation between serum uric acid (SUA) level and severity of coronary artery disease (CAD) in nondiabetic, nonhypertensive patients (n = 246) with acute coronary syndrome (ACS)." | 7.78 | High levels of serum uric acid predict severity of coronary artery disease in patients with acute coronary syndrome. ( Akpek, M; Duran, M; Elcik, D; Ergin, A; Eryol, NK; Inanc, MT; Kalay, N; Kasapkara, HA; Kaya, MG; Ocak, A; Oguzhan, A; Orscelik, O, 2012) |
| " Overall serum uric acid (UA) concentration increased, whereas in patients with hyperuricemia there was a significant reduction in this value." | 7.78 | Antihypertensive effect of a fixed-dose combination of losartan/hydrochlorothiazide in patients with uncontrolled hypertension: a multicenter study. ( Akaba, K; Endo, S; Fukui, A; Gomi, H; Hamaguchi, A; Hanaoka, K; Hara, Y; Hasegawa, T; Hayakawa, H; Hayashi, F; Hikida, M; Hirano, K; Horiguchi, M; Hosoya, M; Hosoya, T; Ichida, K; Ikeda, M; Imai, T; Ishii, T; Ishikawa, H; Ishikawa, M; Kameda, C; Kanai, T; Kasai, T; Kawamura, T; Kobayashi, A; Kobayashi, H; Kurashige, M; Kuriyama, S; Kusama, Y; Maezawa, H; Maezawa, Y; Maruyama, Y; Matsuda, H; Matsuo, N; Matsuo, T; Miura, Y; Miyajima, M; Miyakawa, M; Miyazaki, Y; Mizuguchi, M; Morita, T; Nakao, M; Nokano, H; Ogura, M; Ohkido, I; Ohno, I; Ohtsuka, Y; Okada, K; Okamoto, H; Okonogi, H; Saikawa, H; Saito, H; Sekiguchi, C; Soejima, M; Suetsugu, Y; Sugano, N; Suzuki, T; Takahashi, H; Takahashi, Y; Takamizawa, S; Takane, K; Takazoe, K; Tanaka, H; Tanaka, S; Terawaki, H; Tokudome, G; Tomonari, H; Toyoshima, R; Tsuboi, N; Udagawa, T; Ueda, H; Ueda, Y; Uetake, M; Unemura, S; Utsunomiya, M; Utsunomiya, Y; Yamada, T; Yamada, Y; Yamaguchi, Y; Yamamoto, H; Yokoo, T; Yokoyama, K; Yonezawa, H; Yoshida, H; Yoshida, M; Yoshizawa, T, 2012) |
| "Despite some epidemiologic research demonstrating a positive relationship between serum uric acid (SUA) levels and the prevalence of metabolic syndrome (MetS), prospective data on SUA as a predictor of MetS incidence are limited." | 7.78 | Uric acid level as a risk marker for metabolic syndrome: a Chinese cohort study. ( Bai, CH; Chien, KL; Chou, WY; Chou, YC; Chu, CH; Hwang, LC; Su, TC; Sun, CA; Tseng, CH; Yang, T; You, SL, 2012) |
| " Associations between uric acid (UA), metabolic syndrome (MetS) and carotid IMT have been reported, but findings regarding the relationship have been inconsistent." | 7.78 | Uric acid is an independent risk factor for carotid atherosclerosis in a Japanese elderly population without metabolic syndrome. ( Abe, M; Kawamoto, R; Kusunoki, T; Onji, M; Takayama, S, 2012) |
| " Women were grouped according to diagnosis (pre-eclampsia or gestational hypertension) and logistic regression analysis was used to determine the relationship between uric acid, haemoglobin, haematocrit and adverse outcomes; an α level of P < 0." | 7.78 | Plasma uric acid remains a marker of poor outcome in hypertensive pregnancy: a retrospective cohort study. ( Brown, MA; Davis, GK; Hawkins, TL; Mangos, GJ; Roberts, JM; Roberts, LM, 2012) |
| "For more than 200 years initially seen as a cause of gout, speaking in a politically correct 21st century term, a disease of the rich and very well nourished people, many experimental and epidemiological studies have associated increased levels of serum uric acid (UA) with the classical components of the metabolic syndrome (MS), type 2 diabetes, and cardiovascular disease [1]." | 7.78 | Elevated uric acid, the metabolic syndrome and cardiovascular disease: cause, consequence, or just a not so innocent bystander? ( Santos, RD, 2012) |
| "Although hyperuricemia is suggested to increase allantoin production in both pro- and antioxidant manners, it remains undetermined whether it increases the serum concentration of allantoin." | 7.78 | Relationship between serum allantoin and urate in healthy subjects and effects of benzbromarone in gout patients. ( Koga, M; Koyama, H; Kurajoh, M; Moriwaki, Y; Shoji, T; Sumida, C; Tsutsumi, Z; Yamamoto, A; Yamamoto, T, 2012) |
| " We reasoned that AKI resulted from hyperuricemia during MZ administration because serum concentrations of uric acid (31." | 7.78 | A case of acute kidney injury with marked hyperuricemia during mizoribine administration. ( Kohno, S; Nishino, T; Obata, Y; Ohta, Y; Shinzato, K; Shinzato, T; Yamashita, H, 2012) |
| "The aim of this study was to explore the prognostic role of serum uric acid (UA) measurement in the hospital and long-term mortality assessment in subjects with acute heart failure (AHF) from the Acute HEart FAilure Database registry (AHEAD)." | 7.78 | Uric acid, allopurinol therapy, and mortality in patients with acute heart failure--results of the Acute HEart FAilure Database registry. ( Coufal, Z; Fedorco, M; Jarkovský, J; Krűger, A; Linhart, A; Málek, F; Miklík, R; Ošťádal, P; Pařenica, J; Špinar, J; Vítovec, J; Vondraková, D; Widimský, P, 2012) |
| "Uric acid, the levels of which have been shown to increase after menopause, has been associated with metabolic syndrome." | 7.77 | Relationship between uric acid and metabolic syndrome according to menopausal status. ( Ahn, KH; Cho, GJ; Hur, JY; Kim, SH; Kim, T; Kim, YT; Lee, HJ; Park, HT; Shin, JH; Yi, KW, 2011) |
| "Experiments were performed in freshly harvested aortas from untreated animals and rats fed with oxonic acid (hyperuricemia), and compared to hyperuricemic rats treated with either allopurinol, benzbromarone or arginine." | 7.77 | Hyperuricemia attenuates aortic nitric oxide generation, through inhibition of arginine transport, in rats. ( Chernichovski, T; Engel, A; Grupper, A; Hillel, O; Schwartz, D; Schwartz, IF, 2011) |
| "First trimester elevated uric acid was associated with later pre-eclampsia and more strongly with pre-eclampsia and gestational hypertension with hyperuricemia." | 7.77 | First trimester uric acid and adverse pregnancy outcomes. ( Catov, J; Gandley, RE; Laughon, SK; Powers, RW; Roberts, JM, 2011) |
| "To explore the association of elevated serum uric acid with metabolic disorders and the risk factors of hyperuricemia in type 2 diabetes mellitus (T2DM)." | 7.77 | [Association of elevated uric acid with metabolic disorders and analysis of the risk factors of hyperuricemia in type 2 diabetes mellitus]. ( LI, SH; LIU, H; WU, D, 2011) |
| "To examine the association between renal function, serum uric acid and markers of both pro-inflammatory and prothrombotic state in patients with diabetes mellitus (DM), metabolic syndrome and coronary artery disease." | 7.77 | Uric acid as a link between renal dysfunction and both pro-inflammatory and prothrombotic state in patients with metabolic syndrome and coronary artery disease. ( Buraczyńska, MJ; Kondracki, B; Rychta, E; Waciński, P; Wysokiński, A; Zapolski, T, 2011) |
| " Previous studies using uric acid-lowering drugs in normouricemic animals are not suitable to answer the effect of hyperuricemia on ventricular remodeling after myocardial infarction." | 7.77 | Impact of elevated uric acid on ventricular remodeling in infarcted rats with experimental hyperuricemia. ( Chen, CC; Hsu, YJ; Lee, TM, 2011) |
| "The average uric acid concentration of patients with psoriasis was not significantly different from that of the healthy population, for both genders (P > 0." | 7.77 | Cross-sectional study on the correlation of serum uric acid with disease severity in Korean patients with psoriasis. ( Choi, JW; Kwon, HH; Kwon, IH; Youn, JI, 2011) |
| "Hyperuricemia-mediated uric acid crystal formation may cause joint inflammation and provoke the destruction of joints through the activation of inflammasome-mediated innate immune responses." | 7.77 | Activation of human fibroblast-like synoviocytes by uric acid crystals in rheumatoid arthritis. ( Chen, DP; Lam, CW; Li, EK; Tam, LS; Wong, CK, 2011) |
| "A high serum uric acid is common in subjects with pulmonary hypertension." | 7.76 | Could uric acid be a modifiable risk factor in subjects with pulmonary hypertension? ( Block, ER; Johnson, RJ; Lanaspa, M; Patel, JM; Swenson, ER; Zharikov, SI, 2010) |
| "Recent genome-wide association and functional studies have shown that the ABCG2 gene encodes for a urate transporter, and a common causal ABCG2 variant, rs2231142, leads to elevated uric acid levels and prevalent gout among Whites and Blacks." | 7.76 | The rs2231142 variant of the ABCG2 gene is associated with uric acid levels and gout among Japanese people. ( Folsom, AR; Iso, H; Kitamura, A; Köttgen, A; Tanigawa, T; Yamagishi, K, 2010) |
| "We examined the relationship between serum uric acid levels and changes in renal circulation in women with twin pregnancy compared with those in women with singleton pregnancy." | 7.76 | Effect of changes in renal circulation on serum uric acid levels in women with twin pregnancy. ( Igarashi, M; Miyake, H; Suzuki, S, 2010) |
| "The aim of the study was to investigate endothelial function in patients with arterial hypertension and impaired uric acid metabolism in comparison with patients having arterial hypertension and normal uric acid metabolism." | 7.76 | [Endothelial function in patients with arterial hypertension and impaired uric acid metabolism]. ( Lebedeva, MV; Minakova, EG; Pulin, AA; Severova, MM; Stakhova, TIu; Zaĭtseva, LI, 2010) |
| "Epidemiologic studies suggest an independent positive association of elevated serum uric acid with essential hypertension." | 7.75 | Serum uric acid level in primary hypertension among Chinese nonagenarians/centenarians. ( Chen, T; Dong, B; Lu, Z; Wu, H; Wu, J; Xiao, H; Zhang, Y, 2009) |
| "In PsA patients without clinically evident CV disease there is a correlation between serum uric acid concentration and subclinical atherosclerosis." | 7.75 | Asymptomatic hyperuricemia and serum uric acid concentration correlate with subclinical atherosclerosis in psoriatic arthritis patients without clinically evident cardiovascular disease. ( Gomez-Acebo, I; Gonzalez-Gay, MA; Gonzalez-Juanatey, C; Llorca, J; Martin, J; Miranda-Filloy, JA; Paz-Carreira, J; Vazquez-Rodriguez, TR, 2009) |
| " Mortality from all causes, total cardiovascular disease (CVD), ischemic stroke, congestive heart failure, hypertensive disease, and coronary heart disease were compared according to increasing serum uric acid levels." | 7.75 | Serum uric acid level as an independent risk factor for all-cause, cardiovascular, and ischemic stroke mortality: a Chinese cohort study. ( Chen, HJ; Chen, JH; Chuang, SY; Pan, WH; Yeh, WT, 2009) |
| "To determine longterm urate-lowering efficacy and clinical benefits and safety of therapy with febuxostat or allopurinol in subjects with gout." | 7.75 | Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. ( Becker, MA; Lademacher, C; Lloyd, E; MacDonald, PA; Schumacher, HR, 2009) |
| "The association of elevated serum uric acid (UA) with cardiovascular events in patients with severe coronary artery stenosis was examined." | 7.75 | Elevated serum uric acid is an independent predictor for cardiovascular events in patients with severe coronary artery stenosis: subanalysis of the Japanese Coronary Artery Disease (JCAD) Study. ( Hayashi, D; Higaki, J; Irita, J; Kohro, T; Kurata, M; Miyoshi, K; Nagai, R; Okura, T; Yamazaki, T, 2009) |
| "We examined the association between serum uric acid (SUA) level and the frequency, risk, and cost of gout flares among the elderly." | 7.75 | Frequency, risk, and cost of gout-related episodes among the elderly: does serum uric acid level matter? ( Cahill, KE; Krishnan, E; Mody, RR; Patel, PA; Tang, J; Wu, EQ; Yu, AP, 2009) |
| "The relationship among serum uric acid (SUA), metabolic syndrome, and chronic kidney disease (CKD) is unclear." | 7.75 | Serum uric acid is independently associated with metabolic syndrome in subjects with and without a low estimated glomerular filtration rate. ( Chen, HW; Chen, YM; Chuang, FH; Kuo, CF; Li, HY; See, LC; Yu, KH, 2009) |
| "Uric acid (UA) is an emerging cardiovascular (CV) risk factor that is associated with hypertension and CV disease (CVD) in the general population, but whose role in renal transplant recipients (RTR) has not been defined." | 7.75 | Role of uric acid in post-renal transplantation hypertension. ( Bandukwala, F; Huang, M; Prasad, GV, 2009) |
| "We sought to investigate whether uric acid concentrations are increased in pregnant women with insulin resistance and to correlate both with fetal growth." | 7.75 | Uric acid concentrations are associated with insulin resistance and birthweight in normotensive pregnant women. ( Catov, J; Laughon, SK; Roberts, JM, 2009) |
| "Serum uric acid (SUA) level is often elevated in participants with metabolic syndrome (MS), and hyperuricemia appears linked inextricably to the presence of MS." | 7.75 | The relationship between serum uric acid concentration and metabolic syndrome in university freshmen. ( Lin, KP, 2009) |
| "As oxonic acid diet increased plasma renin activity, plasma aldosterone, and urine K to Na ratio, these changes may play a significant role in the harmful cardiovascular actions of hyperuricemia." | 7.74 | Oxonic acid-induced hyperuricemia elevates plasma aldosterone in experimental renal insufficiency. ( Eräranta, A; Kööbi, P; Kurra, V; Lakkisto, P; Mustonen, JT; Niemelä, OJ; Pörsti, IH; Tahvanainen, AM; Tikkanen, I; Vehmas, TI, 2008) |
| "High normal concentrations of serum uric acid (UA) are associated with mild cognitive dysfunction and increased cerebral ischemia as indexed by white matter hyperintensity volumes." | 7.74 | Cerebral ischemia mediates the effect of serum uric acid on cognitive function. ( Gordon, B; Jinnah, HA; Kraut, M; Schretlen, DJ; Vannorsdall, TD, 2008) |
| "We identified three genetic loci associated with uric acid concentration and gout." | 7.74 | Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study. ( Astor, BC; Benjamin, EJ; Boerwinkle, E; Coresh, J; Dehghan, A; Fox, CS; Hofman, A; Hwang, SJ; Kao, WL; Köttgen, A; Levy, D; Rivadeneira, F; van Duijn, CM; Witteman, JC; Yang, Q, 2008) |
| "Data on children with IgAN from two pediatric nephrology centers were retrospectively reviewed (renal biopsy - subclasses according Hass I-V, ambulatory blood pressure monitoring ABPM, serum uric acid, proteinuria)." | 7.74 | Ambulatory blood pressure, proteinuria and uric acid in children with IgA nephropathy and their correlation with histopathological findings. ( Dusek, J; Groene, HJ; Janda, J; John, U; Misselwitz, J; Pohl, M; Seeman, T; Stejskal, J; Vondrák, K, 2008) |
| "Epidemiological studies have shown that a high serum uric acid concentration is a risk factor for coronary artery disease (CAD)." | 7.74 | Independent association of high serum uric acid concentration with angiographically defined coronary artery disease. ( Bogavac-Stanojević, N; Jelić-Ivanović, Z; Memon, L; Spasić, S; Spasojević-Kalimanovska, V, 2007) |
| "Hyperuricemia has been reported as being an adverse effect of pegylated-interferon-alpha2b (Peg-IFNalpha2b) and ribavirin combination therapy for chronic hepatitis C and hyperuricemic changes occur in some patients during the therapy." | 7.74 | Investigation of hyperuricemia during pegylated-interferon-alpha2b plus ribavirin combination therapy in patients with chronic hepatitis C. ( Enjoji, M; Higuchi, N; Horikawa, Y; Kato, M; Kinukawa, N; Kotoh, K; Nakamuta, M; Tajiri, H; Takayanagi, R; Ueda, A; Yamashita, N, 2008) |
| "Serum uric acid (UA) has been implicated in the pathogenesis of hypertension." | 7.73 | Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence. ( D'Agostino, RB; Kannel, WB; Levy, D; Sullivan, L; Sundström, J; Vasan, RS, 2005) |
| "Patients with system lupus erythematosus, rheumatic arthritis, chronic active hepatitis and gout were found to have considerable hyperuricemia and be decreased in aminoacides content, which are the predecessors of purine." | 7.73 | [Hyperuricemia and disorders in content of amino acids-purine precursors in patients with autoimmune diseases and gout]. ( Anan'eva, MN; Dubiaga, VV; Nikolenko, IuI; Nikolenko, VIu; Shchukin, IN; Siniachenko, OV, 2005) |
| "We investigated changes in serum uric acid across pregnancy in women with gestational hyperuricemia at delivery, with and without preeclampsia, compared with normal pregnant and women with preeclampsia without gestational hyperuricemia." | 7.73 | Uric acid concentrations in early pregnancy among preeclamptic women with gestational hyperuricemia at delivery. ( Bodnar, LM; Cooper, KM; Daftary, AR; Frank, MP; Gallaher, MJ; Ness, RB; Powers, RW; Roberts, JM, 2006) |
| "Hyperuricemia is considered a feature of the metabolic syndrome (MS) despite serum uric acid (SUA) is not considered a diagnostic criterion." | 7.73 | [Serum urate levels and urinary uric acid excretion in subjects with metabolic syndrome]. ( Bascuñana-Quirell, A; Benítez-Rodríguez, E; Elvira-González, J; Escribano-Serrano, J; López-Suárez, A; Michán-Doña, A; Rosal-Obrador, J, 2006) |
| "To evaluate the relationship between uric acid (UA) and peripheral arterial disease (PAD) in Chinese patients with coronary heart disease (CHD)." | 7.73 | [Study on the independent association of uric acid levels with peripheral arterial disease in Chinese patients with coronary heart disease]. ( Hasimu, B; Hu, DY; Li, J; Yu, JM; Zheng, LQ, 2006) |
| "In adults, serum uric acid levels are positively correlated with body mass index (BMI) and hyperuricemia is considered to be a common lifestyle disorder related with obesity." | 7.73 | Serum uric acid as an obesity-related indicator in early adolescence. ( Komatsu, K; Miyashita, M; Ohno, T; Oyama, C; Oyamada, M; Oyamada, T; Saito, S; Takada, G; Takahashi, T; Takashina, K, 2006) |
| "Adherence to published allopurinol dosing guidelines led to suboptimal control of hyperuricemia in this population of patients with gout." | 7.73 | Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. ( Dalbeth, N; Gow, P; Kumar, S; Stamp, L, 2006) |
| "To study effects of uric acid disbolism in combination with other metabolic disturbances on prevalence and clinical symptoms of arterial hypertension; contribution of uric acid nephropathy to its development." | 7.73 | [Relationships between arterial hypertension, metabolic disturbances and uric acid nephropathy]. ( Balkarov, IM; Britov, AN; Deev, AD; Eliseeva, NA, 2006) |
| "Experimental evidence supports a causative role for uric acid in the pathogenesis of hypertension." | 7.73 | Uric acid and the development of hypertension: the normative aging study. ( Gaziano, M; Gumieniak, O; Litonjua, AA; Perlstein, TS; Sparrow, D; Vokonas, PS; Weiss, ST; Williams, GH, 2006) |
| "Serum uric acid (UA) could be a valid prognostic marker and useful for metabolic, hemodynamic, and functional (MFH) staging in chronic heart failure (CHF)." | 7.72 | Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. ( Anker, SD; Cicoira, M; Coats, AJ; Davos, CH; Doehner, W; Francis, D; Hetzer, R; Kemp, M; Knosalla, C; Leyva, F; Osterziel, KJ; Ponikowski, P; Rauchhaus, M; Segal, R; Shamim, W; Sharma, R, 2003) |
| " Besides alcohol consumption and the use of antihypertensive therapy, mainly diuretics, serum uric acid is markedly associated with parameters of the metabolic syndrome, in particular serum triglycerides." | 7.72 | Prevalence of hyperuricemia and relation of serum uric acid with cardiovascular risk factors in a developing country. ( Bovet, P; Burnier, M; Conen, D; Paccaud, F; Riesen, W; Shamlaye, C; Wietlisbach, V, 2004) |
| "The serum uric acid level has been said to be an independent predictor of cardiovascular disease death, mainly for women, and to be linked with the metabolic Syndrome X of insulin resistance, obesity, hypertension, and dyslipidemia." | 7.71 | Elevated serum leptin concentrations in women with hyperuricemia. ( Chiba, H; Katayose, S; Maruoka, S; Matsubara, M, 2002) |
| "Hyperuricemia is associated with the activation of the Nod-like receptor protein 3 inflammasome." | 7.30 | C-reactive Protein Levels and Cardiovascular Outcomes After Febuxostat Treatment in Patients with Asymptomatic Hyperuricemia: Post-hoc Analysis of a Randomized Controlled Study. ( Hayashi, T; Hiramitsu, S; Hisatome, I; Jinnouchi, H; Kakuda, H; Kawai, N; Kimura, K; Kojima, S; Matsui, K; Mori, H; Ogawa, H; Ohya, Y; Saito, Y; Sugawara, M; Tokutake, E; Tsujita, K; Uchiyama, K; Wakasa, Y; Waki, M; Yokota, N, 2023) |
| " The primary aim of the present study was to study the pharmacokinetic drug‒drug interactions (DDIs) of HP501, febuxostat, and colchicine in hyperuricemic patients." | 7.30 | A Phase I Study to Evaluate the Pharmacokinetic Drug‒Drug Interaction of HP501, Febuxostat, and Colchicine in Male Chinese Patients with Hyperuricemia. ( Chen, H; Chen, L; Ding, R; Hu, X; Jiang, F; Li, X; Li, Y; Liu, K; Peng, Q; Wu, J; Xiong, T; Zhou, Y, 2023) |
| " The MGH Acupuncture Sensation Scale and adverse events related to acupuncture will be measured after each treatment." | 7.30 | Evaluating the effectiveness and safety of acupuncture on serum uric acid in asymptomatic hyperuricemia population: a randomized controlled clinical trial study protocol. ( Chen, Z; Fang, MY; Huang, Y; Li, CN; Lin, FP; Liu, WH; Ma, Y; Tu, SH; Wang, B; Wang, Y; Xie, WX; Yu, LL; Zhang, RY; Zheng, CH, 2023) |
| "Hyperuricemia is a metabolic disease caused by purine nucleotide metabolism disorder." | 7.01 | Mechanistic insights of soluble uric acid-induced insulin resistance: Insulin signaling and beyond. ( Cheng, J; Koyama, H; Yamamoto, T; Yu, W, 2023) |
| "Gout is a multifactorial metabolic and inflammatory disease that occurs when increased uric acid (UA) induce HU resulting in monosodium urate (MSU) crystal deposition in joints." | 7.01 | Uric acid en route to gout. ( Zhang, WZ, 2023) |
| "Hyperuricemia is a recognized risk factor for cardiovascular diseases." | 6.80 | Can soy intake affect serum uric acid level? Pooled analysis from two 6-month randomized controlled trials among Chinese postmenopausal women with prediabetes or prehypertension. ( Chen, YM; Ho, CS; Liu, ZM; Woo, J, 2015) |
| "Treatment with febuxostat resulted in a significant decrease in serum UA level and a significant decrease in MDA-LDL compared with baseline, but no significant difference was observed in hsCRP level or blood pressure." | 6.80 | Febuxostat improves endothelial function in hemodialysis patients with hyperuricemia: A randomized controlled study. ( Akiba, T; Itabashi, M; Kikuchi, K; Moriyama, T; Nitta, K; Sasaki, Y; Takei, T; Tsuchiya, K; Tsuruta, Y; Uchida, K, 2015) |
| "Hyperuricemia is increasing in prevalence and this is paralleled by an increased incidence of acute gout." | 6.79 | Febuxostat (Feburic tablet) in the management of hyperuricemia in a general practice cohort of Japanese patients with a high prevalence of cardiovascular problems. ( Hasegawa, K; Hiramitsu, S; Ishiguro, Y; Ishii, J; Kani, A; Kato, H; Kato, K; Kato, Y; Kimura, H; Matsubara, S; Matsubara, Y; Matsuyama, H; Mori, K; Noba, M; Shino, K; Tokuda, M; Uchiyama, T; Uemura, A; Yamada, K; Yoshida, S, 2014) |
| "Azelnidipine was administered to 72 patients at a daily dose of 8 mg or 16 mg." | 6.79 | Effects of azelnidipine on uric acid metabolism in patients with essential hypertension. ( Cheng, J; Hamada, T; Hirata, S; Hisatome, I; Igawa, O; Kato, M; Kuwabara, M; Miyazaki, S; Mizuta, E; Moriwaki, Y; Ninomiya, H; Nosaka, Y; Ogino, K; Ohtahara, A; Yamamoto, K; Yamamoto, Y; Yoshida, A, 2014) |
| "Despite an increasing incidence of gout in older age patients with multiple metabolic and cardiovascular comorbidities, there are limited data addressing whether currently available urate-lowering therapy is comparably effective and safe in older (≥65 years of age) versus younger (<65 years of age) patients." | 6.76 | Treating hyperuricemia of gout: safety and efficacy of febuxostat and allopurinol in older versus younger subjects. ( Becker, MA; Gunawardhana, L; Hunt, B; MacDonald, PA, 2011) |
"Treatment with benzbromarone monotherapy (range: 100-200 mg/day; mean 138 mg/day) resulted in 92% of patients reaching target levels sUr | 6.73 | Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-treated gout patients. ( Brouwers, JR; Houtman, PM; Jansen, TL; Reinders, MK; van Roon, EN, 2007) | |
| "Treatment with febuxostat resulted in a significant reduction of sUA levels at all dosages." | 6.71 | Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. ( Becker, MA; Eustace, D; Joseph-Ridge, N; MacDonald, PA; Palo, WA; Schumacher, HR; Vernillet, L; Wortmann, RL, 2005) |
| "Although hyperuricemia has been associated with CKD in many studies, it remains controversial whether this is the cause or the result of decreased renal function." | 6.66 | Renal effects of uric acid: hyperuricemia and hypouricemia. ( Jo, YI; Lee, JH; Park, JH, 2020) |
| "Hyperuricemia affects one out of five adults as a result of the Western diet, insulin resistance, and renal dysfunction." | 6.61 | Uric acid and hypertension: a focused review and practical recommendations. ( Borghi, C; Burnier, M; De Becker, B; van de Borne, P, 2019) |
| "Atorvastatin, which has proven safe in NAFLD/NASH, reduces SUA levels, ameliorates NAFLD/NASH, prevents liver fibrosis, and above all substantially reduces CVD morbidity and mortality in comparison with those on statins but without NAFLD/NASH." | 6.58 | Can Serum Uric Acid Lowering Therapy Contribute to the Prevention or Treatment of Nonalcoholic Fatty Liver Disease? ( Athyros, VG; Giouleme, O; Grammatikos, N; Katsoula, A; Paschos, P; Tsimperidis, A, 2018) |
| "Gout is a clinical disorder that is characterized by the deposition of monosodium urate crystals (MSU) in joints and tendons, usually in the presence of prolonged hyperuricaemia." | 6.55 | Review of the ophthalmic manifestations of gout and uric acid crystal deposition. ( Ao, J; Casson, RJ; Goldblatt, F, 2017) |
| "Nonalcoholic fatty liver disease (NAFLD) is a major, worldwide public health problem." | 6.53 | Serum uric acid: a new therapeutic target for nonalcoholic fatty liver disease. ( Braddock, M; Liu, WY; Lu, QD; Shi, KQ; Song, D; Sun, DQ; Wu, SJ; Zheng, MH; Zhu, GQ, 2016) |
| "Allopurinol is a safe option, slightly better than other ULDs." | 6.52 | Safety of allopurinol compared with other urate-lowering drugs in patients with gout: a systematic review and meta-analysis. ( Carmona, L; Castrejon, I; Loza, E; Pérez-Ruiz, F; Rosario, MP; Toledano, E, 2015) |
| "Uric acid has a stimulating effect on the cerebral cortex, and this could have allowed humans, compared with other animals, to develop higher brain mass volume, better intellectual performances, and maybe evolutionary supremacy." | 6.52 | Uric acid: friend or foe? Uric acid and cognitive function "Gout kills more wise men than simple". ( De Giorgi, A; Fabbian, F; Manfredini, R; Misurati, E; Pala, M; Parisi, C; Tiseo, R, 2015) |
| "Hyperuricemia is seen when kidney function declines." | 6.48 | Hyperuricemia and the progression of chronic kidney disease: is uric acid a marker or an independent risk factor? ( Fried, LF; Nashar, K, 2012) |
| "Hyperuricemia is a prevalent finding in patients presenting metabolic syndrome, although its clinical meaning is still controversial and often underestimated." | 6.46 | Uric acid as a factor in the metabolic syndrome. ( Batista, MC; Borges, RL; Ribeiro, AB; Zanella, MT, 2010) |
| "Uric acid is a major product of purine metabolism in humans." | 6.46 | Uric acid and the development of hypertension. ( Hwu, CM; Lin, KH, 2010) |
| "Uric acid is an antioxidant and perhaps helps to control blood pressure during a low Na+ diet through stimulation of the renin-angiotensin system." | 6.44 | Uric acid: bystander or culprit in hypertension and progressive renal disease? ( Menè, P; Punzo, G, 2008) |
| "Hyperuricemia is a common finding in preeclamptic pregnancies evident from early pregnancy." | 6.44 | Uric acid as a pathogenic factor in preeclampsia. ( Bainbridge, SA; Roberts, JM, 2008) |
| "Uric acid is a weak acid that exists largely as MSU, the ionized form, in urate pool at physiologic pH." | 6.44 | [Physiology and dynamics of uric acid in hyperuricemia]. ( Nakamura, T; Takagi, K; Ueda, T, 2008) |
| "Uric acid may increase as a result of pathophysiological processes such as impaired renal sodium handling but may also contribute to renal and vascular damage, particularly endothelial dysfunction." | 6.43 | Uric acid and hypertension. ( Schachter, M, 2005) |
| "Hyperuricemia has long been known to be associated with cardiovascular disease, and it is particularly common in people with hypertension, metabolic syndrome, or kidney disease." | 6.43 | Role of uric acid in hypertension, renal disease, and metabolic syndrome. ( Heinig, M; Johnson, RJ, 2006) |
| "Hyperuricemia is associated with hypertension, vascular disease, renal disease, and cardiovascular events." | 6.42 | Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? ( Feig, D; Herrera-Acosta, J; Johnson, RJ; Kanellis, J; Kang, DH; Kivlighn, S; Mazzali, M; Rodriguez-Iturbe, B; Tuttle, KR; Watanabe, S, 2003) |
| "Gender-based evidence on the association between serum uric acid (SUA) and left ventricular hypertrophy (LVH), as assessed by echocardiography, is still based on single studies." | 5.94 | Uric acid and left ventricular hypertrophy: a gender-based meta-analysis of echocardiographic studies. ( Carugo, S; Cuspidi, C; Faggiano, A; Gherbesi, E; Grassi, G; Sala, C; Tadic, M, 2024) |
| " Obesity, lipids, glucose tolerance and insulin resistance are risk factors for numerous cardiovascular diseases and are often accompanied by a considerable increase in serum uric acid (SUA) concentrations." | 5.94 | Insights into the relationship between serum uric acid and pulmonary hypertension (Review). ( Chen, M; He, Y; Lei, W; Luo, H; Shui, X; Zheng, J; Zhou, Y, 2024) |
| "Chloroquine (CQ) is an anti-inflammatory and disease-modifying anti-rheumatic drug (DMARD) utilized in treating autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus." | 5.91 | Chloroquine inhibits NLRP3 inflammasomes activation and alleviates renal fibrosis in mouse model of hyperuricemic nephropathy with aggravation by a high-fat-diet. ( Cui, J; Hong, P; Li, Z; Lin, J; Nie, K; Wan, J; Wu, X; Zhang, X, 2023) |
| " Dose-response relationships were analyzed using restricted cubic spline regression." | 5.91 | Association of N, N-diethyl-m-toluamide (DEET) with hyperuricemia among adult participants. ( Cui, Q; Guan, G; Hui, R; Liu, Z; Wu, R; Xing, Y; Zhang, Y; Zhu, L; Zhu, X, 2023) |
| "Hyperuricemia is perceived as one of the risk factors for developing and progressing cardiovascular disease and metabolic syndrome through various pathological mechanisms." | 5.91 | Effect of Alcohol Consumption Habits on Early Arterial Aging in Subjects with Metabolic Syndrome and Elevated Serum Uric Acid. ( Badarienė, J; Čypienė, A; Gimžauskaitė, S; Jasiūnas, E; Laucevičius, A; Rinkūnienė, E; Ryliškytė, L, 2023) |
| "Hyperuricemia was defined as SUA ≥ 7 mg/100 ml in the all sample." | 5.72 | Reference range of serum uric acid and prevalence of hyperuricemia: a cross-sectional study from baseline data of ELSA-Brasil cohort. ( Benseñor, IM; Dório, M; Fuller, R; Lotufo, P; Santos, IS, 2022) |
| "Hyperuricemia is closely related to a variety of diseases and has been listed as one of the twenty most persistent diseases in the 21st century by the United Nations." | 5.72 | Quantification of uric acid concentration in tears by using PDMS inverse opal structure surface-enhanced Raman scattering substrates: Application in hyperuricemia. ( Cao, H; Cui, X; Feng, Y; He, W; Li, J; Li, Y; Qiu, Y; Wang, D; Yang, X; Yang, Z, 2022) |
| "Hyperuricemia is a common metabolic disease with a series of complications." | 5.72 | Synthesis and bioactivity evaluation of novel nuciferine derivatives with antihyperuricemia and nephroprotective effects. ( Chen, JS; Liu, C; Liu, YF; Sun, B; Sun, JY; Wang, CZ; Wang, MM; Wang, MX; Wang, Z; Yang, QL; Zhang, YK, 2022) |
| " In addition, the dose-response curve was also used to discuss the relationship between SUA and pSS-HT." | 5.72 | Relationship between serum uric acid and hypertension in patients with primary Sjögren's syndrome: A retrospective cohort study. ( Luo, Q; Qin, L; Wang, H; Yang, X; Zhang, Y, 2022) |
| "Hyperuricemia is associated with aortic dissection and cardiovascular diseases." | 5.72 | Post-operative uric acid: a predictor for 30-days mortality of acute type A aortic dissection repair. ( Chen, X; Hu, Q; Huang, L; Lin, G; Luo, W; Ma, S; Wu, D; Xu, Q, 2022) |
| "Acne vulgaris is a chronic inflammatory disease affecting the pilosebaceous unit." | 5.72 | A retrospective evaluation of laboratory parameters and hyperuricemia in patients with acne vulgaris under systemic isotretinoin treatment. ( Atilla, S; Ozdemir, S; Pancar, GS; Sarac, N, 2022) |
| " Logistic regression and restricted cubic spline were performed to assess the association and dose-response relationship between eating-out frequency and hyperuricemia." | 5.72 | Association of eating out frequency and other factors with serum uric acid levels and hyperuricemia in Chinese population. ( Cui, N; Dong, X; Hou, J; Huo, W; Li, L; Li, X; Li, Y; Liao, W; Liu, X; Mao, Z; Wang, C; Xue, Y, 2022) |
| "Serum uric acid (SUA) is activated in catabolic, hypoxic, and inflammatory conditions characteristic of heart failure (HF) and is a source of reactive oxygen species." | 5.69 | High- versus low-dose losartan and uric acid: An analysis from HEAAL. ( Ferreira, JP; Kiernan, MS; Konstam, MA; Zannad, F, 2023) |
| "Our study demonstrated the efficiency of benzbromarone in hypertensive patients with concomitant asymptomatic hyperuricemia, including the benefits on ameliorating LV diastolic dysfunction as well as improving composite endpoints." | 5.69 | Uric acid-lowering therapy with benzbromarone in hypertension with asymptomatic hyperuricemia: a randomized study focusing left ventricular diastolic function. ( Gu, J; Han, Z; Ke, J; Lin, H; Pan, J, 2023) |
| " The aim of this study was to determine whether urate-lowering therapy with an XO inhibitor (febuxostat) and that with a uricosuric drug (benzbromarone) are comparable in slowing renal function decline in patients with CKD complicated with hypertension and hyperuricemia." | 5.69 | Urate-lowering drugs for chronic kidney disease with asymptomatic hyperuricemia and hypertension: a randomized trial. ( Arima, H; Funakoshi, R; Iseki, K; Ishida, A; Kinjyo, K; Kochi, M; Kohagura, K; Nakamura, T; Ohya, Y; Sakima, A; Satoh, A; Tana, T; Yamazato, M; Zamami, R, 2023) |
| "Calcitriol treatment attenuated the injury with reducing uric acid and creatinine levels, as well as tubular injury." | 5.62 | Calcitriol Treatment Attenuates Uric Acid-Induced Kidney Injury via Super Oxide Dismutase-1 (SOD-1) Upregulation and Fibrosis Reduction ( Arefian, N; Juffrie, M; Perdana Putri, RG; Ratna Sari, DC; Romi, MM; Wahyu Setyaningsih, WA, 2021) |
| "Hyperuricemia is the primary cause of gouty arthritis and other metabolic disorders." | 5.62 | Eggshell Membrane Ameliorates Hyperuricemia by Increasing Urate Excretion in Potassium Oxonate-Injected Rats. ( Kim, DS; Sung, YY, 2021) |
| " However, BBR exhibits low bioavailability due to its extensive metabolism and limited absorption." | 5.62 | Berberrubine attenuates potassium oxonate- and hypoxanthine-induced hyperuricemia by regulating urate transporters and JAK2/STAT3 signaling pathway. ( Chen, J; Huang, Z; Jiang, L; Li, Y; Lin, G; Lin, Z; Liu, Y; Mai, L; Su, Z; Xie, J; Xu, L; Yu, Q, 2021) |
| "Inflammation is an important pathological feature of hyperuricemia, which in turn aggravates hyperuricemia." | 5.62 | Astaxanthin attenuated hyperuricemia and kidney inflammation by inhibiting uric acid synthesis and the NF-κ B/NLRP3 signaling pathways in potassium oxonate and hypoxanthine-induced hyperuricemia mice. ( Chen, Y; Liu, T; Yang, Z; Yuan, F; Zhang, L; Zhang, S; Zhou, X; Zhuang, J, 2021) |
| "Hyperuricemia is a well-known key risk factor for gout and can cause a variety of metabolic diseases." | 5.62 | Multiomics Integrative Analysis for Discovering the Potential Mechanism of Dioscin against Hyperuricemia Mice. ( Gao, J; Han, L; Ma, J; Tan, Y; Wang, L; Wang, T; Yu, H; Zhang, Y, 2021) |
| "Thus, hyperuricemia is associated with impaired endothelial function." | 5.62 | Uric Acid as a Risk Factor for Chronic Kidney Disease and Cardiovascular Disease - Japanese Guideline on the Management of Asymptomatic Hyperuricemia. ( Bahrudin, U; Hisatome, I; Kuwabara, M; Li, P; Maharani, N; Mahati, E; Miake, J; Ninomiya, H; Taufiq, F; Utami, SB, 2021) |
| " Simulations based on the uric acid model were performed to assess dose-response of verinurad in combination with XOI, and to investigate the impact of covariates." | 5.62 | A semi-mechanistic exposure-response model to assess the effects of verinurad, a potent URAT1 inhibitor, on serum and urine uric acid in patients with hyperuricemia-associated diseases. ( Aksenov, S; Eriksson, UG; Johansson, S; Leander, J; Parkinson, J; Rekić, D; Sunnåker, M, 2021) |
| "Uric Acid (UA) has been related to the development of Cardio-Vascular (CV) events in patients affected by Chronic Coronary Syndromes (CCS)." | 5.62 | Uric acid in chronic coronary syndromes: Relationship with coronary artery disease severity and left ventricular diastolic parameter. ( Bossi, I; De Chiara, B; Giannattasio, C; Maloberti, A; Moreo, A; Nava, S; Oliva, F; Oreglia, J; Piccalò, G; Piccaluga, E; Pirola, R; Racioppi, A; Rebora, P; Soriano, F; Tassistro, E; Vallerio, P; Valsecchi, MG, 2021) |
| "Patients with hyperuricemia are among the high-risk group of postoperative gout attacks." | 5.62 | Factors Influencing Early Serum Uric Acid Fluctuation After Bariatric Surgery in Patients with Hyperuricemia. ( Fu, L; Liu, Y; Wen, J; Xu, C; Yan, T; Yang, H; You, Y; Yu, J; Zhan, D; Zhang, T, 2021) |
| "Uric acid wGRS was not associated with fasting serum glucose, HbA1C, waist circumference, or BMI." | 5.56 | The causal role of elevated uric acid and waist circumference on the risk of metabolic syndrome components. ( Biradar, MI; Chiang, KM; Huang, YT; Pan, WH; Yang, HC, 2020) |
| "Hyperuricemia is independently associated with cardiovascular disease (CVD) and is considered to be one of the major risk factors for CVD." | 5.56 | Association of variability in uric acid and future clinical outcomes of patient with coronary artery disease undergoing percutaneous coronary intervention. ( Chan, WL; Charng, MJ; Chen, JW; Chen, SC; Chen, YH; Cheng, HM; Chou, CY; Hsu, PF; Huang, CC; Huang, PH; Huang, SS; Leu, HB; Lim, SS; Lin, SJ; Lin, YJ; Lu, TM; Pan, JP; Sung, SH; Wu, CH; Wu, TC; Yang, YL, 2020) |
| "Hyperuricemia is an important risk factor of chronic kidney disease, metabolic syndrome and cardiovascular disease." | 5.56 | The Time-Feature of Uric Acid Excretion in Hyperuricemia Mice Induced by Potassium Oxonate and Adenine. ( Bao, R; Chen, Q; Liu, L; Liu, M; Wang, D; Wang, T; Wen, S; Yu, H; Zhang, Y, 2020) |
| "Hyperuricemia was defined as serum UA ≥7 mg/dl in men and ≥ 6 mg/dl in women." | 5.56 | The relationship between serum uric acid and cognitive function in patients with chronic heart failure. ( Lu, C; Niu, W; Yang, H, 2020) |
| "Esculetin is a candidate urate-lowering drug with renoprotective activity and the ability to inhibit XO, promote excretion of UA, protect oxidative stress injury, and reduce renal fibrosis." | 5.56 | Multiple-Purpose Connectivity Map Analysis Reveals the Benefits of Esculetin to Hyperuricemia and Renal Fibrosis. ( Huang, B; Kong, W; Meng, J; Wang, L; Wang, Y; Xie, Z; Yang, B; Zhang, T; Zhou, H, 2020) |
| "Hyperuricemia is more likely to occur in women (risk ratio (RR) = 1." | 5.56 | The effect of serum uric acid levels on the long-term prognosis of patients with non-ST-elevation myocardial infarction. ( Bachórzewska-Gajewska, H; Dobrzycki, S; Kulikowska, A; Kurasz, A; Kuźma, Ł; Niwińska, MM; Zalewska-Adamiec, M, 2020) |
| "To assess the efficacy of febuxostat combined with hydration on contrast-induced nephropathy (CIN) in coronary heart disease patients with hyperuricemia undergoing percutaneous coronary intervention (PCI)." | 5.51 | Febuxostat combined with hydration for the prevention of contrast-induced nephropathy in hyperuricemia patients undergoing percutaneous coronary intervention: A CONSORT-compliant randomized controlled trial. ( He, Z; Li, M; Ma, G; Teng, W; Xia, Z; Zhai, X, 2022) |
| "To investigate whether serum urate levels, number of gout flares, and tophi burden are related to death from cardiovascular (CV) causes after treatment with febuxostat or allopurinol in patients with gout from the Cardiovascular Safety of Febuxostat or Allopurinol in Patients With Gout and Cardiovascular Comorbidities (CARES) trial." | 5.51 | Evaluation of the Relationship Between Serum Urate Levels, Clinical Manifestations of Gout, and Death From Cardiovascular Causes in Patients Receiving Febuxostat or Allopurinol in an Outcomes Trial. ( Becker, MA; Borer, JS; Castillo, M; Gorelick, PB; Gunawardhana, L; Hunt, B; Saag, KG; Whelton, A; White, WB, 2022) |
| "The sodium-glucose cotransporter-2 inhibitor empagliflozin decreases the risk of cardiovascular death or hospitalization for heart failure (HF) in patients with HF with reduced ejection fraction." | 5.51 | Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial. ( Anker, SD; Brueckmann, M; Butler, J; Doehner, W; Ferreira, JP; Filippatos, G; Januzzi, JL; Kaempfer, C; Packer, M; Pocock, SJ; Salsali, A; Zannad, F, 2022) |
| "The predominant mechanism driving hyperuricemia in gout is renal uric acid underexcretion; however, the standard urate-lowering therapy (ULT) recommendation is first-line xanthine oxidase inhibitor (XOI), irrespective of the cause of hyperuricemia." | 5.51 | Superiority of Low-Dose Benzbromarone to Low-Dose Febuxostat in a Prospective, Randomized Comparative Effectiveness Trial in Gout Patients With Renal Uric Acid Underexcretion. ( Chen, Y; Cheng, X; Cui, L; Dalbeth, N; He, Y; Hu, S; Ji, A; Li, C; Li, H; Liu, Z; Lu, J; Ma, L; Qi, H; Ran, Z; Sun, M; Terkeltaub, R; Wang, C; Xue, X; Yan, F; Yu, Q; Yuan, X, 2022) |
| "XO inhibition with febuxostat was associated with reduced visit-to-visit BP variability as well as reduced PR variability in patients with hyperuricemia and carotid plaques." | 5.51 | Impact of febuxostat on visit-to-visit blood pressure variability: insights from the randomised PRIZE Study. ( Kobayashi, Y; Koide, Y; Matsunaga, K; Node, K; Saito, Y; Tanaka, A; Uchida, D; Ueyama, C; Yokota, N; Yoshida, H, 2022) |
| "The present study compared the efficacy and safety of low-dose febuxostat versus allopurinol in chronic kidney disease (CKD) patients complicated with hyperuricemia (HUA)." | 5.51 | Low-dose febuxostat exhibits a superior renal-protective effect and non-inferior safety profile compared to allopurinol in chronic kidney disease patients complicated with hyperuricemia: A double-centre, randomized, controlled study. ( Cao, B; Yang, N, 2022) |
| "Myricitrin has many pharmacological effects, such as anti-inflammation, liver protection and anti-oxidation." | 5.51 | Preparation, characterization, pharmacokinetics and anti-hyperuricemia activity studies of myricitrin-loaded proliposomes. ( Adu-Frimpong, M; Ji, H; Man, N; Toreniyazov, E; Wang, Q; Wei, C; Wei, Q; Weng, W; Xu, X; Yu, J; Zhang, K, 2019) |
| "Preventing and treating renal fibrosis was an optimal treatment for hyperuricemia-induced kidney diseases." | 5.51 | Pterostilbene, a bioactive component of blueberries, alleviates renal fibrosis in a severe mouse model of hyperuricemic nephropathy. ( Feng, Y; Fu, P; Guo, F; Li, L; Liu, J; Ma, L; Pan, J; Shi, M, 2019) |
| "Gout that caused by hyperuricemia affects human health seriously and more efficient drugs are urgently required clinically." | 5.51 | New Rice-Derived Short Peptide Potently Alleviated Hyperuricemia Induced by Potassium Oxonate in Rats. ( Bian, W; Hu, Y; Liu, N; Meng, B; Sun, J; Wang, S; Wang, Y; Xiong, Z; Yang, M; Yang, X; Yin, S; Zeng, L, 2019) |
| "Hyperuricemia is becoming a serious public health issue, which is highly influenced by environmental factors, although there is still controversial information on the potential influence of the exposure to Persistent Toxic Substances (PTSs) in the general population." | 5.51 | Associations of multiple exposures to persistent toxic substances with the risk of hyperuricemia and subclinical uric acid levels in BIOAMBIENT.ES study. ( Arrebola, JP; Bartolomé, M; Calvo, E; Cañas, AI; Castaño, A; Esteban, M; Huetos, O; López-Herranz, A; Pérez-Gómez, B; Ramos, JJ, 2019) |
| " In-hospital UA-increase was associated with higher risk of mortality even after adjusting for confounding variables including creatine change and diuretic dosage [harzard ratio (HR) 1." | 5.51 | Association of serum uric acid change with mortality, renal function and diuretic dose administered in treatment of acute heart failure. ( Bai, YJ; Huang, XF; Liu, SR; Xu, DL; Xu, TY; Zeng, QC; Zhan, Q; Zhou, HB, 2019) |
| "Uric acid is an endogenous danger signal and activator of the inflammasome, and has been independently associated with an increased risk of cirrhosis." | 5.51 | Higher levels of serum uric acid influences hepatic damage in patients with non-alcoholic fatty liver disease (NAFLD). ( Aller, R; Ampuero, J; Andrade, RJ; Aspichueta, P; Buque, X; Burgos-Santamaría, D; Fernández Rodríguez, CM; Gómez-Camarero, J; Gutiérrez García, ML; Hernández-Guerra, M; Latorre, M; Martín-Mateos, RMª; Romero-Gómez, M; Rosales, JM, 2019) |
| "Hyperuricemia was common in youth with T2D." | 5.51 | Elevated Serum Uric Acid Is Associated With Greater Risk for Hypertension and Diabetic Kidney Diseases in Obese Adolescents With Type 2 Diabetes: An Observational Analysis From the Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) Stu ( Bjornstad, P; El Ghormli, L; Laffel, L; Lynch, J; Nadeau, KJ; Tollefsen, SE; Weinstock, RS, 2019) |
| "Risk of hyperuricemia is modified by genetic and environmental factors." | 5.51 | Influence of Genetic and Non-Genetic Risk Factors for Serum Uric Acid Levels and Hyperuricemia in Mexicans. ( Canizales-Quinteros, S; de la Cruz-Montoya, A; Denova-Gutiérrez, E; Fernandez-Lopez, JC; Flores, YN; Macías-Kauffer, L; Martinez-Aguilar, MM; Quiterio, M; Ramírez-Palacios, P; Ramírez-Salazar, EG; Rivera-Paredez, B; Romero-Hidalgo, S; Salmerón, J; Velázquez-Cruz, R; Villalobos-Comparán, M; Villamil-Ramírez, H; Villarreal-Molina, MT, 2019) |
| "Multiterritorial atherosclerosis has dramatically increased annual risk of adverse cardiovascular events than atherosclerotic disease with single-artery affected." | 5.51 | Longitudinal association between serum uric acid levels and multiterritorial atherosclerosis. ( Chen, J; Cheng, W; Cui, Q; Geng, B; Li, N; Song, M; Wang, K; Wang, Y; Yang, J; Yao, Y; Zhou, Y, 2019) |
| " The serum levels of uric acid (UA), creatinine, other biochemical parameters, estimated glomerular filtration rate (eGFR), and adverse events were measured at baseline as well as at 1, 3, and 6 months after the switch to febuxostat." | 5.51 | Switching from allopurinol to febuxostat: efficacy and safety in the treatment of hyperuricemia in renal transplant recipients. ( Li, Y; Liu, M; Lu, Y; Meng, J; Zhang, X, 2019) |
| "Febuxostat was significantly more potent than allopurinol or benzbromarone in lowering SUA levels in the fully adjusted model." | 5.48 | Comparative effectiveness of allopurinol, febuxostat and benzbromarone on renal function in chronic kidney disease patients with hyperuricemia: a 13-year inception cohort study. ( Chiu, HT; Chou, HW; Huang, HC; Kuo, CC; Ting, IW; Tsai, CW; Yeh, HC, 2018) |
| "Hyperuricemia was present in 356 (29." | 5.48 | Uric acid is associated with long-term adverse cardiovascular outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention. ( Farhan, S; Freynhofer, MK; Hauser, C; Herman, R; Huber, K; Rohla, M; Tscharre, M; Weiss, TW, 2018) |
| "Hyperuricemia is highly prevalent and especially common in subjects with metabolic, cardiovascular and renal diseases." | 5.48 | Probiotic supplements prevented oxonic acid-induced hyperuricemia and renal damage. ( Blas-Marron, MG; Frank, DN; García-Arroyo, FE; Gonzaga, G; Ir, D; Irvin, A; Johnson, RJ; Muñoz-Jiménez, I; Ranganathan, N; Ranganathan, P; Robertson, CE; Sánchez-Lozada, LG; Silverio, O; Soto, V; Tapia, E; Vyas, U, 2018) |
| "WIT and post-LT hyperuricemia are associated with the prevalence of PTMS." | 5.48 | Warm ischemia time and elevated serum uric acid are associated with metabolic syndrome after liver transplantation with donation after cardiac death. ( Chai, YC; Hu, LS; Jia, A; Lv, Y; Shi, JH; Tian, M; Wang, B; Zhang, C; Zheng, J, 2018) |
| "Hyperuricemia is associated with metabolic syndrome (MetS), but the association is often confounded by the shared background of obesity." | 5.46 | Combined effect of obesity and uric acid on nonalcoholic fatty liver disease and hypertriglyceridemia. ( Du, T; Li, M; Lin, X; Lu, H; Yu, X; Zhang, S, 2017) |
| "Hyperuricemia was defined as a serum UA concentration ≥416." | 5.46 | Cadmium exposure and its association with serum uric acid and hyperuricemia. ( Chen, C; Chen, Y; Han, B; Hu, B; Jiang, B; Li, Q; Lu, Y; Nie, X; Sun, H; Wang, N; Xia, F; Zhai, H; Zhu, C, 2017) |
| "Hyperuricemia is an important risk factor for cardiovascular and renal diseases." | 5.46 | Phloretin attenuates hyperuricemia-induced endothelial dysfunction through co-inhibiting inflammation and GLUT9-mediated uric acid uptake. ( Chen, Y; Cheng, J; Liu, J; Liu, S; Lu, Y; Yuan, Y; Zhao, M; Zhou, Y, 2017) |
| "Hyperuricemia is associated with the development of chronic kidney disease." | 5.46 | Qi-Zhu-Xie-Zhuo-Fang reduces serum uric acid levels and ameliorates renal fibrosis in hyperuricemic nephropathy rats. ( Beibei, T; Huijuan, W; Jianchun, M; Rui, S; Xiaoxu, C; Xinghui, L, 2017) |
| "Hyperuricemia is associated with incident cardiovascular events in different settings of patients." | 5.46 | Risk reclassification ability of uric acid for cardiovascular outcomes in essential hypertension. ( Addesi, D; Baggetta, R; Cimellaro, A; Maio, R; Perticone, F; Perticone, M; Sciacqua, A; Sesti, G; Tripepi, G, 2017) |
| "Whether hyperuricemia is an independent risk factor for hypertension in adults is still under debate." | 5.46 | Association of serum uric acid and risk of hypertension in adults: a prospective study of Kailuan Corporation cohort. ( Cui, LF; Han, YX; Liu, N; Mu, R; Shi, HJ; Shu, R; Song, HC; Sun, K; Wang, GY; Wang, J; Wang, JR; Wu, SL; Yang, WH; Yu, P; Zhou, B, 2017) |
| "Benzbromarone has been reported to suppress uric acid reabsorption via uric acid transporter 1 inhibition in renal tubular cells." | 5.42 | Direct radical scavenging activity of benzbromarone provides beneficial antioxidant properties for hyperuricemia treatment. ( Chuang, VT; Hirata, S; Kadowaki, D; Maruyama, T; Miyamoto, Y; Muraya, N; Narita, Y; Otagiri, M; Sakaguchi, S; Sato, K; Taguchi, K, 2015) |
| "The prevalence of NAFLD was higher in participants with higher SUA levels (10." | 5.42 | Association between serum uric acid and nonalcoholic fatty liver disease in the US population. ( Bonekamp, S; Clark, JM; Hernaez, R; Lazo, M; Liu, SH; Shih, MH, 2015) |
| "Hyperuricemia is an independent risk factor for hypertension." | 5.42 | Does elevated serum uric acid level predict the hypertension incidence? A Chinese prospective cohort study. ( Gao, Y; Huang, J; Li, Y; Niu, K; Sun, Y; Wan, Z; Wu, X; Yao, W; Zhang, W; Zhao, H, 2015) |
| "Hyperuricemia is frequently reported in adults, but there are few data for the pediatric population." | 5.42 | Is Hyperuricemia Overlooked when Treating Pediatric Tuberculosis Patients with Pyrazinamide? ( Aslan, AT; Budakoğlu, I; Şişmanlar, T, 2015) |
| "Hyperuricemia is an independent risk factor for chronic kidney disease and cardiovascular disease." | 5.42 | Chinese Herbal Formulas Si-Wu-Tang and Er-Miao-San Synergistically Ameliorated Hyperuricemia and Renal Impairment in Rats Induced by Adenine and Potassium Oxonate. ( Gui, D; Guo, Y; Jiang, Q; Wang, N, 2015) |
| "Febuxostat is potentially more effective than allopurinol for treating patients with chronic HF and hyperuricemia." | 5.41 | Comparison between febuxostat and allopurinol uric acid-lowering therapy in patients with chronic heart failure and hyperuricemia: a multicenter randomized controlled trial. ( Ishibashi, T; Kobayashi, A; Konno, I; Kunii, H; Machii, H; Miyamoto, T; Nakazato, K; Niizeki, T; Nozaki, N; Suzuki, S; Takeishi, Y; Tsuda, A; Tsuda, T; Yamaguchi, O; Yamaki, T; Yokokawa, T; Yoshihisa, A, 2021) |
| "This network meta-analysis demonstrated an important absolute benefit of dotinurad 4 mg once daily to achieve target serum uric acid and low risk of adverse events for drug treatment of gout or hyperuricemia patients." | 5.41 | Comparative efficacy and safety of uricosuric agents in the treatment of gout or hyperuricemia: a systematic review and network meta-analysis. ( Chen, LR; Guo, Y; He, GH; Jiang, FF; Li, YJ; Qian, K; Wang, P; Yang, M; Yang, ZL; Yin, SJ, 2023) |
| "The aim of the present study is to present a historical and unified perspective on the association of serum uric acid (SUA) in the cause of cardiovascular diseases (CVDs)." | 5.41 | Association of hyperuricemia with cardiovascular diseases: current evidence. ( Chrysant, SG, 2023) |
| "Relevant clinical studies up to January 28, 2023 were identified and retrieved from electronic databases including PubMed, Scopus, EMBASE and Web of Science, with periodontitis, uric acid, hyperuricemia and gout as the keywords." | 5.41 | Association between periodontitis and uric acid levels in blood and oral fluids: a systematic review and meta-analysis. ( Mei, ZS; Ye, LW; Yu, T; Zhao, L; Zhou, YH, 2023) |
| "Theaflavins exert anti-gout effects by down regulating the gene and protein expression of glucose transporter 9 (GLUT9) and uric acid transporter 1 (URAT1), while upregulating the mRNA expression levels of organic anion transporter 1 (OAT1), organic cation transporter N1 (OCTN1), organic cation transporters 1/2 (Oct1/2), and organic anion transporter 2 (OAT2)." | 5.41 | Mechanisms of theaflavins against gout and strategies for improving the bioavailability. ( Chen, J; Gong, S; Hu, J; Li, X; Ma, L; Yu, H; Zheng, Y; Zheng, Z, 2023) |
| " Epidemiological and genetic studies have shown an independent role of uric acid in the risk of coronary artery disease, heart failure, chronic kidney disease, and cardiovascular mortality." | 5.41 | Advances in pharmacotherapies for hyperuricemia. ( Agnoletti, D; Borghi, C; Piani, F, 2023) |
| "A direct relationship between serum uric acid levels and hypertension, cardiovascular, renal and metabolic diseases has been reported in many basic and epidemiological studies." | 5.41 | Update in uric acid, hypertension, and cardiovascular diseases. ( Ae, R; Andres-Hernando, A; Borghi, C; Hisatome, I; Kanbay, M; Kodama, T; Kuwabara, M; Lanaspa, MA, 2023) |
| "Hyperuricemia nephropathy, also known as gouty nephropathy, refers to renal damage induced by hyperuricemia caused by excessive production of serum uric acid or low excretion of uric acid." | 5.41 | Possible correlated signaling pathways with chronic urate nephropathy: A review. ( Fu, T; Gao, Y; Huang, H; Li, J; Li, K; Ma, Y; Tong, Y; Wang, X; Xia, X; Zhang, S, 2023) |
| "Uric acid (UA) is the final product of purine metabolism in human body,and its metabolic disorder will induce hyperuricemia (HUA)." | 5.41 | [Effect of High-Concentration Uric Acid on Nitric Oxide]. ( Bai, X; Guan, BS; Hou, ZL; Jiang, H; Lan, RY; Li, WL; Pei, SY; Qin, SY; Qiu, HB; Qu, MH; Qu, RJ; Wang, JT; Yin, XL; Zeng, J, 2023) |
| "Xanthine oxidase inhibitors such as allopurinol and febuxostat have been the mainstay urate-lowering therapy (ULT) for treating hyperuricaemia in patients with gout." | 5.41 | Mechanisms and rationale for uricase use in patients with gout. ( Lioté, F; Pérez-Ruiz, F; Schlesinger, N, 2023) |
| "Gout is a common inflammatory arthritis caused by persistently elevated uric acid levels." | 5.41 | Gout therapeutics and drug delivery. ( Boucetta, H; Chen, Z; He, W; Lai, Y; Li, X; Peng, X; Sosnik, A; Xie, B, 2023) |
| "The relationship between Serum Uric Acid (UA) and Cardiovascular (CV) diseases has already been extensively evaluated, and it was found to be an independent predictor of all-cause and cardiovascular mortality but also acute coronary syndrome, stroke and heart failure." | 5.41 | The Results of the URRAH (Uric Acid Right for Heart Health) Project: A Focus on Hyperuricemia in Relation to Cardiovascular and Kidney Disease and its Role in Metabolic Dysregulation. ( Agabiti Rosei, E; Angeli, F; Barbagallo, CM; Bernardino, B; Bombelli, M; Borghi, C; Cappelli, F; Casiglia, E; Cianci, R; Ciccarelli, M; Cicero, AFG; Cirillo, M; Cirillo, P; D'Elia, L; Dell'Oro, R; Desideri, G; Facchetti, R; Ferri, C; Galletti, F; Gesualdo, L; Giannattasio, C; Grassi, G; Iaccarino, G; Lippa, L; Mallamaci, F; Maloberti, A; Masi, S; Masulli, M; Mazza, A; Mengozzi, A; Muiesan, ML; Nazzaro, P; Palatini, P; Parati, G; Pauletto, P; Pontremoli, R; Pugliese, NR; Quarti-Trevano, F; Rattazzi, M; Reboldi, G; Rivasi, G; Russo, E; Salvetti, M; Tikhonoff, V; Tocci, G; Ungar, A; Verdecchia, P; Viazzi, F; Virdis, A; Volpe, M, 2023) |
| " This review article focuses on the relationship between uric acid and thirteen specific domains: transporters, genetic factors, diet, lifestyle, gout, diabetes mellitus, metabolic syndrome, atherosclerosis, hypertension, kidney diseases, cardiovascular diseases, neurological diseases, and malignancies." | 5.41 | Exploring the Multifaceted Nexus of Uric Acid and Health: A Review of Recent Studies on Diverse Diseases. ( Abe, K; Akashi, N; Aoki, Y; Fukuuchi, T; Hisatome, I; Ichida, K; Kurajoh, M; Kuwabara, M; Maruhashi, T; Miyata, H; Mizuta, E; Morikawa, N; Morita, M; Nishimiya, K; Ogino, K; Otani, N; Ouchi, M; Takada, T; Tanaka, A; Tanaka, Y; Tsutani, H, 2023) |
| "Thirty-nine subjects with persistent hyperuricemia were randomized to receive curcumin (500-mg capsules twice daily, 20 subjects) or placebo (19 subjects)." | 5.41 | Effect of Curcumin on Serum Urate in Asymptomatic Hyperuricemia: A Randomized Placebo-Controlled Trial. ( Asavatanabodee, P; Bupparenoo, P; Chaiamnuay, S; Narongroeknawin, P; Pakchotanon, R, 2021) |
| "Elevated serum uric acid is a cardiovascular risk factor in patients with hypertension, even when blood pressure (BP) is well controlled." | 5.41 | Comparative effects of topiroxostat and febuxostat on arterial properties in hypertensive patients with hyperuricemia. ( Abe, Y; Fukumoto, Y; Hisatome, I; Hongou, M; Hoshide, S; Kario, K; Kasai, T; Kiuchi, M; Kiyosue, A; Kuga, H; Kuramochi, J; Miyazaki, S; Nishizawa, M; Ohtani, H; Tomita, F; Yasu, T, 2021) |
| " We undertook this study to determine whether moderate hyperuricemia induced by inosine supplements influences bone turnover markers in postmenopausal women over a 6-month period." | 5.41 | Elevated Urate Levels Do Not Alter Bone Turnover Markers: Randomized Controlled Trial of Inosine Supplementation in Postmenopausal Women. ( Dalbeth, N; Gamble, GD; Horne, A; Merriman, TR; Mihov, B; Reid, IR; Stamp, LK; Stewart, A, 2021) |
| " We examined whether differences in methylation potential, measured as plasma levels of S-adenosyl methionine (SAM) and S-adenosyl homocysteine (SAH), occur at baseline and during anti-oxidant therapy with the xanthine oxidase inhibitor allopurinol in patients with heart failure with reduced ejection fraction." | 5.41 | Associations of methyl donor and methylation inhibitor levels during anti-oxidant therapy in heart failure. ( Alhanti, B; Cheema, AK; Giczewska, A; Givertz, MM; Handy, DE; Joseph, J; Loscalzo, J; Mann, DL, 2021) |
| "Hypertension was defined according to blood pressure readings by definitions of the Seventh Report of the Joint National Committee." | 5.40 | Serum uric acid level in newly diagnosed essential hypertension in a Nepalese population: a hospital based cross sectional study. ( Jha, B; Kumar, A; Poudel, B; Raut, KB; Yadav, BK, 2014) |
| "Hyperuricemia was defined as an SUA level of ≥7." | 5.40 | Prevalence of hyperuricemia and the relationship between serum uric acid and metabolic syndrome in the Asian Mongolian area. ( Liu, A; Wang, P; Wu, H; Wuyun, G; You, L, 2014) |
| "Hyperuricemia is a common finding in patients with NAFLD and is independently associated with early histological findings in this clinically relevant condition." | 5.40 | The relationship of serum uric acid with non-alcoholic fatty liver disease. ( Celebi, G; Dogru, T; Ercin, CN; Genc, H; Gurel, H; Kara, M; Kayadibi, H; Sertoglu, E, 2014) |
| "Mild hyperuricemia is a strong, independent marker of MS and high cardio-renal risk profile in hypertensive patients under specialist care." | 5.40 | Serum uric acid and its relationship with metabolic syndrome and cardiovascular risk profile in patients with hypertension: insights from the I-DEMAND study. ( Agabiti Rosei, E; Ambrosioni, E; Costa, FV; Deferrari, G; Garneri, D; Gonnella, A; Leoncini, G; Leonetti, G; Muiesan, ML; Pessina, AC; Pontremoli, R; Trimarco, B; Viazzi, F; Volpe, M, 2014) |
| "Febuxostat is a novel xanthine oxidase inhibitor that is metabolized by many metabolic pathways in the kidney and the liver." | 5.40 | Switching from allopurinol to febuxostat for the treatment of hyperuricemia and renal function in patients with chronic kidney disease. ( Itabashi, M; Mochizuki, T; Moriyama, T; Nitta, K; Takei, T; Tsuchiya, K; Tsuruta, Y, 2014) |
| "Gout is a metabolic disorder associated with hyperuricemia resulting in the deposition of monosodium urate (MSU) crystals in joints and tissues." | 5.40 | Study on the anti-gout activity of chlorogenic acid: improvement on hyperuricemia and gouty inflammation. ( Cao, L; Ding, G; Guo, CR; Huang, WZ; Meng, ZQ; Tang, ZH; Wang, KD; Wang, ZZ; Xiao, W; Yan, YX; Yang, ZL, 2014) |
| "Hyperuricemia is related to a variety of pathologies, including chronic kidney disease (CKD)." | 5.39 | Hyperuricemia influences tryptophan metabolism via inhibition of multidrug resistance protein 4 (MRP4) and breast cancer resistance protein (BCRP). ( Dankers, AC; Dijkman, HB; Hoenderop, JG; Masereeuw, R; Mutsaers, HA; Russel, FG; Sweep, FC; van den Heuvel, LP, 2013) |
| "Hyperuricemia has been associated with an increased risk of endothelial dysfunction (ED), cardiovascular and renal disease." | 5.38 | Effect of the treatment with allopurinol on the endothelial function in patients with hyperuricemia. ( Espinola-Zavaleta, N; Kuri-Alfaro, J; López-Osorio, C; Meléndez-Ramírez, G; Pérez-Méndez, O, 2012) |
| "Hyperuricemia was defined as SUA ≥70 mg/L in men and ≥60 mg/L in women." | 5.38 | Cross-sectional and longitudinal associations between serum uric acid and metabolic syndrome. ( Gonçalves, JP; Lopes, C; Oliveira, A; Santos, AC; Severo, M, 2012) |
| "Hyperuricemia is an independent predictor for early atherosclerosis in hypertensive subjects with normal renal function." | 5.38 | Uric acid is an important predictor for hypertensive early atherosclerosis. ( Bahadir, E; Citil, R; Deger, SM; Durmaz, AO; Mutluay, R; Sindel, S, 2012) |
| "Hyperuricemia was defined as UA ≥ 7 mg/dL in men and UA ≥ 6 mg/dL in women." | 5.38 | Association between Uric Acid and Metabolic Syndrome in Qazvin Metabolic Diseases Study (QMDS), Iran. ( Asefzadeh, S; Esmailzadehha, N; Ghorbani, A; Ziaee, A, 2012) |
| "Because preeclampsia is associated with placental immune⁄ inflammatory dysregulation, we sought to determine in the trophoblast, the presence of the Nalp3 inflammasome, and the effect of MSU on its activation." | 5.37 | Uric acid induces trophoblast IL-1β production via the inflammasome: implications for the pathogenesis of preeclampsia. ( Abrahams, VM; Boeras, C; Guller, S; Kavathas, PB; Mulla, MJ; Myrtolli, K; Norwitz, ER; Potter, J; Sfakianaki, AK; Tadesse, S, 2011) |
| "Hyperuricemia was more common in men than in women (51." | 5.37 | Relation of uric acid with components of metabolic syndrome before and after Roux-en-Y gastric bypass in morbidly obese subjects. ( Rossi, FM; Rossi, M; Serpa Neto, A; Teixeira, GK; Valle, LG, 2011) |
| "Astilbin is a flavonoid compound isolated from the rhizome of Smilax china L." | 5.37 | Astilbin attenuates hyperuricemia and ameliorates nephropathy in fructose-induced hyperuricemic rats. ( Chen, L; Lan, Z; Li, F; Li, P; Yang, Z; Zhang, C; Zhang, X; Zhou, Y, 2011) |
| "Hyperuricemia was defined as a serum UA value >7." | 5.36 | The relationship between serum uric acid level and metabolic syndrome: differences by sex and age in Taiwanese. ( Chiou, WK; Chiu, HT; Huang, DH; Lee, YJ; Lin, JD; Wang, MH, 2010) |
| "Hyperuricaemia was associated with cardiac hypertrophy with an odds ratio (OR) of 1." | 5.36 | Role of uric acid in the link between arterial stiffness and cardiac hypertrophy: a cross-sectional study. ( Chen, CC; Chen, HW; Hung, KC; Hwang, JS; Ko, YS; Kuo, CF; Lin, CM; Lin, YS; Luo, SF; See, LC; Shen, YM; Tseng, WY; Wen, MS; Yu, KH, 2010) |
| "Uric acid was significantly associated with increased likelihood for diastolic HTN (OR = 2." | 5.35 | Serum uric acid and ambulatory blood pressure in children with primary hypertension. ( Alpert, BS; Jones, DP; Li, R; Richey, PA, 2008) |
| "Hyperuricemia is common after kidney transplantation." | 5.35 | Association of uric acid with inflammation, progressive renal allograft dysfunction and post-transplant cardiovascular risk. ( Bandukwala, F; Huang, M; Nash, MM; Prasad, GV; Zaltzman, JS, 2009) |
| "Hyperuricemia is often found in patients with chronic heart failure (CHF)." | 5.35 | Is uric acid itself a player or a bystander in the pathophysiology of chronic heart failure? ( Duan, X; Ling, F, 2008) |
| "The metabolic syndrome was defined by the original ATP III criteria and the modified ATP III criteria that include a reduced waist circumference." | 5.35 | Association between serum uric acid and the Adult Treatment Panel III-defined metabolic syndrome: results from a single hospital database. ( Choi, SJ; Ji, JD; Lee, YH; Rho, YH; Song, GG; Woo, JH, 2008) |
| "Moreover, hyperuricemia is significantly correlated with hypertriglyceridemia, hypertension, and visceral obesity." | 5.35 | Serum uric acid levels and risk of metabolic syndrome in healthy adults. ( Bandarian, F; Ebrahimpour, P; Fakhrzadeh, H; Heshmat, R; Larijani, B, 2008) |
| "Febuxostat had stronger renoprotective and antioxidant effects than topiroxostat in patients with hyperuricemia and CKD." | 5.34 | Changeover Trial of Febuxostat and Topiroxostat for Hyperuricemia with Cardiovascular Disease: Sub-Analysis for Chronic Kidney Disease (TROFEO CKD Trial). ( Osaka, S; Sekino, H; Sezai, A; Tanaka, M; Taoka, M; Unosawa, S, 2020) |
| "Dotinurad, a novel selective urate reabsorption inhibitor (SURI) that has a future potential for the treatment of hyperuricemia, reduces serum uric acid levels by selectively inhibiting urate transporter 1 (URAT1)." | 5.34 | Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: an exploratory, randomized, multicenter, double-blind, placebo-controlled, parallel-group early phase 2 stu ( Fushimi, M; Hosoya, T; Ohashi, T; Sano, T; Sasaki, T, 2020) |
| "Dotinurad, a novel selective urate reabsorption inhibitor (SURI), reduces serum uric acid levels by selectively inhibiting urate transporter 1 (URAT1) for the treatment of hyperuricemia with or without gout." | 5.34 | Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: randomized, multicenter, double-blind, placebo-controlled, parallel-group, confirmatory phase 2 study. ( Fushimi, M; Hosoya, T; Ohashi, T; Sano, T; Sasaki, T, 2020) |
| "Dotinurad at doses of 2-4-mg sufficiently reduced serum uric acid levels in hyperuricemic patients with or without gout, and its efficacy and safety were verified for long-term administration." | 5.34 | Open-label study of long-term administration of dotinurad in Japanese hyperuricemic patients with or without gout. ( Fushimi, M; Hosoya, T; Ohashi, T; Okui, D; Sasaki, T, 2020) |
| " We evaluated the efficacy and safety of dotinurad versus febuxostat, a widely used drug in Japan, in hyperuricemic Japanese patients with or without gout." | 5.34 | A non-inferiority study of the novel selective urate reabsorption inhibitor dotinurad versus febuxostat in hyperuricemic patients with or without gout. ( Furuno, K; Hosoya, T; Kanda, S, 2020) |
| "Dotinurad 2 mg was verified to have a non-inferior serum uric acid lowering effect compared with benzbromarone 50 mg, in Japanese hyperuricemic patients with or without gout." | 5.34 | Dotinurad versus benzbromarone in Japanese hyperuricemic patient with or without gout: a randomized, double-blind, parallel-group, phase 3 study. ( Fushimi, M; Hosoya, T; Ohashi, T; Sano, T; Sasaki, T, 2020) |
| "In Japanese patients with asymptomatic hyperuricemia, 24 months of febuxostat treatment did not delay carotid atherosclerosis progression, compared with non-pharmacological care." | 5.34 | Febuxostat does not delay progression of carotid atherosclerosis in patients with asymptomatic hyperuricemia: A randomized, controlled trial. ( Eguchi, K; Higashi, Y; Ishibashi, R; Ishizaka, N; Ishizu, T; Kanzaki, Y; Kario, K; Kato, T; Maemura, K; Murohara, T; Node, K; Ohishi, M; Oyama, JI; Sata, M; Sezai, A; Taguchi, I; Tanaka, A; Teragawa, H; Tomiyama, H; Toyoda, S; Ueda, S; Yamada, H; Yokote, K, 2020) |
| "Uric acid is generated with reactive oxygen species via xanthine oxidase (XO), and hyperuricemia, which is identified as the excess of uric acid in the blood, has been associated with vascular endothelial dysfunction." | 5.34 | Randomized, Open-Label, Cross-Over Comparison of the Effects of Benzbromarone and Febuxostat on Endothelial Function in Patients with Hyperuricemia. ( Doi, Y; Fukae, S; Ikeda, S; Kawano, H; Koga, S; Maemura, K; Minami, T; Nakata, T; Tsuneto, A; Yonekura, T, 2020) |
| "Metabolic syndrome was diagnosed using the WHO criteria." | 5.34 | Serum uric acid level as an independent component of the metabolic syndrome in type 2 diabetic blacks. ( Akande, AA; Akinyinka, OA; Jimoh, AK; Olarinoye, GO, 2007) |
| "Hyperuricemia is associated with cardiovascular risk." | 5.33 | Lys418Asn polymorphism of the alpha2-adrenoceptor gene relates to serum uric acid levels but not to insulin sensitivity. ( Fu, Y; Katsuya, T; Masuo, K; Ogihara, T; Rakugi, H; Tuck, ML, 2005) |
| "Hyperuricemia has been identified in patients who have congestive heart failure and is a marker of poor prognosis in such patients." | 5.33 | Prognostic usefulness of serum uric acid after acute myocardial infarction (the Japanese Acute Coronary Syndrome Study). ( Hiraoka, H; Honda, T; Ishihara, M; Kimura, K; Kojima, S; Matsui, K; Miyazaki, S; Ogata, Y; Ogawa, H; Sakamoto, T; Shimoyama, N; Sonoda, M; Tei, C; Tsuchihashi, K; Yamagishi, M, 2005) |
| "Uric acid levels were measured before transplantation and after transplantation within six months intervals for two yr." | 5.33 | Frequency of hyperuricemia and effect of calcineurin inhibitors on serum uric acid levels in liver transplanted children. ( Arikan, C; Aydogdu, S; Kilic, M; Tumgor, G, 2006) |
| "Hyperuricemia is part of the "metabolic syndrome"." | 5.32 | Serum uric acid levels in obese children and adolescents: linkage to testosterone levels and pre-metabolic syndrome. ( Debatin, KM; Denzer, C; Heinze, E; Mayer, H; Muche, R; Wabitsch, M, 2003) |
| "URC102, a novel and potent inhibitor of human uric acid transporter 1 (hURAT1), is currently under clinical development to treat patients with gout." | 5.30 | URC102, a potent and selective inhibitor of hURAT1, reduced serum uric acid in healthy volunteers. ( Ahn, Y; Lee, H; Lee, HA; Onohara, M; Park, SI; Yoon, S; Yu, KS, 2019) |
| " A total of 65 patients with hyperuricemia and diabetic nephropathy with microalbuminuria were enrolled and assigned to either the topiroxostat group or the placebo group." | 5.27 | Uric acid-lowering and renoprotective effects of topiroxostat, a selective xanthine oxidoreductase inhibitor, in patients with diabetic nephropathy and hyperuricemia: a randomized, double-blind, placebo-controlled, parallel-group study (UPWARD study). ( Honda, D; Hosoya, T; Kimura, K; Narita, K; Okui, D; Sakamoto, R; Sasaki, T; Wada, T, 2018) |
| "6 years) with hyperuricemia (fasting serum uric acid ≥0." | 5.27 | Ultrasonographic assessment of joint pathology in type 2 diabetes and hyperuricemia: The Fremantle Diabetes Study Phase II. ( Davis, TME; Davis, WA; Drinkwater, JJ; Keen, HI; Latkovic, E; Nossent, J, 2018) |
| " Nevertheless, it remains unclear whether lowering of serum uric acid (UA) alters any of the features of the metabolic syndrome." | 5.27 | Effects of pharmacological reversal of hyperuricemia on features of the metabolic syndrome in patients with gouty arthritis. ( Maalouf, NM; Marin, M, 2018) |
| " In the benzbromarone group, kidney stones in one case increased in quantity." | 5.27 | Safety and Efficacy of Benzbromarone and Febuxostat in Hyperuricemia Patients with Chronic Kidney Disease: A Prospective Pilot Study. ( Bao, H; Cheng, J; Liu, X; Peng, A; Qin, L; Song, Y; Wang, L; Yu, H; Zhou, X, 2018) |
| "Japanese male subjects aged 21-65 years with gout (n = 37) or asymptomatic hyperuricaemia (n = 35) and serum urate (sUA) ⩾8 mg/dl were randomized to febuxostat (10, 20, 40 mg) in combination with verinurad (2." | 5.27 | Verinurad combined with febuxostat in Japanese adults with gout or asymptomatic hyperuricaemia: a phase 2a, open-label study. ( Gillen, M; Hall, J; Ito, Y; Liu, S; Shen, Z; Shiramoto, M; Yamamoto, A; Yan, X, 2018) |
| "The aim of this research work was to observe and analyze the efficacy of febuxostat and allopurinol in the treatment of gout with hyperuricemia." | 5.27 | The efficacy of febuxostat and allopurinol in the treatment of gout with hyperuricemia. ( Wang, S, 2018) |
| "This multicenter, open-label study evaluated the efficacy and safety of long-term twice-daily oral topiroxostat administration in patients with or without gout." | 5.27 | Multicenter, Open-Label Study of Long-Term Topiroxostat (FYX-051) Administration in Japanese Hyperuricemic Patients with or Without Gout. ( Hosoya, T; Ishikawa, T; Ogawa, Y; Ohashi, T; Sakamoto, R, 2018) |
| "We previously reported that febuxostat was more effective for hyperuricemia than allopurinol." | 5.24 | Cross-Over Trial of Febuxostat and Topiroxostat for Hyperuricemia With Cardiovascular Disease (TROFEO Trial). ( Abe, K; Kanno, S; Obata, K; Sekino, H; Sezai, A, 2017) |
| "Previous studies have discussed the relationship between simple renal cysts (SRC) and serum uric acid level in healthy individuals." | 5.24 | Hyperuricemia and overexcretion of uric acid increase the risk of simple renal cysts in type 2 diabetes. ( Bao, Y; Chen, H; Han, J; Han, Y; Jia, W; Lu, J; Zhang, L; Zhang, M; Zhao, F, 2017) |
| "Hyperuricemia is common in approximately 50% of patients with kidney failure due to decreased uric acid excretion, and it has been recently known as an independent factor in the progression of renal insufficiency." | 5.24 | Allopurinol Against Progression of Chronic Kidney Disease. ( Almasi, A; Golmohammadi, S; Manouchehri, M; Omrani, HR; Zandkarimi, MR, 2017) |
| "The relation between uric acid (UA) and heart failure has been described; however, there is little detail concerning acute heart failure (AHF) in patients with reduced versus preserved ejection fraction heart failure (HFrEF, HFpEF)." | 5.24 | Prevalence of Hyperuricemia in Patients With Acute Heart Failure With Either Reduced or Preserved Ejection Fraction. ( De Vivo, O; McCullough, PA; Nuti, R; Palazzuoli, A; Ruocco, G, 2017) |
| "There is little evidence guiding selection of nondiuretic, antihypertensive agents with a goal of lowering uric acid (SUA) and minimizing gout risk." | 5.24 | Metoprolol Increases Uric Acid and Risk of Gout in African Americans With Chronic Kidney Disease Attributed to Hypertension. ( Appel, LJ; Juraschek, SP; Miller, ER, 2017) |
| "In this double-blind, placebo-controlled study, 314 subjects with hyperuricemia (serum uric acid [UA] level of ≥7." | 5.24 | Effects of Febuxostat in Early Gout: A Randomized, Double-Blind, Placebo-Controlled Study. ( Choi, HK; Dalbeth, N; Gunawardhana, L; Hunt, B; MacDonald, PA; Palmer, WE; Saag, KG; Thienel, U, 2017) |
| "Hyperuricemia is associated with hypertension, with elevated serum uric acid levels postulated to have a causal role in the development of hypertension." | 5.24 | Effect of Febuxostat on Ambulatory Blood Pressure in Subjects With Hyperuricemia and Hypertension: A Phase 2 Randomized Placebo-Controlled Study. ( Feig, DI; Gunawardhana, L; Hunt, B; McLean, L; Palmer, RN; Punzi, HA; Whelton, A, 2017) |
| "Since uric acid is associated with cardiovascular and renal disease, a treatment to maintain blood uric acid level may be required in patients with hyperuricemia." | 5.24 | Rationale, design, and baseline characteristics of a study to evaluate the effect of febuxostat in preventing cerebral, cardiovascular, and renal events in patients with hyperuricemia. ( Hayashi, T; Hiramitsu, S; Hisatome, I; Jinnouchi, H; Kakuda, H; Kawai, N; Kimura, K; Kojima, S; Matsui, K; Mori, H; Ogawa, H; Ohya, Y; Saito, Y; Sugawara, M; Tokutake, E; Uchiyama, K; Wakasa, Y; Waki, M; Yokota, N, 2017) |
| "Our objectives were to determine whether a change in serum uric acid (sUA) resulted in a corresponding change in the fractional excretion of uric acid (FEUA) and whether the renal response was different in patients with gout versus healthy subjects." | 5.24 | Patients with gout differ from healthy subjects in renal response to changes in serum uric acid. ( Liu, S; Miner, JN; Perez-Ruiz, F, 2017) |
| "Uric acid (UA) has been associated with hypertension, renal disease and cardiovascular disease." | 5.24 | Effective uric acid-lowering treatment for hypertensive patients with hyperuricemia. ( Arima, H; Hayashi, S; Ishizuka, A; Iwashima, Y; Kawano, Y; Kishida, M; Nakamura, S; Ohta, Y; Yoshihara, F, 2017) |
| "Topiroxostat, a selective xanthine oxidoreductase inhibitor, is used in Japan for the treatment of hyperuricemic patients with or without gout." | 5.24 | Clinical efficacy and safety of topiroxostat in Japanese hyperuricemic patients with or without gout: a randomized, double-blinded, controlled phase 2b study. ( Hosoya, T; Ohashi, T; Sasaki, T, 2017) |
| "Hyperuricemia is caused by reduced renal/extrarenal excretion and overproduction of uric acid." | 5.22 | Impact of hyperuricemia on chronic kidney disease and atherosclerotic cardiovascular disease. ( Maeda, N; Nishizawa, H; Shimomura, I, 2022) |
| "Increased serum uric acid (SUA) levels are commonly seen in patients with metabolic syndrome and are widely accepted as risk factors for hypertension, gout, non-alcoholic fatty liver disease, chronic kidney disease (CKD), and cardiovascular diseases." | 5.22 | Uric acid in metabolic syndrome: Does uric acid have a definitive role? ( Copur, S; Demiray, A; Kanbay, M, 2022) |
| "Uric acid is the final product of purine metabolism, and its increased serum levels have been directly involved in the pathogenesis and natural history of hypertension." | 5.22 | Uric Acid and Hypertension: a Review of Evidence and Future Perspectives for the Management of Cardiovascular Risk. ( Agnoletti, D; Borghi, C; Cicero, AFG; Lurbe, E; Virdis, A, 2022) |
| "In the present study, we employed meta-analysis and a hyperuricemia quail model to evaluate the uric acid-lowering effect of SLBZ." | 5.22 | An integrated study of Shenling Baizhu San against hyperuricemia: Efficacy evaluation, core target identification and active component discovery. ( Chu, MZ; Ding, XL; Huang, J; Li, WJ; Lin, ZJ; Mao, QY; Wang, Y; Zhang, B, 2022) |
| "We thoroughly searched five electronic resource databases for randomized controlled trials (RCTs) that compared the efficacy and safety of allopurinol versus conventional treatment or placebo for the treatment of patients with diabetes mellitus." | 5.22 | Effects of allopurinol on renal function in patients with diabetes: a systematic review and meta-analysis. ( Cai, Y; Liu, WJ; Liu, Y; Luo, Q; Tian, L; Zhao, Q, 2022) |
| "Uric acid (UA) is the final product of purine metabolism in the human body, and impaired purine metabolism can increase the uric acid in serum, finally resulting in hyperuricemia (HUA)." | 5.22 | Excess Uric Acid Induces Gouty Nephropathy Through Crystal Formation: A Review of Recent Insights. ( Dong, B; Geng, Z; Mei, Y; Xu, L, 2022) |
| "Hyperuricemia is a metabolic disease caused by the accumulation of uric acid in the body." | 5.22 | Research Progress of Natural Active Substances with Uric-Acid-Reducing Activity. ( Cui, J; Hou, J; Wang, W; Zhang, X, 2022) |
| "Hyperuricemia (HUA) is a metabolic disorder caused by abnormal uric acid (UA) metabolism, which is a complex physiological process involving multiple organs (liver, kidney, and intestine)." | 5.22 | The gut microbiota as a target to control hyperuricemia pathogenesis: Potential mechanisms and therapeutic strategies. ( Cai, L; Chen, F; Chen, Y; Feng, F; Hu, X; Regenstein, J; Wang, J; Zhong, H, 2022) |
| "Alcohol is recognized a risk factor for increased uric acid and gout flare." | 5.22 | The role of alcohol consumption in pathogenesis of gout. ( Nieradko-Iwanicka, B, 2022) |
| "Hyperuricemia is a prognostic factor in patients with chronic heart failure, but whether uric acid level can predict clinical outcome of acute heart failure (AHF) remains to be elucidated." | 5.22 | Determinants and Prognostic Impact of Hyperuricemia in Hospitalization for Acute Heart Failure. ( Chen, CH; Cheng, HM; Cheng, YL; Guo, CY; Hsu, PF; Huang, WM; Lu, DY; Sung, SH; Yu, WC, 2016) |
| "This phase IIIB study compared the efficacy and safety of febuxostat and allopurinol in gout patients with or without tophi who were HLA-B*5801 negative." | 5.22 | Safety and efficacy of oral febuxostat for treatment of HLA-B*5801-negative gout: a randomized, open-label, multicentre, allopurinol-controlled study. ( Chen, CJ; Chen, DY; Hsu, PN; Lai, JH; Lin, HY; Yu, KH, 2016) |
| "Elevated plasma uric acid concentration is a risk factor for gout, insulin resistance and type 2 diabetes." | 5.22 | Quercetin lowers plasma uric acid in pre-hyperuricaemic males: a randomised, double-blinded, placebo-controlled, cross-over trial. ( Shi, Y; Williamson, G, 2016) |
| "Control of serum uric acid (sUA) levels is very important during chemotherapy in patients with malignant tumors, as the risks of tumor lysis syndrome (TLS) and renal events are increased with increasing levels of sUA." | 5.22 | Efficacy and safety of febuxostat for prevention of tumor lysis syndrome in patients with malignant tumors receiving chemotherapy: a phase III, randomized, multi-center trial comparing febuxostat and allopurinol. ( Fujimaki, K; Fujisaki, T; Gemba, K; Goto, T; Kaneko, M; Kawai, Y; Kiguchi, T; Kirito, K; Maemondo, M; Nakajima, A; Okamoto, M; Takeda, K; Tamura, K; Ueda, T, 2016) |
| "Serum uric acid (UA) is associated with death and hospitalization in chronic heart failure (HF)." | 5.22 | Prognostic Significance of Hyperuricemia in Patients With Acute Heart Failure. ( Beltrami, M; Giordano, N; McCullough, PA; Nuti, R; Palazzuoli, A; Pellegrini, M; Ruocco, G, 2016) |
| "In Japan, although topiroxostat, a selective xanthine oxidoreductase inhibitor, has been used for the treatment of patients with hyperuricemia including gout, no published randomized controlled studies evaluating the dose-dependent relationship with respect to the serum urate-lowering efficacy have been reported." | 5.22 | Clinical efficacy and safety of topiroxostat in Japanese male hyperuricemic patients with or without gout: an exploratory, phase 2a, multicentre, randomized, double-blind, placebo-controlled study. ( Hashimoto, H; Hosoya, T; Ohashi, T; Sakamoto, R; Sasaki, T, 2016) |
| " Patients who had inadequate serum urate levels (a gout patient: serum urate level ≥416·4 μmol/L; an asymptomatic hyperuricemic patient with specific complications (urinary lithiasis, hypertension, hyperlipidemia and/or diabetes): serum urate level ≥475·8 μmol/L; and an asymptomatic hyperuricemic patient with no specific complications: serum urate level ≥535·3 μmol/L) were randomized to topiroxostat 120 mg/day or allopurinol 200 mg/day, with an equal allocation ratio, for 16 weeks." | 5.22 | Comparison of topiroxostat and allopurinol in Japanese hyperuricemic patients with or without gout: a phase 3, multicentre, randomized, double-blind, double-dummy, active-controlled, parallel-group study. ( Hashimoto, H; Hosoya, T; Ogawa, Y; Ohashi, T; Sakamoto, R, 2016) |
| " A total of 500 patients with asymptomatic hyperuricemia (uric acid >7." | 5.22 | Rationale and design of a multicenter randomized study for evaluating vascular function under uric acid control using the xanthine oxidase inhibitor, febuxostat: the PRIZE study. ( Ako, J; Bando, YK; Eguchi, K; Higashi, Y; Inoue, T; Ishizaka, N; Ishizu, T; Kanzaki, Y; Kuroyanagi, T; Maemura, K; Murohara, T; Node, K; Ohishi, M; Oyama, J; Sata, M; Sato, Y; Taguchi, I; Tanaka, A; Teragawa, H; Tomiyama, H; Ueda, S; Yamada, H, 2016) |
| "Elevated serum uric acid (UA), a biomarker of renal insufficiency, is also an independent prognostic marker for morbidity in coronary artery disease (CAD) and poses serious health risks." | 5.22 | Almond supplementation reduces serum uric acid in coronary artery disease patients: a randomized controlled trial. ( Amin, F; Arslan, J; Ghani, S; Gilani, AU; Jamshed, H; Masroor, M; Sultan, FA, 2016) |
| "Asymptomatic hyperuricemia is not a current indication for therapy as the definite role of serum uric acid elevation as a cardiovascular risk factor is extremely likely but still controversial." | 5.22 | Effects of a Novel Fixed Combination of Nutraceuticals on Serum Uric Acid Concentrations and the Lipid Profile in Asymptomatic Hyperuricemic Patients : Results from the PICONZ-UA Study. ( Ferri, C; Grassi, D; Izzo, R; Rozza, F; Trimarco, V, 2016) |
| "The association between serum uric acid (UA) levels and atrial fibrillation (AF) in the general population in Japan is not well known." | 5.22 | Uric Acid Level and Prevalence of Atrial Fibrillation in a Japanese General Population of 285,882. ( Kawasoe, S; Kubozono, T; Maenohara, S; Miyahara, H; Miyata, M; Ohishi, M; Ojima, S; Oketani, N; Yoshifuku, S, 2016) |
| "We assume that decreasing uric acid levels with allopurinol treatment seems to be helpful in restoring endothelial functions, preventing metabolic acidosis and slowing down the progression of CKD." | 5.20 | The effects of allopurinol on metabolic acidosis and endothelial functions in chronic kidney disease patients. ( Altuntaş, A; Bayram, D; İnal, S; Kıdır, V; Orhan, H; Tuğrul Sezer, M, 2015) |
| " We designed a prospective study to investigate the correlation of serum uric acid (SUA) concentration and weight loss." | 5.20 | The use of serum uric acid concentration as an indicator of laparoscopic sleeve gastrectomy success. ( Almpanopoulos, K; Doulami, G; Kokoroskos, N; Leandros, E; Menenakos, E; Natoudi, M; Theodorou, D; Tzanetakou, IP; Zografos, G, 2015) |
| "The NU-FLASH trial demonstrated that febuxostat was more effective for hyperuricemia than allopurinol." | 5.20 | Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery patients with chronic kidney disease (NU-FLASH trial for CKD). ( Hata, H; Ishii, Y; Nakata, K; Osaka, S; Sezai, A; Shiono, M; Soma, M; Yaoita, H, 2015) |
| "We assessed the efficacy and adverse effects of febuxostat in male hyperuricemia patients." | 5.20 | Effects of febuxostat on serum urate level in Japanese hyperuricemia patients. ( Fujimori, S; Hidaka, Y; Higami, K; Hosoya, T; Inaba, M; Ishimura, E; Kakuda, H; Mineo, I; Moriwaki, Y; Nishikawa, H; Ohtawara, A; Ooyama, H; Taniguchi, A; Ueda, T; Yamamoto, T; Yamanaka, H; Yamauchi, T, 2015) |
| "To compare the efficiency and safety of febuxostat with those of allopurinol in Chinese patients with gout and hyperuricemia." | 5.20 | A phase 3, multicenter, randomized, allopurinol-controlled study assessing the safety and efficacy of oral febuxostat in Chinese gout patients with hyperuricemia. ( Chen, S; Ji, H; Ji, Q; Lin, J; Liu, B; Liu, H; Liu, P; Liu, X; Lu, Y; Ming, J; Peng, Y; Wang, J; Wang, Y; Xu, S; Zhang, Y, 2015) |
| "The aim of this study was to investigate the long-term effective control of serum uric acid by allopurinol on the carotid intima-media thickness (IMT) in patients with type 2 diabetes (T2DM) and asymptomatic hyperuricemia (HUA)." | 5.20 | The Effects of Allopurinol on the Carotid Intima-media Thickness in Patients with Type 2 Diabetes and Asymptomatic Hyperuricemia: A Three-year Randomized Parallel-controlled Study. ( Chen, Y; Liu, P; Wang, D; Wang, H; Wang, Y; Zhang, F, 2015) |
| "Although many studies have indicated a relationship between nonalcoholic fatty liver disease (NAFLD) and hyperuricemia, a few studies specifically examining the effects of the severity of liver fat content (LFC) on serum uric acid (SUA) and the presence of hyperuricemia because of the limitation of the examination methods for NAFLD." | 5.20 | Liver Fat Content Is Associated with Elevated Serum Uric Acid in the Chinese Middle-Aged and Elderly Populations: Shanghai Changfeng Study. ( Gao, X; Li, Q; Li, X; Lin, H; Liu, X; Ma, H; Pan, B; Wang, D; Wu, J; Xia, M; Zhao, N, 2015) |
| "Allopurinol lowers uric acid and improves insulin resistance and systemic inflammation in asymptomatic hyperuricemia." | 5.20 | Lowering Uric Acid With Allopurinol Improves Insulin Resistance and Systemic Inflammation in Asymptomatic Hyperuricemia. ( Afsar, B; ALanaspa, M; Bakan, A; Elcioglu, OC; Erek, A; Johnson, RJ; Kanbay, M; Kostek, O; Mutlu, HH; Odabas, AR; Ozkok, A; Semerci, A; Sharma, S; Smits, G; Takir, M; Telci, O, 2015) |
| "Increased serum uric acid (SUA) or hyperuricemia, a risk factor for gout, renal and cardiovascular diseases, is caused by either increased production or decreased excretion of uric acid or a mix of both." | 5.19 | Replication of the effect of SLC2A9 genetic variation on serum uric acid levels in American Indians. ( Cole, SA; Comuzzie, AG; Franceschini, N; Haack, K; Laston, S; MacCluer, JW; North, KE; Umans, JG; Voruganti, VS, 2014) |
| "The FEATHER (FEbuxostat versus placebo rAndomized controlled Trial regarding reduced renal function in patients with Hyperuricemia complicated by chRonic kidney disease stage 3) study is a prospective, multicenter, double-blind, randomized, placebo-controlled trial of febuxostat-a novel, nonpurine, selective, xanthine oxidase inhibitor." | 5.19 | The effect of febuxostat to prevent a further reduction in renal function of patients with hyperuricemia who have never had gout and are complicated by chronic kidney disease stage 3: study protocol for a multicenter randomized controlled study. ( Hayakawa, H; Hosoya, T; Iimuro, S; Imai, N; Inaba, M; Itoh, S; Kimura, K; Kuwabara, M; Makino, H; Matsuo, S; Ohno, I; Shibagaki, Y; Tomino, Y; Uchida, S; Yamamoto, T, 2014) |
| "Topiroxostat, a selective xanthine oxidase inhibitor, shows effective reduction in the serum urate level in hyperuricemic patients with or without gout." | 5.19 | Effects of topiroxostat on the serum urate levels and urinary albumin excretion in hyperuricemic stage 3 chronic kidney disease patients with or without gout. ( Fujimori, S; Hara, S; Hisatome, I; Hosoya, T; Nomura, S; Ohno, I; Uchida, S; Yamamoto, T, 2014) |
| "Gout patients (n = 512) with serum uric acid (sUA) concentrations of at least 8." | 5.19 | An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia. ( Bao, C; Du, H; Gu, J; Huang, A; Huang, X; Jiang, L; Li, J; Li, X; Li, Z; Liu, Y; Zhang, Y; Zhang, Z; Zhao, D; Zhu, P; Zuo, X, 2014) |
| "We evaluated the association between baseline uric acid and the primary composite outcome of doubling of interstitium or ESRD from interstitial fibrosis and tubular atrophy (IF/TA) in the Angiotensin II Blockade for Chronic Allograft Nephropathy (ABCAN) Trial participants." | 5.19 | Uric acid and allograft loss from interstitial fibrosis/tubular atrophy: post hoc analysis from the angiotensin II blockade in chronic allograft nephropathy trial. ( Hart, A; Ibrahim, HN; Jackson, S; Kasiske, BL; Matas, AJ; Mauer, MS; Najafian, B; Spong, R, 2014) |
| "The aim of this study was to evaluate the pharmacodynamics (PDs), pharmacokinetics (PKs) and safety of lesinurad (selective uric acid reabsorption inhibitor) in combination with febuxostat (xanthine oxidase inhibitor) in patients with gout." | 5.19 | Pharmacodynamic, pharmacokinetic and tolerability evaluation of concomitant administration of lesinurad and febuxostat in gout patients with hyperuricaemia. ( Baumgartner, S; Fleischmann, R; Hingorani, V; Kerr, B; Manhard, K; Miner, JN; Polvent, E; Quart, B; Shen, Z; Suster, M; Yeh, LT, 2014) |
| " Although hyperuricemia is a risk factor for cardiovascular diseases, the relationship between serum uric acid (UA) levels and thromboembolic risk has not been fully elucidated in patients with AF." | 5.19 | Hyperuricemia and transesophageal echocardiographic thromboembolic risk in patients with atrial fibrillation at clinically low-intermediate risk. ( Fukuda, N; Hirai, T; Inoue, H; Nakagawa, K; Nozawa, T; Numa, S; Ohara, K, 2014) |
| "The aims of this study were to establish whether, in patients with gout, MPO is released from neutrophils and urate is oxidized to allantoin and if these effects are attenuated by allopurinol." | 5.19 | Myeloperoxidase and oxidation of uric acid in gout: implications for the clinical consequences of hyperuricaemia. ( Drake, J; Forbes, LV; Kettle, AJ; Khalilova, IS; Stamp, LK; Turner, R; Zhang, M, 2014) |
| " A short-term administration of allopurinol increases plasma concentrations of 1,25(OH)2D3 in mild to moderate renal failure, with or without hyperuricemia." | 5.19 | Inhibition of xanthine oxidase and exercise on serum uric acid, 25(OH)D3, and calcium concentrations. ( Lippi, G; Salvagno, GL; Sanchis-Gomar, F, 2014) |
| "Primary hyperuricemia, an excess of uric acid in the blood, is a major public health problem." | 5.19 | Apolipoprotein E gene polymorphisms are associated with primary hyperuricemia in a Chinese population. ( Cheng, XQ; Di, Q; Guo, XZ; Li, PC; Ni, L; Qiu, L; Wang, Q; Wu, J; Xu, T; Zhang, L; Zhu, GJ, 2014) |
| "To evaluate the efficacy and safety of IL-1 inhibitor rilonacept (IL-1 Trap) for gout flare (GF) prevention during initiation of uric acid-lowering therapy (ULT) with allopurinol in a multiregional phase 3 clinical trial." | 5.17 | Rilonacept for gout flare prevention during initiation of uric acid-lowering therapy: results from the PRESURGE-2 international, phase 3, randomized, placebo-controlled trial. ( Evans, RR; Fouche, L; King-Davis, S; Luo, SF; Mitha, E; Schumacher, HR; Wang, J; Weinstein, SP; Yancopoulos, GD, 2013) |
| "Febuxostat has been reported to have a stronger effect on hyperuricemia than allopurinol." | 5.17 | Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery patients (NU-FLASH Trial). ( Hata, H; Hata, M; Nakata, K; Sezai, A; Shiono, M; Soma, M; Wakui, S; Yoshitake, I, 2013) |
| "Although hyperuricemia was associated with several cardiovascular diseases, the role of uric acid (UA) in left atrial (LA) remodeling and new-onset atrial fibrillation (AF) has not been fully explored." | 5.17 | The association between hyperuricemia, left atrial size and new-onset atrial fibrillation. ( Chang, SL; Chao, TF; Chen, SA; Chen, SJ; Chen, TJ; Hu, YF; Hung, CL; Lin, YJ; Lo, LW; Tuan, TC; Wang, KL, 2013) |
| "Assess the impact of urate-lowering therapy on renal function in subjects with gout who were treated with febuxostat for ≤ 48 months." | 5.17 | Preservation of renal function during gout treatment with febuxostat: a quantitative study. ( Chefo, S; Gunawardhana, L; MacDonald, PA; Whelton, A, 2013) |
| "Thirty-four symptomatic CHF participants with hyperuricemia (≥ 565 μmol/L) were randomized to receive prednisone (1 mg/kg/d, orally) or allopurinol (100 mg, thrice daily, orally) for 4 weeks." | 5.17 | Prednisone in Uric Acid lowering in Symptomatic Heart Failure Patients With Hyperuricemia (PUSH-PATH) study. ( Gao, Y; Ji, L; Ji, Z; Liu, C; Liu, G; Liu, K; Tian, L; Wang, L; Zhao, Q; Zhen, Y, 2013) |
| "To compare the characteristics of female versus male gout patients and assess urate-lowering efficacy and safety of febuxostat or allopurinol treatment in women with gout." | 5.16 | Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol. ( Becker, MA; Chefo, S; Chohan, S; Jackson, RL; MacDonald, PA, 2012) |
| "During its development, ticagrelor, a drug designed to prevent thrombotic events in patients with acute coronary syndromes, was found to have an association with mild hyperuricemia." | 5.16 | Evaluation and characterization of the effects of ticagrelor on serum and urinary uric acid in healthy volunteers. ( Butler, K; Teng, R, 2012) |
| "0 mg/dL) gout subjects were enrolled in the 6-month, double-blind, randomized, comparative CONFIRMS trial and randomized, 1:1:1, to receive febuxostat, 40 mg or 80 mg, or allopurinol (200 mg or 300 mg based on renal function) once daily." | 5.16 | The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age. ( Hunt, B; Jackson, RL; MacDonald, PA, 2012) |
| "Epidemiological, experimental and clinical studies support a role for uric acid in acute kidney injury (AKI)." | 5.16 | Lowering serum uric acid to prevent acute kidney injury. ( Arif, AA; Dass, B; Dhatt, GS; Ejaz, AA; Ejaz, NI; Faldu, C; Johnson, RJ; Kambhampati, G; Lanaspa, MA; Maroz, N; Shah, G, 2012) |
| "To determine the efficacy and safety of increasing the allopurinol dose above the proposed creatinine clearance-based dose in patients with gout." | 5.15 | Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment. ( Barclay, ML; Chapman, PT; Frampton, C; James, J; O'Donnell, JL; Stamp, LK; Zhang, M, 2011) |
| "To evaluate the independent impact of congestive heart failure (CHF) status (compensation or decompensation) on serum uric acid levels among men with high cardiovascular risk profile." | 5.15 | The independent impact of congestive heart failure status and diuretic use on serum uric acid among men with a high cardiovascular risk profile: a prospective longitudinal study. ( Choi, HK; Misra, D; Zhang, Y; Zhu, Y, 2011) |
| "Febuxostat or allopurinol was administered to patients with hyperuricemia including gout for 8 weeks to compare the efficacy and safety of these drugs." | 5.15 | An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: p ( Fujimori, S; Hada, T; Hosoya, T; Kamatani, N; Kohri, K; Matsuzawa, Y; Nakamura, T; Ueda, T; Yamamoto, T; Yamanaka, H, 2011) |
| "Allopurinol has been widely used for treatment of hyperuricemia, however, it may be associated with various adverse effects." | 5.15 | A repeated oral administration study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with impaired renal function in Japan: pharmacokinetic and pharmacodynamic study. ( Hosoya, T; Iwao, O; Ohno, I; Tatsuo, H, 2011) |
| "A multicenter study with randomized, placebo-controlled, double-blind, parallel, intergroup comparison was carried out to evaluate the dose-response relationship, efficacy, and safety of febuxostat in 202 patients with hyperuricemia (including patients with gout) in Japan." | 5.15 | Placebo-controlled double-blind dose-response study of the non-purine-selective xanthine oxidase inhibitor febuxostat (TMX-67) in patients with hyperuricemia (including gout patients) in japan: late phase 2 clinical study. ( Fujimori, S; Hada, T; Hisashi, Y; Hosoya, T; Kamatani, N; Kenjiro, K; Kohri, K; Matsuzawa, Y; Nakamura, T; Naoyuki, K; Shin, F; Takanori, U; Tatsuo, H; Tetsuya, Y; Toshikazu, H; Toshitaka, N; Ueda, T; Yamamoto, T; Yamanaka, H; Yuji, M, 2011) |
| "Febuxostat was administered to patients with hyperuricemia including gout in Japan to compare its efficacy and safety with those of allopurinol." | 5.15 | An allopurinol-controlled, multicenter, randomized, open-label, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phas ( Fujimori, S; Hada, T; Hisashi, Y; Hosoya, T; Kamatani, N; Kenjiro, K; Kohri, K; Matsuzawa, Y; Nakamura, T; Naoyuki, K; Shin, F; Takanori, U; Tatsuo, H; Tetsuya, Y; Toshikazu, H; Toshitaka, N; Ueda, T; Yamamoto, T; Yamanaka, H; Yuji, M, 2011) |
| "In previous clinical studies of hyperuricemia including gout, although serum uric acid (sUA) levels reduced to 6." | 5.15 | Multicenter, open-label study of long-term administration of febuxostat (TMX-67) in Japanese patients with hyperuricemia including gout. ( Fujimori, S; Hada, T; Hosoya, T; Kamatani, N; Kohri, K; Matsuzawa, Y; Nakamura, T; Ueda, T; Yamamoto, T; Yamanaka, H, 2011) |
| "Treatment of hyperuricemia with allopurinol improves endothelial dysfunction and eGFR in subjects with asymptomatic hyperuricemia." | 5.15 | A randomized study of allopurinol on endothelial function and estimated glomular filtration rate in asymptomatic hyperuricemic subjects with normal renal function. ( Azak, A; Covic, A; Duranay, M; Huddam, B; Johnson, RJ; Kadioglu, GK; Kanbay, M; Kirbas, I; Solak, Y, 2011) |
| "The precise relationship of Hyperuricemia found in hypertensive patients is still obscure; this study is a urinary uric acid lowering intervention with Losartan in hypertensive patients induced by Thiazide diuretics." | 5.15 | To study the efficacy of Losartan on urinary uric acid excretion in Thiazide induced hyperuricemic and hypertensive patients. ( Islam, F; Jamali, SN; Khan, M; Khan, RA; Laghari, J, 2011) |
| "99 patients with hyperuricemia were randomly assigned to the XCR group, the Benzbromarone group, and the blank control group." | 5.15 | [Assessment on the clinical efficacy and safety of xiezhuo chubi recipe in treating hyperuricemia]. ( Sun, WF; Xu, W; Zhang, XX, 2011) |
| "Patients with arterial hypertension of the first-second degree with persistent elevated levels of uric acid in blood serum had significantly higher levels of ED markers: albuminuria, plasmic endothelin concentration." | 5.15 | [Clinical implication of endothelial dysfunction in patients with essential arterial hypertension and urate dysbolism with renal damage]. ( , 2011) |
| "Hyperuricemia is prevalent in patients with chronic kidney disease (CKD); however, data are limited about the relationship of uric acid levels with long-term outcomes in this patient population." | 5.14 | Uric acid and long-term outcomes in CKD. ( Beck, GJ; Collins, AJ; Greene, T; Kusek, JW; Levey, AS; Madero, M; Menon, V; Sarnak, MJ; Wang, X, 2009) |
| "Micronised fenofibrate treatment could significantly improve lipid and uric acid metabolism in patients with hypertriglyceridemia and hyperuricemia, and is generally safe and well tolerated." | 5.14 | [Effects of micronized fenofibrate on lipid and uric acid metabolism in patients with hyperlipidemia]. ( Chen, H; Li, LJ; Luo, Y; Ren, JY; Wang, L, 2009) |
| "Losartan may be an effective agent for treatment of hyperuricemia and PTE in Han Chinese patients after kidney transplantation." | 5.14 | Efficacy and safety of losartan in treatment of hyperuricemia and posttransplantation erythrocytosis: results of a prospective, open, randomized, case-control study. ( Chen, J; Cheng, M; Ding, X; Han, F; Le, Y; Xu, L; Zhang, L; Zhu, X, 2009) |
| " The treatment effect of the uricosuric agent benzbromarone was tested in 14 patients with CHF with hyperuricemia in a double-blind, placebo-controlled, randomized crossover study design." | 5.14 | Uric acid-lowering treatment with benzbromarone in patients with heart failure: a double-blind placebo-controlled crossover preliminary study. ( Anker, SD; Doehner, W; Furuse, Y; Hisatome, I; Igawa, O; Ishida, K; Kato, M; Kinugasa, Y; Kinugawa, T; Ogino, K; Osaki, S; Shigemasa, C, 2010) |
| "The purpose of this study was to compare urate-lowering (UL) efficacy and safety of daily febuxostat and allopurinol in subjects with gout and serum urate (sUA) > or = 8." | 5.14 | The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. ( Becker, MA; Espinoza, LR; Lademacher, C; Lloyd, E; MacDonald, P; Schumacher, HR; Wells, AF, 2010) |
| "Rasburicase is effective in controlling plasma uric acid in pediatric patients with hematologic malignancies." | 5.14 | Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone--results of a multicenter phase III study. ( Abboud, CN; Brown, A; Cortes, J; Craig, M; Dey, BR; Krishnamurthy, M; Laadem, A; Luger, S; Matous, J; Maziarz, RT; Moore, JO; Pham, D; Schiller, GJ; Seiter, K; Wetzler, M, 2010) |
| "These results indicate that an additional use of citrate preparations with xanthine oxidase inhibitors is beneficial for patients with hyperuricemia, reducing circulating uric acid and improving their glomerular filtration rates." | 5.14 | The alkalizer citrate reduces serum uric Acid levels and improves renal function in hyperuricemic patients treated with the xanthine oxidase inhibitor allopurinol. ( Ito, H; Ito, Y; Kino, T; Matsuzawa, Y; Nishikawa, T; Omura, M; Saito, J; Yajima, Y; Yoshimura, K, 2010) |
| " Of 2,963 patients with coronary artery disease enrolled in the Bezafibrate Infarction Prevention study, 1,410 had MS, as established by the presence of ≥3 of the following 5 criteria: serum fasting glucose >110 mg/dl, triglycerides >150 mg/dl, high-density lipoprotein cholesterol <40 mg/dl in men and <50 mg/dl in women, systolic and diastolic blood pressures >130 and 80 mm Hg, respectively, and body mass index >28 kg/m²." | 5.14 | Effect of the metabolic syndrome and hyperuricemia on outcome in patients with coronary artery disease (from the Bezafibrate Infarction Prevention Study). ( Behar, S; Boyko, V; Brodov, Y; Chouraqui, P, 2010) |
| "Use of urate-lowering therapy (ULT), such as febuxostat or allopurinol, is recommended for the long-term management of hyperuricemia in patients with gout to reduce the incidence of acute flares." | 5.14 | Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials. ( Hunt, B; Jackson, RL; Macdonald, PA; Wortmann, RL, 2010) |
| "To determine whether lowering uric acid lowers blood pressure (BP) in hyperuricemic adolescents with newly diagnosed hypertension." | 5.13 | Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. ( Feig, DI; Johnson, RJ; Soletsky, B, 2008) |
| "To compare the urate-lowering efficacy and safety of febuxostat, allopurinol, and placebo in a large group of subjects with hyperuricemia and gout, including persons with impaired renal function." | 5.13 | Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. ( Becker, MA; Hunt, B; Joseph-Ridge, N; Lademacher, C; Macdonald, PA; Schumacher, HR; Streit, J; Wortmann, RL, 2008) |
| "To survey the prevalence of hyperuricacidemia and serum uric acid (SUA) changes and electrolyte changes after 6 weeks antihypertensive treatment with thiazide diuretics, losartan or losartan+hydrochlorothiazide (Hyzaar) in patients with essential hypertension (EH)." | 5.13 | [Serum uric acid prevalence and changes post various antihypertensive agents in patients with essential hypertension]. ( Chen, H; Gui, W; Lu, LH; Wu, XY; Yang, LQ; Yu, L, 2008) |
| "To evaluate the major cardiovascular (CV) events of febuxostat compared to allopurinol for the treatment of gout or asymptomatic hyperuricemia." | 5.12 | The major cardiovascular events of febuxostat versus allopurinol in treating gout or asymptomatic hyperuricemia: a systematic review and meta-analysis. ( Li, H; Sun, J; Wang, M; Wen, C; Xie, Z; Zhang, M; Zhang, Y; Zhao, T, 2021) |
| " Elevated uric acid levels are risk factors for gout, hypertension, and chronic kidney diseases." | 5.12 | Uric Acid in Inflammation and the Pathogenesis of Atherosclerosis. ( Kimura, Y; Kono, H; Tsukui, D, 2021) |
| " Xanthine oxidase (XO) induced uric acid (UA) serves as a risk factor and has the independent prognostic and functional impact of heart failure (HF), but whether it plays a positive role in the pathogenesis of HF has remained unclear." | 5.12 | Hyperuricemia and the Risk of Heart Failure: Pathophysiology and Therapeutic Implications. ( Chen, Y; Dong, B; Huang, Y; Lv, W; Si, K; Wang, Y; Wang, Z; Wei, C; Xu, L; Zhou, Y, 2021) |
| "This review aims to summarize recent evidence regarding the complex relationship between uric acid (UA), gout, and brain diseases." | 5.12 | Hyperuricemia, Gout, and the Brain-an Update. ( Dumurgier, J; Latourte, A; Paquet, C; Richette, P, 2021) |
| "Chronical hyperuricemia, a severe metabolic disease characterized by increased serum uric acid, urea nitrogen, and creatinine, has a positive correlation with the risks of gouty arthritis, diabetes, hypertension, and kidney damage." | 5.12 | [Research progress on anti-hyperuricemia effects and mechanisms of Chinese medicines based on regulation of intestinal flora and metabolites]. ( He, D; Tang, XY; Wen, XY; Zeng, HL; Zhang, HC; Zhang, SH, 2021) |
| "To assess the efficacy and safety of the commonly used urate-lowering therapies (ULTs): febuxostat, allopurinol, and lesinurad in hyperuricemic patients with gout." | 5.12 | Comparison of efficacy and safety of urate-lowering therapies for hyperuricemic patients with gout: a meta-analysis of randomized, controlled trials. ( Fan, M; Gu, J; Li, X; Liu, J; Schlesinger, N; Wu, X; Zhao, B, 2021) |
| "This network meta-analysis aimed to assess the current efficacy of decreasing the uric acid (UA) level with drugs to reduce mortality in patients with heart failure (HF)." | 5.12 | Network Meta-Analysis of Drug Therapies for Lowering Uric Acid and Mortality Risk in Patients with Heart Failure. ( Fujihara, K; Horikawa, C; Kitazawa, M; Kodama, S; Matsubayashi, Y; Sato, T; Sone, H; Watanabe, K; Yaguchi, Y; Yamada, M; Yamada, T; Yamamoto, M, 2021) |
| "Uric acid, the end-product of purine metabolism in humans, is not only a cause of gout, but also may play roles in developing cardiovascular diseases such as hypertension, atrial fibrillation, chronic kidney disease, heart failure, coronary artery disease, and cardiovascular death." | 5.12 | Uric acid and cardiovascular disease: A clinical review. ( Kobayashi, Y; Node, K; Saito, Y; Tanaka, A, 2021) |
| " High-serum uric acid can trigger renal inflammation." | 5.12 | The roles of NLRP3 inflammasome-mediated signaling pathways in hyperuricemic nephropathy. ( Fu, P; Ma, L; Wen, L; Yang, H, 2021) |
| " Results of multiple studies have demonstrated independent associations between increased levels of uric acid and risk of arterial hypertension, cardiovascular diseases, and chronic kidney disease." | 5.12 | [Asymptomatic Hyperuricemia: Treatment Approaches According to the Risk of Cardiovascular and Renal Events]. ( Kobalava, ZD; Troitskaya, EA, 2021) |
| " The keywords used to retrieve the literature were carotid intima thickness, intima-media thickness, carotid atherosclerosis, carotid stenosis, carotid artery, uric acid, blood uric acid, and hyperuricaemia." | 5.12 | Meta-analysis of the correlation between serum uric acid level and carotid intima-media thickness. ( Huang, W; Li, L; Ma, M; Mao, M; Peng, B; Wang, H; Wang, L; Zhong, X, 2021) |
| "The treatment of gout with allopurinol is effective at reducing urate levels and the frequency of flares." | 5.12 | Effectiveness of Allopurinol in Reducing Mortality: Time-Related Biases in Observational Studies. ( Hudson, M; Suissa, K; Suissa, S, 2021) |
| "The Febuxostat versus Placebo Randomized Controlled Trial Regarding Reduced Renal Function in Patients with Hyperuricemia Complicated by Chronic Kidney Disease Stage 3 trial evaluated the effect of febuxostat in 443 patients with stage 3 CKD (mean estimated glomerular filtration rate [eGFR] 45 mL/min/1." | 5.12 | Recent evidence on the effect of urate-lowering treatment on the progression of kidney disease. ( Badve, SV; Johnson, DW; Tiku, A, 2021) |
| "Despite the high incidence and mortality of cardiovascular events in hyperuricemia patients, the role of serum uric acid in cardiovascular diseases is still controversial." | 5.12 | Carotid intima-media thickness in patients with hyperuricemia: a systematic review and meta-analysis. ( Chen, J; He, CS; He, Y; Liu, M; Luo, X; Peng, LH; Xu, WD; Zhao, ZX, 2021) |
| " It is noninferior to benzbromarone or febuxostat in reducing serum urate levels in hyperuricemic patients with or without gout." | 5.12 | Dotinurad: a novel selective urate reabsorption inhibitor for the treatment of hyperuricemia and gout. ( Hosoya, T; Ishikawa, T; Takahashi, T; Taniguchi, T, 2021) |
| "The description of gout dates back almost 5000 years, and scientific interest in uric acid increased when it was found to be involved in the pathogenesis of gout." | 5.12 | The Impact of Uric Acid and Hyperuricemia on Cardiovascular and Renal Systems. ( Agnoletti, D; Borghi, C; Cicero, AFG, 2021) |
| "Increasing evidence supports the hypothesis that high serum uric acid (SUA) levels are related to atrial fibrillation (AF)." | 5.12 | Relationship between serum uric acid levels and different types of atrial fibrillation: An updated meta-analysis. ( Hou, Y; Li, H; Li, Z; Ren, M; Shang, L; Wang, X; Zhang, Y; Zhou, J, 2021) |
| "This meta-analysis aimed to investigate whether uric acid lowering treatment can improve β-cell function and insulin sensitivity." | 5.12 | Uric acid lowering improves insulin sensitivity and lowers blood pressure: a meta-analysis of randomized parallel-controlled clinical trials. ( Ma, G; Wang, T; Zong, Q, 2021) |
| "2 mg/kg/day once daily for 3-5 days (twice daily allowed during the first 72 hr) by intravenous route for hyperuricemia (uric acid > 7." | 5.12 | Recombinant urate oxidase (Rasburicase) for the treatment of hyperuricemia in pediatric patients with hematologic malignancies: Results of a compassionate prospective multicenter study in Korea. ( Ahn, HS; Choi, HS; Choi, YM; Chung, NG; Ghim, T; Hwang, TJ; Kang, HJ; Kim, HK; Kim, SY; Koo, HH; Kook, H; Lee, KC; Lee, KS; Lee, MJ; Lee, SM; Lee, WS; Lyu, CJ; Moon, HN; Park, ES; Seo, JJ; Shin, HY; Yoo, KH, 2006) |
| " Comparing the data of a subgroup of 12 patients receiving rasburicase with that of a historic cohort of 14 patients treated with allopurinol indicated the superiority of rasburicase over allopurinol in prophylaxis and treatment of hyperuricemia in children with leukemia and lymphoma." | 5.12 | Prevention and treatment of hyperuricemia with rasburicase in children with leukemia and non-Hodgkin's lymphoma. ( Bárdi, E; Bartyik, K; Galántai, I; Kajtár, P; Kiss, C; Kovács, G; Masát, P; Nagy, K; Rényi, I; Udvardi, E, 2007) |
| "It is still undefined whether serum uric acid (SUA) is an independent risk factor for target organ damage (TOD) and cardiovascular events in human hypertension." | 5.12 | Lack of association between serum uric acid and organ damage in a never-treated essential hypertensive population at low prevalence of hyperuricemia. ( Cuspidi, C; Esposito, A; Mancia, G; Meani, S; Sala, C; Valerio, C; Zanchetti, A, 2007) |
| "To evaluate the effects of sequential colon dialysis (SCD), hemodialysis (HD) and peritoneal dialysis (PD) on the serum level of uric acid (UA) in patients with hyperuricemia." | 5.12 | [Comparative study on sequential colon dialysis, hemodialysis and peritoneal dialysis in patients with hyperuricemia]. ( Chen, Y; Huang, YH; Wang, HT, 2007) |
| "To observe the clinical effect of Rebixiao granule (RBXG) in treating repeatedly attacking acute gouty arthritis and through experimental study on blood uric acid to explore RBXG's therapeutic mechanism." | 5.11 | Effects of Rebixiao granules on blood uric acid in patients with repeatedly attacking acute gouty arthritis. ( Ji, W; Lu, Y; Tan, WF; Zhu, XX, 2005) |
| "Although hyperuricemia is a well-known adverse effect of cyclosporine (CsA) treatment, there are contradictory data regarding the effect of tacrolimus on uric acid levels." | 5.11 | Influence of cyclosporine and tacrolimus on serum uric acid levels in stable kidney transplant recipients. ( Akcay, A; Arat, Z; Haberal, M; Huddam, B; Kanbay, M; Ozdemir, FN; Usluogullari, CA, 2005) |
| "Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase, is a potential alternative to allopurinol for patients with hyperuricemia and gout." | 5.11 | Febuxostat compared with allopurinol in patients with hyperuricemia and gout. ( Becker, MA; Eustace, D; Joseph-Ridge, N; MacDonald, PA; Palo, WA; Schumacher, HR; Streit, J; Wortmann, RL, 2005) |
| "To assess the short-term urate-lowering effect of fenofibrate in men on long-term allopurinol therapy for hyperuricaemia and gout." | 5.10 | Fenofibrate enhances urate reduction in men treated with allopurinol for hyperuricaemia and gout. ( Ball, SG; Feher, MD; Hepburn, AL; Hogarth, MB; Kaye, SA, 2003) |
| " The pooled analysis found that patients with primary hyperparathyroidism had a significantly higher level of serum uric acid than individuals without hyperparathyroidism with the pooled MD of 65." | 5.05 | Primary hyperparathyroidism is associated with a higher level of serum uric acid: A systematic review and meta-analysis. ( Charoenngam, N; Ponvilawan, B; Ungprasert, P, 2020) |
| "Uric acid, the metabolic mediator of gout and urate renal stones, is associated with increased cardiovascular risk burden." | 5.05 | Hyperuricemia: a novel old disorder-relationship and potential mechanisms in heart failure. ( Borghi, C; Cosentino, E; Landolfo, M; Palazzuoli, A, 2020) |
| " The Mesh Terms considered were: uric acid, antioxidant, oxidant, metabolic syndrome, diabetes, cerebrovascular diseases, stroke, haemorrhagic stroke, neurocognitive disorders, and their combinations." | 5.05 | Uric Acid in Metabolic and Cerebrovascular Disorders: A Review. ( Andriani, A; Calculli, G; Ciccone, MM; Cortese, AM; Cortese, F; Giordano, P; Meliota, G; Scicchitano, P; Truncellito, L, 2020) |
| " Uric acid has anti-oxidant properties, but high levels predispose to gout and may play a role in metabolic syndrome." | 5.05 | Management of hyperuricemia in asymptomatic patients: A critical appraisal. ( Brucato, A; Carnovale, C; Cianci, F, 2020) |
| "Among kidney transplant patients, treating hyperuricemia with febuxostat showed a higher odds of reaching the target of serum uric acid < 6 mg/dL compared with allopurinol without causing significant side effects including change in tacrolimus level, liver function, decline in renal graft function, and bone marrow function." | 5.05 | Efficacy and safety of febuxostat for treatment of asymptomatic hyperuricemia among kidney transplant patients: A meta-analysis of observational studies. ( Bathini, T; Chang, YT; Cheungpasitporn, W; Chewcharat, A; Crisafio, A; Mao, MA; Thongprayoon, C, 2020) |
| "This study aimed to investigate the association of serum uric acid (SUA) levels with dyslipidemia and its components and to further explore the age- and gender-specific association of SUA levels with dyslipidemia in Chinese adults." | 5.05 | Association between serum uric acid levels and dyslipidemia in Chinese adults: A cross-sectional study and further meta-analysis. ( Chen, S; Chen, Y; Miao, M; Wang, J; Xu, C; Xu, L; Yang, H, 2020) |
| "Increased serum uric acid (SUA) levels cause gout and are associated with multiple diseases, including chronic kidney disease." | 5.05 | Polygenic analysis of the effect of common and low-frequency genetic variants on serum uric acid levels in Korean individuals. ( Chang, Y; Cho, SK; Kim, B; Kim, HL; Kim, HN; Kuo, PH; Myung, W; Ryu, S; Winkler, CA; Won, HH, 2020) |
| " While uric acid is usually discussed in the context of gout, hyperuricaemia is also associated with hypertension, chronic kidney disease, hypertriglyceridaemia, obesity, atherosclerotic heart disease, metabolic syndrome, and type 2 diabetes." | 5.05 | Hyperuricaemia and gout in cardiovascular, metabolic and kidney disease. ( Agabiti-Rosei, E; Borghi, C; Johnson, RJ; Kielstein, JT; Lurbe, E; Mancia, G; Redon, J; Stack, AG; Tsioufis, KP, 2020) |
| " Based on the patent literature of last five years, we can expect a burst of novel alternate compounds in the near future which could have the ability to reduce the uric acid level, by inhibiting XO enzyme in patients, which at the moment are striving hard to fight against the dreadful disease condition like gout." | 5.05 | Xanthine oxidase inhibitors: patent landscape and clinical development (2015-2020). ( Bedi, PMS; Sharma, S; Singh, H; Singh, JV, 2020) |
| "Hyperuricemia is a state in which the serum levels of uric acid are elevated." | 5.05 | Hyperuricemia, the heart, and the kidneys - to treat or not to treat? ( Bevc, S; Ekart, R; Hojs, R; Petreski, T, 2020) |
| "Hyperuricemia coincides with coronary artery calcification (CAC) development, but the role of serum uric acid (SUA) as a risk factor for CAC remains unclear." | 5.01 | The association between hyperuricemia and coronary artery calcification development: A systematic review and meta-analysis. ( Bainey, KR; Banh, HL; Hou, X; Li, W; Liang, L; Qi, Z; Tymchak, W; Zhang, Y, 2019) |
| "Current research has proved that psoriasis is associated with serum uric acid (SUAC) levels." | 5.01 | The association of serum uric acid levels in psoriasis patients: A systematic review and network meta-analysis. ( Du, H; Liu, M; Liu, W; Yuan, Y, 2019) |
| "Gout is a systemic disease, characterized by the formation and deposition of crystals in tissues (mainly in and around the joints) of individuals with elevated serum uric acid levels." | 5.01 | Gout and arrhythmias: In search for causation beyond association. ( Angelidis, C; Deftereos, S; Giannopoulos, G, 2019) |
| "The abnormal metabolism of uric acid results in many disease such as chronic kidney disease, hyperuricemia, nephrolithiasis, gout, hypertension, vascular disease and so on." | 5.01 | The effect of polymorphism of uric acid transporters on uric acid transport. ( Ci, X; Cui, T; Li, Y; Liu, C; Liu, R; Sun, Y; Wang, Z; Wu, W; Yi, X; Zhao, F, 2019) |
| "Conflicting results have been reported on the prognostic significance of serum uric acid (SUA) in patients with acute heart failure (AHF)." | 5.01 | Prognostic value of serum uric acid in patients with acute heart failure: A meta-analysis. ( Deng, X; Huang, G; Luo, G; Qin, J; Wang, L; Yu, D; Zhang, M; Zhou, S, 2019) |
| " Cardioprotective benefits of allopurinol, a first-line agent for the treatment of gout, have been demonstrated to potentially prevent myocardial infarction, stroke, atrial fibrillation, and other cardiovascular diseases in observational studies in select populations." | 5.01 | Cardiovascular Disease in Gout and the Protective Effect of Treatments Including Urate-Lowering Therapy. ( Gupta, MK; Singh, JA, 2019) |
| "Purine metabolism in the circulatory system yields uric acid as its final oxidation product, which is believed to be linked to the development of gout and kidney stones." | 5.01 | Hyperuricemia and Cardiovascular Disease. ( Cheng, J; Huangfu, N; Wang, Y; Xu, Z; Zhang, D; Zhang, F; Zhang, S; Zhao, R; Zheng, W, 2019) |
| "Studies have demonstrated the presence of a strong association between serum uric acid (SUA) and acute kidney injury (AKI) consistently across several disease models." | 5.01 | The Role of Uric Acid in Acute Kidney Injury. ( Alquadan, KF; Beaver, TM; Dass, B; Ejaz, AA; Johnson, RJ; Lapsia, V; Mohandas, R; Shimada, M, 2019) |
| " The current obesity epidemic has in fact made it relatively frequent even among children and adolescents to find some cardiovascular risk factors known in adults such as arterial hypertension, dyslipidemia, glucose metabolism disorders and increased of uric acid values." | 5.01 | Prevention of Cardiovascular Diseases in Children and Adolescents. ( Battaglino, MG; Genovesi, S; Giussani, M; Nava, E; Orlando, A; Parati, G, 2019) |
| "This study aimed to examine whether the uric acid level or gout is causally associated with bone mineral density (BMD)." | 5.01 | Uric acid level, gout and bone mineral density: A Mendelian randomization study. ( Lee, YH; Song, GG, 2019) |
| " allopurinol was associated with the improved safety outcome and have comparable mortality and net clinical outcome in patients with hyperuricemia." | 5.01 | The net clinical benefits of febuxostat versus allopurinol in patients with gout or asymptomatic hyperuricemia - A systematic review and meta-analysis. ( Chang, WC; Chen, TC; Hsu, FS; Hwang, JJ; Lee, CC; Liu, CW; Lo, C; Shau, WY; Wang, ML, 2019) |
| "Hyperuricemia (chronically elevated serum uric acid) is the main pathology underlying the development of gout, the most common inflammatory arthropathy." | 4.98 | ABCG2 as a therapeutic target candidate for gout. ( Fujita, K; Ichida, K, 2018) |
| "This review brings together concepts of uric acid metabolism affecting renal parenchyma and its function and the current therapies to reduce hyperuricemia (HyU) and avoid renal disease progression." | 4.98 | Uric Acid: The Unknown Uremic Toxin. ( Treviño-Becerra, A, 2018) |
| " For many years, hyperuricemia was attributed to the effects of insulin resistance to reduce urinary excretion of uric acid, and it was believed that uric acid may not have any causal role in the metabolic syndrome." | 4.98 | Uric Acid as a Cause of the Metabolic Syndrome. ( Jensen, T; Johnson, RJ; King, C; Lanaspa, MA; Sánchez-Lozada, LG; Tolan, DR, 2018) |
| "Xanthine oxidoreductase (XOR) could contribute to the pathogenesis of metabolic syndrome through the oxidative stress and the inflammatory response induced by XOR-derived reactive oxygen species and uric acid." | 4.98 | The role of xanthine oxidoreductase and uric acid in metabolic syndrome. ( Battelli, MG; Bolognesi, A; Bortolotti, M; Polito, L, 2018) |
| "The relationship between serum uric acid (UA) and the risk of intracerebral hemorrhage (ICH) remains controversial." | 4.98 | Serum uric acid concentrations and risk of intracerebral hemorrhage: A systematic review and meta-analysis. ( Liang, Y; Lin, J; Qu, H; Xu, J; Zhang, X; Zhao, C; Zhao, M; Zhou, Z, 2018) |
| "Gout develops in four stages beginning with an asymptomatic increase in blood levels of uric acid." | 4.98 | Crystal arthritides - gout and calcium pyrophosphate arthritis : Part 2: clinical features, diagnosis and differential diagnostics. ( Bertsch, T; Bollheimer, LC; Härle, P; Schlee, S; Sieber, CC, 2018) |
| "Conflicting findings of the association between serum uric acid (UA) and stroke have been reported in both men and women, and it is unclear whether this association was different between men and women." | 4.95 | Sex-Specific Relationship Between Serum Uric Acid and Risk of Stroke: A Dose-Response Meta-Analysis of Prospective Studies. ( Xu, T; Zhang, Y; Zhong, C; Zhong, X, 2017) |
| " It arises through the deposition of uric acid crystals in joints as a result of hyperuricemia." | 4.95 | Treatment Options for Gout. ( Bleckwenn, M; Engel, B; Just, J; Weckbecker, K, 2017) |
| "Gout is the most common form of inflammatory arthropathy and is caused by an excess of uric acid in the blood (hyperuricemia)." | 4.95 | Change gout: the need for a new approach. ( Punzi, L, 2017) |
| "The mechanisms of hyperhomocysteinemia (HHcy) and hyperuricemia (HUA) that promote atherosclerosis were seldom explored and always indefinite." | 4.95 | Role of Hyperhomocysteinemia and Hyperuricemia in Pathogenesis of Atherosclerosis. ( Chen, H; Chen, J; Gu, Y; Liu, N; Yang, K; Zhao, J, 2017) |
| "This was a pooled analysis of phase III trials on allopurinol and febuxostat, including 4101 patients with gout and hyperuricemia." | 4.95 | Potency on lowering serum uric acid in gout patients: a pooled analysis of registrative studies comparing febuxostat vs. allopurinol. ( Cimmino, MA; Cutolo, M; Perez-Ruiz, F, 2017) |
| "Several epidemiological studies have demonstrated the existence of a correlation between high serum uric acid (SUA) levels, hypertension, and chronic kidney disease (CKD)." | 4.95 | The Effect of Xanthine Oxidase Inhibitors on Blood Pressure and Renal Function. ( Borghi, C; Bove, M; Cicero, AFG, 2017) |
| "These results support that allopurinol decreases BP and creatinine levels in patients with hyperuricemia." | 4.95 | Effect of uric acid-lowering therapy on blood pressure: systematic review and meta-analysis. ( Chen, JH; Jiang, H; Qu, LH, 2017) |
| "It appears that soluble uric acid has a much larger role to play than just being a risk factor for gout." | 4.95 | Factors modulating the inflammatory response in acute gouty arthritis. ( Cleophas, MC; Crişan, TO; Joosten, LA, 2017) |
| "[PubMed and Google Scholar databases] were search for all articles and trials published before 2016, using the key terms [hyperuricemia, gout, tophi, joint erosion, joint damage, treatment guidelines, American College of Rheumatology (ACR), European League Against Rheumatism (EULAR), flare, comorbidity, epidemiology, adherence, serum uric acid (sUA), monosodium urate (MSU), <6 mg/dL, MSU crystal formation, as well as individual drug names and classes of treatments of interest (allopurinol, febuxostat, colchicine, non-steroidal anti-inflammatories (NSAIDs)]." | 4.95 | Limitations of the Current Standards of Care for Treating Gout and Crystal Deposition in the Primary Care Setting: A Review. ( Keenan, RT, 2017) |
| " In addition, various other abnormalities such as inflammation, oxidative stress, and elevated levels of uric acid are also part of this syndrome." | 4.95 | Excessive consumption of fructose causes cardiometabolic dysfunctions through oxidative stress and inflammation. ( Akolkar, G; Ayyappan, P; Bagchi, A; Belló-Klein, A; Bernardes, N; da Silva Dias, D; De Angelis, K; Singal, PK, 2017) |
| "Recent evidence would indicate that high serum uric acid (SUA) levels can be a significant and independent risk factor for hypertension and cardiovascular diseases, such as ischemic heart disease and heart failure." | 4.93 | Uric acid lowering therapy in cardiovascular diseases. ( Iellamo, F; Romeo, F; Sposato, B; Volterrani, M, 2016) |
| "Uric acid is the end product of dietary or endogenous purines degradation, and hyperuricemia is one of the most common metabolic disorders." | 4.93 | Hyperuricemia and nonalcoholic fatty liver disease: from bedside to bench and back. ( Xu, C, 2016) |
| "Uric acid, once viewed as an inert metabolic end-product of purine metabolism, has been recently incriminated in a number of chronic disease states, including hypertension, metabolic syndrome, diabetes, non-alcoholic fatty liver disease, and chronic kidney disease." | 4.93 | Uric acid in metabolic syndrome: From an innocent bystander to a central player. ( Jensen, T; Johnson, RJ; Kanbay, M; Lanaspa, MA; Le, M; Nakagawa, T; Rivard, C; Roncal-Jimenez, C; Solak, Y, 2016) |
| "Several studies were published to assess the association between serum uric acid levels and atrial fibrillation risk, but no consistent results were reported." | 4.93 | Association Between Serum Uric Acid Levels and Atrial Fibrillation Risk. ( Huang, DS; Ma, YJ; Shen, D; Sun, HY; Wang, YM; Zhang, CH; Zhang, LW, 2016) |
| "High levels of serum uric acid (SUAC) are frequently detected in patients with psoriasis." | 4.93 | Association of Serum Uric Acid Levels in Psoriasis: A Systematic Review and Meta-Analysis. ( Cui, R; Li, B; Li, F; Li, X; Miao, X; Wang, H; Wang, Y; Yang, Q, 2016) |
| "Besides the well accepted need to treat hyperuricemia associated with gout, some large observational studies and small prospective therapeutic trials have suggested that treating asymptomatic hyperuricemia, especially by xanthine oxidase inhibition, the enzyme producing uric acid, could be beneficial for cardiovascular and renal risk prevention." | 4.93 | [HYPERURICEMIA AND POTENTIAL RISK OF CARDIOVASCULAR AND RENAL DISEASES]. ( Krzesinski, JM; Schils, R, 2016) |
| "Hyperuricemia (elevated serum uric acid) is prevalent, and an important mediator of gout, an increasingly common condition." | 4.93 | Hyperuricemia, the kidneys, and the spectrum of associated diseases: a narrative review. ( Jalal, DI, 2016) |
| " It is caused by factors that elevate the concentration of serum uric acid (sUA), leading to hyperuricemia (sUA >6." | 4.93 | Overview of Serum Uric Acid Treatment Targets in Gout: Why Less Than 6 mg/dL? ( Edwards, NL; Ruoff, G, 2016) |
| "Serum uric acid (SUA) accounts for about 50% of extracellular antioxidant activity, suggesting that hyperuricemia may have a protective role in diseases characterized by high levels of oxidative stress, such as osteoporosis." | 4.93 | Hyperuricemia protects against low bone mineral density, osteoporosis and fractures: a systematic review and meta-analysis. ( Bano, G; Caccialanza, R; Carraro, S; Cereda, E; Luchini, C; Manzato, E; Nicetto, D; Sergi, G; Solmi, M; Trevisan, C; Veronese, N, 2016) |
| "The first-line treatment of hyperuricemia, which causes gout, is allopurinol." | 4.91 | Genome-wide association study identifies ABCG2 (BCRP) as an allopurinol transporter and a determinant of drug response. ( Banda, Y; Giacomini, KM; Hoffmann, TJ; Jorgenson, E; Kvale, MN; Liang, X; Risch, N; Schaefer, C; Wen, CC; Yee, SW, 2015) |
| " Hyperuricemia is a key biochemical feature in preeclampsia with elevated levels of uric acid being diagnosed as early as the 10(th) week of gestation." | 4.91 | The involvement of uric acid in the pathogenesis of preeclampsia. ( Athanasiadis, A; Kourtis, A; Makedou, K; Masoura, S; Theodoridis, T; Zepiridis, L, 2015) |
| "The goal of emerging therapies is to address the unsatisfactory control of serum uric acid in patients with symptomatic hyperuricemia such as those with gout, to provide better tolerability compared to traditional agents and minimize the risk of adverse events, especially in patients with comorbidities and the elderly." | 4.91 | Investigational drugs for hyperuricemia. ( Shahid, H; Singh, JA, 2015) |
| "Emerging evidence has shown that serum uric acid (SUA) elevation might cause metabolic derangements, including metabolic syndrome (MetS) and non-alcoholic fatty liver disease (NAFLD); however, magnitude of the risk has not been quantified." | 4.91 | Dose-response Relationship of Serum Uric Acid with Metabolic Syndrome and Non-alcoholic Fatty Liver Disease Incidence: A Meta-analysis of Prospective Studies. ( Liu, Z; Que, S; Zheng, S; Zhou, L, 2015) |
| "In gouty patients, urate lowering therapies (ULTs) are recommended to bring serum uric acid (SUA) levels below 6." | 4.91 | Why focus on uric acid? ( Johnson, RJ, 2015) |
| "We aimed to perform a systematic review and meta-analysis to assess the association between serum uric acid and incident heart failure (HF)/prognosis of HF patients." | 4.90 | Uric acid and risk of heart failure: a systematic review and meta-analysis. ( Chen, J; Huang, B; Huang, H; Huang, Y; Jing, X; Li, J; Li, Y; Wang, J; Yao, H, 2014) |
| "To discuss the evolving data regarding uric acid as a potential cause of hypertension and progressive renal dysfunction and its clinical and research implications." | 4.90 | Serum uric acid and the risk of hypertension and chronic kidney disease. ( Feig, DI, 2014) |
| " Better understanding of the transporters URAT1 and ABCG2 in particular would appear to provide opportunities for more selective, better tolerated agents to increase the renal clearance of uric acid and thereby control hyperuricemia." | 4.90 | Uricosuric drugs: the once and future therapy for hyperuricemia? ( Bach, MH; Simkin, PA, 2014) |
| " Although several studies reported serum uric acid as a marker of an underlying pathophysiological process, other studies hypothesis a potential causal link between serum uric acid and cardiovascular diseases." | 4.90 | Serum uric acid and cardiovascular risk: state of the art and perspectives. ( Blacher, J; Fenech, G; Mazighi, M; Rajzbaum, G, 2014) |
| "The relationship between elevated serum uric acid level and metabolic syndrome (MS) has been debated." | 4.90 | Association of serum uric acid and metabolic syndrome in type 2 diabetes. ( Bonakdaran, S; Kharaqani, B, 2014) |
| " The search terms were 'gout', 'gouty arthritis', 'hyperuricemia', 'uric acid', 'xanthine oxidase (XO) inhibitor', 'uricosuric', 'urate transporter 1(URAT1)' and 'glucose transporter 9 (GLUT9)'." | 4.90 | A review of phytotherapy of gout: perspective of new pharmacological treatments. ( Bochu, W; Ling, X, 2014) |
| " It has been observed that treatment of hyperuricemia with allopurinol in chronic kidney failure has resulted in a fall in blood pressure and inhibition of the progression of kidney injury." | 4.90 | Aggravation of immunoglobulin a nephropathy by hyperuricemia: a mini-review on current findings and new concepts. ( Baradaran, A; Nasri, H, 2014) |
| "We searched MEDLINE, EMBASE, CBM (Chinese Biomedicine Database) through September 2013 and reference lists of retrieved studies to identify cohort studies and nested case-control studies with uric acid levels as exposure and incident hypertension as outcome variables." | 4.90 | Hyperuricemia and risk of incident hypertension: a systematic review and meta-analysis of observational studies. ( Chen, J; Huang, H; Li, J; Li, Y; Qin, T; Wang, J; Wang, L, 2014) |
| "Over the last decade, the biologic interference of uric acid with the cardiovascular (CV) system and the kidney has been intensively investigated, and several experimental studies in animal models and in vitro documented that hyperuricemia may trigger hypertension and incite endothelial dysfunction, vascular damage and renal disease." | 4.89 | Uric acid, hypertension, and cardiovascular and renal complications. ( Mallamaci, F; Zoccali, C, 2013) |
| "To evaluate the safety and efficacy of febuxostat compared to allopurinol for the treatment of chronic gout." | 4.89 | A systematic review and meta-analysis on the safety and efficacy of febuxostat versus allopurinol in chronic gout. ( Ehteshami-Afshar, A; Faruque, LI; Homik, J; Tjosvold, L; Tonelli, M; Wiebe, N, 2013) |
| "Traditionally, serum uric acid (SUA) has been implicated in acute gouty arthritis or chronic gouty arthropathy." | 4.89 | Hyperuricaemia: more than just a cause of gout? ( Athyros, VG; Karagiannis, A; Katsiki, N; Mikhailidis, DP, 2013) |
| " Concordantly, recent studies have revived the controversy over the role of circulating uric acid, hyperuricemia, and gout as an independent prognostic factor for cardiovascular morbidity and mortality." | 4.89 | Chronic hyperuricemia, uric acid deposit and cardiovascular risk. ( Cheli, P; Del Pinto, R; Desideri, G; Di Giosia, P; Ferri, C; Ferri, L; Grassi, D; Properzi, G, 2013) |
| "Febuxostat has been approved for the treatment of hyperuricemia in patients with/without gout." | 4.89 | Efficacy and tolerability of febuxostat in hyperuricemic patients with or without gout: a systematic review and meta-analysis. ( Chen, S; Cheng, Q; Li, Q; Liu, L; Luo, T; Lv, Q; Mei, M; Yang, S; Ye, P; Zhang, W, 2013) |
| "Elevated uric acid levels are a common finding in patients with metabolic syndrome and in those with cardiovascular and renal disease, but the meaning of this elevation is still unclear." | 4.88 | Uric acid: a starring role in the intricate scenario of metabolic syndrome with cardio-renal damage? ( Di Giorgio, C; Gesualdo, L; Morrone, LF; Stellato, D, 2012) |
| "(a) To examine the latest information about renal tubular handling of uric acid, its genetic background and contribution to the causation of hyperuricemia." | 4.88 | Hyperuricemia, gout and the kidney. ( Gibson, T, 2012) |
| " The relationship between hyperuricemia and gout was first documented in the nineteenth century by Alfred Baring Garrod, who demonstrated deposits of uric acid crystals on a linen thread held dipped in acidified blood (the so-called "thread method")." | 4.88 | Some historical remarks on microcrystalline arthritis (gout and chondrocalcinosis). ( Marson, P; Pasero, G, 2012) |
| "A number of epidemiological studies have reported an association between serum uric acid levels and a wide variety of high-risk conditions including hypertension, insulin resistance, and kidney and cerebro-cardiovascular disease." | 4.88 | Cardiovascular and renal effects of hyperuricaemia and gout. ( Leoncini, G; Pontremoli, R; Viazzi, F, 2012) |
| "With considering serum concentration of the uric acid in humans we are observing hyperuricemia and possible gout development." | 4.88 | Uric acid as one of the important factors in multifactorial disorders--facts and controversies. ( Feher-Turkovic, L; Marinkovic, N; Pasalic, D, 2012) |
| "Uric acid has been suspected to be a risk factor for hypertension since the 1870s." | 4.88 | The role of uric acid in the pathogenesis of hypertension in the young. ( Feig, DI, 2012) |
| "Uric acid (UA) increase is considered an important risk factor for the development of cardiovascular disease (CVD) favoring oxidative stress and endothelial dysfunction and is also involved in metabolic syndrome (MS) pathophysiology." | 4.88 | The uric acid metabolism pathway as a therapeutic target in hyperuricemia related to metabolic syndrome. ( Dichi, I; Lozovoy, MA; Simão, AN, 2012) |
| "In addition to its role as a metabolic waste product, uric acid has been proposed to be an important molecule with multiple functions in human physiologic and pathophysiologic processes and may be linked to human diseases beyond nephrolithiasis and gout." | 4.88 | Renal transport of uric acid: evolving concepts and uncertainties. ( Bobulescu, IA; Moe, OW, 2012) |
| "Gout is a metabolic disorder of purine metabolism and uric acid elimination." | 4.88 | Safety of urate-lowering therapies: managing the risks to gain the benefits. ( Keenan, RT, 2012) |
| "To review and interpret the recently published data on hyperuricemia and cardiovascular disease to present an opinion on the nature of link between serum uric acid concentration and the risk for cardiovascular outcomes, and to comment on its implications for clinical practice." | 4.87 | Uric acid in heart disease: a new C-reactive protein? ( Krishnan, E; Sokolove, J, 2011) |
| "Through the use of a systematic computer-based literature analysis, this pharmacoeconomic review evaluated costs, risks, and benefits of Colcrys (colchicine) compared with other treatments for gout in the US." | 4.87 | A new perspective on the pharmacoeconomics of colchicine. ( Davis, MW; Lauterio, TJ; Wertheimer, AI, 2011) |
| "In France, colchicine remains the standard treatment for the acute flare of gout." | 4.87 | [Treatment of gout]. ( Dubost, JJ; Mathieu, S; Soubrier, M, 2011) |
| "Both elevated levels of uric acid and non-alcoholic fatty liver disease (NAFLD) have been associated with increased vascular risk." | 4.87 | Hyperuricaemia and non-alcoholic fatty liver disease (NAFLD): a relationship with implications for vascular risk? ( Athyros, VG; Karagiannis, A; Katsiki, N; Mikhailidis, DP, 2011) |
| " However, emerging data suggest that elevated uric acid (UA) is actually one of the most important factors for cardiovascular disease and that it also plays a significant role in the development of renal disease and metabolic syndrome." | 4.87 | Uric acid as a cardiometabolic risk factor: to be or not to be. ( Afsar, B; Covic, A; Kanbay, M, 2011) |
| " Data are accumulated on existence of links between elevated uric acid level and arterial hypertension, diabetes mellitus, ischemic heart disease, and chronic heart failure (CHF)." | 4.87 | [Hyperuricemia in chronic heart failure]. ( Bart, BIa; Brodskiĭ, MS; Larina, VN, 2011) |
| "High uric acid (UA) levels can cause gout, urolithiasis and acute and chronic nephropathy, all of which are due to the deposit of urate crystals." | 4.87 | Is there anything good in uric acid? ( Alvarez-Lario, B; Macarrón-Vicente, J, 2011) |
| "Uric acid is a terminal metabolite of the degradation of nucleotides, which increases their blood levels in patients with preeclampsia-eclampsia, increasing its synthesis by damage and death of trophoblastic cells in proliferation and decreased urinary excretion due a lower glomerular filtration rate and increased absorption in the proximal tubule." | 4.87 | [Role of uric acid in preeclampsia-eclampsia]. ( Rico-Trejo, EI; Vázquez-Rodríguez, JG, 2011) |
| "Many patients with acute gout (11%-49%) have normal serum uric acid (SUA) levels." | 4.87 | Clinical inquiry. Are serum uric acid levels always elevated in acute gout? ( Fletcher, A; Leiszler, M; Poddar, S, 2011) |
| "During the past few decades, the mean serum uric acid levels and the prevalence of hyperuricemia in the general population appear to have increased." | 4.87 | The epidemiology of uric acid and fructose. ( Choi, HK; Rho, YH; Zhu, Y, 2011) |
| "A link between serum uric acid and the development of hypertension was first hypothesized in the 1870s." | 4.87 | Uric acid and hypertension. ( Feig, DI, 2011) |
| "Recently, much attention of medical professionals is directed to correlations between hyperuricemia, arterial hypertension, metabolic syndrome and renal affection because of the evidence that elevated blood level of uric acid raises the risk of cardiovascular complications not only in arterial hypertension and metabolic syndrome but also in diabetes mellitus type 2, coronary heart disease, congestive heart failure and renal dysfunction." | 4.87 | [Lozartan potential in hyperuricemia correction]. ( , 2011) |
| "Uric acid was first associated with primary hypertension in 1874, yet its role in this condition remains unclear." | 4.86 | Uric acid and hypertension: cause or effect? ( Feig, DI; Jalal, D; Johnson, RJ; Kanbay, M; Mazzali, M; Segal, MS; Shafiu, M, 2010) |
| "Interest has been renewed over the role of uric acid in the pathogenesis of hypertension, endothelial dysfunction and renal dysfunction, which are all features of pre-eclampsia." | 4.86 | Could uric acid have a pathogenic role in pre-eclampsia? ( Brown, MA; Martin, AC, 2010) |
| " Chronic hyperuricemia (uric acid serum levels >6." | 4.86 | Crystal arthropathies: recognizing and treating "the gouch". ( Quillen, DM, 2010) |
| "After uric acid was recognized as the causative factor in gout, increased prevalence of renal disease and hypertension in this patient population caught the attention of the medical community." | 4.86 | Uric acid in hypertension and renal disease: the chicken or the egg? ( Covic, A; Dogan, E; Kanbay, M; Lanaspa, MA; Solak, Y, 2010) |
| " Prospective cohort studies were included only if they contained data on stroke incidences or mortalities related to serum uric acid levels in adults." | 4.85 | Hyperuricemia and risk of stroke: a systematic review and meta-analysis. ( Albert, DA; Choi, HK; Guevara, JP; Heitjan, DF; Kim, KM; Kim, SY, 2009) |
| "Elevated serum uric acid is a marker for decreased renal function, may have a mechanistic role in the incidence and progression of renal functional decline and likely has a causal role in hypertension and vascular disease." | 4.85 | Uric acid: a novel mediator and marker of risk in chronic kidney disease? ( Feig, DI, 2009) |
| "Gout is a common rheumatic disease in humans which is characterized by elevation in serum uric acid levels, and deposition of uric acid crystals in the joint." | 4.85 | Recent insights into the pathogenesis of hyperuricaemia and gout. ( Ralston, SH; Riches, PL; Wright, AF, 2009) |
| "Febuxostat, a nonpurine selective inhibitor of both the oxidized and reduced forms of xanthine oxidase, was approved in February 2009 by the US Food and Drug Administration for the management of hyperuricemia in adults with gout." | 4.85 | Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout. ( Ernst, ME; Fravel, MA, 2009) |
| "Although in the past decade a large number of studies have been performed to identify the relationship between uric acid and stroke, the issue remains unresolved and it is not clear whether the correlation between uric acid and stroke is circumstantial or causal." | 4.84 | The role of uric acid in stroke: the issue remains unresolved. ( Dimitroula, HV; Hatzitolios, AI; Karvounis, HI, 2008) |
| "*Febuxostat is an orally administered, non-purine, selective inhibitor of xanthine oxidase approved for the management of chronic hyperuricaemia in patients with gout." | 4.84 | Febuxostat. ( Hair, PI; Keating, GM; McCormack, PL, 2008) |
| " A rapid and massive raise of uric acid, during tumor lysis syndrome (TLS), and also a lower and chronic hyperuricemia, as in gout, mainly damage the kidney." | 4.84 | Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout. ( Cammalleri, L; Malaguarnera, M, 2007) |
| " While physicians have understood for at least a century that uric acid causes gout, we are now beginning to address the question of why hyperuricemia exists and the mechanisms by which uric acid acts to stimulate inflammation." | 4.84 | Hyperuricemia and gout: new insights into pathogenesis and treatment. ( Abeles, AM; Pillinger, MH; Rosenthal, P, 2007) |
| " Specifically, we review newly discovered mechanisms of uric acid-induced inflammation, uric acid's putative role as a "danger signal" in innate immunity, the possible link between hyperuricemia and cardiovascular disease, and evolutionary evidence suggesting that hyperuricemia conferred a survival advantage in primates (when the gene for uricase was lost) several million years ago." | 4.84 | Update on gout: pathophysiology and potential treatments. ( Abeles, AM; Cronstein, BN; Park, JY; Pillinger, MH, 2007) |
| "The level of serum uric acid in human has been increasing over the last decades, and correlates with an increase prevalence of renal disease and metabolic syndrome." | 4.84 | The conundrum of hyperuricemia, metabolic syndrome, and renal disease. ( Cirillo, P; Gersch, M; Johnson, RJ; Mu, W; Nakagawa, T; Roncal, C; Sánchez-Lozada, LG; Sato, W; Sautin, Y, 2008) |
| "Impaired renal uric acid excretion is the major mechanism of hyperuricemia in patients with primary gout." | 4.84 | Control of renal uric acid excretion and gout. ( Kamatani, N; Taniguchi, A, 2008) |
| "Hyperuricemia (serum urate level >7 mg/dL) is caused by accelerated generation of uric acid and/or impaired excretion in the kidney." | 4.84 | [Definition and classification of hyperuricemia]. ( Yamamoto, T, 2008) |
| " Although only about 10% of hyperuricemia results from overproduction of urate, purine biosynthesis has substantial impacts on the pathogenesis of hyperuricemia." | 4.84 | [Urate production and regulation]. ( Morisaki, H; Morisaki, T, 2008) |
| " Recently it has been identified that hypertension are frequently associated with myogenic hyperuricemia converted from overproduced hypoxanthine in the skeletal muscles." | 4.84 | [Idiopathic hyperuricemia with overproduction of uric acid]. ( Hisatome, I; Igawa, O; Mizuta, E, 2008) |
| "Hyperuricemia reflects extracellular fluid supersaturation for uric acid." | 4.84 | [Primary hyperuricemia due to decreased renal uric acid excretion]. ( Ueda, T; Yamauchi, T, 2008) |
| "Hyperuricemia caused secondly from acquired disorders which affect production or excretion of uric acid is defined as secondary hyperuricemia." | 4.84 | [Pathophysiology and treatment of secondary hyperuricemia]. ( Tsutani, H, 2008) |
| " Accelerated generation of uric acid and impaired excretion in the kidney are promoted by several dietary factors, such as foods with higher content of sugars (fructose and xylitol), fat and purine bases, and by alcohol consumption, starvation and dehydration." | 4.84 | [How do we set the standard value of serum uric acid levels?]. ( Hamada, T; Hisatome, I; Igawa, O; Shigemasa, C, 2008) |
| "Urate lowering treatment is indicated in patients with recurrent acute attacks, tophi, gouty arthropathy, radiographic changes of gout, multiple joint involvement, or associated uric acid nephrolithiasis." | 4.84 | [Uricosuric agent]. ( Ohno, I, 2008) |
| "Although uric acid is considered an antioxidant in plasma, recent clinical and epidemiological studies have found that hyperuricemia is associated with mortality and development of hypertension, cardiovascular and chronic renal diseases." | 4.83 | Hormonal and cytokine effects of uric acid. ( Feig, DI; Franco, M; Herrera-Acosta, J; Johnson, RJ; Kang, DH; Nakagawa, T; Sánchez-Lozada, LG, 2006) |
| "Epidemiologic studies published during the past 3 years support the possible role of uric acid in the onset of essential hypertension." | 4.83 | Uric acid and hypertension. ( Feig, DI; Johnson, RJ; Kang, DH; Mazzali, M; Nakagawa, T, 2006) |
| "Although dietary, genetic, or disease-related excesses in urate production may contribute to hyperuricemia, impaired renal excretion of uric acid is the dominant cause of hyperuricemia in the majority of patients with gout." | 4.83 | Recent developments in our understanding of the renal basis of hyperuricemia and the development of novel antihyperuricemic therapeutics. ( Becker, MA; Bushinsky, DA; Terkeltaub, R, 2006) |
| "Elevated serum uric acid (SUA) levels are commonly seen in patients with the metabolic syndrome (MetS)." | 4.83 | Elevated serum uric acid levels in metabolic syndrome: an active component or an innocent bystander? ( Athyros, VG; Elisaf, MS; Liberopoulos, EN; Mikhailidis, DP; Tsouli, SG, 2006) |
| "The association of elevated serum uric acid (hyperuricemia, gout) with the presence of classical coronary risk factors and coronary artery disease (CAD) or myocardial infarction (MI) has been analysed in many epidemiological studies." | 4.83 | [Is hyperuricemia a cardiovascular risk factor?]. ( Chizyński, K; Rózycka, M, 2006) |
| "Pre-eclampsia is strongly associated with hyperuricemia, and in some studies the increase in serum uric acid has been found to correlate with both maternal and fetal morbidity." | 4.82 | Uric acid, endothelial dysfunction and pre-eclampsia: searching for a pathogenetic link. ( Finch, J; Granger, J; Johnson, RJ; Kanellis, J; Kang, DH; Karumanchi, SA; Nakagawa, T, 2004) |
| "Although allopurinol has been available for approximately 50 years, hyperuricemia and its sequelae are not only prevalent, but the incidence and costs associated with this disorder continue to increase." | 4.82 | Serum uric acid-lowering therapies: where are we heading in management of hyperuricemia and the potential role of uricase. ( Bomalaski, JS; Clark, MA, 2004) |
| "Although hyperuricemia has long been associated with renal disease, uric acid has not been considered as a true mediator of progression of renal disease." | 4.82 | Uric acid and chronic renal disease: possible implication of hyperuricemia on progression of renal disease. ( Kang, DH; Nakagawa, T, 2005) |
| " However, ARF may also develop due to aetiologies arising from cancer treatment or the disease itself, including: nephrotoxic chemotherapy agents, post-renal obstruction, compression and infiltration by malignancy, tumour lysis syndrome, uric acid, sepsis and contrast agent nephropathy." | 4.82 | Acute renal failure in cancer patients. ( Flombaum, CD; Lameire, NH; Moreau, D; Ronco, C, 2005) |
| "The association of elevated serum uric acid (hyperuricemia, gout) with the presence of classical coronary risk factors and coronary artery disease or myocardial infarction has been analysed in many epidemiological studies." | 4.82 | [Hyperuricemia]. ( Chizyński, K; Rózycka, M, 2005) |
| "Cellular cytoplasmic xanthine oxidase (XO)-mediated uric acid synthesis and extracellular excess uric acid exposure are both causes of cardiomyocytic injury under the condition of hyperuricemia (HUA)." | 4.31 | Assessment of the influence on left ventricle by potassium oxonate and hypoxanthine-induced chronic hyperuricemia. ( Huang, Q; Jiang, Y; Li, Y; Liao, H; Lin, C; Luo, J; Pang, J; Wu, T; Yan, C; Yang, Y; Zhang, L; Zhang, W; Zheng, Q, 2023) |
| "Palmatine (Pal) is a major bioactive alkaloid originated from ancient Chinese herbal medicine Cortex Phellodendri Amurensis (CPA), which has long been applied to treat hyperuricemia (HUA)-related diseases." | 4.31 | Hypouricemic and nephroprotective effects of palmatine from Cortex Phellodendri Amurensis: A uric acid modulator targeting Keap1-Nrf2/NLRP3 axis. ( Ai, G; Chen, J; Dou, Y; Huang, R; Qin, Z; Su, Z; Wu, X; Xie, J; Yang, X; Zhong, L, 2023) |
| "Uric acid has promoted renal fibrosis and inflammation in experimental studies, but some studies have shown nephroprotective effects due to alleviated oxidative stress." | 4.31 | Moderate hyperuricaemia ameliorated kidney damage in a low-renin model of experimental renal insufficiency. ( Eräranta, A; Honkanen, T; Kurra, V; Lakkisto, P; Mustonen, J; Myllymäki, J; Paavonen, T; Pörsti, I; Riutta, A; Tikkanen, I, 2023) |
| " Hyperuricemia mice are induced via daily oral gavage of potassium oxonate and hypoxanthine." | 4.31 | Anti-Hyperuricemic, Nephroprotective, and Gut Microbiota Regulative Effects of Separated Hydrolysate of α-Lactalbumin on Potassium Oxonate- and Hypoxanthine-Induced Hyperuricemic Mice. ( Du, L; Shen, Y; Su, E; Wei, D; Xie, D; Xie, J, 2023) |
| "The study objective was to verify the uric acid-lowering effects and the regulation of the gut-kidney axis mediated by sulforaphane and identify host-microbial co-metabolites in hyperuricemia." | 4.31 | Sulforaphane-driven reprogramming of gut microbiome and metabolome ameliorates the progression of hyperuricemia. ( Halimulati, M; Huang, X; Li, L; Ma, Y; Wang, R; Zhang, Z, 2023) |
| " This study aimed to investigate the effects of berberine on uric acid (UA) metabolism and gut microbiota in a hyperuricemia rat model established using potassium oxonate." | 4.31 | Berberine Regulates the Metabolism of Uric Acid and Modulates Intestinal Flora in Hyperuricemia Rats Model. ( Chen, Q; He, X; Li, D; Liu, Y; Sun, C; Wang, H; Wu, F; Zhou, Y, 2023) |
| " First, after adjusting for the related variables, the hemoglobin [Hb] level in the hyperuricemia subgroup (uric acid [UA] ≥ 7." | 4.31 | The relationship between hyperuricemia and anemia and metabolic syndrome in Korean adults: The Korea National Health and Nutrition Examination Survey 2019. ( Bin Choi, S; Hwang, JH; Lee, JH; Mun, CY; Park, CY; Seo, HY; Yoon, H, 2023) |
| "Our findings linked normouricemic erosive gout to attenuated lubricin, with impaired control of cathepsin G activity, compounded by deleterious NLRP3 variants." | 4.31 | Amplification of Inflammation by Lubricin Deficiency Implicated in Incident, Erosive Gout Independent of Hyperuricemia. ( Cadzow, M; Campeau, A; Chhana, A; Dalbeth, N; Dambruoso, TJ; Elsaid, K; Elsayed, S; Ghassemian, M; Gonzalez, DJ; Höglund, J; Jay, GD; Karlsson, NG; Karsh, J; Liu-Bryan, R; Maltez, N; Merriman, TR; Miner, M; Phipps-Green, A; Qadri, M; Rossitto, LA; Schmidt, TA; Terkeltaub, R, 2023) |
| "The accumulation of uric acid (UA) in the body can lead to the occurrence of hyperuricemia or uric acid nephropathy." | 4.31 | Uric acid accumulation in the kidney triggers mast cell degranulation and aggravates renal oxidative stress. ( Cui, R; Gou, X; Jin, Y; Ma, Y; Wu, X; Yang, J; Zhang, M; Zhou, Y, 2023) |
| " The results showed that MFPP could effectively reduce the serum uric acid (SUA) levels compared with the model group rats; kidney histopathology and the levels of inflammatory factors (TNF-α, IL-6, and IL-10) indicated that MFPP attenuated HUA-induced kidney inflammation." | 4.31 | Marine Fish Protein Peptide Regulating Potassium Oxonate-Induced Intestinal Dysfunction in Hyperuricemia Rats Helps Alleviate Kidney Inflammation. ( Hu, Q; Luo, J; Peng, X; Wu, C; Zhang, G, 2023) |
| " Patients (N = 133) with chronic heart failure and comorbid hyperuricemia who enrolled in the Excited-UA study were divided into three tertiles based on their serum uric acid level 24 weeks after initiating xanthine oxidase inhibitor treatment with topiroxostat or allopurinol (i." | 4.31 | Optimal uric acid reduction to improve vascular endothelial function in patients with chronic heart failure complicated by hyperuricemia. ( Abe, S; Iida, K; Inoue, K; Inoue, R; Inoue, T; Kato, T; Kitahara, K; Kohno, Y; Koshiji, N; Naganuma, J; Sakuma, M; Toyoda, S; Yamauchi, F; Yokomachi, J, 2023) |
| "Studies have shown that elevated serum uric acid (SUA) may increase the risk of coronary heart disease (CHD)." | 4.31 | Mediating effect of metabolic diseases on the relationship between hyperuricemia and coronary heart disease. ( Bai, Y; Chen, Y; Cheng, Z; Hu, Y; Li, J; Li, S; Wang, Y; Xu, L; Yin, C, 2023) |
| "Uric acid (UA) accumulation triggers endothelial dysfunction, oxidative stress, and inflammation." | 4.31 | HDAC Inhibitors Alleviate Uric Acid-Induced Vascular Endothelial Cell Injury by Way of the HDAC6/FGF21/PI3K/AKT Pathway. ( Du, Y; Guan, C; Huang, Z; Li, P; Wang, K; Zhang, Y; Zhou, M, 2023) |
| "Allopurinol (AP) is widely used to treat hyperuricemia which may cause severe side effects upon oral administration." | 4.31 | Transdermal delivery of allopurinol to acute hyperuricemic mice ( Aharodnikau, UE; Jiang, G; Liu, T; Nie, L; Shavandi, A; Solomevich, SO; Sun, Y; Wang, H; Wang, R; Yunusov, KE, 2023) |
| "Hyperuricemia is the result of overproduction and/or underexcretion of uric acid, and it is a well-known risk factor for gout, hypertension, and diabetes." | 4.31 | Hypouricemic Actions of the Pericarp of Mangosteen ( Gao, L; Li, L; Li, N; Li, Q; Lin, H; Niu, Y; Tu, C; Wang, Z; Zhou, Z, 2023) |
| " In the stratified analysis by uric acid levels, the prevalence of NAFLD was significantly higher in participants with MHO, MUNW, and MUO in the hyperuricemia group than those in the normal uric acid group, and the interaction effect of metabolic phenotypes and uric acid on NAFLD was statistical significant (P < 0." | 4.31 | Hyperuricemia as an effect modifier of the association between metabolic phenotypes and nonalcoholic fatty liver disease in Chinese population. ( Li, X; Miao, Y; Zhang, Q; Zhang, Y; Zheng, J, 2023) |
| "This study aimed to explore the clinical characteristics of perioperative acute gout attacks in patients with varying uric acid levels undergoing orthopedic surgery, identify the risk factors for gout recurrence within the first postoperative year, and provide a disease prevention and diagnostic reference." | 4.31 | Acute gout attacks during the perioperative period and risk factors of recurrence after orthopedic surgery among untreated gout patients. ( Sun, X; Wang, H; Wang, W; Wu, Q; Yan, C; Zeng, H; Zhang, Z, 2023) |
| " A murine model of angiotensin II-induced AAA was used to assess the effects of hyperuricemia on AAA growth in vivo, and human aortic smooth muscle cells (HASMCs) were used to study the pathways involved in these effects in vitro." | 4.31 | Hyperuricemia exacerbates abdominal aortic aneurysm formation through the URAT1/ERK/MMP-9 signaling pathway. ( Huang, PH; Lin, SJ; Tsai, HY; Tsai, SH; Wang, JC, 2023) |
| "A hyperuricemic rat model induced by adenine and ethambutol was established to investigate the anti-hyperuricemia activity and its mechanism of the flavonoid extract from saffron floral bio-residues." | 4.31 | [Anti-hyperuricemia activity and its mechanism of flavonoid extract from saffron floral bio-residues]. ( Chen, N; Li, H; Meng, J; Yang, B; Yang, YF, 2023) |
| "Previous studies have found a relationship between hypertension or cardiovascular disease and simple renal cysts (SRCs) in health check-up population, but SRCs incidence is still controversially associated with serum uric acid (SUA) concentration in the nondiabetic participants." | 4.31 | Association between serum uric acid levels and simple renal cyst risk in a nondiabetic population: A nested case-control study. ( Chen, M; Wang, S; Xie, J; Yang, X; Zhao, D, 2023) |
| " Carotid-femoral pulse wave velocity (cfPWV), assessed using applanation tonometry, was evaluated as an early vascular aging parameter in patients with hyperuricemia and with normal serum uric acid (sUA) levels." | 4.31 | The Association between Water Consumption and Hyperuricemia and Its Relation with Early Arterial Aging in Middle-Aged Lithuanian Metabolic Patients. ( Badarienė, J; Čypienė, A; Gimžauskaitė, S; Jasiūnas, E; Kazėnaitė, E; Rinkūnienė, E; Rugienė, R; Ryliškytė, L, 2023) |
| "Correlation influence factor analysis of gout patients' serum uric acid (SUA) levels, their examination fees, and various complications were explored." | 4.31 | Association between serum uric acid levels of patients with gout and their complications and examination fees: A cross-sectional analysis. ( Dang, W; Liu, J; Wang, J; Xu, D; You, L; Zhao, L, 2023) |
| "Objective To investigate the level of serum uric acid in patients with diabetes insipidus (DI),summarize the clinical characteristics of central diabetes insipidus (CDI) patients with hyperuricemia (HUA),and analyze the factors affecting the level of serum uric acid in the patients with CDI." | 4.31 | [Serum Uric Acid Level and Its Influencing Factors in Patients with Diabetes Insipidus]. ( Chi, Y; Duan, L; Ping, F; Wang, SH; Wang, X; Yuan, T; Zhu, HJ, 2023) |
| " Based on serum uric acid (UA) level, the patients were divided into hyperuricemia (HUA) group (n = 213) and normal serum uric acid (NUA) group (n = 481)." | 4.31 | Clinicopathological characteristics and associated factors of idiopathic membranous nephropathy with hyperuricemia: a single-centered cross-sectional study. ( Chen, Z; Dong, H; Liang, D; Lin, Q; Liu, Y; Wang, Y; Wu, X; Yang, M; Zhang, H; Zhang, X, 2023) |
| " Our aim was to identify the frequency of MHO in obese subjects, to assess the potential associations of demographic characteristics, serum uric acid, alanine transaminase (ALT), pediatric nonalcoholic fatty liver disease fibsosis score probability (PNFS p) with MHO status and to evaluate the differences between MHO and metabolically unhealthy obesity (MUO) with regard to metabolic syndrome surrogates." | 4.31 | Comparative analyses of surrogates of metabolic syndrome in children and adolescents with metabolically healthy obesity vs. metabolically unhealthy obesity according to Damanhoury's criteria. ( Ada, Hİ; Cakir, AD; Mohamad, R; Uçar, A, 2023) |
| "Considering the positive effect of hyperuricemia on sarcopenia, avoiding aggressive uric acid-lowering therapy may be a good option in older adults with asymptomatic hyperuricemia." | 4.31 | Hyperuricemia may be associated with muscle wellness in older adults. ( Ates Bulut, E; Aydin, AE; Dost, FS; Isik, AT; Oncel Yoruk, E; Ontan, MS, 2023) |
| "Spontaneous serum uric acid (SUA) decrease has been found in many patients during acute gout attacks, but its mechanism remains unclear." | 4.31 | Intestinal uric acid excretion contributes to serum uric acid decrease during acute gout attack. ( Cao, L; Du, X; Lin, C; Wan, W; Xu, R; Yang, X; Zhao, T; Zhou, M; Zhu, X; Zou, H, 2023) |
| "According to our findings, higher mean uric acid levels were reported in recipients with metabolic syndrome (6." | 4.31 | Association of Metabolic Syndrome and Hyperuricemia in the Recipients of Kidney Transplants: A Single-Center Study. ( Hami, M; Mehrad-Majd, H; Miri, M; Salari, M; Yaghoubi, MA, 2023) |
| " However, its mechanism of action on lowering uric acid (UA) and inhibiting inflammation still deserves further investigation." | 4.31 | Simiao San alleviates hyperuricemia and kidney inflammation by inhibiting NLRP3 inflammasome and JAK2/STAT3 signaling in hyperuricemia mice. ( Dai, X; Gao, S; Liu, T; Liu, Y; Orekhov, AN; Shi, H; Sukhorukov, V; Wang, L; Wang, S; Xu, T; Yin, J; Zhang, D; Zhang, Y; Zhao, D, 2023) |
| "The objective of the study was to compare the relative effects of benzbromarone and allopurinol on the risk of developing chronic kidney disease in persons with asymptomatic hyperuricemia." | 4.31 | Comparison of benzbromarone and allopurinol on the risk of chronic kidney disease in people with asymptomatic hyperuricemia. ( Hwang, BF; Kuo, YH; Lai, SW; Liao, KF; Liu, CS, 2023) |
| "This study uncovered an important and previously unrecognized role of hyperuricemia in mediating the pathogenesis of TAAD, and uric acid-lowering drug may represent a promising therapeutic approach for TAAD." | 4.31 | Urate-Lowering Therapy Inhibits Thoracic Aortic Aneurysm and Dissection Formation in Mice. ( Cai, Z; Dai, R; Fu, Y; Gong, Z; Kong, W; Li, W; Li, Z; Luo, C; Shen, Y; Wang, J; Wu, H; Yang, L; Yu, F; Zhang, T; Zhang, X; Zhao, H; Zhao, Y; Zhu, J, 2023) |
| " A Mendelian randomization analysis of the association between caffeine-containing drinks and gout risk was conducted." | 4.31 | Exploring the mechanism underlying hyperuricemia using comprehensive research on multi-omics. ( Dai, Q; Fang, J; Li, B; Liu, H; Xie, R; Xu, Y, 2023) |
| " Based on the first serum uric acid level within 24 h of admission to the ICU, patients were divided into groups with or without hyperuricemia, and the incidence of AKI within seven days of ICU admission was compared between the two groups." | 4.31 | Association between hyperuricemia and acute kidney injury in critically ill patients with sepsis. ( Gong, CL; Jiang, YX; Liu, FG; Shi, YL; Tang, Y; Xie, KQ; Yi, Y; Zhou, HW; Zhou, JW, 2023) |
| "It is unclear whether uric acid (UA) has a negative or positive effect on anemia, and this may vary depending on the presence or absence of chronic disease such as hypertension (HTN)." | 4.31 | The relationship between anemia and hyperuricemia and hypertension in Korean adults: the Korea National Health and Nutrition Examination Survey 2016-2018. ( Cha, JA; Gi, MY; Park, CH; Park, SM; Park, SY; Sung, HH; Yoon, H, 2023) |
| "Uric acid, the end product of purine degradation, causes hyperuricemia and gout, afflicting hundreds of millions of people." | 4.31 | Anaerobic purinolytic enzymes enable dietary purine clearance by engineered gut bacteria. ( Gao, L; Hu, Y; Ju, Y; Li, L; Li, P; Li, Z; Liu, D; Liu, S; Luo, Y; Tong, Y; Wang, J; Wang, Y; Wei, Y; Yu, H; Zhang, Y, 2023) |
| "Hyperuricemic nephropathy may be induced by the elevation and accumulation of uric acid in kidney after hyperuricemia, which leads to kidney residential cells apoptosis and inflammation." | 4.31 | Renal herb formula protects against hyperuricemic nephropathy by inhibiting apoptosis and inflammation. ( Feng, Y; Li, S; Tang, GY; Wang, N; Xu, L; Xu, XY; Xu, Y; Zhang, C, 2023) |
| "SIM0295, a novel inhibitor of human uric acid transporter 1 (hURAT1), is used to treat patients with gout and hyperuricemia." | 4.31 | Model Informed Development of SIM0295 in Patients with Gout and Hyperuricemia and Healthy Volunteers Using a Population Pharmacokinetics/ Pharmacodynamics Approach. ( Chen, Y; Huang, Q; Jiao, Z; Kim, JS; Shu, P; Wang, C; Xu, S; Yang, Y; Zhang, X, 2023) |
| "The effects were assessed in a potassium oxonate (PO)- and hypoxanthine (HX)-induced hyperuricemia mice model by analyzing the levels of serum uric acid (SUA), urine uric acid (UUA), serum creatinine (SCRE), serum urea nitrogen (SBUN), and histological changes." | 4.31 | Amelioration effects of α-viniferin on hyperuricemia and hyperuricemia-induced kidney injury in mice. ( Gao, YY; Guan, HY; Guo, XL; He, X; Liao, SG; Wang, Y; Wei, MC; Xu, GB; Yang, YX; Zhang, CL; Zhang, J; Zhang, JJ; Zhu, QF; Zou, SH, 2023) |
| "Xanthine oxidase (XO), a key enzyme in purine catabolism, catalyzes the oxidation of xanthine to uric acid in the body, but overproduction of uric acid may lead to hyperuricemia." | 4.31 | In vitro xanthine oxidase inhibitory and in vivo anti-hyperuricemic properties of sodium kaempferol-3'-sulfonate. ( Cui, Z; Huang, Y; Luo, Y; Wang, X; Yang, X, 2023) |
| "Serum uric acid (UA) level is associated with the high cumulative incidence or prevalence of coronary artery disease (CAD), and hyperuricemia is considered as an independent risk marker for CAD." | 4.31 | Overnight changes in uric acid, xanthine oxidoreductase and oxidative stress levels and their relationships with sleep-disordered breathing in patients with coronary artery disease. ( Daida, H; Hiki, M; Ishiwata, S; Kasai, T; Kato, T; Kuwabara, M; Matsumoto, H; Murase, T; Murata, A; Naito, R; Nakamura, T; Sato, A; Shimizu, M; Shitara, J; Suda, S; Yatsu, S, 2023) |
| "<b>Background and Objective:</b> Hyperuricemia is a disease triggered by disorders of uric acid metabolism." | 4.31 | Potential of Leave and Fruit Ethanolic Extract of ( Adika, AR; Karyadi, B; Melani, NAA; Nursaadah, E; Parlindungan, D; Ruyani, A, 2023) |
| "While prior research has shown that consuming alcohol may raise the risk of hyperuricemia, little is known about how individual types of alcohol are linked to levels of uric acid in China." | 4.31 | Association between alcoholic beverage intake and hyperuricemia in Chinese adults: Findings from the China Health and Nutrition Survey. ( Shin, D; Wu, Y, 2023) |
| "Hyperuricemia was induced in rats by administration of 10% fructose and 20% yeast, and the uricosuric effect was assessed by measuring the uric acid (UA) levels in serum and cecal contents." | 4.31 | Study on the mechanism of Orthosiphon aristatus (Blume) Miq. in the treatment of hyperuricemia by microbiome combined with metabonomics. ( Bian, M; Niu, H; Zhang, X; Zhou, Z; Zhu, C, 2023) |
| " Hyperuricemia was defined based on the serum uric acid levels, determined as ≥ 7 mg/dL for males and ≥ 6 mg/dL for females." | 4.31 | Association between dietary intake of flavonoids and hyperuricemia: a cross-sectional study. ( Chen, X; Li, H; Shi, L; Wang, M, 2023) |
| " It suppressed liver xanthine oxidase activity to decrease uric acid synthesis and modulated renal urate transporters to stimulate uric acid excretion, alleviating kidney damage caused by hyperuricemia." | 4.31 | Paeonia × suffruticosa Andrews leaf extract and its main component apigenin 7-O-glucoside ameliorate hyperuricemia by inhibiting xanthine oxidase activity and regulating renal urate transporters. ( An, J; Li, C; Li, Y; Lin, F; Ma, S; Wang, S; Xie, Y; Xu, L; Zhang, Y; Zhao, Y, 2023) |
| "Approximately 15% of US adults have circulating levels of uric acid above its solubility limit, which is causally linked to the disease gout." | 4.31 | A widely distributed gene cluster compensates for uricase loss in hominids. ( Augustijn, HE; Cabrera, AV; Chen, H; DeFeo, ME; Dodd, D; Ganesan, C; Gombar, S; Hou, BH; Huang, S; Jarman, JB; Liu, Y; Low, YS; Medema, MH; Meng, X; Pao, AC; Sekiba, K; van Wezel, G; Weakley, AM; Zhou, Z, 2023) |
| "37 g/kg/d) on potassium oxonate (750 mg/kg/d)-induced hyperuricemia in rats were evaluated by serum uric acid (UA), creatinine (CRE), blood urea nitrogen (BUN), and renal pathological changes." | 4.31 | Dispelling Dampness, Relieving Turbidity and Dredging Collaterals Decoction, Attenuates Potassium Oxonate-Induced Hyperuricemia in Rat Models. ( Huang, XY; Li, W; Liu, HB; Liu, T; Luo, T; Luo, Y; Wu, Y; Yang, M; Zhang, YL, 2023) |
| "The upper limits of normal serum uric acid (SUA) or the lower limits of hyperuricemia were frequently set at 420 or 360 μmol/L (7." | 4.31 | High-normal serum uric acid predicts macrovascular events in patients with type 2 diabetes mellitus without hyperuricemia based on a 10-year cohort. ( Chen, Y; Fu, H; Li, Y; Lv, Y; Ma, C; Wan, G; Xie, R; Yang, G; Yu, H; Yuan, M; Yuan, S; Zhang, J; Zhang, W; Zhang, X; Zhu, L, 2023) |
| "In the present study, we investigated the association between risk factors for atherosclerosis [including HU, HTN, blood pressure and serum uric acid (UA) levels] and paroxysmal atrial fibrillation (Paro-AF) or persistent atrial fibrillation (Pers-AF) in patients who underwent coronary computed tomography angiography (CCTA)." | 4.31 | Association between paroxysmal or persistent atrial fibrillation and hyperuricemia in patients who underwent coronary computed tomography angiography: from the FU-CCTA-AF Registry. ( Higashi, S; Ideishi, A; Kawahira, Y; Komaki, T; Mikagi, M; Miura, SI; Ogawa, M; Shiga, Y; Suematsu, Y; Tachibana, T; Tashiro, K, 2023) |
| "This study was to observe the effect of Sodium TanshinoneⅡA Sulfonate (ST-ⅡAS) on blood uric acid (UA), human Soluble Intercellular Adhesion Molecule-1 (sICAM-1), Endothelin-1 (ET-1) and percentage of brachial artery Flow-Mediated Dilatation (FMD) in individuals with Hyperuricemia Complicated Coronary Heart Disease (HC-CHD)." | 4.31 | Effect of Sodium TanshinoneⅡA Sulfonate on Uric Acid, Sicam-1, ET-1 and FMD in Patients with Coronary Heart Disease Complicated with Hyperuricemia. ( Liu, X; Sun, L; Wang, Y; Zhang, J; Zhou, W, 2023) |
| "Diabetes and other metabolic diseases have been linked to the development of periodontitis, but little research has been done to determine whether serum uric acid (SUA) levels and hyperuricemia play a role." | 4.31 | Association between serum uric acid, hyperuricemia and periodontitis: a cross-sectional study using NHANES data. ( Hu, M; Jia, Y; Mao, Z; Qiu, T; Wei, X; Xu, J, 2023) |
| "Higher serum uric acid (SUA) can cause gout, which is principally characterized by arthritis due to monosodium urate crystal deposition in the lower extremities." | 4.31 | Association between serum uric acid levels and peripheral artery disease in Chinese adults with hypertension. ( Bao, H; Cheng, X; Han, F; Hu, F; Huang, X; Wang, T; Yu, C; Zhou, W; Zhu, L, 2023) |
| " Hyperuricemia was defined as a serum uric acid level above 7." | 4.31 | Hip circumference has independent association with the risk of hyperuricemia in middle-aged but not in older male patients with type 2 diabetes mellitus. ( Feng, Y; Lu, W; Niu, Y; Sheng, J; Tang, Q; Zhang, H; Zhao, X, 2023) |
| "This cohort study intended to elucidate the association between serum uric acid (SUA) levels and cardiovascular disease events in Japanese patients with obesity." | 4.31 | Novel pathological implications of serum uric acid with cardiovascular disease risk in obesity. ( Kasahara, M; Kasama, S; Kato, H; Kato, S; Kusakabe, T; Ozu, N; Satoh-Asahara, N; Tanaka, M; Wakabayashi, D; Yamakage, H, 2023) |
| "VFA has a positive correlation with serum uric acid levels and may serve as a crucial predictive marker for hyperuricemia." | 4.31 | Association between visceral fat area and serum uric acid in Chinese adults: A cross-sectional study. ( Hang, Y; Huang, X; Jiang, L; Liu, Y; Ma, H; Pan, H; Rong, S; Zhang, X; Zhou, Z; Zou, L, 2023) |
| "Hyperuricemia nephropathy (HN) is a metabolic disease characterized by tubular damage, tubulointerstitial fibrosis, and uric acid kidney stones and has been demonstrated to be associated with hyperuricemia." | 4.31 | Coffee Leaf Tea Extracts Improve Hyperuricemia Nephropathy and Its Associated Negative Effect in Gut Microbiota and Amino Acid Metabolism in Rats. ( Guo, J; Wang, S; Zhang, B; Zhang, P; Zhao, X; Zhou, X; Zhuang, Y, 2023) |
| " Hyperuricemia was defined as serum uric acid levels exceeding 7." | 4.31 | Major adverse cardiovascular events and hyperuricemia during tuberculosis treatment. ( Jeong, SH; Kho, BG; Kim, TO; Kim, YI; Kwon, YS; Lee, JK; Lim, SC; Na, YO; Shin, HJ; Yoon, JY, 2023) |
| "Hyperuricemia is a clinical disease characterized by a continuous increase in uric acid (UA) due to purine metabolism disorder." | 4.31 | Peptide NCTX15 derived from spider toxin gland effectively relieves hyperuricemia in mice. ( Bian, W; Fu, Z; Li, C; Liu, N; Liu, Y; Peng, Y; Ru, Z; Wang, Y; Wu, Y; Yang, X; Zhang, Y, 2023) |
| "Previous evidence suggests that higher blood uric acid (UA) levels are associated with adverse cardiovascular outcomes during pregnancy and subsequent birth outcomes." | 4.31 | Associations of early pregnancy serum uric acid levels with risk of gestational diabetes and birth outcomes: a retrospective cohort study. ( Chen, GD; Guo, XL; Li, PS; Liu, ZP; Ma, HT; Pang, TT; Shen, XY; Wan, YC; Zhou, ZX, 2023) |
| " Hyperuricemia was defined using uric acid levels as > 420 μmol/L and > 350 μmol/L in NHANES for men and women, respectively; in the NILS-LSA, serum uric acid was repeatedly measured at baseline and follow-up surveys." | 4.31 | Mushroom consumption and hyperuricemia: results from the National Institute for Longevity Sciences-Longitudinal Study of Aging and the National Health and Nutrition Examination Survey (2007-2018). ( Ba, DM; Gao, X; Muscat, J; Nishita, Y; Otsuka, R; Qiu, T; Tange, C; Zhang, S, 2023) |
| " The asymptomatic hyperuricemia group was defined according to serum uric acid levels." | 4.31 | Association between Asymptomatic Hyperuricemia with Adiposity Indices: A Cross-Sectional Study in a Spanish Population. ( Calderón-García, JF; Juárez-Vela, R; López-Espuela, F; Rey-Sánchez, P; Rico-Martín, S; Sánchez Muñoz-Torrero, JF; Sánchez-Bacaicoa, C; Santano-Mogena, E, 2023) |
| "The serum samples from hyperuricemia subjects were used to analyze the correlation between serum uric acid and clinical characteristics." | 4.31 | Pseudohypoadrenalism, a subclinical cortisol metabolism disorder in hyperuricemia. ( Bao, R; Chen, B; Chen, Q; Pan, J; Wang, A; Wang, T; Yu, H; Zhang, Y, 2023) |
| " Two definitions of hyperuricemia were used: capillary level equivalent to plasma uric acid level>360μmol/l (6mg/dl) and>420μmol/l (7mg/dl) and/or urate-lowering drug treatment for both thresholds." | 4.12 | Epidemiology of gout and hyperuricemia in New Caledonia. ( Bardin, T; Clerson, P; Magnat, E; Richette, P; Rouchon, B, 2022) |
| "It is not clear whether serum uric acid (SUA) levels and their changes over time are associated with the risk of stroke." | 4.12 | Serum Uric Acid Levels and Their Changes and Risk of Stroke: A 7-Year Prospective Cohort Study in Northwest China. ( Bai, Y; Cheng, Z; Liu, Y; Luo, Y; Lv, K; Miao, Q; Wang, M; Yin, C; Zhang, D; Zheng, S, 2022) |
| "Febuxostat is recommended for lowering serum uric acid (sUA) concentration in chronic kidney disease (CKD) patients with hyperuricemia." | 4.12 | Effects of Renal Function on Urinary Excretion and Serum Concentration of Uric Acid in Patients Treated with Febuxostat for Chronic Kidney Disease. ( Kashiwagi, T; Sakai, Y; Yamada, T, 2022) |
| "Whether hyperuricemia is a true risk factor for elevated blood pressure (BP) is controversial, and the sex-specific effects of serum uric acid (SUA) on BP during a follow-up period remain unclear." | 4.12 | Serum uric acid level is associated with an increase in systolic blood pressure over time in female subjects: Linear mixed-effects model analyses. ( Furuhashi, M; Hanawa, N; Higashiura, Y; Koyama, M; Mori, K; Ohnishi, H; Tanaka, M, 2022) |
| "The role of serum uric acid (SUA) in stroke remains controversial and analyses of changes in SUA and stroke are limited." | 4.12 | Effect of changes in serum uric acid on the risk of stroke and its subtypes. ( Chen, S; Luo, Y; Mo, D; Tian, X; Wang, A; Wang, Y; Wu, S; Zhang, L; Zuo, Y, 2022) |
| "Patients with high baseline serum uric acid levels or who achieved high steady-state serum favipiravir concentrations during therapy were susceptible to hyperuricemia." | 4.12 | Baseline uric acid levels and steady-state favipiravir concentrations are associated with occurrence of hyperuricemia among COVID-19 patients. ( Doi, Y; Iwasaki, H; Koseki, T; Mizuno, T; Nakajima, K; Takahashi, K; Yamada, S, 2022) |
| " Hence, it has been of particular interest to dissect the exact role of alteration in uric acid (UA) levels in the context of inflammation." | 4.12 | Evidence for the effect of soluble uric acid in augmenting endoplasmic reticulum stress markers in human peripheral blood mononuclear cells. ( Ebrahimi, R; Emamgholipour, S; Pasalar, P; Shabani, M; Shokri, H, 2022) |
| " It is may necessary to encourage people to check blood uric acid levels when they first time to be diagnosed with hypertension, especially in the elderly." | 4.12 | High prevalence and low awareness of hyperuricemia in hypertensive patients among adults aged 50-79 years in Southwest China. ( Fan, X; Hu, R; Huang, XB; Liu, JX; Liu, Y; Nie, FQ; Tang, W; Wang, TD; Wei, D; Xu, RH; Zhang, WQ; Zhang, Y, 2022) |
| " Pregnant women were divided into hyperuricemia-HU (uric acid ≥ 6 mg/dL) or normouricemia (uric acid, 2." | 4.12 | Serum uric acid levels associated with biochemical parameters linked to preeclampsia severity and to adverse perinatal outcomes. ( da Silva, JVF; de Mendonça, ELSS; de Oliveira, ACM; Mello, CS, 2022) |
| "serum uric acid, but not the serum uric acid/creatinine ratio, results strongly influenced by the number of cardiovascular risk factors and by the insulin resistance degree." | 4.12 | Uric acid and uric acid/creatinine ratio and their correlations with the hemorheological determinants in subjects with subclinical carotid atherosclerosis. ( Amato, C; Brucculeri, S; Caimi, G; Carlisi, M; Lo Presti, R; Urso, C, 2022) |
| "Elevated serum uric acid (UA) level has been shown to be influenced by multiple genetic variants, but it remains uncertain how UA-associated variants differ in their influence on hyperuricemia risk in people taking antihypertensive drugs." | 4.12 | Genetic risk of hyperuricemia in hypertensive patients associated with antihypertensive drug therapy: A longitudinal study. ( Chen, Y; Cui, B; Fu, L; Hui, R; Kong, T; Li, J; Wu, C; Yang, S; Yang, Y; Zhang, S; Zhang, W; Zhong, Y, 2022) |
| " Of total 92 patients 34 (37%) patients had hyperuricemia (HU) and 58 patients had normal serum uric acid levels." | 4.12 | Is Hyperuricemia a Marker of Severity of Disease in Scrub Typhus? ( Mahajan, SK; Sharma, R; Singh, B, 2022) |
| " Univariable and multivariate analyses were used for investigating the independent predictors of hyperuricemia and serum uric acid (SUA) change." | 4.12 | Prevalence and Clinical Predictors of Hyperuricemia in Chinese Bariatric Surgery Patients. ( Jia, B; Lin, W; Qu, X; Zheng, L; Zu, B, 2022) |
| "Lesinurad is a uricosuric agent for the treatment of hyperuricemia associated with gout, which was found lacking in efficacy and safety." | 4.12 | Discovery of Novel Bicyclic Imidazolopyridine-Containing Human Urate Transporter 1 Inhibitors as Hypouricemic Drug Candidates with Improved Efficacy and Favorable Druggability. ( Ji, J; Liang, R; Liao, H; Liu, X; Pang, J; Shi, X; Tao, Y; Wu, T; Zhan, P; Zhang, J; Zhang, Z; Zhao, F; Zhao, T, 2022) |
| "Hyperuricemia is widely thought as a risk factor for myocardial infarction (MI) and all-cause mortality; however, the relation of serum uric acid (sUA) and subclinical myocardial injury (SCeMI) remains unclear." | 4.12 | Impact of serum uric acid on subclinical myocardial injury in general population. ( Chen, S; Huang, Y; Li, Z; Lin, W; Lin, Z; Wang, F; Yan, L; Yang, X; Zhang, L, 2022) |
| "Asymptomatic hyperuricemia (AHU) is elevated serum uric acid (UA) without symptoms." | 4.12 | Effects of uric acid-lowering therapy in patients with essential arterial hypertension. ( Bijak, M; Bilo, G; Drożdż, D; Drożdż, T; Gruszka, K; Hering, D; Jankowski, P; Rajzer, M; Terlecki, M; Wojciechowska, W, 2022) |
| " Patients were aged ≥19 years; had CKD G3-G4; and used drugs including colchicine, allopurinol and febuxostat for hyperuricaemia or chronic gout during the period from April 2000 to October 2020." | 4.12 | Colchicine use and the risk of CKD progression: a multicentre nested case-control study. ( Chang, TI; Han, SH; Jhee, JH; Joo, YS; Kang, SW; Kim, HW; Kim, JY; Park, JT; Roh, YH; Yoo, TH; Yun, HR, 2022) |
| "The anti-hyperuricemic bioactivity of the non-alkaloids fraction and compounds were evaluated with potassium oxonate (PO) induced hyperuricemia mice model in vivo, and monosodium urate (MSU) induced human renal tubular epithelial cells (HK-2) was selected to test in vitro, respectively, with benzobromarone as the positive control." | 4.12 | Anti-hyperuricemic bioactivity of Alstonia scholaris and its bioactive triterpenoids in vivo and in vitro. ( Hu, BY; Luo, XD; Ma, DY; Xiang, ML; Zhao, LX; Zhao, YL, 2022) |
| " We hypothesized that asymptomatic HU would attenuate AKD because soluble, in contrast to crystalline, uric acid (sUA) can attenuate sterile inflammation." | 4.12 | Asymptomatic Hyperuricemia Promotes Recovery from Ischemic Organ Injury by Modulating the Phenotype of Macrophages. ( Anders, HJ; Carangelo, G; De Chiara, L; Gnemmi, V; Li, C; Li, Q; Ma, Q; Molina-Van den Bosch, M; Romagnani, P; Steiger, S, 2022) |
| "Hyperuricemia (HUA) is the second most common metabolic disease nowadays, and is characterized by permanently increased concentrations of serum uric acid." | 4.12 | Novel anti-hyperuricemic hexapeptides derived from ( Ding, L; Fan, S; Han, J; Huang, Y; Li, Y; Lu, C; Lu, G; Ming, T; Su, X; Sun, N; Wang, R; Zhou, J, 2022) |
| " We herein report a Fabry disease patient with enzyme replacement therapy (ERT)-resistant proteinuria who showed improvement in the estimated glomerular filtration rate (eGFR) decline rate after uric acid (UA)-lowering therapy." | 4.12 | Improvement in Decline Rate of Estimated Glomerular Filtration Rate after Febuxostat Treatment in a Fabry Disease Patient with Enzyme Replacement Therapy-resistant Proteinuria. ( Chin-Kanasaki, M; Imamura-Uehara, Y; Kato, K; Kume, S; Kuwagata, S; Maegawa, H; Nakagawa, Y; Ohno, S; Takeda, N; Yamahara, K; Yasuda-Yamahara, M, 2022) |
| " Hyperuricemia was diagnosed as fasting serum uric acid > 420 µmol/L in men and women." | 4.12 | Association between circulating cystatin C and hyperuricemia: a cross-sectional study. ( Chen, Y; Guo, Y; Huang, H; Shen, C; Xu, C, 2022) |
| "This study aimed to assess the association of dietary fiber intake with serum uric acid (SUA) levels and risk of hyperuricemia (HUA) among Chinese adults using the latest nationally representative data." | 4.12 | Association between Dietary Fiber Intake and Hyperuricemia among Chinese Adults: Analysis of the China Adult Chronic Disease and Nutrition Surveillance (2015). ( Jia, S; Li, Y; Man, Q; Yu, L; Zhang, J; Zhou, Y; Zhu, Q; Zuo, H, 2022) |
| "The above study shows that serum uric acid levels are significantly elevated in patients with metabolic syndrome." | 4.12 | Study of Serum Uric Acid Levels in Patients of Metabolic Syndrome in a Tertiary Care Centre in South India. ( Kulkarni, A; N, R; Subhash, N; T, AK, 2022) |
| " We observed higher levels of serum uric acid levels in patients with severe sepsis." | 4.12 | Hyperuricemia as an Early Marker in Predicting Mortality and Morbidity in Patients with Sepsis. ( Maldar, A, 2022) |
| "Uric acid (UA) and high-density lipoprotein cholesterol (HDL-C) are positively and negatively associated with atherosclerosis, respectively." | 4.12 | Elevated serum uric acid was associated with pre-inflammatory state and impacted the role of HDL-C on carotid atherosclerosis. ( Dong, H; Hu, X; Li, G; Li, W; Liu, J; Wang, C; Zhou, Y, 2022) |
| "Characterized by an excessively increased uric acid (UA) level in serum, hyperuricemia induces gout and also poses a great threat to renal and cardiovascular systems." | 4.12 | Noninvasive and Individual-Centered Monitoring of Uric Acid for Precaution of Hyperuricemia via Optical Supramolecular Sensing. ( Chai, S; Chai, X; Geng, WC; Guo, DS; Li, JJ; Wang, L; Wang, Y; Yu, H; Yue, YX; Zhang, Y, 2022) |
| "Gouty arthritis is generally induced by the accumulation of monosodium urate (MSU) crystals in the joints due to elevated serum uric acid levels, potentially leading to serious pathological disorders such as nephrolithiasis, renal failure, and acute gouty arthritis." | 4.12 | Carvacrol Alleviates Hyperuricemia-Induced Oxidative Stress and Inflammation by Modulating the NLRP3/NF-κB Pathwayt. ( Al Kury, LT; Alattar, A; Alshaman, R; Atzaz, N; Li, S; Riaz, M; Shah, FA, 2022) |
| " Indirect associations were mediated through the triglyceride-glucose (TyG) index (as an indicator of insulin resistance), mean arterial pressure (MAP), uric acid (UA), and total cholesterol (TC)." | 4.12 | The Association of Excess Body Weight with Risk of ESKD Is Mediated Through Insulin Resistance, Hypertension, and Hyperuricemia. ( Brozek, W; Concin, H; Fritz, J; Kerschbaum, J; Lhotta, K; Nagel, G; Ulmer, H; Zitt, E, 2022) |
| "Although serum uric acid (UA) is considered as a risk factor for cardiovascular disease, few data exist regarding the relationship between hyperuricemia, coronary blood flow, and subsequent outcome in patients with acute myocardial infarction (AMI)." | 4.12 | Impact of hyperuricemia on coronary blood flow and in-hospital mortality in patients with acute myocardial infarction undergoing percutaneous coronary intervention. ( Dohi, K; Hanada, H; Higuma, T; Kumagai, N; Masuda, J; Nakahashi, T; Nakamura, M; Ogimoto, A; Sakata, K; Takamura, M; Tanigawa, T, 2022) |
| " 113 patients fulfilled the criteria for central obesity with the mean uric acid level of 8." | 4.12 | A Clinical Profile of Patients with Hyperuricemia and the Relationship between Hyperuricemia and Metabolic Syndrome: A Cross-sectional Study at a Tertiary Hospital in the Indian Population. ( Ingawale, S; Raghorte, N; Rajadhyaksha, A; Sarate, N, 2022) |
| " the xanthine oxidase inhibitors allopurinol and febuxostat), traditional Chinese medicine has fewer side effects in the treatment of gout and can safely control serum uric acid and the level of inflammation." | 4.12 | Phytochemicals in traditional Chinese medicine can treat gout by regulating intestinal flora through inactivating NLRP3 and inhibiting XOD activity. ( Liu, ZB; Liu, ZQ; Sun, X; Wu, CJ; Zhang, LL; Zhang, T, 2022) |
| "Hyperuricemia is characterized with high serum uric acids (SUAs) and directly causes suffering gout." | 4.12 | Caffeic acid phenethyl ester alleviated hypouricemia in hyperuricemic mice through inhibiting XOD and up-regulating OAT3. ( Cai, M; Chen, S; Gao, X; Hu, H; Huang, L; Li, X; Liang, D; Liu, Y; Wu, Q; Xiao, C; Xie, Y; Yong, T, 2022) |
| "Adipose tissue plays a crucial role in serum uric acid (UA) metabolism, but the relative contribution of adipose tissue insulin resistance (IR) to serum UA levels and hyperuricemia have not explicitly been illustrated." | 4.12 | Adipose Tissue Insulin Resistance Is Positively Associated With Serum Uric Acid Levels and Hyperuricemia in Northern Chinese Adults. ( An, Y; Bian, N; Chang, X; Leng, S; Liu, J; Sun, H; Wang, G, 2022) |
| "The role of uric acid as a risk factor for cerebrovascular disease, particularly acute ischemic stroke, is controversial and there is little information about this in our setting." | 4.12 | Relationship of Serum Uric Acid Level with Acute Ischemic Stroke: A Single-Center, Hospital-Based Study from Bangladesh. ( Hossain, MS; Jasmine, T; Kamrul-Hasan, AB; Rahman, MM; Saha, PK; Sarker, MA, 2022) |
| " In this study, the xanthine oxidase (XO) inhibition and uric acid-lowering effect of corni fructus extract (CFE) were evaluated in mice with potassium oxonate-induced hyperuricemia." | 4.12 | Protective effects of corni fructus extract in mice with potassium oxonate-induced hyperuricemia. ( Chen, C; Chen, FA; Chen, HC; Chiu, PY; Li, YL; Wang, CC, 2022) |
| "This study aimed to identify the relationship between abnormal serum uric acid levels or a history of hyperuricemia and COVID-19 severity in the Japanese population." | 4.12 | U-shaped association between abnormal serum uric acid levels and COVID-19 severity: reports from the Japan COVID-19 Task Force. ( Arimura, K; Chubachi, S; Fukunaga, K; Fukushima, T; Harada, N; Hasegawa, N; Imoto, S; Ishiguro, T; Ishii, M; Kamata, H; Kanai, T; Kimura, A; Kitagawa, Y; Koike, R; Kusumoto, T; Lee, H; Masaki, K; Miyano, S; Morita, A; Murakami, K; Mutoh, Y; Nakagawara, K; Nakano, Y; Namkoong, H; Ogawa, S; Okada, Y; Otake, S; Saito, F; Suzuki, Y; Tanaka, H; Ueda, S; Ueda, T; Watase, M; Yoshiyama, T, 2022) |
| "Patients with psoriasis had higher serum uric acid levels than healthy controls (6." | 4.12 | Effects of secukinumab and adalimumab on serum uric acid level in patients with plaque psoriasis. ( Cai, L; Li, C; Liu, X; Zhang, H; Zhang, J; Zhang, S; Zhao, Y; Zhao, Z, 2022) |
| "A total of 86 patients with IgAN and normal renal functions were divided into a hyperuricemia group and a normal serum uric acid group (control group)." | 4.12 | The relationship between serum uric acid levels and glomerular ischemic lesions in patients with Immunoglobin A nephropathy-a analytical cross-sectional study. ( Dai, F; Dong, X; Fang, B; Kang, Y; Qi, L; Wang, Y; Wei, L; Yu, Y, 2022) |
| "Sera of gout patients meeting the 2015 ACR/EULAR gout classification criteria (n = 20) and with hyperuricemia were studied at time zero and weeks 12 and 24 of febuxostat or allopurinol dose titration ULT." | 4.12 | Xanthine oxidase inhibitor urate-lowering therapy titration to target decreases serum free fatty acids in gout and suppresses lipolysis by adipocytes. ( Bittleman, D; Coras, R; Dadpey, B; Guma, M; Hamilton, B; Lauro, K; Liu-Bryan, R; Mikuls, TR; Quehenberger, O; Reilly, SM; Terkeltaub, R; Thorisdottir, H, 2022) |
| " Hyperuricemia was defined as a serum uric acid level >7 mg/dL for males and >6 mg/dL for females." | 4.12 | Interaction between Hyperuricemia and Admission Lactate Increases the Risk of Acute Kidney Injury in Patients with ST-Segment Elevation Myocardial Infarction. ( He, Y; Hong, X; Huang, W; Liang, D; Lin, Q; Shan, P; Wang, D; Zhou, X; Zhu, Q, 2022) |
| "Abnormal uric acid level result in the development of hyperuricemia and hallmark of various diseases, including renal injury, gout, cardiovascular disorders, and non-alcoholic fatty liver." | 4.12 | Anti-inflammatory potential of stevia residue extract against uric acid-associated renal injury in mice. ( Alharthi, F; Althobaiti, F; Chen, X; Mehmood, A; Murtaza, MA; Nadeem, M; Ranjha, MMAN; Shah, AA; Soliman, MM; Usman, M; Wang, C; Zhao, L, 2022) |
| " Ongoing research is examining the association of obesity, dietary patterns, and blood pressure (BP) with serum uric acid (sUA)." | 4.12 | Correlation of obesity, dietary patterns, and blood pressure with uric acid: data from the NHANES 2017-2018. ( Fan, GJ; Lin, YP; Lu, QY; Yao, J; Zhang, Y; Zhao, J, 2022) |
| " Overweight/obesity, alcohol consumption, smoking and sedentary behavior are modifiable risk factors (MRFs) for elevated serum uric acid (SUA), but their population attributable fractions (PAFs) for hyperuricemia is still unclear." | 4.12 | Prevalence of hyperuricemia and the population attributable fraction of modifiable risk factors: Evidence from a general population cohort in China. ( Chen, S; Guo, F; Guo, P; He, H; He, J; Li, Q; Liu, F; Ma, S; Niu, Y; Pan, L; Shan, G; Zhang, B; Zhang, J; Zhang, M; Zhang, R, 2022) |
| "This study aims to investigate the anti-hyperuricemia effect and mechanism of anserine in hyperuricemic rats." | 4.12 | Anserine beneficial effects in hyperuricemic rats by inhibiting XOD, regulating uric acid transporter and repairing hepatorenal injury. ( Chen, M; Ji, H; Liu, S; Song, W; Su, W; Zhang, D, 2022) |
| "Excessive serum uric acid (SUA) causes hyperuricemic nephropathy (HN), characterized by inflammatory infiltration and tubulointerstitial fibrosis." | 4.12 | Fufang Zhenzhu Tiaozhi capsule ameliorates hyperuricemic nephropathy by inhibition of PI3K/AKT/NF-κB pathway. ( Chen, Z; Guan, J; Guo, J; Hu, XG; Lan, T; Li, MH; Mo, JX; Wu, KR, 2022) |
| "To investigate whether serum uric acid (SUA) levels and hyperuricemia can be predictive biomarkers of incident metabolic syndrome(MS) among different body mass index(BMI) categories, and to investigate SUA cutoffs that best discriminate individuals with incident MS." | 4.12 | Serum uric acid is a predictive biomarker of incident metabolic syndrome at the Brazilian longitudinal study of adult Health (ELSA - Brasil). ( B Duncan, B; Haueisen Sander Diniz, MF; Inês Schmidt, M; Isabel Rodrigues Galvão, A; Luiz P Ribeiro, A; M Benseñor, I; M R Beleigoli, A; Maria Barreto, S; Vidigal, PG; Weiss Telles, R, 2022) |
| "Patients with hyperuricemia or gout or patients with high and low levels of serum uric acid may face poor outcomes of hip fractures." | 4.12 | The paradoxical relation between serum uric acid and outcomes of hip fracture in older patients after surgery: A 1-year follow-up study. ( Chu, Q; Fu, M; Liu, M; Sun, G; Wang, J; Yang, C; Zhang, Z, 2022) |
| "Hyperuricemia is a state in which the serum levels of uric acid (UA) are elevated." | 4.12 | Effects of rosuvastatin on serum glucose and insulin in hyperuricemic rats. ( Aili, A; Nuermaimaiti, B; Rehemu, N; Sun, H; Tuerxun, Z; Xilifu, D; Zhang, X, 2022) |
| "Undoubtedly, the relationship between serum uric acid (SUA) and obesity is less data for Chinese patients with obesity." | 4.12 | Prevalence of hyperuricemia in patients with severe obesity and the relationship between serum uric acid and severe obesity: A decade retrospective cross-section study in Chinese adults. ( Chan, W; Cheang, C; Dong, Z; Law, S; Ren, J; Wang, C, 2022) |
| " The language was used to formalize one- and two-drug titration of chronic and acute cases, and to perform retrospective analysis of the drug titration processes on 253 patients diagnosed of diabetes mellitus type 2 and treated with metformin, 321 patients treated of chonic heart failure with furosemide, 155 patients with hyperuricemia treated with allopurinol as initial drug and febuxostat as alternative drug, and 187 hyperuricemia patients with primary drug allopurinol and supplementary drug probenecid, in order to identify different types of drug titration deviations from standard DT methods." | 4.12 | Modelling and assessing one- and two-drug dose titrations. ( Alonso, JR; Kamišalić, A; Pečnik, Š; Riaño, D, 2022) |
| " Whether hyperuricemia is an independent risk factor for renal progression and whether there are sex differences in the relationships between serum uric acid (UA) and a decline in renal function are unclear." | 4.12 | Sex Difference in the Associations among Hyperuricemia with New-Onset Chronic Kidney Disease in a Large Taiwanese Population Follow-Up Study. ( Chen, JH; Chen, SC; Chung, TL; Huang, JC; Liu, YH; Su, HM; Tsai, CC; Wu, PY, 2022) |
| " Our previous studies confirmed that hyperuricemia or high uric acid (HUA) treatment induced an IR state in several peripheral tissues to promote the development of type 2 diabetes mellitus (T2DM)." | 4.12 | Hyperuricemia contributes to glucose intolerance of hepatic inflammatory macrophages and impairs the insulin signaling pathway ( Chen, B; Cheng, J; He, F; Koyama, H; Liu, W; Lu, J; Wang, M; Wang, Q; Wang, W; Xi, Y; Xu, C; Yamamoto, T; Yan, Y; Yu, L; Yu, W; Zhang, C; Zhao, H, 2022) |
| "Urate Transporter 1 (URAT1) plays a crucial role in uric acid transport, making it an attractive target for the treatment of gout and hyperuricemia." | 4.12 | Design, synthesis and activity evaluation of novel lesinurad analogues containing thienopyrimidinone or pyridine substructure as human urate transporter 1 inhibitors. ( Dong, Y; Gao, S; Liang, R; Liao, H; Liu, X; Pang, J; Qi, D; Shi, X; Wu, T; Zhan, P; Zhang, J; Zhang, X; Zhang, Z; Zhao, T, 2022) |
| " We also tested whether the addition of an insulin resistance index (HOMA-index >90th percentile by sex and age) and the presence of hyperuricemia (serum uric acid >90th percentile by sex and age) to the definition of MUO better identified obese children with early cardiac damage." | 4.12 | Association of obesity phenotypes with left ventricular mass index and left ventricular hypertrophy in children and adolescents. ( Antolini, L; Genovesi, S; Giussani, M; Lieti, G; Montemerlo, M; Orlando, A; Parati, G; Patti, I; Tassistro, E, 2022) |
| "The uric acid serum level is higher in people with hypertension and overweight/obesity." | 4.12 | Hyperuricaemia and its association with other risk factors for cardiovascular diseases: A population-based study. ( Baniasad, A; Najafipour, H; Najafzadeh, MJ; Shakibi, MR; Sistani, S; Yazdi, F, 2022) |
| "Little research has been conducted into the effects of the combined manifestation of hyperuricemia and hyperhomocysteinemia on cardiometabolic risk factors and markers in young subjects." | 4.12 | The Presence of Hyperhomocysteinemia Does Not Aggravate the Cardiometabolic Risk Imposed by Hyperuricemia in Young Individuals: A Retrospective Analysis of a Cross-Sectional Study. ( Gurecká, R; Koborová, I; Podracká, Ľ; Repiská, G; Šebeková, K, 2022) |
| "Hyperuricemia (HUA) refers to a physiological condition of high serum uric acid (SUA) level in the body, which may cause an increased risk of several chronic diseases." | 4.12 | Exercise serum regulates uric acid transporters in normal rat kidney cells. ( Cao, H; Cao, J; Fan, Y; Jiang, H; Jiang, Z; Su, H; Sun, Z, 2022) |
| "This study aimed to assess the relationship of serum uric acid with metabolic syndrome and its components in Tibetan adults on the Tibetan plateau." | 4.12 | Association between hyperuricemia and metabolic syndrome: A cross-sectional study in Tibetan adults on the Tibetan plateau. ( Bao, S; Feng, H; Ge, W; Xu, L; Yao, S; Zhang, Q; Zhou, Y, 2022) |
| "Hyperuricemia is prevalent and associated with individual cardiometabolic diseases, highlighting the potential role of serum uric acid (SUA) in the development and progression of cardiometabolic multimorbidity (CMM, the coexistence of diabetes, heart disease, or stroke)." | 4.12 | Change of serum uric acid and progression of cardiometabolic multimorbidity among middle aged and older adults: A prospective cohort study. ( Dai, X; Li, D; Ni, Y; Wang, D; Xu, X, 2022) |
| "Hyperuricemia was associated with the overproduction or inadequate excretion of uric acid, while its association with gut microbiota has emerged although few studies were focused on it." | 4.12 | Flavonoid extract of saffron by-product alleviates hyperuricemia via inhibiting xanthine oxidase and modulating gut microbiota. ( Chen, N; Li, H; Wang, L; Wang, R; Wang, W; Yang, B; Yao, R; Yin, X, 2022) |
| "Epidemiological evidence of the associations between metal exposure and gout-related outcomes (including serum uric acid [SUA], hyperuricemia and gout) is scarce." | 4.12 | Associations of metal exposure with hyperuricemia and gout in general adults. ( Hui, R; Shi, S; Wang, J; Xing, Y; Xu, J; Zhang, Y; Zhu, L; Zhu, X, 2022) |
| " The relationship between the uric acid metabolism target and the NLRP3 inflammasome may be the critical immune response between hyperuricemia and gouty arthritis." | 4.12 | Overnutrition-induced gout: An immune response to NLRP3 inflammasome dysregulation by XOD activity increased in quail. ( Huang, J; Li, Y; Lin, Z; Ren, Z; Wang, Y; Wu, H; Zhang, B, 2022) |
| " Hyperuricemia was defined as serum uric acid ≥ 7 mg/dL in men and ≥ 6 mg/dL in women." | 4.12 | The elevated visceral adiposity index increases the risk of hyperuricemia in Chinese hypertensive patients: A cross-sectional study. ( Bao, H; Cheng, X; Liu, H; Song, X; Wang, T; Yu, C; Zhou, W; Zhu, J; Zhu, L, 2022) |
| " However, a better understanding of the relationship among uric acid (UA) values, glomerular filtration rate (GFR) and albuminuria may shed light on the mechanisms underlying the excess of cardiovascular mortality associated with both chronic kidney disease and hyperuricemia and lead to better risk stratification." | 4.12 | Association of uric acid with kidney function and albuminuria: the Uric Acid Right for heArt Health (URRAH) Project. ( Barbagallo, CM; Bombelli, M; Borghi, C; Casiglia, E; Cicero, AFG; Cirillo, M; Cirillo, P; D'Elia, L; Desideri, G; Ferri, C; Galletti, F; Gesualdo, L; Giannattasio, C; Grassi, G; Iaccarino, G; Leoncini, G; Mallamaci, F; Maloberti, A; Masi, S; Mazza, A; Mengozzi, A; Muiesan, ML; Nazzaro, P; Palatini, P; Parati, G; Pontremoli, R; Rattazzi, M; Rivasi, G; Russo, E; Salvetti, M; Tikhonoff, V; Tocci, G; Ungar, A; Verdecchia, P; Viazzi, F; Virdis, A; Volpe, M, 2022) |
| "Heavy metals, including cadmium, are suspected to increase serum uric acid levels and hyperuricemia in both gender, but the evidences about this are inconclusive." | 4.12 | Association Between Low-Level Blood Cadmium Exposure and Hyperuricemia in the American General Population: a Cross-sectional Study. ( Li, S; Sun, D; Zeng, A; Zhou, Y, 2022) |
| "Rats with hyperuricemia induced by fructose and potassium oxonate were administered with DoMRE and vehicle control, respectively, to compare the effects of the drugs." | 4.12 | Effects of Macroporous Resin Extract of Dendrobium officinale Leaves in Rats with Hyperuricemia Induced by Fructose and Potassium Oxonate. ( Chen, SH; Dong, YJ; He, XL; Li, B; Li, LZ; Lv, GY; Wang, YZ; Xu, WF; Yu, QX; Zheng, X; Zhou, C; Zhu, LJ, 2022) |
| "In the context of an aging population, this study aims to evaluate serum uric acid levels and arterial hypertension prevalence and control in a subgroup of Romanian adults (>65 years), concerning the influence of age on these parameters." | 4.02 | Arterial Hypertension and Serum Uric Acid in Elderly- SEPHAR III Study. ( Albulescu, N; Ardelean, M; Buzas, R; Dorobantu, M; Gheorghe-Fronea, OF; Ivan, VS; Lighezan, DF; Morgovan, AF, 2021) |
| " Uric acids disorders in particular hyperuricemia are significant problems in essential hypertensive patients and can cause substantial morbidity and mortality." | 4.02 | Evaluation of uric acid disorders and associated factors in essential hypertensive patients at Wolkite University specialized hospital, Southern Ethiopia. ( Haile, K; Timerga, A, 2021) |
| "Treatment with STAT3 inhibitor S3I-201 improved renal dysfunction, reduced serum uric acid level, and delayed the progression of kidney fibrosis." | 4.02 | Pharmacologic inhibiting STAT3 delays the progression of kidney fibrosis in hyperuricemia-induced chronic kidney disease. ( Fu, P; Guo, F; Ma, L; Pan, J; Shi, M, 2021) |
| " Hyperuricemia was defined as serum uric acid (SUA) level 420 umol/L in men and 360 umol/L in women." | 4.02 | Positive association between body fat percentage and hyperuricemia in patients with hypertension: The China H-type hypertension registry study. ( Bao, H; Cheng, X; Huang, X; Wang, S; Wangsheng, F; Xiong, Y; Zhou, W, 2021) |
| "Elevated serum uric acid (SUA) levels, body shape index (BSI) and body roundness index (BRI) were associated with incident metabolic syndrome (MetS)." | 4.02 | Serum uric acid is associated with incident metabolic syndrome independent of body shape index and body roundness index in healthy individuals. ( Chen, CC; Liu, CW; Tseng, GS; Tu, CM; Wei, TE, 2021) |
| "Serum uric acid (SUA) has been found correlated with an increased risk of hypertension, but evidence is sparse regarding the association in Gansu Province, especially in Yugur people." | 4.02 | Association between Serum Uric Acid and Hypertension in Han and Yugur of Gansu Province: The China National Health Survey. ( Chang, L; He, H; Pan, L; Ren, X; Shan, G; Wang, Y; Xi, J; Yu, C; Zhao, H, 2021) |
| "Elevated serum uric acid (SUA)-hyperuricemia-is caused by overproduction of urate or by its decreased renal and/or intestinal excretion." | 4.02 | Increase of serum uric acid levels associated with APOE ε2 haplotype: a clinico-genetic investigation and in vivo approach. ( Ayaori, M; Harada-Shiba, M; Higashino, T; Hishida, A; Ikewaki, K; Kawai, S; Kawamura, Y; Matsuo, H; Naito, M; Nakajima, M; Nakayama, A; Ogura, M; Okada, R; Sakiyama, M; Sasaki, M; Shimizu, S; Shinomiya, N; Suzuki, H; Takada, T; Takata, K; Toyoda, Y; Yamanashi, Y, 2021) |
| " Hyperuricemia was defined as serum uric acid level of at least 357 μmol/L." | 4.02 | Neck Circumference Is Associated With Hyperuricemia in Women With Polycystic Ovary Syndrome. ( Ding, L; Jin, C; Liu, C; Mu, L; Yang, H; Yu, R, 2021) |
| " Both WP and EP extracts showed pronounced antihyperuricemia activities, with a remarkable decline in serum uric acid and a marked increase in urine uric acid in hyperuricemic mice." | 4.02 | Antihyperuricemia and antigouty arthritis effects of Persicaria capitata herba in mice. ( Chen, TX; Dong, L; Fu, Y; Guan, HY; He, X; Liao, SG; Tang, KF; Xu, GB; Yang, XS; Yang, YX; Zhang, CL; Zhang, JJ; Zhu, QF, 2021) |
| "Previous studies reported that the level of serum uric acid (SUA) was an important risk factor for acute cerebral infarction (ACI)." | 4.02 | The Prognostic Value of Serum Uric Acid in Hospitalized Patients with Acute Cerebral Infarction. ( Cao, L; Liu, B; Pan, Y; Yang, J, 2021) |
| "Serum uric acid (SUA) level has been suggested to be associated with cardiovascular disease, diabetes and metabolic syndrome." | 4.02 | Assessment of the relationship between serum uric acid levels and liver enzymes activity in Bangladeshi adults. ( Ali, N; Barman, Z; Fariha, KA; Hasan, A; Kathak, RR; Mahmud, F; Molla, NH; Mou, AD; Sumon, AH, 2021) |
| "Self-reported gout or hyperuricemia and uric acid level." | 4.02 | Should we be more aware of gender aspects in hyperuricemia? Analysis of the population-based German health interview and examination survey for adults (DEGS1). ( Engel, B; Freitag, MH; Hoffmann, F; Jacobs, H, 2021) |
| "Asymptomatic hyperuricemia patients exposed to a higher level of uric acid (>=428 mmol/L) could significantly increase the incidence risk of CHD and stroke, with or without hyperuricemia-related comorbidities." | 4.02 | High-level uric acid in asymptomatic hyperuricemia could be an isolated risk factor of cardio-cerebrovascular diseases: A prospective cohort study. ( Bai, Y; Cheng, Z; Hu, X; Li, J; Li, N; Ren, X; Shi, D; Wang, M; Yang, J; Yin, C; Zhang, D; Zheng, S; Zheng, T, 2021) |
| " Nevertheless, the association between uric acid levels and the development of albuminuria has been under-investigated in patients with type 2 diabetes mellitus." | 4.02 | Association between uric acid level and incidence of albuminuria in patients with type 2 diabetes mellitus: A 4.5-year cohort study. ( Chen, LJ; Chen, YY; Ku, PW; Lai, YJ; Yen, YF, 2021) |
| "Hyperuricemia is a metabolic condition closely linked to xanthine oxidase (XOD) function, which is involved in the production of uric acid (UA)." | 4.02 | Isorhamnetin, the xanthine oxidase inhibitor from ( Fang, L; Song, D; Su, X; Wang, F; Zhao, X; Zou, F, 2021) |
| "We aimed to investigate the association between serum uric acid (SUA) level and development of hypertension as well as the interaction effect of chronic kidney disease (CKD) on this relationship in the general Japanese population." | 4.02 | Effect of chronic kidney disease on the association between hyperuricemia and new-onset hypertension in the general Japanese population: ISSA-CKD study. ( Arima, H; Fujii, H; Funakoshi, S; Ishida, S; Ito, K; Kawanami, D; Kawazoe, M; Kondo, S; Maeda, T; Masutani, K; Mukobara, S; Nabeshima, S; Okutsu, S; Satoh, A; Tada, K; Takahashi, K; Tsuji, M; Yasuno, T; Yokota, S; Yoshimura, C, 2021) |
| "Data on the relationship of baseline serum uric acid (SUA) with development of low-density lipoprotein cholesterol (LDL-C) level in patients with first acute myocardial infarction (AMI) are limited." | 4.02 | Association between baseline serum uric acid and development of LDL-C level in patients with first acute myocardial infarction. ( Chen, Y; Dai, C; Ding, C; Hu, L; Liao, H; Liao, Y; Ruan, Y; Xia, Y; Yang, R; Zhao, Y; Zou, K, 2021) |
| "Our previous research showed that uric acid lowering therapy (ULT) for gout and hyperuricemia is being prescribed for pediatric patients even though these drugs have not been approved for use in children." | 4.02 | Urate-lowering therapy for gout and asymptomatic hyperuricemia in the pediatric population: a cross-sectional study of a Japanese health insurance database. ( Honda, M; Horiuchi, H; Iijima, T; Ito, S; Murano, H; Nakajima, A; Torii, T; Yamanaka, H, 2021) |
| " Serum uric acid was obtained to determine hyperuricemia levels." | 4.02 | Dietary Inflammatory Index and the Risk of Hyperuricemia: A Cross-Sectional Study in Chinese Adult Residents. ( Aihemaitijiang, S; Halimulati, M; Huang, X; Wang, R; Ye, C; Zhang, Z, 2021) |
| "To evaluate the efficacy of serum uric acid on inpatient morbidity and mortality among acute coronary syndrome patients." | 4.02 | The effect of serum uric acid in hospitalised patients with acute coronary syndrome in Al-Yarmouk Teaching Hospital. ( Abdul Khaliq, SM; Al-Sharifi, AN, 2021) |
| "This study aims to investigate the correlation between serum uric acid levels and body fat distribution in patients with polycystic ovary syndrome (PCOS)." | 4.02 | Correlation Between Serum Uric Acid and Body Fat Distribution in Patients With Polycystic Ovary Syndrome. ( Cai, M; Cui, R; Dilimulati, D; Fei, H; Gao, X; Lin, Z; Qu, S; Shao, X; Sun, H; Zeng, Q; Zhang, M; Zhang, Y, 2021) |
| " Current data suggest that the mechanism of action of metformin contributes to the development of an anti-inflammatory effect, as well as a decrease in the level of uric acid, and its use can be potentially useful in patients with hyperuricemia and gout." | 4.02 | [Advantages of the use of metformin in patients with impaired uric acid metabolism]. ( Eliseev, MS; Nasonov, EL; Panevin, TS; Zhelyabina, OV, 2021) |
| "To evaluate the prognostic impact of serum uric acid (SUA) on clinical outcomes in patients with acute decompensated heart failure, as well as identify the correlation between hyperuricemia and renal function and diuretic resistance in these patients." | 4.02 | [Prognostic impact of uric acid in patients with acute decompensated heart failure]. ( Lapteva, AE; Mindzaev, DR; Nasonova, SN; Tereshchenko, SN; Zhirov, IV, 2021) |
| "Although several individual nutrients/foods are associated with uric acid status, the association of overall diet quality with hyperuricemia remains unclear." | 4.02 | Adherence to the Dietary Approaches to Stop Hypertension Diet and Hyperuricemia: A Cross-Sectional Study. ( Cui, LF; Gao, X; Gao, Y; Sun, YY; Wang, JR; Wu, SL; Yang, WH, 2021) |
| "To investigate the efficacy and tolerability of febuxostat in gout patients on dialysis." | 4.02 | Efficacy and tolerability of febuxostat in gout patients on dialysis. ( Choi, SW; Choi, SY; Lee, S; Lim, DH; Oh, JS; So, MW, 2021) |
| "The objectives of our study were to compare the efficacy of febuxostat with allopurinol in Thai subjects with gout, as well as to determine the predictive factors of responsiveness to urate-lowering agents and to evaluate the safety of febuxostat in a real-world setting." | 4.02 | Efficacy of febuxostat versus allopurinol and the predictors of achieving target serum urate in a cohort of Thai people with gout. ( Jatuworapruk, K; Lertnawapan, R, 2021) |
| "This cross-sectional study investigates the association between insulin resistance (IR) and serum uric acid (sUA) and relative fat (RFM) and lean mass (RLM) profiles in children with chronic kidney disease (CKD)." | 4.02 | Association between relative fat mass, uric acid, and insulin resistance in children with chronic kidney disease. ( Christoforidis, A; Dotis, J; Karava, V; Kollios, K; Kondou, A; Liakopoulos, V; Papachristou, F; Printza, N; Tsioni, K, 2021) |
| "While hyperuricemia is recognized as a risk factor for chronic kidney disease (CKD), the risk of CKD in subjects with a low level of serum uric acid (UA) remains controversial." | 4.02 | U-shaped relationship between serum uric acid level and decline in renal function during a 10-year period in female subjects: BOREAS-CKD2. ( Furuhashi, M; Hanawa, N; Higashiura, Y; Hisasue, T; Inyaku, M; Koyama, M; Matsumoto, M; Miura, T; Moniwa, N; Mori, K; Numata, K; Ohnishi, H; Osanami, A; Tanaka, M, 2021) |
| "Hyperuricemia was significantly associated with increased on-treatment residual ADP-inducible platelet reactivity in clopidogrel- and prasugrel-treated patients in univariate analyses and after adjustment for differences in patient characteristics by multivariate regression analyses." | 4.02 | Decreased Platelet Inhibition by Thienopyridines in Hyperuricemia. ( Gremmel, T; Hoberstorfer, T; Kopp, CW; Lee, S; Panzer, S; Pultar, J; Wadowski, PP; Weikert, C, 2021) |
| " However, the mechanism underlying high levels of uric acid inducing gouty arthritis has not been clarified." | 4.02 | Matrix Metalloproteinase-3 induces proteoglycan degradation in gouty arthritis model. ( Chen, AS; Jiang, JQ; Liang, T; Liang, XL; Liu, J; Shi, L; Wu, XW; Yang, F; Yuan, DP; Zhu, FF, 2021) |
| "This study assessed factors associated with achieving target serum uric acid (sUA) level and occurrence of gouty arthritis in Japanese clinical practice." | 4.02 | Factors associated with achieving target serum uric acid level and occurrence of gouty arthritis: A retrospective observational study of Japanese health insurance claims data. ( Horiuchi, H; Koto, R; Nakajima, A; Yamanaka, H, 2021) |
| "Pre-eclampsia is commonly associated with higher serum uric acid levels, which is known to increase vascular tone." | 4.02 | Association of Maternal Hyperuricemia with Post-Spinal Hypotension in Pre-Eclamptic Parturients Undergoing Emergency Cesarean Delivery: a Prospective Observational Study. ( Bhatia, N; Jain, K; Mehra, D; Sikka, P; Singla, K; Verma, I, 2021) |
| "Seventy-one individuals were enrolled in this study and divided into three groups according to their serum uric acid (SUA) level and clinical symptoms: healthy controls (HC, n = 23), asymptomatic hyperuricemia (AH, n = 22) and gouty arthritis (GA, n = 26)." | 4.02 | Combined application of DTI and BOLD-MRI in the assessment of renal injury with hyperuricemia. ( Cai, XR; Chen, PK; Cheng, ZY; Feng, YZ; Lin, QT; Qian, L; Si-Tu, DK, 2021) |
| "Insufficient renal urate excretion and/or overproduction of uric acid (UA) are the dominant causes of hyperuricemia." | 4.02 | Baicalein alleviates hyperuricemia by promoting uric acid excretion and inhibiting xanthine oxidase. ( Cao, Y; Chen, Y; Jiang, Y; Li, L; Li, Y; Lin, C; Pang, J; Tian, Y; Wu, T; Yang, Y; Zhao, Z; Zhou, P, 2021) |
| "High levels of serum uric acid is closely associated with atrial fibrillation (AF); nonetheless, the detailed mechanisms remain unknown." | 4.02 | Increased Susceptibility of Atrial Fibrillation Induced by Hyperuricemia in Rats: Mechanisms and Implications. ( Li, Y; Liang, D; Liang, Z; Liu, H; Liu, Y; Su, M; Sun, L; Wang, D; Wei, Y; Yin, S; Zhang, G; Zhang, S; Zhao, J, 2021) |
| "We investigated the distribution of serum uric acid (SUA) levels and estimated the prevalence of hyperuricemia and hypouricemia in the Korean population." | 4.02 | Distribution of serum uric acid levels and prevalence of hyper- and hypouricemia in a Korean general population of 172,970. ( Jeong, HJ; Jun, JB; Kim, GH; Kim, HJ; Kim, SH; Koo, BS; Son, CN, 2021) |
| "The URic acid Right for heArt Health (URRAH) study is a nationwide, multicentre, observational cohort study involving data on individuals recruited from all the Italy territory under the patronage of the Italian Society of Hypertension with an average follow-up period of 122." | 4.02 | Relationships between diuretic-related hyperuricemia and cardiovascular events: data from the URic acid Right for heArt Health study. ( Barbagallo, CM; Bernardino, B; Bombelli, M; Borghi, C; Casiglia, E; Cicero, AFG; Cirillo, M; Cirillo, P; D'elia, L; Dell'Oro, R; Desideri, G; Facchetti, R; Ferri, C; Galletti, F; Giannattasio, C; Grassi, G; Iaccarino, G; Lippa, L; Loreto, G; Mallamaci, F; Maloberti, A; Masi, S; Mazza, A; Muiesan, ML; Nazzaro, P; Palatini, P; Parati, G; Pauletto, P; Pontremoli, R; Quarti-Trevano, F; Rattazzi, M; Rivasi, G; Rosei, EA; Salvetti, M; Tikhonoff, V; Tocci, G; Ungar, A; Verdecchia, P; Viazzi, F; Virdis, A; Volpe, M, 2021) |
| " We used a case study of febuxostat versus allopurinol for the treatment of hyperuricemia in patients with gout." | 4.02 | Combining Model-Based Clinical Trial Simulation, Pharmacoeconomics, and Value of Information to Optimize Trial Design. ( Hill-McManus, D; Hughes, DA, 2021) |
| "Hyperuricemia is defined by the European Rheumatology Society as a uric acid level greater than 6 mg/dl (60 mg/l or 360 μmol/l)." | 4.02 | Creation of an adequate animal model of hyperuricemia (acute and chronic hyperuricemia); study of its reversibility and its maintenance. ( Affes, H; Charfi, S; Dhouibi, R; Hammami, S; Jamoussi, K; Ksouda, K; Marekchi, R; Moalla, D; Sahnoun, Z; Salem, MB; Zeghal, KM, 2021) |
| "Our study analyzes the frequency and risk factors of hyperuricemia and the use of allopurinol in a representative cohort of the older Polish adult population." | 4.02 | Prevalence of Hyperuricemia and the Use of Allopurinol in Older Poles-Results from a Population-Based PolSenior Study. ( Broczek, K; Chudek, J; Grodzicki, T; Mossakowska, M; Owczarek, AJ; Wierucki, Ł; Winder, M, 2021) |
| "In this nonrandomized, open-label, single-arm trial, we administered topiroxostat 40-160 mg/day to HFpEF patients with hyperuricemia or gout to achieve a target uric acid level of 6." | 4.02 | Effect of Topiroxostat on Brain Natriuretic Peptide Level in Patients with Heart Failure with Preserved Ejection Fraction: A Pilot Study. ( Asai, K; Koen, M; Kubota, Y; Shimizu, W; Wakita, M, 2021) |
| "A high serum uric acid (SUA) concentration is associated with hyperuricemia (HUA) and gout." | 4.02 | Expression, localization and metabolic function of "resurrected" human urate oxidase in human hepatocytes. ( Chen, J; Duan, Y; Jiang, N, 2021) |
| " Hyperuricemia, a serum uric acid level ≥ 416 μmol/L in men and in menopausal women and ≥ 357 μmol/L in premenopausal women, was used as the dependent variable." | 4.02 | The visceral fat area to leg muscle mass ratio is significantly associated with the risk of hyperuricemia among women: a cross-sectional study. ( Ji, YP; Jiang, WR; Li, CJ; Lin, JN; Shi, YX; Wang, XH; Zhang, MY, 2021) |
| "Asymptomatic hyperuricemia is a condition where the serum uric acid levels are elevated but the individual does not have any sign or symptoms of gout or renal stones." | 4.02 | Study of Endothelial Dysfunction by Flow Mediated Vasodilation in Individuals with Asymptomatic Hyperuricemia. ( Fatima, J; Joshi, P; Kugashiya, R; Shukla, V; Varshney, AR, 2021) |
| "Although high serum uric acid (SUA) at baseline has been linked to increased risk for metabolic syndrome (MetS), the association of longitudinal SUA changes with MetS risk is unclear." | 4.02 | Dose-response relationship between distinct serum uric acid trajectories and metabolic syndrome risk: A 5-year prospective cohort study. ( Guo, X; Han, Y; Li, Q; Liu, J; Ma, Z; Tao, L; Yang, X; Zhang, J; Zhang, S, 2021) |
| "To report a case of ribavirin-associated severe hyperuricemia in an immunocompromised patient treated for respiratory syncytial virus (RSV) infection." | 4.02 | Acute and severe ribavirin-associated hyperuricemia and acute kidney injury: An underrecognized adverse effect. ( Ammuri, H; Elias, A; Frisch, A; Kurnik, D; Sakran, R; Sliman, H, 2021) |
| "Elevated serum uric acid (SUA) is associated with hypertension according to its traditional definition." | 4.02 | Elevated serum uric acid is associated with incident hypertension in the health according to various contemporary blood pressure guidelines. ( Hwang, JJ; Ke, SR; Liu, CW; Tseng, GS; Wu, YW, 2021) |
| "The relationship between uric acid and incident hypertension tended to be dependent on age and sex." | 4.02 | Age and sex dependent association of uric acid and incident hypertension. ( Choi, CU; Choi, JY; Go, TH; Kang, DO; Kang, DR; Kim, EJ; Kim, JY; Kim, W; Lee, J; Na, JO; Park, CG; Rha, SW; Roh, SY; Seo, HS, 2021) |
| "The aim of this paper was to investigate the effect of ethanol extract of Phellinus igniarius in lowering uric acid and changing the gut microbiome in hyperuricemia rats." | 4.02 | [Preliminary study on effect of Phellinus igniarius ethanol extract on serum uric acid metabolism and gut microbiome in rats]. ( Chu, FJ; Jiang, SL; Jin, XB; Li, X, 2021) |
| "Hyperuricemia is highly prevalent in chronic kidney disease (CKD) patients, but the evidence for a relationship between uric acid (UA) and clinical outcomes in CKD patients is limited and inconsistent." | 4.02 | Different clinical impact of hyperuricemia according to etiologies of chronic kidney disease: Gonryo Study. ( Ito, S; Miyazaki, M; Nakayama, M; Sato, H; Watanabe, K; Yamada, G; Yamamoto, T, 2021) |
| "Patients with primary hypertension and without any uric acid (UA)-lowering treatment were enrolled." | 4.02 | Association of hyperuricemia and hypertension phenotypes in hypertensive patients without uric acid lowering treatment. ( Hou, J; Liao, H; Lin, J; Liu, C; Qiu, D; Zhang, M, 2021) |
| "To investigate the association between serum uric acid (SUA) levels and vision-threatening diabetic retinopathy (VTDR) in patients with type 2 diabetes." | 4.02 | Higher Serum Uric Acid Levels Are Associated With an Increased Risk of Vision-Threatening Diabetic Retinopathy in Type 2 Diabetes Patients. ( Chan, Z; Chen, H; Gu, C; Hu, Y; Li, C; She, X; Shi, Y; Wang, Y; Zhao, S; Zheng, Z; Zhou, C, 2021) |
| "Increased concentration of uric acid may play a role in the pathogenesis of primary hypertension (PH)." | 4.02 | [Uric acid in children and adolescents with primary hypertension]. ( Pańczyk-Tomaszewska, M; Skrzypczyk, P; Szyszka, M, 2021) |
| "Serum uric acid (SUA) levels have been reported to be associated with an increased risk of coronary artery disease (CAD) among patients with diabetes in observational study." | 4.02 | Genetically predicted serum uric acid levels and the risk of coronary artery disease in patients with diabetes: A Mendelian randomization study. ( Chen, S; Fu, G; Wang, Y; Xu, T; Yang, F; Zhang, K; Zhang, W, 2021) |
| "Fisetin lowered uricemia, suppressed renal inflammatory response, and improved kidney fibrosis to protect against hyperuricemic nephropathy via modulation of STAT3 and TGF-β signaling pathways." | 4.02 | Natural flavonol fisetin attenuated hyperuricemic nephropathy via inhibiting IL-6/JAK2/STAT3 and TGF-β/SMAD3 signaling. ( Fu, P; Guo, F; Ma, L; Ren, Q; Tao, S; Wang, B; Yang, L, 2021) |
| "Hyperuricemia (HUA) is induced by abnormal purine metabolism and elevated serum uric acid (UA) concentrations, and it is often accompanied by inflammatory responses and intestinal disorders." | 4.02 | Chlorogenic acid supplementation ameliorates hyperuricemia, relieves renal inflammation, and modulates intestinal homeostasis. ( Hu, N; Lin, Y; Wang, J; Wang, S; Wang, X; Zhang, B; Zhao, X; Zhou, X, 2021) |
| " Dietary administration of AJOP significantly alleviates hyperuricemia, regulates uric acid metabolism, inhibites the activation of the NLRP3 inflammasome and NF-κB-related signaling pathway, and restores m6A methylation levels." | 4.02 | Apostichopus japonicus Oligopeptide Induced Heterogeneity in the Gastrointestinal Tract Microbiota and Alleviated Hyperuricemia in a Microbiota-Dependent Manner. ( Fan, S; Han, J; Huang, Y; Li, Y; Lu, C; Ming, T; Su, X; Tang, S; Zhang, Z; Zhou, J, 2021) |
| "The purpose of this study was to investigate the application value of serum 25(OH)D3, uric acid, triglyceride (TG), and homeostasis model assessment of insulin resistance (HOMA-IR) in male patients with hyperuricemia combined with hypogonadism." | 4.02 | The application value of serum 25(OH)D3, uric acid, triglyceride, and homeostasis model assessment of insulin resistance in male patients with hyperuricemia combined with hypogonadism. ( Chen, W; Wang, J; Yun, C; Zhang, Q, 2021) |
| "Recently, studies have shown a positive association between serum uric acid (UA) and metabolic syndrome (MS)." | 4.02 | Uric acid: A new marker for metabolic syndrome? Results of a population-based study with adults. ( da Silva, DCG; de Magalhães, ELG; Ferreira, FG; Hinnig, PF; Juvanhol, LL; Longo, GZ; Roberto, DMT, 2021) |
| " The effects of API on renal function, inflammation, fibrosis, and uric acid (UA) metabolism in mice with HN were evaluated." | 4.02 | Apigenin ameliorates hyperuricemic nephropathy by inhibiting URAT1 and GLUT9 and relieving renal fibrosis via the Wnt/β-catenin pathway. ( Cao, Y; Chen, Y; Huang, Q; Jiang, Y; Li, L; Li, Y; Luo, J; Pang, J; Wu, T; Zhang, L; Zhao, Z; Zhou, P, 2021) |
| "High uric acid (HUA) is associated with insulin resistance (IR) in cardiomyocytes." | 4.02 | Metformin protects against insulin resistance induced by high uric acid in cardiomyocytes via AMPK signalling pathways in vitro and in vivo. ( Chen, Y; Jiao, Z; Li, Y; Li, Z; Xie, Y, 2021) |
| "To observe the effect of application at Back-Shu with Front-Mu acupoints on serum uric acid (SUA) and kidney uric acid transport related proteins in hyperuricemia rats, so as to explore the mechanism of Shu-Mu acupoint application on treatment of hyperuricemia." | 4.02 | [Effect of application at Shu-Mu acupoint on serum uric acid in hyperuricemic rats]. ( He, XQ; Liu, JN; Sui, MH; Tang, XQ; Wu, XM, 2021) |
| " Hyperuricemia was defined as serum uric acid ≥7 mg/dL in men and ≥6 mg/dL in women." | 4.02 | Short sleep duration increases the risk of hyperuricemia among Chinese adults: findings from the China Health and Nutrition Survey. ( Chen, J; Ding, X; Gong, S; Gu, Y; Lv, S; Shen, Z; Wang, Y; Yu, X; Zhang, D; Zhang, H; Zhang, X, 2021) |
| " Hyperuricemia was defined as uric acid ≥7." | 4.02 | Sugar-sweetened soft drinks consumption and risk of hyperuricemia: Results of the ELSA-Brasil study. ( Barreto, SM; Benseñor, IM; Mill, JG; Molina, MCB; Pereira, TSS; Siqueira, JH; Velasquez-Melendez, G, 2021) |
| "Background Serum uric acid (SUA) has been demonstrated as a risk factor for myocardial infarction (MI) and all-cause mortality; however, the impact of cumulative SUA (cumSUA) remains unclear." | 4.02 | Cumulative Serum Uric Acid and Its Time Course Are Associated With Risk of Myocardial Infarction and All-Cause Mortality. ( Chen, S; Luo, Y; Mo, D; Tian, X; Wang, A; Wu, S; Zhang, L; Zuo, Y, 2021) |
| "We investigated serum uric acid changes and incident hyperuricemia in relation to the achieved blood pressure (BP) after 12 weeks of antihypertensive therapy with the irbesartan/hydrochlorothiazide combination." | 4.02 | Incident hyperuricemia in relation to antihypertensive therapy with the irbesartan/hydrochlorothiazide combination. ( Huang, QF; Li, Y; Wang, JG; Zhang, D, 2021) |
| "Compared with patients with normal serum uric acid level, asymptomatic hyperuricemia can lead to worse recovery after arthroscopic rotator cuff repair in patients with rotator cuff tears." | 4.02 | ( Aslan, R; Celik, C; Han, Z; Hasbek, M; Kafa, AHT; Li, T; Ma, W; Qi, C; Yu, T; Zhang, Y; Zhao, X, 2021) |
| "In patients with gout, treating to target serum uric acid levels (sUA) of ≤6." | 4.02 | Serum uric acid control for prevention of gout flare in patients with asymptomatic hyperuricaemia: a retrospective cohort study of health insurance claims and medical check-up data in Japan. ( Horiuchi, H; Koto, R; Nakajima, A; Yamanaka, H, 2021) |
| "Dotinurad is a selective urate reabsorption inhibitor (SURI), which selectively inhibits URAT1 to lower serum uric acid levels in patients with hyperuricemia." | 4.02 | Comparative study of a novel selective urate reabsorption inhibitor "dotinurad" among patient groups with different stages of renal dysfunction. ( Beppu, T; Hidaka, Y; Hosoya, T; Takahashi, T, 2021) |
| "In a multi-center study (n=2495), we used unsupervised machine learning to cluster patients with obesity from Shanghai Tenth People's hospital (n=882, main cohort) based on three clinical variables (AUCs of glucose and of insulin during OGTT, and uric acid)." | 4.02 | Machine Learning to Identify Metabolic Subtypes of Obesity: A Multi-Center Study. ( Arefan, D; Cheng, X; Du, L; Feng, W; Gao, L; Lin, Z; Liu, Y; Ma, C; Qu, S; Wu, S; You, H; Yu, J; Zhou, D; Zhu, D; Zhu, J, 2021) |
| "Berberine (BBR) is an active component of Phellodendri Cortex (PC), which is a traditional Chinese medicine that has been prescribed clinically for hyperuricemia (HUA) for hundreds of years." | 4.02 | Effect of Berberine on Hyperuricemia and Kidney Injury: A Network Pharmacology Analysis and Experimental Validation in a Mouse Model. ( Chen, J; Huang, Z; Li, Q; Li, Y; Liu, D; Su, Z; Xie, J; Zeng, H; Zheng, J, 2021) |
| "Recent studies on uric acid as a biomarker for the prognosis of acute stroke have found conflicting results." | 4.02 | Hyperuricaemia as a prognostic factor for acute ischaemic stroke. ( Cabrera Naranjo, FH; Fabre Pi, O; González Hernández, A; Saavedra Santana, P; Sosa-Henríquez, M, 2021) |
| " The changes in serum uric acid (SUA) levels in chronic hepatitis C patients who receive antivirals are not well understood." | 3.96 | Improvement of hyperuricemia in chronic hepatitis C patients receiving directly acting antiviral agents. ( Chen, SC; Chuang, WL; Dai, CY; Hou, NJ; Hsieh, MY; Huang, CF; Huang, CI; Huang, JF; Jang, TY; Liang, PC; Lin, YH; Lin, ZY; Tsai, PC; Yeh, ML; Yu, ML, 2020) |
| "The prognostic value of serum uric acid (SUA) for incident acute coronary syndrome (ACS) in hypertensive subjects is uncertain." | 3.96 | J-shaped association between serum uric acid and acute coronary syndrome in patients with essential hypertension. ( Chen, CL; Feng, YQ; Huang, JY; Huang, YQ; Liu, L; Shen, G; Yu, YL; Zhang, B, 2020) |
| "In addition to the controversy regarding the association of hyperuricemia with mortality, uncertainty also remains regarding the association between low serum uric acid (SUA) and mortality." | 3.96 | U-Shaped Association of Serum Uric Acid With All-Cause and Cause-Specific Mortality in US Adults: A Cohort Study. ( Bao, H; Cheng, X; Hu, G; Hu, L; Wang, T; Xu, BP; Zhou, W; Zhu, L, 2020) |
| "The results showed that, in patients with CKD and hyperuricemia, febuxostat can be used to reduce the serum uric acid level." | 3.96 | Comparison of long-term efficacy and renal safety of febuxostat and allopurinol in patients with chronic kidney diseases . ( Yang, AY, 2020) |
| "Hyperuricemia is caused by hepatic overproduction of uric acid and/or underexcretion of urate from the kidneys and small intestine." | 3.96 | Comprehensive analysis of mechanism underlying hypouricemic effect of glucosyl hesperidin. ( Harada-Shiba, M; Hirata, H; Ogura, M; Ota-Kontani, A; Tsuchiya, Y, 2020) |
| " The effects of phloretin on renal function, fibrosis, oxidative stress, inflammation, and UA metabolism in HUA mice were evaluated." | 3.96 | Phloretin ameliorates hyperuricemia-induced chronic renal dysfunction through inhibiting NLRP3 inflammasome and uric acid reabsorption. ( Chen, Y; Cheng, J; Cui, D; Li, L; Liu, J; Liu, S; Lu, Y; Mao, R; Tang, M; Wang, C; Yuan, Y; Zhao, M, 2020) |
| "Leveraging a longitudinal cohort including 1981 Chinese adults who had blood pressures, urinary albumin to creatinine ratio (UACR), and uric acid measured twice 4 years apart, we examined the temporal relationships among hyperuricemia, microalbuminuria, and hypertension by cross-lagged panel analysis followed by a causal mediation analysis to confirm the temporal consequence." | 3.96 | Microalbuminuria mediates the association between serum uric acid and elevation of blood pressure: a longitudinal analysis in the Gusu cohort. ( He, Y; Jiang, Y; Li, J; Ma, S; Peng, H; Ren, L; Yu, J; Zhang, M; Zhang, Q, 2020) |
| "High serum uric acid levels increase the risk of liver steatosis in lean patients." | 3.96 | Hepatic Steatosis in Lean Patients: Risk Factors and Impact on Mortality. ( Eigenbauer, E; Forstner, B; Mandorfer, M; Muckenhuber, M; Paternostro, R; Pfisterer, N; Reiberger, T; Scheiner, B; Scheuba, K; Trauner, M; Unger, LW, 2020) |
| " A potassium oxonate (PO) induced hyperuricemic mouse model was used to evaluate antihyperuricemia and nephroprotective effects of O." | 3.96 | Antihyperuricemic and nephroprotective effects of extracts from Orthosiphon stamineus in hyperuricemic mice. ( Liang, ML; Su, WK; Sun, Y; Wang, HT; Xu, WH; Xue, ZC, 2020) |
| "While rasburicase has shown efficacy to rapidly correct hyperuricemia compared with allopurinol, its overall impact in improving clinically significant outcomes, such as acute kidney injury (AKI), in tumor lysis syndrome (TLS) is unknown." | 3.96 | Comparative effectiveness of rasburicase versus allopurinol for cancer patients with renal dysfunction and hyperuricemia. ( Estey, E; Frieze, D; Garcia, DA; Hingorani, S; Khalighi, PR; Li, A; Li, S; Martens, KL; Silgard, E; White, AA, 2020) |
| " The mechanism of development of hyperuricemia (defined, serum uric acid (UA) ≥ 5." | 3.96 | Hyperuricemia is associated with a lower glomerular filtration rate in pediatric sickle cell disease patients. ( Beach, I; Feig, D; Kaspar, CDW; Newlin, J; Sisler, I; Smith, W, 2020) |
| " Male SD rats were assigned to control group or oxonic acid-induced hyperuricemia (HUA) group." | 3.96 | ABCG2 expression and uric acid metabolism of the intestine in hyperuricemia model rat. ( Asakawa, S; Hosoyamada, M; Kuribayashi-Okuma, E; Li, J; Morimoto, C; Murase, T; Nakamura, T; Nemoto, Y; Shibata, S; Tamura, Y; Uchida, S, 2020) |
| "Elevated blood uric acid (UA) levels have been positively associated with the severity of periodontitis." | 3.96 | Hyperuricemia as a potential plausible risk factor for periodontitis. ( Chen, ZY; Gao, J; Liang, ZJ; Ye, LW; Yu, T; Zhao, L, 2020) |
| "Hyperuricemia is an abnormal increase in uric acid levels in the blood." | 3.96 | Impact of Lesinurad and allopurinol on experimental Hyperuricemia in mice: biochemical, molecular and Immunohistochemical study. ( Alghamdi, YS; Nassan, MA; Soliman, MM, 2020) |
| "Despite the growing pieces of evidence linking hyperuricemia with metabolic syndrome and cardiovascular disease, the relationship between dyslipidemia and serum uric acid has not yet been established." | 3.96 | Association between dyslipidemia and serum uric acid levels in Korean adults: Korea National Health and Nutrition Examination Survey 2016-2017. ( Seo, J; Son, M; Yang, S, 2020) |
| "Background Elevated serum uric acid concentrations have been associated with metabolic syndrome." | 3.96 | Elevated serum uric acid, hyperuricaemia and dietary patterns among adolescents in mainland China. ( Du, Y; Lu, Y; Ma, ZF; Pan, B; Shao, J; Wang, L; Wei, H; Wu, Q; Zhao, Q; Zhou, H; Zhu, W, 2020) |
| " Hyperuricemia is the hallmark of developing gout and mostly caused by uric acid underexcretion." | 3.96 | The prevalence of the gout-associated polymorphism rs2231142 G>T in ABCG2 in a pregnant female Filipino cohort. ( Prom-Wormley, E; Roman, Y; Tiirikainen, M, 2020) |
| " Our study was to discover different lipid levels of gout and asymptomatic hyperuricemia and the predictors of sUA (serum uric acid) levels." | 3.96 | The comparison of dyslipidemia and serum uric acid in patients with gout and asymptomatic hyperuricemia: a cross-sectional study. ( Gu, J; Huang, Y; Jiang, Y; Li, X; Liang, J; Ou, J; Song, W; Wei, Q, 2020) |
| "At present, the treatment of hyperuricemia is designed primarily to decrease the production of uric acid using xanthine oxidase inhibitors; however, the therapeutic effect is not satisfactory." | 3.96 | Construction and expression of recombinant uricase‑expressing genetically engineered bacteria and its application in rat model of hyperuricemia. ( Cai, L; Deng, Y; Du, W; Jiang, X; Li, Q; Liu, X, 2020) |
| "The role of serum uric acid (SUA) in development of myocardial infarction (MI) is controversial." | 3.96 | Associations between changes in serum uric acid and the risk of myocardial infarction. ( An, J; Chen, S; He, Y; Li, H; Luo, Y; Tian, X; Wang, A; Wu, S; Zhang, L; Zuo, Y, 2020) |
| "Little is known about sex- and age-specific variations and temporal trends in serum uric acid (SUA) concentrations, the prevalence of hyperuricemia and its association with metabolic risk factors in the general population." | 3.96 | Sex- and age-specific variations, temporal trends and metabolic determinants of serum uric acid concentrations in a large population-based Austrian cohort. ( Concin, H; Fischer, A; Lhotta, K; Nagel, G; Zitt, E, 2020) |
| "Conclusions: Concentric and excentric left ventricular hypertrophy, increased left ventricular mass index proportionally to uric acid levels (r = 0,31; p = 0,04) is the confirmation of important role of hyperuricemia in the left ventricular hypertrophy development in patients with arterial hypertension." | 3.96 | Arterial hypertension associated with hyperuricemia: features of heart damage. ( Chernatska, OM; Fadieieva, HA; Liashenko, AV; Prystupa, LN; Smiianova, YO, 2020) |
| " This study was designed to evaluate the influences of long-term xanthine oxidase inhibitor (febuxostat) prescription on left ventricular hypertrophy (LVH), left ventricular (LV) diastolic function, and new-onset heart failure with preserved ejection fraction (HFpEF) in these patients." | 3.96 | Association between long-term prescription of febuxostat and the progression of heart failure with preserved ejection fraction in patients with hypertension and asymptomatic hyperuricemia. ( Gu, J; Lin, H; Pan, JA; Wang, CQ; Zhang, JF, 2020) |
| "Observational studies have shown that high levels of serum uric acid (UA) were associated with atrial fibrillation (AF)." | 3.96 | A mendelian randomization analysis: The causal association between serum uric acid and atrial fibrillation. ( Hong, M; Hwang, I; Jee, SH; Joung, B; Kim, TH; Lee, MH; Pak, HN; Park, JW; Uhm, JS; Yang, PS; Yu, HT, 2020) |
| "This is a retrospective analysis of 100 CKD patients treated with febuxostat for asymptomatic hyperuricemia in two private Lebanese clinics." | 3.96 | A formula predicting the effective dose of febuxostat in chronic kidney disease patients with asymptomatic hyperuricemia based on a retrospective study and a validation cohort . ( Aoun, M; Chelala, D; Dfouni, A; Salloum, R; Sleilaty, G, 2020) |
| " The objective of the study is to investigate whether there is an association between concurrent serum levels of several PFAAs and gout, serum uric acid (SUA) or hyperuricemia in the U." | 3.96 | Perfluoroalkyl acids, hyperuricemia and gout in adults: Analyses of NHANES 2009-2014. ( Abadin, HG; Attanasio, R; Balluz, L; Buser, MC; Gehle, K; Murray, HE; Scinicariello, F, 2020) |
| "Topiroxostat, a selective xanthine oxidoreductase inhibitor, is used for the management of hyperuricemic patients with or without gout in Japan." | 3.96 | Long-Term Safety and Effectiveness of the Xanthine Oxidoreductase Inhibitor, Topiroxostat in Japanese Hyperuricemic Patients with or Without Gout: A 54-week Open-label, Multicenter, Post-marketing Observational Study. ( Hashimoto, T; Ichikawa, K; Ishikawa, T; Kanno, Y; Maeda, T; Nakagawa, T; Sato, Y, 2020) |
| "Hyperuricemia arises from the buildup of excessive uric acid in the blood, and it is implicated in the development of periodontitis." | 3.96 | Analyzing the Association between Hyperuricemia and Periodontitis: A Cross-Sectional Study Using KoGES HEXA Data. ( Byun, SH; Choi, HG; Lee, JW; Yoo, DM, 2020) |
| " Hyperuricemia was defined as serum uric acid levels ≥7." | 3.96 | Sugar-containing carbonated beverages consumption is associated with hyperuricemia in general adults: A cross-sectional study. ( Bian, S; Cao, X; Gu, Y; Jia, Q; Jiao, H; Li, H; Li, X; Liu, L; Liu, Y; Meng, G; Niu, K; Song, K; Sun, S; Wang, X; Wang, Y; Wu, H; Wu, XH; Wu, Y; Zhang, Q; Zhang, S; Zhang, T; Zhou, M, 2020) |
| "To investigate the effects of serum uric acid (SUA) level and its fluctuation on renal dysfunction in gout patients." | 3.96 | Uric acid fluctuation had no effect on renal function among gout patients. ( Fu, Y; Mo, M; Shao, B; Shen, J; Shen, Y; Si, S; Wang, S; Wu, H; Xin, X; Yu, Y; Zhu, J, 2020) |
| " The present study was undertaken to evaluate the therapeutic effects and the underlying mechanisms of polydatin on potassium oxonate-induced hyperuricemia in rats through metabonomic technology from a holistic view." | 3.96 | NMR-Based Metabonomic Study Reveals Intervention Effects of Polydatin on Potassium Oxonate-Induced Hyperuricemia in Rats. ( Gong, M; Han, B; Li, Z; Qiu, Y; Zou, Z, 2020) |
| " Subsequently, he showed increased uric acid levels and developed acute gouty arthritis." | 3.96 | Acute Gouty Arthritis During Favipiravir Treatment for Coronavirus Disease 2019. ( Hase, R; Ishida, K; Kurata, R; Kurita, T; Mito, H; Muranaka, E, 2020) |
| "Hyperuricemia is related to health issues among children and adolescents, once the uric acid concentration is associated with metabolic syndrome, hypertension, insulin resistance, obesity, and dyslipidemia." | 3.96 | Food Consumption is Associated with Hyperuricemia in Boys. ( Borfe, L; Brand, C; Brazo-Sayavera, J; Franke, SIR; Gaya, AR; Reis, LN; Renner, JDP; Reuter, CP, 2020) |
| "Conflicting findings have been reported regarding the sex-specific association between serum uric acid (SUA) level and type 2 diabetes mellitus (T2DM) risk, and no study has explored the association between the change in hyperuricemia status and T2DM risk." | 3.96 | Sex-Specific Association of Serum Uric Acid Level and Change in Hyperuricemia Status with Risk of Type 2 Diabetes Mellitus: A Large Cohort Study in China. ( Chen, H; Han, D; Hu, D; Hu, F; Li, Y; Liu, D; Lou, Y; Ma, J; Peng, X; Qin, P; Wang, C; Wang, L; Xu, S; Zhao, D; Zhao, P, 2020) |
| " Here, we report the use of whole genome sequencing (WGS) to establish a diagnosis in a family in which individuals were affected with gout, hyperuricemia associated with reduced fractional excretion of uric acid, chronic kidney disease (CKD), and secondary hyperparathyroidism, that are consistent with familial juvenile hyperuricemic nephropathy (FJHN)." | 3.96 | Whole genome sequence analysis identifies a PAX2 mutation to establish a correct diagnosis for a syndromic form of hyperuricemia. ( Gorvin, CM; Lhotta, K; Lines, KE; Pagnamenta, AT; Philpott, C; Reichart, S; Stevenson, M; Taylor, JC; Thakker, RV, 2020) |
| "Hyperuricemia was defined as uric acid (UA) > 420 μmol/L for men and > 360 μmol/L for women." | 3.96 | Economic Status Moderates the Association Between Early-Life Famine Exposure and Hyperuricemia in Adulthood. ( Cai, Y; Chen, C; Chen, Y; Guo, M; Lu, Y; Wan, H; Wang, N; Wang, Y; Weng, P; Xia, F; Zhang, W, 2020) |
| "Lesch-Nyhan syndrome (LNS) is an X-linked recessive disorder presenting with uric acid overproduction, neurocognitive disability, and behavioral disturbances." | 3.96 | Delayed emergence from propofol anesthesia in a patient with Lesch-Nyhan syndrome: A case report. ( Jeon, S; Jung, SM; Lee, J, 2020) |
| " Serum uric acid (UA) is a terminal metabolite of purine compound, while hyperuricemia (HU) and UA crystals are recognized causes of gout." | 3.96 | Association between hyperuricemia, gout, urate lowering therapy, and osteoarthritis: A protocol for a systematic review and meta-analysis. ( Chen, Y; Li, H; Li, X; Wang, Y; Yang, Z; Zhu, J, 2020) |
| "results indicate serum uric acid is positively correlated with hypertension and a reliable indicator of LVH in study population." | 3.96 | Serum uric acid and left ventricular hypertrophy in hypertensive patients in Ado-Ekiti. ( Adebayo, RA; Adewuya, OA; Ajayi, EA; Ojo, OE; Olaoye, OB, 2020) |
| " Outcomes were measured for prevalence, patient characteristics, treatment with uric acid lowering drugs for gout and asymptomatic hyperuricemia, and prevalence and incidence of gouty arthritis." | 3.96 | Prevalence of gout and asymptomatic hyperuricemia in the pediatric population: a cross-sectional study of a Japanese health insurance database. ( Honda, M; Horiuchi, H; Iijima, T; Ito, S; Murano, H; Nakajima, A; Torii, T; Yamanaka, H, 2020) |
| " Participants in the lowest quartile of FVC % predicted and FEV1% predicted were compared to those in the remaining quartiles according to age, education level, household income, smoking status, alcohol consumption, aerobic exercise, obesity, hypertension, diabetes, renal impairment, serum uric acid, and hyperuricemia." | 3.96 | Association between serum uric acid and spirometric pulmonary function in Korean adults: The 2016 Korea National Health and Nutrition Examination Survey. ( Hong, JW; Kim, DJ; Noh, JH, 2020) |
| "Hyperuricemia (HUA) is a metabolic disease caused by the overproduction or underexcretion of uric acid (UA)." | 3.96 | Dendrobium officinalis six nostrum ameliorates urate under-excretion and protects renal dysfunction in lipid emulsion-induced hyperuricemic rats. ( Chen, SH; Chen, X; Ge, HZ; He, X; Jiang, ZT; Lei, SS; Li, B; Lv, GY; Su, J; Wang, HY; Yu, QX; Zheng, X, 2020) |
| "Hyperuricemia is defined as a disease with high uric acid (UA) levels in the blood and a strong risk factor for gout." | 3.96 | Antihyperuricemic Effect of Urolithin A in Cultured Hepatocytes and Model Mice. ( Adachi, SI; Isoda, H; Komatsu, W; Kondo, S; Sasaki, K; Yagasaki, K; Yoshizawa, F, 2020) |
| "This study was designed to investigate the effects and underlying mechanisms of Astaxanthin (AST) on high-fructose-induced hyperuricemia (HUA) from the perspectives of the uric acid (UA) synthesis and excretion in rat models." | 3.96 | Anti-Hyperuricemic Effects of Astaxanthin by Regulating Xanthine Oxidase, Adenosine Deaminase and Urate Transporters in Rats. ( Chen, Y; Ding, G; Le, Y; Tang, Y; Yang, Z; Yu, F; Zheng, J; Zhou, X, 2020) |
| " The subjects were divided into hyperuricemia group and nonhyperuricemia group according to serum uric acid level, and the differences of the sociodemographic information (age, gender, and region), health status (weight status, blood pressure, blood sugar status), living habits (alcohol consumption, smoking status) and food intake (purine-rich food, other food) were compared between the two groups." | 3.96 | The Association between Purine-Rich Food Intake and Hyperuricemia: A Cross-Sectional Study in Chinese Adult Residents. ( Aihemaitijiang, S; Halimulati, M; Yang, J; Ye, C; Zhang, L; Zhang, W; Zhang, Y; Zhang, Z, 2020) |
| "12 a week-long combined therapy of the allopurinol-reducing drug with the anti-inflammatory dose movalis prevents the exacerbation of the articular syndrome and improves the quality of life of patients with gout." | 3.96 | [Evaluation of a 12-week allopurinol-lowering therapy in combination with the non-steroidal anti-inflammatory drug meloxicam in patients with gout]. ( Gromova, MA; Kislyak, OA; Malysheva, NV; Tsurko, VV, 2020) |
| "The aim of this paper was to study the specific mechanism of Fangji Huangqi Decoction(FHT) in decreasing uric acid and improving renal function in mice with hyperuricemia(HUA) induced by potassium oxonate, so as to provide theoretical basis for the research and development of drugs for clinical prevention and treatment of HUA and the modernization of traditional Chinese medicine." | 3.96 | [Study on mechanism of Fangji Huangqi Decoction on hypouricemic effect and renal protection in hyperuricemia mice]. ( Hong-Lei, LI; Ning, X; Wan, YU; Xing, W; Zhen, C, 2020) |
| "Hyperuricemia, defined as the presence of elevated serum uric acid (sUA), could lead to urate deposit in joints, tendons, kidney and other tissues." | 3.96 | Mechanistic Insights of Soluble Uric Acid-related Kidney Disease. ( Fu, P; Ma, L; Pan, J; Shi, M, 2020) |
| " Serum uric acid levels and estimated glomerular filtration rate (eGFR) of patients with gouty arthritis were collected at baseline and 1 year after febuxostat administration." | 3.96 | Renal safety and urate-lowering efficacy of febuxostat in gout patients with stage 4-5 chronic kidney disease not yet on dialysis. ( Kim, JM; Kim, SH; Lee, SY; Son, CN, 2020) |
| " Adherence to guidelines has not been well studied, and the correlation between uric acid reduction and clinically relevant outcomes, such as acute kidney injury, remains unclear." | 3.96 | Utilization patterns and clinical outcomes of rasburicase administration according to tumor risk stratification. ( Frieze, D; Garcia, DA; Khalighi, PR; Li, A; Li, S; Martens, KL; Silgard, E; White, AA, 2020) |
| "Plasma cysteine, glutamine, phenylalanine, threonine, and long-chain acylcarnitines are positively associated with incident hyperuricemia." | 3.96 | Associations of Amino Acid and Acylcarnitine Profiles With Incident Hyperuricemia in Middle-Aged and Older Chinese Individuals. ( Gao, X; Huo, S; Lin, X; Niu, Z; Sun, L; Sun, Q; Wang, F; Xiong, Q; Zeng, R; Zhang, H; Zong, G, 2020) |
| "To assess the association between the consumption of non-soy legumes and different subtypes of non-soy legumes and serum uric acid (SUA) or hyperuricemia in elderly individuals with overweight or obesity and metabolic syndrome." | 3.96 | Cross-sectional association between non-soy legume consumption, serum uric acid and hyperuricemia: the PREDIMED-Plus study. ( Abellán Cano, I; Alonso-Gómez, ÁM; Babio, N; Becerra-Tomás, N; Bernal-Lopez, MR; Bueno-Cavanillas, A; Casas, R; Cenoz, JC; Corbella, E; Corella, D; Crespo-Oliva, E; Daimiel, L; Del Mar Bibiloni, M; Díaz-López, A; Estruch, R; Fernandez-Brufal, N; Fernández-Carrión, R; Fernández-García, JC; Freixer, G; Gaforio, JJ; Lapetra, J; Llimona, R; López-Miranda, J; Martín-Sánchez, V; Martínez, JA; Martínez-González, MÁ; Matía-Martín, P; Mena-Sánchez, G; Morey, M; Navarrete-Muñoz, EM; Pintó, X; Prieto, RM; Quifer, M; Razquin, C; Romaguera, D; Ros, E; Ruiz-Canela, M; Salas-Salvadó, J; Salaverria Lete, I; Sanchez-Villegas, A; Santos-Lozano, JM; Serra-Majem, L; Sorli, JV; Tojal Sierra, L; Torres, L; Tur, JA; Vázquez, C; Vidal, J; Vioque, J; Wärnberg, J; Zulet, MÁ, 2020) |
| "The urate transporter-1 (URAT1) is crucial in developing hyperuricemia via reabsorption of uric acid in renal tubules, and its function is regulated by several single nucleotide polymorphisms (SNPs) within SLC22A12 gene encoding URAT1." | 3.91 | The association between genotypes of urate transporter-1, Serum uric acid, and mortality in the community-based population: the Yamagata (Takahata) Study. ( Ichikawa, K; Ishizawa, K; Kayama, T; Kon, S; Konta, T; Sato, H; Ueno, Y; Watanabe, M; Yamashita, H, 2019) |
| " This study found that lemon water soluble extract (LET) can reduce uric acid levels in mice with potassium oxonate induced hyperuricemia." | 3.91 | Effect of lemon water soluble extract on hyperuricemia in a mouse model. ( Chen, L; Li, JX; Li, M; Ma, ZC; Wu, JL, 2019) |
| " Therefore, we compared the effects of different EDG extracts (water, 50% ethanol and 95% ethanol) on serum uric acid concentrations in the hyperuricemia model mouse." | 3.91 | Constituents and Anti-Hyperuricemia Mechanism of Traditional Chinese Herbal Formulae Erding Granule. ( Chen, H; Du, W; Feng, Y; Li, G; Yang, S; Yang, W; Zhang, C; Zhang, W, 2019) |
| " On comparing with women showing normal uric acid levels, hyperuricemic parturients experienced significantly lower incidence of post-spinal hypotension (45." | 3.91 | Maternal hyperuricemia as a marker of post-spinal hypotension and uterine tone during cesarean delivery: a prospective observational study. ( Bhatia, N; Jain, K; Shanmugam, R; Sikka, P; Verma, I, 2019) |
| "There is limited evidence examining the relationship between elevated serum uric acid (sUA) concentration and heart failure (HF) in United States (US) adults." | 3.91 | Elevated Serum Uric Acid and Self-Reported Heart Failure in US Adults: 2007-2016 National Health and Nutrition Examination Survey. ( Churilla, JR; Guevara, L; Rand, BG; Richardson, MR; Stone, ML, 2019) |
| " Hyperuricemia was defined as serum uric acid ≥ 420 μmol/l for males and ≥ 360 μmol/l for females." | 3.91 | Visceral adipose accumulation increased the risk of hyperuricemia among middle-aged and elderly adults: a population-based study. ( Chen, L; Gao, P; Hua, F; Huang, X; Jiang, X; Wang, L; Wu, Y, 2019) |
| " The presence of hyperuricemia in the subjects was determined by measuring serum uric acid (SUA) concentration (SUA ≥6 mg/dL [male], SUA ≥7 mg/dL [female])." | 3.91 | The association between sedentary behavior, physical activity and hyperuricemia. ( Jin, YS; Kim, YS; Park, DY; Ryu, SH, 2019) |
| "In this study, we aimed to analyze the relationship between serum uric acid (UA) and microalbuminuria as a marker of renal injury in type 2 diabetes mellitus." | 3.91 | Is Uric Acid elevation a random finding or a causative agent of diabetic nephropathy? ( Aktas, G; Atak, BM; Duman, TT; Kocak, MZ; Savli, H, 2019) |
| "Gout is caused by deposition of monosodium urate crystals in joints when plasma uric acid levels are chronically elevated beyond the saturation threshold, mostly due to renal underexcretion of uric acid." | 3.91 | Hyperuricemia and gout caused by missense mutation in d-lactate dehydrogenase. ( Birk, OS; Drabkin, M; Gurevich, E; Halperin, D; Kadir, R; Landau, D; Perez, Y; Wormser, O; Yogev, Y; Zalk, R; Zarivach, R; Zeller, L, 2019) |
| "To analyze the efficacy and safety of benzbromarone in elderly hypertensive patients with hyperuricemia." | 3.91 | Clinical efficacy and safety of benzbromarone in elderly hypertensive patients with hyperuricemia. ( Gao, H, 2019) |
| "Reduced renal clearance of uric acid is a major contributor to hyperuricemia." | 3.91 | Population-specific factors associated with fractional excretion of uric acid. ( Dalbeth, N; Merriman, TR; Narang, RK; Phipps-Green, A; Stamp, LK; Vincent, Z, 2019) |
| "Hyperuricemia (HUA) is a metabolic disorder that occurs due to the overproduction or under-excretion of uric acid (UA) and is directly linked to the development of many life-threatening diseases." | 3.91 | Stevia residue extract increases intestinal uric acid excretion via interactions with intestinal urate transporters in hyperuricemic mice. ( Hossen, I; Mehmood, A; Raka, RN; Wang, C; Zhang, H; Zhao, L, 2019) |
| "This study aims to evaluate whether serum Bisphenol A (BPA) is a risk factor for hyperuricemia." | 3.91 | Serum Bisphenol A is an independent risk factor of hyperuricemia: A 6-year prospective study. ( Cheng, Q; Gao, R; Hu, J; Li, J; Li, Q; Luo, T; Ma, L; Peng, C; Qing, H; Wang, Y; Wang, Z; Yang, S; Yang, Y; Zhang, A; Zhang, L, 2019) |
| "5% potassium oxonate (an uricase inhibitor) to induce hyperuricemia." | 3.91 | Feeding-produced subchronic high plasma levels of uric acid improve behavioral dysfunction in 6-hydroxydopamine-induced mouse model of Parkinson's disease. ( Dohgu, S; Fukae, J; Kataoka, Y; Koga, M; Matsumoto, J; Nakashima, A; Takata, F; Tsuboi, Y; Yamauchi, A, 2019) |
| "This is a medical records review study of 348 hyperuricemia patients identified in 2015, as having been followed with serial uric acid measurements." | 3.91 | Effect of Uric Acid Control on Serum Creatinine. ( Block, C; Field, C; Li, Z; Taylor, T; Xie, J; Yamamoto, T, 2019) |
| "Hyperuricemia is associated with cardiovascular disease, but the relationship between uric acid (UA) and pulse pressure (PP) is unclear." | 3.91 | Gender difference in the relationship between uric acid and pulse pressure among Korean adults. ( Jung, EY; Kim, HS; Moon, AE; Park, CE; Sung, HH; Yoon, H, 2019) |
| "Serum uric acid (SUA) level was shown in various studies to be related to the presence of coronary artery disease and subsequent cardiovascular events." | 3.91 | Association of serum uric acid levels with SYNTAX score II and long term mortality in the patients with stable angina pectoris who undergo percutaneous coronary interventions due to multivessel and/or unprotected left main disease. ( Atalay, E; Burak, C; Çağdaş, M; Çağdaş, ÖS; Gürsoy, MO; Karabağ, Y; Karakoyun, S; Rencuzogullari, I; Tanboğa, HI; Yesin, M, 2019) |
| "The role of serum uric acid in ischemic stroke is controversial." | 3.91 | Association between serum uric acid and carotid disease in patients with atherosclerotic acute ischemic stroke. ( Arévalo-Lorido, JC; Carretero-Gómez, J; Robles Pérez-Monteoliva, NR, 2019) |
| "Uric acid to lymphocyte ratio, combining the effect of uric acid and lymphocyte count, produced more prognostic value in elderly patients with rheumatic heart disease undergoing valve replacement surgery, which could be considered as a preoperative risk-stratified method." | 3.91 | Joint effects of uric acid and lymphocyte count on adverse outcomes in elderly patients with rheumatic heart disease undergoing valve replacement surgery. ( Chen, WJ; Duan, CY; Geng, QS; Jiang, L; Qin, TH; Wei, XB; Yu, Y, 2019) |
| "Metformin is always used as the baseline antidiabetic therapy for patients with type 2 diabetes mellitus (T2DM) and hyperuricemia." | 3.91 | Effect of high uric acid on the disposition of metformin: in vivo and in vitro studies. ( Ma, Y; Rao, Z; Sun, X; Wu, X; Xi, D; Zhang, G, 2019) |
| "With co-treatment of potassium oxonate (PO) and xanthine sodium salt (XSS), a zebrafish larva model of acute hyperuricemia has been constructed for the first time." | 3.91 | A zebrafish (danio rerio) model for high-throughput screening food and drugs with uric acid-lowering activity. ( Li, Q; Wang, F; Xing, C; Zhang, Y, 2019) |
| " However, the dose-response effects of serum uric acid (SUA) on the prevalence of MetS and electrocardiographic left ventricular hypertrophy (LVH) are unclear." | 3.91 | The dose-response effects of uric acid on the prevalence of metabolic syndrome and electrocardiographic left ventricular hypertrophy in healthy individuals. ( Chang, WC; Chen, KH; Hwang, JJ; Liu, CW; Tseng, CK; Wu, YW, 2019) |
| "Hyperuricemia is an important risk factor for vascular inflammation, yet the potential mechanisms of uric acid (UA) in endothelial cells are not well understood." | 3.91 | Uric acid induced inflammatory responses in endothelial cells via up-regulating(pro)renin receptor. ( Cheng, Y; Gu, J; Jiang, Y; Li, H; Liu, Y; Lv, H; Yang, X, 2019) |
| "A retrospective cohort study was performed in early post-renal transplant recipients with new onset of hyperuricemia receiving febuxostat or allopurinol therapy." | 3.91 | Comparison of efficacy and safety between febuxostat and allopurinol in early post-renal transplant recipients with new onset of hyperuricemia. ( Chen, P; Chen, X; Fu, Q; Gao, X; Li, J; Liu, L; Shen, X; Wang, C, 2019) |
| " However, the relationship between uric acid (UA) and the risk of acute kidney injury (AKI) and mortality remain unresolved in hospitalized patients." | 3.91 | Hyperuricemia is associated with acute kidney injury and all-cause mortality in hospitalized patients. ( Chin, HJ; Han, SS; Joo, KW; Kang, MW; Kim, S; Na, KY, 2019) |
| "Serum uric acid (SUA), hyperuricemia (HUA) and gout are complex traits with relatively high heritability." | 3.91 | Common variants in the ( Cheng, X; Li, C; Li, X; Li, Z; Shi, Y; Wang, C; Zhou, Z, 2019) |
| "Hyperuricemia (HUA) is a universal metabolic disorder characterized by a high level of uric acid in the serum." | 3.91 | Hypouricemic and nephroprotective roles of anthocyanins in hyperuricemic mice. ( Jiang, X; Ling, W; Liu, Y; Luo, J; Pang, J; Qian, X; Wang, X; Xie, J; Xu, Z; Zhang, H, 2019) |
| "The association between uric acid (UA) and coronary artery disease (CAD) was controversial." | 3.91 | Association between serum uric acid levels and coronary artery disease in different age and gender: a cross-sectional study. ( Chen, L; Li, J; Qi, G; Shi, L; Sun, Y; Tian, W; Zhang, H; Zhao, S, 2019) |
| "The aim of this study was to assess the association between serum uric acid concentration (SUAC) and the parameters of the metabolic syndrome (MetS) and insulin resistance (IR)." | 3.91 | Associations Between Serum Uric Acid Concentrations and Cardiometabolic Risk and Renal Injury in Obese and Overweight Children ( Ersoy, B; Özalp Kızılay, D; Şen, S, 2019) |
| "To further explore the possibility of xanthine and hypoxanthine to be gout biomarkers as substitutes for uric acid." | 3.91 | Study on the diagnosis of gout with xanthine and hypoxanthine. ( Deng, B; Deng, M; Fei, X; Huang, Z; Wang, Y; Ye, L, 2019) |
| "Potassium oxonate (PO) was used to establish a mouse model of hyperuricemia." | 3.91 | Modified Chuanhu anti-gout mixture, a traditional Chinese medicine, protects against potassium oxonate-induced hyperuricemia and renal dysfunction in mice. ( Che, K; Fei, H; Hou, X; Wang, J; Wang, Y; You, W; Zou, Y, 2019) |
| "It has not been determined whether changes in serum uric acid (SUA) level are associated with incident metabolic syndrome (MetS)." | 3.91 | The Protective Effects of Increasing Serum Uric Acid Level on Development of Metabolic Syndrome. ( Bae, JC; Jee, JH; Jin, SM; Kim, JH; Lee, MK; Yu, TY, 2019) |
| " Total 220 antenatal women ≥34 weeks of gestation with 110 cases having hypertensive disorder of pregnancy and 110 controls with normal blood pressure were compared for maternal uric acid and calcium levels and maternal, perinatal outcomes." | 3.91 | Maternal serum uric acid and calcium as predictors of hypertensive disorder of pregnancy: A case control study. ( Kumar, N; Singh, AK, 2019) |
| " The RSGE treatment dose-dependently reduced PO- and MSU-induced paw edema, serum TNF-α, IL-1β, IL-6, IL-12, uric acid, and BUN, while significantly elevated serum IL-10, urinary uric acid and creatinine levels as compared with the respective values in the hyperuricemic and gouty mice group (vehicle group)." | 3.91 | Protective effects of Rhizoma smilacis glabrae extracts on potassium oxonate- and monosodium urate-induced hyperuricemia and gout in mice. ( Chang, Y; Liang, C; Liang, G; Nie, Y; Xiao, D; Zeng, S; Zhan, S; Zheng, Q; Zheng, X, 2019) |
| "This study investigated the association between serum uric acid (sUA) and stroke risk in men with hypertriglyceridemia." | 3.91 | Is serum uric acid a predictive factor for stroke in men with hypertriglyceridemia? ( Hsu, CY; Lai, YJ, 2019) |
| "Allopurinol is the first-line medication for hyperuricemia treatment." | 3.91 | Highly Acylated Anthocyanins from Purple Sweet Potato ( Ipomoea batatas L.) Alleviate Hyperuricemia and Kidney Inflammation in Hyperuricemic Mice: Possible Attenuation Effects on Allopurinol. ( Wang, Y; Yang, Y; Zhang, JL; Zhang, ZC; Zhou, Q, 2019) |
| "The prospective acute heart failure registry (AHEAD) was used to select 3160 hospitalized patients with a known level of uric acid (UA) who were discharged in a stable condition." | 3.91 | Hyperuricemia treatment in acute heart failure patients does not improve their long-term prognosis: A propensity score matched analysis from the AHEAD registry. ( Al-Hiti, H; Bambuch, M; Belohlavek, J; Benesova, K; Bohacova, S; Cihalik, C; Dostalova, G; Dusek, L; Fedorco, M; Felsoci, M; Fojt, R; Havranek, S; Jarkovsky, J; Kettner, J; Kruger, A; Linhart, A; Malek, F; Malek, J; Miklik, R; Mikusova, T; Monhart, Z; Ostadal, P; Parenica, J; Pavlusova, M; Pohludkova, L; Rohac, F; Spac, J; Spinar, J; Spinarova, L; Svobodová, I; Vaclavik, J; Vitovec, J; Vondrakova, D; Vyskocilova, K; Widimsky, P; Zeman, K, 2019) |
| "Few studies have investigated the sex-related associations between serum uric acid and depression." | 3.91 | Associations between serum uric acid and depression among middle-aged and elderly participants in China. ( Ding, G; Li, Y; Yu, D; Zhao, L, 2019) |
| "The treat-to-target approach for serum uric acid is the recommended model in gout management according to the 2012 American College of Rheumatology (ACR) guidelines." | 3.91 | Pharmacist-managed titration of urate-lowering therapy to streamline gout management. ( Bays, AM; Crawford, C; Huang, IJ; Liew, JW; Morcos, MB; Zuo, S, 2019) |
| "Although mizoribine (MZR) is used as an immunosuppressant after renal transplantation, the occurrence of hyperuricemia has been reported." | 3.91 | Hyperuricemia in Living Donor Kidney Transplantation Patients During Mizoribine Administration Caused Mainly by Changes in Kidney Function. ( Chen, XG; Liu, H; Shen, ZY; Shi, Y, 2019) |
| "Because the serum uric acid level increases as the glomerular filtration rate (GFR) decreases, hyperuricemia is associated with chronic kidney disease (CKD)." | 3.91 | Urate-lowering agents for asymptomatic hyperuricemia in stage 3 - 4 chronic kidney disease: Controversial role of kidney function. ( Jeon, HJ; Oh, J; Shin, DH, 2019) |
| " Therefore, this study aimed to evaluate the association between lead, cadmium and mercury exposure and hyperuricemia in the Korean general population." | 3.91 | Associations between blood lead, cadmium, and mercury levels with hyperuricemia in the Korean general population: A retrospective analysis of population-based nationally representative data. ( Jung, W; Kang, J; Kim, Y; Lihm, H, 2019) |
| "Hyperuricemia is a metabolic disease of the kidney that results in decreased uric acid excretion." | 3.91 | The Effects of Ginsenosides and Anserine on the Up-Regulation of Renal Aquaporins 1-4 in Hyperuricemic Mice. ( Kong, J; Su, H; Zhang, J; Zhang, Y, 2019) |
| " Urate oxidase (UOX) is a therapeutic enzyme that catalyzes the conversion of uric acid (UA) into a soluble metabolite, and it is used clinically for the treatment of hyperuricemia." | 3.91 | Co-delivery of therapeutic protein and catalase-mimic nanoparticle using a biocompatible nanocarrier for enhanced therapeutic effect. ( Jung, S; Kim, M; Kim, S; Kwon, I; Kwon, K; Park, J; Tae, G, 2019) |
| " The objective is to determine whether therapy with TNF inhibitors (TNFis) affects SUA levels in patients with systemic autoimmune rheumatic diseases (SARDs) and whether SUA changes correlate with pro-inflammatory cytokines or with the oxidative stress marker allantoin." | 3.91 | Serum uric acid increases in patients with systemic autoimmune rheumatic diseases after 3 months of treatment with TNF inhibitors. ( Hasikova, L; Herrmann, M; Hulejova, H; Kalikova, K; Kozlik, P; Mahajan, A; Pavlikova, M; Stiburkova, B; Zavada, J, 2019) |
| "Hyperuricemia significantly reduces the semen volume and total sperm count of infertile men, and the level of serum uric acid is closely related with semen quality." | 3.88 | [Hyperuricemia reduces semen parameters in infertile men]. ( An, XT; Cui, T; Han, RY; Ma, J; Wang, SS; Wang, XC; Zhang, ZD, 2018) |
| " Hyperuricemia was defined as a serum uric acid level >7 mg/dl for men and >6 mg/dl for women or allopurinol use." | 3.88 | Hyperuricemia is associated with an increased prevalence of paroxysmal atrial fibrillation in patients with type 2 diabetes referred for clinically indicated 24-h Holter monitoring. ( Bolzan, B; Bonapace, S; Bonora, E; Civettini, A; Dugo, C; Mantovani, A; Morani, G; Rigolon, R; Targher, G; Zoppini, G, 2018) |
| "The urate oxidase (Uox) gene encodes uricase that in the rodent liver degrades uric acid into allantoin, forming an obstacle for establishing stable mouse models of hyperuricemia." | 3.88 | Knockout of the urate oxidase gene provides a stable mouse model of hyperuricemia associated with metabolic disorders. ( Cheng, X; Cui, L; Hou, X; Jia, Z; Li, C; Li, X; Liu, Z; Lu, J; Ma, L; Mi, QS; Ren, W; Sun, R; Tian, Z; Wang, C; Wang, X; Xin, Y; Yuan, X; Zhang, K, 2018) |
| " laboratory evidence of kidney function decline (reference indicator), uric acid, and hypertension in different patient groups, separated according to their baseline uProt levels and baseline eGFR." | 3.88 | Effects of topiroxostat in hyperuricemic patients with chronic kidney disease. ( Hatakeyama, Y; Horino, T; Ichii, O; Inoue, K; Matsumoto, T; Okuhara, Y; Shimamura, Y; Terada, Y, 2018) |
| "This was a hospital-based prospective cohort study that included patients with ischemic stroke with baseline uric acid levels and 3-month post-stroke follow-up data." | 3.88 | The Prognostic Value of Serum Uric Acid in the Acute Phase of Ischemic Stroke in Black Africans. ( Ayeah, CM; Ba, H; Hentchoya, R; Luma, HN; Mapoure, YN, 2018) |
| "Heterogeneous results have been obtained in the relationship between serum uric acid (SUA) and target organ damage (TOD) in patients with hypertension." | 3.88 | Sex-related relationships between uric acid and target organ damage in hypertension. ( Casati, M; Falbo, R; Giannattasio, C; Grassi, G; Maggioni, S; Maloberti, A; Nava, S; Occhi, L; Panzeri, F; Signorini, S; Triglione, N, 2018) |
| "The role of serum uric acid (SUA) as a prognostic marker for incident heart failure (HF) in hypertensive subjects is uncertain." | 3.88 | Serum uric acid as a potential marker for heart failure risk in men on antihypertensive treatment: The British Regional Heart Study. ( Lennon, L; Papacosta, O; Wannamethee, SG; Whincup, PH, 2018) |
| "After oral administration of Dioscin in potassium oxonate (PO) induced hyperuricemia rats and adenine-PO induced hyperuricemia mice models, serum uric acid and creatinine levels, clearance of uric acid and creatinine, fractional excretion of uric acid, and renal pathological lesions were determined were used to evaluate the antihyperuricemic effects." | 3.88 | Effect and mechanism of dioscin from Dioscorea spongiosa on uric acid excretion in animal model of hyperuricemia. ( Chen, Q; Jin, L; Li, J; Liu, J; Wang, T; Wang, W; Yu, H; Zhang, Y, 2018) |
| "Insulin and uric acid were shown affect the prevalence of Metabolic Syndrome (MetS), but no studies examine their interaction." | 3.88 | Low serum uric acid concentration augments insulin effects on the prevalence of metabolic syndrome. ( Gonzalez-Mejia, ME; Pérez-Fuentes, R; Porchia, LM; Ruiz-Vivanco, G; Torres-Rasgado, E, 2018) |
| "Uric acid is best known for its role in gout-the most prevalent inflammatory arthritis in humans-that is also described as an unusual complication of anorexia nervosa (AN)." | 3.88 | Anorexia nervosa and uric acid beyond gout: An idea worth researching. ( Maas, J; Simeunovic Ostojic, M, 2018) |
| "Hyperuricemia is the term for an abnormally high serum uric acid level." | 3.88 | Antacids' side effect hyperuricaemia could be alleviated by long-term aerobic exercise via accelerating ATP turnover rate. ( Li, ZL; Yuan, S; Zhang, ZW, 2018) |
| " Serum uric acid (SUA) level and other clinical parameters were measured and hyperuricemia was defined as SUA level greater or equal to 360 umol/L in females and 420 umol/L in males." | 3.88 | Hyperuricemia in Asian psoriatic arthritis patients. ( Lai, TL; Leung, MC; Ng, WL; Wong, PY; Yim, CW, 2018) |
| " Hypoadiponectinemia has been documented in patients with hyperuricemia, however, whether soluble uric acid (SUA) regulates the expression of APN and APN receptor 1 (AdipoR1) in renal proximal tubule epithelial cells (PTECs) remains to be elucidated." | 3.88 | Uric acid upregulates the adiponectin‑adiponectin receptor 1 pathway in renal proximal tubule epithelial cells. ( Fu, C; Xiao, J; Yang, Q; Ye, Z, 2018) |
| "This narrative review aims to highlight recent findings on the relation between uric acid level and cognitive decline or dementia." | 3.88 | Uric acid and cognitive decline: a double-edge sword? ( Bardin, T; Latourte, A; Richette, P, 2018) |
| "Hyperuricemia is a risk factor for causing end-stage kidney disease and cardiovascular disease in the general population; however, several aspects, such as the site of kidney damaged by hyperuricemia and the threshold levels of serum uric acid for the development of renal damage, have not been fully clarified." | 3.88 | The Association between Serum Uric Acid and Renal Damage: The Takahata Study - New Insights. ( Ichikawa, K; Kamei, K; Kayama, T; Konta, T; Kubota, I, 2018) |
| "Although the clinical implication of hyperuricemia in chronic kidney disease has been an issue of active debate, recent data suggested a causative role of uric acid (UA) in the development of renal disease." | 3.88 | Hyperuricemia and Progression of Chronic Kidney Disease: Role of Phenotype Transition of Renal Tubular and Endothelial Cells. ( Kang, DH, 2018) |
| "The relationship between hyperuricemia and hypertensive disorders is well established; however, until today, the role of uric acid in the clinical course of severe preeclampsia has not been elucidated." | 3.88 | Uric Acid in Pregnancy: New Concepts. ( Briones Garduño, JC; Diaz de Leon Ponce, MA; Moreno Santillan, AA, 2018) |
| " Disturbance in purine metabolism pathway and a higher level of serum uric acid, called hyperuricemia, is a risk factor of CKD, and it has been linked to increased prevalence and progression of the disease." | 3.88 | Disturbed purine nucleotide metabolism in chronic kidney disease is a risk factor for cognitive impairment. ( Bhattacharjee, A; Borah, A; Mazumder, MK; Phukan, BC, 2018) |
| "Many studies have reported the independent association between uric acid and cardiovascular disease, its role as a risk predictor for outcomes in people with acute coronary syndrome remains controversial." | 3.88 | Hyperuricemia as a prognostic factor after acute coronary syndrome. ( Bertomeu-Gonzalez, V; Bertomeu-Martinez, V; Carratala-Munuera, C; Cordero, A; Gil-Guillen, VF; Lopez-Pineda, A; Orozco-Beltran, D; Quesada, JA, 2018) |
| "The purpose of this study was to examine the association between serum uric acid (sUA) and the incidence of hypertension in nonmetabolic syndrome (non-MetS) subjects." | 3.88 | Assessment of the association between serum uric acid levels and the incidence of hypertension in nonmetabolic syndrome subjects: A prospective observational study. ( Chen, Q; Chen, WY; Huang, X; Wu, JN; Yin, YJ, 2018) |
| "The relationship between serum uric acid (SUA) levels and stroke is controversial." | 3.88 | Serum uric acid levels and outcome during admission in acute ischaemic stroke, depending on renal function. ( Arévalo-Lorido, JC; Carretero-Gómez, J; Robles, NR, 2018) |
| "The objective of the present study was to evaluate clinical implications of serum uric acid (UA) on the progression of heart failure with preserved ejection fraction (HFpEF) in hypertensive patients." | 3.88 | Serum uric acid is associated with incidence of heart failure with preserved ejection fraction and cardiovascular events in patients with arterial hypertension. ( Fan, YQ; Gu, J; Wang, CQ; Zhang, HL; Zhang, JF, 2018) |
| "Conflicting results suggest a link between serum uric acid (SUA), inflammation and glucose/insulin homeostasis; however, the role of adiposity in this relationship is not clear." | 3.88 | The link between insulin resistance parameters and serum uric acid is mediated by adiposity. ( Banach, M; Katsiki, N; Mazidi, M; Mikhailidis, DP, 2018) |
| "To provide insight into pharmacological treatment of hyperuricemia we developed a semi-mechanistic, dynamical model of uric acid (UA) disposition in human." | 3.88 | Individualized treatment strategies for hyperuricemia informed by a semi-mechanistic exposure-response model of uric acid dynamics. ( Aksenov, S; Eriksson, UG; Peck, CC; Stanski, DR, 2018) |
| "Hyperuricemia was induced by potassium oxonate in male rats." | 3.88 | Hypouricemic and Nephroprotective Effects of an Active Fraction from Polyrhachis Vicina Roger On Potassium Oxonate-Induced Hyperuricemia in Rats. ( Chen, N; Chu, S; He, F; Li, D; Liao, L; Lu, W; Nong, Z; Su, H; Su, Q; Wang, L; Wei, B; Wei, G; Ya, Q; Zeng, X; Zhao, J, 2018) |
| "Elevated serum uric acid (sUA) concentrations have been associated with worse prognosis in heart failure (HF) but little is known about elderly patients." | 3.88 | Elevated serum uric acid concentration at discharge confers additive prognostic value in elderly patients with acute heart failure. ( Alunni, G; Ambrosio, G; Biagioli, P; Borghi, C; Carluccio, E; Coiro, S; D'Antonio, A; Girerd, N; Mengoni, A; Murrone, A; Zuchi, C, 2018) |
| "The present study suggests that luteolin and luteolin-4'-O-glucoside could be developed as therapeutics for treating hyperuricemia and gouty arthritis." | 3.88 | Luteolin-4'-O-glucoside and its aglycone, two major flavones of Gnaphalium affine D. Don, resist hyperuricemia and acute gouty arthritis activity in animal models. ( Hu, YJ; Liang, WQ; Lin, Y; Liu, PG; Pu, JB; Xu, P; Zhang, HJ; Zhou, J, 2018) |
| "Hyperuricemia induction in vivo resulted in cellular apoptosis, interstitial fibrosis and diastolic dysfunction in the rat hearts, as well as increased activation of calpain-1 and endoplasmic reticulum (ER) stress, while allopurinol treatment mitigated the above changes." | 3.88 | Uric Acid Induces Cardiomyocyte Apoptosis via Activation of Calpain-1 and Endoplasmic Reticulum Stress. ( Chen, K; He, L; Huang, D; Li, J; Li, S; Yan, M, 2018) |
| "Uric acid (UA), an antioxidant with neuroprotective effects, favorably affects stroke outcome." | 3.88 | Associations between Uric Acid Level and 3-Month Functional Outcome in Acute Ischemic Stroke Patients Treated with/without Edaravone. ( Ando, Y; Inatomi, Y; Naganuma, M; Nakajima, M; Yonehara, T, 2018) |
| " (i) Insulin is considered to stimulate uric acid reabsorption via specific transporter and the effect of hyperuricaemia on the new-onset T2DM should be evaluated by considering insulin resistance." | 3.88 | Hyperuricaemia and type 2 diabetes mellitus. ( Kawada, T, 2018) |
| " In a rat hyperuricemic model, treatment with Morin/HES-DOCA-NPs demonstrated superior therapeutic efficacy over Morin in decreasing serum uric acid level, increasing the uricosuric action, as well as attenuating hyperuricemia-associated inflammation in kidney of rats." | 3.88 | Preparation, characterization and systemic application of self-assembled hydroxyethyl starch nanoparticles-loaded flavonoid Morin for hyperuricemia therapy. ( Li, J; Lu, L; Ma, Q; Yang, Y; Zhang, J, 2018) |
| "In addition to the controversy regarding the association of hyperuricemia with cardiovascular disease (CVD) mortality, few studies have examined the impact of a low uric acid level on mortality." | 3.88 | U-Shaped Association Between Serum Uric Acid Level and Risk of Mortality: A Cohort Study. ( Chang, Y; Cho, SK; Kim, I; Ryu, S, 2018) |
| "Febuxostat is tolerable in chronic kidney disease (CKD) patients with hyperuricemia." | 3.88 | The impact of serum uric acid reduction on renal function and blood pressure in chronic kidney disease patients with hyperuricemia. ( Fujigaki, Y; Goto, D; Kato, A; Ohashi, N; Ohishi, K; Sato, T; Takeda, A; Tsuji, T; Yasuda, H, 2018) |
| " For each journal, articles relevant to gout and hyperuricaemia were identified by the search terms 'gout' and/or 'urate' and/or 'uric acid' using MEDLINE." | 3.88 | The nomenclature of the basic disease elements of gout: A content analysis of contemporary medical journals. ( Bursill, D; Dalbeth, N; Taylor, WJ; Terkeltaub, R, 2018) |
| "These findings indicated that increased uric acid levels probably associated with obesity and type 2 diabetes, and more definite research is needed to define any role for uric acid in relation to these diseases." | 3.88 | Temporal relationship between hyperuricemia and obesity, and its association with future risk of type 2 diabetes. ( Guo, X; Han, T; Li, Y; Liu, L; Ma, H; Meng, X; Na, L; Qu, R; Shan, R; Shi, D; Sun, C; Zhao, Y; Zi, T, 2018) |
| "The uric acid (UA) level in patients with gout is a key factor in disease management and is typically measured in the laboratory using plasma samples obtained after venous puncture." | 3.88 | Accuracy of the HumaSens ( Abrahamsson, A; Bardin, T; Clerson, P; Fabre, S; Gautier, JF; Hughes, G; Launay, JM; Miner, JN; Platt, A; Richette, P; Riveline, JP; Vidal-Trecan, T, 2018) |
| " Hyperuricemia is defined as a serum uric acid level of 7 mg/dL or more in men or 6 mg/dL or more in women." | 3.88 | Hyperuricemia Is Associated With a Higher Prevalence of Metabolic Syndrome in Military Individuals. ( Chang, WC; Chen, KH; Hwang, JJ; Lee, CC; Liu, CW; Wu, YW, 2018) |
| "As uncontrolled hyperuricemia has been associated with an increased risk of cardiovascular disease and the progression of chronic kidney disease (CKD), management of serum uric acid levels is important." | 3.88 | Effectiveness of febuxostat in patients with allopurinol-refractory hyperuricemic chronic kidney disease . ( Cho, YS; Han, N; Kim, YS; Kwak, CH; Oh, JM; Sohn, M, 2018) |
| "Previously, we formulated a PK-PD model for predicting the hypouricaemic effects of febuxostat as a function of baseline serum urate levels, body weight, renal function and drug dose, using datasets reported in preapproval studies." | 3.88 | Evaluation of a pharmacokinetic-pharmacodynamic model for hypouricaemic effects of febuxostat using datasets obtained from real-world patients. ( Echizen, H; Hirai, T; Itoh, T; Kimura, T, 2018) |
| "Three SNPs, URAT1 rs11231825, GLUT9 rs16890979 and ABCG2 rs2231142, previously associated in our population with hyperuricemia and gout, were analyzed in 27 patients with HPRT deficiency treated with allopurinol for at least 5 years." | 3.88 | GLUT9 influences uric acid concentration in patients with Lesch-Nyhan disease. ( Puig, JG; Torres, RJ, 2018) |
| " Because of the close connections between hyperuricemia and gout, we hypothesized that the effect of rs7903456 on gout might be mediated by hyperuricemia or its related quantitative trait, uric acid level." | 3.88 | Genetic association and functional analysis of rs7903456 in FAM35A gene and hyperuricemia: a population based study. ( Dai, Y; Sun, P; Yan, F; Zhang, N; Zhao, C; Zhao, H, 2018) |
| "Fraxini Cortex (also known as Qinpi, QP) has been used for the treatment of hyperuricemia with a significant difference on efficacy of QP from different regions." | 3.88 | Research on the pharmacodynamics and mechanism of Fraxini Cortex on hyperuricemia based on the regulation of URAT1 and GLUT9. ( Feng, L; Han, L; Jia, X; Li, C; Li, Z; Liu, J; Qiao, X; Song, J; Tan, X; Wang, G; Yuan, X; Zhang, X; Zhou, Y, 2018) |
| "Our objective was to determine if elevated uric acid (UA) is associated with postpartum hypertension (PP HTN) in women without chronic hypertension." | 3.88 | The association of hyperuricemia and immediate postpartum hypertension in women without a diagnosis of chronic hypertension. ( Dixon, L; Marrs, CC; Olson, G; Rahman, M, 2018) |
| "Hyperuricemia has been associated with cardiovascular risk factors but it remains controversial if uric acid is an independent predictor of cardiac mortality." | 3.88 | Risk factors for hyperuricemia in congenital heart disease patients and its relation to cardiovascular death. ( Martínez-Quintana, E; Riaño-Ruiz, M; Rodríguez-González, F; Rodríguez-Hernández, JL, 2018) |
| "According to multiple linear regression analysis, in hypertension group, fractional excretion of sodium (FEna) was negatively correlated with 24 hour urinary uric acid (24-hUur) and uric acid clearance rate (Cur) (beta coefficients [B]=-0." | 3.88 | The Association of Urinary Sodium and Potassium with Renal Uric Acid Excretion in Patients with Chronic Kidney Disease. ( Chen, W; Fu, C; Guo, H; Li, F; Lu, Y; Xiao, J; Ye, Z; Zhang, X; Zou, J, 2018) |
| "Uric acid is a molecule that is known to act as a natural antioxidant in acute oxidative stress conditions such as acute ischemic stroke (AIS)." | 3.88 | Can high uric acid levels be an independent risk factor for acute ischemic stroke due to large-artery atherosclerosis? ( Acar, AB; Acar, T; Gül, SS; Güzey Aras, Y, 2018) |
| "Subjects included 633 Japanese subjects not receiving medication for hyperuricemia, diabetes mellitus, dyslipidemia, or chronic renal disease who underwent an annual health examination that included determination of small, dense low-density lipoprotein cholesterol (sdLDL-C) and malondialdehyde-modified low-density lipoprotein (MDA-LDL) levels." | 3.88 | Low-density Lipoprotein Subclasses are Associated with Serum Uric Acid Levels. ( Moriyama, K, 2018) |
| "There is an ongoing debate regarding the relationship between uric acid and osteoarthritis (OA)." | 3.88 | Serum uric acid level is not associated with osteoarthritis in Korean population: data from the Seventh Korea National Health and Nutrition Examination Survey 2016. ( Choe, JY; Kim, SK; Kwak, SG, 2018) |
| "There is evidence that uric acid may have antioxidant and neuroprotective effects and might therefore alter the risk for neurodegenerative diseases such as dementia." | 3.88 | Hyperuricemia and dementia - a case-control study. ( Broich, K; Engel, B; Gomm, W; Haenisch, B; Maier, W; Weckbecker, K, 2018) |
| " We included 1416 subjects with complete data including serum uric acid and medical history to analyze the prevalence of hyperuricemia and correlated factors." | 3.88 | The prevalence of hyperuricemia and its correlates in Ganzi Tibetan Autonomous Prefecture, Sichuan Province, China. ( Chen, X; Diao, Y; Feng, J; Langtai, Z; Liao, H; Meng, Q; Renqian, L; Shi, D; Shi, R; Zhang, X, 2018) |
| " SUA was downregulated during acute gouty arthritis, which might be associated with increased urinary excretion of uric acid." | 3.88 | Renal excretion is a cause of decreased serum uric acid during acute gout. ( Cao, L; Guo, M; Lv, X; Wan, W; Xue, Y; Zhao, T; Zheng, S; Zhu, X; Zou, H, 2018) |
| "The serum uric acid (SUA) level and the prevalence of hyperuricemia markedly increased in women with PCOS." | 3.88 | Association between the prevalence of hyperuricemia and reproductive hormones in polycystic ovary syndrome. ( Chen, Q; Chen, X; Chen, Y; Huang, X; Mu, L; Pan, J; Tang, R; Teng, Y; Wang, P; Yang, H; Yang, L, 2018) |
| "The aim of the study was to assess the independent contribution of hyperuricemia to coronary artery disease (CAD) confirmed by coronary angiography (CAG), and to explore associations between serum uric acid (SUA) level and CAD." | 3.88 | Evaluation of the association between hyperuricemia and coronary artery disease: A STROBE-compliant article. ( He, Q; Lan, M; Liu, B, 2018) |
| " In this study, we used a mouse model of hyperuricemia, the Urahplt2/plt2 (PLT2) mouse, to investigate the effect of high uric acid levels on anti-tumor immune responses and tumor growth." | 3.88 | Hyperuricaemic UrahPlt2/Plt2 mice show altered T cell proliferation and defective tumor immunity after local immunotherapy with Poly I:C. ( Baey, C; Harper, JL; Ronchese, F; Yang, J, 2018) |
| " The association between chronic hepatitis C (CHC) and uric acid levels has rarely been investigated." | 3.88 | Association of hyperuricemia with disease severity in chronic hepatitis C patients. ( Chen, SC; Chuang, WL; Dai, CY; Hsieh, MH; Huang, CF; Huang, CI; Huang, JF; Jang, TY; Lin, ZY; Yeh, ML; Yu, ML, 2018) |
| "This work aims to explore the amelioration of fucoidan on adenine-induced hyperuricemia and hepatorental damage." | 3.88 | Production Inhibition and Excretion Promotion of Urate by Fucoidan from ( Li, Y; Liu, H; Luo, P; Zhang, D, 2018) |
| "We indicated that uric acid, AIP, and proteinuria are closely related." | 3.88 | Relationship Between Uric Acid, Proteinuria, and Atherogenic Index of Plasma in Renal Transplant Patients. ( Biyik, Z; Guney, I, 2018) |
| " Hyperuricemia was determined as serum uric acid level above 420 μmol/L in men and 360 μmol/L in women (N Engl J Med 359(17):1811-1821, 2008)." | 3.88 | Association between hyperuricemia and metabolic syndrome in patients suffering from bipolar disorder. ( Chen, H; Chen, J; Feng, J; Huang, XF; Jones, A; Li, J; Li, R; Tan, Y; Wang, S; Wilson, I; Yang, F; Zhang, L, 2018) |
| " We injected uric acid intraperitoneally, 125mg/kg/day for 7 days (UA7) and 14 days (UA14), to induce hyperuricemia and then gave allopurinol 50mg/kg/day for 7 days to lower serum uric acid levels (UA7AL7 and UA14AL7)." | 3.88 | Reduction of Serum Uric Acid Associated with Attenuation of Renal Injury, Inflammation and Macrophages M1/M2 Ratio in Hyperuricemic Mice Model. ( Arfian, N; Haryono, A; Nugrahaningsih, DAA; Romi, MM; Sari, DCR, 2018) |
| " The diagnostic value of changes in serum uric acid levels has been established in chronic heart failure, but no data are available on the prognostic value of hyperuricemia in a CRT population." | 3.88 | Hyperuricemia predicts adverse clinical outcomes after cardiac resynchronization therapy. ( Boros, AM; Gellér, L; Merkely, B; Perge, P; Széplaki, G; Zima, E, 2018) |
| "An association between ABCC4 and gout and fractional excretion of uric acid is consistent with the established role of MRP4 as a unidirectional renal uric acid efflux pump." | 3.85 | Population-Specific Resequencing Associates the ATP-Binding Cassette Subfamily C Member 4 Gene With Gout in New Zealand Māori and Pacific Men. ( Boocock, J; Cadzow, M; Choi, HK; Dalbeth, N; Dobbyn, A; Hindmarsh, JH; Mandal, AK; Merriman, TR; Mount, DB; Phipps-Green, AJ; Stahl, EA; Stamp, LK; Tanner, C; Topless, RK, 2017) |
| " were tested in vivo using the model oxonate-induced hyperuricemia rats through determination of serum uric acid levels and inhibitory effects on xanthine oxidase (XO) in the rat liver." | 3.85 | Anti-Hyperuricemic, Anti-Inflammatory and Analgesic Effects of Siegesbeckia orientalis L. Resulting from the Fraction with High Phenolic Content. ( Hoang, TK; Hwang, IH; Na, M; Nguyen, HA; Nguyen, MK; Nguyen, TD; Thuong, PT, 2017) |
| "The mean eGFR was statistically significantly lower in patients with hyperuricemia than in those with normal uric acid levels (143 vs." | 3.85 | Evaluating risk factors for chronic kidney disease in pediatric patients with sickle cell anemia. ( Cutter, GR; Feig, DI; Howard, TH; Lebensburger, JD; Muntner, P, 2017) |
| "Gout is caused by elevated serum urate levels, which can be treated using inhibitors of the uric acid transporter, URAT1." | 3.85 | Discovery and characterization of verinurad, a potent and specific inhibitor of URAT1 for the treatment of hyperuricemia and gout. ( Gunic, E; Liu, S; Miner, JN; Tan, PK, 2017) |
| " affine extract was evaluated in an experimental model with potassium oxonate (PO) induced hyperuricemia in mice which was used to evaluate anti-hyperuricemia activity and xanthine oxidase (XO) inhibition." | 3.85 | Effects of Gnaphalium affine D. Don on hyperuricemia and acute gouty arthritis. ( Cheng, L; Hu, YJ; Li, LN; Liang, WQ; Liu, PG; Pu, JB; Xu, P; Yang, QQ; Zhang, HJ; Zhang, YQ; Zhou, J, 2017) |
| "The objective of this study is to determine the serum uric acid (SUA) level and the prevalence of hyperuricemia (HUA) in Chinese population." | 3.85 | Prevalence and risk factors of hyperuricemia: results of the Kailuan cohort study. ( Cui, L; Li, Z; Meng, L; Mu, R; Wang, G; Wu, S; Yuan, X, 2017) |
| " As a consequence, the bioengineered hybrid hydrogel normalized the serum uric acid level in hypoxanthine/potassium oxonate-induced hyperuricemia mice, and no obvious side effects were observed in the major organs." | 3.85 | Bioengineered robust hybrid hydrogels enrich the stability and efficacy of biological drugs. ( Cho, J; Giang Phan, VH; Gil, MS; Kwon, I; Lee, DS; Thambi, T, 2017) |
| "Metabolic Syndrome (Mets) and increased serum uric acid (SUA), are well known renal risk predictors and often coexist in patients with type 2 diabetes (T2D)." | 3.85 | Metabolic syndrome, serum uric acid and renal risk in patients with T2D. ( Ceriello, A; De Cosmo, S; Fioretto, P; Genovese, S; Giorda, C; Guida, P; Piscitelli, P; Pontremoli, R; Russo, G; Viazzi, F, 2017) |
| "Little is known about the relationship serum uric acid (SUA) and hypertension in Chinese population." | 3.85 | An observational study on the relationship between serum uric acid and hypertension in a Northern Chinese population aged 45 to 59 years. ( Cheng, HY; Huang, XL; Liu, SS; Shi, YX; Yu, FN, 2017) |
| "Febuxostat has currently played pivotal role in the treatment of hyperuricemia, but there is little comprehensive information for the determinants of individual difference in efficacy of febuxostat." | 3.85 | Previous Dosage of Allopurinol Is a Strong Determinant of Febuxostat Efficacy. ( Hira, D; Ikeda, Y; Katsube, Y; Koide, H; Minegaki, T; Morita, SY; Nishiguchi, K; Terada, T; Tsujimoto, M; Uzu, T, 2017) |
| "Resveratrol contributes to URAT1 expression, which is potentially useful in therapeutic strategies aimed at treating hyperuricemia." | 3.85 | Negative correlation between serum uric acid and kidney URAT1 mRNA expression caused by resveratrol in rats. ( Chang, LC; Lee, CT; Liu, CW; Wu, PF, 2017) |
| "Hyperuricemia is a clinical condition characterized by an elevated level of serum uric acid and is a key risk factor for the development of gout and metabolic disorders." | 3.85 | Salvia plebeia Extract Inhibits Xanthine Oxidase Activity In Vitro and Reduces Serum Uric Acid in an Animal Model of Hyperuricemia. ( Choi, CW; Choi, Y; Hong, SS; Hyun, JM; Kim, JK; Kim, P; Kim, WJ; Kwon, JG; Lee, JK; Lee, JS; Park, K; Seo, C; Song, MJ; Sung, H, 2017) |
| " One-hundred and seventy-eight CKD patients with hyperuricemia who received febuxostat therapy were included in this study." | 3.85 | Identification of chronic kidney disease patient characteristics influencing the renoprotective effects of febuxostat therapy: a retrospective follow-up study. ( Harada, M; Hashimoto, K; Kamijo, Y; Yamada, Y; Yamaguchi, A, 2017) |
| "An elevated level of serum uric acid-hyperuricemia, is strongly associated with the development of gout and chronic kidney disease (CKD) which is often accompanied by a significantly reduced glomerular filtration rate (GFR)." | 3.85 | Oral uricase eliminates blood uric acid in the hyperuricemic pig model. ( Goncharova, K; Grujic, D; Lozinska, L; Mosiichuk, N; Pierzynowski, SG; Pieszka, M; Święch, E; Szczurek, P; Woliński, J; Yatsenko, T, 2017) |
| " pensylvanicum extract showed activity in reducing serum uric acid (Sur) through effect renal glucose transporter 9 (GLUT9), organic anion transporter 1 (OAT1) and urate transporter 1 (URAT1) mainly and inhibited XO activity in vivo of mice with PO induced hyperuricemia." | 3.85 | Caffeoylquinic acid derivatives rich extract from Gnaphalium pensylvanicum willd. Ameliorates hyperuricemia and acute gouty arthritis in animal model. ( Hu, YJ; Jiang, Y; Lin, Y; Pan, HH; Song, XJ; Zhang, HJ, 2017) |
| "Previous studies have examined the association between elevated serum uric acid (SUA) level and hypertension; however, the association in the Chinese elderly is still uncertain." | 3.85 | Association between serum uric acid level and hypertension in a Chinese elderly rural population. ( He, Y; Jiang, B; Liu, M; Wang, J; Wang, Y; Wu, L; Zeng, J; Zhang, D, 2017) |
| "The present study aimed to identify a potential association between serum UA and cardiac troponin I (cTnI) levels and to find out whether uric acid could differentiate patients presenting with the acute myocardial infarction (AMI) and unstable angina pectoris (UAP) in hyperuricemic and normouricemic acute coronary syndrome (ACS) patients." | 3.85 | Serum Uric Acid Could Differentiate Acute Myocardial Infarction and Unstable Angina Pectoris in Hyperuricemic Acute Coronary Syndrome Patients. ( Hasic, S; Jadric, R; Kadic, D; Kiseljakovic, E; Spahic, E, 2017) |
| " Patients in the 3rd serum uric acid tertile had a higher prevalence of any cardiac conduction defects than those belonging to 2nd or 1st tertile, respectively (35." | 3.85 | Relation of elevated serum uric acid levels to first-degree heart block and other cardiac conduction defects in hospitalized patients with type 2 diabetes. ( Bonapace, S; Bonora, E; Dugo, C; Mantovani, A; Morani, G; Pichiri, I; Rigolon, R; Targher, G; Zoppini, G, 2017) |
| "Previous studies found elevated serum uric acid (SUA) was associated with the development or progression of non-alcoholic fatty liver disease (NAFLD) in general population; in this study we aim to investigate the association of SUA and the severity of NAFLD based on grade of fatty liver on ultrasonography in non-obese subjects." | 3.85 | Serum uric acid and non-alcoholic fatty liver disease in non-obesity Chinese adults. ( Chen, H; Gong, L; Luo, R; Peng, B; Ren, W; Wang, Y; Zheng, X, 2017) |
| "Uric acid (UA) plays important roles in inducing renal inflammation, intra-renal vasoconstriction and renal damage." | 3.85 | Uric acid causes kidney injury through inducing fibroblast expansion, Endothelin-1 expression, and inflammation. ( Arfian, N; Romi, MM; Sari, DCR; Setyaningsih, WAW; Tranggono, U, 2017) |
| "To investigate the effects of gender on the association of serum uric acid (SUA) levels and atrial fibrillation (AF) prevalence in a community-based Chinese population." | 3.85 | Association between serum uric acid and atrial fibrillation: a cross-sectional community-based study in China. ( Chen, Y; Han, X; Liu, H; Liu, Y; Qiu, J; Xia, Y; Yang, Y; Yin, X; Zhou, Y, 2017) |
| "Hyperuricemia leads to insulin resistance, whereas insulin resistance decreases renal excretion of uric acid, both mechanisms link elevated serum uric acid with metabolic syndrome." | 3.85 | Circulating Levels of Uric Acid and Risk for Metabolic Syndrome. ( Durán-Salgado, MB; Garro-Almendaro, AK; Huerta-Ramírez, S; Lozano-Nuevo, JJ; Morales-López, H; Rubio-Guerra, AF; Vargas-Ayala, G, 2017) |
| "Hyperuricemia and angiotensin II (Ang II) may have a pathogenetic role in the development of hypertension and atherosclerosis as well as cardiovascular disease (CVD) and its prognosis." | 3.85 | Uric acid stimulates proliferative pathways in vascular smooth muscle cells through the activation of p38 MAPK, p44/42 MAPK and PDGFRβ. ( Çetin, A; Kırça, M; Oğuz, N; Uzuner, F; Yeşilkaya, A, 2017) |
| " This study investigated the association between serum uric acid and the incidence of nonfatal stroke in a Japanese community-based population." | 3.85 | Associations between serum uric acid levels and the incidence of nonfatal stroke: a nationwide community-based cohort study. ( Asahi, K; Fujimoto, S; Hirayama, A; Ichikawa, K; Iseki, K; Kamei, K; Kasahara, M; Kondo, M; Konta, T; Kubota, I; Moriyama, T; Narita, I; Shibagaki, Y; Tsuruya, K; Watanabe, T; Yamagata, K, 2017) |
| "Prenatal exposure to the earthquake was associated with higher serum uric acid and higher odds of hyperuricemia in early adulthood." | 3.85 | Prenatal Earthquake Exposure and Midlife Uric Acid Levels Among Chinese Adults. ( Cai, J; Cheng, FW; Cui, L; Curhan, GC; Gao, X; Ji, C; Li, Y; Shi, J; Wu, S, 2017) |
| "Serum uric acid (SUA) has been associated to incident hypertension and increased risk of cardiovascular diseases." | 3.85 | High serum uric acid is associated to poorly controlled blood pressure and higher arterial stiffness in hypertensive subjects. ( Borghi, C; Cicero, AF; D'Addato, S; Fogacci, F; Grandi, E; Rosticci, M, 2017) |
| "Atherosclerosis induces the elevation of uric acid (UA), and an elevated UA level is well known to lead to a poor prognosis in patients with acute heart failure (AHF)." | 3.85 | Are atherosclerotic risk factors associated with a poor prognosis in patients with hyperuricemic acute heart failure? The evaluation of the causal dependence of acute heart failure and hyperuricemia. ( Asai, K; Hata, N; Kobayashi, N; Matsushita, M; Nishigoori, S; Okazaki, H; Shibata, Y; Shibuya, J; Shimizu, W; Shinada, T; Shiomura, R; Shirakabe, A; Yamamoto, Y, 2017) |
| "The influence of serum urate on kidney disease is attracting attention, but the effects of uric acid (UA) on nephrosclerosis have not been elucidated." | 3.85 | Hyperuricemia as a Predictive Marker for Progression of Nephrosclerosis: Clinical Assessment of Prognostic Factors in Biopsy-Proven Arterial/Arteriolar Nephrosclerosis. ( Kataoka, H; Mochizuki, T; Momoki, K; Moriyama, T; Nitta, K, 2017) |
| "The relationship between serum uric acid (SUA) and atrial fibrillation (AF) remains unclear because many parameters and diseases influence AF." | 3.85 | Hyperuricemia is an independent competing risk factor for atrial fibrillation. ( Hisatome, I; Kario, K; Kuwabara, M; Nishi, Y; Nishihara, S; Niwa, K; Takahashi, O; Yamamoto, K; Yamashita, T, 2017) |
| "Objective To explore the possible correlation between uric acid levels and leukoaraiosis (LA)." | 3.85 | The association of uric acid with leukoaraiosis. ( Cai, RW; Chen, YF; Huang, YH; Li, JJ; Li, MM; Lin, YY, 2017) |
| "The aim of the study was to compare reductions in uric acid (UA), length of stay (LOS), and hospitalization costs in patients with tumor lysis syndrome (TLS) treated with rasburicase or allopurinol." | 3.85 | A Clinical and Economic Comparison of Rasburicase and Allopurinol in the Treatment of Patients With Clinical or Laboratory Tumor Lysis Syndrome. ( Cairo, MS; Eaddy, MT; Tangirala, K; Thompson, S, 2017) |
| " Fifty patients with hyperuricemia defined as a serum uric acid greater than 7 mg/dL (average of ~9 mg/dL), newly started on allopurinol for any reason, with evidence of treatment compliance, were matched by age, race, sex, and estimated glomerular filtration rate (EGFR) to 50 hyperuricemic control subjects." | 3.85 | The Effect of Allopurinol on Renal Function. ( Blumenthal, D; Gerber, D; Krishnamurthy, A; Lazaro, D; Patel, S; Stefanov, DG, 2017) |
| " Cox regression analysis showed that the baseline clinical and biochemical variables which associated with MACE were age, being illiterate, a widow or widower, and/or economically dependent, having triple vessel disease, stent implantation, anemia, and/or diabetes mellitus, waist to hip ratio (WHR), diastolic blood pressure, fasting glucose, total cholesterol, high-density lipoprotein cholesterol (HDL-C), creatinine, estimated glomerular filtration rate (eGFR), red blood cell count, hemoglobin, hematocrit, and mean corpuscular-hemoglobin concentration (MCHC) in ACS patients, and age, malnourished, and/or economically dependent, taking hypoglycemic medication, having triple vessel disease, stent implantation, anemia, diabetes mellitus, and/or hypertension, WHR, fasting glucose, HDL-C, uric acid, creatinine, eGFR, high-sensitivity C-reactive protein, mean corpuscular volume, and MCHC in elective PCI patients." | 3.85 | The burden of major adverse cardiac events in patients with coronary artery disease. ( Chung, FM; Hsu, CC; Hung, WC; Lee, YJ; Lu, LF; Lu, YC; Tsai, IT; Wang, CP; Wu, CC; Yu, TH, 2017) |
| "Uric acid (UA) may not only prevent development of cognitive dysfunction owing to its antioxidant efficacy, but also may worsen cognitive functions by gaining pro-oxidant character." | 3.85 | Uric acid may be protective against cognitive impairment in older adults, but only in those without cardiovascular risk factors. ( Isik, AT; Kaya, D; Soysal, P; Tuven, B; Unutmaz, G, 2017) |
| "To evaluate the effect of hyperuricemia (HU) on subclinical changes of left ventricle (LV) function and structure in patients with hypertension (HT) using three-dimensional speckle-tracking echocardiography (3DSTE) and to explore the relationships between serum uric acid (SUA) levels and three-dimensional speckle tracking echocardiography (3DSTE) parameters in hypertensive and nonhypertensive patients with HU." | 3.85 | Assessment of subclinical left ventricular changes in essential hypertensive patients with hyperuricemia: A three-dimensional speckle-tracking echocardiography study. ( Chen, Y; Fang, X; Jiang, L; Pan, C; Shu, X; Sun, M; Wang, X; Zhang, Z, 2017) |
| "To explore the effects of Rhizoma Polygoni Cuspidati and Ramulus Cinnamomi compatibility (PR) on uric acid metabolism and the expression of urinary neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury molecule-1 (KIM-1) in rats with hyperuricemia." | 3.85 | Effect of Rhizoma Polygoni Cuspidati and Ramulus Cinnamomi compatibility on uric acid metabolism and urinary neutrophil gelatinase-associated lipocalin and kidney injury molecule-1 in rats with hyperuricemia. ( Han, B; Hu, XG; Huang, HZ; Lei, M; Li, Z; Shi, W; Zhou, XM; Zhu, CX, 2017) |
| "The association of serum uric acid (SUA) with risk of hypertension is controversial and may be modulated by lifestyle factors." | 3.85 | Regular physical activity prevents development of hypertension in young people with hyperuricemia. ( Casiglia, E; Fania, C; Garavelli, G; Mos, L; Palatini, P; Saladini, F, 2017) |
| "The objective was to determine whether serum uric acid concentrations were associated with metabolic syndrome in a population from Wuhan." | 3.85 | Positive association between metabolic syndrome and serum uric acid in Wuhan. ( Chen, M; Fan, ZF; Fu, YQ; Li, D; Wang, L; Yang, H; Zeng, W; Zeng, XY; Zheng, JS, 2017) |
| " Therefore, in this study, we investigated one-pot enzyme-nanozyme cascade reactions using urate oxidase (UOX) and catalase-mimic gold nanoparticle nanozyme (AuNP) with the ultimate goal of treatment of hyperuricemia." | 3.85 | Synergistic Degradation of a Hyperuricemia-Causing Metabolite Using One-Pot Enzyme-Nanozyme Cascade Reactions. ( Jung, S; Kwon, I, 2017) |
| "Potassium oxonate, a selectively competitive uricase inhibitor, produced hyperuricemia (HUA) in rodents in a previous study." | 3.85 | Potassium oxonate induces acute hyperuricemia in the tree shrew (tupaia belangeri chinensis). ( Li, ZL; Ma, KL; Tang, DH; Wang, CY; Ye, YS; Zheng, H, 2017) |
| "Associations between high serum uric acid (SUA) levels and high blood pressure (BP), as well as between SUA levels and metabolic syndrome (MetS) have already been reported." | 3.83 | Uric acid blood levels and relationship with the components of metabolic syndrome in hypertensive patients. ( Kalogeropoulos, P; Karamanou, AG; Moustakas, G; Papavasileiou, MV; Patsianis, S; Pittaras, A, 2016) |
| " Hyperuricemia was defined as a serum uric acid level >7 mg/dl for men and >6 mg/dl for women or allopurinol use." | 3.83 | Hyperuricemia is associated with an increased prevalence of atrial fibrillation in hospitalized patients with type 2 diabetes. ( Bergamini, C; Bonora, E; Mantovani, A; Pernigo, M; Pichiri, I; Rigolon, R; Targher, G; Zoppini, G, 2016) |
| "This cross-sectional study from January 2012 to December 2012 aimed to examine the sex-specific association between serum uric acid (SUA) levels/hyperuricemia and hypertension among Japanese patients." | 3.83 | Association Between Serum Uric Acid Levels/Hyperuricemia and Hypertension Among 85,286 Japanese Workers. ( Fujibayashi, K; Fukuda, H; Hisaoka, T; Isonuma, H; Jose, PA; Matsuo, H; Miwa, Y; Naito, T; Nakayama, A; Sanada, H; Suzuki, A; Uehara, Y; Yokokawa, H, 2016) |
| "The objective of this paper is to assess whether pulmonary hypertension (PH) may be detected at one point in time or longitudinally predicted by serum uric acid (sUA) levels in systemic lupus erythematosus (SLE)." | 3.83 | Levels of uric acid may predict the future development of pulmonary hypertension in systemic lupus erythematosus: a seven-year follow-up study. ( Amezcua-Guerra, LM; Castillo-Martínez, D; Juárez, M; Lozada-Navarro, AC; Marroquín-Fabián, E; Mora-Ramírez, M; Sánchez-Muñoz, F; Sandoval, J; Vargas-Barrón, J, 2016) |
| " Hyperuricemia was defined as serum uric acid level >7." | 3.83 | Association of Visceral Fat and Liver Fat With Hyperuricemia. ( Boyko, EJ; Endo, G; Fujimoto, WY; Hayashi, T; Hikita, Y; Kinuhata, S; Sato, KK; Uehara, S; Yamada, A, 2016) |
| "Serum uric acid (SUA) is the end-product of purine metabolism in humans, and its levels often increase in subjects with metabolic syndrome (MetS)." | 3.83 | High serum uric acid levels increase the risk of metabolic syndrome in elderly women: The PRO.V.A study. ( Crepaldi, G; Giantin, V; Maggi, S; Manzato, E; Maselli, M; Musacchio, E; Perissinotto, E; Sartori, L; Sergi, G; Toffanello, ED; Veronese, N; Zambon, S; Zurlo, A, 2016) |
| "Psoriasis has been reported to be associated with raised serum uric acid levels and gout, and uric acid has been demonstrated to mediate inflammatory pathways via secretion of pro-inflammatory chemokines." | 3.83 | Psoriasis and uric acid: a population-based cross-sectional study. ( Lai, YC; Yew, YW, 2016) |
| " As hyperuricemia activates platelet turnover, aspirin resistance may be specifically induced by increased serum uric acid (SUA) levels." | 3.83 | Does high serum uric acid level cause aspirin resistance? ( Alihanoglu, YI; Bilgin, M; Ergin, A; Esin, F; Evrengul, H; Kaftan, HA; Kilic, ID; Ozkan, E; Ozkan, H; Yildiz, BS, 2016) |
| "To examine the cross-sectional associations of the serum uric acid level and hyperuricemia (HU) with the radiographic features of osteoarthritis (OA), including osteophytes (OST) and joint space narrowing (JSN), a total of 4685 subjects were included in this study." | 3.83 | The associations of serum uric acid level and hyperuricemia with knee osteoarthritis. ( Ding, X; Gao, SG; Lei, GH; Li, H; Li, YS; Wei, J; Xiong, YL; Yang, T; Zeng, C; Zhang, Y, 2016) |
| "In this cross-sectional study, consecutive inpatients with a non-ST elevation acute coronary event and asymptomatic hyperuricemia (serum uric acid concentration of ≥7." | 3.83 | Silent Monosodium Urate Crystal Deposits Are Associated With Severe Coronary Calcification in Asymptomatic Hyperuricemia: An Exploratory Study. ( Andrés, M; Pascual, E; Quintanilla, MA; Ruiz-Nodar, JM; Sánchez-Payá, J; Sivera, F; Vela, P, 2016) |
| "Anti-hyperuricemic effect was investigated using xanthine oxidase assay and uricosuric studies with rats in which hyperuricemia was induced by potassium oxonate and uric acid." | 3.83 | Effects of Pimenta pseudocaryophyllus extracts on gout: Anti-inflammatory activity and anti-hyperuricemic effect through xantine oxidase and uricosuric action. ( Antunes Saúde-Guimarães, D; Barros, CH; de Paula Michel Araújo, MC; Ferrari, FC; Lemos Lima, Rde C; Schimith Ferraz Filha, Z, 2016) |
| "Serum uric acid level is regulated by gender, dietary habit, genetic predisposition, and renal function, and is associated with the development of renal and cardiovascular diseases." | 3.83 | Serum uric acid levels and mortality in the Japanese population: the Yamagata (Takahata) study. ( Hirayama, A; Ichikawa, K; Kabasawa, A; Kamei, K; Kato, T; Kayama, T; Konta, T; Kubota, I; Sato, H; Shibata, Y; Suzuki, K; Suzuki, N; Ueno, Y; Watanabe, T, 2016) |
| "Longitudinal changes in uric acid levels were independently associated with the renal function decline in elderly patients with hypertension." | 3.83 | Influence of changes in serum uric acid levels on renal function in elderly patients with hypertension: a retrospective cohort study with 3.5-year follow-up. ( Chen, H; Huang, F; Lin, C; Lin, F; Zhang, H; Zhu, P, 2016) |
| "The mechanisms by which weight loss decreases serum uric acid (SUA) levels are poorly known." | 3.83 | Weight Loss, Xanthine Oxidase, and Serum Urate Levels: A Prospective Longitudinal Study of Obese Patients. ( Bardin, T; Bouillot, JL; Clément, K; Denis, J; Manivet, P; Oppert, JM; Poitou, C; Richette, P, 2016) |
| "A metabolic syndrome (MetS) is accompanied by hyperuricemia, during which xanthine oxidoreductase (XOR) catalyzes the production of uric acid." | 3.83 | Xanthine oxidoreductase activation is implicated in the onset of metabolic arthritis. ( Aibibula, Z; Ailixiding, M; Asou, Y; Hara, Y; Iwata, M; Okawa, A; Piao, J, 2016) |
| "This study sought to observe the effects of allopurinol on the cardiac function of non-hyperuricaemic patients with chronic heart failure and determine the safety of allopurinol for clinical applications." | 3.83 | Allopurinol ameliorates cardiac function in non-hyperuricaemic patients with chronic heart failure. ( Deng, SB; Kao, GY; Li, J; Ma, Y; She, Q; Wang, JS; Xiao, J, 2016) |
| " The simple definition had similar performance to a SUGAR data-driven case definition with 5 weighted items: self-report, self-report of doctor diagnosis, colchicine use, urate-lowering therapy use, and hyperuricemia (sensitivity 87%, specificity 70%)." | 3.83 | Survey Definitions of Gout for Epidemiologic Studies: Comparison With Crystal Identification as the Gold Standard. ( Brown, M; Cavagna, L; Chen, JH; Chou, YY; Cimmino, MA; da Rocha Castelar-Pinheiro, G; Dalbeth, N; Ea, HK; Eliseev, M; Fransen, J; Gerritsen, M; Jansen, TL; Janssen, M; Lin, C; Louthrenoo, W; McCarthy, G; Neogi, T; Perez-Ruiz, F; Schumacher, HR; Scire, CA; Sivera, F; Stamp, LK; Tausche, AK; Taylor, WJ; Uhlig, T; Vazquez-Mellado, J, 2016) |
| "Elevated uric acid (UA) is associated with the presence of the metabolic syndrome (MetS)." | 3.83 | Overweight modifies the longitudinal association between uric acid and some components of the metabolic syndrome: The Tromsø Study. ( Eriksen, BO; Jenssen, TG; Norvik, JV; Solbu, MD; Storhaug, HM; Ytrehus, K; Zykova, SN, 2016) |
| "Whether renal dysfunction influences the hypouricemic effect of febuxostat, a xanthine oxidase (XO) inhibitor, in patients with hyperuricemia due to overproduction or underexcretion of uric acid (UA) remains unclear." | 3.83 | Modeling and Simulation for Estimating the Influence of Renal Dysfunction on the Hypouricemic Effect of Febuxostat in Hyperuricemic Patients Due to Overproduction or Underexcretion of Uric Acid. ( Echizen, H; Hirai, T; Kimura, T, 2016) |
| "The serum level of uric acid (UA) is a well-known prognostic factor for heart failure (HF) patients." | 3.83 | The prognostic impact of uric acid in patients with severely decompensated acute heart failure. ( Asai, K; Hata, N; Kobayashi, N; Matsushita, M; Nishigoori, S; Okazaki, H; Shibuya, J; Shimizu, W; Shinada, T; Shiomura, R; Shirakabe, A; Yamamoto, Y, 2016) |
| "Fish consumption is a recognized risk factor for elevated serum uric acid (UA) levels, hyperuricemia, and gout." | 3.83 | The consumption of fish cooked by different methods was related to the risk of hyperuricemia in Japanese adults: A 3-year follow-up study. ( Cui, Y; Huang, C; Momma, H; Nagatomi, R; Niu, K; Ren, Z; Sugiyama, S, 2016) |
| "Allopurinol is a commonly used medication to treat hyperuricemia and its complications." | 3.83 | Hypouricemic effect of allopurinol are improved by Pallidifloside D based on the uric acid metabolism enzymes PRPS, HGPRT and PRPPAT. ( Anderson, S; He, Y; Hou, PY; Li, HG; Wang, SQ; Wu, XH; Zhang, J; Zhang, X; Zhang, YW, 2016) |
| " The effects and possible molecular mechanisms of astilbin on potassium oxonate-induced hyperuricemia mice were investigated in this study." | 3.83 | Astilbin improves potassium oxonate-induced hyperuricemia and kidney injury through regulating oxidative stress and inflammation response in mice. ( Chen, J; Wang, M; Zhang, N; Zhao, J, 2016) |
| "Both the serum uric acid (SUA) level and elevated alanine aminotransferase (ALT) are related to metabolic syndrome." | 3.83 | Association between Serum Uric Acid and Elevated Alanine Aminotransferase in the General Population. ( Chen, S; Guo, X; Li, Z; Sun, G; Sun, Y; Yang, H; Yu, S, 2016) |
| " We evaluated the association between serum uric acid and uACR in persons with 0, and 1-2 metabolic syndrome (MetS) components and determined the modification effects of visceral adiposity index (VAI), mean arterial pressure (MAP), and fasting glucose on this association." | 3.83 | The Impact of Blood Pressure and Visceral Adiposity on the Association of Serum Uric Acid With Albuminuria in Adults Without Full Metabolic Syndrome. ( Bruthans, J; Cifkova, R; Hamet, P; Krajcoviechova, A; Tahir, MR; Tremblay, J; Wohlfahrt, P, 2016) |
| "Uric acid is a metabolite obtained from purine by xanthine oxidase activity (XO) and high levels of serum uric acid leads to hyperuricemia and gout." | 3.83 | Hypouricemic effects of Mesona procumbens Hemsl. through modulating xanthine oxidase activity in vitro and in vivo. ( Hsu, CL; Jhang, JJ; Liao, JW; Lin, JH; Lu, CC; Ong, JW; Yen, GC, 2016) |
| "Patients with hyperuricemia had higher levels of cystatin C and urine β2-microglobulin and lower levels of HDL-C in comparison to that in patients with normal serum uric acid levels (p < 0." | 3.83 | Independent Association between Hyperuricemia and Histopathological Parameters in Chinese Patients with Henöch-Schönlein Purpura Nephritis. ( Cheng, G; Dou, Y; Liu, D; Liu, Z; Lu, S; Wang, X; Xiao, J; Yuan, W; Zhang, X; Zhao, Z, 2016) |
| "Fixed, low dose rasburicase produced a consistent lowering of uric acid levels and may be utilized in the management of hyperuricemia in TLS." | 3.81 | Fixed, low-dose rasburicase for the treatment or prevention of hyperuricemia in adult oncology patients. ( Dinh, BC; Herrington, JD, 2015) |
| "We report three Caucasian patients affected by gout and type 2 diabetes, who were treated with the recombinant nonglycosylated human interleukin-1 receptor antagonist anakinra (100 mg/day subcutaneously) after an unsatisfactory or incomplete response to urate-lowering therapy, colchicine, nonsteroidal anti-inflammatory drugs, and prednisone." | 3.81 | Anakinra treatment in patients with gout and type 2 diabetes. ( Bardelli, M; Cantarini, L; Galeazzi, M; Rigante, D; Vitale, A, 2015) |
| "High serum uric acid (SUA) levels are present in patients with metabolic syndrome (MetS), when the latter is associated with endothelial dysfunction, inflammation, and hypertension." | 3.81 | Association of serum uric acid levels to inflammation biomarkers and endothelial dysfunction in obese prepubertal children. ( Bermudo, F; Cañete, MD; Cañete, R; Martos, R; Valle, M; Valle, R; van Donkelaar, EL, 2015) |
| "A larger LAAPD and an elevated serum uric acid level were found to be independent predictors of LA thrombosis in patients with MS in SR." | 3.81 | Usefulness of the uric acid and CHA₂DS₂-VASc score in prediction of left atrial thrombosis in patients with mitral stenosis and sinus rhythm. ( Akın, F; Akturk, F; Aslan, S; Bırand, A; Celık, O; Ozturk, D; Ozyılmaz, SO; Yıldırım, A, 2015) |
| " Hyperuricemia was diagnosed by serum uric acid levels of >420 µmol/L in males or >357 µmol/L in females." | 3.81 | Association between serum uric acid and mortality in a Chinese population of hypertensive patients. ( Guo, X; Wang, J; Wang, Y; Zhao, D; Zhong, JQ, 2015) |
| " Obesity and overweight had no direct influence on the lithogenic risk profile in the urinary stone formers in our study, but there was an indication that higher serum uric acid may be associated with impairment in renal function, which in turn could influence the excretion of lithogenic parameters." | 3.81 | Does obesity or hyperuricemia influence lithogenic risk profile in children with urolithiasis? ( Kirejczyk, JK; Kuroczycka-Saniutycz, E; Porowska, H; Porowski, T; Protas, PT; Pszczółkowska, M; Wasilewska, A, 2015) |
| "There is very limited information on the association between arsenic and serum uric acid levels or gout." | 3.81 | Arsenic exposure, hyperuricemia, and gout in US adults. ( Fadrowski, JJ; Guallar, E; Kuo, CC; Lin, YS; Navas-Acien, A; Weaver, V, 2015) |
| "Several studies have demonstrated a relationship between increased serum uric acid (SUA) concentrations and the prevalence of metabolic syndrome (MetS) in the oriental population." | 3.81 | Associations between serum uric acid concentrations and metabolic syndrome and its components in the PREDIMED study. ( Babio, N; Basora, J; Becerra-Tomás, N; Corella, D; Estruch, R; Fitó, M; Martínez-González, MA; Ortega-Calvo, M; Recondo, J; Ros, E; Salas-Salvadó, J; Serra-Majem, L; Wärnberg, J, 2015) |
| "The ability of XZCBF to facilitate the excretion of uric acid and to lower its level in the model group was mediated by the upregulation of miR-34a and the inhibition of URAT1 mRNA expression, which suggests that XZCBF could be an option for the treatment of hyperuricemia in mice." | 3.81 | Effects of Xie-Zhuo-Chu-Bi-Fang on miR-34a and URAT1 and their relationship in hyperuricemic mice. ( Li, J; Liu, YW; Liu, ZG; Sun, WF; Wu, XR; Zhang, XX; Zhu, MM, 2015) |
| "To quantify the risk of non-fatal acute myocardial infarction (AMI) among users of allopurinol." | 3.81 | Allopurinol use and risk of non-fatal acute myocardial infarction. ( Álvarez, A; Bryant, V; de Abajo, FJ; García-Poza, P; García-Rodríguez, LA; Gil, MJ; Rodríguez, A, 2015) |
| " Allopurinol is a commonly used medication to treat hyperuricemia and its complications." | 3.81 | Anti-hyperuricemia effects of allopurinol are improved by Smilax riparia, a traditional Chinese herbal medicine. ( Anderson, S; He, Y; Mi, C; Wang, CZ; Wang, SQ; Wu, XH; Yuan, CS; Zhang, J; Zhang, YW, 2015) |
| "Hyperhomocysteinemia and hyperuricemia are both considered risk factors for coronary artery disease." | 3.81 | Assessment of a possible link between hyperhomocysteinemia and hyperuricemia. ( Cohen, E; Garty, M; Goldberg, E; Krause, I; Levi, A; Vecht-Lifshitz, SE, 2015) |
| " We investigated the role of soluble uric acid in NLRP3 inflammasome activation in macrophages to demonstrate the effect of systemic hyperuricemia on progressive kidney damage in type 2 diabetes." | 3.81 | Hyperuricemia-induced NLRP3 activation of macrophages contributes to the progression of diabetic nephropathy. ( Choi, YW; Ihm, CG; Jeong, KH; Kim, DJ; Kim, SM; Kim, SY; Kim, YG; Lee, SH; Lee, TW; Moon, JY; Seo, JW; Won, KY, 2015) |
| "We asked, is uric acid as effective as proteinuria at identifying perinatal risk in high-risk women with gestational hypertension? Uric acid was measured in samples obtained ≈4." | 3.81 | Uric Acid Determination in Gestational Hypertension: Is it as Effective a Delineator of Risk as Proteinuria in High-Risk Women? ( Althouse, AD; Clifton, RG; Roberts, JM; Schmella, MJ, 2015) |
| "Inefficient renal excretion of uric acid is the main pathophysiological mechanism for hyperuricemia in gout patients." | 3.81 | Renal clearance of uric acid is linked to insulin resistance and lower excretion of sodium in gout patients. ( Aniel-Quiroga, MA; Chinchilla, SP; Erauskin, GG; Herrero-Beites, AM; Merriman, T; Perez-Ruiz, F, 2015) |
| "Serum uric acid (UA, mg/dl) levels associate with the pathophysiology and prognosis in patients with chronic heart failure." | 3.81 | Hyperuricemia reflects global Fontan pathophysiology and associates with morbidity and mortality in patients after the Fontan operation. ( Hayama, Y; Miyazaki, A; Negishi, J; Noritake, K; Ohuchi, H; Sasaki, O; Taniguchi, Y; Yamada, O, 2015) |
| "Prednisone therapy was administered for a short time to 191 symptomatic HF patients with hyperuricemia (serum uric acid > 7 mg/dl)." | 3.81 | Prednisone in Uric Acid Lowering in Symptomatic Heart Failure Patients with Hyperuricemia -- The PUSH-PATH3 Study. ( Duan, L; Ji, L; Li, L; Liu, C; Liu, G; Liu, K; Ma, G; Meng, H; Tian, L; Wang, L; Zhai, J; Zhao, Q; Zhen, Y; Zheng, M, 2015) |
| "Obesity and diets rich in uric acid-raising components appear to account for the increased prevalence of hyperuricemia in Westernized populations." | 3.81 | Uric Acid and Cardiovascular Events: A Mendelian Randomization Study. ( Delgado, G; Grammer, TB; Huang, J; Kleber, ME; Krämer, BK; März, W; Ritz, E; Silbernagel, G, 2015) |
| "The hyperuricemia was induced by gavage of hypoxanthine and subcutaneous injection of potassium oxonate (model A) or subcutaneous injection of uric acid (model B) in ICR male mice." | 3.81 | [Hypouricemic effect of ethanol extracts from Dioscoreae Nipponicae Rhizoma]. ( Fu, XC; Shan, HL; Shan, RP, 2015) |
| " This study assessed association between ApoE polymorphisms with hyperuricemia and uric acid metabolism in Uygur men, Xinjiang, China." | 3.81 | Association of apolipoprotein E (ApoE) polymorphisms with risk of primary hyperuricemia in Uygur men, Xinjiang, China. ( Haliakpaer, G; Luo, L; Miao, L; Sun, YP; Wang, XM; Xia, H; Xin, G; Yao, H; Ying, L; Yu, JH; Zhang, B, 2015) |
| " Risk factors for hyperuricemia and the effects of plasma uric acid levels at 3, 6, 12, and 36 months on allograft outcomes were evaluated." | 3.81 | Effects of hyperuricemia on renal function in pediatric renal transplant recipients. ( Akdur, A; Baskın, E; Fidan, C; Gülleroğlu, K; Haberal, M; Kantar, A; Moray, G, 2015) |
| "It is controversial whether serum uric acid (SUA) is a risk factor for the prevalence of metabolic syndrome (MetS)." | 3.81 | Cross-sectional and longitudinal associations between serum uric acid and metabolic syndrome: Results from Fangchenggang Area Male Health and Examination Survey in China. ( Chen, D; Gao, Y; Jiang, Y; Lin, X; Lu, Z; Mo, Z; Tan, A; Wu, C; Yang, X; Yao, Z; Zhang, H, 2015) |
| "Recent studies have demonstrated an association between serum uric acid (SUA) levels and metabolic syndrome (MetS)." | 3.81 | Prospective study of serum uric acid levels and incident metabolic syndrome in a Korean rural cohort. ( Ahn, SV; Choi, E; Chung, CH; Kim, HM; Koh, SB; Lee, ES; Lee, EY; Lim, JS; Yadav, D, 2015) |
| "We recruited 43 chronic kidney disease (CKD) patients who did not receive RAS blockers and antihyperuricaemic drugs, and investigated the relationship among serum uric acid (sUA) levels, the circadian rhythm of urinary angiotensinogen (U-AGT) excretion levels, and the levels of albuminuria (U-ACR) and proteinuria (U-P/Cr)." | 3.81 | Hyperuricaemia is associated with renal damage independently of hypertension and intrarenal renin-angiotensin system activation, as well as their circadian rhythms. ( Ishigaki, S; Isobe, S; Iwakura, T; Kato, A; Ohashi, N; Ono, M; Sakao, Y; Tsuji, N; Tsuji, T; Yasuda, H, 2015) |
| " Linear regression was used to evaluate associations between uric acid and clinical and laboratory findings associated with metabolic syndrome." | 3.81 | [Metabolic complications of obesity during adolescence, particularly regarding elevated uric acid levels]. ( Almási, A; Barkai, L; Fehér, V; Kiss-Tóth, E; Ságodi, L, 2015) |
| "Recent studies have revealed an association between elevated levels of uric acid and conditions correlated to chronic kidney diseases such as hypertension, cardiovascular and cerebral disease, insulin resistance." | 3.81 | [Hyperuricemia and renal risk]. ( Bonino, B; Desideri, G; Pontremoli, R; Ratto, E; Viazzi, F, 2015) |
| " Allopurinol is a commonly used medication to treat hyperuricemia and its complications." | 3.81 | Pallidifloside D from Smilax riparia enhanced allopurinol effects in hyperuricemia mice. ( Anderson, S; He, Y; Hou, PY; Mi, C; Wang, SQ; Wu, XH; Yu, F; Zhang, J; Zhang, YW, 2015) |
| "There are data describing that cardiovascular risks related to serum uric acid (SUA) levels may begin below the current diagnostic level for hyperuricemia." | 3.81 | Uric acid levels within the normal range predict increased risk of hypertension: a cohort study. ( Dinour, D; Holtzman, EJ; Leiba, A; Shani, M; Vinker, S, 2015) |
| "Uric acid (UA) is associated with high blood pressure in adolescents and with left ventricular hypertrophy (LVH) and cardiovascular disease (CVD) in adults." | 3.81 | Elevated uric acid and obesity-related cardiovascular disease risk factors among hypertensive youth. ( Appel, LJ; Brady, TM; Fadrowski, JJ; Holmes, KW; Loeffler, LF; Miller, ER; Reschke, LD, 2015) |
| " Hyperuricemia was defined according to sex-specific serum uric acid levels (SUA): SUA≥7." | 3.81 | Combination of hyperuricemia and metabolic syndrome is an independent and powerful predictor for left ventricular hypertrophy in rural Chinese. ( Guo, X; Sun, Y; Yang, H; Yu, S, 2015) |
| "To explore the association between serum uric acid (SUA) levels, metabolic syndrome (MetS) and cardiovascular disease (CVD) in patients treated with lipid-lowering agents from multiple centers in China." | 3.81 | The association between serum uric acid levels, metabolic syndrome and cardiovascular disease in middle aged and elderly Chinese: results from the DYSlipidemia International Study. ( Chen, K; Fang, Y; Hu, D; Mu, Y; Nie, Y; Tian, Y; Wang, H; Xie, Z, 2015) |
| "Elevated serum uric acid concentration was strongly associated with obesity and hyperlipidemia in both men and women." | 3.81 | Relationship Between Hyperuricemia and Cardiovascular Disease Risk Factors in a Chinese Population: A Cross-Sectional Study. ( Hong, L; Li, L; Su, P; Sun, H; Zhao, Y, 2015) |
| "The main purpose of the present supplement, which is based on a symposium held in Bologna, 6-8 November 2014, is twofold: first of all, to reinforce the role of uric acid in the pathogenesis of gout and gout-related non-rheumatic diseases including renal involvement; second, to provide an updated review of the evidence supporting the relevant role of elevated uric acid as a risk factor for cardiovascular diseases." | 3.81 | The role of uric acid in the development of cardiovascular disease. ( Borghi, C, 2015) |
| "This study evaluated the effects of crude drugs obtained from the silkworm in mice with oxonic acid-induced hyperuricemia using xanthine oxidase inhibitory activity and plasma uric acid levels." | 3.81 | [The Xanthine Oxidase Inhibitory Activity and Hypouricemic Effects of Crude Drugs Obtained from the Silkworm in Mice]. ( Minakuchi, N; Miyata, Y; Murakami, A; Sakazaki, F; Tanaka, R, 2015) |
| "An elevated serum concentration of uric acid may be associated with an increased risk of acute kidney injury (AKI)." | 3.81 | Relationship between Serum Uric Acid Concentration and Acute Kidney Injury after Coronary Artery Bypass Surgery. ( Baek, SH; Chin, JH; Choi, IC; Choi, JH; Ji, SM; Joung, KW; Kim, JY; Lee, EH, 2015) |
| "This study aimed to assess the associations of serum uric acid (SUA) levels and hyperuricemia with cardiometabolic risk factors in a Chinese community-dwelling population." | 3.81 | Epidemiological associations between hyperuricemia and cardiometabolic risk factors: a comprehensive study from Chinese community. ( Fu, S; Luo, L; Xiao, W; Ye, P, 2015) |
| "To investigate the mechanisms underlying the therapeutic effects of losartan on hyperuricemia-induced aortic atherosclerosis, in an experimental rabbit model." | 3.81 | Losartan alleviates hyperuricemia-induced atherosclerosis in a rabbit model. ( Ding, Y; Li, N; Miao, P; Zheng, H, 2015) |
| " UOMVLs decrease serum uric acid levels in rats with hyperuricemia more effectively than UOX." | 3.81 | [The Pharmacokinetics and Pharmacodynamics of Intravenous Uricase Multivesicular Liposomes]. ( Deng, X; He, D; Xiong, HR; Zhang, JQ; Zhou, YL, 2015) |
| " oldhamii leaf extracts was investigated using potassium oxonate (PO)-induced acute hyperuricemia." | 3.81 | Antioxidative phytochemicals from Rhododendron oldhamii Maxim. leaf extracts reduce serum uric acid levels in potassium oxonate-induced hyperuricemic mice. ( Chiu, CC; Chuang, HL; Ho, ST; Huang, CC; Lin, CY; Lin, LC; Liu, YL; Tung, YT; Wu, JH, 2015) |
| "Although a direct causal relationship between hyperuricaemia and stroke continues to be debated, strong associations between serum uric acid (SUA) and cerebrovascular disease exist." | 3.81 | Highly Prevalent Hyperuricaemia is Associated with Adverse Clinical Outcomes Among Ghanaian Stroke Patients: An Observational Prospective Study. ( Adamu, S; Akassi, J; Akpalu, A; Antwi, NK; Bedu-Addo, G; Obese, V; Sarfo, FS, 2015) |
| "Our objective was to evaluate data on the cost-effectiveness of febuxostat compared with standard clinical practice with allopurinol in patients with gout that was presented to the Scottish Medicines Consortium (SMC) in 2010." | 3.80 | Cost-effectiveness of febuxostat in chronic gout. ( Beard, SM; Nuki, G; Pearson, IV; von Scheele, BG, 2014) |
| "Serum levels of uric acid (UA) are associated with metabolic syndrome (MetS)." | 3.80 | Serum uric acid is an independent predictor of metabolic syndrome in a Japanese health screening population. ( Oda, E, 2014) |
| "Hyperuricemia is common in chronic kidney disease (CKD), but data regarding the relationship between serum uric acid levels and the long-term outcomes of CKD patients have been limited." | 3.80 | Serum uric acid levels and long-term outcomes in chronic kidney disease. ( Miyaoka, T; Mochizuki, T; Nitta, K; Takei, T; Tsuchiya, K, 2014) |
| "Few studies have examined the association between elevated serum uric acid (SUA) levels and psoriasis, and their results have been inconclusive because most of these studies did not take into account the confounding effects of coexisting features of the metabolic syndrome." | 3.80 | Hyperuricemia in patients with chronic plaque psoriasis. ( Cagalli, A; Girolomoni, G; Gisondi, P; Targher, G, 2014) |
| "Between 2009 and 2012, we conducted a study among 406 consecutive first-ever ischemic stroke patients to assess the relationship between uric acid and carotid artery." | 3.80 | Association of uric acid and carotid artery disease in patients with ischemic stroke. ( Kabaroglu, C; Karaman, B; Kumral, E; Orman, M, 2014) |
| "We assessed the effect of increased serum uric acid (SUA) concentration and hyperuricemia on subclinical organ damage." | 3.80 | Serum uric acid concentration and asymptomatic hyperuricemia with subclinical organ damage in general population. ( Li, Y; Lu, J; Wu, X; Yang, C, 2014) |
| "Serum uric acid levels were not significantly different in the asymptomatic hyperuricaemia, gouty arthritis without tophi and gouty tophi groups." | 3.80 | The effects of gout on left atrial volume remodelling: a prospective echocardiographic study. ( Chang, PJ; Chang, ST; Chen, MC; Chung, CM; Hsiao, JF; Lin, CL; Lin, JC; Pan, KL, 2014) |
| "Plasma uric acid levels indicate tubular interstitial lesions in IgAN and hyperuricemia may be considered as a marker for tubulointerstitial lesions." | 3.80 | Plasma uric acid level indicates tubular interstitial leisions at early stage of IgA nephropathy. ( Chen, Y; Li, X; Liu, Y; Shi, S; Wang, S; Zhang, H; Zhou, J, 2014) |
| "We tested the hypothesis that uric acid levels predict new-onset hypertension in the Japanese general population." | 3.80 | Uric acid levels predict future blood pressure and new onset hypertension in the general Japanese population. ( Dohi, Y; Kimura, G; Takase, H, 2014) |
| " riparia in reducing serum uric acid levels in a potassium oxonate-induced hyperuricemia mouse model." | 3.80 | Smilax riparia reduces hyperuricemia in mice as a potential treatment of gout. ( Anderson, S; Wu, XH; Yu, CH; Zhang, CF; Zhang, YW, 2014) |
| "To investigate the effect of total saponin of dioscorea (TSD) on uric acid excretion indicators in chronic hyperuricemia rats, and to study the correlation between blood levels of uric acid (SUA) and uric acid excretion indicators." | 3.80 | [Effect of total saponin of dioscorea on uric acid excretion indicators in chronic hyperuricemia rats]. ( Chen, GL; Li, L; Na, S; Wu, S, 2014) |
| "The relationship between metabolic syndrome (MetS) and uric acid (UA) has been explored in many studies, but there is paucity of information on hypo-uricemia and MetS." | 3.80 | Is lower uric acid level better? A combined cross-sectional and longitudinal study in the elderly. ( Chen, YL; Hsieh, CH; Hsu, CH; Liang, YJ; Lin, JD; Pei, D; Wu, CZ, 2014) |
| "A link between uric acid (UA) levels and cardiovascular diseases has been previously reported." | 3.80 | Association between serum uric acid levels and cardiovascular disease in middle-aged and elderly Chinese individuals. ( Gu, H; Li, R; Li, X; Lu, S; Ning, G; Qin, L; Shi, Q; Su, Q; Xing, Y; Yang, Z, 2014) |
| " Treating asymptomatic hyperuricemia with urate-lowering drugs such as allopurinol may reduce CV events." | 3.80 | Treatment of asymptomatic hyperuricemia and prevention of vascular disease: a decision analytic approach. ( Akkineni, R; Albert, DA; Choi, HK; Lee, A; Miller, KL; Tapp, S; Tosteson, AN; Zhu, Y, 2014) |
| "Post-transplant hyperuricemia (PTHU), defined as serum uric acid concentration ≥7." | 3.80 | Efficacy and safety of febuxostat in the treatment of hyperuricemia in stable kidney transplant recipients. ( Hara, T; Hayashida, Y; Inui, M; Kakehi, Y; Kohno, M; Moriwaki, K; Nishijima, Y; Nishiyama, A; Sofue, T; Ueda, N, 2014) |
| "Serum uric acid (UA) is now beginning to be considered a risk predictor for cardiovascular diseases." | 3.80 | Serum uric acid as a risk predictor for erectile dysfunction. ( Heydari, R; Mehrsai, A; Pourmand, G; Salem, S, 2014) |
| "Among adults free of metabolic syndrome, elevated uric acid, but not elevated CRP, is independently associated with prevalent hypertension." | 3.80 | Interaction of inflammation, hyperuricemia, and the prevalence of hypertension among adults free of metabolic syndrome: NHANES 2009-2010. ( Krishnan, E, 2014) |
| "Maternal hyperuricemia (uric acid one standard deviation greater than the appropriate gestational age) was independently associated with preterm birth (odds ratio (OR), 3." | 3.80 | Maternal hyperuricemia in normotensive singleton pregnancy, a prenatal finding with continuous perinatal and postnatal effects, a prospective cohort study. ( Abdollahi, A; Amini, E; Hantoushzadeh, S; Kashanian, M; Shariat, M; Sheikh, M, 2014) |
| " Despite evidence of uric acid-induced endothelial dysfunction, a relationship with insulin resistance has not been clearly established." | 3.80 | Uric acid induces endothelial dysfunction by vascular insulin resistance associated with the impairment of nitric oxide synthesis. ( Choi, YJ; Hien, TT; Kang, DH; Kang, KW; Kim, KC; Lee, BH; Lee, J; Lee, KY; Lee, MY; Lee, SM; Yoon, Y, 2014) |
| "The cause and effect relationship between serum uric acid levels and hypertension can be difficult to evaluate because antihypertensive drugs sometimes affect uric acid levels." | 3.80 | Relationship between serum uric acid levels and hypertension among Japanese individuals not treated for hyperuricemia and hypertension. ( Asano, T; Hisatome, I; Komatsu, I; Kuwabara, M; Masuda, K; Mizuno, A; Nishi, Y; Niwa, K; Takahashi, O; Yamazoe, M, 2014) |
| "Increased serum uric acid levels and vascular atherosclerosis are very common in diabetes." | 3.80 | Serum uric acid is associated with arterial stiffness in men with newly diagnosed type 2 diabetes mellitus. ( Sun, H; Xiang, G; Xiang, L; Zhang, J, 2014) |
| "Preliminary data suggest that serum uric acid (SUA) could be involved in the prognosis of chronic heart failure (HF)." | 3.80 | Uricaemia and ejection fraction in elderly heart failure outpatients. ( Borghi, C; Cicero, AF; Cosentino, ER; Rinaldi, ER, 2014) |
| "Elevated albuminuria as well as an increased serum uric acid concentration is associated with poor cardiovascular outcome." | 3.80 | The association of albuminuria with tubular reabsorption of uric acid: results from a general population cohort. ( Bakker, SJ; de Jong, PE; Gansevoort, RT; Joosten, MM; Scheven, L, 2014) |
| "This is the first large study showing that serum uric acid is not associated with an increase in the risk of periprocedural myocardial infarction in patients undergoing percutaneous coronary revascularization." | 3.80 | Uric acid and risk of periprocedural myocardial infarction in patients undergoing percutaneous coronary intervention. ( Barbieri, L; De Luca, G; Di Giovine, G; Marino, P; Schaffer, A; Verdoia, M, 2014) |
| "To assess the relationship between serum uric acid and target organ damage (left ventricular hypertrophy and microalbuminuria) in untreated patients with essential hypertension." | 3.80 | Serum uric acid and target organ damage in essential hypertension. ( Odia, OJ; Ofori, SN, 2014) |
| " Hyperuricemia was defined as uric acid levels ≥ 7." | 3.80 | Sweetened beverage consumption and the risk of hyperuricemia in Mexican adults: a cross-sectional study. ( Castañón-Robles, S; Cervantes-Rodríguez, M; Denova-Gutiérrez, E; Granados-García, V; Huitrón-Bravo, GG; Meneses-Leon, J; Quiterio-Trenado, M; Rivera-Paredez, B; Rudolph, SE; Salmerón, J; Talavera, JO, 2014) |
| "cross-sectional and prospective multivariate analysis of the relation between tertiles of serum uric acid and individual traditional CV risk factors in a cohort of gouty arthritis (GA, n=172), rheumatoid arthritis (RA, n=480) and osteoarthritis (OA, n=206) patients." | 3.80 | Hyperuricaemia: a marker of increased cardiovascular risk in rheumatic patients: analysis of the ACT-CVD cohort. ( Meek, IL; van de Laar, MA; Vonkeman, HE, 2014) |
| "ATP-binding cassette transporter, sub-family G, member 2 (ABCG2/BCRP) is identified as a high-capacity urate exporter, and its dysfunction has an association with serum uric acid levels and gout/hyperuricemia risk." | 3.80 | ABCG2 dysfunction increases the risk of renal overload hyperuricemia. ( Chiba, T; Hosoya, T; Ichida, K; Matsuo, H; Nakamura, T; Nakashima, H; Nakayama, A; Sakiyama, M; Sakurai, Y; Shimizu, S; Shimizu, T; Shinomiya, N; Takada, T; Takada, Y, 2014) |
| "In order to elucidate the mechanism of hyperuricemia in hematologic malignancies, we have retrospectively investigated the uric acid metabolism in 418 chemotherapy-naïve patients with hematologic malignancies." | 3.80 | Hyperuricemia in hematologic malignancies is caused by an insufficient urinary excretion. ( Akiyama, N; Fujimori, S; Kawasugi, K; Oka, Y; Shirafuji, N; Sirasaki, R; Tashiro, H; Yamamoto, T, 2014) |
| " Hyperuricemia was defined as levels of uric acid >7." | 3.80 | Hyperuricemia and incident atrial fibrillation in a normotensive elderly population in Taiwan. ( Chia-Yu Chen, R; Chuang, SY; Hsu, PF; Hsu, YY; Liu, WL; Pan, WH; Wu, CC, 2014) |
| "The aim of this study was to determine the association between vitamin C intake and risk of hyperuricemia or serum uric acid levels in male and female subjects in the Korean Multi-Rural Communities Prospective Cohort." | 3.80 | The effect of vitamin C intake on the risk of hyperuricemia and serum uric acid level in Korean Multi-Rural Communities Cohort. ( Bae, J; Choi, BY; Chun, BY; Kim, MK; Kim, SK; Lee, YH; Park, PS; Shin, DH; Shin, MH, 2014) |
| "We applied Chrysanthemum flower oil (CFO) to a hyperuricemia model by feeding rats a hyperuricemia-inducing diet (HID) and investigated its effect on serum uric acid (SUA) levels and its mode of action." | 3.80 | Administered chrysanthemum flower oil attenuates hyperuricemia: mechanism of action as revealed by DNA microarray analysis. ( Abe, K; Hirata, D; Honda, S; Kawamoto, S; Kishida, H; Kitagawa, M; Nakai, Y; Tanaka, H, 2014) |
| "To identify the risk factors of kidney injuries in hypertensive patients with uric acid (UA) metabolic disorders in order to choose the optimal management tactics, by analyzing the changes in markers for endothelial dysfunction (endothelin-1 (ET-1), microalbuminuria (MAU), intima-media thickness (IMT)) and tubulointerstitial tissue lesion (beta2-microglobulin (beta2-MG, monocyte chemotactic protein-1 (MCP-1))." | 3.80 | [Clinical value of the determination of markers for endothelial dysfunction (endothelin-1, microalbuminuria) and tubulointerstitial tissue lesion (β2-microglobulin, monocyte chemotactic protein-1) in hypertensive patients with uric acid metabolic disorder ( Balkarov, IM; Kozlovskaia, LV; Shcherbak, AV; Stakhova, TIu; Taranova, MV, 2014) |
| "Excess circulating uric acid, a product of hepatic glycolysis and purine metabolism, often accompanies metabolic syndrome." | 3.80 | Early-onset metabolic syndrome in mice lacking the intestinal uric acid transporter SLC2A9. ( DeBosch, BJ; Fujiwara, H; Kluth, O; Moley, K; Schürmann, A, 2014) |
| "Gout with uric acid underexcretion is associated with transporter gene SNP related mainly to tubular reabsorption, whereas uric acid normoexcretion is associated only with tubular secretion SNP." | 3.80 | Tubular urate transporter gene polymorphisms differentiate patients with gout who have normal and decreased urinary uric acid excretion. ( Bailén, R; Banegas, JR; de Miguel, E; Puig, JG; Torres, RJ, 2014) |
| "Among a renal transplant population with at least 1 year of follow-up, we included 27 patients with sustained hyperuricemia and 11 with normal serum uric acid (SUA) levels." | 3.80 | A pilot study on dual-energy computed tomography for detection of urate deposits in renal transplant patients with asymptomatic hyperuricemia. ( Alberú, J; Betanzos, JL; Criales-Vera, S; Hernández-Molina, G; Kimura-Hayama, E; Nicolaou, S; Rivera, Y; Rull-Gabayet, M, 2014) |
| "To date, no study in the published literature has investigated the role of various serum uric acid (SUA) concentrations in the development of angiographically-proven coronary artery disease (CAD) in premenopausal women." | 3.80 | Association of serum uric acid and coronary artery disease in premenopausal women. ( Cao, SJ; He, LJ; Yang, Q; Yang, SW; Zhang, JW; Zhou, YJ, 2014) |
| " The relationship between uric acid levels and left ventricular mass in hypertension, however, is unclear." | 3.80 | Uricaemia and left ventricular mass in hypertensive patients. ( Brosolo, G; Capobianco, F; Catena, C; Colussi, G; Sechi, LA, 2014) |
| "5% fat UHT milk diet or allopurinol therapy in rat experimental hyperuricemia." | 3.80 | Short communication: Effect of commercial or depurinized milk diet on plasma advanced oxidation protein products, cardiovascular markers, and bone marrow CD34+ stem cell potential in rat experimental hyperuricemia. ( Cvetkovic, T; Jevtovic, T; Jovanovic, A; Jovanovic, J; Kocic, G; Kocic, H; Sokolovic, D; Stojanovic, S; Veljkovic, A; Zivkovic, P, 2014) |
| "The association between serum uric acid (SUA) levels and metabolic syndrome (MetS) has recently been reported in several cross-sectional and longitudinal studies." | 3.80 | A possible role of serum uric acid as a marker of metabolic syndrome. ( Cho, S; Kim, SR; Lee, YJ, 2014) |
| " Of note, diabetic subjects with glycosuria, who represented 24% of the diabetic participants, had a null prevalence of hyperuricemia, and statistically higher values for fractional excretion of uric acid, Na excretion index, and prevalence of microalbuminuria than those without glycosuria." | 3.80 | Serum uric acid and disorders of glucose metabolism: the role of glycosuria. ( Andrade, JA; Garcia Rosa, ML; Greffin, S; Kang, HC; Lugon, JR, 2014) |
| "These results suggest that pallidifloside D possesses a potent uricosuric effect in hyperuricemic mice through decreasing renal mURAT1 and GLUT9, which contribute to the enhancement of uric acid excretion and attenuate hyperuricemia-induced renal dysfunction." | 3.80 | Pallidifloside D, a saponin glycoside constituent from Smilax riparia, resist to hyperuricemia based on URAT1 and GLUT9 in hyperuricemic mice. ( Ruan, JL; Wang, SQ; Wu, XH; Zhang, J; Zhang, YW, 2014) |
| "To study the effects of uric acid on cardiac lesions and its possible mechanism by establishing an early-stage CKD animal model with hyperuricemia." | 3.80 | Effects of uric acid on hearts of rats with chronic kidney disease. ( Bao, X; Wang, Y; Wei, C; Zhang, Q, 2014) |
| "While the prevalence of gout was calculated by counting patients with this diagnosis hyperuricemia was inferred in patients taking allopurinol at hospital admission or discharge, on the assumption that this drug was only prescribed owing to the finding of high serum levels of uric acid." | 3.80 | Gout, allopurinol intake and clinical outcomes in the hospitalized multimorbid elderly. ( Conca, A; Corrao, S; Djade, CD; Franchi, C; Mannucci, PM; Marcucci, M; Marengoni, A; Nobili, A; Pasina, L; Salerno, F; Tettamanti, M, 2014) |
| " Thus, application of ursodeoxycholic acid, rosuvastatin and allopurinol in these study patients with NAFLD dosages in combination with hyperuricemia improves the clinical symptoms and normalization of biochemical parameters and normalizes the spectrum of biliary acids." | 3.80 | [CORRECTION OF BILE FLOW CHARACTERISTICS IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE IN COMBINATION WITH HYPERURICEMIA]. ( Barabanchyk, OV; Kozak, NP; Svintsits'kyĭ, AS, 2014) |
| "To examine the association between hematological indices and serum uric acid in adolescents with hyperuricemia." | 3.80 | Hematological parameters in adolescents with hyperuricemia. ( Protas, P; Stelmach, MJ; Szczerbinski, L; Wasilewska, A; Wasilewska, N, 2014) |
| " Compared to those in normal serum uric acid group, the incidence of hypertension (33%, 16/48), serum triglyceride [2." | 3.80 | [Relationship between hyperuricemia and primary nephrotic syndrome in children]. ( Li, Q; Wang, F; Xiao, H; Yao, Y; Zhong, X, 2014) |
| " d-1 ) to prepare the hyperuricemia model, and divided into normal, model, Allopurinol, LE high dosage, middle dosage and low dose (200, 100, 50 mg ." | 3.80 | [Regulatory effect of leonurus extracts on hyperuricemia in rats]. ( An, YT; Li, J; Wang, T; Wu, ZZ; Yan, M, 2014) |
| "Hyperuricemia mice model was established with uricase inhibitor (potassium oxonate) and uric acids in serum were observed." | 3.80 | [Anti-hyperuricemia effect and mechanism of polydatin in mice]. ( Jiang, H; Wu, G; Wu, HB, 2014) |
| "Current evidence shows that uric acid is a potent antioxidant whose serum concentration increases rapidly after acute ischemic stroke (AIS)." | 3.79 | Serum uric acid and outcome after acute ischemic stroke: PREMIER study. ( Arauz, A; Barinagarrementeria, F; Cantú-Brito, C; Chiquete, E; León-Jiménez, C; Murillo-Bonilla, LM; Ochoa-Guzmán, A; Orozco-Valera, DR; Ramos-Moreno, A; Ruiz-Sandoval, JL; Villarreal-Careaga, J, 2013) |
| " Hyperuricemia was defined as serum uric acid >6." | 3.79 | Dose-response association of uncontrolled blood pressure and cardiovascular disease risk factors with hyperuricemia and gout. ( Gelber, AC; Juraschek, SP; Kovell, LC; Miller, ER, 2013) |
| "Experimental and epidemiological studies have demonstrated that urinary angiotensinogen (AGT) is a novel biomarker for the intrarenal activity of the renin-angiotensin system in hypertension (HT)." | 3.79 | Urinary angiotensinogen as a marker of intrarenal angiotensin II activity in adolescents with primary hypertension. ( Kuroczycka-Saniutycz, E; Milewski, R; Sulik, A; Wasilewska, A, 2013) |
| "Gout and serum uric acid are associated with mortality but their simultaneous contributions have not been fully evaluated in the general population." | 3.79 | Independent and conjoint associations of gout and hyperuricaemia with total and cardiovascular mortality. ( Abdalla, AA; Casserly, LF; Cronin, CJ; Hanley, A; Hannigan, A; Hegarty, A; Kiernan, TJ; Murthy, BV; Nguyen, HT; Stack, AG, 2013) |
| "To observe serum uric acid (UA) level distribution and explore risk factors of hyperuricemia (HUA) in a large cohort of active and retired employees underwent physical examination." | 3.79 | [Risk factors for hyperuricemia in active and retired employees underwent physical examination]. ( Chen, P; Fan, GL; Fan, JD; Feng, C; He, DC; Liao, YH; Qian, DF; Zhou, ZH; Zhu, PG, 2013) |
| "Compared to the hyperuricemia control group, Wuling San significantly reduced serum uric acid and creatinine levels, increased 24 h urate and creatinine excretion, and FEUA in hyperuricemic mice, exhibiting its ability to enhance urate excretion and improve kidney function." | 3.79 | Wuling san ameliorates urate under-excretion and renal dysfunction in hyperuricemic mice. ( Ding, XQ; Kong, LD; Ma, YX; Pan, Y; Wang, X, 2013) |
| " High uricemia in humans may protect against oxidative stress, but hyperuricemia also associates with the metabolic syndrome, and urate and uric acid can crystallize to cause gout and renal dysfunctions." | 3.79 | Urate-induced acute renal failure and chronic inflammation in liver-specific Glut9 knockout mice. ( Bazin, D; Da Costa, A; Daudon, M; Dessombz, A; Laverriere-Loss, A; Metref, S; Moret, C; Preitner, F; Rotman, S; Sandt, C; Thorens, B, 2013) |
| "Gout is a common disease caused by hyperuricemia, which shows elevated serum uric acid (SUA) levels." | 3.79 | Common missense variant of monocarboxylate transporter 9 (MCT9/SLC16A9) gene is associated with renal overload gout, but not with all gout susceptibility. ( Chiba, T; Hamajima, N; Hishida, A; Ichida, K; Inoue, K; Kato, Y; Kawai, S; Matsuo, H; Nakamura, T; Nakashima, H; Nakayama, A; Ogata, H; Sakiyama, M; Sakurai, Y; Shimizu, S; Shimizu, T; Shinomiya, N; Takada, T; Takada, Y; Ushiyama, C; Wakai, K, 2013) |
| "Hyperuricemia, excess of uric acid in the blood, is a clinical problem that causes gout and is also considered a risk factor for cardiovascular disease." | 3.79 | 3,4-Dihydroxy-5-nitrobenzaldehyde (DHNB) is a potent inhibitor of xanthine oxidase: a potential therapeutic agent for treatment of hyperuricemia and gout. ( Chen, C; Lü, JM; Yao, Q, 2013) |
| "An existing generalized mass action system model of human uric acid (UA) metabolism was used to formulate the fuzzy optimization method for detecting two types of enzymopathies: hyperuricemia caused by phosphoribosylpyrophosphate synthetase (PRPPS) overactivity and Lesch-Nyhan syndrome." | 3.79 | Fuzzy optimization for detecting enzyme targets of human uric acid metabolism. ( Hsu, KC; Wang, FS, 2013) |
| " Potassium oxonate and ethambutol were adopted to establish the chronic hyperuricemia model Since the third week, all the rats were intragastrically administered with drugs for 4 weeks, once a day, in order to determine their uric acid in serum and urine, uric acid excretion and xanthine oxidase (XOD)." | 3.79 | [Effect of total saponin of Dioscorea on chronic hyperuricemia and expression of URAT1 in rats]. ( Chen, GL; Li, L; Na, S; Zhu, LR, 2013) |
| "The purpose of this work was to investigate if in adolescents with hyperuricemia serum levels of asymmetric and symmetric dimethylarginine (ADMA, SDMA) are increased and if their levels correlate with serum uric acid (UA)." | 3.79 | Asymmetric and symmetric dimethylarginine in adolescents with hyperuricemia. ( Korzeniecka-Kozerska, A; Taranta-Janusz, K; Tenderenda-Banasiuk, E; Wasilewska, A, 2013) |
| "The aim of this study was to compare serum uric acid values in two ethnically distinct Chinese populations: Uyghur, with a high prevalence of nonalcoholic fatty liver disease, and Han, with a lower prevalence." | 3.79 | Serum uric acid levels and non-alcoholic fatty liver disease in Uyghur and Han ethnic groups in northwestern China. ( Cai, W; Miao, L; Sun, YP; Wu, X; Yao, H; Zhang, B; Zou, Y, 2013) |
| "Treatment with Jianpihuashi Decoction for 30 days, the serum uric acid level of rats with hyperuricemia were significantly decreased (P < 0." | 3.79 | [Effect of jianpihuashi decoction on rats with hyperuricemia]. ( Chen, JW; Guo, J; Jiang, JM; Li, C; Xue, ZY; Zhou, LY; Zhou, Y, 2013) |
| "Hyperuricemia in mice was induced by intraperitoneally administering uric acid (250 mg/ kg)." | 3.79 | Pretreatment with Jieduxiezhuo decoction impedes elevations in serum uric acid levels in mice. ( Chu, Z; Pan, Y; Wang, W; Yang, B, 2013) |
| " In other rats, glucose, insulin, uric acid, and insulin sensitivity index, were determined before and after fructose or lipoic acid plus fructose." | 3.79 | A single oral dose of fructose induces some features of metabolic syndrome in rats: role of oxidative stress. ( Hong, E; Moreno, JA, 2013) |
| " Significant changes of biochemical parameters in cases of hypertensive disorders in pregnancy are increased levels of blood glucose, urea, creatinine, uric acid (hyperuricemia), transaminases, and LDH." | 3.79 | Correlation of biochemical parameters and neonatal outcome in patients with gestational hypertension. ( Aksam, S; Kocijancic, A; Kocijancic, DM; Plecas, D; Plesinac, S, 2013) |
| "Current evidence suggests a direct association of uric acid with diabetes risk, but it is still unclear whether this is independent of risk factors such as obesity and diet." | 3.79 | Plasma uric acid is associated with increased risk of type 2 diabetes independent of diet and metabolic risk factors. ( Beulens, JW; Schulze, MB; Sluijs, I; Spijkerman, AM; van der A, DL; van der Schouw, YT, 2013) |
| " As a potentially modifiable risk factor, we examined whether serum uric acid levels correlate with early hypertension, kidney volume and progression to end-stage renal disease (ESRD) in autosomal-dominant polycystic kidney disease (ADPKD)." | 3.79 | Serum uric acid, kidney volume and progression in autosomal-dominant polycystic kidney disease. ( Fick-Brosnahan, GM; Helal, I; McFann, K; Reed, B; Schrier, RW; Yan, XD, 2013) |
| "Hyperuricemia and left ventricular (LV) hypertrophy are prevalent in chronic kidney disease (CKD), but the association of uric acid (UA) and left ventricular mass index (LVMI) with renal outcomes in patients with CKD is unclear." | 3.79 | Association of uric acid and left ventricular mass index with renal outcomes in chronic kidney disease. ( Chang, JM; Chen, HC; Chen, SC; Su, HM; Yeh, SM, 2013) |
| "The associations and gene-diet interactions involving VEGFR-2 gene polymorphisms and FD on uric acid provide new information on gout and hyperuricaemia risks in Malays." | 3.78 | Association and interaction effect between VEGF receptor-2 (VEGFR-2) gene polymorphisms and dietary pattern on blood uric acid in Malays and Indians. ( Hon, WM; Masaki, M; Roseline, YW; Shidoji, Y, 2012) |
| " Hyperuricemia was defined by uric acid ≥458." | 3.78 | Relationship between serum uric acid and cerebral white matter lesions in the elderly. ( Chen, CY; Kuo, HK; Liu, HM; Shih, CY; Wen, CJ, 2012) |
| " We assessed the prevalence of hyperuricemia and determined the independent risk factors for raised serum uric acid level by multiple logistic regression analyses." | 3.78 | Prevalence of hyperuricemia and its association with antihypertensive treatment in hypertensive patients in Taiwan. ( Chang, SC; Chen, KF; Chi, WC; Hung, YJ; Lee, DY; Lee, WL; Lin, CS, 2012) |
| "Our study showed that uric acid is not associated with platelet aggregation, the extent of coronary artery disease and IMT." | 3.78 | Uric acid does not affect the prevalence and extent of coronary artery disease. Results from a prospective study. ( Bellomo, G; Cassetti, E; Coppo, L; De Luca, G; Di Mario, C; Iorio, S; Marino, P; Santagostino, M; Secco, GG; Venegoni, L; Verdoia, M, 2012) |
| "Hyperuricemia was defined as blood uric acid level >7." | 3.78 | Purine-rich foods, protein intake, and the prevalence of hyperuricemia: the Shanghai Men's Health Study. ( Cai, H; Cai, Q; Elasy, T; Fazio, S; Linton, MF; Shu, XO; Villegas, R; Xiang, YB; Xu, WH; Zheng, W, 2012) |
| "We evaluated the association of serum uric acid (SUA) level and development of coronary collateral vessels (CCVs) in patients with acute coronary syndrome (ACS)." | 3.78 | High levels of serum uric acid impair development of coronary collaterals in patients with acute coronary syndrome. ( Demircelik, MB; Doger, C; Duran, M; Murat, SN; Ocak, A; Ornek, E; Turfan, M; Vatankulu, MA; Yalcin, AA, 2012) |
| ", isotretinoin used for severe acne) and high doses of preformed vitamin A have been implicated in the pathogenesis of hyperuricemia and gout, whereas a trial reported that β-carotene may lower serum uric acid (UA) levels." | 3.78 | Independent association of serum retinol and β-carotene levels with hyperuricemia: A national population study. ( Choi, HK; Choi, WJ; Curhan, G; Ford, ES; Rankin, JI, 2012) |
| "Acute kidney injury (AKI) with elevated serum uric acid (UA) levels has been reported in patients with hemolytic uremic syndrome (HUS)." | 3.78 | Rasburicase for hyperuricemia in hemolytic uremic syndrome. ( Acosta, AA; Hogg, RJ, 2012) |
| "The objective of this study was to explore the relationships between circulating uric acid and lipid levels and components of the metabolic syndrome (MetS) in Arab dyslipidemic patients, a group already at high coronary artery disease risk." | 3.78 | Determinants of blood uric acid levels in a dyslipidemic Arab population. ( Akanji, AO; Al-Meshaweh, AF; Asem, M; Jafar, Y, 2012) |
| "We aimed to elucidate the relation between serum uric acid (SUA) level and severity of coronary artery disease (CAD) in nondiabetic, nonhypertensive patients (n = 246) with acute coronary syndrome (ACS)." | 3.78 | High levels of serum uric acid predict severity of coronary artery disease in patients with acute coronary syndrome. ( Akpek, M; Duran, M; Elcik, D; Ergin, A; Eryol, NK; Inanc, MT; Kalay, N; Kasapkara, HA; Kaya, MG; Ocak, A; Oguzhan, A; Orscelik, O, 2012) |
| " The effect of preventing hyperuricemia was determined by concomitant treatment with a xanthine oxidase inhibitor, allopurinol (CsAALP), or with a uricosuric, benzbromarone (CsABENZ), in drinking water." | 3.78 | Use of uric acid-lowering agents limits experimental cyclosporine nephropathy. ( Johnson, RJ; Mazali, FC; Mazzali, M, 2012) |
| " Overall serum uric acid (UA) concentration increased, whereas in patients with hyperuricemia there was a significant reduction in this value." | 3.78 | Antihypertensive effect of a fixed-dose combination of losartan/hydrochlorothiazide in patients with uncontrolled hypertension: a multicenter study. ( Akaba, K; Endo, S; Fukui, A; Gomi, H; Hamaguchi, A; Hanaoka, K; Hara, Y; Hasegawa, T; Hayakawa, H; Hayashi, F; Hikida, M; Hirano, K; Horiguchi, M; Hosoya, M; Hosoya, T; Ichida, K; Ikeda, M; Imai, T; Ishii, T; Ishikawa, H; Ishikawa, M; Kameda, C; Kanai, T; Kasai, T; Kawamura, T; Kobayashi, A; Kobayashi, H; Kurashige, M; Kuriyama, S; Kusama, Y; Maezawa, H; Maezawa, Y; Maruyama, Y; Matsuda, H; Matsuo, N; Matsuo, T; Miura, Y; Miyajima, M; Miyakawa, M; Miyazaki, Y; Mizuguchi, M; Morita, T; Nakao, M; Nokano, H; Ogura, M; Ohkido, I; Ohno, I; Ohtsuka, Y; Okada, K; Okamoto, H; Okonogi, H; Saikawa, H; Saito, H; Sekiguchi, C; Soejima, M; Suetsugu, Y; Sugano, N; Suzuki, T; Takahashi, H; Takahashi, Y; Takamizawa, S; Takane, K; Takazoe, K; Tanaka, H; Tanaka, S; Terawaki, H; Tokudome, G; Tomonari, H; Toyoshima, R; Tsuboi, N; Udagawa, T; Ueda, H; Ueda, Y; Uetake, M; Unemura, S; Utsunomiya, M; Utsunomiya, Y; Yamada, T; Yamada, Y; Yamaguchi, Y; Yamamoto, H; Yokoo, T; Yokoyama, K; Yonezawa, H; Yoshida, H; Yoshida, M; Yoshizawa, T, 2012) |
| "Despite some epidemiologic research demonstrating a positive relationship between serum uric acid (SUA) levels and the prevalence of metabolic syndrome (MetS), prospective data on SUA as a predictor of MetS incidence are limited." | 3.78 | Uric acid level as a risk marker for metabolic syndrome: a Chinese cohort study. ( Bai, CH; Chien, KL; Chou, WY; Chou, YC; Chu, CH; Hwang, LC; Su, TC; Sun, CA; Tseng, CH; Yang, T; You, SL, 2012) |
| " Associations between uric acid (UA), metabolic syndrome (MetS) and carotid IMT have been reported, but findings regarding the relationship have been inconsistent." | 3.78 | Uric acid is an independent risk factor for carotid atherosclerosis in a Japanese elderly population without metabolic syndrome. ( Abe, M; Kawamoto, R; Kusunoki, T; Onji, M; Takayama, S, 2012) |
| "Baseline levels of serum uric acid were negatively correlated with HbA1c, were higher in men and in the elderly and were independently associated with components of the metabolic syndrome." | 3.78 | Uric acid is not an independent predictor of cardiovascular mortality in type 2 diabetes: a population-based study. ( Barutta, F; Bruno, G; Cavallo-Perin, P; Fornengo, P; Ghezzo, G; Greco, E; Gruden, G; Panero, F; Perotto, M; Runzo, C, 2012) |
| " Women were grouped according to diagnosis (pre-eclampsia or gestational hypertension) and logistic regression analysis was used to determine the relationship between uric acid, haemoglobin, haematocrit and adverse outcomes; an α level of P < 0." | 3.78 | Plasma uric acid remains a marker of poor outcome in hypertensive pregnancy: a retrospective cohort study. ( Brown, MA; Davis, GK; Hawkins, TL; Mangos, GJ; Roberts, JM; Roberts, LM, 2012) |
| "These were post hoc analyses of datasets from the Aspirin Myocardial Infarction Study, a 1:1 randomized, double-blind clinical trial, conducted from 1975 to 1979, that examined mortality rates following daily aspirin administration over three years in individuals with documented MI." | 3.78 | Hyperuricemia and untreated gout are poor prognostic markers among those with a recent acute myocardial infarction. ( Dabbous, O; Hariri, A; Krishnan, E; Lingala, B; Pandya, BJ, 2012) |
| "Several genome-wide association studies (GWASs) have reported associations between single nucleotide polymorphisms (SNPs) and uric acid concentrations or gout in a number of different ethnic populations." | 3.78 | Association between gout and polymorphisms in GCKR in male Han Chinese. ( Chu, N; Han, L; Li, C; Liu, S; Ma, X; Meng, D; Miao, Z; Wang, B; Wang, J; Zhang, K, 2012) |
| "These nationally representative data indicate that serum PTH levels are independently associated with serum uric acid levels and the frequency of hyperuricemia at the population level." | 3.78 | The independent association between parathyroid hormone levels and hyperuricemia: a national population study. ( Choi, HK; Choi, JW; Hui, JY; Mount, DB; Zhang, Y; Zhu, Y, 2012) |
| "For more than 200 years initially seen as a cause of gout, speaking in a politically correct 21st century term, a disease of the rich and very well nourished people, many experimental and epidemiological studies have associated increased levels of serum uric acid (UA) with the classical components of the metabolic syndrome (MS), type 2 diabetes, and cardiovascular disease [1]." | 3.78 | Elevated uric acid, the metabolic syndrome and cardiovascular disease: cause, consequence, or just a not so innocent bystander? ( Santos, RD, 2012) |
| "Although hyperuricemia is suggested to increase allantoin production in both pro- and antioxidant manners, it remains undetermined whether it increases the serum concentration of allantoin." | 3.78 | Relationship between serum allantoin and urate in healthy subjects and effects of benzbromarone in gout patients. ( Koga, M; Koyama, H; Kurajoh, M; Moriwaki, Y; Shoji, T; Sumida, C; Tsutsumi, Z; Yamamoto, A; Yamamoto, T, 2012) |
| " We reasoned that AKI resulted from hyperuricemia during MZ administration because serum concentrations of uric acid (31." | 3.78 | A case of acute kidney injury with marked hyperuricemia during mizoribine administration. ( Kohno, S; Nishino, T; Obata, Y; Ohta, Y; Shinzato, K; Shinzato, T; Yamashita, H, 2012) |
| "The aim of this study was to explore the prognostic role of serum uric acid (UA) measurement in the hospital and long-term mortality assessment in subjects with acute heart failure (AHF) from the Acute HEart FAilure Database registry (AHEAD)." | 3.78 | Uric acid, allopurinol therapy, and mortality in patients with acute heart failure--results of the Acute HEart FAilure Database registry. ( Coufal, Z; Fedorco, M; Jarkovský, J; Krűger, A; Linhart, A; Málek, F; Miklík, R; Ošťádal, P; Pařenica, J; Špinar, J; Vítovec, J; Vondraková, D; Widimský, P, 2012) |
| "0 mg/dL within 1 year after transplantation were defined as having hyperuricemia, and all were treated with allopurinol." | 3.78 | Hyperuricemia at 1 year after renal transplantation, its prevalence, associated factors, and graft survival. ( Habuchi, T; Horikawa, Y; Inoue, T; Kagaya, H; Maita, S; Miura, M; Narita, S; Numakura, K; Obara, T; Saito, M; Satoh, S; Tsuchiya, N; Tsuruta, H, 2012) |
| " trichocarpha, its ethyl acetate fraction and its main bioactive compounds could be useful to treat gouty arthritis by countering hyperuricemia and inflammation." | 3.78 | Pharmacological basis for use of Lychnophora trichocarpha in gouty arthritis: anti-hyperuricemic and anti-inflammatory effects of its extract, fraction and constituents. ( de Paula, CA; de Souza Filho, JD; de Souza, MR; Grabe-Guimarães, A; Pereira de Resende, ML; Saúde-Guimarães, DA, 2012) |
| "Several works observed a link between uric acid serum levels and clinical and histological features of nonalcoholic fatty liver disease." | 3.78 | Hyperuricaemia: another metabolic feature affecting the severity of chronic hepatitis because of HCV infection. ( Cabibi, D; Cammà, C; Craxì, A; Macaluso, FS; Marco, VD; Petta, S, 2012) |
| "The uricosuric and nephroprotective actions of resveratrol and its analogues were mediated by regulating renal organic ion transporters in hyperuricemic mice, supporting their beneficial effects for the prevention of hyperuricemia." | 3.78 | Antihyperuricemic and nephroprotective effects of resveratrol and its analogues in hyperuricemic mice. ( Hong, Y; Kong, LD; Li, Z; Liu, L; Liu, YL; Shi, YW; Wang, CP; Wang, X, 2012) |
| "These findings demonstrate that mangiferin has the potential to be developed as a new therapeutic agent for the treatment of hyperuricemia and gout." | 3.78 | Reducing effect of mangiferin on serum uric acid levels in mice. ( Gao, L; Li, L; Lin, H; Liu, X; Lu, W; Niu, Y, 2012) |
| "As elevated serum uric acid (SUA) is an independent risk factor for hypertension, we examined whether baseline SUA may influence the blood pressure (BP) response to antihypertensive medications." | 3.78 | Effect of hyperuricemia on the blood pressure response to antihypertensive agents in hospitalized elderly patients. ( Chen, H; Hong, D; Lin, C; Lin, F; Lin, K; Zhu, P, 2012) |
| "Over the past century, uric acid has been considered a possible risk factor for hypertension and cardiovascular disease." | 3.78 | Hyperuricemia and hypertension. ( Feig, DI, 2012) |
| "Maximum weight is a strong risk factor for increased uric acid level in the Chinese population, which might serve as a novel clinical indicator suggesting hyperuricemia." | 3.78 | Association of maximum weight with hyperuricemia risk: a retrospective study of 21,414 Chinese people. ( Chen, F; Fu, J; Gao, B; Ge, J; Ji, Q; Jia, H; Lau, WB; Li, X; Wan, Y; Wang, L; Xing, Y; Zhang, N; Zhang, Y; Zhao, X; Zhou, J, 2012) |
| "Individuals with hypertension and hyperuricemia have an increased risk of coronary artery disease and cerebral vascular disease as compared to patients with normal uric acid levels." | 3.77 | A multicenter study of the association of serum uric acid, serum creatinine, and diuretic use in hypertensive patients. ( Chen, CY; Chen, GY; Huang, CH; Huang, WP; Hung, YJ; Lee, DY; Lin, CS; Tzeng, TF, 2011) |
| "Uric acid, the levels of which have been shown to increase after menopause, has been associated with metabolic syndrome." | 3.77 | Relationship between uric acid and metabolic syndrome according to menopausal status. ( Ahn, KH; Cho, GJ; Hur, JY; Kim, SH; Kim, T; Kim, YT; Lee, HJ; Park, HT; Shin, JH; Yi, KW, 2011) |
| "Experiments were performed in freshly harvested aortas from untreated animals and rats fed with oxonic acid (hyperuricemia), and compared to hyperuricemic rats treated with either allopurinol, benzbromarone or arginine." | 3.77 | Hyperuricemia attenuates aortic nitric oxide generation, through inhibition of arginine transport, in rats. ( Chernichovski, T; Engel, A; Grupper, A; Hillel, O; Schwartz, D; Schwartz, IF, 2011) |
| "The aim of this study was to examine the independent relationship between serum uric acid (SUA) and blood pressure, and to assess their joint effects on obesity, fasting glucose and lipids." | 3.77 | Interaction between serum uric acid and triglycerides in relation to blood pressure. ( Liang, J; Song, H; Teng, F; Xue, Y; Yang, M; Zhu, R; Zou, C, 2011) |
| "Xanthine oxidase is a key enzyme that catalyses hypoxanthine and xanthine to uric acid and the overproduction of uric acid will lead to hyperuricemia which is an important cause of gout." | 3.77 | 3,5,2',4'-Tetrahydroxychalcone, a new non-purine xanthine oxidase inhibitor. ( Fan, H; Li, L; Liu, J; Liu, X; Lu, W; Niu, Y; Sun, L; Zhu, H, 2011) |
| "First trimester elevated uric acid was associated with later pre-eclampsia and more strongly with pre-eclampsia and gestational hypertension with hyperuricemia." | 3.77 | First trimester uric acid and adverse pregnancy outcomes. ( Catov, J; Gandley, RE; Laughon, SK; Powers, RW; Roberts, JM, 2011) |
| "XZCBD could significantly reduce the serum uric acid level; its effect on hyperuricemia might be through affecting microRNA expressions." | 3.77 | MicroRNA expression patterns of the kidney in hyperuricemia mice treated with Xiezhuo Chubi Decoction. ( Feng, SM; Liang, J; Sun, FY; Sun, WF; Wang, T; Xu, W; Zhang, XX, 2011) |
| "To explore the association of elevated serum uric acid with metabolic disorders and the risk factors of hyperuricemia in type 2 diabetes mellitus (T2DM)." | 3.77 | [Association of elevated uric acid with metabolic disorders and analysis of the risk factors of hyperuricemia in type 2 diabetes mellitus]. ( LI, SH; LIU, H; WU, D, 2011) |
| "Hyperuricemia was defined as a serum uric acid concentration of at least 7." | 3.77 | Hyperuricemia after renal transplantation. ( Einollahi, B; Hossieni, MS; Kalantar, E; Khalili, N; Rostami, Z, 2011) |
| "Serum uric acid (UA) is positively associated with hypertension (HTN)." | 3.77 | Serum uric acid is associated with high blood pressure in pediatric hemodialysis patients. ( Feig, DI; Goldstein, SL; Mattison, P; Midgley, L; Moudgil, A; Silverstein, DM; Srivaths, PR; Upadhyay, K, 2011) |
| " MetS was defined according to Japanese criteria, and serum uric acid (UA) levels in the upper half of the fifth (highest) quintile range were defined as severe hyperuricemia, whereas those in the lower half of this quintile range were defined as mild hyperuricemia." | 3.77 | Relationships among hyperuricemia, metabolic syndrome, and endothelial function. ( Higashi, Y; Inoue, T; Ishibashi, Y; Node, K; Sata, M; Shimada, K; Takase, B; Tomiyama, H; Ueda, S; Yamashina, A, 2011) |
| "To examine the association between renal function, serum uric acid and markers of both pro-inflammatory and prothrombotic state in patients with diabetes mellitus (DM), metabolic syndrome and coronary artery disease." | 3.77 | Uric acid as a link between renal dysfunction and both pro-inflammatory and prothrombotic state in patients with metabolic syndrome and coronary artery disease. ( Buraczyńska, MJ; Kondracki, B; Rychta, E; Waciński, P; Wysokiński, A; Zapolski, T, 2011) |
| "Trichlormethiazide, a thiazide diuretic, was introduced in 1960 and remains one of the most frequently used diuretics for treating hypertension in Japan." | 3.77 | Adverse effect profile of trichlormethiazide: a retrospective observational study. ( Asai, S; Nakayama, T; Nishida, Y; Takahashi, Y, 2011) |
| " Previous studies using uric acid-lowering drugs in normouricemic animals are not suitable to answer the effect of hyperuricemia on ventricular remodeling after myocardial infarction." | 3.77 | Impact of elevated uric acid on ventricular remodeling in infarcted rats with experimental hyperuricemia. ( Chen, CC; Hsu, YJ; Lee, TM, 2011) |
| " This study investigated trends in uric acid levels, hyperuricemia and gout among adults in Taiwan from 1993-1996 to 2005-2008, using data collection from, Nutrition and health surveys in Taiwan (NAHSIT) conducted in 1993-1996 and 2005-2008." | 3.77 | Trends in hyperuricemia and gout prevalence: Nutrition and Health Survey in Taiwan from 1993-1996 to 2005-2008. ( Chuang, SY; Hsieh, YT; Lee, SC; Pan, WH, 2011) |
| "The average uric acid concentration of patients with psoriasis was not significantly different from that of the healthy population, for both genders (P > 0." | 3.77 | Cross-sectional study on the correlation of serum uric acid with disease severity in Korean patients with psoriasis. ( Choi, JW; Kwon, HH; Kwon, IH; Youn, JI, 2011) |
| " Subjects were further categorized into 3 diagnostic groups: gout, asymptomatic hyperuricemia (no gout, serum uric acid [UA] ≥6." | 3.77 | Reproducibility of musculoskeletal ultrasound for determining monosodium urate deposition: concordance between readers. ( Gyftopoulos, S; Howard, RG; Pillinger, MH; Samuels, J; Swearingen, CJ; Thiele, RG, 2011) |
| " Hyperuricemia (serum uric acid >7 mg/dL) was found in 15." | 3.77 | Joint association of hyperuricemia and reduced GFR on cardiovascular morbidity: a historical cohort study based on laboratory and claims data from a national insurance provider. ( Dukes, J; Hinyard, LJ; Lentine, KL; Neri, L; Pinsky, B; Rocca Rey, LA; Schnitzler, MA; Xiao, H, 2011) |
| " In this line recent studies observed an independent link between higher uric acid serum levels and clinical diagnosis of non-alcoholic fatty liver disease (NAFLD)." | 3.77 | Hyperuricemia is associated with histological liver damage in patients with non-alcoholic fatty liver disease. ( Cabibi, D; Cammà, C; Craxì, A; Di Marco, V; Petta, S, 2011) |
| "Hyperuricemia-mediated uric acid crystal formation may cause joint inflammation and provoke the destruction of joints through the activation of inflammasome-mediated innate immune responses." | 3.77 | Activation of human fibroblast-like synoviocytes by uric acid crystals in rheumatoid arthritis. ( Chen, DP; Lam, CW; Li, EK; Tam, LS; Wong, CK, 2011) |
| "We have retrospectively evaluated the uric acid control status and renal function changes over a period of up to 7 years in 35 patients with renal impairment who had stage 3 or higher chronic kidney disease (CKD; stage 3 in 32 patients, stage 4 in 2 patients, and stage 5 in 1 patient) associated with hyperuricemia and were receiving monotherapy with benzbromarone as an antihyperuricemic drug." | 3.77 | Efficacy of benzbromarone in hyperuricemic patients associated with chronic kidney disease. ( Fujimori, S; Moromizato, H; Ooyama, H; Ooyama, K, 2011) |
| "Because approximately 70% of uric acid is excreted from the kidney, hyperuricemia occurs when renal function deteriorates." | 3.77 | Relationship between hyperuricemia and chronic kidney disease. ( Ohno, I, 2011) |
| "Recent genome-wide association studies showed that serum uric acid (SUA) levels relate to ABCG2/BCRP gene, which locates in a gout-susceptibility locus revealed by a genome-wide linkage study." | 3.77 | ABCG2/BCRP dysfunction as a major cause of gout. ( Hosoya, T; Ichida, K; Matsuo, H; Nakamura, T; Nakayama, A; Shinomiya, N; Suzuki, H; Takada, T, 2011) |
| " Hyperuricemia was defined if serum uric acid was ≥ 416." | 3.77 | Elderly renal transplant recipients and renal dysfunction: a risk factor for hyperuricemia. ( Einollahi, B; Einollahi, H; Rostami, Z, 2011) |
| "Of the 5461 community-dwelling older adults, >or=65 years, in the Cardiovascular Health Study without HF at baseline, 1505 had hyperuricemia (baseline serum uric acid >or=6 mg/dL for women and >or=7 mg/dL for men)." | 3.76 | Association between hyperuricemia and incident heart failure among older adults: a propensity-matched study. ( Aban, I; Ahmed, A; Anker, SD; Arnett, D; Bakris, G; Dell'Italia, LJ; Ekundayo, OJ; Filippatos, G; Lloyd-Jones, DM; Love, TE; Mujib, M; Sanders, PW, 2010) |
| "Allopurinol and urate oxidase are both effective in preventing or treating hyperuricemia during remission induction therapy for lymphoid malignancies, but to the authors' knowledge, their effects on concomitant anticancer drug therapy have not been compared." | 3.76 | Effect of allopurinol versus urate oxidase on methotrexate pharmacokinetics in children with newly diagnosed acute lymphoblastic leukemia. ( Crews, KR; Howard, SC; Jeha, S; Pauley, JL; Pui, CH; Relling, MV; Zhou, Y, 2010) |
| " Multivariate logistic regression analysis showed that the OR of having hyperuricemia at the 6-year followup was significantly associated with the Arg64 allele, after adjusting for age, weight gain, baseline levels of triglycerides, serum uric acid, and insulin resistance (OR 3." | 3.76 | Trp64Arg polymorphism of the ADRB3 gene predicts hyperuricemia risk in a population from southern Spain. ( de la Cruz Almaraz, M; García-Fuentes, E; Gómez-Zumaquero, JM; Martín-Núñez, GM; Morcillo, S; Rojo-Martínez, G; Ruiz de Adana, M; Soriguer, F, 2010) |
| "A high serum uric acid is common in subjects with pulmonary hypertension." | 3.76 | Could uric acid be a modifiable risk factor in subjects with pulmonary hypertension? ( Block, ER; Johnson, RJ; Lanaspa, M; Patel, JM; Swenson, ER; Zharikov, SI, 2010) |
| " Hyperuricemia was defined as a serum uric acid concentration of at least 420 micromol/l in men and 360 micromol/l in women." | 3.76 | Association of serum uric acid with aortic stiffness and pressure in a Chinese workplace setting. ( Chen, X; Huang, QF; Li, Y; Sheng, CS; Wang, JG; Zheng, Y, 2010) |
| " In our study, calcium and uric acid abnormalities were the most common, and vesicoureteral reflux seemed to be the most common urological abnormality which led to urinary stasis and calculus formation." | 3.76 | Metabolic factors associated with urinary calculi in children. ( Alamdaran, SA; Naseri, M; Varasteh, AR, 2010) |
| "We studied 40 patients with World Health Organization stage I-II essential hypertension, 9 with high serum UA levels (hyperuricemic group) and 31 with normal serum UA levels (normouricemic group, either normouricemics, n = 15, or formerly hyperuricemics in chronic allopurinol treatment, n = 16)." | 3.76 | Serum uric acid levels and renal damage in hyperuricemic hypertensive patients treated with renin-angiotensin system blockers. ( Berardino, S; Berni, A; Boddi, M; Cecioni, I; Chiostri, M; Fattori, EB; Montuschi, F; Poggesi, L, 2010) |
| "Recent genome-wide association and functional studies have shown that the ABCG2 gene encodes for a urate transporter, and a common causal ABCG2 variant, rs2231142, leads to elevated uric acid levels and prevalent gout among Whites and Blacks." | 3.76 | The rs2231142 variant of the ABCG2 gene is associated with uric acid levels and gout among Japanese people. ( Folsom, AR; Iso, H; Kitamura, A; Köttgen, A; Tanigawa, T; Yamagishi, K, 2010) |
| "Participants with hyperuricemia tended to have higher systolic blood pressure, sugar levels, body mass index, and cholesterol and triglyceride levels but lower estimated glomerular filtration rate (eGFR) levels; eGFR negatively correlated with serum uric acid level." | 3.76 | Hyperuricemia as an independent risk factor of chronic kidney disease in middle-aged and elderly population. ( Chang, HH; Chang, HY; Chao, YS; Chen, CY; Fang, KY; Hsu, YC; Jong, MC; Lee, PH; Lei, CC; Lin, CL; Lu, LC; Shih, YH; Tung, CW; Yang, HF, 2010) |
| " This has led to the hypothesis that uric acid may contribute to renal fibrosis and progressive renal disease." | 3.76 | Uric acid increases fibronectin synthesis through upregulation of lysyl oxidase expression in rat renal tubular epithelial cells. ( Junwei, Y; Lei, J; Li, F; Mingxia, X; Ping, W; Ruoyun, T; Weichun, H; Xiaohua, W; Yang, Z, 2010) |
| "We examined the relationship between serum uric acid levels and changes in renal circulation in women with twin pregnancy compared with those in women with singleton pregnancy." | 3.76 | Effect of changes in renal circulation on serum uric acid levels in women with twin pregnancy. ( Igarashi, M; Miyake, H; Suzuki, S, 2010) |
| "In this study, the antihyperuricemic effect of Acacia confusa heartwood extracts and their phytochemicals on potassium oxonate (PO)-induced acute hyperuricemia was investigated for the first time." | 3.76 | Phytochemicals from Acacia confusa heartwood extracts reduce serum uric acid levels in oxonate-induced mice: their potential use as xanthine oxidase inhibitors. ( Chang, ST; Chen, CS; Hsu, CA; Huang, CC; Tung, YT; Yang, SC, 2010) |
| "Rasburicase is indicated for the initial management of plasma uric acid levels in adults receiving anticancer therapy who are at risk for acute tumor lysis syndrome (TLS) and subsequent hyperuricemia." | 3.76 | Fixed-dose rasburicase 6 mg for hyperuricemia and tumor lysis syndrome in high-risk cancer patients. ( Shanholtz, CB; Thompson, JL; Vines, AN, 2010) |
| "Increased serum uric acid (UA) is associated with incident heart failure (HF)." | 3.76 | Effect of serum insulin on the association between hyperuricemia and incident heart failure. ( Aban, IB; Ahmed, A; Ahmed, MI; Aronow, WS; Desai, RV; Filippatos, GS; Fonarow, GC; White, M, 2010) |
| "To enable clinicians to initiate appropriate steps for long-term management of gout, including controlling acute exacerbations and pain and sustaining target serum uric acid (SUA) levels to control hyperuricemia as the underlying metabolic disorder." | 3.76 | The current state of care in gout: Addressing the need for better understanding of an ancient disease. ( Graser, E; Pope, RS; Zychowicz, ME, 2010) |
| "Familial Juvenile hyperuricemic nephropathy (FJHN, OMIM #162000) is a rare autosomal dominant disorder characterized by hyperuricemia with renal uric acid under-excretion, gout and chronic kidney disease." | 3.76 | A case of familial juvenile hyperuricemic nephropathy with novel uromodulin gene mutation, a novel heterozygous missense mutation in Korea. ( Kim, JK; Lee, DH; Lee, YK; Noh, JW; Oh, SE, 2010) |
| "Morin (2′,3,4′,5,7-pentahydroxyflavone), a plant-derived flavonoid, has beneficial effects on hyperuricemia and renal dysfunction in animals." | 3.76 | Morin improves urate excretion and kidney function through regulation of renal organic ion transporters in hyperuricemic mice. ( Kong, LD; Liu, L; Shi, YW; Wang, CP; Wang, X; Zhang, X, 2010) |
| "The aim of this study was to investigate the prevalence of hyperuricemia and factors predicting its occurrence, and to establish the relationship over time between serial changes in estimated glomerular filtration rate (eGFR) and uric acid (UR) concentration in kidney transplant (KT) recipients with eGFR >60 mL/min/1." | 3.76 | Hyperuricemia in kidney transplant recipients with intact graft function. ( Han, DJ; Kim, KM; Kim, SS; Park, JS; Park, SK; Yang, WS, 2010) |
| "Clinical studies have suggested that high levels of uric acid may contribute to the development of hypertension and kidney disease." | 3.76 | High levels of uric acid correlate with decline of glomerular filtration rate in chronic kidney disease. ( Choovichian, P; Duangurai, K; Kanjanakul, I; Nata, N; Phulsuksombuti, D; Satirapoj, B; Supasyndh, O; Utennam, D, 2010) |
| "The aim of the study was to investigate endothelial function in patients with arterial hypertension and impaired uric acid metabolism in comparison with patients having arterial hypertension and normal uric acid metabolism." | 3.76 | [Endothelial function in patients with arterial hypertension and impaired uric acid metabolism]. ( Lebedeva, MV; Minakova, EG; Pulin, AA; Severova, MM; Stakhova, TIu; Zaĭtseva, LI, 2010) |
| "The presence of hyperuricemia and renal function impairment, especially in the absence of urate stone formation is strongly suggestive of lead nephropathy." | 3.76 | Association of lead exposure, serum uric acid and parameters of renal function in Nigerian lead-exposed workers. ( Alasia, DD; Emem-Chioma, PC; Wokoma, FS, 2010) |
| "Epidemiologic studies suggest an independent positive association of elevated serum uric acid with essential hypertension." | 3.75 | Serum uric acid level in primary hypertension among Chinese nonagenarians/centenarians. ( Chen, T; Dong, B; Lu, Z; Wu, H; Wu, J; Xiao, H; Zhang, Y, 2009) |
| "In PsA patients without clinically evident CV disease there is a correlation between serum uric acid concentration and subclinical atherosclerosis." | 3.75 | Asymptomatic hyperuricemia and serum uric acid concentration correlate with subclinical atherosclerosis in psoriatic arthritis patients without clinically evident cardiovascular disease. ( Gomez-Acebo, I; Gonzalez-Gay, MA; Gonzalez-Juanatey, C; Llorca, J; Martin, J; Miranda-Filloy, JA; Paz-Carreira, J; Vazquez-Rodriguez, TR, 2009) |
| "The cases comprised 3028 male office workers with hyperuricemia (serum uric acid level >or=7." | 3.75 | The effect of the interaction between obesity and drinking on hyperuricemia in Japanese male office workers. ( Shiraishi, H; Une, H, 2009) |
| " Mortality from all causes, total cardiovascular disease (CVD), ischemic stroke, congestive heart failure, hypertensive disease, and coronary heart disease were compared according to increasing serum uric acid levels." | 3.75 | Serum uric acid level as an independent risk factor for all-cause, cardiovascular, and ischemic stroke mortality: a Chinese cohort study. ( Chen, HJ; Chen, JH; Chuang, SY; Pan, WH; Yeh, WT, 2009) |
| "Xanthine oxidase (XOD) catalyzes the oxidation of hypoxanthine to xanthine and then to uric acid, and is a key enzyme in the pathogenesis of hyperuricemia." | 3.75 | Lonicera hypoglauca inhibits xanthine oxidase and reduces serum uric acid in mice. ( Chien, SC; Kuo, YH; Tsay, HS; Tseng, YH; Wang, SY; Yang, CW, 2009) |
| "To determine longterm urate-lowering efficacy and clinical benefits and safety of therapy with febuxostat or allopurinol in subjects with gout." | 3.75 | Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. ( Becker, MA; Lademacher, C; Lloyd, E; MacDonald, PA; Schumacher, HR, 2009) |
| "The aim of this study was to investigate prevalences of hyperuricemia and the metabolic syndrome (MS) in the Hangzhou population, and the relationship between serum uric acid and the MS." | 3.75 | Hyperuricemia and the metabolic syndrome in Hangzhou. ( Cai, Z; Li, D; Wu, X; Xu, X; Zhou, C, 2009) |
| " Rosiglitazone was also administered to demonstrate whether improved insulin sensitivity would prevent high-purine diet induced renal injury and gouty-like lesions." | 3.75 | Insulin resistance acts as an independent risk factor exacerbating high-purine diet induced renal injury and knee joint gouty lesions. ( Gu, J; Li, C; Li, Y; Meng, D; Miao, Z; Wang, B; Wang, CY; Wang, J; Wang, L; Xing, X; Yan, S; Yuan, Y; Zhang, S, 2009) |
| "The association of elevated serum uric acid (UA) with cardiovascular events in patients with severe coronary artery stenosis was examined." | 3.75 | Elevated serum uric acid is an independent predictor for cardiovascular events in patients with severe coronary artery stenosis: subanalysis of the Japanese Coronary Artery Disease (JCAD) Study. ( Hayashi, D; Higaki, J; Irita, J; Kohro, T; Kurata, M; Miyoshi, K; Nagai, R; Okura, T; Yamazaki, T, 2009) |
| "We examined the association between serum uric acid (SUA) level and the frequency, risk, and cost of gout flares among the elderly." | 3.75 | Frequency, risk, and cost of gout-related episodes among the elderly: does serum uric acid level matter? ( Cahill, KE; Krishnan, E; Mody, RR; Patel, PA; Tang, J; Wu, EQ; Yu, AP, 2009) |
| "Hyperuricemia may play a role in the pathogenesis of cardiovascular disease, but uric acid is also a significant antioxidant." | 3.75 | Hyperuricemia, oxidative stress, and carotid artery tone in experimental renal insufficiency. ( Eräranta, A; Jolma, P; Kalliovalkama, J; Kurra, V; Moilanen, E; Mustonen, J; Myllymäki, J; Niemelä, O; Pörsti, I; Riutta, A; Tahvanainen, A; Vehmas, TI, 2009) |
| "The relationship among serum uric acid (SUA), metabolic syndrome, and chronic kidney disease (CKD) is unclear." | 3.75 | Serum uric acid is independently associated with metabolic syndrome in subjects with and without a low estimated glomerular filtration rate. ( Chen, HW; Chen, YM; Chuang, FH; Kuo, CF; Li, HY; See, LC; Yu, KH, 2009) |
| "Uric acid (UA) is an emerging cardiovascular (CV) risk factor that is associated with hypertension and CV disease (CVD) in the general population, but whose role in renal transplant recipients (RTR) has not been defined." | 3.75 | Role of uric acid in post-renal transplantation hypertension. ( Bandukwala, F; Huang, M; Prasad, GV, 2009) |
| "We sought to investigate whether uric acid concentrations are increased in pregnant women with insulin resistance and to correlate both with fetal growth." | 3.75 | Uric acid concentrations are associated with insulin resistance and birthweight in normotensive pregnant women. ( Catov, J; Laughon, SK; Roberts, JM, 2009) |
| "We prospectively analyzed the relationship between serum uric acid concentration at baseline and subsequent heart failure among the participants of the Framingham Offspring cohort (n=4912; mean baseline age, 36 years; 52% women)." | 3.75 | Hyperuricemia and incident heart failure. ( Krishnan, E, 2009) |
| "Serum uric acid (SUA) level is often elevated in participants with metabolic syndrome (MS), and hyperuricemia appears linked inextricably to the presence of MS." | 3.75 | The relationship between serum uric acid concentration and metabolic syndrome in university freshmen. ( Lin, KP, 2009) |
| "As oxonic acid diet increased plasma renin activity, plasma aldosterone, and urine K to Na ratio, these changes may play a significant role in the harmful cardiovascular actions of hyperuricemia." | 3.74 | Oxonic acid-induced hyperuricemia elevates plasma aldosterone in experimental renal insufficiency. ( Eräranta, A; Kööbi, P; Kurra, V; Lakkisto, P; Mustonen, JT; Niemelä, OJ; Pörsti, IH; Tahvanainen, AM; Tikkanen, I; Vehmas, TI, 2008) |
| " Fructose induced an increase in serum uric acid after 8-10 weeks of increased fructose exposure, but no correlation was found between hyperuricemia and hypertension." | 3.74 | Does an apple a day put hypertension in play? ( Günthner, T; Jankowski, J, 2008) |
| "High normal concentrations of serum uric acid (UA) are associated with mild cognitive dysfunction and increased cerebral ischemia as indexed by white matter hyperintensity volumes." | 3.74 | Cerebral ischemia mediates the effect of serum uric acid on cognitive function. ( Gordon, B; Jinnah, HA; Kraut, M; Schretlen, DJ; Vannorsdall, TD, 2008) |
| "We identified three genetic loci associated with uric acid concentration and gout." | 3.74 | Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study. ( Astor, BC; Benjamin, EJ; Boerwinkle, E; Coresh, J; Dehghan, A; Fox, CS; Hofman, A; Hwang, SJ; Kao, WL; Köttgen, A; Levy, D; Rivadeneira, F; van Duijn, CM; Witteman, JC; Yang, Q, 2008) |
| "Data on children with IgAN from two pediatric nephrology centers were retrospectively reviewed (renal biopsy - subclasses according Hass I-V, ambulatory blood pressure monitoring ABPM, serum uric acid, proteinuria)." | 3.74 | Ambulatory blood pressure, proteinuria and uric acid in children with IgA nephropathy and their correlation with histopathological findings. ( Dusek, J; Groene, HJ; Janda, J; John, U; Misselwitz, J; Pohl, M; Seeman, T; Stejskal, J; Vondrák, K, 2008) |
| "In rats with hyperuricemia induced by 2% oxonic acid and 0." | 3.74 | Activation of ATP-sensitive potassium channels protects vascular endothelial cells from hypertension and renal injury induced by hyperuricemia. ( Chen, K; Cui, WY; Liu, GS; Long, CL; Pan, ZY; Qin, XC; Wang, H; Zhang, YF, 2008) |
| "To analyze the association of hyperuricemia with incidence of carotid plaque in general population and furthermore to explore the predictive value of serum uric acid in the early prevention of atherosclerotic disease." | 3.74 | [The association between hyperuricemia and prevalence of carotid plaque]. ( Li, Y; Li, ZA; Liu, J; Wang, W; Yong, Q; Zhao, D, 2008) |
| "To investigate the state of oxidative stress in the subjects with different levels of serum uric acid and to explore the cause of endothelial dysfunction induced by hyperuricemia." | 3.74 | [Oxidative stress and endothelial dysfunction at different serum uric acid levels]. ( Jia, SD; Li, HF; Li, J; Wang, HY; Wang, YG, 2008) |
| "In severe chronic heart failure (CHF) elevated serum levels of uric acid (UA) predict poor survival." | 3.74 | Hyperuricaemia predicts poor outcome in patients with mild to moderate chronic heart failure. ( Banasiak, W; Borodulin-Nadzieja, L; Jankowska, EA; Majda, J; Ponikowska, B; Ponikowski, P; Reczuch, K; Trzaska, M; Zymlinski, R, 2007) |
| "Results from this study suggest that mutation of 5-MTHFR C677T contributes to the higher uric acid levels in both males and females and may be a risk factor for hyperuricemia." | 3.74 | Association of methylenetetrahydrofolate reductase (C677T) polymorphism with hyperuricemia. ( Al-Shboul, QM; Aminzadeh, MA; Golbahar, J; Kassab, S; Rezaian, GR, 2007) |
| "Uric acid (UA) may be involved in chronic heart failure (HF) pathogenesis, entailing a worse outcome." | 3.74 | Hyperuricaemia and long-term outcome after hospital discharge in acute heart failure patients. ( Antolinos, MJ; Hurtado-Martínez, JA; Pascual-Figal, DA; Redondo, B; Ruiperez, JA; Valdes, M, 2007) |
| "The aim of this project was to study the risk of developing hypertension over a 6-year follow-up in normotensive men with baseline hyperuricemia (serum uric acid >7." | 3.74 | Hyperuricemia and incidence of hypertension among men without metabolic syndrome. ( Krishnan, E; Kuller, L; Kwoh, CK; Schumacher, HR, 2007) |
| " Single-dose treatment with UA, as well as acute hyperuricemia induced by the inhibition of uricase, caused a robust mobilization of EPCs, whereas administration of adenosine or inosine seemed to lack this effect." | 3.74 | Uric acid heralds ischemic tissue injury to mobilize endothelial progenitor cells. ( Chintala, S; Gobe, GG; Goligorsky, MS; Patschan, D; Patschan, S, 2007) |
| "Epidemiological studies have shown that a high serum uric acid concentration is a risk factor for coronary artery disease (CAD)." | 3.74 | Independent association of high serum uric acid concentration with angiographically defined coronary artery disease. ( Bogavac-Stanojević, N; Jelić-Ivanović, Z; Memon, L; Spasić, S; Spasojević-Kalimanovska, V, 2007) |
| "By using data from 8669 participants aged 20 years and more in The Third National Health and Nutrition Examination Survey (1988-1994), we determined the prevalence of the metabolic syndrome at different serum uric acid levels." | 3.74 | Prevalence of the metabolic syndrome in individuals with hyperuricemia. ( Choi, HK; Ford, ES, 2007) |
| "Hyperuricemia is a common complication in renal transplant recipients, and uric acid (UA) may play a role in renal dysfunction." | 3.74 | Is uric acid a predictive factor for graft dysfunction in renal transplant recipients? ( Akgul, A; Arat, Z; Bilgic, A; Haberal, M; Ibis, A; Ozdemir, FN, 2007) |
| "These findings from a nationally representative sample of US adults suggest that coffee consumption is associated with lower serum uric acid level and hyperuricemia frequency, but tea consumption is not." | 3.74 | Coffee, tea, and caffeine consumption and serum uric acid level: the third national health and nutrition examination survey. ( Choi, HK; Curhan, G, 2007) |
| " The uric acid-lowering effects and regulatory effects on autonomic functions of SYGCT in vegetarians with asymptomatic hyperuricemia were evaluated in the present study." | 3.74 | Hypouricemic effect and regulatory effects on autonomic function of Shao-Yao Gan-Cao Tang, a Chinese herbal prescription, in asymptomatic hyperuricemic vegetarians. ( Chen, LC; Wu, TH; Yang, LL, 2007) |
| " Additionally, serum uric acid is positively associated with metabolic syndrome." | 3.74 | Relationship between hyperuricemia and metabolic syndrome. ( Chen, JH; Chen, LQ; Chen, LY; Chen, ZW; Dai, HL; Fang, LZ; Ren, JJ; Zhu, WH, 2007) |
| "We investigated the relationship between serum uric acid (SUA) and body fat area, serum lipid level, insulin resistance, and metabolic syndrome in Japanese men." | 3.74 | Relationship between hyperuricemia and body fat distribution. ( Hikita, M; Hosoya, T; Ichida, K; Mori, Y; Ohno, I; Yokose, T, 2007) |
| " Potassium supplementation improves their insulin resistance and hypertension, whereas allopurinol reduces serum levels of uric acid and ameliorates hypertension, hypertriglyceridemia, hyperglycemia, and insulin resistance." | 3.74 | Thiazide diuretics exacerbate fructose-induced metabolic syndrome. ( Johnson, RJ; Mu, W; Nakagawa, T; Reungjui, S; Roncal, CA; Sirivongs, D; Srinivas, TR, 2007) |
| "Hyperuricemia has been reported as being an adverse effect of pegylated-interferon-alpha2b (Peg-IFNalpha2b) and ribavirin combination therapy for chronic hepatitis C and hyperuricemic changes occur in some patients during the therapy." | 3.74 | Investigation of hyperuricemia during pegylated-interferon-alpha2b plus ribavirin combination therapy in patients with chronic hepatitis C. ( Enjoji, M; Higuchi, N; Horikawa, Y; Kato, M; Kinukawa, N; Kotoh, K; Nakamuta, M; Tajiri, H; Takayanagi, R; Ueda, A; Yamashita, N, 2008) |
| "Greater intakes of total vitamin C were significantly associated with lower serum uric acid concentrations, after adjustment for smoking, BMI, ethnicity, blood pressure, presence of gout, use of aspirin, and intake of energy, alcohol, dairy protein, fructose, meat, seafood and coffee." | 3.74 | Vitamin C intake and serum uric acid concentration in men. ( Ascherio, A; Choi, HK; Curhan, G; Forman, JP; Gao, X, 2008) |
| "Serum uric acid (UA) has been implicated in the pathogenesis of hypertension." | 3.73 | Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence. ( D'Agostino, RB; Kannel, WB; Levy, D; Sullivan, L; Sundström, J; Vasan, RS, 2005) |
| "Uric acid has been proposed as an important risk factor in the development of primary hypertension in humans." | 3.73 | Childhood uric acid predicts adult blood pressure: the Bogalusa Heart Study. ( Alper, AB; Berenson, GS; Chen, W; Hamm, LL; Srinivasan, SR; Yau, L, 2005) |
| " We evaluated the hypouricemic effect of propolis from China on hyperuricemia induced by the uricase inhibitor, oxonic acid (500 mg/kg p." | 3.73 | [Xanthine oxidase inhibitory activity and hypouricemia effect of propolis in rats]. ( Nishioka, N; Tsuji, T; Yoshizumi, K, 2005) |
| " Partial HPRT deficiency usually causes hyperuricemia, precocious gout, and uric acid nephrolithiasis." | 3.73 | Eighteen-year follow-up of a patient with partial hypoxanthine phosphoribosyltransferase deficiency and a new mutation. ( Gregoric, A; Kokalj Vokac, N; Rabelink, GM; Varda, NM; Zagradisnik, B, 2005) |
| "Patients with system lupus erythematosus, rheumatic arthritis, chronic active hepatitis and gout were found to have considerable hyperuricemia and be decreased in aminoacides content, which are the predecessors of purine." | 3.73 | [Hyperuricemia and disorders in content of amino acids-purine precursors in patients with autoimmune diseases and gout]. ( Anan'eva, MN; Dubiaga, VV; Nikolenko, IuI; Nikolenko, VIu; Shchukin, IN; Siniachenko, OV, 2005) |
| "To find out if there is any association between serum uric acid level and positional vertigo." | 3.73 | Benign positional vertigo and hyperuricaemia. ( Adam, AM, 2005) |
| "The effects of acacetin (1) and 4,5-O-dicaffeoylquinic acid methyl ester (2), compounds contained in the flowers of Chrysanthemum sinense SABINE, on the serum uric acid level were investigated using the rats pretreated with the uricase inhibitor potassium oxonate as an animal model for hyperuricemia." | 3.73 | Hypouricemic effects of acacetin and 4,5-o-dicaffeoylquinic acid methyl ester on serum uric acid levels in potassium oxonate-pretreated rats. ( Awale, S; Kadota, S; Matsumoto, K; Murakami, Y; Nguyen, MT; Shi, L; Tezuka, Y; Tran, QL; Ueda, JY; Zaidi, SF, 2005) |
| "We investigated changes in serum uric acid across pregnancy in women with gestational hyperuricemia at delivery, with and without preeclampsia, compared with normal pregnant and women with preeclampsia without gestational hyperuricemia." | 3.73 | Uric acid concentrations in early pregnancy among preeclamptic women with gestational hyperuricemia at delivery. ( Bodnar, LM; Cooper, KM; Daftary, AR; Frank, MP; Gallaher, MJ; Ness, RB; Powers, RW; Roberts, JM, 2006) |
| "Hyperuricemia is considered a feature of the metabolic syndrome (MS) despite serum uric acid (SUA) is not considered a diagnostic criterion." | 3.73 | [Serum urate levels and urinary uric acid excretion in subjects with metabolic syndrome]. ( Bascuñana-Quirell, A; Benítez-Rodríguez, E; Elvira-González, J; Escribano-Serrano, J; López-Suárez, A; Michán-Doña, A; Rosal-Obrador, J, 2006) |
| "To evaluate the relationship between uric acid (UA) and peripheral arterial disease (PAD) in Chinese patients with coronary heart disease (CHD)." | 3.73 | [Study on the independent association of uric acid levels with peripheral arterial disease in Chinese patients with coronary heart disease]. ( Hasimu, B; Hu, DY; Li, J; Yu, JM; Zheng, LQ, 2006) |
| "In adults, serum uric acid levels are positively correlated with body mass index (BMI) and hyperuricemia is considered to be a common lifestyle disorder related with obesity." | 3.73 | Serum uric acid as an obesity-related indicator in early adolescence. ( Komatsu, K; Miyashita, M; Ohno, T; Oyama, C; Oyamada, M; Oyamada, T; Saito, S; Takada, G; Takahashi, T; Takashina, K, 2006) |
| "Adherence to published allopurinol dosing guidelines led to suboptimal control of hyperuricemia in this population of patients with gout." | 3.73 | Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. ( Dalbeth, N; Gow, P; Kumar, S; Stamp, L, 2006) |
| "To study the islet beta-cell function in patients with simple hyperuricemia (HUA) and to explore the relationship between the level of serum uric acid and insulin resistance." | 3.73 | [An analysis of islet beta-cell function in hyperuricemia]. ( Jia, SD; Li, J; Wang, YG, 2006) |
| "During normal pregnancy, plasma concentrations of creatinine and uric acid normally decrease as a consequence of their increased glomerular filtration." | 3.73 | Relationship between serum uric acid, creatinine, albumin and gestational diabetes mellitus. ( Danişman, N; Güngör, ES; Mollamahmutoğlu, L, 2006) |
| "To study effects of uric acid disbolism in combination with other metabolic disturbances on prevalence and clinical symptoms of arterial hypertension; contribution of uric acid nephropathy to its development." | 3.73 | [Relationships between arterial hypertension, metabolic disturbances and uric acid nephropathy]. ( Balkarov, IM; Britov, AN; Deev, AD; Eliseeva, NA, 2006) |
| "Experimental evidence supports a causative role for uric acid in the pathogenesis of hypertension." | 3.73 | Uric acid and the development of hypertension: the normative aging study. ( Gaziano, M; Gumieniak, O; Litonjua, AA; Perlstein, TS; Sparrow, D; Vokonas, PS; Weiss, ST; Williams, GH, 2006) |
| "The plasma levels of lipoproteins, cholesterol, triglycerides and uric acid, and the renal excretion of uric acid were studied in 68 patients with gout and in another control group of 50 healthy subjects." | 3.72 | The elevated prevalence of apolipoprotein E2 in patients with gout is associated with reduced renal excretion of urates. ( Cardona, F; Collantes, E; Escudero, A; García-Fuentes, E; Soriguer, FJ; Tinahones, FJ, 2003) |
| "To explore the factors influencing serum uric acid concentrations and the prevalence of hyperuricemia in aboriginal children from an area in Taiwan with a high prevalence of gouty arthritis." | 3.72 | The epidemiology of hyperuricemia in children of Taiwan aborigines. ( Li, TC; Lin, CC; Liu, CS, 2003) |
| "Serum uric acid (UA) could be a valid prognostic marker and useful for metabolic, hemodynamic, and functional (MFH) staging in chronic heart failure (CHF)." | 3.72 | Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. ( Anker, SD; Cicoira, M; Coats, AJ; Davos, CH; Doehner, W; Francis, D; Hetzer, R; Kemp, M; Knosalla, C; Leyva, F; Osterziel, KJ; Ponikowski, P; Rauchhaus, M; Segal, R; Shamim, W; Sharma, R, 2003) |
| " The cardinal clinical features in individuals with the uromodulin mutation included hyperuricemia, decreased fractional excretion of uric acid, and chronic interstitial renal disease leading to end-stage renal disease (ESRD) in the fifth through seventh decade." | 3.72 | Clinical characterization of a family with a mutation in the uromodulin (Tamm-Horsfall glycoprotein) gene. ( Bleyer, AJ; Deterding, E; Ganier, D; Gorry, MC; Hart, TC; McBride, D; Sandhu, J; Satko, SG; Shihabi, Z; Weller, N; Woodard, AS; Xu, L; Zhu, H, 2003) |
| "Overactivity of phosphoribosylpyrophosphate synthetase (PRS) is an X chromosome-linked disorder of purine metabolism that is characterized by gout with uric acid overproduction and, in some families, neurodevelopmental impairment." | 3.72 | Phosphoribosylpyrophosphate synthetase overactivity as a cause of uric acid overproduction in a young woman. ( Ahmed, M; Becker, MA; García-Pavía, P; García-Puig, J; Rivero, M; Torres, RJ, 2003) |
| "Experimental animal models suggest that uric acid might have a pathogenic role in the early development of primary hypertension." | 3.72 | Hyperuricemia in childhood primary hypertension. ( Feig, DI; Johnson, RJ, 2003) |
| "In 99% of the cases, the underlying cause of gout is an inborn disorder of uric acid excretion." | 3.72 | [Avoid purine-rich foods, drink a lot, reduce weight. The most important recipes against hyperuricemia]. ( Benecke, M, 2003) |
| " Besides alcohol consumption and the use of antihypertensive therapy, mainly diuretics, serum uric acid is markedly associated with parameters of the metabolic syndrome, in particular serum triglycerides." | 3.72 | Prevalence of hyperuricemia and relation of serum uric acid with cardiovascular risk factors in a developing country. ( Bovet, P; Burnier, M; Conen, D; Paccaud, F; Riesen, W; Shamlaye, C; Wietlisbach, V, 2004) |
| "The aim of the present study was to determine the change of serum uric acid (UA) levels in male adolescents and to characterize the relationship between UA levels and obesity or its related factors." | 3.72 | Recent trends of hyperuricemia and obesity in Japanese male adolescents, 1991 through 2002. ( Kishida, M; Matsumoto, Y; Matsuura, K; Mimura, Y; Ogura, T; Otsuka, F; Tobe, K, 2004) |
| "A 7-year followup study among men with hyperuricemia was conducted to study the longterm relationships between serum uric acid concentrations and cardiovascular diseases." | 3.72 | Hypertension was the major risk factor leading to development of cardiovascular diseases among men with hyperuricemia. ( Chen, CH; Chou, P; Lin, KC; Tsao, HM, 2004) |
| "Anthropometric parameters, blood lipid spectrum, levels of glucose, uric acid (UA), immunoreactive insulin, HOMA index were studied in 55 male patients with gout (mean age 50." | 3.72 | [Insulin resistance syndrome in patients with gout and its influence on formation of clinical characteristics of the disease]. ( Barskova, VG; Eliseev, MS; Iakunina, IA; Il'inykh, EV; Nasonov, EL; Zilov, AV, 2004) |
| "We have observed that the elevated plasma adenosine levels are associated with hyperuricemia in nonpreeclamptic twin pregnancies." | 3.72 | Maternal plasma hypoxanthine levels in nonpreeclamptic twin pregnancies. ( Suzuki, S; Yoneyama, Y, 2004) |
| "Serum uric acid independently predicted blunted renal vascular responsiveness to Ang II, consistent with results from experimental hyperuricemia showing an activated intrarenal RAS." | 3.72 | Uric acid and the state of the intrarenal renin-angiotensin system in humans. ( Brown, NJ; Fisher, ND; Gumieniak, O; Hollenberg, NK; Hopkins, PN; Murphey, LJ; Perlstein, TS; Williams, GH, 2004) |
| "Uric acid stones occur in 10% of all kidney stones and are the second most-common cause of urinary stones after calcium oxalate and calcium phosphate calculi." | 3.72 | [Diagnosis and prevention of uric acid stones]. ( Bonny, O; Ferrari, P, 2004) |
| "We have examined whether hyperuricemia in essential hypertension may be related to an increased insulin secretion thereby enhancing the tubular reabsorption of sodium and thus uric acid." | 3.72 | The pathophysiology of hyperuricemia in essential hypertension: a pilot study. ( Bernardino, JI; Campo, C; Grande, C; Puig, JG; Ruilope, LM; Sancho, T; Torres, RJ, 2004) |
| "Blood levels of uric acid, cholesterol, triglycerides (TG), high and low density lipoproteins were examined and glucose tolerance test was made in 108 adolescents with arterial hypertension (AH) and different physical constitution (normal, with overweight and obese)." | 3.72 | [Arterial hypertension in adolescents with different physical constitution including those with signs of metabolic syndrome]. ( Kazakova, LM; Rovda, EIu; Rovda, IuI; Rovda, TS, 2004) |
| "Humans have a non-sense codon inserted into the 5 prime end of the open reading frame of urate oxidase, and thus express an enzymatically inactive fragment of this enzyme; and consequently are unable to metabolize uric acid into allantoin and are prone to develop hyperuricemia and gout." | 3.71 | Uricase formulated with polyethylene glycol (uricase-PEG 20): biochemical rationale and preclinical studies. ( Bomalaski, JS; Clark, MA; Ensor, CM; Holtsberg, FW, 2002) |
| "The serum uric acid level has been said to be an independent predictor of cardiovascular disease death, mainly for women, and to be linked with the metabolic Syndrome X of insulin resistance, obesity, hypertension, and dyslipidemia." | 3.71 | Elevated serum leptin concentrations in women with hyperuricemia. ( Chiba, H; Katayose, S; Maruoka, S; Matsubara, M, 2002) |
| "To compare renal handling of uric acid in patients with primary gout with that of a control group." | 3.71 | Renal underexcretion of uric acid is present in patients with apparent high urinary uric acid output. ( Calabozo, M; Erauskin, GG; Herrero-Beites, AM; Perez-Ruiz, F; Ruibal, A, 2002) |
| "The uricase inhibitor potassium oxonate was used to induce hyperuricemia in mice, and serum uric acid level was determined with the phosphotungstic acid method." | 3.71 | [Effects of aqueous extract in herba of Lysimachia christinae on hyperuricemia in mice]. ( Ge, F; Guo, YS; Kong, LD; Wang, HD, 2002) |
| "The characteristic phenomena of acute gouty arthritis are acute arthritis in a middle-aged male, associated with serum uric acid above 6 mg." | 3.63 | Diagnosis and treatment of gouty arthritis. ( TALBOTT, JH, 1953) |
| "Hyperuricemia is associated with the activation of the Nod-like receptor protein 3 inflammasome." | 3.30 | C-reactive Protein Levels and Cardiovascular Outcomes After Febuxostat Treatment in Patients with Asymptomatic Hyperuricemia: Post-hoc Analysis of a Randomized Controlled Study. ( Hayashi, T; Hiramitsu, S; Hisatome, I; Jinnouchi, H; Kakuda, H; Kawai, N; Kimura, K; Kojima, S; Matsui, K; Mori, H; Ogawa, H; Ohya, Y; Saito, Y; Sugawara, M; Tokutake, E; Tsujita, K; Uchiyama, K; Wakasa, Y; Waki, M; Yokota, N, 2023) |
| " The incidence of adverse events was 50." | 3.30 | Serum Urate-Lowering Efficacy and Safety of Tigulixostat in Gout Patients With Hyperuricemia: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Trial. ( Lee, J; Min, J; Saag, KG; Shin, S; Terkeltaub, R, 2023) |
| "Febuxostat is a selective xanthine oxidase inhibitor that reportedly exhibits antioxidant properties." | 3.30 | Effect of febuxostat on the level of malondialdehyde-modified low-density lipoprotein, an oxidative stress marker: A subanalysis of the PRIZE study. ( Bando, YK; Fujii, Y; Kadokami, T; Koide, H; Murohara, T; Node, K; Nomura, S; Saito, M; Sano, H; Tanaka, A; Teragawa, H; Ueda, T; Yoshida, H, 2023) |
| " The primary objective was to assess the safety of rasburicase by the incidence of adverse events (AEs)." | 3.30 | Safety and Effectiveness of Rasburicase in the Control of Hyperuricemia in Pediatric Patients with Non-Hodgkin's Lymphoma and Acute Leukemia: An Open-Label, Single-Arm, Multi-center, Interventional Study. ( Chen, Y; Fang, J; Gao, J; He, Y; Liu, R; Shen, S; Sun, J; Tang, Y; Wang, T; Wu, X; Zhang, H; Zhang, J; Zhang, M; Zhu, X, 2023) |
| " The primary aim of the present study was to study the pharmacokinetic drug‒drug interactions (DDIs) of HP501, febuxostat, and colchicine in hyperuricemic patients." | 3.30 | A Phase I Study to Evaluate the Pharmacokinetic Drug‒Drug Interaction of HP501, Febuxostat, and Colchicine in Male Chinese Patients with Hyperuricemia. ( Chen, H; Chen, L; Ding, R; Hu, X; Jiang, F; Li, X; Li, Y; Liu, K; Peng, Q; Wu, J; Xiong, T; Zhou, Y, 2023) |
| " The MGH Acupuncture Sensation Scale and adverse events related to acupuncture will be measured after each treatment." | 3.30 | Evaluating the effectiveness and safety of acupuncture on serum uric acid in asymptomatic hyperuricemia population: a randomized controlled clinical trial study protocol. ( Chen, Z; Fang, MY; Huang, Y; Li, CN; Lin, FP; Liu, WH; Ma, Y; Tu, SH; Wang, B; Wang, Y; Xie, WX; Yu, LL; Zhang, RY; Zheng, CH, 2023) |
| "Uricosuric agents are the typical approach to the control of hyperuricemia; however, their use has been eclipsed by adverse reactions, and a safer uricosuric drug is badly needed." | 3.11 | Safety, Efficacy, and Pharmacokinetics of HP501 in Healthy Volunteers and Hyperuricemic Patients: A Phase I/IIa Study. ( Chen, Y; Di, X; Fan, L; Jin, Y; Li, X; Liu, R; Wang, Y; Wang, Z; Zheng, L; Zhou, Y, 2022) |
| "Hyperuricemia and gout are a group of disorders of purine metabolism." | 3.01 | The biomarkers discovery of hyperuricemia and gout: proteomics and metabolomics. ( Wu, X; You, C, 2023) |
| "Hyperuricemia is a metabolic disease caused by purine nucleotide metabolism disorder." | 3.01 | Mechanistic insights of soluble uric acid-induced insulin resistance: Insulin signaling and beyond. ( Cheng, J; Koyama, H; Yamamoto, T; Yu, W, 2023) |
| "So far, to treat hyperuricemia, it has been recommended to use a low-purine diet characterized by limiting protein-containing products." | 3.01 | High-Fructose Diet-Induced Hyperuricemia Accompanying Metabolic Syndrome-Mechanisms and Dietary Therapy Proposals. ( Formanowicz, D; Lubawy, M, 2023) |
| "Gout is one of the most common noncommunicable diseases in Hong Kong." | 3.01 | The Hong Kong Society of Rheumatology consensus recommendations for the management of gout. ( Chan, JP; Cheung, TT; Ho, CT; So, H; Tsang, HH; Wong, PC; Yip, RM; Yu, CK, 2023) |
| " In this review, we discuss recent advances and novel insights into the effects exerted by HUA conditions in ED and related underlying mechanisms focusing on impaired UA metabolism, reduction in the synthesis and bioavailability of nitric oxide, endothelial cell injury, the endothelial-to-mesenchymal transition, insulin resistance, procoagulant activity, and acquisition of an inflammatory phenotype." | 3.01 | Hyperuricemia: A key contributor to endothelial dysfunction in cardiovascular diseases. ( He, Y; Huang, S; Lan, X; Lei, W; Luo, H; Wei, X; Zhang, M; Zheng, J, 2023) |
| "Undertreated, gout can progress to palpable tophi and joint damage." | 3.01 | Emerging Urate-Lowering Drugs and Pharmacologic Treatment Strategies for Gout: A Narrative Review. ( Terkeltaub, R, 2023) |
| "Gout is a multifactorial metabolic and inflammatory disease that occurs when increased uric acid (UA) induce HU resulting in monosodium urate (MSU) crystal deposition in joints." | 3.01 | Uric acid en route to gout. ( Zhang, WZ, 2023) |
| "Gout is characterized by hyperuricemia and the deposition of monosodium urate (MSU) crystals around joints." | 3.01 | Agents for the Treatment of Gout: Current Advances and Future Perspectives. ( Fan, Y; Liu, Y; Meng, Y; Qin, M; Wu, D; Zeng, X, 2023) |
| "Hyperuricemia is an independent risk factor in chronic kidney disease (CKD)." | 2.94 | A randomized, double-blind, positive-controlled, prospective, dose-response clinical study to evaluate the efficacy and tolerability of an aqueous extract of Terminalia bellerica in lowering uric acid and creatinine levels in chronic kidney disease subjec ( Koilagundla, N; Nutalapati, C; Pingali, U; Taduri, G, 2020) |
| "Allopurinol treatment resulted in a decrease in SUA, a decrease in systolic and diastolic BP, a decrease in hsCRP, and an increase in eGFR compared with the baseline values (p < 0." | 2.87 | Effect of allopurinol on the glomerular filtration rate of children with chronic kidney disease. ( Assadi, F; Ghane Sharbaf, F, 2018) |
| "Gout is an auto-inflammatory disease driven by urate deposits with a second co-stimulatory factor evoking an (peri)arthritic fulminant inflammation often with a debute at night; inflammatory signals are enhanced via a NLRP3 pathway." | 2.82 | A historical journey of searching for uricosuric drugs. ( Jansen, TL; Matthijs, J; Tanja, G, 2022) |
| "Gout is a common hyperuricaemic metabolic condition that leads to painful inflammatory arthritis and a high comorbidity burden, especially cardiometabolic-renal (CMR) conditions, including hypertension, myocardial infarction, stroke, obesity, hyperlipidaemia, type 2 diabetes mellitus and chronic kidney disease." | 2.82 | Excess comorbidities in gout: the causal paradigm and pleiotropic approaches to care. ( Choi, HK; McCormick, N; Yokose, C, 2022) |
| "Hyperuricemia has been reported to be correlated with IgA nephropathy (IgAN)." | 2.82 | Is hyperuricemia an independent prognostic factor for IgA nephropathy: a systematic review and meta-analysis of observational cohort studies. ( Cai, Z; Cui, FQ; Jiang, SS; Meng, Y; Tang, L; Wang, MD; Wang, YF; Zhang, K; Zhao, WJ, 2022) |
| "Gout is a common inflammatory arthritis caused by the deposition of sodium urate crystals in the joints." | 2.82 | The Role of the Intestine in the Development of Hyperuricemia. ( Chen, J; Liu, N; Yin, H, 2022) |
| "Hyperuricemia is an independent risk factor for the progression of chronic kidney disease." | 2.82 | Research progress on related mechanisms of uric acid activating NLRP3 inflammasome in chronic kidney disease. ( Lin, X; Wang, M; Yang, X; Yang, Y, 2022) |
| "Gout is the most common inflammatory arthritis in the United States." | 2.82 | Management and Cure of Gouty Arthritis. ( Keller, SF; Mandell, BF, 2022) |
| "Gout is a common and potentially debilitating disease characterized by a painful inflammatory arthritis ("gout flare"), caused by the deposition of monosodium urate crystals in joints and surrounding tissues." | 2.82 | Emerging strategies for treating gout. ( Gaffo, AL; Huddleston, EM, 2022) |
| "Febuxostat was the most effective treatment in lowering urate levels according to the rank probability." | 2.82 | Efficacy of Urate-Lowering Therapy in Patients With Chronic Kidney Disease: A Network Meta-Analysis of Randomized Controlled Trials. ( Gu, M; Kong, W; Yu, X; Zhang, L; Zhu, Y; Zou, Y, 2022) |
| "In addition to traditional treatments for gout, novel therapies have been introduced in recent years." | 2.82 | Current state and prospects of gout treatment in Korea. ( Choi, ST; Park, EH; Song, JS, 2022) |
| "Gout is a chronic metabolic disease that seriously affects human health." | 2.82 | Susceptibility genes of hyperuricemia and gout. ( Nian, YL; You, CG, 2022) |
| "Hypertension is common in CKD patients and many mechanisms inducing it (upregulation of renin-angiotensin-aldosterone system, endothelial dysfunction and atherosclerosis) may be influenced by XOR products." | 2.82 | Chronic kidney disease: Which role for xanthine oxidoreductase activity and products? ( Battelli, MG; Bolognesi, A; Bortolotti, M; Polito, L, 2022) |
| "Gout is a metabolic disorder, and one of the most common inflammatory arthritic conditions, caused by elevated serum urate (SU)." | 2.82 | Moving the Needle in Gout Management: The Role of Culture, Diet, Genetics, and Personalized Patient Care Practices. ( Roman, YM, 2022) |
| " All of the above RCTs showed that probiotics did not increase the incidence of adverse events." | 2.82 | Safety and efficacy of probiotic supplementation in 8 types of inflammatory arthritis: A systematic review and meta-analysis of 34 randomized controlled trials. ( Chen, H; Deng, Y; He, Q; Li, J; Liu, H; Xiang, W; Yang, K; Zeng, L; Zhu, X, 2022) |
| "It is known that hyperuricemia is recognized as an independent cardiovascular risk factor." | 2.82 | [The role of hyperuricemia in the development of cognitive changes in the elderly.] ( Ariev, AL; Kunitskaya, NA, 2022) |
| "We studied 62 patients with untreated hypertension, randomly assigned to cilnidipine or amlodipine for 48 weeks." | 2.82 | Long-term effects of L- and N-type calcium channel blocker on uric acid levels and left atrial volume in hypertensive patients. ( Eguchi, A; Fujiwara, S; Hirotani, S; Komamura, K; Koshiba, M; Mano, T; Masaki, M; Masuyama, T; Sugahara, M; Tsujino, T, 2016) |
| " Although dosing was otherwise well tolerated, two subjects experienced serious adverse events of acute kidney injury." | 2.82 | Acute kidney injury observed during phase 1 clinical trials of a novel xanthine oxidase/URAT1 dual inhibitor PF-06743649. ( Dua, P; Gurrell, R; Kirby, S; Loudon, PT; Sudworth, M, 2016) |
| " In conclusion, the model was found useful for predicting therapeutic effect of rasburicase and individually determining rational dosage regimen of rasburicase." | 2.82 | Prediction of Therapeutic Effect of Rasburicase on Hyperuricemia Associated with Chemotherapy Based on Theoretical Model. ( Homma, M; Kanehira, N; Kimura, K; Minohara, H; Takayanagi, R; Yamada, Y, 2016) |
| "Hyperuricemia is a recognized risk factor for cardiovascular diseases." | 2.80 | Can soy intake affect serum uric acid level? Pooled analysis from two 6-month randomized controlled trials among Chinese postmenopausal women with prediabetes or prehypertension. ( Chen, YM; Ho, CS; Liu, ZM; Woo, J, 2015) |
| "Hyperuricemia is associated with the onset of chronic kidney disease (CKD) and renal disease progression." | 2.80 | Renoprotective effects of febuxostat in hyperuricemic patients with chronic kidney disease: a parallel-group, randomized, controlled trial. ( Asahi, K; Hayashi, Y; Kanno, M; Kimura, H; Nakayama, M; Tanaka, K; Tani, Y; Terawaki, H; Watanabe, K; Watanabe, T, 2015) |
| "Treatment with febuxostat resulted in a significant decrease in serum UA level and a significant decrease in MDA-LDL compared with baseline, but no significant difference was observed in hsCRP level or blood pressure." | 2.80 | Febuxostat improves endothelial function in hemodialysis patients with hyperuricemia: A randomized controlled study. ( Akiba, T; Itabashi, M; Kikuchi, K; Moriyama, T; Nitta, K; Sasaki, Y; Takei, T; Tsuchiya, K; Tsuruta, Y; Uchida, K, 2015) |
| "Allopurinol is a potent xanthine oxidase inhibitor used in hyperuricemic patients." | 2.80 | Benefits of Allopurinol Treatment on Blood Pressure and Renal Function in Patients with Early Stage of Chronic Kidney Disease. ( Burata, A; Ruangkanchanasetr, P; Satirapoj, B; Supasyndh, O; Wirajit, O, 2015) |
| "Hyperuricemia is increasing in prevalence and this is paralleled by an increased incidence of acute gout." | 2.79 | Febuxostat (Feburic tablet) in the management of hyperuricemia in a general practice cohort of Japanese patients with a high prevalence of cardiovascular problems. ( Hasegawa, K; Hiramitsu, S; Ishiguro, Y; Ishii, J; Kani, A; Kato, H; Kato, K; Kato, Y; Kimura, H; Matsubara, S; Matsubara, Y; Matsuyama, H; Mori, K; Noba, M; Shino, K; Tokuda, M; Uchiyama, T; Uemura, A; Yamada, K; Yoshida, S, 2014) |
| "Azelnidipine was administered to 72 patients at a daily dose of 8 mg or 16 mg." | 2.79 | Effects of azelnidipine on uric acid metabolism in patients with essential hypertension. ( Cheng, J; Hamada, T; Hirata, S; Hisatome, I; Igawa, O; Kato, M; Kuwabara, M; Miyazaki, S; Mizuta, E; Moriwaki, Y; Ninomiya, H; Nosaka, Y; Ogino, K; Ohtahara, A; Yamamoto, K; Yamamoto, Y; Yoshida, A, 2014) |
| "Hyperuricemia is associated with the presence and severity of obstructive sleep apnea (OSA)." | 2.78 | Serum urate levels are unchanged with continuous positive airway pressure therapy for obstructive sleep apnea: a randomized controlled trial. ( Prudon, B; Roddy, E; Stradling, JR; West, SD, 2013) |
| "Hyperuricemia is the greatest risk factor for gout and is caused by an overproduction and/or inefficient renal clearance of urate." | 2.77 | Fractional clearance of urate: validation of measurement in spot-urine samples in healthy subjects and gouty patients. ( Day, RO; Graham, GG; Indraratna, PL; Jones, G; Kannangara, DR; Portek, I; Ramasamy, SN; Stocker, SL; Williams, KM, 2012) |
| "Despite an increasing incidence of gout in older age patients with multiple metabolic and cardiovascular comorbidities, there are limited data addressing whether currently available urate-lowering therapy is comparably effective and safe in older (≥65 years of age) versus younger (<65 years of age) patients." | 2.76 | Treating hyperuricemia of gout: safety and efficacy of febuxostat and allopurinol in older versus younger subjects. ( Becker, MA; Gunawardhana, L; Hunt, B; MacDonald, PA, 2011) |
| "Allopurinol treatment slowed down renal disease progression independently of age, gender, diabetes, C-reactive protein, albuminuria, and renin-angiotensin system blockers use." | 2.75 | Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. ( Ampuero, J; Arroyo, D; de Vinuesa, SG; Goicoechea, M; Luño, J; Rincón, A; Ruiz-Caro, C; Verdalles, U, 2010) |
"Treatment with benzbromarone monotherapy (range: 100-200 mg/day; mean 138 mg/day) resulted in 92% of patients reaching target levels sUr | 2.73 | Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-treated gout patients. ( Brouwers, JR; Houtman, PM; Jansen, TL; Reinders, MK; van Roon, EN, 2007) | |
| "Hyperuricemia is a risk factor associated with cardiovascular and renal disease." | 2.73 | Efficacy and (pharmaco)kinetics of one single dose of rasburicase in patients with chronic kidney disease. ( Boni, P; Guardigli, M; Mandreoli, M; Ramazzotti, E; Roda, A; Santoro, A; Sestigiani, E, 2008) |
| " The dosing regimens to maintain uric acid levels below the therapeutic target of 6 mg/dL were then predicted by the model." | 2.73 | Population pharmacokinetic and pharmacodynamic analysis of pegloticase in subjects with hyperuricemia and treatment-failure gout. ( Alton, M; Huang, W; Marco, MD; Maroli, AN; Waltrip, RW; Wright, D; Yue, CS, 2008) |
| "Gout is a common form of inflammatory arthritis where urate crystals deposit in joints and surrounding tissues." | 2.72 | The Role of Advanced Imaging in Gout Management. ( Cao, H; Li, S; Liang, J; Lin, J; Wan, L; Xu, G, 2021) |
| "Hyperuricemia is defined as an abnormally high level of uric acid (UA; i." | 2.72 | Role of asymptomatic hyperuricemia in the progression of chronic kidney disease and cardiovascular disease. ( Sun, D; Waheed, Y; Yang, F, 2021) |
| "Atherosclerosis is regarded as the disease of the arterial vasculature." | 2.72 | Harnessing hyperuricemia to atherosclerosis and understanding its mechanistic dependence. ( Jayachandran, M; Qu, S, 2021) |
| "Hyperuricemia is associated with insulin resistance, pancreatic β-cell dysfunction and consequently with development of type 2 diabetes." | 2.72 | Uric acid-induced pancreatic β-cell dysfunction. ( Ghasemi, A, 2021) |
| " The three outcomes used to assess the safety of uric acid lowering medications were treatment-related adverse events, liver damage, and major adverse cardiovascular events (MACE)." | 2.72 | The association between urate-lowering therapies and treatment-related adverse events, liver damage, and major adverse cardiovascular events (MACE): A network meta-analysis of randomized trials. ( Chen, J; Deng, Q; Guo, J; Xie, Q; Xie, S; Yu, Y; Zhang, S; Zhong, L, 2021) |
| "The key to the treatment of hyperuricemia is to control the level of serum UA within the normal range." | 2.72 | A review on the fruit components affecting uric acid level and their underlying mechanisms. ( Wang, F; Zhao, X; Zou, F, 2021) |
| "Hyperuricemia is associated strongly with the development of hypertension, renal disease, and progression." | 2.72 | Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. ( Kwan, TH; Leung, KT; Siu, YP; Tong, MK, 2006) |
| "Hyperuricemia and tumor lysis syndrome are well-known complications during induction treatment of aggressive non-Hodgkin's lymphomas (NHLs)." | 2.71 | Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on R ( Belhadj, K; Bologna, S; Casasnovas, O; Christian, B; Coiffier, B; Fermé, C; Herbrecht, R; Jourdan, E; Mounier, N; Sonet, A; Tilly, H, 2003) |
| "Epidemiological characteristics of preeclampsia such as its uniqueness to humans and an increased incidence of preeclampsia in multiple pregnancies, increased body mass index, renal and hypertensive disease all have uric acid as their common denominator." | 2.71 | Hyperuricaemia and preeclampsia: is there a pathogenic link? ( Schackis, RC, 2004) |
| " These results suggested that Y-700 is a new effective inhibitor of XO in rats and humans with high oral bioavailability being predominantly eliminated via the liver unlikely to allopurinol." | 2.71 | Pharmacokinetics/pharmacodynamics of Y-700, a novel xanthine oxidase inhibitor, in rats and man. ( Fukunari, A; Iwane, J; Kamezawa, M; Mori, H; Osajima, T; Yamada, I, 2004) |
| "Treatment with febuxostat resulted in a significant reduction of sUA levels at all dosages." | 2.71 | Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. ( Becker, MA; Eustace, D; Joseph-Ridge, N; MacDonald, PA; Palo, WA; Schumacher, HR; Vernillet, L; Wortmann, RL, 2005) |
| "allopurinol is a safe and effective dose in Red-tailed Hawks (Buteo jamaicensis) to reduce plasma uric acid concentrations, experimental studies were performed using the physiologically occurring postprandial hyperuricaemia." | 2.70 | Further studies on the use of allopurinol to reduce plasma uric acid concentrations in the Red-tailed Hawk (Buteo jamaicensis) hyperuricaemic model. ( Lumeij, JT; Poffers, J; Redig, PT; Timmermans-Sprang, EP, 2002) |
| "Hyperuricemia is highly prevalent, affecting approximately 38 million individuals in the United States." | 2.66 | Asymptomatic hyperuricemia: is it really asymptomatic? ( Cohen, RE; Pillinger, MH; Yip, K, 2020) |
| "Gout is a chronic inflammatory disease caused by precipitation of urate crystals in the joints, kidneys, and urinary tract." | 2.66 | Dotinurad: a novel selective urate reabsorption inhibitor as a future therapeutic option for hyperuricemia. ( Kuriyama, S, 2020) |
| "Hyperuricemia is the main risk factor for gout and is linked to the development of comorbidities." | 2.66 | Urate-induced immune programming: Consequences for gouty arthritis and hyperuricemia. ( Cabău, G; Crișan, TO; Joosten, LAB; Klück, V; Popp, RA, 2020) |
| "Hyperuricemia is a strong precursor of gout, which deteriorates patients' health and quality of life." | 2.66 | Evaluation of urate-lowering therapy in hyperuricemia patients: a systematic review and Bayesian network meta-analysis of randomized controlled trials. ( Chang, SS; Lin, CH; Lin, SY; Lin, YJ; Wang, ST, 2020) |
| "However, whether treating hyperuricemia and gout with ULTs modifies cardiovascular risks remains controversial." | 2.66 | Cardiovascular events in hyperuricemia population and a cardiovascular benefit-risk assessment of urate-lowering therapies: a systematic review and meta-analysis. ( Cao, L; Wan, WG; Xue, Y; Yang, X; Zhao, L; Zhao, TY; Zhu, XX; Zou, HJ, 2020) |
| "Gout is a chronic disease due to the deposition of monosodium urate microcrystals in joints and tissues." | 2.66 | [Gout]. ( Bernard, A; Oehler, E; Pascart, T; Scuiller, A, 2020) |
| "Asymptomatic hyperuricemia is frequently observed in patients with kidney disease." | 2.66 | Uric acid and inflammation in kidney disease. ( Jung, SW; Kim, SM; Kim, YG; Lee, SH; Moon, JY, 2020) |
| " Allopurinol, a urate synthesis inhibitor, is generally administered at a reduced dosage to patients with renal impairment." | 2.66 | Recent approaches to gout drug discovery: an update. ( Anzai, N; Hisatome, I; Kudo, H; Otani, N; Ouchi, M; Tsuruoka, S, 2020) |
| "Febuxostat had the best efficacy and safety results among the tested agents, and topiroxostat and allopurinol appeared to have fewer adverse events." | 2.66 | Efficacy and safety of urate-lowering treatments in patients with hyperuricemia: A comprehensive network meta-analysis of randomized controlled trials. ( Lin, CJ; Lin, JY; Shi, Y; Sun, SS; Zhang, DH, 2020) |
| "Hyperuricemia is present in 20-35% of patients with chronic kidney disease." | 2.66 | The role of uric acid in inflammasome-mediated kidney injury. ( Braga, TT; Camara, NOS; Foresto-Neto, O, 2020) |
| "Gout is the most common inflammatory arthritis and occurs when hyperuricaemia, sustained elevation of serum urate levels resulting in supersaturation of body tissues with urate, leads to the formation and deposition of monosodium urate crystals in and around the joints." | 2.66 | Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors. ( Dehlin, M; Jacobsson, L; Roddy, E, 2020) |
| "Gout is a disease in which the metabolic condition hyperuricemia leads to the formation of monosodium urate crystals, which provoke acute and chronic inflammatory responses through activation of the innate immune system." | 2.66 | Therapeutic approaches in the treatment of gout. ( Mandell, BF; Pillinger, MH, 2020) |
| "Although hyperuricemia has been associated with CKD in many studies, it remains controversial whether this is the cause or the result of decreased renal function." | 2.66 | Renal effects of uric acid: hyperuricemia and hypouricemia. ( Jo, YI; Lee, JH; Park, JH, 2020) |
| "Hyperuricemia is characterized by excessive production and deposition of urate crystals." | 2.66 | Recent advances in fructose intake and risk of hyperuricemia. ( Li, L; Zeng, C; Zhang, C; Zhang, Y, 2020) |
| "Hyperuricemia is the key risk factor for gout and is considered a prerequisite for monosodium urate (MSU) crystal formation." | 2.66 | Pathophysiology of Gout. ( Dalbeth, N; Narang, RK, 2020) |
| " Dose-response analysis was also carried out." | 2.61 | Serum uric acid and risk of cardiovascular mortality: a systematic review and dose-response meta-analysis of cohort studies of over a million participants. ( Bellissimo, N; Hekmatdoost, A; Maroofi, M; Rahimi-Sakak, F; Rahmani, J, 2019) |
| "Gout is one of the most prevalent inflammatory rheumatic disease." | 2.61 | Dietary Interventions for Gout and Effect on Cardiovascular Risk Factors: A Systematic Review. ( de Vries, R; Gerritsen, M; Heslinga, M; Nurmohamed, M; van Schaardenburg, D; Vedder, D; Walrabenstein, W, 2019) |
| " The main management issues are related to patient adherence, because gout patients have the lowest rate of medication possession ratio at 1 year, but they also include clinical inertia by physicians, meaning XOI dosage is not titrated according to regular serum uric acid level measurements for targeting serum uric acid levels for uncomplicated (6." | 2.61 | Gout: state of the art after a decade of developments. ( Lioté, F; Pascart, T, 2019) |
| "Osteoarthritis is the most common form of arthritis overall, and gout and osteoarthritis frequently coexist in the same patient." | 2.61 | Urate and osteoarthritis: Evidence for a reciprocal relationship. ( Krasnokutsky, S; Neogi, T; Pillinger, MH, 2019) |
| "Hypoalbuminemia and hyperuricemia are independently associated with the occurrence of CIN among the patients undergoing CAG and/or intervention." | 2.61 | Predictive Value of Hepatorenal Status in Contrast-Induced Nephropathy Among Patients Receiving Coronary Angiography and/or Intervention: A Systematic Review and Meta-Analysis. ( Chen, G; Huang, L; Lu, Y; Qin, Q; Wang, C; Zhang, E; Zhang, J, 2019) |
| "Hyperuricemia affects one out of five adults as a result of the Western diet, insulin resistance, and renal dysfunction." | 2.61 | Uric acid and hypertension: a focused review and practical recommendations. ( Borghi, C; Burnier, M; De Becker, B; van de Borne, P, 2019) |
| "Atorvastatin, which has proven safe in NAFLD/NASH, reduces SUA levels, ameliorates NAFLD/NASH, prevents liver fibrosis, and above all substantially reduces CVD morbidity and mortality in comparison with those on statins but without NAFLD/NASH." | 2.58 | Can Serum Uric Acid Lowering Therapy Contribute to the Prevention or Treatment of Nonalcoholic Fatty Liver Disease? ( Athyros, VG; Giouleme, O; Grammatikos, N; Katsoula, A; Paschos, P; Tsimperidis, A, 2018) |
| "Treatment with empagliflozin resulted in a superior reduction in SUA (WMD -45." | 2.58 | Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: A meta-analysis of randomized controlled trials. ( Chen, L; Tian, D; Wang, L; Xia, P; Xu, L; Zhao, Y; Zheng, H, 2018) |
| "Crystal arthritis is the most common type of inflammatory arthritis, and fractures contribute to significant morbidity and mortality, therefore, the relationship between the two is of clinical importance." | 2.58 | Crystalline arthropathy and bone health. ( Chang, I; Gazeley, D, 2018) |
| "Gout is an inflammatory disease manifested by the deposition of monosodium urate (MSU) crystals in joints, cartilage, synovial bursa, tendons or soft tissues." | 2.58 | Management of gout and hyperuricemia: Multidisciplinary consensus in Taiwan. ( Chen, DY; Chen, JH; Chen, SM; Chen, SY; Cheng, TT; Hsieh, SC; Hsieh, TY; Hsu, PF; Kuo, CF; Kuo, MC; Lam, HC; Lee, IT; Liang, TH; Lin, HY; Lin, SC; Tsai, WC; Tsai, WP; Tsay, GJ; Wei, JC; Yang, CH; Yu, KH, 2018) |
| "Hyperuricemia has been recognized as an independent cardiovascular risk factor in epidemiological studies." | 2.58 | Uric Acid and Cognitive Function in Older Individuals. ( Meschi, T; Nouvenne, A; Prati, B; Tana, C; Ticinesi, A, 2018) |
| "Examining therapies aimed at treating gout flares [anti-inflammatory action], bucillamine has some potential, but more data and Phase III studies are needed, to better understand its efficacy and safety." | 2.58 | Expert opinion on emerging urate-lowering therapies. ( Merriman, TR; Singh, JA; Stamp, LK, 2018) |
| " In the process of purine metabolism, reactive oxygen species, including superoxide, are generated concomitantly with uric acid production, which may deteriorate endothelial function through the reaction of superoxide with nitric oxide (NO), leading to decreased NO bioavailability and increased production of peroxynitrite, a reactive oxidant." | 2.58 | Hyperuricemia and endothelial function: From molecular background to clinical perspectives. ( Higashi, Y; Hisatome, I; Kihara, Y; Maruhashi, T, 2018) |
| " The use of allopurinol has been researched extensively and newer strategies for safer effective dosing are now recommended." | 2.58 | Gout - An update of aetiology, genetics, co-morbidities and management. ( Robinson, PC, 2018) |
| " Genetic data may inform assessment of disease prognosis in individuals with hyperuricaemia or established gout, personalised lifestyle advice, selection and dosing of urate-lowering therapy, and prevention of serious medication adverse effects." | 2.55 | The genetics of gout: towards personalised medicine? ( Dalbeth, N; Merriman, TR; Stamp, LK, 2017) |
| "Hyperuricemia is a significant risk factor for nonalcoholic fatty liver disease (NAFLD)." | 2.55 | Hyperuricemia is associated with nonalcoholic fatty liver disease activity score in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis. ( Ahuja, W; Jaruvongvanich, V; Ungprasert, P; Wijarnpreecha, K; Wirunsawanya, K, 2017) |
| "Gout is a common disease responsible for recurrent flares triggered by the deposition of monosodium urate crystals secondary to longstanding hyperuricaemia." | 2.55 | Current and future therapies for gout. ( Pascart, T; Richette, P, 2017) |
| "Hyperuricemia has been linked to metabolic syndrome, cardiovascular disease, and chronic kidney disease." | 2.55 | Effects of Sodium Glucose Cotransporter-2 Inhibitors on Serum Uric Acid in Type 2 Diabetes Mellitus. ( Ahmadieh, H; Azar, S, 2017) |
| "Hyperuricemia has recently emerged as an independent risk factor in the development of type 2 diabetes mellitus and hypertension through several proposed mechanisms." | 2.55 | Hyperuricemia, Type 2 Diabetes Mellitus, and Hypertension: an Emerging Association. ( Mortada, I, 2017) |
| "Gout is both an inflammatory and a metabolic disease." | 2.55 | Gout and Metabolic Syndrome: a Tangled Web. ( Krasnokutsky, S; Pillinger, MH; Thottam, GE, 2017) |
| "Hyperuricemia has long been known to cause gout, and has recently been correlated with cardiovascular disease, hypertension, and renal disease." | 2.55 | The role of urate-lowering treatment on cardiovascular and renal disease: evidence from CARES, FAST, ALL-HEART, and FEATHER studies. ( Pontremoli, R, 2017) |
| "If hyperuricemia is an independent risk factor in blood-pressure control, urate-lowering therapy should be used to reduce cardiovascular risk." | 2.55 | Effects of serum uric acid on blood-pressure lowering treatment. ( Grassi, G, 2017) |
| "Gout is a clinical disorder that is characterized by the deposition of monosodium urate crystals (MSU) in joints and tendons, usually in the presence of prolonged hyperuricaemia." | 2.55 | Review of the ophthalmic manifestations of gout and uric acid crystal deposition. ( Ao, J; Casson, RJ; Goldblatt, F, 2017) |
| "The risk of NAFLD in subjects with hyperuricaemia was significantly higher than subjects with normal uric acid level with the pooled odds ratio (OR) of 1." | 2.55 | Hyperuricaemia and risk of nonalcoholic fatty liver disease: A meta-analysis. ( Cheungpasitporn, W; Lekuthai, N; Panjawatanan, P; Thongprayoon, C; Ungprasert, P; Wijarnpreecha, K, 2017) |
| "Although gout is one of the most common forms of inflammatory arthritis, it has been relatively neglected until recently." | 2.55 | Major unanswered questions in the clinical gout field. ( Stamp, LK, 2017) |
| " Expert opinion: The initial dosage of allopurinol should be low, particularly in patients with renal impairment." | 2.55 | Allopurinol: insights from studies of dose-response relationships. ( Carland, JE; Day, RO; Graham, GG; Kannangara, DR; Stocker, SL; Williams, KM, 2017) |
| "Hyperuricemia is associated with a number of effects on the vascular endothelium and vascular smooth muscle cells, including an increase in oxidative stress, production of vasoconstrictors, and changes on the structural properties of the large artery wall." | 2.55 | Uric Acid, Vascular Stiffness, and Chronic Kidney Disease: Is There a Link? ( Madero, M; Ramirez-Sandoval, JC; Sanchez-Lozada, LG, 2017) |
| "Uric acid is a natural antioxidant." | 2.55 | Hyperuricemia is not associated with severity of liver fibrosis in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis. ( Ahuja, W; Jaruvongvanich, V; Ungprasert, P; Wijarnpreecha, K, 2017) |
| "Hyperuricemia was also significantly associated with increased risk of peripheral neuropathy in patients with type 2 diabetes (risk ratio [RR] = 2." | 2.53 | Serum Uric Acid Levels and Diabetic Peripheral Neuropathy in Type 2 Diabetes: a Systematic Review and Meta-analysis. ( Che, K; Chen, Y; Hou, X; Li, C; Wang, B; Wang, Y; Xu, D; Yan, S; Yu, S, 2016) |
| "Thus, therapeutic strategies used to treat hyperuricemia in the past decades have often been focused on limiting acute episodes." | 2.53 | The treatment of hyperuricemia. ( Gliozzi, M; Malara, N; Mollace, V; Muscoli, S, 2016) |
| "Nonalcoholic fatty liver disease (NAFLD) is a major, worldwide public health problem." | 2.53 | Serum uric acid: a new therapeutic target for nonalcoholic fatty liver disease. ( Braddock, M; Liu, WY; Lu, QD; Shi, KQ; Song, D; Sun, DQ; Wu, SJ; Zheng, MH; Zhu, GQ, 2016) |
| "Hyperuricemia is associated with an increased risk of NAFLD in Asian populations." | 2.53 | Hyperuricemia and risk of nonalcoholic fatty liver disease: a systematic review and meta-analysis. ( Gong, S; Song, J; Wang, L; Wang, Y; Zhang, S, 2016) |
| "Acute kidney injury is a frequent complication among ST segment elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention (PCI), and is associated with adverse outcomes." | 2.53 | Acute kidney injury among ST elevation myocardial infarction patients treated by primary percutaneous coronary intervention: a multifactorial entity. ( Arbel, Y; Shacham, Y; Steinvil, A, 2016) |
| "Gout is a common inflammatory arthritis among middle-aged men and postmenopausal women and can be a debilitating disease." | 2.53 | Beyond Joints: a Review of Ocular Abnormalities in Gout and Hyperuricemia. ( Schlesinger, N; Sharon, Y, 2016) |
| "The prevalence of gout is rising and is likely attributed to several factors including increased incidence of comorbidities, lifestyle factors, and increased use of causative medications." | 2.53 | Gouty Arthritis: A Review of Acute Management and Prevention. ( Saseen, JJ; Wilson, L, 2016) |
| "Hyperuricemia has been widely accepted to be associated with the incidence of paroxysmal or persistent AF, as well as to the risk of AF in post cardiovascular surgery patients." | 2.53 | Hyperuricemia and Atrial Fibrillation. ( Hisatome, I; Kuwabara, M; Maharani, N, 2016) |
| " For dose-response analysis, a linear relationship (8 studies; Pfor non-linearity=0." | 2.53 | Serum uric acid and mortality in chronic kidney disease: A systematic review and meta-analysis. ( Huang, F; Li, B; Lin, Z; Luo, Q; Xia, X; Yu, X, 2016) |
| " Drug efficacy and safety, as outcomes, were measured by whether the target level of serum urate acid was achieved and whether any adverse events occurred, respectively." | 2.53 | Comparative efficacy and safety of urate-lowering therapy for the treatment of hyperuricemia: a systematic review and network meta-analysis. ( Gao, Y; Guo, Y; Li, D; Li, M; Li, S; Li, W; Sun, L; Wang, Y; Wei, F; Xu, W; Yang, H; Yang, X, 2016) |
| "Uric acid is a product of purine metabolism and has been linked to gout and kidney calculi." | 2.53 | Hyperuricemia, Hypertension, and Chronic Kidney Disease: an Emerging Association. ( Al Kattar, S; Jurjus, A; Mallat, SG; Tanios, BY, 2016) |
| "Hyperuricemia was associated with an increased risk of CHD mortality (RR: 1." | 2.53 | Hyperuricemia and coronary heart disease mortality: a meta-analysis of prospective cohort studies. ( Guo, L; Jiang, L; Liu, X; Mao, S; Yin, X; Zuo, T, 2016) |
| "Allopurinol is a safe option, slightly better than other ULDs." | 2.52 | Safety of allopurinol compared with other urate-lowering drugs in patients with gout: a systematic review and meta-analysis. ( Carmona, L; Castrejon, I; Loza, E; Pérez-Ruiz, F; Rosario, MP; Toledano, E, 2015) |
| "Uric acid has a stimulating effect on the cerebral cortex, and this could have allowed humans, compared with other animals, to develop higher brain mass volume, better intellectual performances, and maybe evolutionary supremacy." | 2.52 | Uric acid: friend or foe? Uric acid and cognitive function "Gout kills more wise men than simple". ( De Giorgi, A; Fabbian, F; Manfredini, R; Misurati, E; Pala, M; Parisi, C; Tiseo, R, 2015) |
| "Hyperuricemia is one of the many metabolic changes that occur during the course of chronic kidney disease (CKD)." | 2.52 | [Uric acid, the kidney and cardiovascular mortality]. ( Mandreoli, M; Santoro, A, 2015) |
| "Allopurinol, which has been used in clinical practice for almost 50 years, is the drug of first choice for long-term control of gout." | 2.52 | [The role of uric acid and allopurinol therapy in cardiovascular disease]. ( Linhart, A; Rob, D, 2015) |
| "Hyperuricemia is associated with hypertension, kidney disease, vascular and cardiovascular (CV) events." | 2.52 | Hyperuricemia, urate deposition and the association with hypertension. ( Borghi, C; Grassi, G; Mancia, G, 2015) |
| "Gout is a common crystal-induced arthritis, in which monosodium urate (MSU) crystals precipitate within joints and soft tissues and elicit an inflammatory response." | 2.50 | The crystallization of monosodium urate. ( Crittenden, DB; Martillo, MA; Nazzal, L, 2014) |
| "Gout is defined as an arthritic condition resulting from the deposition of monosodium urate (MSU) crystals in and/or around joints, following long-standing hyperuricemia." | 2.50 | Definition of hyperuricemia and gouty conditions. ( Bardin, T; Richette, P, 2014) |
| "Gout has been academically considered to be a step-up disease consisting of different stages: acute gout, intercritical gout, and chronic gout." | 2.50 | Clinical manifestations and diagnosis of gout. ( Castillo, E; Chinchilla, SP; Herrero-Beites, AM; Perez-Ruiz, F, 2014) |
| "Gout is a common inflammatory arthritis precipitated by an inflammatory reaction to urate crystals in the joint." | 2.50 | Gout: joints and beyond, epidemiology, clinical features, treatment and co-morbidities. ( Horsburgh, S; Robinson, PC, 2014) |
| "Psoriatic arthritis is a condition that causes inflammation of the joints of psoriatic patients." | 2.50 | Association of rheumatoid factor and uric acid with psoriatic arthritis: a review. ( Khan, SI; Khondker, L, 2014) |
| " This meta-analysis study evaluated the efficacy and cost savings of a single-dose rasburicase (SDR) regimen compared with the Food and Drug Administration-approved daily dosing of rasburicase (DDR) for 5 days or the traditional treatment with allopurinol in adult cancer patients with hyperuricaemia or at high risk for TLS." | 2.49 | Efficacy and cost of single-dose rasburicase in prevention and treatment of adult tumour lysis syndrome: a meta-analysis. ( Bhutada, NS; Dong, K; Feng, X; Inciardi, J; Pence, S; Pham, D, 2013) |
| "Hyperuricemia is considered to be a component of cardiovascular continuum, risk factor of chronic heart failure and marker of its unfavourable outcome." | 2.49 | [Hyperuricemia and cardiovascular continuum]. ( Bart, BIa; Donskov, AS; Larin, VG; Larina, VN, 2013) |
| "In addition, hyperuricemia is largely prevalent in patients with CKD." | 2.49 | Uric acid as a target of therapy in CKD. ( Chen, W; Chonchol, M; Jalal, DI; Targher, G, 2013) |
| "Gout is a painful inflammatory arthritis associated with hyperuricemia, with a prevalence of almost 10 million in the USA." | 2.49 | The kidney in hyperuricemia and gout. ( Mount, DB, 2013) |
| "Gout is a growing health problem worldwide especially in affluent countries, such as Australia." | 2.48 | Systematic review of the prevalence of gout and hyperuricaemia in Australia. ( Merriman, TR; Robinson, PC; Taylor, WJ, 2012) |
| "Hyperuricemia is particularly common in patients with arterial hypertension, metabolic syndrome, or kidney disease." | 2.48 | New insights into uric acid effects on the progression and prognosis of chronic kidney disease. ( Filiopoulos, V; Hadjiyannakos, D; Vlassopoulos, D, 2012) |
| "Gout is a metabolic disease characterized by hyperuricemia and the deposition of monosodium urate (MSU) crystals in the joints and soft tissues, consisting of a self-limited acute phase characterized by recurrent attacks of synovitis and a chronic phase in which inflammatory and structural changes of the joints and periarticular tissues may lead to persistent symptoms." | 2.48 | Clinical features of gout. ( De Angelis, R; Grassi, W, 2012) |
| "Uric acid has been formerly considered a major antioxidant in human plasma with possible beneficial anti-atherosclerotic effects." | 2.48 | Relationships among hyperuricemia, endothelial dysfunction and cardiovascular disease: molecular mechanisms and clinical implications. ( Cravero, E; Muscari, A; Puddu, GM; Puddu, P; Vizioli, L, 2012) |
| "Hyperuricemia is linked to gout and features of metabolic syndrome." | 2.48 | The effects of fructose intake on serum uric acid vary among controlled dietary trials. ( Beyene, J; Carleton, AJ; Chiavaroli, L; Cozma, AI; de Souza, RJ; Di Buono, M; Ha, V; Jenkins, AL; Jenkins, DJ; Kendall, CW; Leiter, LA; Mirrahimi, A; Sievenpiper, JL; Wang, DD; Wolever, TM; Yu, ME, 2012) |
| "The management of gouty arthritis is focused on treating pain and inflammation associated with acute flares and preventing further acute flares and urate crystal deposition." | 2.48 | Treatment of chronic gouty arthritis: it is not just about urate-lowering therapy. ( Schlesinger, N, 2012) |
| "Gout is probably one of the oldest diseases affecting men." | 2.48 | Gout as autoinflammatory disease: new mechanisms for more appropriated treatment targets. ( Oliviero, F; Punzi, L; Ramonda, R; Scanu, A, 2012) |
| "Gout is a common and very painful inflammatory arthritis caused by hyperuricaemia." | 2.48 | The genetics of hyperuricaemia and gout. ( Choi, HK; Mount, DB; Reginato, AM; Yang, I, 2012) |
| "The new epidemic of gout is likely secondary in significant part to the rise in fructose consumption, as well as to the increase in obesity, the endurance of other dietary and non-dietary gout risk factors such as consumption of meat and alcohol, the continued use of culprit medications and potentially to the under-recognition of the benefits of certain foods and drinks (such as dairy products and coffee)." | 2.48 | A perspective on diet and gout. ( Kedar, E; Simkin, PA, 2012) |
| "Hyperuricemia is seen when kidney function declines." | 2.48 | Hyperuricemia and the progression of chronic kidney disease: is uric acid a marker or an independent risk factor? ( Fried, LF; Nashar, K, 2012) |
| "Gout and hyperuricemia have likewise been associated with the development of cardiovascular disease and metabolic syndrome." | 2.48 | The interplay between diet, urate transporters and the risk for gout and hyperuricemia: current and future directions. ( De Jesus, E; Rachabattula, S; Torralba, KD, 2012) |
| "Gout is not common in childhood compared with adulthood, and careful consideration of inborn errors of metabolism should be considered in these cases." | 2.47 | Gout and hyperuricemia in young people. ( Yamanaka, H, 2011) |
| "The definition of hyperuricemia is currently arbitrary." | 2.47 | Allopurinol, uric acid, and oxidative stress in cardiorenal disease. ( Covic, A; Goldsmith, D; Riegersperger, M, 2011) |
| " The total number of participants was 556, the median dosage of vitamin C was 500 mg/day, trial size ranged from 8-184 participants, and the median study duration was 30 days." | 2.47 | Effect of oral vitamin C supplementation on serum uric acid: a meta-analysis of randomized controlled trials. ( Gelber, AC; Juraschek, SP; Miller, ER, 2011) |
| "Hyperuricemia is a specific risk factor for cardiovascular morbidity and mortality." | 2.47 | [Hyperuricemia and uro-nephrological disorders]. ( Hurtes, X; Meria, P, 2011) |
| "Hyperuricemia is considered to be a risk factor of not only gout but also renal and cardiovascular diseases, thus, it is important to use CCBs without adverse effect on uric acid metabolisms." | 2.46 | [Calcium antagonists: current and future applications based on new evidence. The mechanisms on lowering serum uric acid level by calcium channel blockers]. ( Hamada, T; Hisatome, I; Igawa, O; Mizuta, E; Shigemasa, C, 2010) |
| "Hyperuricemia is a prevalent finding in patients presenting metabolic syndrome, although its clinical meaning is still controversial and often underestimated." | 2.46 | Uric acid as a factor in the metabolic syndrome. ( Batista, MC; Borges, RL; Ribeiro, AB; Zanella, MT, 2010) |
| "Gout and hyperuricemia have long been suspected to be risk factors for cardiovascular disease." | 2.46 | Gout, hyperuricemia, and the risk of cardiovascular disease: cause and effect? ( Keenan, RT; Shah, A, 2010) |
| "Idiopathic uric acid nephrolithiasis appears to be increasing in prevalence." | 2.46 | Update on the pathophysiology and management of uric acid renal stones. ( Goldfarb, DS; Kenny, JE, 2010) |
| "Gout is the most common cause of inflammatory arthritis among men and postmenopausal women." | 2.46 | Gout: epitome of painful arthritis. ( VanItallie, TB, 2010) |
| "Gout is an acute inflammatory arthritis with the potency to fully destroy the integrity of the joint leading to severe disability." | 2.46 | Gout: a clinical syndrome illustrated and discussed. ( Bhansing, KJ; Janssen, M; Radstake, TR; van Bon, L, 2010) |
| "Uric acid is a major product of purine metabolism in humans." | 2.46 | Uric acid and the development of hypertension. ( Hwu, CM; Lin, KH, 2010) |
| "Uric acid has previously been viewed as a benign solute in serum until it exceeds its saturation level." | 2.45 | The role of hyperuricemia in vascular disorders. ( Edwards, NL, 2009) |
| "is utilized for the prevention and treatment of hyperuricemia (HUA)." | 2.44 | Preliminary study on the material basis and mechanism underlying uric acid reduction by Thlaspi arvense L. ( Hou, C; Ke, X; Wang, Y; Wu, T; Yang, R; Yang, X; Zhou, Y, 2024) |
| "Tumor lysis syndrome is a complication of malignancies caused by massive tumor cell lysis due to either spontaneous tumor cell lysis or to different therapies and it may cause hyperuricemia." | 2.44 | [Rasburicase therapy may cause hydrogen peroxide shock]. ( Góth, L, 2008) |
| "Hyperuricemia has also been found to be an independent risk factor for cardiovascular disease and hypertension." | 2.44 | The role of hyperuricemia and gout in kidney and cardiovascular disease. ( Edwards, NL, 2008) |
| "Uric acid is an antioxidant and perhaps helps to control blood pressure during a low Na+ diet through stimulation of the renin-angiotensin system." | 2.44 | Uric acid: bystander or culprit in hypertension and progressive renal disease? ( Menè, P; Punzo, G, 2008) |
| "In most women with preeclampsia, renal plasma flow and glomerular filtration rate are at most only modestly decreased as a consequence of increased afferent arteriolar resistance and/or reduced ultrafiltration coefficient." | 2.44 | Renal function during normal pregnancy and preeclampsia. ( Conrad, KP; Jeyabalan, A, 2007) |
| "An 8-year-old boy with stage 3 Burkitt's lymphoma, TLS was successfully treated with hyper-hydration, diuretics and rasburicase, without dialysis." | 2.44 | Avoiding dialysis in tumour lysis syndrome: is urate oxidase effective? - a case report and review of literature. ( Loh, TF; Tan, AM; Teo, WY, 2007) |
| "Hyperuricemia is a common finding in preeclamptic pregnancies evident from early pregnancy." | 2.44 | Uric acid as a pathogenic factor in preeclampsia. ( Bainbridge, SA; Roberts, JM, 2008) |
| "Gout has been a recognized disease since the fifth century B." | 2.44 | [Historical review of gout and hyperuricemia investigations]. ( Nakamura, T, 2008) |
| "Uric acid is a weak acid that exists largely as MSU, the ionized form, in urate pool at physiologic pH." | 2.44 | [Physiology and dynamics of uric acid in hyperuricemia]. ( Nakamura, T; Takagi, K; Ueda, T, 2008) |
| "Gout is a crystal deposition disease." | 2.44 | [Establishment of therapeutic goal and plan of gout and asymptomatic hyperuricemia]. ( Fujimori, S, 2008) |
| "Thus, the treatment of hypertension and hyperlipidemia associated with hyperuricemia is also important." | 2.44 | [Other antihyperuricemic agents]. ( Hisatome, I; Igawa, O; Ogino, K, 2008) |
| "Metabolic syndrome is a cluster of cardiovascular risk factors such as hypertriglyceridemia, hypertension, insulin resistance, based on visceral fat accumulation." | 2.44 | [Relationship between hyperuricemia and metabolic syndrome]. ( Tomita, K; Yamasaki, T, 2008) |
| "Hypertension is epidemic and currently affects 25% of the world's population and is a major cause of stroke, congestive heart failure, and end-stage renal disease." | 2.43 | Uric acid, evolution and primitive cultures. ( Cade, JR; Johnson, RJ; Oliver, WJ; Rideout, BA; Titte, S, 2005) |
| "Hyperuricemia is a common complication in organ transplant recipients, and frequently is associated with chronic cyclosporine immunosuppressive therapy." | 2.43 | Uric acid and transplantation. ( Mazzali, M, 2005) |
| "Gout is one of the best understood among the rheumatological disorders and one of the most satisfying to treat." | 2.43 | Diagnosis and management of gout: a rational approach. ( Suresh, E, 2005) |
| "Gout is one of the most readily manageable of the rheumatic diseases." | 2.43 | Understanding treatments for gout. ( Cannella, AC; Mikuls, TR, 2005) |
| "Future directions in the treatment of gout, in part guided by a better understanding of pathophysiology, are discussed." | 2.43 | Overview of hyperuricaemia and gout. ( Agudelo, C; Liu-Bryan, R; Masseoud, D; Rott, K, 2005) |
| "Uric acid may increase as a result of pathophysiological processes such as impaired renal sodium handling but may also contribute to renal and vascular damage, particularly endothelial dysfunction." | 2.43 | Uric acid and hypertension. ( Schachter, M, 2005) |
| "Hyperuricemia and gout are common conditions that have long been known to have a heritable component." | 2.43 | Genetic factors associated with gout and hyperuricemia. ( Bleyer, AJ; Hart, TC, 2006) |
| "Asymptomatic hyperuricemia is clearly associated with hypertension, chronic kidney disease, cardiovascular disease, and the insulin resistance syndrome, and the pathogenetic significance of these associations is under intensive study." | 2.43 | Crystal-induced arthropathies: recent investigative advances. ( Becker, MA; Ellman, MH, 2006) |
| "Hyperuricemia is a frequent finding in diseases in which the clinical manifestations are thought to be secondary to a state of generalized vascular endothelial dysfunction and related to the cardiovascular disease present in conditions associated with the metabolic syndrome, such as hypertension or diabetes." | 2.43 | Uric acid and the vasculature. ( Corry, DB; Tuck, ML, 2006) |
| "Throughout history, gout has been associated with rich foods and excessive alcohol consumption." | 2.43 | A concise history of gout and hyperuricemia and their treatment. ( Nuki, G; Simkin, PA, 2006) |
| "Hyperuricemia is commonly associated with traditional risk factors such as abnormalities in glucose metabolism, dyslipidemia, and hypertension." | 2.43 | Serum uric acid as a risk factor for cardiovascular and renal disease: an old controversy revived. ( Leoncini, G; Pontremoli, R; Ratto, E; Viazzi, F, 2006) |
| "Hyperuricemia has long been known to be associated with cardiovascular disease, and it is particularly common in people with hypertension, metabolic syndrome, or kidney disease." | 2.43 | Role of uric acid in hypertension, renal disease, and metabolic syndrome. ( Heinig, M; Johnson, RJ, 2006) |
| "Hyperuricemia is associated with hypertension, vascular disease, renal disease, and cardiovascular events." | 2.42 | Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? ( Feig, D; Herrera-Acosta, J; Johnson, RJ; Kanellis, J; Kang, DH; Kivlighn, S; Mazzali, M; Rodriguez-Iturbe, B; Tuttle, KR; Watanabe, S, 2003) |
| "The standard prophylaxis or treatment of hyperuricemia consists of decreasing uric acid production with allopurinol and facilitating its excretion by urinary alkalinization and hyperhydration." | 2.42 | Management of hyperuricemia with rasburicase review. ( de Bont, JM; Pieters, R, 2004) |
| " Moreover, the PRS also revealed a dose-response trend between AH rates and quartile scores." | 1.91 | Genetic contributions to female gout and hyperuricaemia using genome-wide association study and polygenic risk score analyses. ( Chang, JG; Chang, SJ; Chang, YS; Chen, YC; Chung, CC; Huang, CM; Lin, CY; Liu, TY; Tsai, FJ, 2023) |
| "Gout is a common crystal induced disease of high personal and social burden, characterised by severe arthritis and comorbidity if untreated." | 1.91 | Genetic polymorphisms and decreased protein expression of ABCG2 urate transporters are associated with susceptibility to gout, disease severity and renal-overload hyperuricemia. ( Juhász, P; Kulin, A; Mózner, O; Nagy, K; Pálinkás, M; Poór, G; Rásonyi, R; Sarkadi, B; Szabó, E; Várady, G; Vörös, D; Zámbó, B, 2023) |
| "Metabolic syndrome and hyperinsulinemia are associated with hyperuricemia." | 1.91 | Genetic and Physiological Effects of Insulin-Like Growth Factor-1 (IGF-1) on Human Urate Homeostasis. ( Choi, HK; Leask, MP; Mandal, AK; Merriman, TR; Mount, DB; Sumpter, NA, 2023) |
| "Gout is associated with a higher risk of fracture; however, findings on the associations of hyperuricemia and urate-lowering therapy (ULT) with the risk of fracture have been inconsistent." | 1.91 | Lowering Serum Urate With Urate-Lowering Therapy to Target and Incident Fracture Among People With Gout. ( Choi, HK; Dalbeth, N; Lane, NE; Lei, G; Lyu, H; Wei, J; Wu, J; Zeng, C; Zhang, Y, 2023) |
| "could treat hyperuricemia by reducing the production of uric acid via inhibition of xanthine oxidase and increasing the excretion of uric acid via regulation of urate transporters." | 1.91 | In vivo anti-hyperuricemia and anti-gouty arthritis effects of the ethanol extract from Amomumvillosum Lour. ( Chen, L; Dong, L; Dong, Y; Huang, J; Li, L; Long, T; Lu, J; Mao, Y; Qi, Z; Wen, J; Zhang, J; Zhang, S; Zhao, F, 2023) |
| "Apparent treatment-resistant hypertension (aTRH) was defined as a SBP ≥ 140 mmHg or DBP ≥ 90 mmHg with concurrent use of three classes of antihypertensive medications, or taking four or more classes of antihypertensive medication regardless of BP level." | 1.91 | Hypertension severity, apparent treatment resistant hypertension and hyperuricemia in the REasons for Geographic And Racial Differences in Stroke (REGARDS) study. ( Bridges, SL; Chaudary, N; Colantonio, LD; Cushman, M; Howard, G; Irvin, MR; Limdi, N; Merriman, TR; Muntner, P; Reynolds, RJ; Saag, K; Tanner, RM, 2023) |
| "In Japan, hyperuricemia is on the rise." | 1.91 | Effect of Dietary Counseling on Patients with Asymptomatic Hyperuricemia. ( Akiyama, M; Arai, H; Asai, T; Kawakami, Y; Koike, R; Kondo, R; Onishi, M, 2023) |
| "Chloroquine (CQ) is an anti-inflammatory and disease-modifying anti-rheumatic drug (DMARD) utilized in treating autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus." | 1.91 | Chloroquine inhibits NLRP3 inflammasomes activation and alleviates renal fibrosis in mouse model of hyperuricemic nephropathy with aggravation by a high-fat-diet. ( Cui, J; Hong, P; Li, Z; Lin, J; Nie, K; Wan, J; Wu, X; Zhang, X, 2023) |
| "Hyperuricemia was defined by serum uric acid level." | 1.91 | The correlation between dietary inflammatory index and risk of hyperuricemia in the U.S. population. ( Bao, K; Hong, X; Huang, X; Li, P; Liu, H; Wang, D; Wang, L; Wang, Y; Zhao, D, 2023) |
| " Dose-response relationships were analyzed using restricted cubic spline regression." | 1.91 | Association of N, N-diethyl-m-toluamide (DEET) with hyperuricemia among adult participants. ( Cui, Q; Guan, G; Hui, R; Liu, Z; Wu, R; Xing, Y; Zhang, Y; Zhu, L; Zhu, X, 2023) |
| "Hyperuricemia is an independent risk factor for chronic kidney disease." | 1.91 | Eurycoma longifolia alkaloid components ameliorate hyperuricemic nephropathy via regulating serum uric acid level and relieving inflammatory reaction. ( Cao, H; Chen, Q; Li, K; Liu, L; Liu, M; Wang, D; Wang, T; Wu, Y; Zhang, Y, 2023) |
| "Hyperuricemia is an independent predictor of incident CKD." | 1.91 | Serum uric acid is associated with chronic kidney disease in elderly Chinese patients with diabetes. ( Guo, Y; Ke, S; Liu, Q; Yan, Y; Zhou, Q, 2023) |
| " Logistic regression was used to estimate the association between hyperuricemia and nephrolithiasis, and a restricted cubic spline (RCS) model was used to explore the dose-response relationship between SUA and the risk of nephrolithiasis." | 1.91 | Asymptomatic hyperuricemia associated with increased risk of nephrolithiasis: a cross-sectional study. ( Cheng, N; Deng, H; Hou, Z; Li, Y; Meng, Q; Song, C; Sun, Y; Wang, Q; Yin, J; Zhang, J; Zhang, X, 2023) |
| "Hyperuricemia is perceived as one of the risk factors for developing and progressing cardiovascular disease and metabolic syndrome through various pathological mechanisms." | 1.91 | Effect of Alcohol Consumption Habits on Early Arterial Aging in Subjects with Metabolic Syndrome and Elevated Serum Uric Acid. ( Badarienė, J; Čypienė, A; Gimžauskaitė, S; Jasiūnas, E; Laucevičius, A; Rinkūnienė, E; Ryliškytė, L, 2023) |
| "Although obesity is associated with hyperuricemia, data on sex differences in this association are scarce." | 1.91 | Sex Difference in the Associations among Obesity-Related Indices with Hyperuricemia in a Large Taiwanese Population Study. ( Chen, SC; Huang, JC; Lin, TH; Liu, YH; Su, HM; Su, SY; Wu, PY, 2023) |
| "Current drugs for the treatment of hyperuricemia usually cause a degree of cardiovascular damage." | 1.91 | Honey Mushroom, ( Li, ZL; Wang, H; Wang, SM, 2023) |
| "Gout is the most common inflammatory arthritis and closely related to metabolic syndrome, leading to excruciating pain and the decline in quality of patients' life." | 1.91 | Metabolomic analysis for asymptomatic hyperuricemia and gout based on a combination of dried blood spot sampling and mass spectrometry technology. ( Liu, S; Liu, Y; Liu, Z; Wu, X, 2023) |
| "Hyperuricemia was defined as SUA concentrations >420 umol/L in males or >360 umol/L in females." | 1.91 | Associations between vitamin C intake and serum uric acid in US adults: Findings from National Health and Nutrition Examination Survey 2011-2016. ( Feng, Y; Yang, Y; Zheng, S, 2023) |
| "And gout and hyperuricemia are also possible connection with cardiovascular disease and metabolic syndrome." | 1.72 | Triterpenoid acids from medicinal mushroom Inonotus obliquus (Chaga) alleviate hyperuricemia and inflammation in hyperuricemic mice: Possible inhibitory effects on xanthine oxidase activity. ( Dai, LJ; He, FX; Luo, LS; Wang, Y; Zhang, JL; Zhou, Q, 2022) |
| "022), while arsenic levels showed a positive and linear dose-response relationship with HUA risk (p for non-linearity = 0." | 1.72 | Associations of plasma multiple metals with risk of hyperuricemia: A cross-sectional study in a mid-aged and older population of China. ( Chen, G; Cheng, J; Huang, H; Huang, S; Liu, N; Liu, R; Lv, Z; Peng, C; Wang, T; Wen, Y; Yu, S; Zhang, Y; Zheng, S; Zhong, D; Zhou, G; Zou, X, 2022) |
| "Chronic diseases have become main killers affecting the health of human, and environmental pollution is a major health risk factor that cannot be ignored." | 1.72 | Metabolome-wide association study of serum exogenous chemical residues in a cohort with 5 major chronic diseases. ( Chen, Q; Kou, J; Li, X; Liu, X; Mei, S; Su, C; Wang, L; Wang, X; Wang, Y; Xu, G; You, L; Zhang, B; Zheng, F, 2022) |
| "Gouty arthritis is the inflammation of tissues and joints caused by the deposition of monosodium urate crystals." | 1.72 | In Vivo Effects of Orally Administered Different Concentrations of Silver Oxide Nanoparticles in Hyperuricemic Mice. ( Abbas, HB; Bokhari, SAI; Butt, MA; Javed, A; Kiyani, MM; Moghul, NB; Rajput, TA; Rehman, H, 2022) |
| "Hyperuricemia is a precursor to gout and is often present in other metabolic diseases that are promoted by microbiome dysbiosis." | 1.72 | Association Between Gut Microbiota and Elevated Serum Urate in Two Independent Cohorts. ( Dalbeth, N; Lei, G; Li, J; Terkeltaub, R; Wang, Y; Wei, J; Wu, Z; Yang, T; Yang, Z; Zeng, C; Zhang, Y, 2022) |
| "Hyperuricemia was determined as serum uric acid ≥357μmol/L (6 mg/dl) for females and ≥417μmol/L (7 mg/dl) for males." | 1.72 | Mediation effect of obesity on the association between triglyceride-glucose index and hyperuricemia in Chinese hypertension adults. ( Bao, Q; Cai, S; Cheng, B; Li, M; Ma, S; Su, Y; Sun, J; Sun, M; Wang, S; Zhang, A; Zhang, Y; Zhu, P, 2022) |
| "Asymptomatic hyperuricemia is prevalent among young adults and associated with markers of prediabetes, dyslipidemia, and subclinical inflammation." | 1.72 | Prevalence of asymptomatic hyperuricemia and its association with prediabetes, dyslipidemia and subclinical inflammation markers among young healthy adults in Qatar. ( Al Shanableh, Y; Al-Mansoori, A; Al-Mohannadi, M; Aljalham, B; Hussein, YY; Nurulhoque, H; Robelah, F; Saidwali, AH; Zughaier, SM, 2022) |
| "Hyperuricemia is common among patients with chronic kidney disease (CKD)." | 1.72 | Hyperuricemia is associated with secondary hyperparathyroidism in patients with chronic kidney disease. ( Coelho, VA; Costa, TEM; Elias, RM; Innecchi, MLR; Lauar, JC; Moysés, RMA, 2022) |
| "Pharmacological treatment of gout consists of treating acute flares with anti-inflammatory drugs and, if indicated, of urate lowering therapies (ULT)." | 1.72 | [Gout: an overview of diagnostics and treatment]. ( Flendrie, M; Jansen, TLTA; Janssen, M; Moses, A; Oude Voshaar, AMH; Peeters, IR; van Herwaarden, N, 2022) |
| "Hyperuricemia is a common laboratory finding in pregnant women compromised by preeclampsia." | 1.72 | Glucose Transporter 9 (GLUT9) Plays an Important Role in the Placental Uric Acid Transport System. ( Albrecht, C; Baumann, MU; Lüscher, BP; Stieger, B; Surbek, DV, 2022) |
| "Recent studies showed that treatment of hyperuricemia did not affect the progression in chronic kidney disease (CKD) patients." | 1.72 | [Management of hyperuricemia in chronic kidney disease]. ( Auberson, M; Bonny, O; Livio, F; Schwotzer, N; So, A, 2022) |
| "Asymptomatic hyperuricemia is frequently observed in pediatric kidney transplant recipients; symptomatic hyperuricemia, however, is a rare complication." | 1.72 | Prevalence and potential relevance of hyperuricemia in pediatric kidney transplant recipients-a CERTAIN registry analysis. ( Babenko, N; Bald, M; Dello Strologo, L; Ehren, R; Ernst, A; Habbig, S; König, S; Krupka, K; Murer, L; Özçakar, ZB; Pohl, M; Spartà, G; Staude, H; Szabó, AJ; Tönshoff, B; Weber, LT, 2022) |
| "Hyperuricemia has become a common metabolic disease, and is a risk factor for multiple diseases, including chronic kidney disease." | 1.72 | Blockade of Autophagy Prevents the Progression of Hyperuricemic Nephropathy Through Inhibiting NLRP3 Inflammasome-Mediated Pyroptosis. ( Chen, H; Hu, Y; Li, J; Liu, N; Ma, X; Shi, Y; Tao, M; Wang, Y; Zhou, X, 2022) |
| "Hyperuricemia was defined as a serum uric acid level of ≥7." | 1.72 | Association between serum uric acid and α-klotho protein levels in the middle-aged population. ( Choi, JY; Kim, D; Lee, HJ; Lee, J; Min, JY; Min, KB, 2022) |
| "hyperuricemia has attracted greater attention." | 1.72 | Can Uric Acid be Used as a Prognostic Factor to Determine the Severity of Covid 19 Infection. ( Balaraj, K; G, S; Mukherjee, T; Prabhu, R; Sc, R, 2022) |
| "Gout is a disease that manifests itself after decades of following a high-purine diet, with excessive alcohol consumption assumed to be one of the main contributors to the development of the disease." | 1.72 | The Relationship between Alcohol Consumption and Gout: A Mendelian Randomization Study. ( Chen, H; Chen, J; Fahira, A; Li, Z; Shi, Y; Syed, AAS; Yang, Q, 2022) |
| "Background Hyperuricemia is associated with poor cardiovascular outcomes, although it is uncertain whether this relationship is causal in nature." | 1.72 | Weak Association Between Genetic Markers of Hyperuricemia and Cardiorenal Outcomes: Insights From the STANISLAS Study Cohort With a 20-Year Follow-Up. ( Bacq-Daian, D; Boivin, JM; Dandine-Roulland, C; Deleuze, JF; Ferreira, JP; Girerd, N; Kanbay, M; Le Floch, E; Rossignol, P; Wagner, S; Xhaard, C; Zannad, F, 2022) |
| "Low-grade inflammation has been postulated to have a key role in the pathogenesis of MetS and has been linked to insulin resistance (IR)." | 1.72 | Association Between Low-Grade Inflammation and Hyperuricemia in Adults With Metabolic Syndrome in Yucatán, México. ( Avila-Nava, A; Banik, SD; Chim Aké, R; Gutiérrez Solis, AL; Lugo, R, 2022) |
| "Hyperuricemia is closely related to a variety of diseases and has been listed as one of the twenty most persistent diseases in the 21st century by the United Nations." | 1.72 | Quantification of uric acid concentration in tears by using PDMS inverse opal structure surface-enhanced Raman scattering substrates: Application in hyperuricemia. ( Cao, H; Cui, X; Feng, Y; He, W; Li, J; Li, Y; Qiu, Y; Wang, D; Yang, X; Yang, Z, 2022) |
| "Gout is the most common inflammatory arthritis in men with a rising incidence worldwide." | 1.72 | [Gout]. ( Tausche, AK, 2022) |
| "In conclusion, Hyperuricemia is prevalent among Chinese adults." | 1.72 | Association of Hyperuricemia with 10-Year Atherosclerotic Cardiovascular Disease Risk among Chinese Adults and Elders. ( Chen, F; Han, S; Liu, J; Xu, T; Yuan, L, 2022) |
| "Osteoporosis was observed in 8243 (9%) and 1871 (8%) participants in the control and hyperuricemia groups, respectively." | 1.72 | Hyperuricemia and Its Association with Osteoporosis in a Large Asian Cohort. ( Chen, CH; Chen, SC; Chiu, CT; Geng, JH; Lee, JI; Li, JY; Lu, CC; Su, YD, 2022) |
| "Hyperuricemia is a common metabolic disease with a series of complications." | 1.72 | Synthesis and bioactivity evaluation of novel nuciferine derivatives with antihyperuricemia and nephroprotective effects. ( Chen, JS; Liu, C; Liu, YF; Sun, B; Sun, JY; Wang, CZ; Wang, MM; Wang, MX; Wang, Z; Yang, QL; Zhang, YK, 2022) |
| "Hyperuricemia has a suspected relationship with hypertension, metabolic syndrome, kidney disease, and cardiovascular disease." | 1.72 | Relationship between bisphenol A, bisphenol S, and bisphenol F and serum uric acid concentrations among school-aged children. ( Cho, YM; Hong, YC; Kim, BN; Kim, JI; Lee, YA; Lee, YJ; Lim, YH; Shin, CH, 2022) |
| "Hyperuricemia was associated with greater NLRP3 and gasdermin-D expression on human atheroma plaques in patients with peripheral artery disease." | 1.72 | Birefringent crystals deposition and inflammasome expression in human atheroma plaques by levels of uricemia. ( Andrés, M; Argente-Del-Castillo, E; Mendieta, L; Miñano, A; Pascual, E; Trigueros, M, 2022) |
| "Hyperuricemia is associated with the risk of developing atrial fibrillation (AF) and heart failure." | 1.72 | Association of Hyperuricemia with Impaired Left Ventricular Systolic Function in Patients with Atrial Fibrillation and Preserved Kidney Function: Analysis of the POL-AF Registry Cohort. ( Bakuła-Ostalska, E; Bednarski, J; Bil, J; Błaszczyk, R; Gawałko, M; Gorczyca-Głowacka, I; Jelonek, O; Kapłon-Cieślicka, A; Krzciuk, M; Lubas, A; Maciorowska, M; Mamcarz, A; Rajtar-Salwa, R; Szpotowicz, A; Szyszkowska, A; Tokarek, T; Tomaszuk-Kazberuk, A; Uziębło-Życzkowska, B; Wełnicki, M; Wójcik, M; Wójcik, W; Wojewódzki, M; Wożakowska-Kapłon, B, 2022) |
| "Hyperuricemia was defined as SUA higher than 360μmol/L (approximately 6 mg/dl)." | 1.72 | The Mediation Effect of Body Composition on the Association Between Menopause and Hyperuricemia: Evidence From China National Health Survey. ( Cui, Z; Du, J; He, H; Liu, F; Pa, L; Pan, L; Peng, X; Ren, X; Shan, G; Wang, D; Wang, H; Wang, X; Wang, Y; Yu, C; Zhao, J, 2022) |
| " The current study indicated that tea consumption may have a mitigating effect on the HUA population and provided a basis for further research on the efficacy of tea on the dosage and mechanism of uric acid-lowering effects in humans." | 1.72 | Tea ( ( Cao, F; Chen, R; Lai, X; Li, Q; Sun, L; Sun, S; Wen, S; Wu, D; Zhang, Z, 2022) |
| " In addition, the dose-response curve was also used to discuss the relationship between SUA and pSS-HT." | 1.72 | Relationship between serum uric acid and hypertension in patients with primary Sjögren's syndrome: A retrospective cohort study. ( Luo, Q; Qin, L; Wang, H; Yang, X; Zhang, Y, 2022) |
| "Hyperuricemia is a critical threat to human health, and conventional medical treatment only aims to treat acute gouty arthritis." | 1.72 | Lacticaseibacillus rhamnosus Fmb14 prevents purine induced hyperuricemia and alleviate renal fibrosis through gut-kidney axis. ( Chen, X; Lu, Y; Lu, Z; Meng, F; Pang, X; Zhang, L; Zhao, H; Zhou, L, 2022) |
| " Adverse events (AEs) resulting from febuxostat treatment were collected from medical records." | 1.72 | The safety and urate-lowering efficacy of febuxostat in patients undergoing peritoneal dialysis: a retrospective single-arm cohort study of 84 patients. ( Bao, S; Bian, X; Dai, L; Huang, J; Ma, J; Yu, Q; Zhang, A, 2022) |
| "Hyperuricemia is an independent risk factor for high AIP level." | 1.72 | Association of hyperuricemia with apolipoprotein AI and atherogenic index of plasma in healthy Chinese people: a cross-sectional study. ( An, Y; Chang, X; Ding, X; Duan, Y; Liu, J; Wang, G, 2022) |
| " There was a nonlinear dose-response between TG, HDL-C, and serum uric acid (SUA)." | 1.72 | Association between dyslipidaemia and the risk of hyperuricaemia: a six-year longitudinal cohort study of elderly individuals in China. ( Dong, H; Ma, Q; Sun, H; Xu, Y; Zhang, B; Zhang, J, 2022) |
| "Hyperuricemia is associated with aortic dissection and cardiovascular diseases." | 1.72 | Post-operative uric acid: a predictor for 30-days mortality of acute type A aortic dissection repair. ( Chen, X; Hu, Q; Huang, L; Lin, G; Luo, W; Ma, S; Wu, D; Xu, Q, 2022) |
| "Hyperuricemia is a purine metabolism disorder, with increasing prevalence worldwide." | 1.72 | A modified xanthine oxidase cell model for screening of antihyperuricemic functional compounds. ( Hou, C; Li, Y; Ren, J; Sha, W; Yao, M, 2022) |
| "Asymptomatic hyperuricemia is a common comorbidity among older outpatients with knee osteoarthritis." | 1.72 | Association between asymptomatic hyperuricemia and knee osteoarthritis in older outpatients. ( Cao, TN; Huynh, KN; Nguyen, MD; Tran, HT, 2022) |
| "Gout is a highly hereditary disease, but not all those carrying well-known risk variants have developing gout attack even in hyperuricemia status." | 1.72 | Polygenic risk score trend and new variants on chromosome 1 are associated with male gout in genome-wide association study. ( Chang, JG; Chang, SJ; Chang, YS; Chen, YC; Chung, CC; Huang, CM; Lin, CY; Liu, TY; Tsai, FJ, 2022) |
| "Hyperuricemia is a well-known cause of gout and also a risk factor for various comorbidities." | 1.72 | Screening of lactic acid bacteria strains with urate-lowering effect from fermented dairy products. ( Chen, S; Chen, Z; Gao, K; Ge, H; Li, L; Li, Y; Lin, G; Zhu, J, 2022) |
| "Hyperuricemia is the chief cause of gout and has been linked with hypertension, cardiovascular and renal disease, diabetes and metabolic syndrome." | 1.72 | Associations of Liver Function Parameters with New-Onset Hyperuricemia in a Large Taiwanese Population Study. ( Chen, SC; Lee, WH; Liu, YH; Lu, CC; Su, HM, 2022) |
| "Hyperuricemia was categorized as a serum uric acid level ≥ 420 umol/L (7 mg/dL)." | 1.72 | Triglyceride-glucose index is significantly associated with the risk of hyperuricemia in patients with diabetic kidney disease. ( Cui, Z; Fan, X; Li, Q; Liu, H; Shao, X; Wang, T; Yu, P; Zhou, S, 2022) |
| "Hyperuricemia is prevalent among middle-aged and elderly individuals, which affects the development of various chronic diseases." | 1.72 | Plasma S-Klotho level affects the risk of hyperuricemia in the middle-aged and elderly people. ( Chen, J; Chen, X; Han, J; Li, N; Liu, Q; Shen, L; Wang, H; Xie, H; Yu, P; Zhou, G, 2022) |
| "Hyperuricemia is a common feature in pregnancies compromised by pre-eclampsia, a pregnancy disease characterized by hypertension and proteinuria." | 1.72 | Hyperuricemia during Pregnancy Leads to a Preeclampsia-Like Phenotype in Mice. ( Baumann, MU; Lüscher, BP; Schoeberlein, A; Surbek, DV, 2022) |
| "Risk of hyperuricemia was high among those who remained metabolically unhealthy but of normal weight (OR, 3." | 1.72 | Association between metabolic obesity phenotype, transition of metabolic phenotypes and the risk of hyperuricemia in Chinese adults: A cohort study. ( Zhao, C; Zhao, W, 2022) |
| " Logistic regression models were used to estimate the association between LAP and HWH risk, restricted cubic splines (RCS) were used to analyze the dose-response relationship between them." | 1.72 | The lipid accumulation product (LAP) association with hyperuricemic hypertension in the China Health and Nutrition Survey: A cross-sectional study. ( Geng, Y; Ping, Z; Shang, Y; Wang, H; Wang, J; Yin, X; Zhou, M, 2022) |
| "Hyperuricemia and gout have become gradually more common." | 1.72 | Associations between serum urate and telomere length and inflammation markers: Evidence from UK Biobank cohort. ( Cui, J; Lv, Z; Zhang, J, 2022) |
| "Hyperuricemia was an independent risk factor of leukocyte in Tertile 3 (odds ratio [OR] = 1." | 1.72 | The relationship between leukocyte level and hypertension in elderly patients with hyperuricemia. ( Dong, Y; Li, M; Liu, Y; Shen, L; Zhang, J; Zhao, W; Zhou, Z, 2022) |
| "Non-alcoholic fatty liver disease (NAFLD) and metabolic syndrome (MetS) are two pathologies that intersect each other." | 1.72 | Non-alcoholic fatty liver disease: correlation with hyperuricemia in a European Mediterranean population. ( Catanzaro, R; He, F; Marotta, F; Sciuto, M; Singh, B, 2022) |
| "Acne vulgaris is a chronic inflammatory disease affecting the pilosebaceous unit." | 1.72 | A retrospective evaluation of laboratory parameters and hyperuricemia in patients with acne vulgaris under systemic isotretinoin treatment. ( Atilla, S; Ozdemir, S; Pancar, GS; Sarac, N, 2022) |
| "We aimed to evaluate the UA lowering effectiveness and provider adherence to the institutional protocol, as well as the cost-efficiency of this dosing strategy." | 1.72 | A retrospective observational study of a low fixed-dose rasburicase protocol for the treatment of tumor lysis syndrome in adults. ( Hossain, S; Naber, M; Yacobucci, MJ, 2022) |
| "Meanwhile, untreated hyperuricemia was also suggested to lead to hypertension." | 1.72 | Increased Systolic Blood Pressure Mediates the Relationship Between Urate and Gout Risk in Indonesia: A Novel Application of a Partial Least Squares-Structural Equation Model. ( Dyah Kurniasari, M; Huruta, AD; Karwur, FF; Lin, YH; Rayanti, RE; Tsai, HT; Weng, SF, 2022) |
| "Hyperuricemia is often associated with pre-eclampsia and when this occurs, fetal outcome may become worse." | 1.72 | Maternal serum uric acid: a reliable prognostic indicator of foetal outcome among pre-eclamptic patients in a low resource setting. ( Adebara, IO; Adeniyi, AA; Adewara, OE; Adeyemo, OT; Awoyinka, SB; Ayankunle, OM; Bakare, A; Jimoh, AK; Olumodeji, AM, 2022) |
| "Hyperuricemia has been associated with a number of chronic diseases, such as type 2 diabetes mellitus, hypertension, and cardiovascular diseases." | 1.62 | Dietary Acid Load Is Positively Associated with the Incidence of Hyperuricemia in Middle-Aged and Older Korean Adults: Findings from the Korean Genome and Epidemiology Study. ( Lee, KW; Shin, D, 2021) |
| "Calcitriol treatment attenuated the injury with reducing uric acid and creatinine levels, as well as tubular injury." | 1.62 | Calcitriol Treatment Attenuates Uric Acid-Induced Kidney Injury via Super Oxide Dismutase-1 (SOD-1) Upregulation and Fibrosis Reduction ( Arefian, N; Juffrie, M; Perdana Putri, RG; Ratna Sari, DC; Romi, MM; Wahyu Setyaningsih, WA, 2021) |
| "Hyperuricemia is the primary cause of gouty arthritis and other metabolic disorders." | 1.62 | Eggshell Membrane Ameliorates Hyperuricemia by Increasing Urate Excretion in Potassium Oxonate-Injected Rats. ( Kim, DS; Sung, YY, 2021) |
| " However, BBR exhibits low bioavailability due to its extensive metabolism and limited absorption." | 1.62 | Berberrubine attenuates potassium oxonate- and hypoxanthine-induced hyperuricemia by regulating urate transporters and JAK2/STAT3 signaling pathway. ( Chen, J; Huang, Z; Jiang, L; Li, Y; Lin, G; Lin, Z; Liu, Y; Mai, L; Su, Z; Xie, J; Xu, L; Yu, Q, 2021) |
| "Inflammation is an important pathological feature of hyperuricemia, which in turn aggravates hyperuricemia." | 1.62 | Astaxanthin attenuated hyperuricemia and kidney inflammation by inhibiting uric acid synthesis and the NF-κ B/NLRP3 signaling pathways in potassium oxonate and hypoxanthine-induced hyperuricemia mice. ( Chen, Y; Liu, T; Yang, Z; Yuan, F; Zhang, L; Zhang, S; Zhou, X; Zhuang, J, 2021) |
| "Hyperuricemia was not significantly associated to uncontrolled diabetes (OR=2." | 1.62 | Association between hyperuricemia and glycated hemoglobin in type 2 diabetes at the District Hospital of Dschang. ( Donkeng, M; Koudjou, PN; Kuaté, D; Kuiate, JR; Noubiap, JJ, 2021) |
| "Hyperuricemia was more common in men with 19." | 1.62 | Prevalence of Hyperuricemia Among Chinese Adults: Findings From Two Nationally Representative Cross-Sectional Surveys in 2015-16 and 2018-19. ( Huang, Z; Li, C; Wan, W; Wang, L; Wu, J; Xue, Y; Zhang, M; Zhang, W; Zhang, X; Zhao, Z; Zhou, M; Zhu, X; Zou, H, 2021) |
| " Dose-response analyses revealed a novel linear trend between the risk of hyperuricaemia and total, animal-derived retinol intake separately." | 1.62 | Association between retinol intake and hyperuricaemia in adults. ( Guo, Y; Han, M; Sun, J; Sun, Y; Yang, F; Zhang, P, 2021) |
| "Gout is a complex inflammatory arthritis affecting ~20% of people with an elevated serum urate level (hyperuricemia)." | 1.62 | Trans-ancestral dissection of urate- and gout-associated major loci SLC2A9 and ABCG2 reveals primate-specific regulatory effects. ( Bixley, M; Cadzow, M; Choi, HK; Dalbeth, N; Guo, H; He, M; Hu, H; Li, C; Li, Z; Major, TJ; Markie, D; Merriman, TR; Phipps-Green, A; Shi, Y; Stamp, LK; Takei, R; Wei, WH, 2021) |
| "Hyperuricemia is a common metabolic disease that is intimately correlated with inflammation." | 1.62 | Estimate of prevalent hyperuricemia by systemic inflammation response index: results from a rural Chinese population. ( Chen, MQ; Shi, WR; Sun, YX; Wang, HY, 2021) |
| "Hyperuricemia is an important problem also in healthy subjects and its prevalence could further increase if lower cut-off will be used." | 1.62 | Hyperuricemia prevalence in healthy subjects and its relationship with cardiovascular target organ damage. ( Bombelli, M; Brambilla, P; Cartella, I; Casati, M; Giannattasio, C; Grassi, G; Grasso, E; Maloberti, A; Milani, M; Occhi, L; Qualliu, E; Signorini, S; Sun, J; Tavecchia, G; Tognola, C; Vallerio, P, 2021) |
| "Hyperuricemia is a well-known key risk factor for gout and can cause a variety of metabolic diseases." | 1.62 | Multiomics Integrative Analysis for Discovering the Potential Mechanism of Dioscin against Hyperuricemia Mice. ( Gao, J; Han, L; Ma, J; Tan, Y; Wang, L; Wang, T; Yu, H; Zhang, Y, 2021) |
| "In view of the current status of treatment of hyperuricemia, we evaluated the hypouricemic effects of ISO in vivo and in vitro, and explored the underlying mechanisms." | 1.62 | Isoorientin exerts a urate-lowering effect through inhibition of xanthine oxidase and regulation of the TLR4-NLRP3 inflammasome signaling pathway. ( An, MF; Shen, C; Sheng, J; Sun, ZR; Wang, MY; Wang, XJ; Zhao, YL, 2021) |
| "Hyperuricemia has been associated with hypertension, however, whether this association exists across all decades of adult life is unknown." | 1.62 | Hyperuricemia is independently associated with hypertension in men under 60 years in a general Chinese population. ( Charchar, FJ; Drummond, GR; Golledge, J; Hou, X; Hu, W; Qian, T; Sobey, CG; Sun, H; Wang, Y; Xu, Q; Yang, G; Zhang, G, 2021) |
| "Thus, hyperuricemia is associated with impaired endothelial function." | 1.62 | Uric Acid as a Risk Factor for Chronic Kidney Disease and Cardiovascular Disease - Japanese Guideline on the Management of Asymptomatic Hyperuricemia. ( Bahrudin, U; Hisatome, I; Kuwabara, M; Li, P; Maharani, N; Mahati, E; Miake, J; Ninomiya, H; Taufiq, F; Utami, SB, 2021) |
| "In the 2369 patients with STEMI considered, 30-day mortality was 5." | 1.62 | Elevated serum uric acid is associated with a greater inflammatory response and with short- and long-term mortality in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. ( Camporotondo, R; Cornara, S; Crimi, G; De Ferrari, GM; Demarchi, A; Ferlini, M; Ferrario, M; Galazzi, M; Gnecchi, M; Mandurino-Mirizzi, A; Montalto, C; Oltrona-Visconti, L; Puccio, S; Somaschini, A, 2021) |
| "Gout is the most common inflammatory arthritis in adults." | 1.62 | Non-alcoholic fatty kidney disease (NAFKD): A novel disease that explains the etiology of hyperuricemia and gout in metabolic syndrome. ( Abrahim, M, 2021) |
| "Hyperuricemia has an important influence on the progression of ANCA-associated renal vasculitis." | 1.62 | Clinicopathological characteristics and outcomes of anti-neutrophil cytoplasmic autoantibody-related renal vasculitis with hyperuricemia: a retrospective case-control study. ( An, D; Guo, Y; Ma, P; Tang, L; Wang, R; Wu, Y, 2021) |
| "Hyperuricemia has not been found to increase the risk of cognitive impairment in people 55 years and older." | 1.62 | [Association between mild cognitive impairment and serum uric acid levels among people aged 55 and above in 4 provinces of China]. ( Chen, P; Fu, Z; Hu, D; Su, C; Wang, H; Wang, X; Wang, Z; Zhang, B; Zhang, Z, 2021) |
| "Hyperuricemia was defined as SUA ≥416." | 1.62 | Predictive Value of Thyroid Hormones for Incident Hyperuricemia in Euthyroid Subjects: The Tianjin Chronic Low-Grade Systemic Inflammation and Health Cohort Study. ( Gu, Y; Jia, Q; Liu, L; Meng, G; Niu, K; Song, K; Sun, S; Wang, X; Wang, Y; Wu, H; Wu, X; Zhang, Q; Zhang, S; Zhang, T; Zhou, M, 2021) |
| "Potassium oxonate was used to induce HUA in model rats, who were then administered WPH for 21 days." | 1.62 | Anti-hyperuricemic and nephroprotective effects of whey protein hydrolysate in potassium oxonate induced hyperuricemic rats. ( Chen, H; Guan, K; Ma, Y; Qi, X; Wang, R, 2021) |
| "Studies show that hyperuricemia is an element of the pathophysiology of many conditions." | 1.62 | How Are We Managing Patients with Hyperuricemia and Gout: A Cross Sectional Study Assessing Knowledge and Attitudes of Primary Care Physicians? ( Bozic, J; Rada, M; Rumboldt, M; Rumboldt, Z; Rusic, D; Tomicic, M; Zuzic Furlan, S, 2021) |
| "Novel coronavirus disease 2019 (COVID-19), an acute respiratory disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), rapidly progressed to a global pandemic." | 1.62 | Laboratory Predictors of COVID-19 Mortality: A Retrospective Analysis from Tongji Hospital in Wuhan. ( Dong, L; Gong, Q; Li, X; Liu, X; Wei, Y; Zheng, B; Zheng, T; Zhong, J, 2021) |
| "Gout is the most common inflammatory arthritis in men with a rising incidence worldwide." | 1.62 | [Gout]. ( Tausche, AK, 2021) |
| " Simulations based on the uric acid model were performed to assess dose-response of verinurad in combination with XOI, and to investigate the impact of covariates." | 1.62 | A semi-mechanistic exposure-response model to assess the effects of verinurad, a potent URAT1 inhibitor, on serum and urine uric acid in patients with hyperuricemia-associated diseases. ( Aksenov, S; Eriksson, UG; Johansson, S; Leander, J; Parkinson, J; Rekić, D; Sunnåker, M, 2021) |
| "Uric acid is a powerful antioxidant." | 1.62 | Detrimental effects of long-term elevated serum uric acid on cognitive function in rats. ( Gu, CW; Jia, H; Li, SJ; Li, TT; Liu, XR; Nie, ZC; Tang, Y; Tian, T; Xu, WD, 2021) |
| "Uric Acid (UA) has been related to the development of Cardio-Vascular (CV) events in patients affected by Chronic Coronary Syndromes (CCS)." | 1.62 | Uric acid in chronic coronary syndromes: Relationship with coronary artery disease severity and left ventricular diastolic parameter. ( Bossi, I; De Chiara, B; Giannattasio, C; Maloberti, A; Moreo, A; Nava, S; Oliva, F; Oreglia, J; Piccalò, G; Piccaluga, E; Pirola, R; Racioppi, A; Rebora, P; Soriano, F; Tassistro, E; Vallerio, P; Valsecchi, MG, 2021) |
| "Hyperuricemia is associated with cardiovascular mortality, but the association of the age at hyperuricemia onset with cardiovascular disease (CVD) and mortality is still unclear." | 1.62 | Early onset of hyperuricemia is associated with increased cardiovascular disease and mortality risk. ( Chen, S; Cui, L; Li, L; Wang, C; Wu, S; Xue, H; Yun, C; Zhang, S; Zhao, M, 2021) |
| "Gout is a multifaceted inflammatory disease involving vascular impairments induced by hyperuricemia." | 1.62 | Gout-induced endothelial impairment: The role of SREBP2 transactivation of YAP. ( He, M; Li, X; Shi, W; Shyy, JY; Wang, L; Zhang, Y; Zhao, Y; Zhao, Z, 2021) |
| "Hyperuricemia is closely associated with insulin resistance syndrome (and its many cardiometabolic sequelae); however, whether they are causally related has long been debated." | 1.62 | Assessing the Causal Relationships Between Insulin Resistance and Hyperuricemia and Gout Using Bidirectional Mendelian Randomization. ( Choi, HK; Leong, A; McCormick, N; Merriman, TR; Mount, DB; O'Connor, MJ; Yokose, C, 2021) |
| "Gout is a metabolically-related joint disease, characterized by recurrent episodic arthritis." | 1.62 | Non-pharmacological treatment of gout. ( Líška, D, 2021) |
| " Restricted cubic spline regression was used to estimate the dose-response association between UPF consumption and risk of hyperuricemia." | 1.62 | Association between consumption of ultra-processed foods and hyperuricemia: TCLSIH prospective cohort study. ( Gan, S; Gu, Y; Jia, Q; Jiao, H; Liu, L; Meng, G; Niu, K; Song, K; Sun, S; Wang, X; Wang, Y; Wu, H; Wu, Y; Ye, M; Zhang, Q; Zhang, S; Zhang, T; Zhou, M, 2021) |
| "Anthropometric, clinical biochemical data, and serum samples were collected from patients with MetS, MetS combined with HUA (MetS & HUA) and healthy controls." | 1.62 | NMR spectroscopy based metabolomics confirms the aggravation of metabolic disorder in metabolic syndrome combined with hyperuricemia. ( Bian, C; Pan, H; Rong, S; Yang, Y; Zhang, H; Zhang, Y, 2021) |
| "When uric acid was examined as a continuous variable, multivariable-adjusted HR of diabetes for each 1 mg/dL (60 μmol/L) increase in serum uric acid was 1." | 1.62 | Serum uric acid and its change with the risk of type 2 diabetes: A prospective study in China. ( Fan, Y; Hu, G; Li, Y; Liu, M; Liu, T; Meng, Z; Su, H; Wang, B; Zhang, Q, 2021) |
| "Uric acid is a metabolic product of nucleic acid and protein." | 1.62 | Fine-needle aspiration cytology finding uric acid crystals produced by ( Khairwa, A, 2021) |
| "Patients with hyperuricemia are among the high-risk group of postoperative gout attacks." | 1.62 | Factors Influencing Early Serum Uric Acid Fluctuation After Bariatric Surgery in Patients with Hyperuricemia. ( Fu, L; Liu, Y; Wen, J; Xu, C; Yan, T; Yang, H; You, Y; Yu, J; Zhan, D; Zhang, T, 2021) |
| "A total of 244 patients with IgA nephropathy enrolled in Jiangjin Center Hospital were divided into a group with normal serum uric acid level and a group with elevated level." | 1.62 | Association between hyperuricaemia and clinical pathological characteristics of patients with IgA nephropathy. ( Dai, G; Feng, H; Feng, Y; Li, B; Lu, L, 2021) |
| "Sarcopenia has been recognized as a diabetic complication, and hyperuricemia is often accompanied by type 2 diabetes mellitus (T2DM)." | 1.62 | Higher Serum Uric Acid is a Risk Factor of Reduced Muscle Mass in Men with Type 2 Diabetes Mellitus. ( Kanazawa, I; Notsu, M; Sugimoto, T; Tanaka, KI, 2021) |
| "Uric acid wGRS was not associated with fasting serum glucose, HbA1C, waist circumference, or BMI." | 1.56 | The causal role of elevated uric acid and waist circumference on the risk of metabolic syndrome components. ( Biradar, MI; Chiang, KM; Huang, YT; Pan, WH; Yang, HC, 2020) |
| "Gout has significant impact on the quality of life with over-utilisation of health resources." | 1.56 | Burden and management of gout in a multi-ethnic Asian cohort. ( Cheung, PP; Chua, CKT; Lim, AYN; Santosa, A; Teng, GG, 2020) |
| "Hyperuricemia has been reported to be a risk factor for hypertension, but this association may be affected by alcohol consumption." | 1.56 | Hyperuricemia predicts the risk for developing hypertension independent of alcohol drinking status in men and women: the Saku study. ( Asayama, K; Izawa, S; Miyamatsu, N; Miyamoto, Y; Morimoto, A; Ohkubo, T; Ohno, Y; Satoh, M; Sonoda, N; Tatsumi, Y, 2020) |
| "In particular, apparent treatment-resistant hypertension (systolic blood pressure ≥140 mm Hg or diastolic blood pressure ≥90 mm Hg on 3 antihypertensive medications or use of ≥4 antihypertensive medications) and the count of antihypertensive medication classes significantly reduced the effect of hyperuricemia on ischemic stroke." | 1.56 | Severity of Hypertension Mediates the Association of Hyperuricemia With Stroke in the REGARDS Case Cohort Study. ( Bridges, SL; Chaudhary, NS; Colantonio, LD; Curtis, JR; Cushman, M; Flaherty, ML; Gaffo, A; Howard, G; Irvin, MR; Judd, S; Levitan, EB; Limdi, NA; Rahn, EJ; Reynolds, RJ; Saag, KG; Singh, JA, 2020) |
| "The prevalence of hyperuricemia has increased substantially in recent decades." | 1.56 | Association between dairy product consumption and hyperuricemia in an elderly population with metabolic syndrome. ( Abete, I; Alonso-Gómez, ÁM; Altozano Rodado, MC; Álvarez-Pérez, J; Arellano, AG; Babio, N; Barragán, R; Becerra-Tomás, N; Bernal, R; Cano-Ibáñez, N; Carmona-González, FJ; Caro, JLL; Casas, R; Corbella, E; Corella, D; Daimiel, L; de la Hera, MG; Díaz-López, A; Estruch, R; Fernández-Carrión, R; Fernández-García, JC; Fitó, M; Gaforio, JJ; Goday, A; Lapetra, J; Lopez-Miranda, J; Martín, M; Martínez, JA; Martínez-González, MÁ; Matía-Martín, P; Mena-Sánchez, G; Morey, M; Palau, A; Pérez-Vega, KA; Pintó, X; Romaguera, D; Ros, E; Ruiz-Canela, M; Salas-Salvadó, J; Santos-Lozano, JM; Serra-Majem, L; Sureda, A; Toledo, E; Tur, JA; Vaquero-Luna, J; Vázquez, C; Vidal, J; Vioque, J; Wärnberg, J; Zomeño, MD, 2020) |
| "The prevalence of hyperuricemia is increasing in adults, while the prevalence among adolescents is seldom reported." | 1.56 | A cross-sectional study on uric acid levels among Chinese adolescents. ( Cui, L; Han, L; He, Y; Ji, A; Ji, X; Li, C; Li, H; Li, X; Liu, Z; Lu, J; Ren, W; Sun, W; Wang, C; Wang, X; Zhang, H, 2020) |
| "Hyperuricemia is an important risk factor for many diseases including hypertension and type 2 diabetes." | 1.56 | Comparisons of protective effects between two sea cucumber hydrolysates against diet induced hyperuricemia and renal inflammation in mice. ( Bao, W; Han, J; Li, Y; Lu, C; Ming, T; Su, X; Tang, S; Wan, H; Zhou, J, 2020) |
| "Hyperuricemia is associated with the development, progression and outcome of several diseases." | 1.56 | Uric Acid Level as a Predictor of Long-Term Mortality in Advanced Age Population. ( Abu Sneineh, M; Breuer, GS; Freier Dror, Y; Nesher, G; Schwartz, Y, 2020) |
| "Gout and hyperuricemia are common public health problem." | 1.56 | The prevalence of gout and hyperuricemia in middle-aged and elderly people in Tibet Autonomous Region, China: A preliminary study. ( Baima, Y; Gong, H; Lin, C; Lin, J; Liu, Q; Wang, Y; Zhang, Q, 2020) |
| "Currently, the treatment of gout mainly includes two basic methods: reducing uric acid and alleviating inflammation." | 1.56 | Development of novel NLRP3-XOD dual inhibitors for the treatment of gout. ( Ha, EH; Hu, Q; Li, H; Li, Z; Pang, J; Tian, S; Wang, W; Zhou, M, 2020) |
| "Vitamin D deficiency has been shown to be associated with coronary artery disease (CAD)." | 1.56 | The relationship between a combination of vitamin D deficiency and hyperuricemia and the severity of coronary artery disease in myocardial infarction patients. ( Akgül, F; Akgün, T; Çakır, MO; Can, M; Serbest, NG; Somuncu, MU; Tatar, FP; Tekin, A, 2020) |
| "Hyperuricemia is independently associated with cardiovascular disease (CVD) and is considered to be one of the major risk factors for CVD." | 1.56 | Association of variability in uric acid and future clinical outcomes of patient with coronary artery disease undergoing percutaneous coronary intervention. ( Chan, WL; Charng, MJ; Chen, JW; Chen, SC; Chen, YH; Cheng, HM; Chou, CY; Hsu, PF; Huang, CC; Huang, PH; Huang, SS; Leu, HB; Lim, SS; Lin, SJ; Lin, YJ; Lu, TM; Pan, JP; Sung, SH; Wu, CH; Wu, TC; Yang, YL, 2020) |
| "Hyperuricemia is a major risk for non-alcoholic fatty liver disease." | 1.56 | Uric acid induced hepatocytes lipid accumulation through regulation of miR-149-5p/FGF21 axis. ( Chen, D; Chen, S; Wang, J; Wang, X; Xu, C; Yang, H, 2020) |
| "Hyperuricemia is closely associated with cardiovascular disease (CVD)." | 1.56 | Association between serum level of urate and subclinical atherosclerosis: results from the SCAPIS Pilot. ( Angerås, O; Bergström, G; Dehlin, M; Drivelegka, P; Forsblad-d'Elia, H; Jacobsson, LTH; Schmidt, C, 2020) |
| "Among men with stable COPD, hyperuricemia is not an independent predictor of all-cause mortality or future acute exacerbation of COPD." | 1.56 | Hyperuricemia Is Not Predictive of Long-Term Outcome in Patients with Stable Chronic Obstructive Pulmonary Disease. ( Hwang, JJ; Kim, EK; Kim, TH; Lee, JH; Lee, JS; Lee, SD; Lee, SW; Lim, SY; Oh, YM; Park, YB; Rhee, CK; Yoo, KH; Yoon, HI, 2020) |
| "Although hyperuricemia is associated with congestive heart failure (CHF), hyperuricemic patients frequently have other comorbidities." | 1.56 | Asymptomatic hyperuricemia and incident congestive heart failure in elderly patients without comorbidities. ( Cheng, H; Jian, G; Tang, Y; Wang, N; Wu, J; Wu, X, 2020) |
| "Hyperuricemia was defined as levels of serum UA > 6." | 1.56 | The relationship between self-reported habitual snoring and hyperuricemia among Chinese urban adults: a cross-sectional study. ( Ge, X; He, F; Li, Y; Shi, Y; Sun, G; Xiong, X; Xu, R; Zheng, S, 2020) |
| "Hyperuricemia has been associated with metabolic syndrome, and the association with various cardiometabolic risk factors may be affected by sex." | 1.56 | Sex-specific association of hyperuricemia with cardiometabolic abnormalities in a military cohort: The CHIEF study. ( Hoshide, S; Kwon, Y; Lee, JT; Lin, CS; Lin, GM; Lin, YK; Lin, YP; Su, FY; Tsai, KZ; Wu, TJ, 2020) |
| "Hyperuricemia has been well studied in the past two decades, revealing mechanistic insights into UA homeostasis." | 1.56 | Effects of uric acid dysregulation on the kidney. ( Dissanayake, LV; Palygin, O; Spires, DR; Staruschenko, A, 2020) |
| "Hyperuricemia is a central risk factor for gout and increases the risk for other chronic diseases, including cardiometabolic disease, kidney disease, and hypertension." | 1.56 | High-Protein Diet Induces Hyperuricemia in a New Animal Model for Studying Human Gout. ( Dai, S; Guo, Y; Hong, F; Li, L; Liu, G; Pan, S; Qiao, X; Wang, J; Xie, X; Xu, P; Xue, T; Zhai, Y; Zheng, A, 2020) |
| "Prolonged hyperuricemia is a cause of gout and an independent risk factor for chronic health conditions including diabetes and chronic kidney diseases." | 1.56 | A population-specific low-frequency variant of SLC22A12 (p.W258*) explains nearby genome-wide association signals for serum uric acid concentrations among Koreans. ( Chae, J; Cho, B; Im, SW; Kim, JI; Park, JH; Son, HY, 2020) |
| "Uric acid (UA) levels were significantly higher in the intensive care patients (6." | 1.56 | Plasma xanthine oxidoreductase (XOR) activity in patients who require cardiovascular intensive care. ( Asai, K; Asano, K; Goda, H; Hata, N; Kiuchi, K; Kobayashi, N; Matsushita, M; Murase, T; Nakamura, T; Okazaki, H; Shibata, Y; Shigihara, S; Shimizu, W; Shirakabe, A; Tani, K, 2020) |
| "Hyperuricemia and gout are common in patients with heart failure (HF) and are associated with poor outcomes." | 1.56 | Comparison of Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction With Versus Without Hyperuricemia or Gout. ( Andersson, K; Bjursell, M; Carnicelli, AP; Chiswell, K; Clare, R; Hedman, K; Lytle, B; Mentz, RJ; Pagidipati, N; Perl, S; Roe, MT; Vemulapalli, S, 2020) |
| "Hyperuricemia is a risk factor for cardiovascular metabolic diseases." | 1.56 | Hyperuricemia is associated with metabolic syndrome in the community very elderly in Chengdu. ( Cai, L; Huang, G; Liu, H; Wu, J; Xu, J; Yu, X; Zhang, T, 2020) |
| "Hyperuricemia has been recognized as a worldwide public health concern." | 1.56 | Association between serum copper levels and prevalence of hyperuricemia: a cross-sectional study. ( He, H; Jiang, T; Wang, H; Wang, N; Wang, Y; Wu, J; Xie, D; Yang, T; Zhu, Z, 2020) |
| "Allopurinol treatment significantly reduced MAGE (4." | 1.56 | Blood glucose fluctuations detected by continuous glucose monitoring system in gout patients with normal glucose tolerance and the effect of urate-lowering therapy. ( Chen, Y; Dong, B; Lv, W; Mu, Z; Wang, F; Wang, J; Wang, W; Wang, Y; Wang, Z; Zhao, Y, 2020) |
| "Hyperuricemia is considered a risk factor for increased postoperative complications and adverse functional outcomes in a variety of orthopedic surgeries." | 1.56 | Effect of hyperuricemia on functional outcomes and complications in patients with elbow stiffness after open arthrolysis combined with hinged external fixation: a retrospective study. ( Chen, S; Fan, C; Liu, W; Peng, S; Sun, Z; Wang, W; Xiong, H, 2020) |
| " The effect of uricosuric agents on the decrease in hospitalized stroke risk indicated a dose-response relationship." | 1.56 | Urate-lowering therapy may mitigate the risks of hospitalized stroke and mortality in patients with gout. ( Hsu, CC; Hwu, CM; Li, HL; Wei, JC; Yen, FS, 2020) |
| "Febuxostat was associated with greater reduction in SUA level than allopurinol in patients with CKD." | 1.56 | Comparison of uric acid reduction and renal outcomes of febuxostat vs allopurinol in patients with chronic kidney disease. ( Hsu, CN; Huang, YB; Lee, CT; Peng, YL; Tain, YL; Wen, YH; Yang, YH, 2020) |
| " UHLN/UHLNM had significantly increased bioavailability (∼533% and ∼331% compared to Uase) and demonstrated greatly improved efficacy, whereby the time required for UHLN/UHLNM to lower the plasma uric acid concentration to a normal level was much shorter than that for free Uase." | 1.56 | Biomimetic polysaccharide-cloaked lipidic nanovesicles/microassemblies for improving the enzymatic activity and prolonging the action time for hyperuricemia treatment. ( Abagyan, R; He, D; Li, K; Li, Y; Shi, D; Wang, T; Xie, J; Yang, L; Zhang, J; Zhang, Y; Zhong, C, 2020) |
| "Hyperuricemia is an important risk factor of chronic kidney disease, metabolic syndrome and cardiovascular disease." | 1.56 | The Time-Feature of Uric Acid Excretion in Hyperuricemia Mice Induced by Potassium Oxonate and Adenine. ( Bao, R; Chen, Q; Liu, L; Liu, M; Wang, D; Wang, T; Wen, S; Yu, H; Zhang, Y, 2020) |
| "Our results explore the promising evidences that SUA level showed a positive correlation with AAC score in a dose-response manner." | 1.56 | Clinical relevance of serum uric acid and abdominal aortic-calcification in a national survey. ( Chen, WL; Li, YW, 2020) |
| "Hyperuricemia is an independent risk factor for the development of many diseases." | 1.56 | Comparison of the Effects of Allopurinol and Febuxostat on the Values of Triglycerides in Hyperuricemic Patients. ( Lagumdzija, D; Muratovic, S; Omerovic, N; Pehlivanovic, B; Skrbo, S; Ziga-Smajic, N, 2020) |
| "Hyperuricemia was defined as serum UA ≥7 mg/dl in men and ≥ 6 mg/dl in women." | 1.56 | The relationship between serum uric acid and cognitive function in patients with chronic heart failure. ( Lu, C; Niu, W; Yang, H, 2020) |
| "Nevertheless, gout is a "curable disease" by ULT, a treatment which in adequate doses may also have positive effect on several associated co-morbidities." | 1.56 | [Consequences of Gout and Hyperuricemia]. ( Bengtsson Boström, K; Dehlin, M; Forsblad d'Elia, H; Jacobsson, L; Kapetanovic, M; Sigurdardottir, V; Svärd, A; Wändell, P, 2020) |
| "Gout has a prevalence of 1." | 1.56 | [Gout - a common and well known disease]. ( Bengtsson Boström, K; Dehlin, M; Forsblad d'Elia, H; Jacobsson, L; Kapetanovic, M; Sigurdardottir, V; Svärd, A; Wändell, P, 2020) |
| "Olsalazine sodium was screened from 3167 authorized small compounds/drugs, targeting xanthine oxidoreductase." | 1.56 | Olsalazine Sodium Increases Renal Urate Excretion by Modulating Urate Transporters in Hyperuricemic Animals. ( Gao, L; Li, H; Li, L; Li, Q; Lin, H; Niu, Y; Yang, P, 2020) |
| "There were 115 deaths from aortic dissection and aortic aneurysm rupture during the follow-up period of 1,803,955 person-years." | 1.56 | Impact of hyperuricemia on mortality related to aortic diseases: a 3.8-year nationwide community-based cohort study. ( Asahi, K; Fujimoto, S; Iseki, K; Kasahara, M; Kondo, M; Konta, T; Moriyama, T; Narita, I; Otaki, Y; Shibagaki, Y; Tsuruya, K; Watanabe, M; Watanabe, T; Yamagata, K, 2020) |
| "Hyperuricemia was defined as the serum uric acid level of more than 6 mg/dl." | 1.56 | Association between Hyperuricemia and Ischemic Stroke: A Case-Control Study. ( Fatima, T; Iftikhar, S; Qureshi, IH, 2020) |
| "Hyperuricemia is a common laboratory finding in different types of patients." | 1.56 | Hyperuricemia in renal disease patients. ( Bandúr, Š, 2020) |
| "Hyperuricemia is prevalent throughout the world." | 1.56 | Prevalence and associated factors of hyperuricemia among urban adults aged 35-79 years in southwestern China: a community-based cross-sectional study. ( Huang, C; Huang, XB; Liu, JX; Liu, Y; Ning, Y; Tang, WW; Wang, TD; Xu, RH; Yi, YJ; Zhang, WQ, 2020) |
| "Esculetin is a candidate urate-lowering drug with renoprotective activity and the ability to inhibit XO, promote excretion of UA, protect oxidative stress injury, and reduce renal fibrosis." | 1.56 | Multiple-Purpose Connectivity Map Analysis Reveals the Benefits of Esculetin to Hyperuricemia and Renal Fibrosis. ( Huang, B; Kong, W; Meng, J; Wang, L; Wang, Y; Xie, Z; Yang, B; Zhang, T; Zhou, H, 2020) |
| "Hyperuricemia is more likely to occur in women (risk ratio (RR) = 1." | 1.56 | The effect of serum uric acid levels on the long-term prognosis of patients with non-ST-elevation myocardial infarction. ( Bachórzewska-Gajewska, H; Dobrzycki, S; Kulikowska, A; Kurasz, A; Kuźma, Ł; Niwińska, MM; Zalewska-Adamiec, M, 2020) |
| "Uric acid level is a risk factor for kidney disease." | 1.56 | Uric acid level and kidney function: a cross-sectional study of the Korean national health and nutrition examination survey (2016-2017). ( Choi, DW; Joo, HJ; Joo, JH; Kim, GR; Park, EC, 2020) |
| "Uric acid elevation was reported in many systemic diseases and might be elevated during direct antiviral therapy." | 1.56 | Efficacy of antiviral therapy in patients with post-hepatitis C liver cirrhosis: is hyperuricaemia a potential adverse effect? ( Abbas, A; Elsayed, A; Hassan, H; Hassnine, A; M Abdelraheem, E, 2020) |
| "Although gout is the most common inflammatory arthritis, it is still frequently misdiagnosed." | 1.56 | 2018 updated European League Against Rheumatism evidence-based recommendations for the diagnosis of gout. ( Bardin, T; Barskova, V; Becce, F; Castaneda, J; Coyfish, M; Doherty, M; Guillo, S; Jansen, T; Janssens, H; Lioté, F; Mallen, CD; Nuki, G; Pascual, E; Perez-Ruiz, F; Pimentao, J; Punzi, L; Pywell, A; Richette, P; So, AK; Tausche, AK; Tubach, F; Uhlig, T; Zavada, J; Zhang, W, 2020) |
| "Intermittent hand joint pain was also an independent risk factor for worse general health description." | 1.51 | Hyperuricemia is associated with intermittent hand joint pain in a cross sectional study of elderly females: The AGES-Reykjavik Study. ( Aspelund, T; Eiriksdottir, G; Gudnason, V; Harris, TB; Jonsson, H; Launer, LJ, 2019) |
| "Hyperuricemia is an independent risk factor for renal dysfunction, cardiovascular events, and gouty arthritis." | 1.51 | Topiroxostat influences circulating lipid concentrations in hyperuricemic patients . ( Tohyo, S, 2019) |
| "Uric acid levels were greater for each log-unit increase in branched PFOA (β = 0." | 1.51 | Isomers of per- and polyfluoroalkyl substances and uric acid in adults: Isomers of C8 Health Project in China. ( Bloom, MS; Chu, C; Dharmage, SC; Dong, GH; Hu, LW; Li, QQ; Liu, KK; Lodge, CJ; Yang, BY; Yang, M; Yu, Y; Zeng, XW, 2019) |
| "Hyperuricemia has been recognized as a risk factor for insulin resistance as well as one of the factors leading to diabetic kidney disease (DKD)." | 1.51 | Xanthine Oxidase Inhibitor Febuxostat Exerts an Anti-Inflammatory Action and Protects against Diabetic Nephropathy Development in KK-Ay Obese Diabetic Mice. ( Asano, T; Fujishiro, M; Inoue, MK; Kikuchi, T; Kushiyama, A; Masaki, T; Matsunaga, Y; Mizuno, Y; Morii, K; Nakatsu, Y; Ono, H; Sakoda, H; Sasaki, K; Takahashi, M; Ueda, K; Yamamotoya, T, 2019) |
| "Hyperuricemia has received increasing attention as a major public health problem." | 1.51 | Risk factors for the development of hyperuricemia: A STROBE-compliant cross-sectional and longitudinal study. ( Chen, C; Du, H; Lu, X; Ni, Q; Zhang, R, 2019) |
| "Myricitrin has many pharmacological effects, such as anti-inflammation, liver protection and anti-oxidation." | 1.51 | Preparation, characterization, pharmacokinetics and anti-hyperuricemia activity studies of myricitrin-loaded proliposomes. ( Adu-Frimpong, M; Ji, H; Man, N; Toreniyazov, E; Wang, Q; Wei, C; Wei, Q; Weng, W; Xu, X; Yu, J; Zhang, K, 2019) |
| "Uric acid has been reported to activate Nod-like receptor protein 3 (NLRP3)-inflammasome and alter vascular smooth muscle cells (VSMC)." | 1.51 | Elevated Uric Acid Levels Promote Vascular Smooth Muscle Cells (VSMC) Proliferation via an Nod-Like Receptor Protein 3 (NLRP3)-Inflammasome-Dependent Mechanism. ( Li, H; Liu, H; Qian, F; Zhang, Z, 2019) |
| "Hyperuricemia has been reported to be associated with the development of postoperative acute kidney injury (pAKI)." | 1.51 | Influence of hyperuricemia treatment on postoperative acute kidney injury among hyperuricemia patients: a single-center retrospective database analysis. ( Hatakeyama, Y; Horino, T; Kawano, T; Locatelli, FM; Matsumoto, T; Nagata, K; Okuhara, Y; Terada, Y; Watanabe, S; Yokoyama, M, 2019) |
| "l-Carnitine is an antioxidant, affecting mitochondria and cellular energetics; however, little is known about its effects in hyperuricemic states." | 1.51 | Possible role of l-carnitine in improvement of metabolic and hepatic changes in hyperuricemic and hyperuricemic-Fructose-supplemented rats. ( Ahmed, MA; El-Kafoury, BMA; ElKady, AH; Hammouda, GA; Lasheen, NN, 2019) |
| "Introduction: Hyperuricemia is an independent risk factor for high-normal blood pressure (BP) both in men and women." | 1.51 | The influence of uric acid level on erythrocyte morphology in normotensive patients. ( Kovalenko, YL; Melekhovets, OK; Melekhovets, YV; Orlovskiy, VF, 2019) |
| "Hyperuricemia is an important potential pathogenic factor for hypertension, cardiovascular disease and stroke." | 1.51 | Risk Factors For Hyperuricemia In Chinese Centenarians And Near-Centenarians. ( Cai, GY; Chen, XM; Han, QX; Li, J; Liu, DW; Liu, L; Liu, ZS; Luan, FX; Zhang, D; Zhang, F; Zhao, YL; Zhu, HY, 2019) |
| "Hyperuricemia was shown to be an independent risk factor for CAD severity in young adults with ACS (18-35 years of age)." | 1.51 | Hyperuricemia and severity of coronary artery disease: An observational study in adults 35 years of age and younger with acute coronary syndrome. ( Alhelal, JW; Liu, W; Liu, X; Liu, Y; Lv, S; Ravuru, KSS; Shi, D; Zhao, Y; Zhou, Y, 2019) |
| "Hyperuricemia has been associated with high blood pressure (BP) values, diabetes mellitus, metabolic syndrome and chronic kidney disease (CKD)." | 1.51 | Gender-related differences in serum uric acid in treated hypertensive patients from central and east European countries: findings from the Blood Pressure control rate and CArdiovascular Risk profilE study. ( Bombelli, M; Facchetti, R; Grassi, G; Lurbe, E; Maloberti, A; Mancia, G; Redon, J; Redon, P, 2019) |
| "Whether hyperuricemia affects biological response to acute stress remains largely unknown, suggesting a need to clarify this potential connection." | 1.51 | Salivary uric acid: Associations with resting and reactive blood pressure response to social evaluative stress in healthy African Americans. ( Granger, DA; Lucas, T; Pierce, J; Riis, JL; Woerner, J, 2019) |
| "Uric acid (UA) has been found to stimulate macrophage migration inhibitory factor (MIF) up-regulation in renal tubules from rats subjected to UA-induced nephropathy." | 1.51 | Blockage of macrophage migration inhibitory factor (MIF) suppressed uric acid-induced vascular inflammation, smooth muscle cell de-differentiation, and remodeling. ( Fu, X; Li, G; Liu, Q; Lou, Y; Mei, J; Niu, N; Qu, P; Sui, Z; Sun, J; Xu, M, 2019) |
| "Hyperthyroidism was a risk factor for hyperuricemia with an odd ratio of 4." | 1.51 | Gender impact on the correlations between Graves' hyperthyroidism and hyperuricemia in Chinese. ( Hu, T; Jia, Q; Li, X; Liu, N; Liu, X; Meng, Z; Song, K; Tan, J; Zhang, G; Zhang, J; Zhang, Q; Zhou, P, 2019) |
| "In conclusion, hyperuricemia is relatively common among patients with severe CAD and is independently associated with mortality." | 1.51 | Implications of Hyperuricemia in Severe Coronary Artery Disease. ( Feng, X; Gao, R; Hui, R; Jiang, L; Liu, J; Song, L; Sun, K; Tian, J; Wang, D; Xu, B; Xu, L; Yuan, J; Zhang, C; Zhang, Y; Zhao, W; Zhao, X, 2019) |
| "Preventing and treating renal fibrosis was an optimal treatment for hyperuricemia-induced kidney diseases." | 1.51 | Pterostilbene, a bioactive component of blueberries, alleviates renal fibrosis in a severe mouse model of hyperuricemic nephropathy. ( Feng, Y; Fu, P; Guo, F; Li, L; Liu, J; Ma, L; Pan, J; Shi, M, 2019) |
| "Gout that caused by hyperuricemia affects human health seriously and more efficient drugs are urgently required clinically." | 1.51 | New Rice-Derived Short Peptide Potently Alleviated Hyperuricemia Induced by Potassium Oxonate in Rats. ( Bian, W; Hu, Y; Liu, N; Meng, B; Sun, J; Wang, S; Wang, Y; Xiong, Z; Yang, M; Yang, X; Yin, S; Zeng, L, 2019) |
| "Hyperuricemia has been identified as an independent risk factor for chronic kidney disease (CKD) and is associated with the progression of kidney diseases." | 1.51 | Blockade of enhancer of zeste homolog 2 alleviates renal injury associated with hyperuricemia. ( Bao, W; Fang, L; Gu, H; Lin, T; Liu, N; Lu, J; Ma, S; Qiu, A; Shi, Y; Tao, M; Wang, Y; Xu, L; Zhuang, S, 2019) |
| "Hyperuricemia was defined as having a serum urate level of >7." | 1.51 | Contemporary Prevalence of Gout and Hyperuricemia in the United States and Decadal Trends: The National Health and Nutrition Examination Survey, 2007-2016. ( Chen-Xu, M; Choi, HK; Pillinger, MH; Rai, SK; Yokose, C, 2019) |
| "Uric acid (UA) and XOD were evaluated in the serum, urine, and liver of the mice." | 1.51 | Effects of ChondroT on potassium Oxonate-induced Hyperuricemic mice: downregulation of xanthine oxidase and urate transporter 1. ( Choi, CH; Choi, CY; Kang, BY; Kim, JR; Kim, SJ; Kim, YR; Na, CS; Oh, DR, 2019) |
| "Hyperuricemia is becoming a serious public health issue, which is highly influenced by environmental factors, although there is still controversial information on the potential influence of the exposure to Persistent Toxic Substances (PTSs) in the general population." | 1.51 | Associations of multiple exposures to persistent toxic substances with the risk of hyperuricemia and subclinical uric acid levels in BIOAMBIENT.ES study. ( Arrebola, JP; Bartolomé, M; Calvo, E; Cañas, AI; Castaño, A; Esteban, M; Huetos, O; López-Herranz, A; Pérez-Gómez, B; Ramos, JJ, 2019) |
| "In contrast, Uox-KO mice with carotid atherosclerosis showed severe neointimal changes in histology staining consistent with increases in intimal area and increases in proliferating cell nuclear antigen (PCNA)- and F4/80-positive cells." | 1.51 | Urate-lowering therapy alleviates atherosclerosis inflammatory response factors and neointimal lesions in a mouse model of induced carotid atherosclerosis. ( Ji, X; Li, C; Liu, Z; Lu, J; Merriman, TR; Qu, X; Sun, M; Wu, X; Yuan, X, 2019) |
| "Gout is a disease driven solely by IL-1β secretion in response to monosodium urate (MSU) crystals which form during periods of hyperuricemia and thus presents an opportunity to study factors contributing to IL-1β secretion." | 1.51 | Secretion of IL-1β From Monocytes in Gout Is Redox Independent. ( Alberts, BM; Basnayake, K; Bruce, C; Davies, KA; Ghezzi, P; Mullen, LM, 2019) |
| "Hyperuricemia was defined as > 7." | 1.51 | Association between smoking and serum uric acid in Korean population: Data from the seventh Korea national health and nutrition examination survey 2016. ( Choe, JY; Kim, SK, 2019) |
| " In-hospital UA-increase was associated with higher risk of mortality even after adjusting for confounding variables including creatine change and diuretic dosage [harzard ratio (HR) 1." | 1.51 | Association of serum uric acid change with mortality, renal function and diuretic dose administered in treatment of acute heart failure. ( Bai, YJ; Huang, XF; Liu, SR; Xu, DL; Xu, TY; Zeng, QC; Zhan, Q; Zhou, HB, 2019) |
| "Uric acid is an endogenous danger signal and activator of the inflammasome, and has been independently associated with an increased risk of cirrhosis." | 1.51 | Higher levels of serum uric acid influences hepatic damage in patients with non-alcoholic fatty liver disease (NAFLD). ( Aller, R; Ampuero, J; Andrade, RJ; Aspichueta, P; Buque, X; Burgos-Santamaría, D; Fernández Rodríguez, CM; Gómez-Camarero, J; Gutiérrez García, ML; Hernández-Guerra, M; Latorre, M; Martín-Mateos, RMª; Romero-Gómez, M; Rosales, JM, 2019) |
| "Hyperuricemia was identified in 30." | 1.51 | Hyperuricemia and acute gout after laparoscopic sleeve gastrectomy. ( Katsogridaki, G; Magouliotis, D; Perivoliotis, K; Sioka, E; Tasiopoulou, V; Tzovaras, G; Zachari, E; Zacharoulis, D, 2019) |
| "Hyperuricemia is a metabolic condition characterized by an elevated serum uric acid, and associated with renal damage, diabetes, autoimmune disorders, and cardiovascular diseases." | 1.51 | Hyperuricemia is Associated with Immunoglobulin G ( An, K; Cao, W; Dong, H; Ge, S; Hou, H; Hu, S; Li, D; Li, Y; Song, M; Sun, F; Sun, Q; Wang, L; Wang, W; Wang, Y; Xing, W; Xu, X; Zhang, X, 2019) |
| "Hyperuricemia is prevalent in CKD." | 1.51 | Hyperuricemia and its related histopathological features on renal biopsy. ( Fan, S; Hong, D; Li, G; Wang, AY; Wang, L; Wang, X; Zhang, P, 2019) |
| "Hyperuricemia was common in youth with T2D." | 1.51 | Elevated Serum Uric Acid Is Associated With Greater Risk for Hypertension and Diabetic Kidney Diseases in Obese Adolescents With Type 2 Diabetes: An Observational Analysis From the Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) Stu ( Bjornstad, P; El Ghormli, L; Laffel, L; Lynch, J; Nadeau, KJ; Tollefsen, SE; Weinstock, RS, 2019) |
| "Hyperuricemia is a metabolic disease caused by disorders of purine metabolism, the prevalence of which has increased worldwide." | 1.51 | Novel xanthine oxidase-based cell model using HK-2 cell for screening antihyperuricemic functional compounds. ( Gong, C; Hou, C; Li, Y; Liu, D; Ren, J; Wang, M; Yang, L; Yao, M; Yuan, E, 2019) |
| "Uric acid could increase inflammatory cytokines and upregulate tissue RAS in rat adipocytes, which were both blocked with TLR2/4-siRNA infection." | 1.51 | TLR2 and TLR4 mediate an activation of adipose tissue renin-angiotensin system induced by uric acid. ( Diao, B; Lin, X; Tang, F; Xu, J; Zhang, J, 2019) |
| "001), and a positive dose-response relationship was observed." | 1.51 | Dose-response relationship between higher serum calcium level and higher prevalence of hyperuricemia: A cross-sectional study. ( Ding, X; He, H; Liu, Z; Tian, J; Wang, Y; Wu, J; Wu, Z; Xie, D; Yang, Z, 2019) |
| "People with gout are at an increased risk of readmission for heart failure and have longer hospital stays." | 1.51 | Associations of Gout and Baseline Serum Urate Level With Cardiovascular Outcomes: Analysis of the Coronary Disease Cohort Study. ( Doughty, RN; Drake, J; Frampton, C; Richards, AM; Stamp, LK; Troughton, RW, 2019) |
| "Intervention for hyperuricemia is considered to improve patient outcomes." | 1.51 | Effect of hyperuricemia and treatment for hyperuricemia in Japanese hemodialysis patients: A cohort study. ( Kidoguchi, S; Maruyama, Y; Masakane, I; Ohno, I; Shigematsu, T; Sugano, N; Wada, A; Yokoo, T, 2019) |
| "Thus, AE may be a potential treatment for hyperuricemia and gout." | 1.51 | Anti-hyperuricemic effect of Alpinia oxyphylla seed extract by enhancing uric acid excretion in the kidney. ( Kim, DS; Kim, JS; Lee, S; Lee, YS; Son, E; Sung, YY; Yuk, HJ, 2019) |
| "Multiterritorial atherosclerosis has dramatically increased annual risk of adverse cardiovascular events than atherosclerotic disease with single-artery affected." | 1.51 | Longitudinal association between serum uric acid levels and multiterritorial atherosclerosis. ( Chen, J; Cheng, W; Cui, Q; Geng, B; Li, N; Song, M; Wang, K; Wang, Y; Yang, J; Yao, Y; Zhou, Y, 2019) |
| "Hyperuricemia is a risk factor for nonalcoholic fatty liver disease (NAFLD), however, the effect of gender on the hyperuricemia-related NAFLD development remains unclear." | 1.51 | Gender effect of hyperuricemia on the development of nonalcoholic fatty liver disease (NAFLD): A clinical analysis and mechanistic study. ( Bao, J; Cai, Z; Fu, X; Li, Y; Li, Z; Miao, L; Qiao, L; Xu, K; Zhao, X, 2019) |
| " The serum levels of uric acid (UA), creatinine, other biochemical parameters, estimated glomerular filtration rate (eGFR), and adverse events were measured at baseline as well as at 1, 3, and 6 months after the switch to febuxostat." | 1.51 | Switching from allopurinol to febuxostat: efficacy and safety in the treatment of hyperuricemia in renal transplant recipients. ( Li, Y; Liu, M; Lu, Y; Meng, J; Zhang, X, 2019) |
| "Hyperuricemia was defined by cut-off values of 7." | 1.51 | Association of dietary fiber intake with hyperuricemia in U.S. adults. ( Cai, J; Ma, A; Sun, J; Sun, Y; Zhang, P; Zhong, F, 2019) |
| "Coronary atherosclerotic plaques (calcified, mixed, and non-calcified plaques) were assessed using CCTA." | 1.51 | Serum uric acid level and subclinical coronary atherosclerosis in asymptomatic individuals: An observational cohort study. ( Choe, J; Choi, SW; Hong, S; Kang, JW; Kim, HK; Kim, YG; Kim, YH; Lee, CK; Lee, SW; Lee, Y; Lim, DH; Lim, TH; Park, GM; Yang, DH; Yoo, B, 2019) |
| "Febuxostat was significantly more potent than allopurinol or benzbromarone in lowering SUA levels in the fully adjusted model." | 1.48 | Comparative effectiveness of allopurinol, febuxostat and benzbromarone on renal function in chronic kidney disease patients with hyperuricemia: a 13-year inception cohort study. ( Chiu, HT; Chou, HW; Huang, HC; Kuo, CC; Ting, IW; Tsai, CW; Yeh, HC, 2018) |
| "Hyperuricemia has been associated with an increased risk of comorbidities such as metabolic syndrome or cardiovascular diseases." | 1.48 | The association between serum uric acid and asymptomatic intracranial arterial stenosis in middle-aged Koreans. ( Ahn, JK; Chung, PW; Hwang, J; Hwang, JH; Ryu, S; Yoon, WT, 2018) |
| " No other adverse events were reported." | 1.48 | Efficacy and Safety of Febuxostat in Kidney Transplant Patients. ( Baek, CH; Han, DJ; Kim, H; Park, SK; Yang, WS, 2018) |
| " The cellular mechanisms that lead to those outcomes require an increase in intracellular concentrations of uric acid inducing oxidative stress that then activates the synthesis and secretion of proinflammatory factors and vasoconstrictive substances, and diminishes the bioavailability of nitric oxide produced by eNOS." | 1.48 | The Pathophysiology of Uric Acid on Renal Diseases. ( Sánchez-Lozada, LG, 2018) |
| "Hyperuricemia is associated with metabolic syndrome, diabetes, hypertension, and kidney and cardiovascular diseases." | 1.48 | Renal Effects of Hyperuricemia. ( Méndez Landa, CE, 2018) |
| "Key Message: Hyperuricemia is closely associated with the incidence and progression of CKD." | 1.48 | Significance of Hyperuricemia among Community-Based Screening Participants. ( Iseki, K, 2018) |
| "Patients with UA nephrolithiasis have normal acid-base parameters assessed according to conventional clinical tests." | 1.48 | Uric Acid Renal Lithiasis: New Concepts. ( Pazos Pérez, F, 2018) |
| "Hyperuricemia was present in 356 (29." | 1.48 | Uric acid is associated with long-term adverse cardiovascular outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention. ( Farhan, S; Freynhofer, MK; Hauser, C; Herman, R; Huber, K; Rohla, M; Tscharre, M; Weiss, TW, 2018) |
| "Hyperuricemia was frequently noted in subjects with a high risk of cardiovascular disease (CVD)." | 1.48 | Elevated serum uric acid predicts the development of moderate coronary artery calcification independent of conventional cardiovascular risk factors. ( Ahn, JY; Hur, KY; Jin, SM; Jun, JE; Kang, MR; Kim, G; Kim, JH; Lee, MK; Lee, SE; Lee, YB, 2018) |
| "Gout is an inflammatory arthritis characterized by abrupt self-limiting attacks of inflammation caused by precipitation of monosodium urate crystals (MSU) in the joint." | 1.48 | 4-(2-(4-chlorophenyl)-1-((4-chlorophenyl)amino)ethyl)benzene-1, 3-diol is a potential agent for gout therapy as a dual inhibitor of XOD and NLRP3. ( Hu, Q; Li, S; Liu, W; Song, L; Zhou, M, 2018) |
| "Hyperuricemia is not only a risk factor for gout but also an independent determinant of hypertension, diabetes, and chronic kidney diseases." | 1.48 | Prevalence of hyperuricemia and its associated factors in the general Korean population: an analysis of a population-based nationally representative sample. ( Kang, J; Kim, GT; Kim, Y, 2018) |
| "Hyperuricemia is not associated with poor clinical outcomes after repeat PCI for ISR lesions." | 1.48 | Impact of hyperuricemia on clinical outcomes after percutaneous coronary intervention for in-stent restenosis. ( Hong, SJ; Jeong, HS; Joo, HJ; Kook, H; Lee, SH; Lim, DS; Park, JH; Yu, CW, 2018) |
| "Obesity is a risk factor for hypertension, diabetes mellitus (DM), dyslipidemia, and hyperuricemia." | 1.48 | Different Risk for Hypertension, Diabetes, Dyslipidemia, and Hyperuricemia According to Level of Body Mass Index in Japanese and American Subjects. ( Hisatome, I; Jalal, DI; Johnson, RJ; Kuwabara, M; Kuwabara, R; Lanaspa, MA; MacLean, PS; Niwa, K; Ohno, M; Roncal-Jimenez, CA; Smits, G; Yracheta, JM, 2018) |
| "Hyperuricemia is a risk factor for cardiovascular diseases." | 1.48 | Hyperuricemia is associated with atrial fibrillation prevalence in very elderly - a community based study in Chengdu, China. ( Huang, G; Liu, Y; Liu, ZH; Xie, X; Xu, JB; Xu, RH; Zhang, TJ, 2018) |
| "Hyperuricemia is highly prevalent and especially common in subjects with metabolic, cardiovascular and renal diseases." | 1.48 | Probiotic supplements prevented oxonic acid-induced hyperuricemia and renal damage. ( Blas-Marron, MG; Frank, DN; García-Arroyo, FE; Gonzaga, G; Ir, D; Irvin, A; Johnson, RJ; Muñoz-Jiménez, I; Ranganathan, N; Ranganathan, P; Robertson, CE; Sánchez-Lozada, LG; Silverio, O; Soto, V; Tapia, E; Vyas, U, 2018) |
| "Hyperuricemia is the main risk factor for gout." | 1.48 | The benchmark dose estimation of reference levels of serum urate for gout. ( Chen, X; Cui, W; Ding, X; Duan, N; Jin, T; Wang, Z, 2018) |
| "Hyperuricemia is an independent risk factor for progression of kidney disease." | 1.48 | Urate-Lowering Therapy in Moderate to Severe Chronic Kidney Disease. ( Cheetham, TC; Levy, G; Rashid, N; Shi, JM, 2018) |
| "sinensis) has been used to treat hyperuricemia and gout." | 1.48 | Anti-hyperuricemic and nephroprotective effects of extracts from Chaenomeles sinensis (Thouin) Koehne in hyperuricemic mice. ( Barba, FJ; He, J; Li, S; Lorenzo, JM; Zhan, S; Zhang, R; Zhu, Z, 2018) |
| "Whether hyperuricemia is the cause or the effect is debatable." | 1.48 | Hypertension as Determinant of Hyperuricemia: A Case Control Study from the Sub-Himalayan Region in North India. ( Agarwal, VK; Kapoor, D; Raina, S; Sharma, KN; Yadav, RS, 2018) |
| "WIT and post-LT hyperuricemia are associated with the prevalence of PTMS." | 1.48 | Warm ischemia time and elevated serum uric acid are associated with metabolic syndrome after liver transplantation with donation after cardiac death. ( Chai, YC; Hu, LS; Jia, A; Lv, Y; Shi, JH; Tian, M; Wang, B; Zhang, C; Zheng, J, 2018) |
| "Uric acid (UA) is a risk marker of CKD and SUA level in CKD 3-4 patients closely correlates with hyperuricemic nephropathy (HN) morbidity." | 1.48 | Risk factors analysis for hyperuricemic nephropathy among CKD stages 3-4 patients: an epidemiological study of hyperuricemia in CKD stages 3-4 patients in Ningbo, China. ( Gao, C; Qiu, XH; Wu, F; Wu, YY; Xia, G; Ye, Y, 2018) |
| "Hyperuricemia is known to be a risk factor for diabetes." | 1.48 | Two-Year Changes in Hyperuricemia and Risk of Diabetes: A Five-Year Prospective Cohort Study. ( Guo, X; Liu, J; Mu, Y; Tao, L; Zhang, J; Zhao, Z; Zou, D, 2018) |
| "Stroke is a growing disease and it is the second common cause of death in the world after coronary heart disease especially in the elderly." | 1.48 | Serum Uric Acid Levels and Serum Lipid Levels in Patients with Ischemic Cerebrovascular Accident. ( Arora, T; Bidri, RC; Mantur, PG; Mulimani, MS, 2018) |
| "Hyperuricemia is associated with metabolic syndrome (MetS), but the association is often confounded by the shared background of obesity." | 1.46 | Combined effect of obesity and uric acid on nonalcoholic fatty liver disease and hypertriglyceridemia. ( Du, T; Li, M; Lin, X; Lu, H; Yu, X; Zhang, S, 2017) |
| "Although hyperuricemia is shown to accelerate chronic kidney disease, the mechanisms remain unclear." | 1.46 | Podocyte Injury and Albuminuria in Experimental Hyperuricemic Model Rats. ( Asakawa, S; Hosoyamada, M; Kumagai, T; Morimoto, C; Nakamura, T; Shibata, S; Shiraishi, T; Tamura, Y; Uchida, S, 2017) |
| "Hyperuricemia is a common complication in renal transplant recipients." | 1.46 | Risk Factors of Hyperuricemia After Renal Transplantation and Its Long-term Effects on Graft Functions. ( Akturk, S; Eyupoglu, D; Eyupoglu, S; Kendi-Celebi, Z; Keven, K; Sengul, S; Tuzuner, A, 2017) |
| "Although hyperuricemia is common after orthotopic liver transplantation (OLT), its relationship to mortality, progressive kidney disease, or the development of end stage renal disease (ESRD) is not well-described." | 1.46 | Hyperuricemia after orthotopic liver transplantation: divergent associations with progression of renal disease, incident end-stage renal disease, and mortality. ( Atta, MG; Bandak, G; Gelber, AC; Longenecker, JC; McMahon, BA; Murakami, CA; Waheed, S, 2017) |
| "Hyperuricemia is an important risk factor for cardiovascular and renal diseases." | 1.46 | Phloretin attenuates hyperuricemia-induced endothelial dysfunction through co-inhibiting inflammation and GLUT9-mediated uric acid uptake. ( Chen, Y; Cheng, J; Liu, J; Liu, S; Lu, Y; Yuan, Y; Zhao, M; Zhou, Y, 2017) |
| "The prevalence of COPD and asthma is increasing all over the world; however, their morbidities are thought to be greatly underestimated because of unawareness of patients' conditions and respiratory symptoms." | 1.46 | The association between risk of airflow limitation and serum uric acid measured at medical health check-ups. ( Fukuhara, A; Fukuhara, N; Munakata, M; Rinno, K; Saito, J; Saito, K; Sato, S; Suzuki, H; Tanino, Y; Wang, X, 2017) |
| "Hyperuricemia is associated with the development of chronic kidney disease." | 1.46 | Qi-Zhu-Xie-Zhuo-Fang reduces serum uric acid levels and ameliorates renal fibrosis in hyperuricemic nephropathy rats. ( Beibei, T; Huijuan, W; Jianchun, M; Rui, S; Xiaoxu, C; Xinghui, L, 2017) |
| "Hyperuricemia was defined as a serum uric acid level ≥ 7." | 1.46 | Early onset hyperuricemia is a prognostic marker for kidney graft failure: Propensity score matching analysis in a Korean multicenter cohort. ( Ahn, C; Ha, J; Han, DJ; Han, M; Jung, IM; Kim, Y; Kim, YC; Kim, YH; Kim, YS; Lee, JP; Lim, CS; Oh, YK; Park, S, 2017) |
| "Hyperuricemia is associated with incident cardiovascular events in different settings of patients." | 1.46 | Risk reclassification ability of uric acid for cardiovascular outcomes in essential hypertension. ( Addesi, D; Baggetta, R; Cimellaro, A; Maio, R; Perticone, F; Perticone, M; Sciacqua, A; Sesti, G; Tripepi, G, 2017) |
| "Uric acid is a significant predictor of systolic BP and hypertension prevalence in the general adult population in Germany independently of several known dietary BP influences." | 1.46 | Diet-independent relevance of serum uric acid for blood pressure in a representative population sample. ( Esche, J; Krupp, D; Mensink, GB; Neuhauser, HK; Remer, T, 2017) |
| "Uric acid is a product of purine catabolism formed by the activity of xanthine-oxidase and prevalently excreted by the kidney." | 1.46 | [The uric acid cardio-nephropathy]. ( Bonino, B; Cappadona, F; Pontremoli, R; Viazzi, F, 2017) |
| "BACKGROUND Hyperuricemia is associated with an increased risk of cardiovascular disease and chronic allograft nephropathy after renal transplantation." | 1.46 | Serum Uric Acid and Arterial Function After Renal Transplantation. ( Babel, N; Bauer, F; Pagonas, N; Seibert, FS; Viebahn, R; Westhoff, TH; Zidek, W, 2017) |
| " Furthermore, there was a dose-response association between the number of CVD risk factors clustering and hyperuricemia." | 1.46 | Hyperuricemia and clustering of cardiovascular risk factors in the Chinese adult population. ( Cheng, Q; Cheng, XQ; Guo, XZ; Liu, L; Liu, Q; Qiu, L; Wu, J; Wu, W; Xu, CL; Xu, T; Ye, YC; Zeng, XJ; Zhu, GJ, 2017) |
| "Uric acid (UA) is an end product of purine metabolism by the enzyme xanthine oxidase (XOD)." | 1.46 | Evaluating the urate-lowering effects of different microbial fermented extracts in hyperuricemic models accompanied with a safety study. ( Chen, HM; Chen, MH; Chen, RJ; Chen, SJ; Chen, YL; Hsiao, CM; Wang, YJ; Wu, MD; Yech, YJ; Yuan, GF, 2017) |
| "There was a significant association in NAFLD found in males, compared with females (Wald = 118." | 1.46 | Gender difference on the relationship between hyperuricemia and nonalcoholic fatty liver disease among Chinese: An observational study. ( Shen, XM; Shu, L; Yu, XL; Zhang, XY; Zheng, PF, 2017) |
| "Hyperuricemia is an independent risk factor for causing chronic kidney disease and contributes to kidney fibrosis." | 1.46 | High Uric Acid-Induced Epithelial-Mesenchymal Transition of Renal Tubular Epithelial Cells via the TLR4/NF-kB Signaling Pathway. ( He, T; Huang, Y; Li, Y; Liu, H; Xiao, T; Xiong, J; Xu, X; Yu, Y; Zhang, B; Zhang, J; Zhao, J, 2017) |
| "Hyperuricemia is associated with the progression of chronic kidney disease (CKD), but it is not known whether the relationship is causal." | 1.46 | Impact of Uric Acid Levels on Kidney Disease Progression. ( Arrigain, S; Jolly, SE; Konig, V; Nakhoul, G; Nally, JV; Navaneethan, SD; Rincon-Choles, H; Rothberg, MB; Schold, JD, 2017) |
| "Hyperuricemia is highly heritable and is associated with sex and body weight." | 1.46 | Association of ABCG2 rs2231142-A allele and serum uric acid levels in male and obese individuals in a Han Taiwanese population. ( Cheng, ST; Hsu, LA; Ko, YL; Su, CW; Teng, MS; Wu, S, 2017) |
| "Uric acid (UA) levels were dichotomized using 6." | 1.46 | Hyperuricemia, Cardiovascular Profile, and Comorbidity in Older Men and Women: The Pro.V.A. Study. ( Baggio, G; Corti, MC; Crepaldi, G; Manzato, E; Musacchio, E; Perissinotto, E; Punzi, L; Ramonda, R; Sartori, L; Veronese, N; Zambon, S, 2017) |
| "Hyperuricemia is associated with cardiovascular disease and its prevalence is unknown in black Africans." | 1.46 | Distribution of Serum Uric Acid in Black Africans and Its Association With Cardiovascular Risk Factors. ( Baldo, MP; Capingana, DP; Luchi, WM; Magalhães, P; Mill, JG; Moulin, SR; Souza, JB, 2017) |
| "Hyperuricemia is becoming increasingly frequent in the population, and is known to be sometimes the cause of gout." | 1.46 | Hyperferritinemia increases the risk of hyperuricemia in HFE-hereditary hemochromatosis. ( Bardou-Jacquet, E; Chalès, G; Coiffier, G; Deugnier, Y; Flais, J; Guggenbuhl, P; Loréal, O; Perdriger, A; Ropert, M, 2017) |
| "Hyperuricemia was defined as serum uric acid levels >7." | 1.46 | Increased risk for hyperuricemia in adults sensitized to cow milk allergen. ( Min, JY; Min, KB, 2017) |
| "Hyperuricemia is significantly associated with hypertension, renal dysfunction, MACE, and independently confers a higher risk of mortality in patients with AMI." | 1.46 | Association Between Hyperuricemia and Major Adverse Cardiac Events in Patients with Acute Myocardial Infarction. ( Mayise, C; Myeni, NN; Ranjith, N; Sartorius, B, 2017) |
| "Hyperuricemia is a kind of metabolic disease resulted from imbalance between urate production and excretion." | 1.46 | (E)-2-(4-bromophenyl)-1-(2, 4-dihydroxyphenyl)ethanone oxime is a potential therapeutic agent for treatment of hyperuricemia through its dual inhibitory effects on XOD and URAT1. ( Hao, K; Hu, Q; Li, H; Lu, G; Zheng, D; Zhou, M; Zhu, H, 2017) |
| "Uric acid (UA) has been proven to directly cause mesangial cell (MC) proliferation with elusive mechanisms." | 1.46 | COX-2/mPGES-1/PGE2 cascade activation mediates uric acid-induced mesangial cell proliferation. ( Chen, Q; Ding, G; Gong, W; He, JC; Huang, S; Jia, Z; Li, S; Ruan, Y; Sun, Z; Xia, W; Yu, J; Zhang, A; Zhang, Y, 2017) |
| "Uric acid (UA) is an antioxidant found in human serum." | 1.46 | Aldose reductase mediates endothelial cell dysfunction induced by high uric acid concentrations. ( Cai, G; Chen, X; Cui, S; Feng, Z; Hong, Q; Huang, Z; Lv, Y; Wang, L; Wu, D; Xiao, W; Zhang, X, 2017) |
| "Whether hyperuricemia is an independent risk factor for hypertension in adults is still under debate." | 1.46 | Association of serum uric acid and risk of hypertension in adults: a prospective study of Kailuan Corporation cohort. ( Cui, LF; Han, YX; Liu, N; Mu, R; Shi, HJ; Shu, R; Song, HC; Sun, K; Wang, GY; Wang, J; Wang, JR; Wu, SL; Yang, WH; Yu, P; Zhou, B, 2017) |
| "Hyperuricemia was defined as uric acid ≥416 mmol/l for males and ≥360 mmol/l for females." | 1.46 | Relationship between hyperuricemia and risk of coronary heart disease in a middle-aged and elderly Chinese population. ( Lei, GH; Li, H; Li, LJ; Tian, J; Wei, J; Xie, X; Yang, T; Yang, Y; Zeng, C, 2017) |
| "Gout is a common arthritis resulting from increased serum urate, and many loci have been identified that are associated with serum urate and gout." | 1.46 | Effects of multiple genetic loci on the pathogenesis from serum urate to gout. ( Dong, Z; He, H; Ji, H; Jiang, S; Jin, L; Li, Y; Ma, Y; Pang, Y; Wang, J; Wang, X; Wang, Y; Xu, X; Yang, C; Yang, Y; Zhao, D; Zhou, J; Zou, H, 2017) |
| "CONCLUSIONS GPS may be an effective treatment for hyperuricemia via a decrease in xanthine oxidoreductase through the XOD/XDH system; and via an increase in urate excretion through regulating URAT1, GLUT9, and OAT1 transporters." | 1.46 | Gypenosides Inhibits Xanthine Oxidoreductase and Ameliorates Urate Excretion in Hyperuricemic Rats Induced by High Cholesterol and High Fat Food (Lipid Emulsion). ( Chen, B; Chen, S; Fang, Y; Hu, H; Li, B; Liang, K; Lv, G; Pang, M; Shan, C; Su, J; Yang, Y; Yu, J; Zhu, X, 2017) |
| "Hyperuricemia was defined as serum uric acid ≥416 μmol/l in men and ≥357 μmol/l in women." | 1.43 | Prevalence of hyperuricemia and its correlates in rural Northeast Chinese population: from lifestyle risk factors to metabolic comorbidities. ( Guo, X; Ou, Q; Sun, Y; Yang, H; Yu, S; Zhang, X; Zheng, L; Zhou, Y, 2016) |
| "A total of 8274 patients with type 2 diabetes from the Shanghai Diabetes Registry (SDR) participated." | 1.43 | Association between uric acid, cancer incidence and mortality in patients with type 2 diabetes: Shanghai diabetes registry study. ( Bao, Y; Deng, Z; Gu, Y; Hou, X; Hu, C; Jia, W; Zhang, L, 2016) |
| "Recently hyperuricemia has been identified as a risk factor for progression of chronic kidney disease (CKD)." | 1.43 | Revisiting medullary tophi: a link between uric acid and progressive chronic kidney disease? ( Almaani, S; Ayoub, I; Brodsky, S; Hebert, L; Nadasdy, T; Prosek, J; Rovin, B, 2016) |
| "Hyperuricemia has been shown to be associated with increased risks of gout and cardiovascular diseases." | 1.43 | Ideal Cardiovascular Health Metrics and Incident Hyperuricemia. ( Chen, S; Cong, H; Cui, L; Gao, J; Gao, X; Huang, Z; Li, W; Li, Z; Meng, L; Wang, Z; Wu, S; Zhang, G; Zhang, R; Zheng, X; Zhou, J, 2016) |
| "Uric acid was detected on Beckman Coulter AU 5800." | 1.43 | Association between high-sensitivity C-reactive protein and hyperuricemia. ( Ding, X; Gao, SG; Lei, GH; Li, H; Li, YS; Wang, YL; Wei, J; Xiong, YL; Yang, T; Zeng, C, 2016) |
| "Hyperuricemia is a risk factor for not only gout, but also to a variety of disorders that affect the vital organ systems of the human body." | 1.43 | Antihyperuricemic effects of thiadiazolopyrimidin-5-one analogues in oxonate treated rats. ( Gopal, S; Rangappa, KS; Sathisha, KR, 2016) |
| " However, the pharmacokinetic studies in rats showed that its oral bioavailability was only 1." | 1.43 | Hypouricaemic action of mangiferin results from metabolite norathyriol via inhibiting xanthine oxidase activity. ( Feng, GH; Gao, LH; Li, L; Liu, HY; Liu, J; Liu, X; Niu, Y, 2016) |
| " UNAs increased the bioavailability and uric acid-lowering efficacy of uricase, while the immunogenicity and hemolysis rate of uricase were decreased." | 1.43 | Nanocapsule assemblies as effective enzyme delivery systems against hyperuricemia. ( Deng, X; He, D; Sun, Q; Xiong, H; Zhang, J; Zhou, Q; Zhou, Y, 2016) |
| "Prevalence of hyperuricemia is high in patients with hypertension." | 1.43 | Hyperuricemia and Cardiovascular Disease in Patients with Hypertension. ( Acevedo, A; Benavides, J; Chowdhury, M; Lievano, M; Lombo, B; Lopez, M; Montenegro, A; Pena, L, 2016) |
| "123 participants who had NAFLD at baseline lost NAFLD during the 8-year follow-up period." | 1.43 | Prevalence of and risk factors for non-alcoholic fatty liver disease in a Chinese population: An 8-year follow-up study. ( Chen, XH; Li, YL; Lu, ZY; Shao, Z; Wulasihan, M, 2016) |
| "Hyperuricemia was defined as SUA ≥7mg/dl (420mmol/L) in men or ≥6mg/dl (360mmol/L) in women." | 1.43 | Metabolically healthy obesity also has risk for hyperuricemia among Chinese general population: A cross-sectional study. ( Chen, Y; Guo, X; Sun, G; Sun, Y; Yang, H; Yu, S; Zhang, N; Zheng, L, 2016) |
| "In 3207 type 2 diabetes patients, seventeen SNPs (single nucleotide polymorphisms) related to uric acid were genotyped." | 1.43 | A causal relationship between uric acid and diabetic macrovascular disease in Chinese type 2 diabetes patients: A Mendelian randomization analysis. ( Bao, Y; Chen, H; He, Z; Hu, C; Jia, W; Jiang, F; Peng, D; Wang, J; Wang, S; Wang, T; Yan, D; Zhang, R, 2016) |
| " According to ADME (absorption, distribution, metabolism, and excretion) simulation in silico, flazin had good oral bioavailability in vivo." | 1.43 | Effect of Soy Sauce on Serum Uric Acid Levels in Hyperuricemic Rats and Identification of Flazin as a Potent Xanthine Oxidase Inhibitor. ( Li, H; Lin, L; Su, G; Wang, Y; Zhao, M, 2016) |
| "BACKGROUND Hyperuricemia is very common after renal transplantation." | 1.43 | Effects of Treatment of Asymptomatic Hyperuricemia on Graft Survival and Mortality in Kidney Transplant Recipients. ( Babel, N; Bauer, F; Giese, A; Kor, S; Pagonas, N; Reinke, P; Seibert, FS; Westhoff, TH; Westoff, TH; Zidek, W, 2016) |
| "Chronic hyperuricemia is responsible for a relevant burden of articular diseases and cardio-nephrometabolic disorders." | 1.43 | Hyperuricemia is associated with increased hospitalization risk and healthcare costs: Evidence from an administrative database in Italy. ( Borghi, C; Buda, S; Degli Esposti, L; Desideri, G; Pontremoli, R; Saragoni, S, 2016) |
| "Gout is a systemic disorder characterized by hyperuricemia and recurrent arthritis, most involvement of ankles, midfoot joint and first metatarsophalangeal joint, with monosodium urate crystals deposition in synovial fluid and other tissues." | 1.43 | Miliarial gout: a rare presentation of extensive cutaneous tophi. ( Chiang, CP; Hung, TL; Wang, WM, 2016) |
| "These findings suggested that higher SUA levels were independently associated with a dose-response increased risk of CHD incidence." | 1.43 | Dose-response relationship between serum uric acid levels and risk of incident coronary heart disease in the Dongfeng-Tongji Cohort. ( Angileri, F; Chen, X; Fang, Q; He, MA; Lai, X; Légaré, S; Li, X; Min, X; Wu, T; Xu, C; Yang, H; Yang, L; Yuan, J; Zhang, C; Zhang, X, 2016) |
| "Hyperuricemia is a common symptom in adult population." | 1.43 | Familial juvenile hyperuricemic nephropathy as rare cause of dialysis-dependent chronic kidney disease-a series of cases in two families. ( Adamczyk, P; Beck, B; Dyga, K; Kaminska-Pajak, KA; Szczepańska, M; Tkaczyk, M; Zaniew, M, 2016) |
| "Hyperuricemia is an important predictor for poor prognosis in patients with LN." | 1.43 | Hyperuricemia is an independent risk factor for renal pathological damage and poor prognosis in lupus nephritis patients. ( Chen, M; Li, G; Li, J; Tang, X; Wang, X; Xie, T; Yin, H; Zhang, W; Zuo, X, 2016) |
| "Hyperuricemia is strongly linked to cardiovascular complications including atherosclerosis and thrombosis." | 1.43 | Blood-borne phagocytes internalize urate microaggregates and prevent intravascular NETosis by urate crystals. ( Bengtsson, AA; Biermann, MH; Bilyy, R; Czegley, C; Dumych, T; Herrmann, M; Hoffmann, M; Jeremic, I; Maueröder, C; Munoz, LE; Pieterse, E; Schauer, C; Schett, G; van der Vlag, J; Veissi, S; Weidner, D, 2016) |
| "Hyperuricemia is an important risk factor for atherosclerosis, yet the potential mechanisms are not well understood." | 1.42 | Uric acid promotes chemokine and adhesion molecule production in vascular endothelium via nuclear factor-kappa B signaling. ( Feng, XR; Liang, WY; Liu, ML; Wang, YC; Zhang, JW; Zhu, XY, 2015) |
| "Hyperuricemia is characterized by inhibited nitric oxide system and enhanced synthesis of reactive oxygen species." | 1.42 | Uric acid levels and the risk of Contrast Induced Nephropathy in patients undergoing coronary angiography or PCI. ( Barbieri, L; Cassetti, E; De Luca, G; Marino, P; Schaffer, A; Suryapranata, H; Verdoia, M, 2015) |
| "High uric acid level is a known risk factor for deterioration of renal function in chronic kidney disease (CKD), but its influence on the progression of IgA nephropathy (IgAN) remains unclear." | 1.42 | High uric acid level is a risk factor for progression of IgA nephropathy with chronic kidney disease stage G3a. ( Itabashi, M; Iwabuchi, Y; Kataoka, H; Moriyama, T; Nishida, M; Nitta, K; Sato, M; Shimizu, A; Takei, T; Uchida, K, 2015) |
| " Since disturbed NO bioavailability is a major pathway whereby high uric may cause renal damage, we tested the interaction between the major endogenous inhibitor of NO synthase, asymmetric-dimethylargine (ADMA), and the rs734553 polymorphism for CKD progression in the same cohort." | 1.42 | Synergism between asymmetric dimethylarginine (ADMA) and a genetic marker of uric acid in CKD progression. ( Leonardis, D; Mallamaci, F; Pisano, A; Sanguedolce, MC; Spoto, B; Testa, A; Tripepi, G; Zoccali, C, 2015) |
| "Uric acid level was associated with an increased risk of total graft failure in time-fixed and time-varying models (HR 1." | 1.42 | Uric acid and the risk of graft failure in kidney transplant recipients: a re-assessment. ( Famure, O; Kim, ED; Kim, SJ; Li, Y, 2015) |
| "Hyperuricemia is a common feature of patients with non-alcoholic fatty liver disease (NAFLD)." | 1.42 | Xanthine oxidase in non-alcoholic fatty liver disease and hyperuricemia: One stone hits two birds. ( Dooley, S; Li, Y; Miao, M; Sun, Y; Wan, X; Weng, H; Xu, C; Xu, G; Xu, L; Yan, M; Yu, C, 2015) |
| "Hyperuricemia is very common in industrialized countries and known to promote vascular smooth muscle cell proliferation." | 1.42 | Smaller caliber renal arteries are a novel feature of uromodulin-associated kidney disease. ( Adamczak, M; Blondin, D; Dekomien, G; Epplen, JT; Helmchen, U; Januszewicz, A; Januszewicz, M; Litwin, M; Matuszkiewicz-Rowińska, J; Michałowska, I; Prejbisz, A; Rump, LC; Sajnaga, D; Sellin, L; Szwench-Pietrasz, E; Więcek, A; Woznowski, M, 2015) |
| "Benzbromarone has been reported to suppress uric acid reabsorption via uric acid transporter 1 inhibition in renal tubular cells." | 1.42 | Direct radical scavenging activity of benzbromarone provides beneficial antioxidant properties for hyperuricemia treatment. ( Chuang, VT; Hirata, S; Kadowaki, D; Maruyama, T; Miyamoto, Y; Muraya, N; Narita, Y; Otagiri, M; Sakaguchi, S; Sato, K; Taguchi, K, 2015) |
| "Hyperuricemia has been considered to be a key risk factor for kidney disease." | 1.42 | Anti-hyperuricemic and nephroprotective effects of rhein in hyperuricemic mice. ( Ding, G; Guo, C; Huang, W; Li, N; Meng, Z; Tang, Z; Wang, Z; Xiao, W; Yan, Y; Yang, Z, 2015) |
| "Uric acid-lowering treatments may be beneficial for the prevention of progression of IgAN." | 1.42 | Hyperuricemia is associated with progression of IgA nephropathy. ( Bakan, A; Basci, S; Covic, A; Elcioglu, OC; Kanbay, M; Kostek, O; Oral, A; Ozkok, A; Ozturk, S; Sipahioglu, M; Sumnu, A; Takir, M; Turkmen, A; Voroneanu, L, 2015) |
| "Gefitinib treatment also inhibited hyperuricemia-induced activation of the TGF-β1 and NF-κB signaling pathways and expression of multiple profibrogenic cytokines/chemokines in the kidney." | 1.42 | EGF Receptor Inhibition Alleviates Hyperuricemic Nephropathy. ( Bao, W; Cheng, SB; Chin, YE; Liu, N; Qiu, A; Shi, Y; Wang, L; Xiong, C; Xu, L; Yan, H; Yang, T; Zhuang, S, 2015) |
| "Sixty-one patients with gout, 30 with ankylosing spondylitis and 30 with rheumatoid arthritis were included in the study." | 1.42 | [Value of dual-energy computed tomography in the diagnosis of gouty arthritis]. ( Cai, X; Ren, J; Wu, H; Zhou, Y; Zhu, L, 2015) |
| "The prevalence of NAFLD was higher in participants with higher SUA levels (10." | 1.42 | Association between serum uric acid and nonalcoholic fatty liver disease in the US population. ( Bonekamp, S; Clark, JM; Hernaez, R; Lazo, M; Liu, SH; Shih, MH, 2015) |
| "Hyperuricemia was induced in mice by yeast extract paste or potassium oxonate." | 1.42 | Traditional Uighur Medicine Karapxa decoction, inhibits liver xanthine oxidase and reduces serum uric acid concentrations in hyperuricemic mice and scavenges free radicals in vitro. ( Amat, N; Anaydulla, M; Aziz, R; Hoxur, P; Imam, G; Kijjoa, A; Moore, N; Umar, A; Upur, H, 2015) |
| "Hyperuricemia is an independent risk factor for hypertension." | 1.42 | Does elevated serum uric acid level predict the hypertension incidence? A Chinese prospective cohort study. ( Gao, Y; Huang, J; Li, Y; Niu, K; Sun, Y; Wan, Z; Wu, X; Yao, W; Zhang, W; Zhao, H, 2015) |
| "Uric acid was positively correlated with albuminuria and creatinine levels (p < 0." | 1.42 | Uric Acid is independently associated with diabetic kidney disease: a cross-sectional study in a Chinese population. ( Bao, Y; Hu, C; Jia, W; Jiang, F; Sun, X; Tu, Y; Wang, J; Wang, S; Wang, T; Yan, D; Zhang, R, 2015) |
| "Hyperuricemia has been reported to affect renal hemodynamics in rat models." | 1.42 | Relationship between serum uric acid levels and intrarenal hemodynamic parameters. ( Ichii, M; Inaba, M; Ishimura, E; Mori, K; Nakatani, S; Nakatani, T; Ochi, A; Ohno, Y; Tsuda, A; Uchida, J; Uedono, H; Yasumoto, M, 2015) |
| "Hyperuricemia is frequently reported in adults, but there are few data for the pediatric population." | 1.42 | Is Hyperuricemia Overlooked when Treating Pediatric Tuberculosis Patients with Pyrazinamide? ( Aslan, AT; Budakoğlu, I; Şişmanlar, T, 2015) |
| "In summary, hyperuricemia is highly prevalent among the adult participants in this Chinese community, especially for men." | 1.42 | Relationship between hyperuricemia and dietary risk factors in Chinese adults: a cross-sectional study. ( Li, G; Li, J; Li, X; Song, P; Wang, P, 2015) |
| "Hyperuricemia is associated with essential hypertension in children." | 1.42 | Hyperuricemia and Progression of CKD in Children and Adolescents: The Chronic Kidney Disease in Children (CKiD) Cohort Study. ( Furth, SL; Mitsnefes, MM; Moxey-Mims, MM; Rodenbach, KE; Schneider, MF; Schwartz, GJ; Warady, BA; Weaver, DJ, 2015) |
| "Hyperuricemia is a risk factor for various diseases, but knowledge on acute hyperuricemia is still not sufficient." | 1.42 | [Research on Hemorheology in Rats with Acute Hyperuricemia]. ( Li, K; Li, L; Liu, Y; Tong, X; Wang, X; Xie, L; Xu, S; Yao, W, 2015) |
| "Gout is an inflammatory arthritis characterised by hyperuricemia, which, if poorly controlled, can lead to the development of tophi." | 1.42 | Ulcerated tophaceous gout. ( Filanovsky, MG; McNamara, MC; Sukhdeo, K, 2015) |
| "Monitoring blood uric acid (UA) is important in all patients on urate-lowering therapy so that the selection of the effective drugs and dosage adjustments could be made until the target level is reached." | 1.42 | Salivary uric acid as a noninvasive biomarker for monitoring the efficacy of urate-lowering therapy in a patient with chronic gouty arthropathy. ( Huang, Y; Zhao, J, 2015) |
| "Gout is a consequence of an innate immune reaction to monosodium urate crystals deposited in joints." | 1.42 | Positive association of tomato consumption with serum urate: support for tomato consumption as an anecdotal trigger of gout flares. ( Cadzow, M; Dalbeth, N; Flynn, TJ; Hindmarsh, JH; Jones, PB; Merriman, TR; Stamp, LK; Todd, AS; Topless, R; Walker, RJ, 2015) |
| "Although gout is potentially curable with long-term urate lowering therapy, confusion about the details of urate measurement has contributed to suboptimal care." | 1.42 | Urate testing in gout: why, when and how. ( Arroll, B; Boswell, DR; Dalbeth, N; Gow, PJ; Lindsay, K; Stamp, LK; Te Karu, L; Winnard, D, 2015) |
| "Hyperuricemia is an independent risk factor for chronic kidney disease and cardiovascular disease." | 1.42 | Chinese Herbal Formulas Si-Wu-Tang and Er-Miao-San Synergistically Ameliorated Hyperuricemia and Renal Impairment in Rats Induced by Adenine and Potassium Oxonate. ( Gui, D; Guo, Y; Jiang, Q; Wang, N, 2015) |
| "Gout is a common metabolic disorder characterized by hyperuricemia and chronic inflammation." | 1.42 | Gout, not hyperuricemia alone, impairs left ventricular diastolic function. ( Chang, PJ; Chang, ST; Chen, MC; Chung, CM; Lin, CL; Lin, JC; Pan, KL, 2015) |
| " Dose-response investigation on 3 at doses of 0." | 1.42 | Flavonoids and phenylethanoid glycosides from Lippia nodiflora as promising antihyperuricemic agents and elucidation of their mechanism of action. ( Chan, KL; Cheng, LC; Murugaiyah, V, 2015) |
| "In conclusion, hyperuricemia is a promising biomarker of early mortality in patients with COPD." | 1.42 | Hyperuricemia is a biomarker of early mortality in patients with chronic obstructive pulmonary disease. ( Jin, S; Liang, R; Liu, L; Zhang, X, 2015) |
| "Hypertension was defined according to blood pressure readings by definitions of the Seventh Report of the Joint National Committee." | 1.40 | Serum uric acid level in newly diagnosed essential hypertension in a Nepalese population: a hospital based cross sectional study. ( Jha, B; Kumar, A; Poudel, B; Raut, KB; Yadav, BK, 2014) |
| "Mean uric acid level was 7." | 1.40 | Relationship between serum uric acid and all-cause and cardiovascular mortality in patients treated with peritoneal dialysis. ( He, F; Huang, F; Peng, F; Wu, X; Xia, X; Yu, X, 2014) |
| " However, inadequate dosing and patient nonadherence or intolerance to therapy often lead to treatment failure." | 1.40 | CaseBook challenges: Managing gout, hyperuricemia and comorbidities -- dialogue with the experts. ( Bakris, GL; Doghramji, PP; Keenan, RT; Silber, SH, 2014) |
| "Hyperuricemia was defined as an SUA level of ≥7." | 1.40 | Prevalence of hyperuricemia and the relationship between serum uric acid and metabolic syndrome in the Asian Mongolian area. ( Liu, A; Wang, P; Wu, H; Wuyun, G; You, L, 2014) |
| "We found that hyperuricemia is an independent risk factor for the development of CKD." | 1.40 | Hyperuricemia is a significant risk factor for the onset of chronic kidney disease. ( Ishizaka, Y; Tani, M; Toda, A; Yamakado, M, 2014) |
| "In the drug treatment of hyperuricemia and hyperlipidemia complications, Atorvastatin (ATV), which inhibits urinary protein, increases glomerular filtration rate (GFR) and has renal protective effects, and Rosuvastatin (ROS) were found be suitable because they promote serum uric acid (SUA) excretion." | 1.40 | Effects on serum uric acid by difference of the renal protective effects with atorvastatin and rosuvastatin in chronic kidney disease patients. ( An, T; Hayashi, H; Kikkawa, A; Kose, E; Matsumoto, Y, 2014) |
| "Gout was diagnosed at the last visit in 34 subjects; four in the normouricemia group and 30 in the hyperuricemia group (0." | 1.40 | The degree of asymptomatic hyperuricemia and the risk of gout. A retrospective analysis of a large cohort. ( Cohen, E; Duskin-Bitan, H; Garty, M; Goldberg, E; Krause, I; Levi, A; Shochat, T, 2014) |
| "Hyperuricemia is a common finding in patients with NAFLD and is independently associated with early histological findings in this clinically relevant condition." | 1.40 | The relationship of serum uric acid with non-alcoholic fatty liver disease. ( Celebi, G; Dogru, T; Ercin, CN; Genc, H; Gurel, H; Kara, M; Kayadibi, H; Sertoglu, E, 2014) |
| "Mild hyperuricemia is a strong, independent marker of MS and high cardio-renal risk profile in hypertensive patients under specialist care." | 1.40 | Serum uric acid and its relationship with metabolic syndrome and cardiovascular risk profile in patients with hypertension: insights from the I-DEMAND study. ( Agabiti Rosei, E; Ambrosioni, E; Costa, FV; Deferrari, G; Garneri, D; Gonnella, A; Leoncini, G; Leonetti, G; Muiesan, ML; Pessina, AC; Pontremoli, R; Trimarco, B; Viazzi, F; Volpe, M, 2014) |
| "Sixty patients with type 2 diabetes mellitus were enrolled to the study." | 1.40 | Association of serum uric acid with level of blood pressure in type 2 diabetic patients. ( Behradmanesh, S; Kheiri, S; Nasri, H; Rafieian-Kopaei, M, 2014) |
| "Hyperuricemia is a non-communicable disease that threatens human health, and its prevalence has been increasing in recent decades." | 1.40 | Prevalence of hyperuricemia among Chinese adults: a national cross-sectional survey using multistage, stratified sampling. ( Liu, BC; Liu, H; Wang, YL; Zhang, XM, 2014) |
| "Hyperuricemia is an independent risk factor for renal function decline." | 1.40 | Effect of urate-lowering therapies on renal disease progression in patients with hyperuricemia. ( Cheetham, TC; Levy, GD; Niu, F; Rashid, N, 2014) |
| "Uric acid crystals were identified with DECT in 140 of 143 (97." | 1.40 | The application of dual-energy computed tomography in the diagnosis of acute gouty arthritis. ( Shi, D; Wu, H; Xu, R; Xue, J; Ye, L; Zhou, Q, 2014) |
| "Uric acid was significantly higher in those who had a cardiovascular event even in the mild, moderate and severe OSA groups." | 1.40 | Uric acid as a potential mediator of cardiovascular morbidity in obstructive sleep apnea syndrome. ( Erden, A; Inonu, H; Johnson, RJ; Kanbay, A; Kanbay, M; McFann, K; Ozturk, MA; Solak, Y; Uslu, E; Yuksel, SA, 2014) |
| "Hypertension was defined as systolic blood pressure (SBP) ≥ 140 mmHg or diastolic blood pressure (DBP) ≥ 90 mmHg." | 1.40 | Gender difference in the association of hyperuricemia with hypertension in a middle-aged Chinese population. ( Bo, QL; Hu, AL; Hu, CQ; Liu, KY; Mu, M; Sheng, J; Shu, L; Tao, FB; Wang, S; Wang, SF; Wang, XQ; Zhao, QH, 2014) |
| "Uric acid levels were correlated with eGFR(cr-cys) (r = -0." | 1.40 | Uric acid levels, kidney function, and cardiovascular mortality in US adults: National Health and Nutrition Examination Survey (NHANES) 1988-1994 and 1999-2002. ( Amadu, AR; Lo, L; Odden, MC; Peralta, CA; Smit, E, 2014) |
| "Gout/hyperuricemia is a common multifactorial disease having typical environmental risks." | 1.40 | Common dysfunctional variants of ABCG2 have stronger impact on hyperuricemia progression than typical environmental risk factors. ( Abe, J; Akashi, A; Chiba, T; Hosoya, T; Ichida, K; Kawai, S; Kawamura, Y; Matsuo, H; Nakamura, T; Nakaoka, H; Nakashima, H; Nakayama, A; Oikawa, Y; Okada, R; Sakiyama, M; Sakurai, Y; Shichijo, Y; Shimizu, S; Shinomiya, N; Suzuki, H; Takada, T; Takada, Y; Tamura, T; Wakai, K, 2014) |
| "Cardiorenal syndrome is a general term describing concomitant cardiac and renal dysfunction, and recently there has been renewed interest in the role of uric acid (UA) in its pathophysiology and management." | 1.40 | Uric acid as a cardiorenal risk factor - ready for prime-time? ( Goldsmith, DJ; Patel, KH, 2014) |
| "Chlorogenic acid is a superoxide radical scavenger with weak xanthine oxidase inhibitory activity." | 1.40 | In vitro and in vivo studies on adlay-derived seed extracts: phenolic profiles, antioxidant activities, serum uric acid suppression, and xanthine oxidase inhibitory effects. ( Dong, Y; Lin, L; Su, G; Sun-Waterhouse, D; Wang, X; Zhao, M; Zhu, D, 2014) |
| "Febuxostat is a novel xanthine oxidase inhibitor that is metabolized by many metabolic pathways in the kidney and the liver." | 1.40 | Switching from allopurinol to febuxostat for the treatment of hyperuricemia and renal function in patients with chronic kidney disease. ( Itabashi, M; Mochizuki, T; Moriyama, T; Nitta, K; Takei, T; Tsuchiya, K; Tsuruta, Y, 2014) |
| "Hyperuricemia is a risk factor for adverse renal outcomes in patients with chronic kidney disease." | 1.40 | A slight increase within the normal range of serum uric acid and the decline in renal function: associations in a community-based population. ( Asahi, K; Fujimoto, S; Hirayama, A; Ichikawa, K; Iseki, K; Kamei, K; Kimura, K; Kondo, M; Konta, T; Moriyama, T; Narita, I; Suzuki, K; Tsuruya, K; Watanabe, T; Yamagata, K, 2014) |
| "Age of onset of gout has recently decreased; however, patients with early-onset gout remain uncommon, and relevant information is scant." | 1.40 | Clinical characteristics of and relationship between metabolic components and renal function among patients with early-onset juvenile tophaceous gout. ( Chen, HY; Chung, WS; Lee, MC; Lu, CC; Wu, SK; Yeh, CJ, 2014) |
| "Uric acid was divided into quartiles in men (Q1: 59." | 1.40 | High uric acid level associated with increased arterial stiffness in apparently healthy women. ( Chang, CJ; Fang, JI; Lu, FH; Wang, RH; Wu, JS; Yang, YC, 2014) |
| "Hyperuricemia is well known as the cause of gout." | 1.40 | Screening and characterization of purine nucleoside degrading lactic acid bacteria isolated from Chinese sauerkraut and evaluation of the serum uric acid lowering effect in hyperuricemic rats. ( Li, M; Mei, L; Xie, A; Yang, D; Yuan, J; Yuan, L, 2014) |
| "Insulin resistance is associated with inadequate body composition, in biochemical levels and lifestyle, being the factors associated different in each phase of adolescence." | 1.40 | [Insulin resistance and components of metabolic syndrome, analysis by gender and stage of adolescence]. ( Faria, ER; Faria, FR; Franceschini, Sdo C; Novaes, JF; Peluzio, Mdo C; Priore, SE; Ribeiro, AQ; Ribeiro, SM; Sant Ana, LF, 2014) |
| "Hyperuricemia is an important foundation of gouty arthritis." | 1.40 | Total saponins from Discorea nipponica ameliorate urate excretion in hyperuricemic mice. ( Liu, SM; Lu, F; Yu, DH; Zhang, C; Zhou, Q, 2014) |
| " The high and low dosage of chicory inulin also decreased serum UA levels on days 7, 14, and 28." | 1.40 | Effects of chicory inulin on serum metabolites of uric acid, lipids, glucose, and abdominal fat deposition in quails induced by purine-rich diets. ( Jin, R; Lin, Z; Liu, X; Zhang, B; Zhu, W, 2014) |
| " Dosing levels of SUA could be appropriate in the global management of patients with psoriasis, particularly in those who are obese and with serum triglycerides upper the normal range." | 1.40 | Hyperuricemia in patients with chronic plaque psoriasis. ( Gisondi, P, 2014) |
| "Gout is a metabolic disorder associated with hyperuricemia resulting in the deposition of monosodium urate (MSU) crystals in joints and tissues." | 1.40 | Study on the anti-gout activity of chlorogenic acid: improvement on hyperuricemia and gouty inflammation. ( Cao, L; Ding, G; Guo, CR; Huang, WZ; Meng, ZQ; Tang, ZH; Wang, KD; Wang, ZZ; Xiao, W; Yan, YX; Yang, ZL, 2014) |
| "To evaluate single fixed dosing versus weight-based dosing strategies for rasburicase to determine the minimum dose required to mitigate hyperuricemia in the treatment or prevention of tumor lysis syndrome." | 1.39 | Comparative evaluation of single fixed dosing and weight-based dosing of rasburicase for tumor lysis syndrome. ( Augustin, KM; Boehmer, L; Butler, SK; Lathon, SC; McBride, A; Westervelt, P, 2013) |
| "Hyperuricemia was defined as SUA equal to 7 mg/dL or over." | 1.39 | No association between MTHFR C677T and serum uric acid levels among Japanese with ABCG2 126QQ and SLC22A12 258WW. ( Hamajima, N; Higashibata, T; Hinohara, Y; Kawai, S; Matsuo, H; Mori, A; Morita, E; Naito, M; Okada, R; Tamura, T; Wakai, K; Yin, G, 2013) |
| "Hyperuricemia is known to be a risk factor for incident type 2 diabetes mellitus, but the absolute magnitude of the association is not known." | 1.39 | Relative and attributable diabetes risk associated with hyperuricemia in US veterans with gout. ( Akhras, KS; Krishnan, E; Liu, J; Marynchenko, M; Sharma, H; Shi, L; Tawk, R; Wu, EQ, 2013) |
| "Hyperuricemia is now regarded as a risk factor for cardiovascular disease." | 1.39 | Hyperuricemia is an independent risk factor for new onset micro-albuminuria in a middle-aged and elderly population: a prospective cohort study in taiwan. ( Chang, HY; Hsu, YC; Huang, TJ; Lee, PH; Lei, CC; Lin, CL; Lu, LC; Tung, CW, 2013) |
| "Hyperuricemia is related to a variety of pathologies, including chronic kidney disease (CKD)." | 1.39 | Hyperuricemia influences tryptophan metabolism via inhibition of multidrug resistance protein 4 (MRP4) and breast cancer resistance protein (BCRP). ( Dankers, AC; Dijkman, HB; Hoenderop, JG; Masereeuw, R; Mutsaers, HA; Russel, FG; Sweep, FC; van den Heuvel, LP, 2013) |
| "The patient demographics, etiology of ESRD, comorbid conditions and other laboratory parameters were collected." | 1.39 | Uric acid levels and all-cause mortality in peritoneal dialysis patients. ( Feng, S; Jiang, L; Jin, D; Shen, H; Shi, X; Shi, Y; Wang, Z; Zeng, Y, 2013) |
| "Hyperuricemia has been shown to be a strong correlate of hypertension in children." | 1.39 | Serum uric acid and blood pressure in children at cardiovascular risk. ( Antolini, L; Brambilla, P; Galbiati, S; Genovesi, S; Giussani, M; Mastriani, S; Pontremoli, R; Stella, A; Valsecchi, MG; Viazzi, F, 2013) |
| " We herein conducted a dose-response analysis of TRT in 160 patients with female to male GID." | 1.39 | Testosterone replacement elevates the serum uric acid levels in patients with female to male gender identity disorder. ( Araki, M; Ariyoshi, Y; Ishii, K; Kumon, H; Kurahashi, H; Mahmood, S; Nagai, A; Nasu, Y; Sugimoto, M; Watanabe, M, 2013) |
| "Uric acid-treated mice exhibited significantly impaired glucose tolerance and lower insulin levels in response to glucose challenge than did control mice." | 1.39 | Hyperuricemia causes pancreatic β-cell death and dysfunction through NF-κB signaling pathway. ( Ding, Y; Guo, J; Jia, L; Liang, X; Liu, Y; Ren, W; Shen, Y; Shi, X; Su, D; Wan, M; Xing, J; Zheng, S, 2013) |
| "Gout is estimated to affect 1." | 1.39 | Improvement in the management of gout is vital and overdue: an audit from a UK primary care medical practice. ( Cottrell, E; Crabtree, V; Edwards, JJ; Roddy, E, 2013) |
| "Hyperuricemia was defined as serum uric acid >420 μmol/L for men and >360 μmol/L for women." | 1.39 | Relationship between lifestyle choices and hyperuricemia in Chinese men and women. ( Liu, L; Lou, S; Meng, Z; Song, K; Xu, K; Zhang, Q, 2013) |
| "Endothelial dysfunction characterized by decreased nitric oxide (NO) bioavailability is the first stage of coronary artery disease." | 1.39 | Uric acid modulates vascular endothelial function through the down regulation of nitric oxide production. ( Baldus, S; Klinke, A; Kolářová, H; Kubala, L; Lau, D; Lojek, A; Papežíková, I; Pekarová, M, 2013) |
| "Hyperuricemia is a risk factor for end-stage renal disease." | 1.39 | The association between serum uric acid and renal damage in a community-based population: the Takahata study. ( Ichikawa, K; Ikeda, A; Kato, T; Kayama, T; Konta, T; Kubota, I; Kudo, K; Sato, H; Suzuki, K; Ueno, Y, 2013) |
| "Hyperuricemia was defined as serum uric acid ≥ 416 μmol/L in men and ≥ 357 μmol/L in women." | 1.39 | The prevalence of hyperuricemia and its correlates in an inland Chinese adult population, urban and rural of Jinan. ( Li, J; Liu, Z; Lu, F; Sun, S; Wang, S; Yang, J; Zhang, C; Zhang, Y; Zhao, Y, 2013) |
| " There was a positive, dose-response relationship between alcohol intake and the risk of incident hyperuricaemia." | 1.38 | Alcohol intake and the risk of hyperuricaemia: a 6-year prospective study in Japanese men. ( Ishizaki, M; Kido, T; Miura, K; Morikawa, Y; Nakagawa, H; Nakamura, K; Naruse, Y; Sakurai, M; Suwazono, Y; Yoshita, K, 2012) |
| "Mean uric acid serum level was 281." | 1.38 | [Hyperuricemia in sickle cell disease in France]. ( Arlet, JB; Chatellier, G; Courbebaisse, M; de Montalembert, M; Pouchot, J; Prié, D; Ribeil, JA, 2012) |
| "Hyperuricemia is considered as a risk factor for the development of renal dysfunction." | 1.38 | Quercetin regulates organic ion transporter and uromodulin expression and improves renal function in hyperuricemic mice. ( Hu, QH; Jiao, RQ; Kong, LD; Wang, X; Zhang, X, 2012) |
| "Hyperuricemia has been associated with an increased risk of endothelial dysfunction (ED), cardiovascular and renal disease." | 1.38 | Effect of the treatment with allopurinol on the endothelial function in patients with hyperuricemia. ( Espinola-Zavaleta, N; Kuri-Alfaro, J; López-Osorio, C; Meléndez-Ramírez, G; Pérez-Méndez, O, 2012) |
| "Hyperuricemia was defined as ≥ 6." | 1.38 | Gender distribution of serum uric acid and cardiovascular risk factors: population based study. ( Baldo, MP; Capingana, P; Dantas, EM; Magalhães, P; Mill, JG; Molina, Mdel C; Morelato, RL; Rodrigues, SL; Salaroli, LB, 2012) |
| "Hyperuricemia is an independent risk factor for mortality, cardiovascular disease, and renal disease in general population." | 1.38 | Association of hyperuricemia with renal outcomes, cardiovascular disease, and mortality. ( Chang, JM; Chen, HC; Chen, SC; Chiu, YW; Hung, CC; Hwang, SJ; Kuo, MC; Lin, MY; Liu, WC; Yeh, SM, 2012) |
| "Hyperuricemia was defined as SUA ≥70 mg/L in men and ≥60 mg/L in women." | 1.38 | Cross-sectional and longitudinal associations between serum uric acid and metabolic syndrome. ( Gonçalves, JP; Lopes, C; Oliveira, A; Santos, AC; Severo, M, 2012) |
| "Uric acid (UA) has proven to be a causal agent in endothelial dysfunction in which ROS production plays an important role." | 1.38 | Hyperuricemia induces endothelial dysfunction via mitochondrial Na+/Ca2+ exchanger-mediated mitochondrial calcium overload. ( Chen, X; Cui, S; Ding, R; Feng, Z; Fu, B; Hong, Q; Huang, Z; Qi, K; Wang, L; Wu, D; Yang, J, 2012) |
| "Hyperuricemia is an independent predictor for early atherosclerosis in hypertensive subjects with normal renal function." | 1.38 | Uric acid is an important predictor for hypertensive early atherosclerosis. ( Bahadir, E; Citil, R; Deger, SM; Durmaz, AO; Mutluay, R; Sindel, S, 2012) |
| "Uric acid (UA) is a product of purine metabolism and is a natural antioxidant that can relieve the oxidative stress that occurs in PD." | 1.38 | Lower serum UA levels in Parkinson's disease patients in the Chinese population. ( Guo, JF; He, D; Lei, LF; Shen, L; Tan, LM; Tang, BS; Wang, CY; Wang, YQ; Yan, XX; Zhang, HN, 2012) |
| "Generally, hyperuricemia has been classified into urate 'overproduction type' and/or 'underexcretion type' based solely on renal urate excretion, without considering an extra-renal pathway." | 1.38 | Decreased extra-renal urate excretion is a common cause of hyperuricemia. ( Hosoya, T; Hosoyamada, M; Ichida, K; Ikebuchi, Y; Inoue, H; Ito, K; Kasuga, H; Kawamura, Y; Matsuo, H; Murakami, K; Nakamura, M; Nakamura, T; Nakashima, H; Nakayama, A; Okada, C; Sakurai, Y; Shimizu, T; Shinohara, Y; Shinomiya, N; Suzuki, H; Takada, T; Takada, Y; Utsumi, Y; Yamanashi, Y, 2012) |
| "Uric acid has also antioxidant properties and is a surrogate marker of metabolic syndrome." | 1.38 | Long-term activation of semicarbazide-sensitive amine oxidase lowers circulating levels of uric acid in diabetic conditions. ( Carpéné, C; Desquesnes, A; Gomez-Ruiz, A; Iffiú-Soltész, Z; Le Gonidec, S; Mercader, J, 2012) |
| "Hyperuricemia was induced by potassium oxonate (250 mg/kg) in male mice." | 1.38 | Uricosuric and nephroprotective properties of Ramulus Mori ethanol extract in hyperuricemic mice. ( Hu, LS; Kong, LD; Liu, L; Shi, YW; Wang, CP; Wang, RW; Wang, X; Ye, JF; Zhang, YL, 2012) |
| "Hyperuricemia is a common complication after kidney transplantation that may adversely affect graft survival." | 1.38 | Hyperuricemia in adult renal allograft recipients: prevalence and predictors. ( Almeida, M; Cabrita, A; Dias, L; Fonseca, I; Henriques, AC; Malheiro, J; Martins, LS; Pedroso, S, 2012) |
| "Gout is an ancient disease." | 1.38 | Management of gout: a 57-year-old man with a history of podagra, hyperuricemia, and mild renal insufficiency. ( Shmerling, RH, 2012) |
| "Hyperuricemia is common in those subjects and might be considered a potential clinical parameter in the definition of MetS." | 1.38 | Hyperuricemia and metabolic syndrome: lessons from a large cohort from Israel. ( Cohen, E; Fraser, A; Garty, M; Goldberg, E; Krause, I, 2012) |
| "Hyperuricemia was defined as UA ≥ 7 mg/dL in men and UA ≥ 6 mg/dL in women." | 1.38 | Association between Uric Acid and Metabolic Syndrome in Qazvin Metabolic Diseases Study (QMDS), Iran. ( Asefzadeh, S; Esmailzadehha, N; Ghorbani, A; Ziaee, A, 2012) |
| "96 million (96%) direct cost savings for the 48 patients in this study when compared to the cost of manufacturer's dosing recommendation." | 1.37 | Evaluation of a low, weight-based dose of rasburicase in adult patients for the treatment or prophylaxis of tumor lysis syndrome. ( Crank, CW; Knoebel, RW; Lo, M, 2011) |
| "Necrosis was assessed by acridine orange and ethidium bromide." | 1.37 | Pro-inflammatory and oxidative effects of noncrystalline uric acid in human mesangial cells: contribution to hyperuricemic glomerular damage. ( Borges, FT; Convento, MS; Dalboni, MA; Pessoa, E; Schor, N, 2011) |
| "Hyperuricemia is associated with worse outcomes of patients with chronic heart failure (HF)." | 1.37 | Hyperuricemia predicts adverse outcomes in patients with heart failure. ( Furumoto, T; Goto, D; Goto, K; Hamaguchi, S; Kinugawa, S; Takeshita, A; Tsuchihashi-Makaya, M; Tsutsui, H; Yokoshiki, H; Yokota, T, 2011) |
| "Gouty panniculitis is an unusual clinical manifestation of gout, characterized by the deposition of monosodium urate crystals in the lobular hypodermis." | 1.37 | Panniculitis: another clinical expression of gout. ( Espinoza, LR; Iglesias-Gamarra, A; Mejia, J; Ochoa, CD; Restrepo, JF; Rondon, F; Valderrama, V; Villaroya, N, 2011) |
| "Early-onset hyperuricemia is a significant predictor of cardiovascular complications and graft survival independently of graft function." | 1.37 | Clinical significance of early-onset hyperuricemia in renal transplant recipients. ( Choi, BS; Chung, BH; Hwang, HS; Kang, SH; Kim, JI; Kim, YS; Moon, IS; Park, CW; Yang, CW, 2011) |
| "Hyperuricemia was defined as serum UA ≥ 6." | 1.37 | Uric acid contributes to glomerular filtration rate deterioration in renal transplantation. ( Han, DJ; Kim, KM; Kim, SS; Lee, MS; Park, JS; Park, SK; Yang, WS; Yun, S, 2011) |
| "Mulberroside A is a major stilbene glycoside of MORUS ALBA L." | 1.37 | Mulberroside a possesses potent uricosuric and nephroprotective effects in hyperuricemic mice. ( Hu, LS; Kong, LD; Wang, CP; Wang, X; Wang, Y; Ye, JF; Zhang, X, 2011) |
| "Hyperuricemia was defined as serum uric acid (SUA) >420 μmol/L for men, >360 μmol/L for women." | 1.37 | Gender and age impacts on the correlations between hyperuricemia and metabolic syndrome in Chinese. ( Lou, S; Meng, Z; Ren, X; Zhang, Q, 2011) |
| "INTRODUCTION." | 1.37 | Hyperuricemia and albuminuria in patients with type 2 diabetes mellitus. ( Bonakdaran, S; Hami, M; Shakeri, MT, 2011) |
| " The most frequently used maximal dosage of allopurinol was 100 mg/day at each stage." | 1.37 | Management of asymptomatic hyperuricaemia in patients with chronic kidney disease by Japanese nephrologists: a questionnaire survey. ( Fukuhara, S; Nakata, T; Nakaya, I; Namikoshi, T; Onishi, Y; Shibagaki, Y; Tsuruta, Y, 2011) |
| "Uric acid-induced increase in MCP-1 production was blocked by scavenging superoxide or by inhibiting NADPH oxidase and by stimulating peroxisome-proliferator-activated receptor-γ with rosiglitazone." | 1.37 | Hyperuricemia as a mediator of the proinflammatory endocrine imbalance in the adipose tissue in a murine model of the metabolic syndrome. ( Baldwin, W; Baylis, C; Johnson, RJ; Marek, G; McRae, S; Pannu, V; Sautin, YY; Wymer, D, 2011) |
| "Because preeclampsia is associated with placental immune⁄ inflammatory dysregulation, we sought to determine in the trophoblast, the presence of the Nalp3 inflammasome, and the effect of MSU on its activation." | 1.37 | Uric acid induces trophoblast IL-1β production via the inflammasome: implications for the pathogenesis of preeclampsia. ( Abrahams, VM; Boeras, C; Guller, S; Kavathas, PB; Mulla, MJ; Myrtolli, K; Norwitz, ER; Potter, J; Sfakianaki, AK; Tadesse, S, 2011) |
| "Ninety-eight subjects developed type 2 diabetes during the 3." | 1.37 | Serum uric acid associates with the incidence of type 2 diabetes in a prospective cohort of middle-aged and elderly Chinese. ( Bi, Y; Huang, Y; Li, X; Ning, G; Wang, T; Wang, W; Xu, M; Xu, Y, 2011) |
| "Hyperuricemia was more common in men than in women (51." | 1.37 | Relation of uric acid with components of metabolic syndrome before and after Roux-en-Y gastric bypass in morbidly obese subjects. ( Rossi, FM; Rossi, M; Serpa Neto, A; Teixeira, GK; Valle, LG, 2011) |
| "Astilbin is a flavonoid compound isolated from the rhizome of Smilax china L." | 1.37 | Astilbin attenuates hyperuricemia and ameliorates nephropathy in fructose-induced hyperuricemic rats. ( Chen, L; Lan, Z; Li, F; Li, P; Yang, Z; Zhang, C; Zhang, X; Zhou, Y, 2011) |
| "Gout has not been described previously as a complication in cystic fibrosis (CF)." | 1.37 | Gout and hyperuricaemia in adults with cystic fibrosis. ( Brennan, A; Bright-Thomas, R; Helm, J; Horsley, A; Jones, A; Webb, K, 2011) |
| "Hyperuricemia is a risk factor for CKD in Taiwan, future studies are still necessary to determine whether hypouricemia increases the risk of CKD." | 1.37 | Uric acid and incident chronic kidney disease in a large health check-up population in Taiwan. ( Li, L; Shu, Z; Tao, Q; Wang, S; Yu, C; Zhan, S, 2011) |
| "Uric acid level was associated with lower all-cause mortality (HR: 0." | 1.37 | Uric acid levels and all-cause and cardiovascular mortality in the hemodialysis population. ( Arrington, CJ; Karaboyas, A; Kleophas, W; Latif, W; Levin, NW; Marshall, MR; Pisoni, RL; Robinson, BM; Saran, R; Sen, A; Tong, L; Winchester, JF, 2011) |
| "Gout is increasing in prevalence throughout the world, particularly in developed countries." | 1.37 | Hyperuricaemia and gout. ( Shipley, M, 2011) |
| "Hyperuricemia is a common complication in organ transplant recipients, with a higher incidence in kidney and heart recipients." | 1.37 | Uric acid and transplantation. ( Mazali, FC; Mazzali, M, 2011) |
| "Totally 148 patients diagnosed as IgA nephropathy by renal biopsy in our hospital from January 2007 to December 2010 were divided into hyperuricaemic group (41 cases) and non-hyperuricaemic group (107 cases) according to the level of serum uric acid." | 1.37 | [The relationship between hyperuricaemia and clinic pathology of IgA nephropathy]. ( Cui, MJ; Wang, HY; Xiao, QF; Zhang, BH; Zhu, FL, 2011) |
| "The blood Cr level just reached the chronic renal failure level on the 26th day of the administration (about the 4th week), and obviously exceeded the renal failure level on the 41st day (about the 6th week)." | 1.37 | [Exploration on the establishment of animal models for gouty nephropathy complicated with chronic renal failure]. ( Meng, DM; Ren, W; Xing, RL, 2011) |
| "Hyperuricemia was defined as the values over the mean value plus 2 standard deviations for each age group." | 1.37 | Investigation on hyperuricemia in children with obesity or various pediatric disorders. ( Kubota, M; Nagai, A; Tang, L; Tokuda, M, 2011) |
| "Asymptomatic hyperuricemia affects one in five adults in the general population and is associated with elevated cardiovascular risk." | 1.37 | [Contribution of the CoLaus study to decipher the determinants of serum uric acid]. ( Bochud, M; Vollenweider, P; Waeber, G, 2011) |
| "Hyperuricemia is associated with metabolic syndrome and has emerged as a marker for both type 2 diabetes and cardiovascular disease." | 1.36 | Prevalence and determinants of hyperuricemia in middle-aged, urban Chinese men. ( Cai, Q; Elasy, T; Fazio, S; Li, H; Linton, M; Shu, XO; Villegas, R; Xiang, YB; Zheng, W, 2010) |
| " The effects of casein or soya protein combined with palm or safflower-seed oil on various serum parameters and renal histology were investigated on hyperuricaemic rats." | 1.36 | Relative efficacy of casein or soya protein combined with palm or safflower-seed oil on hyperuricaemia in rats. ( Chiou, HY; Lai, SH; Lo, HC; Wang, YH; Yang, Y, 2010) |
| "Uric acid transport was saturable with K(m) of 1168+/-335 muM (mean and S." | 1.36 | Renal secretion of uric acid by organic anion transporter 2 (OAT2/SLC22A7) in human. ( Anzai, N; Mamada, H; Nakanishi, T; Sato, M; Shirasaka, Y; Tamai, I, 2010) |
| "Hyperuricemia was defined as a serum UA value >7." | 1.36 | The relationship between serum uric acid level and metabolic syndrome: differences by sex and age in Taiwanese. ( Chiou, WK; Chiu, HT; Huang, DH; Lee, YJ; Lin, JD; Wang, MH, 2010) |
| "Hyperuricaemia was associated with cardiac hypertrophy with an odds ratio (OR) of 1." | 1.36 | Role of uric acid in the link between arterial stiffness and cardiac hypertrophy: a cross-sectional study. ( Chen, CC; Chen, HW; Hung, KC; Hwang, JS; Ko, YS; Kuo, CF; Lin, CM; Lin, YS; Luo, SF; See, LC; Shen, YM; Tseng, WY; Wen, MS; Yu, KH, 2010) |
| "Asymptomatic hyperuricemia is not associated with suppressed neutrophil function." | 1.36 | Differences in MSU-induced superoxide responses by neutrophils from gout subjects compared to healthy controls and a role for environmental inflammatory cytokines and hyperuricemia in neutrophil function and survival. ( Grainger, R; Harper, JL; Harrison, A; Martin, WJ, 2010) |
| "Gout is commonly associated with obesity, arterial hypertension, diabetes, and dyslipidemia." | 1.36 | Metabolic syndrome characteristics in gout patients. ( de Miguel, ME; Fraile, JM; Lundelin, KJ; Martínez, P; Puig, JG; Torres, RJ; Vázquez, JJ, 2010) |
| " Decreased nitric oxide bioavailability may be the main reason." | 1.36 | Association between endothelial dysfunction and hyperuricaemia. ( Ho, WJ; Hsu, TS; Kuo, CT; Tsai, WP; Tsay, PK; Wang, CL; Yu, KH, 2010) |
| "Hyperuricemia and gouty arthritis are commonly seen in adults with BS, but to our knowledge there is no report of gouty arthritis in pediatric literature." | 1.36 | Gouty arthritis in a 15-year-old girl with Bartter's syndrome. ( Basiratnia, M; Derakhshan, A; Derakhshan, D; Derakhshan, N; Fallahzadeh, MH; Hashemi, G, 2010) |
| "Mangiferin was found to down-regulate mRNA and protein levels of urate transporter 1 (mURAT1) and glucose transporter 9 (mGLUT9), as well as up-regulate organic anion transporter 1 (mOAT1) in the kidney of hyperuricemic mice." | 1.36 | [Mangiferin promotes uric acid excretion and kidney function improvement and modulates related renal transporters in hyperuricemic mice]. ( Hu, QH; Kong, LD; Wang, Y; Zhang, X, 2010) |
| "Hyperuricemia is a common feature in adult liver transplant recipients but there is limited information in children." | 1.35 | Hyperuricemia after liver transplantation in children. ( Boillot, O; Cochat, P; Dubourg, L; Fargue, S; Hadj-Aïssa, A; Harambat, J; Lachaux, A; Ranchin, B; Rivet, C, 2008) |
| "Uric acid was significantly associated with increased likelihood for diastolic HTN (OR = 2." | 1.35 | Serum uric acid and ambulatory blood pressure in children with primary hypertension. ( Alpert, BS; Jones, DP; Li, R; Richey, PA, 2008) |
| "Moreover, hyperuricemia is likely a risk factor for the development of diabetes mellitus." | 1.35 | Dietary and lifestyle changes associated with high prevalence of hyperuricemia and gout in the Shandong coastal cities of Eastern China. ( Chen, X; Chen, Y; Hu, J; Li, C; Miao, Z; Song, W; Sun, R; Wang, CY; Wang, F; Wang, Y; Wang, Z; Xu, F; Yan, S; Zhao, S, 2008) |
| " The hyperuricemic mice were oral administrated cinnamaldehyde at a dosage of 150 mg/kg, the uric acid value in serum was reduced from 5." | 1.35 | Essential oil from leaves of Cinnamomum osmophloeum acts as a xanthine oxidase inhibitor and reduces the serum uric acid levels in oxonate-induced mice. ( Chang, ST; Chu, FH; Liao, JW; Wang, SY; Yang, CW; Zhen, WW, 2008) |
| "Hyperuricemia is a significant factor in a variety of diseases, including gout and cardiovascular diseases." | 1.35 | Plasma urate level is directly regulated by a voltage-driven urate efflux transporter URATv1 (SLC2A9) in humans. ( Anzai, N; Babu, E; Endou, H; Hisatome, I; Ichida, K; Jin, CJ; Jutabha, P; Kimura, T; Kitamura, K; Sakurai, H; Srivastava, S, 2008) |
| "Hyperuricemia was induced by intraperitoneal injection of 250 mg kg(-1) potassium oxonate in rats." | 1.35 | Effects of onion on serum uric acid levels and hepatic xanthine dehydrogenase/xanthine oxidase activities in hyperuricemic rats. ( Eshraghian, MR; Haidari, F; Keshavarz, SA; Mahboob, SA; Rashidi, MR; Shahi, MM, 2008) |
| "and quercetin treatments for 14 days significantly reduced (p=0." | 1.35 | Hypouricemic and antioxidant activities of Allium cepa Lilliaceae and quercetin in normal and hyperuricemic rats. ( Eshraghian, MR; Haidari, F; Keshavarz, SA; Mahboob, SA; Rashidi, MR; Shahi, MM, 2008) |
| "Hyperuricemia is significantly predicted by anthropometric measure of SFT which is a simple clinical screening method along with creatinine levels." | 1.35 | Hyperuricemia and its related factors in an urban population, Izmir, Turkey. ( Akar, S; Akkoc, N; Birlik, M; Gurler, O; Onen, F; Pakoz, B; Sari, I; Sisman, AR, 2009) |
| "Triuret was also found to be elevated in the urine of subjects with preeclampsia, a pregnancy-specific hypertensive syndrome that is associated with oxidative stress, whereas very little triuret is produced in normal healthy volunteers." | 1.35 | Reactions of peroxynitrite with uric acid: formation of reactive intermediates, alkylated products and triuret, and in vivo production of triuret under conditions of oxidative stress. ( Angerhofer, A; Gersch, C; Henderson, GN; Imaram, W; Johnson, RJ; Karumanchi, SA; Kim, KM; Palii, SP, 2009) |
| "Hyperuricemia is a prevalent condition in chronic heart failure (CHF), describing increased oxidative stress and inflammation." | 1.35 | Hyperuricemia in acute heart failure. More than a simple spectator? ( Alimonda, AL; Bodí, V; Darmofal, H; Husser, O; Llácer, A; Mainar, L; Merlos, P; Miñana, G; Núñez, E; Núñez, J; Robles, R; Sanchis, J, 2009) |
| " The drug dosing was calculated based on the patients' ideal body weight (IBW) or adjusted body weight (aBW) for those who were more than 30% above their IBW." | 1.35 | Single-dose rasburicase for tumour lysis syndrome in adults: weight-based approach. ( Campara, M; Haaf, CM; Shord, SS, 2009) |
| "Hyperuricemia is common after kidney transplantation." | 1.35 | Association of uric acid with inflammation, progressive renal allograft dysfunction and post-transplant cardiovascular risk. ( Bandukwala, F; Huang, M; Nash, MM; Prasad, GV; Zaltzman, JS, 2009) |
| "Allopurinol treatment significantly lowered uric acid levels, reduced albuminuria, and ameliorated tubulointerstitial injury, but it did not prevent mesangial expansion." | 1.35 | Effect of lowering uric acid on renal disease in the type 2 diabetic db/db mice. ( Heinig, M; Johnson, RJ; Kosugi, T; Nakagawa, T; Nakayama, T; Roncal, C; Sanchez-Lozada, LG; Yuzawa, Y; Zhang, L, 2009) |
| "Hyperuricemia is a common finding in hypertensive patients, especially among those who are on diuretic therapy." | 1.35 | Uric acid as a marker for renal dysfunction in hypertensive women on diuretic and nondiuretic therapy. ( Batista, MC; Borges, RL; Hirota, AH; Quinto, BM; Ribeiro, AB; Zanella, MT, 2009) |
| "Hyperuricemia is associated with the metabolic syndrome, gout, renal and cardiovascular disease (CVD)." | 1.35 | Genetic influence on variation in serum uric acid in American Indians: the strong heart family study. ( Almasy, L; Best, LG; Cole, SA; Comuzzie, AG; Devereux, RB; Fabsitz, RR; Franceschini, N; Göring, HH; Haack, K; Howard, BV; Laston, S; Lee, ET; MacCluer, JW; Mottl, A; Umans, JG; Voruganti, VS, 2009) |
| "Uric acid was measured in 1570 plasma samples collected at mean gestational age of 8." | 1.35 | Elevated first-trimester uric acid concentrations are associated with the development of gestational diabetes. ( Catov, J; Gandley, RE; Laughon, SK; Provins, T; Roberts, JM, 2009) |
| "In conclusion, hyperuricemia is associated with hypertension in a Chinese population at a high risk of hypertension." | 1.35 | Association between hyperuricemia and hypertension in a Chinese population at a high risk of hypertension. ( Li, L; Lu, H; Lu, ZH; Lu, ZS; Wang, JA; Yan, SG; You, W, 2009) |
| "The prevalence of hyperuricemia is low in Uygurs, who have a high prevalence of cardiovascular risk factors such as hypertension, overweight-obesity, dyslipidemia, hyperglycemia, and insulin resistance (IR)." | 1.35 | Serum uric acid is associated with metabolic risk factors for cardiovascular disease in the Uygur population. ( Hong, J; Li, NF; Wang, HM; Yang, J; Yao, XG; Zhou, L, 2009) |
| "To study the effect of retention enema of Chinese herbal medicine combined with allopurinol in treating hyperuricaemia (HUE)." | 1.35 | Clinical study on treatment of hyperuricaemia by retention enema of Chinese herbal medicine combined with allopurinol. ( Akebaier, W; Chen, Q; Ma, L, 2009) |
| "Hyperuricemia was defined as serum urate >7." | 1.35 | Dietary factors associated with hyperuricemia in adults. ( Huang, YC; See, LC; Sun, JH; Yang, CH; Yu, KH, 2008) |
| "Hyperuricemia is often found in patients with chronic heart failure (CHF)." | 1.35 | Is uric acid itself a player or a bystander in the pathophysiology of chronic heart failure? ( Duan, X; Ling, F, 2008) |
| "The metabolic syndrome was defined by the original ATP III criteria and the modified ATP III criteria that include a reduced waist circumference." | 1.35 | Association between serum uric acid and the Adult Treatment Panel III-defined metabolic syndrome: results from a single hospital database. ( Choi, SJ; Ji, JD; Lee, YH; Rho, YH; Song, GG; Woo, JH, 2008) |
| "Moreover, hyperuricemia is significantly correlated with hypertriglyceridemia, hypertension, and visceral obesity." | 1.35 | Serum uric acid levels and risk of metabolic syndrome in healthy adults. ( Bandarian, F; Ebrahimpour, P; Fakhrzadeh, H; Heshmat, R; Larijani, B, 2008) |
| "Hyperuricemia is postulated to be a risk factor for atherosclerotic diseases, although whether it is independent of classical atherogenic risk factors is controversial." | 1.34 | Higher serum uric acid is associated with increased arterial stiffness in Japanese individuals. ( Hashimoto, H; Ishizaka, N; Ishizaka, Y; Nagai, R; Toda, E; Yamakado, M, 2007) |
| "Uric acid levels were significantly higher in the lower CFR group than in the higher CFR group (7." | 1.34 | Elevated serum uric acid levels impair coronary microvascular function in patients with idiopathic dilated cardiomyopathy. ( Caliskan, M; Erdogan, D; Gullu, H; Kulaksizoglu, S; Muderrisoglu, H; Tok, D; Yildirir, A, 2007) |
| "Marked hyperuricemia is known to cause acute renal failure via intrarenal crystal deposition." | 1.34 | Effect of elevated serum uric acid on cisplatin-induced acute renal failure. ( Croker, B; Ejaz, AA; Johnson, RJ; Mu, W; Ouyang, X; Reungjui, S; Roncal, CA; Tabah-Fisch, I, 2007) |
| "Hyperuricemia is associated with hypertension, vascular disease and cardiovascular (CV) disease." | 1.34 | Association between serum uric acid levels and coronary flow reserve in hypertensive patients without concomitant risk factors. ( Caliskan, M; Erdogan, D; Gullu, H; Muderrisoglu, H; Ozer, I; Yildirim, I; Yildirir, A, 2007) |
| "Metabolic syndrome was diagnosed using the WHO criteria." | 1.34 | Serum uric acid level as an independent component of the metabolic syndrome in type 2 diabetic blacks. ( Akande, AA; Akinyinka, OA; Jimoh, AK; Olarinoye, GO, 2007) |
| "Uric acid is a metabolic product synthesized from nucleic acids, amino acids and the Krebs cycle, reflecting a multiple metabolic associations in humans." | 1.33 | The serum uric acid and related cardiovascular risk factors in south Taiwan. ( Chang, YY; Chen, SS; Chen, WH; Huang, CC; Liu, JS; Peng, MC; Tsai, WC, 2005) |
| "Hyperuricemia is associated with cardiovascular risk." | 1.33 | Lys418Asn polymorphism of the alpha2-adrenoceptor gene relates to serum uric acid levels but not to insulin sensitivity. ( Fu, Y; Katsuya, T; Masuo, K; Ogihara, T; Rakugi, H; Tuck, ML, 2005) |
| "Hyperuricemia has been identified in patients who have congestive heart failure and is a marker of poor prognosis in such patients." | 1.33 | Prognostic usefulness of serum uric acid after acute myocardial infarction (the Japanese Acute Coronary Syndrome Study). ( Hiraoka, H; Honda, T; Ishihara, M; Kimura, K; Kojima, S; Matsui, K; Miyazaki, S; Ogata, Y; Ogawa, H; Sakamoto, T; Shimoyama, N; Sonoda, M; Tei, C; Tsuchihashi, K; Yamagishi, M, 2005) |
| "Hyperuricemia is associated with a number of pathological conditions such as gout." | 1.33 | The dual actions of morin (3,5,7,2',4'-pentahydroxyflavone) as a hypouricemic agent: uricosuric effect and xanthine oxidase inhibitory activity. ( Cheng, CH; Fong, WP; Yu, Z, 2006) |
| "Hyperuricemia is a lifestyle-related disease." | 1.33 | A longitudinal study of the influence of shift work on serum uric acid levels in workers at a telecommunications company. ( Inaba, T; Kobayashi, E; Nogawa, K; Oishi, M; Suwazono, Y; Uetani, M, 2006) |
| "All patients had never been treated for hyperuricemia, were on no medications, and were free of any other known diseases." | 1.33 | Status of endothelial dependent vasodilation in patients with hyperuricemia. ( Hisatome, I; Igawa, O; Ishida, K; Kato, M; Kinugawa, T; Kotani, K; Ogino, K; Shigemasa, C; Somers, VK; Tomikura, Y, 2005) |
| "As gout is very often primarily caused by a renal secretion disturbance of uric acid special diagnostics should be done." | 1.33 | [Hyperuricemia and gout: diagnosis and therapy]. ( Grässler, J; Richter, K; Roch, B; Schröder, HE; Tausche, AK; Unger, S; Wunderlich, C, 2006) |
| "Hyperuricemia is commonly associated with obesity, glucose intolerance, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease." | 1.33 | Is hyperuricemia another facet of the metabolic syndrome? ( Chan, WL; Ho, LT; Hsiao, LC; Hwu, CM; Lin, MW; Liou, TL; Tsai, TT, 2006) |
| "Uric acid levels were analyzed in 247 CHF patients, and patients were followed up for 451 +/- 235 days (mean +/- SD)." | 1.33 | Hyperuricemia associated with high cardiac event rates in the elderly with chronic heart failure. ( Arimoto, T; Hirono, O; Koyama, Y; Kubota, I; Miyashita, T; Niizeki, T; Nitobe, J; Nozaki, N; Okuyama, H; Takahashi, H; Takeishi, Y; Tsunoda, Y; Watanabe, T, 2006) |
| "Hyperuricemia and gout have shown an increase worldwide." | 1.33 | The prevalence of hyperuricemia in a population of the coastal city of Qingdao, China. ( Dong, Y; Gao, W; Nan, H; Qian, R; Qiao, Q; Tang, B; Tuomilehto, J, 2006) |
| "Hyperuricemia is one of the risk factors for cardiovascular disease." | 1.33 | Longevity-associated NADH dehydrogenase subunit-2 237 Leu/Met polymorphism influences the effects of alcohol consumption on serum uric acid levels in nonobese Japanese men. ( Honmyo, R; Ishikawa, M; Kokaze, A; Masuda, Y; Matsunaga, N; Satoh, M; Takashima, Y; Teruya, K; Uchida, Y; Yorimitsu, M; Yoshida, M, 2006) |
| "Uric acid levels were measured before transplantation and after transplantation within six months intervals for two yr." | 1.33 | Frequency of hyperuricemia and effect of calcineurin inhibitors on serum uric acid levels in liver transplanted children. ( Arikan, C; Aydogdu, S; Kilic, M; Tumgor, G, 2006) |
| "Hyperuricemia and gout are common complications in adult renal transplant recipients." | 1.33 | Hyperuricemia and gout following pediatric renal transplantation. ( Kemper, MJ; Neuhaus, TJ; Spartà, G, 2006) |
| "Hyperuricemia is prevalent among Thai men and women receiving routine health exams." | 1.33 | Prevalence of hyperuricemia and its relationship with metabolic syndrome in Thai adults receiving annual health exams. ( Dhanamun, B; Lohsoonthorn, V; Williams, MA, 2006) |
| "Hyperuricemia is a common feature in patients with chronic kidney disease (CKD)." | 1.33 | J-shaped mortality relationship for uric acid in CKD. ( Axelsson, J; Bárány, P; Carrero, JJ; García-López, E; Heimbürger, O; Johnson, RJ; Lindholm, B; Molinaei, H; Qureshi, AR; Stenvinkel, P; Suliman, ME, 2006) |
| "Since hyperuricemia is associated with obesity, renal disease, hyperlipidemia, and atherosclerosis, whether or not serum urate is a cardiovascular risk factor per se has remained elusive." | 1.32 | Leptin might be a regulator of serum uric acid concentrations in humans. ( Alvur, M; Arik, N; Bedir, A; Tanyeri, F; Topbas, M, 2003) |
| "Three children with acute lymphoblastic leukemia presenting with hyperuricemia received rasburicase as a single intravenous dose just prior to the start of chemotherapy." | 1.32 | Treatment of impending tumor lysis with single-dose rasburicase. ( Chan, R; Lee, AC; Li, CH; So, KT, 2003) |
| "Hyperuricemia is part of the "metabolic syndrome"." | 1.32 | Serum uric acid levels in obese children and adolescents: linkage to testosterone levels and pre-metabolic syndrome. ( Debatin, KM; Denzer, C; Heinze, E; Mayer, H; Muche, R; Wabitsch, M, 2003) |
| "Underexcretory hyperuricemia is strongly related to hypertensive organ damage and this relationship does not seem to be mediated by a decreased renal function." | 1.32 | Hyperuricemia, low urine urate excretion and target organ damage in arterial hypertension. ( Campo, C; Garcia-Puig, J; García-Robles, R; Rodicio, JL; Ruilope, LM; Segura, J, 2003) |
| "The cumulative incidence of ESRD was calculated according to quartiles of baseline serum uric acid levels for each sex." | 1.32 | Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort. ( Ikemiya, Y; Inoue, T; Iseki, C; Iseki, K; Kinjo, K; Takishita, S, 2004) |
| "Hyperuricemia is the hallmark of severe gout with tophi formation." | 1.32 | [Rasburicase (Fasturtec)]. ( Frey, FJ; Gugger, M; Vogt, B, 2004) |
| "Hypertension was the most common followed infrequency by dyslipidemia, diabetes mellitus, ischemic heart disease, and chronic obstructive pulmonary disease consecutively." | 1.32 | Clinical manifestations of patients with hyperuricemia. ( Akkasilpa, S; Avihingsanon, Y; Hanvivadhanakul, P; Wonchinsri, J, 2004) |
| "Hyperuricemia is associated with renal disease, but it is usually considered a marker of renal dysfunction rather than a risk factor for progression." | 1.31 | A role for uric acid in the progression of renal disease. ( Feng, L; Han, L; Harris, R; Johnson, RJ; Kang, DH; Mazzali, M; Nakagawa, T; Truong, L; Watanabe, S, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 106 (3.49) | 18.7374 |
| 1990's | 1 (0.03) | 18.2507 |
| 2000's | 430 (14.14) | 29.6817 |
| 2010's | 1538 (50.58) | 24.3611 |
| 2020's | 966 (31.77) | 2.80 |
| Authors | Studies |
|---|---|
| Rocić, B | 1 |
| Vucić-Lovrencić, M | 1 |
| Poje, N | 1 |
| Poje, M | 1 |
| Bertuzzi, F | 1 |
| Buzas, R | 1 |
| Ivan, VS | 1 |
| Gheorghe-Fronea, OF | 1 |
| Morgovan, AF | 1 |
| Ardelean, M | 1 |
| Albulescu, N | 1 |
| Dorobantu, M | 1 |
| Lighezan, DF | 1 |
| Wang, M | 9 |
| Zhang, Y | 85 |
| Zhang, M | 23 |
| Li, H | 33 |
| Wen, C | 1 |
| Zhao, T | 8 |
| Xie, Z | 4 |
| Sun, J | 12 |
| Timerga, A | 1 |
| Haile, K | 1 |
| Pan, J | 9 |
| Shi, M | 3 |
| Guo, F | 4 |
| Ma, L | 14 |
| Fu, P | 5 |
| Xiong, Y | 2 |
| Wangsheng, F | 1 |
| Wang, S | 30 |
| Zhou, W | 8 |
| Huang, X | 17 |
| Bao, H | 6 |
| Cheng, X | 10 |
| Tu, CM | 1 |
| Wei, TE | 1 |
| Tseng, GS | 2 |
| Chen, CC | 3 |
| Liu, CW | 7 |
| Yu, C | 9 |
| Ren, X | 8 |
| Pan, L | 5 |
| Zhao, H | 11 |
| Wang, Y | 109 |
| Chang, L | 1 |
| He, H | 14 |
| Xi, J | 1 |
| Shan, G | 5 |
| Luo, LS | 1 |
| Dai, LJ | 1 |
| He, FX | 1 |
| Zhang, JL | 3 |
| Zhou, Q | 11 |
| Ogura, M | 3 |
| Toyoda, Y | 5 |
| Sakiyama, M | 10 |
| Kawamura, Y | 8 |
| Nakayama, A | 15 |
| Yamanashi, Y | 2 |
| Takada, T | 19 |
| Shimizu, S | 10 |
| Higashino, T | 5 |
| Nakajima, M | 3 |
| Naito, M | 8 |
| Hishida, A | 4 |
| Kawai, S | 6 |
| Okada, R | 4 |
| Sasaki, M | 1 |
| Ayaori, M | 1 |
| Suzuki, H | 15 |
| Takata, K | 1 |
| Ikewaki, K | 1 |
| Harada-Shiba, M | 2 |
| Shinomiya, N | 15 |
| Matsuo, H | 18 |
| Yang, H | 21 |
| Liu, C | 15 |
| Jin, C | 1 |
| Yu, R | 1 |
| Ding, L | 2 |
| Mu, L | 2 |
| Zhou, Z | 11 |
| Zhang, L | 44 |
| Xie, Q | 4 |
| Liu, Q | 9 |
| Tong, M | 1 |
| Yu, X | 15 |
| Xiong, S | 1 |
| Wang, T | 25 |
| Lv, Z | 2 |
| Wen, Y | 1 |
| Zou, X | 1 |
| Zhou, G | 4 |
| Cheng, J | 19 |
| Zhong, D | 1 |
| Yu, S | 13 |
| Liu, N | 16 |
| Peng, C | 2 |
| Chen, G | 12 |
| Zheng, S | 9 |
| Huang, H | 7 |
| Liu, R | 5 |
| Huang, S | 6 |
| Jansen, TL | 5 |
| Tanja, G | 1 |
| Matthijs, J | 1 |
| Feng, YZ | 2 |
| Dong, XN | 1 |
| Lin, QT | 2 |
| Chen, PK | 2 |
| Xiong, XQ | 1 |
| DingKun, S | 1 |
| Qian, L | 2 |
| Cheng, ZY | 2 |
| Cai, XR | 2 |
| Bardin, T | 13 |
| Magnat, E | 1 |
| Clerson, P | 2 |
| Richette, P | 15 |
| Rouchon, B | 1 |
| Kojima, S | 8 |
| Uchiyama, K | 5 |
| Yokota, N | 6 |
| Tokutake, E | 5 |
| Wakasa, Y | 5 |
| Hiramitsu, S | 6 |
| Waki, M | 5 |
| Jinnouchi, H | 5 |
| Kakuda, H | 6 |
| Hayashi, T | 7 |
| Kawai, N | 5 |
| Sugawara, M | 6 |
| Mori, H | 6 |
| Tsujita, K | 3 |
| Matsui, K | 6 |
| Hisatome, I | 36 |
| Ohya, Y | 10 |
| Kimura, K | 12 |
| Saito, Y | 8 |
| Ogawa, H | 7 |
| Chen, J | 41 |
| Xu, L | 21 |
| Jiang, L | 12 |
| Wu, Y | 19 |
| Wei, L | 5 |
| Wu, X | 24 |
| Xiao, S | 1 |
| Liu, Y | 73 |
| Gao, C | 5 |
| Cai, J | 4 |
| Su, Z | 9 |
| Zhang, CL | 2 |
| Zhang, JJ | 2 |
| Zhu, QF | 2 |
| Guan, HY | 2 |
| Yang, YX | 2 |
| He, X | 8 |
| Fu, Y | 6 |
| Chen, TX | 1 |
| Dong, L | 4 |
| Yang, XS | 1 |
| Tang, KF | 1 |
| Xu, GB | 2 |
| Liao, SG | 2 |
| Liu, B | 6 |
| Pan, Y | 6 |
| Cao, L | 6 |
| Yang, J | 17 |
| Vargas-Morales, JM | 2 |
| Guevara-Cruz, M | 2 |
| Aradillas-García, C | 2 |
| G Noriega, L | 2 |
| Tovar, A | 2 |
| Alegría-Torres, JA | 2 |
| Dong, J | 1 |
| Hu, Q | 10 |
| You, L | 3 |
| Zheng, F | 2 |
| Su, C | 2 |
| Wang, L | 46 |
| Li, X | 45 |
| Chen, Q | 16 |
| Kou, J | 2 |
| Wang, X | 64 |
| Mei, S | 1 |
| Zhang, B | 27 |
| Liu, X | 34 |
| Xu, G | 4 |
| Molla, NH | 3 |
| Kathak, RR | 3 |
| Sumon, AH | 3 |
| Barman, Z | 1 |
| Mou, AD | 1 |
| Hasan, A | 1 |
| Mahmud, F | 1 |
| Fariha, KA | 1 |
| Ali, N | 3 |
| Wen, S | 3 |
| Arakawa, H | 1 |
| Tamai, I | 4 |
| Shin, D | 2 |
| Lee, KW | 1 |
| Romi, MM | 3 |
| Arefian, N | 1 |
| Wahyu Setyaningsih, WA | 1 |
| Perdana Putri, RG | 1 |
| Juffrie, M | 1 |
| Ratna Sari, DC | 1 |
| Tsukamoto, S | 1 |
| Okami, N | 1 |
| Yamada, T | 5 |
| Azushima, K | 1 |
| Yamaji, T | 1 |
| Kinguchi, S | 1 |
| Uneda, K | 1 |
| Kanaoka, T | 1 |
| Wakui, H | 2 |
| Tamura, K | 4 |
| Borghi, C | 38 |
| Piani, F | 3 |
| Luo, Y | 16 |
| Miao, Q | 1 |
| Cheng, Z | 3 |
| Lv, K | 1 |
| Zhang, D | 15 |
| Yin, C | 3 |
| Bai, Y | 3 |
| Engel, B | 3 |
| Hoffmann, F | 1 |
| Freitag, MH | 1 |
| Jacobs, H | 1 |
| Zheng, T | 2 |
| Hu, X | 10 |
| Li, J | 47 |
| Shi, D | 7 |
| Li, N | 14 |
| Ming, J | 2 |
| Zhu, T | 1 |
| Ye, Z | 7 |
| Shi, C | 3 |
| Guo, Z | 4 |
| Wang, J | 48 |
| Chen, X | 32 |
| Zheng, N | 1 |
| Sung, YY | 3 |
| Kim, DS | 4 |
| Gao, X | 19 |
| Zhang, H | 23 |
| Sarker, MMR | 1 |
| Zhao, C | 9 |
| Halperin Kuhns, VL | 3 |
| Woodward, OM | 5 |
| Lin, G | 3 |
| Yu, Q | 5 |
| Huang, Z | 11 |
| Mai, L | 2 |
| Xie, J | 12 |
| Li, Y | 94 |
| Lin, Z | 9 |
| Bezerra, TTD | 1 |
| Bezerra, LS | 1 |
| Santos-Veloso, MAO | 1 |
| Lordsleem, ABMDS | 1 |
| Lima, SG | 1 |
| Nie, Q | 2 |
| Liu, M | 20 |
| Zhang, Z | 27 |
| Zhang, X | 58 |
| Wang, C | 33 |
| Song, G | 1 |
| Zhang, T | 14 |
| Rayamajhi, S | 1 |
| Meng, G | 5 |
| Zhang, Q | 32 |
| Liu, L | 24 |
| Wu, H | 17 |
| Gu, Y | 9 |
| Zhang, S | 33 |
| Zhang, J | 52 |
| Thapa, A | 1 |
| Sun, S | 8 |
| Zhou, M | 17 |
| Jia, Q | 9 |
| Song, K | 10 |
| Niu, K | 8 |
| Kiyani, MM | 3 |
| Moghul, NB | 2 |
| Javed, A | 1 |
| Butt, MA | 2 |
| Abbas, HB | 1 |
| Rehman, H | 3 |
| Rajput, TA | 2 |
| Bokhari, SAI | 3 |
| Wei, J | 7 |
| Dalbeth, N | 48 |
| Terkeltaub, R | 16 |
| Yang, T | 13 |
| Yang, Z | 14 |
| Wu, Z | 4 |
| Zeng, C | 9 |
| Lei, G | 2 |
| Lai, YJ | 2 |
| Chen, YY | 3 |
| Ku, PW | 1 |
| Chen, LJ | 1 |
| Yen, YF | 1 |
| Ji, H | 11 |
| Song, W | 5 |
| Peng, S | 2 |
| Zhan, S | 4 |
| Qu, Y | 1 |
| Chen, M | 9 |
| Liu, S | 12 |
| Zhuang, J | 2 |
| Zhou, X | 15 |
| Liu, T | 8 |
| Yuan, F | 1 |
| Chen, Y | 61 |
| Bao, R | 3 |
| Li, Z | 35 |
| Wang, D | 20 |
| Wei, X | 4 |
| Fu, B | 4 |
| Chen, W | 13 |
| Wang, Z | 24 |
| Yu, D | 5 |
| Jiang, G | 2 |
| Wang, F | 14 |
| Zhao, X | 16 |
| Su, X | 8 |
| Song, D | 2 |
| Zou, F | 2 |
| Fang, L | 4 |
| Kawazoe, M | 1 |
| Funakoshi, S | 1 |
| Ishida, S | 1 |
| Yoshimura, C | 1 |
| Satoh, A | 2 |
| Maeda, T | 2 |
| Tsuji, M | 1 |
| Yokota, S | 1 |
| Tada, K | 1 |
| Takahashi, K | 3 |
| Ito, K | 3 |
| Yasuno, T | 1 |
| Fujii, H | 1 |
| Okutsu, S | 1 |
| Mukobara, S | 1 |
| Kawanami, D | 1 |
| Nabeshima, S | 1 |
| Kondo, S | 2 |
| Masutani, K | 2 |
| Arima, H | 3 |
| Chen, MM | 1 |
| Meng, LH | 1 |
| Hou, C | 5 |
| Hu, Y | 13 |
| Jiang, H | 5 |
| Xu, Z | 5 |
| Sha, W | 3 |
| Liu, J | 36 |
| Ren, J | 7 |
| Yao, M | 4 |
| Kimura, Y | 1 |
| Tsukui, D | 1 |
| Kono, H | 1 |
| Amakye, WK | 1 |
| Du, J | 7 |
| Cui, Z | 9 |
| Zhao, J | 11 |
| Wang, H | 29 |
| Liu, F | 9 |
| Pa, L | 3 |
| Peng, X | 6 |
| Kashiwagi, T | 1 |
| Sakai, Y | 3 |
| Ding, C | 1 |
| Hu, L | 3 |
| Ruan, Y | 2 |
| Zou, K | 1 |
| Dai, C | 2 |
| Liao, Y | 1 |
| Liao, H | 7 |
| Xia, Y | 3 |
| Zhao, Y | 21 |
| Yang, R | 4 |
| Mori, K | 6 |
| Furuhashi, M | 3 |
| Tanaka, M | 9 |
| Higashiura, Y | 3 |
| Koyama, M | 3 |
| Hanawa, N | 3 |
| Ohnishi, H | 3 |
| Wang, A | 9 |
| Tian, X | 6 |
| Zuo, Y | 4 |
| Chen, S | 28 |
| Mo, D | 2 |
| Wu, S | 18 |
| Si, K | 1 |
| Wei, C | 5 |
| Zhou, Y | 41 |
| Lv, W | 3 |
| Dong, B | 4 |
| Huang, Y | 21 |
| Lin, S | 4 |
| Qiu, M | 1 |
| Sun, M | 5 |
| Su, Y | 1 |
| Li, M | 13 |
| Ma, S | 7 |
| Zhang, A | 4 |
| Cai, S | 1 |
| Cheng, B | 1 |
| Bao, Q | 1 |
| Zhu, P | 5 |
| Koseki, T | 1 |
| Nakajima, K | 2 |
| Iwasaki, H | 1 |
| Yamada, S | 2 |
| Doi, Y | 2 |
| Mizuno, T | 1 |
| Suzuki, S | 4 |
| Yoshihisa, A | 1 |
| Yokokawa, T | 1 |
| Kobayashi, A | 2 |
| Yamaki, T | 2 |
| Kunii, H | 1 |
| Nakazato, K | 1 |
| Tsuda, A | 2 |
| Tsuda, T | 1 |
| Ishibashi, T | 1 |
| Konno, I | 1 |
| Yamaguchi, O | 1 |
| Machii, H | 1 |
| Nozaki, N | 2 |
| Niizeki, T | 2 |
| Miyamoto, T | 1 |
| Takeishi, Y | 2 |
| Choi, HK | 26 |
| McCormick, N | 3 |
| Yokose, C | 4 |
| Honda, M | 4 |
| Horiuchi, H | 4 |
| Torii, T | 2 |
| Nakajima, A | 5 |
| Iijima, T | 2 |
| Murano, H | 2 |
| Yamanaka, H | 11 |
| Ito, S | 3 |
| Gutierrez, M | 3 |
| Sandoval, H | 1 |
| Bertolazzi, C | 1 |
| Soto-Fajardo, C | 1 |
| Tellez-Gastelum, RM | 1 |
| Reginato, AM | 5 |
| Clavijo-Cornejo, D | 1 |
| Shasha-Lavsky, H | 1 |
| Awadia, P | 1 |
| Sheffer, V | 1 |
| Weissman, I | 1 |
| Ye, C | 4 |
| Wang, R | 13 |
| Halimulati, M | 5 |
| Aihemaitijiang, S | 4 |
| Latourte, A | 4 |
| Dumurgier, J | 1 |
| Paquet, C | 1 |
| Guo, Y | 13 |
| Lu, H | 4 |
| Gan, J | 1 |
| Li, D | 16 |
| Gao, J | 9 |
| Zhang, C | 17 |
| Ebrahimi, R | 1 |
| Pasalar, P | 1 |
| Shokri, H | 1 |
| Shabani, M | 1 |
| Emamgholipour, S | 1 |
| Nie, FQ | 1 |
| Huang, XB | 2 |
| Tang, W | 3 |
| Hu, R | 1 |
| Zhang, WQ | 2 |
| Liu, JX | 2 |
| Xu, RH | 3 |
| Wei, D | 2 |
| Wang, TD | 2 |
| Fan, X | 6 |
| Kawada, T | 7 |
| de Mendonça, ELSS | 1 |
| da Silva, JVF | 1 |
| Mello, CS | 1 |
| de Oliveira, ACM | 1 |
| Wen, XY | 1 |
| Tang, XY | 1 |
| He, D | 7 |
| Zhang, HC | 1 |
| Zhang, SH | 1 |
| Zeng, HL | 1 |
| Sansone, A | 1 |
| Reisman, Y | 1 |
| Jannini, EA | 1 |
| Zhao, Z | 11 |
| Kuang, P | 2 |
| Luo, J | 6 |
| Surineni, G | 1 |
| Cen, X | 1 |
| Wu, T | 14 |
| Cao, Y | 7 |
| Zhou, P | 4 |
| Pang, J | 9 |
| Caimi, G | 1 |
| Urso, C | 1 |
| Brucculeri, S | 1 |
| Amato, C | 1 |
| Lo Presti, R | 1 |
| Carlisi, M | 1 |
| Donkeng, M | 1 |
| Kuaté, D | 1 |
| Koudjou, PN | 1 |
| Noubiap, JJ | 1 |
| Kuiate, JR | 1 |
| Sands, E | 1 |
| Kivitz, A | 1 |
| DeHaan, W | 1 |
| Leung, SS | 1 |
| Johnston, L | 1 |
| Kishimoto, TK | 1 |
| Yang, Y | 27 |
| Zhong, Y | 2 |
| Kong, T | 1 |
| Yang, S | 11 |
| Wu, C | 4 |
| Cui, B | 1 |
| Fu, L | 2 |
| Hui, R | 4 |
| Zhang, W | 21 |
| Al Shanableh, Y | 1 |
| Hussein, YY | 1 |
| Saidwali, AH | 1 |
| Al-Mohannadi, M | 1 |
| Aljalham, B | 1 |
| Nurulhoque, H | 1 |
| Robelah, F | 1 |
| Al-Mansoori, A | 1 |
| Zughaier, SM | 1 |
| Chen, WY | 2 |
| Fu, YP | 1 |
| Nishizawa, H | 1 |
| Maeda, N | 1 |
| Shimomura, I | 1 |
| Mahajan, SK | 2 |
| Sharma, R | 2 |
| Singh, B | 2 |
| Zhong, Z | 1 |
| Ma, J | 10 |
| Han, R | 3 |
| Cui, T | 3 |
| Yang, C | 16 |
| Qu, X | 2 |
| Zheng, L | 8 |
| Zu, B | 1 |
| Jia, B | 1 |
| Lin, W | 2 |
| Zhang, TJ | 2 |
| Zhang, ZH | 1 |
| Wang, ZR | 1 |
| Hu, SS | 1 |
| Lu, PF | 1 |
| Guo, S | 1 |
| Meng, FH | 1 |
| Tao, Y | 2 |
| Zhao, F | 4 |
| Liang, R | 4 |
| Shi, X | 6 |
| Ji, J | 2 |
| Zhan, P | 4 |
| Ma, G | 3 |
| Teng, W | 2 |
| He, Z | 2 |
| Zhai, X | 1 |
| Xia, Z | 1 |
| Li, S | 21 |
| Liang, J | 5 |
| Wan, L | 1 |
| Cao, H | 5 |
| Lin, J | 7 |
| Costa, TEM | 1 |
| Lauar, JC | 1 |
| Innecchi, MLR | 1 |
| Coelho, VA | 1 |
| Moysés, RMA | 1 |
| Elias, RM | 1 |
| Jin, Y | 5 |
| Di, X | 1 |
| Fan, L | 1 |
| Yang, X | 28 |
| Yan, L | 2 |
| Gruszka, K | 2 |
| Drożdż, T | 2 |
| Wojciechowska, W | 1 |
| Jankowski, P | 1 |
| Terlecki, M | 2 |
| Bijak, M | 1 |
| Hering, D | 1 |
| Bilo, G | 1 |
| Drożdż, D | 1 |
| Rajzer, M | 2 |
| Abdul Khaliq, SM | 1 |
| Al-Sharifi, AN | 1 |
| Wang, W | 21 |
| Jing, Z | 1 |
| Liu, W | 15 |
| Zhu, L | 10 |
| Ren, H | 2 |
| Hou, X | 9 |
| Shen, J | 3 |
| Li, W | 14 |
| Xu, X | 16 |
| Liu, Z | 14 |
| Ma, Y | 21 |
| Yuan, C | 1 |
| Peeters, IR | 1 |
| Oude Voshaar, AMH | 1 |
| Moses, A | 1 |
| Jansen, TLTA | 2 |
| Flendrie, M | 1 |
| van Herwaarden, N | 1 |
| Janssen, M | 6 |
| Kim, HW | 2 |
| Joo, YS | 1 |
| Yun, HR | 1 |
| Kim, JY | 4 |
| Jhee, JH | 1 |
| Roh, YH | 1 |
| Park, JT | 2 |
| Chang, TI | 2 |
| Yoo, TH | 2 |
| Kang, SW | 2 |
| Han, SH | 1 |
| Cai, M | 3 |
| Dilimulati, D | 1 |
| Sun, H | 12 |
| Cui, R | 5 |
| Fei, H | 2 |
| Zeng, Q | 1 |
| Shao, X | 5 |
| Qu, S | 3 |
| Hu, BY | 1 |
| Zhao, YL | 3 |
| Ma, DY | 1 |
| Xiang, ML | 1 |
| Zhao, LX | 1 |
| Luo, XD | 1 |
| Zhang, K | 6 |
| Tang, L | 3 |
| Jiang, SS | 1 |
| Wang, YF | 1 |
| Meng, Y | 2 |
| Wang, MD | 1 |
| Cui, FQ | 1 |
| Cai, Z | 5 |
| Zhao, WJ | 1 |
| Ruan, F | 2 |
| Hu, W | 3 |
| Ruan, J | 2 |
| Ding, X | 15 |
| Zuo, Z | 3 |
| He, C | 2 |
| Huang, J | 13 |
| Shiina, K | 2 |
| Tomiyama, H | 5 |
| Tanaka, A | 9 |
| Yoshida, H | 8 |
| Eguchi, K | 3 |
| Kario, K | 6 |
| Kato, T | 7 |
| Teragawa, H | 4 |
| Toyoda, S | 4 |
| Ohishi, M | 4 |
| Fukumoto, Y | 2 |
| Takase, B | 2 |
| Ishizu, T | 4 |
| Node, K | 10 |
| Pérez Ruiz, F | 2 |
| Pérez Herrero, N | 1 |
| Gantes Pedraza, MÁ | 1 |
| Zhu, X | 12 |
| Wu, J | 16 |
| Xue, Y | 8 |
| Wan, W | 4 |
| Li, C | 31 |
| Zou, H | 11 |
| Gnemmi, V | 1 |
| Li, Q | 27 |
| Ma, Q | 8 |
| De Chiara, L | 1 |
| Carangelo, G | 1 |
| Molina-Van den Bosch, M | 1 |
| Romagnani, P | 1 |
| Anders, HJ | 2 |
| Steiger, S | 2 |
| Lüscher, BP | 5 |
| Albrecht, C | 2 |
| Stieger, B | 1 |
| Surbek, DV | 5 |
| Baumann, MU | 5 |
| Mikolaitytė, J | 2 |
| Badarienė, J | 4 |
| Puronaitė, R | 1 |
| Čypienė, A | 4 |
| Rutkauskienė, I | 1 |
| Dadonienė, J | 2 |
| Laucevičius, A | 3 |
| Hamada, T | 7 |
| Wakimizu, T | 1 |
| Kato, M | 5 |
| Gotou, T | 1 |
| Koga, A | 1 |
| Endo, Y | 1 |
| Taniguchi, SI | 1 |
| Yamamoto, K | 11 |
| Ninomiya, H | 5 |
| Tsuboi, H | 1 |
| Yamaguchi, M | 1 |
| Yamada, N | 1 |
| Kano, H | 1 |
| Asami, Y | 1 |
| Crawley, WT | 1 |
| Jungels, CG | 1 |
| Stenmark, KR | 1 |
| Fini, MA | 1 |
| Schwotzer, N | 1 |
| Auberson, M | 1 |
| Livio, F | 1 |
| So, A | 6 |
| Bonny, O | 2 |
| Luo, L | 4 |
| Hu, S | 3 |
| Gan, R | 1 |
| Zeng, L | 5 |
| Gao, Y | 18 |
| Yu, Y | 12 |
| Qin, W | 3 |
| Fan, N | 1 |
| Qi, Y | 2 |
| Chen, H | 27 |
| Duan, W | 2 |
| Gao, L | 12 |
| Ren, S | 1 |
| Sun, G | 8 |
| Lin, Y | 8 |
| Wu, B | 2 |
| Kataoka, H | 4 |
| Mochizuki, T | 4 |
| Ohara, M | 1 |
| Tsuruta, Y | 5 |
| Iwasa, N | 1 |
| Yoshida, R | 1 |
| Tsuchiya, K | 4 |
| Nitta, K | 6 |
| Hosoya, T | 40 |
| Ehren, R | 1 |
| Habbig, S | 1 |
| Krupka, K | 1 |
| Ernst, A | 1 |
| Bald, M | 1 |
| König, S | 1 |
| Murer, L | 1 |
| Özçakar, ZB | 1 |
| Pohl, M | 2 |
| Babenko, N | 1 |
| Spartà, G | 2 |
| Staude, H | 1 |
| Dello Strologo, L | 1 |
| Szabó, AJ | 1 |
| Tönshoff, B | 1 |
| Weber, LT | 1 |
| Sun, W | 4 |
| Ji, A | 4 |
| He, Y | 22 |
| Qu, H | 3 |
| Zheng, G | 1 |
| Shi, Y | 16 |
| Fang, X | 2 |
| Merriman, TR | 42 |
| Fan, S | 3 |
| Lu, G | 3 |
| Sun, N | 4 |
| Lu, C | 8 |
| Han, J | 10 |
| Zhou, J | 20 |
| Ming, T | 5 |
| Yan, F | 4 |
| Ji, X | 4 |
| Yin, H | 5 |
| Masulli, M | 3 |
| D'Elia, L | 6 |
| Angeli, F | 3 |
| Barbagallo, CM | 6 |
| Bilancio, G | 1 |
| Bombelli, M | 9 |
| Bruno, B | 2 |
| Casiglia, E | 9 |
| Cianci, R | 2 |
| Cicero, AFG | 13 |
| Cirillo, M | 6 |
| Cirillo, P | 7 |
| Dell'Oro, R | 5 |
| Desideri, G | 13 |
| Ferri, C | 10 |
| Gesualdo, L | 6 |
| Giannattasio, C | 10 |
| Grassi, G | 14 |
| Iaccarino, G | 6 |
| Lippa, L | 5 |
| Mallamaci, F | 10 |
| Maloberti, A | 12 |
| Masi, S | 6 |
| Mazza, A | 7 |
| Mengozzi, A | 4 |
| Muiesan, ML | 7 |
| Nazzaro, P | 6 |
| Palatini, P | 7 |
| Parati, G | 8 |
| Pontremoli, R | 17 |
| Quarti-Trevano, F | 4 |
| Rattazzi, M | 6 |
| Reboldi, G | 3 |
| Rivasi, G | 6 |
| Salvetti, M | 6 |
| Tikhonoff, V | 6 |
| Tocci, G | 6 |
| Ungar, A | 6 |
| Verdecchia, P | 6 |
| Viazzi, F | 15 |
| Virdis, A | 8 |
| Volpe, M | 7 |
| Galletti, F | 6 |
| Kume, S | 1 |
| Yasuda-Yamahara, M | 1 |
| Imamura-Uehara, Y | 1 |
| Kuwagata, S | 1 |
| Yamahara, K | 1 |
| Takeda, N | 2 |
| Chin-Kanasaki, M | 1 |
| Kato, K | 4 |
| Ohno, S | 1 |
| Nakagawa, Y | 1 |
| Maegawa, H | 1 |
| Türker, PF | 1 |
| Hoca, M | 1 |
| Özduran, G | 1 |
| Akçil Ok, M | 1 |
| Demir Çelebi, M | 1 |
| Tao, M | 4 |
| Ma, X | 3 |
| Kahaer, M | 2 |
| Liang, M | 4 |
| Li, R | 14 |
| Tian, T | 4 |
| Hu, C | 6 |
| Sun, Y | 23 |
| Gherghina, ME | 1 |
| Peride, I | 1 |
| Tiglis, M | 1 |
| Neagu, TP | 1 |
| Niculae, A | 1 |
| Checherita, IA | 1 |
| Laučytė-Cibulskienė, A | 1 |
| Smaliukaitė, M | 1 |
| Ryliškytė, L | 3 |
| Peng, L | 4 |
| Ma, N | 1 |
| Nie, C | 1 |
| Tang, X | 3 |
| Hong, F | 2 |
| Hong, X | 3 |
| Xie, M | 3 |
| Dong, Y | 10 |
| Zou, Z | 3 |
| Zheng, C | 2 |
| Reichetzeder, C | 1 |
| Krämer, BK | 2 |
| Lv, Y | 7 |
| Hocher, B | 1 |
| Dong, X | 5 |
| Tu, R | 3 |
| Liao, W | 2 |
| Hou, J | 7 |
| Mao, Z | 6 |
| Lee, HJ | 2 |
| Choi, JY | 2 |
| Lee, J | 6 |
| Kim, D | 1 |
| Min, JY | 2 |
| Min, KB | 2 |
| Yuan, D | 1 |
| Lin, L | 5 |
| Peng, Y | 6 |
| Li, L | 48 |
| Xiao, W | 5 |
| Gong, Z | 2 |
| Shen, C | 3 |
| Xu, C | 11 |
| Chen, T | 5 |
| Chen, L | 15 |
| Mao, D | 1 |
| Song, L | 6 |
| Lian, X | 1 |
| Hilsabeck, TAU | 1 |
| Liu-Bryan, R | 6 |
| Guo, T | 1 |
| Wilson, KA | 1 |
| Bose, N | 1 |
| Raftery, D | 1 |
| Beck, JN | 1 |
| Lang, S | 1 |
| Jin, K | 1 |
| Nelson, CS | 1 |
| Oron, T | 1 |
| Stoller, M | 1 |
| Promislow, D | 1 |
| Brem, RB | 1 |
| Kapahi, P | 1 |
| Lin, X | 7 |
| Schlesinger, N | 10 |
| Brunetti, L | 1 |
| Androulakis, IP | 1 |
| Keller, SF | 1 |
| Mandell, BF | 4 |
| Zhu, Q | 4 |
| Yu, L | 4 |
| Man, Q | 2 |
| Jia, S | 2 |
| Zuo, H | 2 |
| Hamasaki, S | 1 |
| Watarai, M | 1 |
| Ueda, S | 5 |
| Inoue, T | 6 |
| Lee, Y | 3 |
| Kim, N | 1 |
| Werlinger, P | 1 |
| Suh, DA | 1 |
| Lee, H | 3 |
| Cho, JH | 1 |
| Ghamri, RA | 1 |
| Galai, TA | 1 |
| Ismail, RA | 1 |
| Aljuhani, JM | 1 |
| Alotaibi, DS | 1 |
| Aljahdali, MA | 1 |
| Biswal, M | 1 |
| M, B | 1 |
| N, R | 1 |
| T, AK | 1 |
| Kulkarni, A | 1 |
| Subhash, N | 1 |
| G, S | 1 |
| Balaraj, K | 1 |
| Prabhu, R | 1 |
| Mukherjee, T | 1 |
| Sc, R | 1 |
| Maldar, A | 1 |
| Syed, AAS | 1 |
| Fahira, A | 1 |
| Yang, Q | 8 |
| ALRashdi, BM | 1 |
| Elgebaly, HA | 1 |
| Germoush, MO | 1 |
| Qarmush, MM | 1 |
| Azab, MS | 1 |
| Alruhaimi, RS | 1 |
| Ahmeda, AF | 1 |
| Abukhalil, MH | 1 |
| Kamel, EM | 1 |
| Arab, HH | 1 |
| Alzoghaibi, MA | 1 |
| Alotaibi, MF | 1 |
| Mahmoud, AM | 1 |
| Tomomitsu, Y | 1 |
| Asakawa, S | 3 |
| Arai, S | 1 |
| Nagura, M | 1 |
| Ishizawa, K | 2 |
| Yamazaki, O | 1 |
| Tamura, Y | 5 |
| Uchida, S | 10 |
| Ohashi, R | 1 |
| Shibata, S | 5 |
| Fujigaki, Y | 2 |
| Chen, JS | 4 |
| Wang, MX | 3 |
| Wang, MM | 2 |
| Zhang, YK | 2 |
| Guo, X | 18 |
| Zhang, MQ | 2 |
| Sun, JY | 3 |
| Liu, YF | 2 |
| Li, G | 8 |
| Dong, H | 4 |
| Kanbay, M | 17 |
| Xhaard, C | 1 |
| Le Floch, E | 1 |
| Dandine-Roulland, C | 1 |
| Girerd, N | 4 |
| Ferreira, JP | 4 |
| Boivin, JM | 2 |
| Wagner, S | 2 |
| Bacq-Daian, D | 1 |
| Deleuze, JF | 1 |
| Zannad, F | 4 |
| Rossignol, P | 2 |
| Jiang, J | 7 |
| Dai, Q | 2 |
| Kang, Y | 2 |
| Yu, W | 3 |
| Wang, Q | 10 |
| Lv, J | 2 |
| He, F | 8 |
| Chen, B | 6 |
| Yamamoto, T | 25 |
| Koyama, H | 4 |
| Banik, SD | 1 |
| Avila-Nava, A | 1 |
| Lugo, R | 1 |
| Chim Aké, R | 1 |
| Gutiérrez Solis, AL | 1 |
| Yu, H | 10 |
| Chai, S | 1 |
| Chai, X | 1 |
| Geng, WC | 1 |
| Li, JJ | 2 |
| Yue, YX | 1 |
| Guo, DS | 1 |
| Qu, J | 1 |
| Dou, J | 1 |
| Chen, K | 4 |
| Zang, L | 1 |
| Mu, Y | 3 |
| Yang, D | 2 |
| Bai, J | 2 |
| Mubarik, S | 1 |
| Riaz, M | 1 |
| Al Kury, LT | 1 |
| Atzaz, N | 1 |
| Alattar, A | 1 |
| Alshaman, R | 1 |
| Shah, FA | 1 |
| Fritz, J | 1 |
| Brozek, W | 2 |
| Concin, H | 3 |
| Nagel, G | 3 |
| Kerschbaum, J | 1 |
| Lhotta, K | 5 |
| Ulmer, H | 2 |
| Zitt, E | 3 |
| Natsuko, PD | 1 |
| Laura, SC | 1 |
| Denise, CC | 1 |
| Lucio, VR | 1 |
| Carlos, AS | 1 |
| Fausto, SM | 1 |
| Ambar, LM | 1 |
| Copur, S | 1 |
| Demiray, A | 1 |
| Dório, M | 1 |
| Benseñor, IM | 4 |
| Lotufo, P | 1 |
| Santos, IS | 2 |
| Fuller, R | 1 |
| Saag, KG | 10 |
| Becker, MA | 12 |
| White, WB | 1 |
| Whelton, A | 3 |
| Borer, JS | 1 |
| Gorelick, PB | 1 |
| Hunt, B | 7 |
| Castillo, M | 1 |
| Gunawardhana, L | 5 |
| Cui, X | 2 |
| Qiu, Y | 3 |
| He, W | 2 |
| Feng, Y | 12 |
| Yuan, X | 6 |
| Chen, R | 4 |
| Nakahashi, T | 1 |
| Sakata, K | 1 |
| Masuda, J | 1 |
| Kumagai, N | 1 |
| Higuma, T | 1 |
| Ogimoto, A | 1 |
| Tanigawa, T | 2 |
| Hanada, H | 1 |
| Nakamura, M | 5 |
| Takamura, M | 1 |
| Dohi, K | 1 |
| Weisshaar, S | 1 |
| Litschauer, B | 1 |
| Reichardt, B | 1 |
| Gruber, F | 1 |
| Leitner, S | 1 |
| Sibinovic, S | 1 |
| Kossmeier, M | 1 |
| Wolzt, M | 1 |
| Tausche, AK | 8 |
| Rajadhyaksha, A | 1 |
| Sarate, N | 1 |
| Raghorte, N | 1 |
| Ingawale, S | 1 |
| Shu, L | 5 |
| Yang, M | 11 |
| Huddleston, EM | 1 |
| Gaffo, AL | 5 |
| Wu, L | 4 |
| Ma, H | 6 |
| Lin, H | 14 |
| Gu, M | 1 |
| Zhu, Y | 11 |
| Kong, W | 3 |
| Zou, Y | 3 |
| Sandoval-Plata, G | 4 |
| Morgan, K | 4 |
| Abhishek, A | 4 |
| Liu, ZQ | 1 |
| Sun, X | 6 |
| Liu, ZB | 1 |
| Zhang, LL | 1 |
| Wu, CJ | 2 |
| Zhuang, Y | 3 |
| Cai, Q | 3 |
| He, L | 5 |
| Wang, N | 12 |
| Fan, Y | 5 |
| Agnoletti, D | 3 |
| Lurbe, E | 3 |
| Qian, X | 3 |
| Jiang, Y | 11 |
| Lowell, CA | 1 |
| Chen, F | 3 |
| Yuan, L | 4 |
| Xu, T | 8 |
| Han, S | 1 |
| Li, JY | 1 |
| Lee, JI | 1 |
| Lu, CC | 4 |
| Su, YD | 1 |
| Chiu, CT | 1 |
| Chen, SC | 12 |
| Geng, JH | 1 |
| Chen, CH | 5 |
| Wang, CZ | 3 |
| Yang, QL | 1 |
| Sun, B | 6 |
| Lin, ZJ | 6 |
| Chu, MZ | 2 |
| Ding, XL | 1 |
| Li, WJ | 2 |
| Mao, QY | 1 |
| Rao, J | 1 |
| Ye, P | 3 |
| Lu, J | 12 |
| Bo, H | 1 |
| Liu, H | 29 |
| Wei, H | 3 |
| Wu, Q | 7 |
| Yan, Y | 4 |
| Mi, J | 1 |
| Lee, YJ | 7 |
| Lim, YH | 1 |
| Shin, CH | 1 |
| Kim, BN | 1 |
| Kim, JI | 3 |
| Hong, YC | 1 |
| Cho, YM | 1 |
| Lee, YA | 1 |
| Xu, B | 4 |
| Yu, T | 4 |
| Yong, T | 3 |
| Liang, D | 7 |
| Xiao, C | 2 |
| Xie, Y | 8 |
| Huang, L | 7 |
| Hu, H | 5 |
| Andrés, M | 9 |
| Mendieta, L | 1 |
| Argente-Del-Castillo, E | 1 |
| Trigueros, M | 1 |
| Miñano, A | 1 |
| Pascual, E | 11 |
| Van Demark, RE | 1 |
| Brown, J | 1 |
| Hayes, M | 2 |
| Smith, VJS | 1 |
| Yan, J | 2 |
| Orji, OC | 1 |
| López-Domínguez, MB | 1 |
| Guetta-Baranes, T | 1 |
| Valdes, AM | 1 |
| Doherty, M | 4 |
| Hull, SD | 1 |
| Andersen, MW | 1 |
| Bengtsson, J | 1 |
| Skovgaard, N | 1 |
| Backe, MB | 1 |
| Pedersen, ML | 1 |
| Wełnicki, M | 1 |
| Gorczyca-Głowacka, I | 1 |
| Lubas, A | 1 |
| Wójcik, W | 1 |
| Jelonek, O | 1 |
| Maciorowska, M | 1 |
| Uziębło-Życzkowska, B | 1 |
| Wójcik, M | 1 |
| Błaszczyk, R | 1 |
| Rajtar-Salwa, R | 1 |
| Tokarek, T | 1 |
| Bil, J | 1 |
| Wojewódzki, M | 1 |
| Szpotowicz, A | 1 |
| Krzciuk, M | 1 |
| Gawałko, M | 1 |
| Kapłon-Cieślicka, A | 1 |
| Tomaszuk-Kazberuk, A | 1 |
| Szyszkowska, A | 1 |
| Bednarski, J | 1 |
| Bakuła-Ostalska, E | 1 |
| Wożakowska-Kapłon, B | 1 |
| Mamcarz, A | 1 |
| Qian, Y | 1 |
| Kong, YW | 1 |
| Wan, NJ | 1 |
| Yan, YK | 1 |
| Chang, X | 2 |
| Bian, N | 1 |
| An, Y | 3 |
| Leng, S | 1 |
| Wang, G | 7 |
| Khimion, LV | 1 |
| Burianov, OA | 1 |
| Nayshtetik, IM | 1 |
| Rotova, SO | 1 |
| Smiyan, SI | 1 |
| Danyliuk, SV | 1 |
| Trofanchuk, VV | 1 |
| Lin, CY | 3 |
| Chang, YS | 2 |
| Liu, TY | 2 |
| Huang, CM | 3 |
| Chung, CC | 2 |
| Chen, YC | 3 |
| Tsai, FJ | 2 |
| Chang, JG | 2 |
| Chang, SJ | 3 |
| Fukuuchi, T | 3 |
| Itahashi, I | 1 |
| Takayanagi, F | 2 |
| Yamaoka, N | 3 |
| Kaneko, K | 3 |
| Rahman, MM | 2 |
| Kamrul-Hasan, AB | 1 |
| Jasmine, T | 1 |
| Hossain, MS | 1 |
| Saha, PK | 1 |
| Sarker, MA | 1 |
| Wang, CC | 3 |
| Li, YL | 2 |
| Chiu, PY | 1 |
| Chen, C | 7 |
| Chen, HC | 3 |
| Chen, FA | 1 |
| Leung, N | 1 |
| Yip, K | 2 |
| Pillinger, MH | 11 |
| Toprover, M | 2 |
| Doehner, W | 7 |
| Anker, SD | 7 |
| Butler, J | 1 |
| Filippatos, G | 2 |
| Salsali, A | 1 |
| Kaempfer, C | 1 |
| Brueckmann, M | 1 |
| Pocock, SJ | 1 |
| Januzzi, JL | 1 |
| Packer, M | 1 |
| Bazid, HAS | 1 |
| Shoeib, MA | 1 |
| El-Sayed, S | 1 |
| Mostafa, MI | 1 |
| Shoeib, MM | 1 |
| Eldeen, ES | 1 |
| Xue, X | 1 |
| Qi, H | 1 |
| Cui, L | 10 |
| Ran, Z | 1 |
| Klocek, M | 1 |
| Oku, F | 1 |
| Hara, A | 1 |
| Tsujiguchi, H | 1 |
| Suzuki, K | 6 |
| Pham, KO | 1 |
| Suzuki, F | 1 |
| Miyagi, S | 1 |
| Takazawa, C | 1 |
| Sato, K | 3 |
| Yanagisawa, T | 1 |
| Kannon, T | 1 |
| Tajima, A | 1 |
| Nakamura, H | 1 |
| Wu, D | 12 |
| Lai, X | 4 |
| Sun, L | 8 |
| Cao, F | 1 |
| Luo, Q | 3 |
| Qin, L | 4 |
| Fukushima, T | 2 |
| Chubachi, S | 1 |
| Namkoong, H | 1 |
| Otake, S | 1 |
| Nakagawara, K | 1 |
| Tanaka, H | 4 |
| Morita, A | 1 |
| Watase, M | 1 |
| Kusumoto, T | 1 |
| Masaki, K | 1 |
| Kamata, H | 2 |
| Ishii, M | 1 |
| Hasegawa, N | 1 |
| Harada, N | 1 |
| Ueda, T | 12 |
| Ishiguro, T | 1 |
| Arimura, K | 1 |
| Saito, F | 1 |
| Yoshiyama, T | 1 |
| Nakano, Y | 1 |
| Mutoh, Y | 1 |
| Suzuki, Y | 2 |
| Murakami, K | 2 |
| Okada, Y | 2 |
| Koike, R | 2 |
| Kitagawa, Y | 1 |
| Kimura, A | 1 |
| Imoto, S | 1 |
| Miyano, S | 1 |
| Ogawa, S | 1 |
| Kanai, T | 2 |
| Fukunaga, K | 1 |
| Park, EH | 1 |
| Choi, ST | 1 |
| Song, JS | 1 |
| Akari, S | 2 |
| Nakamura, T | 28 |
| Furusawa, K | 1 |
| Miyazaki, Y | 2 |
| Guo, B | 1 |
| Wan, Y | 3 |
| Duoji, Z | 1 |
| Qian, W | 1 |
| Danzhen, W | 1 |
| Meng, Q | 3 |
| Wu, K | 2 |
| Feng, S | 3 |
| Jiang, M | 2 |
| Xiong, H | 5 |
| Chen, N | 7 |
| Han, T | 3 |
| Cao, J | 4 |
| Zuo, D | 2 |
| Lan, X | 2 |
| Jin, X | 1 |
| Weng, Y | 1 |
| Cai, L | 5 |
| Meng, F | 1 |
| Zhou, L | 7 |
| Pang, X | 1 |
| Lu, Z | 3 |
| Lu, Y | 21 |
| Fang, B | 1 |
| Qi, L | 2 |
| Dai, F | 1 |
| Cai, Y | 3 |
| Zhao, Q | 4 |
| Tian, L | 3 |
| Liu, WJ | 1 |
| Galozzi, P | 1 |
| Oliviero, F | 3 |
| Scanu, A | 3 |
| Lorenzin, M | 1 |
| Ortolan, A | 1 |
| Favero, M | 1 |
| Doria, A | 3 |
| Ramonda, R | 3 |
| Lupi, AS | 2 |
| Sumpter, NA | 5 |
| Leask, MP | 2 |
| O'Sullivan, J | 1 |
| Fadason, T | 1 |
| de Los Campos, G | 1 |
| Reynolds, RJ | 8 |
| Vazquez, AI | 3 |
| Guma, M | 1 |
| Dadpey, B | 1 |
| Coras, R | 1 |
| Mikuls, TR | 4 |
| Hamilton, B | 1 |
| Quehenberger, O | 1 |
| Thorisdottir, H | 1 |
| Bittleman, D | 1 |
| Lauro, K | 1 |
| Reilly, SM | 1 |
| Mei, Y | 2 |
| Geng, Z | 1 |
| Lin, Q | 2 |
| Huang, W | 6 |
| Shan, P | 1 |
| Uchino, T | 1 |
| Motoki, N | 1 |
| Uchida, K | 3 |
| Asakura, H | 1 |
| Uno-Eder, K | 1 |
| Nomura, T | 1 |
| Tsukamoto, K | 1 |
| Nian, YL | 1 |
| You, CG | 2 |
| Bao, S | 2 |
| Dai, L | 5 |
| Bian, X | 1 |
| Mehmood, A | 3 |
| Althobaiti, F | 1 |
| Zhao, L | 15 |
| Usman, M | 2 |
| Alharthi, F | 1 |
| Soliman, MM | 2 |
| Shah, AA | 1 |
| Murtaza, MA | 1 |
| Nadeem, M | 2 |
| Ranjha, MMAN | 1 |
| Yao, J | 2 |
| Lin, YP | 4 |
| Lu, QY | 1 |
| Fan, GJ | 1 |
| Pálinkás, M | 1 |
| Szabó, E | 1 |
| Kulin, A | 1 |
| Mózner, O | 1 |
| Rásonyi, R | 1 |
| Juhász, P | 1 |
| Nagy, K | 2 |
| Várady, G | 1 |
| Vörös, D | 1 |
| Zámbó, B | 1 |
| Sarkadi, B | 1 |
| Poór, G | 1 |
| Yue, J | 1 |
| Li, T | 5 |
| Deng, JH | 1 |
| Zhong, GW | 1 |
| Zhang, JX | 1 |
| She, D | 1 |
| Luo, N | 1 |
| Xu, J | 12 |
| Xie, S | 2 |
| Guo, J | 8 |
| Duan, Y | 2 |
| Guo, P | 1 |
| He, J | 2 |
| Niu, Y | 13 |
| Zhang, R | 7 |
| Su, W | 1 |
| Li, MH | 1 |
| Guan, J | 2 |
| Chen, Z | 10 |
| Mo, JX | 1 |
| Wu, KR | 1 |
| Hu, XG | 2 |
| Lan, T | 2 |
| Polito, L | 3 |
| Bortolotti, M | 2 |
| Battelli, MG | 3 |
| Bolognesi, A | 3 |
| Feng, H | 3 |
| Lin, C | 8 |
| Zhuoma, D | 1 |
| Yuan, R | 1 |
| Pu, Z | 1 |
| Zeren, L | 1 |
| Tan, M | 1 |
| Haueisen Sander Diniz, MF | 4 |
| M R Beleigoli, A | 1 |
| Isabel Rodrigues Galvão, A | 1 |
| Weiss Telles, R | 1 |
| Inês Schmidt, M | 1 |
| B Duncan, B | 1 |
| M Benseñor, I | 1 |
| Luiz P Ribeiro, A | 1 |
| Vidigal, PG | 1 |
| Maria Barreto, S | 1 |
| Lin, F | 7 |
| Jiang, Z | 4 |
| Chu, Q | 1 |
| Fu, M | 2 |
| Li, YJ | 1 |
| Chen, LR | 1 |
| Yang, ZL | 2 |
| Wang, P | 9 |
| Jiang, FF | 1 |
| Qian, K | 1 |
| Yin, SJ | 1 |
| He, GH | 1 |
| Ge, H | 2 |
| Li, B | 9 |
| Xu, P | 4 |
| Xu, W | 6 |
| Xiong, T | 2 |
| Lv, G | 2 |
| Zhao, M | 10 |
| Jiang, B | 3 |
| Yu, J | 8 |
| Hao, Q | 1 |
| Hu, Z | 1 |
| Song, C | 2 |
| Xu, Y | 13 |
| Guan, H | 1 |
| Zheng, Y | 3 |
| Diao, X | 1 |
| Xiao, J | 6 |
| Xilifu, D | 1 |
| Tuerxun, Z | 1 |
| Nuermaimaiti, B | 1 |
| Aili, A | 1 |
| Rehemu, N | 1 |
| Roman, YM | 1 |
| Su, HY | 1 |
| An, N | 1 |
| Wu, HL | 1 |
| Guo, XY | 1 |
| Li, ZH | 1 |
| Chen, XC | 1 |
| Zhu, SP | 1 |
| Li, HY | 3 |
| Pan, QJ | 1 |
| Liu, HF | 1 |
| Cheang, C | 1 |
| Law, S | 1 |
| Chan, W | 1 |
| Dong, Z | 6 |
| Pai, HL | 1 |
| Hsieh, SM | 1 |
| Su, YS | 1 |
| Sue, XY | 1 |
| Chang, HH | 2 |
| Lin, DP | 1 |
| Riaño, D | 1 |
| Pečnik, Š | 1 |
| Alonso, JR | 1 |
| Kamišalić, A | 1 |
| Koide, Y | 1 |
| Uchida, D | 1 |
| Matsunaga, K | 1 |
| Ueyama, C | 1 |
| Kobayashi, Y | 3 |
| Xu, Q | 5 |
| Luo, W | 1 |
| Zheng, Q | 2 |
| Huang, Q | 4 |
| Yan, C | 3 |
| Guan, X | 1 |
| Meng, H | 3 |
| He, M | 5 |
| Guo, H | 5 |
| Meremo, A | 1 |
| Paget, G | 1 |
| Duarte, R | 1 |
| Dickens, C | 1 |
| Dix-Peek, T | 1 |
| Bintabara, D | 1 |
| Naicker, S | 1 |
| Ghosh, P | 1 |
| Ganguly, S | 1 |
| Mukherjee, SK | 1 |
| Dutta, S | 1 |
| Shaikh, AR | 1 |
| Ali, SS | 1 |
| Singh, NK | 1 |
| Bhattacharya, P | 1 |
| Koley, M | 2 |
| Saha, S | 2 |
| Qu, C | 1 |
| Yi, X | 2 |
| Zeng, H | 4 |
| Jiang, X | 4 |
| Deng, Y | 4 |
| Sun, F | 3 |
| Lin, P | 1 |
| Chen, JH | 7 |
| Tsai, CC | 1 |
| Liu, YH | 5 |
| Wu, PY | 3 |
| Huang, JC | 3 |
| Chung, TL | 1 |
| Su, HM | 8 |
| Johnson, RJ | 64 |
| Xi, Y | 1 |
| Cao, TN | 1 |
| Huynh, KN | 1 |
| Tran, HT | 1 |
| Nguyen, MD | 1 |
| Ai, G | 1 |
| Huang, R | 1 |
| Zhong, L | 4 |
| Qin, Z | 1 |
| Dou, Y | 2 |
| Rubín-García, M | 1 |
| Vitelli-Storelli, F | 1 |
| Álvarez-Álvarez, L | 1 |
| Martínez-González, MÁ | 4 |
| Salas-Salvadó, J | 4 |
| Corella, D | 4 |
| Hernáez, Á | 1 |
| Martínez, JA | 3 |
| Alonso-Gómez, ÁM | 3 |
| Wärnberg, J | 4 |
| Vioque, J | 3 |
| Romaguera, D | 3 |
| López-Miranda, J | 3 |
| Estruch, R | 4 |
| Tinahones, FJ | 3 |
| Serra-Majem, LI | 1 |
| Cano-Ibañez, N | 2 |
| Tur, JA | 3 |
| Marcos-Delgado, A | 1 |
| Tresserra-Rimbau, A | 1 |
| Pintó, X | 3 |
| Delgado-Rodríguez, M | 1 |
| Matía-Martín, P | 3 |
| Vidal, J | 3 |
| Vázquez, C | 3 |
| Daimiel, L | 3 |
| Ros, E | 4 |
| Vázquez-Ruiz, Z | 1 |
| Babio, N | 4 |
| Barragán, R | 2 |
| Castañer-Niño, O | 1 |
| Razquin, C | 2 |
| Tojal-Sierra, L | 1 |
| Gómez-Gracia, E | 1 |
| González-Palacios, S | 1 |
| Morey, M | 3 |
| García-Rios, A | 1 |
| Castro-Barquero, S | 1 |
| Bernal-López, MR | 2 |
| Santos-Lozano, JM | 3 |
| Ruiz-Canela, M | 3 |
| Castro-Salomó, A | 1 |
| Pascual-Castelló, EC | 1 |
| Moldon, V | 1 |
| Bullón-Vela, V | 1 |
| Sorto-Sanchez, C | 1 |
| Cenoz-Osinaga, JC | 1 |
| Gutiérrez, L | 1 |
| Mengual, M | 1 |
| Lamuela-Raventós, RM | 1 |
| Martín-Sánchez, V | 2 |
| He, Q | 3 |
| Yang, K | 2 |
| Xiang, W | 2 |
| Gao, S | 5 |
| Qi, D | 1 |
| Kurra, V | 4 |
| Eräranta, A | 4 |
| Paavonen, T | 1 |
| Honkanen, T | 1 |
| Myllymäki, J | 2 |
| Riutta, A | 2 |
| Tikkanen, I | 2 |
| Lakkisto, P | 2 |
| Mustonen, J | 3 |
| Pörsti, I | 3 |
| Balestracci, A | 1 |
| Meni Battaglia, L | 1 |
| Toledo, I | 1 |
| Beaudoin, L | 1 |
| Martin, SM | 1 |
| Grisolía, NA | 1 |
| Hogg, RJ | 2 |
| Mass, BB | 1 |
| Talevi, V | 1 |
| Hou, R | 1 |
| North, KE | 2 |
| Voruganti, VS | 3 |
| Bai, B | 1 |
| Cui, Y | 8 |
| Xiong, W | 3 |
| Genovesi, S | 3 |
| Tassistro, E | 2 |
| Giussani, M | 3 |
| Lieti, G | 1 |
| Patti, I | 1 |
| Orlando, A | 2 |
| Montemerlo, M | 1 |
| Antolini, L | 2 |
| Zhu, J | 9 |
| Gao, K | 1 |
| Chen, ZX | 3 |
| Liu, HQ | 1 |
| Wu, ZH | 1 |
| He, JL | 1 |
| Zhong, HJ | 1 |
| Shan, B | 2 |
| Wu, M | 3 |
| Li, P | 9 |
| Yazdi, F | 2 |
| Shakibi, MR | 1 |
| Baniasad, A | 1 |
| Najafzadeh, MJ | 1 |
| Najafipour, H | 1 |
| Sistani, S | 1 |
| Shui, G | 1 |
| Mi, X | 1 |
| Zhou, S | 5 |
| Sun, R | 3 |
| Aoki, Y | 2 |
| Sofue, T | 3 |
| Kawakami, R | 1 |
| Ozaki, T | 1 |
| Manabe, M | 1 |
| Kanda, K | 1 |
| Yoda, T | 1 |
| Kusaka, T | 1 |
| Hirao, T | 1 |
| Minamino, T | 1 |
| Eliseev, MS | 3 |
| Panevin, TS | 1 |
| Zhelyabina, OV | 1 |
| Nasonov, EL | 2 |
| Nasonova, SN | 1 |
| Lapteva, AE | 1 |
| Zhirov, IV | 1 |
| Mindzaev, DR | 1 |
| Tereshchenko, SN | 1 |
| Šebeková, K | 1 |
| Gurecká, R | 1 |
| Repiská, G | 1 |
| Koborová, I | 1 |
| Podracká, Ľ | 1 |
| Sun, Z | 7 |
| Tan, Y | 3 |
| Dong, M | 1 |
| Su, H | 4 |
| Xie, D | 6 |
| Shen, Y | 5 |
| Su, E | 1 |
| Du, L | 2 |
| Seong, JM | 1 |
| Gi, MY | 2 |
| Cha, JA | 2 |
| Sung, HH | 3 |
| Park, SY | 3 |
| Park, CH | 2 |
| Yoon, H | 6 |
| Gong, S | 7 |
| Yao, S | 1 |
| Ge, W | 1 |
| Lee, WH | 2 |
| Jin, T | 2 |
| Qin, N | 3 |
| Xia, X | 5 |
| Dai, X | 6 |
| Ni, Y | 4 |
| Yang, N | 5 |
| Cao, B | 3 |
| Fajardo, VC | 3 |
| Barreto, SM | 5 |
| Coelho, CG | 3 |
| Bisi Molina, MDC | 3 |
| Pinho Ribeiro, AL | 3 |
| Telles, RW | 3 |
| Yu, P | 7 |
| Xie, H | 4 |
| Shen, L | 6 |
| Zou, YW | 3 |
| Li, QH | 3 |
| Zhu, YY | 3 |
| Gao, JW | 3 |
| Lin, JZ | 3 |
| Zheng, HW | 3 |
| Mo, YQ | 3 |
| Ma, JD | 3 |
| Li, K | 8 |
| Wu, G | 5 |
| Zheng, X | 11 |
| Zheng, J | 9 |
| Lu, X | 7 |
| Wu, F | 4 |
| Sun, C | 6 |
| Schoeberlein, A | 3 |
| Chien, CY | 3 |
| Chien, YJ | 3 |
| Lin, YH | 8 |
| Chan, ST | 3 |
| Hu, WC | 3 |
| Wu, HF | 3 |
| Chiang, CF | 3 |
| Hsu, CL | 4 |
| Piao, W | 3 |
| Bo, YC | 3 |
| Zhao, LY | 3 |
| Yu, DM | 3 |
| Zhao, W | 6 |
| Seo, HY | 3 |
| Mun, CY | 3 |
| Park, CY | 3 |
| Bin Choi, S | 3 |
| Hwang, JH | 4 |
| Lee, JH | 9 |
| Elsaid, K | 3 |
| Rossitto, LA | 3 |
| Karsh, J | 3 |
| Phipps-Green, A | 13 |
| Jay, GD | 3 |
| Elsayed, S | 3 |
| Qadri, M | 3 |
| Miner, M | 3 |
| Cadzow, M | 14 |
| Dambruoso, TJ | 3 |
| Schmidt, TA | 3 |
| Chhana, A | 4 |
| Höglund, J | 3 |
| Ghassemian, M | 3 |
| Campeau, A | 3 |
| Maltez, N | 3 |
| Karlsson, NG | 3 |
| Gonzalez, DJ | 3 |
| Cao, P | 3 |
| Xiao, Z | 4 |
| Ruan, Z | 3 |
| Gou, X | 3 |
| Shang, M | 2 |
| Liang, H | 3 |
| Yin, X | 6 |
| Yao, R | 2 |
| Yang, B | 7 |
| Cui, J | 5 |
| Luo, X | 4 |
| Yuan, J | 6 |
| Chang, Z | 2 |
| Wang, B | 14 |
| Tu, Y | 3 |
| He, P | 3 |
| Zhang, G | 10 |
| Xing, Y | 5 |
| Shi, S | 3 |
| Naganuma, J | 1 |
| Sakuma, M | 1 |
| Kitahara, K | 1 |
| Yokomachi, J | 1 |
| Yamauchi, F | 1 |
| Inoue, R | 1 |
| Iida, K | 1 |
| Kohno, Y | 1 |
| Inoue, K | 4 |
| Koshiji, N | 1 |
| Abe, S | 1 |
| Ferro, Y | 1 |
| Maurotti, S | 1 |
| Mazza, E | 1 |
| Pujia, R | 1 |
| Sciacqua, A | 2 |
| Musolino, V | 1 |
| Mollace, V | 2 |
| Pujia, A | 1 |
| Montalcini, T | 1 |
| Ren, Z | 2 |
| Vanoli, J | 1 |
| Finotto, A | 1 |
| Facchetti, R | 5 |
| Redon, P | 2 |
| Mancia, G | 7 |
| Geng, Y | 1 |
| Ping, Z | 1 |
| Shang, Y | 2 |
| Kuwabara, M | 16 |
| Gu, J | 9 |
| Yue, H | 1 |
| Song, X | 3 |
| Liu, D | 8 |
| Yi, S | 1 |
| Ni, X | 1 |
| Yang, P | 2 |
| Peng, J | 1 |
| Dramou, P | 1 |
| Li, QQ | 2 |
| Gong, LL | 1 |
| Liang, RX | 1 |
| Yin, XJ | 1 |
| Wang, K | 3 |
| Du, Y | 3 |
| Guan, C | 1 |
| Kunitskaya, NA | 1 |
| Ariev, AL | 1 |
| da Silva-Júnior, EF | 1 |
| Xu, S | 5 |
| Nie, L | 1 |
| Shavandi, A | 1 |
| Yunusov, KE | 1 |
| Aharodnikau, UE | 1 |
| Solomevich, SO | 1 |
| Yang, YS | 1 |
| Jiao, QC | 1 |
| Qin, P | 2 |
| You, C | 1 |
| Tu, C | 2 |
| Ohashi, Y | 1 |
| Toyoda, M | 1 |
| Saito, N | 1 |
| Koizumi, M | 2 |
| Kanai, G | 1 |
| Komaba, H | 2 |
| Kimura, M | 1 |
| Wada, T | 4 |
| Takahashi, H | 5 |
| Takahashi, Y | 3 |
| Ishida, N | 1 |
| Kakuta, T | 1 |
| Fukagawa, M | 2 |
| Ichida, K | 27 |
| Nakagawa, T | 20 |
| Kang, DH | 24 |
| Min, J | 2 |
| Shin, S | 1 |
| Chang, JM | 3 |
| Wei, B | 2 |
| Ren, P | 1 |
| Tang, Q | 2 |
| Xue, C | 2 |
| Miao, Y | 1 |
| Zhai, H | 2 |
| Wang, JC | 1 |
| Tsai, SH | 1 |
| Tsai, HY | 1 |
| Lin, SJ | 3 |
| Huang, PH | 3 |
| Amatjan, M | 1 |
| Mai, X | 1 |
| Jiang, Q | 2 |
| Osonoi, T | 1 |
| Saito, M | 3 |
| Hosoya, M | 4 |
| Douguchi, S | 1 |
| Ofuchi, K | 1 |
| Katoh, M | 1 |
| Ejaz, AA | 7 |
| Mohandas, R | 2 |
| Beaver, TM | 3 |
| Wen, YF | 1 |
| Culhane-Pera, KA | 1 |
| Pergament, SL | 1 |
| Moua, Y | 1 |
| Vue, B | 1 |
| Lo, M | 2 |
| Knights, D | 1 |
| Straka, RJ | 1 |
| Yang, YC | 5 |
| Duobujie, J | 1 |
| Liu, XX | 1 |
| Wu, YB | 1 |
| Meng, J | 6 |
| Yang, YF | 1 |
| Chrysant, SG | 1 |
| Gu, C | 2 |
| Zhao, D | 11 |
| Mandal, AK | 3 |
| Mount, DB | 8 |
| Chou, H | 1 |
| Wei, M | 2 |
| Shi, L | 8 |
| Duan, J | 1 |
| Kohagura, K | 6 |
| Song, R | 1 |
| Hua, Y | 1 |
| Ma, Z | 4 |
| Du, H | 4 |
| Dou, F | 1 |
| Quan, P | 1 |
| Gimžauskaitė, S | 2 |
| Rinkūnienė, E | 2 |
| Jasiūnas, E | 2 |
| Rugienė, R | 1 |
| Kazėnaitė, E | 1 |
| Kamianowska, M | 1 |
| Kamianowska, A | 1 |
| Wasilewska, A | 7 |
| Georgoulis, M | 1 |
| Mikhailidis, DP | 8 |
| Panagiotakos, DB | 2 |
| Dang, W | 1 |
| Xu, D | 5 |
| Lubawy, M | 1 |
| Formanowicz, D | 1 |
| Zhu, W | 4 |
| Klück, V | 2 |
| Cabău, G | 2 |
| Mies, L | 1 |
| Bukkems, F | 1 |
| van Emst, L | 1 |
| Bakker, R | 1 |
| van Caam, A | 1 |
| Crişan, TO | 5 |
| Joosten, LAB | 5 |
| Wang, SH | 1 |
| Zhu, HJ | 1 |
| Duan, L | 3 |
| Ping, F | 1 |
| Chi, Y | 1 |
| Yuan, T | 1 |
| Teramura, S | 1 |
| Yamagishi, K | 2 |
| Umesawa, M | 1 |
| Hayama-Terada, M | 1 |
| Muraki, I | 1 |
| Maruyama, K | 1 |
| Kishida, R | 1 |
| Kihara, T | 1 |
| Takada, M | 1 |
| Ohira, T | 3 |
| Imano, H | 1 |
| Shimizu, Y | 1 |
| Sankai, T | 1 |
| Okada, T | 1 |
| Kitamura, A | 2 |
| Kiyama, M | 1 |
| Iso, H | 3 |
| Tsukamoto, SI | 1 |
| Tu, YC | 1 |
| Lane, NE | 1 |
| Lyu, H | 1 |
| Tian, Z | 3 |
| Pan, H | 3 |
| Guan, M | 3 |
| Tong, X | 2 |
| Tao, L | 5 |
| Lin, CT | 2 |
| Chen, IC | 1 |
| Chen, YJ | 1 |
| Lin, YC | 1 |
| Chang, JC | 1 |
| Wang, TJ | 1 |
| Huang, WN | 1 |
| Chen, YH | 3 |
| Lin, CH | 3 |
| Chen, YM | 5 |
| Ye, LW | 2 |
| Mei, ZS | 1 |
| Zhou, YH | 1 |
| Xiang, H | 1 |
| Deng, Q | 3 |
| Fu, W | 1 |
| Yu, Z | 3 |
| Mei, Z | 1 |
| Lu, T | 1 |
| Zheng, Z | 3 |
| Hu, J | 5 |
| Sesti, G | 2 |
| Zong, W | 1 |
| Fujii, Y | 1 |
| Nomura, S | 3 |
| Kadokami, T | 2 |
| Koide, H | 2 |
| Sano, H | 1 |
| Bando, YK | 2 |
| Murohara, T | 3 |
| Long, T | 1 |
| Wen, J | 5 |
| Mao, Y | 1 |
| Qi, Z | 2 |
| Yip, RM | 1 |
| Cheung, TT | 1 |
| So, H | 1 |
| Chan, JP | 1 |
| Ho, CT | 2 |
| Tsang, HH | 1 |
| Yu, CK | 1 |
| Wong, PC | 1 |
| Tanner, RM | 1 |
| Chaudary, N | 1 |
| Colantonio, LD | 2 |
| Bridges, SL | 4 |
| Cushman, M | 2 |
| Saag, K | 1 |
| Limdi, N | 1 |
| Muntner, P | 3 |
| Howard, G | 2 |
| Irvin, MR | 3 |
| Mohamad, R | 1 |
| Cakir, AD | 1 |
| Ada, Hİ | 1 |
| Uçar, A | 1 |
| Zhan, H | 1 |
| Oncel Yoruk, E | 1 |
| Dost, FS | 1 |
| Ontan, MS | 1 |
| Ates Bulut, E | 1 |
| Aydin, AE | 1 |
| Isik, AT | 2 |
| Kiernan, MS | 1 |
| Konstam, MA | 1 |
| Xu, R | 5 |
| Du, X | 3 |
| Salari, M | 1 |
| Yaghoubi, MA | 1 |
| Miri, M | 1 |
| Mehrad-Majd, H | 1 |
| Hami, M | 2 |
| Bao, D | 1 |
| Lv, N | 1 |
| Duan, X | 2 |
| Zhao, MH | 1 |
| Kodama, T | 1 |
| Ae, R | 1 |
| Andres-Hernando, A | 2 |
| Lanaspa, MA | 13 |
| Shi, H | 4 |
| Yin, J | 3 |
| Sukhorukov, V | 2 |
| Orekhov, AN | 2 |
| Tran, L | 1 |
| Das, S | 1 |
| Finn, MG | 1 |
| Gaucher, EA | 2 |
| Lai, SW | 3 |
| Liao, KF | 3 |
| Kuo, YH | 4 |
| Hwang, BF | 1 |
| Liu, CS | 2 |
| Yang, L | 9 |
| Luo, C | 3 |
| Dai, R | 1 |
| Yu, F | 3 |
| Timsans, J | 1 |
| Kauppi, JE | 1 |
| Kerola, AM | 1 |
| Lehto, TM | 1 |
| Kautiainen, H | 1 |
| Kauppi, MJ | 2 |
| Xie, R | 2 |
| Fang, J | 4 |
| Oprea, TE | 1 |
| Barbu, CG | 1 |
| Martin, SC | 1 |
| Sarbu, AE | 1 |
| Calapod, RI | 1 |
| Nistor, IM | 1 |
| Fica, SV | 1 |
| Jiang, YX | 1 |
| Gong, CL | 1 |
| Tang, Y | 7 |
| Yi, Y | 1 |
| Liu, FG | 1 |
| Zhou, JW | 1 |
| Shi, YL | 1 |
| Zhou, HW | 1 |
| Xie, KQ | 1 |
| Park, SM | 1 |
| Tong, Y | 3 |
| Wei, Y | 7 |
| Ju, Y | 1 |
| Kawakami, Y | 1 |
| Kondo, R | 1 |
| Onishi, M | 1 |
| Akiyama, M | 2 |
| Asai, T | 1 |
| Arai, H | 1 |
| Shen, S | 2 |
| Mironova, OI | 1 |
| Tang, GY | 1 |
| Xu, XY | 2 |
| Shu, P | 2 |
| Kim, JS | 2 |
| Jiao, Z | 3 |
| Guo, XL | 2 |
| Gao, YY | 1 |
| Zou, SH | 1 |
| Wei, MC | 1 |
| Kang, SH | 2 |
| Kim, BY | 1 |
| Son, EJ | 1 |
| Kim, GO | 1 |
| Do, JY | 1 |
| Ding, R | 3 |
| Liu, K | 5 |
| Jiang, F | 3 |
| Peng, Q | 1 |
| Shimizu, M | 1 |
| Kasai, T | 3 |
| Naito, R | 1 |
| Sato, A | 1 |
| Ishiwata, S | 1 |
| Yatsu, S | 1 |
| Shitara, J | 1 |
| Matsumoto, H | 1 |
| Murata, A | 1 |
| Suda, S | 1 |
| Hiki, M | 1 |
| Murase, T | 6 |
| Daida, H | 1 |
| Karyadi, B | 1 |
| Adika, AR | 1 |
| Melani, NAA | 1 |
| Parlindungan, D | 1 |
| Nursaadah, E | 1 |
| Ruyani, A | 1 |
| Han, C | 1 |
| Huang, C | 6 |
| Zhong, H | 3 |
| Holbrook, HS | 1 |
| Calandruccio, JH | 1 |
| Luo, H | 3 |
| Lei, W | 2 |
| Hong, P | 1 |
| Nie, K | 1 |
| Wan, J | 1 |
| Hua, L | 1 |
| Zhu, B | 1 |
| Cao, M | 2 |
| Guo, W | 3 |
| Bao, Z | 1 |
| Ke, J | 1 |
| Han, Z | 3 |
| Sun, KX | 1 |
| Feng, CY | 1 |
| Barreira, JCM | 1 |
| Prieto, MA | 1 |
| Zhang, JD | 1 |
| Li, NY | 1 |
| Kochi, M | 3 |
| Zamami, R | 2 |
| Tana, T | 3 |
| Kinjyo, K | 1 |
| Funakoshi, R | 1 |
| Yamazato, M | 3 |
| Ishida, A | 2 |
| Sakima, A | 4 |
| Iseki, K | 10 |
| Bao, K | 1 |
| Zhu, C | 10 |
| Niu, H | 1 |
| Bian, M | 2 |
| Singh, SK | 2 |
| Singh, R | 1 |
| Paul, R | 1 |
| Sarkar, R | 1 |
| Wu, R | 1 |
| Guan, G | 1 |
| Cui, Q | 2 |
| Imasuen, UJ | 1 |
| Swanson, KJ | 1 |
| Parajuli, S | 1 |
| Han, Y | 6 |
| Han, X | 3 |
| Di, H | 1 |
| Yin, Y | 3 |
| Zeng, X | 3 |
| Taguchi, I | 3 |
| Hisauchi, I | 1 |
| Shimabukuro, M | 2 |
| Hongo, H | 1 |
| Ishikawa, T | 4 |
| Yagi, S | 1 |
| Sata, M | 4 |
| Ji, L | 3 |
| Gao, R | 3 |
| Ni, Z | 2 |
| Cui, H | 1 |
| Zong, M | 1 |
| Van Bockstaele, F | 1 |
| Lou, W | 1 |
| He, B | 1 |
| Liu, P | 4 |
| An, J | 2 |
| Xue, M | 1 |
| Yan, H | 2 |
| Qiu, X | 1 |
| Tian, Y | 5 |
| Ke, S | 1 |
| Jarman, JB | 1 |
| Low, YS | 1 |
| Augustijn, HE | 1 |
| DeFeo, ME | 1 |
| Sekiba, K | 1 |
| Hou, BH | 1 |
| Meng, X | 3 |
| Weakley, AM | 1 |
| Cabrera, AV | 1 |
| van Wezel, G | 1 |
| Medema, MH | 1 |
| Ganesan, C | 1 |
| Pao, AC | 1 |
| Gombar, S | 1 |
| Dodd, D | 1 |
| Liu, HB | 1 |
| Luo, T | 4 |
| Huang, XY | 2 |
| Zhang, YL | 2 |
| Dong, JF | 2 |
| Yan, WJ | 1 |
| Feng, XX | 1 |
| Li, LS | 2 |
| Cheng, W | 3 |
| Sun, CS | 1 |
| Li, CR | 1 |
| Deng, H | 2 |
| Cheng, N | 1 |
| Hou, Z | 1 |
| Fu, T | 1 |
| Su, SY | 1 |
| Lin, TH | 3 |
| Ma, C | 2 |
| Fu, H | 1 |
| Wan, G | 1 |
| Yang, G | 3 |
| Yuan, S | 3 |
| Yuan, M | 1 |
| Mikagi, M | 1 |
| Tashiro, K | 1 |
| Komaki, T | 1 |
| Shiga, Y | 1 |
| Tachibana, T | 1 |
| Higashi, S | 1 |
| Kawahira, Y | 1 |
| Suematsu, Y | 1 |
| Ideishi, A | 1 |
| Ogawa, M | 1 |
| Miura, SI | 1 |
| Nata, N | 2 |
| Ninwisut, N | 1 |
| Inkong, P | 1 |
| Supasyndh, O | 4 |
| Satirapoj, B | 4 |
| Ke, X | 1 |
| Lan, L | 3 |
| Ren, W | 8 |
| Jia, Y | 1 |
| Qiu, T | 2 |
| Hu, M | 3 |
| Zheng, A | 2 |
| Zhao, S | 5 |
| Qin, SY | 1 |
| Lan, RY | 1 |
| Zeng, J | 3 |
| Bai, X | 1 |
| Wang, JT | 1 |
| Yin, XL | 1 |
| Qu, RJ | 1 |
| Qu, MH | 1 |
| Li, WL | 1 |
| Pei, SY | 1 |
| Hou, ZL | 1 |
| Guan, BS | 1 |
| Qiu, HB | 1 |
| Han, F | 2 |
| Hu, F | 2 |
| Pérez-Ruiz, F | 19 |
| Lioté, F | 9 |
| Xie, B | 1 |
| Lai, Y | 1 |
| Sosnik, A | 1 |
| Boucetta, H | 1 |
| Castilla-Ojo, N | 1 |
| Turkson-Ocran, RA | 1 |
| Conlin, PR | 1 |
| Appel, LJ | 5 |
| Miller, ER | 7 |
| Juraschek, SP | 7 |
| Wan, X | 2 |
| Luo, G | 2 |
| Gherbesi, E | 1 |
| Faggiano, A | 1 |
| Sala, C | 2 |
| Carugo, S | 1 |
| Tadic, M | 1 |
| Cuspidi, C | 2 |
| Lu, W | 5 |
| Sheng, J | 4 |
| Wani, SK | 1 |
| Bhat, MDA | 1 |
| Malik, R | 1 |
| Wakabayashi, D | 1 |
| Kato, S | 5 |
| Yamakage, H | 1 |
| Kato, H | 3 |
| Kusakabe, T | 1 |
| Ozu, N | 1 |
| Kasama, S | 1 |
| Kasahara, M | 3 |
| Satoh-Asahara, N | 1 |
| Meng, R | 1 |
| Lian, F | 1 |
| Jiang, C | 4 |
| Lu, M | 1 |
| Mo, F | 1 |
| Russo, E | 4 |
| Agabiti Rosei, E | 2 |
| Bernardino, B | 3 |
| Cappelli, F | 1 |
| Ciccarelli, M | 1 |
| Pauletto, P | 3 |
| Pugliese, NR | 1 |
| Li, ZL | 4 |
| Wang, SM | 1 |
| Hang, Y | 1 |
| Zou, L | 1 |
| Rong, S | 2 |
| Kong, B | 1 |
| Xiong, J | 2 |
| Yao, P | 1 |
| Zhang, WZ | 1 |
| Luan, H | 2 |
| Xiao, Y | 2 |
| Miao, Z | 5 |
| Xing, W | 3 |
| Ye, H | 2 |
| Si, Y | 1 |
| Andres Cerezo, L | 1 |
| Navrátilová, A | 1 |
| Hulejová, H | 2 |
| Pavlíková, M | 4 |
| Závada, J | 4 |
| Pavelka, K | 3 |
| Šenolt, L | 1 |
| Stiburkova, B | 6 |
| Yamaguchi, A | 2 |
| Mukai, Y | 1 |
| Sakuma, T | 1 |
| Suganuma, Y | 1 |
| Furugen, A | 1 |
| Narumi, K | 2 |
| Kobayashi, M | 3 |
| Mizuta, E | 5 |
| Ouchi, M | 3 |
| Kurajoh, M | 2 |
| Maruhashi, T | 2 |
| Morikawa, N | 1 |
| Nishimiya, K | 1 |
| Akashi, N | 1 |
| Tanaka, Y | 2 |
| Otani, N | 3 |
| Morita, M | 1 |
| Miyata, H | 3 |
| Tsutani, H | 4 |
| Ogino, K | 7 |
| Abe, K | 3 |
| Yu, LL | 1 |
| Li, CN | 1 |
| Fang, MY | 1 |
| Lin, FP | 1 |
| Liu, WH | 1 |
| Tu, SH | 1 |
| Xie, WX | 1 |
| Zhang, RY | 1 |
| Zheng, CH | 1 |
| Qin, M | 1 |
| Li, ZW | 1 |
| Liu, XR | 2 |
| Liu, XY | 2 |
| Lv, Q | 3 |
| Shu, XP | 1 |
| Zeng, MH | 1 |
| Peng, D | 2 |
| Zhang, P | 4 |
| Felten, R | 2 |
| Widawski, L | 1 |
| Spielmann, L | 2 |
| Gaillez, C | 1 |
| Bao, W | 4 |
| Gottenberg, JE | 2 |
| Duret, PM | 2 |
| Messer, L | 2 |
| Shin, HJ | 1 |
| Yoon, JY | 1 |
| Na, YO | 1 |
| Lee, JK | 2 |
| Kho, BG | 1 |
| Kim, TO | 1 |
| Kim, YI | 1 |
| Lim, SC | 1 |
| Jeong, SH | 1 |
| Kwon, YS | 1 |
| Bian, W | 2 |
| Ru, Z | 1 |
| Fu, Z | 2 |
| Pang, TT | 1 |
| Zhou, ZX | 1 |
| Li, PS | 1 |
| Ma, HT | 1 |
| Shen, XY | 1 |
| Wan, YC | 1 |
| Liu, ZP | 1 |
| Chen, GD | 1 |
| Ba, DM | 1 |
| Nishita, Y | 1 |
| Tange, C | 1 |
| Muscat, J | 1 |
| Otsuka, R | 1 |
| Shui, X | 1 |
| Sánchez-Bacaicoa, C | 1 |
| Santano-Mogena, E | 1 |
| Rico-Martín, S | 1 |
| Rey-Sánchez, P | 1 |
| Juárez-Vela, R | 1 |
| Sánchez Muñoz-Torrero, JF | 1 |
| López-Espuela, F | 1 |
| Calderón-García, JF | 1 |
| Kvasnička, A | 1 |
| Friedecký, D | 1 |
| Brumarová, R | 1 |
| Pavelcová, K | 2 |
| Mašínová, J | 1 |
| Hasíková, L | 2 |
| Ješina, P | 1 |
| Ouyang, J | 1 |
| Lin, D | 1 |
| Quan, H | 2 |
| Fu, X | 4 |
| Mao, W | 1 |
| Jang, TY | 2 |
| Huang, CI | 2 |
| Yeh, ML | 2 |
| Liang, PC | 1 |
| Tsai, PC | 1 |
| Hsieh, MY | 2 |
| Hou, NJ | 1 |
| Lin, ZY | 2 |
| Huang, JF | 3 |
| Dai, CY | 3 |
| Huang, CF | 2 |
| Chuang, WL | 3 |
| Yu, ML | 3 |
| Kong, H | 1 |
| Lu, F | 3 |
| Efstathiadou, A | 1 |
| Gill, D | 1 |
| McGrane, F | 1 |
| Quinn, T | 1 |
| Dawson, J | 5 |
| Jonsson, H | 1 |
| Aspelund, T | 1 |
| Eiriksdottir, G | 1 |
| Harris, TB | 1 |
| Launer, LJ | 1 |
| Gudnason, V | 1 |
| Roumeliotis, S | 1 |
| Roumeliotis, A | 1 |
| Dounousi, E | 1 |
| Eleftheriadis, T | 1 |
| Liakopoulos, V | 2 |
| Kwong, JS | 1 |
| Chung, SC | 1 |
| Shah, A | 3 |
| An, Z | 1 |
| Hemingway, H | 1 |
| Tian, H | 2 |
| Stamp, LK | 26 |
| Chapman, P | 1 |
| Hudson, B | 1 |
| Frampton, C | 5 |
| Hamilton, G | 1 |
| Judd, A | 1 |
| Kon, S | 1 |
| Konta, T | 8 |
| Ichikawa, K | 7 |
| Watanabe, M | 4 |
| Sato, H | 4 |
| Ueno, Y | 3 |
| Yamashita, H | 2 |
| Kayama, T | 4 |
| Wu, JL | 1 |
| Li, JX | 1 |
| Ma, ZC | 1 |
| Shen, G | 1 |
| Huang, JY | 1 |
| Yu, YL | 1 |
| Chen, CL | 1 |
| Huang, YQ | 1 |
| Feng, YQ | 1 |
| Du, W | 2 |
| Yang, W | 3 |
| Lin, KM | 1 |
| Lu, CL | 1 |
| Hung, KC | 2 |
| Wu, PC | 1 |
| Pan, CF | 1 |
| Syu, RS | 1 |
| Hsiao, PJ | 1 |
| Lu, KC | 1 |
| Tohyo, S | 1 |
| Clémençon, B | 1 |
| Marini, C | 1 |
| Hediger, MA | 1 |
| Zeng, XW | 2 |
| Lodge, CJ | 1 |
| Dharmage, SC | 1 |
| Bloom, MS | 1 |
| Chu, C | 2 |
| Hu, LW | 1 |
| Liu, KK | 1 |
| Yang, BY | 2 |
| Dong, GH | 2 |
| Bhatia, N | 2 |
| Shanmugam, R | 1 |
| Jain, K | 2 |
| Sikka, P | 2 |
| Verma, I | 2 |
| Mizuno, Y | 1 |
| Yamamotoya, T | 2 |
| Nakatsu, Y | 2 |
| Ueda, K | 1 |
| Matsunaga, Y | 2 |
| Inoue, MK | 1 |
| Sakoda, H | 2 |
| Fujishiro, M | 2 |
| Ono, H | 1 |
| Kikuchi, T | 1 |
| Takahashi, M | 2 |
| Morii, K | 1 |
| Sasaki, K | 3 |
| Masaki, T | 1 |
| Asano, T | 3 |
| Kushiyama, A | 2 |
| Ko, J | 1 |
| Kang, HJ | 2 |
| Kim, DA | 1 |
| Kim, MJ | 4 |
| Ryu, ES | 2 |
| Lee, S | 6 |
| Ryu, JH | 1 |
| Roncal, C | 5 |
| Stone, ML | 1 |
| Richardson, MR | 1 |
| Guevara, L | 1 |
| Rand, BG | 1 |
| Churilla, JR | 1 |
| Skeete, J | 1 |
| Ridley, E | 1 |
| DiPette, DJ | 1 |
| Higa, S | 1 |
| Shima, D | 1 |
| Tomitani, N | 1 |
| Fujimoto, Y | 1 |
| Taher, R | 1 |
| Sara, JD | 1 |
| Prasad, M | 1 |
| Kolluri, N | 1 |
| Toya, T | 1 |
| Lerman, LO | 1 |
| Lerman, A | 2 |
| Liang, L | 1 |
| Bainey, KR | 1 |
| Tymchak, W | 1 |
| Banh, HL | 1 |
| Mazidi, M | 2 |
| Katsiki, N | 6 |
| Bartłomiejczyk, MA | 1 |
| Banach, M | 2 |
| Ai, W | 1 |
| Zalloum, WA | 1 |
| Kang, D | 1 |
| Gao, P | 1 |
| Hua, F | 1 |
| Rahimi-Sakak, F | 1 |
| Maroofi, M | 1 |
| Rahmani, J | 1 |
| Bellissimo, N | 1 |
| Hekmatdoost, A | 1 |
| Park, DY | 1 |
| Kim, YS | 5 |
| Ryu, SH | 1 |
| Jin, YS | 1 |
| Kocak, MZ | 1 |
| Aktas, G | 1 |
| Duman, TT | 1 |
| Atak, BM | 1 |
| Savli, H | 1 |
| Ni, Q | 1 |
| Zhou, B | 2 |
| Drabkin, M | 1 |
| Yogev, Y | 1 |
| Zeller, L | 1 |
| Zarivach, R | 1 |
| Zalk, R | 1 |
| Halperin, D | 1 |
| Wormser, O | 1 |
| Gurevich, E | 1 |
| Landau, D | 1 |
| Kadir, R | 1 |
| Perez, Y | 1 |
| Birk, OS | 1 |
| Ruocco, G | 3 |
| Palazzuoli, A | 4 |
| Hu, G | 2 |
| Xu, BP | 1 |
| Okuya, Y | 1 |
| Takahashi, T | 4 |
| Kishi, K | 1 |
| Yang, AY | 1 |
| Stack, AG | 7 |
| Karra Gurunath, R | 1 |
| García de Yébenes, MJ | 1 |
| Carmona, L | 4 |
| Jung, S | 3 |
| Sayad, K | 1 |
| Staitieh, BS | 1 |
| Gao, H | 1 |
| Cohen, RE | 1 |
| Yuan, Y | 7 |
| Ponvilawan, B | 1 |
| Charoenngam, N | 1 |
| Ungprasert, P | 4 |
| Weng, W | 1 |
| Man, N | 1 |
| Wei, Q | 3 |
| Adu-Frimpong, M | 1 |
| Toreniyazov, E | 1 |
| Qian, F | 1 |
| Ota-Kontani, A | 2 |
| Hirata, H | 2 |
| Tsuchiya, Y | 2 |
| Narang, RK | 3 |
| Vincent, Z | 1 |
| Okui, D | 3 |
| Sasaki, T | 8 |
| Fushimi, M | 5 |
| Ohashi, T | 9 |
| Huang, ZP | 1 |
| Huang, BX | 1 |
| Zhu, MF | 1 |
| Zhu, HL | 1 |
| Landolfo, M | 2 |
| Cosentino, E | 2 |
| Sezai, A | 5 |
| Unosawa, S | 1 |
| Taoka, M | 1 |
| Osaka, S | 2 |
| Sekino, H | 2 |
| Watanabe, S | 3 |
| Kawano, T | 1 |
| Horino, T | 2 |
| Matsumoto, T | 3 |
| Nagata, K | 1 |
| Hatakeyama, Y | 2 |
| Locatelli, FM | 1 |
| Yokoyama, M | 1 |
| Terada, Y | 3 |
| Okuhara, Y | 2 |
| Biradar, MI | 1 |
| Chiang, KM | 1 |
| Yang, HC | 1 |
| Huang, YT | 1 |
| Pan, WH | 6 |
| Sano, T | 3 |
| Kuriyama, S | 2 |
| Chua, CKT | 1 |
| Cheung, PP | 1 |
| Santosa, A | 1 |
| Lim, AYN | 1 |
| Teng, GG | 1 |
| Lee, SY | 2 |
| Park, W | 1 |
| Suh, YJ | 1 |
| Lim, MJ | 1 |
| Kwon, SR | 1 |
| Joo, YB | 1 |
| Oh, YK | 2 |
| Jung, KH | 1 |
| Yu, HX | 1 |
| Song, XX | 1 |
| Tatsumi, Y | 1 |
| Asayama, K | 1 |
| Morimoto, A | 1 |
| Satoh, M | 2 |
| Sonoda, N | 1 |
| Miyamatsu, N | 1 |
| Ohno, Y | 2 |
| Miyamoto, Y | 2 |
| Izawa, S | 1 |
| Ohkubo, T | 1 |
| Morimoto, K | 2 |
| Nakaoka, H | 5 |
| Hosomichi, K | 2 |
| Ooyama, K | 4 |
| Ooyama, H | 7 |
| Shimizu, T | 9 |
| Ueno, M | 1 |
| Ito, T | 4 |
| Tamura, T | 3 |
| Nakashima, H | 9 |
| Kawaguchi, M | 3 |
| Takao, M | 2 |
| Kawai, Y | 2 |
| Osada, N | 1 |
| Inoue, I | 3 |
| El-Kafoury, BMA | 1 |
| Ahmed, MA | 1 |
| Hammouda, GA | 1 |
| ElKady, AH | 1 |
| Lasheen, NN | 1 |
| Chaudhary, NS | 1 |
| Rahn, EJ | 2 |
| Curtis, JR | 1 |
| Gaffo, A | 2 |
| Limdi, NA | 1 |
| Levitan, EB | 1 |
| Singh, JA | 8 |
| Flaherty, ML | 1 |
| Judd, S | 1 |
| Hossen, I | 1 |
| Raka, RN | 2 |
| Cui, D | 1 |
| Tang, M | 2 |
| Mao, R | 1 |
| Mena-Sánchez, G | 2 |
| Becerra-Tomás, N | 3 |
| Díaz-López, A | 2 |
| Zomeño, MD | 1 |
| Serra-Majem, L | 3 |
| Bernal, R | 1 |
| Lapetra, J | 2 |
| Gaforio, JJ | 2 |
| Caro, JLL | 1 |
| Arellano, AG | 1 |
| Palau, A | 1 |
| Fernández-Carrión, R | 2 |
| Pérez-Vega, KA | 1 |
| de la Hera, MG | 1 |
| Vaquero-Luna, J | 1 |
| Carmona-González, FJ | 1 |
| Abete, I | 1 |
| Álvarez-Pérez, J | 1 |
| Casas, R | 2 |
| Fernández-García, JC | 2 |
| Corbella, E | 2 |
| Sureda, A | 1 |
| Goday, A | 1 |
| Martín, M | 1 |
| Altozano Rodado, MC | 1 |
| Toledo, E | 1 |
| Fitó, M | 2 |
| Han, L | 6 |
| Vedder, D | 1 |
| Walrabenstein, W | 1 |
| Heslinga, M | 1 |
| de Vries, R | 1 |
| Nurmohamed, M | 1 |
| van Schaardenburg, D | 1 |
| Gerritsen, M | 2 |
| Bjornstad, P | 2 |
| Chilunga, FP | 1 |
| Henneman, P | 1 |
| Requena-Méndez, A | 1 |
| Meeks, K | 1 |
| Beune, E | 1 |
| Mannens, MMAM | 1 |
| Agyemang, C | 1 |
| Wan, H | 4 |
| Tang, S | 3 |
| Ren, L | 1 |
| Peng, H | 8 |
| Martin, WP | 1 |
| le Roux, CW | 1 |
| Shriner, D | 1 |
| Doumatey, AP | 1 |
| Bentley, AR | 1 |
| Lei, L | 1 |
| Adeyemo, A | 1 |
| Rotimi, CN | 1 |
| Cortese, F | 2 |
| Scicchitano, P | 2 |
| Cortese, AM | 1 |
| Meliota, G | 2 |
| Andriani, A | 1 |
| Truncellito, L | 1 |
| Calculli, G | 2 |
| Giordano, P | 2 |
| Ciccone, MM | 2 |
| Popp, RA | 1 |
| Kovalenko, YL | 1 |
| Melekhovets, OK | 1 |
| Orlovskiy, VF | 1 |
| Melekhovets, YV | 1 |
| Wahba, NS | 1 |
| Abdel-Ghany, RH | 1 |
| Ghareib, SA | 1 |
| Abdel-Aal, M | 1 |
| Alsemeh, AE | 1 |
| Song, Q | 1 |
| Unger, LW | 1 |
| Forstner, B | 1 |
| Muckenhuber, M | 1 |
| Scheuba, K | 1 |
| Eigenbauer, E | 1 |
| Scheiner, B | 1 |
| Pfisterer, N | 1 |
| Paternostro, R | 1 |
| Trauner, M | 1 |
| Mandorfer, M | 1 |
| Reiberger, T | 1 |
| Gao, Z | 3 |
| Huang, F | 6 |
| Kawamoto, R | 5 |
| Ninomiya, D | 3 |
| Akase, T | 2 |
| Kikuchi, A | 3 |
| Kumagi, T | 4 |
| Yan, Z | 1 |
| Tian, J | 4 |
| Han, H | 2 |
| Ye, F | 1 |
| Fujita, K | 2 |
| Yamada, H | 5 |
| Iijima, M | 1 |
| Abu Sneineh, M | 1 |
| Schwartz, Y | 2 |
| Nesher, G | 2 |
| Freier Dror, Y | 1 |
| Breuer, GS | 2 |
| Han, QX | 1 |
| Zhang, F | 4 |
| Luan, FX | 1 |
| Liu, DW | 1 |
| Liu, ZS | 1 |
| Cai, GY | 1 |
| Chen, XM | 2 |
| Zhu, HY | 1 |
| Xu, WH | 2 |
| Wang, HT | 2 |
| Xue, ZC | 1 |
| Liang, ML | 1 |
| Su, WK | 1 |
| Gong, H | 1 |
| Baima, Y | 1 |
| Ha, EH | 1 |
| Tian, S | 1 |
| Mao, Q | 1 |
| Zou, Q | 1 |
| Lei, Y | 1 |
| Bonino, B | 3 |
| Leoncini, G | 5 |
| Wu, QY | 1 |
| Chen, ZH | 1 |
| Yan, GY | 1 |
| Dai, HJ | 1 |
| Yang, PT | 1 |
| Yuan, H | 4 |
| Martens, KL | 2 |
| Khalighi, PR | 2 |
| White, AA | 2 |
| Silgard, E | 2 |
| Frieze, D | 2 |
| Estey, E | 1 |
| Garcia, DA | 2 |
| Hingorani, S | 1 |
| Li, A | 2 |
| Rospleszcz, S | 1 |
| Dermyshi, D | 1 |
| Müller-Peltzer, K | 1 |
| Strauch, K | 1 |
| Bamberg, F | 1 |
| Peters, A | 1 |
| Brucato, A | 1 |
| Cianci, F | 1 |
| Carnovale, C | 1 |
| İnanir, M | 1 |
| Kaspar, CDW | 1 |
| Beach, I | 1 |
| Newlin, J | 1 |
| Sisler, I | 1 |
| Feig, D | 2 |
| Smith, W | 1 |
| Cui, LF | 2 |
| Sun, YY | 1 |
| Yang, WH | 2 |
| Wang, JR | 2 |
| Wu, SL | 2 |
| Nishikawa, T | 2 |
| Nagata, N | 1 |
| Shimakami, T | 1 |
| Shirakura, T | 1 |
| Matsui, C | 1 |
| Zhuge, F | 1 |
| Nagashimada, M | 1 |
| Yamashita, T | 5 |
| Mizukoshi, E | 1 |
| Kaneko, S | 2 |
| Ota, T | 2 |
| Lin, YJ | 3 |
| Lin, SY | 1 |
| Wang, ST | 1 |
| Chang, SS | 1 |
| Furuno, K | 2 |
| Kanda, S | 2 |
| Somuncu, MU | 1 |
| Serbest, NG | 1 |
| Akgül, F | 1 |
| Çakır, MO | 1 |
| Akgün, T | 1 |
| Tatar, FP | 1 |
| Can, M | 1 |
| Tekin, A | 1 |
| Bragagni, A | 1 |
| Morimoto, C | 2 |
| Kuribayashi-Okuma, E | 1 |
| Nemoto, Y | 1 |
| Hosoyamada, M | 9 |
| Jiang, S | 3 |
| Jin, L | 6 |
| Chen, ZY | 1 |
| Liang, ZJ | 1 |
| Pei, L | 1 |
| Xie, L | 2 |
| Chewcharat, A | 1 |
| Chang, YT | 1 |
| Thongprayoon, C | 2 |
| Crisafio, A | 1 |
| Bathini, T | 1 |
| Mao, MA | 1 |
| Cheungpasitporn, W | 2 |
| Alghamdi, YS | 1 |
| Nassan, MA | 1 |
| Wang, ZJ | 2 |
| Choi, SY | 1 |
| Choi, SW | 2 |
| So, MW | 2 |
| Oh, JS | 2 |
| Lim, DH | 3 |
| Son, M | 1 |
| Seo, J | 1 |
| Lim, SS | 1 |
| Yang, YL | 1 |
| Wu, CH | 1 |
| Huang, SS | 1 |
| Chan, WL | 2 |
| Chen, JW | 2 |
| Chou, CY | 1 |
| Pan, JP | 1 |
| Charng, MJ | 1 |
| Wu, TC | 1 |
| Lu, TM | 1 |
| Hsu, PF | 4 |
| Cheng, HM | 2 |
| Huang, CC | 5 |
| Sung, SH | 2 |
| Leu, HB | 1 |
| Zhou, H | 3 |
| Ma, ZF | 1 |
| Shao, J | 1 |
| Pan, B | 2 |
| Chen, D | 5 |
| Chi, H | 1 |
| Liao, E | 1 |
| Teng, D | 1 |
| Teng, X | 1 |
| Ba, J | 1 |
| Qin, G | 1 |
| Qin, Y | 3 |
| Shi, B | 1 |
| Tong, N | 1 |
| Zhang, JA | 1 |
| Yao, Y | 5 |
| Zhu, M | 3 |
| Shan, Z | 1 |
| Drivelegka, P | 1 |
| Forsblad-d'Elia, H | 1 |
| Angerås, O | 1 |
| Bergström, G | 1 |
| Schmidt, C | 1 |
| Jacobsson, LTH | 1 |
| Dehlin, M | 5 |
| Hwang, JJ | 5 |
| Oh, YM | 1 |
| Rhee, CK | 1 |
| Yoo, KH | 2 |
| Park, YB | 2 |
| Yoon, HI | 1 |
| Lim, SY | 1 |
| Kim, EK | 1 |
| Kim, TH | 4 |
| Lee, SW | 3 |
| Lee, SD | 2 |
| Lee, JS | 3 |
| Zhao, TY | 1 |
| Zhu, XX | 3 |
| Zou, HJ | 2 |
| Wan, WG | 1 |
| Folkmane, I | 1 |
| Tzivian, L | 1 |
| Folkmane, E | 1 |
| Valdmane, E | 1 |
| Kuzema, V | 1 |
| Petersons, A | 1 |
| Roman, Y | 1 |
| Tiirikainen, M | 1 |
| Prom-Wormley, E | 1 |
| Ou, J | 1 |
| Jian, G | 1 |
| Cheng, H | 2 |
| Rebora, P | 2 |
| Andreano, A | 1 |
| Triglione, N | 2 |
| Piccinelli, E | 1 |
| Palazzini, M | 1 |
| Occhi, L | 3 |
| Valsecchi, MG | 3 |
| Xiong, X | 1 |
| Ge, X | 1 |
| Xia, F | 4 |
| Rosei, EA | 3 |
| Wrigley, R | 1 |
| Phipps-Green, AJ | 5 |
| Topless, RK | 3 |
| Major, TJ | 4 |
| Riches, P | 1 |
| Harré Hindmarsh, J | 1 |
| Miao, M | 2 |
| Wei, Z | 1 |
| Dan, X | 1 |
| Lin, YK | 1 |
| Lee, JT | 1 |
| Lin, CS | 4 |
| Wu, TJ | 1 |
| Tsai, KZ | 1 |
| Su, FY | 1 |
| Kwon, Y | 1 |
| Hoshide, S | 2 |
| Lin, GM | 1 |
| Cheng, MDCA | 1 |
| Pérez, RE | 1 |
| Santiago, JC | 1 |
| Galindo, AC | 1 |
| Carreño Rodríguez, YR | 1 |
| Guerrero Rosario, AO | 1 |
| Meléndez, AR | 1 |
| Villanueva, AI | 1 |
| Jiménez, EM | 1 |
| Bobadilla Lugo, RA | 1 |
| De León, CV | 1 |
| Hernández Rivera, JCH | 1 |
| Sierra, RP | 1 |
| Scuiller, A | 1 |
| Pascart, T | 6 |
| Bernard, A | 1 |
| Oehler, E | 1 |
| Semplicini, A | 1 |
| Han, RY | 2 |
| Wang, XC | 1 |
| An, XT | 1 |
| Zhang, ZD | 1 |
| Wang, SS | 1 |
| Dissanayake, LV | 1 |
| Spires, DR | 1 |
| Palygin, O | 1 |
| Staruschenko, A | 1 |
| Jung, SW | 1 |
| Kim, SM | 2 |
| Kim, YG | 6 |
| Lee, SH | 6 |
| Moon, JY | 2 |
| Ge, JY | 1 |
| Zhang, YY | 2 |
| Wang, FF | 1 |
| Ji, Y | 2 |
| Ristic, B | 1 |
| Sivaprakasam, S | 1 |
| Narayanan, M | 1 |
| Ganapathy, V | 1 |
| Xue, T | 1 |
| Dai, S | 1 |
| Pan, S | 1 |
| Xie, X | 4 |
| Qiao, X | 2 |
| Liu, G | 5 |
| Zhai, Y | 1 |
| Fogacci, F | 3 |
| Machu, JL | 1 |
| Bozec, E | 2 |
| Duarte, K | 1 |
| Im, SW | 1 |
| Chae, J | 1 |
| Son, HY | 1 |
| Cho, B | 1 |
| Park, JH | 3 |
| Bilal, M | 1 |
| Ahmad, S | 1 |
| Rehman, T | 1 |
| Abbasi, WM | 1 |
| Ghauri, AO | 1 |
| Arshad, MA | 1 |
| Ayaz, S | 1 |
| Nawaz, A | 1 |
| Shu, R | 3 |
| Nguyen, US | 1 |
| Misra, D | 2 |
| Sato, Y | 5 |
| Feig, DI | 25 |
| Sánchez-Lozada, LG | 19 |
| Ishizaka, N | 3 |
| Kanzaki, Y | 2 |
| Ishibashi, R | 1 |
| Maemura, K | 3 |
| Higashi, Y | 5 |
| Yokote, K | 1 |
| Oyama, JI | 1 |
| Kudo, H | 1 |
| Tsuruoka, S | 2 |
| Anzai, N | 10 |
| Shibata, Y | 4 |
| Shirakabe, A | 4 |
| Okazaki, H | 4 |
| Matsushita, M | 4 |
| Goda, H | 1 |
| Shigihara, S | 1 |
| Asano, K | 1 |
| Kiuchi, K | 1 |
| Tani, K | 2 |
| Kobayashi, N | 5 |
| Hata, N | 4 |
| Asai, K | 5 |
| Shimizu, W | 5 |
| Ishaq, M | 1 |
| Zad, OD | 1 |
| Hossain, I | 1 |
| Naveed, M | 1 |
| Brennan, P | 1 |
| Clare, K | 1 |
| George, J | 1 |
| Dillon, JF | 1 |
| Huang, YY | 2 |
| Gu, SW | 1 |
| Jiang, ZY | 1 |
| Fischer, A | 1 |
| Hirai, T | 4 |
| Kawagoe, Y | 1 |
| Kei, M | 1 |
| Ogawa, R | 1 |
| Itoh, T | 2 |
| Chernatska, OM | 1 |
| Prystupa, LN | 1 |
| Fadieieva, HA | 1 |
| Liashenko, AV | 1 |
| Smiianova, YO | 1 |
| Carnicelli, AP | 1 |
| Clare, R | 1 |
| Chiswell, K | 1 |
| Lytle, B | 1 |
| Bjursell, M | 1 |
| Perl, S | 1 |
| Andersson, K | 1 |
| Hedman, K | 1 |
| Pagidipati, N | 1 |
| Vemulapalli, S | 1 |
| Roe, MT | 1 |
| Mentz, RJ | 1 |
| Yan, W | 2 |
| Luo, A | 1 |
| Tan, W | 2 |
| Sun, SS | 1 |
| Zhang, DH | 1 |
| Lin, CJ | 1 |
| Lin, JY | 1 |
| Hu, AM | 1 |
| Brown, JN | 1 |
| Bupparenoo, P | 1 |
| Pakchotanon, R | 1 |
| Narongroeknawin, P | 1 |
| Asavatanabodee, P | 1 |
| Chaiamnuay, S | 1 |
| Pan, JA | 1 |
| Wang, CQ | 2 |
| Zhang, JF | 2 |
| Watanabe, K | 4 |
| Watanabe, T | 8 |
| Otaki, Y | 2 |
| Shishido, T | 1 |
| Tamura, H | 1 |
| Nishiyama, S | 1 |
| Arimoto, T | 2 |
| Han, M | 2 |
| Yang, F | 9 |
| Han, B | 5 |
| Wang, GQ | 1 |
| Rui, HL | 1 |
| Dong, HR | 1 |
| Sun, LJ | 1 |
| Wang, YY | 2 |
| Ye, N | 2 |
| Zhao, ZR | 1 |
| Liu, XJ | 1 |
| Chen, YP | 2 |
| Braga, TT | 1 |
| Foresto-Neto, O | 1 |
| Camara, NOS | 1 |
| Huang, G | 6 |
| Jiang, T | 1 |
| Zhu, Z | 3 |
| Hong, M | 1 |
| Park, JW | 1 |
| Yang, PS | 1 |
| Hwang, I | 1 |
| Yu, HT | 1 |
| Uhm, JS | 1 |
| Joung, B | 1 |
| Lee, MH | 1 |
| Jee, SH | 4 |
| Pak, HN | 1 |
| Mu, Z | 1 |
| Saito, H | 4 |
| Hoque, KM | 1 |
| Dixon, EE | 1 |
| Lewis, RM | 1 |
| Allan, J | 1 |
| Gamble, GD | 6 |
| Horne, AM | 1 |
| Zuo, T | 2 |
| Cho, SK | 4 |
| Kim, B | 1 |
| Myung, W | 1 |
| Chang, Y | 6 |
| Ryu, S | 3 |
| Kim, HN | 1 |
| Kim, HL | 1 |
| Kuo, PH | 1 |
| Winkler, CA | 1 |
| Won, HH | 1 |
| Kang, L | 1 |
| Miao, JX | 1 |
| Cao, LH | 1 |
| Miao, YY | 1 |
| Miao, MS | 1 |
| Liu, HJ | 1 |
| Xiang, LL | 1 |
| Song, YG | 1 |
| Mishima, E | 1 |
| Miyazaki, M | 2 |
| Abe, T | 1 |
| Jacobsson, L | 6 |
| Roddy, E | 7 |
| Yin, S | 5 |
| Xie, C | 3 |
| Fan, C | 1 |
| Qiu, A | 3 |
| Zhuang, S | 4 |
| Su, M | 2 |
| Pan, Z | 1 |
| Catanzaro, R | 1 |
| Sciuto, M | 1 |
| Marotta, F | 1 |
| Arenas, MD | 2 |
| Soriano, R | 1 |
| Yen, FS | 1 |
| Hsu, CC | 5 |
| Li, HL | 1 |
| Wei, JC | 4 |
| Hwu, CM | 3 |
| Oliveira, IO | 1 |
| Mintem, GC | 1 |
| Oliveira, PD | 1 |
| Freitas, DF | 1 |
| Brum, CB | 1 |
| Wehrmeister, FC | 1 |
| Gigante, DP | 1 |
| Horta, BL | 1 |
| Menezes, AMB | 1 |
| Serdarevic, N | 1 |
| Stanciu, AE | 1 |
| Begic, L | 1 |
| Uncanin, S | 1 |
| Song, F | 1 |
| Tan, N | 1 |
| Aoun, M | 1 |
| Salloum, R | 1 |
| Dfouni, A | 1 |
| Sleilaty, G | 1 |
| Chelala, D | 1 |
| Scinicariello, F | 1 |
| Buser, MC | 1 |
| Balluz, L | 1 |
| Gehle, K | 1 |
| Murray, HE | 1 |
| Abadin, HG | 1 |
| Attanasio, R | 1 |
| Novikova, AM | 1 |
| Lertnawapan, R | 1 |
| Jatuworapruk, K | 1 |
| Peng, YL | 1 |
| Tain, YL | 1 |
| Lee, CT | 2 |
| Yang, YH | 2 |
| Huang, YB | 1 |
| Wen, YH | 1 |
| Hsu, CN | 1 |
| Keenan, RT | 6 |
| Hashimoto, T | 1 |
| Kanno, Y | 3 |
| Cheng, FM | 1 |
| Tien, JZ | 1 |
| Chen, TT | 1 |
| Yeh, SP | 1 |
| Lin, CC | 4 |
| Tseng, CC | 1 |
| Wong, MC | 1 |
| Liao, WT | 1 |
| Chen, CJ | 3 |
| Lee, SC | 2 |
| Yen, JH | 1 |
| Byun, SH | 1 |
| Yoo, DM | 1 |
| Lee, JW | 2 |
| Choi, HG | 1 |
| Zhong, C | 3 |
| Abagyan, R | 1 |
| Ponticelli, C | 1 |
| Podestà, MA | 1 |
| Moroni, G | 1 |
| Fan, M | 3 |
| Zhao, B | 1 |
| Inaguma, D | 1 |
| Koshi-Ito, E | 1 |
| Ogata, S | 1 |
| Kitagawa, A | 1 |
| Koide, S | 1 |
| Hayashi, H | 2 |
| Hasegawa, M | 1 |
| Yuzawa, Y | 2 |
| Tsuboi, N | 3 |
| Bian, S | 1 |
| Cao, X | 1 |
| Jiao, H | 3 |
| Wu, XH | 9 |
| Si, S | 1 |
| Mo, M | 1 |
| Xin, X | 1 |
| Shao, B | 1 |
| Barrientos-Regala, M | 1 |
| Macabeo, RA | 1 |
| Ramirez-Ragasa, R | 1 |
| Pestaño, NS | 1 |
| Punzalan, FER | 1 |
| Tumanan-Mendoza, B | 1 |
| Castillo, RR | 1 |
| Sung, KT | 1 |
| Lo, CI | 1 |
| Lai, YH | 1 |
| Tsai, JP | 1 |
| Yun, CH | 1 |
| Hsiao, CC | 1 |
| Kuo, JY | 1 |
| Hou, CJ | 1 |
| Hung, TC | 1 |
| Su, CH | 1 |
| Hung, CL | 2 |
| Yeh, HI | 1 |
| Kassai, H | 1 |
| Nakao, K | 1 |
| Nakatochi, M | 2 |
| Aiba, A | 1 |
| Li, YZ | 1 |
| Gong, M | 1 |
| Sarac, N | 1 |
| Pancar, GS | 1 |
| Ozdemir, S | 1 |
| Atilla, S | 1 |
| Hashimoto, S | 2 |
| Nagai, M | 3 |
| Fukuma, S | 1 |
| Yasumura, S | 2 |
| Satoh, H | 1 |
| Sakai, A | 3 |
| Ohtsuru, A | 1 |
| Kawasaki, Y | 1 |
| Takahashi, A | 5 |
| Okazaki, K | 3 |
| Kobashi, G | 1 |
| Kamiya, K | 2 |
| Yamashita, S | 1 |
| Fukuhara, SI | 1 |
| Ohto, H | 2 |
| Li, YW | 1 |
| Chen, WL | 2 |
| Hase, R | 2 |
| Kurata, R | 1 |
| Ishida, K | 3 |
| Kurita, T | 1 |
| Muranaka, E | 1 |
| Mito, H | 1 |
| Kim, HS | 4 |
| Kim, H | 5 |
| Kim, JH | 3 |
| Agabiti-Rosei, E | 1 |
| Kielstein, JT | 2 |
| Redon, J | 2 |
| Tsioufis, KP | 1 |
| Karava, V | 1 |
| Dotis, J | 1 |
| Kondou, A | 1 |
| Christoforidis, A | 1 |
| Tsioni, K | 1 |
| Kollios, K | 1 |
| Papachristou, F | 1 |
| Printza, N | 1 |
| Lai, CH | 1 |
| Huang, RJ | 1 |
| Wong, JK | 1 |
| Chang, SW | 1 |
| Chung, AH | 1 |
| Chi, YC | 1 |
| Yu, YC | 1 |
| Ting, H | 1 |
| Bao, M | 1 |
| Zhao, N | 2 |
| Hussain, M | 1 |
| Yi, J | 1 |
| Chen, P | 4 |
| Reis, LN | 2 |
| Borfe, L | 1 |
| Brand, C | 1 |
| Franke, SIR | 1 |
| Renner, JDP | 1 |
| Gaya, AR | 1 |
| Brazo-Sayavera, J | 1 |
| Reuter, CP | 2 |
| Lou, Y | 2 |
| Zhao, P | 2 |
| Han, D | 2 |
| Hu, D | 3 |
| Stevenson, M | 1 |
| Pagnamenta, AT | 1 |
| Reichart, S | 1 |
| Philpott, C | 1 |
| Lines, KE | 1 |
| Gorvin, CM | 1 |
| Taylor, JC | 1 |
| Thakker, RV | 3 |
| Takei, R | 2 |
| Markie, D | 1 |
| Bixley, M | 1 |
| Wei, WH | 2 |
| Sun, Q | 4 |
| Xu, H | 2 |
| Weng, P | 1 |
| Guo, M | 2 |
| Numata, K | 1 |
| Hisasue, T | 1 |
| Osanami, A | 1 |
| Inyaku, M | 1 |
| Matsumoto, M | 2 |
| Moniwa, N | 2 |
| Miura, T | 3 |
| Singh, JV | 1 |
| Bedi, PMS | 1 |
| Singh, H | 1 |
| Sharma, S | 2 |
| Ziga-Smajic, N | 1 |
| Skrbo, S | 1 |
| Muratovic, S | 1 |
| Pehlivanovic, B | 1 |
| Lagumdzija, D | 1 |
| Omerovic, N | 1 |
| Liu, XZ | 2 |
| Chen, DS | 1 |
| Li, HH | 1 |
| Liu, LY | 2 |
| Fan, J | 2 |
| Niu, W | 1 |
| Huang, XQ | 1 |
| Dong, JL | 1 |
| Lu, HM | 1 |
| Lin, YW | 1 |
| Yi, ZB | 1 |
| Wu, LM | 1 |
| Huang, YM | 1 |
| Wadowski, PP | 1 |
| Hoberstorfer, T | 1 |
| Weikert, C | 1 |
| Pultar, J | 1 |
| Kopp, CW | 1 |
| Panzer, S | 1 |
| Gremmel, T | 1 |
| Jung, SM | 1 |
| Jeon, S | 1 |
| Kapetanovic, M | 2 |
| Svärd, A | 2 |
| Bengtsson Boström, K | 2 |
| Wändell, P | 2 |
| Sigurdardottir, V | 2 |
| Forsblad d'Elia, H | 2 |
| Asahi, K | 4 |
| Yamagata, K | 4 |
| Fujimoto, S | 3 |
| Tsuruya, K | 5 |
| Narita, I | 4 |
| Shibagaki, Y | 4 |
| Moriyama, T | 8 |
| Kondo, M | 3 |
| Jo, YI | 1 |
| Esche, J | 4 |
| Krupp, D | 4 |
| Mensink, GB | 2 |
| Remer, T | 4 |
| Hlophe, NB | 1 |
| Opoku, AR | 1 |
| Osunsanmi, FO | 1 |
| Djarova-Daniels, TG | 1 |
| Lawal, OA | 1 |
| Mosa, RA | 1 |
| Fatima, T | 2 |
| Iftikhar, S | 1 |
| Qureshi, IH | 1 |
| Liang, T | 1 |
| Zhu, FF | 1 |
| Jiang, JQ | 1 |
| Wu, XW | 1 |
| Chen, AS | 1 |
| Yuan, DP | 1 |
| Liang, XL | 1 |
| Nguyen, QD | 1 |
| Tran, KM | 1 |
| Le, NH | 1 |
| Do, MD | 1 |
| Letavernier, E | 1 |
| Correas, JM | 1 |
| Resche-Rigon, M | 1 |
| Luis-Rodríguez, D | 1 |
| Donate-Correa, J | 1 |
| Martín-Núñez, E | 1 |
| Tagua, VG | 1 |
| Pérez Castro, A | 1 |
| Mora-Fernández, C | 1 |
| Navarro-González, JF | 1 |
| Drovandi, S | 1 |
| Salvidio, G | 1 |
| Verzola, D | 1 |
| Esposito, P | 1 |
| Garibotto, G | 1 |
| Bodofsky, S | 1 |
| Thomas, TJ | 1 |
| Chen, MQ | 1 |
| Wang, HY | 4 |
| Shi, WR | 1 |
| Sun, YX | 1 |
| Nakata, T | 2 |
| Ikeda, S | 1 |
| Koga, S | 1 |
| Yonekura, T | 1 |
| Tsuneto, A | 1 |
| Fukae, S | 1 |
| Minami, T | 1 |
| Kawano, H | 1 |
| Pingali, U | 1 |
| Nutalapati, C | 1 |
| Koilagundla, N | 1 |
| Taduri, G | 1 |
| Kang, X | 2 |
| Zheng, D | 2 |
| Koto, R | 2 |
| Chou, YT | 1 |
| Li, CH | 2 |
| Shen, WC | 1 |
| Lu, FH | 3 |
| Wu, JS | 3 |
| Chang, CJ | 3 |
| Adewuya, OA | 1 |
| Ajayi, EA | 1 |
| Adebayo, RA | 1 |
| Ojo, OE | 1 |
| Olaoye, OB | 1 |
| Bandúr, Š | 1 |
| Petreski, T | 1 |
| Ekart, R | 1 |
| Hojs, R | 1 |
| Bevc, S | 1 |
| Tang, WW | 1 |
| Ning, Y | 1 |
| Yi, YJ | 1 |
| Balakumar, P | 1 |
| Alqahtani, A | 1 |
| Khan, NA | 1 |
| Mahadevan, N | 1 |
| Dhanaraj, SA | 1 |
| Eun, Y | 1 |
| Han, KD | 1 |
| Kim, DH | 1 |
| Kim, IY | 1 |
| Park, EJ | 3 |
| Cha, HS | 2 |
| Koh, EM | 1 |
| Kim, SH | 8 |
| Qualliu, E | 1 |
| Grasso, E | 1 |
| Tognola, C | 1 |
| Tavecchia, G | 1 |
| Cartella, I | 1 |
| Milani, M | 1 |
| Vallerio, P | 2 |
| Signorini, S | 2 |
| Brambilla, P | 2 |
| Casati, M | 2 |
| Taylor, W | 1 |
| Mehra, D | 1 |
| Singla, K | 1 |
| Waheed, Y | 1 |
| Sun, D | 2 |
| Isnuwardana, R | 1 |
| Bijukchhe, S | 1 |
| Thadanipon, K | 1 |
| Ingsathit, A | 2 |
| Thakkinstian, A | 2 |
| Badve, SV | 4 |
| Nakagawa, N | 1 |
| Kanda, E | 3 |
| Nagasu, H | 1 |
| Matsushita, K | 2 |
| Nangaku, M | 1 |
| Maruyama, S | 2 |
| Yanagita, M | 1 |
| Sugiyama, H | 1 |
| Shigematsu, T | 3 |
| Isaka, Y | 3 |
| Okada, H | 1 |
| Yokoyama, H | 1 |
| Nakashima, N | 1 |
| Ohe, K | 1 |
| Okada, M | 1 |
| Kashihara, N | 1 |
| Qin, X | 3 |
| Kong, Y | 1 |
| Wan, Q | 2 |
| Liu, A | 2 |
| Hou, FF | 1 |
| Liang, X | 3 |
| Luo, Z | 1 |
| Tan, L | 1 |
| Xing, S | 1 |
| Si-Tu, DK | 1 |
| Goldwater, R | 1 |
| Johansson, S | 2 |
| Dronamraju, N | 1 |
| Oscarsson, J | 1 |
| Johnsson, E | 1 |
| Parkinson, J | 2 |
| Erlandsson, F | 1 |
| Nayak, C | 1 |
| Pattanaik, N | 1 |
| Chattopadhyay, A | 1 |
| Misra, P | 1 |
| Bhar, K | 1 |
| Michael, J | 1 |
| Huang, B | 5 |
| Jayachandran, M | 1 |
| Takakubo, Y | 1 |
| Imamura, Y | 1 |
| Tezuka, H | 1 |
| Okada, S | 1 |
| Naganuma, Y | 1 |
| Ito, J | 1 |
| Oki, H | 1 |
| Sasaki, A | 2 |
| Takagi, M | 1 |
| Lukkunaprasit, T | 1 |
| Rattanasiri, S | 1 |
| Turongkaravee, S | 1 |
| Suvannang, N | 1 |
| Attia, J | 1 |
| Hong, JW | 1 |
| Noh, JH | 1 |
| Kim, DJ | 3 |
| Kodama, S | 1 |
| Fujihara, K | 1 |
| Horikawa, C | 1 |
| Yamada, M | 1 |
| Sato, T | 2 |
| Yaguchi, Y | 1 |
| Yamamoto, M | 2 |
| Kitazawa, M | 1 |
| Matsubayashi, Y | 1 |
| Sone, H | 1 |
| Liang, Z | 1 |
| Ge, HZ | 1 |
| Lei, SS | 1 |
| Jiang, ZT | 1 |
| Su, J | 4 |
| Yu, QX | 2 |
| Lv, GY | 2 |
| Chen, SH | 2 |
| Jummaat, F | 1 |
| Adnan, AS | 1 |
| Ab Hamid, SA | 1 |
| Hor, JN | 1 |
| Nik Mustofar, NN | 1 |
| Muhammad Asri, NA | 1 |
| Wan Mohd Aminuddin, WI | 1 |
| Wan Zalik, WEA | 1 |
| Azmi, NFA | 1 |
| Che Hasnan, NA | 1 |
| Nie, A | 1 |
| Adachi, SI | 1 |
| Komatsu, W | 1 |
| Yoshizawa, F | 1 |
| Isoda, H | 1 |
| Yagasaki, K | 1 |
| Alford, A | 1 |
| Furrow, E | 1 |
| Borofsky, M | 1 |
| Lulich, J | 1 |
| Meng, B | 2 |
| An, MF | 1 |
| Wang, MY | 1 |
| Sun, ZR | 1 |
| Wang, XJ | 2 |
| Xiao, X | 2 |
| Yi, C | 1 |
| Adeyanju, OA | 1 |
| Badejogbin, OC | 1 |
| Areola, DE | 1 |
| Olaniyi, KS | 1 |
| Dibia, C | 1 |
| Soetan, OA | 1 |
| Oniyide, AA | 1 |
| Michael, OS | 1 |
| Olatunji, LA | 1 |
| Soladoye, AO | 1 |
| Moulin-Mares, SRA | 1 |
| Oliosa, PR | 1 |
| Faria, ER | 2 |
| Zago-Gomes, MP | 1 |
| Mill, JG | 5 |
| Koo, BS | 1 |
| Jeong, HJ | 1 |
| Son, CN | 4 |
| Kim, HJ | 4 |
| Kim, GH | 1 |
| Jun, JB | 5 |
| Kobalava, ZD | 2 |
| Troitskaya, EA | 2 |
| Cheng, C | 1 |
| Tedeschi, A | 1 |
| Agostoni, P | 1 |
| Pezzuto, B | 1 |
| Corra', U | 1 |
| Scrutinio, D | 1 |
| La Gioia, R | 1 |
| Raimondo, R | 1 |
| Passantino, A | 1 |
| Piepoli, MF | 1 |
| Loreto, G | 1 |
| Kuźma, Ł | 1 |
| Kulikowska, A | 1 |
| Kurasz, A | 1 |
| Niwińska, MM | 1 |
| Zalewska-Adamiec, M | 1 |
| Dobrzycki, S | 1 |
| Bachórzewska-Gajewska, H | 1 |
| Le, Y | 2 |
| Ding, G | 5 |
| Joo, HJ | 2 |
| Kim, GR | 1 |
| Choi, DW | 1 |
| Joo, JH | 1 |
| Park, EC | 1 |
| Elsayed, A | 1 |
| M Abdelraheem, E | 1 |
| Hassan, H | 1 |
| Abbas, A | 1 |
| Hassnine, A | 1 |
| Nakafero, G | 1 |
| Chakravorty, M | 1 |
| Hill-McManus, D | 1 |
| Hughes, DA | 1 |
| Qian, T | 1 |
| Drummond, GR | 1 |
| Sobey, CG | 1 |
| Charchar, FJ | 1 |
| Golledge, J | 1 |
| Miake, J | 1 |
| Taufiq, F | 1 |
| Mahati, E | 1 |
| Maharani, N | 3 |
| Utami, SB | 1 |
| Bahrudin, U | 1 |
| Gromova, MA | 1 |
| Tsurko, VV | 2 |
| Kislyak, OA | 1 |
| Malysheva, NV | 1 |
| Ning, X | 2 |
| Hong-Lei, LI | 1 |
| Zhen, C | 1 |
| Wan, YU | 1 |
| Mandurino-Mirizzi, A | 2 |
| Cornara, S | 2 |
| Somaschini, A | 2 |
| Demarchi, A | 2 |
| Galazzi, M | 2 |
| Puccio, S | 1 |
| Montalto, C | 1 |
| Crimi, G | 2 |
| Ferlini, M | 2 |
| Camporotondo, R | 2 |
| Gnecchi, M | 2 |
| Ferrario, M | 2 |
| Oltrona-Visconti, L | 2 |
| De Ferrari, GM | 2 |
| Abrahim, M | 1 |
| Yin, F | 1 |
| Yuan, DM | 1 |
| Xin, HL | 1 |
| Gao, WG | 1 |
| Sun, JP | 1 |
| Wen, L | 1 |
| Köttgen, A | 6 |
| Köttgen, M | 2 |
| Floege, J | 1 |
| Bai, Z | 2 |
| Dai, H | 2 |
| Meng, S | 1 |
| Kang, T | 1 |
| Ye, Q | 1 |
| Bi, Y | 2 |
| Premachandra, KH | 1 |
| Day, RO | 7 |
| Roberts, DM | 1 |
| Nishizawa, M | 1 |
| Kiuchi, M | 1 |
| Kiyosue, A | 1 |
| Tomita, F | 1 |
| Ohtani, H | 1 |
| Abe, Y | 2 |
| Kuga, H | 1 |
| Miyazaki, S | 3 |
| Hongou, M | 1 |
| Yasu, T | 1 |
| Kuramochi, J | 1 |
| Gamble, GG | 1 |
| Topless, R | 5 |
| Long, K | 1 |
| Ouyang, X | 3 |
| Cai, X | 2 |
| Feng, X | 4 |
| Huo, W | 3 |
| Dhouibi, R | 1 |
| Affes, H | 1 |
| Salem, MB | 1 |
| Moalla, D | 1 |
| Marekchi, R | 1 |
| Charfi, S | 1 |
| Hammami, S | 1 |
| Sahnoun, Z | 1 |
| Jamoussi, K | 1 |
| Zeghal, KM | 1 |
| Ksouda, K | 1 |
| Winder, M | 1 |
| Owczarek, AJ | 1 |
| Mossakowska, M | 1 |
| Broczek, K | 1 |
| Grodzicki, T | 1 |
| Wierucki, Ł | 1 |
| Chudek, J | 1 |
| Peng, A | 3 |
| Zhao, K | 1 |
| Wang, CP | 6 |
| Lu, YC | 2 |
| Hung, WC | 2 |
| Tsai, IT | 2 |
| Chang, YH | 2 |
| Hu, DW | 1 |
| Wu, CC | 3 |
| Wei, CT | 1 |
| Chung, FM | 2 |
| Shi, Q | 2 |
| Xu, CY | 1 |
| Di, L | 1 |
| Zhao, LL | 1 |
| Jin, W | 1 |
| Min, JZ | 1 |
| Wakita, M | 1 |
| Kubota, Y | 1 |
| Koen, M | 1 |
| An, D | 1 |
| Ma, P | 1 |
| Regenstein, J | 1 |
| Feng, F | 1 |
| Zhen, L | 1 |
| Guo, D | 1 |
| Song, Y | 4 |
| Xing, X | 2 |
| Chang, D | 1 |
| Deng, J | 1 |
| Jiang, N | 1 |
| Wang, XH | 1 |
| Jiang, WR | 1 |
| Zhang, MY | 1 |
| Shi, YX | 2 |
| Ji, YP | 1 |
| Li, CJ | 1 |
| Lin, JN | 1 |
| Cui, S | 3 |
| Shen, X | 4 |
| Zuo, M | 1 |
| Zhu, H | 5 |
| Chang, B | 1 |
| Shukla, V | 1 |
| Fatima, J | 1 |
| Varshney, AR | 1 |
| Joshi, P | 1 |
| Kugashiya, R | 1 |
| Mozzini, C | 1 |
| Girelli, D | 1 |
| Setti, A | 1 |
| Croce, J | 1 |
| Stefanoni, F | 1 |
| Castagna, A | 1 |
| Pizzolo, F | 1 |
| Friso, S | 1 |
| Olivieri, O | 1 |
| Martinelli, N | 1 |
| Lin, WT | 1 |
| Kao, YH | 1 |
| Lin, HY | 3 |
| Li, MS | 1 |
| Fritz, JM | 1 |
| Seal, DW | 1 |
| Lee, CH | 2 |
| Hu, CY | 1 |
| Tseng, TS | 1 |
| Qi, X | 1 |
| Guan, K | 1 |
| Hwang, J | 3 |
| Lee, MY | 2 |
| Ahn, JK | 3 |
| Honda, K | 1 |
| Tanaka, K | 4 |
| Kazama, JJ | 1 |
| Maeda, M | 1 |
| Yabe, H | 1 |
| Nakano, H | 1 |
| Hayashi, F | 2 |
| Nagao, M | 1 |
| Ohira, H | 1 |
| Vernerová, A | 1 |
| Kujovská Krčmová, L | 1 |
| Melichar, B | 1 |
| Švec, F | 1 |
| Ma, M | 1 |
| Zhong, X | 4 |
| Peng, B | 2 |
| Mao, M | 1 |
| Zuzic Furlan, S | 1 |
| Rusic, D | 1 |
| Bozic, J | 1 |
| Rumboldt, M | 1 |
| Rumboldt, Z | 1 |
| Rada, M | 1 |
| Tomicic, M | 1 |
| Horne, A | 6 |
| Mihov, B | 1 |
| Stewart, A | 4 |
| Reid, IR | 1 |
| Ghasemi, A | 2 |
| Joseph, J | 1 |
| Giczewska, A | 1 |
| Alhanti, B | 1 |
| Cheema, AK | 1 |
| Handy, DE | 1 |
| Mann, DL | 1 |
| Loscalzo, J | 1 |
| Givertz, MM | 1 |
| Sakran, R | 1 |
| Frisch, A | 1 |
| Elias, A | 1 |
| Sliman, H | 1 |
| Ammuri, H | 1 |
| Kurnik, D | 1 |
| Ke, SR | 1 |
| Wu, YW | 3 |
| Kim, W | 1 |
| Go, TH | 1 |
| Kang, DO | 1 |
| Roh, SY | 1 |
| Na, JO | 1 |
| Choi, CU | 1 |
| Rha, SW | 1 |
| Park, CG | 1 |
| Seo, HS | 1 |
| Kang, DR | 1 |
| Kim, EJ | 1 |
| Arnett, DK | 1 |
| Chu, FJ | 1 |
| Jiang, SL | 1 |
| Jin, XB | 1 |
| Suissa, S | 1 |
| Suissa, K | 1 |
| Hudson, M | 1 |
| Kim, T | 2 |
| Kim, Y | 4 |
| Kang, J | 3 |
| Liu, YN | 1 |
| Che, X | 1 |
| Liu, KX | 1 |
| Topless, RKG | 1 |
| Florez, JC | 1 |
| Hirschhorn, JN | 1 |
| Wilcox, PL | 1 |
| Cole, JB | 1 |
| Zheng, B | 1 |
| Gong, Q | 1 |
| Zhong, J | 1 |
| Shen, Z | 5 |
| Lv, S | 4 |
| Tang, DH | 2 |
| Wang, CY | 5 |
| Yi, HK | 1 |
| Ma, KL | 2 |
| Ye, YS | 2 |
| Zhang, JW | 3 |
| Leander, J | 1 |
| Sunnåker, M | 1 |
| Rekić, D | 1 |
| Aksenov, S | 2 |
| Eriksson, UG | 2 |
| Li, TT | 1 |
| Nie, ZC | 1 |
| Li, SJ | 1 |
| Gu, CW | 1 |
| Xu, WD | 2 |
| Jia, H | 2 |
| Nakayama, M | 2 |
| Yamada, G | 1 |
| Tiku, A | 2 |
| Johnson, DW | 3 |
| Qiu, D | 1 |
| Wan, Z | 2 |
| Lei, X | 1 |
| Bossi, I | 1 |
| Racioppi, A | 1 |
| Nava, S | 2 |
| Soriano, F | 1 |
| Piccaluga, E | 1 |
| Piccalò, G | 1 |
| Oreglia, J | 1 |
| Pirola, R | 1 |
| De Chiara, B | 1 |
| Oliva, F | 1 |
| Moreo, A | 1 |
| Sanikidze, Q | 1 |
| Mamacashvili, I | 1 |
| Petriashvili, S | 1 |
| Kou, F | 1 |
| Preyer, O | 1 |
| Peng, LH | 1 |
| Zhao, ZX | 1 |
| He, CS | 1 |
| Zeng, A | 1 |
| Yun, C | 2 |
| Xue, H | 1 |
| Mikhailichenko, N | 1 |
| Wang, YH | 2 |
| Lai, TJ | 1 |
| Chan, Z | 1 |
| She, X | 1 |
| Zhou, C | 3 |
| Nieradko-Iwanicka, B | 1 |
| Lyu, S | 1 |
| Rao, Y | 1 |
| OuYang, H | 1 |
| Hu, T | 2 |
| Qiu, S | 1 |
| Szyszka, M | 1 |
| Skrzypczyk, P | 1 |
| Pańczyk-Tomaszewska, M | 1 |
| Taniguchi, T | 1 |
| Li, XM | 2 |
| Miao, JL | 1 |
| Tokumoto, Y | 1 |
| Fu, G | 2 |
| Shi, W | 3 |
| Shyy, JY | 1 |
| O'Connor, MJ | 1 |
| Leong, A | 1 |
| Ren, Q | 2 |
| Tao, S | 1 |
| Hu, N | 1 |
| de Magalhães, ELG | 1 |
| Juvanhol, LL | 1 |
| da Silva, DCG | 1 |
| Ferreira, FG | 1 |
| Roberto, DMT | 1 |
| Hinnig, PF | 1 |
| Longo, GZ | 1 |
| Kajana, V | 1 |
| Wang, YZ | 1 |
| Zhu, LJ | 1 |
| He, XL | 1 |
| Li, LZ | 2 |
| Xu, WF | 1 |
| Dong, YJ | 1 |
| Líška, D | 1 |
| Liu, JN | 1 |
| Tang, XQ | 2 |
| He, XQ | 2 |
| Wu, XM | 1 |
| Sui, MH | 2 |
| Gulab, A | 1 |
| Torres, R | 1 |
| Pelayo, J | 1 |
| Lo, KB | 1 |
| Shahzad, A | 1 |
| Pradhan, S | 1 |
| Rangaswami, J | 1 |
| Hossain, S | 1 |
| Naber, M | 1 |
| Yacobucci, MJ | 1 |
| Saitoh, S | 1 |
| Shimamoto, K | 1 |
| Siqueira, JH | 2 |
| Pereira, TSS | 1 |
| Velasquez-Melendez, G | 2 |
| Molina, MCB | 1 |
| Gan, S | 1 |
| Ye, M | 1 |
| Huang, QF | 2 |
| Wang, JG | 2 |
| Feitosa, GS | 1 |
| Seki, H | 1 |
| Kaneko, H | 1 |
| Morita, H | 1 |
| Itoh, H | 1 |
| Morita, K | 1 |
| Matsuoka, S | 1 |
| Kiriyama, H | 1 |
| Kamon, T | 1 |
| Fujiu, K | 1 |
| Michihata, N | 1 |
| Jo, T | 1 |
| Yano, Y | 1 |
| Nakamura, S | 2 |
| Yasunaga, H | 1 |
| Komuro, I | 1 |
| Ma, W | 2 |
| Qi, C | 1 |
| Kafa, AHT | 1 |
| Aslan, R | 1 |
| Celik, C | 1 |
| Hasbek, M | 1 |
| Bian, C | 1 |
| Masood, R | 1 |
| Meng, Z | 8 |
| Zhu, JX | 5 |
| Yang, HY | 1 |
| Hu, WQ | 1 |
| Yi, LT | 2 |
| Cheng, HY | 2 |
| Khairwa, A | 1 |
| Tao, H | 1 |
| Liao, L | 2 |
| Deng, P | 1 |
| Song, H | 2 |
| Man, S | 1 |
| Cui, N | 1 |
| You, Y | 1 |
| Zhan, D | 1 |
| Yan, T | 1 |
| Bahadoran, Z | 1 |
| Mirmiran, P | 1 |
| Kashfi, K | 1 |
| Noori, S | 1 |
| Mirzababaei, A | 1 |
| Amini, MR | 1 |
| Clark, CCT | 1 |
| Mirzaei, K | 1 |
| Beppu, T | 1 |
| Hidaka, Y | 3 |
| Feng, W | 1 |
| Arefan, D | 1 |
| Zhou, D | 2 |
| You, H | 1 |
| Zhu, D | 2 |
| Dyah Kurniasari, M | 1 |
| Karwur, FF | 1 |
| Rayanti, RE | 1 |
| Huruta, AD | 1 |
| Weng, SF | 1 |
| Tsai, HT | 1 |
| Hou, Y | 1 |
| Shang, L | 1 |
| Ren, M | 1 |
| Cheng, D | 1 |
| An, X | 1 |
| Liao, G | 1 |
| Omura, K | 1 |
| Motoki, K | 1 |
| Kobashi, S | 1 |
| Miyata, K | 1 |
| Yamano, K | 1 |
| Iwanaga, T | 1 |
| Yan, M | 4 |
| Ji, S | 1 |
| Xu, M | 4 |
| Dong, W | 1 |
| Shi, J | 2 |
| Zong, Q | 1 |
| Ayankunle, OM | 1 |
| Adeniyi, AA | 1 |
| Adewara, OE | 1 |
| Awoyinka, SB | 1 |
| Adebara, IO | 1 |
| Adeyemo, OT | 1 |
| Bakare, A | 1 |
| Olumodeji, AM | 1 |
| Jimoh, AK | 2 |
| Tsuchihashi, T | 1 |
| Lu, L | 2 |
| Dai, G | 1 |
| Handa, R | 1 |
| Malaviya, AN | 1 |
| Du, P | 1 |
| Deng, C | 1 |
| Liu, JH | 1 |
| Wu, MZ | 1 |
| Li, SM | 1 |
| Ren, QW | 1 |
| Lin, QS | 1 |
| Ng, MY | 1 |
| Tse, HF | 1 |
| Yiu, KH | 1 |
| McMullan, CJ | 1 |
| Borgi, L | 1 |
| Fisher, N | 1 |
| Curhan, G | 5 |
| Forman, J | 1 |
| Du, T | 1 |
| Ya, Z | 1 |
| Fei, L | 1 |
| Yue, Z | 1 |
| Dan, L | 1 |
| Neng-Bo, L | 1 |
| Yi, L | 1 |
| Ying, M | 1 |
| Shiraishi, T | 1 |
| Kumagai, T | 3 |
| Park, B | 1 |
| Lee, HA | 2 |
| Park, BM | 1 |
| Park, EA | 1 |
| Cho, SJ | 1 |
| Park, H | 2 |
| Eyupoglu, S | 1 |
| Eyupoglu, D | 1 |
| Kendi-Celebi, Z | 1 |
| Akturk, S | 1 |
| Tuzuner, A | 1 |
| Keven, K | 1 |
| Sengul, S | 1 |
| Ao, GZ | 1 |
| Zhou, MZ | 1 |
| Li, YY | 1 |
| Li, SN | 1 |
| Wang, HN | 1 |
| Wan, QW | 1 |
| Li, HQ | 1 |
| Hu, QH | 7 |
| Beydoun, MA | 1 |
| Canas, JA | 1 |
| Fanelli-Kuczmarski, MT | 1 |
| Tajuddin, SM | 1 |
| Evans, MK | 1 |
| Zonderman, AB | 1 |
| Longenecker, JC | 1 |
| Waheed, S | 1 |
| Bandak, G | 1 |
| Murakami, CA | 1 |
| McMahon, BA | 1 |
| Gelber, AC | 4 |
| Atta, MG | 1 |
| Tanner, C | 1 |
| Boocock, J | 1 |
| Stahl, EA | 2 |
| Dobbyn, A | 1 |
| Hindmarsh, JH | 3 |
| Nie, X | 1 |
| Hu, B | 1 |
| Nguyen, TD | 1 |
| Thuong, PT | 1 |
| Hwang, IH | 1 |
| Hoang, TK | 1 |
| Nguyen, MK | 1 |
| Nguyen, HA | 1 |
| Na, M | 1 |
| Lebensburger, JD | 1 |
| Cutter, GR | 1 |
| Howard, TH | 1 |
| Choi, AR | 1 |
| Kim, S | 6 |
| Choi, HY | 1 |
| Park, HC | 1 |
| Tan, PK | 2 |
| Gunic, E | 1 |
| Miner, JN | 6 |
| Hsieh, YP | 2 |
| Chang, CC | 2 |
| Kor, CT | 1 |
| Wen, YK | 2 |
| Chiu, PF | 2 |
| Zhang, HJ | 3 |
| Li, LN | 1 |
| Yang, QQ | 1 |
| Liu, PG | 2 |
| Liang, WQ | 2 |
| Cheng, L | 1 |
| Zhang, YQ | 1 |
| Pu, JB | 2 |
| Hu, YJ | 3 |
| Meng, L | 2 |
| Mu, R | 2 |
| Gul, A | 1 |
| Harford, A | 1 |
| Zager, P | 1 |
| Yamada, Y | 7 |
| Sakuma, J | 2 |
| Takeuchi, I | 2 |
| Yasukochi, Y | 2 |
| Oguri, M | 2 |
| Fujimaki, T | 2 |
| Horibe, H | 2 |
| Muramatsu, M | 1 |
| Sawabe, M | 1 |
| Fujiwara, Y | 1 |
| Taniguchi, Y | 2 |
| Obuchi, S | 1 |
| Kawai, H | 1 |
| Shinkai, S | 1 |
| Mori, S | 1 |
| Arai, T | 1 |
| Gil, MS | 1 |
| Cho, J | 1 |
| Thambi, T | 1 |
| Giang Phan, VH | 1 |
| Kwon, I | 3 |
| Lee, DS | 1 |
| Caliceti, C | 2 |
| Calabria, D | 2 |
| Roda, A | 3 |
| Piscitelli, P | 1 |
| Giorda, C | 1 |
| Ceriello, A | 1 |
| Genovese, S | 1 |
| Russo, G | 1 |
| Guida, P | 1 |
| Fioretto, P | 1 |
| De Cosmo, S | 1 |
| Deeks, ED | 1 |
| Ciccarelli, G | 1 |
| Mangiacapra, F | 1 |
| Pellicano, M | 1 |
| Barbato, E | 1 |
| Just, J | 1 |
| Bleckwenn, M | 1 |
| Weckbecker, K | 2 |
| Gu, H | 3 |
| Yu, FN | 1 |
| Huang, XL | 1 |
| Liu, SS | 1 |
| Vargas-Santos, AB | 2 |
| Neogi, T | 7 |
| Hira, D | 1 |
| Tsujimoto, M | 1 |
| Katsube, Y | 1 |
| Minegaki, T | 1 |
| Uzu, T | 1 |
| Ikeda, Y | 1 |
| Morita, SY | 1 |
| Nishiguchi, K | 1 |
| Terada, T | 1 |
| Fukuhara, A | 1 |
| Saito, J | 2 |
| Sato, S | 2 |
| Saito, K | 1 |
| Fukuhara, N | 1 |
| Tanino, Y | 1 |
| Rinno, K | 1 |
| Munakata, M | 1 |
| Lin, ZM | 1 |
| Zhang, RS | 1 |
| Fan, CX | 1 |
| Liang, YL | 1 |
| Qu, JC | 1 |
| Zhao, HY | 1 |
| Liu, XN | 1 |
| Zhu, KS | 1 |
| Huijuan, W | 1 |
| Xiaoxu, C | 1 |
| Rui, S | 1 |
| Xinghui, L | 1 |
| Beibei, T | 1 |
| Jianchun, M | 1 |
| Lee, JP | 1 |
| Park, S | 2 |
| Kim, YC | 1 |
| Ahn, C | 3 |
| Han, DJ | 4 |
| Ha, J | 2 |
| Jung, IM | 1 |
| Lim, CS | 1 |
| Kim, YH | 2 |
| Lü, K | 1 |
| Cleophas, MCP | 1 |
| Novakovic, B | 1 |
| Erler, K | 1 |
| van de Veerdonk, FL | 1 |
| Stunnenberg, HG | 1 |
| Netea, MG | 1 |
| Dinarello, CA | 1 |
| Yoon, IS | 2 |
| Park, DH | 2 |
| Kim, JE | 1 |
| Yoo, JC | 1 |
| Bae, MS | 1 |
| Oh, DS | 1 |
| Shim, JH | 1 |
| Choi, CY | 2 |
| An, KW | 1 |
| Kim, EI | 1 |
| Kim, GY | 1 |
| Cho, SS | 2 |
| Chang, LC | 1 |
| Wu, PF | 1 |
| Ronda, L | 2 |
| Marchetti, M | 2 |
| Piano, R | 1 |
| Liuzzi, A | 2 |
| Corsini, R | 2 |
| Percudani, R | 2 |
| Bettati, S | 2 |
| Kim, JK | 2 |
| Kim, WJ | 1 |
| Hyun, JM | 1 |
| Kwon, JG | 1 |
| Seo, C | 1 |
| Song, MJ | 1 |
| Choi, CW | 1 |
| Hong, SS | 1 |
| Park, K | 1 |
| Kim, P | 1 |
| Sung, H | 1 |
| Choi, Y | 2 |
| Harada, M | 1 |
| Hashimoto, K | 1 |
| Kamijo, Y | 1 |
| Perticone, M | 1 |
| Tripepi, G | 4 |
| Maio, R | 1 |
| Cimellaro, A | 1 |
| Addesi, D | 1 |
| Baggetta, R | 1 |
| Perticone, F | 1 |
| Kong, X | 3 |
| Lei, P | 1 |
| Bangalore, S | 1 |
| Klein, AB | 1 |
| Baumgartner, S | 2 |
| Morlock, R | 1 |
| Fang, ZR | 1 |
| Shen, YT | 1 |
| Liu, YB | 1 |
| Liu, LL | 1 |
| Chen, YS | 1 |
| Ge, HM | 1 |
| Kong, LD | 20 |
| Szczurek, P | 1 |
| Mosiichuk, N | 1 |
| Woliński, J | 1 |
| Yatsenko, T | 1 |
| Grujic, D | 1 |
| Lozinska, L | 1 |
| Pieszka, M | 1 |
| Święch, E | 1 |
| Pierzynowski, SG | 1 |
| Goncharova, K | 1 |
| Obata, K | 1 |
| Kanno, S | 1 |
| Song, XJ | 1 |
| Pan, HH | 1 |
| Na, S | 3 |
| Bao, Y | 4 |
| Jia, W | 4 |
| Li, YP | 1 |
| Ran, A | 1 |
| Xu, DY | 1 |
| Wei, JM | 1 |
| Zhao, ZL | 1 |
| Jaruvongvanich, V | 2 |
| Ahuja, W | 2 |
| Wirunsawanya, K | 1 |
| Wijarnpreecha, K | 3 |
| Soysal, P | 2 |
| Li, ZJ | 1 |
| Dong, XY | 1 |
| Lu, LF | 2 |
| Wang, CL | 2 |
| Liao, S | 2 |
| Neuhauser, HK | 1 |
| Yue, G | 1 |
| Du, Z | 1 |
| Paschos, P | 1 |
| Athyros, VG | 5 |
| Tsimperidis, A | 1 |
| Katsoula, A | 1 |
| Grammatikos, N | 1 |
| Giouleme, O | 1 |
| Punzi, L | 8 |
| Rasheed, H | 2 |
| Cappadona, F | 1 |
| Feng, Z | 3 |
| Song, JU | 2 |
| Bauer, F | 3 |
| Pagonas, N | 3 |
| Seibert, FS | 3 |
| Zidek, W | 4 |
| Viebahn, R | 1 |
| Babel, N | 3 |
| Westhoff, TH | 2 |
| Qiu, L | 2 |
| Cheng, XQ | 2 |
| Wu, W | 3 |
| Zeng, XJ | 2 |
| Ye, YC | 1 |
| Guo, XZ | 2 |
| Cheng, Q | 3 |
| Xu, CL | 1 |
| Zhu, GJ | 2 |
| Mantovani, A | 3 |
| Rigolon, R | 3 |
| Civettini, A | 1 |
| Bolzan, B | 1 |
| Morani, G | 2 |
| Bonapace, S | 2 |
| Dugo, C | 2 |
| Zoppini, G | 4 |
| Bonora, E | 4 |
| Targher, G | 10 |
| Noma, K | 1 |
| Kihara, Y | 2 |
| Xin, Y | 1 |
| Jia, Z | 2 |
| Mi, QS | 1 |
| Ferraro, PM | 1 |
| Curhan, GC | 2 |
| Freier-Dror, Y | 1 |
| Ahmadieh, H | 1 |
| Azar, S | 1 |
| Ichii, O | 1 |
| Shimamura, Y | 1 |
| Castro, VMF | 1 |
| Melo, AC | 1 |
| Belo, VS | 1 |
| Chaves, VE | 1 |
| Giovannini, M | 1 |
| Colletti, A | 1 |
| Veronesi, M | 2 |
| Mortada, I | 1 |
| Bang, SY | 2 |
| Sung, YK | 2 |
| Bae, SC | 2 |
| Hasic, S | 1 |
| Kadic, D | 1 |
| Kiseljakovic, E | 1 |
| Jadric, R | 1 |
| Spahic, E | 1 |
| Chini, LSN | 1 |
| Assis, LIS | 1 |
| Lugon, JR | 3 |
| Golmohammadi, S | 1 |
| Almasi, A | 2 |
| Manouchehri, M | 1 |
| Omrani, HR | 1 |
| Zandkarimi, MR | 1 |
| De Vivo, O | 1 |
| Nuti, R | 2 |
| McCullough, PA | 2 |
| Wyss, A | 1 |
| Qu, R | 2 |
| Jiang, R | 1 |
| Na, L | 2 |
| Leng, J | 1 |
| Thottam, GE | 1 |
| Krasnokutsky, S | 2 |
| Tian, D | 1 |
| Xia, P | 1 |
| Zheng, H | 3 |
| Mitsuboshi, S | 1 |
| Nagai, K | 1 |
| Okajima, H | 1 |
| Chen, RJ | 1 |
| Chen, MH | 1 |
| Chen, YL | 3 |
| Hsiao, CM | 1 |
| Chen, HM | 1 |
| Chen, SJ | 2 |
| Wu, MD | 1 |
| Yech, YJ | 1 |
| Yuan, GF | 1 |
| Wang, YJ | 1 |
| Battaggia, A | 1 |
| Scalisi, A | 1 |
| Puccetti, L | 1 |
| Miyagi, T | 2 |
| Nagahama, K | 3 |
| Yonemoto, K | 1 |
| Tai, LL | 2 |
| Wan, XC | 2 |
| Li, DX | 2 |
| Zhao, YQ | 1 |
| Yu, XL | 1 |
| Shen, XM | 1 |
| Zhang, XY | 2 |
| Zheng, PF | 1 |
| Palmer, WE | 1 |
| MacDonald, PA | 10 |
| Thienel, U | 1 |
| Castro-Torres, Y | 1 |
| Khan, NY | 1 |
| Carmona-Puerta, R | 1 |
| Kokott, P | 1 |
| Nie, AZ | 1 |
| Li, LY | 1 |
| He, T | 1 |
| Xiao, T | 2 |
| Majumder, K | 1 |
| Ning, Z | 1 |
| Matsukuma, Y | 1 |
| Tanaka, S | 2 |
| Tsuchimoto, A | 1 |
| Haruyama, N | 1 |
| Okabe, Y | 1 |
| Kitazono, T | 1 |
| Cutolo, M | 1 |
| Cimmino, MA | 2 |
| Peng, Z | 1 |
| Yuan, Q | 1 |
| Ao, X | 1 |
| Rincon-Choles, H | 1 |
| Jolly, SE | 1 |
| Arrigain, S | 1 |
| Konig, V | 1 |
| Schold, JD | 1 |
| Nakhoul, G | 1 |
| Navaneethan, SD | 1 |
| Nally, JV | 1 |
| Rothberg, MB | 1 |
| Pichiri, I | 3 |
| Cheng, P | 1 |
| Jiao, R | 1 |
| Tang, J | 2 |
| Gong, L | 2 |
| Luo, R | 3 |
| Zuo, J | 1 |
| Bou-Chacra, N | 1 |
| Löbenberg, R | 1 |
| Zhao, R | 2 |
| Bove, M | 2 |
| Sampson, AL | 1 |
| Singer, RF | 1 |
| Walters, GD | 1 |
| Butković, M | 1 |
| Arfian, N | 2 |
| Tranggono, U | 1 |
| Setyaningsih, WAW | 1 |
| Sari, DCR | 2 |
| Liu, ZH | 2 |
| Gao, LH | 2 |
| Zou, CG | 1 |
| McLean, L | 1 |
| Punzi, HA | 1 |
| Palmer, RN | 1 |
| Kung, H | 1 |
| Lin, MC | 1 |
| Leung, KS | 1 |
| Wong, MH | 1 |
| Gao, F | 1 |
| Braga, F | 2 |
| Ferraro, S | 2 |
| Pasqualetti, S | 2 |
| Panteghini, M | 2 |
| Cleveland, J | 1 |
| Mapoure, YN | 2 |
| Ayeah, CM | 2 |
| Ba, H | 2 |
| Hentchoya, R | 2 |
| Luma, HN | 2 |
| Lazzeroni, D | 1 |
| Bini, M | 1 |
| Camaiora, U | 1 |
| Castiglioni, P | 1 |
| Moderato, L | 1 |
| Bosi, D | 1 |
| Geroldi, S | 1 |
| Ugolotti, PT | 1 |
| Brambilla, L | 1 |
| Brambilla, V | 1 |
| Coruzzi, P | 1 |
| Chou, HW | 1 |
| Chiu, HT | 2 |
| Tsai, CW | 1 |
| Ting, IW | 1 |
| Yeh, HC | 1 |
| Huang, HC | 1 |
| Kuo, CC | 2 |
| Kim, SJ | 4 |
| Maggioni, S | 1 |
| Panzeri, F | 1 |
| Falbo, R | 1 |
| Heikamp, E | 1 |
| Dreyer, ZE | 1 |
| Yoon, WT | 1 |
| Chung, PW | 1 |
| Chang, I | 1 |
| Gazeley, D | 1 |
| Wannamethee, SG | 1 |
| Papacosta, O | 1 |
| Lennon, L | 1 |
| Whincup, PH | 1 |
| Nobili, V | 1 |
| Mosca, A | 1 |
| De Vito, R | 1 |
| Raponi, M | 1 |
| Scorletti, E | 1 |
| Byrne, CD | 1 |
| Nagaoka, Y | 1 |
| Yoshimoto, H | 1 |
| Suzuki, R | 1 |
| Ryu, K | 1 |
| Ueda, M | 1 |
| Miyaoka, Y | 1 |
| Iwai, S | 1 |
| Nagaoka, M | 1 |
| Zhi, X | 1 |
| Mahbub, MH | 1 |
| Yamaguchi, N | 1 |
| Ishimaru, Y | 1 |
| Sunagawa, H | 1 |
| Amano, H | 1 |
| Kobayashi-Miura, M | 1 |
| Kanda, H | 1 |
| Fujita, Y | 1 |
| Yamamoto, H | 2 |
| Kikuchi, S | 1 |
| Ikeda, A | 2 |
| Kageyama, N | 1 |
| Tanabe, T | 1 |
| Kei, A | 1 |
| Koutsouka, F | 1 |
| Makri, A | 1 |
| Elisaf, M | 1 |
| Baek, CH | 1 |
| Yang, WS | 3 |
| Park, SK | 4 |
| Qiu, J | 1 |
| Georgiopoulos, G | 1 |
| Tsioufis, C | 1 |
| Kalos, T | 1 |
| Magkas, N | 1 |
| Roussos, D | 1 |
| Chrysohoou, C | 3 |
| Sarri, G | 1 |
| Syrmali, K | 1 |
| Georgakopoulos, P | 1 |
| Tousoulis, D | 1 |
| Ma, WG | 1 |
| Bu, XW | 1 |
| Zhang, HH | 2 |
| Zhang, JP | 1 |
| Zhang, XX | 5 |
| He, YX | 1 |
| Wang, DL | 1 |
| Zhang, ZJ | 1 |
| Meng, FX | 1 |
| Porchia, LM | 1 |
| Gonzalez-Mejia, ME | 1 |
| Torres-Rasgado, E | 1 |
| Ruiz-Vivanco, G | 1 |
| Pérez-Fuentes, R | 1 |
| Simeunovic Ostojic, M | 1 |
| Maas, J | 1 |
| Zhang, ZW | 1 |
| Lai, TL | 1 |
| Yim, CW | 1 |
| Wong, PY | 1 |
| Leung, MC | 1 |
| Ng, WL | 1 |
| Abraham, I | 1 |
| Fu, C | 2 |
| Atıl, A | 1 |
| Deniz, A | 1 |
| Yu, KH | 9 |
| Chen, DY | 3 |
| Chen, SY | 1 |
| Chen, SM | 1 |
| Cheng, TT | 1 |
| Hsieh, SC | 1 |
| Hsieh, TY | 1 |
| Kuo, CF | 5 |
| Kuo, MC | 2 |
| Lam, HC | 1 |
| Lee, IT | 1 |
| Liang, TH | 1 |
| Lin, SC | 1 |
| Tsai, WP | 3 |
| Tsay, GJ | 1 |
| Yang, CH | 2 |
| Tsai, WC | 2 |
| Honda, D | 1 |
| Sakamoto, R | 4 |
| Narita, K | 1 |
| Mensink, GBM | 1 |
| Kamei, K | 4 |
| Kubota, I | 5 |
| Treviño-Becerra, A | 1 |
| Méndez Landa, CE | 1 |
| Bellomo, G | 3 |
| Selvi, A | 1 |
| Andrade Sierra, J | 1 |
| Flores Fonseca, MM | 1 |
| Chang, WX | 2 |
| Pazos Pérez, F | 1 |
| Moreno Santillan, AA | 1 |
| Briones Garduño, JC | 1 |
| Diaz de Leon Ponce, MA | 1 |
| Tamayo Y Orozco, JA | 1 |
| King, C | 1 |
| Jensen, T | 2 |
| Tolan, DR | 1 |
| Mauer, M | 1 |
| Alegría-Díaz, A | 1 |
| Valdez-Ortiz, R | 1 |
| Murguía-Romero, M | 1 |
| Jiménez-Flores, R | 1 |
| Villalobos-Molina, R | 1 |
| Mummidi, S | 1 |
| Duggirala, R | 1 |
| López-Alvarenga, JC | 1 |
| Pérez-Navarro, M | 1 |
| Fanning, N | 1 |
| Mazumder, MK | 1 |
| Phukan, BC | 1 |
| Bhattacharjee, A | 1 |
| Borah, A | 1 |
| Lopez-Pineda, A | 2 |
| Cordero, A | 2 |
| Carratala-Munuera, C | 1 |
| Orozco-Beltran, D | 1 |
| Quesada, JA | 1 |
| Bertomeu-Gonzalez, V | 1 |
| Gil-Guillen, VF | 1 |
| Bertomeu-Martinez, V | 2 |
| Yin, YJ | 1 |
| Wu, JN | 1 |
| Li, GX | 1 |
| Jiao, XH | 1 |
| Cheng, XB | 1 |
| Tscharre, M | 1 |
| Herman, R | 1 |
| Rohla, M | 1 |
| Hauser, C | 1 |
| Farhan, S | 1 |
| Freynhofer, MK | 1 |
| Huber, K | 1 |
| Weiss, TW | 1 |
| Arévalo-Lorido, JC | 2 |
| Carretero-Gómez, J | 2 |
| Robles, NR | 1 |
| Wilcox, CS | 1 |
| Shen, W | 1 |
| Boulton, DW | 1 |
| Leslie, BR | 1 |
| Griffen, SC | 1 |
| Tseng, WC | 2 |
| Chen, YT | 2 |
| Ou, SM | 2 |
| Shih, CJ | 1 |
| Tarng, DC | 3 |
| Fan, YQ | 1 |
| Zhang, HL | 1 |
| Tanriverdi, Z | 1 |
| Besli, F | 2 |
| Gungoren, F | 1 |
| Altiparmak, İH | 1 |
| Yesilay, AB | 1 |
| Mulè, G | 3 |
| Nardi, E | 2 |
| Lattuca, L | 1 |
| Cottone, S | 3 |
| Estevez-Garcia, IO | 1 |
| Gallegos-Nava, S | 1 |
| Vera-Pérez, E | 1 |
| Silveira, LH | 1 |
| Ventura-Ríos, L | 2 |
| Vancini, G | 1 |
| Hernández-Díaz, C | 2 |
| Sánchez-Muñoz, F | 2 |
| Ballinas-Verdugo, MA | 1 |
| Pineda, C | 3 |
| Rodriguez-Henriquez, P | 1 |
| Castillo-Martínez, D | 2 |
| Amezcua-Guerra, LM | 2 |
| Kasai, Y | 1 |
| Senzaki, K | 1 |
| Kusunoki, T | 2 |
| Ohtsuka, N | 1 |
| Taylor, WJ | 7 |
| Jun, JE | 1 |
| Lee, YB | 1 |
| Lee, SE | 1 |
| Ahn, JY | 1 |
| Kim, G | 1 |
| Jin, SM | 2 |
| Hur, KY | 1 |
| Lee, MK | 2 |
| Kang, MR | 1 |
| Keen, HI | 1 |
| Davis, WA | 1 |
| Latkovic, E | 1 |
| Drinkwater, JJ | 1 |
| Nossent, J | 2 |
| Davis, TME | 1 |
| Peck, CC | 1 |
| Stanski, DR | 1 |
| Su, Q | 2 |
| Nong, Z | 1 |
| Chu, S | 1 |
| Ya, Q | 1 |
| Wei, G | 1 |
| Lee, CA | 1 |
| Shah, V | 1 |
| Wilson, DM | 1 |
| Ostertag, TM | 1 |
| Girardet, JL | 1 |
| Hall, J | 2 |
| Gillen, M | 2 |
| Yuan, Z | 2 |
| Pang, Y | 3 |
| Qiu, H | 2 |
| Coiro, S | 1 |
| Carluccio, E | 1 |
| Biagioli, P | 1 |
| Alunni, G | 1 |
| Murrone, A | 1 |
| D'Antonio, A | 1 |
| Zuchi, C | 1 |
| Mengoni, A | 1 |
| Ambrosio, G | 1 |
| Ricotti, R | 1 |
| Genoni, G | 1 |
| Giglione, E | 1 |
| Monzani, A | 1 |
| Nugnes, M | 1 |
| Zanetta, S | 1 |
| Castagno, M | 1 |
| Marolda, A | 1 |
| Bona, G | 1 |
| Bellone, S | 1 |
| Prodam, F | 1 |
| Alhelal, JW | 1 |
| Ravuru, KSS | 1 |
| Cabrera Naranjo, FH | 1 |
| Saavedra Santana, P | 1 |
| González Hernández, A | 1 |
| Fabre Pi, O | 1 |
| Sosa-Henríquez, M | 1 |
| Huang, D | 1 |
| Harman, JL | 1 |
| Coresh, J | 5 |
| McAdams-DeMarco, MA | 3 |
| Correa, A | 1 |
| Young, BA | 1 |
| Katz, R | 1 |
| Rebholz, CM | 1 |
| Ghane Sharbaf, F | 1 |
| Assadi, F | 1 |
| Naganuma, M | 1 |
| Inatomi, Y | 1 |
| Yonehara, T | 1 |
| Ando, Y | 1 |
| Ala-Mutka, EM | 1 |
| Rimpelä, JM | 1 |
| Fyhrquist, F | 1 |
| Kontula, KK | 1 |
| Hiltunen, TP | 1 |
| Shuai, O | 1 |
| Pirro, M | 1 |
| Bianconi, V | 1 |
| Schiaroli, E | 1 |
| Francisci, D | 1 |
| Mannarino, MR | 1 |
| Bagaglia, F | 1 |
| Sahebkar, A | 2 |
| Merriman, T | 4 |
| Baldelli, F | 1 |
| Marin, M | 1 |
| Maalouf, NM | 2 |
| Long, J | 1 |
| Qing, H | 1 |
| Ramirez, AJ | 1 |
| Christen, AI | 1 |
| Sanchez, RA | 1 |
| Viggiano, D | 1 |
| Gigliotti, G | 1 |
| Vallone, G | 1 |
| Giammarino, A | 1 |
| Nigro, M | 1 |
| Capasso, G | 3 |
| Kim, I | 1 |
| Tsuji, T | 3 |
| Ohishi, K | 1 |
| Takeda, A | 1 |
| Goto, D | 2 |
| Ohashi, N | 2 |
| Kato, A | 2 |
| Yasuda, H | 2 |
| Tasić, I | 1 |
| Kostić, S | 1 |
| Stojanović, NM | 1 |
| Skakić, V | 1 |
| Cvetković, J | 1 |
| Djordjević, A | 1 |
| Karadzić, M | 1 |
| Djordjević, D | 1 |
| Andonov, S | 1 |
| Stoičkov, V | 1 |
| Tasić, D | 1 |
| Vanka, M | 1 |
| Lović, D | 1 |
| Bursill, D | 2 |
| Shan, R | 1 |
| Zi, T | 1 |
| Fabre, S | 1 |
| Launay, JM | 1 |
| Gautier, JF | 1 |
| Vidal-Trecan, T | 1 |
| Riveline, JP | 1 |
| Platt, A | 1 |
| Abrahamsson, A | 1 |
| Hughes, G | 1 |
| Liang, Q | 1 |
| Wang, XY | 1 |
| Hu, HF | 1 |
| Lai, JB | 1 |
| Yao, WL | 1 |
| Chen, ML | 2 |
| Rao, X | 1 |
| Chang, WC | 4 |
| Lee, CC | 2 |
| Chen, KH | 2 |
| Kwak, CH | 1 |
| Sohn, M | 1 |
| Han, N | 1 |
| Cho, YS | 1 |
| Oh, JM | 1 |
| Kim, GT | 2 |
| Grainger, R | 3 |
| Louthrenoo, W | 3 |
| Edwards, NL | 6 |
| Tedeschi, SK | 1 |
| Kim, SC | 1 |
| Harrold, LR | 1 |
| McCarthy, G | 3 |
| Kumar, N | 2 |
| Chapman, PT | 2 |
| Vazquez-Mellado, J | 4 |
| da Rocha Castelar-Pinheiro, G | 2 |
| Fisher, MC | 1 |
| Burgos-Vargas, R | 3 |
| Robinson, PC | 4 |
| Slot, O | 1 |
| Uhlig, T | 4 |
| Solomon, DH | 1 |
| Scire, CA | 2 |
| Biernat-Kaluza, E | 1 |
| Nuki, G | 5 |
| Sivera, F | 3 |
| Ea, HK | 2 |
| Rosenthal, A | 1 |
| Hershfield, MS | 2 |
| Czegley, C | 2 |
| Choi, SJ | 2 |
| Nakashima, A | 2 |
| Yamauchi, A | 2 |
| Matsumoto, J | 1 |
| Dohgu, S | 1 |
| Takata, F | 1 |
| Koga, M | 3 |
| Fukae, J | 1 |
| Tsuboi, Y | 1 |
| Kataoka, Y | 1 |
| Kumar A U, A | 1 |
| Browne, LD | 1 |
| Adeeb, F | 1 |
| Fraser, AD | 1 |
| Hanai, K | 1 |
| Tauchi, E | 1 |
| Nishiwaki, Y | 1 |
| Mori, T | 1 |
| Yokoyama, Y | 1 |
| Uchigata, Y | 1 |
| Babazono, T | 1 |
| Shiramoto, M | 1 |
| Yan, X | 1 |
| Yamamoto, A | 4 |
| Ito, Y | 4 |
| Kimura, T | 5 |
| Echizen, H | 2 |
| Torres, RJ | 10 |
| Puig, JG | 11 |
| Jeong, HS | 1 |
| Kook, H | 2 |
| Hong, SJ | 1 |
| Yu, CW | 1 |
| Lim, DS | 1 |
| Zhou, GX | 1 |
| Jiang, W | 1 |
| Liu, BL | 1 |
| Mattson, DL | 1 |
| Mancusi, C | 1 |
| Izzo, R | 2 |
| Ferrara, LA | 1 |
| Rozza, F | 2 |
| Losi, MA | 1 |
| Canciello, G | 1 |
| Pepe, M | 1 |
| de Luca, N | 1 |
| Trimarco, B | 2 |
| de Simone, G | 1 |
| Ma, A | 2 |
| Weaver, DJ | 2 |
| Bai, W | 1 |
| Giannopoulos, G | 1 |
| Angelidis, C | 1 |
| Deftereos, S | 1 |
| Kobylecki, CJ | 1 |
| Afzal, S | 1 |
| Nordestgaard, BG | 2 |
| Sun, P | 1 |
| Zhang, N | 6 |
| Dai, Y | 1 |
| Field, C | 1 |
| Block, C | 1 |
| Taylor, T | 1 |
| Vlachopoulos, C | 1 |
| Iwasaki, Y | 1 |
| Matsumoto, C | 1 |
| Fujii, M | 1 |
| Chikamori, T | 1 |
| Yamashina, A | 2 |
| Murea, M | 2 |
| Tucker, BM | 1 |
| Tan, X | 1 |
| Song, J | 2 |
| Jia, X | 1 |
| Feng, L | 2 |
| Marrs, CC | 1 |
| Rahman, M | 2 |
| Dixon, L | 1 |
| Olson, G | 1 |
| Liang, Y | 1 |
| Rosenthal, TR | 1 |
| Williams, JS | 1 |
| Shelton, JM | 1 |
| Bobulescu, IA | 3 |
| Black-Maier, E | 1 |
| Daubert, JP | 1 |
| Tana, C | 1 |
| Ticinesi, A | 1 |
| Prati, B | 1 |
| Nouvenne, A | 1 |
| Meschi, T | 1 |
| Moreira, AD | 1 |
| Molina, MDCB | 1 |
| Rodríguez-Hernández, JL | 1 |
| Rodríguez-González, F | 2 |
| Riaño-Ruiz, M | 1 |
| Martínez-Quintana, E | 2 |
| Mohan, C | 1 |
| Kuwabara, R | 1 |
| Niwa, K | 4 |
| Smits, G | 2 |
| Roncal-Jimenez, CA | 2 |
| MacLean, PS | 1 |
| Yracheta, JM | 1 |
| Ohno, M | 2 |
| Jalal, DI | 4 |
| Li, F | 6 |
| Zou, J | 1 |
| Acar, T | 1 |
| Güzey Aras, Y | 1 |
| Gül, SS | 1 |
| Acar, AB | 1 |
| Xu, JB | 1 |
| Pyo, YH | 1 |
| Hwang, JY | 1 |
| Seong, KS | 1 |
| Zhou, XW | 1 |
| Fei, YY | 1 |
| Jiang, JL | 1 |
| Ye, SD | 1 |
| Park, CE | 1 |
| Jung, EY | 1 |
| Moon, AE | 1 |
| García-Arroyo, FE | 2 |
| Gonzaga, G | 1 |
| Muñoz-Jiménez, I | 1 |
| Blas-Marron, MG | 1 |
| Silverio, O | 1 |
| Tapia, E | 4 |
| Soto, V | 4 |
| Ranganathan, N | 1 |
| Ranganathan, P | 1 |
| Vyas, U | 1 |
| Irvin, A | 1 |
| Ir, D | 1 |
| Robertson, CE | 1 |
| Frank, DN | 1 |
| Karabağ, Y | 1 |
| Rencuzogullari, I | 1 |
| Çağdaş, M | 1 |
| Karakoyun, S | 1 |
| Yesin, M | 1 |
| Atalay, E | 1 |
| Çağdaş, ÖS | 1 |
| Gürsoy, MO | 1 |
| Burak, C | 1 |
| Tanboğa, HI | 1 |
| Duan, N | 1 |
| Cui, W | 1 |
| Moriyama, K | 1 |
| Kim, SK | 5 |
| Kwak, SG | 1 |
| Choe, JY | 2 |
| Kapetanovic, MC | 1 |
| Nilsson, P | 1 |
| Turesson, C | 1 |
| Englund, M | 1 |
| Gomm, W | 1 |
| Broich, K | 1 |
| Maier, W | 1 |
| Haenisch, B | 1 |
| Levy, G | 1 |
| Shi, JM | 1 |
| Cheetham, TC | 3 |
| Rashid, N | 3 |
| Robles Pérez-Monteoliva, NR | 1 |
| Ogawa, Y | 2 |
| Calvo Aranda, E | 1 |
| Gonzalez Martin, J | 1 |
| Abdelkader Abu-Sneimeh, A | 1 |
| Carrion, O | 1 |
| Sainz, F | 1 |
| Garcia de la Peña, P | 1 |
| Lee, YS | 2 |
| Yuk, HJ | 2 |
| Ebrahimpour-Koujan, S | 1 |
| Saneei, P | 1 |
| Larijani, B | 2 |
| Esmaillzadeh, A | 1 |
| Feng, J | 3 |
| Shi, R | 1 |
| Renqian, L | 1 |
| Langtai, Z | 1 |
| Diao, Y | 1 |
| Yu, XN | 1 |
| Wu, HY | 1 |
| Deng, YP | 1 |
| Zhuang, GT | 1 |
| Tan, BH | 1 |
| Huang, YZ | 2 |
| Tang, SY | 1 |
| Tu, X | 1 |
| Jordan, JB | 1 |
| Zhong, S | 2 |
| Pollo Renner, JD | 1 |
| Burgos, LT | 1 |
| Rech Franke, SI | 1 |
| Burgos, MS | 1 |
| Lorenzo, JM | 1 |
| Barba, FJ | 1 |
| Ferreira, TDS | 1 |
| Fernandes, JFR | 1 |
| Araújo, LDS | 1 |
| Nogueira, LP | 1 |
| Leal, PM | 1 |
| Antunes, VP | 1 |
| Rodrigues, MLG | 1 |
| Valença, DCT | 1 |
| Kaiser, SE | 1 |
| Klein, MRST | 1 |
| Wardhana, W | 1 |
| Rudijanto, A | 1 |
| Uk Kang, T | 1 |
| Park, KY | 2 |
| Ahn, HS | 3 |
| Yim, SY | 2 |
| Tiwaskar, M | 1 |
| Raina, S | 1 |
| Agarwal, VK | 1 |
| Kapoor, D | 1 |
| Sharma, KN | 1 |
| Yadav, RS | 1 |
| Lv, X | 1 |
| Saigal, R | 2 |
| Goyal, LK | 1 |
| Jain, DK | 1 |
| Feng, D | 1 |
| Teng, Y | 3 |
| Tang, R | 1 |
| Olofsson, C | 1 |
| Anderstam, B | 1 |
| Bragfors-Helin, AC | 1 |
| Eriksson, M | 1 |
| Qureshi, AR | 3 |
| Lindholm, B | 3 |
| Hilding, A | 1 |
| Wiczkowski, W | 1 |
| Orsini, N | 1 |
| Stenvinkel, P | 2 |
| Rajamand Ekberg, N | 1 |
| Ci, X | 1 |
| Lan, M | 1 |
| Perveen, R | 1 |
| Rahman, S | 3 |
| Mahmood, S | 2 |
| Islam, S | 2 |
| Haque, T | 2 |
| Islam, F | 3 |
| Mohanto, NC | 2 |
| Nurunnabi, SM | 2 |
| Ahmed, S | 2 |
| Baey, C | 1 |
| Ronchese, F | 1 |
| Harper, JL | 4 |
| Tykarski, A | 1 |
| Widecka, K | 1 |
| Filipiak, KJ | 1 |
| Domienik-Karłowicz, J | 1 |
| Kostka-Jeziorny, K | 1 |
| Varga, A | 1 |
| Jaguszewski, M | 1 |
| Narkiewicz, K | 1 |
| Hsieh, MH | 1 |
| Woerner, J | 1 |
| Lucas, T | 1 |
| Pierce, J | 1 |
| Riis, JL | 1 |
| Granger, DA | 1 |
| Kiss, LZ | 1 |
| Bagyura, Z | 1 |
| Csobay-Novák, C | 1 |
| Lux, Á | 1 |
| Polgár, L | 1 |
| Jermendy, Á | 1 |
| Soós, P | 1 |
| Szelid, Z | 1 |
| Maurovich-Horvat, P | 1 |
| Becker, D | 1 |
| Merkely, B | 2 |
| Wei, XB | 1 |
| Chen, WJ | 1 |
| Duan, CY | 1 |
| Qin, TH | 1 |
| Geng, QS | 1 |
| Luo, P | 1 |
| Hu, LS | 3 |
| Chai, YC | 1 |
| Shi, JH | 1 |
| Tian, M | 1 |
| Jia, A | 1 |
| Xi, D | 1 |
| Rao, Z | 1 |
| Wu, YY | 1 |
| Qiu, XH | 1 |
| Ye, Y | 1 |
| Xia, G | 1 |
| Niu, N | 1 |
| Mei, J | 1 |
| Sui, Z | 1 |
| Qu, P | 1 |
| Xing, C | 1 |
| Biyik, Z | 1 |
| Guney, I | 1 |
| Tan, J | 2 |
| Zhang, E | 1 |
| Qin, Q | 1 |
| Sun, K | 2 |
| Tanaka, KI | 1 |
| Kanazawa, I | 1 |
| Notsu, M | 1 |
| Sugimoto, T | 1 |
| Tseng, CK | 1 |
| Lv, H | 1 |
| Cheng, Y | 2 |
| Chen, HF | 1 |
| Li, JM | 4 |
| Du, WD | 1 |
| Li, ML | 1 |
| Yang, SL | 1 |
| Feng, YL | 1 |
| Zhang, WG | 1 |
| Balasar, M | 1 |
| Sönmez, MG | 1 |
| Aydın, A | 1 |
| Göger, YE | 1 |
| Özkent, MS | 1 |
| Poyraz, N | 1 |
| Xiong, Z | 2 |
| Wilson, I | 1 |
| Jones, A | 2 |
| Huang, XF | 2 |
| Lin, T | 1 |
| Fu, Q | 1 |
| Lee, KH | 1 |
| Stubnova, V | 1 |
| Os, I | 2 |
| Høieggen, A | 2 |
| Solbu, MD | 2 |
| Grundtvig, M | 1 |
| Westheim, AS | 1 |
| Atar, D | 1 |
| Waldum-Grevbo, B | 1 |
| Chen-Xu, M | 1 |
| Rai, SK | 1 |
| De Becker, B | 1 |
| Burnier, M | 2 |
| van de Borne, P | 1 |
| Sawatani, T | 1 |
| Uchiyama, S | 1 |
| Takayasu, T | 1 |
| Asano, M | 1 |
| Duong, NT | 1 |
| Ngoc, NT | 1 |
| Thang, NTM | 1 |
| Phuong, BTH | 1 |
| Nga, NT | 1 |
| Tinh, ND | 1 |
| Quynh, DH | 1 |
| Ton, ND | 1 |
| Hai, NV | 1 |
| Oh, DR | 1 |
| Kim, JR | 1 |
| Choi, CH | 1 |
| Na, CS | 1 |
| Kang, BY | 1 |
| Kim, YR | 1 |
| Arrebola, JP | 1 |
| Ramos, JJ | 1 |
| Bartolomé, M | 1 |
| Esteban, M | 1 |
| Huetos, O | 1 |
| Cañas, AI | 1 |
| López-Herranz, A | 1 |
| Calvo, E | 1 |
| Pérez-Gómez, B | 1 |
| Castaño, A | 1 |
| Katayama, A | 1 |
| Yokokawa, H | 2 |
| Fukuda, H | 2 |
| Ono, Y | 1 |
| Isonuma, H | 2 |
| Hisaoka, T | 2 |
| Naito, T | 2 |
| Kang, MW | 1 |
| Chin, HJ | 2 |
| Joo, KW | 1 |
| Na, KY | 1 |
| Han, SS | 1 |
| Haryono, A | 1 |
| Nugrahaningsih, DAA | 1 |
| Kwon, OC | 1 |
| Lee, CK | 2 |
| Yoo, B | 2 |
| Hong, S | 2 |
| Zou, D | 1 |
| Ling, W | 1 |
| Tian, W | 1 |
| Qi, G | 1 |
| Yang, CY | 1 |
| Tang, F | 2 |
| Perge, P | 1 |
| Boros, AM | 1 |
| Zima, E | 1 |
| Gellér, L | 1 |
| Széplaki, G | 1 |
| Chaloemwong, J | 1 |
| Tantiworawit, A | 1 |
| Rattanathammethee, T | 1 |
| Chai-Adisaksopha, C | 1 |
| Rattarittamrong, E | 1 |
| Norasetthada, L | 1 |
| Charoenkwan, P | 1 |
| Thounaojam, MC | 1 |
| Montemari, A | 1 |
| Powell, FL | 1 |
| Malla, P | 1 |
| Gutsaeva, DR | 1 |
| Bachettoni, A | 1 |
| Ripandelli, G | 1 |
| Repossi, A | 1 |
| Tawfik, A | 1 |
| Martin, PM | 1 |
| Facchiano, F | 1 |
| Bartoli, M | 1 |
| Zhou, F | 2 |
| Yu, G | 1 |
| Jacomelli, G | 2 |
| Baldini, E | 1 |
| Mugnaini, C | 1 |
| Micheli, V | 2 |
| Bernardini, G | 1 |
| Santucci, A | 1 |
| Özalp Kızılay, D | 1 |
| Şen, S | 2 |
| Ersoy, B | 1 |
| Alberts, BM | 1 |
| Bruce, C | 1 |
| Basnayake, K | 1 |
| Ghezzi, P | 1 |
| Davies, KA | 1 |
| Mullen, LM | 1 |
| Bernal, JA | 1 |
| Kerola, T | 1 |
| Kauppi, J | 1 |
| Sares-Jäske, L | 1 |
| Anttonen, O | 1 |
| Junttila, MJ | 1 |
| Huikuri, HV | 1 |
| Nieminen, T | 1 |
| Rissanen, H | 1 |
| Heliövaara, M | 1 |
| Knekt, P | 1 |
| Eranti, A | 1 |
| Koguchi, T | 1 |
| Tadokoro, T | 1 |
| Asaduzzaman, M | 1 |
| Hasnat, MA | 1 |
| Zhou, HB | 1 |
| Xu, TY | 1 |
| Liu, SR | 1 |
| Bai, YJ | 1 |
| Zhan, Q | 1 |
| Zeng, QC | 1 |
| Xu, DL | 1 |
| Deng, M | 1 |
| Deng, B | 1 |
| Ye, L | 2 |
| Fei, X | 1 |
| Fernández Rodríguez, CM | 1 |
| Aller, R | 1 |
| Gutiérrez García, ML | 1 |
| Ampuero, J | 2 |
| Gómez-Camarero, J | 1 |
| Martín-Mateos, RMª | 1 |
| Burgos-Santamaría, D | 1 |
| Rosales, JM | 1 |
| Aspichueta, P | 1 |
| Buque, X | 1 |
| Latorre, M | 1 |
| Andrade, RJ | 1 |
| Hernández-Guerra, M | 1 |
| Romero-Gómez, M | 1 |
| Qin, J | 1 |
| Deng, X | 4 |
| Katsogridaki, G | 1 |
| Tzovaras, G | 1 |
| Sioka, E | 1 |
| Perivoliotis, K | 1 |
| Zachari, E | 1 |
| Magouliotis, D | 1 |
| Tasiopoulou, V | 1 |
| Zacharoulis, D | 1 |
| You, W | 2 |
| Che, K | 3 |
| Hou, H | 1 |
| Ge, S | 1 |
| An, K | 1 |
| Cao, W | 1 |
| Song, M | 2 |
| Fang, C | 1 |
| Gupta, MK | 1 |
| Yu, TY | 1 |
| Jee, JH | 1 |
| Bae, JC | 1 |
| Wang, AY | 1 |
| Hong, D | 2 |
| Hao, Y | 1 |
| Lei, M | 2 |
| Chu, B | 1 |
| Qian, Z | 2 |
| Singh, AK | 1 |
| Qiu, SH | 1 |
| Guo, HJ | 1 |
| Sun, ZL | 1 |
| Chen, MY | 1 |
| Wang, AP | 1 |
| Wang, JW | 1 |
| Ke, JF | 1 |
| Yu, TP | 1 |
| Li, LX | 2 |
| Jia, WP | 2 |
| Disveld, IJM | 1 |
| Zoakman, S | 1 |
| Rongen, GA | 1 |
| Kienhorst, LBE | 1 |
| Janssens, HJEM | 1 |
| Fransen, J | 2 |
| Hou, YL | 1 |
| Yang, XL | 1 |
| Wang, CX | 1 |
| Zhi, LX | 1 |
| Yang, MJ | 1 |
| Nishizawa, K | 1 |
| Yoda, N | 1 |
| Morokado, F | 1 |
| Komori, H | 1 |
| Nakanishi, T | 3 |
| Kim, JM | 1 |
| Huangfu, N | 1 |
| Zheng, W | 5 |
| Laffel, L | 1 |
| Lynch, J | 1 |
| El Ghormli, L | 1 |
| Weinstock, RS | 1 |
| Tollefsen, SE | 1 |
| Nadeau, KJ | 1 |
| Antonini-Canterin, F | 1 |
| Di Nora, C | 1 |
| Pellegrinet, M | 1 |
| Vriz, O | 1 |
| La Carrubba, S | 1 |
| Carerj, S | 1 |
| Zito, C | 1 |
| Matescu, A | 1 |
| Ravasel, A | 1 |
| Cosei, I | 1 |
| Popescu, BA | 1 |
| Zhou, R | 2 |
| Gong, C | 1 |
| Yuan, E | 1 |
| Shimada, M | 1 |
| Alquadan, KF | 1 |
| Lapsia, V | 1 |
| Dass, B | 2 |
| Diao, B | 1 |
| Mančíková, A | 1 |
| Krylov, V | 1 |
| Bohatá, J | 1 |
| Liang, G | 1 |
| Nie, Y | 2 |
| Zeng, S | 1 |
| Liang, C | 1 |
| Xiao, D | 1 |
| Xu, A | 1 |
| Sun, YP | 3 |
| Xu, FL | 1 |
| Yan, DD | 1 |
| Zhang, XJ | 1 |
| Guo, YY | 1 |
| Hsu, CY | 1 |
| Ding, J | 2 |
| Oh, TR | 1 |
| Choi, HS | 3 |
| Kim, CS | 1 |
| Bae, EH | 1 |
| Ma, SK | 1 |
| Sung, SA | 1 |
| Oh, KH | 1 |
| Kim, SW | 1 |
| Battaglino, MG | 1 |
| Nava, E | 1 |
| Üsküdar Cansu, D | 1 |
| Erdoğan, B | 1 |
| Korkmaz, C | 1 |
| Yu, KS | 1 |
| Park, SI | 1 |
| Yoon, S | 1 |
| Onohara, M | 1 |
| Ahn, Y | 1 |
| Riches, PL | 2 |
| Sing, K | 1 |
| Berg, K | 1 |
| Yu, M | 1 |
| Hussain, MA | 1 |
| Jahan, S | 1 |
| Afzal, M | 1 |
| Nawaz, I | 1 |
| Mahmood, T | 1 |
| Huo, Y | 1 |
| Tang, G | 1 |
| Jiao, X | 1 |
| Zhang, XM | 4 |
| Zhang, ZC | 2 |
| Lan, Y | 1 |
| El-Tantawy, WH | 1 |
| Pavlusova, M | 1 |
| Jarkovsky, J | 2 |
| Benesova, K | 1 |
| Vitovec, J | 2 |
| Linhart, A | 3 |
| Widimsky, P | 2 |
| Spinarova, L | 1 |
| Zeman, K | 1 |
| Belohlavek, J | 1 |
| Malek, F | 2 |
| Felsoci, M | 1 |
| Kettner, J | 1 |
| Ostadal, P | 2 |
| Cihalik, C | 1 |
| Spac, J | 1 |
| Al-Hiti, H | 1 |
| Fedorco, M | 2 |
| Fojt, R | 1 |
| Kruger, A | 2 |
| Malek, J | 1 |
| Mikusova, T | 1 |
| Monhart, Z | 1 |
| Bohacova, S | 1 |
| Pohludkova, L | 1 |
| Rohac, F | 1 |
| Vaclavik, J | 1 |
| Vondrakova, D | 2 |
| Vyskocilova, K | 1 |
| Bambuch, M | 1 |
| Dostalova, G | 1 |
| Havranek, S | 1 |
| Svobodová, I | 1 |
| Dusek, L | 1 |
| Spinar, J | 2 |
| Miklik, R | 2 |
| Parenica, J | 2 |
| Dong, YZ | 1 |
| Huang, IJ | 1 |
| Liew, JW | 1 |
| Morcos, MB | 1 |
| Zuo, S | 1 |
| Crawford, C | 1 |
| Bays, AM | 1 |
| Faienza, MF | 1 |
| De Pergola, G | 1 |
| Chen, XG | 1 |
| Shen, ZY | 1 |
| Liu, XF | 1 |
| Chen, HY | 2 |
| Yun, S | 2 |
| Drake, J | 2 |
| Doughty, RN | 1 |
| Troughton, RW | 1 |
| Richards, AM | 1 |
| Barskova, V | 2 |
| Becce, F | 1 |
| Castaneda, J | 1 |
| Coyfish, M | 1 |
| Guillo, S | 1 |
| Jansen, T | 1 |
| Janssens, H | 1 |
| Mallen, CD | 1 |
| Pimentao, J | 2 |
| Pywell, A | 1 |
| So, AK | 1 |
| Tubach, F | 1 |
| Sugano, N | 2 |
| Maruyama, Y | 2 |
| Kidoguchi, S | 1 |
| Ohno, I | 11 |
| Wada, A | 1 |
| Masakane, I | 1 |
| Yokoo, T | 2 |
| Yang, TH | 1 |
| Yan, DX | 1 |
| Hou, B | 1 |
| Ma, YB | 1 |
| Chen, JJ | 2 |
| Geng, CA | 1 |
| Son, E | 1 |
| Min, HK | 1 |
| Cho, H | 1 |
| Park, SH | 2 |
| Jeon, HJ | 1 |
| Oh, J | 2 |
| Shin, DH | 4 |
| Rivera-Paredez, B | 2 |
| Macías-Kauffer, L | 1 |
| Fernandez-Lopez, JC | 1 |
| Villalobos-Comparán, M | 1 |
| Martinez-Aguilar, MM | 1 |
| de la Cruz-Montoya, A | 1 |
| Ramírez-Salazar, EG | 1 |
| Villamil-Ramírez, H | 1 |
| Quiterio, M | 1 |
| Ramírez-Palacios, P | 1 |
| Romero-Hidalgo, S | 1 |
| Villarreal-Molina, MT | 1 |
| Denova-Gutiérrez, E | 2 |
| Flores, YN | 1 |
| Canizales-Quinteros, S | 1 |
| Salmerón, J | 2 |
| Velázquez-Cruz, R | 1 |
| Gurol, ME | 1 |
| Bhatt, DL | 1 |
| Fonarow, GC | 2 |
| Benjamin, EJ | 2 |
| Xing, A | 1 |
| Jung, W | 1 |
| Lihm, H | 1 |
| Zong, G | 1 |
| Xiong, Q | 1 |
| Huo, S | 1 |
| Niu, Z | 1 |
| Zeng, R | 1 |
| Geng, B | 1 |
| Tourzel, E | 1 |
| Munck, S | 1 |
| Fournier, JP | 1 |
| Maisonneuve, H | 1 |
| Martins de Sá Müller, C | 1 |
| Coelho, GB | 1 |
| Carolina de Paula Michel Araújo, M | 1 |
| Saúde-Guimarães, DA | 3 |
| Xu, K | 3 |
| Miao, L | 3 |
| Qiao, L | 1 |
| Bao, J | 1 |
| He, R | 1 |
| Cheng, G | 2 |
| Nagase, M | 1 |
| Shirahama, Y | 1 |
| Nishida, Y | 3 |
| Shimoshikiryo, I | 1 |
| Katsuura-Kamano, S | 1 |
| Uemura, H | 1 |
| Ibusuki, R | 1 |
| Hara, M | 2 |
| Iwasawa, S | 1 |
| Ohnaka, K | 2 |
| Ichihara, S | 1 |
| Yokota, M | 1 |
| Saitoh, T | 2 |
| Kamatani, Y | 1 |
| Arisawa, K | 1 |
| Takezaki, T | 1 |
| Wakai, K | 7 |
| Kubo, M | 2 |
| Lee, YH | 6 |
| Song, GG | 2 |
| Gamala, M | 1 |
| Jacobs, JWG | 1 |
| Ngahane, HBM | 1 |
| Kong, J | 1 |
| Arora, T | 1 |
| Mantur, PG | 1 |
| Bidri, RC | 1 |
| Mulimani, MS | 1 |
| Jee, YH | 1 |
| Jung, KJ | 1 |
| Spiller, W | 1 |
| Zhong, F | 1 |
| Park, GM | 1 |
| Yang, DH | 1 |
| Kang, JW | 1 |
| Lim, TH | 1 |
| Kim, HK | 2 |
| Choe, J | 1 |
| Kim, M | 1 |
| Kwon, K | 1 |
| Park, J | 1 |
| Tae, G | 1 |
| Jakše, B | 2 |
| Pajek, M | 1 |
| Pajek, J | 1 |
| Kozlik, P | 1 |
| Kalikova, K | 1 |
| Mahajan, A | 1 |
| Herrmann, M | 2 |
| Brombo, G | 1 |
| Bonetti, F | 1 |
| Volpato, S | 1 |
| Morieri, ML | 1 |
| Napoli, E | 1 |
| Bandinelli, S | 1 |
| Cherubini, A | 1 |
| Maggio, M | 1 |
| Guralnik, J | 1 |
| Ferrucci, L | 1 |
| Zuliani, G | 1 |
| Shau, WY | 1 |
| Hsu, FS | 1 |
| Wang, ML | 1 |
| Chen, TC | 1 |
| Lo, C | 1 |
| Freixer, G | 1 |
| Bueno-Cavanillas, A | 1 |
| Abellán Cano, I | 1 |
| Sorli, JV | 1 |
| Torres, L | 1 |
| Navarrete-Muñoz, EM | 1 |
| Tojal Sierra, L | 1 |
| Crespo-Oliva, E | 1 |
| Zulet, MÁ | 1 |
| Sanchez-Villegas, A | 1 |
| Del Mar Bibiloni, M | 1 |
| Quifer, M | 1 |
| Prieto, RM | 1 |
| Fernandez-Brufal, N | 1 |
| Salaverria Lete, I | 1 |
| Cenoz, JC | 1 |
| Llimona, R | 1 |
| Kwon, M | 1 |
| Lee, HY | 1 |
| Shivappa, N | 1 |
| Hébert, JR | 1 |
| Sohn, C | 1 |
| Na, W | 1 |
| Kim, MK | 4 |
| Madero, M | 5 |
| Chatzipavlou, M | 1 |
| Magiorkinis, G | 1 |
| Koutsogeorgopoulou, L | 1 |
| Kassimos, D | 1 |
| Lu, S | 3 |
| Yan, S | 4 |
| Tao, Z | 1 |
| Inaba, S | 1 |
| Sautin, Y | 4 |
| Garcia, GE | 1 |
| Von Zingel, M | 1 |
| Ishiro, M | 1 |
| Takaya, R | 1 |
| Mori, Y | 2 |
| Takitani, K | 1 |
| Kono, Y | 1 |
| Okasora, K | 1 |
| Kasahara, T | 1 |
| Tamai, H | 1 |
| Chiquete, E | 1 |
| Ruiz-Sandoval, JL | 1 |
| Murillo-Bonilla, LM | 1 |
| Arauz, A | 1 |
| Orozco-Valera, DR | 1 |
| Ochoa-Guzmán, A | 1 |
| Villarreal-Careaga, J | 1 |
| León-Jiménez, C | 1 |
| Barinagarrementeria, F | 1 |
| Ramos-Moreno, A | 1 |
| Cantú-Brito, C | 1 |
| McBride, A | 1 |
| Lathon, SC | 1 |
| Boehmer, L | 1 |
| Augustin, KM | 1 |
| Butler, SK | 1 |
| Westervelt, P | 1 |
| Mazzali, M | 10 |
| Sautin, YY | 6 |
| Kovell, LC | 1 |
| Mitha, E | 1 |
| Schumacher, HR | 11 |
| Fouche, L | 1 |
| Luo, SF | 5 |
| Weinstein, SP | 1 |
| Yancopoulos, GD | 1 |
| King-Davis, S | 1 |
| Evans, RR | 1 |
| Nishimura, H | 1 |
| Shintani, M | 1 |
| Maeda, K | 1 |
| Otoshi, K | 1 |
| Fukuda, M | 1 |
| Okuda, J | 1 |
| Nishi, S | 1 |
| Ohashi, S | 1 |
| Baba, Y | 1 |
| Kuroczycka-Saniutycz, E | 2 |
| Sulik, A | 1 |
| Milewski, R | 1 |
| de Denus, S | 1 |
| Rouleau, JL | 1 |
| Hinohara, Y | 1 |
| Yin, G | 2 |
| Higashibata, T | 1 |
| Morita, E | 2 |
| Mori, A | 1 |
| Hamajima, N | 5 |
| Dong, K | 1 |
| Pham, D | 2 |
| Pence, S | 1 |
| Inciardi, J | 1 |
| Bhutada, NS | 1 |
| Nishino, M | 1 |
| Mori, N | 1 |
| Yoshimura, T | 1 |
| Nakamura, D | 1 |
| Taniike, M | 1 |
| Makino, N | 1 |
| Egami, Y | 1 |
| Shutta, R | 1 |
| Tanouchi, J | 1 |
| Geiger, SD | 1 |
| Shankar, A | 1 |
| Hsu, PC | 2 |
| Duran, M | 3 |
| Murat, SN | 2 |
| Ornek, E | 3 |
| Hanley, A | 1 |
| Casserly, LF | 1 |
| Cronin, CJ | 1 |
| Abdalla, AA | 1 |
| Kiernan, TJ | 1 |
| Murthy, BV | 1 |
| Hegarty, A | 1 |
| Hannigan, A | 1 |
| Nguyen, HT | 1 |
| Chao, X | 3 |
| Krishnan, E | 15 |
| Akhras, KS | 2 |
| Sharma, H | 2 |
| Marynchenko, M | 2 |
| Wu, EQ | 2 |
| Tawk, R | 1 |
| Rizzo, M | 1 |
| Obradovic, M | 1 |
| Labudovic-Borovic, M | 1 |
| Nikolic, D | 1 |
| Montalto, G | 1 |
| Rizvi, AA | 1 |
| Isenovic, ER | 1 |
| Chang, HY | 2 |
| Lee, PH | 2 |
| Lei, CC | 3 |
| Tung, CW | 2 |
| Hsu, YC | 2 |
| Huang, TJ | 1 |
| Lu, LC | 2 |
| Lin, CL | 4 |
| Qian, DF | 1 |
| Fan, GL | 1 |
| He, DC | 1 |
| Fan, JD | 1 |
| Feng, C | 1 |
| Zhu, PG | 1 |
| Zhou, ZH | 1 |
| Liao, YH | 1 |
| Larina, VN | 3 |
| Bart, BIa | 2 |
| Larin, VG | 2 |
| Donskov, AS | 2 |
| Dankers, AC | 1 |
| Mutsaers, HA | 1 |
| Dijkman, HB | 1 |
| van den Heuvel, LP | 1 |
| Hoenderop, JG | 1 |
| Sweep, FC | 1 |
| Russel, FG | 1 |
| Masereeuw, R | 1 |
| Soma, M | 2 |
| Nakata, K | 2 |
| Hata, M | 1 |
| Yoshitake, I | 1 |
| Wakui, S | 1 |
| Hata, H | 2 |
| Shiono, M | 2 |
| Gerdan, V | 1 |
| Akkoc, N | 2 |
| Ucan, ES | 1 |
| Bulac Kir, S | 1 |
| Wu, E | 1 |
| Tawk, RH | 1 |
| Cai, B | 1 |
| Huang, T | 2 |
| Jing, X | 2 |
| Beard, SM | 1 |
| von Scheele, BG | 1 |
| Pearson, IV | 1 |
| Ding, XQ | 1 |
| Ma, YX | 1 |
| Zhang, LF | 1 |
| Zhao, YC | 1 |
| Si, L | 1 |
| Wei, W | 2 |
| Shen, H | 1 |
| Jin, D | 1 |
| Zeng, Y | 1 |
| Kemter, E | 1 |
| Prueckl, P | 1 |
| Sklenak, S | 1 |
| Rathkolb, B | 1 |
| Habermann, FA | 1 |
| Hans, W | 1 |
| Gailus-Durner, V | 1 |
| Fuchs, H | 1 |
| Hrabě de Angelis, M | 1 |
| Wolf, E | 1 |
| Aigner, B | 1 |
| Wanke, R | 1 |
| Ryoo, JH | 1 |
| Choi, JM | 1 |
| Oh, CM | 1 |
| Kim, MG | 1 |
| Galbiati, S | 1 |
| Mastriani, S | 1 |
| Stella, A | 1 |
| Preitner, F | 1 |
| Laverriere-Loss, A | 1 |
| Metref, S | 1 |
| Da Costa, A | 1 |
| Moret, C | 1 |
| Rotman, S | 1 |
| Bazin, D | 1 |
| Daudon, M | 1 |
| Sandt, C | 1 |
| Dessombz, A | 1 |
| Thorens, B | 2 |
| Oda, E | 1 |
| Hsia, SH | 1 |
| Chou, IJ | 2 |
| See, LC | 5 |
| Huang, JL | 1 |
| Wu, CT | 1 |
| Lin, KL | 1 |
| Wang, HS | 1 |
| Fathallah-Shaykh, SA | 1 |
| Cramer, MT | 1 |
| Kannangara, DR | 4 |
| Graham, GG | 6 |
| Williams, KM | 6 |
| House, ME | 6 |
| Purvis, L | 3 |
| Merriman, M | 3 |
| Palmer, TM | 1 |
| Benn, M | 1 |
| Tybjærg-Hansen, A | 1 |
| Davey Smith, G | 1 |
| Lawlor, DA | 1 |
| Timpson, NJ | 1 |
| Chao, TF | 1 |
| Wang, KL | 1 |
| Chen, TJ | 1 |
| Chang, SL | 1 |
| Lo, LW | 1 |
| Hu, YF | 1 |
| Tuan, TC | 1 |
| Chen, SA | 1 |
| Shcherbak, AV | 3 |
| Kozlovskaia, LV | 2 |
| Bobkova, IN | 1 |
| Balkarov, IM | 6 |
| Lebedeva, MV | 3 |
| Stakhova, TIu | 3 |
| Bao, X | 3 |
| Wei, LL | 1 |
| Miao, MX | 1 |
| Maejima, I | 1 |
| Omori, H | 1 |
| Takabatake, Y | 1 |
| Hamasaki, M | 1 |
| Noda, T | 1 |
| Yoshimori, T | 1 |
| Miyaoka, T | 1 |
| Takei, T | 4 |
| Yao, H | 3 |
| Onat, A | 1 |
| Can, G | 1 |
| Altay, S | 1 |
| Yüksel, M | 1 |
| Ademoğlu, E | 1 |
| Mavlianov, IR | 1 |
| Abdullaev, AK | 1 |
| Lecoultre, V | 1 |
| Egli, L | 1 |
| Theytaz, F | 1 |
| Despland, C | 1 |
| Schneiter, P | 1 |
| Tappy, L | 1 |
| Ogata, H | 2 |
| Takada, Y | 7 |
| Chiba, T | 5 |
| Ushiyama, C | 1 |
| Sakurai, Y | 7 |
| Kato, Y | 3 |
| Lü, JM | 1 |
| Yao, Q | 1 |
| Hong, Q | 7 |
| Hou, K | 2 |
| Guan, L | 1 |
| Momma, H | 2 |
| Chujo, M | 1 |
| Otomo, A | 1 |
| Tadaura, H | 1 |
| Nagatomi, R | 2 |
| Batt, C | 1 |
| Black, MA | 1 |
| Merriman, ME | 1 |
| Gow, P | 2 |
| Harrison, A | 2 |
| Highton, J | 1 |
| Jones, P | 1 |
| Stamp, L | 2 |
| Kurahashi, H | 1 |
| Sugimoto, M | 1 |
| Ariyoshi, Y | 1 |
| Araki, M | 1 |
| Ishii, K | 1 |
| Nasu, Y | 1 |
| Nagai, A | 2 |
| Kumon, H | 1 |
| Jaipakdee, J | 1 |
| Jiamjarasrangsri, W | 1 |
| Lohsoonthorn, V | 2 |
| Lertmaharit, S | 1 |
| Shafiu, M | 3 |
| Sundaram, S | 1 |
| Le, M | 2 |
| Ishimoto, T | 2 |
| Zoccali, C | 4 |
| Hsu, KC | 1 |
| Wang, FS | 1 |
| Ndrepepa, G | 1 |
| Cassese, S | 1 |
| Braun, S | 1 |
| Fusaro, M | 1 |
| King, L | 1 |
| Tada, T | 1 |
| Schömig, A | 1 |
| Kastrati, A | 1 |
| Schmidt, R | 1 |
| Bae, JS | 1 |
| Park, PS | 3 |
| Choi, BY | 3 |
| Shin, MH | 3 |
| Chun, BY | 3 |
| Xu, WA | 1 |
| Yin, L | 2 |
| Pan, HY | 1 |
| Duan, JA | 1 |
| Poudel, B | 1 |
| Yadav, BK | 1 |
| Kumar, A | 1 |
| Jha, B | 1 |
| Raut, KB | 1 |
| Otsuka, T | 1 |
| Ohno, D | 1 |
| Murasawa, T | 1 |
| Sato, N | 2 |
| Prudon, B | 1 |
| Stradling, JR | 1 |
| West, SD | 1 |
| Ishiguro, Y | 1 |
| Matsuyama, H | 1 |
| Yamada, K | 1 |
| Noba, M | 1 |
| Uemura, A | 1 |
| Matsubara, Y | 1 |
| Yoshida, S | 1 |
| Kani, A | 1 |
| Tokuda, M | 2 |
| Hasegawa, K | 1 |
| Uchiyama, T | 1 |
| Matsubara, S | 1 |
| Kimura, H | 3 |
| Shino, K | 1 |
| Ishii, J | 1 |
| Nasi, S | 1 |
| Peng, F | 1 |
| Gisondi, P | 2 |
| Cagalli, A | 1 |
| Girolomoni, G | 1 |
| Chen, GL | 3 |
| Zhu, LR | 1 |
| Matfin, G | 1 |
| Jia, L | 1 |
| Xing, J | 1 |
| Ding, Y | 3 |
| Wan, M | 1 |
| Su, D | 1 |
| Tenderenda-Banasiuk, E | 1 |
| Taranta-Janusz, K | 2 |
| Korzeniecka-Kozerska, A | 1 |
| Cottrell, E | 1 |
| Crabtree, V | 1 |
| Edwards, JJ | 1 |
| Gao, HL | 1 |
| Jia, ZP | 1 |
| Li, DP | 1 |
| Sun, DY | 1 |
| Wang, BY | 2 |
| Ford, ES | 3 |
| Bakris, GL | 1 |
| Doghramji, PP | 1 |
| Silber, SH | 1 |
| Roncal-Jimenez, C | 2 |
| Lanaspa, M | 2 |
| Gerard, S | 1 |
| Chonchol, M | 3 |
| Jalal, D | 3 |
| Hollis-Moffatt, JE | 1 |
| Franklin, C | 3 |
| Jones, PB | 2 |
| White, DH | 1 |
| Franceschini, N | 2 |
| Haack, K | 2 |
| Laston, S | 2 |
| MacCluer, JW | 2 |
| Umans, JG | 2 |
| Comuzzie, AG | 2 |
| Cole, SA | 2 |
| Kumral, E | 1 |
| Karaman, B | 1 |
| Orman, M | 1 |
| Kabaroglu, C | 1 |
| Faruque, LI | 1 |
| Ehteshami-Afshar, A | 1 |
| Wiebe, N | 1 |
| Tjosvold, L | 1 |
| Homik, J | 1 |
| Tonelli, M | 1 |
| Doucet, BP | 1 |
| Jegatheesan, D | 1 |
| Burke, J | 1 |
| Law, A | 1 |
| Maynard, JW | 2 |
| Baer, AN | 2 |
| Oberbach, A | 1 |
| Neuhaus, J | 1 |
| Inge, T | 1 |
| Kirsch, K | 1 |
| Schlichting, N | 1 |
| Blüher, S | 1 |
| Kullnick, Y | 1 |
| Kugler, J | 1 |
| Baumann, S | 1 |
| Till, H | 1 |
| Liu, YL | 4 |
| Fan, CY | 1 |
| Wang, SJ | 2 |
| Cai, W | 1 |
| Martillo, MA | 1 |
| Nazzal, L | 1 |
| Crittenden, DB | 1 |
| Arora, K | 1 |
| Tomar, M | 1 |
| Gupta, V | 1 |
| Wuyun, G | 1 |
| Pan, KL | 2 |
| Lin, JC | 2 |
| Chen, MC | 2 |
| Chang, PJ | 2 |
| Hsiao, JF | 1 |
| Chang, ST | 4 |
| Chung, CM | 2 |
| Takase, H | 1 |
| Kimura, G | 1 |
| Dohi, Y | 1 |
| Reynolds, TM | 1 |
| Hirata, S | 2 |
| Ohtahara, A | 2 |
| Yamamoto, Y | 5 |
| Nosaka, Y | 1 |
| Igawa, O | 10 |
| Yoshida, A | 1 |
| Moriwaki, Y | 5 |
| Itoh, S | 1 |
| Inaba, M | 3 |
| Tomino, Y | 1 |
| Makino, H | 1 |
| Matsuo, S | 1 |
| Iimuro, S | 1 |
| Imai, N | 1 |
| Hayakawa, H | 2 |
| Toda, A | 1 |
| Ishizaka, Y | 2 |
| Tani, M | 1 |
| Yamakado, M | 2 |
| Oikawa, Y | 2 |
| Abe, J | 3 |
| Inoue, H | 3 |
| Guang, Y | 1 |
| Nakagawa, H | 3 |
| Bach, MH | 1 |
| Simkin, PA | 5 |
| Fujimori, S | 13 |
| Hara, S | 1 |
| Wiwanitkit, V | 1 |
| Yu, CH | 1 |
| Zhang, CF | 1 |
| Anderson, S | 5 |
| Zhang, YW | 8 |
| Zuo, X | 2 |
| Huang, A | 1 |
| Bao, C | 1 |
| Pool, B | 3 |
| Kose, E | 1 |
| An, T | 1 |
| Kikkawa, A | 1 |
| Matsumoto, Y | 3 |
| Hart, A | 1 |
| Jackson, S | 1 |
| Kasiske, BL | 1 |
| Mauer, MS | 1 |
| Najafian, B | 1 |
| Matas, AJ | 1 |
| Spong, R | 1 |
| Ibrahim, HN | 1 |
| Chu, CY | 1 |
| Lee, CS | 1 |
| Yen, HW | 1 |
| Lai, WT | 1 |
| Sheu, SH | 1 |
| Voon, WC | 1 |
| Fleischmann, R | 1 |
| Kerr, B | 1 |
| Yeh, LT | 1 |
| Suster, M | 1 |
| Polvent, E | 1 |
| Hingorani, V | 1 |
| Quart, B | 1 |
| Manhard, K | 1 |
| Duskin-Bitan, H | 1 |
| Cohen, E | 3 |
| Goldberg, E | 3 |
| Shochat, T | 1 |
| Levi, A | 2 |
| Garty, M | 3 |
| Krause, I | 3 |
| Sertoglu, E | 1 |
| Ercin, CN | 1 |
| Celebi, G | 1 |
| Gurel, H | 1 |
| Kayadibi, H | 1 |
| Genc, H | 2 |
| Kara, M | 1 |
| Dogru, T | 2 |
| Tunstall-Pedoe, H | 1 |
| Woodward, M | 1 |
| Herrington, JD | 1 |
| Dinh, BC | 1 |
| Hsieh, CH | 2 |
| Lin, JD | 2 |
| Wu, CZ | 1 |
| Hsu, CH | 1 |
| Pei, D | 1 |
| Liang, YJ | 1 |
| Xue, P | 1 |
| Fenech, G | 1 |
| Rajzbaum, G | 1 |
| Mazighi, M | 1 |
| Blacher, J | 1 |
| Roseline, YW | 1 |
| Shidoji, Y | 1 |
| Hon, WM | 1 |
| Masaki, M | 2 |
| Ning, G | 2 |
| Akkineni, R | 1 |
| Tapp, S | 1 |
| Tosteson, AN | 1 |
| Lee, A | 1 |
| Miller, KL | 1 |
| Albert, DA | 2 |
| Murota, I | 1 |
| Taguchi, S | 1 |
| Park, EY | 1 |
| Nakamura, Y | 2 |
| Bonakdaran, S | 2 |
| Kharaqani, B | 1 |
| Inui, M | 1 |
| Hara, T | 1 |
| Nishijima, Y | 1 |
| Moriwaki, K | 1 |
| Hayashida, Y | 1 |
| Ueda, N | 1 |
| Nishiyama, A | 1 |
| Kakehi, Y | 1 |
| Kohno, M | 1 |
| Xue, ZY | 1 |
| Zhou, LY | 1 |
| Jiang, JM | 1 |
| Salem, S | 1 |
| Mehrsai, A | 1 |
| Heydari, R | 1 |
| Pourmand, G | 1 |
| Amini, E | 1 |
| Sheikh, M | 1 |
| Hantoushzadeh, S | 1 |
| Shariat, M | 1 |
| Abdollahi, A | 1 |
| Kashanian, M | 1 |
| Choi, YJ | 1 |
| Yoon, Y | 1 |
| Lee, KY | 1 |
| Hien, TT | 1 |
| Kang, KW | 1 |
| Kim, KC | 1 |
| Lee, SM | 2 |
| Lee, BH | 3 |
| Liu, ZM | 1 |
| Ho, CS | 1 |
| Woo, J | 1 |
| Chu, Z | 1 |
| Nishi, Y | 2 |
| Mizuno, A | 1 |
| Masuda, K | 1 |
| Komatsu, I | 1 |
| Yamazoe, M | 1 |
| Takahashi, O | 2 |
| Garneri, D | 1 |
| Gonnella, A | 1 |
| Ambrosioni, E | 1 |
| Costa, FV | 1 |
| Leonetti, G | 1 |
| Pessina, AC | 1 |
| Deferrari, G | 1 |
| Riccobene, R | 1 |
| Castiglia, A | 2 |
| D'Ignoto, F | 1 |
| Ajello, E | 1 |
| Geraci, G | 2 |
| Guarino, L | 2 |
| Vaccaro, F | 2 |
| Cerasola, G | 1 |
| Xiang, G | 1 |
| Xiang, L | 1 |
| Rafieian-Kopaei, M | 1 |
| Behradmanesh, S | 1 |
| Kheiri, S | 1 |
| Nasri, H | 2 |
| Wang, YL | 3 |
| Liu, BC | 1 |
| Levy, GD | 2 |
| Niu, F | 1 |
| Castillo, E | 1 |
| Chinchilla, SP | 2 |
| Herrero-Beites, AM | 6 |
| Bennett, M | 1 |
| Vitale, A | 1 |
| Cantarini, L | 1 |
| Rigante, D | 1 |
| Bardelli, M | 1 |
| Galeazzi, M | 1 |
| Xue, J | 1 |
| Cosentino, ER | 1 |
| Rinaldi, ER | 1 |
| Cicero, AF | 6 |
| Ran, J | 1 |
| Tan, R | 1 |
| Lao, G | 1 |
| Scheven, L | 1 |
| Joosten, MM | 1 |
| de Jong, PE | 1 |
| Bakker, SJ | 1 |
| Gansevoort, RT | 1 |
| Ling, X | 1 |
| Bochu, W | 1 |
| Kanbay, A | 1 |
| Inonu, H | 1 |
| Solak, Y | 4 |
| Erden, A | 1 |
| Uslu, E | 1 |
| Yuksel, SA | 1 |
| Ozturk, MA | 1 |
| McFann, K | 3 |
| Numa, S | 1 |
| Nakagawa, K | 1 |
| Ohara, K | 1 |
| Fukuda, N | 1 |
| Nozawa, T | 1 |
| Testa, A | 4 |
| Leonardis, D | 3 |
| Tripepi, R | 2 |
| Pisano, A | 3 |
| Spoto, B | 3 |
| Sanguedolce, MC | 3 |
| Parlongo, RM | 2 |
| Michels, G | 1 |
| Bunck, AC | 1 |
| Pfister, R | 1 |
| Verdoia, M | 4 |
| Schaffer, A | 3 |
| Barbieri, L | 3 |
| Di Giovine, G | 1 |
| Marino, P | 4 |
| De Luca, G | 4 |
| Ofori, SN | 1 |
| Odia, OJ | 1 |
| Gouri, A | 1 |
| Dekaken, A | 1 |
| Bentorki, AA | 1 |
| Touaref, A | 1 |
| Yakhlef, A | 1 |
| Kouicem, N | 1 |
| Liu, LM | 1 |
| Cheng, SF | 1 |
| Shieh, PC | 1 |
| Lee, JC | 1 |
| Kuo, SC | 1 |
| Kuo, DH | 1 |
| Huang, LJ | 1 |
| Way, TD | 1 |
| Castaldo, G | 1 |
| Lombardi, A | 1 |
| Mussap, M | 1 |
| Kitajiri, S | 1 |
| Ohya, M | 1 |
| Stelmach, MJ | 2 |
| Wasilewska, N | 2 |
| Wicklund-Liland, LI | 1 |
| Horsburgh, S | 1 |
| Meneses-Leon, J | 1 |
| Castañón-Robles, S | 1 |
| Granados-García, V | 1 |
| Talavera, JO | 1 |
| Huitrón-Bravo, GG | 1 |
| Cervantes-Rodríguez, M | 1 |
| Quiterio-Trenado, M | 1 |
| Rudolph, SE | 1 |
| Meek, IL | 1 |
| Vonkeman, HE | 1 |
| van de Laar, MA | 1 |
| Akasaka, H | 1 |
| Takizawa, H | 1 |
| Tobisawa, T | 1 |
| Togashi, N | 1 |
| Kuroda, S | 1 |
| Ura, N | 1 |
| Elsurer, R | 1 |
| Afsar, B | 4 |
| Turner, R | 2 |
| Khalilova, IS | 1 |
| Forbes, LV | 1 |
| Kettle, AJ | 2 |
| Wang, SF | 1 |
| Wang, XQ | 1 |
| Mu, M | 1 |
| Hu, CQ | 1 |
| Liu, KY | 1 |
| Zhao, QH | 1 |
| Hu, AL | 1 |
| Bo, QL | 1 |
| Tao, FB | 1 |
| Odden, MC | 1 |
| Amadu, AR | 1 |
| Smit, E | 1 |
| Lo, L | 1 |
| Peralta, CA | 1 |
| Wang, SQ | 6 |
| Yang, VC | 1 |
| Shichijo, Y | 1 |
| Akashi, A | 1 |
| Bae, J | 2 |
| Nacak, H | 2 |
| van Diepen, M | 2 |
| de Goeij, MC | 1 |
| Rotmans, JI | 1 |
| Dekker, FW | 2 |
| Oka, Y | 1 |
| Tashiro, H | 1 |
| Sirasaki, R | 1 |
| Akiyama, N | 1 |
| Kawasugi, K | 2 |
| Shirafuji, N | 1 |
| Patel, KH | 1 |
| Goldsmith, DJ | 1 |
| Chuang, SY | 3 |
| Chia-Yu Chen, R | 1 |
| Liu, WL | 1 |
| Hsu, YY | 1 |
| Sun-Waterhouse, D | 1 |
| Su, G | 2 |
| Honda, S | 1 |
| Kawamoto, S | 1 |
| Kishida, H | 1 |
| Kitagawa, M | 1 |
| Nakai, Y | 1 |
| Hirata, D | 1 |
| Itabashi, M | 3 |
| Wen, CP | 2 |
| Wu, SB | 2 |
| Lan, JL | 1 |
| Tsai, MK | 2 |
| Tai, YP | 1 |
| Tsao, CK | 1 |
| Wai, JP | 1 |
| Chiang, PH | 2 |
| Hsiung, CA | 1 |
| Hirayama, A | 3 |
| Bayram, D | 1 |
| Tuğrul Sezer, M | 1 |
| İnal, S | 1 |
| Altuntaş, A | 1 |
| Kıdır, V | 1 |
| Orhan, H | 1 |
| Wu, SK | 1 |
| Chung, WS | 2 |
| Lee, MC | 1 |
| Yeh, CJ | 1 |
| Taranova, MV | 1 |
| Yuan, CS | 2 |
| DeBosch, BJ | 1 |
| Kluth, O | 1 |
| Fujiwara, H | 1 |
| Schürmann, A | 1 |
| Moley, K | 1 |
| Dousdampanis, P | 1 |
| Trigka, K | 1 |
| Musso, CG | 1 |
| Fourtounas, C | 1 |
| de Miguel, E | 1 |
| Bailén, R | 1 |
| Banegas, JR | 1 |
| Valle, M | 1 |
| Martos, R | 1 |
| Cañete, MD | 1 |
| Valle, R | 1 |
| van Donkelaar, EL | 1 |
| Bermudo, F | 1 |
| Cañete, R | 1 |
| Zhang, YF | 2 |
| Ding, HH | 1 |
| Dai, W | 1 |
| Lv, YM | 1 |
| Zeng, HB | 1 |
| Alanazi, M | 1 |
| Al-Arfaj, AS | 1 |
| Abduljaleel, Z | 1 |
| Fahad Al-Arfaj, H | 1 |
| Reddy Parine, N | 1 |
| Purusottapatnam Shaik, J | 1 |
| Khan, Z | 1 |
| Ali Khan Pathan, A | 1 |
| Fang, JI | 1 |
| Wang, RH | 1 |
| Kimura-Hayama, E | 1 |
| Criales-Vera, S | 1 |
| Nicolaou, S | 1 |
| Betanzos, JL | 1 |
| Rivera, Y | 1 |
| Alberú, J | 1 |
| Rull-Gabayet, M | 1 |
| Hernández-Molina, G | 1 |
| Jeon, JS | 1 |
| Chung, SH | 1 |
| Han, DC | 1 |
| Noh, H | 1 |
| Kwon, SH | 1 |
| Lee, HB | 1 |
| Khondker, L | 1 |
| Khan, SI | 1 |
| Ozturk, D | 1 |
| Celık, O | 1 |
| Akın, F | 1 |
| Akturk, F | 1 |
| Aslan, S | 1 |
| Ozyılmaz, SO | 1 |
| Bırand, A | 1 |
| Yıldırım, A | 1 |
| Sorensen, LB | 1 |
| He, LJ | 1 |
| Cao, SJ | 1 |
| Yang, SW | 1 |
| Zhou, YJ | 1 |
| Mei, L | 1 |
| Xie, A | 1 |
| Sanchis-Gomar, F | 1 |
| Salvagno, GL | 3 |
| Lippi, G | 5 |
| Catena, C | 1 |
| Colussi, G | 1 |
| Capobianco, F | 1 |
| Brosolo, G | 1 |
| Sechi, LA | 1 |
| Verardi, FM | 1 |
| Pareo, I | 1 |
| Bentivenga, C | 1 |
| Baradaran, A | 1 |
| Biniaz, V | 1 |
| Tayebi, A | 1 |
| Ebadi, A | 1 |
| Sadeghi Shermeh, M | 1 |
| Einollahi, B | 3 |
| Lou, BS | 1 |
| Hsu, FL | 1 |
| Hou, CC | 1 |
| Faria, FR | 1 |
| Franceschini, Sdo C | 1 |
| Peluzio, Mdo C | 1 |
| Sant Ana, LF | 1 |
| Novaes, JF | 1 |
| Ribeiro, SM | 1 |
| Ribeiro, AQ | 1 |
| Priore, SE | 1 |
| Kocic, G | 1 |
| Sokolovic, D | 1 |
| Jevtovic, T | 1 |
| Cvetkovic, T | 1 |
| Veljkovic, A | 1 |
| Kocic, H | 1 |
| Stojanovic, S | 1 |
| Jovanovic, A | 1 |
| Jovanovic, J | 1 |
| Zivkovic, P | 1 |
| Cho, S | 1 |
| Kim, SR | 1 |
| Miyake, T | 1 |
| Furukawa, S | 1 |
| Hirooka, M | 1 |
| Kawasaki, K | 1 |
| Todo, Y | 1 |
| Yamamoto, S | 1 |
| Abe, M | 2 |
| Kitai, K | 1 |
| Matsuura, B | 1 |
| Hiasa, Y | 1 |
| Yu, DH | 1 |
| Liu, SM | 2 |
| Andrade, JA | 2 |
| Kang, HC | 2 |
| Greffin, S | 1 |
| Garcia Rosa, ML | 1 |
| Zhong, JQ | 1 |
| Ruan, JL | 1 |
| Jin, R | 1 |
| Kosacka, M | 1 |
| Brzecka, A | 1 |
| Piesiak, P | 1 |
| Korzeniewska, A | 1 |
| Jankowska, R | 1 |
| Liang, WY | 2 |
| Zhu, XY | 1 |
| Feng, XR | 2 |
| Wang, YC | 1 |
| Liu, ML | 2 |
| Cassetti, E | 2 |
| Suryapranata, H | 2 |
| Sato, M | 2 |
| Shimizu, A | 1 |
| Iwabuchi, Y | 1 |
| Nishida, M | 1 |
| Li, PC | 1 |
| Di, Q | 1 |
| Ni, L | 1 |
| Ersoy, A | 1 |
| Porowski, T | 1 |
| Protas, PT | 1 |
| Pszczółkowska, M | 1 |
| Porowska, H | 1 |
| Kirejczyk, JK | 1 |
| Němec, P | 1 |
| Marotta, T | 2 |
| Liccardo, M | 2 |
| Schettini, F | 2 |
| Verde, F | 2 |
| Ferrara, AL | 2 |
| Meng, ZQ | 1 |
| Tang, ZH | 1 |
| Yan, YX | 1 |
| Guo, CR | 1 |
| Huang, WZ | 1 |
| Wang, ZZ | 1 |
| Wang, KD | 1 |
| Deguchi, F | 1 |
| Izumi, K | 1 |
| Ishigaki, H | 1 |
| Sarui, H | 1 |
| Segawa, T | 1 |
| Kojima, T | 1 |
| Ohashi, H | 1 |
| Geng, W | 1 |
| Cai, G | 2 |
| Chou, YC | 3 |
| Kuan, JC | 1 |
| Chou, WY | 2 |
| Hsieh, PC | 1 |
| Bai, CH | 2 |
| You, SL | 2 |
| Wei, CY | 2 |
| Sun, CA | 3 |
| Doumas, M | 1 |
| Karagiannis, A | 3 |
| Qin, T | 1 |
| Franchi, C | 1 |
| Salerno, F | 1 |
| Conca, A | 1 |
| Djade, CD | 1 |
| Tettamanti, M | 1 |
| Pasina, L | 1 |
| Corrao, S | 1 |
| Marengoni, A | 1 |
| Marcucci, M | 1 |
| Mannucci, PM | 1 |
| Nobili, A | 1 |
| Wakuda, H | 1 |
| Ikeda, M | 2 |
| Tabuchi, M | 1 |
| Akahoshi, Y | 1 |
| Shinozuka, K | 1 |
| Reis, LO | 1 |
| Zamuner, M | 1 |
| Sanches, BC | 1 |
| Ikari, O | 1 |
| Mandokhel, R | 1 |
| Pritchard, G | 1 |
| Jones, J | 1 |
| Adams-Huet, B | 1 |
| Poindexter, J | 1 |
| Wei, F | 2 |
| Moe, OW | 3 |
| Sakhaee, K | 1 |
| Angelopoulos, TJ | 1 |
| Lowndes, J | 1 |
| Sinnett, S | 1 |
| Rippe, JM | 1 |
| Weaver, V | 1 |
| Fadrowski, JJ | 2 |
| Lin, YS | 2 |
| Guallar, E | 1 |
| Navas-Acien, A | 1 |
| Zhang, DM | 2 |
| Lemos Lima, Rde C | 2 |
| Ferrari, FC | 2 |
| de Souza, MR | 2 |
| de Sá Pereira, BM | 1 |
| de Paula, CA | 2 |
| Aribas, A | 1 |
| Akilli, H | 1 |
| Kayrak, M | 1 |
| Alibasic, H | 1 |
| Yildirim, O | 1 |
| Sertdemir, AL | 1 |
| Karanfil, M | 1 |
| Ozdemir, K | 1 |
| Recondo, J | 1 |
| Ortega-Calvo, M | 1 |
| Basora, J | 1 |
| Rosticci, M | 2 |
| Reggi, A | 1 |
| Derosa, G | 2 |
| Parini, A | 1 |
| Grandi, E | 2 |
| D'Addato, S | 2 |
| Castrejon, I | 1 |
| Toledano, E | 1 |
| Rosario, MP | 1 |
| Loza, E | 1 |
| Barabanchyk, OV | 1 |
| Svintsits'kyĭ, AS | 1 |
| Kozak, NP | 1 |
| Sun, WF | 4 |
| Zhu, MM | 1 |
| Liu, YW | 2 |
| Wu, XR | 1 |
| Liu, ZG | 1 |
| Mehta, T | 1 |
| Nuccio, E | 1 |
| Sarnak, MJ | 2 |
| Szczerbinski, L | 1 |
| Protas, P | 1 |
| de Abajo, FJ | 1 |
| Gil, MJ | 1 |
| Rodríguez, A | 1 |
| García-Poza, P | 1 |
| Álvarez, A | 1 |
| Bryant, V | 1 |
| García-Rodríguez, LA | 1 |
| Cheng, K | 1 |
| Lam, T | 1 |
| Xiao, H | 3 |
| Menenakos, E | 1 |
| Doulami, G | 1 |
| Tzanetakou, IP | 1 |
| Natoudi, M | 1 |
| Kokoroskos, N | 1 |
| Almpanopoulos, K | 1 |
| Leandros, E | 1 |
| Zografos, G | 1 |
| Theodorou, D | 1 |
| Davies, MJ | 1 |
| Trujillo, A | 1 |
| Vijapurkar, U | 1 |
| Damaraju, CV | 1 |
| Meininger, G | 1 |
| Kim, ED | 1 |
| Famure, O | 1 |
| Kodithuwakku, ND | 1 |
| Feng, YD | 1 |
| Pan, M | 1 |
| Fang, WR | 1 |
| Li, YM | 1 |
| Mi, C | 2 |
| Weng, H | 1 |
| Dooley, S | 1 |
| Peng, TC | 1 |
| Kao, TW | 1 |
| Chan, JY | 1 |
| Chang, YW | 1 |
| Aati, O | 1 |
| Tan, P | 2 |
| Doyle, AJ | 1 |
| McQueen, FM | 2 |
| Shaw, OM | 1 |
| Cornish, J | 1 |
| Naot, D | 1 |
| Danjoh, I | 1 |
| Terashige, S | 1 |
| Tatsukawa, S | 1 |
| Tokumasu, A | 1 |
| Onoue, H | 1 |
| Iwaya, K | 1 |
| Kanai, Y | 2 |
| Vecht-Lifshitz, SE | 1 |
| Ishii, Y | 1 |
| Yaoita, H | 1 |
| Kim, SY | 4 |
| Seo, JW | 1 |
| Choi, YW | 1 |
| Jeong, KH | 1 |
| Lee, TW | 1 |
| Ihm, CG | 1 |
| Won, KY | 1 |
| Muneyuki, T | 1 |
| Suwa, K | 1 |
| Lazzeri, C | 1 |
| Valente, S | 1 |
| Chiostri, M | 2 |
| Spini, V | 1 |
| Angelotti, P | 1 |
| Gensini, GF | 1 |
| Ishimura, E | 2 |
| Higami, K | 1 |
| Ohtawara, A | 1 |
| Nishikawa, H | 1 |
| Taniguchi, A | 4 |
| Yamauchi, T | 2 |
| Mineo, I | 3 |
| Prejbisz, A | 1 |
| Sellin, L | 1 |
| Szwench-Pietrasz, E | 1 |
| Woznowski, M | 1 |
| Michałowska, I | 1 |
| Blondin, D | 1 |
| Sajnaga, D | 1 |
| Epplen, JT | 1 |
| Litwin, M | 1 |
| Dekomien, G | 1 |
| Januszewicz, M | 1 |
| Helmchen, U | 1 |
| Matuszkiewicz-Rowińska, J | 1 |
| Adamczak, M | 1 |
| Więcek, A | 1 |
| Januszewicz, A | 1 |
| Rump, LC | 1 |
| Kanno, M | 1 |
| Tani, Y | 1 |
| Hayashi, Y | 1 |
| Terawaki, H | 2 |
| Wen, CC | 1 |
| Yee, SW | 1 |
| Hoffmann, TJ | 1 |
| Kvale, MN | 1 |
| Banda, Y | 1 |
| Jorgenson, E | 1 |
| Schaefer, C | 1 |
| Risch, N | 1 |
| Giacomini, KM | 1 |
| Schmella, MJ | 1 |
| Clifton, RG | 1 |
| Althouse, AD | 1 |
| Roberts, JM | 7 |
| De Giorgi, A | 1 |
| Fabbian, F | 1 |
| Pala, M | 1 |
| Tiseo, R | 1 |
| Parisi, C | 1 |
| Misurati, E | 1 |
| Manfredini, R | 1 |
| Kadowaki, D | 1 |
| Sakaguchi, S | 1 |
| Taguchi, K | 1 |
| Muraya, N | 1 |
| Narita, Y | 1 |
| Chuang, VT | 1 |
| Maruyama, T | 2 |
| Otagiri, M | 2 |
| Tang, Z | 1 |
| Guo, C | 1 |
| Bakan, A | 2 |
| Oral, A | 1 |
| Elcioglu, OC | 2 |
| Takir, M | 2 |
| Kostek, O | 2 |
| Ozkok, A | 2 |
| Basci, S | 1 |
| Sumnu, A | 1 |
| Ozturk, S | 1 |
| Sipahioglu, M | 1 |
| Turkmen, A | 1 |
| Voroneanu, L | 1 |
| Covic, A | 5 |
| Aniel-Quiroga, MA | 1 |
| Erauskin, GG | 2 |
| Ohuchi, H | 1 |
| Negishi, J | 1 |
| Hayama, Y | 1 |
| Sasaki, O | 1 |
| Noritake, K | 1 |
| Miyazaki, A | 1 |
| Yamada, O | 1 |
| Zhai, J | 1 |
| Zhen, Y | 2 |
| Zheng, M | 1 |
| Geng, X | 1 |
| Kleber, ME | 1 |
| Delgado, G | 1 |
| Grammer, TB | 1 |
| Silbernagel, G | 1 |
| Ritz, E | 1 |
| März, W | 1 |
| Xiong, C | 1 |
| Chin, YE | 1 |
| Cheng, SB | 1 |
| Reid, G | 1 |
| Shih, MH | 1 |
| Lazo, M | 1 |
| Liu, SH | 1 |
| Bonekamp, S | 1 |
| Hernaez, R | 1 |
| Clark, JM | 1 |
| Peluso, I | 1 |
| Teichner, A | 1 |
| Manafikhi, H | 1 |
| Palmery, M | 1 |
| Shan, HL | 1 |
| Shan, RP | 1 |
| Fu, XC | 1 |
| Zamudio-Cuevas, Y | 1 |
| Cerna-Cortés, JF | 1 |
| López-Reyes, A | 1 |
| Ying, K | 1 |
| Vehmas, T | 1 |
| Jokihaara, J | 1 |
| Pirttiniemi, P | 1 |
| Ruskoaho, H | 1 |
| Tokola, H | 1 |
| Niemelä, O | 2 |
| Wang, XM | 1 |
| Yu, JH | 1 |
| Ying, L | 1 |
| Xin, G | 1 |
| Haliakpaer, G | 1 |
| Xia, H | 1 |
| Gupta, S | 1 |
| Yui, JC | 1 |
| Fitzhugh, CD | 1 |
| Clark, C | 1 |
| Siddiqui, S | 1 |
| Conrey, AK | 1 |
| Kato, GJ | 1 |
| Minniti, CP | 1 |
| Fidan, C | 1 |
| Kantar, A | 1 |
| Baskın, E | 1 |
| Gülleroğlu, K | 1 |
| Akdur, A | 1 |
| Moray, G | 1 |
| Haberal, M | 3 |
| An, YT | 1 |
| Wu, ZZ | 1 |
| Amat, N | 1 |
| Umar, A | 1 |
| Hoxur, P | 1 |
| Anaydulla, M | 1 |
| Imam, G | 1 |
| Aziz, R | 1 |
| Upur, H | 1 |
| Kijjoa, A | 1 |
| Moore, N | 1 |
| Yao, Z | 1 |
| Tan, A | 1 |
| Mo, Z | 1 |
| Fukui, T | 1 |
| Maruyama, M | 1 |
| Yamauchi, K | 1 |
| Yoshitaka, S | 1 |
| Yasuda, T | 1 |
| Yao, W | 2 |
| Wu, HB | 1 |
| Kanji, T | 1 |
| Gandhi, M | 1 |
| Clase, CM | 1 |
| Yadav, D | 1 |
| Lee, ES | 1 |
| Kim, HM | 1 |
| Choi, E | 1 |
| Lee, EY | 2 |
| Lim, JS | 1 |
| Ahn, SV | 1 |
| Koh, SB | 1 |
| Chung, CH | 1 |
| Ishigaki, S | 1 |
| Isobe, S | 1 |
| Tsuji, N | 1 |
| Iwakura, T | 1 |
| Ono, M | 1 |
| Sakao, Y | 1 |
| Zykova, SN | 2 |
| Storhaug, HM | 2 |
| Toft, I | 1 |
| Chadban, SJ | 1 |
| Jenssen, TG | 2 |
| White, SL | 1 |
| Lotufo, PA | 1 |
| Baena, CP | 1 |
| Wu, YL | 1 |
| Koblick, R | 1 |
| Kikuchi, K | 2 |
| Sasaki, Y | 1 |
| Akiba, T | 1 |
| Seno, Y | 1 |
| Katasako, A | 1 |
| Kanaoka, R | 1 |
| Ságodi, L | 1 |
| Fehér, V | 1 |
| Kiss-Tóth, E | 1 |
| Barkai, L | 1 |
| Trepiccione, F | 1 |
| Perna, AF | 1 |
| Zacchia, M | 1 |
| Capolongo, G | 1 |
| Rinaldi, L | 1 |
| Santoro, A | 2 |
| Mandreoli, M | 2 |
| Ratto, E | 2 |
| Zhu, CS | 1 |
| Sun, XX | 1 |
| Xiao, ML | 1 |
| Ji, Q | 2 |
| Masoura, S | 1 |
| Makedou, K | 1 |
| Theodoridis, T | 1 |
| Kourtis, A | 1 |
| Zepiridis, L | 1 |
| Athanasiadis, A | 1 |
| Su, ZR | 1 |
| Fan, SY | 1 |
| Shi, WG | 1 |
| Zhong, BH | 1 |
| Yan, D | 2 |
| Yanai, H | 1 |
| Hirowatari, Y | 1 |
| Hou, PY | 2 |
| Uedono, H | 1 |
| Yasumoto, M | 1 |
| Ichii, M | 1 |
| Ochi, A | 1 |
| Nakatani, S | 1 |
| Uchida, J | 1 |
| Nakatani, T | 1 |
| Shahid, H | 1 |
| Rob, D | 1 |
| Leiba, A | 1 |
| Vinker, S | 1 |
| Dinour, D | 1 |
| Holtzman, EJ | 1 |
| Shani, M | 1 |
| Xie, DX | 1 |
| Li, YS | 3 |
| Lei, GH | 5 |
| Ogura, J | 2 |
| Kuwayama, K | 2 |
| Sasaki, S | 2 |
| Kaneko, C | 2 |
| Koizumi, T | 1 |
| Yabe, K | 1 |
| Tsujimoto, T | 1 |
| Takeno, R | 1 |
| Takaya, A | 1 |
| Yamaguchi, H | 1 |
| Papavasileiou, MV | 1 |
| Karamanou, AG | 1 |
| Kalogeropoulos, P | 1 |
| Moustakas, G | 1 |
| Patsianis, S | 1 |
| Pittaras, A | 1 |
| Reschke, LD | 1 |
| Loeffler, LF | 1 |
| Holmes, KW | 1 |
| Brady, TM | 1 |
| Dominiczak, A | 1 |
| Manolis, AJ | 1 |
| Şişmanlar, T | 1 |
| Aslan, AT | 1 |
| Budakoğlu, I | 1 |
| Song, P | 1 |
| Fang, Y | 2 |
| Nishizawa, T | 1 |
| Taniura, T | 1 |
| Hou, SK | 1 |
| Chiu, YH | 1 |
| Tsai, YF | 1 |
| Tai, LC | 1 |
| Hou, PC | 1 |
| How, CK | 1 |
| Yang, CC | 1 |
| Kao, WF | 1 |
| Pernigo, M | 1 |
| Bergamini, C | 1 |
| Carrero, JJ | 2 |
| Stijnen, T | 1 |
| Evans, M | 1 |
| Cheng, LC | 2 |
| Murugaiyah, V | 3 |
| Chan, KL | 3 |
| Su, GH | 1 |
| Luo, CL | 1 |
| Pang, YL | 1 |
| Wen, JH | 1 |
| Rodenbach, KE | 1 |
| Schneider, MF | 1 |
| Furth, SL | 1 |
| Moxey-Mims, MM | 1 |
| Mitsnefes, MM | 1 |
| Warady, BA | 1 |
| Schwartz, GJ | 1 |
| Suzuki, A | 1 |
| Fujibayashi, K | 1 |
| Uehara, Y | 1 |
| Sanada, H | 1 |
| Jose, PA | 1 |
| Miwa, Y | 1 |
| Filanovsky, MG | 1 |
| Sukhdeo, K | 1 |
| McNamara, MC | 1 |
| Sun, CC | 1 |
| Tai, HC | 1 |
| Chung, CF | 1 |
| Lin, PL | 1 |
| Kim, J | 1 |
| Imani, S | 1 |
| de Araujo, WR | 1 |
| Warchall, J | 1 |
| Valdés-Ramírez, G | 1 |
| Paixão, TR | 1 |
| Mercier, PP | 1 |
| Flynn, TJ | 2 |
| Todd, AS | 1 |
| Walker, RJ | 1 |
| Ou, Q | 1 |
| Marroquín-Fabián, E | 1 |
| Lozada-Navarro, AC | 1 |
| Mora-Ramírez, M | 1 |
| Juárez, M | 1 |
| Vargas-Barrón, J | 1 |
| Sandoval, J | 1 |
| Biscaglia, S | 1 |
| Ceconi, C | 1 |
| Malagù, M | 1 |
| Pavasini, R | 1 |
| Ferrari, R | 1 |
| Gliozzi, M | 1 |
| Malara, N | 1 |
| Muscoli, S | 1 |
| Wan, S | 1 |
| Tan, Q | 2 |
| Tan, ML | 1 |
| Li, KK | 1 |
| Leung, PC | 1 |
| Ko, CH | 1 |
| Chin, KY | 1 |
| Nirwana, SI | 1 |
| Ngah, WZ | 1 |
| Su, P | 2 |
| Hong, L | 2 |
| Winnard, D | 1 |
| Gow, PJ | 1 |
| Boswell, DR | 1 |
| Te Karu, L | 2 |
| Lindsay, K | 1 |
| Arroll, B | 1 |
| Eyuboglu, M | 1 |
| Rodríguez-Arias, JJ | 1 |
| Coll-de-Tuero, G | 1 |
| Volterrani, M | 1 |
| Iellamo, F | 1 |
| Sposato, B | 1 |
| Romeo, F | 1 |
| Que, S | 1 |
| Deng, Z | 1 |
| Altaf, S | 1 |
| Yamada, A | 2 |
| Sato, KK | 1 |
| Kinuhata, S | 1 |
| Uehara, S | 1 |
| Endo, G | 1 |
| Hikita, Y | 1 |
| Fujimoto, WY | 1 |
| Boyko, EJ | 2 |
| Sun, DQ | 1 |
| Wu, SJ | 1 |
| Liu, WY | 1 |
| Lu, QD | 1 |
| Zhu, GQ | 1 |
| Shi, KQ | 1 |
| Braddock, M | 1 |
| Zheng, MH | 1 |
| Rubio-Guerra, AF | 1 |
| Morales-López, H | 1 |
| Garro-Almendaro, AK | 1 |
| Vargas-Ayala, G | 1 |
| Durán-Salgado, MB | 1 |
| Huerta-Ramírez, S | 1 |
| Lozano-Nuevo, JJ | 1 |
| Tanaka, R | 1 |
| Miyata, Y | 1 |
| Minakuchi, N | 1 |
| Murakami, A | 1 |
| Sakazaki, F | 1 |
| Lee, EH | 1 |
| Choi, JH | 1 |
| Joung, KW | 1 |
| Baek, SH | 1 |
| Ji, SM | 1 |
| Chin, JH | 1 |
| Choi, IC | 1 |
| Srinivasasainagendra, V | 1 |
| Klimentidis, YC | 1 |
| Allison, DB | 1 |
| Gao, W | 2 |
| Xia, M | 1 |
| Fu, S | 1 |
| Ting, YK | 1 |
| Hasegawa, A | 1 |
| Kurata, Y | 1 |
| Nakayama, Y | 1 |
| Ikeda, N | 1 |
| Morikawa, K | 1 |
| Makita, N | 1 |
| Shirayoshi, Y | 1 |
| Gui, D | 1 |
| Larsen, KS | 1 |
| Pottegård, A | 1 |
| Lindegaard, H | 1 |
| Hallas, J | 1 |
| Erek, A | 1 |
| Mutlu, HH | 1 |
| Telci, O | 1 |
| Semerci, A | 1 |
| Odabas, AR | 1 |
| ALanaspa, M | 1 |
| Hui, W | 1 |
| Yongliang, Y | 1 |
| Yongde, C | 1 |
| Guo, L | 3 |
| Zhonglin, Y | 1 |
| Hui, J | 1 |
| Qinghua, H | 1 |
| Lin, KC | 2 |
| Chang, DM | 1 |
| Huang, WM | 1 |
| Lu, DY | 1 |
| Cheng, YL | 1 |
| Guo, CY | 1 |
| Yu, WC | 1 |
| Sloop, GD | 1 |
| Bialczak, JK | 1 |
| Weidman, JJ | 1 |
| St Cyr, JA | 1 |
| Chung, JY | 1 |
| Miao, P | 1 |
| Xiong, HR | 1 |
| Zhou, YL | 1 |
| Zhang, JQ | 1 |
| Lyu, X | 1 |
| Liang, LB | 1 |
| Tang, GH | 1 |
| Jia, D | 1 |
| An, ZM | 1 |
| Lyu, QG | 1 |
| Wang, SY | 3 |
| Wei, SY | 1 |
| Tang, LZ | 1 |
| Zhou, KJ | 1 |
| Tong, NW | 1 |
| Tung, YT | 2 |
| Lin, LC | 1 |
| Ho, ST | 1 |
| Chuang, HL | 1 |
| Chiu, CC | 1 |
| Wu, JH | 1 |
| Zurlo, A | 1 |
| Veronese, N | 3 |
| Giantin, V | 1 |
| Maselli, M | 1 |
| Zambon, S | 2 |
| Maggi, S | 1 |
| Musacchio, E | 2 |
| Toffanello, ED | 1 |
| Sartori, L | 2 |
| Perissinotto, E | 2 |
| Crepaldi, G | 2 |
| Manzato, E | 3 |
| Sergi, G | 2 |
| Lai, YC | 1 |
| Yew, YW | 1 |
| Jin, S | 1 |
| Mende, C | 1 |
| Yildiz, BS | 1 |
| Ozkan, E | 1 |
| Esin, F | 1 |
| Alihanoglu, YI | 1 |
| Ozkan, H | 1 |
| Bilgin, M | 1 |
| Kilic, ID | 1 |
| Ergin, A | 2 |
| Kaftan, HA | 1 |
| Evrengul, H | 1 |
| Sarfo, FS | 1 |
| Akassi, J | 1 |
| Antwi, NK | 1 |
| Obese, V | 1 |
| Adamu, S | 1 |
| Akpalu, A | 1 |
| Bedu-Addo, G | 1 |
| Rivard, C | 2 |
| Ayoub, I | 1 |
| Almaani, S | 1 |
| Brodsky, S | 1 |
| Nadasdy, T | 1 |
| Prosek, J | 1 |
| Hebert, L | 1 |
| Rovin, B | 2 |
| Peng, FF | 1 |
| Luo, QM | 1 |
| Lin, ZC | 1 |
| Yu, XQ | 1 |
| Huang, FX | 1 |
| Cong, H | 1 |
| Petsch, C | 1 |
| Araujo, EG | 1 |
| Englbrecht, M | 1 |
| Bayat, S | 1 |
| Cavallaro, A | 1 |
| Hueber, AJ | 1 |
| Lell, M | 1 |
| Schett, G | 2 |
| Manger, B | 1 |
| Rech, J | 1 |
| Xiong, YL | 2 |
| Gao, SG | 2 |
| Quintanilla, MA | 2 |
| Sánchez-Payá, J | 1 |
| Vela, P | 3 |
| Ruiz-Nodar, JM | 1 |
| Metzger, SC | 1 |
| Koehm, M | 1 |
| Wichmann, JL | 1 |
| Buettner, S | 1 |
| Scholtz, JE | 1 |
| Beeres, M | 1 |
| Kerl, JM | 1 |
| Albrecht, MH | 1 |
| Hammerstingl, R | 1 |
| Vogl, TJ | 1 |
| Bauer, RW | 1 |
| Ting, K | 1 |
| Gill, TK | 1 |
| Keen, H | 1 |
| Tucker, GR | 1 |
| Hill, CL | 1 |
| Lai, JH | 1 |
| Hsu, PN | 1 |
| Jang, JW | 1 |
| Park, WS | 1 |
| Jung, SH | 1 |
| Schimith Ferraz Filha, Z | 1 |
| Barros, CH | 1 |
| de Paula Michel Araújo, MC | 1 |
| Antunes Saúde-Guimarães, D | 1 |
| Suzuki, N | 1 |
| Kabasawa, A | 1 |
| Williamson, G | 1 |
| Cheng, ST | 1 |
| Su, CW | 1 |
| Teng, MS | 1 |
| Hsu, LA | 1 |
| Ko, YL | 1 |
| Shuai, X | 1 |
| Xiang, N | 1 |
| Gong, T | 1 |
| Shi, YC | 1 |
| Lin, KS | 1 |
| Jhai, YF | 1 |
| Hsu, WH | 1 |
| Wu, SC | 1 |
| Suma, S | 1 |
| Satoh, T | 1 |
| Mano, T | 1 |
| Eguchi, A | 1 |
| Fujiwara, S | 1 |
| Sugahara, M | 1 |
| Hirotani, S | 1 |
| Tsujino, T | 1 |
| Komamura, K | 1 |
| Koshiba, M | 1 |
| Masuyama, T | 1 |
| Zhi, L | 1 |
| Yuzhang, Z | 1 |
| Tianliang, H | 1 |
| Jidong, C | 1 |
| Poitou, C | 1 |
| Manivet, P | 1 |
| Denis, J | 1 |
| Bouillot, JL | 1 |
| Clément, K | 1 |
| Oppert, JM | 1 |
| Shacham, Y | 1 |
| Steinvil, A | 1 |
| Arbel, Y | 1 |
| Venkat-Raman, G | 1 |
| Gast, C | 1 |
| Marinaki, A | 1 |
| Fairbanks, L | 1 |
| Sathisha, KR | 1 |
| Gopal, S | 1 |
| Rangappa, KS | 1 |
| Aibibula, Z | 1 |
| Ailixiding, M | 1 |
| Iwata, M | 1 |
| Piao, J | 1 |
| Hara, Y | 3 |
| Okawa, A | 1 |
| Asou, Y | 1 |
| Wu, IH | 1 |
| Sun, ZJ | 1 |
| Chang, CS | 1 |
| Caliskan, Y | 1 |
| Ozluk, Y | 1 |
| Celik, D | 1 |
| Oztop, N | 1 |
| Aksoy, A | 1 |
| Ucar, AS | 1 |
| Yazici, H | 1 |
| Kilicaslan, I | 1 |
| Sever, MS | 1 |
| Liu, HY | 1 |
| Feng, GH | 1 |
| Yuan, A | 1 |
| Zelber-Sagi, S | 1 |
| Ben-Assuli, O | 1 |
| Rabinowich, L | 1 |
| Shalev, V | 1 |
| Shibolet, O | 1 |
| Chodick, G | 1 |
| Karim, B | 1 |
| Nasution, SA | 1 |
| Wijaya, IP | 1 |
| Harimurti, K | 1 |
| Deng, SB | 1 |
| She, Q | 1 |
| Kao, GY | 1 |
| Wang, JS | 1 |
| Qin, XD | 1 |
| Vaughn, MG | 1 |
| Ward, P | 1 |
| Yuan, P | 1 |
| Paul, G | 1 |
| Hao, YT | 1 |
| Chen, PC | 1 |
| Lee, YL | 1 |
| Bäurle, A | 1 |
| Di, Y | 1 |
| Sidoti, A | 1 |
| Nigrelli, S | 1 |
| Rosati, A | 1 |
| Bigazzi, R | 1 |
| Caprioli, R | 1 |
| Fanelli, R | 1 |
| Acconcia, P | 1 |
| Borracelli, D | 1 |
| Biagioli, M | 1 |
| Angelini, D | 1 |
| Parrini, M | 1 |
| Tonelli, L | 1 |
| Tosi, P | 1 |
| Manzoni, D | 1 |
| Wirajit, O | 1 |
| Burata, A | 1 |
| Ruangkanchanasetr, P | 2 |
| Krittayaphong, R | 1 |
| Rangsin, R | 1 |
| Thinkhamrop, B | 1 |
| Hurst, C | 1 |
| Rattanamongkolgul, S | 1 |
| Sripaiboonkij, N | 1 |
| Yindeengam, A | 1 |
| Hopfer, H | 1 |
| Mayr, M | 2 |
| Ao, J | 1 |
| Goldblatt, F | 1 |
| Casson, RJ | 1 |
| Brown, M | 1 |
| Eliseev, M | 1 |
| Cavagna, L | 1 |
| Chou, YY | 1 |
| Kiguchi, T | 1 |
| Okamoto, M | 1 |
| Kaneko, M | 1 |
| Maemondo, M | 1 |
| Gemba, K | 1 |
| Fujimaki, K | 1 |
| Kirito, K | 1 |
| Goto, T | 1 |
| Fujisaki, T | 1 |
| Takeda, K | 1 |
| Acevedo, A | 1 |
| Benavides, J | 1 |
| Chowdhury, M | 1 |
| Lopez, M | 1 |
| Pena, L | 1 |
| Montenegro, A | 1 |
| Lievano, M | 1 |
| Lombo, B | 1 |
| Pellegrini, M | 1 |
| Beltrami, M | 1 |
| Giordano, N | 1 |
| Lu, ZY | 1 |
| Shao, Z | 1 |
| Wulasihan, M | 1 |
| Chen, XH | 2 |
| Chen, XL | 1 |
| Xiang, T | 2 |
| Sun, BG | 1 |
| Luo, HX | 1 |
| Liu, MT | 1 |
| Zhang, SJ | 1 |
| Wang, CJ | 1 |
| Higa, A | 1 |
| Hashimoto, H | 3 |
| Zhang, CH | 1 |
| Huang, DS | 1 |
| Shen, D | 1 |
| Zhang, LW | 1 |
| Ma, YJ | 1 |
| Wang, YM | 1 |
| Sun, HY | 1 |
| Patel, KS | 1 |
| Lau, JE | 1 |
| Zembillas, AS | 1 |
| Gallagher, EM | 1 |
| Dua, P | 1 |
| Gurrell, R | 1 |
| Kirby, S | 1 |
| Sudworth, M | 1 |
| Loudon, PT | 1 |
| Hyndman, D | 1 |
| Stewart, S | 2 |
| Vandal, AC | 2 |
| Rome, K | 2 |
| Sharon, Y | 1 |
| Kanehira, N | 1 |
| Takayanagi, R | 3 |
| Minohara, H | 1 |
| Homma, M | 1 |
| Keir, M | 1 |
| Ducas, R | 1 |
| Crean, AM | 1 |
| Basar, C | 1 |
| Ozhan, H | 1 |
| Turker, Y | 1 |
| Kayapinar, O | 1 |
| Kecebas, M | 1 |
| Liu, WW | 1 |
| Sun, YS | 1 |
| Norvik, JV | 1 |
| Ytrehus, K | 1 |
| Eriksen, BO | 1 |
| Miao, X | 1 |
| Filiopoulos, V | 3 |
| Franco, J | 1 |
| Formiga, F | 1 |
| Chivite, D | 1 |
| Cerda, P | 1 |
| Corbella, X | 1 |
| Mome, R | 1 |
| Bakinde, N | 1 |
| Hadjiyannakos, D | 2 |
| Vlassopoulos, D | 2 |
| Sircar, D | 1 |
| Baggio, G | 1 |
| Corti, MC | 1 |
| Ai, Z | 1 |
| Jia, P | 1 |
| Maffioli, P | 1 |
| Reiner, Ž | 1 |
| Simental-Mendía, LE | 1 |
| Shinada, T | 2 |
| Shibuya, J | 2 |
| Shiomura, R | 2 |
| Nishigoori, S | 2 |
| Kor, S | 2 |
| Giese, A | 2 |
| Reinke, P | 2 |
| Westoff, TH | 1 |
| Pu, W | 1 |
| Quilis, N | 1 |
| Gil, S | 1 |
| Ranieri, L | 1 |
| Ando, M | 1 |
| Mizukoshi, T | 1 |
| Nagata, T | 1 |
| Katsuno, T | 1 |
| Kosugi, T | 3 |
| Oyama, J | 1 |
| Kuroyanagi, T | 1 |
| Ako, J | 1 |
| Wilson, L | 1 |
| Saseen, JJ | 1 |
| Schils, R | 1 |
| Krzesinski, JM | 1 |
| Kamdem, F | 1 |
| Doualla, MS | 1 |
| Kemta Lekpa, F | 1 |
| Temfack, E | 1 |
| Ngo Nouga, Y | 1 |
| Sontsa Donfack, O | 1 |
| Dzudie, A | 1 |
| Kingue, S | 1 |
| Sugiyama, S | 1 |
| Farrar, JE | 1 |
| Moulin, SR | 1 |
| Baldo, MP | 2 |
| Souza, JB | 1 |
| Luchi, WM | 1 |
| Capingana, DP | 1 |
| Magalhães, P | 2 |
| Li, HG | 1 |
| Kou, Y | 1 |
| Dang, Z | 1 |
| Kırça, M | 1 |
| Oğuz, N | 1 |
| Çetin, A | 1 |
| Uzuner, F | 1 |
| Yeşilkaya, A | 1 |
| Zhu, G | 1 |
| Abraham, MR | 1 |
| Ji, C | 1 |
| Cheng, FW | 1 |
| Pu, J | 2 |
| Feng, T | 1 |
| Gao, A | 1 |
| Zhan, CG | 1 |
| Liao, F | 2 |
| Ben Salem, C | 1 |
| Slim, R | 1 |
| Fathallah, N | 1 |
| Hmouda, H | 1 |
| Ma, CH | 1 |
| Jamshed, H | 1 |
| Gilani, AU | 1 |
| Sultan, FA | 1 |
| Amin, F | 1 |
| Arslan, J | 1 |
| Ghani, S | 1 |
| Masroor, M | 1 |
| Chia, FL | 1 |
| Degli Esposti, L | 1 |
| Saragoni, S | 1 |
| Buda, S | 1 |
| Ruoff, G | 1 |
| Nagasawa, Y | 1 |
| Yamamoto, R | 1 |
| Shoji, T | 2 |
| Shinzawa, M | 1 |
| Hasuike, Y | 1 |
| Nagatoya, K | 1 |
| Kuragano, T | 1 |
| Krajcoviechova, A | 1 |
| Tremblay, J | 1 |
| Wohlfahrt, P | 1 |
| Bruthans, J | 1 |
| Tahir, MR | 1 |
| Hamet, P | 1 |
| Cifkova, R | 1 |
| Tsunoda, T | 1 |
| Sogo, T | 1 |
| Hokari, R | 1 |
| Inui, A | 1 |
| Saddekni, MB | 1 |
| Dudenbostel, T | 1 |
| Oparil, S | 1 |
| Calhoun, DA | 1 |
| Sattui, SE | 1 |
| Redden, DT | 1 |
| Foster, PJ | 1 |
| Biggers, SR | 1 |
| Zou, B | 1 |
| Allen, B | 1 |
| Miranda, R | 1 |
| Carraro, S | 1 |
| Bano, G | 1 |
| Trevisan, C | 1 |
| Solmi, M | 1 |
| Luchini, C | 1 |
| Caccialanza, R | 1 |
| Nicetto, D | 1 |
| Cereda, E | 1 |
| Trimarco, V | 1 |
| Grassi, D | 2 |
| Flais, J | 1 |
| Bardou-Jacquet, E | 1 |
| Deugnier, Y | 1 |
| Coiffier, G | 1 |
| Perdriger, A | 1 |
| Chalès, G | 1 |
| Ropert, M | 1 |
| Loréal, O | 1 |
| Guggenbuhl, P | 1 |
| Hung, TL | 1 |
| Wang, WM | 1 |
| Chiang, CP | 1 |
| Légaré, S | 1 |
| Angileri, F | 1 |
| Fang, Q | 1 |
| Min, X | 1 |
| He, MA | 1 |
| Agrawal, A | 1 |
| Schmitz, B | 1 |
| Brand, SM | 1 |
| Qu, LH | 1 |
| Mallat, SG | 1 |
| Al Kattar, S | 1 |
| Tanios, BY | 1 |
| Jurjus, A | 1 |
| Ki, SH | 1 |
| Hifumi, A | 1 |
| Soejima, H | 1 |
| Jhang, JJ | 1 |
| Ong, JW | 1 |
| Lin, JH | 1 |
| Liao, JW | 2 |
| Yen, GC | 1 |
| Ohta, Y | 2 |
| Ishizuka, A | 1 |
| Hayashi, S | 1 |
| Iwashima, Y | 1 |
| Kishida, M | 2 |
| Yoshihara, F | 1 |
| Kawano, Y | 1 |
| Kaminska-Pajak, KA | 1 |
| Dyga, K | 1 |
| Adamczyk, P | 1 |
| Szczepańska, M | 1 |
| Zaniew, M | 1 |
| Beck, B | 1 |
| Tkaczyk, M | 1 |
| Zhang, GB | 1 |
| Ren, SS | 1 |
| Tian, LQ | 1 |
| Bing, FH | 1 |
| Momoki, K | 1 |
| Mao, S | 1 |
| Xie, T | 1 |
| Kawasoe, S | 1 |
| Kubozono, T | 1 |
| Yoshifuku, S | 1 |
| Ojima, S | 1 |
| Oketani, N | 1 |
| Miyata, M | 1 |
| Miyahara, H | 1 |
| Maenohara, S | 1 |
| Winter, WE | 1 |
| Hongyan, L | 1 |
| Suling, W | 1 |
| Weina, Z | 1 |
| Yajie, Z | 1 |
| Jie, R | 1 |
| Nishihara, S | 1 |
| Panjawatanan, P | 1 |
| Lekuthai, N | 1 |
| Murakami, Y | 2 |
| Miura, K | 3 |
| Sugiyama, D | 1 |
| Ueshima, H | 1 |
| Okamura, T | 2 |
| Beltrán, LM | 1 |
| Mejía-Chew, C | 1 |
| Tevar, D | 1 |
| Okamoto, K | 1 |
| Huang, YH | 2 |
| Lin, YY | 1 |
| Li, MM | 1 |
| Chen, YF | 1 |
| Cai, RW | 1 |
| Okafor, ON | 1 |
| Farrington, K | 1 |
| Gorog, DA | 1 |
| Pieterse, E | 1 |
| Jeremic, I | 1 |
| Weidner, D | 1 |
| Biermann, MH | 1 |
| Veissi, S | 1 |
| Maueröder, C | 1 |
| Schauer, C | 1 |
| Bilyy, R | 1 |
| Dumych, T | 1 |
| Hoffmann, M | 1 |
| Munoz, LE | 1 |
| Bengtsson, AA | 1 |
| van der Vlag, J | 1 |
| Fermi, B | 1 |
| Folli, C | 1 |
| Speranzini, V | 1 |
| Gandolfi, F | 1 |
| Cendron, L | 1 |
| Berni, R | 1 |
| Zanotti, G | 1 |
| Stocker, SL | 3 |
| Carland, JE | 1 |
| Ranjith, N | 1 |
| Myeni, NN | 1 |
| Sartorius, B | 1 |
| Mayise, C | 1 |
| Xie, JX | 1 |
| Hayek, SS | 1 |
| Cleophas, MC | 1 |
| Joosten, LA | 1 |
| Hao, K | 1 |
| Cairo, MS | 1 |
| Thompson, S | 1 |
| Tangirala, K | 1 |
| Eaddy, MT | 1 |
| Raymond, W | 1 |
| Divitini, M | 1 |
| Knuiman, M | 1 |
| Sugimoto, R | 1 |
| Watanabe, H | 1 |
| Ikegami, K | 1 |
| Enoki, Y | 1 |
| Imafuku, T | 1 |
| Sakaguchi, Y | 1 |
| Murata, M | 1 |
| Nishida, K | 1 |
| Miyamura, S | 1 |
| Ishima, Y | 1 |
| Dobrev, D | 1 |
| Krishnamurthy, A | 1 |
| Lazaro, D | 1 |
| Stefanov, DG | 1 |
| Blumenthal, D | 1 |
| Gerber, D | 1 |
| Patel, S | 1 |
| Lenti, S | 1 |
| Schiavon, L | 1 |
| Monte, AD | 1 |
| Townsend, DM | 1 |
| Ramazzina, E | 1 |
| Rubello, D | 1 |
| Kuo, TM | 1 |
| Tu, HP | 1 |
| Min-Shan Ko, A | 1 |
| Lee, CP | 1 |
| Ko, YC | 1 |
| Gong, W | 1 |
| Xia, W | 1 |
| He, JC | 1 |
| Yu, TH | 1 |
| Tuven, B | 1 |
| Unutmaz, G | 1 |
| Kaya, D | 1 |
| Hsu, WL | 1 |
| Li, SY | 1 |
| Liu, JS | 2 |
| Pan, C | 1 |
| Shu, X | 1 |
| Maglio, C | 1 |
| Peltonen, M | 1 |
| Neovius, M | 1 |
| Jacobson, P | 1 |
| Rudin, A | 1 |
| Carlsson, LM | 1 |
| Huangfu, X | 1 |
| Jin, J | 1 |
| Shaikh, SA | 1 |
| Marini, BL | 1 |
| Hough, SM | 1 |
| Perissinotti, AJ | 1 |
| Xue, F | 1 |
| Ramirez-Sandoval, JC | 1 |
| Zhu, CX | 1 |
| Huang, HZ | 1 |
| Zhou, XM | 1 |
| Saladini, F | 1 |
| Mos, L | 1 |
| Fania, C | 1 |
| Garavelli, G | 1 |
| Yuan, W | 1 |
| Shi, HJ | 1 |
| Wang, GY | 1 |
| Song, HC | 1 |
| Han, YX | 1 |
| Bernardes, N | 1 |
| Ayyappan, P | 1 |
| De Angelis, K | 1 |
| Bagchi, A | 1 |
| Akolkar, G | 1 |
| da Silva Dias, D | 1 |
| Belló-Klein, A | 1 |
| Singal, PK | 1 |
| Hu, JW | 1 |
| Lv, YB | 1 |
| Wang, KK | 1 |
| Zheng, WL | 1 |
| Cao, YM | 1 |
| Yuan, ZY | 1 |
| Mu, JJ | 1 |
| Li, LJ | 3 |
| Schlee, S | 1 |
| Bollheimer, LC | 1 |
| Bertsch, T | 1 |
| Sieber, CC | 1 |
| Härle, P | 1 |
| Fu, YQ | 1 |
| Zheng, JS | 1 |
| Zeng, XY | 1 |
| Zeng, W | 1 |
| Fan, ZF | 1 |
| Li, XA | 1 |
| Deng, YH | 1 |
| Pang, M | 1 |
| Shan, C | 1 |
| Liang, K | 1 |
| Morreale, M | 1 |
| Cusumano, C | 1 |
| Altieri, D | 1 |
| Panzica, M | 1 |
| Mark, PB | 1 |
| Pallarés, V | 1 |
| Fácila, L | 1 |
| Morillas, P | 1 |
| Bart, BY | 1 |
| Scheepers, LE | 1 |
| Fontenot, A | 1 |
| Harris, P | 1 |
| Macasa, A | 1 |
| Menon, Y | 1 |
| Quinet, R | 1 |
| Harambat, J | 1 |
| Dubourg, L | 1 |
| Ranchin, B | 1 |
| Hadj-Aïssa, A | 1 |
| Fargue, S | 1 |
| Rivet, C | 1 |
| Boillot, O | 1 |
| Lachaux, A | 1 |
| Cochat, P | 1 |
| Proctor, PH | 2 |
| Jones, DP | 1 |
| Richey, PA | 1 |
| Alpert, BS | 1 |
| Le, MT | 1 |
| Mu, W | 6 |
| Dimitroula, HV | 1 |
| Hatzitolios, AI | 1 |
| Karvounis, HI | 1 |
| Tahvanainen, AM | 1 |
| Vehmas, TI | 2 |
| Kööbi, P | 1 |
| Niemelä, OJ | 1 |
| Mustonen, JT | 1 |
| Pörsti, IH | 1 |
| Xu, F | 1 |
| Jankowski, J | 1 |
| Günthner, T | 1 |
| Yanagihara, K | 1 |
| Sonoyama, K | 2 |
| Sugihara, S | 2 |
| Shigamasa, C | 1 |
| Montagnana, M | 4 |
| Guidi, GC | 2 |
| Yang, CW | 3 |
| Zhen, WW | 1 |
| Chu, FH | 1 |
| Jiao, B | 1 |
| Jutabha, P | 3 |
| Babu, E | 1 |
| Jin, CJ | 1 |
| Srivastava, S | 1 |
| Kitamura, K | 2 |
| Endou, H | 5 |
| Sakurai, H | 3 |
| Góth, L | 1 |
| Gonzalez-Gay, MA | 3 |
| Gonzalez-Juanatey, C | 2 |
| Vazquez-Rodriguez, TR | 2 |
| Gomez-Acebo, I | 1 |
| Miranda-Filloy, JA | 1 |
| Paz-Carreira, J | 1 |
| Martin, J | 1 |
| Llorca, J | 2 |
| Soletsky, B | 1 |
| Chen, LX | 1 |
| Hair, PI | 1 |
| McCormack, PL | 1 |
| Keating, GM | 1 |
| Ho, CK | 1 |
| Ou, TT | 1 |
| Kamath, D | 1 |
| Vannorsdall, TD | 1 |
| Jinnah, HA | 1 |
| Gordon, B | 1 |
| Kraut, M | 1 |
| Schretlen, DJ | 1 |
| Haidari, F | 2 |
| Rashidi, MR | 2 |
| Keshavarz, SA | 2 |
| Mahboob, SA | 2 |
| Eshraghian, MR | 2 |
| Shahi, MM | 2 |
| Weaver, AL | 1 |
| Cheh, MA | 1 |
| Kennison, RH | 1 |
| Aringer, M | 2 |
| Graessler, J | 1 |
| Dehghan, A | 2 |
| Hwang, SJ | 2 |
| Kao, WL | 1 |
| Rivadeneira, F | 1 |
| Boerwinkle, E | 2 |
| Levy, D | 2 |
| Hofman, A | 3 |
| Astor, BC | 1 |
| van Duijn, CM | 1 |
| Witteman, JC | 2 |
| Fox, CS | 1 |
| Punthumapol, C | 1 |
| Kittichotpanich, B | 1 |
| Menè, P | 1 |
| Punzo, G | 1 |
| Cheng, TH | 1 |
| Lin, JW | 1 |
| Chao, HH | 1 |
| Chan, P | 2 |
| Liu, JC | 1 |
| Seeman, T | 1 |
| John, U | 1 |
| Dusek, J | 1 |
| Vondrák, K | 1 |
| Janda, J | 1 |
| Stejskal, J | 1 |
| Groene, HJ | 1 |
| Misselwitz, J | 1 |
| Wortmann, RL | 5 |
| Streit, J | 2 |
| Lademacher, C | 3 |
| Joseph-Ridge, N | 3 |
| Bannasch, D | 1 |
| Safra, N | 3 |
| Young, A | 2 |
| Karmi, N | 2 |
| Schaible, RS | 1 |
| Ling, GV | 1 |
| Roche, A | 1 |
| Pérez-Dueñas, B | 1 |
| Camacho, JA | 1 |
| García-Cazorla, A | 1 |
| Artuch, R | 1 |
| Springer, J | 1 |
| Landmesser, U | 2 |
| Struthers, AD | 3 |
| Long, CL | 1 |
| Qin, XC | 1 |
| Pan, ZY | 1 |
| Cui, WY | 1 |
| Liu, GS | 1 |
| Choi, HJ | 1 |
| Kang, HK | 1 |
| Yoon, HJ | 1 |
| Ha, IS | 1 |
| Cheong, HI | 1 |
| Sari, I | 1 |
| Akar, S | 1 |
| Pakoz, B | 1 |
| Sisman, AR | 1 |
| Gurler, O | 1 |
| Birlik, M | 1 |
| Onen, F | 1 |
| Li, ZA | 1 |
| Yong, Q | 1 |
| Jia, SD | 2 |
| Wang, YG | 2 |
| Li, HF | 1 |
| Yang, LQ | 1 |
| Wu, XY | 1 |
| Lu, LH | 1 |
| Gui, W | 1 |
| Malik, A | 1 |
| Dinnella, JE | 1 |
| Clayburne, GM | 1 |
| Shiraishi, H | 1 |
| Une, H | 1 |
| Lien, SB | 1 |
| Huang, GS | 1 |
| Pan, RY | 1 |
| Shen, HC | 1 |
| Kuo, CL | 1 |
| Shen, PH | 1 |
| Chen, HJ | 1 |
| Yeh, WT | 1 |
| Leow, MK | 1 |
| Chien, SC | 1 |
| Tseng, YH | 2 |
| Tsay, HS | 1 |
| Parmar, MS | 1 |
| Hebert, LA | 1 |
| Won, HY | 1 |
| Kang, SM | 1 |
| Ekundayo, OJ | 1 |
| Dell'Italia, LJ | 1 |
| Sanders, PW | 1 |
| Arnett, D | 1 |
| Aban, I | 1 |
| Love, TE | 1 |
| Lloyd-Jones, DM | 1 |
| Bakris, G | 1 |
| Mujib, M | 1 |
| Ahmed, A | 2 |
| Gersch, C | 1 |
| Palii, SP | 1 |
| Imaram, W | 1 |
| Kim, KM | 4 |
| Karumanchi, SA | 3 |
| Angerhofer, A | 1 |
| Henderson, GN | 1 |
| Alimonda, AL | 1 |
| Núñez, J | 1 |
| Núñez, E | 1 |
| Husser, O | 1 |
| Sanchis, J | 1 |
| Bodí, V | 1 |
| Miñana, G | 1 |
| Robles, R | 1 |
| Mainar, L | 1 |
| Merlos, P | 1 |
| Darmofal, H | 1 |
| Llácer, A | 1 |
| Campara, M | 1 |
| Shord, SS | 1 |
| Haaf, CM | 1 |
| Bandukwala, F | 2 |
| Huang, M | 2 |
| Zaltzman, JS | 1 |
| Nash, MM | 1 |
| Prasad, GV | 2 |
| Lloyd, E | 2 |
| Yamaguchi, Y | 3 |
| Saikawa, H | 3 |
| Uetake, D | 2 |
| Hikita, M | 2 |
| Okabe, H | 2 |
| Greene, T | 1 |
| Beck, GJ | 1 |
| Kusek, JW | 1 |
| Collins, AJ | 1 |
| Levey, AS | 1 |
| Menon, V | 1 |
| Kong, N | 1 |
| Meng, D | 2 |
| Okura, T | 1 |
| Higaki, J | 1 |
| Kurata, M | 1 |
| Irita, J | 1 |
| Miyoshi, K | 1 |
| Yamazaki, T | 3 |
| Hayashi, D | 1 |
| Kohro, T | 1 |
| Nagai, R | 2 |
| Malaguarnera, M | 2 |
| Vacante, M | 1 |
| Russo, C | 1 |
| Dipasquale, G | 1 |
| Gargante, MP | 1 |
| Motta, M | 1 |
| Patel, PA | 1 |
| Mody, RR | 1 |
| Yu, AP | 1 |
| Cahill, KE | 1 |
| Min, SI | 1 |
| Yun, IJ | 1 |
| Kang, JM | 1 |
| Park, YJ | 1 |
| Min, SK | 1 |
| Vukovic, J | 1 |
| Modun, D | 3 |
| Budimir, D | 1 |
| Sutlovic, D | 1 |
| Salamunic, I | 1 |
| Zaja, I | 1 |
| Boban, M | 2 |
| Nakayama, T | 2 |
| Heinig, M | 2 |
| Dierssen, T | 1 |
| Kim, DK | 1 |
| Chang, JH | 1 |
| Kim, E | 1 |
| Han, DS | 1 |
| Guggino, WB | 1 |
| Jolma, P | 1 |
| Moilanen, E | 1 |
| Tahvanainen, A | 1 |
| Kalliovalkama, J | 1 |
| Korpachev, VV | 1 |
| Hurina, NM | 1 |
| Korpacheva, TI | 1 |
| Shuprovych, AA | 1 |
| Mosendz, IO | 1 |
| Chuang, FH | 1 |
| Chen, HW | 3 |
| Borges, RL | 2 |
| Hirota, AH | 1 |
| Quinto, BM | 1 |
| Ribeiro, AB | 2 |
| Zanella, MT | 2 |
| Batista, MC | 2 |
| Zelman, D | 1 |
| Scavulli, J | 1 |
| Guevara, JP | 1 |
| Heitjan, DF | 1 |
| Lazar, HL | 1 |
| Göring, HH | 1 |
| Mottl, A | 1 |
| Almasy, L | 1 |
| Fabsitz, RR | 1 |
| Lee, ET | 1 |
| Best, LG | 1 |
| Devereux, RB | 1 |
| Howard, BV | 1 |
| Kigasawa, H | 1 |
| Tsurusawa, M | 1 |
| Kawa, K | 1 |
| Kikuta, A | 1 |
| Tsuchida, M | 1 |
| Nagatoshi, Y | 1 |
| Asami, K | 1 |
| Horibe, K | 1 |
| Makimoto, A | 1 |
| Tsukimoto, I | 1 |
| Mir, S | 1 |
| Yavascan, O | 1 |
| Mutlubas, F | 1 |
| Berdeli, A | 1 |
| Laughon, SK | 3 |
| Catov, J | 3 |
| Jabur, WL | 1 |
| Provins, T | 1 |
| Gandley, RE | 2 |
| Wright, AF | 1 |
| Ralston, SH | 1 |
| Ren, JY | 1 |
| Crews, KR | 1 |
| Pauley, JL | 1 |
| Howard, SC | 1 |
| Jeha, S | 1 |
| Relling, MV | 1 |
| Pui, CH | 1 |
| Liu, XQ | 1 |
| Yang, HL | 1 |
| Long, LH | 1 |
| Cao, YX | 1 |
| Cheng, M | 1 |
| Itou, S | 1 |
| Goto, Y | 1 |
| Lu, ZS | 1 |
| Lu, ZH | 1 |
| Yan, SG | 1 |
| Wang, JA | 1 |
| Murai, J | 1 |
| Mukai, M | 1 |
| Kasayama, S | 1 |
| Furuse, Y | 1 |
| Kinugasa, Y | 1 |
| Osaki, S | 1 |
| Kinugawa, T | 2 |
| Shigemasa, C | 7 |
| Lin, KP | 1 |
| Indraratna, PL | 3 |
| Sachs, L | 1 |
| Batra, KL | 1 |
| Zimmermann, B | 2 |
| Poon, SH | 1 |
| Hall, HA | 1 |
| Chang, CH | 1 |
| Chuang, YW | 1 |
| Liao, SC | 1 |
| Tang, YJ | 1 |
| Sheu, WH | 2 |
| Morcillo, S | 1 |
| Rojo-Martínez, G | 1 |
| Martín-Núñez, GM | 1 |
| Gómez-Zumaquero, JM | 1 |
| García-Fuentes, E | 3 |
| Ruiz de Adana, M | 1 |
| de la Cruz Almaraz, M | 1 |
| Soriguer, F | 2 |
| Li, NF | 1 |
| Wang, HM | 1 |
| Yao, XG | 1 |
| Hong, J | 1 |
| Luca Salvagno, G | 1 |
| Cesare Guidi, G | 1 |
| Hung, YJ | 2 |
| Chen, GY | 1 |
| Tzeng, TF | 1 |
| Lee, DY | 2 |
| Chen, CY | 3 |
| Huang, WP | 1 |
| Huang, CH | 1 |
| Zharikov, SI | 1 |
| Swenson, ER | 1 |
| Block, ER | 1 |
| Patel, JM | 1 |
| Sheng, CS | 1 |
| Naseri, M | 1 |
| Varasteh, AR | 1 |
| Alamdaran, SA | 1 |
| Akebaier, W | 1 |
| Ernst, ME | 1 |
| Fravel, MA | 1 |
| Villegas, R | 2 |
| Xiang, YB | 2 |
| Fazio, S | 2 |
| Linton, M | 1 |
| Elasy, T | 2 |
| Shu, XO | 2 |
| António, N | 1 |
| Prieto, D | 1 |
| Antunes, MJ | 1 |
| Lo, HC | 1 |
| Chiou, HY | 1 |
| Lai, SH | 1 |
| Mamada, H | 1 |
| Shirasaka, Y | 1 |
| Berni, A | 1 |
| Boddi, M | 1 |
| Fattori, EB | 1 |
| Cecioni, I | 1 |
| Berardino, S | 1 |
| Montuschi, F | 1 |
| Poggesi, L | 1 |
| Jiao, RQ | 2 |
| Lv, YZ | 1 |
| FICARRA, BJ | 2 |
| Chiou, WK | 1 |
| Wang, MH | 1 |
| Huang, DH | 1 |
| Knoebel, RW | 1 |
| Crank, CW | 1 |
| Hermans, MP | 1 |
| Ahn, SA | 1 |
| Rousseau, MF | 1 |
| Espinoza, LR | 2 |
| Wells, AF | 1 |
| MacDonald, P | 1 |
| Ko, YS | 2 |
| Wen, MS | 1 |
| Lin, CM | 1 |
| Hwang, JS | 2 |
| Tseng, WY | 1 |
| Shen, YM | 1 |
| Ghirardello, S | 1 |
| Ardissino, G | 1 |
| Mastrangelo, A | 1 |
| Mosca, F | 1 |
| Hokazono, H | 1 |
| Omori, T | 1 |
| Akaoka, I | 1 |
| Ono, K | 1 |
| Martin, WJ | 1 |
| López-Cuenca, A | 1 |
| Roldán, V | 1 |
| Marín, F | 1 |
| Folsom, AR | 1 |
| Yang, HF | 1 |
| Jong, MC | 1 |
| Fang, KY | 1 |
| Chao, YS | 1 |
| Shih, YH | 1 |
| Segal, MS | 4 |
| Kenny, JE | 1 |
| Goldfarb, DS | 1 |
| Alonso, A | 1 |
| Sovell, KA | 1 |
| Mascitelli, L | 1 |
| Pezzetta, F | 1 |
| Goldstein, MR | 1 |
| Chaiprasert, A | 1 |
| Kanjanakul, I | 2 |
| Phulsuksombuti, D | 2 |
| Utainam, D | 1 |
| Choovichian, P | 2 |
| Xiaohua, W | 1 |
| Lei, J | 1 |
| Ruoyun, T | 1 |
| Mingxia, X | 1 |
| Weichun, H | 1 |
| Ping, W | 1 |
| Junwei, Y | 1 |
| Hernandez-Baldizon, S | 1 |
| Convento, MS | 1 |
| Pessoa, E | 1 |
| Dalboni, MA | 1 |
| Borges, FT | 1 |
| Schor, N | 1 |
| Goicoechea, M | 1 |
| de Vinuesa, SG | 1 |
| Verdalles, U | 1 |
| Ruiz-Caro, C | 1 |
| Rincón, A | 1 |
| Arroyo, D | 1 |
| Luño, J | 1 |
| Park, HT | 1 |
| Cho, GJ | 1 |
| Yi, KW | 1 |
| Ahn, KH | 1 |
| Shin, JH | 1 |
| Kim, YT | 1 |
| Hur, JY | 1 |
| Hamaguchi, S | 1 |
| Furumoto, T | 1 |
| Tsuchihashi-Makaya, M | 1 |
| Goto, K | 1 |
| Yokota, T | 1 |
| Kinugawa, S | 1 |
| Yokoshiki, H | 1 |
| Takeshita, A | 1 |
| Tsutsui, H | 1 |
| Fraile, JM | 1 |
| de Miguel, ME | 1 |
| Martínez, P | 1 |
| Lundelin, KJ | 1 |
| Vázquez, JJ | 1 |
| Peláez-Ballestas, I | 1 |
| Hernández Cuevas, C | 1 |
| Hernández Roque, L | 1 |
| Terán, L | 1 |
| Espinoza, J | 1 |
| Esquivel-Valerio, JA | 1 |
| Goycochea-Robles, MV | 1 |
| Aceves, FJ | 1 |
| Bernard, AG | 1 |
| Ventura, L | 1 |
| Shumsky, C | 1 |
| Hernández Garduño, A | 1 |
| Igarashi, M | 1 |
| Miyake, H | 1 |
| Ho, WJ | 1 |
| Tsay, PK | 1 |
| Hsu, TS | 1 |
| Kuo, CT | 1 |
| Takiue, Y | 1 |
| Shibasaki, T | 2 |
| David Cheng, TY | 1 |
| Chan, HT | 1 |
| Tsai, SP | 1 |
| Wahlqvist, ML | 2 |
| Wen, SF | 1 |
| Spoon, DB | 1 |
| Rule, AD | 2 |
| Prasad, A | 1 |
| Lennon, RJ | 1 |
| Holmes, DR | 1 |
| Rihal, CS | 1 |
| Tangri, N | 1 |
| Weiner, DE | 1 |
| Bannasch, DL | 2 |
| Shih, CY | 1 |
| Wen, CJ | 1 |
| Liu, HM | 1 |
| Kuo, HK | 1 |
| Cortes, J | 1 |
| Moore, JO | 1 |
| Maziarz, RT | 1 |
| Wetzler, M | 1 |
| Craig, M | 1 |
| Matous, J | 1 |
| Luger, S | 1 |
| Dey, BR | 1 |
| Schiller, GJ | 1 |
| Abboud, CN | 1 |
| Krishnamurthy, M | 1 |
| Brown, A | 1 |
| Laadem, A | 1 |
| Seiter, K | 1 |
| Tabara, Y | 1 |
| Kohara, K | 1 |
| Hiura, Y | 1 |
| Nishimura, K | 1 |
| Morisaki, T | 2 |
| Kokubo, Y | 2 |
| Tomoike, H | 1 |
| Iwai, N | 2 |
| Miki, T | 1 |
| Ji, HF | 1 |
| Ochoa, CD | 1 |
| Valderrama, V | 1 |
| Mejia, J | 1 |
| Rondon, F | 1 |
| Villaroya, N | 1 |
| Restrepo, JF | 1 |
| Iglesias-Gamarra, A | 1 |
| Hsu, CA | 1 |
| Chen, CS | 1 |
| Yang, SC | 1 |
| Yan, K | 1 |
| Shimada, H | 1 |
| Katada, T | 1 |
| Fukutomi, T | 1 |
| Tomita, K | 2 |
| Urano, W | 1 |
| Seki, G | 1 |
| Fujita, T | 1 |
| Moriyama, Y | 1 |
| Wempe, MF | 1 |
| Trifilio, SM | 1 |
| Pi, J | 2 |
| Zook, J | 1 |
| Golf, M | 1 |
| Coyle, K | 1 |
| Greenberg, D | 1 |
| Newman, D | 1 |
| Koslosky, M | 1 |
| Mehta, J | 2 |
| VanItallie, TB | 1 |
| Vines, AN | 1 |
| Shanholtz, CB | 1 |
| Thompson, JL | 1 |
| Chung, BH | 1 |
| Hwang, HS | 1 |
| Choi, BS | 1 |
| Park, CW | 1 |
| Moon, IS | 1 |
| Chang, HC | 1 |
| Bhansing, KJ | 1 |
| van Bon, L | 1 |
| Radstake, TR | 1 |
| Lin, KH | 1 |
| Desai, RV | 1 |
| Ahmed, MI | 1 |
| Filippatos, GS | 1 |
| White, M | 1 |
| Aban, IB | 1 |
| Aronow, WS | 1 |
| Bai, H | 1 |
| Martin, AC | 1 |
| Brown, MA | 3 |
| Matsuzawa, Y | 5 |
| Ito, H | 1 |
| Omura, M | 1 |
| Yoshimura, K | 1 |
| Yajima, Y | 1 |
| Kino, T | 1 |
| Piret, SE | 1 |
| Danoy, P | 1 |
| Dahan, K | 2 |
| Reed, AA | 1 |
| Pryce, K | 1 |
| Wong, W | 1 |
| Müller, T | 1 |
| Kotanko, P | 3 |
| Devuyst, O | 2 |
| Quillen, DM | 1 |
| Zychowicz, ME | 1 |
| Pope, RS | 1 |
| Graser, E | 1 |
| Derakhshan, N | 1 |
| Derakhshan, D | 1 |
| Basiratnia, M | 1 |
| Fallahzadeh, MH | 1 |
| Hashemi, G | 1 |
| Derakhshan, A | 1 |
| Lee, DH | 1 |
| Oh, SE | 1 |
| Noh, JW | 1 |
| Lee, YK | 1 |
| Dogan, E | 1 |
| Shi, YW | 3 |
| Kim, SS | 2 |
| Park, JS | 2 |
| Lee, WL | 1 |
| Chen, KF | 1 |
| Chi, WC | 1 |
| Chang, SC | 1 |
| Wu, AH | 1 |
| Ghali, JK | 1 |
| Neuberg, GW | 1 |
| O'Connor, CM | 1 |
| Carson, PE | 1 |
| Levy, WC | 1 |
| Schwartz, IF | 1 |
| Grupper, A | 2 |
| Chernichovski, T | 1 |
| Hillel, O | 1 |
| Engel, A | 1 |
| Schwartz, D | 1 |
| Daoussis, D | 1 |
| Kitas, GD | 2 |
| Bu, Y | 1 |
| Brodov, Y | 1 |
| Behar, S | 1 |
| Boyko, V | 1 |
| Chouraqui, P | 1 |
| Lee, MS | 3 |
| Ye, JF | 2 |
| Teng, F | 1 |
| Zhu, R | 1 |
| Zou, C | 1 |
| Jones, G | 2 |
| Yu, JW | 1 |
| Yang, TG | 1 |
| Diao, WX | 1 |
| Cai, XQ | 1 |
| Hu, DL | 1 |
| Chen, CQ | 1 |
| Jung, DH | 1 |
| Lee, HR | 1 |
| Shim, JY | 1 |
| Fan, H | 1 |
| Sokolove, J | 1 |
| Lou, S | 2 |
| Secco, GG | 1 |
| Santagostino, M | 1 |
| Venegoni, L | 1 |
| Iorio, S | 1 |
| Coppo, L | 1 |
| Di Mario, C | 1 |
| de Andrade, M | 1 |
| Mosley, TH | 1 |
| Kardia, S | 1 |
| Turner, ST | 1 |
| Shakeri, MT | 1 |
| Baldasseroni, S | 1 |
| Urso, R | 1 |
| Maggioni, AP | 1 |
| Orso, F | 1 |
| Fabbri, G | 1 |
| Marchionni, N | 1 |
| Tavazzi, L | 1 |
| Shin, WY | 1 |
| Gil, HW | 1 |
| Lee, SJ | 2 |
| Jin, DK | 1 |
| Hong, SY | 1 |
| Powers, RW | 2 |
| Sun, FY | 1 |
| Feng, SM | 1 |
| Meotti, FC | 1 |
| Jameson, GN | 1 |
| Harwood, DT | 1 |
| Stockwell, S | 1 |
| Rees, MD | 1 |
| Thomas, SR | 1 |
| Cai, H | 1 |
| Linton, MF | 1 |
| O'Donnell, JL | 1 |
| James, J | 1 |
| Barclay, ML | 1 |
| Utennam, D | 1 |
| Duangurai, K | 1 |
| El-Husseini, A | 1 |
| Sabucedo, A | 1 |
| Lamarche, J | 1 |
| Courville, C | 1 |
| Peguero, A | 1 |
| Nakaya, I | 1 |
| Namikoshi, T | 1 |
| Onishi, Y | 1 |
| Fukuhara, S | 1 |
| Brown, F | 1 |
| Hawley, CM | 1 |
| Kanellis, J | 6 |
| Rangan, GK | 1 |
| Perkovic, V | 1 |
| Baldwin, W | 1 |
| McRae, S | 1 |
| Marek, G | 1 |
| Wymer, D | 1 |
| Pannu, V | 1 |
| Baylis, C | 1 |
| Mulla, MJ | 1 |
| Myrtolli, K | 1 |
| Potter, J | 1 |
| Boeras, C | 1 |
| Kavathas, PB | 1 |
| Sfakianaki, AK | 1 |
| Tadesse, S | 1 |
| Norwitz, ER | 1 |
| Guller, S | 1 |
| Abrahams, VM | 1 |
| Jackson, RL | 3 |
| Keller, DL | 1 |
| Wertheimer, AI | 1 |
| Davis, MW | 1 |
| Lauterio, TJ | 1 |
| Fukatsu, M | 1 |
| Joh, T | 1 |
| Dubost, JJ | 1 |
| Mathieu, S | 1 |
| Soubrier, M | 1 |
| Dzhergeniia, SL | 1 |
| Ushakov, IB | 1 |
| Minakova, EG | 1 |
| Zaĭtseva, LI | 1 |
| Severova, MM | 1 |
| Pulin, AA | 1 |
| Mackenzie, IS | 1 |
| MacDonald, TM | 1 |
| GUTMAN, AB | 2 |
| YÜ, TF | 2 |
| Nakamura, K | 1 |
| Sakurai, M | 1 |
| Morikawa, Y | 2 |
| Yoshita, K | 1 |
| Ishizaki, M | 2 |
| Kido, T | 2 |
| Naruse, Y | 1 |
| Suwazono, Y | 3 |
| LI, SH | 1 |
| Hwa, KS | 1 |
| Chung, DM | 1 |
| Chung, YC | 1 |
| Chun, HK | 1 |
| Kalantar, E | 1 |
| Khalili, N | 1 |
| Hossieni, MS | 1 |
| Rostami, Z | 2 |
| Nery, AB | 1 |
| Mesquita, ET | 1 |
| de Miranda, VA | 1 |
| de Souza, BG | 1 |
| Rosa, ML | 1 |
| Serpa Neto, A | 1 |
| Rossi, FM | 1 |
| Valle, LG | 1 |
| Teixeira, GK | 1 |
| Rossi, M | 1 |
| Silverstein, DM | 1 |
| Srivaths, PR | 1 |
| Mattison, P | 1 |
| Upadhyay, K | 1 |
| Midgley, L | 1 |
| Moudgil, A | 1 |
| Goldstein, SL | 1 |
| Ishibashi, Y | 1 |
| Shimada, K | 1 |
| Zapolski, T | 1 |
| Waciński, P | 1 |
| Kondracki, B | 1 |
| Rychta, E | 1 |
| Buraczyńska, MJ | 1 |
| Wysokiński, A | 1 |
| Riegersperger, M | 1 |
| Goldsmith, D | 1 |
| Asai, S | 1 |
| Lan, Z | 1 |
| Xie, YC | 1 |
| Hsu, YJ | 1 |
| Lee, TM | 1 |
| Brodskiĭ, MS | 1 |
| Yao, L | 1 |
| Qiao, Y | 1 |
| Zhu, S | 1 |
| Kamatani, N | 6 |
| Naoyuki, K | 3 |
| Tatsuo, H | 4 |
| Hada, T | 4 |
| Kohri, K | 4 |
| Iwao, O | 1 |
| Shin, F | 2 |
| Toshikazu, H | 2 |
| Kenjiro, K | 2 |
| Toshitaka, N | 2 |
| Takanori, U | 2 |
| Tetsuya, Y | 2 |
| Hisashi, Y | 2 |
| Yuji, M | 2 |
| Hsieh, YT | 1 |
| Kwon, HH | 1 |
| Kwon, IH | 1 |
| Choi, JW | 2 |
| Youn, JI | 1 |
| Hurtes, X | 1 |
| Meria, P | 1 |
| Howard, RG | 1 |
| Gyftopoulos, S | 1 |
| Thiele, RG | 1 |
| Swearingen, CJ | 1 |
| Samuels, J | 1 |
| Dhaun, N | 1 |
| Johnston, NR | 1 |
| Goddard, J | 1 |
| Webb, DJ | 2 |
| Horsley, A | 1 |
| Helm, J | 1 |
| Brennan, A | 1 |
| Bright-Thomas, R | 1 |
| Webb, K | 1 |
| Skoumas, J | 1 |
| Pitsavos, C | 2 |
| Masoura, C | 1 |
| Siasos, G | 1 |
| Galiatsatos, N | 1 |
| Psaltopoulou, T | 1 |
| Mylonakis, C | 1 |
| Margazas, A | 1 |
| Kyvelou, S | 1 |
| Mamatas, S | 1 |
| Panagiotakos, D | 1 |
| Stefanadis, C | 2 |
| Neri, L | 1 |
| Rocca Rey, LA | 1 |
| Lentine, KL | 1 |
| Hinyard, LJ | 1 |
| Pinsky, B | 1 |
| Dukes, J | 1 |
| Schnitzler, MA | 1 |
| Huddam, B | 2 |
| Azak, A | 1 |
| Kadioglu, GK | 1 |
| Kirbas, I | 1 |
| Duranay, M | 1 |
| Petta, S | 2 |
| Cammà, C | 2 |
| Cabibi, D | 2 |
| Di Marco, V | 1 |
| Craxì, A | 2 |
| Krolewski, AS | 1 |
| Stellato, D | 1 |
| Morrone, LF | 1 |
| Di Giorgio, C | 1 |
| Duplancic, D | 1 |
| Kukoc-Modun, L | 1 |
| Radic, N | 1 |
| Shu, Z | 1 |
| Tao, Q | 1 |
| Messina, M | 1 |
| Messina, VL | 1 |
| Bollée, G | 1 |
| Flamant, M | 1 |
| Morinière, V | 1 |
| Pawtowski, A | 1 |
| Heidet, L | 1 |
| Lacombe, D | 1 |
| Pirson, Y | 2 |
| Antignac, C | 1 |
| Knebelmann, B | 1 |
| Latif, W | 1 |
| Karaboyas, A | 1 |
| Tong, L | 1 |
| Winchester, JF | 1 |
| Arrington, CJ | 1 |
| Pisoni, RL | 1 |
| Marshall, MR | 1 |
| Kleophas, W | 1 |
| Levin, NW | 1 |
| Sen, A | 1 |
| Robinson, BM | 1 |
| Saran, R | 1 |
| Walters, M | 1 |
| Singal, R | 1 |
| Krishnamurthy, S | 1 |
| Narayanan, P | 1 |
| Rajesh, NG | 1 |
| Choudhary, B | 1 |
| Arlet, JB | 1 |
| Ribeil, JA | 1 |
| Chatellier, G | 1 |
| Pouchot, J | 1 |
| de Montalembert, M | 1 |
| Prié, D | 1 |
| Courbebaisse, M | 1 |
| Alvarez-Lario, B | 1 |
| Macarrón-Vicente, J | 1 |
| Tapan, S | 1 |
| Bagci, S | 1 |
| Chen, DP | 1 |
| Wong, CK | 1 |
| Tam, LS | 1 |
| Li, EK | 1 |
| Lam, CW | 1 |
| Turfan, M | 1 |
| Vatankulu, MA | 1 |
| Ocak, A | 2 |
| Doger, C | 1 |
| Yalcin, AA | 1 |
| Demircelik, MB | 1 |
| Shipley, M | 1 |
| Ohshiro, K | 1 |
| Nakada, S | 1 |
| Khan, M | 1 |
| Khan, RA | 1 |
| Laghari, J | 1 |
| Jamali, SN | 1 |
| Iyadomi, M | 1 |
| Higaki, Y | 1 |
| Vázquez-Rodríguez, JG | 1 |
| Rico-Trejo, EI | 1 |
| Huang, CQ | 2 |
| Lu, ZC | 1 |
| Dong, BR | 2 |
| Leiszler, M | 1 |
| Poddar, S | 1 |
| Fletcher, A | 1 |
| Meléndez-Ramírez, G | 1 |
| Pérez-Méndez, O | 1 |
| López-Osorio, C | 1 |
| Kuri-Alfaro, J | 1 |
| Espinola-Zavaleta, N | 1 |
| Rho, YH | 2 |
| Mazali, FC | 2 |
| Ortalda, V | 1 |
| Abaterusso, C | 1 |
| Negri, C | 1 |
| Amonpatumrat-Takahashi, S | 1 |
| Chohan, S | 1 |
| Chefo, S | 2 |
| Choi, WJ | 1 |
| Rankin, JI | 1 |
| Acosta, AA | 1 |
| Cui, MJ | 1 |
| Zhang, BH | 1 |
| Xiao, QF | 1 |
| Zhu, FL | 1 |
| Al-Meshaweh, AF | 1 |
| Jafar, Y | 1 |
| Asem, M | 1 |
| Akanji, AO | 1 |
| Kalay, N | 1 |
| Akpek, M | 1 |
| Orscelik, O | 1 |
| Elcik, D | 1 |
| Inanc, MT | 1 |
| Kasapkara, HA | 1 |
| Oguzhan, A | 1 |
| Eryol, NK | 1 |
| Kaya, MG | 2 |
| Xing, RL | 1 |
| Meng, DM | 1 |
| Uratsuji, H | 1 |
| Tada, Y | 1 |
| Kawashima, T | 1 |
| Kamata, M | 1 |
| Hau, CS | 1 |
| Asano, Y | 1 |
| Sugaya, M | 1 |
| Kadono, T | 1 |
| Asahina, A | 1 |
| Tamaki, K | 2 |
| Kawamura, T | 1 |
| Ishikawa, M | 2 |
| Tomonari, H | 1 |
| Soejima, M | 1 |
| Akaba, K | 1 |
| Tokudome, G | 1 |
| Endo, S | 1 |
| Fukui, A | 1 |
| Gomi, H | 1 |
| Hamaguchi, A | 1 |
| Hanaoka, K | 1 |
| Hasegawa, T | 1 |
| Hikida, M | 1 |
| Hirano, K | 1 |
| Horiguchi, M | 1 |
| Imai, T | 1 |
| Ishii, T | 1 |
| Ishikawa, H | 1 |
| Kameda, C | 1 |
| Kobayashi, H | 1 |
| Kurashige, M | 1 |
| Kusama, Y | 1 |
| Maezawa, H | 1 |
| Maezawa, Y | 1 |
| Matsuda, H | 1 |
| Matsuo, N | 1 |
| Matsuo, T | 1 |
| Miura, Y | 1 |
| Miyajima, M | 1 |
| Miyakawa, M | 1 |
| Mizuguchi, M | 2 |
| Nakao, M | 1 |
| Nokano, H | 1 |
| Ohkido, I | 1 |
| Ohtsuka, Y | 1 |
| Okada, K | 1 |
| Okamoto, H | 1 |
| Okonogi, H | 1 |
| Sekiguchi, C | 1 |
| Suetsugu, Y | 1 |
| Suzuki, T | 2 |
| Takamizawa, S | 1 |
| Takane, K | 1 |
| Morita, T | 1 |
| Takazoe, K | 1 |
| Toyoshima, R | 1 |
| Udagawa, T | 1 |
| Ueda, H | 1 |
| Ueda, Y | 1 |
| Uetake, M | 1 |
| Unemura, S | 1 |
| Utsunomiya, M | 1 |
| Utsunomiya, Y | 1 |
| Yokoyama, K | 1 |
| Yonezawa, H | 1 |
| Yoshida, M | 2 |
| Yoshizawa, T | 1 |
| Moromizato, H | 1 |
| Kubota, M | 1 |
| Yoshida, N | 1 |
| Yamanobe, T | 1 |
| Yasuda, M | 1 |
| Ogata, N | 1 |
| Ikebuchi, Y | 2 |
| Einollahi, H | 1 |
| Rodrigues, SL | 1 |
| Capingana, P | 1 |
| Dantas, EM | 1 |
| Molina, Mdel C | 1 |
| Salaroli, LB | 1 |
| Morelato, RL | 1 |
| Yashio, K | 1 |
| Katayama, Y | 1 |
| Takashima, T | 1 |
| Ishiguro, N | 1 |
| Doi, H | 1 |
| Suzuki, M | 1 |
| Wada, Y | 1 |
| Watanabe, Y | 1 |
| Chu, CH | 1 |
| Chien, KL | 2 |
| Hwang, LC | 1 |
| Su, TC | 1 |
| Tseng, CH | 2 |
| Gibson, T | 1 |
| Bochud, M | 1 |
| Vollenweider, P | 1 |
| Waeber, G | 1 |
| Butler, K | 1 |
| Teng, R | 1 |
| Jin, M | 1 |
| Yang, I | 2 |
| Luo, JJ | 1 |
| Yang, XF | 1 |
| Tenderenda, E | 1 |
| Tobolczyk, J | 1 |
| Stypułkowska, J | 1 |
| Sull, JW | 1 |
| Lee, M | 1 |
| Filippou, G | 1 |
| Frediani, B | 1 |
| Delle Sedie, A | 1 |
| Bombardieri, S | 1 |
| Filippucci, E | 1 |
| Grassi, W | 2 |
| Iagnocco, A | 1 |
| Valesini, G | 1 |
| Jacobs, DR | 2 |
| Lewis, CE | 2 |
| Takayama, S | 1 |
| Onji, M | 1 |
| Panero, F | 1 |
| Gruden, G | 1 |
| Perotto, M | 1 |
| Fornengo, P | 1 |
| Barutta, F | 1 |
| Greco, E | 1 |
| Runzo, C | 1 |
| Ghezzo, G | 1 |
| Cavallo-Perin, P | 1 |
| Bruno, G | 1 |
| Falsetti, P | 1 |
| Acciai, C | 1 |
| Hawkins, TL | 1 |
| Mangos, GJ | 1 |
| Davis, GK | 1 |
| Roberts, LM | 1 |
| Pandya, BJ | 2 |
| Lingala, B | 1 |
| Hariri, A | 2 |
| Dabbous, O | 2 |
| Hynes, AM | 1 |
| Sayer, JA | 1 |
| Liu, WC | 1 |
| Hung, CC | 1 |
| Yeh, SM | 2 |
| Lin, MY | 1 |
| Chiu, YW | 1 |
| Marson, P | 1 |
| Pasero, G | 1 |
| De Angelis, R | 1 |
| Chen, XP | 1 |
| Wan, LY | 1 |
| Gonçalves, JP | 1 |
| Oliveira, A | 1 |
| Severo, M | 1 |
| Santos, AC | 1 |
| Lopes, C | 1 |
| Lipkowitz, MS | 1 |
| Qi, K | 1 |
| Pasalic, D | 1 |
| Marinkovic, N | 1 |
| Feher-Turkovic, L | 1 |
| Moreno, JA | 1 |
| Hong, E | 1 |
| Mutluay, R | 1 |
| Deger, SM | 1 |
| Bahadir, E | 1 |
| Durmaz, AO | 1 |
| Citil, R | 1 |
| Sindel, S | 1 |
| Chu, N | 1 |
| Puddu, P | 1 |
| Puddu, GM | 1 |
| Cravero, E | 1 |
| Vizioli, L | 1 |
| Muscari, A | 1 |
| Hui, JY | 1 |
| Zhang, HN | 1 |
| Guo, JF | 1 |
| Lei, LF | 1 |
| Wang, YQ | 1 |
| Tan, LM | 1 |
| Yan, XX | 1 |
| Tang, BS | 1 |
| Tomlinson, B | 1 |
| Li, YC | 1 |
| Santos, RD | 1 |
| Sumida, C | 1 |
| Tsutsumi, Z | 2 |
| Wang, DD | 1 |
| Sievenpiper, JL | 1 |
| de Souza, RJ | 1 |
| Chiavaroli, L | 1 |
| Ha, V | 1 |
| Cozma, AI | 1 |
| Mirrahimi, A | 1 |
| Yu, ME | 1 |
| Carleton, AJ | 1 |
| Di Buono, M | 1 |
| Jenkins, AL | 1 |
| Leiter, LA | 1 |
| Wolever, TM | 1 |
| Beyene, J | 1 |
| Kendall, CW | 1 |
| Jenkins, DJ | 1 |
| Kasuga, H | 1 |
| Okada, C | 1 |
| Utsumi, Y | 1 |
| Shinohara, Y | 1 |
| Carpéné, C | 1 |
| Desquesnes, A | 1 |
| Gomez-Ruiz, A | 1 |
| Iffiú-Soltész, Z | 1 |
| Le Gonidec, S | 1 |
| Mercader, J | 1 |
| Kambhampati, G | 1 |
| Ejaz, NI | 1 |
| Maroz, N | 1 |
| Dhatt, GS | 1 |
| Arif, AA | 1 |
| Faldu, C | 1 |
| Shah, G | 1 |
| Tsai, YT | 1 |
| Liu, JP | 1 |
| Tu, YK | 1 |
| Chen, PR | 1 |
| Hsu, HC | 1 |
| Chen, MF | 1 |
| D'Marco, L | 1 |
| García, I | 1 |
| Vega, C | 1 |
| Beedkar, SD | 1 |
| Khobragade, CN | 1 |
| Bodade, RG | 1 |
| Vinchurkar, AS | 1 |
| Kaufman, M | 1 |
| Guglin, M | 1 |
| Yue, JR | 1 |
| Egorov, IV | 1 |
| Kocijancic, DM | 1 |
| Plesinac, S | 1 |
| Plecas, D | 1 |
| Aksam, S | 1 |
| Kocijancic, A | 1 |
| Nishino, T | 1 |
| Shinzato, T | 1 |
| Obata, Y | 1 |
| Shinzato, K | 1 |
| Kohno, S | 1 |
| Coufal, Z | 1 |
| Sen, T | 1 |
| Aksu, T | 1 |
| Numakura, K | 1 |
| Satoh, S | 1 |
| Tsuchiya, N | 1 |
| Maita, S | 1 |
| Obara, T | 1 |
| Tsuruta, H | 1 |
| Narita, S | 1 |
| Horikawa, Y | 2 |
| Kagaya, H | 1 |
| Miura, M | 1 |
| Habuchi, T | 1 |
| Pereira de Resende, ML | 1 |
| Grabe-Guimarães, A | 1 |
| de Souza Filho, JD | 1 |
| Kao, LW | 1 |
| Chung, L | 1 |
| Macaluso, FS | 1 |
| Marco, VD | 1 |
| Titov, VN | 1 |
| Oshchepkova, EV | 1 |
| Dmitriev, VA | 1 |
| Gushchina, OV | 1 |
| Shiriaeva, IuK | 1 |
| Iashin, AIa | 1 |
| Cipolli, JA | 1 |
| Ferreira-Sae, MC | 1 |
| Martins, RP | 1 |
| Pio-Magalhães, JA | 1 |
| Bellinazzi, VR | 1 |
| Matos-Souza, JR | 1 |
| Junior, WN | 1 |
| Kontogianni, MD | 1 |
| Tsetsekou, E | 1 |
| Zeimbekis, A | 1 |
| Elkoushy, MA | 1 |
| Andonian, S | 1 |
| Su, DX | 1 |
| Li, CF | 1 |
| Hong, Y | 1 |
| Ramasamy, SN | 1 |
| Portek, I | 1 |
| Füessl, HS | 1 |
| Hou, CW | 1 |
| Lee, YC | 1 |
| Hung, HF | 1 |
| Fu, HW | 1 |
| Jeng, KC | 1 |
| Kinjyo, T | 1 |
| Maehara, Y | 1 |
| Lin, K | 1 |
| Wang, RW | 1 |
| Bobridge, KS | 1 |
| Haines, GL | 1 |
| Mori, TA | 1 |
| Beilin, LJ | 1 |
| Oddy, WH | 1 |
| Sherriff, J | 1 |
| O'Sullivan, TA | 1 |
| Sijtsma, F | 1 |
| Xia, MF | 1 |
| Lin, HD | 1 |
| Yan, HM | 1 |
| Bian, H | 1 |
| Chang, XX | 1 |
| He, WY | 1 |
| Jeekel, J | 1 |
| Simão, AN | 1 |
| Lozovoy, MA | 1 |
| Dichi, I | 1 |
| Alasia, DD | 1 |
| Emem-Chioma, PC | 1 |
| Wokoma, FS | 1 |
| Malheiro, J | 1 |
| Almeida, M | 1 |
| Fonseca, I | 1 |
| Martins, LS | 1 |
| Pedroso, S | 1 |
| Dias, L | 1 |
| Henriques, AC | 1 |
| Cabrita, A | 1 |
| Jeemon, P | 1 |
| Prabhakaran, D | 1 |
| Yee, J | 1 |
| Kedar, E | 1 |
| Nashar, K | 1 |
| Fried, LF | 1 |
| Sebesta, I | 2 |
| Petrie, KJ | 1 |
| Huang, YF | 1 |
| Wang, JD | 1 |
| Silva, CR | 1 |
| Fröhlich, JK | 1 |
| Oliveira, SM | 1 |
| Cabreira, TN | 1 |
| Rossato, MF | 1 |
| Trevisan, G | 1 |
| Froeder, AL | 1 |
| Bochi, GV | 1 |
| Moresco, RN | 1 |
| Athayde, ML | 1 |
| Ferreira, J | 1 |
| Yakut, S | 1 |
| Cetin, Z | 1 |
| Arman, M | 1 |
| Akbas, H | 1 |
| Manguoglu, AE | 1 |
| Luleci, G | 1 |
| Krauss, M | 1 |
| Schaller, S | 1 |
| Borchers, S | 1 |
| Findeisen, R | 1 |
| Lippert, J | 1 |
| Kuepfer, L | 1 |
| Papežíková, I | 1 |
| Pekarová, M | 1 |
| Kolářová, H | 1 |
| Klinke, A | 1 |
| Lau, D | 1 |
| Baldus, S | 1 |
| Lojek, A | 1 |
| Kubala, L | 1 |
| Ioannou, GN | 1 |
| Busso, N | 1 |
| Sluijs, I | 1 |
| Beulens, JW | 1 |
| van der A, DL | 1 |
| Spijkerman, AM | 1 |
| Schulze, MB | 1 |
| van der Schouw, YT | 1 |
| Ferri, L | 1 |
| Di Giosia, P | 1 |
| Cheli, P | 1 |
| Del Pinto, R | 1 |
| Properzi, G | 1 |
| Kudo, K | 1 |
| Shmerling, RH | 1 |
| McLaughlin, RJ | 1 |
| Harrison, AA | 1 |
| Helal, I | 1 |
| Reed, B | 1 |
| Yan, XD | 1 |
| Schrier, RW | 1 |
| Fick-Brosnahan, GM | 1 |
| Gao, B | 1 |
| Ge, J | 1 |
| Lau, WB | 1 |
| Fu, J | 1 |
| Takeuchi, F | 2 |
| Isono, M | 1 |
| Katsuya, T | 2 |
| Akiyama, K | 1 |
| Rakugi, H | 2 |
| Yamori, Y | 1 |
| Ogihara, T | 2 |
| Kato, N | 1 |
| Fraser, A | 1 |
| Torralba, KD | 1 |
| De Jesus, E | 1 |
| Rachabattula, S | 1 |
| Papanas, N | 1 |
| Fonseca, VA | 1 |
| Maltezos, E | 1 |
| Ziaee, A | 1 |
| Esmailzadehha, N | 1 |
| Ghorbani, A | 1 |
| Asefzadeh, S | 1 |
| Shin, HS | 1 |
| Jang, YH | 1 |
| Jo, I | 1 |
| Horikoshi, R | 1 |
| Akimoto, T | 1 |
| Inoue, M | 1 |
| Morishita, Y | 1 |
| Kusano, E | 1 |
| Cristóbal, M | 1 |
| Monroy-Sánchez, F | 1 |
| Pacheco, U | 1 |
| Cruz-Robles, D | 1 |
| Martínez-Indart, L | 1 |
| Pijoan, JI | 1 |
| Chang, H | 1 |
| Mei, M | 1 |
| Eisen, A | 1 |
| Benderly, M | 1 |
| Goldbourt, U | 1 |
| Haim, M | 1 |
| Segal, M | 1 |
| Rodriguez-Iturbe, B | 3 |
| Ji, Z | 1 |
| Abdelrahman, M | 1 |
| Rafi, A | 1 |
| Ghacha, R | 1 |
| Youmbissi, JT | 1 |
| Qayyum, T | 1 |
| Karkar, A | 1 |
| Bomalaski, JS | 2 |
| Holtsberg, FW | 1 |
| Ensor, CM | 1 |
| Clark, MA | 2 |
| Matsubara, M | 1 |
| Chiba, H | 1 |
| Maruoka, S | 1 |
| Katayose, S | 1 |
| Wasada, T | 1 |
| Iwatani, M | 2 |
| Truong, L | 1 |
| Harris, R | 1 |
| Canas, G | 1 |
| Stacey, JM | 1 |
| Turner, JJ | 1 |
| Harding, B | 1 |
| Nesbit, MA | 1 |
| Calabozo, M | 1 |
| Ruibal, A | 1 |
| Poffers, J | 1 |
| Lumeij, JT | 1 |
| Timmermans-Sprang, EP | 1 |
| Redig, PT | 1 |
| Feher, MD | 2 |
| Hepburn, AL | 2 |
| Hogarth, MB | 1 |
| Ball, SG | 1 |
| Kaye, SA | 2 |
| Miyazaki, H | 1 |
| Cardona, F | 2 |
| Collantes, E | 2 |
| Escudero, A | 2 |
| Soriguer, FJ | 1 |
| Matsumura, T | 1 |
| Enomoto, A | 2 |
| Hashizume, N | 1 |
| Hasunuma, T | 1 |
| Nakajima, H | 3 |
| Yamanouchi, T | 1 |
| Tomita, M | 1 |
| Murayama, T | 1 |
| Mizuno, S | 1 |
| Inai, K | 1 |
| Sugiyama, T | 1 |
| Shichiri, M | 1 |
| Hirata, Y | 1 |
| Yamasaki, T | 3 |
| Miyake, Y | 1 |
| Nakagawa, C | 1 |
| Tarui, S | 1 |
| Kono, N | 1 |
| Aksentiĭchuk, BI | 2 |
| Li, TC | 1 |
| Dariyerli, N | 1 |
| Andican, G | 1 |
| Catakoğlu, AB | 1 |
| Hatemi, H | 1 |
| Burçak, G | 1 |
| Rauchhaus, M | 1 |
| Francis, D | 1 |
| Knosalla, C | 1 |
| Davos, CH | 1 |
| Cicoira, M | 1 |
| Shamim, W | 1 |
| Kemp, M | 1 |
| Segal, R | 1 |
| Osterziel, KJ | 1 |
| Leyva, F | 1 |
| Hetzer, R | 1 |
| Ponikowski, P | 2 |
| Coats, AJ | 1 |
| Kivlighn, S | 1 |
| Tuttle, KR | 1 |
| Herrera-Acosta, J | 5 |
| Wang, HD | 2 |
| Ge, F | 2 |
| Guo, YS | 2 |
| Bleyer, AJ | 2 |
| Woodard, AS | 1 |
| Shihabi, Z | 1 |
| Sandhu, J | 1 |
| Satko, SG | 1 |
| Weller, N | 1 |
| Deterding, E | 1 |
| McBride, D | 1 |
| Gorry, MC | 1 |
| Ganier, D | 1 |
| Hart, TC | 2 |
| Huang, CT | 1 |
| Huang, LL | 1 |
| Mao, IF | 1 |
| García-Pavía, P | 1 |
| Rivero, M | 1 |
| Ahmed, M | 1 |
| García-Puig, J | 2 |
| Momohara, C | 1 |
| Komori, K | 1 |
| Fujioka, H | 1 |
| Bedir, A | 1 |
| Topbas, M | 1 |
| Tanyeri, F | 1 |
| Alvur, M | 1 |
| Arik, N | 1 |
| TALBOTT, JH | 1 |
| CESARI, G | 1 |
| ANTONACI, BL | 1 |
| HAUGE, M | 1 |
| HARVALD, B | 1 |
| VALLECORSI, G | 1 |
| SALVINI, L | 1 |
| CULLEN, JH | 2 |
| EARLY, LJ | 1 |
| FIORE, JM | 2 |
| BRONSKY, D | 2 |
| DUBIN, A | 2 |
| KUSHNER, DS | 2 |
| PASCALE, LR | 2 |
| HARRIS-JONES, JN | 1 |
| GOLD, GL | 1 |
| FRITZ, RD | 1 |
| LEVINE, M | 1 |
| SHAPIRO, M | 1 |
| HYDE, L | 1 |
| WEISS, W | 1 |
| KAPLAN, A | 1 |
| EISENBERG, GM | 1 |
| FLIPPIN, HF | 1 |
| WYNGAARDEN, JB | 4 |
| VIOLA, PL | 1 |
| BLAIR, AE | 1 |
| HILLEY, L | 1 |
| SEEGMILLER, JE | 3 |
| LASTER, L | 1 |
| LIDDLE, LV | 1 |
| GOLDSMITH, LI | 1 |
| WINKLER, JW | 1 |
| KOHN, PM | 1 |
| PROZAN, GB | 1 |
| ARONOFF, A | 1 |
| BARKUM, H | 1 |
| BAUMANN, RR | 1 |
| JILLSON, OF | 1 |
| FREEMAN, RB | 1 |
| DUNCAN, GG | 1 |
| GLICK, EN | 1 |
| DIXON, AS | 3 |
| OTTAVIANI, P | 1 |
| MANAI, G | 1 |
| MANDELLI, F | 1 |
| BORDONI, C | 1 |
| DOLCI, G | 1 |
| LEEPER, RD | 1 |
| BENUA, RS | 1 |
| BRENER, JL | 1 |
| RAWSON, RW | 1 |
| LOVERING, EF | 1 |
| LONGOBARDI, A | 1 |
| MINTZ, DH | 1 |
| CANARY, JJ | 1 |
| CARREON, G | 1 |
| KYLE, LH | 1 |
| MUGLER, A | 4 |
| TREADWELL, BL | 1 |
| VILLA, L | 1 |
| BALLABIO, CB | 1 |
| WILSON, CP | 1 |
| DAVISON, KS | 1 |
| JEANDET, J | 1 |
| LESTRADET, H | 1 |
| CRAWFORD, G | 1 |
| COPE, I | 1 |
| DOLLERY, CT | 1 |
| DUNCAN, H | 2 |
| SCHUMER, B | 1 |
| DREYFUSS, F | 2 |
| STEENSTRUP, OR | 1 |
| AYVAZIAN, JH | 1 |
| AYVAZIAN, LF | 1 |
| BONGINI, O | 1 |
| GUERRINI, L | 1 |
| BRYANT, JM | 1 |
| BERGER, L | 1 |
| SCHVARTZ, N | 1 |
| TOROSDAG, S | 1 |
| FLETCHER, L | 1 |
| SCHWARTZ, MS | 1 |
| QUAN, RB | 1 |
| COLMAN, RW | 1 |
| SHEIN, HM | 1 |
| DECKER, JL | 2 |
| LANE, JJ | 1 |
| REYNOLDS, WE | 1 |
| GRAYZEL, AI | 1 |
| LIDDLE, L | 1 |
| SISON, AB | 1 |
| REYES, MG | 1 |
| GUTIERREZ, MT | 1 |
| GOSFIELD, E | 1 |
| ITSKOVITZ, HD | 1 |
| SELLERS, AM | 1 |
| SMILO, RP | 1 |
| BEISEL, WR | 1 |
| FORSHAM, PH | 1 |
| CROWLEY, LV | 1 |
| KOELBEL, F | 2 |
| WAKIM, KG | 1 |
| WARD, LE | 1 |
| MURPHY, R | 1 |
| SHIPMAN, KH | 1 |
| THOMPSON, GR | 1 |
| MARTEL, W | 1 |
| RAKIC, MT | 3 |
| HAYES, JT | 1 |
| MUSTARD, JF | 1 |
| MURPHY, EA | 1 |
| OGRYZLO, MA | 1 |
| SMYTHE, HA | 1 |
| YUE, TF | 1 |
| CAPRAMARZANI, P | 2 |
| SCOTT, JT | 1 |
| BYWATERS, EG | 1 |
| MCKECHNIE, JK | 1 |
| ICHISEKI, H | 1 |
| ARAI, K | 1 |
| MEYER, JS | 1 |
| KYPROS, GP | 1 |
| GILROY, J | 1 |
| PETTY, TL | 1 |
| DALRYMPLE, GV | 1 |
| ODA, H | 1 |
| HANSEN, OE | 2 |
| PAKULA, A | 1 |
| VIX, VA | 1 |
| MCCARTY, DJ | 1 |
| ALPERIN, JB | 1 |
| LEVIN, WC | 1 |
| BOURSIER, B | 1 |
| VALKENBURG, HA | 2 |
| DAVIDSON, RT | 2 |
| ENGELS, JP | 1 |
| MIKKELSEN, WM | 3 |
| NEEL, JV | 2 |
| DUFF, IF | 1 |
| RIESELBACH, RE | 1 |
| BENTZEL, CJ | 1 |
| COTLOVE, E | 1 |
| FREI, E | 1 |
| FREIREICH, EJ | 1 |
| GREGOROVA, I | 1 |
| SONKA, J | 1 |
| ALDERMAN, MH | 1 |
| DAVIS, RP | 1 |
| SPERBER, RJ | 1 |
| FISCH, S | 1 |
| DEGRAFF, AC | 1 |
| FREUDENTHAL, RR | 1 |
| BUCHANAN, WW | 1 |
| KLINENBERG, JR | 1 |
| HOEFNAGEL, D | 2 |
| KRAKOFF, IH | 1 |
| MEYER, RL | 1 |
| RIVERA, JV | 1 |
| MARTINEZ MALDONADO, M | 1 |
| RAMIREZDEARELLANO, GA | 1 |
| EHRLICH, L | 1 |
| ANDREW, ED | 1 |
| MIREAULT, NG | 1 |
| BERNDT, WO | 1 |
| DODGE, HJ | 1 |
| VALKENBURG, H | 1 |
| GAST, LF | 1 |
| HAYES, CP | 1 |
| METZ, EN | 1 |
| ROBINSON, RR | 1 |
| RUNDLES, RW | 1 |
| BLOCH, R | 1 |
| VOGT, R | 1 |
| ALLEN, GE | 1 |
| ROGERS, FB | 1 |
| LANSBURY, J | 1 |
| VAGUE, J | 1 |
| PERNET, JL | 1 |
| PERNET, A | 1 |
| FRIEDRICH, S | 1 |
| HEALEY, LA | 1 |
| MAGID, GJ | 1 |
| KERSHBAUM, A | 1 |
| FEINBERG, LJ | 1 |
| DE LEON, AC | 1 |
| BELLET, S | 1 |
| SCHNEEWEISS, J | 1 |
| POOLE, GW | 1 |
| LAUDAT, MH | 1 |
| RYCKEWAERT, A | 1 |
| LAGRUE, G | 1 |
| MILLIEZ, P | 1 |
| MARINOFF, SC | 1 |
| LEMPERT, P | 1 |
| MANDEL, EE | 1 |
| PADOVA, J | 1 |
| BENDERSKY, G | 1 |
| POPERT, AJ | 1 |
| HEWITT, JV | 1 |
| ROSCH, PJ | 1 |
| STURMAN, MF | 1 |
| Benecke, M | 1 |
| Lee, AC | 1 |
| So, KT | 1 |
| Chan, R | 1 |
| Coiffier, B | 1 |
| Mounier, N | 1 |
| Bologna, S | 1 |
| Fermé, C | 1 |
| Tilly, H | 1 |
| Sonet, A | 1 |
| Christian, B | 1 |
| Casasnovas, O | 1 |
| Jourdan, E | 1 |
| Belhadj, K | 1 |
| Herbrecht, R | 1 |
| Marcén, R | 1 |
| Gallego, N | 1 |
| Orofino, L | 1 |
| Sabater, J | 1 |
| Pascual, J | 1 |
| Teruel, JL | 1 |
| Liaño, F | 1 |
| Ortuño, J | 1 |
| Chamorro, A | 1 |
| Planas, AM | 1 |
| Denzer, C | 1 |
| Muche, R | 1 |
| Mayer, H | 1 |
| Heinze, E | 1 |
| Debatin, KM | 1 |
| Wabitsch, M | 1 |
| Gavin, AR | 1 |
| Waring, WS | 1 |
| Adwani, SH | 1 |
| Breukels, O | 1 |
| Maxwell, SR | 1 |
| Meyers, OL | 1 |
| Cassim, B | 1 |
| Mody, GM | 1 |
| Campo, C | 2 |
| Ruilope, LM | 2 |
| Segura, J | 1 |
| Rodicio, JL | 1 |
| García-Robles, R | 1 |
| Lindeberg, S | 1 |
| Cordain, L | 1 |
| Råstam, L | 1 |
| Ahrén, B | 1 |
| Rideout, BA | 2 |
| Alderman, M | 2 |
| Aiyer, KJ | 1 |
| Conen, D | 1 |
| Wietlisbach, V | 1 |
| Bovet, P | 1 |
| Shamlaye, C | 1 |
| Riesen, W | 1 |
| Paccaud, F | 1 |
| Ogura, T | 1 |
| Matsuura, K | 1 |
| Mimura, Y | 1 |
| Otsuka, F | 1 |
| Tobe, K | 1 |
| Finch, J | 1 |
| Granger, J | 1 |
| Broughton Pipkin, F | 1 |
| Hong, YS | 1 |
| Lee, MJ | 2 |
| Kim, KH | 1 |
| Kim, BG | 1 |
| Jeong, B | 1 |
| Yoon, HR | 1 |
| Nishio, H | 1 |
| Cheng, CH | 2 |
| Akagashi, K | 1 |
| Tanda, H | 1 |
| Ohnishi, S | 1 |
| Nanbu, A | 1 |
| Nitta, T | 1 |
| Koroku, M | 1 |
| Hanzawa, T | 1 |
| Tsao, HM | 1 |
| Chou, P | 1 |
| Srinivas, TR | 2 |
| Solangi, GA | 1 |
| Zuberi, BF | 1 |
| Shaikh, S | 1 |
| Shaikh, WM | 1 |
| Barskova, VG | 1 |
| Iakunina, IA | 1 |
| Zilov, AV | 1 |
| Il'inykh, EV | 1 |
| Schackis, RC | 1 |
| López Jiménez, M | 1 |
| García Puig, J | 1 |
| Yoneyama, Y | 1 |
| Mino, Y | 1 |
| Tago, N | 1 |
| Bieber, JD | 1 |
| Terkeltaub, RA | 2 |
| Kuang, CB | 1 |
| Ikemiya, Y | 1 |
| Iseki, C | 1 |
| Kinjo, K | 1 |
| Takishita, S | 1 |
| Perlstein, TS | 2 |
| Gumieniak, O | 2 |
| Hopkins, PN | 1 |
| Murphey, LJ | 1 |
| Brown, NJ | 1 |
| Williams, GH | 2 |
| Hollenberg, NK | 1 |
| Fisher, ND | 1 |
| Mercuro, G | 1 |
| Vitale, C | 1 |
| Cerquetani, E | 1 |
| Zoncu, S | 1 |
| Deidda, M | 1 |
| Fini, M | 1 |
| Rosano, GM | 1 |
| Chan, NN | 1 |
| Lau, EW | 1 |
| Chan, JC | 1 |
| Redfern, JS | 1 |
| Vock, P | 1 |
| Bonel, H | 1 |
| Ferrari, P | 1 |
| Vogt, B | 1 |
| Gugger, M | 1 |
| Frey, FJ | 1 |
| Sundström, J | 1 |
| Sullivan, L | 1 |
| D'Agostino, RB | 1 |
| Kannel, WB | 1 |
| Vasan, RS | 1 |
| Alper, AB | 1 |
| Yau, L | 1 |
| Srinivasan, SR | 1 |
| Berenson, GS | 1 |
| Hamm, LL | 1 |
| Yamada, I | 1 |
| Fukunari, A | 1 |
| Osajima, T | 1 |
| Kamezawa, M | 1 |
| Iwane, J | 1 |
| Grande, C | 1 |
| Sancho, T | 1 |
| Bernardino, JI | 1 |
| de Bont, JM | 1 |
| Pieters, R | 1 |
| Rovda, IuI | 1 |
| Kazakova, LM | 1 |
| Rovda, TS | 1 |
| Rovda, EIu | 1 |
| Titte, S | 1 |
| Cade, JR | 1 |
| Oliver, WJ | 1 |
| Cameron, JS | 2 |
| Simmonds, HA | 1 |
| Lam, C | 1 |
| Lim, KH | 1 |
| Wen, YL | 1 |
| Liu, CY | 1 |
| Sims-McCallum, RP | 1 |
| Schiffer, CA | 1 |
| Yoshizumi, K | 1 |
| Nishioka, N | 1 |
| Palo, WA | 2 |
| Eustace, D | 2 |
| Vernillet, L | 1 |
| Gao, ZQ | 1 |
| Deng, YY | 1 |
| Srinivas, T | 1 |
| Ejaz, A | 1 |
| Gersch, M | 3 |
| Acosta, JH | 1 |
| Kolyvanos Naumann, U | 1 |
| Suter, PM | 1 |
| Käser, L | 1 |
| Vetter, W | 1 |
| Olak-Białoń, B | 1 |
| Marcisz, C | 1 |
| Jonderko, G | 1 |
| Olak, Z | 1 |
| Szymszal, J | 1 |
| Orzeł, A | 1 |
| Lameire, NH | 1 |
| Flombaum, CD | 1 |
| Moreau, D | 1 |
| Ronco, C | 1 |
| Peng, MC | 1 |
| Chang, YY | 1 |
| Chen, WH | 1 |
| Chen, SS | 1 |
| Kjeldsen, SE | 1 |
| Wu, CW | 1 |
| Takahashi, S | 2 |
| Masuo, K | 1 |
| Tuck, ML | 2 |
| Gregoric, A | 1 |
| Rabelink, GM | 1 |
| Kokalj Vokac, N | 1 |
| Varda, NM | 1 |
| Zagradisnik, B | 1 |
| Ji, W | 1 |
| Tan, WF | 1 |
| Solov'eva, OA | 2 |
| Smetnik, VP | 1 |
| Eliseeva, NA | 2 |
| Shovskaia, TN | 1 |
| Aleksandrovskaia, TN | 1 |
| Kniazewska, MH | 1 |
| Zmudzińska-Kitczak, J | 1 |
| Urban, K | 1 |
| Obuchowicz, AK | 1 |
| Niwińska-Faryna, B | 1 |
| Pietrzak, JA | 1 |
| Swietochowska-Chechlińska, AA | 1 |
| Głowacki, JG | 1 |
| Akkasilpa, S | 1 |
| Avihingsanon, Y | 1 |
| Hanvivadhanakul, P | 1 |
| Wonchinsri, J | 1 |
| Zhang, BL | 1 |
| Baker, JF | 1 |
| Sakamoto, T | 1 |
| Ishihara, M | 1 |
| Yamagishi, M | 1 |
| Tei, C | 1 |
| Hiraoka, H | 1 |
| Sonoda, M | 1 |
| Tsuchihashi, K | 1 |
| Shimoyama, N | 1 |
| Honda, T | 1 |
| Ogata, Y | 1 |
| Shin, HY | 1 |
| Park, ES | 1 |
| Chung, NG | 1 |
| Hwang, TJ | 1 |
| Lee, KC | 1 |
| Lee, KS | 1 |
| Koo, HH | 1 |
| Seo, JJ | 1 |
| Moon, HN | 1 |
| Ghim, T | 1 |
| Lyu, CJ | 1 |
| Lee, WS | 1 |
| Choi, YM | 1 |
| Hammoudeh, M | 1 |
| Suresh, E | 1 |
| Brenner-Zada, G | 1 |
| Bistrizer, Z | 1 |
| Goldman, M | 1 |
| Nishio, K | 1 |
| Tamakoshi, A | 1 |
| Nikolenko, IuI | 1 |
| Siniachenko, OV | 1 |
| Anan'eva, MN | 1 |
| Nikolenko, VIu | 1 |
| Dubiaga, VV | 1 |
| Shchukin, IN | 1 |
| Adam, AM | 1 |
| Fong, WP | 1 |
| Mo, SF | 1 |
| Akcay, A | 1 |
| Usluogullari, CA | 1 |
| Arat, Z | 2 |
| Ozdemir, FN | 2 |
| Karri, K | 1 |
| Mowbray, D | 1 |
| Uetani, M | 2 |
| Kobayashi, E | 2 |
| Inaba, T | 1 |
| Oishi, M | 1 |
| Nogawa, K | 2 |
| Dang, A | 1 |
| Cannella, AC | 1 |
| Tomikura, Y | 1 |
| Kotani, K | 1 |
| Somers, VK | 1 |
| Podorol'skaia, LV | 1 |
| Andreenko, GV | 1 |
| Lysenko, LV | 1 |
| Nguyen, MT | 1 |
| Awale, S | 1 |
| Tezuka, Y | 1 |
| Zaidi, SF | 1 |
| Ueda, JY | 1 |
| Tran, QL | 1 |
| Matsumoto, K | 1 |
| Kadota, S | 1 |
| Moreland, LW | 1 |
| Franco, M | 2 |
| Ganson, NJ | 1 |
| Kelly, SJ | 1 |
| Scarlett, E | 1 |
| Sundy, JS | 1 |
| Masseoud, D | 1 |
| Rott, K | 1 |
| Agudelo, C | 1 |
| Schachter, M | 1 |
| Jaeger, P | 1 |
| Robertson, WG | 1 |
| Unwin, RJ | 1 |
| Siu, YP | 1 |
| Leung, KT | 1 |
| Tong, MK | 1 |
| Kwan, TH | 1 |
| Bodnar, LM | 1 |
| Ness, RB | 1 |
| Cooper, KM | 1 |
| Gallaher, MJ | 1 |
| Frank, MP | 1 |
| Daftary, AR | 1 |
| Mutig, K | 1 |
| Bachmann, S | 1 |
| Kumar, S | 2 |
| Johnson, R | 1 |
| Xu, SY | 1 |
| Rayner, BL | 1 |
| Trinder, YA | 1 |
| Baines, D | 1 |
| Isaacs, S | 1 |
| Opie, LH | 1 |
| Hutcherson, DA | 1 |
| Gammon, DC | 1 |
| Bhatt, MS | 1 |
| Faneuf, M | 1 |
| Chizyński, K | 2 |
| Rózycka, M | 2 |
| Lee, JE | 1 |
| Choi, YH | 1 |
| Huh, W | 1 |
| Oh, HY | 1 |
| Simon, JA | 1 |
| Price, K | 1 |
| Kannelis, J | 1 |
| Ellman, MH | 1 |
| Unger, S | 2 |
| Richter, K | 1 |
| Wunderlich, C | 1 |
| Grässler, J | 2 |
| Roch, B | 1 |
| Schröder, HE | 1 |
| Schaible, RH | 1 |
| Liou, TL | 1 |
| Lin, MW | 1 |
| Hsiao, LC | 1 |
| Tsai, TT | 1 |
| Ho, LT | 1 |
| López-Suárez, A | 1 |
| Elvira-González, J | 1 |
| Bascuñana-Quirell, A | 1 |
| Rosal-Obrador, J | 1 |
| Michán-Doña, A | 1 |
| Escribano-Serrano, J | 1 |
| Benítez-Rodríguez, E | 1 |
| Corry, DB | 1 |
| Conaghan, P | 1 |
| Gerster, J | 1 |
| Jacobs, J | 1 |
| Leeb, B | 1 |
| Netter, P | 1 |
| Pignone, A | 1 |
| Zimmermann-Gòrska, I | 1 |
| Trifilio, S | 1 |
| Gordon, L | 1 |
| Singhal, S | 1 |
| Tallman, M | 1 |
| Evens, A | 1 |
| Rashid, K | 1 |
| Fishman, M | 1 |
| Masino, K | 1 |
| Toda, E | 1 |
| Zheng, LQ | 1 |
| Yu, JM | 1 |
| Hasimu, B | 1 |
| Hu, DY | 1 |
| Matavelli, LC | 1 |
| Frohlich, ED | 1 |
| Okuyama, H | 1 |
| Hirono, O | 1 |
| Tsunoda, Y | 1 |
| Nitobe, J | 1 |
| Miyashita, T | 1 |
| Koyama, Y | 1 |
| Oyama, C | 1 |
| Oyamada, M | 1 |
| Oyamada, T | 1 |
| Ohno, T | 1 |
| Miyashita, M | 1 |
| Saito, S | 1 |
| Komatsu, K | 1 |
| Takashina, K | 1 |
| Takada, G | 1 |
| Jankowska, EA | 1 |
| Ponikowska, B | 1 |
| Majda, J | 1 |
| Zymlinski, R | 1 |
| Trzaska, M | 1 |
| Reczuch, K | 1 |
| Borodulin-Nadzieja, L | 1 |
| Banasiak, W | 1 |
| Bushinsky, DA | 1 |
| Nan, H | 1 |
| Qiao, Q | 1 |
| Tang, B | 1 |
| Qian, R | 1 |
| Tuomilehto, J | 1 |
| Walker, UA | 1 |
| Hoffmann, C | 1 |
| Enters, M | 1 |
| Thoden, J | 1 |
| Behrens, G | 1 |
| Mitzel, SL | 1 |
| Güngör, ES | 1 |
| Danişman, N | 1 |
| Mollamahmutoğlu, L | 1 |
| Britov, AN | 1 |
| Deev, AD | 1 |
| Kokaze, A | 1 |
| Matsunaga, N | 1 |
| Teruya, K | 2 |
| Honmyo, R | 1 |
| Yorimitsu, M | 1 |
| Masuda, Y | 1 |
| Uchida, Y | 1 |
| Takashima, Y | 1 |
| Tumgor, G | 1 |
| Arikan, C | 1 |
| Kilic, M | 1 |
| Aydogdu, S | 1 |
| Shima, Y | 1 |
| Ohta, H | 1 |
| Kemper, MJ | 1 |
| Neuhaus, TJ | 1 |
| Pohar, S | 1 |
| Murphy, G | 1 |
| Dhanamun, B | 1 |
| Williams, MA | 1 |
| Tsouli, SG | 1 |
| Liberopoulos, EN | 1 |
| Elisaf, MS | 2 |
| Pływaczewski, R | 2 |
| Bednarek, M | 2 |
| Jonczak, L | 2 |
| Górecka, D | 2 |
| Sliwińiski, P | 1 |
| Golbahar, J | 1 |
| Aminzadeh, MA | 1 |
| Al-Shboul, QM | 1 |
| Kassab, S | 1 |
| Rezaian, GR | 1 |
| Umamaheswari, M | 1 |
| AsokKumar, K | 1 |
| Somasundaram, A | 1 |
| Sivashanmugam, T | 1 |
| Subhadradevi, V | 1 |
| Ravi, TK | 1 |
| Suliman, ME | 1 |
| García-López, E | 1 |
| Molinaei, H | 1 |
| Heimbürger, O | 1 |
| Bárány, P | 1 |
| Axelsson, J | 1 |
| Sparrow, D | 1 |
| Vokonas, PS | 1 |
| Gaziano, M | 1 |
| Weiss, ST | 1 |
| Litonjua, AA | 1 |
| Pascual-Figal, DA | 1 |
| Hurtado-Martínez, JA | 1 |
| Redondo, B | 1 |
| Antolinos, MJ | 1 |
| Ruiperez, JA | 1 |
| Valdes, M | 1 |
| Prior, C | 1 |
| Martínez-Ara, J | 1 |
| Pospísilová, E | 1 |
| Kmoch, S | 1 |
| Jeyabalan, A | 1 |
| Conrad, KP | 1 |
| Gullu, H | 2 |
| Erdogan, D | 2 |
| Caliskan, M | 2 |
| Tok, D | 1 |
| Kulaksizoglu, S | 1 |
| Yildirir, A | 2 |
| Muderrisoglu, H | 2 |
| Kizer, N | 1 |
| Martinez, E | 1 |
| Powell, M | 1 |
| Miroshnichenko, NG | 1 |
| Kireeva, VI | 1 |
| Kwoh, CK | 1 |
| Kuller, L | 1 |
| Roncal, CA | 2 |
| Croker, B | 1 |
| Reungjui, S | 2 |
| Tabah-Fisch, I | 2 |
| Sliwiński, P | 1 |
| Komine, M | 1 |
| Takekoshi, T | 1 |
| Reinders, MK | 1 |
| van Roon, EN | 1 |
| Houtman, PM | 1 |
| Brouwers, JR | 1 |
| Wise, CM | 1 |
| Williams, T | 1 |
| Stine, KC | 1 |
| Walker, PD | 1 |
| Ilyas, M | 1 |
| Blaszak, RT | 1 |
| Rényi, I | 1 |
| Bárdi, E | 1 |
| Udvardi, E | 1 |
| Kovács, G | 1 |
| Bartyik, K | 1 |
| Kajtár, P | 1 |
| Masát, P | 1 |
| Galántai, I | 1 |
| Kiss, C | 1 |
| Trachtman, H | 1 |
| Cammalleri, L | 1 |
| Patschan, D | 1 |
| Patschan, S | 1 |
| Gobe, GG | 1 |
| Chintala, S | 1 |
| Goligorsky, MS | 1 |
| Jelić-Ivanović, Z | 1 |
| Memon, L | 1 |
| Spasojević-Kalimanovska, V | 1 |
| Bogavac-Stanojević, N | 1 |
| Spasić, S | 1 |
| Tavil, Y | 1 |
| Oktar, SO | 1 |
| Sen, N | 1 |
| Okyay, K | 1 |
| Yazici, HU | 1 |
| Cengel, A | 1 |
| Martínez-Villén, G | 1 |
| Canales, V | 1 |
| Hernández-Rossi, A | 1 |
| Herrera, A | 1 |
| Zharikov, S | 1 |
| von Haehling, S | 1 |
| Maliavskaia, SI | 1 |
| Lebedev, AV | 1 |
| Ternovskaia, VA | 1 |
| Akgul, A | 1 |
| Bilgic, A | 1 |
| Ibis, A | 1 |
| Valerio, C | 1 |
| Meani, S | 1 |
| Esposito, A | 1 |
| Zanchetti, A | 1 |
| Huang, YC | 1 |
| Sun, JH | 1 |
| Wu, TH | 1 |
| Chen, LC | 1 |
| Yang, LL | 1 |
| Qiao, N | 1 |
| Tucker, KL | 1 |
| Ascherio, A | 2 |
| Labriola, L | 1 |
| in Dahan, K | 1 |
| Matejcková, J | 1 |
| Tůma, P | 1 |
| Samcová, E | 1 |
| Zemanová, Z | 1 |
| Strazzullo, P | 1 |
| Panoulas, VF | 1 |
| Milionis, HJ | 1 |
| Douglas, KM | 1 |
| Nightingale, P | 1 |
| Kita, MD | 1 |
| Klocke, R | 1 |
| Chen, LY | 1 |
| Zhu, WH | 1 |
| Chen, ZW | 1 |
| Dai, HL | 1 |
| Ren, JJ | 1 |
| Chen, LQ | 1 |
| Fang, LZ | 1 |
| Alvarado-Romano, V | 1 |
| Jiménez-Vaca, AL | 1 |
| Pozo-Molina, G | 1 |
| Cuevas-Covarrubias, SA | 1 |
| Matsubara, K | 1 |
| Igawa, G | 1 |
| Kaetsu, Y | 1 |
| Matsuura, T | 1 |
| Ando, F | 1 |
| Ling, F | 1 |
| Henderson, G | 1 |
| Keller, B | 1 |
| Yu, HL | 1 |
| Vella, M | 1 |
| Karydi, M | 1 |
| Coraci, G | 1 |
| Oriti, R | 1 |
| Melloni, D | 1 |
| Teo, WY | 1 |
| Loh, TF | 1 |
| Tan, AM | 1 |
| Yokose, T | 1 |
| Yildirim, I | 1 |
| Ozer, I | 1 |
| Sirivongs, D | 1 |
| Kutzing, MK | 1 |
| Firestein, BL | 1 |
| Kopprasch, S | 1 |
| Bornstein, SR | 1 |
| Akande, AA | 1 |
| Akinyinka, OA | 1 |
| Olarinoye, GO | 1 |
| Pope, RM | 1 |
| Tschopp, J | 1 |
| Gersch, MS | 1 |
| Benner, S | 1 |
| Rosenthal, P | 1 |
| Abeles, AM | 2 |
| van Hoek, M | 1 |
| Sijbrands, EJ | 1 |
| Avila-Casado, C | 1 |
| Woo, JH | 1 |
| Ji, JD | 1 |
| Bainbridge, SA | 1 |
| SMYTH, CJ | 1 |
| COTTERMAN, CW | 1 |
| FREYBERG, RH | 1 |
| Toschi, V | 1 |
| Park, JY | 1 |
| Cronstein, BN | 1 |
| Koçer, A | 1 |
| Dikici, S | 1 |
| Atakay, S | 1 |
| Okuyucu, S | 1 |
| Hernandez-Divers, SJ | 1 |
| Martinez-Jimenez, D | 1 |
| Bush, S | 1 |
| Latimer, KS | 1 |
| Zwart, P | 1 |
| Kroeze, EJ | 1 |
| Yamashita, N | 1 |
| Enjoji, M | 1 |
| Kotoh, K | 1 |
| Ueda, A | 1 |
| Tajiri, H | 1 |
| Higuchi, N | 1 |
| Kinukawa, N | 1 |
| Nakamuta, M | 1 |
| Huang, CG | 1 |
| Shang, YJ | 1 |
| Zhang, JR | 1 |
| Jiao, BH | 1 |
| Sato, W | 1 |
| Franchini, M | 1 |
| Favaloro, EJ | 1 |
| Kobayashi, T | 1 |
| Inokuchi, T | 1 |
| Ka, T | 1 |
| Morisaki, H | 1 |
| Takagi, K | 1 |
| Kudo, E | 1 |
| Itakura, M | 1 |
| Sestigiani, E | 1 |
| Guardigli, M | 1 |
| Ramazzotti, E | 1 |
| Boni, P | 1 |
| Yue, CS | 1 |
| Alton, M | 1 |
| Maroli, AN | 1 |
| Waltrip, RW | 1 |
| Wright, D | 1 |
| Marco, MD | 1 |
| Ebrahimpour, P | 1 |
| Fakhrzadeh, H | 1 |
| Heshmat, R | 1 |
| Bandarian, F | 1 |
| Forman, JP | 1 |
| Pinelli, M | 1 |
| Bindi, M | 1 |
| Moroni, F | 1 |
| Castiglioni, M | 1 |
| Svendsen, K | 1 |
| Neaton, JD | 1 |
| Grandits, G | 1 |
| Kuller, LH | 1 |
| Gebetsroither, E | 1 |
| Skrabal, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Dose-response Effect of Serum Uric Acid on the Prevalence and Electrocardiographic Left Ventricular Hypertrophy in the Apparently Healthy Individuals[NCT03473951] | 18,000 participants (Anticipated) | Observational | 2018-03-26 | Recruiting | |||
| A Multicenter, Randomized, Comparative Trial on the Effect of Febuxostat in Preventing Cerebral and Cardiorenovascular Events in Patients With Hyperuricemia[NCT01984749] | 1,000 participants (Anticipated) | Interventional | 2013-11-30 | Active, not recruiting | |||
| An Open-Label, Sequential, Ascending Single-Dose Safety, Tolerability, Pharmacokinetic and Pharmacodynamics Study of an Intravenous Infusion of SEL-037 in Subjects With Elevated Blood Uric Acid Levels[NCT02464605] | Phase 1 | 22 participants (Actual) | Interventional | 2015-05-31 | Completed | ||
| A Phase I Single Ascending Dose Safety, Pharmacokinetic and Pharmacodynamics Study of SEL-212 in Subjects With Elevated Blood Uric Acid[NCT02648269] | Phase 1 | 63 participants (Actual) | Interventional | 2015-12-31 | Completed | ||
| A Three Arms, Randomized, Double-blind Controlled Trial of the Efficacy of Amway Uric Acid Lowering Product on Hyperuricemia[NCT06084585] | 180 participants (Anticipated) | Interventional | 2023-10-23 | Recruiting | |||
| Flow Mediated Dilation in Association With Hyperuricemia as Predictors of Cardiovascular Affection in Patients With Systemic Lupus[NCT05342285] | 60 participants (Anticipated) | Observational | 2022-07-30 | Recruiting | |||
| A Multicenter, Randomized, Active-Control, Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Subjects With Gout and Cardiovascular Comorbidities[NCT01101035] | Phase 3 | 6,198 participants (Actual) | Interventional | 2010-04-23 | Completed | ||
| Seven-day Repeated Dose Clinical Pharmacological Study of FYU-981 Administered to Hyperuricemia[NCT02837198] | Phase 2 | 24 participants (Actual) | Interventional | 2016-07-31 | Completed | ||
| Exploratory Study of FYU-981 for Hyperuricemia With or Without Gout (Phase II (IIa) Study)[NCT02344862] | Phase 2 | 80 participants (Actual) | Interventional | 2014-01-31 | Completed | ||
| Confirmatory Study of FYU-981 for Hyperuricemia With or Without Gout (Phase II (IIb) Study)[NCT02416167] | Phase 2 | 200 participants (Anticipated) | Interventional | 2015-05-31 | Completed | ||
| Official Title: Safety and Efficacy Evaluation Study of FYU-981 Long-term Administration for Hyperuricemia With or Without Gout (Phase III Study)[NCT03006445] | Phase 3 | 330 participants (Actual) | Interventional | 2016-12-31 | Completed | ||
| Benzbromarone-Controlled, Double-Blind, Comparative Study of FYU-981 for Hyperuricemia With or Without Gout to Evaluate the Safety and Noninferiority of FYU-981 (Phase III Study)[NCT03100318] | Phase 3 | 201 participants (Actual) | Interventional | 2017-04-01 | Completed | ||
| Aggressive Hydration in Patients With ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention to Prevent Contrast-Induced Nephropathy, A Randomized, Controlled Trial REduction of riSk of Contrast-Induced Nephropathy follow[NCT02067195] | 560 participants (Anticipated) | Interventional | 2014-07-31 | Recruiting | |||
| Losartan and Uric Acid Metabolism in Children With Proteinuric Nephropathies: a Cross-over Randomized Clinical Trail[NCT05402397] | Phase 4 | 40 participants (Anticipated) | Interventional | 2022-07-01 | Recruiting | ||
| Quantifying Uric Acid Excretion With RDEA3170, Febuxostat and Dapagliflozin[NCT03316131] | Phase 2 | 36 participants (Actual) | Interventional | 2017-10-25 | Completed | ||
| [NCT00000544] | Phase 3 | 0 participants | Interventional | 1993-08-31 | Completed | ||
| Data-driven Clustering for Metabolic Classification of Obesity Using Machine Learning[NCT04282837] | 2,495 participants (Actual) | Observational | 2020-03-01 | Completed | |||
| Pediatric Hypertension and the Renin-Angiotensin SystEm (PHRASE): The Role of Angiotensin-(1-7) in Hypertension and Hypertension-Induced Heart and Kidney Damage[NCT04752293] | 125 participants (Anticipated) | Observational | 2021-05-19 | Recruiting | |||
| Chronobiology and Chronopharmacology to Prevent Sickle Cell Kidney Disease[NCT02373241] | Phase 2 | 1 participants (Actual) | Interventional | 2015-04-30 | Terminated (stopped due to Estimated GFR was determined not to be a reliable endpoint for this study. We identified significant variabilty in annual eGFR that it became inappropriate to randomize to a medication but use EGFR as the primary endpoint.) | ||
| African American Study of Kidney Disease and Hypertension ABPM Pilot Study[NCT00582777] | Phase 2/Phase 3 | 180 participants (Anticipated) | Interventional | 2007-11-30 | Completed | ||
| A Multicenter, Randomized, Double-Blind, Phase 2 Study to Evaluate the Effect of Febuxostat Versus Placebo in Joint Damage in Hyperuricemic Subjects With Early Gout[NCT01078389] | Phase 2 | 314 participants (Actual) | Interventional | 2010-03-31 | Completed | ||
| Chinese Cohort Study of Chronic Kidney Disease[NCT03041987] | 5,000 participants (Anticipated) | Observational | 2012-01-01 | Active, not recruiting | |||
| A Phase 2, Double-Blind, Placebo-Controlled Study to Assess the Effect of Febuxostat 80 mg Once Daily Compared to Placebo on Ambulatory Blood Pressure in Subjects With Hyperuricemia and Hypertension[NCT01496469] | Phase 2 | 121 participants (Actual) | Interventional | 2012-02-29 | Completed | ||
| A Randomized, Open-Label, Parallel-group, Multiple-Dose Study to Evaluate the Potential Pharmacokinetic Interaction and Pharmacodynamic Effects on Renal Parameters of Bumetanide (1mg) and Dapagliflozin (10 mg) When Co-administered in Healthy Subjects[NCT00930865] | Phase 1 | 42 participants (Actual) | Interventional | 2009-07-31 | Completed | ||
| Effects of Allopurinol on Inflammatory Markers and Morphostructural Changes Evidenced by Musculoskeletal Ultrasound in Individuals With Asymptomatic Hyperuricemia. A Proof of Concept[NCT04012294] | Phase 3 | 200 participants (Anticipated) | Interventional | 2019-08-30 | Recruiting | ||
| A Randomised Double-blind Cross-over Single-centre Study on Molecular Genetics of Drug Responsiveness in Essential Hypertension[NCT03276598] | Phase 4 | 233 participants (Actual) | Interventional | 1999-11-25 | Completed | ||
| A Triple-Blind, Parallel Study to Investigate the Effect of Losartan Versus Atenolol on the Reduction of Morbidity and Mortality in Hypertensive Patients With Left Ventricular Hypertrophy[NCT00338260] | Phase 3 | 496 participants (Actual) | Interventional | 1995-06-30 | Completed | ||
| Effects of Pharmacological Reversal of Hyperuricemia on Features of the Metabolic Syndrome[NCT01654276] | Phase 4 | 24 participants (Actual) | Interventional | 2012-05-31 | Completed | ||
| A Phase 2a, Randomized, Open-Label, Single-Site Study to Evaluate the Pharmacodynamic Effects and Safety of RDEA3170 Administered in Combination With Febuxostat Compared to RDEA3170 Administered Alone and Febuxostat Administered Alone, Respectively in Jap[NCT02317861] | Phase 1/Phase 2 | 110 participants (Actual) | Interventional | 2014-12-31 | Completed | ||
| Registro Campania Salute Network for the Treatment of Hypertension and Correlated Diseases[NCT02211365] | 10,000 participants (Anticipated) | Observational [Patient Registry] | 2014-02-28 | Recruiting | |||
| Studies to Treat Or Prevent Pediatric Type 2 Diabetes (STOPP-T2D) Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) Clinical Trial[NCT00081328] | Phase 3 | 699 participants (Actual) | Interventional | 2004-05-31 | Completed | ||
| A Phase I, Placebo-controlled, Randomized, Double Blind, Single or Multiple Dose Study of URC102 in Healthy Male Volunteers of Korean and Caucasian to Assess Safety, Pharmacokinetics and Pharmacodynamics[NCT01953497] | Phase 1 | 81 participants (Actual) | Interventional | 2013-05-23 | Completed | ||
| A Phase I, Placebo-controlled, Randomized, Double Blind, Dose-escalation Study to Assess the Safety and Pharmacokinetic and Pharmacodynamic Characteristics of Repeated-dose URC102 in Healthy Korean Adult Males[NCT02524678] | Phase 1 | 21 participants (Actual) | Interventional | 2015-08-05 | Completed | ||
| A Multi-Center, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of Rilonacept for the Prophylaxis of Gout Flares During the Initiation of Allopurinol Therapy[NCT00958438] | Phase 3 | 248 participants (Actual) | Interventional | 2009-07-31 | Completed | ||
| Study on the Effect of Hyperuricaemia on Chronic Renal Disease and Intervention[NCT03425708] | Phase 4 | 400 participants (Anticipated) | Interventional | 2017-01-01 | Recruiting | ||
| Allopurinol in the Treatment of Patients With Diabetes Mellitus and Multivessel Coronary Artery Disease Treated by Either PCI or CABG: Pilot Study[NCT03700645] | Phase 4 | 100 participants (Anticipated) | Interventional | 2018-12-01 | Not yet recruiting | ||
| Genetic-specific Effects of Fructose on Liver Lipogenesis[NCT03783195] | 15 participants (Actual) | Interventional | 2019-01-25 | Completed | |||
| A Double-blind Randomized Controlled Trial on Whole Soy and Daidzein Supplementation on Reduction of Blood Pressure in Prehypertensive Postmenopausal Chinese Women[NCT01270737] | 270 participants (Anticipated) | Interventional | 2011-03-31 | Not yet recruiting | |||
| The Effects of Soy Protein and/or Isoflavones on Glycemic Control, Insulin Sensitivity and Cardiovascular Risk Factors-a Six Months RCT Among Postmenopausal Women[NCT00856882] | 0 participants | Interventional | 2007-10-31 | Completed | |||
| Comparative Study Evaluating the Outcome of Febuxostat Versus Vitamin E in Hyperuricemia Patients With Non-alcoholic Steatohepatitis Without Cirrhosis[NCT05574036] | Phase 2 | 70 participants (Anticipated) | Interventional | 2022-08-25 | Recruiting | ||
| Value of Uric Acid as Early Predictor of Lupus Nephritis in Assiut University Hospital[NCT05402735] | 100 participants (Anticipated) | Observational | 2022-06-15 | Recruiting | |||
| Paediatric Obesity and Cardiovascular Dysfunction: Searching for Early Markers of Damage[NCT03169257] | 100 participants (Actual) | Interventional | 2015-01-15 | Completed | |||
| A Comparison of the Metabolic Effects of Fructose, Glucose, High Fructose Corn Syrup and Sucrose at Normal Population Consumed Levels on Liver and Muscle Fatty Infiltration, Insulin Resistance, Glucose, Insulin, Leptin, Ghrelin, Postprandial Triglycerides[NCT01797042] | 366 participants (Actual) | Interventional | 2012-03-31 | Completed | |||
| Study Protocol for a Prospective Observational Study Investigating the Role of Luminal Pressure on Arteriovenous Fistula Maturation[NCT04017806] | 60 participants (Anticipated) | Observational | 2018-09-19 | Recruiting | |||
| Effect of Allopurinol or Febuxostat to Prevent Contrast Induced Acute Kidney Injury (CI-AKI)[NCT03767322] | Phase 2 | 558 participants (Anticipated) | Interventional | 2018-12-05 | Not yet recruiting | ||
| A Phase 3, Randomized, Multicenter, Allopurinol-Controlled Study Assessing the Safety and Efficacy of Oral Febuxostat in Subjects With Gout[NCT02082769] | Phase 3 | 504 participants (Actual) | Interventional | 2011-07-31 | Completed | ||
| Chronic Kidney Disease in Children Prospective Cohort Study (CKiD)[NCT00327860] | 1,100 participants (Actual) | Observational | 2003-10-31 | Active, not recruiting | |||
| Allopurinol Versus Febuxostat: A New Approach for Management of Hepatic Steatosis in Metabolic-Associated Fatty Liver Disease[NCT05474560] | Phase 4 | 90 participants (Actual) | Interventional | 2022-01-01 | Completed | ||
| Pragmatic, Randomized, Multicenter, Double-blind, Controlled, Clinical Trial of Prednisolone Versus Colchicine for Acute Gout in Primary Care[NCT05698680] | Phase 4 | 314 participants (Anticipated) | Interventional | 2023-01-18 | Recruiting | ||
| [NCT00000608] | Phase 2 | 0 participants | Interventional | 1997-02-28 | Completed | ||
| Effects of Bariatric Surgery in Swedish Obese Subjects[NCT01479452] | 4,047 participants (Actual) | Interventional | 1987-01-31 | Completed | |||
| Comparison of Serum Concentrations, Physical and Psychological Well-being in Patients Having Chronic Musculoskeletal Pain With and Without Metabolic Syndrome[NCT03338868] | 100 participants (Anticipated) | Observational [Patient Registry] | 2015-08-01 | Recruiting | |||
| Randomized Double-blinded, Placebo-controlled, Cross-over Trial of Allopurinol for the Treatment of Newly Diagnosed Essential Hypertension in Adolescents[NCT00288184] | Phase 2 | 30 participants (Actual) | Interventional | 2004-09-30 | Completed | ||
| Pediatric Hypertension Registry (PHREG)[NCT03305562] | 179 participants (Actual) | Observational [Patient Registry] | 2017-09-20 | Terminated (stopped due to Study was a pilot study and the investigators received funding to initiate the main study) | |||
| The Role of the Renin-Angiotensin System in Pediatric Primary Hypertension (PHRAS)[NCT03310684] | 160 participants (Anticipated) | Observational | 2018-12-03 | Active, not recruiting | |||
| [NCT02797028] | Phase 4 | 320 participants (Anticipated) | Interventional | 2015-01-31 | Recruiting | ||
| The Effect of Acute Fructose Load in Patients With Chronic Kidney Disease and Patients With Type 2 Diabetes Compared to Healthy Subjects[NCT03157960] | 20 participants (Actual) | Interventional | 2012-02-01 | Completed | |||
| A Phase 3, Randomized, Multicenter, Allopurinol and Placebo-Controlled Study Assessing the Safety and Efficacy of Oral Febuxostat in Subjects With Gout.[NCT00174915] | Phase 3 | 1,072 participants (Actual) | Interventional | 2003-02-28 | Completed | ||
| Novel Methods for Ascertainment of Gout Flares -A Pilot Study[NCT02855437] | 44 participants (Actual) | Interventional | 2016-09-30 | Completed | |||
| A Phase 3, Open-Label, Randomized, Allopurinol-Controlled Study to Assess the Long-Term Safety of Oral Febuxostat in Subjects With Gout[NCT00175019] | Phase 3 | 1,086 participants (Actual) | Interventional | 2003-07-31 | Completed | ||
| The Differences Between Insulin Glargine U300 and Insulin Degludec U100 in Impact on the Glycaemic Variability, Oxidative Stress, Arterial Stiffness and the Lipid Profiles in Insulin naïve Patients Suffering From Type Two Diabetes Mellitus[NCT04692415] | Phase 4 | 25 participants (Actual) | Interventional | 2018-12-15 | Completed | ||
| Total XV - Total Therapy Study XV for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia[NCT00137111] | Phase 3 | 501 participants (Actual) | Interventional | 2000-07-08 | Completed | ||
| Hyperuricemia and the Effects of the Uricosuric Agents Benzbromarone in Patients With Chronic Heart Failure[NCT00422318] | Phase 4 | 0 participants | Interventional | 2004-01-31 | Completed | ||
| A Phase 3, Randomized, Multicenter, Double-Blind, Allopurinol-Controlled Study Assessing the Efficacy and Safety of Oral Febuxostat in Subjects With Gout.[NCT00430248] | Phase 3 | 2,269 participants (Actual) | Interventional | 2007-02-28 | Completed | ||
| A Phase 3, Randomized, Multicenter Study Comparing the Safety and Efficacy of Oral Febuxostat Versus Allopurinol in Subjects With Gout[NCT00102440] | Phase 3 | 760 participants (Actual) | Interventional | 2002-07-31 | Completed | ||
| The Effect of Allopurinol on Malondialdehyde, Nitric Oxide, Kidney Injury Molecule-1 Urine Levels, Resistive Index and Renal Elastography in Kidney Stone Patients After Extra Corporeal Shockwave Lithotripsy[NCT05414669] | Phase 4 | 35 participants (Actual) | Interventional | 2020-08-06 | Completed | ||
| Effect of Important Food Sources of Fructose-containing Sugars on Cardiometabolic Risk Factors: A Series of Systematic Reviews and Meta-analyses of Controlled Trials to Inform Dietary Guidelines, Public Health Policy, and Future Trial Design[NCT02716870] | 1 participants (Anticipated) | Observational | 2015-06-30 | Active, not recruiting | |||
| Effect of Fructose on Metabolic Control in Humans: A Series of Systematic Reviews and Meta-analyses to Provide Evidence-based Guidance for Nutrition Guidelines Development[NCT01363791] | 1 participants (Anticipated) | Observational | 2009-05-31 | Active, not recruiting | |||
| Effect of Fructose-containing Sugar Sweetened Beverages (SSBs) on Body Weight: A Systematic Review and Meta-analysis of Controlled Feeding Trials to Provide Evidence-based Guidance for Nutrition Guidelines Development[NCT01608607] | 1 participants (Actual) | Observational | 2012-05-31 | Active, not recruiting | |||
| The Relation of Total and Individual Fructose-containing Sugars With Incident Cardiometabolic Diseases: A Series of Systematic Reviews and Meta-analyses of Prospective Observational Studies[NCT01608620] | 1 participants (Anticipated) | Observational | 2012-05-31 | Active, not recruiting | |||
| Renal Transplant Injury and the Renin-Angiotensin System in Kids (RETASK)[NCT03317925] | 29 participants (Actual) | Observational | 2014-07-16 | Completed | |||
| Assessing the Role of the NLRP3 Inflammasome in Driving Inflammation in Affected Joints of Patients With Intercritical Gout[NCT04125459] | 8 participants (Anticipated) | Observational | 2020-01-22 | Active, not recruiting | |||
| Effect of Urinary Alkalinization on Urine Uric Acid Precipitation and Crystallization in Adults With Type 1 DiabetesL a Open-label Trial[NCT02502071] | Phase 4 | 45 participants (Actual) | Interventional | 2017-01-31 | Completed | ||
| Prednisone Versus Allopurinol for Symptomatic Heart Failure Patients With Hyperuricemia[NCT00919243] | Phase 4 | 40 participants (Anticipated) | Interventional | 2009-02-28 | Completed | ||
| Long-term Prednisone Use in Patients With Advanced Heart Failure (ACCF/AHA Stage D) and Hyperuricemia[NCT02282683] | Phase 2/Phase 3 | 90 participants (Anticipated) | Interventional | 2013-12-31 | Recruiting | ||
| A Cohort Dose-Escalation Phase 1 Study of Intravenous Infusion of Uricase-PEG 20[NCT01021241] | Phase 1 | 20 participants (Anticipated) | Interventional | 2009-10-31 | Active, not recruiting | ||
| A Cohort Dose-Escalation Phase 1 Study of Intramuscular Injection of Uricase-PEG 20[NCT01038947] | Phase 1 | 28 participants (Anticipated) | Interventional | 2009-12-31 | Recruiting | ||
| FEnofibRate as a Metabolic INtervention for Coronavirus Disease 2019[NCT04517396] | Phase 2 | 701 participants (Actual) | Interventional | 2020-08-18 | Completed | ||
| Alternative Haemodiafiltration in Summer Season for Chronic Kidney Disease Patients[NCT05861219] | 100 participants (Anticipated) | Interventional | 2023-06-21 | Not yet recruiting | |||
| Using of the Skin as a Third Spare Kidney for Patients With Chronic Renal Failure[NCT03810989] | 86 participants (Anticipated) | Interventional | 2019-06-01 | Not yet recruiting | |||
| Randomized, Double Blind Study Assessing the Clinical Efficacy of Combined Treatment With Uric Acid and rtPA Administered Intravenously in Acute Ischemic Stroke Patients Within the First 4.5 Hours of Symptoms Onset[NCT00860366] | Phase 2/Phase 3 | 421 participants (Actual) | Interventional | 2011-06-30 | Completed | ||
| The Bogalusa Heart Study[NCT00005129] | 11,737 participants (Actual) | Observational | 1972-06-30 | Active, not recruiting | |||
| Phase II, Dose-Response, Safety and Efficacy Study of Oral TMX-67 in Subjects With Gout.[NCT00174967] | Phase 2 | 153 participants (Actual) | Interventional | 2001-01-31 | Completed | ||
| A Phase II Multidose Study of Intravenous PEG-uricase in Patients With Refractory Gout[NCT00111657] | Phase 2 | 30 participants (Actual) | Interventional | 2004-12-31 | Completed | ||
| Effect of Rasburicase on Acute Kidney Injury, Kidney Function, the Incidence of Renal Replacement Therapy and All-cause Mortality Following Cardiac Surgery.[NCT00756964] | Phase 2 | 26 participants (Actual) | Interventional | 2008-10-31 | Completed | ||
| Clinical Investigation of Aging Men With Renal Stones: The Role of Bone Demineralization (Metabolic and Hormonal Assessment)[NCT01246531] | 42 participants (Actual) | Observational | 2008-01-31 | Completed | |||
| Uric Acid and Hypertension in African Americans[NCT00241839] | Phase 3 | 150 participants (Actual) | Interventional | 2005-08-31 | Completed | ||
| Effect of Low Dose of Colchicine on Platelet Reactivty in Patients With Chronic Coronary Disease[NCT05956145] | Phase 3 | 80 participants (Anticipated) | Interventional | 2021-06-17 | Recruiting | ||
| Influence of Food Liking of Adding Spices to Replace Dietary Sugar Using Sequential Monadic CLT Methodology[NCT03139552] | 150 participants (Actual) | Interventional | 2016-10-17 | Completed | |||
| Influence on Food Liking of Adding Spices to Replace Dietary Sugar[NCT03134079] | 160 participants (Actual) | Interventional | 2015-09-10 | Completed | |||
| [NCT00000487] | Phase 3 | 0 participants | Interventional | 1972-06-30 | Completed | ||
| Febuxostat (Zurig) Efficacy & Safety Trial in Comparison With Allopurinol in Hyperuricemic Subjects With or Without Gout[NCT02600780] | Phase 4 | 50 participants (Actual) | Interventional | 2013-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
APTC events were defined as a composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke; these events were adjudicated by an independent cardiovascular endpoints committee. (NCT01101035)
Timeframe: Up to last dose of study drug (approximately 83 months)
| Intervention | percentage of participants (Number) |
|---|---|
| Febuxostat | 9.6 |
| Allopurinol | 8.8 |
Events were adjudicated by an independent cardiovascular endpoints committee as CV death. (NCT01101035)
Timeframe: Up to last dose of study drug (approximately 83 months)
| Intervention | percentage of participants (Number) |
|---|---|
| Febuxostat | 4.3 |
| Allopurinol | 3.2 |
Events were adjudicated by an independent cardiovascular endpoints committee as non-fatal MI. (NCT01101035)
Timeframe: Up to last dose of study drug (approximately 83 months)
| Intervention | percentage of participants (Number) |
|---|---|
| Febuxostat | 3.6 |
| Allopurinol | 3.8 |
Events were adjudicated by an independent cardiovascular endpoints committee as non-fatal stroke. (NCT01101035)
Timeframe: Up to last dose of study drug (approximately 83 months)
| Intervention | percentage of participants (Number) |
|---|---|
| Febuxostat | 2.3 |
| Allopurinol | 2.3 |
Major adverse cardiovascular events (MACE) were defined as a composite of cardiovascular (CV) death, non-fatal myocardial infarction (MI), nonfatal stroke and unstable angina with urgent coronary revascularization; these events were adjudicated by an independent cardiovascular endpoints committee. (NCT01101035)
Timeframe: Up to last dose of study drug (approximately 83 months)
| Intervention | percentage of participants (Number) |
|---|---|
| Febuxostat | 10.8 |
| Allopurinol | 10.4 |
Major adverse cardiovascular events (MACE) were defined as a composite of cardiovascular (CV) death, non-fatal myocardial infarction (MI), nonfatal stroke and unstable angina with urgent coronary revascularization; these events were adjudicated by an independent cardiovascular endpoints committee. (NCT01101035)
Timeframe: Up to last dose of study drug (approximately 83 months)
| Intervention | percentage of participants (Number) |
|---|---|
| Febuxostat | 8.0 |
| Allopurinol | 8.0 |
Events were adjudicated by an independent cardiovascular endpoints committee as unstable angina with urgent coronary revascularization. (NCT01101035)
Timeframe: Up to last dose of study drug (approximately 83 months)
| Intervention | percentage of participants (Number) |
|---|---|
| Febuxostat | 1.6 |
| Allopurinol | 1.8 |
Change from baseline in peak UA excretion during the first 8 hours on Day 7 of treatment to assess the effects of intensive UA lowering therapy with verinurad, febuxostat and dapagliflozin. Urine sample was collected in hourly intervals, and the highest amount of UA excreted in any interval was designated as peak UA excretion for each patient and treatment period. (NCT03316131)
Timeframe: On Day -1 and Day 7 of each treatment period
| Intervention | milligrams (mg) (Least Squares Mean) |
|---|---|
| Treatment Sequence A+B | -12.87 |
| Treatment Sequence B+A | -13.15 |
Change from baseline in sUA to assess the intensive UA lowering effect of RDEA3170, febuxostat and dapagliflozin by evaluating the sUA levels after 7 days of treatment. (NCT03316131)
Timeframe: At Day -1 and Day 7
| Intervention | umol/L (Least Squares Mean) |
|---|---|
| Treatment Sequence A+B | -327.161 |
| Treatment Sequence B+A | -264.851 |
AUClast assessment for Verinurad, M1, and M8 following daily oral administration of verinurad and febuxostat with and without dapagliflozin (NCT03316131)
Timeframe: On Treatment Period 1 and 2: Day 7 (Pre-dose and 15 minutes, 30 minutes, 1 hour, 1.5, 2, 3, 4, 8, 12 and 24 hours post-dose)
| Intervention | h∙ng/mL (Geometric Mean) | ||
|---|---|---|---|
| Verinurad | M1 | M8 | |
| Treatment Sequence A+B | 149.1 | 212.7 | 174.2 |
| Treatment Sequence B+A | 141.0 | 221.3 | 176.5 |
AUCτ assessment for Verinurad, M1, and M8 following daily oral administration of verinurad and febuxostat with and without dapagliflozin (NCT03316131)
Timeframe: On Treatment Period 1 and 2: Day 7 (Pre-dose and 15 minutes, 30 minutes, 1 hour, 1.5, 2, 3, 4, 8, 12 and 24 hours post-dose)
| Intervention | h∙ng/mL (Geometric Mean) | ||
|---|---|---|---|
| Verinurad | M1 | M8 | |
| Treatment Sequence A+B | 149.0 | 212.6 | 174.1 |
| Treatment Sequence B+A | 140.9 | 221.1 | 176.3 |
Cmax assessment for Verinurad, M1, and M8 following daily oral administration of verinurad and febuxostat with and without dapagliflozin (NCT03316131)
Timeframe: On Treatment Period 1 and 2: Day 7 (Pre-dose and 15 minutes, 30 minutes, 1 hour, 1.5, 2, 3, 4, 8, 12 and 24 hours post-dose)
| Intervention | ng/mL (Geometric Mean) | ||
|---|---|---|---|
| Verinurad | M1 | M8 | |
| Treatment Sequence A+B | 17.52 | 25.28 | 18.45 |
| Treatment Sequence B+A | 15.26 | 25.61 | 18.42 |
tlast assessment for Verinurad, M1, and M8 following daily oral administration of verinurad and febuxostat with and without dapagliflozin (NCT03316131)
Timeframe: On Treatment Period 1 and 2: Day 7 (Pre-dose and 15 minutes, 30 minutes, 1 hour, 1.5, 2, 3, 4, 8, 12 and 24 hours post-dose)
| Intervention | hour (Median) | ||
|---|---|---|---|
| Verinurad | M1 | M8 | |
| Treatment Sequence A+B | 24.00 | 24.00 | 24.00 |
| Treatment Sequence B+A | 24.00 | 24.00 | 24.00 |
tmax assessment for Verinurad, M1, and M8 following daily oral administration of verinurad and febuxostat with and without dapagliflozin (NCT03316131)
Timeframe: On Treatment Period 1 and 2: Day 7 (Pre-dose and 15 minutes, 30 minutes, 1 hour, 1.5, 2, 3, 4, 8, 12 and 24 hours post-dose)
| Intervention | hour (Median) | ||
|---|---|---|---|
| Verinurad | M1 | M8 | |
| Treatment Sequence A+B | 4.00 | 4.00 | 4.00 |
| Treatment Sequence B+A | 4.00 | 4.00 | 4.00 |
"Outcome 1a. Document the rate of acceptance (quantitative) and reasons for acceptance/rejection (qualitative) in a randomized trial of trial of losartan for SCD patients with abnormal nocturnal blood pressures.~Outcome 1b. Identify the adherence rate to losartan during a randomized three year trial of losartan for SCD patients (n=40) with abnormal nocturnal blood pressure.~Outcome 1c. Determine the adherence rate to study procedures among participants enrolled in a three year trial of losartan for SCD patients (n=40) with abnormal nocturnal blood pressure." (NCT02373241)
Timeframe: 5 yrs
| Intervention | Participants (Count of Participants) |
|---|---|
| Standard Blood Pressure Management | 0 |
| Experimental Blood Pressure Management | 1 |
As a feasibility trial, the effect of losartan on lowering nocturnal hypertension will be monitored to identify the difference in nocturnal BP improvement between the two treatment arms, and within group standard deviation of BP (NCT02373241)
Timeframe: 5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Experimental Blood Pressure Management | 1 |
We will prospectively evaluate the incidence of hypertension (Clinic BP in pts >5yrs and ABPM in pts >10 yrs) and role of blood and urine biomarkers (pts >5ys) among participants with HbSS or SB0 thalassemia (expected cohort n=200) over 5 yrs. We identified 20 participants (34%) with incident hypertension but randomized one to the study. The study was terminated as the eGFR was determined not to be a reliable endpoint in pediatric sickle cell. (NCT02373241)
Timeframe: 5 yrs
| Intervention | Participants (Count of Participants) |
|---|---|
| Standard Blood Pressure Management | 0 |
| Experimental Blood Pressure Management | 1 |
The single affected joint was defined as the joint with the history of the first acute gout flare. Radiographs (X-rays) of this single joint in the hands or feet were evaluated using the modified Sharp/van der Heijde method. Each erosion was assessed using a 4-point scale where 0=no erosions (best) to 3=large erosion passing the mid-line (worst). Individual erosion scores were summed to a maximum erosion score of 5 for joints in the hands and 10 for joints in the feet. Higher scores indicated more joint damage. A negative change from Baseline indicated improvement. (NCT01078389)
Timeframe: Baseline and Month 24
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Baseline | Change from Baseline at Month 24 | |
| Febuxostat 40 mg or 80 mg | 0.16 | 0.01 |
| Placebo | 0.11 | 0.01 |
Radiographs (X-rays) of 40 joints in the hands and 12 joints in the feet were evaluated using the modified Sharp/van der Heijde method. Each erosion was assessed using a 4-point scale where 0=no erosions (best) to 3=large erosion passing the mid-line (worst) for a total erosion score range of 0 to 320. Higher scores indicated more joint damage. A negative change from Baseline indicated improvement. (NCT01078389)
Timeframe: Baseline and Month 24
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Baseline | Change from Baseline at Month 24 (n=78,74) | |
| Febuxostat 40 mg or 80 mg | 0.36 | 0.17 |
| Placebo | 0.17 | 0.11 |
The single affected joint was defined as the joint with the history of the first acute gout flare. Radiographs (X-rays) of the single affected joint in the hands or feet were evaluated using the modified Sharp/van der Heijde method. Each erosion was assessed using a 4-point scale where 0=no erosions (best) to 3=large erosion passing the mid-line (worst) and Joint space narrowing (JSN) was assessed using a 5-point scale where 0=normal (best) to 4=absence of joint space, presumptive evidence of ankyloses, or complete luxation (worst). The Erosion Score and the JSN Score were summed for the Total Score. Higher scores indicated more joint damage. A negative change from Baseline indicated improvement. (NCT01078389)
Timeframe: Baseline and Month 24
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Baseline | Change from Baseline at Month 24(n=81,76) | |
| Febuxostat 40 mg or 80 mg | 0.85 | 0.00 |
| Placebo | 0.77 | 0.05 |
Radiographs (X-rays) of 40 joints in the hands and 12 joints in the feet were evaluated using the modified Sharp/van der Heijde method. Each erosion was assessed using a 4-point scale where 0=no erosions (best) to 3=large erosion passing the mid-line (worst) for a total erosion score range of 0 to 320. Joint space narrowing (JSN) was assessed using a 5-point scale where 0=normal (best) to 4=absence of joint space, presumptive evidence of ankyloses, or complete luxation (worst) for a total JSN score range of 0 to 208. The Erosion Score and the JSN Score were combined for a total possible score of 0 to 528. Higher scores indicated more joint damage. A negative change from Baseline indicated improvement. (NCT01078389)
Timeframe: Baseline and Month 24
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Baseline | Change from Baseline at Month 24 (n=78,74) | |
| Febuxostat 40 mg or 80 mg | 4.98 | 0.31 |
| Placebo | 4.56 | 0.29 |
The single affected joint was defined as the joint with the history of the first acute gout flare. Magnetic Resonance Imaging (MRI) was evaluated using the Rheumatoid Arthritis MRI Score (RAMRIS). Bone erosion in the proximal and distal location were each assessed in the affected joint using an 11-point scale where 0=no erosion (best) to 10=91-100% bone eroded (worst) for a bone erosion score range of 0 to 20. Bone marrow edema in the proximal and distal location were each assessed using a 4-point scale where 0=no edema (best) to 3=67-100% edema (worst) for a bone marrow edema (BME) score range of 0 to 6. Synovitis was assessed in the affected joint using a 4-point scale where 0=normal (best) to 3=severe (worst). Higher scores indicated more joint damage. A negative change from Baseline indicated improvement. (NCT01078389)
Timeframe: Baseline and Month 24
| Intervention | score on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Synovitis:Baseline (BL)(n=82,76) | Synovitis:Change from Baseline (n=75,67) | Erosion (Distal+Proximal):Baseline (n=84,77) | Erosion (Distal+Proximal):Change from BL(n=79,69) | Edema (Distal+Proximal):Baseline (BL) (n=81,75) | Edema (Distal+Proximal):Change from BL(n=77,66) | |
| Febuxostat 40 mg or 80 mg | 1.29 | -0.43 | 1.63 | -0.01 | 0.73 | -0.36 |
| Placebo | 1.09 | -0.07 | 1.48 | 0.04 | 0.51 | -0.10 |
The change in 24-hour mean DBP measured at final visit or Week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing. (NCT01496469)
Timeframe: Baseline and Week 6
| Intervention | mmHg (Least Squares Mean) | |
|---|---|---|
| Baseline | Change at Week 6 | |
| Febuxostat 80 mg | 83.0 | -2.0 |
| Placebo | 85.9 | -2.7 |
The change in 24-hour mean SBP measured at final visit or Week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing. (NCT01496469)
Timeframe: Baseline and Week 6
| Intervention | millimeters of mercury (mmHg) (Least Squares Mean) | |
|---|---|---|
| Baseline | Change at Week 6 | |
| Febuxostat 80 mg | 139.5 | -3.7 |
| Placebo | 142.3 | -3.4 |
(NCT01496469)
Timeframe: Baseline and Week 6
| Intervention | mg/dL (Least Squares Mean) | |
|---|---|---|
| Baseline | Change at Week 6 | |
| Febuxostat 80 mg | 7.6 | -3.3 |
| Placebo | 7.7 | 0.1 |
Diastolic BP by ambulatory blood pressure monitor. (NCT01654276)
Timeframe: 6 months
| Intervention | mmHg (Mean) |
|---|---|
| Gout and Hyperuricemia | 75 |
Systolic BP by ambulatory blood pressure monitor. (NCT01654276)
Timeframe: 6 months
| Intervention | mmHg (Mean) |
|---|---|
| Gout and Hyperuricemia | 126 |
(NCT01654276)
Timeframe: 6 months
| Intervention | kg/m^2 (Mean) |
|---|---|
| Gout and Hyperuricemia | 33.4 |
(NCT01654276)
Timeframe: 6 months
| Intervention | % of serum uric acid excreted in urine (Mean) |
|---|---|
| Gout and Hyperuricemia | 0.04 |
(NCT01654276)
Timeframe: 6 months
| Intervention | Homeostatic model assessment for Insulin (Mean) |
|---|---|
| Gout and Hyperuricemia | 1.86 |
(NCT01654276)
Timeframe: 6 months
| Intervention | mg/dl (Mean) |
|---|---|
| Gout and Hyperuricemia | 0.98 |
(NCT01654276)
Timeframe: 6 months
| Intervention | mg/dl (Mean) |
|---|---|
| Gout and Hyperuricemia | 107 |
(NCT01654276)
Timeframe: 6 months
| Intervention | mg/dl (Mean) |
|---|---|
| Gout and Hyperuricemia | 49 |
(NCT01654276)
Timeframe: 6 months
| Intervention | mU/L (Mean) |
|---|---|
| Gout and Hyperuricemia | 14 |
(NCT01654276)
Timeframe: 6 months
| Intervention | mg/dl (Mean) |
|---|---|
| Gout and Hyperuricemia | 175 |
(NCT01654276)
Timeframe: 6 months
| Intervention | mg/dl (Mean) |
|---|---|
| Gout and Hyperuricemia | 4.4 |
(NCT01654276)
Timeframe: 6 months
| Intervention | mg/dl (Mean) |
|---|---|
| Gout and Hyperuricemia | 196 |
(NCT01654276)
Timeframe: 6 months
| Intervention | mg/dl (Mean) |
|---|---|
| Gout and Hyperuricemia | 1332 |
(NCT01654276)
Timeframe: 6 months
| Intervention | pH (Mean) |
|---|---|
| Gout and Hyperuricemia | 5.58 |
(NCT01654276)
Timeframe: 6 months
| Intervention | mg/dl (Mean) |
|---|---|
| Gout and Hyperuricemia | 208 |
Body mass index (BMI) measured in kg per meters squared. The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. (NCT00081328)
Timeframe: 24 months
| Intervention | kg per meters squared (Mean) |
|---|---|
| 1 Metformin Alone | 36.7 |
| 2 Metformin + Rosliglitazone | 38.2 |
| 3 Metformin + Lifestyle Program | 35.3 |
Measured by DXA, both whole body scan and AP-spine scan. The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. In addition, in about 1/3 of participants DXA scans could not be obtained on participants weighing more than 300 pounds (136 kg), the upper limit in size set by the machine manufacturers. Scans were considered invalid if a body part (e.g., arm, leg) was completely off or partially off the scanner, there was hand-hip overlap, or there was motion or movement during the scan. (NCT00081328)
Timeframe: 24 months
| Intervention | g/cm squared (Mean) |
|---|---|
| 1 Metformin Alone | 1.15 |
| 2 Metformin + Rosliglitazone | 1.15 |
| 3 Metformin + Lifestyle Program | 1.15 |
Determined by DXA whole body scan. The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. In addition, in about 1/3 of participants DXA scans could not be obtained on participants weighing more than 300 pounds (136 kg), the upper limit in size set by the machine manufacturers. Scans were considered invalid if a body part (e.g., arm, leg) was completely off or partially off the scanner, there was hand-hip overlap, or there was motion or movement during the scan. (NCT00081328)
Timeframe: 24 months
| Intervention | kg (Mean) |
|---|---|
| 1 Metformin Alone | 36.1 |
| 2 Metformin + Rosliglitazone | 39.7 |
| 3 Metformin + Lifestyle Program | 32.2 |
Waist circumference (cm) measured at the iliac crest at its outermost point with the measuring tape placed around the participant in a horizontal plane parallel to the floor at the mark and the measurement teken at the end of normal expiration without the tape compressing the skin. The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. (NCT00081328)
Timeframe: 24 months
| Intervention | cm (Mean) |
|---|---|
| 1 Metformin Alone | 110.8 |
| 2 Metformin + Rosliglitazone | 114.0 |
| 3 Metformin + Lifestyle Program | 108.6 |
A diagnosis was made by an out-of-range value >=95th percentile or systolic >=130 or diastolic >=80 sustained over 6 months or on an anti-hypertensive medication. (NCT00081328)
Timeframe: Data collected at baseline and during follow-up - 2 years to 6.5 years from randomization.
| Intervention | participants (Number) |
|---|---|
| 1 Metformin Alone | 57 |
| 2 Metformin + Rosliglitazone | 53 |
| 3 Metformin + Lifestyle Program | 45 |
A diagnosis was made from out-of-range value >= 130 mg/dL sustained over 6 months or put on lipid lowering medication. (NCT00081328)
Timeframe: Data collected at baseline and during follow-up - 2 years to 6.5 years from randomization.
| Intervention | participants (Number) |
|---|---|
| 1 Metformin Alone | 18 |
| 2 Metformin + Rosliglitazone | 16 |
| 3 Metformin + Lifestyle Program | 15 |
A diagnosis was made by an out-of-range value >=150 mg/dL sustained over 6 months or on appropriate lipid lowering medication. (NCT00081328)
Timeframe: Data collected at baseline and during follow-up - 2 years to 6.5 years from randomization.
| Intervention | participants (Number) |
|---|---|
| 1 Metformin Alone | 20 |
| 2 Metformin + Rosliglitazone | 28 |
| 3 Metformin + Lifestyle Program | 22 |
Insulinogenic index determined from OGTT as difference in insulin at 30 minutes minus 0 minutes divided by difference in glucose at 30 minutes minus 0 minutes. The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. (NCT00081328)
Timeframe: 24 months
| Intervention | uU/mL divided by mg/dL (Median) |
|---|---|
| 1 Metformin Alone | .75 |
| 2 Metformin + Rosliglitazone | .83 |
| 3 Metformin + Lifestyle Program | .71 |
All participants were followed to 24 months. Insulin sensitivity is measured from OGTT as inverse of fasting insulin (mL/uU). The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. (NCT00081328)
Timeframe: 24 months
| Intervention | mL/uU (Median) |
|---|---|
| 1 Metformin Alone | 0.037 |
| 2 Metformin + Rosiglitazone | 0.049 |
| 3 Metformin + Lifestyle Program | 0.039 |
Number of serious adverse events reported during the trial. Participant could have multiple episodes reported. (NCT00081328)
Timeframe: Reported as occurred during study follow-up - 2 years to 6.5 years from randomization.
| Intervention | episodes of serious adverse event (Number) |
|---|---|
| 1 Metformin Alone | 42 |
| 2 Metformin + Rosiglitazone | 34 |
| 3 Metformin + Lifestyle Program | 58 |
Defined as A1c persistently >=8% over a 6-month period or persistent metabolic decompensation (inability to wean insulin within 3 months of initiation or the occurrence of a second episode within three months of discontinuing insulin) (NCT00081328)
Timeframe: Study duration - 2 years to 6.5 years of follow up from randomization
| Intervention | participants (Number) | |
|---|---|---|
| Treatment failure | Did not fail treatment during trial | |
| 1 Metformin Alone | 120 | 112 |
| 2 Metformin + Rosliglitazone | 90 | 143 |
| 3 Metformin + Lifestyle Program | 109 | 125 |
Gout flare was defined as acute articular pain typical of a gout attack that required treatment with an anti-inflammatory therapeutic: had at least 3 of the following 4 signs or symptoms: joint swelling, tenderness, redness, and pain, and with at least 1 of the following: rapid onset of pain, decreased range of motion, joint warmth or other symptoms similar to a prior gout flare. Number of gout flare days per participant was reported for this outcome measure. (NCT00958438)
Timeframe: Day 1 to Day 113 (Week 16)
| Intervention | Gout flare days (Mean) |
|---|---|
| Placebo | 11.7 |
| Rilonacept 80 mg | 4.30 |
| Rilonacept 160 mg | 1.86 |
Participants were asked to complete a telephone diary by calling the IVRS daily beginning at the baseline visit (Day 1) through the follow-up visit (Day 141) and reported their general well-being, gout symptoms, and weekly study drug administrations. At the onset of pain from a gout flare, participants were to answer additional diary questions regarding their gout flare and had to continue daily flare assessments until they reported the flare had ended. If a flare occurred just prior to the follow-up visit (Day 141), participants were to continue completing the daily diary until the flare resolved. Gout flare pain was assessed on a scale from 0 to 10 (with 0=no pain and 10=severe pain) within the past 24 hours. (NCT00958438)
Timeframe: Day 1 to Day 113 (Week 16)
| Intervention | Gout flare days (Mean) |
|---|---|
| Placebo | 4.28 |
| Rilonacept 80 mg | 1.67 |
| Rilonacept 160 mg | 0.88 |
Gout flare was defined as acute articular pain typical of a gout attack that required treatment with an anti-inflammatory therapeutic: had at least 3 of the following 4 signs or symptoms: joint swelling, tenderness, redness, and pain and with at least 1 of the following: rapid onset of pain, decreased range of motion, joint warmth or other symptoms similar to a prior gout flare. Number of gout flares per participant was reported for this outcome measure. (NCT00958438)
Timeframe: Day 1 to Day 113 (Week 16)
| Intervention | Gout flares (Mean) |
|---|---|
| Placebo | 1.23 |
| Rilonacept 80 mg | 0.35 |
| Rilonacept 160 mg | 0.34 |
Modified gout flare was defined using modified definition of a gout flare as participant-reported articular pain typical of a gout attack that was deemed to require treatment with anti-inflammatory therapy. Number of modified gout flares per participant were reported for this outcome measure. (NCT00958438)
Timeframe: Day 1 to Day 113 (Week 16)
| Intervention | Gout flares (Mean) |
|---|---|
| Placebo | 1.51 |
| Rilonacept 80 mg | 0.62 |
| Rilonacept 160 mg | 0.48 |
Gout flare was defined as acute articular pain typical of a gout attack that required treatment with an anti-inflammatory therapeutic: had at least 3 of the following 4 signs or symptoms: joint swelling, tenderness, redness, and pain; and with at least 1 of the following: rapid onset of pain, decreased range of motion, joint warmth or other symptoms similar to a prior gout flare. Percentage of participants with at least one gout flare was reported for this outcome measure. (NCT00958438)
Timeframe: Day 1 to Day 113 (Week 16)
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 56.1 |
| Rilonacept 80 mg | 25.6 |
| Rilonacept 160 mg | 20.5 |
Gout flare was defined as acute articular pain typical of a gout attack that required treatment with an anti-inflammatory therapeutic: had at least 3 of the following 4 signs or symptoms: joint swelling, tenderness, redness, and pain, and with at least 1 of the following: rapid onset of pain, decreased range of motion, joint warmth or other symptoms similar to a prior gout flare. Percentage of participants with at least two gout flares was reported for this outcome measure. (NCT00958438)
Timeframe: Day 1 to Day 113 (Week 16)
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 32.9 |
| Rilonacept 80 mg | 8.5 |
| Rilonacept 160 mg | 6.0 |
(NCT02082769)
Timeframe: Baseline and Final Visit (up to 26 weeks)
| Intervention | umol/l (Mean) |
|---|---|
| Febuxostat 40 mg QD | 182.2 |
| Febuxostat 80 mg QD | 216.0 |
| Allopurinol 100mg QD | 170.4 |
(NCT02082769)
Timeframe: Last 3 visits (any last 3 visits up to week 26)
| Intervention | percentage of participants (Number) |
|---|---|
| Febuxostat 40 mg QD | 22.5 |
| Febuxostat 80 mg QD | 33.5 |
| Allopurinol 100mg QD | 17.0 |
(NCT02082769)
Timeframe: Final Visit (up to 26 weeks)
| Intervention | percentage of participants (Number) |
|---|---|
| Febuxostat 40 mg QD | 45.0 |
| Febuxostat 80 mg QD | 58.9 |
| Allopurinol 100mg QD | 34.6 |
Change in number of tophi/subject was calculated for the subset of subjects with palpable tophi at the Screening. If the tophi were not palpable at the Final Visit, total count was assumed to be 0. The timing of the final visit may have differed for each subject. (NCT00174915)
Timeframe: Final Visit (up to 28 weeks)
| Intervention | number of tophi (Median) |
|---|---|
| Febuxostat 80 mg QD | 0.0 |
| Febuxostat 120 mg QD | 0.0 |
| Febuxostat 240 mg QD | 0.0 |
| Allopurinol QD | 0.0 |
| Placebo QD | 0.0 |
Change from baseline at Week 28 in the total number of tophi per subject was calculated for the subset of subjects with palpable tophi at the Screening Visit. If the tophi were not palpable at the Week 28 visit, the total count was assumed to be 0. (NCT00174915)
Timeframe: Baseline and Week 28
| Intervention | number of tophi (Median) |
|---|---|
| Febuxostat 80 mg QD | 0.0 |
| Febuxostat 120 mg QD | 0.0 |
| Febuxostat 240 mg QD | 0.0 |
| Allopurinol QD | 0.0 |
| Placebo QD | 0.0 |
The percent change in serum urate from baseline to the Final visit was summarized. The percent change in serum urate was calculated as [(Final visit - baseline levels)/baseline]*100. The final visit was the last visit at which a serum urate value was collected. The timing of the final visit may have differed for each subject. (NCT00174915)
Timeframe: Baseline and Final Visit (up to 28 weeks)
| Intervention | Percent change (Mean) |
|---|---|
| Febuxostat 80 mg QD | -45.2 |
| Febuxostat 120 mg QD | -51.9 |
| Febuxostat 240 mg QD | -66.3 |
| Allopurinol QD | -33.7 |
| Placebo QD | -3.0 |
Serum urate values were obtained at the Week 28 visit. The percent change in serum urate was calculated as [(Week 28 - baseline levels)/baseline]*100 and summarized. (NCT00174915)
Timeframe: Baseline and Week 28
| Intervention | Percent change (Mean) |
|---|---|
| Febuxostat 80 mg QD | -47.6 |
| Febuxostat 120 mg QD | -54.9 |
| Febuxostat 240 mg QD | -67.8 |
| Allopurinol QD | -34.4 |
| Placebo QD | -3.6 |
Percent change in primary tophus size was calculated as [(Final Visit - baseline sizes)/baseline]*100 for the subset of subjects with a primary palpable tophus at Screening. If tophus was not palpable at Final visit, the size was assumed to be 0. The timing of the final visit may have differed for each subject. (NCT00174915)
Timeframe: Baseline and Final Visit (up to 28 weeks)
| Intervention | percent change from baseline (Median) |
|---|---|
| Febuxostat 80 mg QD | -33.8 |
| Febuxostat 120 mg QD | -42.4 |
| Febuxostat 240 mg QD | -47.0 |
| Allopurinol QD | -22.6 |
| Placebo QD | -40.3 |
The percent change from baseline in primary tophus size as determined by physical measurement was calculated as [(Week 28 - baseline sizes)/baseline]*100 for the subset of subjects with a primary palpable tophus at the Screening Visit. If the primary tophus was no longer palpable at the Week 28 visit, the size was assumed to be zero. (NCT00174915)
Timeframe: Baseline and Week 28
| Intervention | percent change from baseline (Median) |
|---|---|
| Febuxostat 80 mg QD | -45.6 |
| Febuxostat 120 mg QD | -54.2 |
| Febuxostat 240 mg QD | -53.2 |
| Allopurinol QD | -31.5 |
| Placebo QD | -52.0 |
Percentage of subjects requiring treatment for a gout flare between Weeks 8 and 28 of the double-blind treatment period was summarized. A subject who reported more than 1 gout flare during this period was counted only once. (NCT00174915)
Timeframe: Weeks 8 through 28
| Intervention | percentage of subjects (Number) |
|---|---|
| Febuxostat 80 mg QD | 55 |
| Febuxostat 120 mg QD | 54 |
| Febuxostat 240 mg QD | 57 |
| Allopurinol QD | 46 |
| Placebo QD | 52 |
Each subject's serum urate at the last 3 visits determined the subject's response for the primary efficacy variable. A subject who prematurely discontinued without least 3 postbaseline serum urate levels was considered a nonresponder; if at least 3 serum urate were obtained postbaseline, those 3 visits were used. The last 3 visits used may have differed for each subject. (NCT00174915)
Timeframe: Last 3 visits (any last 3 visits up to week 28)
| Intervention | Percentage of subjects (Number) |
|---|---|
| Febuxostat 80 mg QD | 48 |
| Febuxostat 120 mg QD | 65 |
| Febuxostat 240 mg QD | 69 |
| Allopurinol QD | 22 |
| Placebo QD | 0 |
The percentage of subjects whose serum urate was <6.0 mg/dL at the final visit was summarized. The final visit was the last visit at which a serum urate value was collected and may have differed by subject. (NCT00174915)
Timeframe: Final Visit (up to 28 weeks).
| Intervention | Percentage of subjects (Number) |
|---|---|
| Febuxostat 80 mg QD | 72 |
| Febuxostat 120 mg QD | 79 |
| Febuxostat 240 mg QD | 92 |
| Allopurinol QD | 39 |
| Placebo QD | 1 |
Serum urate values were obtained at the Week 28 visit. The percentage of subjects whose serum urate was <6.0 mg/dL at the Week 28 visit was summarized. (NCT00174915)
Timeframe: Week 28
| Intervention | Percentage of subjects (Number) |
|---|---|
| Febuxostat 80 mg QD | 76 |
| Febuxostat 120 mg QD | 87 |
| Febuxostat 240 mg QD | 94 |
| Allopurinol QD | 41 |
| Placebo QD | 1 |
Feasibility ----Assessed by the percentage of participants completing answer IRV/RheumPRO queries. (NCT02855437)
Timeframe: 6 months
| Intervention | percentage of weekly response (Mean) |
|---|---|
| Interactive Voice Response | 81 |
| RheumPro Smartphone Application | 80 |
Percentage of total study population preferring IVR vs. RheumPRO (NCT02855437)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Interactive Voice Response | 3 |
| RheumPro Smartphone Application | 28 |
The area of the primary tophus was calculated based on the length and width of the tophus measured at baseline and final visit. The percent change from baseline in primary tophus size to the final visit was summarized. (NCT00175019)
Timeframe: Final Visit (up to 40 months).
| Intervention | percent change from baseline (Median) |
|---|---|
| Febuxostat 80 mg QD | -96 |
| Febuxostat 120 mg QD | -84 |
| Allopurinol QD | -67 |
The area of the primary tophus was calculated based on the length and width of the tophus measured at the Month 12 visit. The percent change from baseline in primary tophus size to the Month 12 visit was summarized. (NCT00175019)
Timeframe: Month 12
| Intervention | percent change from baseline (Median) |
|---|---|
| Febuxostat 80 mg QD | -82 |
| Febuxostat 120 mg QD | -79 |
| Allopurinol QD | -56 |
The area of the primary tophus was calculated based on the length and width of the tophus measured at baseline and Month 24 visit. The percent change from baseline in primary tophus size to the Month 24 visit was summarized. (NCT00175019)
Timeframe: Month 24
| Intervention | percent change from baseline (Median) |
|---|---|
| Febuxostat 80 mg QD | -100 |
| Febuxostat 120 mg QD | -96 |
| Allopurinol QD | -87 |
The area of the primary tophus was calculated based on the length and width of the tophus measured at baseline and Month 36 visit. The percent change from baseline in primary tophus size to the Month 36 visit was summarized. (NCT00175019)
Timeframe: Month 36
| Intervention | percent change from baseline (Median) |
|---|---|
| Febuxostat 80 mg QD | -83 |
The number of tophi were counted at baseline and final visits. The percent change from baseline in the number of tophi to the final visit was summarized. (NCT00175019)
Timeframe: Final Visit (up to 40 months).
| Intervention | percent change from baseline (Mean) |
|---|---|
| Febuxostat 80 mg QD | -59.9 |
| Febuxostat 120 mg QD | -58.3 |
| Allopurinol QD | -48.7 |
The percent change in serum urate from baseline to the last visit on treatment was summarized. The last visit on treatment was the last visit at which a serum urate value was collected prior to any changes in drug and/or dose from the initial treatment assignment. (NCT00175019)
Timeframe: Last Visit on treatment (up to 40 months).
| Intervention | percent change from baseline (Mean) |
|---|---|
| Febuxostat 80 mg QD | -46.69 |
| Febuxostat 120 mg QD | -52.99 |
| Allopurinol QD | -32.17 |
The percentage of subjects requiring treatment for gout flare after the first 12 months of final stable treatment was summarized. (NCT00175019)
Timeframe: After Month 12 to Final Visit
| Intervention | percentage of subjects (Number) |
|---|---|
| Febuxostat 80 mg QD | 15.3 |
| Febuxostat 120 mg QD | 19.8 |
| Allopurinol QD | 23.2 |
The percentage of subjects requiring treatment for gout flare during the first twelve months of final stable treatment was summarized. (NCT00175019)
Timeframe: Month 12
| Intervention | percentage of subjects (Number) |
|---|---|
| Febuxostat 80 mg QD | 29.4 |
| Febuxostat 120 mg QD | 42.5 |
| Allopurinol QD | 28.3 |
The percentage of subjects whose serum urate was <6.0 mg/dL at the last visit on treatment was summarized. The last visit on treatment was the last visit at which a serum urate value was collected prior to any changes in drug and/or dose from the initial treatment assignment. (NCT00175019)
Timeframe: Last Visit on treatment (up to 40 months).
| Intervention | percentage of subjects (Number) |
|---|---|
| Febuxostat 80 mg QD | 70.8 |
| Febuxostat 120 mg QD | 82.0 |
| Allopurinol QD | 32.6 |
Serum urate values were obtained at the Month 1 visit. The percentage of subjects whose serum urate was <6.0 mg/dL at the Month 1 visit was summarized. (NCT00175019)
Timeframe: Month 1
| Intervention | percentage of subjects (Number) |
|---|---|
| Febuxostat 80 mg QD | 80.8 |
| Febuxostat 120 mg QD | 87.0 |
| Allopurinol QD | 46.0 |
Serum urate values were obtained at the Month 12 visit. The percentage of subjects whose serum urate was <6.0 mg/dL at the Month 12 visit was summarized. (NCT00175019)
Timeframe: Month 12
| Intervention | percentage of subjects (Number) |
|---|---|
| Febuxostat 80 mg QD | 88.9 |
| Febuxostat 120 mg QD | 86.3 |
| Allopurinol QD | 82.2 |
Serum urate values were obtained at the Month 24 visit. The percentage of subjects whose serum urate was <6.0 mg/dL at the Month 24 visit was summarized. (NCT00175019)
Timeframe: Month 24
| Intervention | percentage of subjects (Number) |
|---|---|
| Febuxostat 80 mg QD | 89.3 |
| Febuxostat 120 mg QD | 87.2 |
| Allopurinol QD | 78.6 |
Serum urate values were obtained at the Month 36 visit. The percentage of subjects whose serum urate was <6.0 mg/dL at the Month 36 visit was summarized. (NCT00175019)
Timeframe: Month 36
| Intervention | percentage of subjects (Number) |
|---|---|
| Febuxostat 80 mg QD | 90.8 |
| Febuxostat 120 mg QD | 91.5 |
| Allopurinol QD | 90.0 |
"White blood cell (leukocytes) counts in peripheral blood by Complete Blood Count~Measurement: Percentage change of leukemia cells from baseline" (NCT00137111)
Timeframe: Immediately before the methotrexate infusion and three days after subsequent infusion
| Intervention | Percent change (Mean) |
|---|---|
| 4 hr | -44 |
| 24 hr | -50 |
CCR was measured from end of week 56 therapy to the date of first treatment failure of any kind (relapse, death, lineage switch, or second malignancy) or to the last date of follow-up. Measurement was determined by Kaplan-Meyer estimate. (NCT00137111)
Timeframe: Median follow up time (range) 4.5 (1 to 7.8) years
| Intervention | Percentage of participants (Number) |
|---|---|
| Patients With High Risk of CNS Relapse | 92.2 |
Children were randomly assigned to receive initial single-agent treatment with HDMTX (1g/m^2) as either a 24-hour infusion or a 4-hour infusion and the outcome measure was the accumulation of MTXPG in leukemia cells. (NCT00137111)
Timeframe: 42 hours after start of high dose methotrexate infusion (HDMTX)
| Intervention | pmol/1,000,000,000 cells (Mean) |
|---|---|
| 4 hr | 1688 |
| 24 hr | 2521 |
EFS was measured from the start of on-study to the date of first treatment failure of any kind (relapse, death, lineage switch, or second malignancy) or to the last date of follow-up. Failure to enter remission was considered an event at time zero. Measurement was determined by Kaplan-Meyer estimate. (NCT00137111)
Timeframe: Median follow-up time (range) 5.6 (1.3 to 8.9) years
| Intervention | Percentage of Participants (Number) |
|---|---|
| Total Therapy | 87.3 |
Prednisolone sensitivity was measured in primary leukemia cells from bone marrow collected at diagnosis. Expression of CASP1 was determined by HG-U133A microarray. Values given are gene expression values, and the unit is arbitrary units (AU) defined as scaled fluorescence measured on microarray. (NCT00137111)
Timeframe: Pre-treatment
| Intervention | arbitrary units (Median) | |
|---|---|---|
| Prednisolone-sensitive cells | Prednisolone-resistant cells | |
| Total Therapy | 341.3 | 447.9 |
Prednisolone sensitivity was measured in primary leukemia cells from bone marrow collected at diagnosis. Expression of NLRP3 was determined by HG-U133A microarray. Values given are gene expression values, and the unit is arbitrary units (AU) defined as scaled fluorescence measured on microarray. (NCT00137111)
Timeframe: Pre-treatment
| Intervention | arbitrary units (Median) | |
|---|---|---|
| Prednisolone-sensitive cells | Prednisolone-resistant cells | |
| Total Therapy | 41.2 | 110.7 |
Detection of MRD at end of induction where positive MRD was defined as one or more leukemic cell per 10,000 mononuclear bone-marrow cells (>=0.01%). (NCT00137111)
Timeframe: End of Induction (Day 46 MRD measurement)
| Intervention | participants (Number) | |
|---|---|---|
| Negative <0.01% | Positive >= 0.01% | |
| Total Therapy | 390 | 102 |
The percent change in serum urate from baseline to the Final visit was summarized. The final visit was the last visit at which a serum urate value was collected. (NCT00430248)
Timeframe: Baseline and Last Visit on treatment (up to 6 months)
| Intervention | percent change from baseline (Mean) |
|---|---|
| Febuxostat 40 mg QD | -33.1 |
| Febuxostat 80 mg QD | -40.6 |
| Allopurinol 200 mg or 300 mg QD | -31.3 |
Serum urate values were obtained at the Month 2 visit. The percent change in serum urate from baseline to the Month 2 visit was summarized. (NCT00430248)
Timeframe: Baseline and Month 2
| Intervention | percent change from baseline (Mean) |
|---|---|
| Febuxostat 40 mg QD | -35.1 |
| Febuxostat 80 mg QD | -44.5 |
| Allopurinol 200 mg or 300 mg QD | -33.8 |
Serum urate values were obtained at the Month 4 visit. The percent change in serum urate from baseline to the Month 4 visit was summarized. (NCT00430248)
Timeframe: Baseline and Month 4
| Intervention | percent change from baseline (Mean) |
|---|---|
| Febuxostat 40 mg QD | -34.9 |
| Febuxostat 80 mg QD | -45.5 |
| Allopurinol 200 mg or 300 mg QD | -34.5 |
Serum urate values were obtained at the Month 6 visit. The percent change in serum urate from baseline to the Month 6 visit was summarized. (NCT00430248)
Timeframe: Baseline and Month 6
| Intervention | percent change from baseline (Mean) |
|---|---|
| Febuxostat 40 mg QD | -35.6 |
| Febuxostat 80 mg QD | -45.1 |
| Allopurinol 200 mg or 300 mg QD | -34.4 |
The percentage of subjects with mild-to-moderate renal impairment whose serum urate was <6.0 mg/dL at the final visit was summarized. The final visit was the last visit at which a serum urate value was collected. (NCT00430248)
Timeframe: Last Visit on treatment (up to 6 months)
| Intervention | percentage of subjects (Number) |
|---|---|
| Febuxostat 40 mg QD | 49.7 |
| Febuxostat 80 mg QD | 71.6 |
| Allopurinol 200 mg or 300 mg QD | 42.3 |
The percentage of subjects whose serum urate level was <6.0 mg/dL at the Final Visit was summarized. The Final Visit was the last visit at which a serum urate value was collected. (NCT00430248)
Timeframe: Last Visit on treatment (up to 6 months)
| Intervention | percentage of subjects (Number) |
|---|---|
| Febuxostat 40 mg QD | 45.2 |
| Febuxostat 80 mg QD | 67.1 |
| Allopurinol 200 mg or 300 mg QD | 42.1 |
The percentage of subjects whose serum urate level was <4.0 mg/dL at the Final Visit was summarized. The Final Visit was the last visit at which a serum urate values was collected. (NCT00430248)
Timeframe: Last Visit on treatment (up to 6 months)
| Intervention | percentage of subjects (Number) |
|---|---|
| Febuxostat 40 mg QD | 2.5 |
| Febuxostat 80 mg QD | 17.5 |
| Allopurinol 200 mg or 300 mg QD | 1.5 |
Serum urate values were obtained at the Month 2 visit. The percentage of subjects whose serum urate was <4.0 mg/dL at the Month 2 visit was summarized. (NCT00430248)
Timeframe: Month 2
| Intervention | percentage of subjects (Number) |
|---|---|
| Febuxostat 40 mg QD | 2.1 |
| Febuxostat 80 mg QD | 17.5 |
| Allopurinol 200 mg or 300 mg QD | 1.5 |
Serum urate values were obtained at the Month 4 visit. The percentage of subjects whose serum urate was <4.0 mg/dL at the Month 4 visit was summarized. (NCT00430248)
Timeframe: Month 4
| Intervention | percentage of subjects (Number) |
|---|---|
| Febuxostat 40 mg QD | 2.0 |
| Febuxostat 80 mg QD | 18.6 |
| Allopurinol 200 mg or 300 mg QD | 1.4 |
Serum urate values were obtained at the Month 6 visit. The percentage of subjects whose serum urate was <4.0 mg/dL at the Month 6 visit was summarized. (NCT00430248)
Timeframe: Month 6
| Intervention | percentage of subjects (Number) |
|---|---|
| Febuxostat 40 mg QD | 3.1 |
| Febuxostat 80 mg QD | 20.3 |
| Allopurinol 200 mg or 300 mg QD | 1.8 |
The percentage of subjects whose serum urate level was <5.0 mg/dL at the Final Visit was summarized. The Final Visit was the last visit at which a serum urate values was collected. (NCT00430248)
Timeframe: Last Visit on treatment (up to 6 months)
| Intervention | percentage of subjects (Number) |
|---|---|
| Febuxostat 40 mg QD | 16.5 |
| Febuxostat 80 mg QD | 44.0 |
| Allopurinol 200 mg or 300 mg QD | 13.2 |
Serum urate values were obtained at the Month 2 visit. The percentage of subjects whose serum urate was <5.0 mg/dL at the Month 2 visit was summarized. (NCT00430248)
Timeframe: Month 2
| Intervention | percentage of subjects (Number) |
|---|---|
| Febuxostat 40 mg QD | 15.4 |
| Febuxostat 80 mg QD | 45.9 |
| Allopurinol 200 mg or 300 mg QD | 11.7 |
Serum urate values were obtained at the Month 4 visit. The percentage of subjects whose serum urate was <5.0 mg/dL at the Month 4 visit was summarized. (NCT00430248)
Timeframe: Month 4
| Intervention | percentage of subjects (Number) |
|---|---|
| Febuxostat 40 mg QD | 15.0 |
| Febuxostat 80 mg QD | 51.6 |
| Allopurinol 200 mg or 300 mg QD | 13.5 |
Serum urate values were obtained at the Month 6 visit. The percentage of subjects whose serum urate was <5.0 mg/dL at the Month 6 visit was summarized. (NCT00430248)
Timeframe: Month 6
| Intervention | percentage of subjects (Number) |
|---|---|
| Febuxostat 40 mg QD | 19.3 |
| Febuxostat 80 mg QD | 49.7 |
| Allopurinol 200 mg or 300 mg QD | 14.8 |
Serum urate values were obtained at the Month 2 visit. The percentage of subjects whose serum urate was <6.0 mg/dL at the Month 2 visit was summarized. (NCT00430248)
Timeframe: Month 2
| Intervention | percentage of subjects (Number) |
|---|---|
| Febuxostat 40 mg QD | 49.1 |
| Febuxostat 80 mg QD | 74.1 |
| Allopurinol 200 mg or 300 mg QD | 43.2 |
Serum urate values were obtained at the Month 4 visit. The percentage of subjects whose serum urate was <6.0 mg/dL at the Month 4 visit was summarized. (NCT00430248)
Timeframe: Month 4
| Intervention | percentage of subjects (Number) |
|---|---|
| Febuxostat 40 mg QD | 47.1 |
| Febuxostat 80 mg QD | 75.2 |
| Allopurinol 200 mg or 300 mg QD | 45.5 |
Serum urate values were obtained at the Month 6 visit. The percentage of subjects whose serum urate was <6.0 mg/dL at the Month 6 visit was summarized. (NCT00430248)
Timeframe: Month 6
| Intervention | percentage of participants (Number) |
|---|---|
| Febuxostat 40 mg QD | 48.9 |
| Febuxostat 80 mg QD | 75.3 |
| Allopurinol 200 mg or 300 mg QD | 46.6 |
Change in number of tophi/subject calculated for the subset of subjects with palpable tophi at Screening. If the tophi were not palpable at the Final Visit, total count was assumed to be 0. The timing of the final visit may have differed for each subject. (NCT00102440)
Timeframe: Baseline and Final Visit (up to 52 weeks)
| Intervention | number of tophi (Median) |
|---|---|
| Febuxostat 80 mg QD | 0.0 |
| Febuxostat 120 mg QD | 0.0 |
| Allopurinol 300 mg QD | 0.0 |
The change from baseline at Week 28 in the total number of tophi per subject was calculated for the subset of subjects with palpable tophi at the Screening Visit. If the tophi were no longer palpable at the Week 28 visit, the total count was assumed to be zero. (NCT00102440)
Timeframe: Baseline and Week 28
| Intervention | number of tophi (Median) |
|---|---|
| Febuxostat 80 mg QD | 0.0 |
| Febuxostat 120 mg QD | 0.0 |
| Allopurinol 300 mg QD | 0.0 |
The change from baseline at Week 52 in the total number of tophi per subject was calculated for the subset of subjects with palpable tophi at the Screening Visit. If the tophi were no longer palpable at the Week 52 visit, the total count was assumed to be zero. (NCT00102440)
Timeframe: Baseline and Week 52
| Intervention | number of tophi (Median) |
|---|---|
| Febuxostat 80 mg QD | 0.0 |
| Febuxostat 120 mg QD | -1.0 |
| Allopurinol 300 mg QD | 0.0 |
The percent change in serum urate from baseline to the Final visit was calculated as [(Final Visit - baseline levels/baseline)]*100 and summarized. The Final visit was the last visit with a serum urate value. The timing of the final visit may have differed for each subject. (NCT00102440)
Timeframe: Baseline and Final Visit (up to 52 weeks)
| Intervention | percent change from baseline (Mean) |
|---|---|
| Febuxostat 80 mg QD | -44.7 |
| Febuxostat 120 mg QD | -51.5 |
| Allopurinol 300 mg QD | -33.0 |
Serum urate values were obtained at the Week 28 visit. The percent change in serum urate was calculated as [(week 28 - baseline levels/baseline)]*100 and summarized. (NCT00102440)
Timeframe: Baseline and Week 28
| Intervention | percent change from baseline (Mean) |
|---|---|
| Febuxostat 80 mg QD | -46.3 |
| Febuxostat 120 mg QD | -53.5 |
| Allopurinol 300 mg QD | -34.8 |
Serum urate values were obtained at the Week 52 visit. The percent change in serum urate was calculated as [(week 52 - baseline levels/baseline)]*100 and summarized. (NCT00102440)
Timeframe: Baseline and Week 52
| Intervention | percent change from baseline (Mean) |
|---|---|
| Febuxostat 80 mg QD | -47.7 |
| Febuxostat 120 mg QD | -53.0 |
| Allopurinol 300 mg QD | -34.8 |
Percent change in primary tophus size was calculated as [(Final Visit - baseline sizes)/baseline]*100 for the subset of subjects with a primary palpable tophus at Screening. If tophus was not palpable at Final visit, the size was assumed to be 0. The timing of the final visit may have differed for each subject. (NCT00102440)
Timeframe: Baseline and Final Visit (up to 52 weeks)
| Intervention | percent change from baseline (Median) |
|---|---|
| Febuxostat 80 mg QD | -51.7 |
| Febuxostat 120 mg QD | -43.8 |
| Allopurinol 300 mg QD | -39.6 |
The percent change from baseline in primary tophus size as determined by physical measurement was calculated as [(Week 28 - baseline sizes)/baseline]*100 for the subset of subjects with a primary palpable tophus at the Screening Visit. If the primary tophus was no longer palpable at the Week 28 visit, the size was assumed to be zero. (NCT00102440)
Timeframe: Baseline and Week 28
| Intervention | percent change from baseline (Median) |
|---|---|
| Febuxostat 80 mg QD | -29.5 |
| Febuxostat 120 mg QD | -49.5 |
| Allopurinol 300 mg QD | -28.6 |
The percent change from baseline in primary tophus size as determined by physical measurement was calculated as [(Week 52 - baseline sizes)/baseline]*100 for the subset of subjects with a primary palpable tophus at the Screening Visit. If the primary tophus was no longer palpable at the Week 52 visit, the size was assumed to be zero. (NCT00102440)
Timeframe: Baseline and Week 52
| Intervention | percent change from baseline (Median) |
|---|---|
| Febuxostat 80 mg QD | -83.4 |
| Febuxostat 120 mg QD | -65.5 |
| Allopurinol 300 mg QD | -49.7 |
The percentage of subjects requiring treatment for a gout flare between Weeks 8 and 52 of the double-blind treatment period was summarized. A subject who reported more than 1 gout flare during this period was counted only once. (NCT00102440)
Timeframe: Weeks 8 through 52
| Intervention | percentage of subjects (Number) |
|---|---|
| Febuxostat 80 mg QD | 64 |
| Febuxostat 120 mg QD | 70 |
| Allopurinol 300 mg QD | 64 |
The percentage of subjects whose serum urate was <6.0 mg/dL at the final visit was summarized. The final visit was the last visit at which a serum urate value was collected. The timing of the final visit may have differed for each subject. (NCT00102440)
Timeframe: Final Visit (up to 52 weeks)
| Intervention | Percentage of subjects (Number) |
|---|---|
| Febuxostat 80 mg QD | 74 |
| Febuxostat 120 mg QD | 80 |
| Allopurinol 300 mg QD | 36 |
Serum urate values were obtained at the Week 28 visit. The percentage of subjects whose serum urate was <6.0 mg/dL at the Week 28 visit was summarized. (NCT00102440)
Timeframe: Week 28
| Intervention | Percentage of subjects (Number) |
|---|---|
| Febuxostat 80 mg QD | 72 |
| Febuxostat 120 mg QD | 82 |
| Allopurinol 300 mg QD | 42 |
Serum urate values were obtained at the Week 52 visit. The percentage of subjects whose serum urate was <6.0 mg/dL at the Week 52 visit was summarized. (NCT00102440)
Timeframe: Week 52
| Intervention | Percentage of subjects (Number) |
|---|---|
| Febuxostat 80 mg QD | 81 |
| Febuxostat 120 mg QD | 82 |
| Allopurinol 300 mg QD | 39 |
Each subject's serum urate at the last 3 visits determined the subject's response for the primary efficacy variable. A subject who prematurely discontinued without least 3 postbaseline serum urate levels was considered a nonresponder; if at least 3 serum urate were obtained postbaseline, those 3 visits were used. The last 3 visits used may have differed for each subject. (NCT00102440)
Timeframe: Last 3 Visits (up to 52 weeks)
| Intervention | Percentage of subjects (Number) |
|---|---|
| Febuxostat 80 mg QD | 53 |
| Febuxostat 120 mg QD | 62 |
| Allopurinol 300 mg QD | 21 |
Urine uric acid crystals were identified by polarized microscopy (Polarized light imaging Zeiss Axiovert 135; 0.3NA objective), and pictures were captured from each urine sample. UA crystals were defined dichotomously as being present or absent. (NCT02502071)
Timeframe: Day 1 (pre-therapy) and Day 2 (post-therapy)
| Intervention | participants (Number) | |
|---|---|---|
| Day 1 (pre-therapy) | Day 2 (post-therapy) | |
| Sodium Bicarbonate | 14 | 3 |
Urine uric acid were evaluated using a QuantiChrom UA kit assay (DIUA-250) with quantitative colorimetric UA determination at 590 nm (BioAssay System, California, USA). (NCT02502071)
Timeframe: Day 1 (pre-therapy) and Day 2 (post-therapy)
| Intervention | mg/dl (Geometric Mean) | |
|---|---|---|
| Day 1 (pre-therapy) | Day 2 (post-therapy) | |
| Sodium Bicarbonate | 23.81 | 22.30 |
Death from any cause during the observation period (NCT04517396)
Timeframe: Up to 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Fenofibrate + Usual Care | 19 |
| Placebo + Usual Care | 22 |
The exploratory global rank score, or global severity score, is a nonparametric, hierarchically ranked outcome. The global rank score was generated by ranking all 701 participants on a scale of 1 to 701, from worst to best clinical outcomes. Participants were ranked by (1) time to death; (2) the number of days supported by invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); (3) The inspired concentration of oxygen/percent oxygen saturation (FiO2/SpO2) ratio area under the curve; (4) The number of days out of the hospital during the 30 day-period following randomization. (NCT04517396)
Timeframe: Up to 30 days
| Intervention | score on a scale (Median) |
|---|---|
| Fenofibrate + Usual Care | 5.03 |
| Placebo + Usual Care | 5.03 |
Number of days that participants were alive and out of the hospital during the 30 days following randomization (NCT04517396)
Timeframe: Up to 30 days
| Intervention | days (Median) |
|---|---|
| Fenofibrate + Usual Care | 30 |
| Placebo + Usual Care | 30 |
Number of days participants were alive, out of the intensive care unit, free of mechanical ventilation/extracorporeal membrane oxygenation, or maximal available respiratory support during the 30 days that followed randomization (NCT04517396)
Timeframe: Up to 30 days
| Intervention | days (Mean) |
|---|---|
| Fenofibrate + Usual Care | 28.8 |
| Placebo + Usual Care | 28.3 |
The primary endpoint of the trial is a global rank score that ranks patient outcomes according to 5 factors. The global rank score, or global severity score, is a nonparametric, hierarchically ranked outcome. The global rank score was generated by ranking all 701 participants on a scale of 1 to 701, from worst to best clinical outcomes. Participants were ranked by (1) time to death; (2) the number of days supported by invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); (3) The inspired concentration of oxygen/percent oxygen saturation (FiO2/SpO2) ratio area under the curve; (4) For participants enrolled as outpatients who are subsequently hospitalized, the number of days out of the hospital during the 30 day-period following randomization; (5) For participants enrolled as outpatients who don't get hospitalized during the 30-day observation period, the modified Borg dyspnea scale (NCT04517396)
Timeframe: 30 days
| Intervention | Ranked Severity Score (Median) |
|---|---|
| Fenofibrate + Usual Care | 5.32 |
| Placebo + Usual Care | 5.33 |
The secondary global rank score, or global severity score, is a nonparametric, hierarchically ranked outcome. The global rank score was generated by ranking all 701 participants on a scale of 1 to 701, from worst to best clinical outcomes. Participants were ranked by (1) time to death; (2) the number of days supported by invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); (3) The inspired concentration of oxygen/percent oxygen saturation (FiO2/SpO2) ratio area under the curve; (4) For participants enrolled as outpatients who are subsequently hospitalized, the number of days out of the hospital during the 30 day-period following randomization; (5) For participants enrolled as outpatients who don't get hospitalized during the 30-day observation period, a COVID-19 symptom scale rating fever, cough, dyspnea, muscle aches, sore throat, loss of smell or taste, headache, diarrhea, fatigue, nausea/vomiting, chest pain (each are rated from 0-10 then summed). (NCT04517396)
Timeframe: Up to 30 days
| Intervention | score on a scale (Median) |
|---|---|
| Fenofibrate + Usual Care | 5.05 |
| Placebo + Usual Care | 5.05 |
A seven-category ordinal scale consisting of the following categories: 1, not hospitalized with resumption of normal activities; 2, not hospitalized, but unable to resume normal activities; 3, hospitalized, not requiring supplemental oxygen; 4, hospitalized, requiring supplemental oxygen; 5, hospitalized, requiring nasal high-flow oxygen therapy, noninvasive mechanical ventilation, or both; 6, hospitalized, requiring extracorporeal membrane oxygenation (ECMO), invasive mechanical ventilation, or both; and 7, death. (NCT04517396)
Timeframe: At 15 days
| Intervention | score on a scale (Median) |
|---|---|
| Fenofibrate + Usual Care | 1 |
| Placebo + Usual Care | 1 |
Serum urate values were obtained at the Day 7, 14, 21,and 28 visits. The maximum percent change in serum urate levels obtained at any visit was summarized. (NCT00174967)
Timeframe: Baseline and Any visit (Day 7, 14, 21,or 28)
| Intervention | percent change from baseline (Mean) |
|---|---|
| Febuxostat 40 mg QD | 42.5 |
| Febuxostat 80 mg QD | 49.2 |
| Febuxostat 120 mg QD | 62.8 |
| Placebo QD | 10.0 |
24-hour urine uric acid levels were obtained at the Day 28 visit. The percent change in 24-hour urine uric acid level from baseline to the Day 28 visit was summarized. (NCT00174967)
Timeframe: Baseline and Day 28.
| Intervention | percent change from baseline (Mean) |
|---|---|
| Febuxostat 40 mg QD | -43.6 |
| Febuxostat 80 mg QD | -46.5 |
| Febuxostat 120 mg QD | -45.7 |
| Placebo QD | 5.9 |
Serum urate values were obtained at the Day 14 visit. The percent change in serum urate from baseline to the Day 14 visit was summarized. (NCT00174967)
Timeframe: Baseline and Day 14.
| Intervention | percent change from baseline (Mean) |
|---|---|
| Febuxostat 40 mg QD | -37.1 |
| Febuxostat 80 mg QD | -41.8 |
| Febuxostat 120 mg QD | -56.9 |
| Placebo QD | 1.62 |
Serum urate values were obtained at the Day 21 visit. The percent change in serum urate from baseline to the Day 21 visit was summarized. (NCT00174967)
Timeframe: Baseline and Day 21.
| Intervention | percent change from baseline (Mean) |
|---|---|
| Febuxostat 40 mg QD | -37.3 |
| Febuxostat 80 mg QD | -43.9 |
| Febuxostat 120 mg QD | -59.4 |
| Placebo QD | -0.57 |
Serum urate values were obtained at the Day 28 visit. The percent change in serum urate from baseline to the Day 28 visit was summarized. (NCT00174967)
Timeframe: Baseline and Day 28.
| Intervention | percent change from baseline (Mean) |
|---|---|
| Febuxostat 40 mg QD | -36.6 |
| Febuxostat 80 mg QD | -44.3 |
| Febuxostat 120 mg QD | -59.1 |
| Placebo QD | -2.2 |
Serum urate values were obtained at the Day 7 visit. The percent change in serum urate from baseline to the Day 7 visit was summarized. (NCT00174967)
Timeframe: Baseline and Day 7.
| Intervention | percent change from baseline (Mean) |
|---|---|
| Febuxostat 40 mg QD | -35.0 |
| Febuxostat 80 mg QD | -39.2 |
| Febuxostat 120 mg QD | -53.44 |
| Placebo QD | 0.71 |
Serum urate values were obtained at the Day 14 visit. The percentage of subjects whose serum urate decreased to <6.0 mg/dL at the Day 14 visit was summarized. (NCT00174967)
Timeframe: Day 14.
| Intervention | percentage of subjects (Number) |
|---|---|
| Febuxostat 40 mg QD | 56 |
| Febuxostat 80 mg QD | 68 |
| Febuxostat 120 mg QD | 94 |
| Placebo QD | 0 |
Serum urate values were obtained at the Day 21 visit. The percentage of subjects whose serum urate decreased to <6.0 mg/dL at the Day 21 visit was summarized. (NCT00174967)
Timeframe: Day 21.
| Intervention | percentage of subjects (Number) |
|---|---|
| Febuxostat 40 mg QD | 59 |
| Febuxostat 80 mg QD | 76 |
| Febuxostat 120 mg QD | 97 |
| Placebo QD | 0 |
Serum urate values were obtained at the Day 7 visit. The percentage of subjects whose serum urate decreased to <6.0 mg/dL at the Day 7 visit was summarized. (NCT00174967)
Timeframe: Day 7.
| Intervention | percentage of subjects (Number) |
|---|---|
| Febuxostat 40 mg QD | 50 |
| Febuxostat 80 mg QD | 59 |
| Febuxostat 120 mg QD | 91 |
| Placebo QD | 3 |
Serum urate values were obtained at the Day 28 visit. The percentage of subjects whose serum urate decreased to <6.0 mg/dL at the Day 28 visit was summarized. (NCT00174967)
Timeframe: Day 28.
| Intervention | percentage of subjects (Number) |
|---|---|
| Febuxostat 40 mg QD | 56 |
| Febuxostat 80 mg QD | 76 |
| Febuxostat 120 mg QD | 94 |
| Placebo QD | 0 |
Number of patients who developed antibodies to PEG-uricase (NCT00111657)
Timeframe: baseline, then prior to infusions and 7 wks after last infusion
| Intervention | participants (Number) |
|---|---|
| Pegloticase | 15 |
The highest drug concentration in the blood after the first infusion of study drug. (NCT00111657)
Timeframe: 2 hours
| Intervention | mU/mL (Mean) |
|---|---|
| Single Arm - Pegloticase | 25.6 |
The lowest drug concentration in the blood after the first infusion of study drug. (NCT00111657)
Timeframe: 21 days after the infusion
| Intervention | mU/mL (Mean) |
|---|---|
| Single Arm - Pegloticase | 4.9 |
(NCT00111657)
Timeframe: Baseline to Day 105
| Intervention | Participants (Number) |
|---|---|
| Single Arm | 17 |
Count of tenderness and swelling of 68 joints (NCT00111657)
Timeframe: Basline and day 134
| Intervention | joints (Median) | |||
|---|---|---|---|---|
| Number of Tender joints at baseline | Number of Tender joints at day 134 | Number of Swollen jonts at baseline | Number of Swollen jonts at day 134 | |
| Pegloticase | 13 | 2 | 9 | 6 |
Acute kidney injury will be defined as an increase in serum creatinine of 0.3mg/dL from baseline or a 50% increase in serum creatinine from baseline values within 48 hours after surgery. (NCT00756964)
Timeframe: Within 48 hours postoperatively
| Intervention | Participants (Number) |
|---|---|
| Rasburicase Group | 13 |
| Placebo Group | 13 |
"The Diastolic BP was taken at Baseline and after 8-10 weeks of treatment or placebo while on chlorthalidone and potassium chloride. The blood pressure was measured according to Shared Care protocol: 15 minutes of quiet, undisturbed rest with three BP measurements obtained subsequently at 5 minute intervals.~The mean of the second and third reading was the value used for analysis for both the Baseline measurement and the measurement after 8 - 10 weeks of treatment. The dependent variable is baseline value minus ending value.~Measures are in millimeters of mercury (mm hg)" (NCT00241839)
Timeframe: Measured at 8-10 weeks on allopurinol / placebo
| Intervention | mm Hg (Mean) |
|---|---|
| A (Allopurinol) | 3.44 |
| B (Placebo) | -0.83 |
Subjects had 24 hr blood pressure monitoring (ABPM) at baseline and treatment end. The readings were averaged and the changes from baseline to treatment end were compared. (NCT00241839)
Timeframe: Baseline and end of treatment (8-10 weeks on allopurinol / placebo)
| Intervention | mm Hg (Mean) |
|---|---|
| A (Allopurinol) | -5.9 |
| B (Placebo) | 0.90 |
"The systolic BP was taken at Baseline and after 8-10 weeks of treatment on placebo, while on chlorthalidone and potassium chloride. The blood pressure was measured according to Shared Care protocol: 15 minutes of quiet, undisturbed rest with three BP measurements obtained subsequently at 5 minute intervals.~The mean of the second and third reading was the value used for analysis for both the Baseline measurement and the measurement after 8 - 10 weeks of treatment. The dependent variable is baseline value minus ending value.~Measures are in millimeters of mercury (mm hg)" (NCT00241839)
Timeframe: Measured at 8-10 weeks on allopurinol or placebo
| Intervention | mm Hg (Mean) |
|---|---|
| A (Allopurinol) | 0.21 |
| B (Placebo) | -0.95 |
Subjects on allopurinol are expected to lower their uric acid levels relative to placebo. (NCT00241839)
Timeframe: Baseline UA levels compared to end of treatment levels (8-10 weeks on allopurinol / placebo)
| Intervention | mg/dl (Mean) |
|---|---|
| A (Allopurinol) | 2.29 |
| B (Placebo) | 0.14 |
Overall liking of apple crisp with a 9-point hedonic rating scale instrument (whereby 0 = dislike extremely and 9 = like extremely ) (NCT03139552)
Timeframe: Day of taste testing
| Intervention | score on likert rating scale (Mean) |
|---|---|
| Full Sugar Recipe | 7.31 |
| Reduced Sugar Recipe | 6.83 |
| Reduced Sugar Plus Spice Recipe | 7.22 |
Overall liking of oatmeal with a 9-point hedonic rating scale instrument (whereby 0 = dislike extremely and 9 = like extremely ) (NCT03139552)
Timeframe: day of taste testing
| Intervention | score on a likert rating scale (Mean) |
|---|---|
| Full Sugar Recipe | 6.84 |
| Reduced Sugar Recipe | 5.70 |
| Reduced Sugar Plus Spice Recipe | 6.15 |
Overall liking of tea with a 9-point hedonic rating scale instrument (whereby 0 = dislike extremely and 9 = like extremely ) (NCT03139552)
Timeframe: day of taste testing
| Intervention | score on a likert rating scale (Mean) |
|---|---|
| Full Sugar Recipe | 6.00 |
| Reduced Sugar Recipe | 5.62 |
| Reduced Sugar Plus Spice Recipe | 5.85 |
Subjects ranked each recipe in order of likability as first, second or third. (NCT03139552)
Timeframe: day of taste testing
| Intervention | Participants (Count of Participants) |
|---|---|
| First Place Ranking | 54 |
| Second Place Ranking | 63 |
| Third Place Ranking | 33 |
Subjects ranked each recipe in order of likability as first, second or third. (NCT03139552)
Timeframe: day of taste testing
| Intervention | Participants (Count of Participants) |
|---|---|
| First Place Ranking | 88 |
| Second Place Ranking | 39 |
| Third Place Ranking | 21 |
Subjects ranked each recipe in order of likability as first, second or third. (NCT03139552)
Timeframe: day of taste testing
| Intervention | Participants (Count of Participants) |
|---|---|
| First Place Ranking | 66 |
| Second Place Ranking | 41 |
| Third Place Ranking | 42 |
Subjects ranked each recipe in order of likability as first, second or third. (NCT03139552)
Timeframe: day of taste testing
| Intervention | Participants (Count of Participants) |
|---|---|
| First Place Ranking | 48 |
| Second Place Ranking | 60 |
| Third Place Ranking | 40 |
Subjects ranked each recipe in order of likability as first, second or third. (NCT03139552)
Timeframe: day of taste testing
| Intervention | Participants (Count of Participants) |
|---|---|
| First Place Ranking | 63 |
| Second Place Ranking | 44 |
| Third Place Ranking | 43 |
Subjects ranked each recipe in order of likability as first, second or third. (NCT03139552)
Timeframe: day of taste testing
| Intervention | Participants (Count of Participants) |
|---|---|
| First Place Ranking | 49 |
| Second Place Ranking | 50 |
| Third Place Ranking | 50 |
Subjects ranked each recipe in order of likability as first, second or third. (NCT03139552)
Timeframe: day of taste testing
| Intervention | Participants (Count of Participants) |
|---|---|
| First Place Ranking | 33 |
| Second Place Ranking | 43 |
| Third Place Ranking | 74 |
Subjects ranked each recipe in order of likability as first, second or third. (NCT03139552)
Timeframe: day of taste testing
| Intervention | Participants (Count of Participants) |
|---|---|
| First Place Ranking | 12 |
| Second Place Ranking | 49 |
| Third Place Ranking | 87 |
Subjects ranked each recipe in order of likability as first, second or third. (NCT03139552)
Timeframe: Day of taste testings
| Intervention | Participants (Count of Participants) |
|---|---|
| First Place Ranking | 34 |
| Second Place Ranking | 58 |
| Third Place Ranking | 57 |
550 reviews available for uric acid and Hyperuricemia
| Article | Year |
|---|---|
The major cardiovascular events of febuxostat versus allopurinol in treating gout or asymptomatic hyperuricemia: a systematic review and meta-analysis.
Topics: Allopurinol; Cardiovascular Diseases; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Tr | 2021 |
A historical journey of searching for uricosuric drugs.
Topics: Aged; Gout; Humans; Hyperuricemia; Pharmaceutical Preparations; Uric Acid; Uricosuric Agents | 2022 |
Prevention of kidney function decline using uric acid-lowering therapy in chronic kidney disease patients: a systematic review and network meta-analysis.
Topics: Febuxostat; Gout Suppressants; Humans; Hyperuricemia; Kidney; Network Meta-Analysis; Renal Dialysis; | 2022 |
Urate transport in health and disease.
Topics: Gout; Humans; Hyperuricemia; Organic Cation Transport Proteins; Uric Acid | 2021 |
The double faced role of xanthine oxidoreductase in cancer.
Topics: Humans; Hyperuricemia; Neoplasms; Reactive Oxygen Species; Uric Acid; Xanthine Dehydrogenase | 2022 |
Uric Acid in Inflammation and the Pathogenesis of Atherosclerosis.
Topics: Animals; Atherosclerosis; Comorbidity; Diabetes Mellitus, Type 2; Gout; Humans; Hypertension; Hyperu | 2021 |
Hyperuricemia and the Risk of Heart Failure: Pathophysiology and Therapeutic Implications.
Topics: Heart Failure; Humans; Hyperuricemia; Oxidative Stress; Reactive Oxygen Species; Risk Factors; Uric | 2021 |
Excess comorbidities in gout: the causal paradigm and pleiotropic approaches to care.
Topics: Adult; Comorbidity; Diabetes Mellitus, Type 2; Gout; Gout Suppressants; Humans; Hyperuricemia; Uric | 2022 |
Update of the current role of ultrasound in asymptomatic hyperuricemia. A systematic literature review.
Topics: Arthritis, Gouty; Gout; Humans; Hyperuricemia; Ultrasonography; Uric Acid | 2022 |
Hyperuricemia, Gout, and the Brain-an Update.
Topics: Brain; Gout; Gout Suppressants; Humans; Hyperuricemia; Uric Acid | 2021 |
[Research progress on anti-hyperuricemia effects and mechanisms of Chinese medicines based on regulation of intestinal flora and metabolites].
Topics: Arthritis, Gouty; China; Gastrointestinal Microbiome; Humans; Hyperuricemia; Uric Acid | 2021 |
Relationship between hyperuricemia with deposition and sexual dysfunction in males and females.
Topics: Aged; Comorbidity; Correlation of Data; Female; Humans; Hyperuricemia; Male; Middle Aged; Risk Facto | 2022 |
Impact of hyperuricemia on chronic kidney disease and atherosclerotic cardiovascular disease.
Topics: Atherosclerosis; Cardiovascular Diseases; Female; Humans; Hyperuricemia; Male; Renal Insufficiency, | 2022 |
The Role of Advanced Imaging in Gout Management.
Topics: Biomarkers; Diagnostic Imaging; Disease Management; Disease Susceptibility; Gout; Humans; Hyperurice | 2021 |
Hyperuricaemia is an important risk factor of the erectile dysfunction: A systematic review and meta-analysis.
Topics: Cross-Sectional Studies; Erectile Dysfunction; Humans; Hyperuricemia; Male; Risk Factors; Uric Acid | 2022 |
Is hyperuricemia an independent prognostic factor for IgA nephropathy: a systematic review and meta-analysis of observational cohort studies.
Topics: Cohort Studies; Glomerulonephritis, IGA; Humans; Hyperuricemia; Observational Studies as Topic; Prog | 2022 |
Gout. What's up doc?
Topics: Gout; Gout Suppressants; Humans; Hyperuricemia; Kidney; Spain; Uric Acid | 2022 |
U-shaped association of uric acid to overall-cause mortality and its impact on clinical management of hyperuricemia.
Topics: Diabetes Mellitus, Type 2; Enzyme Inhibitors; Humans; Hydrogen Peroxide; Hyperuricemia; Uric Acid | 2022 |
The chemistry, processing, and preclinical anti-hyperuricemia potential of tea: a comprehensive review.
Topics: Gout; Humans; Hyperuricemia; Polyphenols; Tea; Uric Acid | 2023 |
The Role of the Intestine in the Development of Hyperuricemia.
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; Gout; Humans; Hyperuricemia; Intestines; Ne | 2022 |
Uric Acid and Oxidative Stress-Relationship with Cardiovascular, Metabolic, and Renal Impairment.
Topics: Humans; Hyperuricemia; Oxidative Stress; Quality of Life; Renal Insufficiency, Chronic; Uric Acid | 2022 |
Early life exposure to the Chinese Famine of 1959 - 1961 is an independent risk factor of adulthood elevated homocysteine, hyperuricemia, high LDL, and hypertension.
Topics: Adult; Cardiovascular Diseases; Child; Child, Preschool; China; Cross-Sectional Studies; Famine; Fem | 2022 |
Research progress on related mechanisms of uric acid activating NLRP3 inflammasome in chronic kidney disease.
Topics: Humans; Hyperuricemia; Inflammasomes; Interleukin-1beta; NLR Family, Pyrin Domain-Containing 3 Prote | 2022 |
Does seasonality of the microbiota contribute to the seasonality of acute gout flare?
Topics: Arthritis, Gouty; Gout; Gout Suppressants; Humans; Hyperuricemia; Microbiota; Symptom Flare Up; Uric | 2022 |
Management and Cure of Gouty Arthritis.
Topics: Arthritis, Gouty; Gout; Gout Suppressants; Humans; Hyperuricemia; Uric Acid | 2022 |
Uric acid in metabolic syndrome: Does uric acid have a definitive role?
Topics: Cardiovascular Diseases; Gout; Humans; Hyperuricemia; Metabolic Syndrome; Uric Acid | 2022 |
Emerging strategies for treating gout.
Topics: Colchicine; Gout; Gout Suppressants; Humans; Hyperuricemia; Uric Acid | 2022 |
Efficacy of Urate-Lowering Therapy in Patients With Chronic Kidney Disease: A Network Meta-Analysis of Randomized Controlled Trials.
Topics: Allopurinol; Bayes Theorem; Febuxostat; Gout Suppressants; Humans; Hyperuricemia; Network Meta-Analy | 2022 |
Uric Acid and Hypertension: a Review of Evidence and Future Perspectives for the Management of Cardiovascular Risk.
Topics: Adolescent; Animals; Cardiovascular Diseases; Heart Disease Risk Factors; Humans; Hypertension; Hype | 2022 |
An integrated study of Shenling Baizhu San against hyperuricemia: Efficacy evaluation, core target identification and active component discovery.
Topics: Animals; Drugs, Chinese Herbal; Hyperuricemia; Luteolin; Molecular Docking Simulation; PPAR gamma; R | 2022 |
Prevalence and related factors of hyperuricaemia in Chinese children and adolescents: a pooled analysis of 11 population-based studies.
Topics: Adolescent; Child; China; Cross-Sectional Studies; Female; Humans; Hyperuricemia; Male; Obesity; Pre | 2022 |
Erosive Tophaceous Gouty Arthropathy of the Hand: A Case Report.
Topics: Arthritis, Gouty; Gout; Humans; Hyperuricemia; Skin Abnormalities; Uric Acid | 2022 |
Lowering and Raising Serum Urate Levels: Off-Label Effects of Commonly Used Medications.
Topics: Aspirin; Gout; Humans; Hyperuricemia; Off-Label Use; Uric Acid | 2022 |
Current state and prospects of gout treatment in Korea.
Topics: Gout; Gout Suppressants; Humans; Hyperuricemia; Republic of Korea; Uric Acid | 2022 |
Effects of allopurinol on renal function in patients with diabetes: a systematic review and meta-analysis.
Topics: Allopurinol; Diabetes Mellitus; Gout; Gout Suppressants; Humans; Hyperuricemia; Kidney; Uric Acid | 2022 |
Excess Uric Acid Induces Gouty Nephropathy Through Crystal Formation: A Review of Recent Insights.
Topics: Endothelial Cells; Gout; Humans; Hyperuricemia; Inflammation; Renal Insufficiency, Chronic; Uric Aci | 2022 |
Susceptibility genes of hyperuricemia and gout.
Topics: Gout; Humans; Hyperuricemia; Mutation; Risk Factors; Uric Acid | 2022 |
Chronic kidney disease: Which role for xanthine oxidoreductase activity and products?
Topics: Atherosclerosis; Diabetes Mellitus, Type 2; Humans; Hypertension; Hyperuricemia; Purines; Reactive O | 2022 |
Comparative efficacy and safety of uricosuric agents in the treatment of gout or hyperuricemia: a systematic review and network meta-analysis.
Topics: Gout; Gout Suppressants; Humans; Hyperuricemia; Network Meta-Analysis; Probenecid; Randomized Contro | 2023 |
Moving the Needle in Gout Management: The Role of Culture, Diet, Genetics, and Personalized Patient Care Practices.
Topics: Aged; Diet; Gout; Gout Suppressants; Humans; Hyperuricemia; Patient Care; Reproducibility of Results | 2022 |
Safety and efficacy of probiotic supplementation in 8 types of inflammatory arthritis: A systematic review and meta-analysis of 34 randomized controlled trials.
Topics: Arthritis, Rheumatoid; Bone Diseases, Metabolic; Chronic Disease; Dietary Supplements; Gout; Humans; | 2022 |
Novel Insights into the Effects of Genetic Variants on Serum Urate Response to an Acute Fructose Challenge: A Pilot Study.
Topics: Adult; Fructose; Gout; Humans; Hyperuricemia; Male; Middle Aged; Pilot Projects; Risk Factors; Uric | 2022 |
Research Progress of Natural Active Substances with Uric-Acid-Reducing Activity.
Topics: Allopurinol; Febuxostat; Humans; Hyperuricemia; Kidney; Uric Acid; Xanthine Oxidase | 2022 |
Research Progress of Natural Active Substances with Uric-Acid-Reducing Activity.
Topics: Allopurinol; Febuxostat; Humans; Hyperuricemia; Kidney; Uric Acid; Xanthine Oxidase | 2022 |
Research Progress of Natural Active Substances with Uric-Acid-Reducing Activity.
Topics: Allopurinol; Febuxostat; Humans; Hyperuricemia; Kidney; Uric Acid; Xanthine Oxidase | 2022 |
Research Progress of Natural Active Substances with Uric-Acid-Reducing Activity.
Topics: Allopurinol; Febuxostat; Humans; Hyperuricemia; Kidney; Uric Acid; Xanthine Oxidase | 2022 |
[The role of hyperuricemia in the development of cognitive changes in the elderly.]
Topics: Aged; Alzheimer Disease; Cognition; Cognitive Dysfunction; Dementia; Dementia, Vascular; Humans; Hyp | 2022 |
Novel urate transporter 1 (URAT1) inhibitors: a review of recent patent literature (2020-present).
Topics: Gout; Humans; Hyperuricemia; Organic Anion Transporters; Organic Cation Transport Proteins; Patents | 2022 |
The biomarkers discovery of hyperuricemia and gout: proteomics and metabolomics.
Topics: Biomarkers; Gout; Humans; Hyperuricemia; Proteomics; Uric Acid | 2023 |
Mechanistic insights of soluble uric acid-induced insulin resistance: Insulin signaling and beyond.
Topics: Endothelial Cells; Humans; Hyperuricemia; Insulin; Insulin Resistance; Uric Acid | 2023 |
Association of hyperuricemia with cardiovascular diseases: current evidence.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Humans; Hypertension; Hyperuricemia; Mal | 2023 |
Are serum uric acid levels predictors of cardiovascular risk? An update.
Topics: Cardiovascular Diseases; Heart Disease Risk Factors; Humans; Hyperuricemia; Risk Factors; Uric Acid | 2023 |
High-Fructose Diet-Induced Hyperuricemia Accompanying Metabolic Syndrome-Mechanisms and Dietary Therapy Proposals.
Topics: Diet; Fructose; Humans; Hyperuricemia; Metabolic Syndrome; Uric Acid | 2023 |
Association between periodontitis and uric acid levels in blood and oral fluids: a systematic review and meta-analysis.
Topics: Gingival Crevicular Fluid; Humans; Hyperuricemia; Periodontitis; Saliva; Uric Acid | 2023 |
Mechanisms of theaflavins against gout and strategies for improving the bioavailability.
Topics: Animals; Biological Availability; Gout; Gout Suppressants; Humans; Hyperuricemia; Uric Acid | 2023 |
Advances in pharmacotherapies for hyperuricemia.
Topics: Enzyme Inhibitors; Gout Suppressants; Heart Failure; Humans; Hyperuricemia; Kidney; Uric Acid | 2023 |
The Hong Kong Society of Rheumatology consensus recommendations for the management of gout.
Topics: Consensus; Gout; Gout Suppressants; Hong Kong; Humans; Hyperuricemia; Rheumatology; Uric Acid | 2023 |
Update in uric acid, hypertension, and cardiovascular diseases.
Topics: Cardiovascular Diseases; Humans; Hypertension; Hyperuricemia; Kidney Diseases; Prospective Studies; | 2023 |
[Hyperuricemia and kidney damage in patients with cardiovascular disease: A review].
Topics: Allopurinol; Cardiovascular Diseases; Febuxostat; Gout Suppressants; Humans; Hyperuricemia; Kidney; | 2023 |
Management of Gout in the Hand and Wrist.
Topics: Adult; Gout; Humans; Hyperuricemia; Upper Extremity; Uric Acid; Wrist | 2023 |
Hyperuricemia: A key contributor to endothelial dysfunction in cardiovascular diseases.
Topics: Antioxidants; Cardiovascular Diseases; Humans; Hypertension; Hyperuricemia; Uric Acid | 2023 |
Serum uric acid levels in kidney transplant recipients: A cause for concern? A review of recent literature.
Topics: Humans; Hyperuricemia; Kidney Transplantation; Renal Insufficiency, Chronic; Risk Factors; Uric Acid | 2023 |
Possible correlated signaling pathways with chronic urate nephropathy: A review.
Topics: Humans; Hyperuricemia; Kidney Calculi; Quality of Life; Signal Transduction; Uric Acid | 2023 |
[Effect of High-Concentration Uric Acid on Nitric Oxide].
Topics: Biological Availability; Cytokines; Humans; Hyperuricemia; Nitric Oxide; Uric Acid | 2023 |
Mechanisms and rationale for uricase use in patients with gout.
Topics: Allopurinol; Gout; Gout Suppressants; Humans; Hyperuricemia; Quality of Life; Urate Oxidase; Uric Ac | 2023 |
Gout therapeutics and drug delivery.
Topics: Drug Delivery Systems; Gout; Humans; Hyperuricemia; Quality of Life; Uric Acid | 2023 |
Uric acid and left ventricular hypertrophy: a gender-based meta-analysis of echocardiographic studies.
Topics: Echocardiography; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Hyperuricemia; Male; | 2024 |
The Results of the URRAH (Uric Acid Right for Heart Health) Project: A Focus on Hyperuricemia in Relation to Cardiovascular and Kidney Disease and its Role in Metabolic Dysregulation.
Topics: Acute Coronary Syndrome; Humans; Hyperuricemia; Kidney Diseases; Metabolic Syndrome; Risk Factors; U | 2023 |
Emerging Urate-Lowering Drugs and Pharmacologic Treatment Strategies for Gout: A Narrative Review.
Topics: Diabetes Mellitus, Type 2; Gout; Gout Suppressants; Humans; Hyperuricemia; Symptom Flare Up; Uric Ac | 2023 |
Uric acid en route to gout.
Topics: Gout; Humans; Hyperuricemia; Symptom Flare Up; Uric Acid | 2023 |
Exploring the Multifaceted Nexus of Uric Acid and Health: A Review of Recent Studies on Diverse Diseases.
Topics: Diet; Gout; Humans; Hyperuricemia; Metabolic Syndrome; Uric Acid | 2023 |
Agents for the Treatment of Gout: Current Advances and Future Perspectives.
Topics: Gout; Gout Suppressants; Humans; Hyperuricemia; Uric Acid; Xanthine Oxidase | 2023 |
Insights into the relationship between serum uric acid and pulmonary hypertension (Review).
Topics: Cardiovascular Diseases; Humans; Hypertension; Hypertension, Pulmonary; Hyperuricemia; Risk Factors; | 2024 |
The dysregulation of immune cells induced by uric acid: mechanisms of inflammation associated with hyperuricemia and its complications.
Topics: Arthritis, Gouty; Gout; Humans; Hyperuricemia; Inflammation; Uric Acid | 2023 |
Dietary Antioxidant Supplements and Uric Acid in Chronic Kidney Disease: A Review.
Topics: Antioxidants; Biomarkers; Dietary Supplements; Humans; Hyperuricemia; Kidney; Oxidative Stress; Rena | 2019 |
Diagnosis and treatment for hyperuricemia and gout: a systematic review of clinical practice guidelines and consensus statements.
Topics: Consensus; Gout; Gout Suppressants; Humans; Hyperuricemia; Practice Guidelines as Topic; Uric Acid | 2019 |
The Paradoxical Role of Uric Acid in Osteoporosis.
Topics: Animals; Biomarkers; Bone and Bones; Bone Remodeling; Humans; Hyperparathyroidism, Secondary; Hyperu | 2019 |
The association between hyperuricemia and coronary artery calcification development: A systematic review and meta-analysis.
Topics: Biomarkers; Coronary Artery Disease; Coronary Vessels; Disease Progression; Global Health; Humans; H | 2019 |
Novel urate transporter 1 (URAT1) inhibitors: a review of recent patent literature (2016-2019).
Topics: Animals; Drug Development; Humans; Hyperuricemia; Organic Anion Transporters; Organic Cation Transpo | 2019 |
Serum uric acid and risk of cardiovascular mortality: a systematic review and dose-response meta-analysis of cohort studies of over a million participants.
Topics: Biomarkers; Cardiovascular Diseases; Cause of Death; Female; Humans; Hyperuricemia; Male; Middle Age | 2019 |
Asymptomatic hyperuricemia: is it really asymptomatic?
Topics: Disease Progression; Gout Suppressants; Humans; Hyperuricemia; Severity of Illness Index; United Sta | 2020 |
The association of serum uric acid levels in psoriasis patients: A systematic review and network meta-analysis.
Topics: Age Factors; Ethnicity; Humans; Hyperuricemia; Incidence; Network Meta-Analysis; Observational Studi | 2019 |
Primary hyperparathyroidism is associated with a higher level of serum uric acid: A systematic review and meta-analysis.
Topics: Biomarkers; Humans; Hyperparathyroidism, Primary; Hyperuricemia; Risk Factors; Uric Acid | 2020 |
Hyperuricemia: a novel old disorder-relationship and potential mechanisms in heart failure.
Topics: Angiotensin II Type 1 Receptor Blockers; Cardiovascular Diseases; Disease Progression; Gout; Gout Su | 2020 |
Dotinurad: a novel selective urate reabsorption inhibitor as a future therapeutic option for hyperuricemia.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Benzbromarone; Benzothiazoles; Drug Interactions; Febuxosta | 2020 |
A novel mutation in gene of PRPS1 in a young Chinese woman with X-linked gout: a case report and review of the literature.
Topics: Asian People; Female; Genes, X-Linked; Gout; Humans; Hyperuricemia; Mutation, Missense; Purine-Pyrim | 2020 |
Dietary Interventions for Gout and Effect on Cardiovascular Risk Factors: A Systematic Review.
Topics: Adult; Aged; Blood Glucose; Blood Pressure; Body Weight; Cardiovascular Diseases; Dietary Supplement | 2019 |
Asymptomatic hyperuricaemia: a silent activator of the innate immune system.
Topics: Asymptomatic Diseases; Biomarkers; Cytokines; Humans; Hyperuricemia; Immunity, Innate; Uric Acid | 2020 |
Uric Acid in Metabolic and Cerebrovascular Disorders: A Review.
Topics: Animals; Biomarkers; Blood Glucose; Cardiometabolic Risk Factors; Cerebrovascular Disorders; Diabete | 2020 |
Urate-induced immune programming: Consequences for gouty arthritis and hyperuricemia.
Topics: Animals; Arthritis, Gouty; Cellular Reprogramming; Epigenesis, Genetic; Humans; Hyperuricemia; Immun | 2020 |
Comorbidities in gout and hyperuricemia: causality or epiphenomena?
Topics: Cardiovascular Diseases; Comorbidity; Gout; Humans; Hyperuricemia; Prevalence; Renal Insufficiency, | 2020 |
Uric acid in CKD: has the jury come to the verdict?
Topics: Disease Progression; Humans; Hyperuricemia; Randomized Controlled Trials as Topic; Renal Insufficien | 2020 |
Management of hyperuricemia in asymptomatic patients: A critical appraisal.
Topics: Allopurinol; Gout; Gout Suppressants; Humans; Hyperuricemia; Uric Acid | 2020 |
Evaluation of urate-lowering therapy in hyperuricemia patients: a systematic review and Bayesian network meta-analysis of randomized controlled trials.
Topics: Bayes Theorem; Gout; Gout Suppressants; Humans; Hyperuricemia; Network Meta-Analysis; Quality of Lif | 2020 |
Efficacy and safety of febuxostat for treatment of asymptomatic hyperuricemia among kidney transplant patients: A meta-analysis of observational studies.
Topics: Febuxostat; Gout Suppressants; Humans; Hyperuricemia; Kidney Transplantation; Observational Studies | 2020 |
At the crossroads of gout and psoriatic arthritis: "psout".
Topics: Arthritis, Psoriatic; Comorbidity; Gout; Humans; Hyperuricemia; Risk Factors; Uric Acid | 2020 |
Cardiovascular events in hyperuricemia population and a cardiovascular benefit-risk assessment of urate-lowering therapies: a systematic review and meta-analysis.
Topics: Allopurinol; Cardiovascular Diseases; Febuxostat; Humans; Hyperuricemia; Risk Assessment; Uric Acid | 2020 |
Association between uric acid and pulse wave velocity in hypertensive patients and in the general population: a systematic review and meta-analysis.
Topics: Adult; Aged; Aged, 80 and over; Ankle Brachial Index; Arterial Pressure; Biomarkers; Carotid-Femoral | 2020 |
Hyperuricemia and Risk of Cardiovascular Outcomes: The Experience of the URRAH (Uric Acid Right for Heart Health) Project.
Topics: Adult; Aged; Biomarkers; Cardiovascular Diseases; Female; Humans; Hyperuricemia; Italy; Male; Middle | 2020 |
Association between serum uric acid levels and dyslipidemia in Chinese adults: A cross-sectional study and further meta-analysis.
Topics: Age Factors; China; Cross-Sectional Studies; Dyslipidemias; Female; Humans; Hyperuricemia; Male; Mid | 2020 |
[Gout].
Topics: Chronic Disease; Diagnosis, Differential; Gout; Humans; Hyperuricemia; Prevalence; Risk Factors; Uri | 2020 |
Uric acid and inflammation in kidney disease.
Topics: Animals; Biomarkers; Humans; Hyperuricemia; Kidney; Nephritis; Risk Assessment; Risk Factors; Signal | 2020 |
Recent approaches to gout drug discovery: an update.
Topics: Allopurinol; Arthritis, Gouty; Drug Discovery; Gout; Gout Suppressants; Humans; Hyperuricemia; Uric | 2020 |
Determining the role for uric acid in non-alcoholic steatohepatitis development and the utility of urate metabolites in diagnosis: An opinion review.
Topics: Biomarkers; Humans; Hyperuricemia; Liver; Non-alcoholic Fatty Liver Disease; Uric Acid | 2020 |
Efficacy and safety of urate-lowering treatments in patients with hyperuricemia: A comprehensive network meta-analysis of randomized controlled trials.
Topics: Allopurinol; Bayes Theorem; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Network Meta | 2020 |
Comparative effect of allopurinol and febuxostat on long-term renal outcomes in patients with hyperuricemia and chronic kidney disease: a systematic review.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chroni | 2020 |
The role of uric acid in inflammasome-mediated kidney injury.
Topics: Animals; Humans; Hyperuricemia; Inflammasomes; NLR Family, Pyrin Domain-Containing 3 Protein; Renal | 2020 |
Polygenic analysis of the effect of common and low-frequency genetic variants on serum uric acid levels in Korean individuals.
Topics: Adult; Aldehyde Dehydrogenase, Mitochondrial; Asian People; Chromosomes, Human, Pair 12; Female; Gen | 2020 |
Uric Acid Elevation by Favipiravir, an Antiviral Drug.
Topics: Aldehyde Oxidase; Amides; Antiviral Agents; Biotransformation; Coronavirus Infections; COVID-19; Dru | 2020 |
Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors.
Topics: Adult; Aged; Case-Control Studies; Comorbidity; Ethnicity; Female; Gout; Gout Suppressants; Humans; | 2020 |
Sex Differences in Urate Handling.
Topics: Female; Genetic Predisposition to Disease; Genome-Wide Association Study; Homeostasis; Humans; Hyper | 2020 |
The biology of urate.
Topics: Gout; Humans; Hyperuricemia; Kidney; Organic Anion Transporters; Uric Acid | 2020 |
Therapeutic approaches in the treatment of gout.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Mal | 2020 |
Hyperuricemia as a trigger of immune response in hypertension and chronic kidney disease.
Topics: Humans; Hypertension; Hyperuricemia; Immunity; Renal Insufficiency, Chronic; Uric Acid | 2020 |
Comparison of efficacy and safety of urate-lowering therapies for hyperuricemic patients with gout: a meta-analysis of randomized, controlled trials.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Treatment Outcome; Uric Aci | 2021 |
The Association of Febuxostat Compared With Allopurinol on Blood Pressure and Major Adverse Cardiac Events Among Adult Patients With Hyperuricemia: A Meta-analysis.
Topics: Aged; Allopurinol; Biomarkers; Blood Pressure; Febuxostat; Female; Gout Suppressants; Humans; Hypert | 2020 |
Hyperuricaemia and gout in cardiovascular, metabolic and kidney disease.
Topics: Diabetes Mellitus, Type 2; Gout; Humans; Hyperuricemia; Metabolic Syndrome; Uric Acid | 2020 |
Xanthine oxidase inhibitors: patent landscape and clinical development (2015-2020).
Topics: Animals; Drug Development; Enzyme Inhibitors; Gout; Humans; Hyperuricemia; Patents as Topic; Reactiv | 2020 |
Renal effects of uric acid: hyperuricemia and hypouricemia.
Topics: Adolescent; Adult; Biomarkers; Child; Disease Progression; Female; Humans; Hyperuricemia; Kidney; Re | 2020 |
Advances in our understanding of gout as an auto-inflammatory disease.
Topics: Comorbidity; Gout; Humans; Hyperuricemia; Inflammation; Uric Acid | 2020 |
Hyperuricemia, the heart, and the kidneys - to treat or not to treat?
Topics: Cardiovascular Diseases; Gout; Humans; Hyperuricemia; Kidney; Myocardium; Renal Insufficiency, Chron | 2020 |
Mechanistic insights into hyperuricemia-associated renal abnormalities with special emphasis on epithelial-to-mesenchymal transition: Pathologic implications and putative pharmacologic targets.
Topics: Animals; Biomarkers; Cytokines; Epithelial-Mesenchymal Transition; Febuxostat; Fibrosis; Gout Suppre | 2020 |
Role of asymptomatic hyperuricemia in the progression of chronic kidney disease and cardiovascular disease.
Topics: Cardiovascular Diseases; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chronic; Uri | 2021 |
Association Between Vitamin D and Uric Acid in Adults: A Systematic Review and Meta-Analysis.
Topics: Humans; Hyperuricemia; Uric Acid; Vitamin D; Vitamin D Deficiency; Vitamins | 2020 |
Effect of Urate-Lowering Therapy on Cardiovascular and Kidney Outcomes: A Systematic Review and Meta-Analysis.
Topics: Blood Pressure; Cardiovascular Diseases; Disease Progression; Glomerular Filtration Rate; Gout Suppr | 2020 |
Harnessing hyperuricemia to atherosclerosis and understanding its mechanistic dependence.
Topics: Atherosclerosis; Endothelial Cells; Humans; Hyperuricemia; Uric Acid; Xanthine Oxidase | 2021 |
The association between genetic polymorphisms in ABCG2 and SLC2A9 and urate: an updated systematic review and meta-analysis.
Topics: Alleles; Asian People; ATP Binding Cassette Transporter, Subfamily G, Member 2; Female; Gene Express | 2020 |
Network Meta-Analysis of Drug Therapies for Lowering Uric Acid and Mortality Risk in Patients with Heart Failure.
Topics: Allopurinol; Gout Suppressants; Heart Failure; Humans; Hyperuricemia; Network Meta-Analysis; Uric Ac | 2021 |
Recent advances in fructose intake and risk of hyperuricemia.
Topics: Animals; Diet; Fructose; Humans; Hyperuricemia; Risk; Uric Acid | 2020 |
Animal models of naturally occurring stone disease.
Topics: Animals; Biomedical Research; Calcium Oxalate; Cats; Cystine; Disease Models, Animal; Dogs; Dolphins | 2020 |
[Asymptomatic Hyperuricemia and Risk Of Cardiovascular and Renal Diseases].
Topics: Asymptomatic Diseases; Cardiovascular Diseases; Disease Progression; Humans; Hyperuricemia; Kidney D | 2020 |
Role of comorbidities in heart failure prognosis Part 2: Chronic kidney disease, elevated serum uric acid.
Topics: Biomarkers; Comorbidity; Heart Disease Risk Factors; Heart Failure; Humans; Hyperuricemia; Prognosis | 2020 |
Uric acid and cardiovascular disease: A clinical review.
Topics: Cardiovascular Diseases; Gout; Humans; Hypertension; Hyperuricemia; Risk Factors; Uric Acid | 2021 |
The roles of NLRP3 inflammasome-mediated signaling pathways in hyperuricemic nephropathy.
Topics: Acute Kidney Injury; Animals; Cytokines; Diabetic Nephropathies; Humans; Hyperuricemia; Inflammasome | 2021 |
Managing hyperuricemia and gout in chronic kidney disease: a clinical conundrum.
Topics: Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chronic; Uric Acid | 2021 |
The gut microbiota as a target to control hyperuricemia pathogenesis: Potential mechanisms and therapeutic strategies.
Topics: Gastrointestinal Microbiome; Humans; Hyperuricemia; Prebiotics; Probiotics; Uric Acid | 2022 |
Elevated serum uric acid and risk of cardiovascular or all-cause mortality in maintenance hemodialysis patients: A meta-analysis.
Topics: Adult; Aged; Biomarkers; Cause of Death; Female; Heart Disease Risk Factors; Humans; Hyperuricemia; | 2021 |
[Asymptomatic Hyperuricemia: Treatment Approaches According to the Risk of Cardiovascular and Renal Events].
Topics: Cardiovascular Diseases; Humans; Hyperuricemia; Kidney; Renal Insufficiency, Chronic; Uric Acid | 2021 |
Serum Uric Acid Levels, but Not rs7442295 Polymorphism of SCL2A9 Gene, Predict Mortality in Clinically Stable Coronary Artery Disease.
Topics: Coronary Artery Disease; Genome-Wide Association Study; Humans; Hyperuricemia; Polymorphism, Genetic | 2021 |
Non-invasive determination of uric acid in human saliva in the diagnosis of serious disorders.
Topics: Biomarkers; Gout; Humans; Hyperuricemia; Saliva; Uric Acid | 2021 |
Meta-analysis of the correlation between serum uric acid level and carotid intima-media thickness.
Topics: Carotid Arteries; Carotid Artery Diseases; Carotid Intima-Media Thickness; Carotid Stenosis; Humans; | 2021 |
Uric acid-induced pancreatic β-cell dysfunction.
Topics: Animals; Cell Death; Diabetes Mellitus, Type 2; Humans; Hyperuricemia; Insulin Secretion; Insulin-Se | 2021 |
Effectiveness of Allopurinol in Reducing Mortality: Time-Related Biases in Observational Studies.
Topics: Allopurinol; Bias; Cause of Death; Gout; Gout Suppressants; Humans; Hyperuricemia; Mortality; Observ | 2021 |
Uric acid metabolism in polycystic ovary syndrome.
Topics: Female; Humans; Hyperuricemia; Insulin Resistance; Metabolic Syndrome; Polycystic Ovary Syndrome; Ur | 2021 |
Pathophysiology of Gout.
Topics: Cytokines; Gout; Humans; Hyperuricemia; Uric Acid | 2020 |
Recent evidence on the effect of urate-lowering treatment on the progression of kidney disease.
Topics: Disease Progression; Febuxostat; Gout Suppressants; Humans; Hyperuricemia; Randomized Controlled Tri | 2021 |
Carotid intima-media thickness in patients with hyperuricemia: a systematic review and meta-analysis.
Topics: Blood Pressure; Cardiovascular Diseases; Carotid Intima-Media Thickness; Humans; Hyperuricemia; Uric | 2021 |
The role of alcohol consumption in pathogenesis of gout.
Topics: Alcohol Drinking; Alcoholic Beverages; Beer; Ethanol; Gout; Humans; Hyperuricemia; Symptom Flare Up; | 2022 |
Dotinurad: a novel selective urate reabsorption inhibitor for the treatment of hyperuricemia and gout.
Topics: Benzothiazoles; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Uric Acid; Uricosuric Ag | 2021 |
Uric acid as a cardiorenal mediator: pathogenesis and mechanistic insights.
Topics: Cardiovascular Diseases; Heart Failure; Humans; Hyperuricemia; Kidney Diseases; Uric Acid | 2021 |
An update of genetics, co-morbidities and management of hyperuricaemia.
Topics: Cardiovascular Diseases; Comorbidity; Genome-Wide Association Study; Gout; Humans; Hyperuricemia; Re | 2021 |
The association between urate-lowering therapies and treatment-related adverse events, liver damage, and major adverse cardiovascular events (MACE): A network meta-analysis of randomized trials.
Topics: Allopurinol; Cardiovascular Diseases; Chemical and Drug Induced Liver Injury; Febuxostat; Gout Suppr | 2021 |
The Impact of Uric Acid and Hyperuricemia on Cardiovascular and Renal Systems.
Topics: Gout; Humans; Hyperuricemia; Kidney; Radiopharmaceuticals; Uric Acid | 2021 |
Hyperuricemia-induced endothelial insulin resistance: the nitric oxide connection.
Topics: Animals; Endothelial Cells; Endothelium, Vascular; Humans; Hyperuricemia; Insulin Resistance; Nitric | 2022 |
Effect of orlistat on serum uric acid level in adults: A systematic review and meta-analysis of randomised controlled trials.
Topics: Adult; Gout; Humans; Hyperuricemia; Orlistat; Randomized Controlled Trials as Topic; Uric Acid; Weig | 2021 |
Relationship between serum uric acid levels and different types of atrial fibrillation: An updated meta-analysis.
Topics: Adult; Aged; Atrial Fibrillation; Biomarkers; Female; Heart Rate; Humans; Hyperuricemia; Incidence; | 2021 |
Uric acid lowering improves insulin sensitivity and lowers blood pressure: a meta-analysis of randomized parallel-controlled clinical trials.
Topics: Blood Glucose; Blood Pressure; China; Diabetes Mellitus, Type 2; Fasting; Female; Humans; Hyperurice | 2021 |
A review on the fruit components affecting uric acid level and their underlying mechanisms.
Topics: Dietary Fiber; Fructose; Fruit; Humans; Hyperuricemia; Uric Acid | 2021 |
Sex-Specific Relationship Between Serum Uric Acid and Risk of Stroke: A Dose-Response Meta-Analysis of Prospective Studies.
Topics: Female; Humans; Hyperuricemia; Male; Prospective Studies; Risk Factors; Sex Factors; Stroke; Uric Ac | 2017 |
Fructose Intake, Serum Uric Acid, and Cardiometabolic Disorders: A Critical Review.
Topics: Cardiovascular Diseases; Diet; Feeding Behavior; Female; Fructose; Humans; Hyperuricemia; Male; Meta | 2017 |
Lesinurad: A Review in Hyperuricaemia of Gout.
Topics: Adult; Allopurinol; Drug Therapy, Combination; Enzyme Inhibitors; Febuxostat; Gout; Humans; Hyperuri | 2017 |
Treatment Options for Gout.
Topics: Adult; Germany; Gout; Gout Suppressants; Humans; Hyperuricemia; Uric Acid | 2017 |
Value and Progress of Ultrasound in Diagnosis and Treatment of Hyperuricemia.
Topics: Arthritis, Gouty; Carotid Artery Diseases; Gout; Humans; Hyperuricemia; Kidney; Non-alcoholic Fatty | 2017 |
The genetics of gout: towards personalised medicine?
Topics: Allopurinol; Genome-Wide Association Study; Gout; Gout Suppressants; Humans; Hyperuricemia; Life Sty | 2017 |
Hyperuricemia is associated with nonalcoholic fatty liver disease activity score in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis.
Topics: Adult; Biomarkers; Biopsy; Chi-Square Distribution; Female; Humans; Hyperuricemia; Liver; Male; Midd | 2017 |
Can Serum Uric Acid Lowering Therapy Contribute to the Prevention or Treatment of Nonalcoholic Fatty Liver Disease?
Topics: Allopurinol; Atorvastatin; Biomarkers; Gout Suppressants; Humans; Hydroxymethylglutaryl-CoA Reductas | 2018 |
Change gout: the need for a new approach.
Topics: Biomarkers; Body Mass Index; Cardiovascular Diseases; Diet Therapy; Disease Progression; Evidence-Ba | 2017 |
Current and future therapies for gout.
Topics: Gout; Gout Suppressants; Humans; Hyperuricemia; Practice Guidelines as Topic; Uric Acid | 2017 |
Effects of Sodium Glucose Cotransporter-2 Inhibitors on Serum Uric Acid in Type 2 Diabetes Mellitus.
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hyperglycemia; Hyperuricemia; Hypoglyc | 2017 |
Effect of allopurinol and uric acid normalization on serum lipids hyperuricemic subjects: A systematic review with meta-analysis.
Topics: Allopurinol; Humans; Hyperuricemia; Lipids; Randomized Controlled Trials as Topic; Time Factors; Uri | 2017 |
Hyperuricemia, Type 2 Diabetes Mellitus, and Hypertension: an Emerging Association.
Topics: Diabetes Mellitus, Type 2; Humans; Hypertension; Hyperuricemia; Risk Factors; Uric Acid | 2017 |
Gout and Metabolic Syndrome: a Tangled Web.
Topics: Cardiovascular Diseases; Comorbidity; Diabetes Mellitus, Type 2; Fructose; Gout; Humans; Hyperlipide | 2017 |
Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: A meta-analysis of randomized controlled trials.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Glucosides; Humans; Hyperglycemia; H | 2018 |
The role of urate-lowering treatment on cardiovascular and renal disease: evidence from CARES, FAST, ALL-HEART, and FEATHER studies.
Topics: Cardiovascular Diseases; Gout; Gout Suppressants; Humans; Hypertension; Hyperuricemia; Kidney Diseas | 2017 |
Effects of serum uric acid on blood-pressure lowering treatment.
Topics: Blood Pressure; Cardiovascular Diseases; Gout Suppressants; Humans; Hypertension; Hyperuricemia; Ris | 2017 |
Role of Hyperhomocysteinemia and Hyperuricemia in Pathogenesis of Atherosclerosis.
Topics: Animals; Atherosclerosis; Biomarkers; Cell Proliferation; Endoplasmic Reticulum Stress; Endothelium, | 2017 |
Topics: Acute Disease; Alcohol Drinking; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Colchici | 2017 |
Potency on lowering serum uric acid in gout patients: a pooled analysis of registrative studies comparing febuxostat vs. allopurinol.
Topics: Adult; Allopurinol; Clinical Trials, Phase III as Topic; Enzyme Inhibitors; Febuxostat; Female; Gout | 2017 |
The Effect of Xanthine Oxidase Inhibitors on Blood Pressure and Renal Function.
Topics: Allopurinol; Blood Pressure; Enzyme Inhibitors; Febuxostat; Glomerular Filtration Rate; Gout Suppres | 2017 |
Uric acid lowering therapies for preventing or delaying the progression of chronic kidney disease.
Topics: Cardiovascular Diseases; Creatinine; Disease Progression; Glomerular Filtration Rate; Humans; Hyperu | 2017 |
[URATE AS A POTENTIAL RISK FACTOR OF CARDIOVASCULAR AND RENAL DISEASES].
Topics: Biomarkers; Cardiovascular Diseases; Gout Suppressants; Humans; Hypertension; Hyperuricemia; Renal I | 2016 |
The significance of uric acid in the diagnosis and treatment of Parkinson disease: An updated systemic review.
Topics: Age Factors; Biomarkers; Disease Progression; Humans; Hyperuricemia; Movement Disorders; Oxidative S | 2017 |
Crystalline arthropathy and bone health.
Topics: Bone and Bones; Bone Density; Chondrocalcinosis; Crystal Arthropathies; Fractures, Bone; Gout; Human | 2018 |
Uric acid and cardiovascular risk: What genes can say.
Topics: Biomarkers; Cardiovascular Diseases; Genetic Predisposition to Disease; Humans; Hyperuricemia; Mende | 2018 |
ABCG2 as a therapeutic target candidate for gout.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; Drug Design; Gout; Gout Suppressan | 2018 |
Management of gout and hyperuricemia: Multidisciplinary consensus in Taiwan.
Topics: Biomarkers; Comorbidity; Consensus; Down-Regulation; Gout; Gout Suppressants; Humans; Hyperuricemia; | 2018 |
Uric Acid: The Unknown Uremic Toxin.
Topics: Allopurinol; Febuxostat; Glomerular Filtration Rate; Gout Suppressants; Humans; Hypertension; Hyperu | 2018 |
Time to Target Uric Acid to Retard Chronic Kidney Disease Progression.
Topics: Allopurinol; Animals; Anion Transport Proteins; ATP Binding Cassette Transporter, Subfamily G, Membe | 2018 |
Uric Acid as a Cause of the Metabolic Syndrome.
Topics: AMP Deaminase; Animals; Diabetes Mellitus; Dietary Sugars; Fatty Liver; Fructose; Humans; Hypertensi | 2018 |
Uric Acid and Diabetic Nephropathy Risk.
Topics: Allopurinol; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Disease Progression; Glomerular Filt | 2018 |
An association of smoking with serum urate and gout: A health paradox.
Topics: Gout; Humans; Hyperuricemia; Risk; Smoking; Uric Acid | 2018 |
Gout: state of the art after a decade of developments.
Topics: Allopurinol; Colchicine; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Uric Acid; Xant | 2019 |
Topics: Cohort Studies; Humans; Hypertension; Hyperuricemia; Japan; Prehypertension; Uric Acid | 2018 |
Urate-Lowering Agents in Asymptomatic Hyperuricemia: Role of Urine Sediment Analysis and Musculoskeletal Ultrasound.
Topics: Antimetabolites; Humans; Hyperuricemia; Musculoskeletal System; Ultrasonography; Uric Acid; Urinalys | 2018 |
Investigational drugs for hyperuricemia, an update on recent developments.
Topics: Animals; Drug Design; Drugs, Investigational; Gout; Gout Suppressants; Humans; Hyperuricemia; Medica | 2018 |
The role of xanthine oxidoreductase and uric acid in metabolic syndrome.
Topics: Adipocytes; Adipogenesis; Animals; Cell Differentiation; Endothelium, Vascular; Humans; Hypertension | 2018 |
An update on the genetics of hyperuricaemia and gout.
Topics: Animals; Disease Progression; Genetic Predisposition to Disease; Genetic Variation; Genome-Wide Asso | 2018 |
Uric acid and progression of chronic kidney disease.
Topics: Age Factors; Allopurinol; Animals; Child; Diet Therapy; Disease Models, Animal; Disease Progression; | 2019 |
Gout and arrhythmias: In search for causation beyond association.
Topics: Ablation Techniques; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Biomarkers; Gout; Gout Suppressan | 2019 |
The physiology of uric acid and the impact of end-stage kidney disease and dialysis.
Topics: Female; Humans; Hyperuricemia; Kidney Failure, Chronic; Male; Peritoneal Dialysis; Prognosis; Renal | 2019 |
Serum uric acid concentrations and risk of intracerebral hemorrhage: A systematic review and meta-analysis.
Topics: Age Factors; Aged; Biomarkers; Cerebral Hemorrhage; Comorbidity; Female; Humans; Hyperuricemia; Male | 2018 |
Uric Acid and Cognitive Function in Older Individuals.
Topics: Aged; Alzheimer Disease; Cognition; Cognitive Dysfunction; Dementia; Dementia, Vascular; Disease Pro | 2018 |
Expert opinion on emerging urate-lowering therapies.
Topics: Anti-Inflammatory Agents; Drug Design; Gout; Gout Suppressants; Humans; Hyperuricemia; Uric Acid | 2018 |
Consumption of sugar sweetened beverages and dietary fructose in relation to risk of gout and hyperuricemia: a systematic review and meta-analysis.
Topics: Fructose; Gout; Humans; Hyperuricemia; Sugar-Sweetened Beverages; Uric Acid | 2020 |
Hyperuricemia and endothelial function: From molecular background to clinical perspectives.
Topics: Antioxidants; Atherosclerosis; Cardiovascular Diseases; Catalysis; Endothelium, Vascular; Humans; Hy | 2018 |
Effect of Uric Acid on Blood Glucose Levels.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Humans; Hyperuricemia; Insulin Resistance; Nitric Oxide; O | 2018 |
Association of hyperuricemia and pulmonary hypertension: A systematic review and meta-analysis.
Topics: Female; Humans; Hypertension, Pulmonary; Hyperuricemia; Male; Middle Aged; Odds Ratio; Prognosis; Ur | 2019 |
The effect of polymorphism of uric acid transporters on uric acid transport.
Topics: Animals; Biomarkers; Genetic Predisposition to Disease; Humans; Hyperuricemia; Kidney; Membrane Tran | 2019 |
Expert consensus for the diagnosis and treatment of patient with hyperuricemia and high cardiovascular risk.
Topics: Cardiovascular Diseases; Consensus; Global Health; Humans; Hyperuricemia; Morbidity; Risk Factors; U | 2018 |
Gout - An update of aetiology, genetics, co-morbidities and management.
Topics: Allopurinol; Chronic Disease; Comorbidity; Diet; Febuxostat; Gout; Gout Suppressants; Humans; Hyperu | 2018 |
Urate and osteoarthritis: Evidence for a reciprocal relationship.
Topics: Biomarkers; Global Health; Humans; Hyperuricemia; Osteoarthritis; Prevalence; Uric Acid | 2019 |
Predictive Value of Hepatorenal Status in Contrast-Induced Nephropathy Among Patients Receiving Coronary Angiography and/or Intervention: A Systematic Review and Meta-Analysis.
Topics: Biomarkers; Blood Urea Nitrogen; Contrast Media; Coronary Angiography; Glomerular Filtration Rate; H | 2019 |
Uric acid and hypertension: a focused review and practical recommendations.
Topics: Animals; Antioxidants; Blood Pressure; Enzyme Inhibitors; Humans; Hypertension; Hyperuricemia; Kidne | 2019 |
Prognostic value of serum uric acid in patients with acute heart failure: A meta-analysis.
Topics: Aged; Aged, 80 and over; Biomarkers; Female; Heart Failure; Humans; Hyperuricemia; Male; Middle Aged | 2019 |
Cardiovascular Disease in Gout and the Protective Effect of Treatments Including Urate-Lowering Therapy.
Topics: Allopurinol; Anti-Inflammatory Agents; Cardiovascular Diseases; Febuxostat; Female; Gout; Gout Suppr | 2019 |
Hyperuricemia and Cardiovascular Disease.
Topics: Cardiovascular Diseases; Gout; Humans; Hyperuricemia; Metabolic Syndrome; Uric Acid | 2019 |
The Role of Uric Acid in Acute Kidney Injury.
Topics: Acute Kidney Injury; Female; Humans; Hyperuricemia; Likelihood Functions; Uric Acid | 2019 |
The effects of fruit consumption in patients with hyperuricaemia or gout.
Topics: Ascorbic Acid; Dietary Fiber; Fructose; Fruit; Fruit and Vegetable Juices; Gout; Humans; Hyperuricem | 2019 |
Prevention of Cardiovascular Diseases in Children and Adolescents.
Topics: Adolescent; Age of Onset; Arterial Pressure; Biomarkers; Blood Glucose; Cardiovascular Diseases; Chi | 2019 |
Can hyperuricemia predict glycogen storage disease (McArdle's disease) in rheumatology practice? (Myogenic hyperuricemia).
Topics: Adult; Antirheumatic Agents; Arthritis; Arthritis, Gouty; Diagnosis, Differential; Diagnostic Errors | 2019 |
[Effect of single-herb traditional Chinese medicine for eliminating dampness on metabolism of uric acid].
Topics: Drugs, Chinese Herbal; Humans; Hyperuricemia; Medicine, Chinese Traditional; Uric Acid | 2019 |
Natural products for the management of hyperuricaemia and gout: a review.
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Gouty; Asteraceae; Biological Products; Double-Blind M | 2021 |
Mouse models for human hyperuricaemia: a critical review.
Topics: Animals; Disease Models, Animal; Gene Expression Regulation; Glucose Transport Proteins, Facilitativ | 2019 |
Uric acid: from a biological advantage to a potential danger. A focus on cardiovascular effects.
Topics: Animals; Biomarkers; Cardiovascular Diseases; Gout Suppressants; Humans; Hyperuricemia; Mutation; Ri | 2019 |
Genome-wide association study revealed novel loci which aggravate asymptomatic hyperuricaemia into gout.
Topics: Adult; Aldehyde Dehydrogenase, Mitochondrial; Asymptomatic Diseases; ATP Binding Cassette Transporte | 2019 |
Uric acid level, gout and bone mineral density: A Mendelian randomization study.
Topics: Bone Density; Causality; Femur Neck; Gout; Humans; Hyperuricemia; Lumbar Vertebrae; Mendelian Random | 2019 |
The case for uric acid-lowering treatment in patients with hyperuricaemia and CKD.
Topics: Humans; Hyperuricemia; Renal Insufficiency, Chronic; Uric Acid | 2019 |
Uric Acid and Plant-Based Nutrition.
Topics: Biomarkers; Diet, Healthy; Diet, Vegetarian; Gout; Humans; Hyperuricemia; Nutritive Value; Protectiv | 2019 |
The net clinical benefits of febuxostat versus allopurinol in patients with gout or asymptomatic hyperuricemia - A systematic review and meta-analysis.
Topics: Aged; Allopurinol; Asymptomatic Diseases; Biomarkers; Enzyme Inhibitors; Febuxostat; Female; Gout; G | 2019 |
Uric acid and the origins of hypertension.
Topics: Humans; Hypertension; Hyperuricemia; Risk Factors; Uric Acid | 2013 |
Efficacy and cost of single-dose rasburicase in prevention and treatment of adult tumour lysis syndrome: a meta-analysis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Female; Humans; Hyperuricemia; Middle Aged; | 2013 |
Uric acid metabolism in pre-hypertension and the metabolic syndrome.
Topics: Animals; Glucose Transport Proteins, Facilitative; Humans; Hyperuricemia; Metabolic Syndrome; Organi | 2014 |
[Hyperuricemia and cardiovascular continuum].
Topics: Cardiovascular Diseases; Heart Failure; Humans; Hyperuricemia; Uric Acid | 2013 |
[Diabetes mellitus related common medical disorders: recent progress in diagnosis and treatment. Topics: I. Pathophysiology, diagnosis and treatment; 8. Asymptomatic hyperuricemia].
Topics: Cardiovascular Diseases; Diabetes Mellitus; Humans; Hyperuricemia; Metabolic Syndrome; Renal Insuffi | 2013 |
Uric acid and the kidney.
Topics: Child; Humans; Hyperuricemia; Kidney; Kidney Diseases; Uric Acid | 2014 |
[Hyperuricemia and the problem of chronic kidney disease].
Topics: Humans; Hyperuricemia; Renal Insufficiency, Chronic; Uric Acid | 2013 |
Treatment of hyperuricaemia and gout.
Topics: Biological Products; Gout; Gout Suppressants; Humans; Hyperuricemia; Uric Acid | 2013 |
Uric acid and risk of heart failure: a systematic review and meta-analysis.
Topics: Global Health; Heart Failure; Humans; Hyperuricemia; Incidence; Prognosis; Risk Factors; Uric Acid | 2014 |
[Pathogenetic significance of hyperuricemia in the formation and development of pathological processes associated with metabolic syndrome].
Topics: Global Health; Humans; Hyperuricemia; Incidence; Metabolic Syndrome; Risk Factors; Uric Acid | 2013 |
Systematic review of the prevalence of gout and hyperuricaemia in Australia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Australia; Blood Donors; Child; Europe; Female; Gout; Hu | 2012 |
Sugar, uric acid, and the etiology of diabetes and obesity.
Topics: Animals; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dietary Sucrose; Disease Models, Animal | 2013 |
Uric acid, hypertension, and cardiovascular and renal complications.
Topics: Animals; Disease Models, Animal; Humans; Hypertension; Hyperuricemia; Kidney Diseases; Uric Acid; Va | 2013 |
Hyperuricemia as an independent predictor of vascular complications and mortality in type 2 diabetes patients: a meta-analysis.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Humans; Hyperuricemia; Male; | 2013 |
Association of the lipoprotein receptor-related protein 2 gene with gout and non-additive interaction with alcohol consumption.
Topics: Adaptor Proteins, Signal Transducing; Alcohol Drinking; Carrier Proteins; Female; Genetic Predisposi | 2013 |
A systematic review and meta-analysis on the safety and efficacy of febuxostat versus allopurinol in chronic gout.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Thiazoles; Treatment Outcom | 2013 |
The crystallization of monosodium urate.
Topics: Cartilage, Articular; Chemistry, Physical; Crystallization; Gout; Humans; Hyperuricemia; Immunity, H | 2014 |
Serum uric acid and the risk of hypertension and chronic kidney disease.
Topics: Animals; Biomarkers; Clinical Trials as Topic; Enzyme Inhibitors; Humans; Hypertension; Hyperuricemi | 2014 |
Definition of hyperuricemia and gouty conditions.
Topics: Cardiovascular Diseases; Crystallization; Female; Gout; Humans; Hyperuricemia; Male; Risk Factors; U | 2014 |
Uricosuric drugs: the once and future therapy for hyperuricemia?
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Drug Dis | 2014 |
Serum uric acid and cardiovascular risk: state of the art and perspectives.
Topics: Cardiovascular Diseases; Humans; Hyperuricemia; Risk Factors; Uric Acid | 2014 |
Association of serum uric acid and metabolic syndrome in type 2 diabetes.
Topics: Adult; Atherosclerosis; Biomarkers; Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Cross-Section | 2014 |
Clinical manifestations and diagnosis of gout.
Topics: Asymptomatic Diseases; Chronic Disease; Disease Progression; Gout; Humans; Hyperuricemia; Uric Acid | 2014 |
Structural joint damage in gout.
Topics: Bone Remodeling; Cartilage; Gout; Gout Suppressants; Humans; Hyperuricemia; Joints; Osteoblasts; Ost | 2014 |
The genetic basis of gout.
Topics: Gene-Environment Interaction; Genome-Wide Association Study; Glycolysis; Gout; Humans; Hyperuricemia | 2014 |
Prophylaxis for acute gout flares after initiation of urate-lowering therapy.
Topics: Acute Disease; Gout; Gout Suppressants; Humans; Hyperuricemia; Uric Acid | 2014 |
A review of phytotherapy of gout: perspective of new pharmacological treatments.
Topics: Animals; Anti-Inflammatory Agents; Gout; Humans; Hyperuricemia; Phytotherapy; Plants, Medicinal; Uri | 2014 |
Is it time to revise the normal range of serum uric acid levels?
Topics: Age Factors; Biomarkers; Female; Gout; Healthy Volunteers; Humans; Hyperuricemia; Male; Predictive V | 2014 |
Gout: joints and beyond, epidemiology, clinical features, treatment and co-morbidities.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Colchicine; Gout; Gout Suppressants; Humans; Hype | 2014 |
Hyperuricemia and chronic kidney disease: an enigma yet to be solved.
Topics: Humans; Hyperuricemia; Kidney; Kidney Transplantation; Renal Insufficiency, Chronic; Risk Factors; U | 2014 |
Effect of uric-acid-lowering therapy on progression of chronic kidney disease: a meta-analysis.
Topics: Blood Pressure; Creatinine; Disease Progression; Female; Glomerular Filtration Rate; Humans; Hyperur | 2014 |
Association of rheumatoid factor and uric acid with psoriatic arthritis: a review.
Topics: Arthritis, Psoriatic; Arthritis, Rheumatoid; Humans; Hyperuricemia; Rheumatoid Factor; Uric Acid | 2014 |
Hyperuricemia and cardiovascular disease risk.
Topics: Cardiovascular Diseases; Humans; Hyperuricemia; Risk Factors; Uric Acid; Xanthine Oxidase | 2014 |
Aggravation of immunoglobulin a nephropathy by hyperuricemia: a mini-review on current findings and new concepts.
Topics: Allopurinol; Disease Progression; Glomerulonephritis, IGA; Gout Suppressants; Humans; Hyperuricemia; | 2014 |
[Gout and cardiovascular risk].
Topics: Cardiovascular Diseases; Gout; Gout Suppressants; Humans; Hyperuricemia; Risk Factors; Uric Acid | 2014 |
The molecular physiology of uric acid homeostasis.
Topics: Animals; Genome-Wide Association Study; Homeostasis; Humans; Hyperuricemia; Molecular Biology; Organ | 2015 |
Hyperuricemia and risk of incident hypertension: a systematic review and meta-analysis of observational studies.
Topics: Humans; Hypertension; Hyperuricemia; Incidence; Risk; Uric Acid | 2014 |
Xanthine oxidoreductase in atherosclerosis pathogenesis: not only oxidative stress.
Topics: Adipocytes; Animals; Atherosclerosis; Cardiovascular Diseases; Cell Differentiation; Cell Movement; | 2014 |
Safety of allopurinol compared with other urate-lowering drugs in patients with gout: a systematic review and meta-analysis.
Topics: Allopurinol; Biomarkers; Down-Regulation; Gout; Gout Suppressants; Humans; Hyperuricemia; Odds Ratio | 2015 |
A review of uric acid, crystal deposition disease, and gout.
Topics: Early Diagnosis; Early Medical Intervention; Gout; Gout Suppressants; Humans; Hyperuricemia; Uric Ac | 2015 |
Serum Uric Acid Levels and Diabetic Peripheral Neuropathy in Type 2 Diabetes: a Systematic Review and Meta-analysis.
Topics: Diabetes Mellitus, Type 2; Diabetic Neuropathies; Humans; Hyperuricemia; Publication Bias; Risk Fact | 2016 |
Genome-wide association study identifies ABCG2 (BCRP) as an allopurinol transporter and a determinant of drug response.
Topics: Aged; Allopurinol; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Tra | 2015 |
Uric acid: friend or foe? Uric acid and cognitive function "Gout kills more wise men than simple".
Topics: Animals; Antioxidants; Cardiovascular Diseases; Cognition; Female; Gout; Humans; Hyperuricemia; Male | 2015 |
Camellia sinensis in asymptomatic hyperuricemia: A meta-analysis of tea or tea extract effects on uric acid levels.
Topics: Antioxidants; Asymptomatic Diseases; Camellia sinensis; Cardiovascular Diseases; Dietary Supplements | 2017 |
Molecular basis of oxidative stress in gouty arthropathy.
Topics: Animals; Antioxidants; Arthritis, Gouty; Crystallization; Cytokines; Humans; Hyperuricemia; Immunity | 2015 |
Urate lowering therapy to improve renal outcomes in patients with chronic kidney disease: systematic review and meta-analysis.
Topics: Cardiovascular Diseases; Creatinine; Disease Progression; Glomerular Filtration Rate; Gout Suppressa | 2015 |
[Uric acid, the kidney and cardiovascular mortality].
Topics: Cardiovascular Diseases; Humans; Hyperuricemia; Kidney; Renal Insufficiency, Chronic; Risk Factors; | 2015 |
The involvement of uric acid in the pathogenesis of preeclampsia.
Topics: Female; Humans; Hyperuricemia; Pre-Eclampsia; Pregnancy; Pregnancy Outcome; Uric Acid | 2015 |
Investigational drugs for hyperuricemia.
Topics: Aged; Animals; Drug Design; Drugs, Investigational; Gout; Gout Suppressants; Humans; Hyperuricemia; | 2015 |
[The role of uric acid and allopurinol therapy in cardiovascular disease].
Topics: Allopurinol; Cardiovascular Diseases; Enzyme Inhibitors; Humans; Hyperuricemia; Uric Acid | 2015 |
Serum uric acid and the risk of cardiovascular and renal disease.
Topics: Cardiovascular Diseases; Gout Suppressants; Humans; Hypertension; Hyperuricemia; Metabolic Syndrome; | 2015 |
ABCG2: the molecular mechanisms of urate secretion and gout.
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Gout; Hu | 2015 |
Uric acid and coronary artery disease: An elusive link deserving further attention.
Topics: Coronary Artery Disease; Humans; Hypertension; Hyperuricemia; Risk Factors; Uric Acid | 2016 |
The treatment of hyperuricemia.
Topics: Enzyme Inhibitors; Gout Suppressants; Humans; Hyperuricemia; Oxidative Stress; Uric Acid; Xanthine D | 2016 |
Hyperuricemia as risk factor for coronary heart disease incidence and mortality in the general population: a systematic review and meta-analysis.
Topics: Cohort Studies; Coronary Disease; Humans; Hyperuricemia; Risk Factors; Uric Acid | 2016 |
Association between hyperuricemia and clinical adverse outcomes after percutaneous coronary intervention: A meta-analysis.
Topics: Coronary Artery Disease; Global Health; Humans; Hyperuricemia; Incidence; Percutaneous Coronary Inte | 2015 |
Uric acid lowering therapy in cardiovascular diseases.
Topics: Cardiovascular Diseases; Enzyme Inhibitors; Gout; Gout Suppressants; Humans; Hyperuricemia; Treatmen | 2016 |
Dose-response Relationship of Serum Uric Acid with Metabolic Syndrome and Non-alcoholic Fatty Liver Disease Incidence: A Meta-analysis of Prospective Studies.
Topics: Adult; Aged; Female; Humans; Hyperuricemia; Male; Metabolic Syndrome; Middle Aged; Non-alcoholic Fat | 2015 |
Association analysis of the beta-3 adrenergic receptor Trp64Arg (rs4994) polymorphism with urate and gout.
Topics: Biomarkers; Case-Control Studies; Gene Frequency; Genetic Association Studies; Genetic Predispositio | 2016 |
Why focus on uric acid?
Topics: Animals; Gout; Gout Suppressants; Humans; Hypertension; Hyperuricemia; Metabolic Syndrome; Risk Fact | 2015 |
Hyperuricemia, urate deposition and the association with hypertension.
Topics: Humans; Hypertension; Hyperuricemia; Kidney; Kidney Diseases; Uric Acid | 2015 |
The management of hyperuricemia with urate deposition.
Topics: Diet; Gout; Humans; Hyperuricemia; Obesity; Overweight; Uric Acid | 2015 |
Serum uric acid: a new therapeutic target for nonalcoholic fatty liver disease.
Topics: Animals; Drug Design; Humans; Hyperuricemia; Inflammasomes; Insulin Resistance; Metabolic Syndrome; | 2016 |
Hyperuricemia and risk of nonalcoholic fatty liver disease: a systematic review and meta-analysis.
Topics: Adult; Aged; Aged, 80 and over; Asian People; Biomarkers; Female; Humans; Hyperuricemia; Male; Middl | 2016 |
Management of Chronic Kidney Disease: The Relationship Between Serum Uric Acid and Development of Nephropathy.
Topics: Blood Glucose; Diabetes Mellitus; Disease Progression; Glucose Transport Proteins, Facilitative; Hum | 2015 |
Hyperuricemia and nonalcoholic fatty liver disease: from bedside to bench and back.
Topics: Animals; Cross-Sectional Studies; Humans; Hyperuricemia; Non-alcoholic Fatty Liver Disease; Prevalen | 2016 |
Uric acid in metabolic syndrome: From an innocent bystander to a central player.
Topics: Diabetes Mellitus; Humans; Hypertension; Hyperuricemia; Metabolic Syndrome; Non-alcoholic Fatty Live | 2016 |
Acute kidney injury among ST elevation myocardial infarction patients treated by primary percutaneous coronary intervention: a multifactorial entity.
Topics: Acute Kidney Injury; Anemia; Biomarkers; Blood Glucose; Contrast Media; Hemodynamics; Hemoglobins; H | 2016 |
From juvenile hyperuricaemia to dysfunctional uromodulin: an ongoing metamorphosis.
Topics: Adolescent; Chromosomes, Human, Pair 16; DNA Mutational Analysis; Exons; Gout; Hepatocyte Nuclear Fa | 2016 |
Effects of coffee consumption on serum uric acid: systematic review and meta-analysis.
Topics: Coffee; Female; Gout; Humans; Hyperuricemia; Male; Sex Factors; Uric Acid | 2016 |
[Studies on association between nonalcoholic fatty liver disease and hyperuricemia: current status and future prospects].
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Gout; Humans; Hyperuricemia; Non-alcoholic Fatty | 2016 |
[Uric acid, kidney disease and nephrolithiasis].
Topics: Acid-Base Equilibrium; Gout; Humans; Hyperuricemia; Insulin Resistance; Kidney; Nephrolithiasis; Ren | 2016 |
Review of the ophthalmic manifestations of gout and uric acid crystal deposition.
Topics: Eye Diseases; Gout; Humans; Hyperuricemia; Uric Acid | 2017 |
Association Between Serum Uric Acid Levels and Atrial Fibrillation Risk.
Topics: Atrial Fibrillation; Databases, Factual; Humans; Hyperuricemia; Risk Factors; Uric Acid | 2016 |
[Advance in treatment of hyperuricemia by Chinese medicine based on uric acid transporterome].
Topics: Animals; Biological Transport; Carrier Proteins; Drugs, Chinese Herbal; Humans; Hyperuricemia; Uric | 2015 |
Urate Handling in the Human Body.
Topics: Gout; Humans; Hyperuricemia; Intestinal Mucosa; Kidney; Kidney Tubules; Organic Anion Transporters; | 2016 |
Beyond Joints: a Review of Ocular Abnormalities in Gout and Hyperuricemia.
Topics: Eye Diseases; Gout; Humans; Hyperuricemia; Risk Factors; Uric Acid; Uveitis | 2016 |
Association of Serum Uric Acid Levels in Psoriasis: A Systematic Review and Meta-Analysis.
Topics: Adult; Aged; Asia, Eastern; Europe; Female; Humans; Hyperuricemia; India; Male; Middle Aged; Observa | 2016 |
Impact of Statin Therapy on Plasma Uric Acid Concentrations: A Systematic Review and Meta-Analysis.
Topics: Atorvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperuricemia; Randomized Cont | 2016 |
Gouty Arthritis: A Review of Acute Management and Prevention.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Colchicine; Gout | 2016 |
[HYPERURICEMIA AND POTENTIAL RISK OF CARDIOVASCULAR AND RENAL DISEASES].
Topics: Aged; Cardiovascular Diseases; Gout; Gout Suppressants; Humans; Hyperuricemia; Kidney Diseases; Male | 2016 |
Time to target uric acid to retard CKD progression.
Topics: Animals; Biomarkers; Disease Progression; Genetic Predisposition to Disease; Gout Suppressants; Huma | 2017 |
Review: Gout: A Roadmap to Approaches for Improving Global Outcomes.
Topics: Comorbidity; Disease Management; Global Health; Gout; Gout Suppressants; Humans; Hyperuricemia; Magn | 2017 |
Hyperuricemia and Atrial Fibrillation.
Topics: Antioxidants; Atrial Fibrillation; Atrial Remodeling; Evidence-Based Medicine; Humans; Hyperuricemia | 2016 |
Hyperuricemia, the kidneys, and the spectrum of associated diseases: a narrative review.
Topics: Gout; Humans; Hyperuricemia; Kidney; Kidney Diseases; Uric Acid | 2016 |
Drug-induced hyperuricaemia and gout.
Topics: Androgens; Antitubercular Agents; Aspirin; Carbohydrates; Cytotoxins; Diuretics; Gout; Humans; Hyper | 2017 |
Serum uric acid and mortality in chronic kidney disease: A systematic review and meta-analysis.
Topics: Adult; Aged; Female; Humans; Hyperuricemia; Male; Middle Aged; Renal Insufficiency, Chronic; Risk As | 2016 |
Overview of Serum Uric Acid Treatment Targets in Gout: Why Less Than 6 mg/dL?
Topics: Disease Management; Gout; Gout Suppressants; Humans; Hyperuricemia; Patient Compliance; Uric Acid | 2016 |
Comparative efficacy and safety of urate-lowering therapy for the treatment of hyperuricemia: a systematic review and network meta-analysis.
Topics: Gout; Gout Suppressants; Humans; Hyperuricemia; Network Meta-Analysis; Odds Ratio; Probability; Rand | 2016 |
Hyperuricemia protects against low bone mineral density, osteoporosis and fractures: a systematic review and meta-analysis.
Topics: Bone Density; Epidemiologic Methods; Female; Humans; Hyperuricemia; Male; Osteoporosis; Osteoporotic | 2016 |
Pathogenesis and Clinical Management of Gouty Arthritis.
Topics: Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Gouty; Colchi | 2015 |
Effect of uric acid-lowering therapy on blood pressure: systematic review and meta-analysis.
Topics: Adolescent; Aged; Allopurinol; Antihypertensive Agents; Blood Pressure; Creatinine; Enzyme Inhibitor | 2017 |
Hyperuricemia, Hypertension, and Chronic Kidney Disease: an Emerging Association.
Topics: Disease Progression; Gout Suppressants; Humans; Hypertension; Hyperuricemia; Renal Insufficiency, Ch | 2016 |
Hyperuricemia and coronary heart disease mortality: a meta-analysis of prospective cohort studies.
Topics: Coronary Artery Disease; Global Health; Humans; Hyperuricemia; Incidence; Prospective Studies; Risk | 2016 |
Hyperuricaemia and risk of nonalcoholic fatty liver disease: A meta-analysis.
Topics: Humans; Hyperuricemia; Non-alcoholic Fatty Liver Disease; Risk Factors; Uric Acid | 2017 |
Allopurinol as a therapeutic option in cardiovascular disease.
Topics: Allopurinol; Animals; Cardiovascular Diseases; Enzyme Inhibitors; Free Radical Scavengers; Humans; H | 2017 |
Major unanswered questions in the clinical gout field.
Topics: Allopurinol; Benzbromarone; Colchicine; Disease Progression; Febuxostat; Gout; Gout Suppressants; Hu | 2017 |
Allopurinol: insights from studies of dose-response relationships.
Topics: Allopurinol; Dose-Response Relationship, Drug; Female; Gout; Gout Suppressants; Humans; Hyperuricemi | 2017 |
Factors modulating the inflammatory response in acute gouty arthritis.
Topics: Arthritis, Gouty; Autophagy; Gastrointestinal Microbiome; Gout; Humans; Hyperuricemia; Inflammasomes | 2017 |
Limitations of the Current Standards of Care for Treating Gout and Crystal Deposition in the Primary Care Setting: A Review.
Topics: Chronic Disease; Comorbidity; Gout; Gout Suppressants; Humans; Hyperuricemia; Patient Compliance; Pr | 2017 |
Uric Acid, Vascular Stiffness, and Chronic Kidney Disease: Is There a Link?
Topics: Humans; Hyperuricemia; Renal Insufficiency, Chronic; Uric Acid; Vascular Stiffness | 2017 |
Excessive consumption of fructose causes cardiometabolic dysfunctions through oxidative stress and inflammation.
Topics: Animals; Blood Pressure; Dietary Sugars; Fructose; Healthy Lifestyle; Humans; Hypertension; Hyperuri | 2017 |
The Role of Uric Acid in Hypertension of Adolescents, Prehypertension and Salt Sensitivity of Blood Pressure.
Topics: Adolescent; Age Factors; Blood Pressure; Essential Hypertension; Humans; Hypertension; Hyperuricemia | 2017 |
An evidence-based review on urate-lowering treatments: implications for optimal treatment of chronic hyperuricemia.
Topics: Antioxidants; Biomarkers; Chronic Disease; Down-Regulation; Enzyme Inhibitors; Evidence-Based Medici | 2017 |
Crystal arthritides - gout and calcium pyrophosphate arthritis : Part 2: clinical features, diagnosis and differential diagnostics.
Topics: Aged; Arthritis; Calcium; Calcium Pyrophosphate; Chondrocalcinosis; Diagnosis, Differential; Gout; H | 2018 |
Is tea consumption associated with the serum uric acid level, hyperuricemia or the risk of gout? A systematic review and meta-analysis.
Topics: Gout; Humans; Hyperuricemia; Observational Studies as Topic; Tea; Uric Acid | 2017 |
Hyperuricemia is not associated with severity of liver fibrosis in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis.
Topics: Biomarkers; Chi-Square Distribution; Humans; Hyperuricemia; Liver Cirrhosis; Non-alcoholic Fatty Liv | 2017 |
SLC2A9--a fructose transporter identified as a novel uric acid transporter.
Topics: Animals; Female; Fructose; Glucose Transport Proteins, Facilitative; Gout; Homeostasis; Humans; Hype | 2008 |
The role of uric acid in stroke: the issue remains unresolved.
Topics: Animals; Humans; Hyperuricemia; Risk Factors; Stroke; Uric Acid | 2008 |
[Rasburicase therapy may cause hydrogen peroxide shock].
Topics: Gout Suppressants; Hemolysis; Humans; Hydrogen Peroxide; Hyperuricemia; Methemoglobin; Shock; Tumor | 2008 |
Febuxostat.
Topics: Administration, Oral; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Molecular Structur | 2008 |
The role of hyperuricemia and gout in kidney and cardiovascular disease.
Topics: Cardiovascular Diseases; Humans; Hyperuricemia; Incidence; Kidney Diseases; Risk Factors; Uric Acid | 2008 |
Clinical manifestations of hyperuricemia and gout.
Topics: Diagnosis, Differential; Gout; Humans; Hyperuricemia; Uric Acid | 2008 |
Uric acid: bystander or culprit in hypertension and progressive renal disease?
Topics: Animals; Disease Models, Animal; Humans; Hypertension; Hyperuricemia; Kidney Diseases; Rats; Uric Ac | 2008 |
Uric acid and cardiovascular risk.
Topics: Cardiovascular Diseases; Humans; Hypertension; Hyperuricemia; Kidney Diseases; Metabolic Syndrome; R | 2008 |
Uric acid and cardiovascular risk.
Topics: Cardiovascular Diseases; Humans; Hypertension; Hyperuricemia; Kidney Diseases; Metabolic Syndrome; R | 2008 |
Uric acid and cardiovascular risk.
Topics: Cardiovascular Diseases; Humans; Hypertension; Hyperuricemia; Kidney Diseases; Metabolic Syndrome; R | 2008 |
Uric acid and cardiovascular risk.
Topics: Cardiovascular Diseases; Humans; Hypertension; Hyperuricemia; Kidney Diseases; Metabolic Syndrome; R | 2008 |
Uric acid and cardiovascular risk.
Topics: Cardiovascular Diseases; Humans; Hypertension; Hyperuricemia; Kidney Diseases; Metabolic Syndrome; R | 2008 |
Uric acid and cardiovascular risk.
Topics: Cardiovascular Diseases; Humans; Hypertension; Hyperuricemia; Kidney Diseases; Metabolic Syndrome; R | 2008 |
Uric acid and cardiovascular risk.
Topics: Cardiovascular Diseases; Humans; Hypertension; Hyperuricemia; Kidney Diseases; Metabolic Syndrome; R | 2008 |
Uric acid and cardiovascular risk.
Topics: Cardiovascular Diseases; Humans; Hypertension; Hyperuricemia; Kidney Diseases; Metabolic Syndrome; R | 2008 |
Uric acid and cardiovascular risk.
Topics: Cardiovascular Diseases; Humans; Hypertension; Hyperuricemia; Kidney Diseases; Metabolic Syndrome; R | 2008 |
Crystal ball gazing: new therapeutic targets for hyperuricaemia and gout.
Topics: Bone Resorption; Crystallization; Glucose Transport Proteins, Facilitative; Gout; Gout Suppressants; | 2009 |
The role of hyperuricemia in vascular disorders.
Topics: Animals; Biological Evolution; Cardiovascular Diseases; Disease Models, Animal; Humans; Hypertension | 2009 |
Hyperuricemia and risk of stroke: a systematic review and meta-analysis.
Topics: Adolescent; Adult; Aged; Female; Humans; Hyperuricemia; Incidence; Male; Middle Aged; Risk Factors; | 2009 |
Uric acid: a novel mediator and marker of risk in chronic kidney disease?
Topics: Animals; Biomarkers; Chronic Disease; Clinical Trials as Topic; Disease Models, Animal; Disease Prog | 2009 |
Gout. Hyperuricemia and cardiovascular disease: how strong is the evidence for a causal link?
Topics: Cardiovascular Diseases; Gout; Humans; Hyperuricemia; Uric Acid | 2009 |
Recent insights into the pathogenesis of hyperuricaemia and gout.
Topics: Animals; Genetic Predisposition to Disease; Genome-Wide Association Study; Gout; Humans; Hyperuricem | 2009 |
Medical implications of hyperuricemia.
Topics: Animals; Cardiovascular Diseases; Gout; Humans; Hypertension; Hyperuricemia; Kidney Diseases; Metabo | 2009 |
Approach to the treatment of hyperuricemia.
Topics: Allopurinol; Febuxostat; Gout Suppressants; Humans; Hyperuricemia; Thiazoles; Uric Acid; Uricosuric | 2009 |
[Calcium antagonists: current and future applications based on new evidence. The mechanisms on lowering serum uric acid level by calcium channel blockers].
Topics: Anaerobiosis; Calcium Channel Blockers; Cardiovascular Diseases; Depression, Chemical; Gout; Humans; | 2010 |
Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout.
Topics: Allopurinol; Biotransformation; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibito | 2009 |
Uric acid and antioxidant effects of wine.
Topics: Antioxidants; Cardiovascular System; Ethanol; Humans; Hyperuricemia; Uric Acid; Wine | 2010 |
Inflammation, oxidative stress and lipids: the risk triad for atherosclerosis in gout.
Topics: Atherosclerosis; Gout; Humans; Hyperuricemia; Inflammasomes; Lipid Metabolism; Lipids; Oxidative Str | 2010 |
Uric acid as a factor in the metabolic syndrome.
Topics: Biomarkers; Brazil; Cardiovascular Diseases; Female; Global Health; Humans; Hyperuricemia; Insulin R | 2010 |
Uric acid and hypertension: cause or effect?
Topics: Allopurinol; Blood Pressure; Gout Suppressants; Humans; Hypertension; Hyperuricemia; Uric Acid | 2010 |
Gout, hyperuricemia, and the risk of cardiovascular disease: cause and effect?
Topics: Animals; Antioxidants; Cardiovascular Diseases; Cells, Cultured; Clinical Trials as Topic; Comorbidi | 2010 |
Update on the pathophysiology and management of uric acid renal stones.
Topics: Alkalies; Diet Therapy; Humans; Hydrogen-Ion Concentration; Hyperuricemia; Kidney Calculi; Potassium | 2010 |
Gout, hyperuricemia, and Parkinson's disease: a protective effect?
Topics: Aged; Biomarkers; Clinical Trials as Topic; Comorbidity; Female; Gout; Humans; Hyperuricemia; Male; | 2010 |
Uric acid transport and disease.
Topics: Animals; Biological Transport; Glucose Transport Proteins, Facilitative; Gout; Humans; Hypertension; | 2010 |
Uric acid, CKD, and cardiovascular disease: confounders, culprits, and circles.
Topics: Animals; Cardiovascular Diseases; Confounding Factors, Epidemiologic; Glomerular Filtration Rate; Hu | 2010 |
Gout: epitome of painful arthritis.
Topics: Arthritis; Female; Gout; Humans; Hyperuricemia; Immunity, Innate; Male; Pain; Uric Acid | 2010 |
Gout: a clinical syndrome illustrated and discussed.
Topics: Aged; Aged, 80 and over; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseas | 2010 |
Uric acid and the development of hypertension.
Topics: Animals; Cross-Sectional Studies; Humans; Hypertension; Hyperuricemia; Insulin Resistance; Kidney; R | 2010 |
Could uric acid have a pathogenic role in pre-eclampsia?
Topics: Female; Humans; Hyperuricemia; Pre-Eclampsia; Pregnancy; Risk Factors; Uric Acid | 2010 |
Crystal arthropathies: recognizing and treating "the gouch".
Topics: Allopurinol; Antimetabolites; Chronic Disease; Colchicine; Febuxostat; Gout; Gout Suppressants; Huma | 2010 |
Uric acid in hypertension and renal disease: the chicken or the egg?
Topics: Allopurinol; Animals; Blood Pressure; Clinical Trials as Topic; Diet; Disease Progression; Fructose; | 2010 |
[Molecular mechanism of renal urate transport: urate transporters as novel targets for drug development].
Topics: Animals; Biological Transport; Drug Design; Gout; Humans; Hyperuricemia; Kidney; Kidney Glomerulus; | 2010 |
[Hyperuricemia and metabolic syndrome].
Topics: Adenosine Monophosphate; Adenosine Triphosphate; Fructose; Humans; Hyperuricemia; Insulin Resistance | 2010 |
[Impact of serum uric acid level on the cardiovascular system as a risk factor].
Topics: Adipokines; Benzbromarone; Cardiovascular Diseases; Hyperuricemia; Kidney; Organic Anion Transporter | 2010 |
Gout and hyperuricemia in young people.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Gout; Humans; Hyperuricemia; Middle Aged; U | 2011 |
Uric acid in heart disease: a new C-reactive protein?
Topics: Cardiovascular Diseases; Humans; Hyperuricemia; Risk; Uric Acid | 2011 |
Clinical practice. Gout.
Topics: Allopurinol; Anti-Inflammatory Agents; Colchicine; Gout; Gout Suppressants; Humans; Hyperuricemia; M | 2011 |
Challenges of conducting a trial of uric-acid-lowering therapy in CKD.
Topics: Allopurinol; Gout Suppressants; Humans; Hyperuricemia; Kidney Failure, Chronic; Randomized Controlle | 2011 |
A new perspective on the pharmacoeconomics of colchicine.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Chronic Disease; Colchicine; Costs and Cos | 2011 |
[Treatment of gout].
Topics: Adrenal Cortex Hormones; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Colchicine; Febuxosta | 2011 |
Hyperuricaemia and non-alcoholic fatty liver disease (NAFLD): a relationship with implications for vascular risk?
Topics: Cardiovascular Diseases; Chronic Disease; Evidence-Based Medicine; Fatty Liver; Humans; Hyperuricemi | 2011 |
Uric acid metabolism in normal man and in primary gout.
Topics: Arthritis, Gouty; Gout; Humans; Hyperuricemia; Inosine Monophosphate; Male; Quaternary Ammonium Comp | 1965 |
Allopurinol, uric acid, and oxidative stress in cardiorenal disease.
Topics: Allopurinol; Animals; Cardiovascular Diseases; Enzyme Inhibitors; Humans; Hyperuricemia; Oxidative S | 2011 |
Uric acid as a cardiometabolic risk factor: to be or not to be.
Topics: Cardiovascular Diseases; Humans; Hypertension; Hyperuricemia; Kidney Diseases; Metabolic Syndrome; R | 2011 |
[Hyperuricemia in chronic heart failure].
Topics: Age Factors; Biomarkers; Chronic Disease; Diuretics; Echocardiography; Free Radicals; Heart Failure; | 2011 |
A new standard of care? Studies on febuxostat in the management of hyperuricemia with and without gout.
Topics: Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Primary Health Care; Thiazoles; Treatmen | 2011 |
Effect of oral vitamin C supplementation on serum uric acid: a meta-analysis of randomized controlled trials.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Ascorbic Acid; Biomarkers; Dietary | 2011 |
[Hyperuricemia and uro-nephrological disorders].
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diagnosis, Differential; Humans; Hypertension; H | 2011 |
Uric acid: a starring role in the intricate scenario of metabolic syndrome with cardio-renal damage?
Topics: Biomarkers; Cardiovascular Diseases; Female; Humans; Hyperuricemia; Male; Metabolic Syndrome; Progno | 2012 |
Soyfoods, hyperuricemia and gout: a review of the epidemiologic and clinical data.
Topics: Asia; Attitude of Health Personnel; Diet; Gout; Humans; Hyperuricemia; Prevalence; Risk Factors; Soy | 2011 |
Uric acid and xanthine oxidase: future therapeutic targets in the prevention of cardiovascular disease?
Topics: Cardiovascular Diseases; Humans; Hyperuricemia; Losartan; Risk Factors; Uric Acid; Xanthine Oxidase | 2006 |
Is there anything good in uric acid?
Topics: Age Factors; Brain Diseases; Cardiovascular Diseases; Female; Gout; Humans; Hypertension; Hyperurice | 2011 |
[Role of uric acid in preeclampsia-eclampsia].
Topics: Animals; Causality; Cesarean Section; Eclampsia; Endothelium, Vascular; Female; Humans; Hypertension | 2011 |
Clinical inquiry. Are serum uric acid levels always elevated in acute gout?
Topics: Acute Disease; Allopurinol; Arthritis, Gouty; Biomarkers; Gout; Gout Suppressants; Humans; Hyperuric | 2011 |
The epidemiology of uric acid and fructose.
Topics: Adult; Aged; Aged, 80 and over; Beverages; Diabetes Mellitus; Female; Fructose; Gout; Humans; Hyperu | 2011 |
Uric acid and fructose: potential biological mechanisms.
Topics: Animals; Fructose; Humans; Hyperuricemia; Uric Acid | 2011 |
Xanthine oxidase and uric acid in cardiovascular disease: clinical impact and therapeutic options.
Topics: Biomarkers; Cardiovascular Diseases; Heart Failure; Humans; Hyperuricemia; Reactive Oxygen Species; | 2011 |
Uric acid and hypertension.
Topics: Animals; Humans; Hypertension; Hyperuricemia; Uric Acid | 2011 |
Recent advances in renal urate transport: characterization of candidate transporters indicated by genome-wide association studies.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; | 2012 |
Hyperuricemia, gout and the kidney.
Topics: Gout; Humans; Hyperuricemia; Kidney Failure, Chronic; Uric Acid | 2012 |
[Lozartan potential in hyperuricemia correction].
Topics: Antihypertensive Agents; Humans; Hypertension; Hyperuricemia; Losartan; Metabolic Syndrome; Uric Aci | 2011 |
Uric acid, hyperuricemia and vascular diseases.
Topics: Coronary Disease; Gout; Humans; Hypertension; Hyperuricemia; Inflammasomes; Inflammation; Metabolic | 2012 |
New insights into uric acid effects on the progression and prognosis of chronic kidney disease.
Topics: Animals; Biomarkers; Disease Progression; Humans; Hyperuricemia; Kidney Failure, Chronic; Prognosis; | 2012 |
Some historical remarks on microcrystalline arthritis (gout and chondrocalcinosis).
Topics: Arthritis, Gouty; Biomarkers; Chondrocalcinosis; Crystallization; Gout; History, 19th Century; Histo | 2012 |
Metabolism of crystals within the joint.
Topics: Arthritis, Gouty; Biomarkers; Calcium Phosphates; Calcium Pyrophosphate; Chondrocalcinosis; Chondroc | 2012 |
Clinical features of gout.
Topics: Acute Disease; Arthritis, Gouty; Biomarkers; Chronic Disease; Crystallization; Diagnosis, Differenti | 2012 |
Cardiovascular and renal effects of hyperuricaemia and gout.
Topics: Biomarkers; Cardiovascular Diseases; Diabetes Complications; Disease Progression; Evidence-Based Med | 2012 |
Regulation of uric acid excretion by the kidney.
Topics: Gout; Humans; Hyperuricemia; Kidney; Organic Anion Transporters; Organic Cation Transport Proteins; | 2012 |
Uric acid as one of the important factors in multifactorial disorders--facts and controversies.
Topics: Biomarkers; Cardiovascular Diseases; Humans; Hypertension; Hyperuricemia; Metabolic Syndrome; Uric A | 2012 |
Relationships among hyperuricemia, endothelial dysfunction and cardiovascular disease: molecular mechanisms and clinical implications.
Topics: Allopurinol; Antioxidants; Atherosclerosis; Cardiovascular Diseases; Endothelium, Vascular; Humans; | 2012 |
Relationships among hyperuricemia, endothelial dysfunction and cardiovascular disease: molecular mechanisms and clinical implications.
Topics: Allopurinol; Antioxidants; Atherosclerosis; Cardiovascular Diseases; Endothelium, Vascular; Humans; | 2012 |
Relationships among hyperuricemia, endothelial dysfunction and cardiovascular disease: molecular mechanisms and clinical implications.
Topics: Allopurinol; Antioxidants; Atherosclerosis; Cardiovascular Diseases; Endothelium, Vascular; Humans; | 2012 |
Relationships among hyperuricemia, endothelial dysfunction and cardiovascular disease: molecular mechanisms and clinical implications.
Topics: Allopurinol; Antioxidants; Atherosclerosis; Cardiovascular Diseases; Endothelium, Vascular; Humans; | 2012 |
The effects of fructose intake on serum uric acid vary among controlled dietary trials.
Topics: Clinical Trials as Topic; Diet, Diabetic; Energy Metabolism; Fructose; Humans; Hyperuricemia; Metabo | 2012 |
The effects of fructose intake on serum uric acid vary among controlled dietary trials.
Topics: Clinical Trials as Topic; Diet, Diabetic; Energy Metabolism; Fructose; Humans; Hyperuricemia; Metabo | 2012 |
The effects of fructose intake on serum uric acid vary among controlled dietary trials.
Topics: Clinical Trials as Topic; Diet, Diabetic; Energy Metabolism; Fructose; Humans; Hyperuricemia; Metabo | 2012 |
The effects of fructose intake on serum uric acid vary among controlled dietary trials.
Topics: Clinical Trials as Topic; Diet, Diabetic; Energy Metabolism; Fructose; Humans; Hyperuricemia; Metabo | 2012 |
The effects of fructose intake on serum uric acid vary among controlled dietary trials.
Topics: Clinical Trials as Topic; Diet, Diabetic; Energy Metabolism; Fructose; Humans; Hyperuricemia; Metabo | 2012 |
The effects of fructose intake on serum uric acid vary among controlled dietary trials.
Topics: Clinical Trials as Topic; Diet, Diabetic; Energy Metabolism; Fructose; Humans; Hyperuricemia; Metabo | 2012 |
The effects of fructose intake on serum uric acid vary among controlled dietary trials.
Topics: Clinical Trials as Topic; Diet, Diabetic; Energy Metabolism; Fructose; Humans; Hyperuricemia; Metabo | 2012 |
The effects of fructose intake on serum uric acid vary among controlled dietary trials.
Topics: Clinical Trials as Topic; Diet, Diabetic; Energy Metabolism; Fructose; Humans; Hyperuricemia; Metabo | 2012 |
The effects of fructose intake on serum uric acid vary among controlled dietary trials.
Topics: Clinical Trials as Topic; Diet, Diabetic; Energy Metabolism; Fructose; Humans; Hyperuricemia; Metabo | 2012 |
The effects of fructose intake on serum uric acid vary among controlled dietary trials.
Topics: Clinical Trials as Topic; Diet, Diabetic; Energy Metabolism; Fructose; Humans; Hyperuricemia; Metabo | 2012 |
The effects of fructose intake on serum uric acid vary among controlled dietary trials.
Topics: Clinical Trials as Topic; Diet, Diabetic; Energy Metabolism; Fructose; Humans; Hyperuricemia; Metabo | 2012 |
The effects of fructose intake on serum uric acid vary among controlled dietary trials.
Topics: Clinical Trials as Topic; Diet, Diabetic; Energy Metabolism; Fructose; Humans; Hyperuricemia; Metabo | 2012 |
The effects of fructose intake on serum uric acid vary among controlled dietary trials.
Topics: Clinical Trials as Topic; Diet, Diabetic; Energy Metabolism; Fructose; Humans; Hyperuricemia; Metabo | 2012 |
The effects of fructose intake on serum uric acid vary among controlled dietary trials.
Topics: Clinical Trials as Topic; Diet, Diabetic; Energy Metabolism; Fructose; Humans; Hyperuricemia; Metabo | 2012 |
The effects of fructose intake on serum uric acid vary among controlled dietary trials.
Topics: Clinical Trials as Topic; Diet, Diabetic; Energy Metabolism; Fructose; Humans; Hyperuricemia; Metabo | 2012 |
The effects of fructose intake on serum uric acid vary among controlled dietary trials.
Topics: Clinical Trials as Topic; Diet, Diabetic; Energy Metabolism; Fructose; Humans; Hyperuricemia; Metabo | 2012 |
Treatment of chronic gouty arthritis: it is not just about urate-lowering therapy.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; | 2012 |
Uric acid in heart failure: a biomarker or therapeutic target?
Topics: Biomarkers; Heart Failure; Humans; Hyperuricemia; Prognosis; Severity of Illness Index; Uric Acid | 2013 |
[Renal affection in gout].
Topics: Creatinine; Gout; Humans; Hyperuricemia; Insulin Resistance; Kidney Diseases; Kidney Glomerulus; Pro | 2012 |
The role of uric acid in the pathogenesis of hypertension in the young.
Topics: Age Factors; Animals; Child; Child Welfare; Disease Models, Animal; Humans; Hypertension; Hyperurice | 2012 |
[The hyperiricosuria as an indicator of derangement of biologic functions of endoecology and adaptation, biologic reactions of excretion, inflammation and arterial tension].
Topics: Animals; Arterial Pressure; Glomerular Filtration Rate; Humans; Hyperuricemia; Inflammation; Kidney | 2012 |
Gout as autoinflammatory disease: new mechanisms for more appropriated treatment targets.
Topics: Animals; Gout; Hereditary Autoinflammatory Diseases; Humans; Hyperuricemia; Uric Acid | 2012 |
The genetics of hyperuricaemia and gout.
Topics: Allopurinol; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transport | 2012 |
The uric acid metabolism pathway as a therapeutic target in hyperuricemia related to metabolic syndrome.
Topics: Animals; Endothelium, Vascular; Humans; Hypertension; Hyperuricemia; Inflammation; Metabolic Syndrom | 2012 |
Hyperuricaemia: more than just a cause of gout?
Topics: Animals; Biomarkers; Cardiovascular Diseases; Female; Gout; Humans; Hyperuricemia; Inflammation; Kid | 2013 |
Uric acid as a target of therapy in CKD.
Topics: Disease Progression; Humans; Hyperuricemia; Predictive Value of Tests; Renal Insufficiency, Chronic; | 2013 |
Renal transport of uric acid: evolving concepts and uncertainties.
Topics: Biological Transport; Glucose Transport Proteins, Facilitative; Gout; Humans; Hyperuricemia; Kidney; | 2012 |
A perspective on diet and gout.
Topics: Diet; Fructose; Gout; Humans; Hyperuricemia; Purines; Risk Factors; Uric Acid | 2012 |
Hyperuricemia and the progression of chronic kidney disease: is uric acid a marker or an independent risk factor?
Topics: Animals; Biomarkers; Disease Progression; Humans; Hyperuricemia; Renal Insufficiency, Chronic; Risk | 2012 |
Genetic disorders resulting in hyper- or hypouricemia.
Topics: Gout; Humans; Hyperuricemia; Renal Insufficiency, Chronic; Renal Tubular Transport, Inborn Errors; U | 2012 |
Advanced kidney failure and hyperuricemia.
Topics: Gout; Humans; Hyperuricemia; Kidney Failure, Chronic; Renal Dialysis; Uric Acid | 2012 |
Effects of urate-lowering therapy in hyperuricemia on slowing the progression of renal function: a meta-analysis.
Topics: Databases, Factual; Disease Progression; Humans; Hyperuricemia; Kidney Diseases; Randomized Controll | 2013 |
Safety of urate-lowering therapies: managing the risks to gain the benefits.
Topics: Allopurinol; Comorbidity; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Risk Factors; | 2012 |
Update on gout 2012.
Topics: Disease Management; Gout; Gout Suppressants; Humans; Hyperuricemia; Tomography, X-Ray Computed; Ultr | 2012 |
Chronic hyperuricemia, uric acid deposit and cardiovascular risk.
Topics: Cardiovascular Diseases; Chronic Disease; Gout; Humans; Hyperuricemia; Risk Factors; Uric Acid | 2013 |
The interplay between diet, urate transporters and the risk for gout and hyperuricemia: current and future directions.
Topics: Animals; Diet; Gout; Humans; Hyperuricemia; Organic Anion Transporters; Risk Factors; Uric Acid | 2012 |
Uric acid and diabetes: Is there a link?
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Angiopathies | 2013 |
The kidney in hyperuricemia and gout.
Topics: Animals; Gout; Homeostasis; Humans; Hyperuricemia; Kidney; Kidney Diseases; Prognosis; Uric Acid | 2013 |
Efficacy and tolerability of febuxostat in hyperuricemic patients with or without gout: a systematic review and meta-analysis.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Randomized Controlled Trial | 2013 |
The role of uric acid in the pathogenesis of human cardiovascular disease.
Topics: Cardiovascular Diseases; Endothelium, Vascular; Humans; Hyperuricemia; Oxidative Stress; Uric Acid; | 2013 |
[Uric acid metabolism and insulin resistance in type 2 diabetes].
Topics: Cardiovascular Diseases; Chromans; Diabetes Mellitus, Type 2; Humans; Hyperuricemia; Insulin Resista | 2002 |
[Identification of a novel urate transporter URAT1 and current status on urate research].
Topics: Animals; Cardiovascular Diseases; Carrier Proteins; Cloning, Molecular; Free Radical Scavengers; Gal | 2003 |
[Phosphoribosylpyrophosphate(PRPP) synthetase].
Topics: Humans; Hyperuricemia; Phosphoribosyl Pyrophosphate; Purine Nucleotides; Purines; Ribose-Phosphate P | 2003 |
[Xanthine dehydrogenase (xanthine oxidase)].
Topics: Allopurinol; Animals; Enzyme Inhibitors; Flavin-Adenine Dinucleotide; Free Radicals; Humans; Hyperur | 2003 |
[Mode of existence and dynamics of uric acid in blood].
Topics: Animals; Gout; Humans; Hyperuricemia; Uric Acid | 2003 |
[Urate transport in human kidney].
Topics: Animals; Biological Transport; Carrier Proteins; Galectins; Humans; Hyperuricemia; Kidney; Organic A | 2003 |
[Influence of sex and age on serum uric acid level].
Topics: Age Factors; Estrogens; Female; Gout; Humans; Hyperuricemia; Male; Sex Factors; Uric Acid | 2003 |
[Effect of foods on serum uric acid level].
Topics: Diet; Dietary Carbohydrates; Dietary Fats; Dietary Proteins; Drinking; Food; Food Analysis; Gout; Hu | 2003 |
[Influence of exercise on serum uric acid].
Topics: Alanine; Anaerobic Threshold; Exercise; Glucose; Humans; Hyperuricemia; Kidney; Muscles; Uric Acid | 2003 |
[Influence of pregnancy on serum uric acid].
Topics: Female; Glomerular Filtration Rate; Humans; Hyperuricemia; Infant, Newborn; Pre-Eclampsia; Pregnancy | 2003 |
[Effect of ethanol on uric acid level].
Topics: Acetaldehyde; Animals; Erythrocytes; Ethanol; Gout; Humans; Hyperuricemia; Purines; Pyrazinamide; Ur | 2003 |
[Definition and determination of serum uric acid level].
Topics: Biomarkers; Blood Chemical Analysis; Gout; Humans; Hyperuricemia; Practice Guidelines as Topic; Refe | 2003 |
[Hyperuricemia--definition and classification].
Topics: Animals; Diagnosis, Differential; Humans; Hyperuricemia; Hypoxanthine Phosphoribosyltransferase; Kid | 2003 |
[Typing of hyperuricemia (uric acid clearance)].
Topics: Biomarkers; Diagnosis, Differential; Humans; Hyperuricemia; Metabolic Clearance Rate; Uric Acid | 2003 |
[Idiopathic hyperuricemia].
Topics: Glyceraldehyde 3-Phosphate; Humans; Hyperuricemia; Hypoxanthine Phosphoribosyltransferase; Insulin R | 2003 |
[Exercise therapy for hyperuricemia].
Topics: Anaerobic Threshold; Exercise; Exercise Therapy; Gout; Humans; Hyperuricemia; Purine Nucleotides; Ur | 2003 |
[Diet therapy for management of hyperuricemia and gout].
Topics: Adult; Alcoholic Beverages; Diet, Reducing; Gout; Humans; Hyperuricemia; Male; Obesity; Purines; Tem | 2003 |
[Gouty arthritis].
Topics: Adrenocorticotropic Hormone; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Colchicine; | 2003 |
[Gouty kidney].
Topics: Animals; Diet; Gout; Humans; Hyperuricemia; Kidney Diseases; Sodium Bicarbonate; Tartrates; Uric Aci | 2003 |
[Effect of hyperglycemia and insulin resistance on serum uric acid].
Topics: Adult; Blood Glucose; Glycosuria; Humans; Hyperglycemia; Hyperuricemia; Insulin; Insulin Resistance; | 2003 |
[Sleep apnea syndrome].
Topics: Cardiovascular Diseases; Gout; Humans; Hyperuricemia; Life Style; Sleep Apnea Syndromes; Uric Acid | 2003 |
[Secondary hyperuricemia in hematologic disease].
Topics: Allopurinol; Enzyme Inhibitors; Hematologic Neoplasms; Humans; Hyperuricemia; Urate Oxidase; Uric Ac | 2003 |
[Hyperuricemia in endocrine disorders].
Topics: Bartter Syndrome; Diabetes Insipidus, Nephrogenic; Diabetes Insipidus, Neurogenic; Endocrine System | 2003 |
[Secondary hyperuricemia in burn and trauma].
Topics: Animals; Burns; Humans; Hyperuricemia; Superoxides; Uric Acid; Wounds and Injuries; Xanthine; Xanthi | 2003 |
[Secondary hyperuricemia in glycogen storage disease types I, III, V and VII].
Topics: Glycogen Storage Disease Type I; Glycogen Storage Disease Type III; Glycogen Storage Disease Type V; | 2003 |
[Secondary hyperuricemia in Down's syndrome].
Topics: Diet; Down Syndrome; Humans; Hyperuricemia; Kidney; Uric Acid; Uricosuric Agents | 2003 |
[Hyperuricemia in preeclampsia].
Topics: Biomarkers; Female; Humans; Hyperuricemia; Kidney; Placenta; Pre-Eclampsia; Predictive Value of Test | 2003 |
[Idiopathic retroperitoneal fibrosis and hyperuricemia].
Topics: Gout; Humans; Hyperuricemia; Male; Middle Aged; Prednisolone; Receptors, Interleukin-2; Retroperiton | 2003 |
[Non-drug substance (over intake of foods which are contained purine body, fat and fructose)].
Topics: Dietary Carbohydrates; Dietary Fats; Food Analysis; Fructose; Humans; Hyperuricemia; Purines; Uric A | 2003 |
[Alcohol-related tissue injury and hyperuricemia].
Topics: Acetaldehyde; Adenosine Triphosphate; Coronary Disease; Cytochrome P-450 CYP2E1; Ethanol; Humans; Hy | 2003 |
Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease?
Topics: Animals; Antioxidants; Cardiotonic Agents; Cardiovascular Diseases; Female; Humans; Hypertension; Hy | 2003 |
[HYPERURICEMIA AND ITS CLINICAL SIGNIFICANCE].
Topics: Blood Chemical Analysis; Carbon Isotopes; Coronary Disease; Humans; Hypertension; Hyperuricemia; Kid | 1963 |
[HYPERURICEMIA AND ATHEROSCLEROSIS].
Topics: Arteriosclerosis; Atherosclerosis; Blood; Cerebrovascular Disorders; Coronary Disease; Gout; Humans; | 1964 |
[THE GOUTY KIDNEY--PATHOGENESIS OF HYPERURICEMIA AND PATHOGENIC ROLE OF THE KIDNEY].
Topics: Blood; Gout; Humans; Hyperuricemia; Kidney; Kidney Diseases; Uric Acid | 1963 |
Hyperuricemia and adverse outcomes in cardiovascular disease: potential for therapeutic intervention.
Topics: Allopurinol; Cardiovascular Diseases; Enzyme Inhibitors; Humans; Hyperuricemia; Uric Acid; Xanthine | 2003 |
Hyperuricaemia and gout: clinical guideline 2003.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Child; Colchicine; Female; Gout; Gout Suppress | 2003 |
Uric acid: role in cardiovascular disease and effects of losartan.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Humans; Hyperuri | 2004 |
Uric acid, endothelial dysfunction and pre-eclampsia: searching for a pathogenetic link.
Topics: Endothelium, Vascular; Female; Humans; Hyperuricemia; Models, Biological; Pre-Eclampsia; Pregnancy; | 2004 |
Uric acid, endothelial dysfunction and pre-eclampsia.
Topics: Animals; Endothelium, Vascular; Female; Humans; Hyperuricemia; Pre-Eclampsia; Pregnancy; Uric Acid | 2004 |
Serum uric acid-lowering therapies: where are we heading in management of hyperuricemia and the potential role of uricase.
Topics: Allopurinol; Amlodipine; Clinical Trials as Topic; Enzyme Inhibitors; Febuxostat; Gout; Humans; Hype | 2004 |
[Purine metabolism in patients with renal failure].
Topics: Allopurinol; Antimetabolites; Glomerulonephritis; Humans; Hyperuricemia; Hypoxanthine; Kidney; Kidne | 2004 |
[Uratic gout].
Topics: Arthritis, Gouty; Diet; Gout; Gout Suppressants; Humans; Hyperuricemia; Uric Acid | 2004 |
Gout: on the brink of novel therapeutic options for an ancient disease.
Topics: Acute Disease; Benzothiadiazines; Diuretics; Female; Gout; Humans; Hypertension; Hyperuricemia; Kidn | 2004 |
[Serum uric acid--a cardiovasular risk factor?].
Topics: Angiotensin II Type 1 Receptor Blockers; Cardiovascular Diseases; Clinical Trials as Topic; Humans; | 2004 |
Management of hyperuricemia with rasburicase review.
Topics: Allopurinol; Antimetabolites; Clinical Trials as Topic; Cost-Benefit Analysis; Free Radical Scavenge | 2004 |
Uric acid, evolution and primitive cultures.
Topics: Animals; Blood Pressure; Global Health; Humans; Hypertension; Hyperuricemia; Morbidity; Mutation; Ur | 2005 |
Hereditary hyperuricemia and renal disease.
Topics: Genetic Predisposition to Disease; Humans; Hyperuricemia; Hypoxanthine Phosphoribosyltransferase; Ki | 2005 |
Uric acid as a mediator of endothelial dysfunction, inflammation, and vascular disease.
Topics: Animals; Arteries; Biomarkers; Disease Progression; Endothelium, Vascular; Humans; Hyperuricemia; Ur | 2005 |
Uric acid and chronic renal disease: possible implication of hyperuricemia on progression of renal disease.
Topics: Animals; Chronic Disease; Disease Progression; Humans; Hyperuricemia; Kidney Diseases; Risk Factors; | 2005 |
Uric acid and transplantation.
Topics: Gout Suppressants; Graft Rejection; Graft Survival; Humans; Hyperuricemia; Immunosuppressive Agents; | 2005 |
Uric acid in chronic heart failure.
Topics: Allopurinol; Animals; Biomarkers; Blood Flow Velocity; Blood Vessels; Chronic Disease; Disease Progr | 2005 |
Does asymptomatic hyperuricaemia contribute to the development of renal and cardiovascular disease? An old controversy renewed.
Topics: Animals; Cardiovascular Diseases; Humans; Hyperuricemia; Kidney Diseases; Muscle, Smooth, Vascular; | 2004 |
[Researches on the establishment of chronic nephropathy models and the effect of TCM on these models].
Topics: Animals; Disease Models, Animal; Drugs, Chinese Herbal; Hyperuricemia; Kidney Diseases; Mice; Phytot | 2005 |
[Hyperuricemia as a unique marker for metabolic syndrome].
Topics: Adipose Tissue; Arteriosclerosis; Biomarkers; Humans; Hyperuricemia; Insulin Resistance; Life Style; | 2005 |
Recent advances in the management of gout and hyperuricemia.
Topics: Gout; Humans; Hyperuricemia; Treatment Outcome; Uric Acid; Uricosuric Agents | 2005 |
Essential hypertension, progressive renal disease, and uric acid: a pathogenetic link?
Topics: Disease Progression; Humans; Hypertension; Hyperuricemia; Kidney Diseases; Kidney Failure, Chronic; | 2005 |
[Hyperuricemia/gout. Main symptoms of arthropathy. Severe acute joint pain, redness, inflammation].
Topics: Allopurinol; Anesthetics, Local; Anti-Inflammatory Agents, Non-Steroidal; Colchicine; Diagnosis, Dif | 2005 |
Acute renal failure in cancer patients.
Topics: Acute Kidney Injury; Antineoplastic Agents; Humans; Hyperuricemia; Neoplasms; Prognosis; Risk Factor | 2005 |
[Uric acid--more deleterious than we thought?].
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Cardiovascular Diseases; Female; H | 2005 |
Renal urate handling: clinical relevance of recent advances.
Topics: Animals; Biological Transport; Carrier Proteins; Gout; Humans; Hyperuricemia; Kidney Tubules; Mutati | 2005 |
Effect of ethanol on metabolism of purine bases (hypoxanthine, xanthine, and uric acid).
Topics: Acetyl Coenzyme A; Alcohol Dehydrogenase; Aldehyde Dehydrogenase; Aldehyde Dehydrogenase, Mitochondr | 2005 |
Serum uric acid and cardiovascular disease: recent developments, and where do they leave us?
Topics: Cardiovascular Diseases; Gout Suppressants; Humans; Hyperuricemia; Risk Factors; Uric Acid | 2005 |
Diagnosis and management of gout: a rational approach.
Topics: Acute Disease; Chronic Disease; Crystallization; Diagnosis, Differential; Gout; Humans; Hyperuricemi | 2005 |
Pathogenesis of gout.
Topics: Cardiovascular Diseases; Crystallization; Diet; Gout; Humans; Hyperuricemia; Inflammation; Insulin R | 2005 |
Understanding treatments for gout.
Topics: Acute Disease; Adrenal Cortex Hormones; Behavior Therapy; Chronic Disease; Colchicine; Female; Gout; | 2005 |
Diagnosis of gout: clinical, laboratory, and radiologic findings.
Topics: Acute Disease; Adult; Age Factors; Aged; Arthrography; Chondrocalcinosis; Diagnosis, Differential; F | 2005 |
Hormonal and cytokine effects of uric acid.
Topics: Antioxidants; Humans; Hyperuricemia; Muscle, Smooth, Vascular; Uric Acid; Vascular Diseases | 2006 |
Uric acid--a uremic toxin?
Topics: Animals; Arteriosclerosis; Biomarkers; Enzyme Inhibitors; Humans; Hypertension; Hypertrophy; Hyperur | 2006 |
Overview of hyperuricaemia and gout.
Topics: Antioxidants; Cardiovascular Diseases; Gout; Humans; Hyperuricemia; Prevalence; Uric Acid | 2005 |
Uric acid and hypertension.
Topics: Humans; Hypertension; Hyperuricemia; Insulin Resistance; Uric Acid | 2005 |
Uric acid and the kidney: urate transport, stone disease and progressive renal failure.
Topics: Animals; Biological Transport; Carrier Proteins; Humans; Hyperuricemia; Kidney; Kidney Calculi; Orga | 2005 |
[Hyperuricemia].
Topics: Allopurinol; Coronary Disease; Gout Suppressants; Humans; Hyperuricemia; Risk Factors; Uric Acid | 2005 |
[Molecular mechanism in biological transport in the kidney: Urate transporter URAT1].
Topics: Animals; Benzbromarone; Carrier Proteins; Humans; Hyperuricemia; Kidney Tubules; Organic Anion Trans | 2006 |
[Hyperuricemic nephropathy: Pathogenesis, pathophysiology, and therapy].
Topics: DNA-Binding Proteins; Gout; Hepatocyte Nuclear Factor 1-beta; Humans; Hyperuricemia; Kidney Diseases | 2006 |
Serum uric acid: a risk factor and a target for treatment?
Topics: Adolescent; Adult; Animals; Blood Pressure; Cardiovascular Diseases; Child; Clinical Trials as Topic | 2006 |
Genetic factors associated with gout and hyperuricemia.
Topics: Blood Group Antigens; Genetic Markers; Genetic Predisposition to Disease; Gout; Humans; Hyperuricemi | 2006 |
Crystal-induced arthropathies: recent investigative advances.
Topics: Aged; Arthritis, Gouty; Chondrocalcinosis; Humans; Hyperuricemia; Organic Anion Transporters; Uric A | 2006 |
Uric acid and hypertension.
Topics: Animals; Child; Disease Models, Animal; Humans; Hypertension; Hyperuricemia; Rats; Uric Acid | 2006 |
Uric acid and the vasculature.
Topics: Blood Vessels; Cardiovascular Diseases; Endothelium, Vascular; Humans; Hyperuricemia; Myocytes, Smoo | 2006 |
EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).
Topics: Advisory Committees; Biomedical Research; Comorbidity; Delphi Technique; Evidence-Based Medicine; Go | 2006 |
Hypertensive renal vascular disease and cardiovascular endpoints.
Topics: Albuminuria; Biomarkers; C-Reactive Protein; Disease Progression; Erythropoietin; Glomerular Filtrat | 2006 |
A concise history of gout and hyperuricemia and their treatment.
Topics: Arthritis, Gouty; Gout; History, 19th Century; History, Ancient; Humans; Hyperuricemia; Politics; Un | 2006 |
Recent developments in our understanding of the renal basis of hyperuricemia and the development of novel antihyperuricemic therapeutics.
Topics: Carrier Proteins; Diet; Enzyme Inhibitors; Humans; Hyperuricemia; Kidney; Organic Anion Transporters | 2006 |
Serum uric acid as a risk factor for cardiovascular and renal disease: an old controversy revived.
Topics: Cardiovascular Diseases; Clinical Trials as Topic; Humans; Hyperuricemia; Kidney Diseases; Risk Fact | 2006 |
New developments in clinically relevant mechanisms and treatment of hyperuricemia.
Topics: Febuxostat; Humans; Hyperuricemia; Prognosis; Thiazoles; Urate Oxidase; Uric Acid; Uricosuric Agents | 2006 |
Elevated serum uric acid levels in metabolic syndrome: an active component or an innocent bystander?
Topics: Animals; Humans; Hyperuricemia; Metabolic Syndrome; Uric Acid | 2006 |
[Is hyperuricemia a cardiovascular risk factor?].
Topics: Cardiovascular Diseases; Comorbidity; Female; Gout; Humans; Hyperuricemia; Obesity; Risk Factors; Se | 2006 |
Uric Acid and renal disease.
Topics: Humans; Hyperuricemia; Kidney; Kidney Calculi; Kidney Diseases; Kidney Glomerulus; Models, Biologica | 2006 |
Renal function during normal pregnancy and preeclampsia.
Topics: Angiogenic Proteins; Animals; Female; Glomerular Filtration Rate; Humans; Hyperuricemia; Kidney; Kid | 2007 |
Role of uric acid in hypertension, renal disease, and metabolic syndrome.
Topics: Biomarkers; Blood Pressure; Fructose; Humans; Hypertension; Hyperuricemia; Kidney Diseases; Metaboli | 2006 |
Crystal-associated arthritis in the elderly.
Topics: Aged; Allopurinol; Arthritis; Arthritis, Gouty; Calcium Pyrophosphate; Chondrocalcinosis; Comorbidit | 2007 |
Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout.
Topics: Gout; Gout Suppressants; Humans; Hyperuricemia; Tumor Lysis Syndrome; Urate Oxidase; Uric Acid | 2007 |
Uric acid and oxidative stress: relative impact on cardiovascular risk?
Topics: Atherosclerosis; Biomarkers; Cardiovascular Diseases; Humans; Hyperuricemia; Oxidative Stress; React | 2007 |
Could uric acid have a role in acute renal failure?
Topics: Acute Kidney Injury; Animals; Humans; Hyperuricemia; Kidney Tubules; Uric Acid | 2007 |
Pathophysiology and clinical aspects of urinary lithiasis.
Topics: Calcium; Cystine; Cystinuria; Drug-Related Side Effects and Adverse Reactions; Humans; Hypercalciuri | 2007 |
Avoiding dialysis in tumour lysis syndrome: is urate oxidase effective? - a case report and review of literature.
Topics: Burkitt Lymphoma; Child; Humans; Hyperuricemia; Male; Renal Dialysis; Singapore; Treatment Outcome; | 2007 |
Altered uric acid levels and disease states.
Topics: Animals; Cardiovascular Diseases; Gout; Humans; Hypertension; Hyperuricemia; Inflammation; Kidney Di | 2008 |
The role of interleukin-1 and the inflammasome in gout: implications for therapy.
Topics: Animals; Arthritis, Gouty; Carrier Proteins; Colchicine; Gout; Gout Suppressants; Humans; Hyperurice | 2007 |
Potential role of sugar (fructose) in the epidemic of hypertension, obesity and the metabolic syndrome, diabetes, kidney disease, and cardiovascular disease.
Topics: Animals; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus, Type 2; Fructose; Genetic Predispo | 2007 |
Potential role of sugar (fructose) in the epidemic of hypertension, obesity and the metabolic syndrome, diabetes, kidney disease, and cardiovascular disease.
Topics: Animals; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus, Type 2; Fructose; Genetic Predispo | 2007 |
Potential role of sugar (fructose) in the epidemic of hypertension, obesity and the metabolic syndrome, diabetes, kidney disease, and cardiovascular disease.
Topics: Animals; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus, Type 2; Fructose; Genetic Predispo | 2007 |
Potential role of sugar (fructose) in the epidemic of hypertension, obesity and the metabolic syndrome, diabetes, kidney disease, and cardiovascular disease.
Topics: Animals; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus, Type 2; Fructose; Genetic Predispo | 2007 |
Potential role of sugar (fructose) in the epidemic of hypertension, obesity and the metabolic syndrome, diabetes, kidney disease, and cardiovascular disease.
Topics: Animals; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus, Type 2; Fructose; Genetic Predispo | 2007 |
Potential role of sugar (fructose) in the epidemic of hypertension, obesity and the metabolic syndrome, diabetes, kidney disease, and cardiovascular disease.
Topics: Animals; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus, Type 2; Fructose; Genetic Predispo | 2007 |
Potential role of sugar (fructose) in the epidemic of hypertension, obesity and the metabolic syndrome, diabetes, kidney disease, and cardiovascular disease.
Topics: Animals; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus, Type 2; Fructose; Genetic Predispo | 2007 |
Potential role of sugar (fructose) in the epidemic of hypertension, obesity and the metabolic syndrome, diabetes, kidney disease, and cardiovascular disease.
Topics: Animals; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus, Type 2; Fructose; Genetic Predispo | 2007 |
Potential role of sugar (fructose) in the epidemic of hypertension, obesity and the metabolic syndrome, diabetes, kidney disease, and cardiovascular disease.
Topics: Animals; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus, Type 2; Fructose; Genetic Predispo | 2007 |
Hyperuricemia and gout: new insights into pathogenesis and treatment.
Topics: Adrenal Cortex Hormones; Animals; Anti-Inflammatory Agents, Non-Steroidal; Colchicine; Febuxostat; G | 2007 |
[New knowledge on the pathophysiology and therapy of gout].
Topics: Animals; Arthritis, Gouty; Endothelium; Humans; Hyperuricemia; Inflammation Mediators; Interleukin-1 | 2007 |
Uric acid as a pathogenic factor in preeclampsia.
Topics: Female; Humans; Hyperuricemia; Placenta; Pre-Eclampsia; Pregnancy; Uric Acid | 2008 |
Update on gout: pathophysiology and potential treatments.
Topics: Animals; Cardiovascular Diseases; Gout; Gout Suppressants; Humans; Hypertension; Hyperuricemia; Immu | 2007 |
Diagnosis of gout.
Topics: Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Synovial Fluid; Uric Acid | 2007 |
The conundrum of hyperuricemia, metabolic syndrome, and renal disease.
Topics: Animals; Humans; Hypertension; Hyperuricemia; Insulin Resistance; Kidney; Metabolic Syndrome; Renal | 2008 |
The paradoxical relationship between serum uric acid and cardiovascular disease.
Topics: Animals; Antioxidants; Cardiovascular Diseases; Heart Failure; Humans; Hypertension; Hyperuricemia; | 2008 |
Control of renal uric acid excretion and gout.
Topics: Genetic Predisposition to Disease; Gout; Humans; Hyperuricemia; Kidney Tubules, Proximal; Organic An | 2008 |
[Historical review of gout and hyperuricemia investigations].
Topics: Gout; History, 17th Century; History, 18th Century; History, 19th Century; History, 20th Century; Hu | 2008 |
[Definition and classification of hyperuricemia].
Topics: Alcohol Drinking; Diet, Reducing; Fructose; Glucose-6-Phosphatase; Glycogen Storage Disease Type I; | 2008 |
[Urate production and regulation].
Topics: Adenosine Triphosphate; Humans; Hyperuricemia; Hypoxanthine Phosphoribosyltransferase; Purines; Ribo | 2008 |
[Physiology and dynamics of uric acid in hyperuricemia].
Topics: Gout; Humans; Hydrogen-Ion Concentration; Hyperuricemia; Solubility; Uric Acid | 2008 |
[Idiopathic hyperuricemia with overproduction of uric acid].
Topics: Antihypertensive Agents; Gout; Humans; Hypertension; Hyperuricemia; Hypoxanthine; Muscle, Skeletal; | 2008 |
[Primary hyperuricemia due to decreased renal uric acid excretion].
Topics: Biological Transport; Humans; Hyperuricemia; Kidney; Mucoproteins; Organic Anion Transporters; Organ | 2008 |
[Pathophysiology and treatment of secondary hyperuricemia].
Topics: Adenosine Triphosphate; Alcoholism; Allopurinol; Diuretics; Gout Suppressants; Humans; Hyperuricemia | 2008 |
[How do we set the standard value of serum uric acid levels?].
Topics: Alcoholic Beverages; Biomarkers; Catalase; Colorimetry; Dehydration; Diet; Humans; Hyperuricemia; Pe | 2008 |
[Establishment of therapeutic goal and plan of gout and asymptomatic hyperuricemia].
Topics: Allopurinol; Benzbromarone; Cardiovascular Diseases; Gout; Gout Suppressants; Humans; Hyperuricemia; | 2008 |
[Uricosuric agent].
Topics: Allopurinol; Benzbromarone; Gout; Humans; Hyperuricemia; Kidney Tubules, Proximal; Organic Anion Tra | 2008 |
[Other antihyperuricemic agents].
Topics: Antihypertensive Agents; Cardiovascular Diseases; Drug Therapy, Combination; Fenofibrate; Gout; Gout | 2008 |
[Relationship between hyperuricemia and metabolic syndrome].
Topics: Adipocytes; Cardiovascular Diseases; Cell Differentiation; Humans; Hyperuricemia; Metabolic Syndrome | 2008 |
[Uromodulin mutation and hyperuricemia].
Topics: Animals; Humans; Hyperuricemia; Kidney Failure, Chronic; Kidney Tubules, Proximal; Mucoproteins; Mut | 2008 |
204 trials available for uric acid and Hyperuricemia
| Article | Year |
|---|---|
Optimal uric acid levels by febuxostat treatment and cerebral, cardiorenovascular risks: post hoc analysis of a randomized controlled trial.
Topics: Aged; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Treatment Outcome; Uric Acid | 2022 |
Comparison between febuxostat and allopurinol uric acid-lowering therapy in patients with chronic heart failure and hyperuricemia: a multicenter randomized controlled trial.
Topics: Allopurinol; Febuxostat; Heart Failure; Humans; Hyperuricemia; Uric Acid | 2021 |
Efficacy of Chinese herbal medicine Jiangniaosuan formula for treatment of hyperuricemia: study protocol for a double-blinded non-inferiority randomized controlled clinical trial.
Topics: China; Double-Blind Method; Drugs, Chinese Herbal; Humans; Hyperuricemia; Medicine, Chinese Traditio | 2022 |
Febuxostat combined with hydration for the prevention of contrast-induced nephropathy in hyperuricemia patients undergoing percutaneous coronary intervention: A CONSORT-compliant randomized controlled trial.
Topics: Combined Modality Therapy; Contrast Media; Coronary Angiography; Coronary Disease; Creatinine; Febux | 2022 |
Safety, Efficacy, and Pharmacokinetics of HP501 in Healthy Volunteers and Hyperuricemic Patients: A Phase I/IIa Study.
Topics: Double-Blind Method; Gout; Healthy Volunteers; Humans; Hyperuricemia; Treatment Outcome; Uric Acid; | 2022 |
Differential effect of a xanthine oxidase inhibitor on arterial stiffness and carotid atherosclerosis: a subanalysis of the PRIZE study.
Topics: Ankle Brachial Index; Atherosclerosis; Awards and Prizes; Carotid Artery Diseases; Enzyme Inhibitors | 2022 |
Urate-lowering therapy for CKD patients with asymptomatic hyperuricemia without proteinuria elucidated by attribute-based research in the FEATHER Study.
Topics: Creatinine; Febuxostat; Female; Gout Suppressants; Humans; Hyperuricemia; Male; Proteinuria; Renal I | 2022 |
Association between serum urate level and carotid atherosclerosis: an insight from a post hoc analysis of the PRIZE randomised clinical trial.
Topics: Adult; Awards and Prizes; Carotid Artery Diseases; Carotid Intima-Media Thickness; Febuxostat; Human | 2022 |
Evaluation of the Relationship Between Serum Urate Levels, Clinical Manifestations of Gout, and Death From Cardiovascular Causes in Patients Receiving Febuxostat or Allopurinol in an Outcomes Trial.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Thiazoles; Treatment Outcom | 2022 |
C-reactive Protein Levels and Cardiovascular Outcomes After Febuxostat Treatment in Patients with Asymptomatic Hyperuricemia: Post-hoc Analysis of a Randomized Controlled Study.
Topics: Atherosclerosis; C-Reactive Protein; Febuxostat; Female; Humans; Hyperuricemia; Inflammation; Male; | 2023 |
Evaluation of the safety and efficacy of a Fuling-Zexie decoction for people with asymptomatic hyperuricemia: protocol for a prospective, double-blinded, randomized, placebo-controlled clinical trial.
Topics: Double-Blind Method; Gout; Humans; Hyperuricemia; Pilot Projects; Prospective Studies; Randomized Co | 2022 |
Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucose; Glucosides; Heart Failure; Humans; | 2022 |
Superiority of Low-Dose Benzbromarone to Low-Dose Febuxostat in a Prospective, Randomized Comparative Effectiveness Trial in Gout Patients With Renal Uric Acid Underexcretion.
Topics: Allopurinol; Benzbromarone; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Prospe | 2022 |
Impact of febuxostat on visit-to-visit blood pressure variability: insights from the randomised PRIZE Study.
Topics: Awards and Prizes; Blood Pressure; Carotid Intima-Media Thickness; Febuxostat; Humans; Hyperuricemia | 2022 |
Individualized Homeopathic Medicines in Treatment of Hyperuricemia: Evaluation by Double-Blind, Randomized, Placebo-Controlled Trial.
Topics: Double-Blind Method; Homeopathy; Humans; Hyperuricemia; Materia Medica; Quality of Life; Treatment O | 2023 |
A Drug-Drug Interaction Study of a Novel Selective Urate Reabsorption Inhibitor, SHR4640, and Xanthine Oxidase Inhibitor, Febuxostat, in Patients With Primary Hyperuricemia.
Topics: Drug Interactions; Enzyme Inhibitors; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Tr | 2023 |
Diagnostic model for predicting hyperuricemia based on alterations of the gut microbiome in individuals with different serum uric acid levels.
Topics: Biomarkers; DNA, Ribosomal; Gastrointestinal Microbiome; Humans; Hyperuricemia; Uric Acid | 2022 |
Simiao pill inhibits epithelial mesenchymal transition in a mouse model of chronic hyperuricemic nephropathy by inhibiting NLRP3 inflammasome activation.
Topics: Actins; Animals; Cadherins; Caspases; Disease Models, Animal; Epithelial-Mesenchymal Transition; Feb | 2022 |
Low-dose febuxostat exhibits a superior renal-protective effect and non-inferior safety profile compared to allopurinol in chronic kidney disease patients complicated with hyperuricemia: A double-centre, randomized, controlled study.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chroni | 2022 |
Low-dose febuxostat exhibits a superior renal-protective effect and non-inferior safety profile compared to allopurinol in chronic kidney disease patients complicated with hyperuricemia: A double-centre, randomized, controlled study.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chroni | 2022 |
Low-dose febuxostat exhibits a superior renal-protective effect and non-inferior safety profile compared to allopurinol in chronic kidney disease patients complicated with hyperuricemia: A double-centre, randomized, controlled study.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chroni | 2022 |
Low-dose febuxostat exhibits a superior renal-protective effect and non-inferior safety profile compared to allopurinol in chronic kidney disease patients complicated with hyperuricemia: A double-centre, randomized, controlled study.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chroni | 2022 |
Low-dose febuxostat exhibits a superior renal-protective effect and non-inferior safety profile compared to allopurinol in chronic kidney disease patients complicated with hyperuricemia: A double-centre, randomized, controlled study.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chroni | 2022 |
Low-dose febuxostat exhibits a superior renal-protective effect and non-inferior safety profile compared to allopurinol in chronic kidney disease patients complicated with hyperuricemia: A double-centre, randomized, controlled study.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chroni | 2022 |
Low-dose febuxostat exhibits a superior renal-protective effect and non-inferior safety profile compared to allopurinol in chronic kidney disease patients complicated with hyperuricemia: A double-centre, randomized, controlled study.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chroni | 2022 |
Low-dose febuxostat exhibits a superior renal-protective effect and non-inferior safety profile compared to allopurinol in chronic kidney disease patients complicated with hyperuricemia: A double-centre, randomized, controlled study.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chroni | 2022 |
Low-dose febuxostat exhibits a superior renal-protective effect and non-inferior safety profile compared to allopurinol in chronic kidney disease patients complicated with hyperuricemia: A double-centre, randomized, controlled study.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chroni | 2022 |
Citrus Bergamia and Cynara Cardunculus Reduce Serum Uric Acid in Individuals with Non-Alcoholic Fatty Liver Disease.
Topics: Citrus; Hyperuricemia; Non-alcoholic Fatty Liver Disease; Risk Factors; Uric Acid | 2022 |
Serum Urate-Lowering Efficacy and Safety of Tigulixostat in Gout Patients With Hyperuricemia: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Trial.
Topics: Double-Blind Method; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Symptom Flare Up; T | 2023 |
Hmong microbiome ANd Gout, Obesity, Vitamin C (HMANGO-C): A phase II clinical study protocol.
Topics: Adult; Ascorbic Acid; Clinical Trials, Phase II as Topic; COVID-19; Gout; Gout Suppressants; Humans; | 2023 |
Febuxostat and renal outcomes: post-hoc analysis of a randomized trial.
Topics: Aged; Cardiovascular Diseases; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Treatment | 2023 |
Cardiovascular and kidney outcomes of uric acid-lowering therapy in patients with different kidney functions: study protocol for a systematic review, pairwise and network meta-analysis.
Topics: Humans; Hyperuricemia; Kidney; Meta-Analysis as Topic; Network Meta-Analysis; Randomized Controlled | 2023 |
Effect of febuxostat on the level of malondialdehyde-modified low-density lipoprotein, an oxidative stress marker: A subanalysis of the PRIZE study.
Topics: Carotid Artery Diseases; Cholesterol, LDL; Febuxostat; Humans; Hyperuricemia; Malondialdehyde; Oxida | 2023 |
High- versus low-dose losartan and uric acid: An analysis from HEAAL.
Topics: Heart Failure; Humans; Hyperuricemia; Losartan; Stroke Volume; Uric Acid; Ventricular Function, Left | 2023 |
Safety and Effectiveness of Rasburicase in the Control of Hyperuricemia in Pediatric Patients with Non-Hodgkin's Lymphoma and Acute Leukemia: An Open-Label, Single-Arm, Multi-center, Interventional Study.
Topics: Child; Child, Preschool; China; Female; Humans; Hyperuricemia; Leukemia; Lymphoma, Non-Hodgkin; Male | 2023 |
A Phase I Study to Evaluate the Pharmacokinetic Drug‒Drug Interaction of HP501, Febuxostat, and Colchicine in Male Chinese Patients with Hyperuricemia.
Topics: Colchicine; East Asian People; Febuxostat; Gout Suppressants; Humans; Hyperuricemia; Male; Treatment | 2023 |
Uric acid-lowering therapy with benzbromarone in hypertension with asymptomatic hyperuricemia: a randomized study focusing left ventricular diastolic function.
Topics: Benzbromarone; Heart Failure; Humans; Hypertension; Hyperuricemia; Stroke Volume; Uric Acid | 2023 |
Urate-lowering drugs for chronic kidney disease with asymptomatic hyperuricemia and hypertension: a randomized trial.
Topics: Benzbromarone; Febuxostat; Gout Suppressants; Humans; Hypertension; Hyperuricemia; Renal Insufficien | 2023 |
Effects of febuxostat on markers of endothelial dysfunction and renal progression in patients with chronic kidney disease.
Topics: C-Reactive Protein; Febuxostat; Humans; Hyperuricemia; Kidney; Renal Insufficiency, Chronic; Uric Ac | 2023 |
Effects of the DASH diet and losartan on serum urate among adults with hypertension: Results of a randomized trial.
Topics: Adult; Dietary Approaches To Stop Hypertension; Female; Gout; Humans; Hypertension; Hyperuricemia; L | 2023 |
Efficacy of Aristolochia rotunda Linn in hyperuricemia: A randomised standard controlled study.
Topics: Aristolochia; Gout; Humans; Hyperuricemia; Single-Blind Method; Uric Acid | 2023 |
Evaluating the effectiveness and safety of acupuncture on serum uric acid in asymptomatic hyperuricemia population: a randomized controlled clinical trial study protocol.
Topics: Acupuncture Therapy; Gout; Humans; Hyperuricemia; Randomized Controlled Trials as Topic; Single-Blin | 2023 |
The effect for hyperuricemia inpatient of uric acid overproduction type or in combination with topiroxostat on the pharmacokinetics, pharmacodynamics and safety of dotinurad, a selective urate reabsorption inhibitor.
Topics: Adult; Aged; Benzothiazoles; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Hyperuricemia; In | 2020 |
Changeover Trial of Febuxostat and Topiroxostat for Hyperuricemia with Cardiovascular Disease: Sub-Analysis for Chronic Kidney Disease (TROFEO CKD Trial).
Topics: Aged; Antioxidants; Biomarkers; Cross-Over Studies; Down-Regulation; Enzyme Inhibitors; Febuxostat; | 2020 |
Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: an exploratory, randomized, multicenter, double-blind, placebo-controlled, parallel-group early phase 2 stu
Topics: Adult; Benzothiazoles; Double-Blind Method; Gout; Humans; Hyperuricemia; Japan; Male; Middle Aged; O | 2020 |
Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: randomized, multicenter, double-blind, placebo-controlled, parallel-group, confirmatory phase 2 study.
Topics: Adult; Aged; Benzothiazoles; Dose-Response Relationship, Drug; Double-Blind Method; Female; Gout; Hu | 2020 |
Open-label study of long-term administration of dotinurad in Japanese hyperuricemic patients with or without gout.
Topics: Adult; Benzothiazoles; Female; Gout; Humans; Hyperuricemia; Japan; Male; Middle Aged; Organic Anion | 2020 |
A non-inferiority study of the novel selective urate reabsorption inhibitor dotinurad versus febuxostat in hyperuricemic patients with or without gout.
Topics: Adult; Aged; Benzothiazoles; Double-Blind Method; Febuxostat; Gout; Humans; Hyperuricemia; Japan; Ma | 2020 |
Dotinurad versus benzbromarone in Japanese hyperuricemic patient with or without gout: a randomized, double-blind, parallel-group, phase 3 study.
Topics: Adult; Aged; Benzbromarone; Benzothiazoles; Double-Blind Method; Female; Gout; Humans; Hyperuricemia | 2020 |
A clinical pharmacology study of the novel, selective urate reabsorption inhibitor dotinurad in outpatients.
Topics: Adult; Aged; Benzothiazoles; Humans; Hyperuricemia; Japan; Male; Middle Aged; Outpatients; Uric Acid | 2020 |
Febuxostat does not delay progression of carotid atherosclerosis in patients with asymptomatic hyperuricemia: A randomized, controlled trial.
Topics: Aged; Aged, 80 and over; Asymptomatic Diseases; Carotid Artery Diseases; Carotid Intima-Media Thickn | 2020 |
Effect of Curcumin on Serum Urate in Asymptomatic Hyperuricemia: A Randomized Placebo-Controlled Trial.
Topics: Curcumin; Female; Gout; Humans; Hyperuricemia; Male; Treatment Outcome; Uric Acid | 2021 |
The relationship between hyperuricemia and contrast-induced acute kidney injury undergoing primary percutaneous coronary intervention: secondary analysis protocol for the ATTEMPT RESCIND-1 study.
Topics: Acute Kidney Injury; China; Contrast Media; Creatinine; Humans; Hyperuricemia; Logistic Models; Mult | 2020 |
Randomized, Open-Label, Cross-Over Comparison of the Effects of Benzbromarone and Febuxostat on Endothelial Function in Patients with Hyperuricemia.
Topics: Adiponectin; Aged; Arginine; Benzbromarone; Cross-Over Studies; Endothelium, Vascular; Febuxostat; F | 2020 |
A randomized, double-blind, positive-controlled, prospective, dose-response clinical study to evaluate the efficacy and tolerability of an aqueous extract of Terminalia bellerica in lowering uric acid and creatinine levels in chronic kidney disease subjec
Topics: Adult; Aged; Creatinine; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hype | 2020 |
Dapagliflozin Added to Verinurad Plus Febuxostat Further Reduces Serum Uric Acid in Hyperuricemia: The QUARTZ Study.
Topics: Adult; Benzhydryl Compounds; Cross-Over Studies; Drug Therapy, Combination; Enzyme Inhibitors; Febux | 2021 |
Individualized homeopathic medicines and
Topics: Female; Humans; Hyperuricemia; Materia Medica; Mothers; Pilot Projects; Treatment Outcome; Uric Acid | 2020 |
Associations between Dietary Glycemic Index and Glycemic Load Values and Cardiometabolic Risk Factors in Adults: Findings from the China Health and Nutrition Survey.
Topics: Adult; Age Factors; Aged; Blood Glucose; Cardiometabolic Risk Factors; China; Fasting; Female; Glyce | 2020 |
Comparative effects of topiroxostat and febuxostat on arterial properties in hypertensive patients with hyperuricemia.
Topics: Febuxostat; Gout Suppressants; Humans; Hypertension; Hyperuricemia; Nitriles; Pyridines; Treatment O | 2021 |
Elevated Urate Levels Do Not Alter Bone Turnover Markers: Randomized Controlled Trial of Inosine Supplementation in Postmenopausal Women.
Topics: Absorptiometry, Photon; Aged; Bone Density; Bone Remodeling; Collagen Type I; Double-Blind Method; F | 2021 |
Associations of methyl donor and methylation inhibitor levels during anti-oxidant therapy in heart failure.
Topics: Aged; Allopurinol; Female; Free Radical Scavengers; Heart Failure; Humans; Hyperuricemia; Male; Meth | 2021 |
Effects of Dietary Patterns on Serum Urate: Results From a Randomized Trial of the Effects of Diet on Hypertension.
Topics: Adult; Dietary Approaches To Stop Hypertension; Dietary Fiber; Female; Fruit; Humans; Hypertension; | 2021 |
Effect of Uric Acid Lowering on Renin-Angiotensin-System Activation and Ambulatory BP: A Randomized Controlled Trial.
Topics: Adult; Allopurinol; Angiotensin II; Biomarkers; Blood Pressure; Blood Pressure Monitoring, Ambulator | 2017 |
Cross-Over Trial of Febuxostat and Topiroxostat for Hyperuricemia With Cardiovascular Disease (TROFEO Trial).
Topics: Adult; Aged; Anti-Inflammatory Agents; Antioxidants; Cardiovascular Diseases; Cross-Over Studies; Fe | 2017 |
Hyperuricemia and overexcretion of uric acid increase the risk of simple renal cysts in type 2 diabetes.
Topics: Aged; Cysts; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Hyperuricemia; Kidne | 2017 |
Effect of apple polyphenols on vascular oxidative stress and endothelium function: a translational study.
Topics: Antioxidants; Blood Glucose; Body Mass Index; Cells, Cultured; Dietary Supplements; Double-Blind Met | 2017 |
Allopurinol Against Progression of Chronic Kidney Disease.
Topics: Allopurinol; Biomarkers; Disease Progression; Female; Glomerular Filtration Rate; Gout Suppressants; | 2017 |
Prevalence of Hyperuricemia in Patients With Acute Heart Failure With Either Reduced or Preserved Ejection Fraction.
Topics: Acute Disease; Aged; Aged, 80 and over; Double-Blind Method; Female; Follow-Up Studies; Heart Failur | 2017 |
Metoprolol Increases Uric Acid and Risk of Gout in African Americans With Chronic Kidney Disease Attributed to Hypertension.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Antihypertensive Agents; Biomarkers; Black or African | 2017 |
Effects of Febuxostat in Early Gout: A Randomized, Double-Blind, Placebo-Controlled Study.
Topics: Adult; Double-Blind Method; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Join | 2017 |
Effect of Febuxostat on Ambulatory Blood Pressure in Subjects With Hyperuricemia and Hypertension: A Phase 2 Randomized Placebo-Controlled Study.
Topics: Adult; Aged; Antihypertensive Agents; Biomarkers; Blood Pressure; Blood Pressure Monitoring, Ambulat | 2017 |
Uric acid-lowering and renoprotective effects of topiroxostat, a selective xanthine oxidoreductase inhibitor, in patients with diabetic nephropathy and hyperuricemia: a randomized, double-blind, placebo-controlled, parallel-group study (UPWARD study).
Topics: Aged; Diabetic Nephropathies; Double-Blind Method; Female; Glomerular Filtration Rate; Humans; Hyper | 2018 |
Interaction Between the Sodium-Glucose-Linked Transporter 2 Inhibitor Dapagliflozin and the Loop Diuretic Bumetanide in Normal Human Subjects.
Topics: Adolescent; Adult; Benzhydryl Compounds; Bumetanide; Drug Interactions; Female; Glucosides; Healthy | 2018 |
Ultrasonographic assessment of joint pathology in type 2 diabetes and hyperuricemia: The Fremantle Diabetes Study Phase II.
Topics: Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Female; Gout; Humans; Hyperuricemia; Joints; Mal | 2018 |
Metabolism and Disposition of Verinurad, a Uric Acid Reabsorption Inhibitor, in Humans.
Topics: Carbon Radioisotopes; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP3A; Feces; Gastrointestinal Tract | 2018 |
Effect of allopurinol on the glomerular filtration rate of children with chronic kidney disease.
Topics: Adolescent; Allopurinol; Child; Child, Preschool; Disease Progression; Female; Glomerular Filtration | 2018 |
Effects of pharmacological reversal of hyperuricemia on features of the metabolic syndrome in patients with gouty arthritis.
Topics: Arthritis, Gouty; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Diastole; Fe | 2018 |
Safety and Efficacy of Benzbromarone and Febuxostat in Hyperuricemia Patients with Chronic Kidney Disease: A Prospective Pilot Study.
Topics: Aged; Alpha-Globulins; Benzbromarone; Febuxostat; Female; Glomerular Filtration Rate; Hemoglobins; H | 2018 |
Verinurad combined with febuxostat in Japanese adults with gout or asymptomatic hyperuricaemia: a phase 2a, open-label study.
Topics: Administration, Oral; Adult; Aged; Benzbromarone; Dose-Response Relationship, Drug; Drug Therapy, Co | 2018 |
The efficacy of febuxostat and allopurinol in the treatment of gout with hyperuricemia.
Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Double-Blind Method; Drug Therapy, Combination; Febuxos | 2018 |
Multicenter, Open-Label Study of Long-Term Topiroxostat (FYX-051) Administration in Japanese Hyperuricemic Patients with or Without Gout.
Topics: Administration, Oral; Adult; Aged; Drug Administration Schedule; Enzyme Inhibitors; Female; Gout; Go | 2018 |
"Yellow-dragon Wonderful-seed Formula" for hyperuricemia in gout patients with dampness-heat pouring downward pattern: a pilot randomized controlled trial.
Topics: Adult; Biomarkers; China; Down-Regulation; Drugs, Chinese Herbal; Gout; Gout Suppressants; Humans; H | 2018 |
Effect of Oral Vitamin C Supplementation on High-Altitude Hyperuricemia in Young Men Initially Migrating to High Altitude: A Pilot Study.
Topics: Adolescent; Altitude; Ascorbic Acid; Blood Urea Nitrogen; Creatinine; Dietary Supplements; Humans; H | 2018 |
Effects of acute fructose loading on levels of serum uric acid-a pilot study.
Topics: Aged; Analysis of Variance; Beverages; Diabetes Mellitus, Type 2; Female; Fructose; Humans; Hyperuri | 2019 |
Hyperuricemia, urine uric excretion, and associated complications in thalassemia patients.
Topics: Adolescent; Adult; Arthritis, Gouty; beta-Thalassemia; Cross-Sectional Studies; Female; Glomerular F | 2019 |
Febuxostat for Cerebral and CaRdiorenovascular Events PrEvEntion StuDy.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Febuxostat; Female; Gou | 2019 |
URC102, a potent and selective inhibitor of hURAT1, reduced serum uric acid in healthy volunteers.
Topics: Administration, Oral; Adult; Asian People; Double-Blind Method; Gout; Healthy Volunteers; Humans; Hy | 2019 |
URC102, a potent and selective inhibitor of hURAT1, reduced serum uric acid in healthy volunteers.
Topics: Administration, Oral; Adult; Asian People; Double-Blind Method; Gout; Healthy Volunteers; Humans; Hy | 2019 |
URC102, a potent and selective inhibitor of hURAT1, reduced serum uric acid in healthy volunteers.
Topics: Administration, Oral; Adult; Asian People; Double-Blind Method; Gout; Healthy Volunteers; Humans; Hy | 2019 |
URC102, a potent and selective inhibitor of hURAT1, reduced serum uric acid in healthy volunteers.
Topics: Administration, Oral; Adult; Asian People; Double-Blind Method; Gout; Healthy Volunteers; Humans; Hy | 2019 |
Rilonacept for gout flare prevention during initiation of uric acid-lowering therapy: results from the PRESURGE-2 international, phase 3, randomized, placebo-controlled trial.
Topics: Adult; Allopurinol; Double-Blind Method; Drug Therapy, Combination; Female; Gout; Gout Suppressants; | 2013 |
Which is a better treatment for hypertensive patients with diabetes: a combination of losartan and hydrochlorothiazide or a maximum dose of losartan?
Topics: Aged; Albuminuria; Antihypertensive Agents; Diabetes Mellitus, Type 2; Dose-Response Relationship, D | 2013 |
Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery patients (NU-FLASH Trial).
Topics: Aged; Albuminuria; Allopurinol; Arachidonic Acid; Blood Pressure; C-Reactive Protein; Cardiac Surgic | 2013 |
The association between hyperuricemia, left atrial size and new-onset atrial fibrillation.
Topics: Adult; Atrial Fibrillation; Biomarkers; Cohort Studies; Female; Heart Atria; Humans; Hyperuricemia; | 2013 |
Serum urate levels are unchanged with continuous positive airway pressure therapy for obstructive sleep apnea: a randomized controlled trial.
Topics: Aged; Continuous Positive Airway Pressure; Diabetes Mellitus, Type 2; Gout; Humans; Hyperuricemia; M | 2013 |
Febuxostat (Feburic tablet) in the management of hyperuricemia in a general practice cohort of Japanese patients with a high prevalence of cardiovascular problems.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Comorbidity; Dose-Response Relationship, Drug; Feb | 2014 |
[Pre-diabetes mellitus influenced by hyperuricemia].
Topics: Adult; Aged; Female; Humans; Hyperuricemia; Insulin Resistance; Male; Middle Aged; Prediabetic State | 2013 |
Replication of the effect of SLC2A9 genetic variation on serum uric acid levels in American Indians.
Topics: Adult; Female; Genetic Predisposition to Disease; Genome-Wide Association Study; Genotype; Glomerula | 2014 |
Effects of azelnidipine on uric acid metabolism in patients with essential hypertension.
Topics: Aged; Aged, 80 and over; Azetidinecarboxylic Acid; Blood Pressure; Calcium Channel Blockers; Creatin | 2014 |
The effect of febuxostat to prevent a further reduction in renal function of patients with hyperuricemia who have never had gout and are complicated by chronic kidney disease stage 3: study protocol for a multicenter randomized controlled study.
Topics: Administration, Oral; Biomarkers; Clinical Protocols; Double-Blind Method; Drug Administration Sched | 2014 |
Effects of topiroxostat on the serum urate levels and urinary albumin excretion in hyperuricemic stage 3 chronic kidney disease patients with or without gout.
Topics: Adiponectin; Aged; Albuminuria; Blood Pressure; Comorbidity; Creatinine; Double-Blind Method; Enzyme | 2014 |
An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia.
Topics: Adult; Allopurinol; Biomarkers; China; Double-Blind Method; Enzyme Inhibitors; Febuxostat; Female; G | 2014 |
Influence of the ABCG2 gout risk 141 K allele on urate metabolism during a fructose challenge.
Topics: Adult; Alleles; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transp | 2014 |
Uric acid and allograft loss from interstitial fibrosis/tubular atrophy: post hoc analysis from the angiotensin II blockade in chronic allograft nephropathy trial.
Topics: Allografts; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Atrophy; Biopsy; Chronic Diseas | 2014 |
Pharmacodynamic, pharmacokinetic and tolerability evaluation of concomitant administration of lesinurad and febuxostat in gout patients with hyperuricaemia.
Topics: Adult; Aged; Colchicine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2014 |
Can soy intake affect serum uric acid level? Pooled analysis from two 6-month randomized controlled trials among Chinese postmenopausal women with prediabetes or prehypertension.
Topics: Aged; Aging; Cardiovascular Diseases; China; Dietary Supplements; Double-Blind Method; Female; Human | 2015 |
Can soy intake affect serum uric acid level? Pooled analysis from two 6-month randomized controlled trials among Chinese postmenopausal women with prediabetes or prehypertension.
Topics: Aged; Aging; Cardiovascular Diseases; China; Dietary Supplements; Double-Blind Method; Female; Human | 2015 |
Can soy intake affect serum uric acid level? Pooled analysis from two 6-month randomized controlled trials among Chinese postmenopausal women with prediabetes or prehypertension.
Topics: Aged; Aging; Cardiovascular Diseases; China; Dietary Supplements; Double-Blind Method; Female; Human | 2015 |
Can soy intake affect serum uric acid level? Pooled analysis from two 6-month randomized controlled trials among Chinese postmenopausal women with prediabetes or prehypertension.
Topics: Aged; Aging; Cardiovascular Diseases; China; Dietary Supplements; Double-Blind Method; Female; Human | 2015 |
Hyperuricemia and transesophageal echocardiographic thromboembolic risk in patients with atrial fibrillation at clinically low-intermediate risk.
Topics: Adult; Aged; Atrial Fibrillation; Echocardiography, Transesophageal; Female; Humans; Hyperuricemia; | 2014 |
Myeloperoxidase and oxidation of uric acid in gout: implications for the clinical consequences of hyperuricaemia.
Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Enzyme-Linked Immunosorbent Assay; Female; Gout; Gout S | 2014 |
Uric acid: association with rate of renal function decline and time until start of dialysis in incident pre-dialysis patients.
Topics: Biomarkers; Female; Humans; Hyperuricemia; Longitudinal Studies; Male; Middle Aged; Netherlands; Ren | 2014 |
The effects of allopurinol on metabolic acidosis and endothelial functions in chronic kidney disease patients.
Topics: Acidosis; Adult; Aged; Allopurinol; Bicarbonates; Creatinine; Endothelium; Female; Gout Suppressants | 2015 |
Novel hypoxanthine guanine phosphoribosyltransferase gene mutations in Saudi Arabian hyperuricemia patients.
Topics: Adult; Aged, 80 and over; Amino Acid Substitution; Female; Humans; Hyperuricemia; Hypoxanthine Phosp | 2014 |
Inhibition of xanthine oxidase and exercise on serum uric acid, 25(OH)D3, and calcium concentrations.
Topics: Adult; Allopurinol; Athletes; Calcifediol; Calcium; Cellulose; Double-Blind Method; Enzyme Inhibitor | 2014 |
Effect of vitamin C supplementation on serum uric acid in patients undergoing hemodialysis: a randomized controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Ascorbic Acid; Creatinine; Dietary Supplements; Female; Humans; Hype | 2014 |
Apolipoprotein E gene polymorphisms are associated with primary hyperuricemia in a Chinese population.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Apolipoproteins E; Asian People; Child; China; Creatinine; | 2014 |
Fructose containing sugars do not raise blood pressure or uric acid at normal levels of human consumption.
Topics: Adult; Blood Pressure; Body Weight; Dietary Carbohydrates; Energy Intake; Female; Fructose; Humans; | 2015 |
The use of serum uric acid concentration as an indicator of laparoscopic sleeve gastrectomy success.
Topics: Adolescent; Adult; Biomarkers; Female; Follow-Up Studies; Gastrectomy; Humans; Hyperuricemia; Laparo | 2015 |
Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Canagliflozin; Cohort Studies; Diabetes Mellitus, Type 2; Dose-Response Relationship, D | 2015 |
Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery patients with chronic kidney disease (NU-FLASH trial for CKD).
Topics: Aged; Albuminuria; Allopurinol; C-Reactive Protein; Cardiac Surgical Procedures; Cholesterol; Creati | 2015 |
Effects of febuxostat on serum urate level in Japanese hyperuricemia patients.
Topics: Adult; Febuxostat; Female; Gout Suppressants; Humans; Hyperuricemia; Japan; Male; Middle Aged; Preva | 2015 |
Renoprotective effects of febuxostat in hyperuricemic patients with chronic kidney disease: a parallel-group, randomized, controlled trial.
Topics: Aged; Aged, 80 and over; Albuminuria; beta 2-Microglobulin; Enzyme Inhibitors; Fatty Acid-Binding Pr | 2015 |
Febuxostat improves endothelial function in hemodialysis patients with hyperuricemia: A randomized controlled study.
Topics: Aged; Febuxostat; Female; Gout Suppressants; Humans; Hyperuricemia; Male; Renal Insufficiency, Chron | 2015 |
A phase 3, multicenter, randomized, allopurinol-controlled study assessing the safety and efficacy of oral febuxostat in Chinese gout patients with hyperuricemia.
Topics: Administration, Oral; Adult; Allopurinol; Biomarkers; China; Double-Blind Method; Febuxostat; Female | 2015 |
The Effects of Allopurinol on the Carotid Intima-media Thickness in Patients with Type 2 Diabetes and Asymptomatic Hyperuricemia: A Three-year Randomized Parallel-controlled Study.
Topics: Adult; Aged; Allopurinol; Asian People; Atherosclerosis; Biomarkers; Blood Pressure; C-Reactive Prot | 2015 |
Liver Fat Content Is Associated with Elevated Serum Uric Acid in the Chinese Middle-Aged and Elderly Populations: Shanghai Changfeng Study.
Topics: Adipose Tissue; Aged; Aging; China; Female; Humans; Hyperuricemia; Liver; Male; Middle Aged; Non-alc | 2015 |
Lowering Uric Acid With Allopurinol Improves Insulin Resistance and Systemic Inflammation in Asymptomatic Hyperuricemia.
Topics: Adult; Aged; Allopurinol; Asymptomatic Diseases; Biomarkers; Female; Humans; Hyperuricemia; Inflamma | 2015 |
Determinants and Prognostic Impact of Hyperuricemia in Hospitalization for Acute Heart Failure.
Topics: Acute Disease; Aged; Aged, 80 and over; Disease-Free Survival; Female; Follow-Up Studies; Heart Fail | 2016 |
Safety and efficacy of oral febuxostat for treatment of HLA-B*5801-negative gout: a randomized, open-label, multicentre, allopurinol-controlled study.
Topics: Administration, Oral; Adult; Alleles; Allopurinol; China; Febuxostat; Female; Gout; Gout Suppressant | 2016 |
Quercetin lowers plasma uric acid in pre-hyperuricaemic males: a randomised, double-blinded, placebo-controlled, cross-over trial.
Topics: Adult; Blood Glucose; Blood Pressure; Body Mass Index; Cross-Over Studies; Diabetes Mellitus, Type 2 | 2016 |
The effects of URAT1/SLC22A12 nonfunctional variants, R90H and W258X, on serum uric acid levels and gout/hyperuricemia progression.
Topics: Adult; Amino Acid Substitution; Female; Gout; Humans; Hyperuricemia; Male; Middle Aged; Mutation, Mi | 2016 |
Long-term effects of L- and N-type calcium channel blocker on uric acid levels and left atrial volume in hypertensive patients.
Topics: Amlodipine; Atrial Function, Left; Atrial Remodeling; Biomarkers; Blood Pressure; Calcium Channel Bl | 2016 |
Comparison of the effect of high fruit and soybean products diet and standard diet interventions on serum uric acid in asymptomatic hyperuricemia adults: an open randomized controlled trial.
Topics: Adult; Asian People; Female; Fruit; Humans; Hyperuricemia; Male; Middle Aged; Soybean Proteins; Uric | 2016 |
Benefits of Allopurinol Treatment on Blood Pressure and Renal Function in Patients with Early Stage of Chronic Kidney Disease.
Topics: Aged; Allopurinol; Biological Availability; Blood Pressure; Cardiovascular Diseases; Enzyme Inhibito | 2015 |
Rationale, design, and baseline characteristics of a study to evaluate the effect of febuxostat in preventing cerebral, cardiovascular, and renal events in patients with hyperuricemia.
Topics: Aged; Aged, 80 and over; Brain Diseases; Cardiovascular Diseases; Cause of Death; Febuxostat; Female | 2017 |
Efficacy and safety of febuxostat for prevention of tumor lysis syndrome in patients with malignant tumors receiving chemotherapy: a phase III, randomized, multi-center trial comparing febuxostat and allopurinol.
Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hy | 2016 |
Prognostic Significance of Hyperuricemia in Patients With Acute Heart Failure.
Topics: Acute Disease; Aged, 80 and over; Biomarkers; Female; Follow-Up Studies; Heart Failure; Humans; Hype | 2016 |
Clinical efficacy and safety of topiroxostat in Japanese male hyperuricemic patients with or without gout: an exploratory, phase 2a, multicentre, randomized, double-blind, placebo-controlled study.
Topics: Adult; Dose-Response Relationship, Drug; Double-Blind Method; Follow-Up Studies; Gout; Gout Suppress | 2016 |
Acute kidney injury observed during phase 1 clinical trials of a novel xanthine oxidase/URAT1 dual inhibitor PF-06743649.
Topics: Acute Kidney Injury; Adolescent; Adult; Aged; Aged, 80 and over; Biomarkers; Double-Blind Method; Fe | 2016 |
Comparison of topiroxostat and allopurinol in Japanese hyperuricemic patients with or without gout: a phase 3, multicentre, randomized, double-blind, double-dummy, active-controlled, parallel-group study.
Topics: Adult; Aged; Allopurinol; Double-Blind Method; Female; Follow-Up Studies; Gout; Gout Suppressants; H | 2016 |
Prediction of Therapeutic Effect of Rasburicase on Hyperuricemia Associated with Chemotherapy Based on Theoretical Model.
Topics: Antineoplastic Agents; Gout Suppressants; Humans; Hyperuricemia; Models, Biological; Recombinant Pro | 2016 |
Randomized control trial for the assessment of the anti-albuminuric effects of topiroxostat in hyperuricemic patients with diabetic nephropathy (the ETUDE study).
Topics: Diabetic Nephropathies; Glomerular Filtration Rate; Humans; Hyperuricemia; Nitriles; Pyridines; Trea | 2016 |
Rationale and design of a multicenter randomized study for evaluating vascular function under uric acid control using the xanthine oxidase inhibitor, febuxostat: the PRIZE study.
Topics: Adult; Aged; Aged, 80 and over; Atherosclerosis; Carotid Artery, Common; Dose-Response Relationship, | 2016 |
Patients with gout differ from healthy subjects in renal response to changes in serum uric acid.
Topics: Adult; Aged; Female; Gout; Gout Suppressants; Healthy Volunteers; Humans; Hyperuricemia; Kidney; Mal | 2017 |
Effects of the Dietary Approaches to Stop Hypertension (DASH) Diet and Sodium Intake on Serum Uric Acid.
Topics: Adult; Black or African American; Cross-Over Studies; Female; Humans; Hypertension; Hyperuricemia; M | 2016 |
Almond supplementation reduces serum uric acid in coronary artery disease patients: a randomized controlled trial.
Topics: Biomarkers; Blood Pressure; Breakfast; Coronary Artery Disease; Diet; Dietary Supplements; Female; H | 2016 |
The effects of urate lowering therapy on inflammation, endothelial function, and blood pressure (SURPHER) study design and rationale.
Topics: Adolescent; Adult; Allopurinol; Black or African American; Blood Pressure; Cross-Over Studies; Doubl | 2016 |
Effects of a Novel Fixed Combination of Nutraceuticals on Serum Uric Acid Concentrations and the Lipid Profile in Asymptomatic Hyperuricemic Patients : Results from the PICONZ-UA Study.
Topics: Aged; Asymptomatic Diseases; Biomarkers; Cholesterol, HDL; Cholesterol, LDL; Dietary Supplements; Dr | 2016 |
Therapeutic strategy for efficient reduction of serum uric acid levels with allopurinol versus benzbromarone in hyperuricemic patients with essential hypertension - A randomized crossover study (terao study).
Topics: Aged; Aged, 80 and over; Allopurinol; Benzbromarone; Drug Administration Schedule; Drug Monitoring; | 2016 |
Effective uric acid-lowering treatment for hypertensive patients with hyperuricemia.
Topics: Aged; Benzbromarone; Cross-Over Studies; Drug Therapy, Combination; Febuxostat; Female; Gout Suppres | 2017 |
Uric Acid Level and Prevalence of Atrial Fibrillation in a Japanese General Population of 285,882.
Topics: Adult; Age Factors; Aged; Asian People; Atrial Fibrillation; Body Mass Index; Female; Glomerular Fil | 2016 |
Clinical efficacy and safety of topiroxostat in Japanese hyperuricemic patients with or without gout: a randomized, double-blinded, controlled phase 2b study.
Topics: Adult; Allopurinol; Double-Blind Method; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Jap | 2017 |
Acupuncture for serum uric acid in patients with asymptomatic hyperuricemia: A randomized, double-blind, placebo-controlled trial.
Topics: Acupuncture Therapy; Adolescent; Adult; Aged; Asymptomatic Diseases; Biomarkers; Double-Blind Method | 2017 |
Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial.
Topics: Adolescent; Allopurinol; Blood Pressure; Cross-Over Studies; Double-Blind Method; Enzyme Inhibitors; | 2008 |
Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial.
Topics: Adolescent; Allopurinol; Blood Pressure; Cross-Over Studies; Double-Blind Method; Enzyme Inhibitors; | 2008 |
Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial.
Topics: Adolescent; Allopurinol; Blood Pressure; Cross-Over Studies; Double-Blind Method; Enzyme Inhibitors; | 2008 |
Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial.
Topics: Adolescent; Allopurinol; Blood Pressure; Cross-Over Studies; Double-Blind Method; Enzyme Inhibitors; | 2008 |
Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial.
Topics: Adolescent; Allopurinol; Blood Pressure; Cross-Over Studies; Double-Blind Method; Enzyme Inhibitors; | 2008 |
Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial.
Topics: Adolescent; Allopurinol; Blood Pressure; Cross-Over Studies; Double-Blind Method; Enzyme Inhibitors; | 2008 |
Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial.
Topics: Adolescent; Allopurinol; Blood Pressure; Cross-Over Studies; Double-Blind Method; Enzyme Inhibitors; | 2008 |
Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial.
Topics: Adolescent; Allopurinol; Blood Pressure; Cross-Over Studies; Double-Blind Method; Enzyme Inhibitors; | 2008 |
Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial.
Topics: Adolescent; Allopurinol; Blood Pressure; Cross-Over Studies; Double-Blind Method; Enzyme Inhibitors; | 2008 |
Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial.
Topics: Adolescent; Allopurinol; Blood Pressure; Cross-Over Studies; Double-Blind Method; Enzyme Inhibitors; | 2008 |
Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial.
Topics: Adolescent; Allopurinol; Blood Pressure; Cross-Over Studies; Double-Blind Method; Enzyme Inhibitors; | 2008 |
Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial.
Topics: Adolescent; Allopurinol; Blood Pressure; Cross-Over Studies; Double-Blind Method; Enzyme Inhibitors; | 2008 |
Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial.
Topics: Adolescent; Allopurinol; Blood Pressure; Cross-Over Studies; Double-Blind Method; Enzyme Inhibitors; | 2008 |
Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial.
Topics: Adolescent; Allopurinol; Blood Pressure; Cross-Over Studies; Double-Blind Method; Enzyme Inhibitors; | 2008 |
Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial.
Topics: Adolescent; Allopurinol; Blood Pressure; Cross-Over Studies; Double-Blind Method; Enzyme Inhibitors; | 2008 |
Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial.
Topics: Adolescent; Allopurinol; Blood Pressure; Cross-Over Studies; Double-Blind Method; Enzyme Inhibitors; | 2008 |
Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.
Topics: Adult; Aged; Allopurinol; Creatinine; Dose-Response Relationship, Drug; Double-Blind Method; Febuxos | 2008 |
Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.
Topics: Adult; Aged; Allopurinol; Creatinine; Dose-Response Relationship, Drug; Double-Blind Method; Febuxos | 2008 |
Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.
Topics: Adult; Aged; Allopurinol; Creatinine; Dose-Response Relationship, Drug; Double-Blind Method; Febuxos | 2008 |
Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.
Topics: Adult; Aged; Allopurinol; Creatinine; Dose-Response Relationship, Drug; Double-Blind Method; Febuxos | 2008 |
[Serum uric acid prevalence and changes post various antihypertensive agents in patients with essential hypertension].
Topics: Aged; Antihypertensive Agents; Chlorthalidone; Drug Therapy, Combination; Female; Humans; Hypertensi | 2008 |
Arthroscopic elimination of monosodium urate deposition of the first metatarsophalangeal joint reduces the recurrence of gout.
Topics: Adult; Arthritis, Gouty; Arthroscopy; Bone Transplantation; Debridement; Follow-Up Studies; Gout Sup | 2009 |
Uric acid and long-term outcomes in CKD.
Topics: Cardiovascular Diseases; Cause of Death; Confidence Intervals; Female; Follow-Up Studies; Glomerular | 2009 |
A single dose of rasburicase in elderly patients with hyperuricaemia reduces serum uric acid levels and improves renal function.
Topics: Aged; Aged, 80 and over; Female; Humans; Hyperuricemia; Kidney; Kidney Diseases; Kidney Function Tes | 2009 |
Acute, food-induced moderate elevation of plasma uric acid protects against hyperoxia-induced oxidative stress and increase in arterial stiffness in healthy humans.
Topics: Acute Disease; Adult; Beverages; Biomarkers; Brachial Artery; Cross-Over Studies; Elasticity; Ethano | 2009 |
A study of rasburicase for the management of hyperuricemia in pediatric patients with newly diagnosed hematologic malignancies at high risk for tumor lysis syndrome.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Drug Hypersensi | 2009 |
[Effects of micronized fenofibrate on lipid and uric acid metabolism in patients with hyperlipidemia].
Topics: Adult; Aged; Female; Fenofibrate; Humans; Hyperlipidemias; Hyperuricemia; Hypolipidemic Agents; Lipi | 2009 |
Efficacy and safety of losartan in treatment of hyperuricemia and posttransplantation erythrocytosis: results of a prospective, open, randomized, case-control study.
Topics: Adult; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Case-Control Studies | 2009 |
Uric acid-lowering treatment with benzbromarone in patients with heart failure: a double-blind placebo-controlled crossover preliminary study.
Topics: Aged; Benzbromarone; Double-Blind Method; Female; Heart Failure; Humans; Hyperuricemia; Male; Middle | 2010 |
The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Comorbidity; Dose-Response Relationship, Dr | 2010 |
The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Comorbidity; Dose-Response Relationship, Dr | 2010 |
The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Comorbidity; Dose-Response Relationship, Dr | 2010 |
The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Comorbidity; Dose-Response Relationship, Dr | 2010 |
Hypouricemic effect of statins: another pleiotropic benefit?
Topics: Atorvastatin; Biomarkers; C-Reactive Protein; Coronary Artery Bypass; Heptanoic Acids; Humans; Hydro | 2010 |
Effect of allopurinol in chronic kidney disease progression and cardiovascular risk.
Topics: Aged; Allopurinol; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Chi-Square Distribution; | 2010 |
Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone--results of a multicenter phase III study.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Antineoplastic Agents | 2010 |
The alkalizer citrate reduces serum uric Acid levels and improves renal function in hyperuricemic patients treated with the xanthine oxidase inhibitor allopurinol.
Topics: Allopurinol; Citric Acid; Creatinine; Drug Therapy, Combination; Female; Glomerular Filtration Rate; | 2010 |
Uric acid level and allopurinol use as risk markers of mortality and morbidity in systolic heart failure.
Topics: Aged; Allopurinol; Biomarkers; Enzyme Inhibitors; Female; Follow-Up Studies; Heart Failure, Systolic | 2010 |
Effect of the metabolic syndrome and hyperuricemia on outcome in patients with coronary artery disease (from the Bezafibrate Infarction Prevention Study).
Topics: Aged; Bezafibrate; Blood Glucose; Coronary Artery Disease; Dose-Response Relationship, Drug; Female; | 2010 |
Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment.
Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Creatinine; Dose-Response Relationship, Drug; Drug Moni | 2011 |
Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Double-Blind Method; Drug Administration Sc | 2010 |
Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Double-Blind Method; Drug Administration Sc | 2010 |
Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Double-Blind Method; Drug Administration Sc | 2010 |
Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Double-Blind Method; Drug Administration Sc | 2010 |
Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Double-Blind Method; Drug Administration Sc | 2010 |
Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Double-Blind Method; Drug Administration Sc | 2010 |
Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Double-Blind Method; Drug Administration Sc | 2010 |
Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Double-Blind Method; Drug Administration Sc | 2010 |
Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Double-Blind Method; Drug Administration Sc | 2010 |
The independent impact of congestive heart failure status and diuretic use on serum uric acid among men with a high cardiovascular risk profile: a prospective longitudinal study.
Topics: Adult; Diuretics; Heart Failure; Humans; Hyperuricemia; Longitudinal Studies; Male; Middle Aged; Pro | 2011 |
An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: p
Topics: Administration, Oral; Allopurinol; Dose-Response Relationship, Drug; Double-Blind Method; Febuxostat | 2011 |
A repeated oral administration study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with impaired renal function in Japan: pharmacokinetic and pharmacodynamic study.
Topics: Administration, Oral; Adult; Aged; Chromatography, High Pressure Liquid; Dose-Response Relationship, | 2011 |
Placebo-controlled double-blind dose-response study of the non-purine-selective xanthine oxidase inhibitor febuxostat (TMX-67) in patients with hyperuricemia (including gout patients) in japan: late phase 2 clinical study.
Topics: Administration, Oral; Dose-Response Relationship, Drug; Double-Blind Method; Febuxostat; Female; Fol | 2011 |
An allopurinol-controlled, multicenter, randomized, open-label, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phas
Topics: Administration, Oral; Allopurinol; Dose-Response Relationship, Drug; Double-Blind Method; Febuxostat | 2011 |
Multicenter, open-label study of long-term administration of febuxostat (TMX-67) in Japanese patients with hyperuricemia including gout.
Topics: Administration, Oral; Adult; Dose-Response Relationship, Drug; Febuxostat; Female; Follow-Up Studies | 2011 |
Chronic selective endothelin A receptor antagonism reduces serum uric acid in hypertensive chronic kidney disease.
Topics: Cross-Over Studies; Double-Blind Method; Endothelin A Receptor Antagonists; Hypertension; Hyperurice | 2011 |
A randomized study of allopurinol on endothelial function and estimated glomular filtration rate in asymptomatic hyperuricemic subjects with normal renal function.
Topics: Adult; Allopurinol; Analysis of Variance; Asymptomatic Diseases; Biomarkers; Blood Pressure; Blood P | 2011 |
To study the efficacy of Losartan on urinary uric acid excretion in Thiazide induced hyperuricemic and hypertensive patients.
Topics: Aged; Humans; Hydrochlorothiazide; Hypertension; Hyperuricemia; Kidney; Losartan; Middle Aged; Sodiu | 2011 |
[Assessment on the clinical efficacy and safety of xiezhuo chubi recipe in treating hyperuricemia].
Topics: Adolescent; Adult; Aged; Benzbromarone; Drugs, Chinese Herbal; Female; Humans; Hyperuricemia; Male; | 2011 |
Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Cardiovascular Diseases; Comorbidity; Febux | 2012 |
Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Cardiovascular Diseases; Comorbidity; Febux | 2012 |
Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Cardiovascular Diseases; Comorbidity; Febux | 2012 |
Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Cardiovascular Diseases; Comorbidity; Febux | 2012 |
Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Cardiovascular Diseases; Comorbidity; Febux | 2012 |
Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Cardiovascular Diseases; Comorbidity; Febux | 2012 |
Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Cardiovascular Diseases; Comorbidity; Febux | 2012 |
Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Cardiovascular Diseases; Comorbidity; Febux | 2012 |
Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Cardiovascular Diseases; Comorbidity; Febux | 2012 |
Treating hyperuricemia of gout: safety and efficacy of febuxostat and allopurinol in older versus younger subjects.
Topics: Adult; Age Distribution; Aged; Aged, 80 and over; Allopurinol; Febuxostat; Gout; Gout Suppressants; | 2011 |
[Clinical implication of endothelial dysfunction in patients with essential arterial hypertension and urate dysbolism with renal damage].
Topics: Adult; Albuminuria; Carotid Intima-Media Thickness; Endothelin-1; Endothelium, Vascular; Female; Hum | 2011 |
Evaluation and characterization of the effects of ticagrelor on serum and urinary uric acid in healthy volunteers.
Topics: Adenosine; Adult; Cross-Over Studies; Humans; Hyperuricemia; Hypoxanthine; Male; Middle Aged; Purine | 2012 |
The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age.
Topics: Aged; Aged, 80 and over; Biomarkers; Cohort Studies; Double-Blind Method; Febuxostat; Female; Gout; | 2012 |
Lowering serum uric acid to prevent acute kidney injury.
Topics: Acute Kidney Injury; Angiogenesis Inhibitors; Animals; Cisplatin; Glomerular Filtration Rate; Humans | 2012 |
Fractional clearance of urate: validation of measurement in spot-urine samples in healthy subjects and gouty patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cross-Over Studies; Female; Gout; Healthy Volunteers; Hu | 2012 |
Preservation of renal function during gout treatment with febuxostat: a quantitative study.
Topics: Adult; Aged; Allopurinol; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Kidney | 2013 |
Prednisone in Uric Acid lowering in Symptomatic Heart Failure Patients With Hyperuricemia (PUSH-PATH) study.
Topics: Adult; Allopurinol; Creatinine; Dyspnea; Female; Glomerular Filtration Rate; Glucocorticoids; Gout S | 2013 |
Prednisone in Uric Acid lowering in Symptomatic Heart Failure Patients With Hyperuricemia (PUSH-PATH) study.
Topics: Adult; Allopurinol; Creatinine; Dyspnea; Female; Glomerular Filtration Rate; Glucocorticoids; Gout S | 2013 |
Prednisone in Uric Acid lowering in Symptomatic Heart Failure Patients With Hyperuricemia (PUSH-PATH) study.
Topics: Adult; Allopurinol; Creatinine; Dyspnea; Female; Glomerular Filtration Rate; Glucocorticoids; Gout S | 2013 |
Prednisone in Uric Acid lowering in Symptomatic Heart Failure Patients With Hyperuricemia (PUSH-PATH) study.
Topics: Adult; Allopurinol; Creatinine; Dyspnea; Female; Glomerular Filtration Rate; Glucocorticoids; Gout S | 2013 |
Hyperuricemia and gout in renal transplant recipients.
Topics: Adult; Biomarkers; Causality; Creatinine; Cyclosporine; Dose-Response Relationship, Drug; Female; Fo | 2002 |
Further studies on the use of allopurinol to reduce plasma uric acid concentrations in the Red-tailed Hawk (Buteo jamaicensis) hyperuricaemic model.
Topics: Allopurinol; Animals; Bird Diseases; Female; Gout Suppressants; Hyperuricemia; Male; Postprandial Pe | 2002 |
Fenofibrate enhances urate reduction in men treated with allopurinol for hyperuricaemia and gout.
Topics: Acute Disease; Adult; Aged; Alkaline Phosphatase; Allopurinol; Arthritis, Gouty; Chronic Disease; Cr | 2003 |
Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on R
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Creatinine; Female; Humans; Hyperuricemia; In | 2003 |
Hyperuricaemia does not impair cardiovascular function in healthy adults.
Topics: Acetylcholine; Adolescent; Adult; Baroreflex; Blood Pressure; Cardiovascular Diseases; Endothelium, | 2004 |
Hyperuricaemia and preeclampsia: is there a pathogenic link?
Topics: Adult; Blood Pressure; Creatine; Female; Humans; Hyperuricemia; Platelet Count; Pre-Eclampsia; Pregn | 2004 |
[Clinical observation on treatment of nonalcoholic fatty liver disease complicating hyperuricemia by Zhifang I Decoction].
Topics: Adult; Aged; Alanine Transaminase; Drugs, Chinese Herbal; Fatty Liver; Female; gamma-Glutamyltransfe | 2004 |
Pharmacokinetics/pharmacodynamics of Y-700, a novel xanthine oxidase inhibitor, in rats and man.
Topics: Administration, Oral; Adult; Animals; Area Under Curve; Dose-Response Relationship, Drug; Enzyme Inh | 2004 |
A single dose of rasburicase is sufficient for the treatment of hyperuricemia in patients receiving chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Child; Humans; Hyperuricemia; Infant; Leukemia; Lymphoma; Middle | 2005 |
Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout.
Topics: Adult; Dose-Response Relationship, Drug; Double-Blind Method; Enzyme Inhibitors; Febuxostat; Female; | 2005 |
Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout.
Topics: Adult; Dose-Response Relationship, Drug; Double-Blind Method; Enzyme Inhibitors; Febuxostat; Female; | 2005 |
Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout.
Topics: Adult; Dose-Response Relationship, Drug; Double-Blind Method; Enzyme Inhibitors; Febuxostat; Female; | 2005 |
Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout.
Topics: Adult; Dose-Response Relationship, Drug; Double-Blind Method; Enzyme Inhibitors; Febuxostat; Female; | 2005 |
Effects of Rebixiao granules on blood uric acid in patients with repeatedly attacking acute gouty arthritis.
Topics: Acute Disease; Adult; Aged; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Dicl | 2005 |
Recombinant urate oxidase (Rasburicase) for the treatment of hyperuricemia in pediatric patients with hematologic malignancies: Results of a compassionate prospective multicenter study in Korea.
Topics: Adolescent; Child; Child, Preschool; Drug Administration Schedule; Female; Hematologic Neoplasms; Hu | 2006 |
Influence of cyclosporine and tacrolimus on serum uric acid levels in stable kidney transplant recipients.
Topics: Adult; Cyclosporine; Female; Humans; Hyperuricemia; Immunosuppressive Agents; Kidney Transplantation | 2005 |
Effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia in Chinese population.
Topics: Angiotensin II Type 1 Receptor Blockers; Asian People; Biphenyl Compounds; Blood Pressure; China; Do | 2006 |
Febuxostat compared with allopurinol in patients with hyperuricemia and gout.
Topics: Allopurinol; Double-Blind Method; Enzyme Inhibitors; Febuxostat; Female; Gout; Gout Suppressants; Hu | 2005 |
Febuxostat compared with allopurinol in patients with hyperuricemia and gout.
Topics: Allopurinol; Double-Blind Method; Enzyme Inhibitors; Febuxostat; Female; Gout; Gout Suppressants; Hu | 2005 |
Febuxostat compared with allopurinol in patients with hyperuricemia and gout.
Topics: Allopurinol; Double-Blind Method; Enzyme Inhibitors; Febuxostat; Female; Gout; Gout Suppressants; Hu | 2005 |
Febuxostat compared with allopurinol in patients with hyperuricemia and gout.
Topics: Allopurinol; Double-Blind Method; Enzyme Inhibitors; Febuxostat; Female; Gout; Gout Suppressants; Hu | 2005 |
Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase.
Topics: Adult; Aged; Carbon Radioisotopes; Female; Gout; Humans; Hyperuricemia; Immunoglobulin G; Male; Midd | 2006 |
Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level.
Topics: Adult; Aged; Allopurinol; Creatinine; Disease Progression; Enzyme Inhibitors; Female; Follow-Up Stud | 2006 |
Effect of losartan versus candesartan on uric acid, renal function, and fibrinogen in patients with hypertension and hyperuricemia associated with diuretics.
Topics: Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Diuretics; Female; Fibr | 2006 |
Association between intronic SNP in urate-anion exchanger gene, SLC22A12, and serum uric acid levels in Japanese.
Topics: Asian People; Creatinine; DNA Mutational Analysis; Female; Genetic Predisposition to Disease; Genoty | 2006 |
Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-treated gout patients.
Topics: Allopurinol; Benzbromarone; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Gou | 2007 |
Prevention and treatment of hyperuricemia with rasburicase in children with leukemia and non-Hodgkin's lymphoma.
Topics: Adolescent; Allopurinol; Child; Child, Preschool; Female; Humans; Hyperuricemia; Infant; Leukemia; L | 2007 |
Lack of association between serum uric acid and organ damage in a never-treated essential hypertensive population at low prevalence of hyperuricemia.
Topics: Adult; Albuminuria; Carotid Artery Diseases; Female; Humans; Hypertension; Hypertrophy, Left Ventric | 2007 |
[Comparative study on sequential colon dialysis, hemodialysis and peritoneal dialysis in patients with hyperuricemia].
Topics: Administration, Rectal; Adolescent; Adult; Aged; Calcium; Chlorides; Colon; Drugs, Chinese Herbal; F | 2007 |
Efficacy and (pharmaco)kinetics of one single dose of rasburicase in patients with chronic kidney disease.
Topics: Adult; Aged; Female; Humans; Hyperuricemia; Infusions, Intravenous; Kidney Failure, Chronic; Kidney | 2008 |
Population pharmacokinetic and pharmacodynamic analysis of pegloticase in subjects with hyperuricemia and treatment-failure gout.
Topics: Adult; Aged; Aged, 80 and over; Body Weight; Dose-Response Relationship, Drug; Drug Administration S | 2008 |
2287 other studies available for uric acid and Hyperuricemia
| Article | Year |
|---|---|
Uric acid may inhibit glucose-induced insulin secretion via binding to an essential arginine residue in rat pancreatic beta-cells.
Topics: Animals; Arginine; Glucose; Hyperuricemia; In Vitro Techniques; Insulin; Insulin Secretion; Islets o | 2005 |
Arterial Hypertension and Serum Uric Acid in Elderly- SEPHAR III Study.
Topics: Adult; Aged; Blood Pressure; Carotid Intima-Media Thickness; Humans; Hypertension; Hyperuricemia; Ri | 2021 |
Evaluation of uric acid disorders and associated factors in essential hypertensive patients at Wolkite University specialized hospital, Southern Ethiopia.
Topics: Adult; Cross-Sectional Studies; Essential Hypertension; Ethiopia; Female; Health Knowledge, Attitude | 2021 |
Pharmacologic inhibiting STAT3 delays the progression of kidney fibrosis in hyperuricemia-induced chronic kidney disease.
Topics: Aminosalicylic Acids; Animals; Benzenesulfonates; Disease Models, Animal; Fibrosis; Hyperuricemia; K | 2021 |
Positive association between body fat percentage and hyperuricemia in patients with hypertension: The China H-type hypertension registry study.
Topics: Adiposity; Biomarkers; Blood Pressure; China; Cross-Sectional Studies; Female; Humans; Hypertension; | 2021 |
Serum uric acid is associated with incident metabolic syndrome independent of body shape index and body roundness index in healthy individuals.
Topics: Adult; Biomarkers; Body Mass Index; Female; Humans; Hyperuricemia; Incidence; Male; Metabolic Syndro | 2021 |
Association between Serum Uric Acid and Hypertension in Han and Yugur of Gansu Province: The China National Health Survey.
Topics: Adult; China; Cross-Sectional Studies; Female; Health Surveys; Humans; Hypertension; Hyperuricemia; | 2021 |
Triterpenoid acids from medicinal mushroom Inonotus obliquus (Chaga) alleviate hyperuricemia and inflammation in hyperuricemic mice: Possible inhibitory effects on xanthine oxidase activity.
Topics: Agaricales; Animals; Gout; Hyperuricemia; Inflammation; Inonotus; Mice; Triterpenes; Uric Acid; Xant | 2022 |
Increase of serum uric acid levels associated with APOE ε2 haplotype: a clinico-genetic investigation and in vivo approach.
Topics: Adult; Aged; Animals; Apolipoprotein E2; Asian People; Female; Genetic Association Studies; Haplotyp | 2021 |
Neck Circumference Is Associated With Hyperuricemia in Women With Polycystic Ovary Syndrome.
Topics: Adult; Anthropometry; Body Mass Index; Cross-Sectional Studies; Female; Humans; Hyperuricemia; Neck; | 2021 |
Soluble expression of bioactive recombinant porcine-human chimeric uricase mutant employing MBP-SUMO fusion system.
Topics: Animals; Bioreactors; Cloning, Molecular; Escherichia coli; Gene Expression; Humans; Hyperuricemia; | 2022 |
Associations of plasma multiple metals with risk of hyperuricemia: A cross-sectional study in a mid-aged and older population of China.
Topics: Adult; China; Cross-Sectional Studies; Humans; Hyperuricemia; Metals; Middle Aged; Uric Acid | 2022 |
Multiparametric MRI analysis for the evaluation of renal function in patients with hyperuricemia: a preliminary study.
Topics: Adult; Area Under Curve; Humans; Hyperuricemia; Kidney; Male; Multiparametric Magnetic Resonance Ima | 2021 |
Epidemiology of gout and hyperuricemia in New Caledonia.
Topics: Adolescent; Adult; Ethnicity; Female; Gout; Humans; Hyperuricemia; Male; Middle Aged; New Caledonia; | 2022 |
Topics: Acute Kidney Injury; Animals; Animals, Outbred Strains; Carrier Proteins; Cytokines; Dietary Supplem | 2021 |
Antihyperuricemia and antigouty arthritis effects of Persicaria capitata herba in mice.
Topics: Animals; Arthritis, Gouty; Hyperuricemia; Mice; Oxonic Acid; Plant Extracts; Uric Acid; Xanthine Oxi | 2021 |
The Prognostic Value of Serum Uric Acid in Hospitalized Patients with Acute Cerebral Infarction.
Topics: Aged; Aged, 80 and over; Cerebral Infarction; Female; Hospital Mortality; Humans; Hyperuricemia; Inp | 2021 |
Polymorphisms of the genes
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; Case-Control Studies; Genetic Predispositio | 2021 |
Polymorphisms of the genes
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; Case-Control Studies; Genetic Predispositio | 2021 |
Polymorphisms of the genes
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; Case-Control Studies; Genetic Predispositio | 2021 |
Polymorphisms of the genes
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; Case-Control Studies; Genetic Predispositio | 2021 |
Triglyceride-glucose index is a predictive index of hyperuricemia events in elderly patients with hypertension: a cross-sectional study.
Topics: Aged; Blood Glucose; Cross-Sectional Studies; Female; Glucose; Humans; Hypertension; Hyperuricemia; | 2022 |
Metabolome-wide association study of serum exogenous chemical residues in a cohort with 5 major chronic diseases.
Topics: Chronic Disease; Fluorocarbons; Humans; Hyperuricemia; Metabolome; Uric Acid | 2022 |
Assessment of the relationship between serum uric acid levels and liver enzymes activity in Bangladeshi adults.
Topics: Adult; Aged; Alanine Transaminase; Bangladesh; Biomarkers; Cross-Sectional Studies; Female; gamma-Gl | 2021 |
CD38 activation by monosodium urate crystals contributes to inflammatory responses in human and murine macrophages.
Topics: ADP-ribosyl Cyclase 1; Animals; Crystallization; Female; Gene Expression Regulation; Gout; Humans; H | 2021 |
Dietary Acid Load Is Positively Associated with the Incidence of Hyperuricemia in Middle-Aged and Older Korean Adults: Findings from the Korean Genome and Epidemiology Study.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Diet; Female; Humans; Hyperuricemia; Incidence; Male; Middle | 2021 |
Calcitriol Treatment Attenuates Uric Acid-Induced Kidney Injury via Super Oxide Dismutase-1 (SOD-1) Upregulation and Fibrosis Reduction
Topics: Animals; Calcitriol; Fibrosis; Hyperuricemia; Mice; Superoxide Dismutase-1; Up-Regulation; Uric Acid | 2021 |
Uric Acid and Risk of Cardiovascular Disease: A Question of Start and Finish.
Topics: Cardiovascular Diseases; Humans; Hyperuricemia; Risk Factors; Uric Acid | 2021 |
Serum Uric Acid Levels and Their Changes and Risk of Stroke: A 7-Year Prospective Cohort Study in Northwest China.
Topics: China; Cohort Studies; Female; Humans; Hyperuricemia; Male; Prospective Studies; Risk Factors; Strok | 2022 |
Should we be more aware of gender aspects in hyperuricemia? Analysis of the population-based German health interview and examination survey for adults (DEGS1).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Comorbidity; Cross-Sectional St | 2021 |
High-level uric acid in asymptomatic hyperuricemia could be an isolated risk factor of cardio-cerebrovascular diseases: A prospective cohort study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Female; Heart Disease Risk Fact | 2021 |
A Novel Cascade Nanoreactor Integrating Two-Dimensional Pd-Ru Nanozyme, Uricase and Red Blood Cell Membrane for Highly Efficient Hyperuricemia Treatment.
Topics: Cell Membrane; Humans; Hyperuricemia; Nanotechnology; Urate Oxidase; Uric Acid | 2021 |
Eggshell Membrane Ameliorates Hyperuricemia by Increasing Urate Excretion in Potassium Oxonate-Injected Rats.
Topics: Animals; Egg Shell; Humans; Hyperuricemia; Inflammation; Injections; Kidney; Kidney Function Tests; | 2021 |
The anti-hyperuricemic effects of green alga Enteromorpha prolifera polysaccharide via regulation of the uric acid transporters in vivo.
Topics: Animals; Chlorophyta; Hyperuricemia; Male; Mice; Microbiota; Organic Anion Transporters; Plant Extra | 2021 |
Berberrubine attenuates potassium oxonate- and hypoxanthine-induced hyperuricemia by regulating urate transporters and JAK2/STAT3 signaling pathway.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; Berberine; Blood Urea Nitrogen; Ch | 2021 |
Association between hyperuricemia and hypertension: a case-control study.
Topics: Case-Control Studies; Diabetes Mellitus; Humans; Hypertension; Hyperuricemia; Risk Factors; Uric Aci | 2021 |
The effects of hyperuricemia on endothelial cells are mediated via GLUT9 and the JAK2/STAT3 pathway.
Topics: China; Endothelial Cells; Glucose Transport Proteins, Facilitative; Human Umbilical Vein Endothelial | 2021 |
Dietary patterns and risk for hyperuricemia in the general population: Results from the TCLSIH cohort study.
Topics: Animals; Cohort Studies; Female; Humans; Hyperuricemia; Male; Prospective Studies; Risk Factors; Uri | 2022 |
In Vivo Effects of Orally Administered Different Concentrations of Silver Oxide Nanoparticles in Hyperuricemic Mice.
Topics: Allopurinol; Animals; Antioxidants; Arthritis, Gouty; Hyperuricemia; Lipids; Metal Nanoparticles; Mi | 2022 |
Association Between Gut Microbiota and Elevated Serum Urate in Two Independent Cohorts.
Topics: Dysbiosis; Feces; Female; Gastrointestinal Microbiome; Humans; Hyperuricemia; Male; Middle Aged; RNA | 2022 |
Association between uric acid level and incidence of albuminuria in patients with type 2 diabetes mellitus: A 4.5-year cohort study.
Topics: Aged; Albuminuria; Animals; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Femal | 2021 |
Hypouricemic, hepatoprotective and nephroprotective roles of oligopeptides derived from
Topics: Animals; Fish Proteins; Hyperuricemia; Kidney; Male; Mice; Oligopeptides; Protective Agents; Uric Ac | 2021 |
Astaxanthin attenuated hyperuricemia and kidney inflammation by inhibiting uric acid synthesis and the NF-κ B/NLRP3 signaling pathways in potassium oxonate and hypoxanthine-induced hyperuricemia mice.
Topics: Animals; Antioxidants; Hyperuricemia; Hypoxanthine; Inflammation; Kidney; Male; Mice; Mice, Inbred I | 2021 |
Eurycomanol alleviates hyperuricemia by promoting uric acid excretion and reducing purine synthesis.
Topics: Animals; Hyperuricemia; Kidney; Mice; Purines; Quassins; Uric Acid | 2022 |
U-Shaped Association Between Serum Uric Acid and Short-Term Mortality in Patients With Infective Endocarditis.
Topics: Adult; Aged; Endocarditis; Female; Follow-Up Studies; Hospital Mortality; Humans; Hyperuricemia; Mal | 2021 |
Isorhamnetin, the xanthine oxidase inhibitor from
Topics: Animals; Disease Models, Animal; Hyperuricemia; Kidney; Male; Mice; Quercetin; Sophora; Uric Acid; X | 2021 |
Effect of chronic kidney disease on the association between hyperuricemia and new-onset hypertension in the general Japanese population: ISSA-CKD study.
Topics: Glomerular Filtration Rate; Humans; Hypertension; Hyperuricemia; Japan; Renal Insufficiency, Chronic | 2021 |
Establishment of a 3D hyperuricemia model based on cultured human liver organoids.
Topics: Hepatocytes; Humans; Hyperuricemia; Liver; Organoids; Uric Acid | 2022 |
Culture and establishment of self-renewing human liver 3D organoids with high uric acid for screening antihyperuricemic functional compounds.
Topics: Gout Suppressants; Humans; Hyperuricemia; Liver; Organoids; Uric Acid | 2022 |
The Effect of Body Weight and Alcohol Consumption on Hyperuricemia and Their Population Attributable Fractions: A National Health Survey in China.
Topics: Alcohol Drinking; Body Weight; China; Cross-Sectional Studies; Female; Health Surveys; Humans; Hyper | 2022 |
Effects of Renal Function on Urinary Excretion and Serum Concentration of Uric Acid in Patients Treated with Febuxostat for Chronic Kidney Disease.
Topics: Febuxostat; Glomerular Filtration Rate; Humans; Hyperuricemia; Kidney; Renal Insufficiency, Chronic; | 2022 |
Association between baseline serum uric acid and development of LDL-C level in patients with first acute myocardial infarction.
Topics: Aged; Biomarkers; China; Cholesterol, LDL; Dyslipidemias; Female; Hospitalization; Humans; Hyperuric | 2021 |
Serum uric acid level is associated with an increase in systolic blood pressure over time in female subjects: Linear mixed-effects model analyses.
Topics: Adult; Blood Pressure; Female; Humans; Hypertension; Hyperuricemia; Male; Middle Aged; Risk Factors; | 2022 |
Effect of changes in serum uric acid on the risk of stroke and its subtypes.
Topics: Adult; Humans; Hyperuricemia; Middle Aged; Myocardial Infarction; Prognosis; Risk Factors; Stroke; U | 2022 |
Hyperuricemia as a possible risk factor for abnormal lipid metabolism in the Chinese population: a cross-sectional study.
Topics: China; Cross-Sectional Studies; Female; Humans; Hyperuricemia; Lipid Metabolism; Lipids; Male; Risk | 2021 |
Mediation effect of obesity on the association between triglyceride-glucose index and hyperuricemia in Chinese hypertension adults.
Topics: Adult; Aged; Biomarkers; Blood Glucose; China; Cross-Sectional Studies; Female; Glucose; Humans; Hyp | 2022 |
Baseline uric acid levels and steady-state favipiravir concentrations are associated with occurrence of hyperuricemia among COVID-19 patients.
Topics: Amides; COVID-19; Humans; Hyperuricemia; Pyrazines; SARS-CoV-2; Uric Acid | 2022 |
Urate-lowering therapy for gout and asymptomatic hyperuricemia in the pediatric population: a cross-sectional study of a Japanese health insurance database.
Topics: Adolescent; Adult; Child; Cross-Sectional Studies; Gout; Gout Suppressants; Humans; Hyperuricemia; I | 2021 |
[RASBURICASE TREATMENT FOR NEONATAL ACUTE KIDNEY INJURY - A CASE REPORT].
Topics: Acute Kidney Injury; Humans; Hyperuricemia; Infant, Newborn; Urate Oxidase; Uric Acid | 2021 |
Dietary Inflammatory Index and the Risk of Hyperuricemia: A Cross-Sectional Study in Chinese Adult Residents.
Topics: Adult; China; Cross-Sectional Studies; Diet; Diet, Healthy; Female; Humans; Hyperuricemia; Inflammat | 2021 |
Evidence for the effect of soluble uric acid in augmenting endoplasmic reticulum stress markers in human peripheral blood mononuclear cells.
Topics: Biomarkers; Endoplasmic Reticulum Stress; Humans; Hyperuricemia; Inflammation; Interleukin-6; Leukoc | 2022 |
High prevalence and low awareness of hyperuricemia in hypertensive patients among adults aged 50-79 years in Southwest China.
Topics: Aged; China; Female; Humans; Hypertension; Hyperuricemia; Male; Middle Aged; Prevalence; Risk Factor | 2022 |
Risk of cardiovascular and all-cause events in hyperuricemia patients with special reference to diuretic use.
Topics: Cardiovascular System; Diuretics; Humans; Hyperuricemia; Uric Acid | 2022 |
Serum uric acid levels associated with biochemical parameters linked to preeclampsia severity and to adverse perinatal outcomes.
Topics: Cross-Sectional Studies; Female; Humans; Hyperuricemia; Infant, Newborn; Infant, Newborn, Diseases; | 2022 |
Discovery of novel verinurad analogs as dual inhibitors of URAT1 and GLUT9 with improved Druggability for the treatment of hyperuricemia.
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; Glucose Transport Proteins, Facilitative; H | 2022 |
Uric acid and uric acid/creatinine ratio and their correlations with the hemorheological determinants in subjects with subclinical carotid atherosclerosis.
Topics: Aged; Carotid Artery Diseases; Creatinine; Female; Humans; Hyperuricemia; Insulin Resistance; Male; | 2022 |
Association between hyperuricemia and glycated hemoglobin in type 2 diabetes at the District Hospital of Dschang.
Topics: Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Hospitals, District | 2021 |
Tolerogenic nanoparticles mitigate the formation of anti-drug antibodies against pegylated uricase in patients with hyperuricemia.
Topics: Adult; Aged; Antibodies; Biological Therapy; Double-Blind Method; Female; Humans; Hyperuricemia; Mal | 2022 |
Tolerogenic nanoparticles mitigate the formation of anti-drug antibodies against pegylated uricase in patients with hyperuricemia.
Topics: Adult; Aged; Antibodies; Biological Therapy; Double-Blind Method; Female; Humans; Hyperuricemia; Mal | 2022 |
Tolerogenic nanoparticles mitigate the formation of anti-drug antibodies against pegylated uricase in patients with hyperuricemia.
Topics: Adult; Aged; Antibodies; Biological Therapy; Double-Blind Method; Female; Humans; Hyperuricemia; Mal | 2022 |
Tolerogenic nanoparticles mitigate the formation of anti-drug antibodies against pegylated uricase in patients with hyperuricemia.
Topics: Adult; Aged; Antibodies; Biological Therapy; Double-Blind Method; Female; Humans; Hyperuricemia; Mal | 2022 |
Genetic risk of hyperuricemia in hypertensive patients associated with antihypertensive drug therapy: A longitudinal study.
Topics: Antihypertensive Agents; Diuretics; Glucose Transport Proteins, Facilitative; Humans; Hypertension; | 2022 |
Prevalence of asymptomatic hyperuricemia and its association with prediabetes, dyslipidemia and subclinical inflammation markers among young healthy adults in Qatar.
Topics: Adolescent; Adult; Biomarkers; Cross-Sectional Studies; Dyslipidemias; Female; Humans; Hyperuricemia | 2022 |
The bidirectional relationship between metabolic syndrome and hyperuricemia in China: A longitudinal study from CHARLS.
Topics: Adult; China; Female; Follow-Up Studies; Humans; Hyperuricemia; Incidence; Longitudinal Studies; Mal | 2022 |
Is Hyperuricemia a Marker of Severity of Disease in Scrub Typhus?
Topics: Female; Fever; Humans; Hyperuricemia; Male; Scrub Typhus; Severity of Illness Index; Uric Acid | 2022 |
Prognostic value of hyperuricemia for patients with sepsis in the intensive care unit.
Topics: Acute Kidney Injury; Adult; Aged; Critical Care; Databases, Factual; Female; Hospital Mortality; Hos | 2022 |
Effects of high serum uric acid levels on oxidative stress levels and semen parameters in male infertile patients.
Topics: Adult; Humans; Hyperuricemia; Infertility, Male; Luteinizing Hormone; Male; Middle Aged; Oxidative S | 2022 |
Prevalence and Clinical Predictors of Hyperuricemia in Chinese Bariatric Surgery Patients.
Topics: Bariatric Surgery; China; Cholesterol, HDL; Creatinine; Female; gamma-Glutamyltransferase; Humans; H | 2022 |
Discovery of 4-(phenoxymethyl)-1H-1,2,3-triazole derivatives as novel xanthine oxidase inhibitors.
Topics: Animals; Dose-Response Relationship, Drug; Drug Discovery; Enzyme Inhibitors; Hyperuricemia; Ligands | 2022 |
Discovery of Novel Bicyclic Imidazolopyridine-Containing Human Urate Transporter 1 Inhibitors as Hypouricemic Drug Candidates with Improved Efficacy and Favorable Druggability.
Topics: Animals; Gout; Humans; Hyperuricemia; Mice; Organic Anion Transporters; Organic Cation Transport Pro | 2022 |
Hyperuricemia is associated with secondary hyperparathyroidism in patients with chronic kidney disease.
Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Calcium; Cholecalciferol; Female; Furosemide; Humans; H | 2022 |
Impact of serum uric acid on subclinical myocardial injury in general population.
Topics: Adult; Female; Humans; Hyperuricemia; Male; Myocardial Infarction; Nutrition Surveys; Risk Factors; | 2022 |
Effects of uric acid-lowering therapy in patients with essential arterial hypertension.
Topics: Adult; Aged; Allopurinol; Blood Pressure; C-Reactive Protein; Carotid Intima-Media Thickness; Essent | 2022 |
The effect of serum uric acid in hospitalised patients with acute coronary syndrome in Al-Yarmouk Teaching Hospital.
Topics: Acute Coronary Syndrome; Adolescent; Female; Hospitals, Teaching; Humans; Hyperuricemia; Iraq; Male; | 2021 |
Association of plasma uric acid levels with cognitive function among non-hyperuricemia adults: A prospective study.
Topics: Adult; Cognition; Female; Humans; Hyperuricemia; Longitudinal Studies; Male; Middle Aged; Prospectiv | 2022 |
[Gout: an overview of diagnostics and treatment].
Topics: Gout; Humans; Hyperuricemia; Tomography, X-Ray Computed; Ultrasonography; Uric Acid | 2022 |
Colchicine use and the risk of CKD progression: a multicentre nested case-control study.
Topics: Case-Control Studies; Colchicine; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal | 2022 |
Correlation Between Serum Uric Acid and Body Fat Distribution in Patients With Polycystic Ovary Syndrome.
Topics: Absorptiometry, Photon; Adipose Tissue; Adult; Body Fat Distribution; Female; Humans; Hyperuricemia; | 2021 |
Anti-hyperuricemic bioactivity of Alstonia scholaris and its bioactive triterpenoids in vivo and in vitro.
Topics: Alstonia; Animals; Cell Line; Disease Models, Animal; Dose-Response Relationship, Drug; Humans; Hype | 2022 |
Early life PCB138 exposure induces kidney injury secondary to hyperuricemia in male mice.
Topics: Animals; Environmental Pollutants; Hyperuricemia; Kidney; Male; Mice; Polychlorinated Biphenyls; Uri | 2022 |
Prevalence of Hyperuricemia Among Chinese Adults: Findings From Two Nationally Representative Cross-Sectional Surveys in 2015-16 and 2018-19.
Topics: Adult; China; Cross-Sectional Studies; Female; Humans; Hyperuricemia; Male; Prevalence; Uric Acid | 2021 |
Asymptomatic Hyperuricemia Promotes Recovery from Ischemic Organ Injury by Modulating the Phenotype of Macrophages.
Topics: Acute Kidney Injury; Animals; Humans; Hyperuricemia; Inflammation; Ischemia; Macrophages; Mice; Phen | 2022 |
Glucose Transporter 9 (GLUT9) Plays an Important Role in the Placental Uric Acid Transport System.
Topics: Animals; Female; Glucose Transport Proteins, Facilitative; Humans; Hyperuricemia; Mice; Mice, Knocko | 2022 |
Which Clusters of Metabolic Syndrome Are the Most Associated with Serum Uric Acid?
Topics: Adult; Cross-Sectional Studies; Female; Humans; Hyperuricemia; Male; Metabolic Syndrome; Middle Aged | 2022 |
Topics: Humans; Hyperuricemia; Lactobacillus gasseri; Uric Acid | 2022 |
[Management of hyperuricemia in chronic kidney disease].
Topics: Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chronic; Uric Acid | 2022 |
Uricase-deficient rats with similarly stable serum uric acid to human's are sensitive model animals for studying hyperuricemia.
Topics: Allopurinol; Animals; Humans; Hyperuricemia; Kidney; Male; Rats; Urate Oxidase; Uric Acid | 2022 |
E4BP4 Regulates Hepatic Solute Carrier Family 2 Member 9 and Uric Acid Disposition in Mice.
Topics: Animals; Basic-Leucine Zipper Transcription Factors; Hyperuricemia; Liver; Mice; Transcription Facto | 2022 |
Prevalence and potential relevance of hyperuricemia in pediatric kidney transplant recipients-a CERTAIN registry analysis.
Topics: Child; Glomerular Filtration Rate; Humans; Hyperuricemia; Kidney Transplantation; Prevalence; Regist | 2022 |
A machine learning-assisted model for renal urate underexcretion with genetic and clinical variables among Chinese men with gout.
Topics: Asian People; Glucose Transport Proteins, Facilitative; Gout; Humans; Hyperuricemia; Machine Learnin | 2022 |
Novel anti-hyperuricemic hexapeptides derived from
Topics: Animals; Gastrointestinal Microbiome; Hyperuricemia; Mice; MicroRNAs; Molecular Docking Simulation; | 2022 |
Kidney and plasma metabolomics provide insights into the molecular mechanisms of urate nephropathy in a mouse model of hyperuricemia.
Topics: Animals; Hyperuricemia; Kidney; Kidney Diseases; Metabolomics; Mice; Uric Acid | 2022 |
Serum uric acid levels threshold for mortality in diabetic individuals: The URic acid Right for heArt Health (URRAH) project.
Topics: Diabetes Mellitus; Humans; Hyperuricemia; Risk Factors; Uric Acid | 2022 |
Improvement in Decline Rate of Estimated Glomerular Filtration Rate after Febuxostat Treatment in a Fabry Disease Patient with Enzyme Replacement Therapy-resistant Proteinuria.
Topics: Adult; alpha-Galactosidase; Enzyme Replacement Therapy; Fabry Disease; Febuxostat; Glomerular Filtra | 2022 |
The correlation of uric acid levels with biochemical parameters and dietary factors in individuals with asymptomatic hyperuricemia and gouty arthritis.
Topics: Arthritis, Gouty; Female; Gout; Humans; Hyperuricemia; Male; Triglycerides; Uric Acid; Vitamins | 2022 |
Blockade of Autophagy Prevents the Progression of Hyperuricemic Nephropathy Through Inhibiting NLRP3 Inflammasome-Mediated Pyroptosis.
Topics: Animals; Autophagy; Caspase 1; Humans; Hyperuricemia; Inflammasomes; NLR Family, Pyrin Domain-Contai | 2022 |
Triglyceride Glucose Index Is More Closely Related to Hyperuricemia Than Obesity Indices in the Medical Checkup Population in Xinjiang, China.
Topics: China; Female; Glucose; Humans; Hyperuricemia; Insulin Resistance; Male; Obesity; Obesity, Abdominal | 2022 |
Inflammaging and Vascular Function in Metabolic Syndrome: The Role of Hyperuricemia.
Topics: Adult; Carotid Arteries; Carotid Intima-Media Thickness; Female; Humans; Hyperuricemia; Male; Metabo | 2022 |
Hyperuricemia is Related to the Risk of Cardiovascular Diseases in Ethnic Chinese Elderly Women.
Topics: Adult; Aged; Cardiovascular Diseases; China; Cross-Sectional Studies; Ethnicity; Female; Humans; Hyp | 2022 |
Snoring and napping independently increased the serum uric acid levels and hyperuricemia risk: The Henan Rural Cohort Study.
Topics: Adult; Cohort Studies; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Humans; Hyperuricemia; Sl | 2022 |
Association between serum uric acid and α-klotho protein levels in the middle-aged population.
Topics: Adult; Aged; Aged, 80 and over; Female; Gout; Humans; Hyperuricemia; Klotho Proteins; Male; Middle A | 2022 |
Effects of black tea and black brick tea with fungal growth on lowering uric acid levels in hyperuricemic mice.
Topics: Animals; Camellia sinensis; Disease Models, Animal; Hyperuricemia; Mice; Organic Anion Transporters; | 2022 |
Association between circulating cystatin C and hyperuricemia: a cross-sectional study.
Topics: Aged; Cross-Sectional Studies; Cystatin C; Female; Humans; Hyperuricemia; Male; Metabolic Syndrome; | 2022 |
Association of self-reported snoring and hyperuricaemia: a large cross-sectional study in Chongqing, China.
Topics: Adult; Aged; China; Cross-Sectional Studies; Female; Humans; Hyperuricemia; Male; Middle Aged; Self | 2022 |
A fly GWAS for purine metabolites identifies human FAM214 homolog medusa, which acts in a conserved manner to enhance hyperuricemia-driven pathologies by modulating purine metabolism and the inflammatory response.
Topics: Animals; Drosophila melanogaster; Drosophila Proteins; Genome-Wide Association Study; Gout; Humans; | 2022 |
Association between Dietary Fiber Intake and Hyperuricemia among Chinese Adults: Analysis of the China Adult Chronic Disease and Nutrition Surveillance (2015).
Topics: Adolescent; Adult; China; Chronic Disease; Dietary Fiber; Edible Grain; Fabaceae; Humans; Hyperurice | 2022 |
Probiotic Characterization of
Topics: Animals; Caco-2 Cells; Gout; Gout Suppressants; Humans; Hyperuricemia; Levilactobacillus brevis; Mic | 2022 |
Prevalence of hyperuricemia and the relationship between serum uric acid concentrations and lipid parameters among King Abdulaziz University Hospital patients.
Topics: Female; Hospitals; Humans; Hyperuricemia; Male; Prevalence; Retrospective Studies; Risk Factors; Tri | 2022 |
Comparison of Serum Uric Acid Levels Among Men and Women with Metabolic Syndrome - A Study.
Topics: Adult; Cross-Sectional Studies; Female; Humans; Hyperuricemia; Male; Metabolic Syndrome; Obesity; Ri | 2022 |
Study of Serum Uric Acid Levels in Patients of Metabolic Syndrome in a Tertiary Care Centre in South India.
Topics: Female; Humans; Hyperuricemia; Male; Metabolic Syndrome; Prevalence; Tertiary Care Centers; Uric Aci | 2022 |
Can Uric Acid be Used as a Prognostic Factor to Determine the Severity of Covid 19 Infection.
Topics: Adolescent; Adult; COVID-19; Female; Humans; Hyperuricemia; Male; Middle Aged; Prognosis; Retrospect | 2022 |
Hyperuricemia as an Early Marker in Predicting Mortality and Morbidity in Patients with Sepsis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Biomarkers; Female; Humans; Hyperuricemia; Male; Middle | 2022 |
The Relationship between Alcohol Consumption and Gout: A Mendelian Randomization Study.
Topics: Alcohol Drinking; Gout; Humans; Hyperuricemia; Mendelian Randomization Analysis; Uric Acid | 2022 |
A flavonoid-rich fraction of Monolluma quadrangula inhibits xanthine oxidase and ameliorates potassium oxonate-induced hyperuricemia in rats.
Topics: Animals; Catalase; Creatinine; Cytokines; Flavonoids; Hyperuricemia; Inflammation; Kidney; Molecular | 2022 |
A Patient with Acute Kidney Injury Associated with Massive Proteinuria and Acute Hyperuricemia after Epileptic Seizures.
Topics: Acute Kidney Injury; Adult; Epilepsy; Humans; Hyperuricemia; Kidney; Male; Proteinuria; Seizures; Ur | 2022 |
Synthesis and biological evaluation of geniposide derivatives as inhibitors of hyperuricemia, inflammatory and fibrosis.
Topics: Animals; Fibrosis; Hyperuricemia; Inflammation; Iridoids; Kidney Diseases; Mice; Molecular Docking S | 2022 |
Elevated serum uric acid was associated with pre-inflammatory state and impacted the role of HDL-C on carotid atherosclerosis.
Topics: Atherosclerosis; Carotid Artery Diseases; Carotid Intima-Media Thickness; Carotid Stenosis; Choleste | 2022 |
Weak Association Between Genetic Markers of Hyperuricemia and Cardiorenal Outcomes: Insights From the STANISLAS Study Cohort With a 20-Year Follow-Up.
Topics: Blood Pressure Monitoring, Ambulatory; Carotid Intima-Media Thickness; Follow-Up Studies; Genetic Ma | 2022 |
Can hyperuricemia predict the progression risk of cerebral small vessel disease?
Topics: Adult; Cerebral Small Vessel Diseases; Disease Progression; Humans; Hyperuricemia; Magnetic Resonanc | 2022 |
High Level of Uric Acid Promotes Atherosclerosis by Targeting NRF2-Mediated Autophagy Dysfunction and Ferroptosis.
Topics: Animals; Atherosclerosis; Autophagy; Ferroptosis; Hyperuricemia; Mice; NF-E2-Related Factor 2; Plaqu | 2022 |
Association Between Low-Grade Inflammation and Hyperuricemia in Adults With Metabolic Syndrome in Yucatán, México.
Topics: Adult; Biomarkers; C-Reactive Protein; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; H | 2022 |
Noninvasive and Individual-Centered Monitoring of Uric Acid for Precaution of Hyperuricemia via Optical Supramolecular Sensing.
Topics: Gout; Humans; Hyperuricemia; Kidney; Uric Acid | 2022 |
Fatty liver index for hyperuricemia diagnosis: a community-based cohort study.
Topics: Adult; Cohort Studies; Fatty Liver; Humans; Hyperuricemia; Incidence; Uric Acid | 2022 |
Combined exposure to multiple metals on serum uric acid in NHANES under three statistical models.
Topics: Arsenic; Bayes Theorem; Cadmium; Cobalt; Humans; Hyperuricemia; Metals, Heavy; Models, Statistical; | 2022 |
Carvacrol Alleviates Hyperuricemia-Induced Oxidative Stress and Inflammation by Modulating the NLRP3/NF-κB Pathwayt.
Topics: Allopurinol; Animals; Arthritis, Gouty; Cymenes; Hyperuricemia; Inflammation; Male; NF-kappa B; NLR | 2022 |
The Association of Excess Body Weight with Risk of ESKD Is Mediated Through Insulin Resistance, Hypertension, and Hyperuricemia.
Topics: Adult; Biomarkers; Blood Glucose; Body Mass Index; Glucose; Humans; Hypertension; Hyperuricemia; Ins | 2022 |
Differential gene expression of ABCG2, SLC22A12, IL-1β, and ALPK1 in peripheral blood leukocytes of primary gout patients with hyperuricemia and their comorbidities: a case-control study.
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; Case-Control Studies; Gene Expression; Gout | 2022 |
Reference range of serum uric acid and prevalence of hyperuricemia: a cross-sectional study from baseline data of ELSA-Brasil cohort.
Topics: Adult; Brazil; Cross-Sectional Studies; Female; Humans; Hyperuricemia; Longitudinal Studies; Male; M | 2022 |
Quantification of uric acid concentration in tears by using PDMS inverse opal structure surface-enhanced Raman scattering substrates: Application in hyperuricemia.
Topics: Gold; Humans; Hyperuricemia; Metal Nanoparticles; Reproducibility of Results; Spectrum Analysis, Ram | 2022 |
Altered Gut Microbiota in Children With Hyperuricemia.
Topics: Adult; Bacteria; Child; Gastrointestinal Microbiome; Gout; Humans; Hyperuricemia; RNA, Ribosomal, 16 | 2022 |
Impact of hyperuricemia on coronary blood flow and in-hospital mortality in patients with acute myocardial infarction undergoing percutaneous coronary intervention.
Topics: Female; Hospital Mortality; Humans; Hyperuricemia; Male; Myocardial Infarction; Percutaneous Coronar | 2022 |
Cardiovascular risk and mortality in patients with hyperuricemia treated with febuxostat or allopurinol: a retrospective nation-wide cohort study in Austria 2014-2017.
Topics: Aged; Allopurinol; Austria; Cardiovascular Diseases; Cohort Studies; Febuxostat; Female; Gout; Gout | 2022 |
[Gout].
Topics: Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Symptom Flare Up; Uric Acid | 2022 |
A Clinical Profile of Patients with Hyperuricemia and the Relationship between Hyperuricemia and Metabolic Syndrome: A Cross-sectional Study at a Tertiary Hospital in the Indian Population.
Topics: Cardiovascular Diseases; Cross-Sectional Studies; Female; Humans; Hypertriglyceridemia; Hyperuricemi | 2022 |
Short Hexapeptide Optimized from Rice-Derived Peptide 1 Shows Promising Anti-hyperuricemia Activities.
Topics: Animals; Hyperuricemia; Kidney; Mice; Oryza; Peptides; Plant Proteins; Tissue Distribution; Uric Aci | 2022 |
Hyperuricemia Associated with Low Skeletal Muscle in the Middle-Aged and Elderly Population in China.
Topics: Aged; Body Mass Index; China; Cholesterol, HDL; Cross-Sectional Studies; Female; Humans; Hyperuricem | 2022 |
Are polymorphisms affecting serum urate, renal urate handling and alcohol intake associated with co-morbidities in gout cases? A case-control study using data from the UK Biobank.
Topics: Alcohol Drinking; Biological Specimen Banks; Case-Control Studies; Genetic Predisposition to Disease | 2022 |
Phytochemicals in traditional Chinese medicine can treat gout by regulating intestinal flora through inactivating NLRP3 and inhibiting XOD activity.
Topics: Gastrointestinal Microbiome; Gout; Humans; Hyperuricemia; Inflammation; Lipopolysaccharides; Medicin | 2022 |
Serum uric acid and diabetic peripheral neuropathy: a double-edged sword.
Topics: Diabetes Mellitus, Type 2; Diabetic Neuropathies; Humans; Hyperuricemia; Risk Factors; Uric Acid | 2023 |
Evaluation of renal microperfusion in hyperuricemic nephropathy by contrast-enhanced ultrasound imaging.
Topics: Animals; Contrast Media; Hyperuricemia; Kidney; Rats; Renal Insufficiency, Chronic; Ultrasonography; | 2022 |
The Anti-hyperuricemia and Anti-inflammatory Effects of Atractylodes Macrocephala in Hyperuricemia and Gouty Arthritis Rat Models.
Topics: AMP-Activated Protein Kinases; Animals; Anti-Inflammatory Agents; Arthritis, Gouty; Atractylodes; Hy | 2023 |
Hyperuricemia reduces neutrophil function.
Topics: CD18 Antigens; Humans; Hyperuricemia; Immunity, Innate; Neutrophil Infiltration; Neutrophils; Uric A | 2022 |
Association of Hyperuricemia with 10-Year Atherosclerotic Cardiovascular Disease Risk among Chinese Adults and Elders.
Topics: Adult; Aged; Atherosclerosis; Cardiovascular Diseases; China; Cross-Sectional Studies; Female; Human | 2022 |
Hyperuricemia and Its Association with Osteoporosis in a Large Asian Cohort.
Topics: Cohort Studies; Female; Humans; Hyperuricemia; Male; Odds Ratio; Osteoporosis; Risk Factors; Uric Ac | 2022 |
Synthesis and bioactivity evaluation of novel nuciferine derivatives with antihyperuricemia and nephroprotective effects.
Topics: Animals; Aporphines; Benzbromarone; Hyperuricemia; Mice; Molecular Docking Simulation; Organic Anion | 2022 |
Relationship between bisphenol A, bisphenol S, and bisphenol F and serum uric acid concentrations among school-aged children.
Topics: Benzhydryl Compounds; Child; Cohort Studies; Humans; Hyperuricemia; Male; Phenols; Sulfones; Uric Ac | 2022 |
Association Between Serum Uric Acid and Carotid Intima-Media Thickness in Different Fasting Blood Glucose Patterns: A Case-Control Study.
Topics: Blood Glucose; Carotid Artery Diseases; Carotid Intima-Media Thickness; Case-Control Studies; Choles | 2022 |
Caffeic acid phenethyl ester alleviated hypouricemia in hyperuricemic mice through inhibiting XOD and up-regulating OAT3.
Topics: Animals; Caffeic Acids; Hyperuricemia; Kidney; Mice; Molecular Docking Simulation; Organic Anion Tra | 2022 |
Birefringent crystals deposition and inflammasome expression in human atheroma plaques by levels of uricemia.
Topics: Caspase 1; Ethanol; Gout; Humans; Hyperuricemia; Inflammasomes; Interleukin-1beta; NLR Family, Pyrin | 2022 |
Synergistic Impacts of
Topics: Allopurinol; Alpinia; Animals; Creatinine; Drugs, Chinese Herbal; Hyperuricemia; Kidney; Plant Extra | 2022 |
Upregulated expression of FFAR2 and SOC3 genes is associated with gout.
Topics: Cytokines; Gout; Humans; Hyperuricemia; Symptom Flare Up; Uric Acid | 2023 |
Association of dietary patterns with blood uric acid concentration and hyperuricemia in northern Chinese adults.
Topics: Animals; China; Diet; Humans; Hyperuricemia; Nutrition Surveys; Risk Factors; Uric Acid | 2022 |
Prevalence of Patients Receiving Urate-Lowering Medicine in Greenland and Denmark: A Cross-Sectional Case-Control Study.
Topics: Case-Control Studies; Cross-Sectional Studies; Female; Gout; Gout Suppressants; Greenland; Humans; H | 2022 |
Association of Hyperuricemia with Impaired Left Ventricular Systolic Function in Patients with Atrial Fibrillation and Preserved Kidney Function: Analysis of the POL-AF Registry Cohort.
Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Diuretics; Humans; Hyperuricemia; Kidney; Middle Aged; | 2022 |
Hypouricemic effect of 2,4-dihydroxybenzoic acid methyl ester in hyperuricemic mice through inhibiting XOD and down-regulating URAT1.
Topics: Allopurinol; Animals; Benzbromarone; Esters; Hydroxybenzoates; Hyperuricemia; Kidney; Mice; Uric Aci | 2022 |
Associations between body mass index in different childhood age periods and hyperuricemia in young adulthood: the China Health and Nutrition Survey cohort study.
Topics: Adolescent; Adult; Body Mass Index; Child, Preschool; China; Cohort Studies; Cross-Sectional Studies | 2022 |
The Mediation Effect of Body Composition on the Association Between Menopause and Hyperuricemia: Evidence From China National Health Survey.
Topics: Body Composition; China; Female; Health Surveys; Humans; Hyperuricemia; Menopause; Uric Acid | 2022 |
Adipose Tissue Insulin Resistance Is Positively Associated With Serum Uric Acid Levels and Hyperuricemia in Northern Chinese Adults.
Topics: Adipose Tissue; Adult; China; Cross-Sectional Studies; Female; Humans; Hyperuricemia; Insulin; Insul | 2022 |
POSSIBILITIES OF RENOPROTECTION IN PATIENTS WITH CHRONIC KIDNEY DISEASE AND HYPERURICEMIA.
Topics: Allopurinol; Febuxostat; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chronic; Tre | 2022 |
Genetic contributions to female gout and hyperuricaemia using genome-wide association study and polygenic risk score analyses.
Topics: Female; Genetic Predisposition to Disease; Genome-Wide Association Study; Glucose Transport Proteins | 2023 |
Effects of Sporisorium reiliana polysaccharides and Phoenix dactylifera monosaccharides on the gut microbiota and serum metabolism in mice with fructose-induced hyperuricemia.
Topics: Animals; Fructose; Gastrointestinal Microbiome; Hyperuricemia; Mice; Monosaccharides; Phoeniceae; Po | 2022 |
Determination of total purine and free purine content in milk, soymilk, and enteral nutritional supplements to assist nutritional therapy for hyperuricemia and gout.
Topics: Aged; Animals; Gout; Humans; Hyperuricemia; Milk; Purines; Uric Acid | 2022 |
Relationship of Serum Uric Acid Level with Acute Ischemic Stroke: A Single-Center, Hospital-Based Study from Bangladesh.
Topics: Bangladesh; Brain Ischemia; Cholesterol; Cross-Sectional Studies; Hospitals; Humans; Hypertension; H | 2022 |
Protective effects of corni fructus extract in mice with potassium oxonate-induced hyperuricemia.
Topics: Animals; Antioxidants; Cornus; Gout; Hyperuricemia; Mice; Oxonic Acid; Plant Extracts; Uric Acid; Xa | 2022 |
Study of purine derivatives and their relation to renal disorders in patients with psoriasis.
Topics: Albumins; Case-Control Studies; Creatinine; Diuretics; Humans; Hyperuricemia; Kidney Diseases; Psori | 2023 |
[Ocena związku stężenia kwasu moczowego z przebiegiem zakażenia SARS-CoV-2].
Topics: C-Reactive Protein; Cardiovascular Diseases; COVID-19; Humans; Hyperuricemia; Retrospective Studies; | 2022 |
Association between Dietary Fat Intake and Hyperuricemia in Men with Chronic Kidney Disease.
Topics: Dietary Fats; Fatty Acids; Glomerular Filtration Rate; Humans; Hyperuricemia; Male; Middle Aged; Ren | 2022 |
Tea (
Topics: Animals; Camellia sinensis; Gastrointestinal Microbiome; Hyperuricemia; Metabolic Networks and Pathw | 2022 |
Relationship between serum uric acid and hypertension in patients with primary Sjögren's syndrome: A retrospective cohort study.
Topics: Humans; Hypertension; Hyperuricemia; Retrospective Studies; Risk Factors; Sjogren's Syndrome; Uric A | 2022 |
U-shaped association between abnormal serum uric acid levels and COVID-19 severity: reports from the Japan COVID-19 Task Force.
Topics: Cohort Studies; COVID-19; Humans; Hyperuricemia; Japan; Risk Factors; Uric Acid | 2022 |
The reality of treatment for hyperuricemia and gout in Japan: A historical cohort study using health insurance claims data.
Topics: Cohort Studies; Gout; Gout Suppressants; Humans; Hypertension; Hyperuricemia; Insurance, Health; Jap | 2022 |
The role of lipid profile in the relationship between particulate matters and hyperuricemia: A prospective population study.
Topics: Air Pollutants; China; Cholesterol, LDL; Environmental Exposure; Female; Humans; Hyperuricemia; Male | 2022 |
Muscle Fat Content Is Strongly Associated With Hyperuricemia: A Cross-Sectional Study in Chinese Adults.
Topics: Adult; China; Cross-Sectional Studies; Female; Humans; Hyperuricemia; Male; Muscle, Skeletal; Uric A | 2022 |
Effects of secukinumab and adalimumab on serum uric acid level in patients with plaque psoriasis.
Topics: Adalimumab; Antibodies, Monoclonal, Humanized; Biological Products; Chronic Disease; Humans; Hyperur | 2022 |
Lacticaseibacillus rhamnosus Fmb14 prevents purine induced hyperuricemia and alleviate renal fibrosis through gut-kidney axis.
Topics: Animals; Fibrosis; Humans; Hyperuricemia; Kidney; Kidney Diseases; Mice; Uric Acid | 2022 |
The relationship between serum uric acid levels and glomerular ischemic lesions in patients with Immunoglobin A nephropathy-a analytical cross-sectional study.
Topics: Cross-Sectional Studies; Glomerulonephritis, IGA; Humans; Hyperuricemia; Retrospective Studies; Uric | 2022 |
Acute joint swelling in psoriatic arthritis: Flare or "psout"-A 10-year-monocentric study on synovial fluid.
Topics: Adult; Arthritis, Psoriatic; Female; Gout; Humans; Hyperuricemia; Male; Retrospective Studies; Synov | 2022 |
Local genetic covariance between serum urate and kidney function estimated with Bayesian multitrait models.
Topics: Bayes Theorem; Genetic Predisposition to Disease; Genome-Wide Association Study; Humans; Hyperuricem | 2022 |
Xanthine oxidase inhibitor urate-lowering therapy titration to target decreases serum free fatty acids in gout and suppresses lipolysis by adipocytes.
Topics: Adipocytes; Allopurinol; Colchicine; Enzyme Inhibitors; Fatty Acids, Nonesterified; Febuxostat; Gout | 2022 |
Interaction between Hyperuricemia and Admission Lactate Increases the Risk of Acute Kidney Injury in Patients with ST-Segment Elevation Myocardial Infarction.
Topics: Acute Kidney Injury; Female; Humans; Hyperuricemia; Lactic Acid; Male; Risk Factors; ST Elevation My | 2022 |
Purine content of hospital meals and its effect on serum uric acid, urine pH, and urinary uric acid excretion.
Topics: Gout; Hospitals; Humans; Hydrogen-Ion Concentration; Hyperuricemia; Meals; Purines; Uric Acid | 2022 |
The safety and urate-lowering efficacy of febuxostat in patients undergoing peritoneal dialysis: a retrospective single-arm cohort study of 84 patients.
Topics: Cohort Studies; Disease Progression; Febuxostat; Female; Gout Suppressants; Humans; Hyperuricemia; M | 2022 |
Anti-inflammatory potential of stevia residue extract against uric acid-associated renal injury in mice.
Topics: Allopurinol; AMP-Activated Protein Kinases; Animals; Anti-Inflammatory Agents; Colchicine; Creatinin | 2022 |
Correlation of obesity, dietary patterns, and blood pressure with uric acid: data from the NHANES 2017-2018.
Topics: Blood Pressure; Cross-Sectional Studies; Gout; Humans; Hyperuricemia; Nutrition Surveys; Obesity; Ri | 2022 |
Genetic polymorphisms and decreased protein expression of ABCG2 urate transporters are associated with susceptibility to gout, disease severity and renal-overload hyperuricemia.
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; Gout; Humans; Hyperuricemia; Neoplasm Prote | 2023 |
Hyperuricemia and risk of hypertension resistant to therapy: a systematic review and meta-analysis: Erratum.
Topics: Humans; Hypertension; Hyperuricemia; Medical History Taking; Risk Factors; Uric Acid | 2022 |
Retinal Microvasculature and Choriocapillaris Flow Deficit in Relation to Serum Uric Acid Using Swept-Source Optical Coherence Tomography Angiography.
Topics: Angiography; Choroid; Cross-Sectional Studies; Female; Humans; Hyperuricemia; Male; Microvessels; Pr | 2022 |
Is febuxostat associated with higher risk of cardiovascular death than allopurinol in treating gout or asymptomatic hyperuricemia?
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Treatment Outcome; Uric Aci | 2022 |
Changes in the prevalence of hyperuricemia in clients of health examination in Eastern China, 2009 to 2019.
Topics: Adult; China; Female; Humans; Hyperuricemia; Male; Middle Aged; Prevalence; Risk Factors; Triglyceri | 2022 |
Chlorogenic Acid Prevents Hyperuricemia Nephropathy via Regulating TMAO-Related Gut Microbes and Inhibiting the PI3K/AKT/mTOR Pathway.
Topics: Animals; Chlorogenic Acid; Fibrosis; Gastrointestinal Microbiome; Hyperuricemia; Mammals; Methylamin | 2022 |
Association of hyperuricemia with apolipoprotein AI and atherogenic index of plasma in healthy Chinese people: a cross-sectional study.
Topics: Apolipoprotein A-I; Cardiovascular Diseases; China; Cross-Sectional Studies; Humans; Hyperuricemia; | 2022 |
Prevalence of hyperuricemia and the population attributable fraction of modifiable risk factors: Evidence from a general population cohort in China.
Topics: Adult; China; Female; Humans; Hyperuricemia; Male; Obesity; Overweight; Prevalence; Uric Acid | 2022 |
Anserine beneficial effects in hyperuricemic rats by inhibiting XOD, regulating uric acid transporter and repairing hepatorenal injury.
Topics: Alanine Transaminase; Alkaline Phosphatase; Allopurinol; Animals; Anserine; ATP-Binding Cassette Tra | 2022 |
Fufang Zhenzhu Tiaozhi capsule ameliorates hyperuricemic nephropathy by inhibition of PI3K/AKT/NF-κB pathway.
Topics: Animals; Fibrosis; Hyperuricemia; Inflammation; Kidney; Mice; NF-kappa B; Phosphatidylinositol 3-Kin | 2022 |
Discovery of novel benzbromarone analogs with improved pharmacokinetics and benign toxicity profiles as antihyperuricemic agents.
Topics: Animals; Benzbromarone; Hyperuricemia; Mice; Organic Anion Transporters; Organic Cation Transport Pr | 2022 |
[Screening, domestication and identification of intestinal uric acid degrading bacteria in low uric acid population].
Topics: Bacteria; Domestication; Ecosystem; Escherichia coli; Humans; Hyperuricemia; RNA, Ribosomal, 16S; Ur | 2022 |
Ethanol extract of Nepeta angustifoia C. Y. Wu ameliorates hyperuricemia in fructose-induced mice.
Topics: Animals; Creatinine; Drugs, Chinese Herbal; Ethanol; Fructose; Hyperuricemia; Kidney; Mice; Nepeta; | 2022 |
Serum uric acid is a predictive biomarker of incident metabolic syndrome at the Brazilian longitudinal study of adult Health (ELSA - Brasil).
Topics: Adult; Biomarkers; Brazil; Humans; Hyperuricemia; Longitudinal Studies; Metabolic Syndrome; Obesity; | 2022 |
Multi-omics analysis reveals therapeutic effects of Bacillus subtilis-fermented Astragalus membranaceus in hyperuricemia via modulation of gut microbiota.
Topics: Animals; Astragalus propinquus; Bacillus subtilis; Gastrointestinal Microbiome; Hyperuricemia; Kidne | 2023 |
The paradoxical relation between serum uric acid and outcomes of hip fracture in older patients after surgery: A 1-year follow-up study.
Topics: Aged; Female; Follow-Up Studies; Gout; Hip Fractures; Humans; Hyperuricemia; Male; Risk Factors; Uri | 2022 |
Topics: Animals; Claudin-1; Dendrobium; Hyperuricemia; Intestines; Kidney; Lipopolysaccharides; Nostrums; Ra | 2023 |
Extraction optimization, structural characterization and potential alleviation of hyperuricemia by flavone glycosides from celery seeds.
Topics: Allopurinol; Animals; Apigenin; Apium; Cytochromes c; Flavones; Glycosides; Hyperuricemia; Luteolin; | 2022 |
Association between dyslipidaemia and the risk of hyperuricaemia: a six-year longitudinal cohort study of elderly individuals in China.
Topics: Aged; China; Cohort Studies; Dyslipidemias; Humans; Hyperuricemia; Longitudinal Studies; Prospective | 2022 |
Clinical Effect of the Guizhi Shaoyao Zhimu Decoction in the Treatment of Hyperuricemia.
Topics: Gout; Humans; Hyperuricemia; Medicine, Chinese Traditional; Treatment Outcome; Uric Acid | 2022 |
Autophagy-dependent Na
Topics: Adenosine Triphosphatases; Adenosine Triphosphate; Animals; Autophagy; Hydroxychloroquine; Hyperuric | 2022 |
Effects of rosuvastatin on serum glucose and insulin in hyperuricemic rats.
Topics: Animals; Blood Glucose; Hyperuricemia; Insulin; Insulin Resistance; Rats; Rats, Sprague-Dawley; Rosu | 2022 |
AMP-activated protein kinase α2 contributes to acute and chronic hyperuricemic nephropathy via renal urate deposition in a mouse model.
Topics: AMP-Activated Protein Kinases; Animals; Disease Models, Animal; Fibrosis; Hyperuricemia; Kidney; Kid | 2022 |
Prevalence of hyperuricemia in patients with severe obesity and the relationship between serum uric acid and severe obesity: A decade retrospective cross-section study in Chinese adults.
Topics: Adult; China; Humans; Hyperuricemia; Obesity; Obesity, Morbid; Overweight; Prevalence; Retrospective | 2022 |
Short-Term Hyperuricemia Leads to Structural Retinal Changes That Can be Reversed by Serum Uric Acid Lowering Agents in Mice.
Topics: Allopurinol; Angiotensin II; Animals; Benzbromarone; Hyperuricemia; Macular Degeneration; Male; Matr | 2022 |
Modelling and assessing one- and two-drug dose titrations.
Topics: Allopurinol; Gout; Gout Suppressants; Humans; Hyperuricemia; Retrospective Studies; Uric Acid | 2022 |
Post-operative uric acid: a predictor for 30-days mortality of acute type A aortic dissection repair.
Topics: Aortic Dissection; Creatinine; Fibrinogen; Humans; Hyperuricemia; Retrospective Studies; Urea; Uric | 2022 |
Assessment of the influence on left ventricle by potassium oxonate and hypoxanthine-induced chronic hyperuricemia.
Topics: Animals; Heart Ventricles; Hyperuricemia; Hypoxanthines; Mice; Uric Acid | 2023 |
Associations of exposure to perfluoroalkyl substances with serum uric acid change and hyperuricemia among Chinese women: Results from a longitudinal study.
Topics: Aged; Alkanesulfonic Acids; Caprylates; China; Cross-Sectional Studies; Decanoic Acids; Environmenta | 2022 |
Demographic and clinical profile of black patients with chronic kidney disease attending a tertiary hospital in Johannesburg, South Africa.
Topics: Acidosis; Aged; Allopurinol; Anemia; Bicarbonates; Cross-Sectional Studies; Diabetes Mellitus; Doxaz | 2022 |
Hypouricemic effect of gallic acid, a bioactive compound from
Topics: Adenosine Deaminase; Adenosine Triphosphatases; Animals; Creatinine; Cyclooxygenase 2; Cystatins; Ga | 2022 |
Sex Difference in the Associations among Hyperuricemia with New-Onset Chronic Kidney Disease in a Large Taiwanese Population Follow-Up Study.
Topics: Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Hyperuricemia; Longitudinal Studies; | 2022 |
A modified xanthine oxidase cell model for screening of antihyperuricemic functional compounds.
Topics: Adenosine; Febuxostat; Gout Suppressants; Humans; Hyperuricemia; Hypoxanthines; Peptides; Uric Acid; | 2022 |
Intestinal Hyperuricemia as a Driving Mechanism for CKD.
Topics: Humans; Hyperuricemia; Renal Insufficiency, Chronic; Uric Acid | 2023 |
Hyperuricemia contributes to glucose intolerance of hepatic inflammatory macrophages and impairs the insulin signaling pathway
Topics: AMP-Activated Protein Kinases; Animals; Cytokines; Diabetes Mellitus, Type 2; Fluorodeoxyglucose F18 | 2022 |
Association between asymptomatic hyperuricemia and knee osteoarthritis in older outpatients.
Topics: Aged; Aged, 80 and over; Cross-Sectional Studies; Female; Humans; Hyperuricemia; Osteoarthritis, Kne | 2022 |
Hypouricemic and nephroprotective effects of palmatine from Cortex Phellodendri Amurensis: A uric acid modulator targeting Keap1-Nrf2/NLRP3 axis.
Topics: Animals; Creatinine; Hyperuricemia; Kelch-Like ECH-Associated Protein 1; Kidney; Mice; Molecular Doc | 2023 |
Association Among Polyphenol Intake, Uric Acid, and Hyperuricemia: A Cross-Sectional Analysis in a Population at High Cardiovascular Risk.
Topics: Cardiovascular Diseases; Coumaric Acids; Cross-Sectional Studies; Female; Heart Disease Risk Factors | 2022 |
Design, synthesis and activity evaluation of novel lesinurad analogues containing thienopyrimidinone or pyridine substructure as human urate transporter 1 inhibitors.
Topics: Animals; Gout; Humans; Hyperuricemia; Mice; Organic Anion Transporters; Organic Cation Transport Pro | 2022 |
Moderate hyperuricaemia ameliorated kidney damage in a low-renin model of experimental renal insufficiency.
Topics: Animals; Fibrosis; Hyperuricemia; Inflammation; Kidney; Kidney Diseases; Nephrectomy; Oxonic Acid; R | 2023 |
Polygenic risk score trend and new variants on chromosome 1 are associated with male gout in genome-wide association study.
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; Chromosomes, Human, Pair 1; Female; Genetic | 2022 |
Hyperuricemia: an unrecognized risk factor for kidney-related sequelae in children with hemolytic uremic syndrome.
Topics: Case-Control Studies; Child; Disease Progression; Escherichia coli Infections; Hemolytic-Uremic Synd | 2023 |
Fat-to-Muscle Ratio Is Independently Associated with Hyperuricemia and a Reduced Estimated Glomerular Filtration Rate in Chinese Adults: The China National Health Survey.
Topics: Adult; China; Cross-Sectional Studies; Electrolytes; Female; Glomerular Filtration Rate; Health Surv | 2022 |
Association of obesity phenotypes with left ventricular mass index and left ventricular hypertrophy in children and adolescents.
Topics: Child; Female; Humans; Hypertrophy, Left Ventricular; Hyperuricemia; Insulin Resistance; Male; Metab | 2022 |
Screening of lactic acid bacteria strains with urate-lowering effect from fermented dairy products.
Topics: Animals; Cultured Milk Products; Guanosine; Humans; Hyperuricemia; Lactobacillales; Rats; Uric Acid; | 2022 |
Type 3 innate lymphoid cells as an indicator of renal dysfunction and serum uric acid in hyperuricemia.
Topics: Humans; Hyperuricemia; Immunity, Innate; Interleukin-17; Kidney Diseases; Leukocytes, Mononuclear; L | 2023 |
Berberine Attenuates Hyperuricemia by Regulating Urate Transporters and Gut Microbiota.
Topics: Animals; Berberine; Gastrointestinal Microbiome; Humans; Hyperuricemia; Mice; RNA, Ribosomal, 16S; U | 2022 |
Hyperuricaemia and its association with other risk factors for cardiovascular diseases: A population-based study.
Topics: Adolescent; Cardiovascular Diseases; Cross-Sectional Studies; Female; Humans; Hypertension; Hyperuri | 2022 |
Association of obesity, triglyceride-glucose and its derivatives index with risk of hyperuricemia among college students in Qingdao, China.
Topics: Adolescent; Adult; China; Cross-Sectional Studies; Female; Glucose; Humans; Hyperuricemia; Male; Obe | 2022 |
Prevalence and factors related to hypouricemia and hyperuricemia in schoolchildren: results of a large-scale cross-sectional population-based study conducted in Japan.
Topics: Acid-Base Imbalance; Adolescent; Child; Cholesterol, HDL; Cholesterol, LDL; Cross-Sectional Studies; | 2022 |
[Advantages of the use of metformin in patients with impaired uric acid metabolism].
Topics: Anti-Inflammatory Agents; Diabetes Mellitus, Type 2; Gout; Humans; Hyperuricemia; Hypoglycemic Agent | 2021 |
[Prognostic impact of uric acid in patients with acute decompensated heart failure].
Topics: Diuretics; Female; Glomerular Filtration Rate; Heart Failure; Humans; Hyperuricemia; Male; Middle Ag | 2021 |
The Presence of Hyperhomocysteinemia Does Not Aggravate the Cardiometabolic Risk Imposed by Hyperuricemia in Young Individuals: A Retrospective Analysis of a Cross-Sectional Study.
Topics: Biomarkers; Blood Glucose; C-Reactive Protein; Cardiovascular Diseases; Cross-Sectional Studies; Hom | 2022 |
Anti-Gouty Arthritis and Anti-Hyperuricemia Properties of
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Arthritis, Gouty; Edema; Hyperuricemia; Interleukin | 2022 |
Exercise serum regulates uric acid transporters in normal rat kidney cells.
Topics: Animals; Hyperuricemia; Kidney; NF-kappa B; Organic Anion Transporters; Rats; Rats, Sprague-Dawley; | 2022 |
Anti-Hyperuricemic, Nephroprotective, and Gut Microbiota Regulative Effects of Separated Hydrolysate of α-Lactalbumin on Potassium Oxonate- and Hypoxanthine-Induced Hyperuricemic Mice.
Topics: Animals; Gastrointestinal Microbiome; Hyperuricemia; Hypoxanthines; Inflammation; Kidney; Lactalbumi | 2023 |
Gender Difference in the Association of Hyperuricemia with Insulin Resistance and beta-cell Function in Nondiabetic Korean Adults: The 2019 Korea National Health and Nutrition Examination Survey.
Topics: Adult; Female; Humans; Hyperuricemia; Insulin Resistance; Male; Nutrition Surveys; Obesity; Republic | 2023 |
Oxyberberrubine, a novel liver microsomes-mediated secondary metabolite of berberine, alleviates hyperuricemic nephropathy in mice.
Topics: Animals; Berberine; Hyperuricemia; Kidney; Mice; Microsomes, Liver; NLR Family, Pyrin Domain-Contain | 2023 |
Association between hyperuricemia and metabolic syndrome: A cross-sectional study in Tibetan adults on the Tibetan plateau.
Topics: Adult; Cross-Sectional Studies; Female; Humans; Hyperuricemia; Male; Metabolic Syndrome; Tibet; Uric | 2022 |
Associations of Liver Function Parameters with New-Onset Hyperuricemia in a Large Taiwanese Population Study.
Topics: Bilirubin; Female; Glucose; Humans; Hyperuricemia; Liver; Male; Risk Factors; Triglycerides; Uric Ac | 2022 |
Sulforaphane-driven reprogramming of gut microbiome and metabolome ameliorates the progression of hyperuricemia.
Topics: Animals; Ecosystem; Gastrointestinal Microbiome; Hyperuricemia; Male; Metabolome; Rats; Rats, Spragu | 2023 |
Live and pasteurized
Topics: Animals; Gastrointestinal Microbiome; Hyperuricemia; Inflammation; Mice; RNA, Messenger; Uric Acid; | 2022 |
Change of serum uric acid and progression of cardiometabolic multimorbidity among middle aged and older adults: A prospective cohort study.
Topics: Aged; Cardiovascular Diseases; Diabetes Mellitus; Humans; Hyperuricemia; Longitudinal Studies; Middl | 2022 |
Change of serum uric acid and progression of cardiometabolic multimorbidity among middle aged and older adults: A prospective cohort study.
Topics: Aged; Cardiovascular Diseases; Diabetes Mellitus; Humans; Hyperuricemia; Longitudinal Studies; Middl | 2022 |
Change of serum uric acid and progression of cardiometabolic multimorbidity among middle aged and older adults: A prospective cohort study.
Topics: Aged; Cardiovascular Diseases; Diabetes Mellitus; Humans; Hyperuricemia; Longitudinal Studies; Middl | 2022 |
Change of serum uric acid and progression of cardiometabolic multimorbidity among middle aged and older adults: A prospective cohort study.
Topics: Aged; Cardiovascular Diseases; Diabetes Mellitus; Humans; Hyperuricemia; Longitudinal Studies; Middl | 2022 |
Change of serum uric acid and progression of cardiometabolic multimorbidity among middle aged and older adults: A prospective cohort study.
Topics: Aged; Cardiovascular Diseases; Diabetes Mellitus; Humans; Hyperuricemia; Longitudinal Studies; Middl | 2022 |
Change of serum uric acid and progression of cardiometabolic multimorbidity among middle aged and older adults: A prospective cohort study.
Topics: Aged; Cardiovascular Diseases; Diabetes Mellitus; Humans; Hyperuricemia; Longitudinal Studies; Middl | 2022 |
Change of serum uric acid and progression of cardiometabolic multimorbidity among middle aged and older adults: A prospective cohort study.
Topics: Aged; Cardiovascular Diseases; Diabetes Mellitus; Humans; Hyperuricemia; Longitudinal Studies; Middl | 2022 |
Change of serum uric acid and progression of cardiometabolic multimorbidity among middle aged and older adults: A prospective cohort study.
Topics: Aged; Cardiovascular Diseases; Diabetes Mellitus; Humans; Hyperuricemia; Longitudinal Studies; Middl | 2022 |
Change of serum uric acid and progression of cardiometabolic multimorbidity among middle aged and older adults: A prospective cohort study.
Topics: Aged; Cardiovascular Diseases; Diabetes Mellitus; Humans; Hyperuricemia; Longitudinal Studies; Middl | 2022 |
Ultra-processed foods: Cross-sectional and longitudinal association with uric acid and hyperuricemia in ELSA-Brasil.
Topics: Adult; Brazil; Cross-Sectional Studies; Food, Processed; Humans; Hyperuricemia; Longitudinal Studies | 2023 |
Ultra-processed foods: Cross-sectional and longitudinal association with uric acid and hyperuricemia in ELSA-Brasil.
Topics: Adult; Brazil; Cross-Sectional Studies; Food, Processed; Humans; Hyperuricemia; Longitudinal Studies | 2023 |
Ultra-processed foods: Cross-sectional and longitudinal association with uric acid and hyperuricemia in ELSA-Brasil.
Topics: Adult; Brazil; Cross-Sectional Studies; Food, Processed; Humans; Hyperuricemia; Longitudinal Studies | 2023 |
Ultra-processed foods: Cross-sectional and longitudinal association with uric acid and hyperuricemia in ELSA-Brasil.
Topics: Adult; Brazil; Cross-Sectional Studies; Food, Processed; Humans; Hyperuricemia; Longitudinal Studies | 2023 |
Ultra-processed foods: Cross-sectional and longitudinal association with uric acid and hyperuricemia in ELSA-Brasil.
Topics: Adult; Brazil; Cross-Sectional Studies; Food, Processed; Humans; Hyperuricemia; Longitudinal Studies | 2023 |
Ultra-processed foods: Cross-sectional and longitudinal association with uric acid and hyperuricemia in ELSA-Brasil.
Topics: Adult; Brazil; Cross-Sectional Studies; Food, Processed; Humans; Hyperuricemia; Longitudinal Studies | 2023 |
Ultra-processed foods: Cross-sectional and longitudinal association with uric acid and hyperuricemia in ELSA-Brasil.
Topics: Adult; Brazil; Cross-Sectional Studies; Food, Processed; Humans; Hyperuricemia; Longitudinal Studies | 2023 |
Ultra-processed foods: Cross-sectional and longitudinal association with uric acid and hyperuricemia in ELSA-Brasil.
Topics: Adult; Brazil; Cross-Sectional Studies; Food, Processed; Humans; Hyperuricemia; Longitudinal Studies | 2023 |
Ultra-processed foods: Cross-sectional and longitudinal association with uric acid and hyperuricemia in ELSA-Brasil.
Topics: Adult; Brazil; Cross-Sectional Studies; Food, Processed; Humans; Hyperuricemia; Longitudinal Studies | 2023 |
Triglyceride-glucose index is significantly associated with the risk of hyperuricemia in patients with diabetic kidney disease.
Topics: Blood Glucose; Cross-Sectional Studies; Diabetes Mellitus; Diabetic Nephropathies; Glucose; Humans; | 2022 |
Triglyceride-glucose index is significantly associated with the risk of hyperuricemia in patients with diabetic kidney disease.
Topics: Blood Glucose; Cross-Sectional Studies; Diabetes Mellitus; Diabetic Nephropathies; Glucose; Humans; | 2022 |
Triglyceride-glucose index is significantly associated with the risk of hyperuricemia in patients with diabetic kidney disease.
Topics: Blood Glucose; Cross-Sectional Studies; Diabetes Mellitus; Diabetic Nephropathies; Glucose; Humans; | 2022 |
Triglyceride-glucose index is significantly associated with the risk of hyperuricemia in patients with diabetic kidney disease.
Topics: Blood Glucose; Cross-Sectional Studies; Diabetes Mellitus; Diabetic Nephropathies; Glucose; Humans; | 2022 |
Triglyceride-glucose index is significantly associated with the risk of hyperuricemia in patients with diabetic kidney disease.
Topics: Blood Glucose; Cross-Sectional Studies; Diabetes Mellitus; Diabetic Nephropathies; Glucose; Humans; | 2022 |
Triglyceride-glucose index is significantly associated with the risk of hyperuricemia in patients with diabetic kidney disease.
Topics: Blood Glucose; Cross-Sectional Studies; Diabetes Mellitus; Diabetic Nephropathies; Glucose; Humans; | 2022 |
Triglyceride-glucose index is significantly associated with the risk of hyperuricemia in patients with diabetic kidney disease.
Topics: Blood Glucose; Cross-Sectional Studies; Diabetes Mellitus; Diabetic Nephropathies; Glucose; Humans; | 2022 |
Triglyceride-glucose index is significantly associated with the risk of hyperuricemia in patients with diabetic kidney disease.
Topics: Blood Glucose; Cross-Sectional Studies; Diabetes Mellitus; Diabetic Nephropathies; Glucose; Humans; | 2022 |
Triglyceride-glucose index is significantly associated with the risk of hyperuricemia in patients with diabetic kidney disease.
Topics: Blood Glucose; Cross-Sectional Studies; Diabetes Mellitus; Diabetic Nephropathies; Glucose; Humans; | 2022 |
Plasma S-Klotho level affects the risk of hyperuricemia in the middle-aged and elderly people.
Topics: Adult; Aged; Cross-Sectional Studies; Female; Humans; Hyperuricemia; Male; Middle Aged; Nutrition Su | 2022 |
Plasma S-Klotho level affects the risk of hyperuricemia in the middle-aged and elderly people.
Topics: Adult; Aged; Cross-Sectional Studies; Female; Humans; Hyperuricemia; Male; Middle Aged; Nutrition Su | 2022 |
Plasma S-Klotho level affects the risk of hyperuricemia in the middle-aged and elderly people.
Topics: Adult; Aged; Cross-Sectional Studies; Female; Humans; Hyperuricemia; Male; Middle Aged; Nutrition Su | 2022 |
Plasma S-Klotho level affects the risk of hyperuricemia in the middle-aged and elderly people.
Topics: Adult; Aged; Cross-Sectional Studies; Female; Humans; Hyperuricemia; Male; Middle Aged; Nutrition Su | 2022 |
Plasma S-Klotho level affects the risk of hyperuricemia in the middle-aged and elderly people.
Topics: Adult; Aged; Cross-Sectional Studies; Female; Humans; Hyperuricemia; Male; Middle Aged; Nutrition Su | 2022 |
Plasma S-Klotho level affects the risk of hyperuricemia in the middle-aged and elderly people.
Topics: Adult; Aged; Cross-Sectional Studies; Female; Humans; Hyperuricemia; Male; Middle Aged; Nutrition Su | 2022 |
Plasma S-Klotho level affects the risk of hyperuricemia in the middle-aged and elderly people.
Topics: Adult; Aged; Cross-Sectional Studies; Female; Humans; Hyperuricemia; Male; Middle Aged; Nutrition Su | 2022 |
Plasma S-Klotho level affects the risk of hyperuricemia in the middle-aged and elderly people.
Topics: Adult; Aged; Cross-Sectional Studies; Female; Humans; Hyperuricemia; Male; Middle Aged; Nutrition Su | 2022 |
Plasma S-Klotho level affects the risk of hyperuricemia in the middle-aged and elderly people.
Topics: Adult; Aged; Cross-Sectional Studies; Female; Humans; Hyperuricemia; Male; Middle Aged; Nutrition Su | 2022 |
Prevalence and influence of hypouricemia on cardiovascular diseases in patients with rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Cardiovascular Diseases; Cross-Sectional Studies; Female; Humans; Hyperuricem | 2022 |
Prevalence and influence of hypouricemia on cardiovascular diseases in patients with rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Cardiovascular Diseases; Cross-Sectional Studies; Female; Humans; Hyperuricem | 2022 |
Prevalence and influence of hypouricemia on cardiovascular diseases in patients with rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Cardiovascular Diseases; Cross-Sectional Studies; Female; Humans; Hyperuricem | 2022 |
Prevalence and influence of hypouricemia on cardiovascular diseases in patients with rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Cardiovascular Diseases; Cross-Sectional Studies; Female; Humans; Hyperuricem | 2022 |
Prevalence and influence of hypouricemia on cardiovascular diseases in patients with rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Cardiovascular Diseases; Cross-Sectional Studies; Female; Humans; Hyperuricem | 2022 |
Prevalence and influence of hypouricemia on cardiovascular diseases in patients with rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Cardiovascular Diseases; Cross-Sectional Studies; Female; Humans; Hyperuricem | 2022 |
Prevalence and influence of hypouricemia on cardiovascular diseases in patients with rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Cardiovascular Diseases; Cross-Sectional Studies; Female; Humans; Hyperuricem | 2022 |
Prevalence and influence of hypouricemia on cardiovascular diseases in patients with rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Cardiovascular Diseases; Cross-Sectional Studies; Female; Humans; Hyperuricem | 2022 |
Prevalence and influence of hypouricemia on cardiovascular diseases in patients with rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Cardiovascular Diseases; Cross-Sectional Studies; Female; Humans; Hyperuricem | 2022 |
Coptisine protects against hyperuricemic nephropathy through alleviating inflammation, oxidative stress and mitochondrial apoptosis via PI3K/Akt signaling pathway.
Topics: Acute Kidney Injury; Animals; Hyperuricemia; Inflammation; Mice; Oxidative Stress; Phosphatidylinosi | 2022 |
Coptisine protects against hyperuricemic nephropathy through alleviating inflammation, oxidative stress and mitochondrial apoptosis via PI3K/Akt signaling pathway.
Topics: Acute Kidney Injury; Animals; Hyperuricemia; Inflammation; Mice; Oxidative Stress; Phosphatidylinosi | 2022 |
Coptisine protects against hyperuricemic nephropathy through alleviating inflammation, oxidative stress and mitochondrial apoptosis via PI3K/Akt signaling pathway.
Topics: Acute Kidney Injury; Animals; Hyperuricemia; Inflammation; Mice; Oxidative Stress; Phosphatidylinosi | 2022 |
Coptisine protects against hyperuricemic nephropathy through alleviating inflammation, oxidative stress and mitochondrial apoptosis via PI3K/Akt signaling pathway.
Topics: Acute Kidney Injury; Animals; Hyperuricemia; Inflammation; Mice; Oxidative Stress; Phosphatidylinosi | 2022 |
Coptisine protects against hyperuricemic nephropathy through alleviating inflammation, oxidative stress and mitochondrial apoptosis via PI3K/Akt signaling pathway.
Topics: Acute Kidney Injury; Animals; Hyperuricemia; Inflammation; Mice; Oxidative Stress; Phosphatidylinosi | 2022 |
Coptisine protects against hyperuricemic nephropathy through alleviating inflammation, oxidative stress and mitochondrial apoptosis via PI3K/Akt signaling pathway.
Topics: Acute Kidney Injury; Animals; Hyperuricemia; Inflammation; Mice; Oxidative Stress; Phosphatidylinosi | 2022 |
Coptisine protects against hyperuricemic nephropathy through alleviating inflammation, oxidative stress and mitochondrial apoptosis via PI3K/Akt signaling pathway.
Topics: Acute Kidney Injury; Animals; Hyperuricemia; Inflammation; Mice; Oxidative Stress; Phosphatidylinosi | 2022 |
Coptisine protects against hyperuricemic nephropathy through alleviating inflammation, oxidative stress and mitochondrial apoptosis via PI3K/Akt signaling pathway.
Topics: Acute Kidney Injury; Animals; Hyperuricemia; Inflammation; Mice; Oxidative Stress; Phosphatidylinosi | 2022 |
Coptisine protects against hyperuricemic nephropathy through alleviating inflammation, oxidative stress and mitochondrial apoptosis via PI3K/Akt signaling pathway.
Topics: Acute Kidney Injury; Animals; Hyperuricemia; Inflammation; Mice; Oxidative Stress; Phosphatidylinosi | 2022 |
Berberine Regulates the Metabolism of Uric Acid and Modulates Intestinal Flora in Hyperuricemia Rats Model.
Topics: Animals; Berberine; Gastrointestinal Microbiome; Hyperuricemia; Kidney; Male; Rats; Rats, Sprague-Da | 2023 |
Berberine Regulates the Metabolism of Uric Acid and Modulates Intestinal Flora in Hyperuricemia Rats Model.
Topics: Animals; Berberine; Gastrointestinal Microbiome; Hyperuricemia; Kidney; Male; Rats; Rats, Sprague-Da | 2023 |
Berberine Regulates the Metabolism of Uric Acid and Modulates Intestinal Flora in Hyperuricemia Rats Model.
Topics: Animals; Berberine; Gastrointestinal Microbiome; Hyperuricemia; Kidney; Male; Rats; Rats, Sprague-Da | 2023 |
Berberine Regulates the Metabolism of Uric Acid and Modulates Intestinal Flora in Hyperuricemia Rats Model.
Topics: Animals; Berberine; Gastrointestinal Microbiome; Hyperuricemia; Kidney; Male; Rats; Rats, Sprague-Da | 2023 |
Berberine Regulates the Metabolism of Uric Acid and Modulates Intestinal Flora in Hyperuricemia Rats Model.
Topics: Animals; Berberine; Gastrointestinal Microbiome; Hyperuricemia; Kidney; Male; Rats; Rats, Sprague-Da | 2023 |
Berberine Regulates the Metabolism of Uric Acid and Modulates Intestinal Flora in Hyperuricemia Rats Model.
Topics: Animals; Berberine; Gastrointestinal Microbiome; Hyperuricemia; Kidney; Male; Rats; Rats, Sprague-Da | 2023 |
Berberine Regulates the Metabolism of Uric Acid and Modulates Intestinal Flora in Hyperuricemia Rats Model.
Topics: Animals; Berberine; Gastrointestinal Microbiome; Hyperuricemia; Kidney; Male; Rats; Rats, Sprague-Da | 2023 |
Berberine Regulates the Metabolism of Uric Acid and Modulates Intestinal Flora in Hyperuricemia Rats Model.
Topics: Animals; Berberine; Gastrointestinal Microbiome; Hyperuricemia; Kidney; Male; Rats; Rats, Sprague-Da | 2023 |
Berberine Regulates the Metabolism of Uric Acid and Modulates Intestinal Flora in Hyperuricemia Rats Model.
Topics: Animals; Berberine; Gastrointestinal Microbiome; Hyperuricemia; Kidney; Male; Rats; Rats, Sprague-Da | 2023 |
Hyperuricemia during Pregnancy Leads to a Preeclampsia-Like Phenotype in Mice.
Topics: Animals; Blood Pressure; Female; Humans; Hypertension; Hyperuricemia; Mice; Phenotype; Pre-Eclampsia | 2022 |
Hyperuricemia during Pregnancy Leads to a Preeclampsia-Like Phenotype in Mice.
Topics: Animals; Blood Pressure; Female; Humans; Hypertension; Hyperuricemia; Mice; Phenotype; Pre-Eclampsia | 2022 |
Hyperuricemia during Pregnancy Leads to a Preeclampsia-Like Phenotype in Mice.
Topics: Animals; Blood Pressure; Female; Humans; Hypertension; Hyperuricemia; Mice; Phenotype; Pre-Eclampsia | 2022 |
Hyperuricemia during Pregnancy Leads to a Preeclampsia-Like Phenotype in Mice.
Topics: Animals; Blood Pressure; Female; Humans; Hypertension; Hyperuricemia; Mice; Phenotype; Pre-Eclampsia | 2022 |
Hyperuricemia during Pregnancy Leads to a Preeclampsia-Like Phenotype in Mice.
Topics: Animals; Blood Pressure; Female; Humans; Hypertension; Hyperuricemia; Mice; Phenotype; Pre-Eclampsia | 2022 |
Hyperuricemia during Pregnancy Leads to a Preeclampsia-Like Phenotype in Mice.
Topics: Animals; Blood Pressure; Female; Humans; Hypertension; Hyperuricemia; Mice; Phenotype; Pre-Eclampsia | 2022 |
Hyperuricemia during Pregnancy Leads to a Preeclampsia-Like Phenotype in Mice.
Topics: Animals; Blood Pressure; Female; Humans; Hypertension; Hyperuricemia; Mice; Phenotype; Pre-Eclampsia | 2022 |
Hyperuricemia during Pregnancy Leads to a Preeclampsia-Like Phenotype in Mice.
Topics: Animals; Blood Pressure; Female; Humans; Hypertension; Hyperuricemia; Mice; Phenotype; Pre-Eclampsia | 2022 |
Hyperuricemia during Pregnancy Leads to a Preeclampsia-Like Phenotype in Mice.
Topics: Animals; Blood Pressure; Female; Humans; Hypertension; Hyperuricemia; Mice; Phenotype; Pre-Eclampsia | 2022 |
Supplementation of
Topics: Animals; Dietary Supplements; Hyperuricemia; Lactobacillus plantarum; Male; Potassium; Rats; Rats, S | 2022 |
Supplementation of
Topics: Animals; Dietary Supplements; Hyperuricemia; Lactobacillus plantarum; Male; Potassium; Rats; Rats, S | 2022 |
Supplementation of
Topics: Animals; Dietary Supplements; Hyperuricemia; Lactobacillus plantarum; Male; Potassium; Rats; Rats, S | 2022 |
Supplementation of
Topics: Animals; Dietary Supplements; Hyperuricemia; Lactobacillus plantarum; Male; Potassium; Rats; Rats, S | 2022 |
Supplementation of
Topics: Animals; Dietary Supplements; Hyperuricemia; Lactobacillus plantarum; Male; Potassium; Rats; Rats, S | 2022 |
Supplementation of
Topics: Animals; Dietary Supplements; Hyperuricemia; Lactobacillus plantarum; Male; Potassium; Rats; Rats, S | 2022 |
Supplementation of
Topics: Animals; Dietary Supplements; Hyperuricemia; Lactobacillus plantarum; Male; Potassium; Rats; Rats, S | 2022 |
Supplementation of
Topics: Animals; Dietary Supplements; Hyperuricemia; Lactobacillus plantarum; Male; Potassium; Rats; Rats, S | 2022 |
Supplementation of
Topics: Animals; Dietary Supplements; Hyperuricemia; Lactobacillus plantarum; Male; Potassium; Rats; Rats, S | 2022 |
Status of Serum Uric Acid and Hyperuricemia among Adults in China: China Nutrition and Health Surveillance (2015).
Topics: Adult; Asian People; China; Humans; Hyperuricemia; Nutritional Status; Uric Acid | 2022 |
Status of Serum Uric Acid and Hyperuricemia among Adults in China: China Nutrition and Health Surveillance (2015).
Topics: Adult; Asian People; China; Humans; Hyperuricemia; Nutritional Status; Uric Acid | 2022 |
Status of Serum Uric Acid and Hyperuricemia among Adults in China: China Nutrition and Health Surveillance (2015).
Topics: Adult; Asian People; China; Humans; Hyperuricemia; Nutritional Status; Uric Acid | 2022 |
Status of Serum Uric Acid and Hyperuricemia among Adults in China: China Nutrition and Health Surveillance (2015).
Topics: Adult; Asian People; China; Humans; Hyperuricemia; Nutritional Status; Uric Acid | 2022 |
Association between metabolic obesity phenotype, transition of metabolic phenotypes and the risk of hyperuricemia in Chinese adults: A cohort study.
Topics: Cohort Studies; Female; Humans; Hyperuricemia; Male; Obesity; Overweight; Phenotype; Prospective Stu | 2022 |
Association between metabolic obesity phenotype, transition of metabolic phenotypes and the risk of hyperuricemia in Chinese adults: A cohort study.
Topics: Cohort Studies; Female; Humans; Hyperuricemia; Male; Obesity; Overweight; Phenotype; Prospective Stu | 2022 |
Association between metabolic obesity phenotype, transition of metabolic phenotypes and the risk of hyperuricemia in Chinese adults: A cohort study.
Topics: Cohort Studies; Female; Humans; Hyperuricemia; Male; Obesity; Overweight; Phenotype; Prospective Stu | 2022 |
Association between metabolic obesity phenotype, transition of metabolic phenotypes and the risk of hyperuricemia in Chinese adults: A cohort study.
Topics: Cohort Studies; Female; Humans; Hyperuricemia; Male; Obesity; Overweight; Phenotype; Prospective Stu | 2022 |
The relationship between hyperuricemia and anemia and metabolic syndrome in Korean adults: The Korea National Health and Nutrition Examination Survey 2019.
Topics: Adult; Anemia; Female; Humans; Hyperuricemia; Male; Metabolic Syndrome; Nutrition Surveys; Republic | 2023 |
The relationship between hyperuricemia and anemia and metabolic syndrome in Korean adults: The Korea National Health and Nutrition Examination Survey 2019.
Topics: Adult; Anemia; Female; Humans; Hyperuricemia; Male; Metabolic Syndrome; Nutrition Surveys; Republic | 2023 |
The relationship between hyperuricemia and anemia and metabolic syndrome in Korean adults: The Korea National Health and Nutrition Examination Survey 2019.
Topics: Adult; Anemia; Female; Humans; Hyperuricemia; Male; Metabolic Syndrome; Nutrition Surveys; Republic | 2023 |
The relationship between hyperuricemia and anemia and metabolic syndrome in Korean adults: The Korea National Health and Nutrition Examination Survey 2019.
Topics: Adult; Anemia; Female; Humans; Hyperuricemia; Male; Metabolic Syndrome; Nutrition Surveys; Republic | 2023 |
Amplification of Inflammation by Lubricin Deficiency Implicated in Incident, Erosive Gout Independent of Hyperuricemia.
Topics: Animals; Arthritis, Gouty; Cathepsin G; Female; Gout; Humans; Hyperuricemia; Inflammation; Interleuk | 2023 |
Amplification of Inflammation by Lubricin Deficiency Implicated in Incident, Erosive Gout Independent of Hyperuricemia.
Topics: Animals; Arthritis, Gouty; Cathepsin G; Female; Gout; Humans; Hyperuricemia; Inflammation; Interleuk | 2023 |
Amplification of Inflammation by Lubricin Deficiency Implicated in Incident, Erosive Gout Independent of Hyperuricemia.
Topics: Animals; Arthritis, Gouty; Cathepsin G; Female; Gout; Humans; Hyperuricemia; Inflammation; Interleuk | 2023 |
Amplification of Inflammation by Lubricin Deficiency Implicated in Incident, Erosive Gout Independent of Hyperuricemia.
Topics: Animals; Arthritis, Gouty; Cathepsin G; Female; Gout; Humans; Hyperuricemia; Inflammation; Interleuk | 2023 |
m(6)A methyltransferase METTL3 relieves cognitive impairment of hyperuricemia mice via inactivating MyD88/NF-κB pathway mediated NLRP3-ASC-Caspase1 inflammasome.
Topics: Adaptor Proteins, Signal Transducing; Animals; CARD Signaling Adaptor Proteins; Caspase 1; Cells, Cu | 2022 |
m(6)A methyltransferase METTL3 relieves cognitive impairment of hyperuricemia mice via inactivating MyD88/NF-κB pathway mediated NLRP3-ASC-Caspase1 inflammasome.
Topics: Adaptor Proteins, Signal Transducing; Animals; CARD Signaling Adaptor Proteins; Caspase 1; Cells, Cu | 2022 |
m(6)A methyltransferase METTL3 relieves cognitive impairment of hyperuricemia mice via inactivating MyD88/NF-κB pathway mediated NLRP3-ASC-Caspase1 inflammasome.
Topics: Adaptor Proteins, Signal Transducing; Animals; CARD Signaling Adaptor Proteins; Caspase 1; Cells, Cu | 2022 |
m(6)A methyltransferase METTL3 relieves cognitive impairment of hyperuricemia mice via inactivating MyD88/NF-κB pathway mediated NLRP3-ASC-Caspase1 inflammasome.
Topics: Adaptor Proteins, Signal Transducing; Animals; CARD Signaling Adaptor Proteins; Caspase 1; Cells, Cu | 2022 |
Uric acid accumulation in the kidney triggers mast cell degranulation and aggravates renal oxidative stress.
Topics: Animals; Cell Degranulation; Hyperuricemia; Kidney; Mast Cells; Oxidative Stress; Rats; Renin; Uric | 2023 |
Uric acid accumulation in the kidney triggers mast cell degranulation and aggravates renal oxidative stress.
Topics: Animals; Cell Degranulation; Hyperuricemia; Kidney; Mast Cells; Oxidative Stress; Rats; Renin; Uric | 2023 |
Uric acid accumulation in the kidney triggers mast cell degranulation and aggravates renal oxidative stress.
Topics: Animals; Cell Degranulation; Hyperuricemia; Kidney; Mast Cells; Oxidative Stress; Rats; Renin; Uric | 2023 |
Uric acid accumulation in the kidney triggers mast cell degranulation and aggravates renal oxidative stress.
Topics: Animals; Cell Degranulation; Hyperuricemia; Kidney; Mast Cells; Oxidative Stress; Rats; Renin; Uric | 2023 |
Folic Acid Protects against Hyperuricemia in C57BL/6J Mice via Ameliorating Gut-Kidney Axis Dysfunction.
Topics: Animals; Hyperuricemia; Kidney; Mice; Mice, Inbred C57BL; Molecular Docking Simulation; Uric Acid | 2022 |
Folic Acid Protects against Hyperuricemia in C57BL/6J Mice via Ameliorating Gut-Kidney Axis Dysfunction.
Topics: Animals; Hyperuricemia; Kidney; Mice; Mice, Inbred C57BL; Molecular Docking Simulation; Uric Acid | 2022 |
Folic Acid Protects against Hyperuricemia in C57BL/6J Mice via Ameliorating Gut-Kidney Axis Dysfunction.
Topics: Animals; Hyperuricemia; Kidney; Mice; Mice, Inbred C57BL; Molecular Docking Simulation; Uric Acid | 2022 |
Folic Acid Protects against Hyperuricemia in C57BL/6J Mice via Ameliorating Gut-Kidney Axis Dysfunction.
Topics: Animals; Hyperuricemia; Kidney; Mice; Mice, Inbred C57BL; Molecular Docking Simulation; Uric Acid | 2022 |
Flavonoid extract of saffron by-product alleviates hyperuricemia via inhibiting xanthine oxidase and modulating gut microbiota.
Topics: Animals; Crocus; Flavonoids; Flowers; Gastrointestinal Microbiome; Hyperuricemia; Plant Extracts; Ra | 2022 |
Flavonoid extract of saffron by-product alleviates hyperuricemia via inhibiting xanthine oxidase and modulating gut microbiota.
Topics: Animals; Crocus; Flavonoids; Flowers; Gastrointestinal Microbiome; Hyperuricemia; Plant Extracts; Ra | 2022 |
Flavonoid extract of saffron by-product alleviates hyperuricemia via inhibiting xanthine oxidase and modulating gut microbiota.
Topics: Animals; Crocus; Flavonoids; Flowers; Gastrointestinal Microbiome; Hyperuricemia; Plant Extracts; Ra | 2022 |
Flavonoid extract of saffron by-product alleviates hyperuricemia via inhibiting xanthine oxidase and modulating gut microbiota.
Topics: Animals; Crocus; Flavonoids; Flowers; Gastrointestinal Microbiome; Hyperuricemia; Plant Extracts; Ra | 2022 |
The Therapeutic Effect and the Potential Mechanism of Flavonoids and Phenolics of
Topics: Flavonoids; Hyperuricemia; Kidney; Molecular Docking Simulation; Moringa oleifera; Organic Anion Tra | 2022 |
The Therapeutic Effect and the Potential Mechanism of Flavonoids and Phenolics of
Topics: Flavonoids; Hyperuricemia; Kidney; Molecular Docking Simulation; Moringa oleifera; Organic Anion Tra | 2022 |
The Therapeutic Effect and the Potential Mechanism of Flavonoids and Phenolics of
Topics: Flavonoids; Hyperuricemia; Kidney; Molecular Docking Simulation; Moringa oleifera; Organic Anion Tra | 2022 |
The Therapeutic Effect and the Potential Mechanism of Flavonoids and Phenolics of
Topics: Flavonoids; Hyperuricemia; Kidney; Molecular Docking Simulation; Moringa oleifera; Organic Anion Tra | 2022 |
Chalcone derivatives as xanthine oxidase inhibitors: synthesis, binding mode investigation, biological evaluation, and ADMET prediction.
Topics: Animals; Chalcone; Chalcones; Enzyme Inhibitors; Gout; Hyperuricemia; Rats; Structure-Activity Relat | 2023 |
Chalcone derivatives as xanthine oxidase inhibitors: synthesis, binding mode investigation, biological evaluation, and ADMET prediction.
Topics: Animals; Chalcone; Chalcones; Enzyme Inhibitors; Gout; Hyperuricemia; Rats; Structure-Activity Relat | 2023 |
Chalcone derivatives as xanthine oxidase inhibitors: synthesis, binding mode investigation, biological evaluation, and ADMET prediction.
Topics: Animals; Chalcone; Chalcones; Enzyme Inhibitors; Gout; Hyperuricemia; Rats; Structure-Activity Relat | 2023 |
Chalcone derivatives as xanthine oxidase inhibitors: synthesis, binding mode investigation, biological evaluation, and ADMET prediction.
Topics: Animals; Chalcone; Chalcones; Enzyme Inhibitors; Gout; Hyperuricemia; Rats; Structure-Activity Relat | 2023 |
Marine Fish Protein Peptide Regulating Potassium Oxonate-Induced Intestinal Dysfunction in Hyperuricemia Rats Helps Alleviate Kidney Inflammation.
Topics: Animals; Carrier Proteins; Fish Proteins; Hyperuricemia; Inflammation; Intestinal Diseases; Kidney; | 2023 |
Associations of metal exposure with hyperuricemia and gout in general adults.
Topics: Cross-Sectional Studies; Gout; Humans; Hyperuricemia; Mercury; Nutrition Surveys; Selenium; Uric Aci | 2022 |
Optimal uric acid reduction to improve vascular endothelial function in patients with chronic heart failure complicated by hyperuricemia.
Topics: Chronic Disease; Diuretics; Endothelium, Vascular; Enzyme Inhibitors; Heart Failure; Humans; Hyperem | 2023 |
Overnutrition-induced gout: An immune response to NLRP3 inflammasome dysregulation by XOD activity increased in quail.
Topics: Animals; Arthritis, Gouty; Enzyme Inhibitors; Gout; Hyperuricemia; Immunity; Inflammasomes; NLR Fami | 2022 |
Uric acid relationships with lipid profile and adiposity indices: Impact of different hyperuricemic thresholds.
Topics: Adiposity; Body Mass Index; Humans; Hypertension; Hyperuricemia; Obesity; Obesity, Abdominal; Trigly | 2023 |
The lipid accumulation product (LAP) association with hyperuricemic hypertension in the China Health and Nutrition Survey: A cross-sectional study.
Topics: Adult; Body Mass Index; China; Cross-Sectional Studies; Female; Humans; Hypertension; Hyperuricemia; | 2022 |
Tips and pitfalls in uric acid clinical research.
Topics: Chronic Disease; Heart Failure; Humans; Hyperuricemia; Uric Acid | 2023 |
Vitamin D pathway gene variation rs3740165 is associated with serological uric acid levels in healthy Chinese women.
Topics: East Asian People; Female; Humans; Hyperuricemia; Middle Aged; Polymorphism, Single Nucleotide; Uric | 2022 |
The elevated visceral adiposity index increases the risk of hyperuricemia in Chinese hypertensive patients: A cross-sectional study.
Topics: Adiposity; Cross-Sectional Studies; East Asian People; Female; Humans; Hypertension; Hyperuricemia; | 2022 |
Associations between serum urate and telomere length and inflammation markers: Evidence from UK Biobank cohort.
Topics: Biological Specimen Banks; Biomarkers; Genome-Wide Association Study; Gout; Humans; Hyperuricemia; I | 2022 |
Preparation and Application of Nanozymes with Uricase-Like Activity Based on Molecularly Imprinted Polymers.
Topics: Humans; Hyperuricemia; Molecularly Imprinted Polymers; Urate Oxidase; Uric Acid | 2023 |
The relationship between leukocyte level and hypertension in elderly patients with hyperuricemia.
Topics: Aged; Cross-Sectional Studies; Endothelial Cells; Humans; Hypertension; Hyperuricemia; Interleukin-1 | 2022 |
Mediating effect of metabolic diseases on the relationship between hyperuricemia and coronary heart disease.
Topics: Cholesterol, HDL; Coronary Disease; Humans; Hyperlipidemias; Hyperuricemia; Risk Factors; Uric Acid | 2023 |
[Effect of granules made by new-medicinal parts of Crocus sativus on hyperuricemia in rats and its mechanism].
Topics: Animals; Creatinine; Crocus; Hyperuricemia; Kidney; Kidney Diseases; Rats; Uric Acid; Xanthine Oxida | 2022 |
HDAC Inhibitors Alleviate Uric Acid-Induced Vascular Endothelial Cell Injury by Way of the HDAC6/FGF21/PI3K/AKT Pathway.
Topics: Animals; Histone Deacetylase 6; Histone Deacetylase Inhibitors; Human Umbilical Vein Endothelial Cel | 2023 |
Transdermal delivery of allopurinol to acute hyperuricemic mice
Topics: Administration, Oral; Allopurinol; Animals; Hyperuricemia; Mice; Polymers; Povidone; Uric Acid | 2023 |
Discovery of coumaric acid derivatives hinted by coastal marine source to seek for uric acid lowering agents.
Topics: Allopurinol; Animals; Coumaric Acids; Humans; Hyperuricemia; Mice; Uric Acid; Xanthine Oxidase | 2023 |
Hypouricemic Actions of the Pericarp of Mangosteen
Topics: Animals; Garcinia mangostana; Hyperuricemia; Kidney; Mice; Rats; Uric Acid; Xanthine Oxidase | 2023 |
Evaluation of ABCG2-mediated extra-renal urate excretion in hemodialysis patients.
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; Gout; Humans; Hyperuricemia; Kidney; Neopla | 2023 |
Hyperuricemia increases the risk of cardiovascular mortality associated with very high HdL-cholesterol level.
Topics: Cardiovascular Diseases; Cholesterol, HDL; Female; Humans; Hypercholesterolemia; Hyperlipidemias; Hy | 2023 |
An elevation in serum uric acid precedes the development of preeclampsia.
Topics: Cohort Studies; Female; Humans; Hyperuricemia; Pre-Eclampsia; Pregnancy; Pregnancy Trimester, First; | 2023 |
Synergetic Association between Anemia and Hyperuricemia on New-Onset Chronic Kidney Disease in a Large Taiwanese Population Follow-Up Study.
Topics: Anemia; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Hyperuricemia; Longitudinal S | 2023 |
Ameliorative Effect of Mannuronate Oligosaccharides on Hyperuricemic Mice via Promoting Uric Acid Excretion and Modulating Gut Microbiota.
Topics: Animals; Blood Urea Nitrogen; Gastrointestinal Microbiome; Hyperuricemia; Kidney; Mice; Uric Acid | 2023 |
Hyperuricemia as an effect modifier of the association between metabolic phenotypes and nonalcoholic fatty liver disease in Chinese population.
Topics: Body Mass Index; East Asian People; Humans; Hyperuricemia; Metabolic Syndrome; Non-alcoholic Fatty L | 2023 |
Acute gout attacks during the perioperative period and risk factors of recurrence after orthopedic surgery among untreated gout patients.
Topics: Arthritis, Gouty; Gout; Humans; Hyperuricemia; Orthopedic Procedures; Perioperative Period; Retrospe | 2023 |
Prevalence and risk factors of hyperuricaemia in non-obese Chinese: a single-centre cross-sectional study.
Topics: Adult; Body Mass Index; China; Cross-Sectional Studies; East Asian People; Female; Humans; Hyperuric | 2022 |
Hyperuricemia exacerbates abdominal aortic aneurysm formation through the URAT1/ERK/MMP-9 signaling pathway.
Topics: Angiotensin II; Animals; Aorta, Abdominal; Aortic Aneurysm, Abdominal; Disease Models, Animal; Human | 2023 |
A Novel Approach Based on Gut Microbiota Analysis and Network Pharmacology to Explain the Mechanisms of Action of
Topics: Adenine; Animals; Cichorium intybus; Creatinine; Drugs, Chinese Herbal; Ethambutol; Gastrointestinal | 2023 |
Efficacy and safety of switching from febuxostat to dotinurad, a novel selective urate reabsorption inhibitor, in hyperuricemic patients with type 2 diabetic kidney disease: Protocol for a single-arm, open-label, prospective, exploratory study.
Topics: Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Substitution; Febuxostat; Humans; Hyperurice | 2022 |
A Crystal-Independent Role for Uric Acid in AKI Associated with Tumor Lysis Syndrome.
Topics: Acute Kidney Injury; Humans; Hyperuricemia; Tumor Lysis Syndrome; Uric Acid | 2023 |
Study on the correlation between maternal serum uric acid and foetal birth weight in Naqu, Tibet.
Topics: Birth Weight; Female; Fetal Weight; Humans; Hyperuricemia; Pregnancy; Retrospective Studies; Tibet; | 2023 |
[Anti-hyperuricemia activity and its mechanism of flavonoid extract from saffron floral bio-residues].
Topics: Adenine; Amino Acids; Animals; Antioxidants; Crocus; Ethambutol; Flavonoids; Hyperuricemia; Kidney; | 2023 |
Targeted and non-targeted metabolomics uncovering the effects of Er-Miao-Wan formula on rats with hyperuricemia.
Topics: Animals; Biomarkers; Chromatography, High Pressure Liquid; Drugs, Chinese Herbal; Fructose; Hyperuri | 2023 |
Association between serum uric acid levels and simple renal cyst risk in a nondiabetic population: A nested case-control study.
Topics: Case-Control Studies; Cysts; Female; Humans; Hyperuricemia; Kidney Diseases, Cystic; Male; Retrospec | 2023 |
Genetic and Physiological Effects of Insulin-Like Growth Factor-1 (IGF-1) on Human Urate Homeostasis.
Topics: Female; Genome-Wide Association Study; Glucose Transport Proteins, Facilitative; Homeostasis; Humans | 2023 |
The association among uric acid, microalbumin and estimated glomerular filtration rate in hypertensive patients: a case control study.
Topics: Adult; Case-Control Studies; Glomerular Filtration Rate; Humans; Hypertension; Hyperuricemia; Risk F | 2023 |
The Bidirectional Relationship between Chronic Kidney Disease and Hyperuricemia: Evidence from a Population-Based Prospective Cohort Study.
Topics: Follow-Up Studies; Glomerular Filtration Rate; Humans; Hyperuricemia; Prospective Studies; Renal Ins | 2023 |
The Association between Water Consumption and Hyperuricemia and Its Relation with Early Arterial Aging in Middle-Aged Lithuanian Metabolic Patients.
Topics: Aging; Blood Pressure; Drinking; Female; Humans; Hyperuricemia; Lithuania; Male; Middle Aged; Pulse | 2023 |
Urinary levels of kidney injury molecule-1 (KIM-1) and interleukin-18 (IL-18) in children and adolescents with hyperuricemia.
Topics: Adolescent; Adult; Biomarkers; Child; Female; Hepatitis A Virus Cellular Receptor 1; Humans; Hyperur | 2023 |
A metabonomic study to explore potential markers of asymptomatic hyperuricemia and acute gouty arthritis.
Topics: Arthritis, Gouty; Biomarkers; Gout; Humans; Hyperuricemia; Metabolomics; Uric Acid | 2023 |
Association between serum uric acid levels of patients with gout and their complications and examination fees: A cross-sectional analysis.
Topics: Cardiovascular Diseases; Cross-Sectional Studies; Female; Gout; Humans; Hyperuricemia; Kidney Diseas | 2023 |
Anti-Hyperuricemic Effect of Anserine Based on the Gut-Kidney Axis: Integrated Analysis of Metagenomics and Metabolomics.
Topics: Animals; Anserine; Hyperuricemia; Intestines; Kidney; Metabolomics; Rats; Uric Acid | 2023 |
TGF-β is elevated in hyperuricemic individuals and mediates urate-induced hyperinflammatory phenotype in human mononuclear cells.
Topics: Gout; Humans; Hyperuricemia; Leukocytes; Leukocytes, Mononuclear; Transforming Growth Factor beta; U | 2023 |
[Serum Uric Acid Level and Its Influencing Factors in Patients with Diabetes Insipidus].
Topics: Adolescent; Adult; Child; Cholesterol; Creatinine; Diabetes Insipidus; Diabetes Mellitus; Humans; Hy | 2023 |
Clinicopathological characteristics and associated factors of idiopathic membranous nephropathy with hyperuricemia: a single-centered cross-sectional study.
Topics: Complement C1q; Creatinine; Cross-Sectional Studies; Female; Glomerulonephritis, Membranous; Humans; | 2023 |
Risk Factors for Hyperuricemia or Gout in Men and Women: The Circulatory Risk in Communities Study (CIRCS).
Topics: Diabetes Mellitus; Female; Gout; Humans; Hypercholesterolemia; Hypertension; Hypertriglyceridemia; H | 2023 |
Temporal relationship between hyperuricemia and hypertension and its impact on future risk of cardiovascular disease.
Topics: Blood Pressure; Cardiovascular Diseases; Humans; Hypertension; Hyperuricemia; Risk Factors; Uric Aci | 2023 |
Effects of Uric Acid-Lowering Therapy on the Kidney (HTR-2023-0096.R2).
Topics: Febuxostat; Humans; Hyperuricemia; Kidney; Uric Acid | 2023 |
Metabolic Syndrome and Its Components Are Associated with New-Onset Hyperuricemia in a Large Taiwanese Population Follow-Up Study.
Topics: Adult; Female; Follow-Up Studies; Humans; Hyperuricemia; Male; Metabolic Syndrome; Middle Aged; Obes | 2023 |
Superiority of low-dose benzbromarone to low-dose febuxostat in gout patients with renal uric acid underexcretion: comment on the article by Yan et al.
Topics: Allopurinol; Benzbromarone; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Treatment Ou | 2023 |
Wuling San Based on Network Pharmacology and in vivo Evidence Against Hyperuricemia via Improving Oxidative Stress and Inhibiting Inflammation.
Topics: Animals; Drugs, Chinese Herbal; Hyperuricemia; Inflammation; Molecular Docking Simulation; Network P | 2023 |
Lowering Serum Urate With Urate-Lowering Therapy to Target and Incident Fracture Among People With Gout.
Topics: Adult; Gout; Gout Suppressants; Hip Fractures; Humans; Hyperuricemia; Uric Acid | 2023 |
Golden mean of serum uric acid level on the risk of kidney function decline.
Topics: Glomerular Filtration Rate; Humans; Hyperuricemia; Kidney; Renal Insufficiency, Chronic; Risk Factor | 2023 |
Protective effect of sodium butyrate on intestinal barrier damage and uric acid reduction in hyperuricemia mice.
Topics: Animals; Butyric Acid; Caco-2 Cells; Disease Models, Animal; Fatty Acids, Volatile; Humans; Hyperuri | 2023 |
Distinct hyperuricemia trajectories are associated with different risks of incident diabetes: A prospective cohort study.
Topics: Adult; Diabetes Mellitus; Dyslipidemias; Humans; Hypertension; Hyperuricemia; Middle Aged; Obesity; | 2023 |
The
Topics: Adult; Aged; ATP Binding Cassette Transporter, Subfamily G, Member 2; Biological Specimen Banks; Cas | 2023 |
Baicalin and baicalein attenuate hyperuricemic nephropathy via inhibiting PI3K/AKT/NF-κB signalling pathway.
Topics: Animals; Hyperuricemia; Inflammation; Mice; Molecular Docking Simulation; NF-kappa B; Phosphatidylin | 2023 |
Uric acid is independently associated with interleukin-1β levels in tear fluid of hyperuricemia and gout patients.
Topics: Gout; Humans; Hyperuricemia; Interleukin-1beta; Tumor Necrosis Factor-alpha; Uric Acid | 2023 |
Clinical implications of the biological ambivalence of uric acid.
Topics: Humans; Hyperuricemia; Uric Acid | 2023 |
Association between dietary approaches to stop hypertension (DASH) diet and hyperuricemia among Chinese adults: findings from a nationwide representative study.
Topics: Adult; Diet; Dietary Approaches To Stop Hypertension; East Asian People; Humans; Hypertension; Hyper | 2023 |
In vivo anti-hyperuricemia and anti-gouty arthritis effects of the ethanol extract from Amomumvillosum Lour.
Topics: Arthritis, Gouty; Ethanol; Humans; Hyperuricemia; Plant Extracts; Uric Acid; Xanthine Oxidase | 2023 |
Hypertension severity, apparent treatment resistant hypertension and hyperuricemia in the REasons for Geographic And Racial Differences in Stroke (REGARDS) study.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Female; Humans; Hypertension; Hyperuricemia; Male; R | 2023 |
Comparative analyses of surrogates of metabolic syndrome in children and adolescents with metabolically healthy obesity vs. metabolically unhealthy obesity according to Damanhoury's criteria.
Topics: Body Mass Index; Child; Female; Humans; Hyperuricemia; Metabolic Syndrome; Obesity, Metabolically Be | 2023 |
Distribution of serum uric acid concentration and its association with lipid profiles: a single-center retrospective study in children aged 3 to 12 years with adenoid and tonsillar hypertrophy.
Topics: Adenoids; Child; Dyslipidemias; Humans; Hypertrophy; Hyperuricemia; Lipids; Retrospective Studies; R | 2023 |
Hyperuricemia may be associated with muscle wellness in older adults.
Topics: Aged; Cross-Sectional Studies; Female; Humans; Hyperuricemia; Male; Malnutrition; Muscles; Retrospec | 2023 |
Intestinal uric acid excretion contributes to serum uric acid decrease during acute gout attack.
Topics: Animals; Arthritis, Gouty; ATP-Binding Cassette Transporters; Caco-2 Cells; Gout; Humans; Hyperurice | 2023 |
Association of Metabolic Syndrome and Hyperuricemia in the Recipients of Kidney Transplants: A Single-Center Study.
Topics: Cross-Sectional Studies; Humans; Hyperuricemia; Kidney Transplantation; Metabolic Syndrome; Tacrolim | 2023 |
Prevalence and clinical association of hyperechoic crystal deposits on ultrasonography in patients with chronic kidney disease: a cross-sectional study from a single center.
Topics: Cross-Sectional Studies; Female; Glomerular Filtration Rate; Gout; Humans; Hyperuricemia; Male; Prev | 2023 |
Simiao San alleviates hyperuricemia and kidney inflammation by inhibiting NLRP3 inflammasome and JAK2/STAT3 signaling in hyperuricemia mice.
Topics: Animals; Creatinine; Hyperuricemia; Inflammasomes; Inflammation; Interleukin-10; Interleukin-6; Janu | 2023 |
Oral Delivery of Nanoparticles Carrying Ancestral Uricase Enzyme Protects against Hyperuricemia in Knockout Mice.
Topics: Animals; Humans; Hyperuricemia; Mice; Mice, Knockout; Nanoparticles; Urate Oxidase; Uric Acid | 2023 |
Comparison of benzbromarone and allopurinol on the risk of chronic kidney disease in people with asymptomatic hyperuricemia.
Topics: Allopurinol; Benzbromarone; Female; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Ren | 2023 |
Urate-Lowering Therapy Inhibits Thoracic Aortic Aneurysm and Dissection Formation in Mice.
Topics: Allopurinol; Aminopropionitrile; Animals; Aortic Aneurysm, Thoracic; Aortic Dissection; Disease Mode | 2023 |
Hyperuricaemia: prevalence and association with mortality in an elderly Finnish population.
Topics: Aged; Female; Finland; Humans; Hyperuricemia; Male; Middle Aged; Prevalence; Prospective Studies; Ri | 2023 |
Exploring the mechanism underlying hyperuricemia using comprehensive research on multi-omics.
Topics: Animals; Caffeine; Gout; Humans; Hyperuricemia; Mice; Multiomics; Tandem Mass Spectrometry; Uric Aci | 2023 |
Uric Acid in Primary Hyperparathyroidism: Assessment of Surgical versus Conservative Approach.
Topics: Calcium; Humans; Hyperparathyroidism, Primary; Hyperuricemia; Parathyroidectomy; Retrospective Studi | 2023 |
Association between hyperuricemia and acute kidney injury in critically ill patients with sepsis.
Topics: Acute Kidney Injury; Adult; China; Critical Illness; Female; Humans; Hyperuricemia; Intensive Care U | 2023 |
The relationship between anemia and hyperuricemia and hypertension in Korean adults: the Korea National Health and Nutrition Examination Survey 2016-2018.
Topics: Adult; Anemia; Female; Humans; Hypertension; Hyperuricemia; Male; Nutrition Surveys; Republic of Kor | 2023 |
Anaerobic purinolytic enzymes enable dietary purine clearance by engineered gut bacteria.
Topics: Anaerobiosis; Animals; Drosophila melanogaster; Escherichia coli; Gout; Humans; Hydrolases; Hyperuri | 2023 |
Effect of Dietary Counseling on Patients with Asymptomatic Hyperuricemia.
Topics: Female; Glomerular Filtration Rate; Gout; Humans; Hyperuricemia; Male; Obesity; Uric Acid | 2023 |
Renal herb formula protects against hyperuricemic nephropathy by inhibiting apoptosis and inflammation.
Topics: Animals; Apoptosis; Chlorogenic Acid; Creatinine; Hyperuricemia; Inflammation; Kidney; Kidney Diseas | 2023 |
Model Informed Development of SIM0295 in Patients with Gout and Hyperuricemia and Healthy Volunteers Using a Population Pharmacokinetics/ Pharmacodynamics Approach.
Topics: Gout; Gout Suppressants; Healthy Volunteers; Humans; Hyperuricemia; Uric Acid | 2023 |
Association of Normal Serum Uric Acid Level and Cardiovascular Disease in People Without Risk Factors for Cardiac Diseases in China.
Topics: Biomarkers; Cardiovascular Diseases; China; Heart Diseases; Humans; Hyperuricemia; Risk Factors; Uri | 2023 |
Amelioration effects of α-viniferin on hyperuricemia and hyperuricemia-induced kidney injury in mice.
Topics: Animals; Hyperuricemia; Interleukin-17; Kidney; Mice; Phosphatidylinositol 3-Kinases; Proto-Oncogene | 2023 |
In vitro xanthine oxidase inhibitory and in vivo anti-hyperuricemic properties of sodium kaempferol-3'-sulfonate.
Topics: Animals; Enzyme Inhibitors; Hyperuricemia; Kaempferols; Kinetics; Mice; Molecular Docking Simulation | 2023 |
Comparison between the Effects of Allopurinol and Febuxostat on the Survival of Patients on Maintenance Hemodialysis.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Dialysis; Treatment O | 2023 |
Overnight changes in uric acid, xanthine oxidoreductase and oxidative stress levels and their relationships with sleep-disordered breathing in patients with coronary artery disease.
Topics: Coronary Artery Disease; Humans; Hyperuricemia; Male; Oxidative Stress; Sleep Apnea Syndromes; Uric | 2023 |
Potential of Leave and Fruit Ethanolic Extract of
Topics: Animals; Body Weight; Ethanol; Fruit; Gout Suppressants; Hyperuricemia; Male; Mice; Plant Extracts; | 2023 |
Association between alcoholic beverage intake and hyperuricemia in Chinese adults: Findings from the China Health and Nutrition Survey.
Topics: Adult; Alcohol Drinking; Alcoholic Beverages; China; East Asian People; Female; Humans; Hyperuricemi | 2023 |
Estradiol protects female mice from hyperuricemia induced by PCB138 exposure.
Topics: Adult; Animals; Estradiol; Female; Humans; Hyperuricemia; Kidney; Kidney Diseases; Male; Mice; Uric | 2023 |
Chloroquine inhibits NLRP3 inflammasomes activation and alleviates renal fibrosis in mouse model of hyperuricemic nephropathy with aggravation by a high-fat-diet.
Topics: Animals; Chloroquine; Creatinine; Diet, High-Fat; Fibrosis; Hyperuricemia; Inflammasomes; Kidney; Ki | 2023 |
Sanghuangporus vaninii ethanol extract alleviates hyperuricemic renal injury by regulating the uric acid transporters and inhibiting HK-2 apoptosis.
Topics: Animals; Hyperuricemia; Kidney; Membrane Transport Proteins; Mice; Mice, Inbred ICR; Organic Anion T | 2023 |
Exploring the Association between Low-dose Aspirin Intake and Hyperuricemia in Individuals over 40: A Cross-Sectional Study using NHANES Data (2011-2018).
Topics: Adult; Aspirin; Child, Preschool; Cross-Sectional Studies; Humans; Hyperuricemia; Middle Aged; Nutri | 2023 |
Corn Silk Flavonoids Ameliorate Hyperuricemia via PI3K/AKT/NF-κB Pathway.
Topics: Flavonoids; Humans; Hyperuricemia; Inflammation; NF-kappa B; Phosphatidylinositol 3-Kinases; Proto-O | 2023 |
The antihyperuricemia activity of Astragali Radix through regulating the expression of uric acid transporters via PI3K/Akt signalling pathway.
Topics: Animals; Drugs, Chinese Herbal; Hyperuricemia; Membrane Transport Proteins; Mice; Phosphatidylinosit | 2023 |
Shizhifang ameliorates pyroptosis of renal tubular epithelial cells in hyperuricemia through inhibiting NLRP3 inflammasome.
Topics: Allopurinol; Animals; Caspases; China; Epithelial Cells; Humans; Hyperuricemia; Inflammasomes; Infla | 2023 |
Positive correlation between fatty liver index and hyperuricemia in hypertensive Chinese adults: a H-type hypertension registry study.
Topics: Adult; East Asian People; Female; gamma-Glutamyltransferase; Humans; Hypertension; Hyperuricemia; Ma | 2023 |
The correlation between dietary inflammatory index and risk of hyperuricemia in the U.S. population.
Topics: Adult; Diet; Female; Humans; Hyperuricemia; Inflammation; Logistic Models; Male; Nutrition Surveys; | 2023 |
Study on the mechanism of Orthosiphon aristatus (Blume) Miq. in the treatment of hyperuricemia by microbiome combined with metabonomics.
Topics: Animals; Gastrointestinal Microbiome; Hyperuricemia; Intestines; Metabolomics; Orthosiphon; Rats; Ur | 2023 |
Association between dietary intake of flavonoids and hyperuricemia: a cross-sectional study.
Topics: Adult; Anthocyanins; Cross-Sectional Studies; Diet; Eating; Female; Flavanones; Flavonoids; Humans; | 2023 |
Prevalence of Hypouricemia and Hyperuricemia and Looking Beyond Serum Uric Acid in Patients with Newly Onset Type 2 Diabetes Mellitus in Eastern Part of Uttar Pradesh: A Cross-sectional Study.
Topics: Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Humans; Hyperuricemia; Prevalence; Risk | 2023 |
Sudden Rise of Uric Acid Levels in a Patient with Chronic Kidney Disease: Is a Common Food to Blame?
Topics: Humans; Hyperuricemia; Kidney; Renal Insufficiency, Chronic; Risk Factors; Uric Acid | 2022 |
Association of N, N-diethyl-m-toluamide (DEET) with hyperuricemia among adult participants.
Topics: Adult; Cross-Sectional Studies; DEET; Humans; Hyperuricemia; Male; Middle Aged; Nutrition Surveys; R | 2023 |
Eurycoma longifolia alkaloid components ameliorate hyperuricemic nephropathy via regulating serum uric acid level and relieving inflammatory reaction.
Topics: Animals; Eurycoma; Hyperuricemia; Inflammation; Kidney; Male; Mice; Mice, Inbred C57BL; Uric Acid | 2023 |
Hyperuricemia and gout increased the risk of long-term mortality in patients with heart failure: insights from the National Health and Nutrition Examination Survey.
Topics: Gout; Heart Failure; Humans; Hyperuricemia; Nutrition Surveys; Uric Acid | 2023 |
Clinical effects of a selective urate reabsorption inhibitor dotinurad in patients with hyperuricemia and treated hypertension: a multicenter, prospective, exploratory study (DIANA).
Topics: Aged; Aged, 80 and over; Female; Humans; Hypertension; Hyperuricemia; Male; Middle Aged; Prospective | 2023 |
A Mendelian randomization study of serum uric acid with the risk of venous thromboembolism.
Topics: Genome-Wide Association Study; Humans; Hyperuricemia; Lower Extremity; Mendelian Randomization Analy | 2023 |
Lactiplantibacillus plantarum enables blood urate control in mice through degradation of nucleosides in gastrointestinal tract.
Topics: Animals; Diet; Hyperuricemia; Intestines; Mice; Nucleosides; Probiotics; Uric Acid | 2023 |
Hyperuricemia promotes the progression of atherosclerosis by activating endothelial cell pyroptosis via the ROS/NLRP3 pathway.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Human Umbilical Vein Endothelial Cells; Humans; Hyperur | 2023 |
Paeonia × suffruticosa Andrews leaf extract and its main component apigenin 7-O-glucoside ameliorate hyperuricemia by inhibiting xanthine oxidase activity and regulating renal urate transporters.
Topics: Animals; Apigenin; Creatinine; Glucosides; Gout; Hyperuricemia; Kidney; Malondialdehyde; Mice; Molec | 2023 |
Fucoidan from
Topics: Animals; Fibrosis; Hyperuricemia; Janus Kinase 2; Kidney; Laminaria; Mice; Polysaccharides; Renal In | 2023 |
Serum uric acid is associated with chronic kidney disease in elderly Chinese patients with diabetes.
Topics: Aged; Cholesterol, HDL; Diabetes Mellitus; East Asian People; Female; Humans; Hyperuricemia; Male; R | 2023 |
Hyperuricemia is accompanied by elevated peripheral CD4
Topics: CD4-Positive T-Lymphocytes; Female; Humans; Hyperuricemia; Leukocytes, Mononuclear; Male; T-Lymphocy | 2023 |
A widely distributed gene cluster compensates for uricase loss in hominids.
Topics: Adult; Animals; Evolution, Molecular; Gout; Hominidae; Humans; Hyperuricemia; Mammals; Mice; Urate O | 2023 |
Dispelling Dampness, Relieving Turbidity and Dredging Collaterals Decoction, Attenuates Potassium Oxonate-Induced Hyperuricemia in Rat Models.
Topics: Animals; Hyperuricemia; Interleukin-17; Kidney; Molecular Docking Simulation; Rats; Uric Acid; Xanth | 2023 |
Antihyperuricemic and Renal Protective Effect of Cordyceps chanhua (Ascomycetes) Fruiting Bodies in Acute Hyperuricemia and Chronic Gout Rodent Models.
Topics: Animals; Cordyceps; Fruiting Bodies, Fungal; Gout; Gout Suppressants; Hyperuricemia; Kidney; Mice; R | 2023 |
Asymptomatic hyperuricemia associated with increased risk of nephrolithiasis: a cross-sectional study.
Topics: China; Cross-Sectional Studies; Female; Gout; Humans; Hyperuricemia; Male; Nephrolithiasis; Risk Fac | 2023 |
Effect of Alcohol Consumption Habits on Early Arterial Aging in Subjects with Metabolic Syndrome and Elevated Serum Uric Acid.
Topics: Aging; Alcohol Drinking; Female; Habits; Humans; Hyperuricemia; Male; Metabolic Syndrome; Middle Age | 2023 |
Sex Difference in the Associations among Obesity-Related Indices with Hyperuricemia in a Large Taiwanese Population Study.
Topics: Adiposity; Body Mass Index; Female; Humans; Hyperuricemia; Male; Obesity; Risk Factors; Sex Characte | 2023 |
High-normal serum uric acid predicts macrovascular events in patients with type 2 diabetes mellitus without hyperuricemia based on a 10-year cohort.
Topics: Diabetes Mellitus, Type 2; Humans; Hyperuricemia; Kidney; Risk Factors; Uric Acid | 2023 |
Association between paroxysmal or persistent atrial fibrillation and hyperuricemia in patients who underwent coronary computed tomography angiography: from the FU-CCTA-AF Registry.
Topics: Atrial Fibrillation; Computed Tomography Angiography; Coronary Angiography; Coronary Artery Disease; | 2023 |
Preliminary study on the material basis and mechanism underlying uric acid reduction by Thlaspi arvense L.
Topics: Animals; Flavonoids; Hyperuricemia; Rats; RNA, Messenger; Thlaspi; Uric Acid; Xanthine Oxidase | 2024 |
Effect of Sodium TanshinoneⅡA Sulfonate on Uric Acid, Sicam-1, ET-1 and FMD in Patients with Coronary Heart Disease Complicated with Hyperuricemia.
Topics: Alkanesulfonates; Coronary Disease; Dilatation; Endothelin-1; Humans; Hyperuricemia; Uric Acid | 2023 |
The correlation between serum uric acid and diabetic kidney disease in type 1 diabetes patients in Anhui, China.
Topics: China; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Humans; Hyperuricemia; Uric Acid | 2023 |
Association between serum uric acid, hyperuricemia and periodontitis: a cross-sectional study using NHANES data.
Topics: Cross-Sectional Studies; Female; Humans; Hyperuricemia; Male; Nutrition Surveys; Periodontitis; Uric | 2023 |
A wide-range UAC sensor for the classification of hyperuricemia in spot samples.
Topics: Body Fluids; Humans; Hyperuricemia; Kinetics; Point-of-Care Testing; Uric Acid | 2024 |
Association between serum uric acid levels and peripheral artery disease in Chinese adults with hypertension.
Topics: Adult; Aged; Aged, 80 and over; Cross-Sectional Studies; East Asian People; Female; Gout; Humans; Hy | 2023 |
Dieting alleviates hyperuricemia and organ injuries in uricase-deficient rats
Topics: Animals; Cell Cycle; Cell Division; Hyperuricemia; Pharmaceutical Vehicles; Rats; Urate Oxidase; Uri | 2023 |
Hip circumference has independent association with the risk of hyperuricemia in middle-aged but not in older male patients with type 2 diabetes mellitus.
Topics: Aged; China; Diabetes Mellitus, Type 2; Humans; Hyperuricemia; Male; Middle Aged; Retrospective Stud | 2023 |
Novel pathological implications of serum uric acid with cardiovascular disease risk in obesity.
Topics: Cardiovascular Diseases; Cohort Studies; Female; Humans; Hyperuricemia; Male; Obesity; Prospective S | 2023 |
Correlation between serum uric acid and body fat distribution in patients with MAFLD.
Topics: Abdominal Fat; Absorptiometry, Photon; Body Fat Distribution; Humans; Hyperuricemia; Non-alcoholic F | 2023 |
Associations of serum uric acid with cardiovascular disease risk factors: a retrospective cohort study in southeastern China.
Topics: Cardiovascular Diseases; China; Female; Humans; Hyperglycemia; Hypertension; Hyperuricemia; Male; Re | 2023 |
Fuling-Zexie formula attenuates hyperuricemia-induced nephropathy and inhibits JAK2/STAT3 signaling and NLRP3 inflammasome activation in mice.
Topics: Albumins; Animals; Chromatography, Liquid; Fibrosis; Hyperuricemia; Inflammasomes; Inflammation; Int | 2024 |
Honey Mushroom,
Topics: alpha-Fetoproteins; Animals; Armillaria; Fermentation; Honey; Hyperuricemia; Kidney; Mice; Organic A | 2023 |
Association between visceral fat area and serum uric acid in Chinese adults: A cross-sectional study.
Topics: Adult; Cross-Sectional Studies; East Asian People; Humans; Hyperuricemia; Intra-Abdominal Fat; Uric | 2023 |
Metabolomic analysis for asymptomatic hyperuricemia and gout based on a combination of dried blood spot sampling and mass spectrometry technology.
Topics: Biomarkers; Gout; Humans; Hyperuricemia; Mass Spectrometry; Metabolomics; Uric Acid | 2023 |
Associations between vitamin C intake and serum uric acid in US adults: Findings from National Health and Nutrition Examination Survey 2011-2016.
Topics: Adult; Ascorbic Acid; Cross-Sectional Studies; Female; Humans; Hyperuricemia; Male; Nutrition Survey | 2023 |
Associations between dietary patterns and serum uric acid concentrations in children and adolescents: a cross-sectional study.
Topics: Adolescent; Animals; Child; Cross-Sectional Studies; Diet; Humans; Hyperuricemia; Risk Factors; Uric | 2023 |
Prevalence of hyperuricaemia among adults from Ningxia Hui Autonomous Region, China: a cross-sectional study.
Topics: China; Cross-Sectional Studies; Female; Humans; Hyperuricemia; Male; Obesity; Prevalence; Risk Facto | 2023 |
Allisartan Isoproxil Promotes Uric Acid Excretion by Interacting with Intestinal Urate Transporters in Hyperuricemic Zebrafish (Danio rerio).
Topics: Animals; Hyperuricemia; Kidney; Losartan; Uric Acid; Zebrafish | 2023 |
Interleukin-37: associations of plasma levels and genetic variants in gout.
Topics: Arthritis, Gouty; Gout; Humans; Hyperuricemia; Interleukin-1beta; Uric Acid | 2023 |
Molecular characteristic analysis of single-nucleotide polymorphisms in SLC16A9/hMCT9.
Topics: Animals; Creatine; Gout; Humans; Hyperuricemia; Oocytes; Polymorphism, Single Nucleotide; Uric Acid; | 2023 |
Hyperuricemia remission after colorectal cancer surgery for colorectal cancer patients.
Topics: Colorectal Neoplasms; Digestive System Surgical Procedures; Humans; Hyperuricemia; Retrospective Stu | 2023 |
Coffee Leaf Tea Extracts Improve Hyperuricemia Nephropathy and Its Associated Negative Effect in Gut Microbiota and Amino Acid Metabolism in Rats.
Topics: Amino Acids; Animals; Coffea; Gastrointestinal Microbiome; Hyperuricemia; Kidney; Kidney Diseases; R | 2023 |
Impact of hyperuricaemia on patients with psoriatic arthritis treated with secukinumab in the FUTURE 2-5 and MAXIMISE studies.
Topics: Arthritis, Psoriatic; Female; Humans; Hyperuricemia; Male; Quality of Life; Uric Acid | 2023 |
Discovery of Novel Biphenyl Carboxylic Acid Derivatives as Potent URAT1 Inhibitors.
Topics: Carboxylic Acids; Humans; Hyperuricemia; Ligands; Organic Anion Transporters; Organic Cation Transpo | 2023 |
Major adverse cardiovascular events and hyperuricemia during tuberculosis treatment.
Topics: Antitubercular Agents; Female; Humans; Hyperuricemia; Male; Myocardial Ischemia; Retrospective Studi | 2023 |
Peptide NCTX15 derived from spider toxin gland effectively relieves hyperuricemia in mice.
Topics: Animals; Gout; Hyperuricemia; Interleukin-6; Kidney; Mice; Uric Acid; Xanthine Oxidase | 2023 |
Associations of early pregnancy serum uric acid levels with risk of gestational diabetes and birth outcomes: a retrospective cohort study.
Topics: Diabetes, Gestational; Female; Fetal Growth Retardation; Fetal Macrosomia; Humans; Hyperuricemia; In | 2023 |
Mushroom consumption and hyperuricemia: results from the National Institute for Longevity Sciences-Longitudinal Study of Aging and the National Health and Nutrition Examination Survey (2007-2018).
Topics: Adult; Agaricales; Aged; Aging; Female; Humans; Hyperuricemia; Longevity; Longitudinal Studies; Male | 2023 |
Association between Asymptomatic Hyperuricemia with Adiposity Indices: A Cross-Sectional Study in a Spanish Population.
Topics: Adiposity; Body Mass Index; Cross-Sectional Studies; Humans; Hyperuricemia; Obesity; Risk Factors; U | 2023 |
Pseudohypoadrenalism, a subclinical cortisol metabolism disorder in hyperuricemia.
Topics: 11-beta-Hydroxysteroid Dehydrogenases; Animals; Bile Acids and Salts; Humans; Hydrocortisone; Hyperu | 2023 |
Alterations in lipidome profiles distinguish early-onset hyperuricemia, gout, and the effect of urate-lowering treatment.
Topics: Gout; Gout Suppressants; Humans; Hyperuricemia; Lipidomics; Uric Acid | 2023 |
Improvement of hyperuricemia in chronic hepatitis C patients receiving directly acting antiviral agents.
Topics: Aged; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Hyperuricemia; Liver Cirrhosis; Male; | 2020 |
Antihyperuricemic and anti-gouty arthritis activities of
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Gouty; Carbon; Drugs, Chinese Herbal; Hyperuricemia; I | 2019 |
Impaired intestinal barrier function in a mouse model of hyperuricemia.
Topics: Animals; Disease Models, Animal; Hyperuricemia; Interleukin-6; Intestinal Mucosa; Mice; Mice, Knocko | 2019 |
Genetically Determined Uric Acid and the Risk of Cardiovascular and Neurovascular Diseases: A Mendelian Randomization Study of Outcomes Investigated in Randomized Trials.
Topics: Biomarkers; Cardiovascular Diseases; Cerebrovascular Disorders; Cognition; Genome-Wide Association S | 2019 |
Hyperuricemia is associated with intermittent hand joint pain in a cross sectional study of elderly females: The AGES-Reykjavik Study.
Topics: Aged; Aged, 80 and over; Area Under Curve; Arthralgia; Cross-Sectional Studies; Female; Hand Joints; | 2019 |
The challenges of managing gout in primary care: Results of a best-practice audit.
Topics: Aged; Allopurinol; Clinical Audit; Clinical Chemistry Tests; Clinical Protocols; Colchicine; Comorbi | 2019 |
The association between genotypes of urate transporter-1, Serum uric acid, and mortality in the community-based population: the Yamagata (Takahata) Study.
Topics: Aged; Biomarkers; Female; Genetic Predisposition to Disease; Heterozygote; Homozygote; Humans; Hyper | 2019 |
Effect of lemon water soluble extract on hyperuricemia in a mouse model.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; Citrus; Disease Models, Animal; Fr | 2019 |
J-shaped association between serum uric acid and acute coronary syndrome in patients with essential hypertension.
Topics: Acute Coronary Syndrome; Aged; China; Essential Hypertension; Female; Humans; Hyperuricemia; Longitu | 2020 |
Constituents and Anti-Hyperuricemia Mechanism of Traditional Chinese Herbal Formulae Erding Granule.
Topics: Animals; Anti-Inflammatory Agents; Chromatography, High Pressure Liquid; Disease Models, Animal; Dos | 2019 |
Topiroxostat influences circulating lipid concentrations in hyperuricemic patients
.
Topics: Cholesterol; Cholesterol, LDL; Humans; Hyperuricemia; Lipids; Nitriles; Pyridines; Retrospective Stu | 2019 |
Different Pharmacological Properties of GLUT9a and GLUT9b: Potential Implications in Preeclampsia.
Topics: Alternative Splicing; Electrophysiology; Female; Glucose Transport Proteins, Facilitative; Humans; H | 2019 |
Isomers of per- and polyfluoroalkyl substances and uric acid in adults: Isomers of C8 Health Project in China.
Topics: Adult; Alkanesulfonic Acids; Caprylates; China; Cross-Sectional Studies; Environmental Pollutants; F | 2019 |
Maternal hyperuricemia as a marker of post-spinal hypotension and uterine tone during cesarean delivery: a prospective observational study.
Topics: Adult; Anesthesia, Spinal; Biomarkers; Cesarean Section; Female; Humans; Hyperuricemia; Hypotension; | 2019 |
Xanthine Oxidase Inhibitor Febuxostat Exerts an Anti-Inflammatory Action and Protects against Diabetic Nephropathy Development in KK-Ay Obese Diabetic Mice.
Topics: Animals; Anti-Inflammatory Agents; Body Weight; Chemokine CCL2; Collagen; Diabetic Nephropathies; Fe | 2019 |
Uric acid induced the phenotype transition of vascular endothelial cells
Topics: Allopurinol; Animals; Cells, Cultured; Endothelium, Vascular; Glycocalyx; Gout Suppressants; Hyperur | 2019 |
Elevated Serum Uric Acid and Self-Reported Heart Failure in US Adults: 2007-2016 National Health and Nutrition Examination Survey.
Topics: Adult; Aged; Female; Heart Failure; Humans; Hyperuricemia; Male; Middle Aged; Nutrition Surveys; Pre | 2019 |
Could uric acid reduction by specific xanthine oxidase inhibition improve vascular function and reduce cardiovascular risk?
Topics: Cardiovascular Diseases; Humans; Hypertension; Hyperuricemia; Nitriles; Pyridines; Risk Factors; Uri | 2019 |
The effects of topiroxostat on vascular function in patients with hyperuricemia.
Topics: Biological Availability; Blood Flow Velocity; Enzyme Inhibitors; Female; Humans; Hyperuricemia; Male | 2019 |
Elevated serum uric acid is associated with peripheral endothelial dysfunction in women.
Topics: Adult; Biomarkers; Cross-Sectional Studies; Endothelium, Vascular; Female; Humans; Hyperemia; Hyperu | 2019 |
Association of Empirical Dietary Atherogenic Indices with All-Cause and Cause-Specific Mortality in a Multi-Ethnic Adult Population of the United States.
Topics: Apolipoprotein B-100; Atherosclerosis; Biomarkers; Cause of Death; Diet, Atherogenic; Feeding Behavi | 2019 |
Visceral adipose accumulation increased the risk of hyperuricemia among middle-aged and elderly adults: a population-based study.
Topics: Adiposity; Adult; Aged; Area Under Curve; Female; Humans; Hyperuricemia; Intra-Abdominal Fat; Male; | 2019 |
The association between sedentary behavior, physical activity and hyperuricemia.
Topics: Adolescent; Adult; Aged; Biomarkers; Cross-Sectional Studies; Exercise; Female; Healthy Lifestyle; H | 2019 |
Is Uric Acid elevation a random finding or a causative agent of diabetic nephropathy?
Topics: Aged; Albuminuria; Biomarkers; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female | 2019 |
Risk factors for the development of hyperuricemia: A STROBE-compliant cross-sectional and longitudinal study.
Topics: Adult; Biomarkers; Blood Pressure; Blood Urea Nitrogen; Body Mass Index; China; Cholesterol, HDL; Ch | 2019 |
Association of high-sensitivity C-reactive protein in middle-aged and elderly Chinese people with hyperuricaemia and risk of coronary heart disease: a cross-sectional study.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; C-Reactive Protein; China; Coronary Disease; Cross-Secti | 2019 |
Hyperuricemia and gout caused by missense mutation in d-lactate dehydrogenase.
Topics: Adult; Animals; Catalytic Domain; Child; DNA; Family Health; Female; Gout; HEK293 Cells; Heterozygot | 2019 |
Hyperuricemia in US Population with Heart Failure: Causal or Incidental Bystander?
Topics: Adult; Heart Failure; Humans; Hyperuricemia; Nutrition Surveys; Self Report; Uric Acid | 2019 |
U-Shaped Association of Serum Uric Acid With All-Cause and Cause-Specific Mortality in US Adults: A Cohort Study.
Topics: Adult; Cardiovascular Diseases; Cause of Death; Cohort Studies; Female; Humans; Hyperuricemia; Male; | 2020 |
Impact of Elevated Serum Uric Acid Level on Target Lesion Revascularization After Percutaneous Coronary Intervention for Chronic Total Occlusion.
Topics: Aged; Cause of Death; Chronic Disease; Cohort Studies; Coronary Angiography; Coronary Occlusion; Dru | 2019 |
Comparison of long-term efficacy and renal safety of febuxostat and allopurinol in patients with chronic kidney diseases
.
Topics: Adult; Allopurinol; Febuxostat; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chron | 2020 |
Failure to reach uric acid target of <0.36 mmol/L in hyperuricaemia of gout is associated with elevated total and cardiovascular mortality.
Topics: Aged; Biomarkers; Cardiovascular Diseases; Comorbidity; Female; Follow-Up Studies; Gout; Humans; Hyp | 2019 |
Low Hemoglobin Saturation in the Setting of Hyperuricemia.
Topics: Aged; Female; Glucosephosphate Dehydrogenase Deficiency; Gout Suppressants; Hemoglobins; Humans; Hyp | 2019 |
Clinical efficacy and safety of benzbromarone in elderly hypertensive patients with hyperuricemia.
Topics: Aged; Benzbromarone; Blood Pressure; Drug-Related Side Effects and Adverse Reactions; Female; Humans | 2019 |
Preparation, characterization, pharmacokinetics and anti-hyperuricemia activity studies of myricitrin-loaded proliposomes.
Topics: Administration, Oral; Animals; Biological Availability; Chemistry, Pharmaceutical; Drug Liberation; | 2019 |
Elevated Uric Acid Levels Promote Vascular Smooth Muscle Cells (VSMC) Proliferation via an Nod-Like Receptor Protein 3 (NLRP3)-Inflammasome-Dependent Mechanism.
Topics: Actins; Animals; Cardiovascular Diseases; Carrier Proteins; Cell Line; Cell Proliferation; China; Hu | 2019 |
Comprehensive analysis of mechanism underlying hypouricemic effect of glucosyl hesperidin.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; Glucose Transport Proteins, Facili | 2020 |
Population-specific factors associated with fractional excretion of uric acid.
Topics: Adult; Aged; Female; Gout; Humans; Hyperuricemia; Male; Middle Aged; Native Hawaiian or Other Pacifi | 2019 |
Waist-to-Height Ratio Is a Better Predictor of Hyperuricemia than Body Mass Index and Waist Circumference in Chinese.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Asian People; Blood Glucose; Blood Pressure; Body Mass I | 2019 |
Influence of hyperuricemia treatment on postoperative acute kidney injury among hyperuricemia patients: a single-center retrospective database analysis.
Topics: Acute Kidney Injury; Aged; Allopurinol; Creatinine; Female; Glomerular Filtration Rate; Humans; Hype | 2019 |
The causal role of elevated uric acid and waist circumference on the risk of metabolic syndrome components.
Topics: Adult; Blood Pressure; Cholesterol, HDL; Female; Humans; Hyperuricemia; Male; Metabolic Syndrome; Mi | 2020 |
Burden and management of gout in a multi-ethnic Asian cohort.
Topics: Adult; Aged; Allopurinol; Comorbidity; Cross-Sectional Studies; Diabetes Mellitus; Dyslipidemias; Em | 2020 |
Association of Serum Uric Acid with Cardiovascular Disease Risk Scores in Koreans.
Topics: Adult; Aged; Alcohol Drinking; Body Mass Index; Cardiovascular Diseases; Creatinine; Cross-Sectional | 2019 |
Hyperuricemia predicts the risk for developing hypertension independent of alcohol drinking status in men and women: the Saku study.
Topics: Adult; Aged; Alcohol Drinking; Female; Humans; Hypertension; Hyperuricemia; Incidence; Japan; Male; | 2020 |
Dysfunctional missense variant of
Topics: Adult; Asian People; Case-Control Studies; Genetic Predisposition to Disease; Gout; Humans; Hyperuri | 2020 |
Possible role of l-carnitine in improvement of metabolic and hepatic changes in hyperuricemic and hyperuricemic-Fructose-supplemented rats.
Topics: Animals; Carnitine; Fructose; Hyperuricemia; Insulin Resistance; Liver; Male; Oxidative Stress; Rats | 2019 |
Severity of Hypertension Mediates the Association of Hyperuricemia With Stroke in the REGARDS Case Cohort Study.
Topics: Aged; Blood Pressure; Cohort Studies; Female; Humans; Hypertension; Hyperuricemia; Male; Middle Aged | 2020 |
Stevia residue extract increases intestinal uric acid excretion via interactions with intestinal urate transporters in hyperuricemic mice.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; Chlorogenic Acid; Flavonoids; Gluc | 2019 |
Phloretin ameliorates hyperuricemia-induced chronic renal dysfunction through inhibiting NLRP3 inflammasome and uric acid reabsorption.
Topics: Animals; Cell Line; Cytokines; Fibrosis; Humans; Hyperuricemia; Inflammasomes; Inflammation; Kidney | 2020 |
Association between dairy product consumption and hyperuricemia in an elderly population with metabolic syndrome.
Topics: Age Factors; Aged; Biomarkers; Cross-Sectional Studies; Dairy Products; Diet, Fat-Restricted; Diet, | 2020 |
A cross-sectional study on uric acid levels among Chinese adolescents.
Topics: Adolescent; China; Cross-Sectional Studies; Female; Humans; Hyperuricemia; Male; Prevalence; Referen | 2020 |
Hyperuricaemia and its association with 10-year risk of cardiovascular disease among migrant and non-migrant African populations: the RODAM study.
Topics: Adult; Aged; Cardiovascular Diseases; Emigrants and Immigrants; Europe; Female; Ghana; Humans; Hyper | 2020 |
Comparisons of protective effects between two sea cucumber hydrolysates against diet induced hyperuricemia and renal inflammation in mice.
Topics: Animals; Cytokines; Hyperuricemia; Inflammation; Kidney; Male; Mice; Mice, Inbred ICR; Myeloid Diffe | 2020 |
Microalbuminuria mediates the association between serum uric acid and elevation of blood pressure: a longitudinal analysis in the Gusu cohort.
Topics: Adult; Albuminuria; Asian People; Blood Glucose; Blood Pressure; Cohort Studies; Female; Humans; Hyp | 2020 |
Comment on: Impact of serum uric acid on renal function after bariatric surgery: a retrospective study.
Topics: Bariatric Surgery; Humans; Hyperuricemia; Retrospective Studies; Uric Acid | 2020 |
Refining genome-wide associated loci for serum uric acid in individuals with African ancestry.
Topics: Angiotensin Amide; Black or African American; Diabetes Mellitus, Type 2; Female; Genetic Loci; Genom | 2020 |
The influence of uric acid level on erythrocyte morphology in normotensive patients.
Topics: Blood Pressure; Erythrocytes; Female; Humans; Hypertension; Hyperuricemia; Male; Uric Acid | 2019 |
Vitamin D3 potentiates the renoprotective effects of vildagliptin in a rat model of fructose/salt-induced insulin resistance.
Topics: AMP-Activated Protein Kinases; Animals; Blood Glucose; Cholecalciferol; Creatinine; Dipeptidyl-Pepti | 2020 |
Lack of Associations between Elevated Serum Uric Acid and Components of Metabolic Syndrome Such as Hypertension, Dyslipidemia, and T2DM in Overweight and Obese Chinese Adults.
Topics: Adolescent; Adult; Aged; Biomarkers; Blood Glucose; Blood Pressure; Body Mass Index; China; Diabetes | 2019 |
Hepatic Steatosis in Lean Patients: Risk Factors and Impact on Mortality.
Topics: Adult; Body Mass Index; Elasticity Imaging Techniques; Fatty Liver; Female; Humans; Hyperuricemia; L | 2020 |
Sex-Specific Association Between Serum Uric Acid and Retinal Microvessels.
Topics: Adult; Arterioles; Asian People; China; Cross-Sectional Studies; Female; Humans; Hyperuricemia; Male | 2019 |
Interactive association of baseline and changes in serum uric acid on renal dysfunction among community-dwelling persons.
Topics: Aged; Female; Glomerular Filtration Rate; Humans; Hyperuricemia; Independent Living; Kidney; Male; M | 2020 |
Urate Transporter URAT1 in Hyperuricemia: New Insights from Hyperuricemic Models.
Topics: Animals; Benzbromarone; Disease Models, Animal; Febuxostat; HEK293 Cells; Humans; Hyperuricemia; Kid | 2019 |
Electrochemical analysis of uric acid excretion to the intestinal lumen: Effect of serum uric acid-lowering drugs and 5/6 nephrectomy on intestinal uric acid levels.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; Cardiovascular Diseases; Disease M | 2019 |
Uric Acid Level as a Predictor of Long-Term Mortality in Advanced Age Population.
Topics: Aged; Aged, 80 and over; Biomarkers; Female; Humans; Hyperuricemia; Male; Middle Aged; Predictive Va | 2020 |
Risk Factors For Hyperuricemia In Chinese Centenarians And Near-Centenarians.
Topics: Age Factors; Aged, 80 and over; Alcohol Drinking; Biomarkers; Cardiovascular Diseases; China; Choles | 2019 |
Antihyperuricemic and nephroprotective effects of extracts from Orthosiphon stamineus in hyperuricemic mice.
Topics: Animals; Creatinine; Hyperuricemia; Kidney; Liver; Male; Mice; Organic Anion Transporters; Orthosiph | 2020 |
The prevalence of gout and hyperuricemia in middle-aged and elderly people in Tibet Autonomous Region, China: A preliminary study.
Topics: Adult; Aged; China; Cross-Sectional Studies; Female; Gout; Humans; Hyperuricemia; Male; Middle Aged; | 2020 |
Development of novel NLRP3-XOD dual inhibitors for the treatment of gout.
Topics: Animals; Benzimidazoles; Benzoxazoles; Cell Line; Disease Models, Animal; Gout; Humans; Hyperuricemi | 2020 |
Novel 3-[4-alkoxy-3-(1H-tetrazol-1-yl) phenyl]-1,2,4-oxadiazol-5(4H)-ones as promising xanthine oxidase inhibitors: Design, synthesis and biological evaluation.
Topics: Drug Design; Enzyme Inhibitors; Hyperuricemia; Inhibitory Concentration 50; Kinetics; Molecular Dock | 2020 |
Elevated triglyceride to high-density lipoprotein cholesterol (TG/HDL-C) ratio increased risk of hyperuricemia: a 4-year cohort study in China.
Topics: Adult; China; Cholesterol, HDL; Cohort Studies; Female; Humans; Hyperuricemia; Male; Retrospective S | 2020 |
Comparative effectiveness of rasburicase versus allopurinol for cancer patients with renal dysfunction and hyperuricemia.
Topics: Adult; Allopurinol; Female; Humans; Hyperuricemia; Kaplan-Meier Estimate; Male; Middle Aged; Neoplas | 2020 |
Association of serum uric acid with visceral, subcutaneous and hepatic fat quantified by magnetic resonance imaging.
Topics: Aged; Cross-Sectional Studies; Female; Humans; Hyperuricemia; Intra-Abdominal Fat; Liver; Magnetic R | 2020 |
Serum uric acid (SUA) in morbidly obese patients and its relationship with metabolic syndrome.
Topics: Female; Humans; Hyperuricemia; Male; Metabolic Syndrome; Obesity, Morbid; Triglycerides; Uric Acid | 2020 |
Hyperuricemia is associated with a lower glomerular filtration rate in pediatric sickle cell disease patients.
Topics: Adolescent; Albuminuria; Anemia, Sickle Cell; Blood Transfusion; Child; Cohort Studies; Cross-Sectio | 2020 |
Adherence to the Dietary Approaches to Stop Hypertension Diet and Hyperuricemia: A Cross-Sectional Study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Biomarkers; China; Cross-Sectional Studies; Diet, Healt | 2021 |
Xanthine oxidase inhibition attenuates insulin resistance and diet-induced steatohepatitis in mice.
Topics: Allopurinol; Animals; Diet, High-Fat; Disease Models, Animal; Fatty Liver; Febuxostat; Hyperuricemia | 2020 |
The relationship between a combination of vitamin D deficiency and hyperuricemia and the severity of coronary artery disease in myocardial infarction patients.
Topics: Biomarkers; Coronary Artery Disease; Cross-Sectional Studies; Female; Humans; Hyperuricemia; Male; M | 2020 |
Hyperuricemia and mortality in heart failure: Is it time to change the route?
Topics: Heart Failure; Humans; Hyperuricemia; Prognosis; Stroke Volume; Uric Acid | 2020 |
ABCG2 expression and uric acid metabolism of the intestine in hyperuricemia model rat.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; Hyperuricemia; Intestines; Male; O | 2020 |
Uric acid and estimate of renal function. Let's stick together.
Topics: Creatinine; Humans; Hyperuricemia; Uric Acid | 2020 |
Epistatic interaction between PKD2 and ABCG2 influences the pathogenesis of hyperuricemia and gout.
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; Body Mass Index; Epistasis, Genetic; Geneti | 2020 |
Hyperuricemia as a potential plausible risk factor for periodontitis.
Topics: Animals; Gout; Humans; Hyperuricemia; Mice; Periodontitis; Risk Factors; Uric Acid | 2020 |
Study on the relationship between FFA and gout flare.
Topics: Adult; Aged; Aged, 80 and over; Arthritis, Gouty; Biomarkers; Cholesterol, LDL; Fatty Acids, Noneste | 2020 |
Impact of Lesinurad and allopurinol on experimental Hyperuricemia in mice: biochemical, molecular and Immunohistochemical study.
Topics: Allopurinol; Animals; Blood Urea Nitrogen; Catalase; Drug Synergism; Glutathione Peroxidase; Gout Su | 2020 |
Protective effects of tuna meat oligopeptides (TMOP) supplementation on hyperuricemia and associated renal inflammation mediated by gut microbiota.
Topics: Animals; Anti-Inflammatory Agents; Dietary Supplements; Fish Proteins, Dietary; Gastrointestinal Mic | 2020 |
Efficacy and tolerability of febuxostat in gout patients on dialysis.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Dialysis; Retrospecti | 2021 |
Association between dyslipidemia and serum uric acid levels in Korean adults: Korea National Health and Nutrition Examination Survey 2016-2017.
Topics: Adult; Dyslipidemias; Female; Health Surveys; Humans; Hyperuricemia; Male; Middle Aged; Republic of | 2020 |
Association of variability in uric acid and future clinical outcomes of patient with coronary artery disease undergoing percutaneous coronary intervention.
Topics: Aged; Aged, 80 and over; Biomarkers; Coronary Artery Disease; Female; Heart Failure; Humans; Hyperur | 2020 |
Elevated serum uric acid, hyperuricaemia and dietary patterns among adolescents in mainland China.
Topics: Adolescent; Child; China; Cross-Sectional Studies; Diet; Female; Follow-Up Studies; Humans; Hyperuri | 2020 |
Uric acid induced hepatocytes lipid accumulation through regulation of miR-149-5p/FGF21 axis.
Topics: Allopurinol; Animals; Antimetabolites; Diet, High-Fat; Enzyme Inhibitors; Fibroblast Growth Factors; | 2020 |
A negative association between urinary iodine concentration and the prevalence of hyperuricemia and gout: a cross-sectional and population-based study in Mainland China.
Topics: Adult; China; Cross-Sectional Studies; Female; Gout; Humans; Hyperuricemia; Iodine; Prevalence; Pros | 2020 |
Association between serum level of urate and subclinical atherosclerosis: results from the SCAPIS Pilot.
Topics: Carotid Intima-Media Thickness; Carotid Stenosis; Cohort Studies; Coronary Artery Disease; Female; H | 2020 |
Hyperuricemia Is Not Predictive of Long-Term Outcome in Patients with Stable Chronic Obstructive Pulmonary Disease.
Topics: Aged; Female; Humans; Hyperuricemia; Kaplan-Meier Estimate; Lung; Lymphocytes; Male; Middle Aged; Ne | 2020 |
Predictors of Hyperuricemia after Kidney Transplantation: Association with Graft Function.
Topics: Adult; Calcineurin Inhibitors; Diuretics; Female; Glomerular Filtration Rate; Graft Survival; Humans | 2020 |
The prevalence of the gout-associated polymorphism rs2231142 G>T in ABCG2 in a pregnant female Filipino cohort.
Topics: Adolescent; Adult; Alleles; Asian People; ATP Binding Cassette Transporter, Subfamily G, Member 2; B | 2020 |
The comparison of dyslipidemia and serum uric acid in patients with gout and asymptomatic hyperuricemia: a cross-sectional study.
Topics: Cholesterol, HDL; Cholesterol, LDL; Cross-Sectional Studies; Dyslipidemias; Female; Gout; Humans; Hy | 2020 |
Asymptomatic hyperuricemia and incident congestive heart failure in elderly patients without comorbidities.
Topics: Age Factors; Aged; Asymptomatic Diseases; Biomarkers; China; Female; Heart Failure; Humans; Hyperuri | 2020 |
The relationship between self-reported habitual snoring and hyperuricemia among Chinese urban adults: a cross-sectional study.
Topics: Adolescent; Adult; China; Cross-Sectional Studies; Female; Humans; Hyperuricemia; Male; Prevalence; | 2020 |
The Associations Between Gonadal Hormones and Serum Uric Acid Levels in Men and Postmenopausal Women With Diabetes.
Topics: Aged; Biomarkers; Blood Glucose; Case-Control Studies; Cross-Sectional Studies; Diabetes Mellitus; F | 2020 |
Pleiotropic effect of the ABCG2 gene in gout: involvement in serum urate levels and progression from hyperuricemia to gout.
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; Disease Progression; Epistasis, Genetic; Eu | 2020 |
ABCG2 rs2231142 variant in hyperuricemia is modified by SLC2A9 and SLC22A12 polymorphisms and cardiovascular risk factors in an elderly community-dwelling population.
Topics: Aged; Aged, 80 and over; Aging; ATP Binding Cassette Transporter, Subfamily G, Member 2; Cardiovascu | 2020 |
Sex-specific association of hyperuricemia with cardiometabolic abnormalities in a military cohort: The CHIEF study.
Topics: Adolescent; Adult; Cross-Sectional Studies; Female; Humans; Hypertension; Hypertriglyceridemia; Hype | 2020 |
Complications of Renal Transplantation That Influence the Presence of Hyperuricemia in Its First Year of Evolution.
Topics: Creatinine; Delayed Graft Function; Female; Humans; Hyperuricemia; Kidney Transplantation; Male; Mex | 2020 |
Mild Hyperuricemia: To Treat, or Not to Treat, That is the Question. Suggestions form the URRAH Study.
Topics: Biomarkers; Cardiovascular Diseases; Clinical Decision-Making; Clinical Trials as Topic; Gout Suppre | 2020 |
[Hyperuricemia reduces semen parameters in infertile men].
Topics: Adult; Case-Control Studies; Fasting; Humans; Hyperuricemia; Infertility, Male; Male; Middle Aged; S | 2018 |
Effects of uric acid dysregulation on the kidney.
Topics: Animals; Biomarkers; Homeostasis; Humans; Hyperuricemia; Kidney; Kidney Diseases; Risk Factors; Uric | 2020 |
The relationship between elevated serum uric acid and arterial stiffness in a healthy population.
Topics: Ankle Brachial Index; ATP Binding Cassette Transporter, Subfamily G, Member 2; Biomarkers; Female; G | 2020 |
Hereditary hemochromatosis disrupts uric acid homeostasis and causes hyperuricemia via altered expression/activity of xanthine oxidase and ABCG2.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; Female; Hemochromatosis; Hemochrom | 2020 |
High-Protein Diet Induces Hyperuricemia in a New Animal Model for Studying Human Gout.
Topics: Allopurinol; Animal Structures; Animals; Chickens; Crystallization; Diet, High-Protein; Disease Mode | 2020 |
Uric acid and thrombotic risk: an emerging link.
Topics: Cardiomyopathy, Hypertrophic; Humans; Hyperuricemia; Risk Factors; Thromboembolism; Uric Acid | 2020 |
Impact of Uric Acid on Hypertension Occurrence and Target Organ Damage: Insights From the STANISLAS Cohort With a 20-Year Follow-up.
Topics: Adult; Aged; Albuminuria; Blood Pressure; Cohort Studies; Creatinine; Female; France; Glomerular Fil | 2020 |
A population-specific low-frequency variant of SLC22A12 (p.W258*) explains nearby genome-wide association signals for serum uric acid concentrations among Koreans.
Topics: Alleles; Asian People; ATP Binding Cassette Transporter, Subfamily G, Member 2; Chromosomes, Human, | 2020 |
Development of herbal formulation of medicinal plants and determination of its antihyperuricemic potential in vitro and in vivo rat's model.
Topics: Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Compounding; Drug Developmen | 2020 |
Repeated measurements of serum urate and mortality: a prospective cohort study of 152,358 individuals over 8 years of follow-up.
Topics: Adult; Aged; China; Cohort Studies; Female; Follow-Up Studies; Humans; Hyperuricemia; Male; Middle A | 2020 |
The case for evidence-based medicine for the association between hyperuricaemia and CKD.
Topics: Evidence-Based Medicine; Humans; Hyperuricemia; Renal Insufficiency, Chronic; Uric Acid | 2020 |
Reply to 'The case for evidence-based medicine for the association between hyperuricaemia and CKD'.
Topics: Evidence-Based Medicine; Humans; Hyperuricemia; Renal Insufficiency, Chronic; Uric Acid | 2020 |
Construction and expression of recombinant uricase‑expressing genetically engineered bacteria and its application in rat model of hyperuricemia.
Topics: Animals; Bacteria; Hyperuricemia; Intestines; Male; Rats; Rats, Sprague-Dawley; Recombinant Proteins | 2020 |
Associations between changes in serum uric acid and the risk of myocardial infarction.
Topics: Humans; Hypertension; Hyperuricemia; Middle Aged; Myocardial Infarction; Risk Factors; Uric Acid | 2020 |
Plasma xanthine oxidoreductase (XOR) activity in patients who require cardiovascular intensive care.
Topics: Aged; Aged, 80 and over; APACHE; Biomarkers; Cardiovascular Diseases; Emergency Service, Hospital; F | 2020 |
Uricostatic and uricosuric effect of grapefruit juice in potassium oxonate-induced hyperuricemic mice.
Topics: Animals; Citrus paradisi; Hyperuricemia; Mice; Oxonic Acid; Uric Acid | 2020 |
The efficacy and tolerability of febuxostat treatment in a cohort of Chinese Han population with history of gout.
Topics: Adult; Asian People; China; Cohort Studies; Double-Blind Method; Ethnicity; Febuxostat; Female; Gout | 2020 |
Sex- and age-specific variations, temporal trends and metabolic determinants of serum uric acid concentrations in a large population-based Austrian cohort.
Topics: Adult; Age Factors; Aged; Austria; Biomarkers; Female; Humans; Hyperuricemia; Male; Middle Aged; Pop | 2020 |
Clinical Predictors of the Hypoglycemic Effect of Sodium-Glucose Co-transporter-2 Inhibitors in Hyperuricemic Patients: A Retrospective Descriptive Observational Study.
Topics: Adult; Aged; Female; Glycated Hemoglobin; Humans; Hyperuricemia; Male; Middle Aged; Potassium; Retro | 2020 |
Arterial hypertension associated with hyperuricemia: features of heart damage.
Topics: Heart Injuries; Humans; Hypertension; Hypertrophy, Left Ventricular; Hyperuricemia; Uric Acid | 2020 |
Comparison of Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction With Versus Without Hyperuricemia or Gout.
Topics: Aged; Cause of Death; Comorbidity; Echocardiography; Female; Follow-Up Studies; Gout; Heart Failure; | 2020 |
Serum uric acid is independently associated with aortic arch calcification in a cross-sectional study of middle-aged and elderly women.
Topics: Age Factors; Aged; Aorta, Thoracic; Aortic Diseases; Biomarkers; China; Cross-Sectional Studies; Fem | 2020 |
Association between long-term prescription of febuxostat and the progression of heart failure with preserved ejection fraction in patients with hypertension and asymptomatic hyperuricemia.
Topics: Aged; Asymptomatic Diseases; Biomarkers; Blood Pressure; Databases, Factual; Diastole; Disease Progr | 2020 |
Impact of plasma xanthine oxidoreductase activity in patients with heart failure with preserved ejection fraction.
Topics: Heart Failure; Humans; Hyperuricemia; Stroke Volume; Uric Acid; Xanthine Dehydrogenase | 2020 |
Association between retinol intake and hyperuricaemia in adults.
Topics: Adult; Animals; Cross-Sectional Studies; Female; Humans; Hyperuricemia; Male; Nutrition Surveys; Uri | 2021 |
Prevalence of hyperuricaemia in an Eastern Chinese population: a cross-sectional study.
Topics: Asian People; Blood Glucose; Blood Pressure; Body Mass Index; China; Cross-Sectional Studies; Female | 2020 |
SMRT sequencing revealed to be an effective method for ADTKD-MUC1 diagnosis through follow-up analysis of a Chinese family.
Topics: Adult; Aged; Asian People; Case-Control Studies; China; Exome Sequencing; Female; Frameshift Mutatio | 2020 |
Hyperuricemia is associated with metabolic syndrome in the community very elderly in Chengdu.
Topics: Aged, 80 and over; Blood Glucose; China; Cholesterol, HDL; Cross-Sectional Studies; Female; Humans; | 2020 |
Association between serum copper levels and prevalence of hyperuricemia: a cross-sectional study.
Topics: Adult; Copper; Cross-Sectional Studies; Female; Humans; Hyperuricemia; Logistic Models; Male; Middle | 2020 |
Associations of serum iron and ferritin with hyperuricemia and serum uric acid.
Topics: Cross-Sectional Studies; Female; Ferritins; Humans; Hyperuricemia; Iron; Male; Middle Aged; Risk Fac | 2020 |
A mendelian randomization analysis: The causal association between serum uric acid and atrial fibrillation.
Topics: Adult; Atrial Fibrillation; Causality; Female; Humans; Hyperuricemia; Male; Mendelian Randomization | 2020 |
Blood glucose fluctuations detected by continuous glucose monitoring system in gout patients with normal glucose tolerance and the effect of urate-lowering therapy.
Topics: Adult; Aged; Allopurinol; Biomarkers; Blood Glucose; Blood Glucose Self-Monitoring; Down-Regulation; | 2020 |
Omega-3 Polyunsaturated Fatty Acids Inhibit the Function of Human URAT1, a Renal Urate Re-Absorber.
Topics: alpha-Linolenic Acid; Cells, Cultured; Docosahexaenoic Acids; Dose-Response Relationship, Drug; Eico | 2020 |
The ABCG2 Q141K hyperuricemia and gout associated variant illuminates the physiology of human urate excretion.
Topics: Alleles; Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; Disease Models, Animal; E | 2020 |
Association between serum vitamin D and uric acid in the eastern Chinese population: a population-based cross-sectional study.
Topics: Adult; Aged; Blood Glucose; Body Mass Index; Case-Control Studies; China; Female; Glycated Hemoglobi | 2020 |
The mechanism of Arhalofenate in alleviating hyperuricemia-Activating PPARγ thereby reducing caspase-1 activity.
Topics: Acetamides; Anti-Inflammatory Agents; Caspase 1; Cell Line; Cell Survival; Humans; Hyperuricemia; In | 2020 |
Uric acid and hypertension.
Topics: Humans; Hypertension; Hyperuricemia; Uric Acid | 2020 |
Total glucosides of herbaceous peony (Paeonia lactiflora Pall.) flower attenuate adenine- and ethambutol-induced hyperuricaemia in rats.
Topics: Adenine; Animals; Biomarkers; Disease Models, Animal; Down-Regulation; Ethambutol; Flowers; Glucosid | 2020 |
RDP3, A Novel Antigout Peptide Derived from Water Extract of Rice.
Topics: Animals; Anti-Inflammatory Agents; Edema; Gout; Gout Suppressants; Humans; Hyperuricemia; Mice; Mice | 2020 |
Effect of hyperuricemia on functional outcomes and complications in patients with elbow stiffness after open arthrolysis combined with hinged external fixation: a retrospective study.
Topics: Adult; Elbow Injuries; Elbow Joint; External Fixators; Female; Humans; Hyperuricemia; Joint Diseases | 2020 |
Delayed treatment with an autophagy inhibitor 3-MA alleviates the progression of hyperuricemic nephropathy.
Topics: Animals; Autophagy; Disease Models, Animal; Disease Progression; Female; Humans; Hyperuricemia; Kidn | 2020 |
Metformin alleviates hyperuricaemia-induced serum FFA elevation and insulin resistance by inhibiting adipocyte hypertrophy and reversing suppressed white adipose tissue beiging.
Topics: 3T3-L1 Cells; Adenylate Kinase; Adipocytes; Adipose Tissue, Beige; Adipose Tissue, White; Adult; Ani | 2020 |
Non-alcoholic fatty liver disease: correlation with hyperuricemia in a European Mediterranean population.
Topics: Cross-Sectional Studies; Female; Humans; Hyperuricemia; Male; Metabolic Syndrome; Non-alcoholic Fatt | 2022 |
Serum Urate Levels of Hemodialyzed Renal Patients Revisited.
Topics: Aged; Aged, 80 and over; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; | 2021 |
Urate-lowering therapy may mitigate the risks of hospitalized stroke and mortality in patients with gout.
Topics: Adult; Aged; Allopurinol; Female; Gout; Gout Suppressants; Hospital Mortality; Hospitalization; Huma | 2020 |
Uric acid is independent and inversely associated to glomerular filtration rate in young adult Brazilian individuals.
Topics: Adult; Age Factors; Biomarkers; Brazil; Cross-Sectional Studies; Female; Glomerular Filtration Rate; | 2020 |
Serum Uric Acid Concentration in Patients with Cerebrovascular Disease (Ischemic Stroke and Vascular Dementia).
Topics: Aged; Aged, 80 and over; Case-Control Studies; Cerebrovascular Disorders; Dementia, Vascular; Humans | 2020 |
A formula predicting the effective dose of febuxostat in chronic kidney disease patients with asymptomatic hyperuricemia based on a retrospective study and a validation cohort
.
Topics: Aged; Febuxostat; Female; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Renal Insuffi | 2020 |
Perfluoroalkyl acids, hyperuricemia and gout in adults: Analyses of NHANES 2009-2014.
Topics: Adult; Alkanesulfonic Acids; Caprylates; Cotinine; Cross-Sectional Studies; Decanoic Acids; Environm | 2020 |
[Comorbidity in gout and hyperuricemia: prevalence, causes, prospects of urate lowering therapy].
Topics: Allopurinol; Comorbidity; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Prevalence; Ur | 2019 |
Efficacy of febuxostat versus allopurinol and the predictors of achieving target serum urate in a cohort of Thai people with gout.
Topics: Allopurinol; Cohort Studies; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Retrospecti | 2021 |
Comparison of uric acid reduction and renal outcomes of febuxostat vs allopurinol in patients with chronic kidney disease.
Topics: Aged; Aged, 80 and over; Allopurinol; Cohort Studies; Febuxostat; Female; Follow-Up Studies; Glomeru | 2020 |
Long-Term Safety and Effectiveness of the Xanthine Oxidoreductase Inhibitor, Topiroxostat in Japanese Hyperuricemic Patients with or Without Gout: A 54-week Open-label, Multicenter, Post-marketing Observational Study.
Topics: Adult; Enzyme Inhibitors; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Incidence; Japan; | 2020 |
Venetoclax plus cytochrome P450 inhibitors without ramp-up strategy led to low risk of tumor lysis syndrome in acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitid | 2020 |
Association between Uric Acid and Bone Mineral Density in Postmenopausal Women with Type 2 Diabetes Mellitus in China: A Cross-Sectional Inpatient Study.
Topics: Age Factors; Aged; Aged, 80 and over; Body Mass Index; Bone Density; China; Cross-Sectional Studies; | 2020 |
Systemic Investigation of Promoter-wide Methylome and Genome Variations in Gout.
Topics: Adult; Aged; CpG Islands; DNA Methylation; Epigenesis, Genetic; Epigenome; Female; Gout; Humans; Hyp | 2020 |
Analyzing the Association between Hyperuricemia and Periodontitis: A Cross-Sectional Study Using KoGES HEXA Data.
Topics: Cross-Sectional Studies; Female; Humans; Hyperuricemia; Male; Periodontitis; Prospective Studies; Ri | 2020 |
Biomimetic polysaccharide-cloaked lipidic nanovesicles/microassemblies for improving the enzymatic activity and prolonging the action time for hyperuricemia treatment.
Topics: Biological Availability; Biomimetics; Humans; Hyperuricemia; Polysaccharides; Uric Acid | 2020 |
Extreme hyperuricemia is a risk factor for infection-related deaths in incident dialysis patients: a multicenter prospective cohort study.
Topics: Aged; Aged, 80 and over; Female; Humans; Hyperuricemia; Japan; Kidney Failure, Chronic; Male; Middle | 2020 |
Sugar-containing carbonated beverages consumption is associated with hyperuricemia in general adults: A cross-sectional study.
Topics: Adult; Biomarkers; Carbonated Beverages; China; Cross-Sectional Studies; Female; Humans; Hyperuricem | 2020 |
Uric acid fluctuation had no effect on renal function among gout patients.
Topics: Adult; Aged; Biomarkers; Electronic Health Records; Female; Glomerular Filtration Rate; Gout; Humans | 2020 |
Associations of serum uric acid level and gout with cardiac structure, function and sex differences from large scale asymptomatic Asians.
Topics: Adult; Asian People; Asymptomatic Diseases; Echocardiography, Doppler; Female; Gout; Heart Atria; He | 2020 |
Identification of GLUT12/SLC2A12 as a urate transporter that regulates the blood urate level in hyperuricemia model mice.
Topics: Animals; Gene Expression Regulation; Glucose Transport Proteins, Facilitative; Hyperuricemia; Mice; | 2020 |
Lowered serum uric acid level may be associated with reduced risk of myocardial infarction.
Topics: Humans; Hyperuricemia; Myocardial Infarction; Uric Acid | 2020 |
NMR-Based Metabonomic Study Reveals Intervention Effects of Polydatin on Potassium Oxonate-Induced Hyperuricemia in Rats.
Topics: Animals; Blood Urea Nitrogen; Creatinine; Disease Models, Animal; Drugs, Chinese Herbal; Glucosides; | 2020 |
A retrospective evaluation of laboratory parameters and hyperuricemia in patients with acne vulgaris under systemic isotretinoin treatment.
Topics: Acne Vulgaris; Adolescent; Adult; Dermatologic Agents; Humans; Hyperuricemia; Isotretinoin; Retrospe | 2022 |
The Time-Feature of Uric Acid Excretion in Hyperuricemia Mice Induced by Potassium Oxonate and Adenine.
Topics: Adenine; Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; Chromatography, High Pres | 2020 |
Influence of post-disaster evacuation on incidence of hyperuricemia in residents of Fukushima Prefecture: the Fukushima Health Management Survey.
Topics: Adult; Aged; Aged, 80 and over; Body Mass Index; Cholesterol, HDL; Cholesterol, LDL; Disaster Victim | 2020 |
Clinical relevance of serum uric acid and abdominal aortic-calcification in a national survey.
Topics: Aorta, Abdominal; Aortic Diseases; Atherosclerosis; Biomarkers; China; Female; Humans; Hyperuricemia | 2020 |
Acute Gouty Arthritis During Favipiravir Treatment for Coronavirus Disease 2019.
Topics: Adult; Amides; Antiviral Agents; Arthritis, Gouty; Betacoronavirus; Coronavirus Infections; COVID-19 | 2020 |
Comparative analysis of the efficacy of angiotensin II receptor blockers for uric acid level change in asymptomatic hyperuricaemia.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cohort Stud | 2020 |
Association between relative fat mass, uric acid, and insulin resistance in children with chronic kidney disease.
Topics: Adolescent; Body Mass Index; Cross-Sectional Studies; Humans; Hyperuricemia; Insulin Resistance; Obe | 2021 |
Confounded by obesity and modulated by urinary uric acid excretion, sleep-disordered breathing indirectly relates to hyperuricaemia in males: A structural equation model.
Topics: Biomarkers; Body Mass Index; Humans; Hyperuricemia; Male; Middle Aged; Obesity; Polysomnography; Sle | 2021 |
A pilot study to identify the longitudinal serum metabolite profiles to predict the development of hyperuricemia in essential hypertension.
Topics: Essential Hypertension; Humans; Hypertension; Hyperuricemia; Longitudinal Studies; Pilot Projects; U | 2020 |
Food Consumption is Associated with Hyperuricemia in Boys.
Topics: Adolescent; Age Factors; Biomarkers; Child; Cross-Sectional Studies; Diet; Eating; Feeding Behavior; | 2020 |
Sex-Specific Association of Serum Uric Acid Level and Change in Hyperuricemia Status with Risk of Type 2 Diabetes Mellitus: A Large Cohort Study in China.
Topics: Adult; China; Cohort Studies; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Humans; Hyperuri | 2020 |
Whole genome sequence analysis identifies a PAX2 mutation to establish a correct diagnosis for a syndromic form of hyperuricemia.
Topics: Adult; Creatinine; DNA Mutational Analysis; Female; Heterozygote; Humans; Hyperparathyroidism, Secon | 2020 |
Trans-ancestral dissection of urate- and gout-associated major loci SLC2A9 and ABCG2 reveals primate-specific regulatory effects.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; Evolution, Molecular; Genetic Pred | 2021 |
Hyperuricemia induces lipid disturbances mediated by LPCAT3 upregulation in the liver.
Topics: 1-Acylglycerophosphocholine O-Acyltransferase; Adult; Animals; Case-Control Studies; Cholesterol; Fe | 2020 |
Economic Status Moderates the Association Between Early-Life Famine Exposure and Hyperuricemia in Adulthood.
Topics: Adverse Childhood Experiences; Aged; Child; China; Economic Factors; Economic Status; Famine; Female | 2020 |
U-shaped relationship between serum uric acid level and decline in renal function during a 10-year period in female subjects: BOREAS-CKD2.
Topics: Adult; Female; Glomerular Filtration Rate; Humans; Hyperuricemia; Kidney; Male; Middle Aged; Renal I | 2021 |
Comparison of the Effects of Allopurinol and Febuxostat on the Values of Triglycerides in Hyperuricemic Patients.
Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Febuxostat; Female; Gout Suppressants; Humans; Hyperuri | 2020 |
Longitudinal associations between metabolic score for visceral fat and hyperuricemia in non-obese adults.
Topics: Adiposity; Adult; Biomarkers; China; Energy Metabolism; Female; Humans; Hyperuricemia; Incidence; In | 2020 |
The relationship between serum uric acid and cognitive function in patients with chronic heart failure.
Topics: Aged; Aged, 80 and over; Biomarkers; Chronic Disease; Cognition; Cognition Disorders; Cross-Sectiona | 2020 |
A novel mouse model of hyperuricemia and gouty nephropathy.
Topics: Animals; Arthritis, Gouty; Disease Models, Animal; Gout; Hyperuricemia; Mice; Uric Acid | 2020 |
Mangiferin promotes intestinal elimination of uric acid by modulating intestinal transporters.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; Hyperuricemia; Intestinal Eliminat | 2020 |
Decreased Platelet Inhibition by Thienopyridines in Hyperuricemia.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Angioplasty; Clopidogrel; Comorbidity; Cytochr | 2021 |
Delayed emergence from propofol anesthesia in a patient with Lesch-Nyhan syndrome: A case report.
Topics: Administration, Intravenous; Adolescent; Anesthesia Recovery Period; Anesthesia, General; Humans; Hy | 2020 |
Relationship between serum uric acid and all-cause mortality in dialysis patients: like being in wonderland, disoriented.
Topics: Humans; Hyperuricemia; Peritoneal Dialysis; Renal Dialysis; Uric Acid | 2020 |
[Consequences of Gout and Hyperuricemia].
Topics: Cardiovascular Diseases; Gout; Gout Suppressants; Humans; Hyperuricemia; Uric Acid | 2020 |
[Gout - a common and well known disease].
Topics: Gout; Humans; Hyperuricemia; Sweden; Ultrasonography; Uric Acid | 2020 |
Olsalazine Sodium Increases Renal Urate Excretion by Modulating Urate Transporters in Hyperuricemic Animals.
Topics: Aminosalicylic Acids; Animals; Blood Urea Nitrogen; Creatinine; Disease Models, Animal; Dose-Respons | 2020 |
Impact of hyperuricemia on mortality related to aortic diseases: a 3.8-year nationwide community-based cohort study.
Topics: Aortic Aneurysm; Aortic Diseases; Aortic Dissection; Aortic Rupture; Female; Humans; Hyperuricemia; | 2020 |
Association between hyperuricemia, gout, urate lowering therapy, and osteoarthritis: A protocol for a systematic review and meta-analysis.
Topics: Gout; Humans; Hyperuricemia; Meta-Analysis as Topic; Observational Studies as Topic; Osteoarthritis; | 2020 |
Estimates of renal net acid excretion and their relationships with serum uric acid and hyperuricemia in a representative German population sample.
Topics: Acids; Adult; Cross-Sectional Studies; Humans; Hyperuricemia; Renal Elimination; Risk Factors; Uric | 2020 |
A Lanosteryl Triterpene (RA-3) Exhibits Antihyperuricemic and Nephroprotective Effects in Rats.
Topics: Animals; Biomarkers; Blood Urea Nitrogen; Body Weight; Creatinine; Hyperuricemia; Interleukin-6; Kid | 2020 |
Association between Hyperuricemia and Ischemic Stroke: A Case-Control Study.
Topics: Brain Ischemia; Case-Control Studies; Humans; Hyperuricemia; Ischemic Stroke; Risk Factors; Stroke; | 2020 |
Matrix Metalloproteinase-3 induces proteoglycan degradation in gouty arthritis model.
Topics: Animals; Arthritis, Gouty; Chondrocytes; Cytokines; Disease Models, Animal; Hyperuricemia; Interleuk | 2021 |
A cross-sectional study of 502 patients found a diffuse hyperechoic kidney medulla pattern in patients with severe gout.
Topics: Cross-Sectional Studies; Gout; Humans; Hyperuricemia; Kidney Medulla; Uric Acid | 2021 |
Serum urate is related to subclinical inflammation in asymptomatic hyperuricaemia.
Topics: C-Reactive Protein; Female; Humans; Hyperuricemia; Inflammation; Interleukin-6; Leukocytes, Mononucl | 2021 |
Increased serum uric acid levels are associated to renal arteriolopathy and predict poor outcome in IgA nephropathy.
Topics: Adult; Aged; Arterioles; Biomarkers; Biopsy; Disease Progression; Female; Glomerulonephritis, IGA; H | 2020 |
Estimate of prevalent hyperuricemia by systemic inflammation response index: results from a rural Chinese population.
Topics: Biomarkers; Cardiometabolic Risk Factors; China; Cross-Sectional Studies; Female; Humans; Hyperurice | 2021 |
Hyperuricemia precedes non-alcoholic fatty liver disease with abdominal obesity moderating this unidirectional relationship: Three longitudinal analyses.
Topics: Beijing; Humans; Hyperuricemia; Non-alcoholic Fatty Liver Disease; Obesity, Abdominal; Uric Acid | 2020 |
Factors associated with achieving target serum uric acid level and occurrence of gouty arthritis: A retrospective observational study of Japanese health insurance claims data.
Topics: Arthritis, Gouty; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Insurance, Health; Japan; | 2021 |
Association of sleep quality and sleep duration with serum uric acid levels in adults.
Topics: Adult; Female; Humans; Hyperuricemia; Male; Middle Aged; Sleep Deprivation; Uric Acid | 2020 |
Serum uric acid and left ventricular hypertrophy in hypertensive patients in Ado-Ekiti.
Topics: Aged; Body Mass Index; Case-Control Studies; Cross-Sectional Studies; Echocardiography; Female; Huma | 2020 |
Hyperuricemia in renal disease patients.
Topics: Disease Progression; Humans; Hyperuricemia; Renal Insufficiency, Chronic; Risk Factors; Uric Acid | 2020 |
Prevalence and associated factors of hyperuricemia among urban adults aged 35-79 years in southwestern China: a community-based cross-sectional study.
Topics: Adult; Aged; China; Comorbidity; Cross-Sectional Studies; Female; Humans; Hyperuricemia; Male; Middl | 2020 |
Increased Overall Heart Rate Irregularity Risk by Hyperuricemia in the General Population: Results from the Korean National Health and Nutrition Examination Survey.
Topics: Adult; Cross-Sectional Studies; Heart Rate; Humans; Hyperuricemia; Nutrition Surveys; Republic of Ko | 2020 |
Dietary and nutritional factors associated with hyperuricemia: The seventh Korean National Health and Nutrition Examination Survey.
Topics: Cross-Sectional Studies; Diet; Female; Humans; Hyperuricemia; Male; Middle Aged; Nutrition Surveys; | 2020 |
Hyperuricemia prevalence in healthy subjects and its relationship with cardiovascular target organ damage.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Biomarkers; Cardiovascular Diseases; Cross-Sectional Stu | 2021 |
Variability in Urate-lowering Therapy Prescribing: A Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN) Physician Survey.
Topics: Gout; Gout Suppressants; Humans; Hyperuricemia; Physicians; Uric Acid | 2021 |
Association of Maternal Hyperuricemia with Post-Spinal Hypotension in Pre-Eclamptic Parturients Undergoing Emergency Cesarean Delivery: a Prospective Observational Study.
Topics: Adult; Anesthesia, Obstetrical; Anesthesia, Spinal; Biomarkers; Blood Pressure; Cesarean Section; Em | 2021 |
Prevalences of hyperuricemia and electrolyte abnormalities in patients with chronic kidney disease in Japan: A nationwide, cross-sectional cohort study using data from the Japan Chronic Kidney Disease Database (J-CKD-DB).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cross-Sectional Studies; Databases, Factual; Electrolyte | 2020 |
Prevalence of gout and asymptomatic hyperuricemia in the pediatric population: a cross-sectional study of a Japanese health insurance database.
Topics: Adolescent; Child; Child, Preschool; Cross-Sectional Studies; Female; Gout; Humans; Hyperuricemia; I | 2020 |
Relationship between Serum Uric Acid and Mortality Risk in Hemodialysis Patients: A Multicenter Prospective Cohort Study.
Topics: Adult; Aged; C-Reactive Protein; Cardiovascular Diseases; Female; Follow-Up Studies; Humans; Hyperur | 2020 |
[Electrolytic drinking water improves the metabolism of uric acid in the SD rats with hyperuricemia].
Topics: Animals; Creatinine; Drinking Water; Hyperuricemia; Rats; Rats, Sprague-Dawley; Uric Acid | 2020 |
Uric acid drives intestinal barrier dysfunction through TSPO-mediated NLRP3 inflammasome activation.
Topics: Animals; Cell Line; Hyperuricemia; Ileum; Inflammasomes; Male; Mice, Knockout; NLR Family, Pyrin Dom | 2021 |
Combined application of DTI and BOLD-MRI in the assessment of renal injury with hyperuricemia.
Topics: Diffusion Tensor Imaging; Humans; Hyperuricemia; Kidney; Magnetic Resonance Imaging; Uric Acid | 2021 |
Baicalein alleviates hyperuricemia by promoting uric acid excretion and inhibiting xanthine oxidase.
Topics: Animals; Antioxidants; Disease Models, Animal; Enzyme Inhibitors; Flavanones; Glucose Transport Prot | 2021 |
Multiple-Purpose Connectivity Map Analysis Reveals the Benefits of Esculetin to Hyperuricemia and Renal Fibrosis.
Topics: Animals; Cell Nucleus; Disease Models, Animal; Down-Regulation; Fibrosis; Hep G2 Cells; Humans; Hype | 2020 |
Rapid disappearance of gouty tophi of the foot by resection of massive gouty tophi of the opposite foot in a patient with hyperuricaemia: a case report.
Topics: Adult; Arthritis, Gouty; Female; Gout; Humans; Hyperuricemia; Uric Acid | 2020 |
Association between serum uric acid and spirometric pulmonary function in Korean adults: The 2016 Korea National Health and Nutrition Examination Survey.
Topics: Adult; Aged; Aged, 80 and over; Cross-Sectional Studies; Female; Forced Expiratory Volume; Humans; H | 2020 |
Increased Susceptibility of Atrial Fibrillation Induced by Hyperuricemia in Rats: Mechanisms and Implications.
Topics: Actins; Animals; Apoptosis; Atrial Fibrillation; Atrial Remodeling; bcl-2-Associated X Protein; Benz | 2021 |
Multiomics Integrative Analysis for Discovering the Potential Mechanism of Dioscin against Hyperuricemia Mice.
Topics: Animals; Diosgenin; Hyperuricemia; Male; Metabolomics; Mice; Uric Acid | 2021 |
Dendrobium officinalis six nostrum ameliorates urate under-excretion and protects renal dysfunction in lipid emulsion-induced hyperuricemic rats.
Topics: Animals; Anti-Inflammatory Agents; Dendrobium; Disease Models, Animal; Dose-Response Relationship, D | 2020 |
Foetal and maternal outcomes in hyperuricaemia pre-eclampsia patients in Hospital Universiti Sains Malaysia.
Topics: Adult; Female; Humans; Hyperuricemia; Infant, Low Birth Weight; Infant, Newborn; Kidney Function Tes | 2021 |
Chicory ameliorates hyperuricemia via modulating gut microbiota and alleviating LPS/TLR4 axis in quail.
Topics: Animals; Anti-Inflammatory Agents; Cichorium intybus; Claudin-1; Gastrointestinal Microbiome; Hyperu | 2020 |
Antihyperuricemic Effect of Urolithin A in Cultured Hepatocytes and Model Mice.
Topics: Animals; Cell Line; Coumarins; Disease Models, Animal; Gout Suppressants; Hepatocytes; Hyperuricemia | 2020 |
Discovery of a novel rice-derived peptide with significant anti-gout potency.
Topics: Animals; Edema; Female; Gout; Hyperuricemia; Inflammasomes; Inflammation; Interleukin-1beta; Kidney; | 2020 |
Isoorientin exerts a urate-lowering effect through inhibition of xanthine oxidase and regulation of the TLR4-NLRP3 inflammasome signaling pathway.
Topics: Animals; Disease Models, Animal; Humans; Hyperuricemia; Inflammasomes; Luteolin; Male; Mice; NLR Fam | 2021 |
The Association between Serum Uric Acid and Appendicular Skeletal Muscle Mass and the Effect of Their Interaction on Mortality in Patients on Peritoneal Dialysis.
Topics: Adult; Female; Humans; Hyperuricemia; Male; Middle Aged; Muscle, Skeletal; Peritoneal Dialysis; Prop | 2020 |
Sodium butyrate arrests pancreato-hepatic synchronous uric acid and lipid dysmetabolism in high fat diet fed Wistar rats.
Topics: Animals; Blood Glucose; Butyric Acid; Diet, High-Fat; Disease Models, Animal; Dyslipidemias; Female; | 2021 |
Association of uric acid with cardiovascular risk in Brazilian children and adolescents.
Topics: Adolescent; Age Factors; Biomarkers; Brazil; Cardiometabolic Risk Factors; Cardiovascular Diseases; | 2021 |
Distribution of serum uric acid levels and prevalence of hyper- and hypouricemia in a Korean general population of 172,970.
Topics: Adult; Cross-Sectional Studies; Female; Humans; Hyperuricemia; Male; Middle Aged; Prevalence; Republ | 2021 |
Uric acid aggravates myocardial ischemia-reperfusion injury via ROS/NLRP3 pyroptosis pathway.
Topics: Animals; Biomarkers; Caspase 3; Cell Hypoxia; Cells, Cultured; Disease Models, Animal; Hyperuricemia | 2021 |
Ecce urate.
Topics: Humans; Hyperuricemia; Inflammation; Postoperative Complications; Uric Acid | 2021 |
Relationships between diuretic-related hyperuricemia and cardiovascular events: data from the URic acid Right for heArt Health study.
Topics: Diuretics; Humans; Hypertension; Hyperuricemia; Male; Middle Aged; Risk Factors; Uric Acid | 2021 |
The effect of serum uric acid levels on the long-term prognosis of patients with non-ST-elevation myocardial infarction.
Topics: Aged; Aged, 80 and over; Female; Humans; Hyperuricemia; Male; Middle Aged; Non-ST Elevated Myocardia | 2020 |
Anti-Hyperuricemic Effects of Astaxanthin by Regulating Xanthine Oxidase, Adenosine Deaminase and Urate Transporters in Rats.
Topics: Adenosine Deaminase; Adenosine Deaminase Inhibitors; Animals; Biomarkers; Disease Models, Animal; Fr | 2020 |
Uric acid level and kidney function: a cross-sectional study of the Korean national health and nutrition examination survey (2016-2017).
Topics: Adult; Aged; Biomarkers; Cross-Sectional Studies; Female; Glomerular Filtration Rate; Humans; Hyperu | 2020 |
Efficacy of antiviral therapy in patients with post-hepatitis C liver cirrhosis: is hyperuricaemia a potential adverse effect?
Topics: Antiviral Agents; Child; Hepacivirus; Hepatitis C; Humans; Hyperuricemia; Liver Cirrhosis; Prospecti | 2020 |
Association between serum urate, gout and comorbidities: a case-control study using data from the UK Biobank.
Topics: Adult; Aged; Cardiovascular Diseases; Case-Control Studies; Comorbidity; Diabetes Mellitus; Female; | 2021 |
Combining Model-Based Clinical Trial Simulation, Pharmacoeconomics, and Value of Information to Optimize Trial Design.
Topics: Allopurinol; Bayes Theorem; Clinical Trials, Phase III as Topic; Computer Simulation; Decision Theor | 2021 |
Hyperuricemia is independently associated with hypertension in men under 60 years in a general Chinese population.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; China; Cross-Sectional Studies; Female; Humans; Hyperten | 2021 |
The Association between Purine-Rich Food Intake and Hyperuricemia: A Cross-Sectional Study in Chinese Adult Residents.
Topics: Adult; Animal Proteins, Dietary; Asian People; China; Cross-Sectional Studies; Diet; Eating; Fabacea | 2020 |
Uric Acid as a Risk Factor for Chronic Kidney Disease and Cardiovascular Disease - Japanese Guideline on the Management of Asymptomatic Hyperuricemia.
Topics: Allopurinol; Cardiovascular Diseases; Endothelial Cells; Febuxostat; Gout; Gout Suppressants; Humans | 2021 |
[Evaluation of a 12-week allopurinol-lowering therapy in combination with the non-steroidal anti-inflammatory drug meloxicam in patients with gout].
Topics: Allopurinol; Drug Therapy, Combination; Gout; Gout Suppressants; Humans; Hyperuricemia; Meloxicam; P | 2020 |
[Study on mechanism of Fangji Huangqi Decoction on hypouricemic effect and renal protection in hyperuricemia mice].
Topics: Animals; Drugs, Chinese Herbal; Hyperuricemia; Kidney; Male; Mice; Uric Acid | 2020 |
Elevated serum uric acid is associated with a greater inflammatory response and with short- and long-term mortality in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
Topics: Aged; Biomarkers; C-Reactive Protein; Female; Humans; Hyperuricemia; Inflammation; Inflammation Medi | 2021 |
Non-alcoholic fatty kidney disease (NAFKD): A novel disease that explains the etiology of hyperuricemia and gout in metabolic syndrome.
Topics: Adult; Female; Gout; Humans; Hyperuricemia; Kidney Diseases; Male; Metabolic Syndrome; Uric Acid | 2021 |
Associations between anthropometric parameters (body mass index, waist circumference and waist to hip ratio) and newly diagnosed hyperuricemia in adults in Qingdao, China: A cross-sectional study.
Topics: Adult; Aged; Body Mass Index; China; Cross-Sectional Studies; Female; Humans; Hyperuricemia; Male; M | 2020 |
A novel mouse model of hyperuricemia expressing a human functional ABCG2 variant.
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; Gout; Humans; Hyperuricemia; Mice; Neoplasm | 2021 |
Hyperuricemia and progression of chronic kidney disease: to treat or not to treat?
Topics: Allopurinol; Diabetes Mellitus, Type 1; Gout Suppressants; Humans; Hyperuricemia; Kidney; Renal Insu | 2021 |
Effects of bariatric surgery on serum uric acid in people with obesity with or without hyperuricaemia and gout: a retrospective analysis.
Topics: Adult; Bariatric Surgery; Female; Gout; Humans; Hyperuricemia; Male; Middle Aged; Obesity; Retrospec | 2021 |
Assessing the Relationship Between Serum Urate and Urolithiasis Using Mendelian Randomization: An Analysis of the UK Biobank.
Topics: Adult; Aged; Causality; Female; Humans; Hyperuricemia; Male; Mendelian Randomization Analysis; Middl | 2021 |
Low expression of estrogen receptor β in renal tubular epithelial cells may cause hyperuricemia in premenopausal patients with systemic lupus erythematosus.
Topics: Adult; Biopsy; Case-Control Studies; Creatinine; Epithelial Cells; Estrogen Receptor beta; Female; G | 2021 |
Association between decreased thyroid stimulating hormone and hyperuricemia in type 2 diabetic patients with early-stage diabetic kidney disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Biomarkers; Case-Control Studies; China; Diabetes Mellit | 2021 |
Independent and interactive effect of sitting time and physical activity on prevalence of hyperuricemia: the Henan Rural Cohort Study.
Topics: Cohort Studies; Cross-Sectional Studies; Exercise; Female; Humans; Hyperuricemia; Male; Prevalence; | 2021 |
Creation of an adequate animal model of hyperuricemia (acute and chronic hyperuricemia); study of its reversibility and its maintenance.
Topics: Animals; Antioxidants; Biomarkers; Chronic Disease; Creatinine; Disease Models, Animal; Hyperuricemi | 2021 |
Prevalence of Hyperuricemia and the Use of Allopurinol in Older Poles-Results from a Population-Based PolSenior Study.
Topics: Aged; Aged, 80 and over; Allopurinol; Cross-Sectional Studies; Female; Humans; Hyperuricemia; Male; | 2021 |
Xanthine oxidase inhibitory activity and antihyperuricemic effect of Moringa oleifera Lam. leaf hydrolysate rich in phenolics and peptides.
Topics: Animals; Creatinine; Disease Models, Animal; Flavonoids; Gout Suppressants; Hyperuricemia; Malondial | 2021 |
Inter-relationship of risk factors and pathways associated with chronic kidney disease in patients with type 2 diabetes mellitus: a structural equation modelling analysis.
Topics: Adult; Aged; Biomarkers; Blood Pressure; Diabetes Mellitus, Type 2; Female; Glomerular Filtration Ra | 2021 |
A convenient sampling and noninvasive dried spot method of uric acid in human saliva: Comparison of serum uric acid value and salivary uric acid in healthy volunteers and hyperuricemia patients.
Topics: Adult; Chromatography, High Pressure Liquid; Clinical Chemistry Tests; Dried Blood Spot Testing; Fem | 2021 |
Effect of Topiroxostat on Brain Natriuretic Peptide Level in Patients with Heart Failure with Preserved Ejection Fraction: A Pilot Study.
Topics: Aged; Aged, 80 and over; Biomarkers; Gout; Heart Failure; Humans; Hyperuricemia; Middle Aged; Natriu | 2021 |
Clinicopathological characteristics and outcomes of anti-neutrophil cytoplasmic autoantibody-related renal vasculitis with hyperuricemia: a retrospective case-control study.
Topics: Aged; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Antineutrophil Cytopla | 2021 |
Relation of BMI and waist circumference with the risk of new-onset hyperuricemia in hypertensive patients.
Topics: Body Mass Index; China; Female; Humans; Hypertension; Hyperuricemia; Male; Risk Factors; Uric Acid; | 2022 |
Obesity interacts with hyperuricemia on the severity of non-alcoholic fatty liver disease.
Topics: Body Mass Index; Cross-Sectional Studies; Female; Humans; Hyperuricemia; Male; Non-alcoholic Fatty L | 2021 |
Expression, localization and metabolic function of "resurrected" human urate oxidase in human hepatocytes.
Topics: Cell Proliferation; Gene Expression; Gout; HEK293 Cells; Hepatocytes; Humans; Hyperuricemia; Microsc | 2021 |
The visceral fat area to leg muscle mass ratio is significantly associated with the risk of hyperuricemia among women: a cross-sectional study.
Topics: Cholesterol, HDL; Cross-Sectional Studies; Female; Humans; Hyperuricemia; Intra-Abdominal Fat; Leg; | 2021 |
High urinary excretion rate of glucose attenuates serum uric acid level in type 2 diabetes with normal renal function.
Topics: Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Glycosuria; Humans; Hyperuricemia; Kidne | 2021 |
Residential greenness associated with lower serum uric acid levels and hyperuricemia prevalence in a large Chinese rural population.
Topics: Aged; Aged, 80 and over; China; Cohort Studies; Cross-Sectional Studies; Female; Humans; Hyperuricem | 2021 |
[Association between mild cognitive impairment and serum uric acid levels among people aged 55 and above in 4 provinces of China].
Topics: China; Cognitive Dysfunction; Cohort Studies; Humans; Hyperuricemia; Middle Aged; Risk Factors; Uric | 2021 |
Predictive Value of Thyroid Hormones for Incident Hyperuricemia in Euthyroid Subjects: The Tianjin Chronic Low-Grade Systemic Inflammation and Health Cohort Study.
Topics: Adult; Cohort Studies; Female; Humans; Hyperuricemia; Inflammation; Male; Risk Factors; Thyroid Horm | 2021 |
Study of Endothelial Dysfunction by Flow Mediated Vasodilation in Individuals with Asymptomatic Hyperuricemia.
Topics: Adult; Case-Control Studies; Endothelium, Vascular; Female; Humans; Hyperuricemia; Male; Middle Aged | 2021 |
Age difference in the combined effect of soda drinks consumption and body adiposity on hyperuricaemia in US adults.
Topics: Adiposity; Adult; Carbonated Beverages; Female; Humans; Hyperuricemia; Male; Middle Aged; Nutrition | 2021 |
Anti-hyperuricemic and nephroprotective effects of whey protein hydrolysate in potassium oxonate induced hyperuricemic rats.
Topics: Adenosine Deaminase; Animals; Creatinine; Humans; Hyperuricemia; Kidney; Liver; Male; Oxonic Acid; P | 2021 |
Relationship Between Changing Body Mass Index and Serum Uric Acid Alteration Among Clinically Apparently Healthy Korean Men.
Topics: Adult; Biomarkers; Body Mass Index; Humans; Hyperuricemia; Male; Republic of Korea; Retrospective St | 2022 |
Dose-response relationship between distinct serum uric acid trajectories and metabolic syndrome risk: A 5-year prospective cohort study.
Topics: Adult; Biomarkers; Cardiometabolic Risk Factors; China; Female; Humans; Hyperuricemia; Longitudinal | 2021 |
Evacuation after the Great East Japan Earthquake is an independent factor associated with hyperuricemia: The Fukushima Health Management Survey.
Topics: Adult; Aged; Biomarkers; Cross-Sectional Studies; Earthquakes; Emergency Shelter; Female; Fukushima | 2021 |
How Are We Managing Patients with Hyperuricemia and Gout: A Cross Sectional Study Assessing Knowledge and Attitudes of Primary Care Physicians?
Topics: Attitude; Cross-Sectional Studies; Gout; Humans; Hyperuricemia; Physicians, Primary Care; Uric Acid | 2021 |
Acute and severe ribavirin-associated hyperuricemia and acute kidney injury: An underrecognized adverse effect.
Topics: Acute Kidney Injury; Adult; Creatinine; Humans; Hyperuricemia; Male; Ribavirin; Uric Acid; Young Adu | 2021 |
Elevated serum uric acid is associated with incident hypertension in the health according to various contemporary blood pressure guidelines.
Topics: Adult; Biomarkers; Blood Pressure; Blood Pressure Determination; Female; Humans; Hypertension; Hyper | 2021 |
Age and sex dependent association of uric acid and incident hypertension.
Topics: Adult; Age Factors; Aged; Biomarkers; Blood Pressure; Female; Humans; Hypertension; Hyperuricemia; I | 2021 |
Genetic correlations between traits associated with hyperuricemia, gout, and comorbidities.
Topics: Bayes Theorem; Blood Pressure; Cardiometabolic Risk Factors; Comorbidity; Creatinine; Genome-Wide As | 2021 |
[Preliminary study on effect of Phellinus igniarius ethanol extract on serum uric acid metabolism and gut microbiome in rats].
Topics: Animals; Ethanol; Gastrointestinal Microbiome; Hyperuricemia; Phellinus; Plant Extracts; Rats; Rats, | 2021 |
Association of electronic cigarette exposure with serum uric acid level and hyperuricemia: 2016-2017 Korea National Health and Nutritional Examination Survey.
Topics: Adult; Electronic Nicotine Delivery Systems; Female; Health Surveys; Humans; Hyperuricemia; Male; Mi | 2021 |
The comparative effect of exposure to various risk factors on the risk of hyperuricaemia: diet has a weak causal effect.
Topics: Diet; Glucose Transport Proteins, Facilitative; Gout; Gout Suppressants; Humans; Hyperuricemia; Risk | 2021 |
Laboratory Predictors of COVID-19 Mortality: A Retrospective Analysis from Tongji Hospital in Wuhan.
Topics: Adult; Aged; Biomarkers; China; COVID-19; Cytokines; Female; Humans; Hyperuricemia; Inflammation Med | 2021 |
Association between urbanisation and the risk of hyperuricaemia among Chinese adults: a cross-sectional study from the China Health and Nutrition Survey (CHNS).
Topics: Adolescent; Adult; China; Cross-Sectional Studies; Female; Humans; Hyperuricemia; Male; Nutrition Su | 2021 |
Inosine induces acute hyperuricaemia in rhesus monkey (
Topics: Acute Disease; Allopurinol; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Febux | 2021 |
Relationship between seaweeds consumption and hyperuricaemia in general adults: a Population-based study from the Tianjin Chronic Low-grade Systemic Inflammation and Health (TCLSIH) cohort study.
Topics: Adult; China; Cohort Studies; Cross-Sectional Studies; Female; Humans; Hyperuricemia; Inflammation; | 2022 |
[Gout].
Topics: Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Symptom Flare Up; Uric Acid | 2021 |
A semi-mechanistic exposure-response model to assess the effects of verinurad, a potent URAT1 inhibitor, on serum and urine uric acid in patients with hyperuricemia-associated diseases.
Topics: Adult; Aged; Aged, 80 and over; Drug Therapy, Combination; Female; Humans; Hyperuricemia; Kidney; Ma | 2021 |
Changes in serum uric acid and the risk of cardiovascular disease and all-cause mortality in the general population.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Biomarkers; Cardiovascular Diseases; Cause of Death; Chi | 2021 |
Studies on effect of Tongfengxiaofang in HUM model mice using a UPLC-ESI-Q-TOF/MS metabolomic approach.
Topics: Animals; Chromatography, High Pressure Liquid; Disease Models, Animal; Drugs, Chinese Herbal; Hyperu | 2021 |
Association of uric acid with kidney function and albuminuria: the Uric Acid Right for heArt Health (URRAH) Project.
Topics: Adult; Aged; Albuminuria; Female; Glomerular Filtration Rate; Humans; Hyperuricemia; Kidney; Male; M | 2022 |
Detrimental effects of long-term elevated serum uric acid on cognitive function in rats.
Topics: Animals; Biomarkers; Cognition; Cognitive Dysfunction; Cytokines; Disease Models, Animal; Disease Su | 2021 |
Different clinical impact of hyperuricemia according to etiologies of chronic kidney disease: Gonryo Study.
Topics: Adult; Aged; Allopurinol; Antimetabolites; Female; Glomerular Filtration Rate; Humans; Hyperuricemia | 2021 |
Association of hyperuricemia and hypertension phenotypes in hypertensive patients without uric acid lowering treatment.
Topics: Blood Pressure Monitoring, Ambulatory; Female; Humans; Hypertension; Hyperuricemia; Male; Phenotype; | 2021 |
Temporal trends in hyperuricaemia among adults in Wuhan city, China, from 2010 to 2019: a cross-sectional study.
Topics: Adult; China; Cross-Sectional Studies; Female; Gout; Humans; Hyperuricemia; Male; Risk Factors; Uric | 2021 |
Uric acid in chronic coronary syndromes: Relationship with coronary artery disease severity and left ventricular diastolic parameter.
Topics: Aged; Biomarkers; Coronary Angiography; Coronary Artery Disease; Cross-Sectional Studies; Diastole; | 2021 |
PREVALENCE OF HYPERURICEMIA IN PATIENTS WITH CHRONIC HEART FAILURE.
Topics: Female; Heart Failure; Humans; Hyperuricemia; Prevalence; Uric Acid; Ventricular Dysfunction, Left; | 2021 |
Association between serum uric acid and major chronic diseases among centenarians in China: based on the CHCCS study.
Topics: Aged, 80 and over; China; Chronic Disease; Cross-Sectional Studies; Humans; Hyperuricemia; Prospecti | 2021 |
Serum uric acid is associated with incident hip fractures in women and men - Results from a large Austrian population-based cohort study.
Topics: Austria; Biomarkers; Cohort Studies; Female; Hip Fractures; Humans; Hyperuricemia; Incidence; Male; | 2021 |
Association Between Low-Level Blood Cadmium Exposure and Hyperuricemia in the American General Population: a Cross-sectional Study.
Topics: Adult; Cadmium; Cross-Sectional Studies; Female; Humans; Hyperuricemia; Male; Nutrition Surveys; Ris | 2022 |
Early onset of hyperuricemia is associated with increased cardiovascular disease and mortality risk.
Topics: Aged; Biomarkers; Cardiovascular Diseases; Cause of Death; China; Follow-Up Studies; Humans; Hyperur | 2021 |
Association between Anti-inflammatory Drug and Dementia in Patients with Gout: A Nationwide, Population-Based Nested Case-Control Study.
Topics: Aged; Aged, 80 and over; Antirheumatic Agents; Case-Control Studies; Dementia; Female; Glucocorticoi | 2021 |
Higher Serum Uric Acid Levels Are Associated With an Increased Risk of Vision-Threatening Diabetic Retinopathy in Type 2 Diabetes Patients.
Topics: Biomarkers; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Female; Follow | 2021 |
Establishment of a clinical diagnostic model for gouty arthritis based on the serum biochemical profile: A case-control study.
Topics: Adult; Area Under Curve; Arthritis, Gouty; Biomarkers; Blood Sedimentation; Blood Urea Nitrogen; C-R | 2021 |
Performance of Ultrasound in the Clinical Evaluation of Gout and Hyperuricemia.
Topics: Adolescent; Adult; Aged; Arthritis, Gouty; Asymptomatic Diseases; Female; Gout; Humans; Hyperuricemi | 2021 |
The elevation of serum uric acid depends on insulin resistance but not fasting plasma glucose in hyperuricaemia.
Topics: Blood Glucose; Fasting; Humans; Hyperuricemia; Insulin Resistance; Uric Acid | 2022 |
[Uric acid in children and adolescents with primary hypertension].
Topics: Adolescent; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Child; Female; Humans; Hypertensi | 2021 |
Real-world treatment of gout and asymptomatic hyperuricemia.
Topics: Gout; Gout Suppressants; Humans; Hyperuricemia; Uric Acid | 2022 |
Metabolic score for visceral fat and the risk of hyperuricemia in Chinese men.
Topics: Adiposity; China; Humans; Hyperuricemia; Intra-Abdominal Fat; Male; Uric Acid | 2021 |
Alcohol consumption and serum uric acid are synergistically associated with renal dysfunction among community-dwelling persons.
Topics: Aged; Alcohol Drinking; Cross-Sectional Studies; Female; Follow-Up Studies; Glomerular Filtration Ra | 2021 |
Genetically predicted serum uric acid levels and the risk of coronary artery disease in patients with diabetes: A Mendelian randomization study.
Topics: Biomarkers; Case-Control Studies; Coronary Artery Disease; Diabetes Mellitus; Genome-Wide Associatio | 2021 |
Gout-induced endothelial impairment: The role of SREBP2 transactivation of YAP.
Topics: Animals; Cell Cycle Proteins; Gout; Human Umbilical Vein Endothelial Cells; Humans; Hyperuricemia; M | 2021 |
Assessing the Causal Relationships Between Insulin Resistance and Hyperuricemia and Gout Using Bidirectional Mendelian Randomization.
Topics: Adult; Aged; Female; Genetic Loci; Gout; Humans; Hyperuricemia; Insulin; Insulin Resistance; Male; M | 2021 |
Natural flavonol fisetin attenuated hyperuricemic nephropathy via inhibiting IL-6/JAK2/STAT3 and TGF-β/SMAD3 signaling.
Topics: Administration, Oral; Animals; Fibrosis; Flavonols; Gene Expression Regulation; Hyperuricemia; Inter | 2021 |
Chlorogenic acid supplementation ameliorates hyperuricemia, relieves renal inflammation, and modulates intestinal homeostasis.
Topics: Animals; Blood Urea Nitrogen; Chlorogenic Acid; Creatinine; Dietary Supplements; Gastrointestinal Mi | 2021 |
Apostichopus japonicus Oligopeptide Induced Heterogeneity in the Gastrointestinal Tract Microbiota and Alleviated Hyperuricemia in a Microbiota-Dependent Manner.
Topics: Animals; Fecal Microbiota Transplantation; Gastrointestinal Microbiome; Hyperuricemia; Male; Mice; M | 2021 |
The application value of serum 25(OH)D3, uric acid, triglyceride, and homeostasis model assessment of insulin resistance in male patients with hyperuricemia combined with hypogonadism.
Topics: Adult; Aged; Calcifediol; Humans; Hyperuricemia; Hypogonadism; Insulin Resistance; Male; Middle Aged | 2021 |
Uric acid: A new marker for metabolic syndrome? Results of a population-based study with adults.
Topics: Adult; Biomarkers; Brazil; Cross-Sectional Studies; Female; Humans; Hyperuricemia; Male; Metabolic S | 2021 |
Elevated serum uric acid is a predictor of contrast associated acute kidney injury in patient with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
Topics: Acute Kidney Injury; Aged; Biomarkers; Contrast Media; Creatinine; Female; Humans; Hyperuricemia; Ma | 2021 |
Apigenin ameliorates hyperuricemic nephropathy by inhibiting URAT1 and GLUT9 and relieving renal fibrosis via the Wnt/β-catenin pathway.
Topics: Animals; Apigenin; beta Catenin; Creatinine; Dose-Response Relationship, Drug; Fibrosis; Glucose Tra | 2021 |
Metformin protects against insulin resistance induced by high uric acid in cardiomyocytes via AMPK signalling pathways in vitro and in vivo.
Topics: AMP-Activated Protein Kinase Kinases; Animals; Cells, Cultured; Glucose; Glucose Transporter Type 4; | 2021 |
Effects of Macroporous Resin Extract of Dendrobium officinale Leaves in Rats with Hyperuricemia Induced by Fructose and Potassium Oxonate.
Topics: Adenosine Triphosphate; Animals; Dendrobium; Fructose; Hyperuricemia; Kidney; Oxonic Acid; Plant Ext | 2022 |
Non-pharmacological treatment of gout.
Topics: Animals; Dairy Products; Diet; Gout; Humans; Hyperuricemia; Risk Factors; Uric Acid | 2021 |
[Effect of application at Shu-Mu acupoint on serum uric acid in hyperuricemic rats].
Topics: Acupuncture Points; Animals; Hyperuricemia; Kidney; Rats; Rats, Sprague-Dawley; Uric Acid | 2021 |
Short sleep duration increases the risk of hyperuricemia among Chinese adults: findings from the China Health and Nutrition Survey.
Topics: Adult; China; Cross-Sectional Studies; Female; Humans; Hyperuricemia; Male; Nutrition Surveys; Risk | 2021 |
Response to: 'Correspondence on 'Variants in urate transporters, ADH1B, GCKR and MEPE genes associated with transition from asymptomatic hyperuricaemia to gout: results of the first gout versus asymptomatic hyperuricaemia GWAS in Caucasians using data fro
Topics: Adaptor Proteins, Signal Transducing; Biological Specimen Banks; Extracellular Matrix Proteins; Geno | 2023 |
Correspondence on 'Variants in urate transporters,
Topics: Adaptor Proteins, Signal Transducing; Biological Specimen Banks; Extracellular Matrix Proteins; Geno | 2023 |
A retrospective observational study of a low fixed-dose rasburicase protocol for the treatment of tumor lysis syndrome in adults.
Topics: Adult; Cohort Studies; Gout Suppressants; Humans; Hyperuricemia; Observational Studies as Topic; Ret | 2022 |
Independent association of plasma xanthine oxidoreductase activity with hypertension in nondiabetic subjects not using medication.
Topics: Female; Humans; Hypertension; Hyperuricemia; Insulin Resistance; Male; Uric Acid; Xanthine Dehydroge | 2021 |
Sugar-sweetened soft drinks consumption and risk of hyperuricemia: Results of the ELSA-Brasil study.
Topics: Adult; Aged; Biomarkers; Brazil; Female; Humans; Hyperuricemia; Incidence; Longitudinal Studies; Mal | 2021 |
Association between consumption of ultra-processed foods and hyperuricemia: TCLSIH prospective cohort study.
Topics: Adult; Biomarkers; China; Diet; Fast Foods; Female; Food Handling; Humans; Hyperuricemia; Incidence; | 2021 |
Cumulative Serum Uric Acid and Its Time Course Are Associated With Risk of Myocardial Infarction and All-Cause Mortality.
Topics: Adult; Biomarkers; Cause of Death; China; Female; Humans; Hyperuricemia; Incidence; Male; Middle Age | 2021 |
Incident hyperuricemia in relation to antihypertensive therapy with the irbesartan/hydrochlorothiazide combination.
Topics: Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Humans; Hydrochlorothiazide; Hypertensi | 2021 |
Still Trying to Understand the Role of Uric Acid in Cardiovascular Diseases.
Topics: Cardiovascular Diseases; Humans; Hyperuricemia; Risk Factors; Uric Acid | 2021 |
Relation of Serum Uric Acid and Cardiovascular Events in Young Adults Aged 20-49 Years.
Topics: Adult; Atrial Fibrillation; Cardiovascular Diseases; Female; Heart Failure; Humans; Hyperuricemia; I | 2021 |
Blood Cadmium and Hyperuricemia in Adults with Special Reference to Sex Difference.
Topics: Adult; Cadmium; Cross-Sectional Studies; Female; Humans; Hyperuricemia; Male; Risk Factors; Sex Char | 2022 |
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Anti-Infective Agents; Arthroscopy; Biofilms; Drug R | 2021 |
NMR spectroscopy based metabolomics confirms the aggravation of metabolic disorder in metabolic syndrome combined with hyperuricemia.
Topics: Adult; Biomarkers; Case-Control Studies; Disease Progression; Energy Metabolism; Humans; Hyperuricem | 2021 |
Serum uric acid control for prevention of gout flare in patients with asymptomatic hyperuricaemia: a retrospective cohort study of health insurance claims and medical check-up data in Japan.
Topics: Adolescent; Adult; Aged; Asymptomatic Diseases; Cohort Studies; Female; Gout; Gout Suppressants; Hum | 2021 |
Lipidomics study of the therapeutic mechanism of Plantaginis Semen in potassium oxonate-induced hyperuricemia rat.
Topics: Animals; Creatinine; Hyperuricemia; Lipid Metabolism; Lipidomics; Oxonic Acid; Psyllium; Rats, Sprag | 2021 |
Anti-Hyperuricemic Effect of Iron Oxide Nanoparticles against Monosodium Urate Crystals Induced Gouty Arthritis in BALB/c Mice.
Topics: Animals; Arthritis, Gouty; Hyperuricemia; Magnetic Iron Oxide Nanoparticles; Mice; Mice, Inbred BALB | 2022 |
Serum uric acid and its change with the risk of type 2 diabetes: A prospective study in China.
Topics: Adult; China; Diabetes Mellitus, Type 2; Humans; Hyperuricemia; Male; Prospective Studies; Risk Fact | 2021 |
Prevalence of and risk factors for high-altitude hyperuricaemia in Bai individuals: a cross-sectional study.
Topics: Adolescent; Adult; Altitude; China; Cross-Sectional Studies; Female; Humans; Hyperuricemia; Male; Pr | 2021 |
Active components from Lagotis brachystachya maintain uric acid homeostasis by inhibiting renal TLR4-NLRP3 signaling in hyperuricemic mice.
Topics: Animals; Dose-Response Relationship, Drug; Drugs, Chinese Herbal; Homeostasis; Hyperuricemia; Kidney | 2021 |
Fine-needle aspiration cytology finding uric acid crystals produced by
Topics: Aspergillus; Biopsy, Fine-Needle; Humans; Hyperuricemia; Male; Middle Aged; Uric Acid | 2021 |
Ameliorative effect and mechanism of Yi-Suan-Cha against hyperuricemia in rats.
Topics: Animals; Anion Transport Proteins; ATP Binding Cassette Transporter, Subfamily G, Member 2; Blood Ur | 2021 |
Differentially expressed microRNA in testicular tissues of hyperuricaemia rats.
Topics: Animals; Gene Expression Profiling; Hyperuricemia; Male; MicroRNAs; Rats; RNA, Messenger; Signal Tra | 2021 |
Simple metabolic markers associated with tophaceous gout.
Topics: Glomerular Filtration Rate; Gout; Humans; Hyperuricemia; Uric Acid | 2021 |
Association of eating out frequency and other factors with serum uric acid levels and hyperuricemia in Chinese population.
Topics: China; Cohort Studies; Cross-Sectional Studies; Humans; Hyperuricemia; Male; Risk Factors; Uric Acid | 2022 |
Factors Influencing Early Serum Uric Acid Fluctuation After Bariatric Surgery in Patients with Hyperuricemia.
Topics: Bariatric Surgery; Gout; Humans; Hyperuricemia; Obesity, Morbid; Symptom Flare Up; Uric Acid | 2021 |
Comparative study of a novel selective urate reabsorption inhibitor "dotinurad" among patient groups with different stages of renal dysfunction.
Topics: Adult; Aged; Benzothiazoles; Biomarkers; Clinical Trials as Topic; Female; Glomerular Filtration Rat | 2021 |
Machine Learning to Identify Metabolic Subtypes of Obesity: A Multi-Center Study.
Topics: Adult; Blood Glucose; Body Mass Index; China; Comorbidity; Female; Glucose Tolerance Test; Humans; H | 2021 |
Increased Systolic Blood Pressure Mediates the Relationship Between Urate and Gout Risk in Indonesia: A Novel Application of a Partial Least Squares-Structural Equation Model.
Topics: Adult; Blood Pressure; Case-Control Studies; Gout; Humans; Hyperuricemia; Indonesia; Least-Squares A | 2022 |
Effect of Berberine on Hyperuricemia and Kidney Injury: A Network Pharmacology Analysis and Experimental Validation in a Mouse Model.
Topics: Animals; Berberine; Disease Models, Animal; Hyperuricemia; Kidney; Kidney Diseases; Male; Mice; Mole | 2021 |
Mesenchymal stem cells transplantation attenuates hyperuricemic nephropathy in rats.
Topics: Animals; Apoptosis Regulatory Proteins; Cell Culture Techniques; Cell Survival; Fibrosis; Hyperurice | 2021 |
Identification of Human UDP-Glucuronosyltransferase and Sulfotransferase as Responsible for the Metabolism of Dotinurad, a Novel Selective Urate Reabsorption Inhibitor.
Topics: Algorithms; Benzothiazoles; Cytosol; Glucuronides; Glucuronosyltransferase; Humans; Hyperuricemia; I | 2021 |
The gut microbiota mediates the protective effects of anserine supplementation on hyperuricaemia and associated renal inflammation.
Topics: Animals; Anserine; Dietary Supplements; Disease Models, Animal; Feces; Functional Food; Gastrointest | 2021 |
Hyperuricemia enhances procoagulant activity of vascular endothelial cells through TMEM16F regulated phosphatidylserine exposure and microparticle release.
Topics: Actin Cytoskeleton; Animals; Anoctamins; Calcium; Cell-Derived Microparticles; Cells, Cultured; Endo | 2021 |
Serum Uric Acid: A Murderer or Bystander for Cardiac-related Mortality?
Topics: Heart; Humans; Hyperuricemia; Risk Factors; Uric Acid | 2021 |
Maternal serum uric acid: a reliable prognostic indicator of foetal outcome among pre-eclamptic patients in a low resource setting.
Topics: Case-Control Studies; Female; Humans; Hyperuricemia; Infant, Newborn; Pre-Eclampsia; Pregnancy; Prog | 2022 |
Which is more important, xanthine oxidase activity or uric acid itself, in the risk for cardiovascular disease?
Topics: Cardiovascular Diseases; Enzyme Inhibitors; Humans; Hyperuricemia; Risk Factors; Uric Acid; Xanthine | 2021 |
Association between hyperuricaemia and clinical pathological characteristics of patients with IgA nephropathy.
Topics: Creatinine; Glomerulonephritis, IGA; Humans; Hyperuricemia; Kidney; Uric Acid | 2021 |
To Treat or Not to treat Asymptomatic Hyperuricemia.
Topics: Asymptomatic Diseases; Gout; Gout Suppressants; Humans; Hyperuricemia; Uric Acid | 2021 |
microRNA-199a downregulation alleviates hyperuricemic nephropathy
Topics: Animals; beta Catenin; Down-Regulation; Fibrosis; Hyperuricemia; Kidney Diseases; MicroRNAs; PPAR ga | 2022 |
Association of serum uric acid with biventricular myocardial dysfunction in patients with type 2 diabetes mellitus.
Topics: Aged; Biomarkers; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Echocardiography; Female; Hong | 2021 |
Combined effect of obesity and uric acid on nonalcoholic fatty liver disease and hypertriglyceridemia.
Topics: Adult; Aged; China; Cohort Studies; Cross-Sectional Studies; Female; Humans; Hypertriglyceridemia; H | 2017 |
Association between serum gamma-glutamyl transferase and serum uric acid levels in Chinese females: A cross-sectional study.
Topics: Adult; Aged; Aging; Biomarkers; China; Cross-Sectional Studies; Female; gamma-Glutamyltransferase; H | 2017 |
Podocyte Injury and Albuminuria in Experimental Hyperuricemic Model Rats.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Actins; Albuminuria; Animals; Blood Pressure; Cyclic N-Oxides; Deoxygua | 2017 |
Association Between Serum Levels of Uric Acid and Blood Pressure Tracking in Childhood.
Topics: Age Factors; Biomarkers; Blood Pressure; Child; Child Development; Child, Preschool; Female; Humans; | 2017 |
Risk Factors of Hyperuricemia After Renal Transplantation and Its Long-term Effects on Graft Functions.
Topics: Adult; Cohort Studies; Female; Glomerular Filtration Rate; Graft Survival; Humans; Hyperuricemia; Ki | 2017 |
Discovery of novel curcumin derivatives targeting xanthine oxidase and urate transporter 1 as anti-hyperuricemic agents.
Topics: Animals; Curcumin; Enzyme Inhibitors; HEK293 Cells; Humans; Hyperuricemia; Male; Mice; Models, Molec | 2017 |
Genetic risk scores, sex and dietary factors interact to alter serum uric acid trajectory among African-American urban adults.
Topics: Adult; Alcohol Drinking; Ascorbic Acid Deficiency; Black or African American; Cohort Studies; Cross- | 2017 |
Hyperuricemia after orthotopic liver transplantation: divergent associations with progression of renal disease, incident end-stage renal disease, and mortality.
Topics: Adult; Creatinine; Disease Progression; Female; Glomerular Filtration Rate; Humans; Hyperuricemia; I | 2017 |
Population-Specific Resequencing Associates the ATP-Binding Cassette Subfamily C Member 4 Gene With Gout in New Zealand Māori and Pacific Men.
Topics: Adult; Animals; Blotting, Western; Case-Control Studies; Female; Gout; Humans; Hyperuricemia; Logist | 2017 |
Cadmium exposure and its association with serum uric acid and hyperuricemia.
Topics: Adult; Aged; Biomarkers; Cadmium; Comorbidity; Environmental Exposure; Female; Humans; Hyperuricemia | 2017 |
Anti-Hyperuricemic, Anti-Inflammatory and Analgesic Effects of Siegesbeckia orientalis L. Resulting from the Fraction with High Phenolic Content.
Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Asteraceae; Carrageenan; Disease Model | 2017 |
Evaluating risk factors for chronic kidney disease in pediatric patients with sickle cell anemia.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Child | 2017 |
Asymptomatic hyperuricemia is independently associated with coronary artery calcification in the absence of overt coronary artery disease: A single-center cross-sectional study.
Topics: Adult; Aged; Asymptomatic Diseases; Coronary Artery Disease; Cross-Sectional Studies; Female; Humans | 2017 |
Discovery and characterization of verinurad, a potent and specific inhibitor of URAT1 for the treatment of hyperuricemia and gout.
Topics: Adult; Animals; Benzbromarone; Biological Transport; Dose-Response Relationship, Drug; Gout; HEK293 | 2017 |
Relationship between uric acid and technique failure in patients on continuous ambulatory peritoneal dialysis: a long-term observational cohort study.
Topics: Adult; Aged; Cohort Studies; Female; Humans; Hyperuricemia; Kidney Failure, Chronic; Longitudinal St | 2017 |
Effects of Gnaphalium affine D. Don on hyperuricemia and acute gouty arthritis.
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Gouty; Chromatography, High Pressure Liquid; Disease M | 2017 |
Prevalence and risk factors of hyperuricemia: results of the Kailuan cohort study.
Topics: Adult; Aged; Asian People; Female; Humans; Hyperuricemia; Life Style; Male; Middle Aged; Posture; Pr | 2017 |
Serum Uric Acid and Cardiometabolic Disease: Another Brick in the Wall?
Topics: Humans; Hyperuricemia; Metabolic Syndrome; Uric Acid | 2017 |
Phloretin attenuates hyperuricemia-induced endothelial dysfunction through co-inhibiting inflammation and GLUT9-mediated uric acid uptake.
Topics: Cell Adhesion; Cell Line, Tumor; Cells, Cultured; Endothelium, Vascular; Glucose Transport Proteins, | 2017 |
Mendelian randomization to establish the causality of uric acid with diabetic nephropathy in type 1 diabetics.
Topics: Diabetes Mellitus, Type 1; Diabetic Nephropathies; Humans; Hyperuricemia; Random Allocation; Uric Ac | 2017 |
Identification of C21orf59 and ATG2A as novel determinants of renal function-related traits in Japanese by exome-wide association studies.
Topics: Aged; Autophagy-Related Proteins; Creatinine; Exome; Female; Genetic Predisposition to Disease; Geno | 2017 |
Bioengineered robust hybrid hydrogels enrich the stability and efficacy of biological drugs.
Topics: Animals; Bioengineering; Biological Products; Cell Survival; Drug Liberation; Drug Stability; Female | 2017 |
Metabolic syndrome, serum uric acid and renal risk in patients with T2D.
Topics: Acute Kidney Injury; Aged; Albuminuria; Blood Pressure; Body Mass Index; Cholesterol, HDL; Databases | 2017 |
Correlation between serum uric acid levels and residual platelet reactivity in patients undergoing PCI.
Topics: Aged; Biomarkers; Blood Platelets; Coronary Artery Disease; Female; Humans; Hyperuricemia; Male; Mid | 2017 |
Pharmacologic targeting ERK1/2 attenuates the development and progression of hyperuricemic nephropathy in rats.
Topics: Animals; Anion Transport Proteins; Cytokines; Disease Models, Animal; Disease Progression; Fibroblas | 2017 |
An observational study on the relationship between serum uric acid and hypertension in a Northern Chinese population aged 45 to 59 years.
Topics: Anthropometry; Biomarkers; Blood Chemical Analysis; Blood Pressure Determination; China; Cross-Secti | 2017 |
Management of Gout and Hyperuricemia in CKD.
Topics: Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Diet Therapy; Disease Management; Febuxostat; | 2017 |
Previous Dosage of Allopurinol Is a Strong Determinant of Febuxostat Efficacy.
Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Febuxostat; Glomerular Filtration Rate; Gout; Gout Supp | 2017 |
The association between risk of airflow limitation and serum uric acid measured at medical health check-ups.
Topics: Adult; Aged; Asthma; Biomarkers; Female; Forced Expiratory Volume; Humans; Hyperuricemia; Japan; Log | 2017 |
[Effect of febuxostat on epithelial-to-mesenchymal transition of kidney tubules, serum interleukin-6 and transforming growth factor β(1) in hyperuricemic rats].
Topics: Animals; Antigens, CD; Cadherins; Chalcone; Creatinine; Drugs, Chinese Herbal; Epithelial-Mesenchyma | 2017 |
Qi-Zhu-Xie-Zhuo-Fang reduces serum uric acid levels and ameliorates renal fibrosis in hyperuricemic nephropathy rats.
Topics: Animals; Collagen; Disease Progression; Down-Regulation; Drugs, Chinese Herbal; Extracellular Matrix | 2017 |
Early onset hyperuricemia is a prognostic marker for kidney graft failure: Propensity score matching analysis in a Korean multicenter cohort.
Topics: Adult; Biomarkers; Female; Graft Rejection; Humans; Hyperuricemia; Kidney Transplantation; Male; Pro | 2017 |
Uric acid priming in human monocytes is driven by the AKT-PRAS40 autophagy pathway.
Topics: Adaptor Proteins, Signal Transducing; Animals; Autophagy; Disease Models, Animal; Gout; Granulomatou | 2017 |
Identification of the biologically active constituents of Camellia japonica leaf and anti-hyperuricemic effect in vitro and in vivo.
Topics: Animals; Antioxidants; Camellia; Enzyme Inhibitors; Hyperuricemia; Male; Mice; Mice, Inbred ICR; Phe | 2017 |
Negative correlation between serum uric acid and kidney URAT1 mRNA expression caused by resveratrol in rats.
Topics: Alanine Transaminase; Allopurinol; Animals; Anion Transport Proteins; Aspartate Aminotransferases; C | 2017 |
A Trivalent Enzymatic System for Uricolytic Therapy of HPRT Deficiency and Lesch-Nyhan Disease.
Topics: Allantoin; Amidohydrolases; Animals; Carboxy-Lyases; Enzyme Therapy; Humans; Hyperuricemia; Hypoxant | 2017 |
Salvia plebeia Extract Inhibits Xanthine Oxidase Activity In Vitro and Reduces Serum Uric Acid in an Animal Model of Hyperuricemia.
Topics: Animals; Camphanes; Disease Models, Animal; Drugs, Chinese Herbal; Enzyme Inhibitors; Hyperuricemia; | 2017 |
Identification of chronic kidney disease patient characteristics influencing the renoprotective effects of febuxostat therapy: a retrospective follow-up study.
Topics: Adolescent; Adult; Age Distribution; Aged; Aged, 80 and over; Comorbidity; Febuxostat; Female; Follo | 2017 |
Risk reclassification ability of uric acid for cardiovascular outcomes in essential hypertension.
Topics: Adult; Aged; Biomarkers; Cardiovascular Diseases; Cohort Studies; Essential Hypertension; Female; Fo | 2017 |
Hyperuricemia as a Protective Factor for Mild Cognitive Impairment in Non-Obese Elderly.
Topics: Aged; C-Reactive Protein; Case-Control Studies; Cognitive Dysfunction; Female; Humans; Hyperuricemia | 2017 |
Cardiovascular Disease and Gout: Real-World Experience Evaluating Patient Characteristics, Treatment Patterns, and Health Care Utilization.
Topics: Cardiovascular Diseases; Female; Gout; Humans; Hyperuricemia; Logistic Models; Male; Middle Aged; Pa | 2017 |
[Effects of Clostridium butyricum on serum uric acid and inflammatory mediators in rats with hyperuricemia].
Topics: Animals; Clostridium butyricum; Hyperuricemia; Inflammation Mediators; Random Allocation; Rats; Rats | 2017 |
Taurine decreased uric acid levels in hyperuricemic rats and alleviated kidney injury.
Topics: Acute Kidney Injury; Adenine; Administration, Oral; Animals; Ethambutol; Hyperuricemia; Male; Rats; | 2017 |
Anti-hyperuricemic and anti-inflammatory actions of vaticaffinol isolated from Dipterocarpus alatus in hyperuricemic mice.
Topics: Animals; Anti-Inflammatory Agents; Dipterocarpaceae; Humans; Hyperuricemia; Interleukin-18; Interleu | 2017 |
Oral uricase eliminates blood uric acid in the hyperuricemic pig model.
Topics: Administration, Oral; Animals; Disease Models, Animal; Hyperuricemia; Intestinal Mucosa; Male; Nephr | 2017 |
Caffeoylquinic acid derivatives rich extract from Gnaphalium pensylvanicum willd. Ameliorates hyperuricemia and acute gouty arthritis in animal model.
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Gouty; Disease Models, Animal; Glucose Transport Prote | 2017 |
Saponins extracted from Dioscorea collettii rhizomes regulate the expression of urate transporters in chronic hyperuricemia rats.
Topics: Animals; Dioscorea; Hyperuricemia; Kidney; Male; Organic Anion Transporters; Organic Anion Transport | 2017 |
Topics: Animals; Aristolochia; Arthritis; Blood Urea Nitrogen; Creatinine; Dinoprostone; Humans; Hyperuricem | 2017 |
Comment on "Serum uric acid is associated with better executive function in men but not in women: Baseline assessment of the ELSA-Brasil study".
Topics: Brazil; Executive Function; Female; Humans; Hyperuricemia; Male; Risk Factors; Uric Acid | 2017 |
Hypouricemic and nephroprotective effects of total flavonoids from the residue of supercritical CO2 extraction of Humulus lupulus in potassium oxonate-induced mice.
Topics: Animals; Carbon Dioxide; Chromatography, Supercritical Fluid; Flavonoids; Humulus; Hyperuricemia; In | 2017 |
Synthesis and evaluation of hydroxychalcones as multifunctional non-purine xanthine oxidase inhibitors for the treatment of hyperuricemia.
Topics: Animals; Antioxidants; Chalcones; Enzyme Inhibitors; Humans; Hyperuricemia; Mice; Models, Molecular; | 2017 |
Diet-independent relevance of serum uric acid for blood pressure in a representative population sample.
Topics: Adolescent; Adult; Aged; Blood Pressure; Cross-Sectional Studies; Diet; Dose-Response Relationship, | 2017 |
Lipidomics to investigate the pharmacologic mechanisms of ginkgo folium in the hyperuricemic rat model.
Topics: Animals; Chromatography, High Pressure Liquid; Computational Biology; Disease Models, Animal; Fructo | 2017 |
Interaction of the GCKR and A1CF loci with alcohol consumption to influence the risk of gout.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Alcohol Drinking; Female; Gene-Environment Intera | 2017 |
[The uric acid cardio-nephropathy].
Topics: Biomarkers; Heart Diseases; Humans; Hyperuricemia; Kidney Diseases; Risk Factors; Uric Acid | 2017 |
[Strengthen and standardize the diagnosis and treatment of hyperuricemia in kidney diseases].
Topics: Humans; Hyperuricemia; Kidney; Kidney Diseases; Uric Acid | 2017 |
Serum uric acid is positively associated with pulmonary function in Korean health screening examinees.
Topics: Aged; Cross-Sectional Studies; Female; Forced Expiratory Volume; Humans; Hyperuricemia; Lung; Male; | 2017 |
Serum Uric Acid and Arterial Function After Renal Transplantation.
Topics: Adult; Aged; Blood Pressure; Cross-Sectional Studies; Female; Humans; Hyperuricemia; Kidney Transpla | 2017 |
Hyperuricemia and clustering of cardiovascular risk factors in the Chinese adult population.
Topics: Adolescent; Adult; Aged; Cardiovascular Diseases; China; Cluster Analysis; Cross-Sectional Studies; | 2017 |
Hyperuricemia is associated with an increased prevalence of paroxysmal atrial fibrillation in patients with type 2 diabetes referred for clinically indicated 24-h Holter monitoring.
Topics: Aged; Atrial Fibrillation; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Humans; Hyper | 2018 |
Is Serum Uric Acid a Biomarker, but not a Mediator in Patients With Lifestyle and Cardiovascular Diseases?
Topics: Aged; Biomarkers; Cardiovascular Diseases; Female; Humans; Hypertrophy, Left Ventricular; Hyperurice | 2017 |
Association between serum uric acid level and hypertension in a Chinese elderly rural population.
Topics: Aged; Aged, 80 and over; Beijing; Blood Pressure; Cross-Sectional Studies; Female; Humans; Hypertens | 2017 |
Knockout of the urate oxidase gene provides a stable mouse model of hyperuricemia associated with metabolic disorders.
Topics: Animals; Biomarkers; Blood Glucose; Blood Pressure; Blood Urea Nitrogen; Creatinine; Diabetes Mellit | 2018 |
Serum Uric Acid and Risk of Kidney Stones.
Topics: Cohort Studies; Humans; Hyperuricemia; Kidney Calculi; Uric Acid | 2017 |
Uric acid level as predictor of mortality in the acute care setting of advanced age population.
Topics: Aged; Aged, 80 and over; Biomarkers; Cause of Death; Emergency Medical Services; Female; Follow-Up S | 2017 |
Effects of topiroxostat in hyperuricemic patients with chronic kidney disease.
Topics: Aged; Biomarkers; Blood Pressure; Enzyme Inhibitors; Female; Humans; Hypertension; Hyperuricemia; In | 2018 |
Relationship between serum uric acid level and mild cognitive impairment in Chinese community elderly.
Topics: Aged; Asian People; China; Cognitive Dysfunction; Cross-Sectional Studies; Female; Humans; Hyperuric | 2017 |
ABCG2 Polymorphism Is Associated with Hyperuricemia in a Study of a Community-Based Korean Cohort.
Topics: Age Factors; Aged; Asian People; ATP Binding Cassette Transporter, Subfamily G, Member 2; Cohort Stu | 2017 |
Serum Uric Acid Could Differentiate Acute Myocardial Infarction and Unstable Angina Pectoris in Hyperuricemic Acute Coronary Syndrome Patients.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Angina, Unstable; Diagnosis, Differential; Female; | 2017 |
Relationship between uric acid levels and risk of chronic kidney disease in a retrospective cohort of Brazilian workers.
Topics: Brazil; Disease Progression; Female; Glomerular Filtration Rate; Humans; Hyperuricemia; Male; Middle | 2017 |
Chicken or the Egg? Hyperuricemia, Insulin Resistance, and Hypertension.
Topics: Humans; Hypertension; Hyperuricemia; Insulin Resistance; Uric Acid | 2017 |
Temporal Relationship Between Hyperuricemia and Insulin Resistance and Its Impact on Future Risk of Hypertension.
Topics: Adult; Aged; Blood Glucose; Blood Pressure Determination; China; Cohort Studies; Female; Humans; Hyp | 2017 |
Prevalence of hyperuricemia and its related risk factors among preschool children from China.
Topics: Child; Child, Preschool; China; Cross-Sectional Studies; Female; Humans; Hyperuricemia; Male; Obesit | 2017 |
Comparison of Clinical Advantage between Topiroxostat and Febuxostat in Hemodialysis Patients.
Topics: Adult; Aged; Febuxostat; Female; Follow-Up Studies; Humans; Hyperuricemia; Male; Middle Aged; Nitril | 2017 |
Evaluating the urate-lowering effects of different microbial fermented extracts in hyperuricemic models accompanied with a safety study.
Topics: Animals; Fermentation; Gout; Gout Suppressants; Hyperuricemia; Mice; Uric Acid; Xanthine Oxidase | 2017 |
Hyperuricemia does not seem to be an independent risk factor for coronary heart disease.
Topics: Coronary Disease; Humans; Hyperuricemia; Risk Factors; Uric Acid | 2018 |
Augmented Association Between Blood Pressure and Proteinuria in Hyperuricemic Patients With Nonnephrotic Chronic Kidney Disease.
Topics: Adult; Antihypertensive Agents; Biomarkers; Blood Pressure; Cross-Sectional Studies; Female; Glomeru | 2018 |
Comparative effects of green and black tea extracts on lowering serum uric acid in hyperuricemic mice.
Topics: Administration, Oral; Animals; Biomarkers; Camellia sinensis; Dose-Response Relationship, Drug; Hype | 2017 |
The problem of cardio-renal diseases in patients with gout.
Topics: Cardiovascular Diseases; Gout; Humans; Hyperuricemia; Renal Insufficiency, Chronic; Risk Factors; Ur | 2017 |
Gender difference on the relationship between hyperuricemia and nonalcoholic fatty liver disease among Chinese: An observational study.
Topics: Anthropometry; Blood Pressure Determination; China; Female; Humans; Hyperuricemia; Liver Function Te | 2017 |
Levels of uric acid and increased diastolic blood pressure: Risk factors for atrial fibrillation in patients older than 60 years.
Topics: Aged; Atrial Fibrillation; Blood Pressure; Cardiovascular Diseases; Electrocardiography; Female; Hum | 2017 |
[Effect of Chinese herb chicory extract on expression of renal transporter Glut9 in rats with hyperuricemia].
Topics: Animals; Benzbromarone; Cichorium intybus; Drugs, Chinese Herbal; Hyperuricemia; Kidney; Male; Monos | 2017 |
High Uric Acid-Induced Epithelial-Mesenchymal Transition of Renal Tubular Epithelial Cells via the TLR4/NF-kB Signaling Pathway.
Topics: Actins; Antigens, CD; Biomarkers; Cadherins; Cell Line; Cytokines; Epithelial Cells; Epithelial-Mese | 2017 |
Moderation of hyperuricemia in rats via consuming walnut protein hydrolysate diet and identification of new antihyperuricemic peptides.
Topics: Animals; Humans; Hyperuricemia; Juglans; Male; Nuts; Peptides; Plant Proteins; Protein Hydrolysates; | 2018 |
Association between serum uric acid level and renal arteriolar hyalinization in individuals without chronic kidney disease.
Topics: Adult; Aged; Arterioles; Arteriosclerosis; Biomarkers; Biopsy; Cross-Sectional Studies; Female; Hosp | 2017 |
Clinical features and CKD-related quality of life in patients with CKD G3a and CKD G3b in China: results from the Chinese Cohort Study of Chronic Kidney Disease (C-STRIDE).
Topics: Adult; Anemia; Bicarbonates; Blood Pressure; China; Cholesterol, HDL; Cost of Illness; Female; Glome | 2017 |
Impact of Uric Acid Levels on Kidney Disease Progression.
Topics: Aged; Aged, 80 and over; Disease Progression; Electronic Health Records; Female; Follow-Up Studies; | 2017 |
Relation of elevated serum uric acid levels to first-degree heart block and other cardiac conduction defects in hospitalized patients with type 2 diabetes.
Topics: Aged; Asymptomatic Diseases; Cardiac Conduction System Disease; Confounding Factors, Epidemiologic; | 2017 |
A Novel Multi-Epitope Vaccine Based on Urate Transporter 1 Alleviates Streptozotocin-Induced Diabetes by Producing Anti-URAT1 Antibody and an Immunomodulatory Effect in C57BL/6J Mice.
Topics: Animals; Antioxidants; Autoantibodies; Autoantigens; Cytokines; Diabetes Mellitus, Experimental; Dia | 2017 |
Serum uric acid and non-alcoholic fatty liver disease in non-obesity Chinese adults.
Topics: Adult; Area Under Curve; Biomarkers; Body Mass Index; Cholesterol, HDL; Cholesterol, LDL; Female; Hu | 2017 |
Emodinol ameliorates urate nephropathy by regulating renal organic ion transporters and inhibiting immune inflammatory responses in rats.
Topics: Animals; Blood Urea Nitrogen; Hyperuricemia; Inflammasomes; Inflammation; Interleukin-1beta; Kidney; | 2017 |
Chinese Multidisciplinary Expert Consensus on the Diagnosis and Treatment of Hyperuricemia and Related Diseases.
Topics: Asian People; Consensus; Female; Humans; Hyperuricemia; Male; Uric Acid | 2017 |
Erding Formula in hyperuricaemia treatment: unfolding traditional Chinese herbal compatibility using modern pharmaceutical approaches.
Topics: Analgesics; Animals; Anti-Inflammatory Agents; Disease Models, Animal; Drugs, Chinese Herbal; Gene E | 2018 |
Effects of Pu-erh ripened tea on hyperuricemic mice studied by serum metabolomics.
Topics: Allopurinol; Animals; Biomarkers; Drugs, Chinese Herbal; Fermentation; Hyperuricemia; Male; Metabolo | 2017 |
Uric acid causes kidney injury through inducing fibroblast expansion, Endothelin-1 expression, and inflammation.
Topics: Acute Kidney Injury; Animals; Cell Proliferation; Endothelin-1; Fibroblasts; Gene Expression; Hyperu | 2017 |
The anti-hyperuricemic effect of epigallocatechin-3-gallate (EGCG) on hyperuricemic mice.
Topics: Animals; Antioxidants; Catechin; Hyperuricemia; Male; Mice; Random Allocation; Tea; Treatment Outcom | 2018 |
Inhibition of 3,5,2',4'-Tetrahydroxychalcone on Production of Uric Acid in Hypoxanthine-Induced Hyperuricemic Mice.
Topics: Animals; Chalcones; Disease Models, Animal; Dose-Response Relationship, Drug; Hyperuricemia; Hypoxan | 2018 |
Identification of CDC42BPG as a novel susceptibility locus for hyperuricemia in a Japanese population.
Topics: Asian People; Cohort Studies; Cross-Sectional Studies; Female; Genetic Predisposition to Disease; Ge | 2018 |
Lesinurad/allopurinol (Duzallo) for gout-associated hyperuricemia.
Topics: Allopurinol; Biomarkers; Drug Combinations; Gout; Gout Suppressants; Humans; Hyperuricemia; Thioglyc | 2017 |
Old drug, new indication: Olsalazine sodium reduced serum uric acid levels in mice via inhibiting xanthine oxidoreductase activity.
Topics: Aminosalicylic Acids; Animals; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Drug Evaluation, | 2017 |
Reply to: Hyperuricemia does not seem to be an independent risk factor for coronary heart disease.
Topics: Coronary Disease; Humans; Hyperuricemia; Risk Factors; Uric Acid | 2018 |
Response to: 'Use of urate-lowering therapies is not associated with an increase in the risk of incident dementia in older adults' by Lee and Song.
Topics: Aged; Dementia; Gout; Humans; Hyperuricemia; Uric Acid | 2018 |
The Prognostic Value of Serum Uric Acid in the Acute Phase of Ischemic Stroke in Black Africans.
Topics: Aged; Biomarkers; Black People; Brain Ischemia; Cameroon; Chi-Square Distribution; Female; Humans; H | 2018 |
Serum uric acid level predicts adverse outcomes after myocardial revascularization or cardiac valve surgery.
Topics: Age Factors; Aged; Biomarkers; Cardiac Rehabilitation; Comorbidity; Coronary Artery Bypass; Coronary | 2018 |
Comparative effectiveness of allopurinol, febuxostat and benzbromarone on renal function in chronic kidney disease patients with hyperuricemia: a 13-year inception cohort study.
Topics: Aged; Allopurinol; Benzbromarone; Cohort Studies; Disease Progression; Drug Monitoring; Febuxostat; | 2018 |
Serum Uric Acid Levels and Kidney Transplant Outcomes: Cause, Consequence, or Confounded?
Topics: Glomerular Filtration Rate; Humans; Hyperuricemia; Kidney Failure, Chronic; Kidney Transplantation; | 2017 |
Sex-related relationships between uric acid and target organ damage in hypertension.
Topics: Adult; Aged; Carotid Artery Diseases; Carotid Intima-Media Thickness; Correlation of Data; Cross-Sec | 2018 |
50 Years Ago in The Journal of Pediatrics: Prevention and Management of Acute Hyperuricemia in Childhood Leukemia.
Topics: Acute Disease; Allopurinol; Child; DNA, Neoplasm; History, 20th Century; Humans; Hyperuricemia; Merc | 2017 |
The association between serum uric acid and asymptomatic intracranial arterial stenosis in middle-aged Koreans.
Topics: Adult; Asymptomatic Diseases; Biomarkers; Comorbidity; Cross-Sectional Studies; Female; Humans; Hype | 2018 |
Serum uric acid as a potential marker for heart failure risk in men on antihypertensive treatment: The British Regional Heart Study.
Topics: Aged; Antihypertensive Agents; Biomarkers; Cohort Studies; England; Follow-Up Studies; Heart Failure | 2018 |
Liver zonation in children with non-alcoholic fatty liver disease: Associations with dietary fructose and uric acid concentrations.
Topics: Adolescent; Child; Diet; Female; Fructose; Humans; Hyperuricemia; Liver; Logistic Models; Male; Non- | 2018 |
The effect of small dose of topiroxostat on serum uric acid in patients receiving hemodialysis.
Topics: Aged; Enzyme Inhibitors; Female; Humans; Hyperuricemia; Male; Middle Aged; Nitriles; Pyridines; Rena | 2018 |
Effect and mechanism of dioscin from Dioscorea spongiosa on uric acid excretion in animal model of hyperuricemia.
Topics: Adenine; Animals; Biomarkers; Creatinine; Dioscorea; Diosgenin; Disease Models, Animal; Dose-Respons | 2018 |
The relationships among hyperuricemia, body mass index and impaired renal function in type 2 diabetic patients.
Topics: Adult; Aged; Body Mass Index; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Diabetic Nephropat | 2018 |
Association of plasma free amino acids with hyperuricemia in relation to diabetes mellitus, dyslipidemia, hypertension and metabolic syndrome.
Topics: Adult; Aged; Amino Acids; Blood Glucose; Blood Pressure; Cholesterol; Diabetes Mellitus; Dyslipidemi | 2017 |
Efficacy and Safety of Febuxostat in Kidney Transplant Patients.
Topics: Adult; Aged; Biomarkers; Febuxostat; Female; Gout Suppressants; Humans; Hyperuricemia; Kidney Transp | 2018 |
Association between serum uric acid and atrial fibrillation: a cross-sectional community-based study in China.
Topics: Adult; Atrial Fibrillation; China; Cross-Sectional Studies; Female; Humans; Hyperuricemia; Logistic | 2017 |
Serum Uric Acid is Independently Associated with Diastolic Dysfunction in Apparently Healthy Subjects with Essential Hypertension.
Topics: Aged; Biomarkers; Diastole; Essential Hypertension; Female; Humans; Hyperuricemia; Male; Middle Aged | 2019 |
Effects of Polygonum cuspidatum on AMPK-FOXO3α Signaling Pathway in Rat Model of Uric Acid-Induced Renal Damage.
Topics: AMP-Activated Protein Kinases; Animals; Chemokine CCL2; Disease Models, Animal; Fallopia japonica; F | 2019 |
Low serum uric acid concentration augments insulin effects on the prevalence of metabolic syndrome.
Topics: Adult; Cross-Sectional Studies; Female; Follow-Up Studies; Humans; Hyperinsulinism; Hyperuricemia; I | 2018 |
Anorexia nervosa and uric acid beyond gout: An idea worth researching.
Topics: Anorexia Nervosa; Gout; Humans; Hyperuricemia; Research; Uric Acid | 2018 |
Antacids' side effect hyperuricaemia could be alleviated by long-term aerobic exercise via accelerating ATP turnover rate.
Topics: Adenosine Triphosphate; Adult; Aged; Antacids; Exercise; Female; Humans; Hyperuricemia; Male; Middle | 2018 |
Hyperuricemia in Asian psoriatic arthritis patients.
Topics: Adult; Aged; Arthritis, Psoriatic; Asymptomatic Diseases; Biomarkers; Body Mass Index; Chi-Square Di | 2018 |
Letter to the Editor: When Claiming a U-shaped Association between Uric Acid Levels and Major Adverse Cardiac Events, Perhaps Show the Evidence?
Topics: Heart; Humans; Hyperuricemia; Myocardial Infarction; Uric Acid | 2018 |
Uric acid upregulates the adiponectin‑adiponectin receptor 1 pathway in renal proximal tubule epithelial cells.
Topics: Adiponectin; Animals; Blood Urea Nitrogen; Cell Line; Cell Survival; Creatinine; Disease Models, Ani | 2018 |
Could be serum uric acid a risk factor for thrombosis and/or uveitis in Behcet's disease?
Topics: Adult; Behcet Syndrome; Biomarkers; Female; Humans; Hyperuricemia; Male; Medical Records; Middle Age | 2018 |
Relationship between serum uric acid and blood pressure by adjusting dietary factors.
Topics: Blood Pressure; Blood Pressure Determination; Diet; Humans; Hypertension; Hyperuricemia; Uric Acid | 2018 |
Response to: Relationship between serum uric acid and blood pressure by adjusting dietary factors.
Topics: Blood Pressure; Blood Pressure Determination; Humans; Hypertension; Hyperuricemia; Uric Acid | 2018 |
Dietary Potential Renal Acid Load Is Positively Associated with Serum Uric Acid and Odds of Hyperuricemia in the German Adult Population.
Topics: Adolescent; Adult; Aged; Cross-Sectional Studies; Dairy Products; Diet; Female; Fruit; Germany; Huma | 2018 |
Uric acid and cognitive decline: a double-edge sword?
Topics: Cognitive Dysfunction; Cross-Sectional Studies; Dementia; Gout; Humans; Hyperuricemia; Oxidative Str | 2018 |
The Association between Serum Uric Acid and Renal Damage: The Takahata Study - New Insights.
Topics: Albuminuria; beta 2-Microglobulin; Cardiovascular Diseases; Creatinine; Female; Glomerular Filtratio | 2018 |
The Pathophysiology of Uric Acid on Renal Diseases.
Topics: Animals; Disease Models, Animal; Hemodynamics; Humans; Hypertension; Hyperuricemia; Kidney Diseases; | 2018 |
Renal Effects of Hyperuricemia.
Topics: Acute Kidney Injury; Animals; Disease Models, Animal; Glomerular Filtration Rate; Humans; Hypertensi | 2018 |
Uric Acid: The Lower the Better?
Topics: Asymptomatic Diseases; Glomerular Filtration Rate; Humans; Hyperuricemia; Randomized Controlled Tria | 2018 |
Renal Handling of Uric Acid.
Topics: Glucose Transport Proteins, Facilitative; Humans; Hyperuricemia; Kidney Tubules; Organic Anion Trans | 2018 |
Hyperuricemia and Progression of Chronic Kidney Disease: Role of Phenotype Transition of Renal Tubular and Endothelial Cells.
Topics: Actins; Animals; Antioxidants; Capillaries; Disease Progression; Endothelial Cells; Epithelial-Mesen | 2018 |
Significance of Hyperuricemia among Community-Based Screening Participants.
Topics: Disease Progression; Glomerular Filtration Rate; Humans; Hyperuricemia; Incidence; Japan; Kidney Fai | 2018 |
Uric Acid Renal Lithiasis: New Concepts.
Topics: Ammonia; Humans; Hydrogen-Ion Concentration; Hyperuricemia; Insulin Resistance; Nephrolithiasis; Ris | 2018 |
Uric Acid in Pregnancy: New Concepts.
Topics: Apgar Score; Biomarkers; Case-Control Studies; Female; Fetal Development; Fetal Growth Retardation; | 2018 |
Systemic Implications of Hyperuricemia.
Topics: Asymptomatic Diseases; Energy Metabolism; Humans; Hyperuricemia; Nitrogen; Syndrome; Uric Acid | 2018 |
Clinical Significance of Serum Uric Acid Levels in Mexican Young Adults.
Topics: Adolescent; Adult; Cholesterol, LDL; Cross-Sectional Studies; Female; Glomerular Filtration Rate; Hu | 2018 |
Disturbed purine nucleotide metabolism in chronic kidney disease is a risk factor for cognitive impairment.
Topics: Acetylcholinesterase; Catalytic Domain; Cognition Disorders; Computational Biology; Disease Progress | 2018 |
Hyperuricemia as a prognostic factor after acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Biomarkers; Decision Support Techniques; Female; H | 2018 |
Assessment of the association between serum uric acid levels and the incidence of hypertension in nonmetabolic syndrome subjects: A prospective observational study.
Topics: Adult; China; Female; Humans; Hypertension; Hyperuricemia; Incidence; Male; Middle Aged; Prospective | 2018 |
Correlations between blood uric acid and the incidence and progression of type 2 diabetes nephropathy.
Topics: Adult; Blood Urea Nitrogen; Body Mass Index; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephrop | 2018 |
Exploration into Uric and Cardiovascular Disease: Uric Acid Right for heArt Health (URRAH) Project, A Study Protocol for a Retrospective Observational Study.
Topics: Biomarkers; Cardiovascular Diseases; Humans; Hyperuricemia; Italy; Prognosis; Research Design; Retro | 2018 |
Uric acid is associated with long-term adverse cardiovascular outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Aged; Biomarkers; Female; Humans; Hyperuricemia; Male; Middle Aged; Percuta | 2018 |
Serum uric acid levels and outcome during admission in acute ischaemic stroke, depending on renal function.
Topics: Aged; Aged, 80 and over; Brain Ischemia; Cross-Sectional Studies; Female; Humans; Hyperuricemia; Mal | 2018 |
U-Shaped Association Between Serum Uric Acid Levels With Cardiovascular and All-Cause Mortality in the Elderly: The Role of Malnourishment.
Topics: Age Factors; Aged; Biomarkers; Cardiovascular Diseases; Cause of Death; Female; Geriatric Assessment | 2018 |
High Uric Acid Inhibits Cardiomyocyte Viability Through the ERK/P38 Pathway via Oxidative Stress.
Topics: Acetylcysteine; Animals; Cell Line; Cell Survival; Disease Models, Animal; Extracellular Signal-Regu | 2018 |
Serum uric acid is associated with incidence of heart failure with preserved ejection fraction and cardiovascular events in patients with arterial hypertension.
Topics: Aged; Echocardiography, Doppler; Female; Heart Failure; Humans; Hypertension; Hyperuricemia; Inciden | 2018 |
Determination of the optimal cut-off value of serum uric acid concentration in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Humans; Hyperuricemia; Prognosis; Uric Acid | 2018 |
Hyperuricemia and high blood pressure at rest and during exercise: Guilty or innocent? The jury is still out.
Topics: Blood Pressure; Guilt; Humans; Hypertension; Hyperuricemia; Male; Uric Acid | 2018 |
Levels of Cytokines and MicroRNAs in Individuals With Asymptomatic Hyperuricemia and Ultrasonographic Findings of Gout: A Bench-to-Bedside Approach.
Topics: Adult; Aged; Asymptomatic Diseases; Biomarkers; Case-Control Studies; Chronic Disease; Circulating M | 2018 |
The link between insulin resistance parameters and serum uric acid is mediated by adiposity.
Topics: Adiposity; Biomarkers; Blood Glucose; Body Mass Index; Cross-Sectional Studies; Female; Glycated Hem | 2018 |
Baseline and changes in serum uric acid independently predict 11-year incidence of metabolic syndrome among community-dwelling women.
Topics: Aged; Biomarkers; Female; Follow-Up Studies; Humans; Hyperuricemia; Incidence; Japan; Metabolic Synd | 2018 |
Relationship between serum urate concentration and clinically evident incident gout: an individual participant data analysis.
Topics: Adult; Age Distribution; Cohort Studies; Data Analysis; Disease Progression; Gout; Humans; Hyperuric | 2018 |
Elevated serum uric acid predicts the development of moderate coronary artery calcification independent of conventional cardiovascular risk factors.
Topics: Calcinosis; Cardiovascular Diseases; Coronary Artery Disease; Coronary Vessels; Female; Follow-Up St | 2018 |
Individualized treatment strategies for hyperuricemia informed by a semi-mechanistic exposure-response model of uric acid dynamics.
Topics: Allopurinol; Clinical Trials as Topic; Febuxostat; Humans; Hyperuricemia; Models, Theoretical; Preci | 2018 |
Hypouricemic and Nephroprotective Effects of an Active Fraction from Polyrhachis Vicina Roger On Potassium Oxonate-Induced Hyperuricemia in Rats.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Ants; Hyperuricemia; Kidney; Liver; Male; Oxonic Ac | 2018 |
Genetic variants in two pathways influence serum urate levels and gout risk: a systematic pathway analysis.
Topics: Asian People; Case-Control Studies; China; Female; Genetic Loci; Genetic Predisposition to Disease; | 2018 |
Dietary Magnesium Intake and Hyperuricemia among US Adults.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Cross-Sectional Studies; Diet; Female; Humans; Hyperuric | 2018 |
Elevated serum uric acid concentration at discharge confers additive prognostic value in elderly patients with acute heart failure.
Topics: Age Factors; Aged; Aged, 80 and over; Biomarkers; Cause of Death; Decision Support Techniques; Disea | 2018 |
High-normal estimated glomerular filtration rate and hyperuricemia positively correlate with metabolic impairment in pediatric obese patients.
Topics: Adolescent; Child; Child, Preschool; Cross-Sectional Studies; Glomerular Filtration Rate; Humans; Hy | 2018 |
Hyperuricemia and severity of coronary artery disease: An observational study in adults 35 years of age and younger with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adolescent; Adult; Age Factors; Biomarkers; China; Coronary Artery Disease; | 2019 |
Luteolin-4'-O-glucoside and its aglycone, two major flavones of Gnaphalium affine D. Don, resist hyperuricemia and acute gouty arthritis activity in animal models.
Topics: Animals; Arthritis, Gouty; Disease Models, Animal; Drugs, Chinese Herbal; Edema; Glucose Transport P | 2018 |
Hyperuricaemia as a prognostic factor for acute ischaemic stroke.
Topics: Brain Ischemia; Humans; Hyperuricemia; Ischemic Stroke; Prognosis; Stroke; United States; Uric Acid | 2021 |
Uric Acid Induces Cardiomyocyte Apoptosis via Activation of Calpain-1 and Endoplasmic Reticulum Stress.
Topics: Allopurinol; Animals; Apoptosis; Calpain; Cell Line; Endoplasmic Reticulum Stress; Hyperuricemia; Ma | 2018 |
Reply to: Serum uric acid levels positively correlates with 10-year cardiovascular risk score in the general population from China.
Topics: Cardiovascular Diseases; China; Humans; Hyperuricemia; Risk Factors; Uric Acid; Xanthine Oxidase | 2018 |
The Dietary Fructose:Vitamin C Intake Ratio Is Associated with Hyperuricemia in African-American Adults.
Topics: Adult; Aged; Aged, 80 and over; Ascorbic Acid; Black or African American; Cross-Sectional Studies; D | 2018 |
Reply to: "Determination of the optimal cut-off value of serum uric acid concentration in patients with acute coronary syndrome".
Topics: Acute Coronary Syndrome; Humans; Hyperuricemia; Prognosis; Risk Factors; Uric Acid | 2018 |
Associations between Uric Acid Level and 3-Month Functional Outcome in Acute Ischemic Stroke Patients Treated with/without Edaravone.
Topics: Aged; Aged, 80 and over; Biomarkers; Brain Ischemia; Disability Evaluation; Edaravone; Female; Free | 2018 |
Reference level of serum urate for clinically evident incident gout.
Topics: Data Analysis; Gout; Humans; Hyperuricemia; Uric Acid | 2019 |
Response to: 'The reference levels of serum urate for clinically evident incident gout' by Chen and Ding.
Topics: Data Analysis; Gout; Humans; Hyperuricemia; Uric Acid | 2019 |
Hyperuricaemia and type 2 diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; Humans; Hyperuricemia; Insulin; Insulin Resistance; Uric Acid | 2018 |
Effect of hydrochlorothiazide on serum uric acid concentration: a genome-wide association study.
Topics: Aged; Antihypertensive Agents; DNA-Binding Proteins; Female; Finland; Genome-Wide Association Study; | 2018 |
Effect of hydrochlorothiazide on serum uric acid concentration: a genome-wide association study.
Topics: Aged; Antihypertensive Agents; DNA-Binding Proteins; Female; Finland; Genome-Wide Association Study; | 2018 |
Effect of hydrochlorothiazide on serum uric acid concentration: a genome-wide association study.
Topics: Aged; Antihypertensive Agents; DNA-Binding Proteins; Female; Finland; Genome-Wide Association Study; | 2018 |
Effect of hydrochlorothiazide on serum uric acid concentration: a genome-wide association study.
Topics: Aged; Antihypertensive Agents; DNA-Binding Proteins; Female; Finland; Genome-Wide Association Study; | 2018 |
Hypouricemic Effects of Armillaria mellea on Hyperuricemic Mice Regulated through OAT1 and CNT2.
Topics: Animals; Armillaria; Down-Regulation; Ethanol; Gastrointestinal Tract; Gene Expression; Glucose Tran | 2018 |
Elevated serum uric acid levels are associated with endothelial dysfunction in HIV patients receiving highly-active antiretroviral therapy.
Topics: Adult; Aged; Antiretroviral Therapy, Highly Active; Biomarkers; Body Mass Index; Brachial Artery; Cr | 2018 |
Gender-specific association of serum uric acid levels and cardio-ankle vascular index in Chinese adults.
Topics: Adult; Ankle Brachial Index; Asian People; Demography; Female; Humans; Hyperuricemia; Logistic Model | 2018 |
Serum Bisphenol A is an independent risk factor of hyperuricemia: A 6-year prospective study.
Topics: Aged; Benzhydryl Compounds; Female; Follow-Up Studies; Humans; Hyperuricemia; Male; Middle Aged; Phe | 2019 |
Serum Uric Acid Elevation is Associated to Arterial Stiffness in Hypertensive Patients with Metabolic Disturbances.
Topics: Arterial Pressure; Biomarkers; Blood Glucose; Cross-Sectional Studies; Essential Hypertension; Femal | 2018 |
4-(2-(4-chlorophenyl)-1-((4-chlorophenyl)amino)ethyl)benzene-1, 3-diol is a potential agent for gout therapy as a dual inhibitor of XOD and NLRP3.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzene Derivatives; Enzyme Inhibitors; Gout; Huma | 2018 |
Preparation, characterization and systemic application of self-assembled hydroxyethyl starch nanoparticles-loaded flavonoid Morin for hyperuricemia therapy.
Topics: Animals; Deoxycholic Acid; Drug Carriers; Drug Delivery Systems; Flavonoids; Hydrophobic and Hydroph | 2018 |
U-Shaped Association Between Serum Uric Acid Level and Risk of Mortality: A Cohort Study.
Topics: Adult; Cardiovascular Diseases; Cause of Death; Female; Humans; Hyperuricemia; Male; Middle Aged; Pr | 2018 |
The impact of serum uric acid reduction on renal function and blood pressure in chronic kidney disease patients with hyperuricemia.
Topics: Adult; Aged; Allopurinol; Blood Pressure; Febuxostat; Female; Glomerular Filtration Rate; Humans; Hy | 2018 |
Significance of asymptomatic hyperuricemia in patients after coronary events.
Topics: Coronary Artery Disease; Demography; Female; Humans; Hyperuricemia; Male; Middle Aged; Risk Factors; | 2018 |
The nomenclature of the basic disease elements of gout: A content analysis of contemporary medical journals.
Topics: Gout; Humans; Hyperuricemia; Terminology as Topic; Uric Acid | 2018 |
Temporal relationship between hyperuricemia and obesity, and its association with future risk of type 2 diabetes.
Topics: Adult; Aged; Body Mass Index; China; Diabetes Mellitus, Type 2; Female; Humans; Hyperuricemia; Longi | 2018 |
Accuracy of the HumaSens
Topics: Blood Specimen Collection; Female; Gout; Humans; Hyperuricemia; Male; Middle Aged; Point-of-Care Sys | 2018 |
Association between Dietary Zinc Intake and Hyperuricemia among Adults in the United States.
Topics: Adult; Aged; Blood Glucose; Cholesterol; Cross-Sectional Studies; Diet; Dietary Carbohydrates; Dieta | 2018 |
[Correlation between fasting C-peptide and serum uric acid in patients with type 2 diabetes mellitus].
Topics: C-Peptide; Diabetes Mellitus, Type 2; Fasting; Humans; Hyperuricemia; Risk Factors; Uric Acid | 2018 |
Hyperuricemia Is Associated With a Higher Prevalence of Metabolic Syndrome in Military Individuals.
Topics: Adult; Cohort Studies; Female; Humans; Hyperuricemia; Logistic Models; Male; Metabolic Syndrome; Mil | 2018 |
Effectiveness of febuxostat in patients with allopurinol-refractory hyperuricemic chronic kidney disease
.
Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Biomarkers; Down-Regulation; Drug Resistance; Drug Subs | 2018 |
Prevalence of hyperuricemia and its associated factors in the general Korean population: an analysis of a population-based nationally representative sample.
Topics: Adult; Aged; Aged, 80 and over; Cross-Sectional Studies; Female; Humans; Hyperuricemia; Male; Middle | 2018 |
Gout, Hyperuricemia, and Crystal-Associated Disease Network Consensus Statement Regarding Labels and Definitions for Disease Elements in Gout.
Topics: Consensus; Crystal Arthropathies; Delphi Technique; Gout; Humans; Hyperuricemia; Uric Acid | 2019 |
Feeding-produced subchronic high plasma levels of uric acid improve behavioral dysfunction in 6-hydroxydopamine-induced mouse model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Apomorphine; Disease Models, Animal; Hyperuricemia; Male; Mental Disorde | 2019 |
Temporal trends in hyperuricaemia in the Irish health system from 2006-2014: A cohort study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cohort Studies; Female; Humans; Hyperuricemia; Ireland; | 2018 |
Effects of uric acid on kidney function decline differ depending on baseline kidney function in type 2 diabetic patients.
Topics: Aged; Cohort Studies; Diabetes Mellitus, Type 2; Female; Glomerular Filtration Rate; Humans; Hyperur | 2019 |
Evaluation of a pharmacokinetic-pharmacodynamic model for hypouricaemic effects of febuxostat using datasets obtained from real-world patients.
Topics: Adult; Aged; Body Weight; Comorbidity; Datasets as Topic; Diabetes Mellitus; Dose-Response Relations | 2018 |
GLUT9 influences uric acid concentration in patients with Lesch-Nyhan disease.
Topics: Adolescent; Adult; Allopurinol; ATP Binding Cassette Transporter, Subfamily G, Member 2; Biomarkers; | 2018 |
Serum uric acid and metabolic components with special reference to diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; Humans; Hyperuricemia; Risk Factors; Uric Acid | 2018 |
Impact of hyperuricemia on clinical outcomes after percutaneous coronary intervention for in-stent restenosis.
Topics: Aged; Biomarkers; Coronary Angiography; Coronary Artery Disease; Coronary Restenosis; Female; Humans | 2018 |
Compounds containing trace element copper or zinc exhibit as potent hyperuricemia inhibitors via xanthine oxidase inactivation.
Topics: Animals; Copper; Coumaric Acids; Enzyme Inhibitors; Hyperuricemia; Male; Mice; Trace Elements; Uric | 2018 |
Heat stress nephropathy and hyperuricemia.
Topics: Allopurinol; Heat-Shock Response; Humans; Hyperuricemia; Liver; Uric Acid | 2018 |
Is increased uric acid a risk factor or a defensive response? The Campania Salute Network.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Arterial Pressure; Biomarkers; | 2018 |
[Analysis of serum ferritin and high sensitive C reactive protein in patients with gout].
Topics: C-Reactive Protein; Ferritins; Gout; Humans; Hyperuricemia; Male; Uric Acid | 2017 |
[Association between SLC22A12 rs1529909 and rs7929627 polymorphism and hyperuricemia].
Topics: Case-Control Studies; Child, Preschool; China; Humans; Hyperuricemia; Male; Organic Anion Transporte | 2017 |
From hyperuricaemia to gout: what are the missing links?
Topics: Data Analysis; Gout; Humans; Hyperuricemia; Risk Factors; Uric Acid | 2018 |
Mangiferin alleviates hypertension induced by hyperuricemia via increasing nitric oxide releases.
Topics: Administration, Oral; Animals; Aorta; C-Reactive Protein; Human Umbilical Vein Endothelial Cells; Hu | 2018 |
Genetically high plasma vitamin C and urate: a Mendelian randomization study in 106 147 individuals from the general population.
Topics: Adult; Aged; Aged, 80 and over; Ascorbic Acid; Female; Genetic Variation; Genotype; Humans; Hyperuri | 2018 |
Genetic association and functional analysis of rs7903456 in FAM35A gene and hyperuricemia: a population based study.
Topics: Adult; Case-Control Studies; Cell Cycle Proteins; Computational Biology; DNA-Binding Proteins; Femal | 2018 |
Effect of Uric Acid Control on Serum Creatinine.
Topics: Aged; Allopurinol; Antimetabolites; Comorbidity; Correlation of Data; Creatinine; Disease Progressio | 2019 |
Involvement of Arterial Stiffness and Inflammation in Hyperuricemia-Related Development of Hypertension.
Topics: Adult; Ankle Brachial Index; Blood Pressure; C-Reactive Protein; Glomerular Filtration Rate; Humans; | 2018 |
Uric Acid and Hypertension Because of Arterial Stiffness.
Topics: Humans; Hypertension; Hyperuricemia; Inflammation; Uric Acid; Vascular Stiffness | 2018 |
Research on the pharmacodynamics and mechanism of Fraxini Cortex on hyperuricemia based on the regulation of URAT1 and GLUT9.
Topics: Aesculus; Animals; Anion Transport Proteins; Biomarkers; Blood Urea Nitrogen; Coumarins; Creatinine; | 2018 |
The association of hyperuricemia and immediate postpartum hypertension in women without a diagnosis of chronic hypertension.
Topics: Adult; Blood Pressure; Female; Humans; Hypertension; Hyperuricemia; Postpartum Period; Pregnancy; Ur | 2018 |
Metabolic and cardiovascular effects of chronic mild hyperuricemia in rodents.
Topics: Animals; Blood Glucose; Blood Pressure; Body Weight; Cardiovascular Diseases; Chronic Disease; Fasti | 2018 |
Editorial Commentary: Prevention and treatment of atrial fibrillation: Is hyperuricemia the next target?
Topics: Atrial Fibrillation; Gout; Humans; Hyperuricemia; Uric Acid | 2019 |
Sugar-Sweetened Soft Drinks and Fructose Consumption Are Associated with Hyperuricemia: Cross-Sectional Analysis from the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil).
Topics: Adult; Aged; Beverages; Brazil; Carbonated Beverages; Cross-Sectional Studies; Diet; Dietary Sucrose | 2018 |
Risk factors for hyperuricemia in congenital heart disease patients and its relation to cardiovascular death.
Topics: Adult; Biomarkers; Cause of Death; Female; Follow-Up Studies; Heart Defects, Congenital; Humans; Hyp | 2018 |
Gender-related differences in serum uric acid in treated hypertensive patients from central and east European countries: findings from the Blood Pressure control rate and CArdiovascular Risk profilE study.
Topics: Aged; Blood Pressure; Comorbidity; Cross-Sectional Studies; Diabetes Mellitus; Europe, Eastern; Fema | 2019 |
Relationship between serum bilirubin levels s and the progression of renal function in patients with chronic kidney disease and hyperuricemia.
Topics: Aged; Bilirubin; Cohort Studies; Disease Progression; Female; Humans; Hyperuricemia; Male; Middle Ag | 2018 |
Different Risk for Hypertension, Diabetes, Dyslipidemia, and Hyperuricemia According to Level of Body Mass Index in Japanese and American Subjects.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Biomarkers; Blood Glucose; Blood Pressure; Body Mass Ind | 2018 |
Genetic Background of a Juvenile Onset Gout Patient.
Topics: Adult; Genetic Background; Gout; Humans; Hyperuricemia; Kidney Diseases; Male; Uric Acid; Young Adul | 2018 |
The Association of Urinary Sodium and Potassium with Renal Uric Acid Excretion in Patients with Chronic Kidney Disease.
Topics: Adult; Aged; Cross-Sectional Studies; Epidermal Growth Factor; Female; Humans; Hypertension; Hyperur | 2018 |
Can high uric acid levels be an independent risk factor for acute ischemic stroke due to large-artery atherosclerosis?
Topics: Atherosclerosis; Bilirubin; Biomarkers; Brain Ischemia; Carotid Intima-Media Thickness; Carotid Sten | 2018 |
Hyperuricemia is associated with atrial fibrillation prevalence in very elderly - a community based study in Chengdu, China.
Topics: Age Factors; Aged; Aged, 80 and over; Atrial Fibrillation; China; Comorbidity; Female; Humans; Hyper | 2018 |
Hypouricemic and Antioxidant Effects of Soy Vinegar Extracts in Hyperuricemic Mice.
Topics: Animals; Antioxidants; Disease Models, Animal; Dose-Response Relationship, Drug; Glycine max; Hyperu | 2018 |
[Related factors of diabetic nephropathy in patients with type 1 diabetes mellitus].
Topics: Blood Glucose; Blood Pressure; Body Mass Index; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2 | 2018 |
Gender difference in the relationship between uric acid and pulse pressure among Korean adults.
Topics: Adult; Blood Pressure; Cross-Sectional Studies; Female; Humans; Hypertension; Hyperuricemia; Inciden | 2019 |
Probiotic supplements prevented oxonic acid-induced hyperuricemia and renal damage.
Topics: Animals; Cytoprotection; Dietary Supplements; Dose-Response Relationship, Drug; Hyperuricemia; Kidne | 2018 |
Association of serum uric acid levels with SYNTAX score II and long term mortality in the patients with stable angina pectoris who undergo percutaneous coronary interventions due to multivessel and/or unprotected left main disease.
Topics: Aged; Angina, Stable; Biomarkers; Coronary Angiography; Coronary Artery Disease; Female; Humans; Hyp | 2019 |
The benchmark dose estimation of reference levels of serum urate for gout.
Topics: Adult; Benchmarking; Female; Follow-Up Studies; Gout; Gout Suppressants; Humans; Hyperuricemia; Male | 2018 |
Low-density Lipoprotein Subclasses are Associated with Serum Uric Acid Levels.
Topics: Adult; Aged; Body Mass Index; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus; Dyslipidemias; | 2018 |
Serum uric acid level is not associated with osteoarthritis in Korean population: data from the Seventh Korea National Health and Nutrition Examination Survey 2016.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Cross-Sectional Studies; Female; Humans; Hyperuricemia; | 2018 |
The risk of clinically diagnosed gout by serum urate levels: results from 30 years follow-up of the Malmö Preventive Project cohort in southern Sweden.
Topics: Adult; Cohort Studies; Female; Follow-Up Studies; Gout; Humans; Hyperuricemia; Male; Mass Screening; | 2018 |
Hyperuricemia and smoking in young adults suspected of coronary artery disease ≤ 35 years of age: a hospital-based observational study.
Topics: Adolescent; Adult; Age of Onset; Beijing; Biomarkers; Coronary Artery Disease; Coronary Stenosis; Fe | 2018 |
Hyperuricemia and dementia - a case-control study.
Topics: Aged; Case-Control Studies; Dementia; Female; Gout; Humans; Hyperuricemia; Male; Middle Aged; Odds R | 2018 |
Urate-Lowering Therapy in Moderate to Severe Chronic Kidney Disease.
Topics: Aged; Allopurinol; Cohort Studies; Febuxostat; Female; Glomerular Filtration Rate; Gout Suppressants | 2018 |
Association between serum uric acid and carotid disease in patients with atherosclerotic acute ischemic stroke.
Topics: Aged; Aged, 80 and over; Biomarkers; Brain Ischemia; Carotid Intima-Media Thickness; Carotid Stenosi | 2019 |
Urate crystals and inflammation. Cardiovascular impact of gout.
Topics: Gout; Humans; Hyperuricemia; Inflammation; Uric Acid | 2018 |
DKB114, A Mixture of
Topics: Animals; Chrysanthemum; Cinnamomum; Enzyme Inhibitors; Flowers; Gene Expression; Glucose Transport P | 2018 |
No associations exists between red blood cell distribution width and serum uric acid in both sexes.
Topics: Body Mass Index; China; Cross-Sectional Studies; Erythrocyte Indices; Female; Healthy Volunteers; Hu | 2018 |
Hyperferritinaemia and hyperuricaemia - a causal connection?
Topics: Ferritins; Gout; Humans; Hyperuricemia; Uric Acid | 2018 |
The prevalence of hyperuricemia and its correlates in Ganzi Tibetan Autonomous Prefecture, Sichuan Province, China.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cholesterol; Cross-Sectional Studies; Dyslipidemias; Fem | 2018 |
High urate concentration is associated with elevated blood pressure in schoolchildren.
Topics: Adolescent; Blood Pressure; Brazil; Child; Cross-Sectional Studies; Female; Humans; Hypertension; Hy | 2018 |
Anti-hyperuricemic and nephroprotective effects of extracts from Chaenomeles sinensis (Thouin) Koehne in hyperuricemic mice.
Topics: Animals; Creatinine; Disease Models, Animal; Fruit; Gene Expression Regulation; Hyperuricemia; Liver | 2018 |
Serum Uric Acid Levels are Associated with Cardiometabolic Risk Factors in Healthy Young and Middle-Aged Adults.
Topics: Adiposity; Adult; Blood Pressure; C-Reactive Protein; Cholesterol; Cross-Sectional Studies; Diet Sur | 2018 |
Hypertension and Hyperuricemia: A Compelling Correlation.
Topics: Case-Control Studies; Humans; Hypertension; Hyperuricemia; India; Uric Acid | 2018 |
Hypertension as Determinant of Hyperuricemia: A Case Control Study from the Sub-Himalayan Region in North India.
Topics: Case-Control Studies; Essential Hypertension; Female; Humans; Hyperuricemia; India; Male; Sex Factor | 2018 |
Renal excretion is a cause of decreased serum uric acid during acute gout.
Topics: Adult; Aged; Arthritis, Gouty; Biomarkers; Down-Regulation; Female; Gout; Humans; Hyperuricemia; Kid | 2018 |
White Powder Over Palm: An Unusual Presentation of Hyperuricemia in Polyarticular Gout.
Topics: Gout; Hand; Humans; Hyperuricemia; Uric Acid | 2018 |
Association between the prevalence of hyperuricemia and reproductive hormones in polycystic ovary syndrome.
Topics: Adult; Body Mass Index; China; Cross-Sectional Studies; Estradiol; Female; Follicle Stimulating Horm | 2018 |
Evaluation of the association between hyperuricemia and coronary artery disease: A STROBE-compliant article.
Topics: Aged; Cohort Studies; Coronary Angiography; Coronary Artery Disease; Female; Humans; Hyperuricemia; | 2018 |
Prevalence of hyperuricemia and the relationship between serum uric acid and obesity: A study on Bangladeshi adults.
Topics: Adolescent; Adult; Bangladesh; Cross-Sectional Studies; Female; Humans; Hyperuricemia; Male; Middle | 2018 |
Hyperuricaemic UrahPlt2/Plt2 mice show altered T cell proliferation and defective tumor immunity after local immunotherapy with Poly I:C.
Topics: Amidohydrolases; Animals; Carcinogenesis; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Cell Prolife | 2018 |
Association of hyperuricemia with disease severity in chronic hepatitis C patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Case-Control Studies; Cohort Studies; Female; Hepatitis | 2018 |
Salivary uric acid: Associations with resting and reactive blood pressure response to social evaluative stress in healthy African Americans.
Topics: Adult; Black or African American; Blood Pressure; Cardiovascular Diseases; Female; Healthy Volunteer | 2019 |
Serum Uric Acid Is Independently Associated with Coronary Calcification in an Asymptomatic Population.
Topics: Aged; Asymptomatic Diseases; Biomarkers; Computed Tomography Angiography; Coronary Angiography; Coro | 2019 |
Joint effects of uric acid and lymphocyte count on adverse outcomes in elderly patients with rheumatic heart disease undergoing valve replacement surgery.
Topics: Biomarkers; Female; Heart Valve Prosthesis Implantation; Hospital Mortality; Humans; Hyperuricemia; | 2019 |
Urate-Lowering Therapy for Preventing Kidney Disease Progression: Are We There Yet?
Topics: Disease Progression; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency | 2018 |
Production Inhibition and Excretion Promotion of Urate by Fucoidan from
Topics: Adenine; Animals; Blood Urea Nitrogen; Creatinine; Disease Models, Animal; Drug Evaluation, Preclini | 2018 |
Warm ischemia time and elevated serum uric acid are associated with metabolic syndrome after liver transplantation with donation after cardiac death.
Topics: Adult; Biomarkers; Donor Selection; End Stage Liver Disease; Female; Follow-Up Studies; Humans; Hype | 2018 |
Effect of high uric acid on the disposition of metformin: in vivo and in vitro studies.
Topics: Animals; Antiporters; Cell Line; Humans; Hyperuricemia; Hypoglycemic Agents; Kidney; Liver; Male; Me | 2019 |
Risk factors analysis for hyperuricemic nephropathy among CKD stages 3-4 patients: an epidemiological study of hyperuricemia in CKD stages 3-4 patients in Ningbo, China.
Topics: Adult; Aged; Blood Pressure; Body Mass Index; China; Epidemiologic Studies; Female; Humans; Hyperuri | 2018 |
Blockage of macrophage migration inhibitory factor (MIF) suppressed uric acid-induced vascular inflammation, smooth muscle cell de-differentiation, and remodeling.
Topics: Animals; Cell Dedifferentiation; Cells, Cultured; Disease Models, Animal; Gene Knockdown Techniques; | 2019 |
A zebrafish (danio rerio) model for high-throughput screening food and drugs with uric acid-lowering activity.
Topics: Allopurinol; Animals; Anserine; Disease Models, Animal; Drug Evaluation, Preclinical; High-Throughpu | 2019 |
Relationship Between Uric Acid, Proteinuria, and Atherogenic Index of Plasma in Renal Transplant Patients.
Topics: Adult; Aged; Atherosclerosis; Cardiovascular Diseases; Cohort Studies; Female; Glomerular Filtration | 2018 |
Gender impact on the correlations between Graves' hyperthyroidism and hyperuricemia in Chinese.
Topics: Adolescent; Adult; Aged; Asian People; Female; Gender Identity; Graves Disease; Humans; Hyperthyroid | 2019 |
Mechanistic Insights of Soluble Uric Acid-related Kidney Disease.
Topics: Humans; Hyperuricemia; Kidney; Kidney Diseases; Risk Factors; Uric Acid | 2020 |
Implications of Hyperuricemia in Severe Coronary Artery Disease.
Topics: Aged; Cohort Studies; Coronary Artery Disease; Female; Humans; Hyperuricemia; Male; Middle Aged; Pro | 2019 |
Higher Serum Uric Acid is a Risk Factor of Reduced Muscle Mass in Men with Type 2 Diabetes Mellitus.
Topics: Absorptiometry, Photon; Adult; Aged; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Hum | 2021 |
The dose-response effects of uric acid on the prevalence of metabolic syndrome and electrocardiographic left ventricular hypertrophy in healthy individuals.
Topics: Adult; Biomarkers; Electrocardiography; Female; Humans; Hypertrophy, Left Ventricular; Hyperuricemia | 2019 |
Uric acid induced inflammatory responses in endothelial cells via up-regulating(pro)renin receptor.
Topics: Cell Adhesion; Cells, Cultured; Cytokines; Endothelium, Vascular; Human Umbilical Vein Endothelial C | 2019 |
Pterostilbene, a bioactive component of blueberries, alleviates renal fibrosis in a severe mouse model of hyperuricemic nephropathy.
Topics: Animals; Blueberry Plants; Creatinine; Disease Models, Animal; Drugs, Chinese Herbal; Fibronectins; | 2019 |
Study on anti-hyperuricemia effects and active ingredients of traditional Tibetan medicine TongFengTangSan (TFTS) by ultra-high-performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry.
Topics: Animals; Chromatography, High Pressure Liquid; Ethanol; Hyperuricemia; Male; Materia Medica; Medicin | 2019 |
Is There A Relation Between Serum Uric Acid Values and Prostatic Calculi Presence?
Topics: Adult; Biomarkers; Calculi; Humans; Hyperuricemia; Male; Prostatic Diseases; Risk Factors; Tomograph | 2019 |
New Rice-Derived Short Peptide Potently Alleviated Hyperuricemia Induced by Potassium Oxonate in Rats.
Topics: Animals; Humans; Hyperuricemia; Liver; Male; Oryza; Oxonic Acid; Peptides; Plant Extracts; Rats; Rat | 2019 |
Association between hyperuricemia and metabolic syndrome in patients suffering from bipolar disorder.
Topics: Adult; Bipolar Disorder; China; Comorbidity; Correlation of Data; Diagnostic and Statistical Manual | 2018 |
Blockade of enhancer of zeste homolog 2 alleviates renal injury associated with hyperuricemia.
Topics: Animals; DNA Methylation; Enhancer of Zeste Homolog 2 Protein; Fibroblasts; Fibrosis; Histones; Hype | 2019 |
Comparison of efficacy and safety between febuxostat and allopurinol in early post-renal transplant recipients with new onset of hyperuricemia.
Topics: Adolescent; Adult; Allopurinol; Cohort Studies; Febuxostat; Female; Glomerular Filtration Rate; Gout | 2019 |
Comparison of renoprotective effects of febuxostat and allopurinol in hyperuricemic patients with chronic kidney disease.
Topics: Aged; Allopurinol; Febuxostat; Female; Glomerular Filtration Rate; Gout Suppressants; Humans; Hyperu | 2019 |
Gender differences in association between uric acid and all-cause mortality in patients with chronic heart failure.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Biomarkers; Cause of Death; Chronic Disease; Female; Hea | 2019 |
Contemporary Prevalence of Gout and Hyperuricemia in the United States and Decadal Trends: The National Health and Nutrition Examination Survey, 2007-2016.
Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hy | 2019 |
Plasma xanthine oxidoreductase activity in patients with decompensated acute heart failure requiring intensive care.
Topics: Acute Disease; Aged; Aged, 80 and over; Biomarkers; Critical Care; Female; Follow-Up Studies; Heart | 2019 |
Polymorphisms of
Topics: Adult; Aged; Alleles; ATP Binding Cassette Transporter, Subfamily G, Member 2; Blood Pressure; Case- | 2019 |
Effects of ChondroT on potassium Oxonate-induced Hyperuricemic mice: downregulation of xanthine oxidase and urate transporter 1.
Topics: Animals; Creatinine; Down-Regulation; Drug Evaluation, Preclinical; Drugs, Chinese Herbal; Humans; H | 2019 |
Associations of multiple exposures to persistent toxic substances with the risk of hyperuricemia and subclinical uric acid levels in BIOAMBIENT.ES study.
Topics: Adult; Cross-Sectional Studies; Endocrine Disruptors; Environmental Pollutants; Feeding Behavior; Fe | 2019 |
Achievement of Target Serum Uric Acid Levels and Factors Associated with Therapeutic Failure among Japanese Men Treated for Hyperuricemia/Gout.
Topics: Adult; Aged; Anthropometry; Body Mass Index; Cross-Sectional Studies; Drug Monitoring; Dyslipidemias | 2019 |
Hyperuricemia is associated with acute kidney injury and all-cause mortality in hospitalized patients.
Topics: Acute Kidney Injury; Adult; Aged; Female; Hospital Mortality; Humans; Hyperuricemia; Male; Middle Ag | 2019 |
Reduction of Serum Uric Acid Associated with Attenuation of Renal Injury, Inflammation and Macrophages M1/M2 Ratio in Hyperuricemic Mice Model.
Topics: Allopurinol; Animals; Creatinine; Gout Suppressants; Hyperuricemia; Inflammation; Kidney; Macrophage | 2018 |
Common variants in the
Topics: Adult; Aged; Asian People; Case-Control Studies; China; Gout; Humans; Hyperuricemia; Male; Membrane | 2019 |
Clinical features and recurrent attack in gout patients according to serum urate levels during an acute attack.
Topics: Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Retrospective Studies; Uric Acid | 2020 |
Urate-lowering therapy alleviates atherosclerosis inflammatory response factors and neointimal lesions in a mouse model of induced carotid atherosclerosis.
Topics: Allopurinol; Animals; Antimetabolites; Carotid Artery Diseases; Human Umbilical Vein Endothelial Cel | 2019 |
Two-Year Changes in Hyperuricemia and Risk of Diabetes: A Five-Year Prospective Cohort Study.
Topics: Adult; China; Diabetes Mellitus; Female; Follow-Up Studies; Humans; Hyperuricemia; Longitudinal Stud | 2018 |
Hypouricemic and nephroprotective roles of anthocyanins in hyperuricemic mice.
Topics: Animals; Anthocyanins; Blood Urea Nitrogen; Creatinine; Diet; Hyperuricemia; Male; Mice; Mice, Inbre | 2019 |
Association between serum uric acid levels and coronary artery disease in different age and gender: a cross-sectional study.
Topics: Adult; Age Distribution; Aged; Aged, 80 and over; Coronary Artery Disease; Cross-Sectional Studies; | 2019 |
Association between platelet distribution width and serum uric acid in Chinese population.
Topics: Adult; Asian People; Blood Platelets; Cross-Sectional Studies; Female; Humans; Hyperuricemia; Logist | 2019 |
Hyperuricemia Predicts an Early Decline in Renal Function among Older People: A Community-Based Cohort Study.
Topics: Aged; Cohort Studies; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Hyperuricemia; | 2019 |
Apelin-13 reduces oxidative stress induced by uric acid via downregulation of renin-angiotensin system in adipose tissue.
Topics: 3T3-L1 Cells; Adipose Tissue; Animals; Dietary Carbohydrates; Down-Regulation; Fructose; Hyperuricem | 2019 |
Hyperuricemia predicts adverse clinical outcomes after cardiac resynchronization therapy.
Topics: Aged; Biomarkers; Cardiac Resynchronization Therapy; Female; Follow-Up Studies; Heart Failure; Human | 2018 |
Monosodium Urate Contributes to Retinal Inflammation and Progression of Diabetic Retinopathy.
Topics: Allopurinol; Animals; Benzbromarone; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Humans; | 2019 |
Association of serum uric acid levels with the incident of kidney disease and rapid eGFR decline in Chinese individuals with eGFR > 60 mL/min/1.73 m
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; China; Disease Progression; Female; Glomerular Filtratio | 2019 |
Inhibiting PNP for the therapy of hyperuricemia in Lesch-Nyhan disease: Preliminary in vitro studies with analogues of immucillin-G.
Topics: Allopurinol; Cells, Cultured; Enzyme Inhibitors; Humans; Hyperuricemia; Hypoxanthine; Hypoxanthine P | 2019 |
Associations Between Serum Uric Acid Concentrations and Cardiometabolic Risk and Renal Injury in Obese and Overweight Children
Topics: Adolescent; Biomarkers; Body Mass Index; Cardiovascular Diseases; Child; Female; Follow-Up Studies; | 2019 |
Secretion of IL-1β From Monocytes in Gout Is Redox Independent.
Topics: Acetylcysteine; Antioxidants; Cell Survival; Furans; Gene Expression; Gout; Heterocyclic Compounds, | 2019 |
Association between smoking and serum uric acid in Korean population: Data from the seventh Korea national health and nutrition examination survey 2016.
Topics: Adult; Age Factors; Alcohol Drinking; Blood Glucose; Blood Pressure; Body Mass Index; Cross-Sectiona | 2019 |
Synovial fluid leukocyte count in asymptomatic hyperuricaemia with crystal deposition: a proof-of-concept study.
Topics: Aged; Asymptomatic Diseases; Crystallization; Female; Humans; Hyperuricemia; Leukocyte Count; Male; | 2019 |
Long-term prognostic impact of hyperuricemia in community.
Topics: Adult; Female; Humans; Hyperuricemia; Male; Middle Aged; Multivariate Analysis; Prognosis; Residence | 2019 |
Beneficial Effect of Dietary Fiber on Hyperuricemia in Rats and Humans: A Review.
Topics: Animals; Diet; Dietary Fiber; Humans; Hypertension; Hyperuricemia; Rats; Uric Acid | 2019 |
The relationship between serum uric acid and lipid profile in Bangladeshi adults.
Topics: Adult; Bangladesh; Biomarkers; Cardiovascular Diseases; Cross-Sectional Studies; Dyslipidemias; Fema | 2019 |
Association of serum uric acid change with mortality, renal function and diuretic dose administered in treatment of acute heart failure.
Topics: Aged; Aged, 80 and over; Biomarkers; Creatinine; Diuresis; Female; Heart Failure; Humans; Hyperurice | 2019 |
Study on the diagnosis of gout with xanthine and hypoxanthine.
Topics: Blood Chemical Analysis; Chromatography, High Pressure Liquid; Gout; Humans; Hyperuricemia; Hypoxant | 2019 |
Higher levels of serum uric acid influences hepatic damage in patients with non-alcoholic fatty liver disease (NAFLD).
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Analysis of Variance; Biomarkers; Body Mass Index; Chol | 2019 |
Hyperuricemia and acute gout after laparoscopic sleeve gastrectomy.
Topics: Adult; Bariatric Surgery; Biomarkers; Body Composition; Body Water; Female; Gastrectomy; Gout; Greec | 2019 |
Modified Chuanhu anti-gout mixture, a traditional Chinese medicine, protects against potassium oxonate-induced hyperuricemia and renal dysfunction in mice.
Topics: Animals; Creatinine; Drugs, Chinese Herbal; Hyperuricemia; Kidney; Male; Mice; Organic Anion Transpo | 2019 |
Hyperuricemia is Associated with Immunoglobulin G
Topics: Adult; Biomarkers; Cross-Sectional Studies; Female; Humans; Hyperuricemia; Immunoglobulin G; Male; M | 2019 |
Molecular mechanistic insight into the anti-hyperuricemic effect of Eucommia ulmoides in mice and rats.
Topics: Animals; Dose-Response Relationship, Drug; Ethanol; Eucommiaceae; Female; Hyperuricemia; Male; Maxim | 2019 |
The Protective Effects of Increasing Serum Uric Acid Level on Development of Metabolic Syndrome.
Topics: Adult; Aged; Antioxidants; Body Mass Index; Female; Follow-Up Studies; Humans; Hyperuricemia; Incide | 2019 |
Hyperuricemia and its related histopathological features on renal biopsy.
Topics: Adult; Biopsy; Cross-Sectional Studies; Female; Glomerular Filtration Rate; Humans; Hyperuricemia; K | 2019 |
Uricase and Horseradish Peroxidase Hybrid CaHPO₄ Nanoflower Integrated with Transcutaneous Patches for Treatment of Hyperuricemia.
Topics: Calcium Phosphates; China; Horseradish Peroxidase; Humans; Hyperuricemia; Nanostructures; Urate Oxid | 2019 |
Maternal serum uric acid and calcium as predictors of hypertensive disorder of pregnancy: A case control study.
Topics: Adult; Biomarkers; Calcium; Case-Control Studies; Female; Humans; Hyperuricemia; Hypocalcemia; Pre-E | 2019 |
Increased urinary glucose excretion is associated with a reduced risk of hyperuricaemia.
Topics: Adult; Blood Glucose; China; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Glucose Tol | 2019 |
Hyperuricaemia and vascular risk: the debate continues.
Topics: Cardiovascular Diseases; Gout; Humans; Hyperuricemia; Risk Factors; Uric Acid; Xanthine Oxidase | 2019 |
Coexistence of hyper-uricaemia and low urinary uric acid excretion further increases risk of chronic kidney disease in type 2 diabetes.
Topics: Aged; Albuminuria; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Femal | 2019 |
Crystal-proven gout patients have an increased mortality due to cardiovascular diseases, cancer, and infectious diseases especially when having tophi and/or high serum uric acid levels: a prospective cohort study.
Topics: Aged; Cardiovascular Diseases; Cause of Death; Communicable Diseases; Female; Gout; Humans; Hyperuri | 2019 |
Hypertriglyceridemia and hyperuricemia: a retrospective study of urban residents.
Topics: Adult; Aged; Female; Humans; Hypertriglyceridemia; Hyperuricemia; Lipid Metabolism; Male; Middle Age | 2019 |
Changes of drug pharmacokinetics mediated by downregulation of kidney organic cation transporters Mate1 and Oct2 in a rat model of hyperuricemia.
Topics: Adenine; Animals; Antiporters; Cephalexin; Creatinine; Disease Models, Animal; Down-Regulation; Huma | 2019 |
Renal safety and urate-lowering efficacy of febuxostat in gout patients with stage 4-5 chronic kidney disease not yet on dialysis.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Dialysis; Renal Insuf | 2020 |
Elevated Serum Uric Acid Is Associated With Greater Risk for Hypertension and Diabetic Kidney Diseases in Obese Adolescents With Type 2 Diabetes: An Observational Analysis From the Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) Stu
Topics: Adolescent; Blood Pressure; Child; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephro | 2019 |
Effect of uric acid serum levels on carotid arterial stiffness and intima-media thickness: A high resolution Echo-Tracking Study.
Topics: Adult; Aged; Atherosclerosis; Carotid Arteries; Carotid Intima-Media Thickness; Female; Humans; Hype | 2019 |
Gender-specific association between uric acid level and chronic kidney disease in the elderly health checkup population in China.
Topics: Aged; Aged, 80 and over; China; Cross-Sectional Studies; Female; Glomerular Filtration Rate; Humans; | 2019 |
Novel xanthine oxidase-based cell model using HK-2 cell for screening antihyperuricemic functional compounds.
Topics: Cell Culture Techniques; Cell Line; Chromatography, High Pressure Liquid; Drug Evaluation, Preclinic | 2019 |
TLR2 and TLR4 mediate an activation of adipose tissue renin-angiotensin system induced by uric acid.
Topics: Adipocytes; Adipose Tissue; Animals; Diet, Carbohydrate Loading; Disease Models, Animal; Fructose; H | 2019 |
Functional Characterization of Clinically-Relevant Rare Variants in
Topics: Adolescent; Adult; Aged; Aged, 80 and over; ATP Binding Cassette Transporter, Subfamily G, Member 2; | 2019 |
Protective effects of Rhizoma smilacis glabrae extracts on potassium oxonate- and monosodium urate-induced hyperuricemia and gout in mice.
Topics: Animals; Antioxidants; Arthritis, Gouty; Disease Models, Animal; Drugs, Chinese Herbal; Edema; Flavo | 2019 |
Dual actions of norathyriol as a new candidate hypouricaemic agent: uricosuric effects and xanthine oxidase inhibition.
Topics: Animals; Enzyme Inhibitors; HEK293 Cells; Humans; Hyperuricemia; Kidney; Mice; Organic Anion Transpo | 2019 |
Association between SLC2A9 Genetic Variants and Risk of Hyperuricemia in a Uygur Population.
Topics: Adult; Asian People; China; Cross-Sectional Studies; Female; Gene Frequency; Genetic Predisposition | 2019 |
Neck circumference is associated with hyperuricemia: a cross-sectional study.
Topics: Adult; Aged; Anthropometry; Body Mass Index; Cross-Sectional Studies; Female; Humans; Hyperuricemia; | 2019 |
Is serum uric acid a predictive factor for stroke in men with hypertriglyceridemia?
Topics: Aged; Biomarkers; Humans; Hypertriglyceridemia; Hyperuricemia; Male; Middle Aged; Predictive Value o | 2019 |
Study on chemical constituents of herbal formula Er Miao Wan and GC-MS based metabolomics approach to evaluate its therapeutic effects on hyperuricemic rats.
Topics: Animals; Discriminant Analysis; Drugs, Chinese Herbal; Gas Chromatography-Mass Spectrometry; Hyperur | 2019 |
[Prevalence and influencing factors of hyperuricemia among natural gas drilling workers in Northwest Sichuan gas field in 2016].
Topics: China; Humans; Hyperuricemia; Natural Gas; Occupational Exposure; Oil and Gas Fields; Prevalence; Ri | 2019 |
Hyperuricemia has increased the risk of progression of chronic kidney disease: propensity score matching analysis from the KNOW-CKD study.
Topics: Adult; Aged; Biomarkers; Disease Progression; Febuxostat; Female; Humans; Hyperuricemia; Kaplan-Meie | 2019 |
Point-of-care uric acid testing is useful in routine clinical care of gout.
Topics: Gout; Humans; Hyperuricemia; Point-of-Care Systems; Punctures; Uric Acid | 2019 |
Lipidomics coupled with pathway analysis characterizes serum metabolic changes in response to potassium oxonate induced hyperuricemic rats.
Topics: Animals; Biomarkers; Chromatography, High Pressure Liquid; Discriminant Analysis; Hyperuricemia; Lea | 2019 |
Inhibition of Hyperuricemia and Gouty Arthritis in BALB/c Mice Using Copper Oxide Nanoparticles.
Topics: Administration, Oral; Animals; Arthritis, Gouty; Copper; Disease Models, Animal; Humans; Hyperuricem | 2020 |
Serum Phosphate and the Risk of New-Onset Hyperuricemia in Hypertensive Patients.
Topics: Age Factors; Aged; Biomarkers; China; Comorbidity; Confidence Intervals; Double-Blind Method; Female | 2019 |
Correlations of serum uric acid with glucose and lipid metabolism and renal function of type 2 diabetes mellitus patients.
Topics: Adult; Aged; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; H | 2020 |
Highly Acylated Anthocyanins from Purple Sweet Potato ( Ipomoea batatas L.) Alleviate Hyperuricemia and Kidney Inflammation in Hyperuricemic Mice: Possible Attenuation Effects on Allopurinol.
Topics: Acylation; Allopurinol; Animals; Anthocyanins; Disease Models, Animal; Enzyme Inhibitors; Humans; Hy | 2019 |
Relationship between carotid-femoral pulse wave velocity and uric acid in subjects with hypertension and hyperuricemia.
Topics: Aged; Carotid-Femoral Pulse Wave Velocity; Cross-Sectional Studies; Female; Humans; Hypertension; Hy | 2019 |
Dose-response relationship between higher serum calcium level and higher prevalence of hyperuricemia: A cross-sectional study.
Topics: Adult; Age Factors; Calcium; China; Cross-Sectional Studies; Female; Health Behavior; Humans; Hyperu | 2019 |
Hyperuricemia treatment in acute heart failure patients does not improve their long-term prognosis: A propensity score matched analysis from the AHEAD registry.
Topics: Acute Disease; Aged; Aged, 80 and over; Allopurinol; Biomarkers; Cause of Death; Czech Republic; Dos | 2019 |
Associations between serum uric acid and depression among middle-aged and elderly participants in China.
Topics: Aged; Aged, 80 and over; China; Comorbidity; Depression; Female; Humans; Hyperuricemia; Longitudinal | 2019 |
Molecular mechanisms involved in drug-induced liver injury caused by urate-lowering Chinese herbs: A network pharmacology study and biology experiments.
Topics: Alanine Transaminase; Alkaline Phosphatase; Antimetabolites; Aspartate Aminotransferases; Benzylisoq | 2019 |
Pharmacist-managed titration of urate-lowering therapy to streamline gout management.
Topics: Adult; Aged; Biomarkers; Databases, Factual; Down-Regulation; Female; Gout; Gout Suppressants; Human | 2019 |
Hyperuricemia in Living Donor Kidney Transplantation Patients During Mizoribine Administration Caused Mainly by Changes in Kidney Function.
Topics: Adult; Female; Humans; Hyperuricemia; Immunosuppressive Agents; Kidney; Kidney Transplantation; Livi | 2019 |
[Effect of acupuncture stimulation of "Shenshu"(BL23)-"Taixi"(KI3)on levels of serum uric acid and renal URAT1 and OAT1 protein expression in hyperuricemia rats].
Topics: Acupuncture Therapy; Animals; Anions; Hyperuricemia; Male; Organic Anion Transport Protein 1; Rats; | 2019 |
Associations of Gout and Baseline Serum Urate Level With Cardiovascular Outcomes: Analysis of the Coronary Disease Cohort Study.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Cardiovascular Diseases; Coronary Artery Disease; | 2019 |
Utilization patterns and clinical outcomes of rasburicase administration according to tumor risk stratification.
Topics: Acute Kidney Injury; Aged; Female; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Neop | 2020 |
2018 updated European League Against Rheumatism evidence-based recommendations for the diagnosis of gout.
Topics: Gout; Humans; Hyperuricemia; Radiography; Risk Factors; Synovial Fluid; Tomography, X-Ray Computed; | 2020 |
Effect of hyperuricemia and treatment for hyperuricemia in Japanese hemodialysis patients: A cohort study.
Topics: Aged; Asian People; Cohort Studies; Female; Humans; Hyperuricemia; Japan; Male; Renal Dialysis; Uric | 2019 |
Termipaniculatones A-F, chalcone-flavonone heterodimers from Terminthia paniculata, and their protective effects on hyperuricemia and acute gouty arthritis.
Topics: Anacardiaceae; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Chalcone; Dose-Re | 2019 |
Anti-hyperuricemic effect of Alpinia oxyphylla seed extract by enhancing uric acid excretion in the kidney.
Topics: Alpinia; Animals; China; Gout; Humans; Hyperuricemia; Kidney; Male; Organic Anion Transport Protein | 2019 |
Pilot study: asymptomatic hyperuricemia patients with obesity and nonalcoholic fatty liver disease have increased risk of double contour sign.
Topics: Gout; Humans; Hyperuricemia; Non-alcoholic Fatty Liver Disease; Obesity; Pilot Projects; Ultrasonogr | 2020 |
Urate-lowering agents for asymptomatic hyperuricemia in stage 3 - 4 chronic kidney disease: Controversial role of kidney function.
Topics: Aged; Asymptomatic Diseases; Biomarkers; Comorbidity; Female; Glomerular Filtration Rate; Humans; Hy | 2019 |
Influence of Genetic and Non-Genetic Risk Factors for Serum Uric Acid Levels and Hyperuricemia in Mexicans.
Topics: Adolescent; Adult; ATP Binding Cassette Transporter, Subfamily G, Member 2; Child; Female; Genome-Wi | 2019 |
Cohort Study of Repeated Measurements of Serum Urate and Risk of Incident Atrial Fibrillation.
Topics: Adult; Atrial Fibrillation; C-Reactive Protein; China; Cohort Studies; Electrocardiography; Female; | 2019 |
Associations between blood lead, cadmium, and mercury levels with hyperuricemia in the Korean general population: A retrospective analysis of population-based nationally representative data.
Topics: Adult; Biomarkers; Cadmium; Cross-Sectional Studies; Female; Humans; Hyperuricemia; Lead; Male; Merc | 2019 |
Associations of Amino Acid and Acylcarnitine Profiles With Incident Hyperuricemia in Middle-Aged and Older Chinese Individuals.
Topics: Aged; Amino Acids; Carnitine; China; Female; Humans; Hyperuricemia; Incidence; Male; Middle Aged; Ri | 2020 |
Longitudinal association between serum uric acid levels and multiterritorial atherosclerosis.
Topics: Adult; Arteries; Asian People; Atherosclerosis; Cohort Studies; Constriction, Pathologic; Female; Hu | 2019 |
Factors influencing Urate Lowering Therapies prescription for asymptomatic hyperuricemia by general practitioners: a qualitative study.
Topics: Adult; Drug-Related Side Effects and Adverse Reactions; Family Practice; Female; General Practitione | 2019 |
Lychnophora pinaster ethanolic extract and its chemical constituents ameliorate hyperuricemia and related inflammation.
Topics: Animals; Anti-Inflammatory Agents; Asteraceae; Ethanol; Gout Suppressants; Hexanes; Hyperuricemia; L | 2019 |
Gender effect of hyperuricemia on the development of nonalcoholic fatty liver disease (NAFLD): A clinical analysis and mechanistic study.
Topics: Adult; Animals; Female; Humans; Hyperuricemia; Liver; Male; Middle Aged; Non-alcoholic Fatty Liver D | 2019 |
Switching from allopurinol to febuxostat: efficacy and safety in the treatment of hyperuricemia in renal transplant recipients.
Topics: Adult; Allografts; Allopurinol; Drug Substitution; Febuxostat; Female; Glomerular Filtration Rate; G | 2019 |
Age-related and gender-stratified differences in the association between high triglyceride and risk of hyperuricemia.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Female; Humans; Hyperuricemia; Logistic Models; Male; M | 2019 |
Allopurinol and the risk of prostate cancer.
Topics: Adult; Aged; Allopurinol; Case-Control Studies; Gout Suppressants; Humans; Hyperuricemia; Male; Midd | 2020 |
Gout and hyperuricaemia: a worldwide health issue of joints and beyond.
Topics: Global Health; Gout; Humans; Hyperuricemia; Prevalence; United States; Uric Acid | 2019 |
The prognostic value of serum uric acid in the acute phase of hemorrhagic stroke patients in black Africans.
Topics: Adult; Aged; Black People; Cameroon; Cohort Studies; Female; Follow-Up Studies; Hospitals, General; | 2019 |
The Effects of Ginsenosides and Anserine on the Up-Regulation of Renal Aquaporins 1-4 in Hyperuricemic Mice.
Topics: Animals; Anserine; Aquaporins; Blood Urea Nitrogen; Creatinine; Drug Synergism; Drug Therapy, Combin | 2019 |
Serum Uric Acid Levels and Serum Lipid Levels in Patients with Ischemic Cerebrovascular Accident.
Topics: Aged; Brain Ischemia; Cholesterol, HDL; Cross-Sectional Studies; Female; Humans; Hyperuricemia; Lipi | 2018 |
Causal effect of alcohol consumption on hyperuricemia using a Mendelian randomization design.
Topics: Alcohol Drinking; Aldehyde Dehydrogenase, Mitochondrial; Alleles; DNA; Female; Humans; Hyperuricemia | 2019 |
Association of dietary fiber intake with hyperuricemia in U.S. adults.
Topics: Adult; Aged; Cross-Sectional Studies; Diet; Dietary Fiber; Female; Fruit; Humans; Hyperuricemia; Mal | 2019 |
Serum uric acid level and subclinical coronary atherosclerosis in asymptomatic individuals: An observational cohort study.
Topics: Asymptomatic Diseases; Biomarkers; Computed Tomography Angiography; Coronary Angiography; Coronary A | 2019 |
Co-delivery of therapeutic protein and catalase-mimic nanoparticle using a biocompatible nanocarrier for enhanced therapeutic effect.
Topics: Animals; Aspergillus flavus; Biomimetic Materials; Catalase; Cell Line, Tumor; Drug Carriers; Female | 2019 |
Serum uric acid increases in patients with systemic autoimmune rheumatic diseases after 3 months of treatment with TNF inhibitors.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allantoin; Antirheumatic Agents; Autoimmune Diseases; Bi | 2019 |
Uric acid within the "normal" range predict 9-year cardiovascular mortality in older individuals. The InCHIANTI study.
Topics: Age Factors; Aged; Aged, 80 and over; Biomarkers; Cardiovascular Diseases; Cause of Death; Female; H | 2019 |
MiR-143-3p directly targets GLUT9 to reduce uric acid reabsorption and inflammatory response of renal tubular epithelial cells.
Topics: Animals; Base Sequence; Case-Control Studies; Chemokine CCL2; Disease Models, Animal; Gene Expressio | 2019 |
Cross-sectional association between non-soy legume consumption, serum uric acid and hyperuricemia: the PREDIMED-Plus study.
Topics: Aged; Cross-Sectional Studies; Fabaceae; Humans; Hyperuricemia; Metabolic Syndrome; Prevalence; Risk | 2020 |
Higher Pro-Inflammatory Dietary Score is Associated with Higher Hyperuricemia Risk: Results from the Case-Controlled Korean Genome and Epidemiology Study_Cardiovascular Disease Association Study.
Topics: Aged; Biomarkers; Case-Control Studies; Cross-Sectional Studies; Diet; Feeding Behavior; Female; Hum | 2019 |
Mediterranean diet intervention for patients with hyperuricemia: a pilot study.
Topics: Asymptomatic Diseases; Body Mass Index; Cholesterol, HDL; Cholesterol, LDL; Cohort Studies; Diet, Me | 2014 |
Hypothermia induced by adenosine 5'-monophosphate attenuates early stage injury in an acute gouty arthritis rat model.
Topics: Animals; Ankle Joint; Arthritis, Gouty; Disease Models, Animal; Hyperuricemia; Hypothermia, Induced; | 2013 |
What can asymptomatic hyperuricaemia and systemic inflammation in the absence of gout tell us?
Topics: Chemokine CCL2; Female; Gout; Humans; Hyperuricemia; Male; Monocytes; Uric Acid | 2013 |
[Case presentation--tophaceous gout].
Topics: Aged, 80 and over; Arthritis, Gouty; Drug Therapy, Combination; Febuxostat; Female; Follow-Up Studie | 2012 |
Association of uric acid with obesity and endothelial dysfunction in children and early adolescents.
Topics: Adolescent; Area Under Curve; Asian People; Biomarkers; Blood Pressure; Body Composition; Body Mass | 2013 |
Serum uric acid and outcome after acute ischemic stroke: PREMIER study.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Brain Ischemia; Chi-Square Distribution; Disability Eval | 2013 |
Comparative evaluation of single fixed dosing and weight-based dosing of rasburicase for tumor lysis syndrome.
Topics: Body Weight; Dose-Response Relationship, Drug; Drug Administration Schedule; Gout Suppressants; Huma | 2013 |
What are the key arguments against uric acid as a true risk factor for hypertension?
Topics: Animals; Blood Pressure; Disease Models, Animal; Humans; Hypertension; Hyperuricemia; Kidney; Risk F | 2013 |
Dose-response association of uncontrolled blood pressure and cardiovascular disease risk factors with hyperuricemia and gout.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Dose-Response Relationship, | 2013 |
Urinary angiotensinogen as a marker of intrarenal angiotensin II activity in adolescents with primary hypertension.
Topics: Adolescent; Angiotensin II; Angiotensinogen; Biomarkers; Body Mass Index; Chi-Square Distribution; C | 2013 |
High-dose prednisone in patients with heart failure and hyperuricemia: friend and foe?
Topics: Allopurinol; Female; Glucocorticoids; Gout Suppressants; Heart Failure; Humans; Hyperuricemia; Male; | 2013 |
No association between MTHFR C677T and serum uric acid levels among Japanese with ABCG2 126QQ and SLC22A12 258WW.
Topics: Adult; Age Factors; Aged; Asian People; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP | 2013 |
Higher serum uric acid and lipoprotein(a) are correlated with coronary spasm.
Topics: Acetylcholine; Aged; Angina Pectoris; Biomarkers; Chi-Square Distribution; Coronary Angiography; Cor | 2014 |
Positive association between perfluoroalkyl chemicals and hyperuricemia in children.
Topics: Adolescent; Alkanesulfonic Acids; Caprylates; Child; Cross-Sectional Studies; Female; Fluorocarbons; | 2013 |
Association between coronary collaterals and serum uric acid level in Chinese population with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Collateral Circulation; Coronary Circulation; Female; Humans; Hyperuricemia | 2013 |
Does serum uric acid level affect coronary collaterals in patients with acute coronary syndrome?
Topics: Acute Coronary Syndrome; Collateral Circulation; Coronary Circulation; Female; Humans; Hyperuricemia | 2013 |
Independent and conjoint associations of gout and hyperuricaemia with total and cardiovascular mortality.
Topics: Adult; Age Factors; Biomarkers; Cardiovascular Diseases; Female; Gout; Humans; Hyperuricemia; Incide | 2013 |
Association between vitamin D insufficiency and elevated serum uric acid among middle-aged and elderly Chinese Han women.
Topics: Adult; Aged; Asian People; Biomarkers; Blood Glucose; Fasting; Female; Humans; Hyperuricemia; Lipids | 2013 |
Relative and attributable diabetes risk associated with hyperuricemia in US veterans with gout.
Topics: Aged; Cohort Studies; Comorbidity; Diabetes Mellitus, Type 2; Female; Gout; Humans; Hyperuricemia; K | 2013 |
Hyperuricemia is an independent risk factor for new onset micro-albuminuria in a middle-aged and elderly population: a prospective cohort study in taiwan.
Topics: Age Factors; Aged; Aged, 80 and over; Albuminuria; Female; Humans; Hyperuricemia; Incidence; Male; M | 2013 |
[Risk factors for hyperuricemia in active and retired employees underwent physical examination].
Topics: Adult; Aged; Female; Humans; Hyperuricemia; Male; Middle Aged; Physical Examination; Prevalence; Ris | 2013 |
Hyperuricemia influences tryptophan metabolism via inhibition of multidrug resistance protein 4 (MRP4) and breast cancer resistance protein (BCRP).
Topics: Acute-Phase Proteins; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette | 2013 |
Paradoxical increase in uric acid level with allopurinol use in pyrazinamide-induced hyperuricaemia.
Topics: Adult; Allopurinol; Arthritis, Psoriatic; Humans; Hyperuricemia; Male; Pyrazinamide; Treatment Outco | 2013 |
Serum urate and incidence of kidney disease among veterans with gout.
Topics: Aged; Body Mass Index; Comorbidity; Gout; Humans; Hyperuricemia; Incidence; Kidney Diseases; Male; M | 2013 |
Uric acid induces oxidative stress and growth inhibition by activating adenosine monophosphate-activated protein kinase and extracellular signal-regulated kinase signal pathways in pancreatic β cells.
Topics: Adenylate Kinase; Animals; Anion Transport Proteins; Cell Line; Cell Proliferation; Enzyme Activatio | 2013 |
Cost-effectiveness of febuxostat in chronic gout.
Topics: Cost-Benefit Analysis; Dose-Response Relationship, Drug; Febuxostat; Gout; Gout Suppressants; Humans | 2014 |
Wuling san ameliorates urate under-excretion and renal dysfunction in hyperuricemic mice.
Topics: Animals; Drugs, Chinese Herbal; Glucose Transport Proteins, Facilitative; Humans; Hyperuricemia; Kid | 2013 |
Trp64Arg (rs4994) polymorphism of β3-adrenergic receptor gene is associated with hyperuricemia in a Chinese male population.
Topics: Adult; Aged; Asian People; Case-Control Studies; Genetic Predisposition to Disease; Genotype; Humans | 2013 |
Uric acid levels and all-cause mortality in peritoneal dialysis patients.
Topics: Aged; Cause of Death; Comorbidity; Female; Forecasting; Humans; Hyperuricemia; Kaplan-Meier Estimate | 2013 |
Type of uromodulin mutation and allelic status influence onset and severity of uromodulin-associated kidney disease in mice.
Topics: Age of Onset; Alleles; Animals; Body Weight; Cystatins; Disease Models, Animal; Disease Progression; | 2013 |
The association between uric acid and chronic kidney disease in Korean men: a 4-year follow-up study.
Topics: Adult; Age Factors; Alcohol Drinking; Asian People; Blood Pressure; Body Mass Index; Cohort Studies; | 2013 |
Serum uric acid and blood pressure in children at cardiovascular risk.
Topics: Adolescent; Age Factors; Blood Pressure; Body Mass Index; Cardiovascular Diseases; Child; Cohort Stu | 2013 |
Urate-induced acute renal failure and chronic inflammation in liver-specific Glut9 knockout mice.
Topics: Acute Kidney Injury; Animals; Crystallization; Diet, High-Fat; Glucose Transport Proteins, Facilitat | 2013 |
Serum uric acid is an independent predictor of metabolic syndrome in a Japanese health screening population.
Topics: Adult; Asian People; Biomarkers; Chi-Square Distribution; Female; Humans; Hyperuricemia; Incidence; | 2014 |
Survival impact of serum uric acid levels in children and adolescents.
Topics: Adolescent; Cardiovascular Diseases; Cause of Death; Child; Female; Humans; Hyperuricemia; Kidney Di | 2013 |
Hypouricemic effects of prednisone and allopurinol: an uneven playing field?
Topics: Allopurinol; Female; Glucocorticoids; Gout Suppressants; Heart Failure; Humans; Hyperuricemia; Male; | 2014 |
Reply to Day et al.--hypouricemic effect of prednisone in heart failure: possible mechanisms.
Topics: Allopurinol; Female; Glucocorticoids; Gout Suppressants; Heart Failure; Humans; Hyperuricemia; Male; | 2014 |
Population-specific effects of SLC17A1 genotype on serum urate concentrations and renal excretion of uric acid during a fructose load.
Topics: Fructose; Genotype; Healthy Volunteers; Humans; Hyperuricemia; Sodium-Phosphate Cotransporter Protei | 2014 |
Association of plasma uric acid with ischaemic heart disease and blood pressure: mendelian randomisation analysis of two large cohorts.
Topics: Adult; Aged; Blood Pressure; Body Mass Index; Denmark; Female; Humans; Hyperuricemia; Male; Mendelia | 2013 |
Effects of uric acid on endothelial dysfunction in early chronic kidney disease and its mechanisms.
Topics: Animals; Disease Models, Animal; Endothelin-1; Endothelium, Vascular; Hyperuricemia; Lipoproteins, L | 2013 |
Fructus Gardenia Extract ameliorates oxonate-induced hyperuricemia with renal dysfunction in mice by regulating organic ion transporters and mOIT3.
Topics: Animals; Blood Urea Nitrogen; Gardenia; Gene Expression Regulation; Humans; Hyperuricemia; Mice; Oxo | 2013 |
Autophagy sequesters damaged lysosomes to control lysosomal biogenesis and kidney injury.
Topics: Animals; Autophagy; Autophagy-Related Protein 7; Cell Line; Dipeptides; Green Fluorescent Proteins; | 2013 |
Serum uric acid levels and long-term outcomes in chronic kidney disease.
Topics: Aged; Allopurinol; Biomarkers; Cause of Death; Female; Glomerular Filtration Rate; Gout Suppressants | 2014 |
Elevated serum uric acid in nondiabetic people mark pro-inflammatory state and HDL dysfunction and independently predicts coronary disease.
Topics: Apolipoproteins B; Biomarkers; Cholesterol, HDL; Cohort Studies; Coronary Disease; Diabetes Mellitus | 2013 |
Fructose-induced hyperuricemia is associated with a decreased renal uric acid excretion in humans.
Topics: Adult; Fructose; Humans; Hyperuricemia; Male; Uric Acid; Young Adult | 2013 |
Common missense variant of monocarboxylate transporter 9 (MCT9/SLC16A9) gene is associated with renal overload gout, but not with all gout susceptibility.
Topics: Aged; Female; Gene Expression; Gene Frequency; Genetic Predisposition to Disease; Genome-Wide Associ | 2013 |
3,4-Dihydroxy-5-nitrobenzaldehyde (DHNB) is a potent inhibitor of xanthine oxidase: a potential therapeutic agent for treatment of hyperuricemia and gout.
Topics: Administration, Oral; Allopurinol; Animals; Antioxidants; Benzaldehydes; Catechols; Cell-Free System | 2013 |
[High concentration uric acid regulates endothelial function via miR-155].
Topics: Cells, Cultured; Down-Regulation; Human Umbilical Vein Endothelial Cells; Humans; Hyperuricemia; Mic | 2013 |
An inverted J-shaped association of serum uric acid with muscle strength among Japanese adult men: a cross-sectional study.
Topics: Adult; Age Factors; Asian People; Biomarkers; Cross-Sectional Studies; Hand Strength; Humans; Hyperu | 2013 |
Sugar-sweetened beverage consumption: a risk factor for prevalent gout with SLC2A9 genotype-specific effects on serum urate and risk of gout.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Beverages; Case-Control Studies; Dietary Sucrose; Female | 2014 |
Testosterone replacement elevates the serum uric acid levels in patients with female to male gender identity disorder.
Topics: Adult; Androgens; Body Composition; Creatinine; Dose-Response Relationship, Drug; Female; Follow-Up | 2013 |
Prevalence of metabolic syndrome and its association with serum uric acid levels in Bangkok Thailand.
Topics: Adult; Blood Pressure; Body Weights and Measures; Cross-Sectional Studies; Female; Humans; Hyperuric | 2013 |
Fuzzy optimization for detecting enzyme targets of human uric acid metabolism.
Topics: Algorithms; Diet; Drug Design; Drug Discovery; Fuzzy Logic; Humans; Hyperuricemia; Kinetics; Lesch-N | 2013 |
A gender-specific analysis of association between hyperuricaemia and cardiovascular events in patients with coronary artery disease.
Topics: Aged; Aged, 80 and over; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Dis | 2013 |
The impact of serum uric acid level on arterial stiffness and carotid atherosclerosis: the Korean Multi-Rural Communities Cohort study.
Topics: Adult; Aged; Ankle Brachial Index; Asian People; Carotid Arteries; Carotid Artery Diseases; Carotid | 2013 |
Study on the correlation between constituents detected in serum from Rhizoma Smilacis Glabrae and the reduction of uric acid levels in hyperuricemia.
Topics: Animals; Hyperuricemia; Male; Plant Extracts; Rats; Rats, Sprague-Dawley; Rhizome; Smilax; Uric Acid | 2013 |
Serum uric acid level in newly diagnosed essential hypertension in a Nepalese population: a hospital based cross sectional study.
Topics: Adult; Aged; Cross-Sectional Studies; Essential Hypertension; Female; Humans; Hypertension; Hyperuri | 2014 |
Febuxostat for treating allopurinol-resistant hyperuricemia in patients with chronic kidney disease.
Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Creatinine; Enzyme Inhibitors; Febuxostat; Glomerular F | 2014 |
Serum concentration of uric acid associated with prehypertension among Chinese population.
Topics: Adult; Biomarkers; China; Cross-Sectional Studies; Female; Health Surveys; Humans; Hyperuricemia; Li | 2014 |
Workshop report: 4th European crystal network meeting.
Topics: Calcium; Calcium Phosphates; Crystallization; Gout; Humans; Hyperuricemia; Uric Acid | 2013 |
Relationship between serum uric acid and all-cause and cardiovascular mortality in patients treated with peritoneal dialysis.
Topics: Adult; Biomarkers; Cardiovascular Diseases; Cohort Studies; Female; Follow-Up Studies; Humans; Hyper | 2014 |
Hyperuricemia in patients with chronic plaque psoriasis.
Topics: Adult; Aged; Arthritis, Psoriatic; Case-Control Studies; Cross-Sectional Studies; Female; Humans; Hy | 2014 |
[Effect of total saponin of Dioscorea on chronic hyperuricemia and expression of URAT1 in rats].
Topics: Animals; Anion Transport Proteins; Benzbromarone; Dioscorea; Gout Suppressants; Hyperuricemia; Kidne | 2013 |
Hyperuricemia causes pancreatic β-cell death and dysfunction through NF-κB signaling pathway.
Topics: Animals; Apoptosis; Cell Death; Cell Survival; Cells, Cultured; Glucose; Hyperuricemia; Insulin; Ins | 2013 |
Asymmetric and symmetric dimethylarginine in adolescents with hyperuricemia.
Topics: Adolescent; Arginine; Biomarkers; Case-Control Studies; Child; Female; Humans; Hyperuricemia; Male; | 2013 |
Improvement in the management of gout is vital and overdue: an audit from a UK primary care medical practice.
Topics: Aged; Blood Glucose; Diet Therapy; Disease Management; Female; Glomerular Filtration Rate; Gout; Gou | 2013 |
Features of urate deposition in patients with gouty arthritis of the foot using dual-energy computed tomography.
Topics: Adult; Aged; Aged, 80 and over; Arthritis, Gouty; Calcaneus; Female; Foot; Humans; Hyperuricemia; Ma | 2015 |
Associations between concentrations of uric acid with concentrations of vitamin A and beta-carotene among adults in the United States.
Topics: Adult; beta Carotene; Cross-Sectional Studies; Dietary Supplements; Female; Humans; Hyperuricemia; M | 2013 |
CaseBook challenges: Managing gout, hyperuricemia and comorbidities -- dialogue with the experts.
Topics: Allopurinol; Comorbidity; Disease Management; Drug Administration Schedule; Febuxostat; Gout; Gout S | 2014 |
Uric acid suppresses 1 alpha hydroxylase in vitro and in vivo.
Topics: 25-Hydroxyvitamin D3 1-alpha-Hydroxylase; Animals; Cross-Sectional Studies; Dose-Response Relationsh | 2014 |
Association of uric acid and carotid artery disease in patients with ischemic stroke.
Topics: Adult; Aged; Aged, 80 and over; Carotid Intima-Media Thickness; Carotid Stenosis; Female; Humans; Hy | 2014 |
Late diagnosis of Lesch-Nyhan disease variant.
Topics: Adult; Allopurinol; Diuretics; Genetic Counseling; Gout; Gout Suppressants; Humans; Hyperuricemia; H | 2013 |
Serum uric acid concentration and asymptomatic hyperuricemia with subclinical organ damage in general population.
Topics: Aged; Aged, 80 and over; Albuminuria; Biomarkers; Cross-Sectional Studies; Humans; Hypertension; Hyp | 2014 |
Risk factors for incident hyperuricemia during mid-adulthood in African American and white men and women enrolled in the ARIC cohort study.
Topics: Black or African American; Cohort Studies; Female; Humans; Hyperuricemia; Incidence; Male; Middle Ag | 2013 |
Bariatric surgery in severely obese adolescents improves major comorbidities including hyperuricemia.
Topics: Adolescent; Bariatric Surgery; Biomarkers; Case-Control Studies; Child; Comorbidity; Female; Gastric | 2014 |
Betaine reduces serum uric acid levels and improves kidney function in hyperuricemic mice.
Topics: Acetylglucosaminidase; Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding | 2014 |
Serum uric acid levels and non-alcoholic fatty liver disease in Uyghur and Han ethnic groups in northwestern China.
Topics: Adult; Body Mass Index; China; Fatty Liver; Feeding Behavior; Female; Humans; Hyperuricemia; Life St | 2013 |
Effect of processing parameters for electrocatalytic properties of SnO(2) thin film matrix for uric acid biosensor.
Topics: Biosensing Techniques; Electrochemical Techniques; Electrochemistry; Enzymes, Immobilized; Humans; H | 2014 |
Prevalence of hyperuricemia and the relationship between serum uric acid and metabolic syndrome in the Asian Mongolian area.
Topics: Adult; Aged; Aged, 80 and over; Cross-Sectional Studies; Female; Humans; Hyperuricemia; Incidence; M | 2014 |
The effects of gout on left atrial volume remodelling: a prospective echocardiographic study.
Topics: Adult; Aged; Arthritis, Gouty; Atrial Remodeling; Cardiac Volume; Case-Control Studies; Cross-Sectio | 2014 |
The frequency of single nucleotide polymorphisms and their association with uric acid concentration based on data from genome-wide association studies in the Korean population.
Topics: Adult; Arthritis, Rheumatoid; Asian People; Cohort Studies; Female; Gene Frequency; Genome-Wide Asso | 2014 |
Plasma uric acid level indicates tubular interstitial leisions at early stage of IgA nephropathy.
Topics: Adult; Biomarkers; Early Diagnosis; Female; Glomerulonephritis, IGA; Humans; Hyperuricemia; Male; Ne | 2014 |
Uric acid levels predict future blood pressure and new onset hypertension in the general Japanese population.
Topics: Adult; Antihypertensive Agents; Asian People; Biomarkers; Blood Pressure; Chi-Square Distribution; F | 2014 |
Serum uric acid and new-onset hypertension: a possible therapeutic avenue?
Topics: Asian People; Blood Pressure; Female; Humans; Hypertension; Hyperuricemia; Male; Uric Acid | 2014 |
Hyperuricemia is a significant risk factor for the onset of chronic kidney disease.
Topics: Adult; Age Factors; Cross-Sectional Studies; Female; Glomerular Filtration Rate; Humans; Hyperuricem | 2014 |
ABCG2 dysfunction causes hyperuricemia due to both renal urate underexcretion and renal urate overload.
Topics: Alleles; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; | 2014 |
Serum uric acid concentration and asymptomatic hyperuricemia.
Topics: Albuminuria; Humans; Hypertension; Hyperuricemia; Male; Uric Acid; Vascular Stiffness | 2014 |
Smilax riparia reduces hyperuricemia in mice as a potential treatment of gout.
Topics: Animals; Disease Models, Animal; Down-Regulation; Drugs, Chinese Herbal; Gout; Gout Suppressants; Hy | 2014 |
Effects on serum uric acid by difference of the renal protective effects with atorvastatin and rosuvastatin in chronic kidney disease patients.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Female; Fluorobenzenes; Glomerular Filtration Rate; He | 2014 |
Association of hyperuricemia with cardiac events in patients with atrial fibrillation.
Topics: Aged; Atrial Fibrillation; Biomarkers; Cause of Death; Female; Glomerular Filtration Rate; Hospitali | 2014 |
[Effect of total saponin of dioscorea on uric acid excretion indicators in chronic hyperuricemia rats].
Topics: Animals; Dioscorea; Hyperuricemia; Male; Rats; Rats, Sprague-Dawley; Saponins; Uric Acid | 2014 |
The degree of asymptomatic hyperuricemia and the risk of gout. A retrospective analysis of a large cohort.
Topics: Adult; Aged; Aged, 80 and over; Alcohol Drinking; Asymptomatic Diseases; Cohort Studies; Female; Glo | 2014 |
The relationship of serum uric acid with non-alcoholic fatty liver disease.
Topics: Adult; Anthropometry; Humans; Hyperuricemia; Male; Multivariate Analysis; Non-alcoholic Fatty Liver | 2014 |
Reply to letter to the editor from Professor Viroj Wiwanitkit, Bankok, Thailand.
Topics: Albuminuria; Humans; Hypertension; Hyperuricemia; Male; Uric Acid; Vascular Stiffness | 2014 |
Serum uric acid and the risk of mortality during 23 years follow-up in the Scottish Heart Health Extended Cohort Study.
Topics: Adult; Aged; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus; Dyslipidemias; Female; Foll | 2014 |
Fixed, low-dose rasburicase for the treatment or prevention of hyperuricemia in adult oncology patients.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Drug Costs; Female; Gout Suppressants; Hospital Costs; H | 2015 |
Is lower uric acid level better? A combined cross-sectional and longitudinal study in the elderly.
Topics: Aged; Blood Glucose; Blood Pressure; Cross-Sectional Studies; Female; Humans; Hyperuricemia; Inciden | 2014 |
ALDR enhanced endothelial injury in hyperuricemia screened using SILAC.
Topics: Aldehyde Reductase; Antioxidants; Gene Expression Regulation, Enzymologic; Human Umbilical Vein Endo | 2014 |
Association and interaction effect between VEGF receptor-2 (VEGFR-2) gene polymorphisms and dietary pattern on blood uric acid in Malays and Indians.
Topics: Adult; Animals; Body Mass Index; Diet; Dietary Proteins; Fast Foods; Female; Food; Fruit; Genotype; | 2012 |
Association between serum uric acid levels and cardiovascular disease in middle-aged and elderly Chinese individuals.
Topics: Age Factors; Aged; Asian People; Biomarkers; Cardiovascular Diseases; China; Cross-Sectional Studies | 2014 |
Treatment of asymptomatic hyperuricemia and prevention of vascular disease: a decision analytic approach.
Topics: Aged; Allopurinol; Decision Support Techniques; Female; Follow-Up Studies; Gout Suppressants; Humans | 2014 |
Identification of antihyperuricemic peptides in the proteolytic digest of shark cartilage water extract using in vivo activity-guided fractionation.
Topics: Amino Acid Sequence; Animal Fins; Animals; Digestion; Gout Suppressants; Humans; Hyperuricemia; Male | 2014 |
Efficacy and safety of febuxostat in the treatment of hyperuricemia in stable kidney transplant recipients.
Topics: Adult; Aged; Febuxostat; Female; Glomerular Filtration Rate; Gout Suppressants; Humans; Hyperuricemi | 2014 |
[Effect of jianpihuashi decoction on rats with hyperuricemia].
Topics: Allopurinol; Animals; Blood Urea Nitrogen; Creatinine; Disease Models, Animal; Drug Combinations; Dr | 2013 |
Serum uric acid as a risk predictor for erectile dysfunction.
Topics: Biomarkers; Cardiovascular Diseases; Case-Control Studies; Confidence Intervals; Erectile Dysfunctio | 2014 |
Interaction of inflammation, hyperuricemia, and the prevalence of hypertension among adults free of metabolic syndrome: NHANES 2009-2010.
Topics: Adult; Biomarkers; C-Reactive Protein; Cross-Sectional Studies; Female; Humans; Hypertension; Hyperu | 2014 |
Maternal hyperuricemia in normotensive singleton pregnancy, a prenatal finding with continuous perinatal and postnatal effects, a prospective cohort study.
Topics: Adult; Blood Pressure; Confidence Intervals; Delivery, Obstetric; Female; Follow-Up Studies; Gestati | 2014 |
Uric acid induces endothelial dysfunction by vascular insulin resistance associated with the impairment of nitric oxide synthesis.
Topics: Animals; Arterial Pressure; Cells, Cultured; Endothelin-1; Endothelium, Vascular; Human Umbilical Ve | 2014 |
Pretreatment with Jieduxiezhuo decoction impedes elevations in serum uric acid levels in mice.
Topics: Animals; Disease Models, Animal; Drugs, Chinese Herbal; Humans; Hyperuricemia; Male; Mice; Uric Acid | 2013 |
Relationship between serum uric acid levels and hypertension among Japanese individuals not treated for hyperuricemia and hypertension.
Topics: Adult; Asian People; Blood Pressure; Cross-Sectional Studies; Female; Humans; Hypertension; Hyperuri | 2014 |
Serum uric acid and its relationship with metabolic syndrome and cardiovascular risk profile in patients with hypertension: insights from the I-DEMAND study.
Topics: Aged; Albuminuria; Biomarkers; Body Mass Index; Cardiovascular Diseases; Cohort Studies; Cross-Secti | 2014 |
Relationships between mild hyperuricaemia and aortic stiffness in untreated hypertensive patients.
Topics: Adult; Albuminuria; Aorta; Body Mass Index; Cross-Sectional Studies; Female; Humans; Hypertension; H | 2014 |
Serum uric acid is associated with arterial stiffness in men with newly diagnosed type 2 diabetes mellitus.
Topics: Adult; Age Factors; Atherosclerosis; C-Reactive Protein; Carotid Arteries; China; Cross-Sectional St | 2014 |
Association of serum uric acid with level of blood pressure in type 2 diabetic patients.
Topics: Aged; Biomarkers; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; | 2014 |
Prevalence of hyperuricemia among Chinese adults: a national cross-sectional survey using multistage, stratified sampling.
Topics: Adult; Age Distribution; Aged; Area Under Curve; Biomarkers; China; Cross-Sectional Studies; Female; | 2014 |
Effect of urate-lowering therapies on renal disease progression in patients with hyperuricemia.
Topics: Adrenal Cortex Hormones; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Colchicine; Databases | 2014 |
Hyperuricaemia in congenital heart disease patients.
Topics: Adolescent; Adult; Biomarkers; C-Reactive Protein; Female; Follow-Up Studies; Heart Defects, Congeni | 2015 |
Aging, not menopause, is associated with higher prevalence of hyperuricemia among older women.
Topics: Adult; Aged; Aging; Body Mass Index; Cross-Sectional Studies; Diuretics; Female; Glomerular Filtrati | 2014 |
Anakinra treatment in patients with gout and type 2 diabetes.
Topics: Aged; Aged, 80 and over; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; | 2015 |
The application of dual-energy computed tomography in the diagnosis of acute gouty arthritis.
Topics: Adult; Aged; Aged, 80 and over; Arthritis, Gouty; Case-Control Studies; Female; Follow-Up Studies; H | 2014 |
Uricaemia and ejection fraction in elderly heart failure outpatients.
Topics: Aged; Female; Heart Failure; Humans; Hyperuricemia; Male; Outpatients; Prospective Studies; Stroke V | 2014 |
High uric acid directly inhibits insulin signalling and induces insulin resistance.
Topics: Acetylcysteine; Animals; Antioxidants; Disease Models, Animal; Glucose Intolerance; Hep G2 Cells; Hu | 2014 |
Low protein diet inhibits uric acid synthesis and attenuates renal damage in streptozotocin-induced diabetic rats.
Topics: Albuminuria; Animals; Cell Proliferation; Cell Size; Diabetes Mellitus, Experimental; Diabetic Nephr | 2014 |
The association of albuminuria with tubular reabsorption of uric acid: results from a general population cohort.
Topics: Absorption; Adult; Albuminuria; Cardiovascular Diseases; Chi-Square Distribution; Disease Progressio | 2014 |
Uric acid as a potential mediator of cardiovascular morbidity in obstructive sleep apnea syndrome.
Topics: Cardiovascular Diseases; Cohort Studies; Humans; Hyperuricemia; Risk Factors; Sleep Apnea, Obstructi | 2014 |
A polymorphism in the major gene regulating serum uric acid associates with clinic SBP and the white-coat effect in a family-based study.
Topics: Animals; Blood Pressure Monitoring, Ambulatory; Genotype; Glucose Transport Proteins, Facilitative; | 2014 |
[82-year-old man with acute coronary syndrome and unclear arthropathy].
Topics: Absorptiometry, Photon; Acute Coronary Syndrome; Aged, 80 and over; Arthritis, Gouty; Comorbidity; C | 2014 |
Uric acid and risk of periprocedural myocardial infarction in patients undergoing percutaneous coronary intervention.
Topics: Aged; Biomarkers; Diabetic Nephropathies; Female; Humans; Hyperuricemia; Intraoperative Complication | 2014 |
Serum uric acid and target organ damage in essential hypertension.
Topics: Adult; Aged; Albuminuria; Biomarkers; Case-Control Studies; Cross-Sectional Studies; Female; Humans; | 2014 |
Serum uric acid level and cardiovascular risks in hemodialysis patients: an Algerian cohort study.
Topics: Adult; Aged; Algeria; Cardiovascular Diseases; Female; Humans; Hyperuricemia; Kidney Failure, Chroni | 2014 |
The methanol extract of Euonymus laxiflorus, Rubia lanceolata and Gardenia jasminoides inhibits xanthine oxidase and reduce serum uric acid level in rats.
Topics: Animals; Disease Models, Animal; Euonymus; Formaldehyde; Gardenia; Gout; Hyperuricemia; Nociception; | 2014 |
Anti-hyperuricemic and nephroprotective effects of Rhizoma Dioscoreae septemlobae extracts and its main component dioscin via regulation of mOAT1, mURAT1 and mOCT2 in hypertensive mice.
Topics: Animals; Creatinine; Dioscorea; Diosgenin; Dose-Response Relationship, Drug; Drugs, Chinese Herbal; | 2014 |
Ethnic differences in ATP-binding cassette transporter, sub-family G, member 2 (ABCG2/BCRP): genotype combinations and estimated functions.
Topics: Asian People; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transpor | 2014 |
A new xanthine oxidase inhibitor: the uric acid reduction and additional efficacy in CKD patients.
Topics: Enzyme Inhibitors; Febuxostat; Humans; Hyperuricemia; Nitriles; Pyridines; Renal Insufficiency, Chro | 2014 |
Blood lipid profile and BMI-Z-score in adolescents with hyperuricemia.
Topics: Adolescent; Body Mass Index; Cholesterol, HDL; Cholesterol, LDL; Female; Humans; Hypertension; Hyper | 2015 |
Sweetened beverage consumption and the risk of hyperuricemia in Mexican adults: a cross-sectional study.
Topics: Adolescent; Adult; Aged; Beverages; Body Mass Index; Causality; Cohort Studies; Cross-Sectional Stud | 2014 |
Hyperuricaemia: a marker of increased cardiovascular risk in rheumatic patients: analysis of the ACT-CVD cohort.
Topics: Aged; Arthritis, Rheumatoid; Biomarkers; Cardiovascular Diseases; Cohort Studies; Cross-Sectional St | 2014 |
The impact of elevation of serum uric acid level on the natural history of glomerular filtration rate (GFR) and its sex difference.
Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Female; Free Radical Scavengers; Glomerular Filtration | 2014 |
Serum uric acid and arterial stiffness in hypertensive chronic kidney disease patients: sex-specific variations.
Topics: Adult; Aged; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circadian Rhythm; Comorbidity; C | 2014 |
Gender difference in the association of hyperuricemia with hypertension in a middle-aged Chinese population.
Topics: Asian People; Body Mass Index; China; Cross-Sectional Studies; Female; Humans; Hypertension; Hyperur | 2014 |
Uric acid levels, kidney function, and cardiovascular mortality in US adults: National Health and Nutrition Examination Survey (NHANES) 1988-1994 and 1999-2002.
Topics: Adult; Aged; Cardiovascular Diseases; Cause of Death; Confounding Factors, Epidemiologic; Creatinine | 2014 |
Riparoside B and timosaponin J, two steroidal glycosides from Smilax riparia, resist to hyperuricemia based on URAT1 in hyperuricemic mice.
Topics: Animals; Disease Models, Animal; Drugs, Chinese Herbal; Gene Expression Regulation; Glycosides; Hype | 2014 |
Common dysfunctional variants of ABCG2 have stronger impact on hyperuricemia progression than typical environmental risk factors.
Topics: Asian People; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transpor | 2014 |
The effect of coffee, tea, and caffeine consumption on serum uric acid and the risk of hyperuricemia in Korean Multi-Rural Communities Cohort.
Topics: Aged; Caffeine; Coffee; Feeding Behavior; Female; Humans; Hyperuricemia; Male; Middle Aged; Multivar | 2015 |
ABCG2 dysfunction increases the risk of renal overload hyperuricemia.
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Gene Fre | 2014 |
Hyperuricemia in hematologic malignancies is caused by an insufficient urinary excretion.
Topics: Aged; Female; Hematologic Neoplasms; Humans; Hyperuricemia; Kidney; Male; Middle Aged; Retrospective | 2014 |
Uric acid as a cardiorenal risk factor - ready for prime-time?
Topics: Cardio-Renal Syndrome; Gout Suppressants; Humans; Hyperuricemia; Risk Factors; Uric Acid | 2014 |
Hyperuricemia and incident atrial fibrillation in a normotensive elderly population in Taiwan.
Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Blood Pressure; Electrocardiography; Female; Follow-Up | 2014 |
The effect of vitamin C intake on the risk of hyperuricemia and serum uric acid level in Korean Multi-Rural Communities Cohort.
Topics: Aged; Ascorbic Acid; Cohort Studies; Cross-Sectional Studies; Female; Humans; Hyperuricemia; Male; M | 2014 |
In vitro and in vivo studies on adlay-derived seed extracts: phenolic profiles, antioxidant activities, serum uric acid suppression, and xanthine oxidase inhibitory effects.
Topics: Animals; Antioxidants; Chlorogenic Acid; Coix; Coumaric Acids; Enzyme Inhibitors; Free Radical Scave | 2014 |
Administered chrysanthemum flower oil attenuates hyperuricemia: mechanism of action as revealed by DNA microarray analysis.
Topics: Animals; Cattle; Chrysanthemum; Flowers; Hyperuricemia; Liver; Male; Oligonucleotide Array Sequence | 2014 |
Switching from allopurinol to febuxostat for the treatment of hyperuricemia and renal function in patients with chronic kidney disease.
Topics: Aged; Aged, 80 and over; Allopurinol; Disease Progression; Drug Substitution; Febuxostat; Female; Go | 2014 |
Associations of non-high density lipoprotein cholesterol and traditional blood lipid profiles with hyperuricemia among middle-aged and elderly Chinese people: a community-based cross-sectional study.
Topics: Aged; Area Under Curve; Biomarkers; China; Cholesterol, HDL; Cholesterol, LDL; Cross-Sectional Studi | 2014 |
Attenuating the mortality risk of high serum uric acid: the role of physical activity underused.
Topics: Adult; Aged; Asymptomatic Diseases; Cause of Death; Cohort Studies; Diabetes Mellitus; Exercise; Fem | 2015 |
A slight increase within the normal range of serum uric acid and the decline in renal function: associations in a community-based population.
Topics: Aged; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Hyperuricemia; Japan; Male; Mid | 2014 |
Clinical characteristics of and relationship between metabolic components and renal function among patients with early-onset juvenile tophaceous gout.
Topics: Adolescent; Adult; Age of Onset; Child; Female; Gout; Humans; Hyperuricemia; Kidney; Male; Uric Acid | 2014 |
[Clinical value of the determination of markers for endothelial dysfunction (endothelin-1, microalbuminuria) and tubulointerstitial tissue lesion (β2-microglobulin, monocyte chemotactic protein-1) in hypertensive patients with uric acid metabolic disorder
Topics: Albuminuria; beta 2-Microglobulin; Biomarkers; Chemokine CCL2; Comorbidity; Endothelin-1; Endotheliu | 2014 |
Effects of Smilaxchinoside A and Smilaxchinoside C, two steroidal glycosides from Smilax riparia, on hyperuricemia in a mouse model.
Topics: Animals; Disease Models, Animal; Drugs, Chinese Herbal; Glucose Transport Proteins, Facilitative; Gl | 2014 |
Early-onset metabolic syndrome in mice lacking the intestinal uric acid transporter SLC2A9.
Topics: Allopurinol; Animals; Body Composition; Calorimetry; Echocardiography; Enterocytes; Glucose Transpor | 2014 |
Tubular urate transporter gene polymorphisms differentiate patients with gout who have normal and decreased urinary uric acid excretion.
Topics: Aged; Alleles; Female; Gout; Humans; Hyperuricemia; Male; Middle Aged; Organic Anion Transporters; P | 2014 |
Association of serum uric acid levels to inflammation biomarkers and endothelial dysfunction in obese prepubertal children.
Topics: Biomarkers; Body Mass Index; C-Reactive Protein; Child; Cross-Sectional Studies; Endothelium, Vascul | 2015 |
High uric acid level associated with increased arterial stiffness in apparently healthy women.
Topics: Adult; Aged; Alcohol Drinking; Ankle Brachial Index; Anthropometry; Asymptomatic Diseases; Blood Glu | 2014 |
A pilot study on dual-energy computed tomography for detection of urate deposits in renal transplant patients with asymptomatic hyperuricemia.
Topics: Adult; Arthrography; Female; Follow-Up Studies; Gout; Humans; Hyperuricemia; Joints; Kidney; Kidney | 2014 |
Mortality predictive role of serum uric acid in diabetic hemodialysis patients.
Topics: Aged; Biomarkers; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus; Female; Follow-Up Studies | 2014 |
Usefulness of the uric acid and CHA₂DS₂-VASc score in prediction of left atrial thrombosis in patients with mitral stenosis and sinus rhythm.
Topics: Adult; Biomarkers; Decision Support Techniques; Echocardiography, Transesophageal; Female; Heart Atr | 2015 |
Urate transporters: transforming the face of hyperuricemia and gout.
Topics: Female; Gout; Humans; Hyperuricemia; Male; Organic Anion Transporters; Polymorphism, Single Nucleoti | 2014 |
Association of serum uric acid and coronary artery disease in premenopausal women.
Topics: Adult; Coronary Angiography; Coronary Artery Disease; Cross-Sectional Studies; Female; Humans; Hyper | 2014 |
Screening and characterization of purine nucleoside degrading lactic acid bacteria isolated from Chinese sauerkraut and evaluation of the serum uric acid lowering effect in hyperuricemic rats.
Topics: Animals; Anti-Bacterial Agents; Bacterial Adhesion; Bile Acids and Salts; Brassica; Diet; Fermentati | 2014 |
Uricaemia and left ventricular mass in hypertensive patients.
Topics: Blood Glucose; Cross-Sectional Studies; Echocardiography; Female; Humans; Hypertension; Hypertrophy, | 2014 |
Use of urinary metabolomics to evaluate the effect of hyperuricemia on the kidney.
Topics: Acute Kidney Injury; Animals; Blood Urea Nitrogen; Creatinine; Hyperuricemia; Interleukin-6; Kidney; | 2014 |
[Insulin resistance and components of metabolic syndrome, analysis by gender and stage of adolescence].
Topics: Adipose Tissue; Adolescent; Age Factors; Blood Glucose; Body Mass Index; Child; Cholesterol; Dyslipi | 2014 |
Short communication: Effect of commercial or depurinized milk diet on plasma advanced oxidation protein products, cardiovascular markers, and bone marrow CD34+ stem cell potential in rat experimental hyperuricemia.
Topics: Advanced Oxidation Protein Products; Allopurinol; Animals; Antigens, CD34; Biomarkers; Bone Marrow; | 2014 |
A possible role of serum uric acid as a marker of metabolic syndrome.
Topics: Adult; Asian People; Biomarkers; Body Mass Index; Cohort Studies; Healthy Volunteers; Humans; Hyperu | 2014 |
Gout: a curable disease that often is undertreated. Long-term treatment is proven and available, but most patients and their physicians continue to take a short-term approach.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Diet; Gout; Gout Suppressants; Humans; Hyperuricemia; Patie | 2014 |
Hyperuricemia is a risk factor for the onset of impaired fasting glucose in men with a high plasma glucose level: a community-based study.
Topics: Adult; Blood Glucose; Fasting; Glucose Intolerance; Humans; Hyperuricemia; Male; Middle Aged; Predic | 2014 |
Total saponins from Discorea nipponica ameliorate urate excretion in hyperuricemic mice.
Topics: Animals; Creatinine; Dioscorea; Disease Models, Animal; Drugs, Chinese Herbal; Gene Expression Regul | 2014 |
Serum uric acid and disorders of glucose metabolism: the role of glycosuria.
Topics: Adult; Age Factors; Blood Glucose; Brazil; Community Health Services; Comorbidity; Cross-Sectional S | 2014 |
Association between serum uric acid and mortality in a Chinese population of hypertensive patients.
Topics: Aged; Cause of Death; China; Female; Humans; Hypertension; Hyperuricemia; Incidence; Male; Middle Ag | 2015 |
Pallidifloside D, a saponin glycoside constituent from Smilax riparia, resist to hyperuricemia based on URAT1 and GLUT9 in hyperuricemic mice.
Topics: Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Down-Regulation; Glucose Transpor | 2014 |
A genetic marker of uric acid level, carotid atherosclerosis, and arterial stiffness: a family-based study.
Topics: Adult; Alleles; Biomarkers; Carotid Artery Diseases; Carotid Intima-Media Thickness; Cross-Sectional | 2015 |
Effects of chicory inulin on serum metabolites of uric acid, lipids, glucose, and abdominal fat deposition in quails induced by purine-rich diets.
Topics: Abdominal Fat; Acetyl-CoA Carboxylase; Animals; Blood Glucose; Cichorium intybus; Diet; Disease Mode | 2014 |
Soluble ligand CD40 and uric acid as markers of atheromatosis in patients with obstructive sleep apnea.
Topics: Adult; Atherosclerosis; Biomarkers; Case-Control Studies; CD40 Ligand; Female; Humans; Hypertension; | 2015 |
Uric acid promotes chemokine and adhesion molecule production in vascular endothelium via nuclear factor-kappa B signaling.
Topics: Animals; Atherosclerosis; Cell Adhesion; Cell Adhesion Molecules; Cell Survival; Chemokine CCL2; Che | 2015 |
Uric acid levels and the risk of Contrast Induced Nephropathy in patients undergoing coronary angiography or PCI.
Topics: Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Diseases; Choleste | 2015 |
Effects of uric acid on hearts of rats with chronic kidney disease.
Topics: Allopurinol; Animals; Disease Models, Animal; Drug Evaluation, Preclinical; Gout Suppressants; Heart | 2014 |
High uric acid level is a risk factor for progression of IgA nephropathy with chronic kidney disease stage G3a.
Topics: Biomarkers; Biopsy; Chi-Square Distribution; Disease Progression; Female; Glomerulonephritis, IGA; H | 2015 |
Re: Effect of vitamin C supplementation on serum uric acid in patients undergoing hemodialysis: a randomized controlled trial.
Topics: Ascorbic Acid; Dietary Supplements; Female; Humans; Hyperuricemia; Male; Uric Acid; Vitamins | 2014 |
Does obesity or hyperuricemia influence lithogenic risk profile in children with urolithiasis?
Topics: Adolescent; Child; Electrolytes; Female; Humans; Hyperuricemia; Male; Obesity; Risk Factors; Uric Ac | 2015 |
Hyperuricemia in patients with chronic plaque psoriasis.
Topics: Adult; Body Mass Index; Female; Humans; Hypertension; Hyperuricemia; Italy; Male; Middle Aged; Obesi | 2014 |
Association of hyperuricemia with conventional cardiovascular risk factors in elderly patients.
Topics: Age Factors; Aged; Cardiovascular Diseases; Female; Humans; Hyperuricemia; Male; Metabolic Syndrome; | 2015 |
Study on the anti-gout activity of chlorogenic acid: improvement on hyperuricemia and gouty inflammation.
Topics: Animals; Chlorogenic Acid; Cytokines; Disease Models, Animal; Gout; Gout Suppressants; Hyperuricemia | 2014 |
Correlation between renal function and common risk factors for chronic kidney disease in a healthy middle-aged population: a prospective observational 2-year study.
Topics: Adult; Age Factors; Blood Glucose; Blood Pressure; Body Mass Index; Cholesterol; Cholesterol, LDL; F | 2014 |
Smilacis Glabrae Rhizoma reduces oxidative stress caused by hyperuricemia via upregulation of catalase.
Topics: Animals; Catalase; Computational Biology; Drugs, Chinese Herbal; Endothelial Cells; Hyperuricemia; K | 2014 |
Elevated uric acid level as a significant predictor of chronic kidney disease: a cohort study with repeated measurements.
Topics: Adult; Biomarkers; Disease Progression; Female; Glomerular Filtration Rate; Humans; Hyperuricemia; L | 2015 |
Hyperuricemia as a risk factor for cardiovascular disease.
Topics: Cardiovascular Diseases; Humans; Hyperuricemia; Uric Acid | 2015 |
Synergism between asymmetric dimethylarginine (ADMA) and a genetic marker of uric acid in CKD progression.
Topics: Aged; Alleles; Arginine; C-Reactive Protein; Calcium; Case-Control Studies; Cohort Studies; Creatini | 2015 |
Gout, allopurinol intake and clinical outcomes in the hospitalized multimorbid elderly.
Topics: Age Factors; Aged; Aged, 80 and over; Allopurinol; Cardiovascular Diseases; Chronic Disease; Comorbi | 2014 |
Is hyperuricemia a risk factor for arteriosclerosis? Uric acid and arteriosclerosis in apolipoprotein e-deficient mice.
Topics: Aging; Allopurinol; Animal Feed; Animals; Apolipoproteins E; Arteriosclerosis; Benzbromarone; Diet; | 2014 |
Glomerular filtration rate, potentially the missed link between serum uric acid and erectile dysfunction.
Topics: Erectile Dysfunction; Humans; Hyperuricemia; Male; Uric Acid | 2014 |
In response: hyperuricemia as a risk factor for cardiovascular disease.
Topics: Cardiovascular Diseases; Humans; Hyperuricemia; Uric Acid | 2015 |
Gouty tophi: here today gone tomorrow.
Topics: Aged, 80 and over; Arthritis, Gouty; Female; Gout Suppressants; Humans; Hyperuricemia; Infusions, In | 2015 |
Relationship between serum uric Acid and bone mineral density in the general population and in rats with experimental hyperuricemia.
Topics: Adult; Animals; Bone Density; Disease Models, Animal; Female; Humans; Hyperuricemia; Male; Middle Ag | 2015 |
Arsenic exposure, hyperuricemia, and gout in US adults.
Topics: Adult; Aged; Arsenic; Arsenicals; Cross-Sectional Studies; Environmental Exposure; Female; Gout; Hum | 2015 |
Nuciferine restores potassium oxonate-induced hyperuricemia and kidney inflammation in mice.
Topics: Animals; Aporphines; Carrier Proteins; Cell Line; Humans; Hyperuricemia; Inflammasomes; Inflammation | 2015 |
Effects of extracts of leaves from Sparattosperma leucanthum on hyperuricemia and gouty arthritis.
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Gouty; Bignoniaceae; Gout Suppressants; Hyperuricemia; | 2015 |
Effect of serum uric acid on the positive predictive value of dobutamine stress echocardiography.
Topics: Adrenergic beta-1 Receptor Agonists; Aged; Area Under Curve; Biomarkers; Chi-Square Distribution; Do | 2016 |
Associations between serum uric acid concentrations and metabolic syndrome and its components in the PREDIMED study.
Topics: Aged; Aged, 80 and over; Asian People; Body Mass Index; Cardiovascular Diseases; Cholesterol, HDL; C | 2015 |
Relationship between serum uric acid and electrocardiographic alterations in a large sample of general population: data from the Brisighella Heart Study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arrhythmias, Cardiac; Biomarkers; Electrocardiography; F | 2015 |
[CORRECTION OF BILE FLOW CHARACTERISTICS IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE IN COMBINATION WITH HYPERURICEMIA].
Topics: Adult; Allopurinol; Bile; Cholagogues and Choleretics; Cholestasis, Intrahepatic; Cholesterol; Choli | 2014 |
Effects of Xie-Zhuo-Chu-Bi-Fang on miR-34a and URAT1 and their relationship in hyperuricemic mice.
Topics: Animals; Disease Models, Animal; Drugs, Chinese Herbal; Gene Expression Regulation; Gout Suppressant | 2015 |
Association of Uric Acid With Vascular Stiffness in the Framingham Heart Study.
Topics: Adult; Age Factors; Biomarkers; Cardiovascular Diseases; Comorbidity; Cross-Sectional Studies; Femal | 2015 |
Hematological parameters in adolescents with hyperuricemia.
Topics: Adolescent; Body Mass Index; Female; Hematologic Tests; Humans; Hyperuricemia; Male; Metabolic Syndr | 2014 |
Allopurinol use and risk of non-fatal acute myocardial infarction.
Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Case-Control Studies; Female; Free Radical Scavengers; | 2015 |
[Association between serum uric acid and fasting plasma glucose in middle and elderly Chinese].
Topics: Aged; Asian People; Blood Glucose; China; Diabetes Mellitus; Fasting; Female; Humans; Hyperuricemia; | 2014 |
[Relationship between hyperuricemia and primary nephrotic syndrome in children].
Topics: Child; Creatinine; Humans; Hypertension; Hyperuricemia; Nephrotic Syndrome; Retrospective Studies; U | 2014 |
Uric acid and the risk of graft failure in kidney transplant recipients: a re-assessment.
Topics: Adult; Biomarkers; Cohort Studies; Female; Graft Rejection; Humans; Hyperuricemia; Kaplan-Meier Esti | 2015 |
The molecular insight into the antihyperuricemic and renoprotective effect of Shuang Qi gout capsule in mice.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; | 2015 |
Anti-hyperuricemia effects of allopurinol are improved by Smilax riparia, a traditional Chinese herbal medicine.
Topics: Allopurinol; Animals; Blood Urea Nitrogen; Chromatography, High Pressure Liquid; Drug Synergism; Dru | 2015 |
Xanthine oxidase in non-alcoholic fatty liver disease and hyperuricemia: One stone hits two birds.
Topics: Adult; Animals; Carrier Proteins; Cohort Studies; Disease Models, Animal; Female; Gene Knockdown Tec | 2015 |
Relationship between hyperuricemia and lipid profiles in US adults.
Topics: Adult; Apolipoprotein A-I; Apolipoproteins B; Cholesterol, HDL; Female; Humans; Hyperuricemia; Lipid | 2015 |
Urate crystal deposition in asymptomatic hyperuricaemia and symptomatic gout: a dual energy CT study.
Topics: Absorptiometry, Photon; Aged; Asymptomatic Diseases; Cross-Sectional Studies; Female; Foot; Foot Joi | 2015 |
Role of miR-146a in regulation of the acute inflammatory response to monosodium urate crystals.
Topics: Animals; Antioxidants; Case-Control Studies; Cell Line; Disease Models, Animal; Female; Gene Express | 2015 |
Genome-wide association study of clinically defined gout identifies multiple risk loci and its association with clinical subtypes.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Asian People; ATP Binding Cassette Transporter, S | 2016 |
Assessment of a possible link between hyperhomocysteinemia and hyperuricemia.
Topics: Adult; Aged; Aged, 80 and over; Female; Homocysteine; Humans; Hyperhomocysteinemia; Hyperuricemia; M | 2015 |
Hyperuricemia-induced NLRP3 activation of macrophages contributes to the progression of diabetic nephropathy.
Topics: Animals; Carrier Proteins; Cell Line; Chemokine CXCL12; Coculture Techniques; Diabetes Mellitus, Typ | 2015 |
Uric acid level has a U-shaped association with loss of kidney function in healthy people: a prospective cohort study.
Topics: Adult; Exercise; Female; Glomerular Filtration Rate; Healthy Volunteers; Humans; Hyperuricemia; Kidn | 2015 |
Uric acid and mild renal impairment in patients with ST-elevation myocardial infarction.
Topics: Aged; Aged, 80 and over; Biomarkers; Female; Glomerular Filtration Rate; Humans; Hyperuricemia; Kidn | 2015 |
Smaller caliber renal arteries are a novel feature of uromodulin-associated kidney disease.
Topics: Adolescent; Adult; Aged; Angiography; Child; Chronic Disease; Female; Genotype; Glomerular Filtratio | 2015 |
Carotid-Femoral Pulse Wave Velocity: An Urgent Need for a Harmonization of Denominations.
Topics: Cardiovascular Diseases; Female; Humans; Hyperuricemia; Male; Uric Acid; Vascular Stiffness | 2015 |
Uric Acid Determination in Gestational Hypertension: Is it as Effective a Delineator of Risk as Proteinuria in High-Risk Women?
Topics: Adolescent; Adult; Biomarkers; Clinical Trials as Topic; Female; Gestational Age; Humans; Hypertensi | 2015 |
Direct radical scavenging activity of benzbromarone provides beneficial antioxidant properties for hyperuricemia treatment.
Topics: Antioxidants; Benzbromarone; Cell Line; Endothelial Cells; Free Radical Scavengers; Human Umbilical | 2015 |
Anti-hyperuricemic and nephroprotective effects of rhein in hyperuricemic mice.
Topics: Animals; Anthraquinones; Blood Urea Nitrogen; Creatinine; Disease Models, Animal; Drugs, Chinese Her | 2015 |
Hyperuricemia is associated with progression of IgA nephropathy.
Topics: Adult; Biomarkers; Disease Progression; Female; Follow-Up Studies; Glomerular Filtration Rate; Glome | 2015 |
Renal clearance of uric acid is linked to insulin resistance and lower excretion of sodium in gout patients.
Topics: Adult; Female; Gout; Humans; Hypertension; Hyperuricemia; Insulin Resistance; Kidney; Male; Middle A | 2015 |
Hyperuricemia reflects global Fontan pathophysiology and associates with morbidity and mortality in patients after the Fontan operation.
Topics: Adolescent; Adult; Biomarkers; Child; Female; Follow-Up Studies; Fontan Procedure; Heart Failure; Hu | 2015 |
Prednisone in Uric Acid Lowering in Symptomatic Heart Failure Patients with Hyperuricemia -- The PUSH-PATH3 Study.
Topics: Adult; Aged; Creatinine; Female; Gout Suppressants; Heart Failure; Humans; Hyperuricemia; Male; Midd | 2015 |
Hyperuricemia starts at 360 micromoles (6 mg/dL).
Topics: Cardiovascular Diseases; Gout; Humans; Hyperuricemia; Risk Factors; Uric Acid | 2015 |
High Concentrations of Uric Acid Inhibit Endothelial Cell Migration via miR-663 Which Regulates Phosphatase and Tensin Homolog by Targeting Transforming Growth Factor-β1.
Topics: Animals; Cell Line; Cell Movement; Endothelial Cells; Gene Expression Regulation, Enzymologic; Hyper | 2015 |
Uric Acid and Cardiovascular Events: A Mendelian Randomization Study.
Topics: Aged; Biomarkers; Cardiovascular Diseases; Coronary Disease; Cross-Sectional Studies; Female; Follow | 2015 |
EGF Receptor Inhibition Alleviates Hyperuricemic Nephropathy.
Topics: Animals; Chemokines; Cytokines; Disease Progression; ErbB Receptors; Fibroblasts; Fibrosis; Gefitini | 2015 |
Impact of sex on uric acid levels and its relationship with the extent of coronary artery disease: A single-centre study.
Topics: Aged; Aged, 80 and over; Biomarkers; Chi-Square Distribution; Coronary Angiography; Coronary Artery | 2015 |
[Value of dual-energy computed tomography in the diagnosis of gouty arthritis].
Topics: Arthritis, Gouty; Arthritis, Rheumatoid; Color; Diagnosis, Differential; Humans; Hyperuricemia; Spon | 2015 |
Ungoutedly time for a change.
Topics: Female; Foot Joints; Gout; Humans; Hyperuricemia; Male; Radiography; Tendons; Uric Acid | 2015 |
Effects of losartan on expression of monocyte chemoattractant protein-1 (MCP-1) in hyperuricemic nephropathy rats.
Topics: Animals; Chemokine CCL2; Dose-Response Relationship, Drug; Hyperuricemia; Kidney; Kidney Diseases; L | 2015 |
Association between serum uric acid and nonalcoholic fatty liver disease in the US population.
Topics: Adult; Aged; Alanine Transaminase; Aspartate Aminotransferases; Female; Humans; Hyperuricemia; Logis | 2015 |
[Hypouricemic effect of ethanol extracts from Dioscoreae Nipponicae Rhizoma].
Topics: Animals; Dioscorea; Disease Models, Animal; Hyperuricemia; Male; Mice; Mice, Inbred ICR; Plant Extra | 2015 |
Compound Tufuling Granules ([characters: see text]) regulate glucose transporter 9 expression in kidney to influence serum uric acid level in hyperuricemia mice.
Topics: Animals; Blotting, Western; Drugs, Chinese Herbal; Glucose Transport Proteins, Facilitative; Hyperur | 2015 |
The association of metabolic syndrome and its components with brachial-ankle pulse wave velocity in south China.
Topics: Adolescent; Adult; Aged; Ankle Brachial Index; Biomarkers; Blood Glucose; Blood Pressure; Cardiovasc | 2015 |
Gender impact on the correlations between subclinical thyroid dysfunction and hyperuricemia in Chinese.
Topics: Adult; Aged; Asian People; China; Creatinine; Cross-Sectional Studies; Female; Glomerular Filtration | 2016 |
Effects of oxonic acid-induced hyperuricemia on mesenteric artery tone and cardiac load in experimental renal insufficiency.
Topics: Analysis of Variance; Animals; Cardiac Output; Disease Models, Animal; Hyperuricemia; Male; Mesenter | 2015 |
Association of apolipoprotein E (ApoE) polymorphisms with risk of primary hyperuricemia in Uygur men, Xinjiang, China.
Topics: Alleles; Apolipoprotein E2; Apolipoprotein E3; Apolipoprotein E4; Apolipoproteins E; Asian People; C | 2015 |
Gout and sickle cell disease: not all pain is sickle cell pain.
Topics: Acute Disease; Adult; Age of Onset; Aged; Aged, 80 and over; Anemia, Sickle Cell; Female; Gout; Hemo | 2015 |
Effects of hyperuricemia on renal function in pediatric renal transplant recipients.
Topics: Adolescent; Age Factors; Biomarkers; Child; Female; Glomerular Filtration Rate; Humans; Hyperuricemi | 2015 |
[Regulatory effect of leonurus extracts on hyperuricemia in rats].
Topics: Allopurinol; Animals; Blood Urea Nitrogen; Creatinine; Disease Models, Animal; Down-Regulation; Gene | 2014 |
Traditional Uighur Medicine Karapxa decoction, inhibits liver xanthine oxidase and reduces serum uric acid concentrations in hyperuricemic mice and scavenges free radicals in vitro.
Topics: Animals; Apiaceae; Asteraceae; Convolvulaceae; Free Radicals; Hyperuricemia; Liver; Medicine, Tradit | 2015 |
Cross-sectional and longitudinal associations between serum uric acid and metabolic syndrome: Results from Fangchenggang Area Male Health and Examination Survey in China.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alcohol Drinking; Blood Pressure; Body Mass Index; China | 2015 |
Effects of Febuxostat on Oxidative Stress.
Topics: Adult; Aged; Allopurinol; Creatinine; Enzyme Inhibitors; Febuxostat; Female; Glomerular Filtration R | 2015 |
Does elevated serum uric acid level predict the hypertension incidence? A Chinese prospective cohort study.
Topics: Adult; Aged; Blood Pressure; China; Female; Follow-Up Studies; Humans; Hypertension; Hyperuricemia; | 2015 |
[Anti-hyperuricemia effect and mechanism of polydatin in mice].
Topics: Animals; Disease Models, Animal; Glucosides; Hyperuricemia; Kidney; Mice; Stilbenes; Uric Acid | 2014 |
A coronary artery disease-associated SNP rs6903956 contributed to asymptomatic hyperuricemia susceptibility in Han Chinese.
Topics: Asian People; Asymptomatic Diseases; Case-Control Studies; China; Coronary Artery Disease; Female; G | 2015 |
Prospective study of serum uric acid levels and incident metabolic syndrome in a Korean rural cohort.
Topics: Adult; Aged; Biomarkers; Blood Pressure; Female; Follow-Up Studies; Health Status Disparities; Human | 2015 |
Relationship between Hyperuricemia and Haar-Like Features on Tongue Images.
Topics: Adult; Aged; Aged, 80 and over; Case-Control Studies; Female; Humans; Hyperuricemia; Male; Middle Ag | 2015 |
Hyperuricaemia is associated with renal damage independently of hypertension and intrarenal renin-angiotensin system activation, as well as their circadian rhythms.
Topics: Adult; Aged; Aged, 80 and over; Albuminuria; Angiotensinogen; Biomarkers; Blood Pressure; Circadian | 2015 |
Cross-sectional analysis of nutrition and serum uric acid in two Caucasian cohorts: the AusDiab Study and the Tromsø study.
Topics: Adult; Aged; Aged, 80 and over; Animals; Australia; Body Mass Index; Choice Behavior; Cholesterol; C | 2015 |
Serum Uric Acid and Prehypertension Among Adults Free of Cardiovascular Diseases and Diabetes: Baseline of the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil).
Topics: Adult; Age Factors; Aged; Biomarkers; Blood Pressure; Brazil; Comorbidity; Female; Health Surveys; H | 2016 |
Patient and clinical characteristics associated with gout flares in an integrated healthcare system.
Topics: Aged; Biomarkers; California; Chi-Square Distribution; Delivery of Health Care, Integrated; Disease | 2015 |
The xanthine oxidase inhibitor febuxostat suppresses development of nonalcoholic steatohepatitis in a rodent model.
Topics: Animals; Apoptosis; Choline Deficiency; Cytoprotection; Diet, High-Fat; Enzyme Inhibitors; Febuxosta | 2015 |
[Metabolic complications of obesity during adolescence, particularly regarding elevated uric acid levels].
Topics: Adolescent; Biomarkers; Blood Pressure; Body Mass Index; Case-Control Studies; Child; Cross-Sectiona | 2015 |
Hyperuricemia and tissue monourate deposits: prospective therapeutic considerations.
Topics: Asymptomatic Diseases; Cardiovascular Diseases; Cartilage; Gout; Humans; Hyperuricemia; Kidney Disea | 2015 |
[Hyperuricemia and cardiovascular diseases: from phylogenesys to patogenetic mechanisms].
Topics: Cardiovascular Diseases; Humans; Hyperuricemia; Phylogeny; Risk Factors; Uric Acid | 2015 |
[Renal handling of uric acid].
Topics: Homeostasis; Humans; Hyperuricemia; Kidney; Uric Acid | 2015 |
[Hyperuricemia and renal risk].
Topics: Humans; Hyperuricemia; Renal Insufficiency, Chronic; Risk Factors; Uric Acid | 2015 |
Relationship between High-Performance Liquid Chromatography Fingerprints and Uric Acid-Lowering Activities of Cichorium intybus L.
Topics: Animals; Cardiovascular Diseases; Chromatography, High Pressure Liquid; Cichorium intybus; Hyperuric | 2015 |
Discovery of xanthine oxidase inhibitors and/or α-glucosidase inhibitors by carboxyalkyl derivatization based on the flavonoid of apigenin.
Topics: alpha-Glucosidases; Animals; Apigenin; Disease Models, Animal; Drug Evaluation, Preclinical; Flavono | 2015 |
Uric Acid is independently associated with diabetic kidney disease: a cross-sectional study in a Chinese population.
Topics: Biomarkers; China; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Femal | 2015 |
Reply to "Association of Serum Uric Acid Concentration With Metabolic Risk Factors in Patients With Type 2 Diabetes".
Topics: Cardiovascular Diseases; Female; Humans; Hyperuricemia; Male; Uric Acid | 2015 |
Association of Serum Uric Acid Concentration With Metabolic Risk Factors in Patients With Type 2 Diabetes.
Topics: Cardiovascular Diseases; Female; Humans; Hyperuricemia; Male; Uric Acid | 2015 |
Pallidifloside D from Smilax riparia enhanced allopurinol effects in hyperuricemia mice.
Topics: Allopurinol; Animals; Creatinine; Disease Models, Animal; Drug Synergism; Glucose Transport Proteins | 2015 |
Relationship between serum uric acid levels and intrarenal hemodynamic parameters.
Topics: Adult; Aged; Algorithms; Blood Pressure; Diabetic Nephropathies; Female; Glomerular Filtration Rate; | 2015 |
Uric acid levels within the normal range predict increased risk of hypertension: a cohort study.
Topics: Adult; Aged; Biomarkers; Female; Follow-Up Studies; Humans; Hypertension; Hyperuricemia; Incidence; | 2015 |
Association between low serum magnesium concentration and hyperuricemia.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Cross-Sectional Studies; Female; Humans; Hyperuricemia; | 2015 |
Reactive oxygen species derived from xanthine oxidase interrupt dimerization of breast cancer resistance protein, resulting in suppression of uric acid excretion to the intestinal lumen.
Topics: Aging; Allopurinol; Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Ca | 2015 |
[Disturbance of uric acid metabolism].
Topics: Gout; Humans; Hyperuricemia; Kidney Diseases; Metabolism, Inborn Errors; Nucleic Acids; Renal Tubula | 2015 |
Uric acid blood levels and relationship with the components of metabolic syndrome in hypertensive patients.
Topics: Adult; Aged; Apolipoprotein A-I; Apolipoprotein B-100; Biomarkers; Blood Glucose; Blood Pressure; Ch | 2016 |
Elevated uric acid and obesity-related cardiovascular disease risk factors among hypertensive youth.
Topics: Adolescent; Blood Pressure; Child; Child, Preschool; Cross-Sectional Studies; Echocardiography; Fema | 2015 |
Is Hyperuricemia Overlooked when Treating Pediatric Tuberculosis Patients with Pyrazinamide?
Topics: Adolescent; Allopurinol; Antitubercular Agents; Child; Child, Preschool; Drug Administration Schedul | 2015 |
Combination of hyperuricemia and metabolic syndrome is an independent and powerful predictor for left ventricular hypertrophy in rural Chinese.
Topics: Adult; Aged; Anthropometry; Asian People; Body Mass Index; China; Cross-Sectional Studies; Female; H | 2015 |
Relationship between hyperuricemia and dietary risk factors in Chinese adults: a cross-sectional study.
Topics: Adult; Beijing; Blood Glucose; Cross-Sectional Studies; Diet; Feeding Behavior; Female; Humans; Hype | 2015 |
The association between serum uric acid levels, metabolic syndrome and cardiovascular disease in middle aged and elderly Chinese: results from the DYSlipidemia International Study.
Topics: Aged; Cardiovascular Diseases; China; Cohort Studies; Coronary Disease; Dyslipidemias; Female; Human | 2015 |
Association between elevated serum alanine aminotransferase and cardiometabolic risk factors in rural Chinese population: a cross-sectional study.
Topics: Adult; Age Factors; Aged; Alanine Transaminase; Blood Pressure; Body Mass Index; Cardiovascular Dise | 2015 |
Effects of febuxostat on platelet-derived microparticles and adiponectin in patients with hyperuricemia.
Topics: Adiponectin; Adult; Aged; Aged, 80 and over; Biomarkers; Blood Platelets; Carotid Artery Thrombosis; | 2015 |
Clinical Impact of Speed Variability to Identify Ultramarathon Runners at Risk for Acute Kidney Injury.
Topics: Acute Kidney Injury; Adult; Athletes; Biomechanical Phenomena; Body Mass Index; Dehydration; Early D | 2015 |
Hyperuricemia is associated with an increased prevalence of atrial fibrillation in hospitalized patients with type 2 diabetes.
Topics: Aged; Aged, 80 and over; Allopurinol; Atrial Fibrillation; Cross-Sectional Studies; Diabetes Mellitu | 2016 |
Uric acid is not associated with decline in renal function or time to renal replacement therapy initiation in a referred cohort of patients with Stage III, IV and V chronic kidney disease.
Topics: Aged; Biomarkers; Cohort Studies; Disease Progression; Female; Glomerular Filtration Rate; Humans; H | 2015 |
In vitro Xanthine Oxidase Inhibitory Studies of Lippia nodiflora and Isolated Flavonoids and Phenylethanoid Glycosides as Potential Uric Acid-lowering Agents.
Topics: Flavonoids; Glycosides; Humans; Hyperuricemia; Lippia; Models, Biological; Plant Extracts; Plant Lea | 2015 |
Effects of anthocyanins from purple sweet potato (Ipomoea batatas L. cultivar Eshu No. 8) on the serum uric acid level and xanthine oxidase activity in hyperuricemic mice.
Topics: Animals; Anthocyanins; Glucose Transport Proteins, Facilitative; Humans; Hyperuricemia; Ipomoea bata | 2015 |
Hyperuricemia and Progression of CKD in Children and Adolescents: The Chronic Kidney Disease in Children (CKiD) Cohort Study.
Topics: Adolescent; Child; Cohort Studies; Cross-Sectional Studies; Disease Progression; Female; Humans; Hyp | 2015 |
[Research on Hemorheology in Rats with Acute Hyperuricemia].
Topics: Animals; Erythrocytes; Hemorheology; Hyperuricemia; Malondialdehyde; Rats; Rats, Sprague-Dawley; Uri | 2015 |
Association Between Serum Uric Acid Levels/Hyperuricemia and Hypertension Among 85,286 Japanese Workers.
Topics: Adult; Blood Pressure; Body Mass Index; Cross-Sectional Studies; Employment; Female; Gout Suppressan | 2016 |
Mangiferin Inhibits Renal Urate Reabsorption by Modulating Urate Transporters in Experimental Hyperuricemia.
Topics: Animals; Anion Transport Proteins; Carrier Proteins; Cytoskeletal Proteins; Hyperuricemia; Kidney; M | 2015 |
Ulcerated tophaceous gout.
Topics: Anemia; Anti-Bacterial Agents; Calculi; Clostridium Infections; Gout; Honey; Humans; Hyperuricemia; | 2015 |
Association between Hyperuricemia and Metabolic Syndrome: An Epidemiological Study of a Labor Force Population in Taiwan.
Topics: Adult; Blood Glucose; Blood Pressure; Cholesterol, HDL; Cross-Sectional Studies; Employment; Epidemi | 2015 |
Salivary uric acid as a noninvasive biomarker for monitoring the efficacy of urate-lowering therapy in a patient with chronic gouty arthropathy.
Topics: Arthritis, Gouty; Benzbromarone; Biomarkers; Chronic Disease; Feasibility Studies; Humans; Hyperuric | 2015 |
Wearable salivary uric acid mouthguard biosensor with integrated wireless electronics.
Topics: Biosensing Techniques; Computer Communication Networks; Conductometry; Equipment Design; Equipment F | 2015 |
Positive association of tomato consumption with serum urate: support for tomato consumption as an anecdotal trigger of gout flares.
Topics: Adolescent; Adult; Aged; Female; Gout; Humans; Hyperuricemia; Male; Middle Aged; Native Hawaiian or | 2015 |
Prevalence of hyperuricemia and its correlates in rural Northeast Chinese population: from lifestyle risk factors to metabolic comorbidities.
Topics: Adult; Aged; Aged, 80 and over; China; Comorbidity; Dyslipidemias; Female; Humans; Hypertension; Hyp | 2016 |
The Effects of Lead Exposure on Serum Uric Acid and Hyperuricemia in Chinese Adults: A Cross-Sectional Study.
Topics: Adult; Aged; Asian People; Body Mass Index; China; Cross-Sectional Studies; Environmental Monitoring | 2015 |
High concentrations of uric acid inhibit angiogenesis via regulation of the Krüppel-like factor 2-vascular endothelial growth factor-A axis by miR-92a.
Topics: Adult; Angiogenesis Inhibitors; Binding Sites; Case-Control Studies; Cells, Cultured; Computational | 2015 |
Levels of uric acid may predict the future development of pulmonary hypertension in systemic lupus erythematosus: a seven-year follow-up study.
Topics: Adult; Arterial Pressure; Biomarkers; Female; Follow-Up Studies; Humans; Hypertension, Pulmonary; Hy | 2016 |
Nanosomal Microassemblies for Highly Efficient and Safe Delivery of Therapeutic Enzymes.
Topics: Animals; Antibodies; Biocatalysis; Disease Models, Animal; Drug Carriers; Enzyme-Linked Immunosorben | 2015 |
Green tea polyphenols decreases uric acid level through xanthine oxidase and renal urate transporters in hyperuricemic mice.
Topics: Animals; Gout Suppressants; Hyperuricemia; Kidney; Liver; Male; Mice; Organic Anion Transport Protei | 2015 |
Significant association between parathyroid hormone and uric acid level in men.
Topics: Adult; Blood Chemical Analysis; Body Mass Index; Body Weights and Measures; Cross-Sectional Studies; | 2015 |
Relationship Between Hyperuricemia and Cardiovascular Disease Risk Factors in a Chinese Population: A Cross-Sectional Study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alcohol Drinking; Blood Glucose; Blood Pressure; Body Ma | 2015 |
Urate testing in gout: why, when and how.
Topics: Biomarkers; Gout; Humans; Hyperuricemia; New Zealand; Quality of Health Care; Risk Factors; Uric Aci | 2015 |
Gender differences in the prognostic role of uric acid and confounding factors.
Topics: Coronary Angiography; Humans; Hyperuricemia; Prognosis; Risk Factors; Uric Acid | 2016 |
Hyperuricemia is independently associated with left ventricular hypertrophy in post-menopausal women but not in pre-menopausal women in rural Northeast China.
Topics: Adult; Age Factors; Aged; Body Mass Index; China; Diabetes Mellitus; Dyslipidemias; Female; Humans; | 2015 |
Could Uric Acid Be Considered a Cardiovascular Risk Factor?
Topics: Cardiovascular Diseases; Humans; Hypertension; Hyperuricemia; Risk Factors; Uric Acid | 2015 |
Association between uric acid, cancer incidence and mortality in patients with type 2 diabetes: Shanghai diabetes registry study.
Topics: Aged; China; Diabetes Mellitus, Type 2; Female; Humans; Hyperuricemia; Incidence; Male; Middle Aged; | 2016 |
Association of Visceral Fat and Liver Fat With Hyperuricemia.
Topics: Adiposity; Adult; Aged; Biomarkers; Chi-Square Distribution; Cross-Sectional Studies; Humans; Hyperu | 2016 |
The role of uric acid in the development of cardiovascular disease.
Topics: Cardiovascular Diseases; Gout; Humans; Hyperuricemia; Risk Factors; Uric Acid | 2015 |
Circulating Levels of Uric Acid and Risk for Metabolic Syndrome.
Topics: Adult; Female; Humans; Hyperuricemia; Insulin Resistance; Male; Metabolic Syndrome; Mexico; Poverty; | 2017 |
[The Xanthine Oxidase Inhibitory Activity and Hypouricemic Effects of Crude Drugs Obtained from the Silkworm in Mice].
Topics: Administration, Oral; Animals; Biological Products; Biomarkers; Blood Pressure; Bombyx; Chromatograp | 2015 |
Relationship between Serum Uric Acid Concentration and Acute Kidney Injury after Coronary Artery Bypass Surgery.
Topics: Acute Kidney Injury; Coronary Artery Bypass; Creatinine; Female; Humans; Hyperuricemia; Kidney Funct | 2015 |
Serum urate gene associations with incident gout, measured in the Framingham Heart Study, are modified by renal disease and not by body mass index.
Topics: Age Factors; Aged; Aged, 80 and over; Biomarkers; Body Mass Index; Comorbidity; Female; Gene Frequen | 2016 |
Significance of the initiation time of urate-lowering therapy in gout patients: A retrospective research.
Topics: Adult; Allopurinol; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Recur | 2015 |
Epidemiological associations between hyperuricemia and cardiometabolic risk factors: a comprehensive study from Chinese community.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Blood Glucose; Blood Pressure; Body Mass In | 2015 |
Molecular Mechanisms Underlying Urate-Induced Enhancement of Kv1.5 Channel Expression in HL-1 Atrial Myocytes.
Topics: Animals; Cell Line; Gene Expression Regulation; Heart Atria; Hyperuricemia; Kv1.5 Potassium Channel; | 2015 |
Chinese Herbal Formulas Si-Wu-Tang and Er-Miao-San Synergistically Ameliorated Hyperuricemia and Renal Impairment in Rats Induced by Adenine and Potassium Oxonate.
Topics: Adenine; Administration, Oral; Animals; Benzbromarone; Creatinine; Drug Synergism; Drugs, Chinese He | 2015 |
Is urate crystal precipitation a predictor of cardiovascular risk in hyperuricemic patients? A Danish cohort study.
Topics: Cardiovascular Diseases; Cohort Studies; Crystallization; Denmark; Female; Gout; Humans; Hyperuricem | 2015 |
Gout, not hyperuricemia alone, impairs left ventricular diastolic function.
Topics: Adult; Aged; Biomarkers; Cohort Studies; Diastole; Female; Gout; Humans; Hyperuricemia; Male; Middle | 2015 |
Hypouricemic and Nephroprotective Effects of Emodinol in Oxonate-Induced Hyperuricemic Mice are Mediated by Organic Ion Transporters and OIT3.
Topics: Animals; Elaeagnaceae; Hyperuricemia; Ion Transport; Kidney; Male; Membrane Proteins; Mice; Molecula | 2016 |
Serum uric acid level as an indicator for CKD regression and progression in patients with type 2 diabetes mellitus-a 4.6-year cohort study.
Topics: Biomarkers; Cohort Studies; Diabetes Mellitus, Type 2; Disease Progression; Female; Glomerular Filtr | 2016 |
Flavonoids and phenylethanoid glycosides from Lippia nodiflora as promising antihyperuricemic agents and elucidation of their mechanism of action.
Topics: Animals; Flavonoids; Glycosides; Gout Suppressants; Hyperuricemia; Lippia; Liver; Male; Plant Extrac | 2015 |
Uric acid increases erythrocyte aggregation: Implications for cardiovascular disease.
Topics: Blood Viscosity; Cardiovascular Diseases; Erythrocyte Aggregation; Humans; Hyperuricemia; Risk Facto | 2016 |
Discovery of URAT1 SNPs and association between serum uric acid levels and URAT1.
Topics: Adult; Alleles; Asian People; Case-Control Studies; Genetic Predisposition to Disease; Genotype; Hum | 2015 |
The role of uric acid in chronic kidney disease patients.
Topics: Aged; Cardiovascular Diseases; Cohort Studies; Female; Glomerular Filtration Rate; Hospitalization; | 2017 |
Losartan alleviates hyperuricemia-induced atherosclerosis in a rabbit model.
Topics: Animals; Antihypertensive Agents; Aorta; Atherosclerosis; Blotting, Western; Disease Models, Animal; | 2015 |
[The Pharmacokinetics and Pharmacodynamics of Intravenous Uricase Multivesicular Liposomes].
Topics: Administration, Intravenous; Animals; Area Under Curve; Biological Availability; Disease Models, Ani | 2015 |
[Effect of Serum Uric Acid on Renal Function of Patients with Abnormal Glucose Metabolism].
Topics: China; Cholesterol; Creatinine; Diabetes Mellitus; Female; Glomerular Filtration Rate; Glucose; Huma | 2015 |
[Epidemiology Study and Risk Factors Analysis of Hyperuricemia in Tibetan Monks of Sichuan Province].
Topics: Adult; Blood Pressure; China; Epidemiologic Studies; Female; Humans; Hyperuricemia; Male; Monks; Pre | 2015 |
Antioxidative phytochemicals from Rhododendron oldhamii Maxim. leaf extracts reduce serum uric acid levels in potassium oxonate-induced hyperuricemic mice.
Topics: Animals; Antioxidants; Disease Models, Animal; Gout Suppressants; Hyperuricemia; Kidney; Male; Mice; | 2015 |
High serum uric acid levels increase the risk of metabolic syndrome in elderly women: The PRO.V.A study.
Topics: Age Factors; Aged; Aged, 80 and over; Biomarkers; Female; Follow-Up Studies; Humans; Hyperuricemia; | 2016 |
Psoriasis and uric acid: a population-based cross-sectional study.
Topics: Adult; Case-Control Studies; Cross-Sectional Studies; Female; Gout; Humans; Hyperuricemia; Logistic | 2016 |
Hyperuricemia is a biomarker of early mortality in patients with chronic obstructive pulmonary disease.
Topics: Adult; Aged; Biomarkers; Chi-Square Distribution; Female; Humans; Hyperuricemia; Kaplan-Meier Estima | 2015 |
Does high serum uric acid level cause aspirin resistance?
Topics: Aged; Angina Pectoris; Aspirin; Biomarkers; Blood Cell Count; Blood Glucose; C-Reactive Protein; Cor | 2016 |
Highly Prevalent Hyperuricaemia is Associated with Adverse Clinical Outcomes Among Ghanaian Stroke Patients: An Observational Prospective Study.
Topics: Aged; Biomarkers; Female; Ghana; Humans; Hyperuricemia; Kaplan-Meier Estimate; Male; Middle Aged; Pr | 2015 |
Revisiting medullary tophi: a link between uric acid and progressive chronic kidney disease?
Topics: Adult; Aged; Biopsy; Cohort Studies; Creatinine; Cross-Sectional Studies; Disease Progression; Femal | 2016 |
Serum uric acid predicts cardiovascular mortality in male peritoneal dialysis patients with diabetes.
Topics: Adult; Aged; Biomarkers; Cardiovascular Diseases; Cause of Death; Chi-Square Distribution; China; Di | 2016 |
Ideal Cardiovascular Health Metrics and Incident Hyperuricemia.
Topics: Adult; Blood Glucose; Blood Pressure; Body Mass Index; Cardiovascular Diseases; China; Cholesterol; | 2016 |
Prevalence of monosodium urate deposits in a population of rheumatoid arthritis patients with hyperuricemia.
Topics: Age Distribution; Aged; Arthritis, Rheumatoid; Comorbidity; Female; Foot Joints; Gout; Hand Joints; | 2016 |
The associations of serum uric acid level and hyperuricemia with knee osteoarthritis.
Topics: Biomarkers; Chi-Square Distribution; China; Cross-Sectional Studies; Female; Humans; Hyperuricemia; | 2016 |
Silent Monosodium Urate Crystal Deposits Are Associated With Severe Coronary Calcification in Asymptomatic Hyperuricemia: An Exploratory Study.
Topics: Aged; Aged, 80 and over; Asymptomatic Diseases; Coronary Artery Disease; Cross-Sectional Studies; Cr | 2016 |
Dual-Energy CT in Patients with Suspected Gouty Arthritis: Effects on Treatment Regimen and Clinical Outcome.
Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Ar | 2016 |
Prevalence and associations of gout and hyperuricaemia: results from an Australian population-based study.
Topics: Adult; Age Distribution; Aged; Australia; Comorbidity; Female; Gout; Gout Suppressants; Humans; Hype | 2016 |
Structure-based design and biological evaluation of novel 2-(indol-2-yl) thiazole derivatives as xanthine oxidase inhibitors.
Topics: Administration, Oral; Animals; Binding Sites; Cattle; Drug Design; Enzyme Inhibitors; Half-Life; Hyp | 2016 |
Effects of Pimenta pseudocaryophyllus extracts on gout: Anti-inflammatory activity and anti-hyperuricemic effect through xantine oxidase and uricosuric action.
Topics: Animals; Anti-Inflammatory Agents; Gout; Gout Suppressants; Hyperuricemia; Male; Mice; Phytotherapy; | 2016 |
Serum uric acid levels and mortality in the Japanese population: the Yamagata (Takahata) study.
Topics: Aged; Cardiovascular Diseases; Cause of Death; Female; Humans; Hyperuricemia; Japan; Male; Middle Ag | 2016 |
Association of ABCG2 rs2231142-A allele and serum uric acid levels in male and obese individuals in a Han Taiwanese population.
Topics: Adult; Alleles; ATP Binding Cassette Transporter, Subfamily G, Member 2; Female; Genetic Predisposit | 2017 |
Biodistribution, hypouricemic efficacy and therapeutic mechanism of morin phospholipid complex loaded self-nanoemulsifying drug delivery systems in an experimental hyperuricemic model in rats.
Topics: Animals; Drug Delivery Systems; Flavonoids; Hyperuricemia; Kidney; Liver; Male; Nanostructures; Orga | 2016 |
Miracle Fruit (Synsepalum dulcificum) Exhibits as a Novel Anti-Hyperuricaemia Agent.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Butanols; Disease Models, Animal; Hyperuricemia; Ma | 2016 |
Hyperuricaemia: contributions of urate transporter ABCG2 and the fractional renal clearance of urate.
Topics: Adult; Aged; Aged, 80 and over; ATP Binding Cassette Transporter, Subfamily G, Member 2; Case-Contro | 2016 |
High Uric Acid Induces Insulin Resistance in Cardiomyocytes In Vitro and In Vivo.
Topics: Animals; Cell Membrane; Cells, Cultured; Disease Models, Animal; Gene Expression; Glucose; Glucose T | 2016 |
Influence of changes in serum uric acid levels on renal function in elderly patients with hypertension: a retrospective cohort study with 3.5-year follow-up.
Topics: Aged; Aged, 80 and over; Biomarkers; Blood Pressure; Cohort Studies; Female; Follow-Up Studies; Glom | 2016 |
Weight Loss, Xanthine Oxidase, and Serum Urate Levels: A Prospective Longitudinal Study of Obese Patients.
Topics: Adult; Bariatric Surgery; Enzyme-Linked Immunosorbent Assay; Female; Humans; Hyperuricemia; Longitud | 2016 |
Association between high-sensitivity C-reactive protein and hyperuricemia.
Topics: Adult; Biomarkers; C-Reactive Protein; Chi-Square Distribution; China; Cross-Sectional Studies; Fema | 2016 |
Antihyperuricemic effects of thiadiazolopyrimidin-5-one analogues in oxonate treated rats.
Topics: Animals; Catalytic Domain; Creatinine; Enzyme Inhibitors; Hyperuricemia; Kidney; Liver; Male; Molecu | 2016 |
The Association Between Hyperuricemia and Hematological Indicators in a Chinese Adult Population.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Cell Count; Case-Control Studies; China; Female; H | 2016 |
A Body Shape Index and Body Roundness Index: Two new body indices for detecting association between obesity and hyperuricemia in rural area of China.
Topics: Adult; Aged; Body Mass Index; China; Cross-Sectional Studies; Female; Humans; Hyperuricemia; Logisti | 2016 |
Xanthine oxidoreductase activation is implicated in the onset of metabolic arthritis.
Topics: Adipose Tissue; Animals; Apoptosis; Carrier Proteins; Chondrocytes; Diet, High-Fat; Enzyme Activatio | 2016 |
Cross-sectional and longitudinal study on the association between serum uric acid and metabolic syndrome.
Topics: Cross-Sectional Studies; Humans; Hyperuricemia; Longitudinal Studies; Metabolic Syndrome; Uric Acid | 2016 |
Higher serum uric acid level increases risk of prehypertension in subjects with normal glucose tolerance, but not pre-diabetes and diabetes.
Topics: Adult; Biomarkers; Blood Glucose; Blood Pressure; Cross-Sectional Studies; Diabetes Mellitus; Female | 2016 |
The Clinical Significance of Uric Acid and Complement Activation in the Progression of IgA Nephropathy.
Topics: Adolescent; Adult; Aged; Biomarkers; Complement Activation; Complement C3; Disease Progression; Fema | 2016 |
Hypouricaemic action of mangiferin results from metabolite norathyriol via inhibiting xanthine oxidase activity.
Topics: Administration, Oral; Animals; Biomarkers; Biotransformation; Disease Models, Animal; Dose-Response | 2016 |
[The prevalence of hyperuricemia in Xinjiang Kazaks in Fuhaii].
Topics: Blood Pressure; Body Mass Index; Body Weight; China; Cross-Sectional Studies; Female; Humans; Hypert | 2015 |
Response to The relationship between serum uric acid levels and NAFLD.
Topics: Humans; Hyperuricemia; Non-alcoholic Fatty Liver Disease; Uric Acid | 2016 |
Hyperuricemia as a Risk Factors of Major Adverse Cardiac Events in Patients with Acute Coronary Syndrome: a Retrospective Cohort Study.
Topics: Acute Coronary Syndrome; Biomarkers; Coronary Angiography; Electrocardiography; Female; Follow-Up St | 2015 |
Allopurinol ameliorates cardiac function in non-hyperuricaemic patients with chronic heart failure.
Topics: Adult; Aged; Allopurinol; Biomarkers; Chronic Disease; Female; Follow-Up Studies; Heart Failure; Hum | 2016 |
Positive associations of serum perfluoroalkyl substances with uric acid and hyperuricemia in children from Taiwan.
Topics: Child; Child, Preschool; Female; Fluorocarbons; Humans; Hyperuricemia; Male; Taiwan; Uric Acid | 2016 |
[Drug reduction of uric acid not just when symptoms appear].
Topics: Allopurinol; Clinical Trials as Topic; Febuxostat; Gout; Humans; Hyperuricemia; Uric Acid | 2016 |
Urate crystals deposition in the feet of overweight juveniles and those with symptomatic hyperuricemia: a dual-energy CT study.
Topics: Adolescent; Biomarkers; Child; Female; Follow-Up Studies; Gout; Humans; Hyperuricemia; Kidney Diseas | 2016 |
Body mass index, fat free mass, uric acid, and renal function as blood pressure levels determinants in young adults.
Topics: Adolescent; Age Factors; Alcohol Drinking; Biomarkers; Blood Pressure; Body Composition; Body Mass I | 2017 |
Prevalence and associating factors of atrial fibrillation in patients with hypertension: a nation-wide study.
Topics: Age Factors; Aged; Atrial Fibrillation; Biomarkers; Chi-Square Distribution; Cholesterol, LDL; Comor | 2016 |
[Uric acid and kidneys – Physiological and pathophysiological aspects].
Topics: Gout; Humans; Hyperuricemia; Kidney; Kidney Failure, Chronic; Kidney Tubules; Risk Factors; Uric Aci | 2016 |
Nanocapsule assemblies as effective enzyme delivery systems against hyperuricemia.
Topics: Animals; Biological Availability; Hemolysis; Hyperuricemia; Nanocapsules; Rats; Urate Oxidase; Uric | 2016 |
Survey Definitions of Gout for Epidemiologic Studies: Comparison With Crystal Identification as the Gold Standard.
Topics: Colchicine; Diagnostic Self Evaluation; Epidemiologic Studies; Female; Gout; Gout Suppressants; Huma | 2016 |
SIRT1 prevents hyperuricemia via the PGC-1α/PPARγ-ABCG2 pathway.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; Cell Line, Tumor; Humans; Hyperuri | 2016 |
Hyperuricemia and Cardiovascular Disease in Patients with Hypertension.
Topics: Aged; Biomarkers; Body Mass Index; Cardiovascular Diseases; Cholesterol, HDL; Colombia; Cross-Sectio | 2016 |
Prevalence of and risk factors for non-alcoholic fatty liver disease in a Chinese population: An 8-year follow-up study.
Topics: Adult; Aged; Biomarkers; Blood Glucose; Body Mass Index; China; Cholesterol, HDL; Cholesterol, LDL; | 2016 |
Metabolically healthy obesity also has risk for hyperuricemia among Chinese general population: A cross-sectional study.
Topics: Adult; Aged; Body Mass Index; China; Cross-Sectional Studies; Female; Health Status; Humans; Hyperur | 2016 |
A causal relationship between uric acid and diabetic macrovascular disease in Chinese type 2 diabetes patients: A Mendelian randomization analysis.
Topics: Adult; Aged; Asian People; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies | 2016 |
Total saponins from dioscorea septemloba thunb reduce serum uric acid levels in rats with hyperuricemia through OATP1A1 up-regulation.
Topics: Animals; Creatinine; Dioscorea; Drugs, Chinese Herbal; Gastric Mucosa; Hyperuricemia; Intestinal Muc | 2016 |
Effects of xanthine oxidase inhibitors on renal function and blood pressure in hypertensive patients with hyperuricemia.
Topics: Aged; Allopurinol; Blood Pressure; Enzyme Inhibitors; Febuxostat; Female; Glomerular Filtration Rate | 2016 |
Single 4.5 mg fixed-dose of rasburicase for hyperuricemia associated with tumor lysis syndrome.
Topics: Aged; Disease Progression; Female; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Over | 2017 |
New therapeutic approach to hyperuricemia and gout in the light of recommendations.
Topics: Europe; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Monitoring, Physiologic; Pract | 2016 |
Spatiotemporal gait parameters and plantar pressure distribution during barefoot walking in people with gout and asymptomatic hyperuricemia: comparison with healthy individuals with normal serum urate concentrations.
Topics: Adult; Aged; Body Mass Index; Case-Control Studies; Cross-Sectional Studies; Female; Foot; Gait; Gou | 2016 |
Uric acid bladder stones in congenital cyanotic heart disease.
Topics: Cyanosis; Gas Chromatography-Mass Spectrometry; Humans; Hydronephrosis; Hyperuricemia; Magnetic Reso | 2016 |
Assessment of myocardial performance index in hypertensive patients with or without hyperuricaemia.
Topics: Aged; Echocardiography, Doppler; Female; Heart; Humans; Hypertension; Hyperuricemia; Male; Middle Ag | 2016 |
Serum uric acid level and left ventricular hypertrophy in elderly male patients with nonvalvular atrial fibrillation.
Topics: Age Factors; Aged; Aged, 80 and over; Atrial Fibrillation; Biomarkers; Chi-Square Distribution; Huma | 2016 |
Overweight modifies the longitudinal association between uric acid and some components of the metabolic syndrome: The Tromsø Study.
Topics: Aged; Biomarkers; Blood Glucose; Blood Pressure; Body Mass Index; Chi-Square Distribution; Female; H | 2016 |
Effect of Soy Sauce on Serum Uric Acid Levels in Hyperuricemic Rats and Identification of Flazin as a Potent Xanthine Oxidase Inhibitor.
Topics: Animals; Body Weight; Carbolines; Drug Evaluation, Preclinical; Enzyme Inhibitors; Furans; Hyperuric | 2016 |
Effects of uric-acid-lowering therapy on renal outcomes: the future looks promising.
Topics: Humans; Hyperuricemia; Kidney; Uric Acid | 2016 |
Prognostic Role of Hyperuricemia in Acute Heart Failure.
Topics: Acute Disease; Aged; Female; Heart Failure; Humans; Hyperuricemia; Male; Middle Aged; Prognosis; Uri | 2016 |
Febuxostat for Asymptomatic Hyperuricemia in CKD.
Topics: Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chronic; Thiazoles; | 2016 |
Febuxostat Renoprotection in CKD Patients With Asymptomatic Hyperuricemia.
Topics: Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chronic; Thiazoles; | 2016 |
In Reply to 'Febuxostat for Asymptomatic Hyperuricemia in CKD' and 'Febuxostat Renoprotection in CKD Patients With Asymptomatic Hyperuricemia'.
Topics: Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chronic; Thiazoles; | 2016 |
Hyperuricemia, Cardiovascular Profile, and Comorbidity in Older Men and Women: The Pro.V.A. Study.
Topics: Aged; Anthropometry; Cardiovascular Diseases; Case-Control Studies; Comorbidity; Female; Humans; Hyp | 2017 |
Clinicopathologic features of IgA nephropathy patients with different levels of proteinuria.
Topics: Adult; Atrophy; Biopsy; Female; Fibrosis; Glomerular Filtration Rate; Glomerulonephritis, IGA; Glome | 2016 |
Modeling and Simulation for Estimating the Influence of Renal Dysfunction on the Hypouricemic Effect of Febuxostat in Hyperuricemic Patients Due to Overproduction or Underexcretion of Uric Acid.
Topics: Computer Simulation; Febuxostat; Gout Suppressants; Humans; Hyperuricemia; Models, Biological; Renal | 2016 |
Allopurinol decreases serum uric acid level and intestinal glucose transporter-5 expression in rats with fructose-induced hyperuricemia.
Topics: Allopurinol; Animals; Benzbromarone; Fructose; Glucose Transporter Type 2; Glucose Transporter Type | 2016 |
The prognostic impact of uric acid in patients with severely decompensated acute heart failure.
Topics: Acute Disease; Aged; Aged, 80 and over; Female; Heart Failure; Humans; Hyperuricemia; Japan; Male; M | 2016 |
Effects of Treatment of Asymptomatic Hyperuricemia on Graft Survival and Mortality in Kidney Transplant Recipients.
Topics: Adult; Female; Graft Survival; Humans; Hyperuricemia; Kidney Transplantation; Male; Middle Aged; Ret | 2016 |
Common UCP2 variants contribute to serum urate concentrations and the risk of hyperuricemia.
Topics: Amino Acid Substitution; Asian People; Female; Genetic Predisposition to Disease; Haplotypes; Humans | 2016 |
Febuxostat for Patients With Gout and Severe Chronic Kidney Disease: Which Is the Appropriate Dosage? Comment on the Article by Saag et al.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chroni | 2016 |
Prevalence and factors associated with hyperuricaemia in newly diagnosed and untreated hypertensives in a sub-Saharan African setting.
Topics: Cameroon; Cross-Sectional Studies; Female; Humans; Hypertension; Hyperuricemia; Male; Middle Aged; P | 2016 |
The consumption of fish cooked by different methods was related to the risk of hyperuricemia in Japanese adults: A 3-year follow-up study.
Topics: Adult; Aged; Biomarkers; Cooking; Diet; Feeding Behavior; Female; Humans; Hyperuricemia; Japan; Logi | 2016 |
Coevolution of URAT1 and Uricase during Primate Evolution: Implications for Serum Urate Homeostasis and Gout.
Topics: Animals; Biological Evolution; Computer Simulation; Evolution, Molecular; Gout; HEK293 Cells; Homeos | 2016 |
Distribution of Serum Uric Acid in Black Africans and Its Association With Cardiovascular Risk Factors.
Topics: Adult; Aged; Angola; Black People; Cardiovascular Diseases; Cross-Sectional Studies; Female; Humans; | 2017 |
Hypouricemic effect of allopurinol are improved by Pallidifloside D based on the uric acid metabolism enzymes PRPS, HGPRT and PRPPAT.
Topics: Allopurinol; Animals; Drug Synergism; Gene Expression Regulation; Hyperuricemia; Hypoxanthine Phosph | 2016 |
Uric acid lowering effect of Tibetan Medicine RuPeng15 powder in animal models of hyperuricemia.
Topics: Animals; Drugs, Chinese Herbal; Humans; Hyperuricemia; Liver; Male; Medicine, Tibetan Traditional; R | 2016 |
Uric acid stimulates proliferative pathways in vascular smooth muscle cells through the activation of p38 MAPK, p44/42 MAPK and PDGFRβ.
Topics: Angiotensin II; Animals; Atherosclerosis; Cardiovascular Diseases; Cell Proliferation; Gene Expressi | 2017 |
Associations between serum uric acid levels and the incidence of nonfatal stroke: a nationwide community-based cohort study.
Topics: Adult; Aged; Biomarkers; Chi-Square Distribution; Databases, Factual; Female; Humans; Hyperuricemia; | 2017 |
The Relation of Moderate Alcohol Consumption to Hyperuricemia in a Rural General Population.
Topics: Adult; Aged; Alcohol Drinking; Alcoholic Intoxication; China; Female; Humans; Hyperuricemia; Life St | 2016 |
Prenatal Earthquake Exposure and Midlife Uric Acid Levels Among Chinese Adults.
Topics: Adult; Asian People; China; Disasters; Earthquakes; Female; Follow-Up Studies; Humans; Hyperuricemia | 2017 |
Extracorporeal delivery of a therapeutic enzyme.
Topics: Animals; Dialysis Solutions; Extracorporeal Membrane Oxygenation; Geese; Hyperuricemia; Renal Dialys | 2016 |
High serum uric acid is associated to poorly controlled blood pressure and higher arterial stiffness in hypertensive subjects.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Cohort Studies; Female; Humans; Hypertension; | 2017 |
Siwu decoction attenuates oxonate-induced hyperuricemia and kidney inflammation in mice.
Topics: Animals; Blood Urea Nitrogen; Creatinine; Drugs, Chinese Herbal; Humans; Hyperuricemia; Interleukin- | 2016 |
Astilbin improves potassium oxonate-induced hyperuricemia and kidney injury through regulating oxidative stress and inflammation response in mice.
Topics: Animals; Carrier Proteins; Flavonols; Hyperuricemia; Inflammasomes; Inflammation; Janus Kinase 2; Ki | 2016 |
Poorly controlled gout: who is doing poorly?
Topics: Allopurinol; Arthritis; Comorbidity; Gout; Humans; Hyperuricemia; Inflammation; Medication Adherence | 2016 |
Hyperuricemia is associated with increased hospitalization risk and healthcare costs: Evidence from an administrative database in Italy.
Topics: Administrative Claims, Healthcare; Aged; Biomarkers; Databases, Factual; Delivery of Health Care; Fe | 2016 |
Serum Uric Acid Level Predicts Progression of IgA Nephropathy in Females but Not in Males.
Topics: Adult; Disease Progression; Female; Glomerulonephritis, IGA; Humans; Hyperuricemia; Male; Middle Age | 2016 |
Association between Serum Uric Acid and Elevated Alanine Aminotransferase in the General Population.
Topics: Adult; Alanine; Alanine Transaminase; Asian People; China; Cross-Sectional Studies; Female; Humans; | 2016 |
The Impact of Blood Pressure and Visceral Adiposity on the Association of Serum Uric Acid With Albuminuria in Adults Without Full Metabolic Syndrome.
Topics: Adiposity; Adult; Albuminuria; Biomarkers; Blood Pressure; Chi-Square Distribution; Creatinine; Cros | 2016 |
Hyperuricemia in acute gastroenteritis is caused by decreased urate excretion via ABCG2.
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; Gastroenteritis; Humans; Hyperuricemia; Int | 2016 |
Atherogenic Index of Plasma Predicts Hyperuricemia in Rural Population: A Cross-Sectional Study from Northeast China.
Topics: Adult; Atherosclerosis; China; Cross-Sectional Studies; Female; Humans; Hyperuricemia; Male; Middle | 2016 |
Inhibitory effect of verbascoside on xanthine oxidase activity.
Topics: Animals; Enzyme Inhibitors; Glucosides; Hyperuricemia; Liver; Male; Molecular Docking Simulation; Ph | 2016 |
Ultrasound Features of the First Metatarsophalangeal Joint in Gout and Asymptomatic Hyperuricemia: Comparison With Normouricemic Individuals.
Topics: Adult; Aged; Female; Gout; Humans; Hyperuricemia; Male; Metatarsophalangeal Joint; Middle Aged; Sing | 2017 |
Hyperferritinemia increases the risk of hyperuricemia in HFE-hereditary hemochromatosis.
Topics: Adult; Female; Ferritins; Hemochromatosis; Hemochromatosis Protein; Humans; Hyperuricemia; Iron Meta | 2017 |
Miliarial gout: a rare presentation of extensive cutaneous tophi.
Topics: Fatal Outcome; Gout; Humans; Hyperuricemia; Male; Middle Aged; Sepsis; Skin Diseases; Uric Acid | 2016 |
Dose-response relationship between serum uric acid levels and risk of incident coronary heart disease in the Dongfeng-Tongji Cohort.
Topics: Aged; Biomarkers; China; Coronary Artery Disease; Female; Follow-Up Studies; Humans; Hyperuricemia; | 2016 |
Are atherosclerotic risk factors associated with a poor prognosis in patients with hyperuricemic acute heart failure? The evaluation of the causal dependence of acute heart failure and hyperuricemia.
Topics: Acute Disease; Aged; Atherosclerosis; Cause of Death; Female; Heart Failure; Humans; Hyperuricemia; | 2017 |
Uric acid and essential hypertension: the endothelial connection.
Topics: Essential Hypertension; Humans; Hypertension; Hyperuricemia; Uric Acid | 2016 |
Effects of extracts from Corylopsis coreana Uyeki (Hamamelidaceae) flos on xanthine oxidase activity and hyperuricemia.
Topics: Animals; Biomarkers; Disease Models, Animal; Dose-Response Relationship, Drug; Enzyme Inhibitors; Et | 2016 |
Hypouricemic effects of Mesona procumbens Hemsl. through modulating xanthine oxidase activity in vitro and in vivo.
Topics: Animals; Humans; Hyperuricemia; Lamiaceae; Liver; Mice; Mice, Inbred ICR; Oxonic Acid; Plant Extract | 2016 |
Familial juvenile hyperuricemic nephropathy as rare cause of dialysis-dependent chronic kidney disease-a series of cases in two families.
Topics: Adolescent; Adult; Child; Child, Preschool; DNA Mutational Analysis; Female; Gout; Humans; Hyperuric | 2016 |
Hypouricemic effect of flaccidoside II in rodents.
Topics: Animals; Hyperuricemia; Male; Mice; Rats; Rats, Sprague-Dawley; Saponins; Uric Acid | 2017 |
Hyperuricemia as a Predictive Marker for Progression of Nephrosclerosis: Clinical Assessment of Prognostic Factors in Biopsy-Proven Arterial/Arteriolar Nephrosclerosis.
Topics: Adolescent; Adult; Aged; Biomarkers; Biopsy; Cohort Studies; Comorbidity; Disease Progression; Femal | 2017 |
Hyperuricemia is an independent risk factor for
renal pathological damage and poor prognosis in
lupus nephritis patients.
Topics: Blood Urea Nitrogen; Creatinine; Female; Glomerular Filtration Rate; Humans; Hypertension; Hypertens | 2016 |
Hyperuricemia and Cardiovascular Disease: What is Left to Prove?
Topics: Cardiovascular Diseases; Humans; Hyperuricemia; Risk Factors; Uric Acid | 2017 |
Increased risk for hyperuricemia in adults sensitized to cow milk allergen.
Topics: Adult; Aged; Aged, 80 and over; Female; Humans; Hyperuricemia; Immunoglobulin E; Male; Middle Aged; | 2017 |
Antihyperuricemic effect of liquiritigenin in potassium oxonate-induced hyperuricemic rats.
Topics: Animals; Dose-Response Relationship, Drug; Female; Flavanones; Gout Suppressants; Hyperuricemia; Mal | 2016 |
Hyperuricemia is an independent competing risk factor for atrial fibrillation.
Topics: Atrial Fibrillation; Cross-Sectional Studies; Female; Humans; Hyperuricemia; Incidence; Male; Middle | 2017 |
Serum Uric Acid and Mortality Form Cardiovascular Disease: EPOCH-JAPAN Study.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Cardiovascular Diseases; Cohort Studies; Female; Humans; | 2016 |
Ultrasonography in the diagnosis of asymptomatic hyperuricemia and gout.
Topics: Gout; Humans; Hyperuricemia; Ultrasonography; Uric Acid | 2016 |
Fructose suppresses uric acid excretion to the intestinal lumen as a result of the induction of oxidative stress by NADPH oxidase activation.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; Fructose; Hyperuricemia; Ileum; Ma | 2017 |
The association of uric acid with leukoaraiosis.
Topics: Aged; Aged, 80 and over; Alcohol Drinking; Asian People; Cognitive Dysfunction; Cross-Sectional Stud | 2017 |
Blood-borne phagocytes internalize urate microaggregates and prevent intravascular NETosis by urate crystals.
Topics: Animals; Extracellular Traps; Humans; Hyperuricemia; Mice; Mice, Inbred BALB C; Neutrophil Activatio | 2016 |
Catalysis and Structure of Zebrafish Urate Oxidase Provide Insights into the Origin of Hyperuricemia in Hominoids.
Topics: Amino Acid Sequence; Animals; Base Sequence; Binding Sites; Biocatalysis; Biological Evolution; Crys | 2016 |
Emerging uricosurics for gout.
Topics: Drug Design; Gout; Humans; Hyperuricemia; Uric Acid; Uricosuric Agents | 2017 |
Association Between Hyperuricemia and Major Adverse Cardiac Events in Patients with Acute Myocardial Infarction.
Topics: Adult; Aged; Cardiovascular Diseases; Diabetes Complications; Female; Heart Failure; Humans; Hyperte | 2017 |
Is it Time to Find a Role for Uric Acid Levels in the Prevention and Management of Hypertension.
Topics: Cohort Studies; Humans; Hypertension; Hyperuricemia; Uric Acid | 2017 |
(E)-2-(4-bromophenyl)-1-(2, 4-dihydroxyphenyl)ethanone oxime is a potential therapeutic agent for treatment of hyperuricemia through its dual inhibitory effects on XOD and URAT1.
Topics: Animals; Dose-Response Relationship, Drug; HEK293 Cells; Humans; Hyperuricemia; Male; Mice; Organic | 2017 |
A Clinical and Economic Comparison of Rasburicase and Allopurinol in the Treatment of Patients With Clinical or Laboratory Tumor Lysis Syndrome.
Topics: Allopurinol; Female; Gout Suppressants; Hospitalization; Humans; Hyperuricemia; Length of Stay; Male | 2017 |
Sex-specific association between serum uric acid and prolonged corrected QT interval: Result from a general rural Chinese population.
Topics: China; Electrocardiography; Female; Humans; Hyperuricemia; Long QT Syndrome; Male; Middle Aged; Prev | 2016 |
Asymptomatic hyperuricemia is not an independent risk factor for cardiovascular events or overall mortality in the general population of the Busselton Health Study.
Topics: Asymptomatic Diseases; Biomarkers; Cardiovascular Diseases; Female; Forecasting; Health Surveys; Hum | 2016 |
Down-regulation of ABCG2, a urate exporter, by parathyroid hormone enhances urate accumulation in secondary hyperparathyroidism.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; Caco-2 Cells; Calcimimetic Agents; | 2017 |
Hyperuricemia: A causal player or a bystander linking inflammatory signaling and atrial fibrillation?
Topics: Atrial Fibrillation; Humans; Hyperuricemia; Inflammasomes; NLR Family, Pyrin Domain-Containing 3 Pro | 2017 |
The Effect of Allopurinol on Renal Function.
Topics: Aged; Allopurinol; Antimetabolites; Creatinine; Glomerular Filtration Rate; Humans; Hyperuricemia; M | 2017 |
Asymptomatic hyperuricemia is a strong risk factor for resistant hypertension in elderly subjects from general population.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Cross-Sectiona | 2017 |
URAT1 inhibition by ALPK1 is associated with uric acid homeostasis.
Topics: Animals; Case-Control Studies; Cells, Cultured; Crystallization; Gout; Homeostasis; Humans; Hyperuri | 2017 |
COX-2/mPGES-1/PGE2 cascade activation mediates uric acid-induced mesangial cell proliferation.
Topics: Aged; Animals; Case-Control Studies; Cell Line; Cell Proliferation; Cyclin A2; Cyclin D1; Cyclooxyge | 2017 |
The burden of major adverse cardiac events in patients with coronary artery disease.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Area Under Curve; Chi-Square Distribution; | 2017 |
Aldose reductase mediates endothelial cell dysfunction induced by high uric acid concentrations.
Topics: Aldehyde Reductase; Animals; Catalase; Cytoprotection; Enzyme Inhibitors; Human Umbilical Vein Endot | 2017 |
Uric acid may be protective against cognitive impairment in older adults, but only in those without cardiovascular risk factors.
Topics: Aged; Aged, 80 and over; Cognitive Dysfunction; Dementia; Female; Heart Failure; Humans; Hypertensio | 2017 |
High Uric Acid Ameliorates Indoxyl Sulfate-Induced Endothelial Dysfunction and Is Associated with Lower Mortality among Hemodialysis Patients.
Topics: Adult; Aged; Biomarkers; Cause of Death; Cells, Cultured; Chi-Square Distribution; Endothelial Cells | 2017 |
Assessment of subclinical left ventricular changes in essential hypertensive patients with hyperuricemia: A three-dimensional speckle-tracking echocardiography study.
Topics: Aged; Echocardiography; Echocardiography, Three-Dimensional; Essential Hypertension; Female; Heart V | 2017 |
Effects of bariatric surgery on gout incidence in the Swedish Obese Subjects study: a non-randomised, prospective, controlled intervention trial.
Topics: Adult; Bariatric Surgery; Body Mass Index; Case-Control Studies; Controlled Clinical Trials as Topic | 2017 |
Association between plasma proANP and hyperuricemia in Chinese Han women: a cross-sectional study.
Topics: Adult; Aged; Aged, 80 and over; Atrial Natriuretic Factor; China; Cross-Sectional Studies; Ethnicity | 2017 |
Rational use of rasburicase for the treatment and management of tumor lysis syndrome.
Topics: Acute Kidney Injury; Adult; Aged; Cohort Studies; Disease Management; Female; Gout Suppressants; Hum | 2018 |
Incidence and Simple Prediction Model of Hyperuricemia for Urban Han Chinese Adults: A Prospective Cohort Study.
Topics: Adult; Age Distribution; Aged; Aged, 80 and over; Biomarkers; Blood Pressure; Body Mass Index; Femal | 2017 |
Effect of Rhizoma Polygoni Cuspidati and Ramulus Cinnamomi compatibility on uric acid metabolism and urinary neutrophil gelatinase-associated lipocalin and kidney injury molecule-1 in rats with hyperuricemia.
Topics: Animals; Blood Urea Nitrogen; Cell Adhesion Molecules; Creatinine; Drugs, Chinese Herbal; Hyperurice | 2017 |
Regular physical activity prevents development of hypertension in young people with hyperuricemia.
Topics: Adult; Exercise; Female; Heart Rate; Humans; Hypertension; Hyperuricemia; Male; Proportional Hazards | 2017 |
Independent Association between Hyperuricemia and Histopathological Parameters in Chinese Patients with Henöch-Schönlein Purpura Nephritis.
Topics: Adult; beta 2-Microglobulin; Biomarkers; China; Cholesterol, HDL; Cystatin C; Female; Glomerulonephr | 2016 |
Association of serum uric acid and risk of hypertension in adults: a prospective study of Kailuan Corporation cohort.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Biomarkers; Blood Pressure; China; Female; Follow-Up Stu | 2017 |
Relationship between hyperuricemia and risk of coronary heart disease in a middle-aged and elderly Chinese population.
Topics: Aged; Asian People; Biomarkers; China; Coronary Disease; Cross-Sectional Studies; Female; Humans; Hy | 2017 |
Positive association between metabolic syndrome and serum uric acid in Wuhan.
Topics: Adult; Age Factors; Body Mass Index; China; Cholesterol, LDL; Cross-Sectional Studies; Female; Human | 2017 |
Effects of multiple genetic loci on the pathogenesis from serum urate to gout.
Topics: Alleles; Case-Control Studies; Disease Progression; Female; Gene Expression; Genetic Association Stu | 2017 |
Gypenosides Inhibits Xanthine Oxidoreductase and Ameliorates Urate Excretion in Hyperuricemic Rats Induced by High Cholesterol and High Fat Food (Lipid Emulsion).
Topics: Animals; Cholesterol; Diet, High-Fat; Gynostemma; Hypercholesterolemia; Hyperuricemia; Kidney; Lipid | 2017 |
Serum uric acid is not independently associated with plasma renin activity and plasma aldosterone in hypertensive adults.
Topics: Adiposity; Adult; Age Factors; Aldosterone; Biomarkers; Blood Pressure; Chi-Square Distribution; Cro | 2017 |
Uric Acid and Decline in Renal Function-Partners in Crime.
Topics: Crime; Glomerular Filtration Rate; Humans; Hyperuricemia; Uric Acid | 2017 |
Synergistic Degradation of a Hyperuricemia-Causing Metabolite Using One-Pot Enzyme-Nanozyme Cascade Reactions.
Topics: Catalase; Coated Materials, Biocompatible; Gold; Humans; Hydrogen Peroxide; Hyperuricemia; Metal Nan | 2017 |
Inflammatory status and uricaemia determine HDL-cholesterol levels in hypertensive adults over 65: an analysis of the FAPRES register.
Topics: Aged; Biomarkers; Chi-Square Distribution; Cholesterol, HDL; Cholesterol, LDL; Cross-Sectional Studi | 2017 |
[High Serum Concentrations of Uric Acid: Clinical and Prognostic Significance in Chronic Heart Failure].
Topics: Chronic Disease; Heart Failure; Humans; Hyperuricemia; Prognosis; Uric Acid | 2016 |
Folic acid: the solution for treating asymptomatic hyperuricemia?
Topics: Folic Acid; Humans; Hyperuricemia; Uric Acid | 2017 |
Potassium oxonate induces acute hyperuricemia in the tree shrew (tupaia belangeri chinensis).
Topics: Acute Disease; Allopurinol; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Enzym | 2017 |
An initial presentation of polyarticular gout with spinal involvement.
Topics: Aged, 80 and over; Allopurinol; Anti-Inflammatory Agents; Diffusion Magnetic Resonance Imaging; Fema | 2008 |
Hyperuricemia after liver transplantation in children.
Topics: Adolescent; Adult; Child; Child, Preschool; Female; Follow-Up Studies; Glomerular Filtration Rate; H | 2008 |
Uric acid and neuroprotection.
Topics: Animals; Antioxidants; Humans; Hyperuricemia; Neuroprotective Agents; Oxidative Stress; Stroke; Uric | 2008 |
Serum uric acid and ambulatory blood pressure in children with primary hypertension.
Topics: Adolescent; Asian; Black or African American; Blood Pressure; Blood Pressure Monitoring, Ambulatory; | 2008 |
Oxonic acid-induced hyperuricemia elevates plasma aldosterone in experimental renal insufficiency.
Topics: Aldosterone; Animal Feed; Animals; Autoradiography; Blood Pressure; Disease Models, Animal; Hyperten | 2008 |
Dietary and lifestyle changes associated with high prevalence of hyperuricemia and gout in the Shandong coastal cities of Eastern China.
Topics: Adult; Aged; China; Comorbidity; Feeding Behavior; Female; Gout; Humans; Hyperuricemia; Life Style; | 2008 |
Does an apple a day put hypertension in play?
Topics: Amino Acid Transport Systems; Animals; Chlorides; Female; Fructose; Glucose Transport Proteins, Faci | 2008 |
Uricosuric action of losartan via the inhibition of urate transporter 1 (URAT 1) in hypertensive patients.
Topics: Administration, Oral; Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compou | 2008 |
Hyperuricaemia is associated with increased C-reactive protein concentrations in a large cohort of unselected outpatients.
Topics: Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Cohort Studies; Humans; Hyperuricemia; Pred | 2008 |
Essential oil from leaves of Cinnamomum osmophloeum acts as a xanthine oxidase inhibitor and reduces the serum uric acid levels in oxonate-induced mice.
Topics: Acrolein; Administration, Oral; Allopurinol; Animals; Cinnamomum; Enzyme Inhibitors; Gout Suppressan | 2008 |
Lithospermic acid as a novel xanthine oxidase inhibitor has anti-inflammatory and hypouricemic effects in rats.
Topics: Allopurinol; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Benzofurans; Depsid | 2008 |
Plasma urate level is directly regulated by a voltage-driven urate efflux transporter URATv1 (SLC2A9) in humans.
Topics: Animals; Cardiovascular Diseases; Female; Gene Expression; Glucose Transport Proteins, Facilitative; | 2008 |
Serum uric acid level in primary hypertension among Chinese nonagenarians/centenarians.
Topics: Age Factors; Aged; Aged, 80 and over; Asian People; China; Cohort Studies; Cross-Sectional Studies; | 2009 |
Asymptomatic hyperuricemia and serum uric acid concentration correlate with subclinical atherosclerosis in psoriatic arthritis patients without clinically evident cardiovascular disease.
Topics: Adult; Aged; Arthritis, Psoriatic; Atherosclerosis; Biomarkers; Carotid Arteries; Cohort Studies; Fe | 2009 |
Febuxostat: a viewpoint by H. Ralph Schumacher Jr and Lan X. Chen.
Topics: Administration, Oral; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Thiazoles; Uric Ac | 2008 |
Febuxostat : a viewpoint by Naomi Schlesinger.
Topics: Administration, Oral; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Thiazoles; Uric Ac | 2008 |
Febuxostat : a viewpoint by N. Lawrence Edwards.
Topics: Administration, Oral; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Thiazoles; Uric Ac | 2008 |
High serum uric acid as a novel risk factor for type 2 diabetes: response to Dehghan et al.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Humans; Hyperuricemia; Reference Values; Reproducibility o | 2008 |
High serum uric acid as a novel risk factor for type 2 diabetes: response to Dehghan et al.
Topics: Diabetes Mellitus, Type 2; Humans; Hyperuricemia; Risk Factors; Uric Acid | 2008 |
Uric acid and hypertension: an age-related relationship?
Topics: Age Factors; Humans; Hypertension; Hyperuricemia; Uric Acid | 2009 |
Cerebral ischemia mediates the effect of serum uric acid on cognitive function.
Topics: Adult; Aged; Brain; Brain Edema; Brain Ischemia; Cognition Disorders; Female; Humans; Hyperuricemia; | 2008 |
Hyperuricemia, gout, and lifestyle factors.
Topics: Adult; Aged; Aged, 80 and over; China; Comorbidity; Feeding Behavior; Gout; Humans; Hyperuricemia; L | 2008 |
Effects of onion on serum uric acid levels and hepatic xanthine dehydrogenase/xanthine oxidase activities in hyperuricemic rats.
Topics: Animals; Hyperuricemia; Liver; Male; Onions; Rats; Rats, Sprague-Dawley; Uric Acid; Xanthine Dehydro | 2008 |
Confessions of a goutophile: Despite its treatability, gout remains a problem.
Topics: Diagnosis, Differential; Gout; Gout Suppressants; Humans; Hyperuricemia; Uric Acid | 2008 |
How PCP education can impact gout management: the gout essentials.
Topics: Anti-Inflammatory Agents; Gout; Gout Suppressants; Humans; Hyperuricemia; Physicians, Family; Uric A | 2008 |
Understanding deficient elimination of uric acid.
Topics: Gout; Humans; Hyperuricemia; Kidney; Metabolic Clearance Rate; Uric Acid | 2008 |
Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study.
Topics: Alleles; Chromosomes, Human, 4-5; Chromosomes, Human, 6-12 and X; Cohort Studies; Female; Genetics, | 2008 |
Serum calcium, magnesium and uric acid in preeclampsia and normal pregnancy.
Topics: Adult; Analysis of Variance; Calcium; Cross-Sectional Studies; Female; Humans; Hyperuricemia; Hypoca | 2008 |
Uric acid activates extracellular signal-regulated kinases and thereafter endothelin-1 expression in rat cardiac fibroblasts.
Topics: Animals; Antioxidants; Cell Division; Cells, Cultured; Endothelin-1; Extracellular Signal-Regulated | 2010 |
Ambulatory blood pressure, proteinuria and uric acid in children with IgA nephropathy and their correlation with histopathological findings.
Topics: Adolescent; Blood Pressure Monitoring, Ambulatory; Child; Circadian Rhythm; Diastole; Female; Glomer | 2008 |
Mutations in the SLC2A9 gene cause hyperuricosuria and hyperuricemia in the dog.
Topics: Amino Acid Sequence; Animals; Chromosome Mapping; Dog Diseases; Dogs; Glucose Transport Proteins, Fa | 2008 |
Efficacy of rasburicase in hyperuricemia secondary to Lesch-Nyhan syndrome.
Topics: Dose-Response Relationship, Drug; Gene Deletion; Gout Suppressants; Humans; Hyperuricemia; Hypoxanth | 2009 |
Hypouricemic and antioxidant activities of Allium cepa Lilliaceae and quercetin in normal and hyperuricemic rats.
Topics: Allium; Animals; Antioxidants; Chromatography, High Pressure Liquid; Hyperuricemia; Male; Oxidative | 2008 |
Uric acid in chronic heart failure--current pathophysiological concepts.
Topics: Endothelium, Vascular; Heart Failure; Humans; Hyperuricemia; Risk Factors; Superoxide Dismutase; Uri | 2008 |
Activation of ATP-sensitive potassium channels protects vascular endothelial cells from hypertension and renal injury induced by hyperuricemia.
Topics: 6-Ketoprostaglandin F1 alpha; Angiotensin II; Angiotensins; Animals; Cells, Cultured; Disease Models | 2008 |
Prevalence of hypouricaemia and SLC22A12 mutations in healthy Korean subjects.
Topics: Adult; Asian People; Blood Pressure; Creatinine; Female; Gene Frequency; Genetic Predisposition to D | 2008 |
Hyperuricemia and its related factors in an urban population, Izmir, Turkey.
Topics: Adult; Blood Glucose; Body Composition; Creatinine; Diabetes Mellitus; Female; Gout; Humans; Hyperte | 2009 |
[The association between hyperuricemia and prevalence of carotid plaque].
Topics: Aged; Carotid Artery Diseases; Cohort Studies; Female; Humans; Hyperuricemia; Male; Middle Aged; Pre | 2008 |
[Oxidative stress and endothelial dysfunction at different serum uric acid levels].
Topics: Case-Control Studies; Endothelium, Vascular; Glutathione Peroxidase; Humans; Hyperuricemia; Male; Ma | 2008 |
Clinical diagnostic criteria for gout: comparison with the gold standard of synovial fluid crystal analysis.
Topics: Aged; Cohort Studies; Crystallization; Female; Gout; Humans; Hyperuricemia; Male; Middle Aged; Predi | 2009 |
The effect of the interaction between obesity and drinking on hyperuricemia in Japanese male office workers.
Topics: Adult; Aged; Alcohol Drinking; Biomarkers; Body Mass Index; Case-Control Studies; Cross-Sectional St | 2009 |
Serum uric acid level as an independent risk factor for all-cause, cardiovascular, and ischemic stroke mortality: a Chinese cohort study.
Topics: Adult; Cardiovascular Diseases; Female; Humans; Hyperuricemia; Male; Middle Aged; Proportional Hazar | 2009 |
Uric acid and cardiovascular risk.
Topics: Animals; Biological Evolution; Cardiovascular Diseases; Hominidae; Humans; Hyperuricemia; Mutation; | 2009 |
Lonicera hypoglauca inhibits xanthine oxidase and reduces serum uric acid in mice.
Topics: Animals; Flavonoids; Hyperuricemia; Lonicera; Male; Medicine, Chinese Traditional; Mice; Mice, Inbre | 2009 |
Uric acid and cardiovascular risk.
Topics: Biomarkers; Cardiovascular Diseases; Humans; Hyperuricemia; Purines; Risk Factors; Uric Acid; Xanthi | 2009 |
Uric acid and cardiovascular risk.
Topics: Allopurinol; Antimetabolites; Biomarkers; Cardiovascular Diseases; Humans; Hyperuricemia; Kidney Dis | 2009 |
Uric acid and cardiovascular risk.
Topics: Biomarkers; Cardiovascular Diseases; Heart Failure; Humans; Hyperuricemia; Prognosis; Risk Factors; | 2009 |
Association between hyperuricemia and incident heart failure among older adults: a propensity-matched study.
Topics: Aged; Aged, 80 and over; Biomarkers; Female; Heart Failure; Humans; Hyperuricemia; Incidence; Kaplan | 2010 |
Reactions of peroxynitrite with uric acid: formation of reactive intermediates, alkylated products and triuret, and in vivo production of triuret under conditions of oxidative stress.
Topics: Antioxidants; Female; Humans; Hyperuricemia; Oxidants; Oxidative Stress; Peroxynitrous Acid; Pre-Ecl | 2009 |
Hyperuricemia in acute heart failure. More than a simple spectator?
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Cause of Death; Female; Follow-Up Studies; Heart Fail | 2009 |
Single-dose rasburicase for tumour lysis syndrome in adults: weight-based approach.
Topics: Aged; Antineoplastic Agents; Creatinine; Drug Costs; Female; Gout Suppressants; Humans; Hyperuricemi | 2009 |
Association of uric acid with inflammation, progressive renal allograft dysfunction and post-transplant cardiovascular risk.
Topics: Adult; C-Reactive Protein; Cardiovascular Diseases; Female; Glomerular Filtration Rate; Humans; Hype | 2009 |
Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Hyperuricemia; Thiazoles; Treatment Outcome; Uric | 2009 |
Sevelamer decreases serum uric acid concentration through adsorption of uric acid in maintenance hemodialysis patients.
Topics: Absorption; Adult; Aged; Aged, 80 and over; Chelating Agents; Female; Follow-Up Studies; Humans; Hyp | 2009 |
High-resolution melting analysis for the rapid detection of an intronic single nucleotide polymorphism in SLC22A12 in male patients with primary gout in China.
Topics: Adult; Aged; Analysis of Variance; Case-Control Studies; China; DNA Mutational Analysis; Genetic Pre | 2009 |
Hyperuricemia and the metabolic syndrome in Hangzhou.
Topics: Adult; Aged; Aged, 80 and over; Blood Pressure; Body Mass Index; China; Cross-Sectional Studies; Fem | 2009 |
Insulin resistance acts as an independent risk factor exacerbating high-purine diet induced renal injury and knee joint gouty lesions.
Topics: Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Gout; Homeostasis; Hyperuricemia; Hypogl | 2009 |
Elevated serum uric acid is an independent predictor for cardiovascular events in patients with severe coronary artery stenosis: subanalysis of the Japanese Coronary Artery Disease (JCAD) Study.
Topics: Aged; Biomarkers; Cardiovascular Diseases; Coronary Stenosis; Female; Follow-Up Studies; Humans; Hyp | 2009 |
Frequency, risk, and cost of gout-related episodes among the elderly: does serum uric acid level matter?
Topics: Aged; Aging; Blood Chemical Analysis; Female; Gout; Gout Suppressants; Health Expenditures; Humans; | 2009 |
Moderate-to-severe early-onset hyperuricaemia: a prognostic marker of long-term kidney transplant outcome.
Topics: Adult; Age of Onset; Biomarkers; Cohort Studies; Female; Glomerular Filtration Rate; Humans; Hyperur | 2009 |
Mechanisms of antihyperuricemic effect of Phyllanthus niruri and its lignan constituents.
Topics: Animals; Disease Models, Animal; Drug Synergism; Gout Suppressants; Hyperuricemia; Inhibitory Concen | 2009 |
Effect of lowering uric acid on renal disease in the type 2 diabetic db/db mice.
Topics: Albuminuria; Allopurinol; Animals; Blood Pressure; Blood Urea Nitrogen; Cell Line; Diabetes Mellitus | 2009 |
Role of asymptomatic hyperuricemia and serum uric acid levels in the pathogenesis of subclinical atherosclerosis in psoriatic arthritis: comment on the article by Chen et al.
Topics: Arthritis, Psoriatic; Atherosclerosis; Cohort Studies; Comorbidity; Female; Humans; Hyperuricemia; M | 2009 |
Uric acid is associated with the rate of residual renal function decline in peritoneal dialysis patients.
Topics: Adult; Aged; Female; Humans; Hypertension; Hyperuricemia; Kidney; Kidney Failure, Chronic; Male; Mid | 2009 |
Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout.
Topics: Amino Acid Sequence; Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding C | 2009 |
Hyperuricemia, oxidative stress, and carotid artery tone in experimental renal insufficiency.
Topics: Animals; Carotid Arteries; Creatinine; Dinoprost; Hyperuricemia; Male; Nephrectomy; NG-Nitroarginine | 2009 |
[Peculiarities of uric acid balance disorders in patients with type 2 diabetes and metabolic syndrome].
Topics: Abdominal Fat; Aged; Diabetes Insipidus, Nephrogenic; Female; Humans; Hyperuricemia; Insulin Resista | 2009 |
Serum uric acid is independently associated with metabolic syndrome in subjects with and without a low estimated glomerular filtration rate.
Topics: Adult; Female; Glomerular Filtration Rate; Humans; Hyperuricemia; Male; Metabolic Syndrome; Middle A | 2009 |
Uric acid as a marker for renal dysfunction in hypertensive women on diuretic and nondiuretic therapy.
Topics: Aged; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Chronic Disease; Creatinine; Cross-Se | 2009 |
Role of uric acid in post-renal transplantation hypertension.
Topics: Adult; Blood Pressure; Female; Humans; Hypertension; Hyperuricemia; Kidney Transplantation; Male; Mi | 2009 |
Gout Study Group: update on hyperuricemia and gout.
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Colchicine; Diet; Europe; Febuxostat; Gout; | 2009 |
Uric acid levels and outcomes from coronary artery bypass grafting: is it the chicken or the egg?
Topics: Coronary Artery Bypass; Humans; Hyperuricemia; Risk Factors; Uric Acid | 2009 |
Genetic influence on variation in serum uric acid in American Indians: the strong heart family study.
Topics: Arizona; Carrier State; Chromosome Mapping; Chromosomes, Human, Pair 11; Family; Female; Genetic Var | 2009 |
Allopurinol, rutin, and quercetin attenuate hyperuricemia and renal dysfunction in rats induced by fructose intake: renal organic ion transporter involvement.
Topics: Allopurinol; Animals; Antioxidants; Dietary Carbohydrates; Dinoprostone; Fructose; Hyperuricemia; Ki | 2009 |
Uric acid: more to learn, more experiments to do.
Topics: Endothelium, Vascular; Enzyme Inhibitors; Humans; Hyperuricemia; Nitric Oxide; Urate Oxidase; Uric A | 2009 |
A rare cause of chronic renal failure in a girl with elevated serum uric acid level.
Topics: Adolescent; Diagnosis, Differential; DNA Mutational Analysis; Family Health; Female; Humans; Hyperur | 2010 |
Uric acid concentrations are associated with insulin resistance and birthweight in normotensive pregnant women.
Topics: Adult; Birth Weight; Blood Glucose; Female; Fetal Growth Retardation; Humans; Hypertension, Pregnanc | 2009 |
Posing the question again: does chronic uric acid nephropathy exist?
Topics: Animals; Humans; Hyperuricemia; Renal Insufficiency, Chronic; Uric Acid | 2010 |
Acute urate nephropathy precipitated by acute diarrhea.
Topics: Acute Disease; Biomarkers; Creatinine; Diarrhea; Fluid Therapy; Humans; Hyperuricemia; Male; Middle | 2009 |
Elevated first-trimester uric acid concentrations are associated with the development of gestational diabetes.
Topics: Body Mass Index; Diabetes, Gestational; Female; Humans; Hyperuricemia; Insulin Resistance; Logistic | 2009 |
Effect of allopurinol versus urate oxidase on methotrexate pharmacokinetics in children with newly diagnosed acute lymphoblastic leukemia.
Topics: Allopurinol; Child; Child, Preschool; Female; Humans; Hyperuricemia; Infant; Male; Methotrexate; Pre | 2010 |
Abdominal fat accumulation with hyperuricemia and hypercholesterolemia quail model induced by high fat diet.
Topics: Abdominal Fat; Animals; Body Weight; Coturnix; Dietary Fats; Disease Models, Animal; Hypercholestero | 2009 |
Montmorillonite adsorbs uric acid and increases the excretion of uric acid from the intestinal tract in mice.
Topics: Animals; Bentonite; Diffusion; Dose-Response Relationship, Drug; Hydrogen-Ion Concentration; Hyperur | 2009 |
Significant association between methylenetetrahydrofolate reductase 677T allele and hyperuricemia among adult Japanese subjects.
Topics: Aged; Female; Genotype; Humans; Hyperuricemia; Japan; Male; Methylenetetrahydrofolate Reductase (NAD | 2009 |
Association between hyperuricemia and hypertension in a Chinese population at a high risk of hypertension.
Topics: Adolescent; Adult; Aged; Asian People; Blood Glucose; Case-Control Studies; China; Cholesterol; Cros | 2009 |
Hyperuricemia and incident heart failure.
Topics: Adult; Biomarkers; Female; Heart Failure; Humans; Hyperuricemia; Incidence; Kaplan-Meier Estimate; M | 2009 |
Serum glycated albumin, but not glycated haemoglobin, is low in relation to glycemia in hyperuricemic men.
Topics: Blood Glucose; Blood Pressure; Body Mass Index; C-Reactive Protein; Glucose Tolerance Test; Glycated | 2010 |
The relationship between serum uric acid concentration and metabolic syndrome in university freshmen.
Topics: Adult; Cross-Sectional Studies; Humans; Hyperuricemia; Metabolic Syndrome; Students; Universities; U | 2009 |
Hyperuricemia, cardiovascular disease, and the metabolic syndrome.
Topics: Angiotensin II; Cardiovascular Diseases; Humans; Hypertension; Hyperuricemia; Metabolic Syndrome; Ob | 2009 |
Relationship between hyperuricemia (HUC) and metabolic syndrome (MS) in institutionalized elderly men.
Topics: Adipose Tissue; Aged; Aged, 80 and over; Biomarkers; Cholesterol, HDL; Creatinine; Homes for the Age | 2009 |
Trp64Arg polymorphism of the ADRB3 gene predicts hyperuricemia risk in a population from southern Spain.
Topics: Adolescent; Adult; Aged; Alleles; Chi-Square Distribution; Cohort Studies; Female; Genetic Predispos | 2010 |
Serum uric acid is associated with metabolic risk factors for cardiovascular disease in the Uygur population.
Topics: Adult; Aged; Cardiovascular Diseases; China; Cross-Sectional Studies; Dyslipidemias; Ethnicity; Fema | 2009 |
Epidemiological association between uric acid concentration in plasma, lipoprotein(a), and the traditional lipid profile.
Topics: Adolescent; Adult; Aged; Biomarkers; Cardiovascular Diseases; Chi-Square Distribution; Cholesterol; | 2010 |
A multicenter study of the association of serum uric acid, serum creatinine, and diuretic use in hypertensive patients.
Topics: Aged; Biomarkers; Creatinine; Diuretics; Female; Follow-Up Studies; Humans; Hypertension; Hyperurice | 2011 |
Could uric acid be a modifiable risk factor in subjects with pulmonary hypertension?
Topics: Animals; Humans; Hypertension, Pulmonary; Hyperuricemia; Hypoxia; Models, Biological; Oxidative Stre | 2010 |
Association of serum uric acid with aortic stiffness and pressure in a Chinese workplace setting.
Topics: Adolescent; Adult; Aged; Aorta; Blood Pressure; Carotid Arteries; China; Cross-Sectional Studies; Fe | 2010 |
Metabolic factors associated with urinary calculi in children.
Topics: Adolescent; Calcium; Child; Child, Preschool; Citric Acid; Cystinuria; Female; Humans; Hypercalciuri | 2010 |
Clinical study on treatment of hyperuricaemia by retention enema of Chinese herbal medicine combined with allopurinol.
Topics: Adult; Aged; Allopurinol; Blood Urea Nitrogen; Drugs, Chinese Herbal; Enema; Female; Humans; Hyperur | 2009 |
Prevalence and determinants of hyperuricemia in middle-aged, urban Chinese men.
Topics: Adult; Aged; Alcohol Drinking; Asian People; Biomarkers; Body Mass Index; China; Cohort Studies; Cro | 2010 |
Uric acid: a prognostic marker not only before but also after heart transplantation.
Topics: Acute Disease; Adult; Aged; Biomarkers; Early Diagnosis; Epidemiologic Methods; Female; Graft Reject | 2010 |
Relative efficacy of casein or soya protein combined with palm or safflower-seed oil on hyperuricaemia in rats.
Topics: Albumins; Analysis of Variance; Animals; Blood Urea Nitrogen; Caseins; Cholesterol; Creatinine; Diet | 2010 |
Renal secretion of uric acid by organic anion transporter 2 (OAT2/SLC22A7) in human.
Topics: Biological Transport; Carbon Isotopes; Carboxylic Acids; Cell Line; Humans; Hydrogen-Ion Concentrati | 2010 |
Serum uric acid levels and renal damage in hyperuricemic hypertensive patients treated with renin-angiotensin system blockers.
Topics: Adult; Aged; Allopurinol; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inh | 2010 |
Simiao pill ameliorates urate underexcretion and renal dysfunction in hyperuricemic mice.
Topics: Allopurinol; Animals; Biological Transport; Gout; Hyperuricemia; Kidney; Male; Mice; Mice, Inbred St | 2010 |
Significance of hyperuricemia in surgery; an introduction to current observations.
Topics: Blood; Humans; Hyperuricemia; Uric Acid | 1947 |
The relationship between serum uric acid level and metabolic syndrome: differences by sex and age in Taiwanese.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Biomarkers; Female; Humans; Hyperuricemia; | 2010 |
Evaluation of a low, weight-based dose of rasburicase in adult patients for the treatment or prophylaxis of tumor lysis syndrome.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Body Weight; Chicago; Cost Savings; Cost-Benefit Analysi | 2011 |
Raised natriuretic peptides, big-endothelin-1 and improved beta-cell function in type 2 diabetic males with hyperuricaemia.
Topics: Aged; Atrial Natriuretic Factor; Biomarkers; Blood Glucose; Cross-Sectional Studies; Diabetes Mellit | 2009 |
Role of uric acid in the link between arterial stiffness and cardiac hypertrophy: a cross-sectional study.
Topics: Adult; Age Factors; Aged; Atherosclerosis; Cardiomegaly; Cross-Sectional Studies; Female; Humans; Hy | 2010 |
Rasburicase in the treatment of hyperuricemia of newborns.
Topics: Biomarkers; Female; Gestational Age; Gout Suppressants; Humans; Hyperuricemia; Infant, Low Birth Wei | 2010 |
Effects of a fermented barley extract on subjects with slightly high serum uric acid or mild hyperuricemia.
Topics: Adult; Dosage Forms; Female; Hordeum; Humans; Hyperuricemia; Male; Middle Aged; Safety; Uric Acid; Y | 2010 |
Differences in MSU-induced superoxide responses by neutrophils from gout subjects compared to healthy controls and a role for environmental inflammatory cytokines and hyperuricemia in neutrophil function and survival.
Topics: Aged; Antibodies, Blocking; Antioxidants; Apoptosis; Cell Survival; Crystallization; Culture Media, | 2010 |
The rs2231142 variant of the ABCG2 gene is associated with uric acid levels and gout among Japanese people.
Topics: Adult; Aged; Aged, 80 and over; Asian People; ATP Binding Cassette Transporter, Subfamily G, Member | 2010 |
Hyperuricemia as an independent risk factor of chronic kidney disease in middle-aged and elderly population.
Topics: Aged; Confounding Factors, Epidemiologic; Female; Glomerular Filtration Rate; Health Surveys; Humans | 2010 |
Comment on: Gout: an independent risk factor for all-cause and cardiovascular mortality.
Topics: Cardiovascular Diseases; Gout; Humans; Hyperuricemia; Iron; Risk Factors; Uric Acid | 2010 |
Relationship between serum uric acid levels with chronic kidney disease in a Southeast Asian population.
Topics: Adult; Asian People; Biomarkers; Chi-Square Distribution; Chronic Disease; Comorbidity; Cross-Sectio | 2010 |
Uric acid increases fibronectin synthesis through upregulation of lysyl oxidase expression in rat renal tubular epithelial cells.
Topics: Animals; Blotting, Western; Cell Line; Disease Models, Animal; Epithelial Cells; Extracellular Matri | 2010 |
Risk factors associated with renal lithiasis during uricosuric treatment of hyperuricemia in patients with gout.
Topics: Allopurinol; Benzbromarone; Cohort Studies; Creatinine; Follow-Up Studies; Gout; Humans; Hyperuricem | 2010 |
Pro-inflammatory and oxidative effects of noncrystalline uric acid in human mesangial cells: contribution to hyperuricemic glomerular damage.
Topics: Cell Line, Transformed; Cell Survival; Cells, Cultured; Cyclooxygenase 2; Dinoprostone; Dose-Respons | 2011 |
Relationship between uric acid and metabolic syndrome according to menopausal status.
Topics: Adult; Aged; Blood Pressure; Cross-Sectional Studies; Female; Health Status; Humans; Hyperuricemia; | 2011 |
Hyperuricemia predicts adverse outcomes in patients with heart failure.
Topics: Aged; Cause of Death; Disease Progression; Female; Follow-Up Studies; Heart Failure; Humans; Hyperur | 2011 |
Metabolic syndrome characteristics in gout patients.
Topics: Aged; Blood Glucose; Blood Pressure; Female; Gout; Humans; Hyperuricemia; Male; Metabolic Syndrome; | 2010 |
Diagnosis of chronic gout: evaluating the american college of rheumatology proposal, European league against rheumatism recommendations, and clinical judgment.
Topics: Chronic Disease; Cohort Studies; Cross-Sectional Studies; Crystallization; European Union; Female; G | 2010 |
Effect of changes in renal circulation on serum uric acid levels in women with twin pregnancy.
Topics: Adult; Female; Gestational Age; Humans; Hyperuricemia; Pregnancy; Pregnancy, Multiple; Renal Artery; | 2010 |
Association between endothelial dysfunction and hyperuricaemia.
Topics: Adult; Biomarkers; Blood Flow Velocity; Brachial Artery; Case-Control Studies; Endothelium, Vascular | 2010 |
The effect of testosterone upon the urate reabsorptive transport system in mouse kidney.
Topics: Animals; Biological Transport; Case-Control Studies; Glucose Transport Proteins, Facilitative; Hyper | 2010 |
Is high serum uric acid a risk marker or a target for treatment? Examination of its independent effect in a large cohort with low cardiovascular risk.
Topics: Adult; Aged; Blood Glucose; Cardiovascular Diseases; Female; Glomerular Filtration Rate; Humans; Hyp | 2010 |
The association of serum uric acid levels with outcomes following percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Cohort Studies; Confidence Intervals; Coronary Artery Disease; | 2010 |
Validation of a urine test and characterization of the putative genetic mutation for hyperuricosuria in Bulldogs and Black Russian Terriers.
Topics: Animals; Creatinine; DNA; Dog Diseases; Dogs; Gene Frequency; Genetic Carrier Screening; Genetic Pre | 2010 |
Relationship between serum uric acid and cerebral white matter lesions in the elderly.
Topics: Aged; Alcohol Drinking; Antihypertensive Agents; Brain; Cardiovascular Diseases; Cerebrum; Cross-Sec | 2012 |
Association of four genetic loci with uric acid levels and reduced renal function: the J-SHIPP Suita study.
Topics: Aged; Asian People; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Tr | 2010 |
Uric acid potentially links fatty liver and high blood pressure.
Topics: Fatty Liver; Humans; Hypertension; Hyperuricemia; Logistic Models; Uric Acid | 2010 |
Panniculitis: another clinical expression of gout.
Topics: Adult; Allopurinol; Colchicine; Crystallization; Gout; Gout Suppressants; Humans; Hyperuricemia; Mal | 2011 |
Phytochemicals from Acacia confusa heartwood extracts reduce serum uric acid levels in oxonate-induced mice: their potential use as xanthine oxidase inhibitors.
Topics: Acacia; Animals; Drug Discovery; Enzyme Inhibitors; Flavonoids; Hyperuricemia; Male; Mice; Mice, Inb | 2010 |
Human sodium phosphate transporter 4 (hNPT4/SLC17A3) as a common renal secretory pathway for drugs and urate.
Topics: Animals; Bumetanide; Diuretics; Furosemide; Genetic Predisposition to Disease; Glucose Transport Pro | 2010 |
Effectiveness of a single 3-mg rasburicase dose for the management of hyperuricemia in patients with hematological malignancies.
Topics: Adult; Aged; Aged, 80 and over; Gout Suppressants; Hematologic Neoplasms; Humans; Hyperuricemia; Mid | 2011 |
Fixed-dose rasburicase 6 mg for hyperuricemia and tumor lysis syndrome in high-risk cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Creatinine; Dose-Response Relationship, Drug; Drug Administration Sc | 2010 |
Clinical significance of early-onset hyperuricemia in renal transplant recipients.
Topics: Adult; Cardiovascular Diseases; Female; Follow-Up Studies; Graft Rejection; Graft Survival; Humans; | 2011 |
Dietary intake and the risk of hyperuricemia, gout and chronic kidney disease in elderly Taiwanese men.
Topics: Aged; Antihypertensive Agents; Chronic Disease; Comorbidity; Diet; Feeding Behavior; Glomerular Filt | 2011 |
Hyperuricaemia and accelerated reduction in renal function.
Topics: Adult; Aged; Chronic Disease; Cohort Studies; Creatinine; Disease Progression; Female; Follow-Up Stu | 2011 |
Effect of serum insulin on the association between hyperuricemia and incident heart failure.
Topics: Aged; Biomarkers; Female; Heart Failure; Humans; Hyperinsulinism; Hyperuricemia; Incidence; Insulin; | 2010 |
[Study on extracting process of ethanol extract with hypouricemic effect from rhizoma alismatis].
Topics: Alismataceae; Animals; Chemical Fractionation; Disease Models, Animal; Ethanol; Humans; Hyperuricemi | 2010 |
Association of an intronic SNP of SLC2A9 gene with serum uric acid levels in the Chinese male Han population by high-resolution melting method.
Topics: Adult; Aged; China; Genotype; Glucose Transport Proteins, Facilitative; Gout; Homozygote; Humans; Hy | 2011 |
Genome-wide study of familial juvenile hyperuricaemic (gouty) nephropathy (FJHN) indicates a new locus, FJHN3, linked to chromosome 2p22.1-p21.
Topics: Chromosomes, Human, Pair 2; Female; Genetic Heterogeneity; Genetic Linkage; Genetic Loci; Genetic Pr | 2011 |
Hyperuricemia in gastric cancer.
Topics: Blood; Humans; Hyperuricemia; Stomach Neoplasms; Uric Acid | 1946 |
The current state of care in gout: Addressing the need for better understanding of an ancient disease.
Topics: Acute Disease; Aged; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Arthrit | 2010 |
Gouty arthritis in a 15-year-old girl with Bartter's syndrome.
Topics: Adolescent; Arthritis, Gouty; Bartter Syndrome; Biomarkers; Female; Gout Suppressants; Humans; Hyper | 2010 |
A case of familial juvenile hyperuricemic nephropathy with novel uromodulin gene mutation, a novel heterozygous missense mutation in Korea.
Topics: Adolescent; Asian People; Chromosomes, Human, Pair 16; Chronic Disease; DNA Mutational Analysis; Gen | 2010 |
Morin improves urate excretion and kidney function through regulation of renal organic ion transporters in hyperuricemic mice.
Topics: Animals; Creatinine; Down-Regulation; Flavonoids; Glucose Transport Proteins, Facilitative; Hyperuri | 2010 |
Hyperuricemia in kidney transplant recipients with intact graft function.
Topics: Adult; Biomarkers; Chi-Square Distribution; Female; Glomerular Filtration Rate; Humans; Hyperuricemi | 2010 |
Prevalence of hyperuricemia and its association with antihypertensive treatment in hypertensive patients in Taiwan.
Topics: Aged; Antihypertensive Agents; Cohort Studies; Female; Glomerular Filtration Rate; Humans; Hypertens | 2012 |
Hyperuricemia attenuates aortic nitric oxide generation, through inhibition of arginine transport, in rats.
Topics: Allopurinol; Animals; Aorta; Arginine; Benzbromarone; Biological Transport; Blood Pressure; Cationic | 2011 |
Uric acid and cardiovascular risk in rheumatoid arthritis.
Topics: Animals; Arthritis, Rheumatoid; Cardiovascular Diseases; Disease Models, Animal; Humans; Hypertensio | 2011 |
A new practical system for evaluating the pharmacological properties of uricase as a potential drug for hyperuricemia.
Topics: Animals; Bacillus; Gout; Half-Life; Hyperuricemia; Male; Polyethylene Glycols; Rabbits; Rats; Rats, | 2010 |
Uric acid contributes to glomerular filtration rate deterioration in renal transplantation.
Topics: Adult; Biomarkers; Cohort Studies; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Hy | 2011 |
Mulberroside a possesses potent uricosuric and nephroprotective effects in hyperuricemic mice.
Topics: Acetylglucosaminidase; Albuminuria; Animals; beta 2-Microglobulin; Blood Urea Nitrogen; Carrier Prot | 2011 |
Interaction between serum uric acid and triglycerides in relation to blood pressure.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Biomarkers; Blood Glucose; Blood Pressure; Bod | 2011 |
A proposal for identifying the low renal uric acid clearance phenotype.
Topics: Humans; Hyperuricemia; Kidney; Kidney Function Tests; Organic Anion Transporters; Phenotype; Uric Ac | 2010 |
[Epidemiological study on hyperuricemia and gout in Foshan areas, Guangdong province].
Topics: Epidemiologic Studies; Gout; Humans; Hyperuricemia; Prevalence; Uric Acid | 2010 |
Association of renal manifestations with serum uric acid in Korean adults with normal uric acid levels.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Blood Glucose; Blood Pressure; Cholesterol; Female; Glo | 2010 |
3,5,2',4'-Tetrahydroxychalcone, a new non-purine xanthine oxidase inhibitor.
Topics: Animals; Chalcone; Chalcones; Disease Models, Animal; Dose-Response Relationship, Drug; Enzyme Inhib | 2011 |
Gender and age impacts on the correlations between hyperuricemia and metabolic syndrome in Chinese.
Topics: Adult; Aging; Asian People; Body Mass Index; China; Cross-Sectional Studies; Female; Humans; Hyperur | 2011 |
Uric acid does not affect the prevalence and extent of coronary artery disease. Results from a prospective study.
Topics: Aged; Aged, 80 and over; Carotid Intima-Media Thickness; Cohort Studies; Coronary Angiography; Coron | 2012 |
Association between SLC2A9 transporter gene variants and uric acid phenotypes in African American and white families.
Topics: Aged; Biological Transport; Black or African American; Female; Genotype; Glucose Transport Proteins, | 2011 |
Hyperuricemia and albuminuria in patients with type 2 diabetes mellitus.
Topics: Albuminuria; Blood Glucose; Creatinine; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Diabetic | 2011 |
Prognostic significance of serum uric acid in outpatients with chronic heart failure is complex and related to body mass index: data from the IN-CHF Registry.
Topics: Aged; Aged, 80 and over; Ambulatory Care; Body Mass Index; Female; Heart Failure; Humans; Hyperurice | 2012 |
The impact of hyperuricemia on in-hospital mortality and incidence of acute kidney injury in patients undergoing percutaneous coronary intervention.
Topics: Acute Kidney Injury; Aged; Angioplasty, Balloon, Coronary; Coronary Artery Disease; Creatinine; Diab | 2011 |
First trimester uric acid and adverse pregnancy outcomes.
Topics: Adult; Female; Humans; Hypertension, Pregnancy-Induced; Hyperuricemia; Infant, Newborn; Infant, Smal | 2011 |
MicroRNA expression patterns of the kidney in hyperuricemia mice treated with Xiezhuo Chubi Decoction.
Topics: Animals; Base Sequence; Dose-Response Relationship, Drug; Drugs, Chinese Herbal; Gene Expression Pro | 2011 |
Urate as a physiological substrate for myeloperoxidase: implications for hyperuricemia and inflammation.
Topics: Allantoin; Cardiovascular Diseases; Humans; Hydrogen Peroxide; Hyperuricemia; Inflammation; NADPH Ox | 2011 |
Purine-rich foods, protein intake, and the prevalence of hyperuricemia: the Shanghai Men's Health Study.
Topics: Adult; Aged; China; Cohort Studies; Cross-Sectional Studies; Diet; Dietary Proteins; Humans; Hyperur | 2012 |
High levels of uric acid correlate with decline of glomerular filtration rate in chronic kidney disease.
Topics: Adult; Aged; Biomarkers; Blood Pressure; Body Mass Index; Chronic Disease; Cross-Sectional Studies; | 2010 |
Acute kidney injury associated with tumor lysis syndrome: a paradigm shift.
Topics: Acute Kidney Injury; Aged; Antineoplastic Agents; Calcium; Creatinine; Humans; Hyperuricemia; Lympho | 2012 |
Management of asymptomatic hyperuricaemia in patients with chronic kidney disease by Japanese nephrologists: a questionnaire survey.
Topics: Chronic Disease; Glomerular Filtration Rate; Humans; Hyperuricemia; Japan; Kidney Diseases; Surveys | 2011 |
Hyperuricemia as a mediator of the proinflammatory endocrine imbalance in the adipose tissue in a murine model of the metabolic syndrome.
Topics: 3T3-L1 Cells; Adipocytes; Adiponectin; Adipose Tissue; Animals; Cells, Cultured; Chemokine CCL2; Hum | 2011 |
[Mangiferin promotes uric acid excretion and kidney function improvement and modulates related renal transporters in hyperuricemic mice].
Topics: Animals; Blood Urea Nitrogen; Carrier Proteins; Creatinine; Glucose Transport Proteins, Facilitative | 2010 |
Uric acid induces trophoblast IL-1β production via the inflammasome: implications for the pathogenesis of preeclampsia.
Topics: Adaptor Proteins, Signal Transducing; Apoptosis Regulatory Proteins; CARD Signaling Adaptor Proteins | 2011 |
Gout and chronic kidney disease.
Topics: Gout; Humans; Hyperuricemia; Kidney Failure, Chronic; Uric Acid | 2011 |
Elevated serum uric acid predicts impaired fasting glucose and type 2 diabetes only among Japanese women undergoing health checkups.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glucose Intolerance; Humans; Hyperuricemia; | 2011 |
[Results of experimental study of psychophysiological state and hematological characteristics in servicemen presenting with hyperuricemia].
Topics: Adult; Aged; Cardiovascular Diseases; Cognitive Behavioral Therapy; Humans; Hyperuricemia; Male; Mid | 2010 |
[Endothelial function in patients with arterial hypertension and impaired uric acid metabolism].
Topics: Adult; Albuminuria; Antihypertensive Agents; Endothelin-1; Endothelium, Vascular; Female; Humans; Hy | 2010 |
Impact of allopurinol use on urate concentration and cardiovascular outcome.
Topics: Aged; Aged, 80 and over; Allopurinol; Cardiovascular Diseases; Cohort Studies; Female; Gout; Gout Su | 2011 |
[Hyperuricemia].
Topics: Biomarkers; Cardiovascular Diseases; Humans; Hypertension; Hyperuricemia; Uric Acid | 2011 |
Alcohol intake and the risk of hyperuricaemia: a 6-year prospective study in Japanese men.
Topics: Adult; Alcohol Drinking; Alcoholic Beverages; Asian People; Beer; Body Mass Index; Follow-Up Studies | 2012 |
[Association of elevated uric acid with metabolic disorders and analysis of the risk factors of hyperuricemia in type 2 diabetes mellitus].
Topics: Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Female; Humans; Hyperuricemia; Male; Midd | 2011 |
Serum uric acid associates with the incidence of type 2 diabetes in a prospective cohort of middle-aged and elderly Chinese.
Topics: Aged; Biomarkers; China; Cohort Studies; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Human | 2011 |
Hypouricemic effects of anthocyanin extracts of purple sweet potato on potassium oxonate-induced hyperuricemia in mice.
Topics: Allopurinol; Animals; Anthocyanins; Disease Models, Animal; Hyperuricemia; Ipomoea batatas; Male; Mi | 2011 |
Hyperuricemia after renal transplantation.
Topics: Adult; Female; Graft Survival; Humans; Hyperuricemia; Kidney Failure, Chronic; Kidney Transplantatio | 2011 |
Prehypertension and cardiovascular risk factors in adults enrolled in a primary care programme.
Topics: Adult; Alcohol Drinking; Biomarkers; Body Mass Index; Brazil; Cardiovascular Diseases; Cross-Section | 2011 |
Relation of uric acid with components of metabolic syndrome before and after Roux-en-Y gastric bypass in morbidly obese subjects.
Topics: Adolescent; Adult; Epidemiologic Methods; Female; Gastric Bypass; Humans; Hyperuricemia; Male; Metab | 2011 |
Serum uric acid is associated with high blood pressure in pediatric hemodialysis patients.
Topics: Adolescent; Antihypertensive Agents; Biomarkers; Blood Pressure; Body Weight; Child; Female; Humans; | 2011 |
Relationships among hyperuricemia, metabolic syndrome, and endothelial function.
Topics: Adult; Brachial Artery; Cross-Sectional Studies; Endothelium, Vascular; Humans; Hyperuricemia; Japan | 2011 |
Uric acid as a link between renal dysfunction and both pro-inflammatory and prothrombotic state in patients with metabolic syndrome and coronary artery disease.
Topics: Aged; Biomarkers; Coronary Artery Disease; Diabetes Mellitus; Female; Humans; Hyperuricemia; Inflamm | 2011 |
Effects of genistein, apigenin, quercetin, rutin and astilbin on serum uric acid levels and xanthine oxidase activities in normal and hyperuricemic mice.
Topics: Animals; Apigenin; Flavonoids; Flavonols; Genistein; Hyperuricemia; Mice; Quercetin; Rutin; Uric Aci | 2011 |
Adverse effect profile of trichlormethiazide: a retrospective observational study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Biomarkers; Blood Urea Nitrogen; Chi-Square Distri | 2011 |
Astilbin attenuates hyperuricemia and ameliorates nephropathy in fructose-induced hyperuricemic rats.
Topics: Animals; Blood Urea Nitrogen; Connective Tissue Growth Factor; Creatinine; Dinoprostone; Disease Mod | 2011 |
Protective effects of cortex fraxini coumarines against oxonate-induced hyperuricemia and renal dysfunction in mice.
Topics: Aesculus; Animals; Coumarins; Drugs, Chinese Herbal; Gene Expression Regulation; Hyperuricemia; Kidn | 2011 |
Impact of elevated uric acid on ventricular remodeling in infarcted rats with experimental hyperuricemia.
Topics: Allopurinol; Analysis of Variance; Animals; Antioxidants; Atrasentan; Biomarkers; Cyclic N-Oxides; D | 2011 |
Association among serum uric acid, cardiovascular risk, and arterial stiffness: a cross-sectional study in She ethnic minority group of Fujian Province in China.
Topics: Adult; Aged; Blood Flow Velocity; Blood Pressure; Cardiovascular Diseases; China; Female; Humans; Hy | 2012 |
Trends in hyperuricemia and gout prevalence: Nutrition and Health Survey in Taiwan from 1993-1996 to 2005-2008.
Topics: Adult; Age Distribution; Aged; Beverages; Coffee; Dairy Products; Diet; Female; Fruit; Glycine max; | 2011 |
Cross-sectional study on the correlation of serum uric acid with disease severity in Korean patients with psoriasis.
Topics: Adolescent; Adult; Aged; Body Mass Index; Cross-Sectional Studies; Female; Humans; Hyperuricemia; Ma | 2011 |
Reproducibility of musculoskeletal ultrasound for determining monosodium urate deposition: concordance between readers.
Topics: Aged; Aged, 80 and over; Asymptomatic Diseases; Crystallization; Gout; Hospitals, Veterans; Humans; | 2011 |
Gout and hyperuricaemia in adults with cystic fibrosis.
Topics: Adult; Cystic Fibrosis; Female; Gout; Humans; Hyperuricemia; Male; Middle Aged; Prevalence; Uric Aci | 2011 |
Long-term adherence to the Mediterranean diet reduces the prevalence of hyperuricaemia in elderly individuals, without known cardiovascular disease: the Ikaria study.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Cross-Sectional Studies; Diet, Mediterranean; Fema | 2011 |
Joint association of hyperuricemia and reduced GFR on cardiovascular morbidity: a historical cohort study based on laboratory and claims data from a national insurance provider.
Topics: Adult; Aged; Cardiovascular Diseases; Cohort Studies; Comorbidity; Creatinine; Databases, Factual; F | 2011 |
Hyperuricemia is associated with histological liver damage in patients with non-alcoholic fatty liver disease.
Topics: Adult; Anthropometry; Biomarkers; Biopsy; Cohort Studies; Fatty Liver; Female; Humans; Hyperuricemia | 2011 |
Diabetes: Lowering serum uric acid levels to prevent kidney failure.
Topics: Angiotensin II Type 1 Receptor Blockers; Diabetic Nephropathies; Humans; Hyperuricemia; Kidney Failu | 2011 |
Simple and rapid method for the determination of uric acid-independent antioxidant capacity.
Topics: Antioxidants; Ascorbic Acid; Humans; Hyperuricemia; Oxidation-Reduction; Spectrophotometry; Urate Ox | 2011 |
Uric acid and incident chronic kidney disease in a large health check-up population in Taiwan.
Topics: Adult; Aged; Cohort Studies; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Hyperuri | 2011 |
Phenotype and outcome in hereditary tubulointerstitial nephritis secondary to UMOD mutations.
Topics: Adult; Belgium; Biomarkers; Central Nervous System Diseases; Chi-Square Distribution; Dental Enamel; | 2011 |
Uric acid levels and all-cause and cardiovascular mortality in the hemodialysis population.
Topics: Adult; Aged; Australia; Biomarkers; Canada; Cardiovascular Diseases; Chronic Disease; Cluster Analys | 2011 |
A two-stage approach to the treatment of hyperuricemia in gout: the "dirty dish" hypothesis.
Topics: Aged; Cohort Studies; Colchicine; Crystallization; Female; Fenofibrate; Follow-Up Studies; Gout; Gou | 2011 |
Urate nephropathy associated with impaired kinetic properties of hypoxanthine phosphoribosyl transferase in a 45-day-old infant.
Topics: Acute Kidney Injury; Fatal Outcome; Humans; Hyperuricemia; Hypoxanthine Phosphoribosyltransferase; I | 2012 |
[Hyperuricemia in sickle cell disease in France].
Topics: Adolescent; Adult; Aged; Anemia, Sickle Cell; Female; France; Gout; Humans; Hyperuricemia; Male; Mid | 2012 |
Quercetin regulates organic ion transporter and uromodulin expression and improves renal function in hyperuricemic mice.
Topics: Allopurinol; Animals; Blood Urea Nitrogen; Carrier Proteins; Creatinine; Disease Models, Animal; Gen | 2012 |
Hyperuricemia in non-alcoholic fatty liver disease.
Topics: Fatty Liver; Female; Humans; Hyperuricemia; Male; Uric Acid | 2011 |
Activation of human fibroblast-like synoviocytes by uric acid crystals in rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Cells, Cultured; Drug Synergism; Enzyme Activation; Enzyme-Linked Immunosorbe | 2011 |
High levels of serum uric acid impair development of coronary collaterals in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Biomarkers; Collateral Circulation; Coronary Angiography; Coronary Circulat | 2012 |
Hyperuricaemia and gout.
Topics: Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Colchicine; Diet; Gout; Gout Suppressants; Hum | 2011 |
Beneficial effect of switching from a combination of angiotensin II receptor blockers other than losartan and thiazides to a fixed dose of losartan/hydrochlorothiazide on uric acid metabolism in hypertensive patients.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Dose-Respons | 2011 |
Influence of physical activity intensity and aerobic fitness on the anthropometric index and serum uric acid concentration in people with obesity.
Topics: Adult; Age Factors; Alcohol Drinking; Anthropometry; Body Mass Index; Exercise; Humans; Hyperuricemi | 2011 |
Association of serum uric acid with Pro12Ala polymorphism in PPAR-γ2 among Chinese nonagenarians/centenarians.
Topics: Age Factors; Aged; Aged, 80 and over; Alanine; Asian People; Female; Genotype; Humans; Hyperuricemia | 2012 |
Effect of the treatment with allopurinol on the endothelial function in patients with hyperuricemia.
Topics: Adolescent; Adult; Aged; Allopurinol; Brachial Artery; Endothelium, Vascular; Gout Suppressants; Hum | 2012 |
Population heterogeneity in the genetic control of serum urate.
Topics: Glucose Transport Proteins, Facilitative; Gout; Humans; Hyperuricemia; Racial Groups; Uric Acid; Whi | 2011 |
Uric acid and transplantation.
Topics: Graft Survival; Humans; Hyperuricemia; Kidney Diseases; Kidney Transplantation; Postoperative Compli | 2011 |
Serum uric acid levels and incident chronic kidney disease in patients with type 2 diabetes and preserved kidney function.
Topics: Aged; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Hype | 2012 |
Independent association of serum retinol and β-carotene levels with hyperuricemia: A national population study.
Topics: Adult; Aged; Aged, 80 and over; beta Carotene; Female; Humans; Hyperuricemia; Male; Middle Aged; Nut | 2012 |
Rasburicase for hyperuricemia in hemolytic uremic syndrome.
Topics: Acute Kidney Injury; Creatinine; Hemolytic-Uremic Syndrome; Humans; Hyperuricemia; Infant; Male; Ura | 2012 |
[The relationship between hyperuricaemia and clinic pathology of IgA nephropathy].
Topics: Adult; Arterioles; Female; Glomerulonephritis, IGA; Humans; Hyperuricemia; Male; Middle Aged; Renal | 2011 |
Determinants of blood uric acid levels in a dyslipidemic Arab population.
Topics: Adult; Arabs; Body Mass Index; Chi-Square Distribution; Coronary Artery Disease; Cross-Sectional Stu | 2012 |
High levels of serum uric acid predict severity of coronary artery disease in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Biomarkers; Coronary Angiography; Coronary Artery Disease; Coronary Disease | 2012 |
[Exploration on the establishment of animal models for gouty nephropathy complicated with chronic renal failure].
Topics: Animals; Disease Models, Animal; Gout; Hyperuricemia; Kidney Failure, Chronic; Male; Rats; Rats, Wis | 2011 |
P2Y6 receptor signaling pathway mediates inflammatory responses induced by monosodium urate crystals.
Topics: Animals; Antioxidants; Cell Line; Cytokines; Disease Models, Animal; Gout; Humans; Hyperuricemia; In | 2012 |
Use of uric acid-lowering agents limits experimental cyclosporine nephropathy.
Topics: Allopurinol; Animals; Benzbromarone; Cell Proliferation; Cyclosporine; Enzyme Inhibitors; Fibrosis; | 2012 |
Antihypertensive effect of a fixed-dose combination of losartan/hydrochlorothiazide in patients with uncontrolled hypertension: a multicenter study.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Blood Pressure Determination; Creatinine; Drug | 2012 |
Efficacy of benzbromarone in hyperuricemic patients associated with chronic kidney disease.
Topics: Benzbromarone; Female; Glomerular Filtration Rate; Humans; Hyperuricemia; Kidney Failure, Chronic; M | 2011 |
Relationship between hyperuricemia and chronic kidney disease.
Topics: Glomerulonephritis, IGA; Humans; Hypertension; Hyperuricemia; Kidney; Kidney Failure, Chronic; Kidne | 2011 |
Investigation on hyperuricemia in children with obesity or various pediatric disorders.
Topics: Adolescent; Age Distribution; Child; Child, Preschool; Female; Humans; Hyperuricemia; Infant; Japan; | 2011 |
Urinary stone analysis in a patient with hyperuricemia to determine the mechanism of stone formation.
Topics: Adolescent; Adult; Humans; Hyperuricemia; Male; Spectrophotometry, Infrared; Uric Acid; Urinary Calc | 2011 |
ABCG2 is a high-capacity urate transporter and its genetic impairment increases serum uric acid levels in humans.
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Humans; | 2011 |
ABCG2/BCRP dysfunction as a major cause of gout.
Topics: Amino Acid Sequence; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette T | 2011 |
Elderly renal transplant recipients and renal dysfunction: a risk factor for hyperuricemia.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Biomarkers; Chi-Square Distribution; Creatinine; Female | 2011 |
Gender distribution of serum uric acid and cardiovascular risk factors: population based study.
Topics: Adult; Biomarkers; Body Mass Index; Brazil; Epidemiologic Methods; Female; Humans; Hypertension; Hyp | 2012 |
Synthesis of [¹¹C]uric acid, using [¹¹C]phosgene, as a possible biomarker in PET imaging for diagnosis of gout.
Topics: Animals; Automation; Biomarkers; Carbon Isotopes; Chromatography, High Pressure Liquid; Disease Mode | 2012 |
Uric acid level as a risk marker for metabolic syndrome: a Chinese cohort study.
Topics: Adult; Analysis of Variance; Biomarkers; Chi-Square Distribution; Female; Humans; Hyperuricemia; Inc | 2012 |
[Contribution of the CoLaus study to decipher the determinants of serum uric acid].
Topics: Biomarkers; Cardiovascular Diseases; Cohort Studies; Glucose Transport Proteins, Facilitative; Gout; | 2011 |
Markers of systemic inflammation in children with hyperuricemia.
Topics: Adolescent; Biomarkers; C-Reactive Protein; Chemokine CCL2; Child; Cross-Sectional Studies; Female; | 2012 |
Effects of SLC2A9 variants on uric acid levels in a Korean population.
Topics: Adult; Chromosomes, Human, Pair 4; Cohort Studies; Female; Genetic Predisposition to Disease; Genome | 2013 |
Interreader agreement in determining monosodium urate deposition using musculoskeletal ultrasound: comment on the article by Howard et al.
Topics: Gout; Humans; Hyperuricemia; Knee Joint; Male; Metatarsophalangeal Joint; Ultrasonography; Uric Acid | 2012 |
Association between being African-American, serum urate levels and the risk of developing hyperuricemia: findings from the Coronary Artery Risk Development in Young Adults cohort.
Topics: Adult; Black or African American; Coronary Artery Disease; Cross-Sectional Studies; Female; Follow-U | 2012 |
Uric acid is an independent risk factor for carotid atherosclerosis in a Japanese elderly population without metabolic syndrome.
Topics: Age Factors; Aged; Aged, 80 and over; Aging; Asian People; Biomarkers; Carotid Artery Diseases; Caro | 2012 |
Uric acid is not an independent predictor of cardiovascular mortality in type 2 diabetes: a population-based study.
Topics: Aged; Biomarkers; Cardiovascular Diseases; Cause of Death; Chi-Square Distribution; Diabetes Complic | 2012 |
Oral vitamin C supplementation and serum uric acid: comment on the article by Juraschek et al.
Topics: Ascorbic Acid; Dietary Supplements; Female; Humans; Hyperuricemia; Male; Randomized Controlled Trial | 2012 |
Plasma uric acid remains a marker of poor outcome in hypertensive pregnancy: a retrospective cohort study.
Topics: Adult; Algorithms; Antioxidants; Australia; Biomarkers; Cohort Studies; Female; Hematocrit; Hemoglob | 2012 |
Hyperuricemia and untreated gout are poor prognostic markers among those with a recent acute myocardial infarction.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cause of Death; Coronary Artery Disease; Co | 2012 |
Is there anything good in uric acid?
Topics: Female; Humans; Hyperuricemia; Male; Uric Acid | 2012 |
Association of hyperuricemia with renal outcomes, cardiovascular disease, and mortality.
Topics: Aged; Biomarkers; Cardiovascular Diseases; Cohort Studies; Disease Progression; Female; Glomerular F | 2012 |
Hyperuricemia and microalbuminuria are separately and independently associated with prehypertension among Chinese Han women.
Topics: Adult; Aged; Albuminuria; Antihypertensive Agents; Asian People; Biomarkers; Blood Pressure; Chi-Squ | 2012 |
[Predictive value of serum uric acid on type 2 diabetes mellitus].
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Female; Humans; Hyperuricemia; Male; Middle Aged; Prevalen | 2011 |
Cross-sectional and longitudinal associations between serum uric acid and metabolic syndrome.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cohort Studies; Confounding Factors, Epidemiologic; Cros | 2012 |
Hyperuricemia induces endothelial dysfunction via mitochondrial Na+/Ca2+ exchanger-mediated mitochondrial calcium overload.
Topics: Calcium; Clonazepam; Cytoplasm; Endothelium; Human Umbilical Vein Endothelial Cells; Humans; Hydroge | 2012 |
A single oral dose of fructose induces some features of metabolic syndrome in rats: role of oxidative stress.
Topics: Administration, Oral; Animals; Blood Glucose; Blood Pressure; Dose-Response Relationship, Drug; Fruc | 2013 |
Uric acid is an important predictor for hypertensive early atherosclerosis.
Topics: Adult; Atherosclerosis; Biomarkers; C-Reactive Protein; Carotid Arteries; Carotid Intima-Media Thick | 2012 |
Association between gout and polymorphisms in GCKR in male Han Chinese.
Topics: Adaptor Proteins, Signal Transducing; Asian People; Blood Glucose; Case-Control Studies; China; Chol | 2012 |
The independent association between parathyroid hormone levels and hyperuricemia: a national population study.
Topics: Adult; Biomarkers; Female; Humans; Hyperuricemia; Male; Middle Aged; Nutrition Surveys; Parathyroid | 2012 |
Lower serum UA levels in Parkinson's disease patients in the Chinese population.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Asian People; Biomarkers; China; Disease Progression; Fe | 2012 |
Gender-dependent associations of uric acid levels with a polymorphism in SLC2A9 in Han Chinese patients.
Topics: Asian People; China; Female; Glucose Transport Proteins, Facilitative; Gout; Humans; Hyperuricemia; | 2012 |
Allopurinol, quercetin and rutin ameliorate renal NLRP3 inflammasome activation and lipid accumulation in fructose-fed rats.
Topics: Allopurinol; Animals; Blotting, Western; Carrier Proteins; Cholesterol; Creatinine; Dyslipidemias; F | 2012 |
Elevated uric acid, the metabolic syndrome and cardiovascular disease: cause, consequence, or just a not so innocent bystander?
Topics: Female; Humans; Hyperuricemia; Male; Metabolic Syndrome; Uric Acid | 2012 |
Relationship between serum allantoin and urate in healthy subjects and effects of benzbromarone in gout patients.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Adult; Allantoin; Benzbromarone; Biomarkers; Case-Control Studies; Crea | 2012 |
Decreased extra-renal urate excretion is a common cause of hyperuricemia.
Topics: Adult; Aged; Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette | 2012 |
Long-term activation of semicarbazide-sensitive amine oxidase lowers circulating levels of uric acid in diabetic conditions.
Topics: Amine Oxidase (Copper-Containing); Ammonia; Animals; Benzylamines; Blood Glucose; Cell Adhesion Mole | 2012 |
Relationship between dietary patterns and serum uric acid concentrations among ethnic Chinese adults in Taiwan.
Topics: Adult; Aged; Asian People; Cross-Sectional Studies; Diet; Discriminant Analysis; Factor Analysis, St | 2012 |
[Uric acid, atherosclerosis and vascular calcifications in chronic kidney disease].
Topics: Adolescent; Adult; Aged; Atherosclerosis; Calcinosis; Cardiovascular Diseases; Chronic Disease; Como | 2012 |
Comparative structural modeling and docking studies of uricase: possible implication in enzyme supplementation therapy for hyperuricemic disorders.
Topics: Bacterial Proteins; Computational Biology; Computer Simulation; Drug Discovery; Hyperuricemia; Model | 2012 |
Association of serum uric acid with body mass index among long-lived Chinese.
Topics: Aged, 80 and over; Anthropometry; Blood Glucose; Blood Pressure; Body Mass Index; Female; Humans; Hy | 2012 |
Correlation of biochemical parameters and neonatal outcome in patients with gestational hypertension.
Topics: Apgar Score; Blood Glucose; Case-Control Studies; Creatinine; Female; HELLP Syndrome; Humans; Hypert | 2013 |
A case of acute kidney injury with marked hyperuricemia during mizoribine administration.
Topics: Acute Kidney Injury; Arthritis; Arthritis, Rheumatoid; Cranial Nerve Diseases; Female; Humans; Hyper | 2012 |
Uric acid, allopurinol therapy, and mortality in patients with acute heart failure--results of the Acute HEart FAilure Database registry.
Topics: Acute Disease; Age Factors; Aged; Aged, 80 and over; Allopurinol; Female; Glomerular Filtration Rate | 2012 |
Uricase from Bacillus fastidious loaded in alkaline enzymosomes: enhanced biochemical and pharmacological characteristics in hypouricemic rats.
Topics: Animals; Bacillus; Disease Models, Animal; Half-Life; Humans; Hydrogen-Ion Concentration; Hyperurice | 2012 |
Serum uric acid level as a part of the metabolic syndrome impairs the coronary collateral formation.
Topics: Acute Coronary Syndrome; Collateral Circulation; Coronary Circulation; Female; Humans; Hyperuricemia | 2012 |
Hyperuricemia at 1 year after renal transplantation, its prevalence, associated factors, and graft survival.
Topics: Adult; Aged; Allopurinol; Female; Genotype; Glomerular Filtration Rate; Graft Survival; Humans; Hype | 2012 |
Pharmacological basis for use of Lychnophora trichocarpha in gouty arthritis: anti-hyperuricemic and anti-inflammatory effects of its extract, fraction and constituents.
Topics: Acetates; Animals; Anti-Inflammatory Agents; Arthritis, Gouty; Asteraceae; Ethanol; Flavonoids; Hype | 2012 |
A urate gene-by-diuretic interaction and gout risk in participants with hypertension: results from the ARIC study.
Topics: Databases, Factual; Diuretics; Drug Interactions; Female; Genotype; Glucose Transport Proteins, Faci | 2013 |
Hyperuricemia in young adults and risk of insulin resistance, prediabetes, and diabetes: a 15-year follow-up study.
Topics: Adolescent; Adult; Body Mass Index; Comorbidity; Cross-Sectional Studies; Diabetes Mellitus; Female; | 2012 |
Hyperuricaemia: another metabolic feature affecting the severity of chronic hepatitis because of HCV infection.
Topics: Biomarkers; Biopsy; Fatty Liver; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Hyperuricemia; M | 2012 |
Relationship between serum uric acid and internal carotid resistive index in hypertensive women: a cross-sectional study.
Topics: Biomarkers; Carotid Artery, Internal; Carotid Intima-Media Thickness; Chi-Square Distribution; Compl | 2012 |
Adherence to the Mediterranean diet and serum uric acid: the ATTICA study.
Topics: Adult; Body Mass Index; Diet, Mediterranean; Female; Humans; Hyperuricemia; Life Style; Male; Middle | 2012 |
Characterization of patients with heterozygous cystinuria.
Topics: Adolescent; Adult; Age Factors; Aged; Calcium Oxalate; Child; Cystine; Cystinuria; Episode of Care; | 2012 |
Hypouricemic effect of the methanol extract from Prunus mume fruit in mice.
Topics: Administration, Oral; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Fruit; Hype | 2012 |
Antihyperuricemic and nephroprotective effects of resveratrol and its analogues in hyperuricemic mice.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; | 2012 |
Reducing effect of mangiferin on serum uric acid levels in mice.
Topics: Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Gout; | 2012 |
[Uric acid 8.4 in an asymptomatic patient. Does he need medication?].
Topics: Diagnosis, Differential; Humans; Hyperuricemia; Male; Middle Aged; Uric Acid; Uricosuric Agents | 2012 |
Longan seed extract reduces hyperuricemia via modulating urate transporters and suppressing xanthine oxidase activity.
Topics: Allopurinol; Animals; Glucose Transporter Type 1; Gout; Gout Suppressants; Hyperuricemia; Hypoxanthi | 2012 |
An association between uric acid levels and renal arteriolopathy in chronic kidney disease: a biopsy-based study.
Topics: Adult; Arterioles; Biopsy; Cross-Sectional Studies; Female; Glomerulosclerosis, Focal Segmental; Hum | 2013 |
Effect of hyperuricemia on the blood pressure response to antihypertensive agents in hospitalized elderly patients.
Topics: Aged; Antihypertensive Agents; Biomarkers; Blood Pressure; Chi-Square Distribution; Diabetes Mellitu | 2012 |
Uricosuric and nephroprotective properties of Ramulus Mori ethanol extract in hyperuricemic mice.
Topics: Animals; Blood Urea Nitrogen; Creatinine; Ethanol; Hyperuricemia; Kidney; Male; Membrane Transport P | 2012 |
Dietary fructose in relation to blood pressure and serum uric acid in adolescent boys and girls.
Topics: Adolescent; Age Factors; Arterial Pressure; Chi-Square Distribution; Cross-Sectional Studies; Dietar | 2013 |
Serum urate association with hypertension in young adults: analysis from the Coronary Artery Risk Development in Young Adults cohort.
Topics: Cohort Studies; Comorbidity; Female; Humans; Hypertension; Hyperuricemia; Male; Retrospective Studie | 2013 |
Renal function-dependent association of serum uric acid with metabolic syndrome and hepatic fat content in a middle-aged and elderly Chinese population.
Topics: Aged; Asian People; Cohort Studies; Cross-Sectional Studies; Fatty Liver; Female; Glomerular Filtrat | 2012 |
Association of lead exposure, serum uric acid and parameters of renal function in Nigerian lead-exposed workers.
Topics: Adult; Creatinine; Cross-Sectional Studies; Female; Humans; Hyperuricemia; Kidney Diseases; Kidney F | 2010 |
Hyperuricemia in adult renal allograft recipients: prevalence and predictors.
Topics: Adult; Allopurinol; Biomarkers; Chi-Square Distribution; Female; Glomerular Filtration Rate; Gout Su | 2012 |
Does uric acid qualify as an independent risk factor for cardiovascular mortality?
Topics: Biomarkers; Coronary Artery Disease; Diabetes Mellitus, Type 2; Humans; Hyperuricemia; Risk Factors; | 2013 |
Uric Acid: a clearer focus.
Topics: Gout; Humans; Hyperuricemia; Uric Acid | 2012 |
Hyperuricemia and hypertension.
Topics: Adolescent; Animals; Disease Models, Animal; Humans; Hypertension; Hyperuricemia; Rats; Risk Factors | 2012 |
The experience and impact of gout in Māori and Pacific people: a prospective observational study.
Topics: Adult; Aged; Female; Follow-Up Studies; Gout; Health Status; Humans; Hyperuricemia; Male; Middle Age | 2013 |
Hyperferritinemia and hyperuricemia may be associated with liver function abnormality in obese adolescents.
Topics: Adolescent; Alanine Transaminase; Body Mass Index; Ferritins; Humans; Hyperuricemia; Leukocyte Count | 2012 |
The antinociceptive and anti-inflammatory effects of the crude extract of Jatropha isabellei in a rat gout model.
Topics: Alkaloids; Animals; Anti-Inflammatory Agents; Arthritis, Gouty; Biomarkers, Pharmacological; Disease | 2013 |
Absence of the SLC22A12 gene mutation in Turkish population with primary gout disease.
Topics: Adult; Female; Genetic Predisposition to Disease; Gout; Humans; Hyperuricemia; Male; Middle Aged; Mu | 2013 |
Relationship between lifestyle choices and hyperuricemia in Chinese men and women.
Topics: Adult; Asian People; China; Educational Status; Feeding Behavior; Female; Humans; Hyperuricemia; Lif | 2013 |
Integrating cellular metabolism into a multiscale whole-body model.
Topics: Acetaminophen; Allopurinol; Ammonia; Chemical and Drug Induced Liver Injury; Computational Biology; | 2012 |
Uric acid modulates vascular endothelial function through the down regulation of nitric oxide production.
Topics: Acetylcholine; Animals; Arginase; Cell Line; Coronary Artery Disease; Down-Regulation; Endothelium, | 2013 |
Effects of menopause and hormone replacement therapy on the associations of hyperuricemia with mortality.
Topics: Adult; Cardiovascular Diseases; Female; Follow-Up Studies; Hormone Replacement Therapy; Humans; Hype | 2013 |
Plasma uric acid is associated with increased risk of type 2 diabetes independent of diet and metabolic risk factors.
Topics: Adiposity; Aged; Body Mass Index; Case-Control Studies; Cohort Studies; Diabetes Mellitus, Type 2; D | 2013 |
The association between serum uric acid and renal damage in a community-based population: the Takahata study.
Topics: Adult; Aged; Albuminuria; beta 2-Microglobulin; Creatinine; Cross-Sectional Studies; Female; Humans; | 2013 |
Management of gout: a 57-year-old man with a history of podagra, hyperuricemia, and mild renal insufficiency.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Colchicine; Gout | 2012 |
Hyperuricaemia elevates circulating CCL2 levels and primes monocyte trafficking in subjects with inter-critical gout.
Topics: Aged; Cell Movement; Chemokine CCL2; Female; Gout; Humans; Hyperuricemia; Lipopolysaccharide Recepto | 2013 |
Reduced glomerular function and prevalence of gout: NHANES 2009-10.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Cross-Sectional Studies; Female; Glomerular | 2012 |
Serum uric acid, kidney volume and progression in autosomal-dominant polycystic kidney disease.
Topics: Adult; Cohort Studies; Disease Progression; Female; Humans; Hypertension; Hyperuricemia; Kidney; Kid | 2013 |
Association of maximum weight with hyperuricemia risk: a retrospective study of 21,414 Chinese people.
Topics: Adult; Asian People; Body Weight; China; Cohort Studies; Female; Humans; Hyperuricemia; Logistic Mod | 2012 |
Genetic impact on uric acid concentration and hyperuricemia in the Japanese population.
Topics: Aged; Asian People; Coronary Disease; Diabetes Mellitus, Type 2; Female; Genetic Loci; Genetic Predi | 2013 |
Hyperuricemia and metabolic syndrome: lessons from a large cohort from Israel.
Topics: Adult; Aged; Aged, 80 and over; Female; Follow-Up Studies; Humans; Hyperuricemia; Insulin Resistance | 2012 |
The prevalence of hyperuricemia and its correlates in an inland Chinese adult population, urban and rural of Jinan.
Topics: Adult; Age Factors; China; Female; Humans; Hyperuricemia; Male; Middle Aged; Prevalence; Risk Factor | 2013 |
Association between Uric Acid and Metabolic Syndrome in Qazvin Metabolic Diseases Study (QMDS), Iran.
Topics: Adult; Aged; Biomarkers; Comorbidity; Cross-Sectional Studies; Female; Humans; Hyperuricemia; Iran; | 2012 |
Uric acid-induced phenotypic transition of renal tubular cells as a novel mechanism of chronic kidney disease.
Topics: Actins; Animals; Cadherins; Creatinine; Disease Models, Animal; Epithelial Cells; Hyperuricemia; Kid | 2013 |
Febuxostat for hyperuricemia: experience with patients on chronic hemodialysis treatment.
Topics: Aged; Aged, 80 and over; Biomarkers; Drug Monitoring; Febuxostat; Gout Suppressants; Humans; Hyperur | 2013 |
Serum uric acid is associated with dietary and lifestyle factors in elderly women in suburban Guangzhou in Guangdong province of south China.
Topics: Aged; Aged, 80 and over; Alcohol Drinking; Animals; Anthropometry; China; Cholesterol, HDL; Choleste | 2013 |
Synergistic effect of uricase blockade plus physiological amounts of fructose-glucose on glomerular hypertension and oxidative stress in rats.
Topics: Animals; Beverages; Fatty Liver; Fructokinases; Fructose; Glucose; Hypertrophy; Hyperuricemia; Insul | 2013 |
Tophaceous gout and high level of hyperuricaemia are both associated with increased risk of mortality in patients with gout.
Topics: Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Cohort Studies; Female; Follow-Up Studies; | 2014 |
Gout treatment: should we aim for rapid crystal dissolution?
Topics: Crystallization; Gout; Gout Suppressants; Humans; Hyperuricemia; Solubility; Time Factors; Uric Acid | 2013 |
Major dietary patterns and risk of asymptomatic hyperuricemia in Chinese adults.
Topics: Adult; Asian People; Asymptomatic Diseases; Case-Control Studies; Cholesterol, HDL; Cholesterol, LDL | 2012 |
Is serum uric acid level an independent predictor of heart failure among patients with coronary artery disease?
Topics: Aged; Biomarkers; Chi-Square Distribution; Coronary Artery Disease; Female; Heart Failure; Humans; H | 2013 |
Population-specific influence of SLC2A9 genotype on the acute hyperuricaemic response to a fructose load.
Topics: Adolescent; Adult; Female; Fructose; Genotype; Glucose Transport Proteins, Facilitative; Gout; Human | 2013 |
Association of uric acid and left ventricular mass index with renal outcomes in chronic kidney disease.
Topics: Aged; Comorbidity; Creatinine; Disease Progression; Female; Follow-Up Studies; Glomerular Filtration | 2013 |
Uricase formulated with polyethylene glycol (uricase-PEG 20): biochemical rationale and preclinical studies.
Topics: Animals; Biological Availability; Candida; Chemistry, Pharmaceutical; Disease Models, Animal; Dose-R | 2002 |
Uricase formulated with polyethylene glycol (uricase-PEG 20): biochemical rationale and preclinical studies.
Topics: Animals; Biological Availability; Candida; Chemistry, Pharmaceutical; Disease Models, Animal; Dose-R | 2002 |
Uricase formulated with polyethylene glycol (uricase-PEG 20): biochemical rationale and preclinical studies.
Topics: Animals; Biological Availability; Candida; Chemistry, Pharmaceutical; Disease Models, Animal; Dose-R | 2002 |
Uricase formulated with polyethylene glycol (uricase-PEG 20): biochemical rationale and preclinical studies.
Topics: Animals; Biological Availability; Candida; Chemistry, Pharmaceutical; Disease Models, Animal; Dose-R | 2002 |
Elevated serum leptin concentrations in women with hyperuricemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arteriosclerosis; Blood Glucose; Body Mass Index; Choles | 2002 |
A role for uric acid in the progression of renal disease.
Topics: Animals; Blood Pressure; Cell Division; Cyclooxygenase 2; Disease Progression; Hypertension; Hypertr | 2002 |
A role for uric acid in the progression of renal disease.
Topics: Animals; Blood Pressure; Cell Division; Cyclooxygenase 2; Disease Progression; Hypertension; Hypertr | 2002 |
A role for uric acid in the progression of renal disease.
Topics: Animals; Blood Pressure; Cell Division; Cyclooxygenase 2; Disease Progression; Hypertension; Hypertr | 2002 |
A role for uric acid in the progression of renal disease.
Topics: Animals; Blood Pressure; Cell Division; Cyclooxygenase 2; Disease Progression; Hypertension; Hypertr | 2002 |
Quiz page. Stones in the kidney allograft and bladder. Nephrolithiasis is common after transplantation. Cyclosporine often leads to chronic hyperuricemia and the formation of uric acid stones.
Topics: Adult; Cyclosporine; Humans; Hyperuricemia; Kidney Calculi; Kidney Transplantation; Male; Transplant | 2003 |
Genetic mapping studies of familial juvenile hyperuricemic nephropathy on chromosome 16p11-p13.
Topics: Child; Chromosome Mapping; Chromosome Segregation; Chromosomes, Human, Pair 16; Female; Genetic Hete | 2003 |
Renal underexcretion of uric acid is present in patients with apparent high urinary uric acid output.
Topics: Adult; Allopurinol; Case-Control Studies; Gout; Gout Suppressants; Humans; Hyperuricemia; Middle Age | 2002 |
Long-term remission from gout associated with fenofibrate therapy.
Topics: Fenofibrate; Gout; Humans; Hyperlipidemias; Hyperuricemia; Hypolipidemic Agents; Lipids; Male; Middl | 2003 |
The elevated prevalence of apolipoprotein E2 in patients with gout is associated with reduced renal excretion of urates.
Topics: Adult; Alleles; Apolipoprotein E2; Apolipoproteins E; Case-Control Studies; Genotype; Gout; Humans; | 2003 |
[Drug-induced hypouricemia: pathophysiology and application to the hyperuricemia with life style related disease].
Topics: Angiotensin-Converting Enzyme Inhibitors; Anti-Infective Agents; Fanconi Syndrome; Humans; Hyperlipi | 2003 |
[Relations between uricemia and some sensomotor functions in liquidators of the accident at the Chernobyl power plant].
Topics: Adaptation, Psychological; Adult; Female; Humans; Hyperuricemia; Male; Mental Processes; Middle Aged | 2003 |
The epidemiology of hyperuricemia in children of Taiwan aborigines.
Topics: Arthritis, Gouty; Blood Pressure; Body Mass Index; Child; Cross-Sectional Studies; Family Health; Fe | 2003 |
Hyperuricemia in hypothyroidism: is it associated with post-insulin infusion glycemic response?
Topics: Animals; Antithyroid Agents; Creatinine; Erythrocytes; Humans; Hyperuricemia; Hypothyroidism; Insuli | 2003 |
Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging.
Topics: Biomarkers; Chronic Disease; Comorbidity; Female; Follow-Up Studies; Heart Failure; Hemodynamics; Hu | 2003 |
[The role of uric acid in effects of balneotherapy on the phagocytic link of immunity and unspecific defense at the Truskavets health resort].
Topics: Balneology; Health Resorts; Humans; Hyperuricemia; Immunity, Cellular; Mineral Waters; Phagocytosis; | 2003 |
[Effects of aqueous extract in herba of Lysimachia christinae on hyperuricemia in mice].
Topics: Animals; Drugs, Chinese Herbal; Female; Hyperuricemia; Mice; Plants, Medicinal; Primulaceae; Uric Ac | 2002 |
Clinical characterization of a family with a mutation in the uromodulin (Tamm-Horsfall glycoprotein) gene.
Topics: Adolescent; Alleles; Base Pairing; Chronic Disease; Creatinine; Female; Gene Deletion; Genes, Domina | 2003 |
Uric acid and urea in human sweat.
Topics: Adult; Gout; Humans; Hyperuricemia; Kidney; Male; Middle Aged; Sweat; Urea; Uric Acid | 2002 |
Uric acid and urea in human sweat.
Topics: Adult; Gout; Humans; Hyperuricemia; Kidney; Male; Middle Aged; Sweat; Urea; Uric Acid | 2002 |
Uric acid and urea in human sweat.
Topics: Adult; Gout; Humans; Hyperuricemia; Kidney; Male; Middle Aged; Sweat; Urea; Uric Acid | 2002 |
Uric acid and urea in human sweat.
Topics: Adult; Gout; Humans; Hyperuricemia; Kidney; Male; Middle Aged; Sweat; Urea; Uric Acid | 2002 |
Editorial comment--Elevated uric acid and ischemic stroke: accumulating evidence that it is injurious and not neuroprotective.
Topics: Animals; Antioxidants; Brain Ischemia; Causality; Humans; Hypertension; Hyperuricemia; Neuroprotecti | 2003 |
Phosphoribosylpyrophosphate synthetase overactivity as a cause of uric acid overproduction in a young woman.
Topics: Adult; Female; Genes, Dominant; Gout; Humans; Hyperuricemia; Point Mutation; Ribose-Phosphate Pyroph | 2003 |
[Oral chemolysis of uric acid stones].
Topics: Administration, Oral; Allopurinol; Citric Acid; Combined Modality Therapy; Drug Therapy, Combination | 2003 |
Hyperuricemia in childhood primary hypertension.
Topics: Adolescent; Analysis of Variance; Blood Pressure; Body Mass Index; Child; Diastole; Female; Glomerul | 2003 |
Leptin might be a regulator of serum uric acid concentrations in humans.
Topics: Adult; Body Mass Index; Cholesterol; Cross-Sectional Studies; Female; Humans; Hypertension; Hyperuri | 2003 |
Diagnosis and treatment of gouty arthritis.
Topics: Arthritis; Arthritis, Gouty; Colchicine; Gout; Humans; Hyperuricemia; Male; Middle Aged; Probenecid; | 1953 |
[Practical outlines: differential diagnosis of uricacidemia and rheumatism].
Topics: Diagnosis, Differential; Humans; Hyperuricemia; Rheumatic Diseases; Uric Acid | 1954 |
[Cortisone in regulation of uricacidemia and uricaciduria in specific experimental conditions].
Topics: Blood; Body Fluids; Cortisone; Humans; Hyperuricemia; Uric Acid; Urine | 1955 |
Heredity in gout and hyperuricemia.
Topics: Blood; Gout; Heredity; Humans; Hyperuricemia; Uric Acid | 1955 |
[Presence and significance of hyperuricemia in primary joint disease].
Topics: Blood; Humans; Hyperuricemia; Joint Diseases; Joints; Uric Acid | 1956 |
The occurrence of hyperuricemia during pyrazinamide-isoniazid therapy.
Topics: Blood; Humans; Hyperuricemia; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Pyrazinamide; Pyrimidin | 1956 |
Hyperuricemia in hypoparathyroidism.
Topics: Disease; Humans; Hyperuricemia; Hypoparathyroidism; Parathyroid Diseases; Parathyroid Glands; Uric A | 1956 |
Hyperuricemia in hypoparathyroidism.
Topics: Disease; Humans; Hyperuricemia; Hypoparathyroidism; Parathyroid Diseases; Parathyroid Glands; Uric A | 1956 |
Hyperuricemia in hypoparathyroidism.
Topics: Disease; Humans; Hyperuricemia; Hypoparathyroidism; Parathyroid Diseases; Parathyroid Glands; Uric A | 1956 |
Hyperuricemia in hypoparathyroidism.
Topics: Disease; Humans; Hyperuricemia; Hypoparathyroidism; Parathyroid Diseases; Parathyroid Glands; Uric A | 1956 |
Hyperuricaemia and essential hypercholesterolaemia.
Topics: Cholesterol; Humans; Hyperlipoproteinemia Type II; Hyperuricemia; Lipidoses; Uric Acid | 1957 |
Hyperuricemia associated with the treatment of acute leukemia.
Topics: Acute Disease; Humans; Hyperuricemia; Leukemia; Uric Acid | 1957 |
Studies of hyperuricemia produced by pyrazinamide.
Topics: Humans; Hyperuricemia; Niacin; Nicotinic Acids; Pyrazinamide; Uric Acid | 1957 |
Hyperuricemia due to pyrazinamide.
Topics: Humans; Hyperuricemia; Niacin; Nicotinic Acids; Pyrazinamide; Uric Acid | 1957 |
The effect of probenecid on pyrazinamide blood levels and pyrazinamide-induced hyperuricemia.
Topics: Humans; Hyperuricemia; Niacin; Nicotinic Acids; Probenecid; Pyrazinamide; Uric Acid | 1957 |
Overproduction of uric acid as the cause of hyperuricemia in primary gout.
Topics: Gout; Humans; Hyperuricemia; Uric Acid | 1957 |
[Origin of hyperuricemia and urate deposition in tissues due to alloxan action; studies in pigeons and ducks].
Topics: Alloxan; Animals; Columbidae; Ducks; Gout; Hyperuricemia; Uric Acid | 1957 |
On the mechanism of overproduction of uric acid in patients with primary gout.
Topics: Gout; Humans; Hyperuricemia; Uric Acid | 1958 |
POLYCYTHEMIA vera, compression fractures and hyperuricemia.
Topics: Fractures, Bone; Fractures, Compression; Humans; Hyperuricemia; Medical Records; Polycythemia Vera; | 1958 |
Normal glycine-C14-incorporation into uric acid in primary gout.
Topics: Glycine; Gout; Humans; Hyperuricemia; Uric Acid | 1958 |
Failure to detect consistent overincorporation of glycine-1-C14 into uric acid in primary gout.
Topics: Glycine; Gout; Humans; Hyperuricemia; Uric Acid | 1958 |
Atypical gout and hyperuricemia.
Topics: Gout; Humans; Hyperuricemia; Uric Acid | 1959 |
Hyperuricemia with uric acid nephropathy following nitrogen mustard therapy of lymphosarcoma; report of a case.
Topics: Hyperuricemia; Lymphoma; Lymphoma, Non-Hodgkin; Mechlorethamine; Nitrogen Mustard Compounds; Uric Ac | 1959 |
Hyperuricemia; relationship to hypercholesteremia and acute myocardial infarction.
Topics: Anterior Wall Myocardial Infarction; Cardiovascular Diseases; Cholesterol; Humans; Hypercholesterole | 1959 |
[Hyperuricemia in the entero-arthrotic syndrome and in the etiology of colitis].
Topics: Colitis; Gout; Humans; Hyperuricemia; Joint Diseases; Osteoarthritis; Syndrome; Uric Acid | 1961 |
Hyperuricemia and acute gouty arthritis precipitated by thiazide derivatives.
Topics: Antihypertensive Agents; Arthritis, Gouty; Chlorothiazide; Gout; Humans; Hyperuricemia; Uric Acid | 1961 |
Hyperuricemia and psoriasis.
Topics: Humans; Hyperuricemia; Psoriasis; Uric Acid | 1961 |
Chlorothiazide-induced hyperuricemia: report of two cases.
Topics: Chlorothiazide; Gout; Humans; Hyperuricemia; Uric Acid | 1960 |
Sulphinpyrazone in the treatment of arthritis associated with hyperuricaemia.
Topics: Arthritis; Humans; Hyperuricemia; Phenylbutazone; Sulfinpyrazone; Uric Acid | 1961 |
Familial hyperuricaemic nephropathy.
Topics: Humans; Hyperuricemia; Kidney Diseases; Nephritis, Hereditary; Uric Acid | 1960 |
[Investigations of the mechanism of appearance of hyperuricemia caused by hydrochlorothiazide].
Topics: Chlorothiazide; Hydrochlorothiazide; Hyperuricemia; Kidney; Uric Acid | 1961 |
Hyperuricemia in myxedema.
Topics: Humans; Hyperuricemia; Myxedema; Uric Acid | 1960 |
Hyperuricemia in myocardial infarction.
Topics: Cardiovascular Diseases; Humans; Hyperuricemia; Myocardial Infarction; Uric Acid | 1961 |
Hyperuricemia in hyperparathyroidism.
Topics: Disease; Humans; Hyperparathyroidism; Hyperuricemia; Parathyroid Diseases; Parathyroid Glands; Uric | 1961 |
[Effects of sulfinpyrazone on uricemia and excretion of uric acid in 50 gouty hyperuricemic patients during diuretic thermal treatment. Comparison of its action in simple gout patients and in tophaceous gout patients].
Topics: Biological Transport; Body Fluids; Diuretics; Gout; Humans; Hyperuricemia; Phenylbutazone; Sulfinpyr | 1961 |
Puerperal hyperuricaemia.
Topics: Female; Humans; Hyperuricemia; Postpartum Period; Uric Acid | 1961 |
[Considerations on the pathogenesis of hyperuricemia in the gout patient].
Topics: Gout; Humans; Hyperuricemia; Uric Acid | 1961 |
Thiazide hypopotassemia and hyperuricemia.
Topics: Chlorothiazide; Humans; Hyperuricemia; Hypokalemia; Potassium; Thiazides; Uric Acid | 1961 |
On the dual etiology of hyperuricemia in primary gout.
Topics: Arthritis, Gouty; Gout; Humans; Hyperuricemia; Uric Acid | 1960 |
[Hyperlactacidemia, probable cause of hyperuricemia, in hepatic glycogenosis].
Topics: Glycogen Storage Disease; Humans; Hyperuricemia; Lactates; Liver; Uric Acid | 1961 |
Liver failure in late pregnancy: hyperuricaemia as an early sign in its detection.
Topics: Female; Humans; Hyperuricemia; Liver Diseases; Liver Failure; Pregnancy; Pregnancy Complications; Ur | 1960 |
Hyperuricaemia related to treatment of hypertension.
Topics: Antihypertensive Agents; Humans; Hypertension; Hyperuricemia; Uric Acid | 1960 |
The role of hyperuricemia in coronary heart disease.
Topics: Coronary Artery Disease; Coronary Disease; Heart; Hematologic Diseases; Humans; Hyperuricemia; Uric | 1960 |
[Hyperuricemia and coronary disease].
Topics: Coronary Disease; Humans; Hyperuricemia; Uric Acid | 1959 |
A note on hyperuricemia during labor.
Topics: Humans; Hyperuricemia; Labor, Obstetric; Uric Acid; Work | 1960 |
A study of the hyperuricemia induced by hydrochlorothiazide and acetazolamide separately and in combination.
Topics: Acetazolamide; Chlorothiazide; Humans; Hydrochlorothiazide; Hyperuricemia; Uric Acid | 1961 |
[On hyperuricemia caused by chlorothiazide].
Topics: Chlorothiazide; Humans; Hyperuricemia; Uric Acid | 1961 |
Hyperuricemia induced by the administration of chlorthalidone and other sulfonamide diuretics.
Topics: Chlorthalidone; Diuretics; Humans; Hypertension; Hyperuricemia; Sulfanilamide; Sulfanilamides; Sulfo | 1962 |
Leukemoid reaction, hyperuricemia and severe hyperpyrexia complicating a fatal case of acute fatty liver of the alcoholic.
Topics: Alcoholism; Fatty Liver; Fever; Humans; Hyperuricemia; Leukemia; Leukemoid Reaction; Liver Diseases; | 1962 |
Hyperuricemia in a male Filipino population.
Topics: Asian People; Humans; Hyperuricemia; Male; Uric Acid | 1962 |
Diagnostic significance of hyperuricemia in arthritis.
Topics: Arthritis; Arthritis, Rheumatoid; Chlorpromazine; Humans; Hyperuricemia; Salicylates; Uric Acid | 1961 |
[Hyperuricemia in Filipinos].
Topics: Gout; Humans; Hyperuricemia; Uric Acid | 1961 |
Thiazide-induced hyperuricemia.
Topics: Bendroflumethiazide; Humans; Hyperuricemia; Thiazides; Uric Acid | 1963 |
Gout and hyperuricemia after adrenalectomy for hypertension.
Topics: Adrenalectomy; Gout; Humans; Hypertension; Hyperuricemia; Uric Acid | 1963 |
Reversal of thiazide-induced transient hyperuricemia by uricosuric agents.
Topics: Chlorthalidone; Humans; Hydrochlorothiazide; Hyperuricemia; Probenecid; Pyrazoles; Thiazides; Uric A | 1962 |
Pitfalls in the interpretation of apparent hyperuricemia.
Topics: Blood Chemical Analysis; Humans; Hyperuricemia; Kidney Diseases; Uric Acid | 1963 |
[Preliminary note on the effect of a hepatocatalase on gout and hyperuricemia. (Apropos of 40 cases)].
Topics: Catalase; Gout; Humans; Hyperuricemia; Liver Extracts; Oxidoreductases; Uric Acid | 1962 |
RENAL LESIONS RESULTING FROM INDUCED HYPERURICEMIA IN ANIMALS.
Topics: Animals; Blood; Dogs; Gout; Hyperuricemia; Injections; Injections, Intravenous; Kidney; Kidney Disea | 1963 |
HYPERURICEMIA DURING TOTAL FASTING: RENAL FACTORS.
Topics: Blood; Fasting; Humans; Hyperuricemia; Kidney; Kidney Function Tests; Metabolism; Obesity; Uric Acid | 1963 |
ANKYLOSING SPONDYLITIS, HYPERURICEMIA, AND ANOMALIES OF THE LUMBOSACRAL JUNCTION. A FAMILY STUDY.
Topics: Blood Chemical Analysis; Genetics, Medical; Gout; Hyperuricemia; Lumbosacral Region; Research; Spine | 1963 |
BLOOD COAGULATION AND PLATELET ECONOMY IN SUBJECTS WITH PRIMARY GOUT.
Topics: Arteriosclerosis; Arthritis, Gouty; Blood Coagulation; Blood Coagulation Tests; Blood Platelets; Gou | 1963 |
AN ABNORMALITY OF GLUTAMINE METABOLISM IN PRIMARY GOUT.
Topics: Ammonia; Creatine; Creatinine; Glutamine; Glycine; Gout; Humans; Hyperuricemia; Kidney; Metabolism; | 1963 |
[EXPERIMENTAL HYPERURICEMIA. RESEARCH ON RABBITS. (ALLANTOIN AND URIC ACID)].
Topics: Allantoin; Animals; Anuria; Blood; Edema; Hydantoins; Hyperuricemia; Kidney Tubules; Lagomorpha; Pat | 1963 |
ASSOCIATION OF HYPERURICAEMIA AND GOUT WITH HYPERPARATHYROIDISM.
Topics: Adenoma; Blood Chemical Analysis; Diagnosis; Gout; Humans; Hyperparathyroidism; Hyperuricemia; Nephr | 1964 |
GOUT, HYPERURICAEMIA AND CARBOHYDRATE METABOLISM.
Topics: Carbohydrate Metabolism; Cholesterol; Glucose Tolerance Test; Gout; Humans; Hypertension; Hyperurice | 1964 |
[ON CASES OF GOUT AND FAMILIAL HYPERURICEMIA].
Topics: Blood; Genetics, Medical; Gout; Humans; Hyperuricemia; Pathology; Uric Acid | 1964 |
HYPERURICEMIA, GOUT AND CEREBROVASCULAR DISEASE.
Topics: Black People; Blood Chemical Analysis; Cerebrovascular Disorders; Cholesterol; Geriatrics; Gout; Hum | 1964 |
INHIBITION OF PYRAZINAMIDE HYPERURICEMIA BY SMALL DOSES OF ACETYLSALICYLIC ACID.
Topics: Aspirin; Blood Chemical Analysis; Drug Therapy; Humans; Hyperuricemia; Pyrazinamide; Toxicology; Tub | 1964 |
[A STUDY ON THE INHERITABLE FACTORS OF GOUT AND HYPERURICEMIA].
Topics: Blood; Genetics, Medical; Gout; Humans; Hyperuricemia; Japan; Pathology; Physiology; Statistics as T | 1964 |
[FURTHER RESEARCH ON EXPERIMENTAL HYPERURICEMIA IN THE RABBIT. BEHAVIOR OF SEVERAL ENZYMES].
Topics: Acute Kidney Injury; Alanine Transaminase; Aspartate Aminotransferases; Blood Chemical Analysis; Cli | 1964 |
ARTICULAR AND FIBROCARTILAGE CALCIFICATION IN HYPERPARATHYROIDISM: ASSOCIATED HYPERURICEMIA.
Topics: Acetabulum; Blood; Calcinosis; Cartilage; Cartilage, Articular; Fibrocartilage; Gout; Humans; Hyperp | 1964 |
THE PENDULUM OF PROGRESS IN GOUT: FROM CRYSTALS TO HYPERURICEMIA AND BACK.
Topics: Blood; Chemical Precipitation; Crystallization; Exudates and Transudates; Geriatrics; Gout; Humans; | 1964 |
EXTREME HYPERURICEMIA ASSOCIATED WITH PREDNISONE THERAPY FOR ACUTE LYMPHOBLASTIC LEUKEMIA.
Topics: Adolescent; Blood; Blood Urea Nitrogen; Humans; Hyperuricemia; Leukemia; Leukemia, Lymphoid; Lymphoc | 1964 |
[CLINICAL CONSIDERATIONS ON THE RELATIONS THAT SEEM TO EXIST BETWEEN CERVICAL PAINS AND HYPERURICEMIA].
Topics: Blood; Cervical Vertebrae; Gout; Humans; Hyperuricemia; Neck Pain; Neuralgia; Spinal Diseases; Torti | 1964 |
OBSERVATIONS ON THE NATURAL HISTORY OF HYPERURICEMIA AND GOUT. I. AN EIGHTEEN YEAR FOLLOW-UP OF NINETEEN GOUTY FAMILIES.
Topics: Adolescent; Blood; Cerebrovascular Disorders; Colorimetry; Coronary Disease; Esophageal and Gastric | 1964 |
URIC ACID EXCRETION AND RENAL FUNCTION IN THE ACUTE HYPERURICEMIA OF LEUKEMIA. PATHOGENESIS AND THERAPY OF URIC ACID NEPHROPATHY.
Topics: Acetazolamide; Bicarbonates; Blood; Carbon Isotopes; Drug Therapy; Fluids and Secretions; Hippurates | 1964 |
HYPERURICAEMIA AND CEREBRAL APOPLEXY.
Topics: Blood; Cerebrovascular Disorders; Humans; Hyperuricemia; Stroke; Uric Acid | 1964 |
HYPERURICAEMIA IN HYPERTENSION.
Topics: Blood; Body Weight; Cholesterol; Creatine; Creatinine; Dehydroepiandrosterone; Fluids and Secretions | 1965 |
STUDIES ON HYPERURICEMIA. II. A RECONSIDERATION OF THE DISTRIBUTION OF SERUM URIC ACID VALUES IN THE FAMILIES OF SMYTH, COTTERMAN, AND FREYBERG.
Topics: Blood; Genetics, Medical; Genetics, Population; Gout; Humans; Hyperuricemia; Metabolic Diseases; Mol | 1965 |
HYPERURICEMIA IN STARVATION.
Topics: Biomedical Research; Blood; Creatine; Creatinine; Hyperuricemia; Kidney Function Tests; Kidney Tubul | 1965 |
CORRECTION OF DIURETIC-INDUCED HYPOKALEMIA AND HYPERURICEMIA.
Topics: Bicarbonates; Blood Chemical Analysis; Chlorthalidone; Diuretics; Drug Therapy; Geriatrics; Hydrochl | 1965 |
THE INFLAMMATORY RESPONSE TO INJECTED MICROCRYSTALLINE MONOSODIUM URATE IN NORMAL, HYPERURICEMIC, GOUTY, AND UREMIC SUBJECTS.
Topics: Blood Chemical Analysis; Blood Urea Nitrogen; Erythema; Geriatrics; Gout; Humans; Hyperuricemia; Inf | 1965 |
THE SYNDROME OF ATHETOID CEREBRAL PALSY, MENTAL DEFICIENCY, SELF-MUTILATION AND HYPERURICEMIA.
Topics: Athetosis; Blood Chemical Analysis; Blood Urea Nitrogen; Cerebral Palsy; Child; Genetics, Medical; H | 1965 |
PREVENTION OF HYPERURICEMIA IN LEUKEMIA AND LYMPHOMA: USE OF ALOPURINOL, A XANTHINE OXIDASE INHIBITOR.
Topics: Adolescent; Antineoplastic Agents; Blood; Blood Urea Nitrogen; Drug Therapy; Geriatrics; Humans; Hyp | 1965 |
ASSOCIATION OF HYPERURICEMIA AND POLYCYSTIC KIDNEY DISEASE.
Topics: Genetics, Medical; Gout; Humans; Hyperuricemia; Kidney; Polycystic Kidney Diseases; Uric Acid | 1965 |
HEREDITARY CHOREOATHETOSIS, SELF-MUTILATION AND HYPERURICEMIA IN YOUNG MALES.
Topics: Athetosis; Blood; Child; Chorea; Colorimetry; Genetics, Medical; Humans; Hyperuricemia; Infant; Male | 1965 |
THE DISTRIBUTION OF SERUM URIC ACID VALUES IN A POPULATION UNSELECTED AS TO GOUT OR HYPERURICEMIA: TECUMSEH, MICHIGAN 1959-1960.
Topics: Aging; Blood Chemical Analysis; Gout; Humans; Hyperuricemia; Mass Screening; Michigan; Sex; Uric Aci | 1965 |
[HYPERURICEMIA AND GOUT WITH DIURETICS].
Topics: Blood; Diuretics; Gout; Humans; Hyperuricemia; Toxicology; Uric Acid | 1965 |
THE USE OF ALLOPURINOL (HPP) TO CONTROL HYPERURICEMIA IN PATIENTS ON CHRONIC INTERMITTENT HEMODIALYSIS.
Topics: Allopurinol; Blood; Creatine; Creatinine; Drug Therapy; Glomerulonephritis; Humans; Hypertension; Hy | 1965 |
[THE ROLE OF THE NORMAL KIDNEY AND THE PATHOLOGICAL KIDNEY IN THE GENESIS OF HYPERURICEMIA].
Topics: Blood; Diuresis; Gout; Humans; Hyperuricemia; Kidney; Kidney Diseases; Kidney Function Tests; Physio | 1965 |
Osteogenesis imperfecta tarda with hyperuricemia and gout; report of three cases.
Topics: Blood; Gout; Humans; Hyperuricemia; Osteogenesis Imperfecta; Uric Acid | 1955 |
[Clinical and therapeutic aspects of hyperuricemia].
Topics: Blood; Humans; Hyperuricemia; Uric Acid | 1955 |
[The role of the kidney in hyperuricemia from the study of 390 clearances of uric acid].
Topics: Blood; Gout; Humans; Hyperuricemia; Kidney; Uric Acid | 1955 |
Uric acid retention due to hydrochlorothiazide.
Topics: Chlorothiazide; Hydrochlorothiazide; Hyperuricemia; Uric Acid | 1959 |
The effect of pyrazinamide-induced hyperuricemia on serum lipids.
Topics: Humans; Hyperuricemia; Lipids; Pyrazinamide; Uric Acid | 1960 |
[Effect of zoxazolamine on hyperuricemia and the excretion of uric acid based on the study of 79 cases].
Topics: Body Fluids; Humans; Hyperuricemia; Uric Acid; Zoxazolamine | 1960 |
Hyperuricaemia due to pyrazinamide.
Topics: Humans; Hyperuricemia; Pyrazinamide; Uric Acid | 1960 |
[The role of uric-elimination renal insufficiency in primary gout].
Topics: Gout; Humans; Hyperuricemia; Kidney; Renal Insufficiency; Uric Acid | 1962 |
Association of hypercholesterolemia with hyperuricemia. A review of the literature.
Topics: Cholesterol; Humans; Hypercholesterolemia; Hyperuricemia; Uric Acid | 1962 |
Hyperuricemia in diabetic ketoacidosis.
Topics: Diabetes Complications; Diabetic Ketoacidosis; Humans; Hyperuricemia; Uric Acid | 1962 |
Gout and hyperuricaemia in rural and urban populations.
Topics: Gout; Humans; Hyperuricemia; Urban Population; Uric Acid | 1962 |
Thiazides and hyperuricaemia.
Topics: Chlorothiazide; Humans; Hyperuricemia; Thiazides; Uric Acid | 1962 |
[Avoid purine-rich foods, drink a lot, reduce weight. The most important recipes against hyperuricemia].
Topics: Alcohol Drinking; Diet; Drinking; Exercise; Food; Gout; Humans; Hyperuricemia; Uric Acid; Weight Los | 2003 |
New standards for uric acid excretion and evidence for an inducible transporter.
Topics: Carrier Proteins; Gout; Humans; Hyperuricemia; Male; Reference Values; Uric Acid | 2003 |
Treatment of impending tumor lysis with single-dose rasburicase.
Topics: Adolescent; Child; Child, Preschool; Humans; Hyperuricemia; Male; Precursor Cell Lymphoblastic Leuke | 2003 |
Influence of cyclosporin A (CyA) on renal handling of urate.
Topics: Adult; Azathioprine; Cyclosporine; Diuretics; Drug Therapy, Combination; Female; Follow-Up Studies; | 1992 |
Yin and yang of uric acid in patients with stroke.
Topics: Animals; Humans; Hyperuricemia; Prognosis; Rats; Research Design; Risk Factors; Stroke; Treatment Ou | 2004 |
Serum uric acid levels in obese children and adolescents: linkage to testosterone levels and pre-metabolic syndrome.
Topics: Adolescent; Blood Pressure; Body Mass Index; Cardiovascular Diseases; Child; Cholesterol, HDL; Cohor | 2003 |
Hyperuricemia, low urine urate excretion and target organ damage in arterial hypertension.
Topics: Adult; Arteries; Cardiovascular Diseases; Creatine; Cross-Sectional Studies; Humans; Hypertension; H | 2003 |
Serum uric acid in traditional Pacific Islanders and in Swedes.
Topics: Adult; Age Distribution; Aged; Aged, 80 and over; Cross-Sectional Studies; Female; Humans; Hyperuric | 2004 |
Uric acid and diet--insights into the epidemic of cardiovascular disease.
Topics: Dairy Products; Diet; Dietary Proteins; Female; Gout; History, 17th Century; History, 18th Century; | 2004 |
Prevalence of hyperuricemia and relation of serum uric acid with cardiovascular risk factors in a developing country.
Topics: Adult; Age Distribution; Alcohol Drinking; Blood Pressure; Body Height; Body Mass Index; Cardiovascu | 2004 |
Recent trends of hyperuricemia and obesity in Japanese male adolescents, 1991 through 2002.
Topics: Adolescent; Adult; Alanine Transaminase; Body Mass Index; Cholesterol; Humans; Hypertension; Hyperur | 2004 |
The C677 mutation in methylene tetrahydrofolate reductase gene: correlation with uric acid and cardiovascular risk factors in elderly Korean men.
Topics: Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Genetic Predisposition to Disease; Genotype | 2004 |
Administration of procyanidins from grape seeds reduces serum uric acid levels and decreases hepatic xanthine dehydrogenase/oxidase activities in oxonate-treated mice.
Topics: Allopurinol; Animals; Antioxidants; Biflavonoids; Catechin; Disease Models, Animal; Dose-Response Re | 2004 |
Characteristics of patients with staghorn calculi in our experience.
Topics: Activities of Daily Living; Adult; Aged; Calcium; Calcium Oxalate; Calcium Phosphates; Catheters, In | 2004 |
Hypertension was the major risk factor leading to development of cardiovascular diseases among men with hyperuricemia.
Topics: Adult; Arrhythmias, Cardiac; Arteriosclerosis; Female; Follow-Up Studies; Humans; Hypertension; Hype | 2004 |
Diuretic-induced hyperuricemia does not decrease cardiovascular risk.
Topics: Antioxidants; Cardiovascular Diseases; Diuretics; Humans; Hyperuricemia; Risk Factors; Uric Acid | 2004 |
Independent association of uric acid levels with peripheral arterial disease in Taiwanese patients with Type 2 diabetes.
Topics: Aged; Arterial Occlusive Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Humans; | 2004 |
Pyrazinamide induced hyperuricemia in patients taking anti-tuberculous therapy.
Topics: Adult; Antitubercular Agents; Creatinine; Female; Humans; Hyperuricemia; Male; Prospective Studies; | 2004 |
[Insulin resistance syndrome in patients with gout and its influence on formation of clinical characteristics of the disease].
Topics: Adult; Aged; Blood Glucose; Blood Pressure; Body Mass Index; Cardiovascular Diseases; Gout; Humans; | 2004 |
A Chinese herbal medicine Ermiao wan reduces serum uric acid level and inhibits liver xanthine dehydrogenase and xanthine oxidase in mice.
Topics: Administration, Oral; Animals; Dose-Response Relationship, Drug; Drugs, Chinese Herbal; Enzyme Inhib | 2004 |
Maternal plasma hypoxanthine levels in nonpreeclamptic twin pregnancies.
Topics: Adenosine; Adult; Female; Humans; Hyperuricemia; Hypoxanthine; Pregnancy; Pregnancy Complications; P | 2004 |
A high prevalence of renal hypouricemia caused by inactive SLC22A12 in Japanese.
Topics: Adult; Aged; Base Sequence; Carrier Proteins; Cohort Studies; Female; Haplotypes; Humans; Hyperurice | 2004 |
Intermittent elevation of serum urate and 24-hour urinary uric acid excretion.
Topics: Adult; Creatinine; Follow-Up Studies; Humans; Hyperuricemia; Male; Middle Aged; Reference Values; Se | 2004 |
Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort.
Topics: Adult; Aged; Cohort Studies; Female; Humans; Hyperuricemia; Kidney Failure, Chronic; Male; Mass Scre | 2004 |
Uric acid and the state of the intrarenal renin-angiotensin system in humans.
Topics: Adult; Angiotensin II; Blood Pressure; Female; Humans; Hypertension, Renal; Hyperuricemia; Kidney; M | 2004 |
Effect of hyperuricemia upon endothelial function in patients at increased cardiovascular risk.
Topics: Aged; Allopurinol; Biomarkers; Brachial Artery; Cardiovascular Diseases; Endothelium, Vascular; Enzy | 2004 |
Hyperuricaemia and cardiovascular disease.
Topics: Female; Humans; Hypertension; Hyperuricemia; Male; Retrospective Studies; Uric Acid | 2004 |
[Uric acid, a neglected molecule--the value of imaging].
Topics: Arthritis, Gouty; Diagnosis, Differential; Diagnostic Imaging; Gout; Humans; Hyperuricemia; Joints; | 2004 |
[Diagnosis and prevention of uric acid stones].
Topics: Adult; Allopurinol; Female; Fluid Therapy; Humans; Hydrogen-Ion Concentration; Hyperuricemia; Kidney | 2004 |
[Rasburicase (Fasturtec)].
Topics: Crystallization; Glomerular Filtration Rate; Gout; Humans; Hyperuricemia; Kidney Failure, Chronic; K | 2004 |
Resurrection of uric acid as a causal risk factor in essential hypertension.
Topics: Animals; Disease Progression; Humans; Hypertension; Hyperuricemia; Predictive Value of Tests; Progno | 2005 |
Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence.
Topics: Adult; Blood Pressure; Cohort Studies; Diabetes Mellitus; Disease Progression; Female; Follow-Up Stu | 2005 |
Childhood uric acid predicts adult blood pressure: the Bogalusa Heart Study.
Topics: Adolescent; Adult; Age Factors; Black or African American; Child; Child, Preschool; Cross-Sectional | 2005 |
The pathophysiology of hyperuricemia in essential hypertension: a pilot study.
Topics: Adult; Aged; Creatinine; Glucose Tolerance Test; Humans; Hypertension; Hyperuricemia; Insulin; Insul | 2004 |
[Arterial hypertension in adolescents with different physical constitution including those with signs of metabolic syndrome].
Topics: Adolescent; Body Mass Index; Body Weights and Measures; Child; Cholesterol; Female; Glucose Toleranc | 2004 |
Uric acid and preeclampsia.
Topics: Animals; Arteries; Blood Pressure; Endothelium, Vascular; Female; Humans; Hyperuricemia; Pre-Eclamps | 2005 |
[Effects of processing Phellodendron amurense with salt on anti-gout].
Topics: Animals; Drugs, Chinese Herbal; Gout Suppressants; Hot Temperature; Hyperuricemia; Liver; Male; Mice | 2005 |
[Xanthine oxidase inhibitory activity and hypouricemia effect of propolis in rats].
Topics: Animals; Anti-Infective Agents; Brazil; Caffeic Acids; China; Coumaric Acids; Disease Models, Animal | 2005 |
Response to a urate-lowering diet according to polymorphisms in the apolipoprotein AI-CIII-AIV cluster.
Topics: Apolipoprotein A-I; Apolipoprotein C-III; Apolipoproteins A; Apolipoproteins C; Humans; Hyperuricemi | 2005 |
[Does coffee drinking influence serum uric acid concentration?].
Topics: Adult; Aged; Caffeine; Chi-Square Distribution; Coffee; Female; Humans; Hypertension; Hyperuricemia; | 2004 |
The serum uric acid and related cardiovascular risk factors in south Taiwan.
Topics: Adult; Age Factors; Aged; Cardiovascular Diseases; Diet; Female; Humans; Hyperuricemia; Life Style; | 2005 |
What do epidemiologic studies tell us about hyperuricemia and cardiovascular disease and death?
Topics: Biomarkers; Cardiovascular Diseases; Cause of Death; Follow-Up Studies; Humans; Hyperuricemia; Male; | 2005 |
Lys418Asn polymorphism of the alpha2-adrenoceptor gene relates to serum uric acid levels but not to insulin sensitivity.
Topics: Adult; Alleles; Asparagine; Gene Frequency; Genotype; Glycine; Homeostasis; Humans; Hyperuricemia; I | 2005 |
Eighteen-year follow-up of a patient with partial hypoxanthine phosphoribosyltransferase deficiency and a new mutation.
Topics: Allopurinol; Child, Preschool; Enzyme Inhibitors; Follow-Up Studies; Humans; Hyperuricemia; Hypoxant | 2005 |
[The features of uric acid metabolism in women in climacterium].
Topics: Adolescent; Adult; Aged; Circadian Rhythm; Female; Humans; Hyperuricemia; Kidney Diseases; Male; Men | 2005 |
[Characteristics of metabolic syndrome in children and adolescents with arterial hypertension].
Topics: Adolescent; Body Mass Index; Child; Cholesterol, HDL; Cholesterol, LDL; Female; Glucose Intolerance; | 2005 |
Clinical manifestations of patients with hyperuricemia.
Topics: Age Distribution; Aged; Arthritis, Gouty; Cross-Sectional Studies; Diabetes Mellitus; Female; Humans | 2004 |
[Acute renal failure induced by primary hyperuricemia in children: a case report].
Topics: Acute Kidney Injury; Child, Preschool; Humans; Hyperuricemia; Kidney; Magnetic Resonance Imaging; Ma | 2005 |
Prognostic usefulness of serum uric acid after acute myocardial infarction (the Japanese Acute Coronary Syndrome Study).
Topics: Aged; Biomarkers; Coronary Angiography; Creatine Kinase; Electrocardiography; Female; Follow-Up Stud | 2005 |
Acute lymphocytic leukemia presenting as lupus-like syndrome.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Antinuclear; Biopsy; Bone Marrow Cells; | 2006 |
[Hyperuricemia following rotavirus infection].
Topics: Child, Preschool; Female; Humans; Hyperuricemia; Rotavirus Infections; Uric Acid | 2005 |
Possible interactions of the endothelial constitutive nitric oxide synthase genotype with alcohol drinking and walking time for high serum uric acid levels among Japanese.
Topics: Adult; Aged; Aged, 80 and over; Alcohol Drinking; Body Mass Index; Female; Genotype; Humans; Hyperur | 2005 |
[Hyperuricemia and disorders in content of amino acids-purine precursors in patients with autoimmune diseases and gout].
Topics: Amino Acids; Autoimmune Diseases; Gout; Humans; Hyperuricemia; Lipid Peroxides; Purines; Uric Acid; | 2005 |
Benign positional vertigo and hyperuricaemia.
Topics: Case-Control Studies; Comorbidity; Female; Humans; Hyperuricemia; Kenya; Male; Middle Aged; Prospect | 2005 |
The dual actions of morin (3,5,7,2',4'-pentahydroxyflavone) as a hypouricemic agent: uricosuric effect and xanthine oxidase inhibitory activity.
Topics: Alkaline Phosphatase; Animals; Antioxidants; Creatinine; Enzyme Inhibitors; Flavonoids; Hyperuricemi | 2006 |
Effects of cassia oil on serum and hepatic uric acid levels in oxonate-induced mice and xanthine dehydrogenase and xanthine oxidase activities in mouse liver.
Topics: Administration, Oral; Allopurinol; Animals; Cinnamomum aromaticum; Dose-Response Relationship, Drug; | 2006 |
Abdominal pain and hyperuricaemia in pregnancy.
Topics: Abdominal Pain; Adult; Apgar Score; Birth Weight; Female; Fetal Growth Retardation; Fluid Therapy; F | 2005 |
A longitudinal study of the influence of shift work on serum uric acid levels in workers at a telecommunications company.
Topics: Adult; Female; Humans; Hyperuricemia; Longitudinal Studies; Male; Middle Aged; Occupational Diseases | 2006 |
Status of endothelial dependent vasodilation in patients with hyperuricemia.
Topics: Adult; Blood Flow Velocity; Brachial Artery; Cardiovascular Diseases; Endothelium, Vascular; Humans; | 2005 |
[The fibrinolytic system in uric acid dysmetabolism].
Topics: Diabetes Mellitus; Female; Fibrinolysis; Humans; Hypertension; Hyperuricemia; Male; Middle Aged; Uri | 2005 |
Hypouricemic effects of acacetin and 4,5-o-dicaffeoylquinic acid methyl ester on serum uric acid levels in potassium oxonate-pretreated rats.
Topics: Administration, Oral; Allopurinol; Animals; Chrysanthemum; Disease Models, Animal; Dose-Response Rel | 2005 |
Febuxostat--treatment for hyperuricemia and gout?
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Probenecid; Thiazoles; Uric | 2005 |
Uric acid concentrations in early pregnancy among preeclamptic women with gestational hyperuricemia at delivery.
Topics: Adult; Case-Control Studies; Creatinine; Delivery, Obstetric; Female; Glomerular Filtration Rate; Hu | 2006 |
Is salt-wasting the long awaited answer to the hyperuricaemia seen in uromodulin storage diseases?
Topics: Animals; Humans; Hyperuricemia; Hyponatremia; Kidney; Kidney Diseases; Mice; Mice, Knockout; Mucopro | 2006 |
Effect and mechanism of total saponin of Dioscorea on animal experimental hyperuricemia.
Topics: Animals; Dioscorea; Disease Models, Animal; Hyperuricemia; Injections, Intraperitoneal; Liver; Male; | 2006 |
Reduced-dose rasburicase in the treatment of adults with hyperuricemia associated with malignancy.
Topics: Aged; Antineoplastic Agents; Creatinine; Female; Humans; Hyperuricemia; Leukemia; Lymphoma; Male; Mi | 2006 |
Serum uric acid is associated with microalbuminuria in prehypertension.
Topics: Albuminuria; Blood Pressure; Female; Humans; Hypertension; Hyperuricemia; Logistic Models; Male; Mid | 2006 |
Clinical trials of uric acid lowering for coronary heart disease risk reduction.
Topics: Clinical Trials as Topic; Coronary Disease; Humans; Hyperuricemia; Myocardial Infarction; Platelet A | 2006 |
[Hyperuricemia and gout: diagnosis and therapy].
Topics: Allopurinol; Anti-Inflammatory Agents; Colchicine; Diagnosis, Differential; Gout; Gout Suppressants; | 2006 |
Linkage analysis with an interbreed backcross maps Dalmatian hyperuricosuria to CFA03.
Topics: Animals; Chromosome Mapping; Crosses, Genetic; Dog Diseases; Dogs; Female; Genetic Linkage; Genetic | 2006 |
Uric acid: an additional component of metabolic syndrome?
Topics: Cardiovascular Diseases; Humans; Hyperuricemia; Metabolic Syndrome; Uric Acid | 2006 |
Is hyperuricemia another facet of the metabolic syndrome?
Topics: Alanine Transaminase; Body Mass Index; Cholesterol, HDL; Humans; Hyperuricemia; Male; Metabolic Synd | 2006 |
[Serum urate levels and urinary uric acid excretion in subjects with metabolic syndrome].
Topics: Aged; Female; Humans; Hyperuricemia; Male; Metabolic Syndrome; Middle Aged; Uric Acid | 2006 |
G-protein beta3 subunit gene variant is unlikely to have a significant influence on serum uric acid level in Japanese workers.
Topics: Cross-Sectional Studies; Female; Genetic Predisposition to Disease; Genetic Variation; Genotype; Het | 2006 |
Reduced-dose rasburicase (recombinant xanthine oxidase) in adult cancer patients with hyperuricemia.
Topics: Adult; Aged; Aged, 80 and over; Creatinine; Female; Hematopoietic Stem Cell Transplantation; Humans; | 2006 |
Higher serum uric acid is associated with increased arterial stiffness in Japanese individuals.
Topics: Aged; Atherosclerosis; Brachial Artery; Carotid Arteries; Carotid Artery Diseases; Elasticity; Femal | 2007 |
[Study on the independent association of uric acid levels with peripheral arterial disease in Chinese patients with coronary heart disease].
Topics: Analysis of Variance; Ankle Brachial Index; China; Coronary Disease; Humans; Hyperuricemia; Middle A | 2006 |
Hyperuricemia associated with high cardiac event rates in the elderly with chronic heart failure.
Topics: Aged; Biomarkers; Female; Heart Failure; Humans; Hyperuricemia; Male; Middle Aged; Multivariate Anal | 2006 |
Serum uric acid as an obesity-related indicator in early adolescence.
Topics: Adolescent; Alanine Transaminase; Aspartate Aminotransferases; Body Height; Body Mass Index; Child; | 2006 |
Hyperuricaemia predicts poor outcome in patients with mild to moderate chronic heart failure.
Topics: Chronic Disease; Female; Heart Failure; Humans; Hyperuricemia; Male; Middle Aged; Prognosis; Severit | 2007 |
Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout.
Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Creatinine; Dose-Response Relationship, Drug; Drug Moni | 2006 |
The prevalence of hyperuricemia in a population of the coastal city of Qingdao, China.
Topics: Adult; Aged; Alcohol Drinking; China; Cross-Sectional Studies; Female; Gout; Humans; Hypercholestero | 2006 |
[An analysis of islet beta-cell function in hyperuricemia].
Topics: Adult; Aged; Female; Glucose Tolerance Test; Humans; Hyperuricemia; Insulin; Insulin Resistance; Ins | 2006 |
High serum urate in HIV-infected persons: the choice of the antiretroviral drug matters.
Topics: Adult; Aged; Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; Hyperuricemia; Male; Middle Age | 2006 |
Relationship between serum uric acid, creatinine, albumin and gestational diabetes mellitus.
Topics: Adult; Creatinine; Diabetes, Gestational; Female; Glomerular Filtration Rate; Glucose Tolerance Test | 2006 |
[Relationships between arterial hypertension, metabolic disturbances and uric acid nephropathy].
Topics: Adult; Female; Follow-Up Studies; Heart Rate; Humans; Hypertension; Hyperuricemia; Insulin; Kidney D | 2006 |
Longevity-associated NADH dehydrogenase subunit-2 237 Leu/Met polymorphism influences the effects of alcohol consumption on serum uric acid levels in nonobese Japanese men.
Topics: Alcohol Drinking; Amino Acid Substitution; Base Sequence; Cross-Sectional Studies; DNA; Humans; Hype | 2006 |
Frequency of hyperuricemia and effect of calcineurin inhibitors on serum uric acid levels in liver transplanted children.
Topics: Adolescent; Chi-Square Distribution; Child; Child, Preschool; Creatinine; Cyclosporine; Female; Huma | 2006 |
Hyperuricemia and gout following pediatric renal transplantation.
Topics: Adolescent; Adult; Child; Child, Preschool; Female; Gout; Humans; Hyperuricemia; Immunosuppressive A | 2006 |
Febuxostat for prevention of gout attacks.
Topics: Allopurinol; Canada; Clinical Trials, Phase III as Topic; Gout; Gout Suppressants; Humans; Hyperuric | 2006 |
Prevalence of hyperuricemia and its relationship with metabolic syndrome in Thai adults receiving annual health exams.
Topics: Adult; Aged; Blood Glucose; Blood Pressure; Body Mass Index; Cholesterol, HDL; Female; Humans; Hyper | 2006 |
[Hyperuricaemia in males with obstructive sleep apnoea (osa)].
Topics: Body Mass Index; Comorbidity; Humans; Hyperuricemia; Male; Metabolic Syndrome; Middle Aged; Obesity; | 2005 |
Association of methylenetetrahydrofolate reductase (C677T) polymorphism with hyperuricemia.
Topics: Adult; Aged; Female; Gene Frequency; Genetic Predisposition to Disease; Heterozygote; Homozygote; Hu | 2007 |
Xanthine oxidase inhibitory activity of some Indian medical plants.
Topics: Animals; Female; Hyperuricemia; India; Lethal Dose 50; Magnoliopsida; Male; Medicine, Traditional; M | 2007 |
J-shaped mortality relationship for uric acid in CKD.
Topics: Adult; Aged; Allopurinol; Antimetabolites; Cause of Death; Comorbidity; Confounding Factors, Epidemi | 2006 |
Uric acid and the development of hypertension: the normative aging study.
Topics: Adult; Aged; Aged, 80 and over; Aging; Follow-Up Studies; Humans; Hypertension; Hyperuricemia; Longi | 2006 |
Hyperuricaemia and long-term outcome after hospital discharge in acute heart failure patients.
Topics: Acute Disease; Aged; Aged, 80 and over; Biomarkers; Case-Control Studies; Female; Follow-Up Studies; | 2007 |
Familial nephropathy associated with hyperuricemia in Spain: our experience with 3 families harbouring a UMOD mutation.
Topics: Adult; DNA Mutational Analysis; Exons; Family Health; Female; Genetic Linkage; Humans; Hyperuricemia | 2006 |
Analysis of excretion fraction of uric acid.
Topics: Adolescent; Adult; Aged; Case-Control Studies; Chemistry, Clinical; Child; Child, Preschool; Humans; | 2006 |
Elevated serum uric acid levels impair coronary microvascular function in patients with idiopathic dilated cardiomyopathy.
Topics: Adult; Aged; Biomarkers; Blood Flow Velocity; Cardiomyopathy, Dilated; Coronary Circulation; Endothe | 2007 |
Report of two cases of rasburicase-induced methemoglobinemia.
Topics: Acquired Immunodeficiency Syndrome; Humans; Hyperuricemia; Lymphoma, AIDS-Related; Lymphoma, Large B | 2006 |
[Acute urate nephropathy in perimenopausal women].
Topics: Acute Disease; Adult; Female; Humans; Hyperuricemia; Kidney Tubules, Distal; Middle Aged; Nephrolith | 2006 |
Hyperuricemia and incidence of hypertension among men without metabolic syndrome.
Topics: Adult; Blood Pressure; Follow-Up Studies; Humans; Hypertension; Hyperuricemia; Incidence; Male; Meta | 2007 |
The role of uric acid in pediatric hypertension.
Topics: Adolescent; Animals; Disease Models, Animal; Gout Suppressants; Humans; Hypertension; Hyperuricemia; | 2007 |
Effect of elevated serum uric acid on cisplatin-induced acute renal failure.
Topics: Acute Kidney Injury; Animals; Antineoplastic Agents; Chemokine CCL2; Cisplatin; Endothelium, Vascula | 2007 |
[Hyperuricaemia in females with obstructive sleep apnoea].
Topics: Aged; Body Mass Index; Comorbidity; Estrogens; Female; Humans; Hypertension, Pulmonary; Hyperuricemi | 2006 |
Serum uric acid levels in patients with vitiligo receiving narrowband ultraviolet B phototherapy.
Topics: Humans; Hyperuricemia; Male; Middle Aged; Phototherapy; Uric Acid; Vitiligo | 2007 |
Clinical quiz. A patient with hyperuricemia and renal failure.
Topics: Acid-Base Equilibrium; Adolescent; Biopsy; Fluid Therapy; Humans; Hyperuricemia; Kidney; Male; Renal | 2007 |
Treatment of hyperuricemia in essential hypertension.
Topics: Allopurinol; Animals; Clinical Trials as Topic; Enzyme Inhibitors; Hypertension; Hyperuricemia; Rats | 2007 |
Uric acid heralds ischemic tissue injury to mobilize endothelial progenitor cells.
Topics: Adenosine; Animals; Cell Movement; Chronic Disease; Endothelial Cells; Hyperuricemia; Inosine; Ische | 2007 |
Independent association of high serum uric acid concentration with angiographically defined coronary artery disease.
Topics: Aged; Biomarkers; Case-Control Studies; Coronary Artery Disease; Female; Humans; Hyperuricemia; Male | 2007 |
Uric acid level and its association with carotid intima-media thickness in patients with hypertension.
Topics: Adult; Carotid Artery Diseases; Carotid Artery, Common; Female; Humans; Hypertension; Hyperuricemia; | 2008 |
[An unusual manifestation of osteo-articular, tendinous and nervous involvement secondary to tophaceous gout of the hand. A report of two cases].
Topics: Carpal Tunnel Syndrome; Contracture; Crystallization; Cubital Tunnel Syndrome; Electromyography; Fin | 2007 |
Adverse effects of the classic antioxidant uric acid in adipocytes: NADPH oxidase-mediated oxidative/nitrosative stress.
Topics: 3T3-L1 Cells; Adipocytes; Animals; Antioxidants; Cardiovascular Diseases; Cell Differentiation; Enzy | 2007 |
Uric acid as a prognostic marker in acute heart failure--new expectations from an old molecule.
Topics: Acute Disease; Biomarkers; Heart Failure; Humans; Hyperuricemia; Patient Discharge; Prognosis; Survi | 2007 |
Prevalence of the metabolic syndrome in individuals with hyperuricemia.
Topics: Adult; Body Mass Index; Female; Humans; Hyperuricemia; Male; Metabolic Syndrome; Middle Aged; Multiv | 2007 |
[Chronic asymptomatic hyperuricemia as a marker of atherogenic risk in children].
Topics: Adolescent; Age Factors; Atherosclerosis; Biomarkers; Blood Glucose; Blood Pressure; Chi-Square Dist | 2007 |
Is uric acid a predictive factor for graft dysfunction in renal transplant recipients?
Topics: Adult; Biomarkers; Female; Follow-Up Studies; Graft Rejection; Graft Survival; Humans; Hyperuricemia | 2007 |
Coffee, tea, and caffeine consumption and serum uric acid level: the third national health and nutrition examination survey.
Topics: Caffeine; Central Nervous System Stimulants; Coffee; Diet Surveys; Drinking Behavior; Female; Humans | 2007 |
Dietary factors associated with hyperuricemia in adults.
Topics: Adolescent; Adult; Aged; Alcohol Drinking; Beer; Child; Child, Preschool; Cross-Sectional Studies; D | 2008 |
Hypouricemic effect and regulatory effects on autonomic function of Shao-Yao Gan-Cao Tang, a Chinese herbal prescription, in asymptomatic hyperuricemic vegetarians.
Topics: Autonomic Nervous System; Case-Control Studies; Diet, Vegetarian; Drugs, Chinese Herbal; Glycyrrhiza | 2007 |
Intake of added sugar and sugar-sweetened drink and serum uric acid concentration in US men and women.
Topics: Adult; Age Distribution; Beverages; Cross-Sectional Studies; Dietary Carbohydrates; Dietary Sucrose; | 2007 |
Outcome of kidney transplantation in familial juvenile hyperuricaemic nephropathy.
Topics: Adult; Cohort Studies; Family Health; Female; Follow-Up Studies; Humans; Hyperuricemia; Kidney Disea | 2007 |
Determination of uric acid in plasma and allantoic fluid of chicken embryos by capillary electrophoresis.
Topics: Acetonitriles; Adsorption; Allantois; Animals; Body Fluids; Buffers; Chemistry Techniques, Analytica | 2007 |
Association of serum uric acid with cardiovascular disease in rheumatoid arthritis.
Topics: Aged; Arthritis, Rheumatoid; Biomarkers; Cardiovascular Diseases; Cross-Sectional Studies; Female; H | 2007 |
Relationship between hyperuricemia and metabolic syndrome.
Topics: Adult; Female; Humans; Hyperuricemia; Male; Metabolic Syndrome; Risk Factors; Sex Characteristics; U | 2007 |
Homozygous frameshift mutation in the SLC22A12 gene in a patient with primary gout and high levels of serum uric acid.
Topics: Adult; Arthritis, Gouty; Frameshift Mutation; Gout; Homozygote; Humans; Hyperuricemia; Male; Mutagen | 2007 |
Status of uric acid management in hypertensive subjects.
Topics: Aged; Aged, 80 and over; Cardiology; Cross-Sectional Studies; Enzyme Inhibitors; Female; Humans; Hyp | 2007 |
Is uric acid itself a player or a bystander in the pathophysiology of chronic heart failure?
Topics: Chronic Disease; Endothelium, Vascular; Heart Failure; Humans; Hyperuricemia; Uric Acid; Xanthine Ox | 2008 |
Hyperuricemia and metabolic syndrome in Taiwanese children.
Topics: Age Factors; Blood Glucose; Blood Pressure; Body Mass Index; Child; Cholesterol; Demography; Female; | 2007 |
Relationship between hyperuricemia and body fat distribution.
Topics: Adipose Tissue; Adult; Body Fat Distribution; Humans; Hyperuricemia; Insulin Resistance; Lipids; Mal | 2007 |
Association between serum uric acid levels and coronary flow reserve in hypertensive patients without concomitant risk factors.
Topics: Adult; Cardiovascular Diseases; Cohort Studies; Coronary Circulation; Coronary Vessels; Echocardiogr | 2007 |
Thiazide diuretics exacerbate fructose-induced metabolic syndrome.
Topics: Allopurinol; Animals; Blood Pressure; Body Weight; Diuretics; Fructose; Gout Suppressants; Hydrochlo | 2007 |
[Molecular basis of primary renal hyperuricemia : role of the human urate transporter hURAT1].
Topics: Arthritis, Gouty; Genetic Markers; Genetic Variation; Humans; Hyperuricemia; Kidney Tubules, Proxima | 2007 |
Serum uric acid level as an independent component of the metabolic syndrome in type 2 diabetic blacks.
Topics: Adult; Aged; Black People; Diabetes Mellitus, Type 2; Epidemiologic Studies; Female; Humans; Hypertr | 2007 |
High serum uric acid as a novel risk factor for type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Humans; Hyperuricemia; Incidence; Male; Nether | 2008 |
Treatment with the xanthine oxidase inhibitor febuxostat lowers uric acid and alleviates systemic and glomerular hypertension in experimental hyperuricaemia.
Topics: Animals; Blood Pressure; Febuxostat; Follow-Up Studies; Gout Suppressants; Hypertension, Renal; Hype | 2008 |
Association between serum uric acid and the Adult Treatment Panel III-defined metabolic syndrome: results from a single hospital database.
Topics: Adult; Blood Glucose; Blood Pressure; Body Mass Index; Cross-Sectional Studies; Female; Humans; Hype | 2008 |
The genetics of gout and hyperuricaemia; an analysis of 19 families.
Topics: Blood; Gout; Humans; Hyperuricemia; Uric Acid | 1948 |
Elevated uric acid and cardiovascular disease. How strong is the evidence of a pathogenetic link?
Topics: C-Reactive Protein; Cardiovascular Diseases; Humans; Hyperuricemia; Inflammation; Risk Factors; Uric | 2007 |
Serum uric acid and lipid levels while taking topiramate for migraine.
Topics: Adult; Cholesterol, HDL; Cholesterol, LDL; Female; Fructose; Humans; Hyperuricemia; Lipids; Male; Mi | 2008 |
Effects of allopurinol on plasma uric acid levels in normouricaemic and hyperuricaemic green iguanas (Iguana iguana).
Topics: Administration, Oral; Allopurinol; Animals; Antimetabolites; Blood Proteins; Body Weight; Cross-Over | 2008 |
Investigation of hyperuricemia during pegylated-interferon-alpha2b plus ribavirin combination therapy in patients with chronic hepatitis C.
Topics: Aged; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Hyperuricemia; Interferon alp | 2008 |
Hypouricemic effects of phenylpropanoid glycosides acteoside of Scrophularia ningpoensis on serum uric acid levels in potassium oxonate-pretreated Mice.
Topics: Animals; Glycosides; Hyperuricemia; Male; Mice; Mice, Inbred ICR; Oxonic Acid; Plant Extracts; Plant | 2008 |
Uric acid: neuroprotective or neurotoxic?
Topics: Animals; Antioxidants; Brain Ischemia; Gout; Humans; Hyperuricemia; Lesch-Nyhan Syndrome; Neuroprote | 2008 |
Acarbose alleviates rise in plasma uric acid concentration induced by sucrose ingestion.
Topics: Acarbose; Administration, Oral; Adult; Glycoside Hydrolase Inhibitors; Humans; Hyperuricemia; Male; | 2008 |
Serum uric acid levels and risk of metabolic syndrome in healthy adults.
Topics: Adult; Biomarkers; Cross-Sectional Studies; Female; Humans; Hypertension; Hypertriglyceridemia; Hype | 2008 |
Vitamin C intake and serum uric acid concentration in men.
Topics: Adult; Aged; Antioxidants; Ascorbic Acid; Diet Surveys; Feeding Behavior; Gout; Humans; Hyperuricemi | 2008 |
Asymptomatic hyperuricemia: perhaps not so benign?
Topics: Cardiovascular Diseases; Gout; Humans; Hyperuricemia; Kidney Diseases; Risk Factors; Uric Acid | 2008 |
Relationship between serum uric acid levels and urinary albumin excretion in patients with heart failure.
Topics: Aged; Albuminuria; Biomarkers; Disease Progression; Female; Follow-Up Studies; Glomerular Filtration | 2008 |
Long-term cardiovascular mortality among middle-aged men with gout.
Topics: Adult; Arthritis, Gouty; Cardiovascular Diseases; Follow-Up Studies; Humans; Hyperuricemia; Male; Mi | 2008 |
Long-term cardiovascular mortality among middle-aged men with gout.
Topics: Adult; Arthritis, Gouty; Cardiovascular Diseases; Follow-Up Studies; Humans; Hyperuricemia; Male; Mi | 2008 |
Long-term cardiovascular mortality among middle-aged men with gout.
Topics: Adult; Arthritis, Gouty; Cardiovascular Diseases; Follow-Up Studies; Humans; Hyperuricemia; Male; Mi | 2008 |
Long-term cardiovascular mortality among middle-aged men with gout.
Topics: Adult; Arthritis, Gouty; Cardiovascular Diseases; Follow-Up Studies; Humans; Hyperuricemia; Male; Mi | 2008 |
Familial juvenile hyperuricaemic nephropathy in a Caucasian family associated with inborn malformations.
Topics: Adult; Austria; Child; Congenital Abnormalities; Creatinine; Female; Humans; Hyperuricemia; Kidney D | 2002 |